<SEC-DOCUMENT>0001628280-20-002582.txt : 20200228
<SEC-HEADER>0001628280-20-002582.hdr.sgml : 20200228
<ACCEPTANCE-DATETIME>20200228165303
ACCESSION NUMBER:		0001628280-20-002582
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		101
CONFORMED PERIOD OF REPORT:	20191231
FILED AS OF DATE:		20200228
DATE AS OF CHANGE:		20200228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SANGAMO THERAPEUTICS, INC
		CENTRAL INDEX KEY:			0001001233
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				680359556
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30171
		FILM NUMBER:		20671493

	BUSINESS ADDRESS:	
		STREET 1:		501 CANAL BLVD
		STREET 2:		POINT RICHMOND TECH CNTR.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94804
		BUSINESS PHONE:		5109706000

	MAIL ADDRESS:	
		STREET 1:		501 CANAL BLVD
		STREET 2:		POINT RICHMOND TECH CNTR.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94804

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANGAMO BIOSCIENCES INC
		DATE OF NAME CHANGE:	20000208
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>sgmo-20191231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:6b105dfa-4da0-4f89-a738-1fa68397e7a0,g:da741c8d-9db4-444a-b42c-06c4caf6626c,d:9a2bf9013aa44980b5a1f5846290b1a8--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:sgmo="http://www.sangamo.com/20191231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sgmo-20191231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF80L2ZyYWc6OWZiNGYxOWM0MGM3NDgzZGJkYzEyMTVmNjA4MzBlMmUvdGFibGU6ZTM1OTBkY2RjM2IyNDU0MDk1ZTZmMTU2NWM1NDM0ZWUvdGFibGVyYW5nZTplMzU5MGRjZGMzYjI0NTQwOTVlNmYxNTY1YzU0MzRlZV8zLTEtMS0xLTA_33a0ba27-13ba-4f77-81fc-2397367aff4b">false</ix:nonNumeric><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF80L2ZyYWc6OWZiNGYxOWM0MGM3NDgzZGJkYzEyMTVmNjA4MzBlMmUvdGFibGU6ZTM1OTBkY2RjM2IyNDU0MDk1ZTZmMTU2NWM1NDM0ZWUvdGFibGVyYW5nZTplMzU5MGRjZGMzYjI0NTQwOTVlNmYxNTY1YzU0MzRlZV81LTEtMS0xLTA_6647db9d-9d14-46db-a28e-41e90a74da75">2019</ix:nonNumeric><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF80L2ZyYWc6OWZiNGYxOWM0MGM3NDgzZGJkYzEyMTVmNjA4MzBlMmUvdGFibGU6ZTM1OTBkY2RjM2IyNDU0MDk1ZTZmMTU2NWM1NDM0ZWUvdGFibGVyYW5nZTplMzU5MGRjZGMzYjI0NTQwOTVlNmYxNTY1YzU0MzRlZV82LTEtMS0xLTA_fb0fdb89-421f-4003-8ee6-bf3f5b044ef3">FY</ix:nonNumeric><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF80L2ZyYWc6OWZiNGYxOWM0MGM3NDgzZGJkYzEyMTVmNjA4MzBlMmUvdGFibGU6ZTM1OTBkY2RjM2IyNDU0MDk1ZTZmMTU2NWM1NDM0ZWUvdGFibGVyYW5nZTplMzU5MGRjZGMzYjI0NTQwOTVlNmYxNTY1YzU0MzRlZV85LTEtMS0xLTA_545adc6b-4db6-4905-b111-fc01be803b8f">0001001233</ix:nonNumeric><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF80L2ZyYWc6OWZiNGYxOWM0MGM3NDgzZGJkYzEyMTVmNjA4MzBlMmUvdGFibGU6ZTM1OTBkY2RjM2IyNDU0MDk1ZTZmMTU2NWM1NDM0ZWUvdGFibGVyYW5nZTplMzU5MGRjZGMzYjI0NTQwOTVlNmYxNTY1YzU0MzRlZV8xMC0xLTEtMS0w_81cbc724-71cd-42ce-a843-ceb9578b6d9e">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i0c83aa6622144db1929cedd8491d3519_D20190101-20191231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfNTczOA_d3889db1-4c3b-4768-aeb6-f18ca1502096">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="id7d82acff2b8474488fc135b1be65d92_D20190101-20191231" name="sgmo:ExtendedResearchTermOfAgreement" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzc2OTY1ODE1MDUyMDY_67f3e1f2-17aa-46c8-a608-4185bf8992f1">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="ie07937e9122d4e52ae687f94e550ec89_D20070101-20071231" name="sgmo:ResearchServicesPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI3OTg0_c09101db-17d8-4575-842f-cc8f133a684e">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="if0b4d17d3d8d4ebc977872aa77c541e2_D20050101-20051231" name="sgmo:InitialResearchTermOfAgreement" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI5MzIy_7d482839-f2da-4dcc-a0a2-fb576c2847cb">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="if46ca43d45c948e98319922d7565a9f7_I20191231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzc2OTY1ODE0MDcwOTQ_38c04c15-1abf-4f53-8e13-ebfe9bb10579">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="i57406eb823ae4dcba23a5c69e7941851_D20180601-20180630" name="sgmo:PurchasePlanOfferingPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzk0NTg_a01f06c3-4780-4e1a-a835-8d6a1d1c86ad">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="i57406eb823ae4dcba23a5c69e7941851_D20180601-20180630" name="sgmo:PurchasePlanPurchasePeriod" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzk1MTY_14ef30bf-8a48-4b2c-8cc7-f55e130f23b6">P6M</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i2079b275b8624be6a51a9674c1a69829_D20190101-20191231" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzYvZnJhZzpjODA1NjZmZjllMjA0ZDhmOWZkMjNmNzZiMjVjNDJhZi90YWJsZTozZjk4OTY5MjBlODQ0YzdiYjJkMWMwZTYzNTgxYjYxZC90YWJsZXJhbmdlOjNmOTg5NjkyMGU4NDRjN2JiMmQxYzBlNjM1ODFiNjFkXzUtMS0xLTEtMA_68db17eb-36a5-482f-b6b9-9a9a43b39fb7">33.33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i4c22448f844d48b8a90cd6b5030ab3b6_D20190101-20191231" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzYvZnJhZzpjODA1NjZmZjllMjA0ZDhmOWZkMjNmNzZiMjVjNDJhZi90YWJsZTozZjk4OTY5MjBlODQ0YzdiYjJkMWMwZTYzNTgxYjYxZC90YWJsZXJhbmdlOjNmOTg5NjkyMGU4NDRjN2JiMmQxYzBlNjM1ODFiNjFkXzctMS0xLTEtMA_543353b8-7ae1-480d-b7e6-57002b790c74">33.33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ia89fc661975a4524b5aefcb074dba5af_D20190101-20191231" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzYvZnJhZzpjODA1NjZmZjllMjA0ZDhmOWZkMjNmNzZiMjVjNDJhZi90YWJsZTozZjk4OTY5MjBlODQ0YzdiYjJkMWMwZTYzNTgxYjYxZC90YWJsZXJhbmdlOjNmOTg5NjkyMGU4NDRjN2JiMmQxYzBlNjM1ODFiNjFkXzktMS0xLTEtMA_1dee2af6-6c4c-4e03-95cb-bf5970e7eca0">33.33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ic900024014ad40cb84ea43fd53db5e7d_D20190101-20191231" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzYvZnJhZzpjODA1NjZmZjllMjA0ZDhmOWZkMjNmNzZiMjVjNDJhZi90YWJsZTozZjk4OTY5MjBlODQ0YzdiYjJkMWMwZTYzNTgxYjYxZC90YWJsZXJhbmdlOjNmOTg5NjkyMGU4NDRjN2JiMmQxYzBlNjM1ODFiNjFkXzEyLTEtMS0xLTk0Nzk_ca892515-186c-463a-8ec7-b09ae53be422">2.08</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ic84a9796c7a541749fdbca1dc1d961a0_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1ZThmNTE5ZGI2YzA0M2RiYTg0NDBjMTE0Y2E0N2NmMC90YWJsZXJhbmdlOjVlOGY1MTlkYjZjMDQzZGJhODQ0MGMxMTRjYTQ3Y2YwXzItMS0xLTEtMA_b2acf6c7-9730-4a23-b4d4-96749ef2606e">2.53</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i4875c47b73b649d89f3d228c46b40d73_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1ZThmNTE5ZGI2YzA0M2RiYTg0NDBjMTE0Y2E0N2NmMC90YWJsZXJhbmdlOjVlOGY1MTlkYjZjMDQzZGJhODQ0MGMxMTRjYTQ3Y2YwXzItMi0xLTEtMA_dd431afd-72e6-45c4-acb5-8f24b8b1afcb">1.81</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i545150c912bd475bb5cc4cfafe39b8c4_D20170101-20171231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1ZThmNTE5ZGI2YzA0M2RiYTg0NDBjMTE0Y2E0N2NmMC90YWJsZXJhbmdlOjVlOGY1MTlkYjZjMDQzZGJhODQ0MGMxMTRjYTQ3Y2YwXzItMy0xLTEtMA_460d101a-1e2e-4e3b-8052-e9bfb3758301">1.13</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i2a0099de9f314f5a919f8b231d4109ab_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1ZThmNTE5ZGI2YzA0M2RiYTg0NDBjMTE0Y2E0N2NmMC90YWJsZXJhbmdlOjVlOGY1MTlkYjZjMDQzZGJhODQ0MGMxMTRjYTQ3Y2YwXzMtMS0xLTEtMA_980876e9-40ba-4e1e-ab0b-e9768d537e70">2.96</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i5c838e5e7b0b46cab8713879fa0ce0e9_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1ZThmNTE5ZGI2YzA0M2RiYTg0NDBjMTE0Y2E0N2NmMC90YWJsZXJhbmdlOjVlOGY1MTlkYjZjMDQzZGJhODQ0MGMxMTRjYTQ3Y2YwXzMtMi0xLTEtMA_c7af1fb2-aff0-4f04-96af-a85a43ce2dee">2.28</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="icd62021ceb204760b751e409e802a4b3_D20170101-20171231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1ZThmNTE5ZGI2YzA0M2RiYTg0NDBjMTE0Y2E0N2NmMC90YWJsZXJhbmdlOjVlOGY1MTlkYjZjMDQzZGJhODQ0MGMxMTRjYTQ3Y2YwXzMtMy0xLTEtMA_b24bd317-ff64-4bb2-b062-dbeea118527a">1.61</ix:nonFraction><ix:nonNumeric contextRef="ic84a9796c7a541749fdbca1dc1d961a0_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1ZThmNTE5ZGI2YzA0M2RiYTg0NDBjMTE0Y2E0N2NmMC90YWJsZXJhbmdlOjVlOGY1MTlkYjZjMDQzZGJhODQ0MGMxMTRjYTQ3Y2YwXzQtMS0xLTEtMA_1d0ab852-51d6-4982-a591-9b59481d53fb">5.59</ix:nonNumeric><ix:nonNumeric contextRef="i4875c47b73b649d89f3d228c46b40d73_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1ZThmNTE5ZGI2YzA0M2RiYTg0NDBjMTE0Y2E0N2NmMC90YWJsZXJhbmdlOjVlOGY1MTlkYjZjMDQzZGJhODQ0MGMxMTRjYTQ3Y2YwXzQtMi0xLTEtMA_95b1f39c-d076-48ab-8586-3db30e67fe69">5.73</ix:nonNumeric><ix:nonNumeric contextRef="i545150c912bd475bb5cc4cfafe39b8c4_D20170101-20171231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1ZThmNTE5ZGI2YzA0M2RiYTg0NDBjMTE0Y2E0N2NmMC90YWJsZXJhbmdlOjVlOGY1MTlkYjZjMDQzZGJhODQ0MGMxMTRjYTQ3Y2YwXzQtMy0xLTEtMA_73fc753c-886b-41f9-9095-bcb754b759da">5.28</ix:nonNumeric><ix:nonNumeric contextRef="i2a0099de9f314f5a919f8b231d4109ab_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1ZThmNTE5ZGI2YzA0M2RiYTg0NDBjMTE0Y2E0N2NmMC90YWJsZXJhbmdlOjVlOGY1MTlkYjZjMDQzZGJhODQ0MGMxMTRjYTQ3Y2YwXzUtMS0xLTEtMA_e26449ef-3546-49ce-93f5-6acf46f01b5c">5.61</ix:nonNumeric><ix:nonNumeric contextRef="i5c838e5e7b0b46cab8713879fa0ce0e9_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1ZThmNTE5ZGI2YzA0M2RiYTg0NDBjMTE0Y2E0N2NmMC90YWJsZXJhbmdlOjVlOGY1MTlkYjZjMDQzZGJhODQ0MGMxMTRjYTQ3Y2YwXzUtMi0xLTEtMA_f14d72cd-975b-4c6d-a125-d9ea1367f994">5.83</ix:nonNumeric><ix:nonNumeric contextRef="icd62021ceb204760b751e409e802a4b3_D20170101-20171231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1ZThmNTE5ZGI2YzA0M2RiYTg0NDBjMTE0Y2E0N2NmMC90YWJsZXJhbmdlOjVlOGY1MTlkYjZjMDQzZGJhODQ0MGMxMTRjYTQ3Y2YwXzUtMy0xLTEtMA_19ca7edf-e25a-41eb-812f-43e0c98df7fe">5.29</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="ic84a9796c7a541749fdbca1dc1d961a0_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1ZThmNTE5ZGI2YzA0M2RiYTg0NDBjMTE0Y2E0N2NmMC90YWJsZXJhbmdlOjVlOGY1MTlkYjZjMDQzZGJhODQ0MGMxMTRjYTQ3Y2YwXzYtMS0xLTEtMA_a35c9e91-216a-420c-bf31-39071a9757cf">0.72</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i4875c47b73b649d89f3d228c46b40d73_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1ZThmNTE5ZGI2YzA0M2RiYTg0NDBjMTE0Y2E0N2NmMC90YWJsZXJhbmdlOjVlOGY1MTlkYjZjMDQzZGJhODQ0MGMxMTRjYTQ3Y2YwXzYtMi0xLTEtMA_b33e8446-242c-46f6-8c62-9f3df70a1759">0.71</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i545150c912bd475bb5cc4cfafe39b8c4_D20170101-20171231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1ZThmNTE5ZGI2YzA0M2RiYTg0NDBjMTE0Y2E0N2NmMC90YWJsZXJhbmdlOjVlOGY1MTlkYjZjMDQzZGJhODQ0MGMxMTRjYTQ3Y2YwXzYtMy0xLTEtMA_52bf5c0c-9e9f-42e9-bdf6-d2c18654a0fb">0.68</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i2a0099de9f314f5a919f8b231d4109ab_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1ZThmNTE5ZGI2YzA0M2RiYTg0NDBjMTE0Y2E0N2NmMC90YWJsZXJhbmdlOjVlOGY1MTlkYjZjMDQzZGJhODQ0MGMxMTRjYTQ3Y2YwXzctMS0xLTEtMA_333205cc-64f8-4f57-8885-c398db84bf2d">0.75</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i5c838e5e7b0b46cab8713879fa0ce0e9_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1ZThmNTE5ZGI2YzA0M2RiYTg0NDBjMTE0Y2E0N2NmMC90YWJsZXJhbmdlOjVlOGY1MTlkYjZjMDQzZGJhODQ0MGMxMTRjYTQ3Y2YwXzctMi0xLTEtMA_b2c41338-0e5a-4761-b3c5-b945f1860d69">0.72</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="icd62021ceb204760b751e409e802a4b3_D20170101-20171231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1ZThmNTE5ZGI2YzA0M2RiYTg0NDBjMTE0Y2E0N2NmMC90YWJsZXJhbmdlOjVlOGY1MTlkYjZjMDQzZGJhODQ0MGMxMTRjYTQ3Y2YwXzctMy0xLTEtMA_f5f15f65-8fee-4d0c-b517-bea3f77beb45">0.70</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i822b57314be44262a52169433cb095e6_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1OGNhNzJlNWQzMTQ0MjQyODU0NWMxNWJjNDg2ZmRlMi90YWJsZXJhbmdlOjU4Y2E3MmU1ZDMxNDQyNDI4NTQ1YzE1YmM0ODZmZGUyXzItMS0xLTEtMA_7c2c8ef5-6b7e-4acf-b52d-0a0679e65bc2">.0216</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i52b452cf7faf4507b5d8744d6e2ccbe1_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1OGNhNzJlNWQzMTQ0MjQyODU0NWMxNWJjNDg2ZmRlMi90YWJsZXJhbmdlOjU4Y2E3MmU1ZDMxNDQyNDI4NTQ1YzE1YmM0ODZmZGUyXzItMi0xLTEtMA_7d214929-0a35-425d-9c90-a4459e7fa49f">0.0044</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i2f722ff8a1bb4847896b093c5949157c_D20170101-20171231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1OGNhNzJlNWQzMTQ0MjQyODU0NWMxNWJjNDg2ZmRlMi90YWJsZXJhbmdlOjU4Y2E3MmU1ZDMxNDQyNDI4NTQ1YzE1YmM0ODZmZGUyXzItMy0xLTEtMA_fc77004d-c058-4a13-89cd-10719c75e3b0">0.0041</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i5ccdd9ccdd8248799ab22a4b8eb8f471_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1OGNhNzJlNWQzMTQ0MjQyODU0NWMxNWJjNDg2ZmRlMi90YWJsZXJhbmdlOjU4Y2E3MmU1ZDMxNDQyNDI4NTQ1YzE1YmM0ODZmZGUyXzMtMS0xLTEtMA_013a7d80-0309-4f2f-9f64-d17a9d25f0cb">.0280</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i99276d8c006448148b510e8ed81523da_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1OGNhNzJlNWQzMTQ0MjQyODU0NWMxNWJjNDg2ZmRlMi90YWJsZXJhbmdlOjU4Y2E3MmU1ZDMxNDQyNDI4NTQ1YzE1YmM0ODZmZGUyXzMtMi0xLTEtMA_ff0015ae-d10f-4cd2-841e-9c2a49a26322">0.0076</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i803d3fabb4d84a7fa36d5b64f9f5b98d_D20170101-20171231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1OGNhNzJlNWQzMTQ0MjQyODU0NWMxNWJjNDg2ZmRlMi90YWJsZXJhbmdlOjU4Y2E3MmU1ZDMxNDQyNDI4NTQ1YzE1YmM0ODZmZGUyXzMtMy0xLTEtMA_7bd3debc-63ef-4e5d-bde6-06afbc6fee73">0.0080</ix:nonFraction><ix:nonNumeric contextRef="i822b57314be44262a52169433cb095e6_D20190101-20191231" format="ixt-sec:durmonth" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1OGNhNzJlNWQzMTQ0MjQyODU0NWMxNWJjNDg2ZmRlMi90YWJsZXJhbmdlOjU4Y2E3MmU1ZDMxNDQyNDI4NTQ1YzE1YmM0ODZmZGUyXzQtMS0xLTEtMA_54445af0-a1bc-4994-b34e-2bac0683e7a0">6</ix:nonNumeric><ix:nonNumeric contextRef="i52b452cf7faf4507b5d8744d6e2ccbe1_D20180101-20181231" format="ixt-sec:durmonth" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1OGNhNzJlNWQzMTQ0MjQyODU0NWMxNWJjNDg2ZmRlMi90YWJsZXJhbmdlOjU4Y2E3MmU1ZDMxNDQyNDI4NTQ1YzE1YmM0ODZmZGUyXzQtMi0xLTEtMA_4e1f82fd-5201-492c-836b-ab40012d43d8">6</ix:nonNumeric><ix:nonNumeric contextRef="i2f722ff8a1bb4847896b093c5949157c_D20170101-20171231" format="ixt-sec:durmonth" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1OGNhNzJlNWQzMTQ0MjQyODU0NWMxNWJjNDg2ZmRlMi90YWJsZXJhbmdlOjU4Y2E3MmU1ZDMxNDQyNDI4NTQ1YzE1YmM0ODZmZGUyXzQtMy0xLTEtMA_ff240962-e298-4945-a3ec-666b9847359f">6</ix:nonNumeric><ix:nonNumeric contextRef="i5ccdd9ccdd8248799ab22a4b8eb8f471_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1OGNhNzJlNWQzMTQ0MjQyODU0NWMxNWJjNDg2ZmRlMi90YWJsZXJhbmdlOjU4Y2E3MmU1ZDMxNDQyNDI4NTQ1YzE1YmM0ODZmZGUyXzUtMS0xLTEtMA_7f3cd019-aafe-4f42-a6dd-82f61d9da711">2</ix:nonNumeric><ix:nonNumeric contextRef="i99276d8c006448148b510e8ed81523da_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1OGNhNzJlNWQzMTQ0MjQyODU0NWMxNWJjNDg2ZmRlMi90YWJsZXJhbmdlOjU4Y2E3MmU1ZDMxNDQyNDI4NTQ1YzE1YmM0ODZmZGUyXzUtMi0xLTEtMA_0066f92d-3606-4e35-b7cc-ee5fcc18c8f6">2</ix:nonNumeric><ix:nonNumeric contextRef="i803d3fabb4d84a7fa36d5b64f9f5b98d_D20170101-20171231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1OGNhNzJlNWQzMTQ0MjQyODU0NWMxNWJjNDg2ZmRlMi90YWJsZXJhbmdlOjU4Y2E3MmU1ZDMxNDQyNDI4NTQ1YzE1YmM0ODZmZGUyXzUtMy0xLTEtMA_879dac81-c3ad-4925-93b3-b238eb39ba56">2</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i822b57314be44262a52169433cb095e6_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1OGNhNzJlNWQzMTQ0MjQyODU0NWMxNWJjNDg2ZmRlMi90YWJsZXJhbmdlOjU4Y2E3MmU1ZDMxNDQyNDI4NTQ1YzE1YmM0ODZmZGUyXzYtMS0xLTEtMA_c3753c4f-f548-4fb3-91f6-75995f14d78f">0.0073</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i52b452cf7faf4507b5d8744d6e2ccbe1_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1OGNhNzJlNWQzMTQ0MjQyODU0NWMxNWJjNDg2ZmRlMi90YWJsZXJhbmdlOjU4Y2E3MmU1ZDMxNDQyNDI4NTQ1YzE1YmM0ODZmZGUyXzYtMi0xLTEtMA_2c984510-c0b2-4701-b7d1-6a802f891538">0.0066</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i2f722ff8a1bb4847896b093c5949157c_D20170101-20171231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1OGNhNzJlNWQzMTQ0MjQyODU0NWMxNWJjNDg2ZmRlMi90YWJsZXJhbmdlOjU4Y2E3MmU1ZDMxNDQyNDI4NTQ1YzE1YmM0ODZmZGUyXzYtMy0xLTEtMA_c1f3a594-97e6-4be5-987e-2b68b53e0371">0.0071</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i5ccdd9ccdd8248799ab22a4b8eb8f471_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1OGNhNzJlNWQzMTQ0MjQyODU0NWMxNWJjNDg2ZmRlMi90YWJsZXJhbmdlOjU4Y2E3MmU1ZDMxNDQyNDI4NTQ1YzE1YmM0ODZmZGUyXzctMS0xLTEtMA_4711fffc-385c-4c26-bd83-e2fc0012254f">0.0083</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i99276d8c006448148b510e8ed81523da_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1OGNhNzJlNWQzMTQ0MjQyODU0NWMxNWJjNDg2ZmRlMi90YWJsZXJhbmdlOjU4Y2E3MmU1ZDMxNDQyNDI4NTQ1YzE1YmM0ODZmZGUyXzctMi0xLTEtMA_ae7f0eb4-66bd-498e-b29c-0a722e3812ba">0.0082</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i803d3fabb4d84a7fa36d5b64f9f5b98d_D20170101-20171231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1OGNhNzJlNWQzMTQ0MjQyODU0NWMxNWJjNDg2ZmRlMi90YWJsZXJhbmdlOjU4Y2E3MmU1ZDMxNDQyNDI4NTQ1YzE1YmM0ODZmZGUyXzctMy0xLTEtMA_4a3f5ad3-e22a-4316-9596-84650a8c5943">0.0076</ix:nonFraction><ix:nonNumeric contextRef="i3107101abd5c446e81202399471630f8_D20200201-20200228" name="sgmo:CollaborativeArrangementStandstillRestrictionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV83Njk2NTgxNDE2MDUx_0d84836a-c95f-4eb8-a58e-c4a119cbf42f">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i3107101abd5c446e81202399471630f8_D20200201-20200228" name="sgmo:CollaborativeArrangementVotingProvisionsExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV83Njk2NTgxNDE2MTM1_d2c3c96b-72c7-45db-9430-d8a812b9fc92">P2Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="sgmo-20191231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i55958765beef474786d9beecda94838d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i91529fcfc109499ebb3512672c167060_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ia8c647fb84f84583814d2cba60abe33f_I20200221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-02-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafee69bb5c304299817c47783c041381_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0627710456a349f7b90cec0a3f5536e8_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a9e59eb89204d6cb59dbc5b2e145c09_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5063163868264343bb3c8784a605dabf_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id50e642517aa459b9ada4af0f93e6b20_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifeb2f797e05149138caa5e72c8aa0d2b_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9057cb83ba040218834cc92910f7361_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ce63a9e5f5542dc8d3b24259ad1ee2e_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc70b211d0654544a6f9c1e9fc810641_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49b4da657a834857bc1d02cc6ef16e7b_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0406f7152c82421aa6b02c6472444482_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fc1ca72aa1645a4b00f8fd2b31d8956_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia218df6fa91f4c1fb7c308b884f2552a_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81d1b464269e4be59411d5313217455a_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5393cf4702d478487f5812f2284bb7d_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13411b9a2fac4f62b4a1b5d13e1a6d13_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb7e952fbd38434585f995fe73c66a44_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6ef95d8de3d4a7d89e36708e8ad41fa_I20180101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ac2058780dd4487b64d9cea81253e0a_I20180101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc92201ce4bc4d35aac109e19e0e5a1f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ad82eaa45484fad83417fd0c193af43_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifaf1fb068f504cafbf0b5ee6c15f15a7_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa3c4c19d5b248f48eeab6d3449c0692_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5616295424184a8eb8bbc9e26f43ed70_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b94d20f29c94303b0b5f428bcfaa12b_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9161aaed0bc4db88c75c765dcacf1d8_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifce327bcf3b8435a8b434c043c9be74b_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i782ffb68f66c4a7b9ab9b5592f7c00fc_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic99ff13e6b8d4ef18b9878c555ae3844_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f940ceeab344a3f93e9875fa4c27245_I20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbd33d4a7d834496bd26b17d12cc0d71_I20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10b0f55eb1164865bbf902ed106c9883_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if320296fd6c04201a11aab2ec6e01e0d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i700728c6360146ffb84d3df9926f1c1b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6afa72951bb45c09b9a911552d7f480_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id40d07a651074bf1bafbd2a12252b23a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife70daa8790b4a53b4ff57301234df5f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35c1aa897a6e445787fa8eaaa2d7f0f3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30d904a948194419aebb5c1fd3919342_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96b90ecaf62c4fada95bd7bb490b3aca_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc3f21983c41481ba4b01cd8667c5b3d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id41b3e1cb35b4ad89ad6d22858d66005_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:PropertyAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfc6db4e7428415f9b757be31f7ba5f9_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:PropertyAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i551b7506aa0a43339495e3e41d87f7ab_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:PropertyAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib59d1ac11e5d43868c898a5a5456c02a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:BuildToSuitLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49968469b9074ef393d1c026828923c4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:BuildToSuitLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00b9b5a15df54eed86abd682441fe4d1_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:BuildToSuitLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45cd48c8f1eb454abb081e66040be393_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">sgmo:ChangeInCollaborationAgreementScopeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="if75e5c9704ce446986262d7c7d8c3fab_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e56cd6c5fb74bd3a43294ab0e9b6330_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1d7fbe1eb014de78444bda067a30d18_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifeac1a9c1b7f4146b761b39496879f94_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf0e324d5bd3407ea444f76424db9da6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0028bf4ff4f2447683894820f58ee41f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09768b80227d4cb4a5a55bae2bc04a19_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9d921a5d8f94da6821ac519170255b3_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c83aa6622144db1929cedd8491d3519_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i213fcfde123a4b9abd25cc2767af7914_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>sgmo:segment</xbrli:measure></xbrli:unit><xbrli:context id="ie5649d96e1864877aaa84d3a06395606_I20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb9ede9189214fb0ba40172a1dbc591a_I20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f20aa798c164804836d3c58f6e64322_I20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbc9e04f074c44ffa8daa55bc133f128_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sgmo:LeaseArrangementsAxis">sgmo:BuildToSuitLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf1327e2b600430586f7a8218d35f3f2_I20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sgmo:LeaseArrangementsAxis">sgmo:BuildToSuitLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5dfe7b638ae41cda6e177ad875be7b5_I20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sgmo:LeaseArrangementsAxis">sgmo:BuildToSuitLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i425b175434d04e418b20de221af1fd33_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if327c6ba5afb4ee28f9cca2b391023fe_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13e727b552f840888ab401cd0d611095_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1916c386d59845db85c0f6b195b6c309_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fedc4e1ca23438283a2d2c6f237fe8b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifedb75e8c33345abb30ce39ac8828048_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a555374195740708b7b535422475c40_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fe30ec7f787449981feb883fd8e7408_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6a8c12c301e487cab97f3ac6cb97945_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d0f5ceb90cd496f91d1edf2102c57d2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dd1f80319a84afbb69e15090417a474_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe28cfabe6384c78b965211fe2b259d6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70b955824d6240a6badd8bb4bbb12d0b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98bf1a1fb6c946f99d2a94a5222f559e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84e857a6b4d64be5bce0f89cc006035f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic69943e18c9d4e908720f488efa6db9c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23ea33c72d45452c8dca1b18861249d0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i878065655eff40a59fa226fbcc58557f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i357038a3295843f7b8bb19efe35d46b1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia948e7072e51466fa0d1a823a8cda9e4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55aa029ca6dd458a8a361b0d9ce3fc27_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4ed7f86404f4a6ba7c31faa2f653426_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7fd88b4bbe14d53a36b2a34dcf1fcbf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42972542d5a643f4ad2306c25b585428_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9501ce5f7d6e456bb6d923b2208d2e71_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d2d295786cf43beaed8e20c63959a56_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94d4458c66c647e9ae4004aea884aea7_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia12bf2d0855544e080b1e3c549ce02c2_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad708dc4322e4296b7279fb10923aa64_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fac6e5a93cf4932b299c93b29103ee4_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id07ed358181b47e991569dc03d1eca59_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8487d3169fa14869a2959a37cb1a1924_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i874bf2bbf8044c5ea86c5b6dec868699_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ac8366f1cf74cbda4eae920c042daef_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i329183fcaae04a14b76d777f4591b0cb_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf402857bd034d28ad83a9627a535af3_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i604e1c483a2144499182a3abf3334884_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27b1fd12142f4694b5053b6268cd9c5a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44eb81c1bb054e35a82f0ad07d8dd13a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52f56fd373e54acdbc14ae1ad4e8621d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i149c7986f92344c09f4c6801f030875f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if20ea12b7bd2424fa4f0d5ddc716792c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5913e464612f4a46aa67a602001a2466_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07c312494713484fb523d49996228eaa_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64c1c287bd47404da4ea630212dedc2e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51862de68d334a6d90ced8ff154add77_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9017742317a7426b8f1655ea852cf27f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if73c9eef08404834bb4f125b2f8334e8_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4b36a1c4d88462a8ee8d85f748c7b16_I20180720"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b97713bc2a74145a84bf16db6e1a142_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifba2b3f6b5f24819b803f8b4290efdef_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2821462afaec43989ae5bb5640358bdb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8637425832d24b439a5841eb6340fe09_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cd83c646e0741f2a6f9af0abef8b909_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eurPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="id158af407d9041baa888cbe9abf2ea9d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e015bf5f3134e418d8cb590b4182340_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ba502e8004f4a51b63eb68808f9ad0c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sgmo:MeasurementInputStockPriceCorrelationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa539cfd54e24b8e8f9bad28ca1ca2e2_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sgmo:MeasurementInputStockPriceCorrelationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33f3835a3a9548d0bb177195bca1c91d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0c0f4a598494b73a9f02d3c32a0337a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i624ddabb3ed14489852a400d3c8823e6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84d9625ccd9e40dcb299cd5ff4f2f7be_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3b6cba6a07b430f9c7d6308a92564cb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3aa31b7f47894ac591b3f5464dc1b173_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdc951c6c13c4c8bb47767567ef80768_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87ef30d5e5634d03ba044c381280c504_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8727918bfc77478d894641bf1ba39f2b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2134d5ba27be42e394846ea5e6f9bbaa_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75f08675fb7643a590d56bf4bcb13e36_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieeb73dab1cf94f2584bc9b78fb4369c1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30cc7310d6c14807bc817509966f5218_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0b60e45bbb54cb5814c2623600b05a7_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea5cd444cca1404bad4fad46fe35b1b5_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c5421c8d9b34ac193b12f580b0e45fe_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6b4614c3ed0431ab9570835b20a0800_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f19f6eef7f447ee90aa653000871c5d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie60f0866d78349d39fcb444b085ce632_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61fd7d98b04648caaf9d32dec4a807ec_D20180404-20180405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-04</xbrli:startDate><xbrli:endDate>2018-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a2cd91a4f284017a4ef2d70e422e99c_D20180404-20180405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-04</xbrli:startDate><xbrli:endDate>2018-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48416dd30d974b1aad80f204b2aabe20_D20180404-20180405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-04</xbrli:startDate><xbrli:endDate>2018-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7d82acff2b8474488fc135b1be65d92_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="option"><xbrli:measure>sgmo:option</xbrli:measure></xbrli:unit><xbrli:context id="i6fff5fa4d22f420dbc13bcf64a19b587_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c5a81250c2e4e6992c7624e2f50a5b0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i654a0f9976964892b5f266a6a5e30461_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5e9da2152d548ad9e46e4ebe09d9cc7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i592dd2531c234441a8b4b503c5e33bdf_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88cf0e3541a3458eae231fe54f01b5e1_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55753e9172b14060be72e0417c8e4ee5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60584ff2a34d45fb9afa66b5a623a4b2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied53c137399045e198eb8eede660e8f2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib08e3f2b116d4fe8846432aa9f1fb42f_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a64f9da293b4fb5998f17bc3ebc159f_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0eb4d4a7fdf7414bbcd0bcbb337d0b56_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9107973e10124be1aa15439229671e5f_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfFirstCommercialSaleMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45470bac3a3d46c59bc142131a59b782_I20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfcf378e55cd4dc89b34b84d7fc85aa2_I20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:OtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if20dd4173a934bb9bfd3c1d39c91de1b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:AmendedCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>sgmo:product</xbrli:measure></xbrli:unit><xbrli:context id="idc78178116cc4805a2503e4d1f1172dd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="milestone"><xbrli:measure>sgmo:milestone</xbrli:measure></xbrli:unit><xbrli:context id="i9b68588d42cd47f383c50071fab098fa_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bbeb9bd0c5c4a2da841e90386104e1a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e978c226de34436b68f163f5e4d3354_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i842d5727afc443408e09ed5a522e2a9e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:AmendedCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ea749f7283a4e3fbab4d679c510b03b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9de85d493b645f38a1e2fc527b2126e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee1c5c93e9564920af22cdeb55d9889b_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8eb9a2216c044b17b0ac853396d42bed_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f1ee4fd337946f69c2e711004e9eb21_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c6f765722544bbfaa11a0f9c28106ee_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76d9c47628c147369b1a84918e870f8d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5b7be714d56483bab2fd4aec159f370_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a295f36997b4eaf8c2fed03755d5526_I20180101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i252ea1e80afe41d99972b07af7af8a3c_I20180101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9888cd53fcb4fb4984e5cdbd778c03e_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbb6596bfa944145ba083c1d73a1a730_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b20df771908439ba01919ecb4994be8_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5bbca9d2dbf4f0e989cbeebb1a8e942_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i784a445513064edf8cf105a58b0207fe_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfCommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i669f42753a6d4d3b8f142135705a640e_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i954ad6bfa1174ad180a78ff9de20535e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79f178df8ea344e18c904ab658ab8f74_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c762905a0724124a285c0f906b72d49_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e9a9a3d68204a2f8ed5bcfe24fa0f3e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c7f53a3724d4a1ea2ce16319a2ee764_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46960a0dc45d40db8392d2fe6db2d9e9_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="program"><xbrli:measure>sgmo:program</xbrli:measure></xbrli:unit><xbrli:context id="i1c5f6e7f39144671adf58c072211193c_D20140101-20140131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide4c76d2770741e89547b697a3e8b894_D20140101-20140131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcd9eaedbbb14396a42bb76c734bf9f5_D20140101-20140131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedSalesMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb1c764229f147c2a7d82f2bb4a2592a_D20140101-20140131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b38594263d44b798c13984fcfd972f8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2073bd7907645caa45aa97ed6850de4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i468bde9877fb45c2847c91221ba681bc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c872fa7b5024839a68c8f629085727c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id798c385c8724e4b930793259339b22a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ca1d25b473647beac3e5c4cee84dd0f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93e6aa3bc6514e649306cb264521204b_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92f62c13c94a433aa1ad8a4a8220be8f_I20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id06c1dce0e884cdcba296deaf34a622e_D20190801-20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39eb352d7a3a4602a414826990f703bc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c9ff652355349cab75acdd86216b11a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1836a0ed76fa4e068cc55bae1f1659ca_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bdd6ca51cf249bc84de380a836fb539_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibab98dee0c264ff0a13f3976dfdd1ed3_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c1fc611498b4ec7ab651f582d24bb0b_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab2ce2c2494147e0a8a6070d64cfe4c8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c8c31caf97141fd95d9194c142029af_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icca18901cecd47eb8ace5d534e3446cc_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bf7f5b8498c4b08a82bb59829d36e28_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7420753e3bf04bfea9bc58e19fe42eea_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i975e5690b7e44643ac9b6ff7c837d1d5_I20180101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfdae914eb9f4568924b2c36819385c0_I20180101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80b254e375704b6cbd33bf07e5d5a03d_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b157638f47c4c3b8ec4455978598450_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37cb993a72c14f14a87486e3f9d110bb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide489651fbb64d8cb62d9ee459e221fc_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia988894eec924d3699114435116dcbb8_D20120101-20120131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-01-01</xbrli:startDate><xbrli:endDate>2012-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i603d866010f94461ba687f9d9fc9fe07_D20140101-20141231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0396d61761914d09b41700c5324f9ab2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ea0635e2f754a1a98f8b6ff31ee597e_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i225c2ca24fb245b1aef427d88cab0b42_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if423ade1135f4a90ba7c01bd4622b719_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60cee58107b34ab3abb80c1536bbbb25_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie07937e9122d4e52ae687f94e550ec89_D20070101-20071231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2007-01-01</xbrli:startDate><xbrli:endDate>2007-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7e8b05b2b84429ea591ae9027f2f01c_I20091031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2009-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19ed0c7322dc4072986f0f09203dc043_D20091001-20091031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-10-01</xbrli:startDate><xbrli:endDate>2009-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d0454da729b48fc9e22bda7f76d2ad5_I20091031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2009-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i278e40ede357423c89bdc1aee03bef48_D20091001-20091031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-10-01</xbrli:startDate><xbrli:endDate>2009-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12a07f5e2768459da813de50c58f1b60_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e4cd48445e44370bba7e39d5af5ce52_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3087b4ee5afa4f2dabb514f4cf15f16c_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0b4d17d3d8d4ebc977872aa77c541e2_D20050101-20051231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2005-01-01</xbrli:startDate><xbrli:endDate>2005-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1d7e675aff548549bda7f384c0b71fe_I20051231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2005-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d6e0b311090479699df435b03b0f9b4_D20050101-20051231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2005-01-01</xbrli:startDate><xbrli:endDate>2005-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b2070f38ef740d580ee67b0026687db_D20050101-20051231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2005-01-01</xbrli:startDate><xbrli:endDate>2005-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i700b128806b74604a574c5a9d52798f4_D20050101-20051231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2005-01-01</xbrli:startDate><xbrli:endDate>2005-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b28cb60703942d78f84fa70547f2d7a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35e0ebbeae2040128ef7a7deb5f4d32f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c13afb7fbda4eb8bf0c38bac4d2c1ff_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38f5aec47ea84bc295354a823c8a5831_D20181001-20181001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a6b4067c84e43e1bdc883068436bfa7_D20181001-20181123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-11-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86361484bbe7475eadd2f54f1495c9bc_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5253724c8c7745708c6743fc72b1bd23_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie44e76842d7f4cde88a0228bac132b9e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib79220f5f92f424dbf1bd1416f1d62af_I20181001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68a40c6357a5417c8e40fc23122e7423_D20181001-20181001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8a9cbb45d2746dcb48a28a379d261b4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0638fbc591ba4ce589a9cfe88a114e95_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe70b54fab8e46b4bea40c2b35ede19a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac226c28c7fb4c64920cad2ca7e259a1_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3c60a720f6b4df19f3f92b51be623e5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac6944dea140420e82c37c6b728de97a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4483a2719984476afd6ceb188081fda_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2471a22261164bf78fea22576f465fb3_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf9dff888e724c4fbe02ba474671d5fe_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5620868d7a3f4744aeeaa72cb2948e05_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="iaf513274ee0c43639e9c1500db2d7963_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:BrisbaneCaliforniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:OfficeAndLaboratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61974f1d85ab49f78df77bf7c87828b4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:RichmondCaliforniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:OfficeAndLaboratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i545fe0f072c9408797e00f296a4a44dd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:ValbonneFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:ResearchAndOfficeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if46ca43d45c948e98319922d7565a9f7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83dc1a1104c8410f962b75bd5a2646f0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebf52cf79a6041878e2eb875ad9b53ba_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:BrisbaneCaliforniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:OfficeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38763d7e12814008b53fbac4a892782d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:BrisbaneCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37d7eb43c08a471b816747e6c8de433d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">sgmo:ManufacturingCapacityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e239f59de424eaeb896378613c4c2fc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">sgmo:ManufacturingCapacityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30aa48009d514a9694cf66cf00207e2e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">sgmo:ManufacturingObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22655d04f591458ebb9c3737889fcaa1_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">sgmo:ManufacturingObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fba1b8b532b45cc848f39f189b1366e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">sgmo:NonCancelableContractualCommitmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c3d46edbdfc47afb7a1080ab7235f2a_I20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">sgmo:NonCancelableContractualCommitmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb4b35fddcc442cb8c1b62aa13aad983_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4f08396a6674db59b83934997d376ca_I20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17fa15d6fbd948fcbb752fa955283c6b_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib60221bf695b4b5c95ff088c3caaf236_I20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if150961a5ee14928826e68c655e5d53f_D20170601-20170630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-06-01</xbrli:startDate><xbrli:endDate>2017-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70ff8798b92448c0b579928fa54468cd_I20170630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37807fd639dc45328330120e8b98348c_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0f7d9825feb4e208361c4ad02284de8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86e7f798089c4c66a4e5b968d764d534_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c7aa74b5db84179b2918daa34c73c69_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38ea9f2d9931428fba1f41e0b36e7bea_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57406eb823ae4dcba23a5c69e7941851_D20180601-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i413bd4488b904c0eb127a3a7f3af5412_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91e4fec1d21b4176925e0d7555154914_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7afd1bb162e74f8188a0eebdfa207e9c_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="installment"><xbrli:measure>sgmo:installment</xbrli:measure></xbrli:unit><xbrli:context id="i6a1a6094e01242c48030234e32514b5b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:TwoThousandThirteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2079b275b8624be6a51a9674c1a69829_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c22448f844d48b8a90cd6b5030ab3b6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia89fc661975a4524b5aefcb074dba5af_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic900024014ad40cb84ea43fd53db5e7d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5101aded6334b1c9c3a881011b6abae_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i277c3b7360f04d3780bef6a633da1c71_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4360f72084d45c580dd59abd6150a88_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib25eb7ae48804546b9f361611f4966bb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f39fb4590c1429f8543e94bc2f27f17_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9d63f212ff549b3a6d95bbdc6243555_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11cbad67c18a49ca910e920c1e2d9646_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i280d0aff0b424211b1e87b1cc76e27a7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0b92851791b4e9e8a15edb926cc2b4e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6568a8c2edac4a3c89060b40650283bd_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf6eda356cbb4886a9bc71ebb4c979a6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12f6a30ee0794a7a8c75e504690f5c2c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7ba96e253094ecbb1f17619de72a1e5_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic84a9796c7a541749fdbca1dc1d961a0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4875c47b73b649d89f3d228c46b40d73_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i545150c912bd475bb5cc4cfafe39b8c4_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a0099de9f314f5a919f8b231d4109ab_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c838e5e7b0b46cab8713879fa0ce0e9_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd62021ceb204760b751e409e802a4b3_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i822b57314be44262a52169433cb095e6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52b452cf7faf4507b5d8744d6e2ccbe1_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f722ff8a1bb4847896b093c5949157c_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ccdd9ccdd8248799ab22a4b8eb8f471_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99276d8c006448148b510e8ed81523da_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i803d3fabb4d84a7fa36d5b64f9f5b98d_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic95b30c3bdb047e09c97a070b92d9bd5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:MinistryOfTheEconomyFinanceAndIndustryFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52834b9e08624c8bacef183387dd51ed_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:FormerExecutiveOfSangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7904976381aa418691f37a32d64b07c0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:FormerExecutiveOfSangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i650fabb9fd3342b194a201cbf6d40308_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d3836ab6ab8497ea22f279a0bfeb107_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2195a0eb53f457697e901d30824c2b3_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecf9c60eda6d47d4a66bc7797840c1d5_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad063cfae7ac486cb8c7a7931ccbc02e_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2cf250af72b4f33993772a39178733a_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibac9f542f2ce4f519e06c7aabb195095_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbad735aad064fe6bda84e11e1e8baab_D20181001-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="product_target"><xbrli:measure>sgmo:product_target</xbrli:measure></xbrli:unit><xbrli:context id="i815aed8f3ed04efa8895ee3a5a249f46_D20200201-20200228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2fcb8b96ce04f23aa5b97d6cacdf777_I20200228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68abcab0cf41405fae245c20e792bbf2_D20200201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c5278bbcb4141f78ac8881b4edfac94_I20200228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1640dffb6cb34c52994dcc5099a67ffd_I20200228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:PreApprovalMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21a4261ff2844d9d957100ee0d0f8fa3_I20200228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:SalesBasedMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i908ad6d97bab414e84166e66b25274be_D20200201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2be6d9a350e04b98992adc724912b287_I20200228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3107101abd5c446e81202399471630f8_D20200201-20200228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dbb06595ef34d1581373015fa20fc10_I20200228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7c1080eb5384ad88c89d65e002242e1_I20200228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-28</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_1"></div><div style="height:6.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-top:4pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:115%;">UNITED STATES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:115%;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Washington,&#160;D.C. 20549</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:115%;">_______________________________________________________________________________________________</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:115%;">Form&#160;<ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGV4dHJlZ2lvbjoyYzI4NzJiODEwMDQ0ZTA5Yjc5NTllZDcyODVkYzVlZF83Njk2NTgxMzk5MTEw_97be82aa-e712-48ea-902c-dfb75bc68458">10-K</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:115%;">_______________________________________________________________________________________________</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:0.1%;"></td><td style="width:2.577%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:95.223%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGFibGU6OWJkZWUzMmEzYTdlNGVjYzk3ZjY1OWYwOTM0NTE3YTMvdGFibGVyYW5nZTo5YmRlZTMyYTNhN2U0ZWNjOTdmNjU5ZjA5MzQ1MTdhM18wLTAtMS0xLTgxMzg_8fe33855-6ded-44c4-9f71-2c7715f28d74">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%;">For the fiscal year ended <ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGV4dHJlZ2lvbjoyYzI4NzJiODEwMDQ0ZTA5Yjc5NTllZDcyODVkYzVlZF83Njk2NTgxMzk5MTc5_894f12a1-544f-426c-9a7b-b619cbaee07e">December&#160;31, 2019</ix:nonNumeric> </span></div><div style="text-align:center;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%;">or</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:0.1%;"></td><td style="width:2.577%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:95.223%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGFibGU6OGY3YmNlYmM1NTg2NGYzYTk4ZGFjZjc3MTRhZjY3OGIvdGFibGVyYW5nZTo4ZjdiY2ViYzU1ODY0ZjNhOThkYWNmNzcxNGFmNjc4Yl8wLTAtMS0xLTgxNDA_e2a26bda-66ea-4422-b696-b074d0d05d50">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%;">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%;">Commission file number: <ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGV4dHJlZ2lvbjoyYzI4NzJiODEwMDQ0ZTA5Yjc5NTllZDcyODVkYzVlZF83Njk2NTgxMzk5MTE3_bcbb6d59-ccfd-4e85-b763-d058a3f8d978">000-30171</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:115%;">_______________________________________________________________________________________________</span></div><div style="text-align:center;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:115%;"><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGV4dHJlZ2lvbjoyYzI4NzJiODEwMDQ0ZTA5Yjc5NTllZDcyODVkYzVlZF83Njk2NTgxMzk5MTI4_2037a7b5-ca12-4f06-ae6e-609db679797c">SANGAMO THERAPEUTICS, INC.</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%;">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:115%;">_______________________________________________________________________________________________</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:36.011%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.549%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:19.052%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.139%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:25.049%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGFibGU6NTIyOWIxOWY1ODNlNGU5MzhjOWYwOTgxYTEyZTQxMTEvdGFibGVyYW5nZTo1MjI5YjE5ZjU4M2U0ZTkzOGM5ZjA5ODFhMTJlNDExMV8wLTAtMS0xLTgxNTI_ff7fe91d-6030-4822-a053-5f35dfab9efc">Delaware</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGFibGU6NTIyOWIxOWY1ODNlNGU5MzhjOWYwOTgxYTEyZTQxMTEvdGFibGVyYW5nZTo1MjI5YjE5ZjU4M2U0ZTkzOGM5ZjA5ODFhMTJlNDExMV8wLTQtMS0xLTgxNTQ_eb7eea35-369f-4c59-a428-cb686d067ea1">68-0359556</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGFibGU6NTIyOWIxOWY1ODNlNGU5MzhjOWYwOTgxYTEyZTQxMTEvdGFibGVyYW5nZTo1MjI5YjE5ZjU4M2U0ZTkzOGM5ZjA5ODFhMTJlNDExMV8zLTAtMS0xLTgxNTY_266e1553-319a-4e5d-82a0-10c81270c855">7000 Marina Blvd.</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGFibGU6NTIyOWIxOWY1ODNlNGU5MzhjOWYwOTgxYTEyZTQxMTEvdGFibGVyYW5nZTo1MjI5YjE5ZjU4M2U0ZTkzOGM5ZjA5ODFhMTJlNDExMV80LTAtMS0xLTE0OTA4L3RleHRyZWdpb246YmRhNzFkNGNmYmRiNDE5ZTg1Yzc4YTNmNGY4ZmU3MDlfNzY5NjU4MTM5NDQ2NA_fcb68523-663f-4725-8db2-d0f36ead84d3">Brisbane</ix:nonNumeric>, <ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGFibGU6NTIyOWIxOWY1ODNlNGU5MzhjOWYwOTgxYTEyZTQxMTEvdGFibGVyYW5nZTo1MjI5YjE5ZjU4M2U0ZTkzOGM5ZjA5ODFhMTJlNDExMV80LTAtMS0xLTE0OTA4L3RleHRyZWdpb246YmRhNzFkNGNmYmRiNDE5ZTg1Yzc4YTNmNGY4ZmU3MDlfNzY5NjU4MTM5NDQ3Ng_2c19dd99-9798-4134-9331-f707b0dfcc01">California</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGFibGU6NTIyOWIxOWY1ODNlNGU5MzhjOWYwOTgxYTEyZTQxMTEvdGFibGVyYW5nZTo1MjI5YjE5ZjU4M2U0ZTkzOGM5ZjA5ODFhMTJlNDExMV80LTQtMS0xLTE0OTM2_7f60a280-c15b-4b08-89cc-a41bc129a3b7">94005</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Address of principal executive offices)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Zip Code)</span></td></tr></table></div><div style="text-align:center;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%;">(<ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGV4dHJlZ2lvbjoyYzI4NzJiODEwMDQ0ZTA5Yjc5NTllZDcyODVkYzVlZF83Njk2NTgxMzk5MTU2_ba06d585-c157-4b9f-9874-a89cafed304d">510</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGV4dHJlZ2lvbjoyYzI4NzJiODEwMDQ0ZTA5Yjc5NTllZDcyODVkYzVlZF83Njk2NTgxMzk5MTYx_3e09fcfb-bff2-42ae-bb2a-3e1ebe5e1a19">970-6000</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%;">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-indent:18pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:36.067%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:21.865%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:36.068%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Title of each class</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Trading Symbol(s)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGFibGU6YTE4YjcyMGE3YThiNGVmOThiYzNmMzAwNWExNDM2MjIvdGFibGVyYW5nZTphMThiNzIwYTdhOGI0ZWY5OGJjM2YzMDA1YTE0MzYyMl8xLTAtMS0xLTgxNzc_bf8abc58-bb3b-49d6-b5c5-cffd75bfa15d">Common Stock, par value  $0.01&#160;per share</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGFibGU6YTE4YjcyMGE3YThiNGVmOThiYzNmMzAwNWExNDM2MjIvdGFibGVyYW5nZTphMThiNzIwYTdhOGI0ZWY5OGJjM2YzMDA1YTE0MzYyMl8xLTEtMS0xLTgxNzc_eb156579-49ab-44aa-bf12-caa74070755a">SGMO</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGFibGU6YTE4YjcyMGE3YThiNGVmOThiYzNmMzAwNWExNDM2MjIvdGFibGVyYW5nZTphMThiNzIwYTdhOGI0ZWY5OGJjM2YzMDA1YTE0MzYyMl8xLTItMS0xLTgxNzc_93212ca9-0d59-4120-a566-e93a76407d13">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%;">Securities registered pursuant to Section&#160;12(g) of the Act: None</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:115%;">_______________________________________________________________________________________________</span></div><div style="text-indent:18pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. &#160;&#160;<ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGV4dHJlZ2lvbjoyYzI4NzJiODEwMDQ0ZTA5Yjc5NTllZDcyODVkYzVlZF83Njk2NTgxMzk5MTcw_6a0c0535-cf89-4cb5-b381-03aec2e38a8f">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="text-indent:18pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Exchange Act. &#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGV4dHJlZ2lvbjoyYzI4NzJiODEwMDQ0ZTA5Yjc5NTllZDcyODVkYzVlZF83Njk2NTgxMzk5MTcx_cdaee1f2-21d5-40cc-b28f-4f5f11d4cf52">No</ix:nonNumeric>&#160;&#160;&#9746;</span></div><div style="text-indent:18pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#160;&#160;<ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGV4dHJlZ2lvbjoyYzI4NzJiODEwMDQ0ZTA5Yjc5NTllZDcyODVkYzVlZF83Njk2NTgxMzk5MTcy_09063e7a-eadf-454c-a23a-736acdf2c5c6">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="text-indent:18pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). &#160;&#160;<ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGV4dHJlZ2lvbjoyYzI4NzJiODEwMDQ0ZTA5Yjc5NTllZDcyODVkYzVlZF83Njk2NTgxMzk5MTcz_0d458b7a-cbcd-4ce6-bfb8-7fed85730e1f">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="text-indent:18pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:17.941%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:25.126%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:3.865%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.941%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:25.127%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGFibGU6MThmYWU4NjYyY2FlNGQzMTlhNTMxNDRiYTAyYzIyNDQvdGFibGVyYW5nZToxOGZhZTg2NjJjYWU0ZDMxOWE1MzE0NGJhMDJjMjI0NF8wLTAtMS0xLTgxOTE_18859e08-bf4f-408f-80cb-9999419c9861">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9746;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accelerated filer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-accelerated&#160;filer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGFibGU6MThmYWU4NjYyY2FlNGQzMTlhNTMxNDRiYTAyYzIyNDQvdGFibGVyYW5nZToxOGZhZTg2NjJjYWU0ZDMxOWE1MzE0NGJhMDJjMjI0NF8xLTQtMS0xLTgxOTM_90a03f86-b7ee-42b3-b641-8d65ef1c7ab4">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Emerging growth company</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGFibGU6MThmYWU4NjYyY2FlNGQzMTlhNTMxNDRiYTAyYzIyNDQvdGFibGVyYW5nZToxOGZhZTg2NjJjYWU0ZDMxOWE1MzE0NGJhMDJjMjI0NF8yLTQtMS0xLTgxOTU_35663eca-4473-413e-be66-6ada400acb3f">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:18pt;text-align:justify;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#9744;</span></div><div style="text-indent:18pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). &#160;&#160;Yes&#160;&#160;<ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGV4dHJlZ2lvbjoyYzI4NzJiODEwMDQ0ZTA5Yjc5NTllZDcyODVkYzVlZF83Njk2NTgxMzk5MTc0_5c633d71-acd6-44b8-a495-f1e40e89fd22">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;No&#160;&#160;&#9746;</span></div><div style="text-indent:18pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;">The aggregate market value of the voting stock held by non-affiliates of the registrant based upon the closing sale price of the common stock on June&#160;30, 2019 (the last business day of the registrant&#8217;s most recently completed second fiscal quarter), as reported on the Nasdaq Global Select Market was $<ix:nonFraction unitRef="usd" contextRef="i91529fcfc109499ebb3512672c167060_I20190630" decimals="0" format="ixt:numdotdecimal" name="dei:EntityPublicFloat" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGV4dHJlZ2lvbjoyYzI4NzJiODEwMDQ0ZTA5Yjc5NTllZDcyODVkYzVlZF83Njk2NTgxMzk5MTc1_897a2ca4-5bb5-46b3-a6dc-61c737bfbe76">1,244,723,752</ix:nonFraction>. For purposes of this calculation, directors and executive officers of the registrant have been deemed affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes.</span></div><div style="text-indent:18pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;">As of February&#160;21, 2020, a total of <ix:nonFraction unitRef="shares" contextRef="ia8c647fb84f84583814d2cba60abe33f_I20200221" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGV4dHJlZ2lvbjoyYzI4NzJiODEwMDQ0ZTA5Yjc5NTllZDcyODVkYzVlZF84Nzk2MDkzMDI3Mzgw_06d2b42c-fc19-4ff4-8d77-5192e79c07e2">116,022,630</ix:nonFraction> shares of common stock $0.01 par value per share were outstanding.</span></div><div style="text-align:center;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%;">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="text-indent:18pt;margin-top:4pt;"><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGV4dHJlZ2lvbjoyYzI4NzJiODEwMDQ0ZTA5Yjc5NTllZDcyODVkYzVlZF83Njk2NTgxMzk5NTg4_0cada863-60a8-4ace-8b60-63e0ee956207" escape="true"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;">Certain information required by Part III, Items 10-14 of this Form 10-K is incorporated by reference to the registrant&#8217;s definitive Proxy Statement for the 2020 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Form 10-K, provided that if such Proxy Statement is not filed within such period, such information will be included in an amendment to this Form 10-K to be filed within such 120-day period</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%;">.</span></ix:nonNumeric></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_7"></div><div style="position:relative;width:100%;height:6.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">TABLE OF CONTENTS</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:8.672%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:80.894%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:4.434%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Page</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_13">PART&#160;I</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_16">Item&#160;1.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_16">Business</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_16">4</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_19">Item&#160;1A.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_19">Risk Factors</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_19">29</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_22">Item&#160;1B.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_22">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_22">54</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_25">Item&#160;2.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_25">Properties</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_25">54</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_28">Item&#160;3.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_28">Legal Proceedings</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_28">54</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_31">Item&#160;4.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_31">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_31">54</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_34">PART&#160;II</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_37">Item&#160;5.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_37">Market for the Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_37">55</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_40">Item&#160;6.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_40">Selected Financial Data</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_40">56</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_43">Item&#160;7.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_43">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_43">56</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_61">Item&#160;7A.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_61">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_61">63</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_64">Item&#160;8.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_64">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_64">65</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_163">Item&#160;9.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_163">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_163">101</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_166">Item&#160;9A.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_166">Controls and Procedures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_166">101</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_169">Item&#160;9B.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_169">Other Information</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_169">104</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_172">PART&#160;III</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_175">Item&#160;10.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_175">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_175">105</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_178">Item&#160;11.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_178">Executive Compensation</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_178">105</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_181">Item&#160;12.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_181">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_181">106</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_184">Item&#160;13.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_184">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_184">106</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_187">Item&#160;14.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_187">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_187">106</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_190">PART&#160;IV</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_193">Item&#160;15.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_193">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_193">107</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_196">Item 16.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_196">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_196">110</a></span></div></td></tr></table></div><div><span><br/></span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_10"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SPECIAL NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Some statements contained in this report are &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. These statements relate to our future events, including our anticipated operations, research, development and commercialization activities, clinical trials, operating results and financial condition. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Forward-looking statements may include, but are not limited to, statements about:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our strategy;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">anticipated product candidate development and potential commercialization of any resulting products;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the initiation, scope, rate of progress, enrollment, anticipated results and timing of our preclinical studies and clinical trials and those of our collaborators or strategic partners;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the therapeutic and commercial potential of, and the ability of Sangamo and our collaborators or strategic partners to advance the development of, product candidates using our zinc finger protein, or ZFP, technology platform, including our ability to effectively deliver our zinc finger nucleases, or ZFNs, and ZFP transcription factors, or ZFP-TFs, to produce a clinical benefit;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt;">the benefits of the acquisition of Sangamo Therapeutics France S.A.S., or Sangamo France (formerly known as TxCell S.A.);</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">our ability to establish and maintain collaborative, licensing and other similar arrangements, including whether or not the collaboration and licensing agreement and stock purchase agreement with Biogen MA, Inc. and Biogen International GmbH, collectively Biogen, become effective;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">anticipated revenues from existing and new collaborations and the timing thereof;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our research and development and other expenses;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to obtain adequate preclinical and clinical supplies of our product candidates from current and potential new suppliers and manufacturers;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the ability of Sangamo and our collaborators or strategic partners to obtain and maintain regulatory approvals for product candidates using our ZFP technology platform;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to comply with, and the impact of, regulatory requirements, obligations and restrictions on our business;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others, including our ability to obtain rights to the gene transfer technologies required to develop and commercialize our product candidates;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our estimates regarding the sufficiency of our cash resources and our expenses, capital requirements and need for additional financing, and our ability to obtain additional financing;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to manage the growth of our business;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our projected operating and financial performance;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our operational and legal risks;&#160;and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our plans, objectives, expectations and intentions and any other statements that are not historical facts.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In some cases, you can identify forward-looking statements by terms such as: &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;continues,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;seeks,&#8221; &#8220;should,&#8221; &#8220;will&#8221; and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events, are based on assumptions and are subject to risks and uncertainties. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. We discuss many of these risks in greater detail under the headings &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in this Form 10-K. Except as required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this Annual Report on Form 10-K.</span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_13"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART&#160;I</span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_16"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160;1 &#8211; BUSINESS </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OVERVIEW</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a clinical stage biotechnology company focused on translating ground-breaking science into genomic medicines with the potential to transform patients&#8217; lives using our platform technologies in gene therapy, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ex vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene-edited cell therapy, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> genome editing and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> genome regulation. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our strategy is to maximize the value and therapeutic use of our technology platforms. For certain therapies, we intend to capture the value of our proprietary gene therapy and genome editing products by incorporating these technologies into our manufacturing, development and commercial operations. For other therapies, we intend to partner with biopharmaceutical companies to develop products as appropriate. Decisions to partner product candidates will be based on review of our internal resources, internal know-how, and commercial considerations. In our proprietary clinical development programs, we are focused on three therapeutic areas: inherited metabolic diseases, or IMDs, central nervous system, or CNS, diseases and immunology, which comprises inflammatory and autoimmune diseases.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We are a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of transcription factor proteins found in humans and other species. We have used our internal know-how and technical expertise to develop a proprietary synthetic ZFP platform with potential clinical utility in </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">ex vivo </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">gene-edited cell therapy, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> genome editing and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">in vivo </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">genome regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by knocking in or knocking out select genes, or genome editing, and ZFP transcription-factors, or ZFP-TFs, proteins that can be used to selectively increase or decrease gene expression. In the process of developing this platform, we have additionally accrued significant scientific, manufacturing, development capabilities, and related know-how that are broadly applicable to the field of gene therapy and have used this knowledge to advance a gene therapy platform.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We have a substantial intellectual property portfolio protecting our technology and product candidates. We continue to license and file new patent applications to strengthen and consolidate our existing patent portfolio. We believe that our intellectual property position is critical to our ability to research, develop, manufacture and commercialize gene therapy, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%;">ex vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> gene-edited cell therapy, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> genome editing and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> genome regulation products and services.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Business Updates</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In February 2020, we entered into a global licensing collaboration agreement with Biogen for the research, development and commercialization of gene regulation therapies for the treatment of neurological diseases, including ST-501 a preclinical ZFP-TF product candidate for tauopathies including Alzheimer&#8217;s disease, and ST-502, a preclinical ZFP-TF product candidate for alpha-synuclein related diseases including Parkinson&#8217;s disease, among other targets. After the collaboration agreement becomes effective, Biogen will pay us an upfront payment of $125.0 million. Concurrently with the execution of the collaboration agreement, we also entered into a stock purchase agreement with Biogen MA, Inc. pursuant to which Biogen MA, Inc. agreed to acquire $225.0 million of shares of our common stock. We are also eligible to receive research, development, regulatory and commercial milestone payments that could total up to approximately $2.37 billion if Biogen selects all of the targets allowed under the agreement and all the specified milestones set forth in the agreement are achieved, which includes up to $925.0 million in pre-approval milestone payments and up to $1,445.0 million in first commercial sale and other sales-based milestone payments. The consummation of the transactions under each of the Biogen collaboration agreement and the stock purchase agreement is subject to the satisfaction of customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. For more information regarding the Biogen agreements, see &#8220;&#8212;Collaborations&#8212;Biogen.&#8221;</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In late December 2019, we completed the transfer to Pfizer of the SB-525 hemophilia A gene therapy investigational new drug, or IND, application for which we earned a $25.0 million milestone payment under the terms of our collaboration agreement with Pfizer for the global development and commercialization of gene therapies for hemophilia A. In 2019, we also completed the manufacturing technology transfer to Pfizer. Pfizer is now advancing SB-525 into a Phase 3 registrational clinical study, which is expected to provide the basis for seeking regulatory approval as a therapeutic.  We presented updated follow-up of the Phase 1/2 Alta Study assessing SB-525 in adult patients with severe hemophilia A in partnership with Pfizer at the 61stAmerican Society of Hematology, or ASH, annual meeting in December 2019. The data showed that SB-525 was generally well tolerated and demonstrated sustained increased Factor VIII levels following treatment with SB-525 through to 44 weeks, the extent of follow-up for the longest treated patient in the 3e13 vg/kg dose cohort.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We are also evaluating our wholly-owned investigational ST-920 gene therapy for Fabry disease, a rare inherited metabolic disease. In 2019, the IND was accepted by the U.S. Food and Drug Administration, or FDA, and a clinical trial authorization, or CTA, was granted in the United Kingdom. The FDA also granted Orphan Drug Designation to ST-920 for the </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">treatment of Fabry disease. We are currently evaluating ST-920 in adult males with classic Fabry disease in the Phase 1/2 STAAR study, an open-label, dose-ascending clinical trial.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We presented preliminary data from the Phase 1/2 THALES Study assessing ST-400, investigational </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">ex vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> gene-edited cell therapy in patients with transfusion-dependent beta thalassemia in partnership with Sanofi at ASH.  In December 2019, we also achieved a $7.5 million milestone from Sanofi for the first patient dosed in its Phase 1/2 PRECIZN-1 trial evaluating BIVV003, investigational </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">ex vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> gene-edited cell therapy for the treatment of sickle cell disease, or SCD.  </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In late 2019, we received CTA authorization in the United Kingdom for the Phase 1/2 STEADFAST clinical study evaluating the CAR-Treg cell therapy TX200 for kidney transplantation, which we expect to initiate in 2020.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Finally, in November 2019, we established a new Scientific Advisory Board comprising industry and academic international thought leaders who will advise us on our current and future clinical programs and research and development strategy.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">INTRODUCTION TO OUR TECHNOLOGY</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We conduct research &amp; development across four distinct but complementary technology platforms &#8211; gene therapy, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">ex vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> cell therapy, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> genome editing, and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> genome regulation. We believe that the optionality and diversity inherent to our technology platforms enables us to design therapeutic approaches to resolve the underlying genetic causes of disease, using whichever technology is best suited to deliver that treatment.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">ZFPs are Naturally Occurring Transcription Factors in Humans</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">ZFPs are naturally occurring transcription factors in humans. A transcription factor recognizes and binds to a specific DNA sequence within or near a particular gene and causes expression of that gene to be &#8220;turned on&#8221; (activated) or &#8220;turned off&#8221; (repressed). ZFPs are the most common class of naturally occurring transcription factors in a wide range of organisms from yeast to humans. Functional domains may be added to ZFPs that enable genome editing (with enzymes such as nucleases or integrases) or genome regulation (with activators and repressors) at a specific genomic site determined by the ZFP DNA-binding domain.</span></div><div style="text-align:center;margin-top:12pt;"><img src="sgmo-20191231_g1.jpg" alt="sgmo-20191231_g1.jpg" style="height:269px;width:498px;"/></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Figure 1:</span></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Schematic of the two-domain structure of a ZFP and its therapeutic functional domain </span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Consistent with the structure of natural ZFPs, we take a modular approach to the design of the proteins that we engineer. The ZFP portion of our engineered proteins, the DNA-recognition domain, is typically composed of four to six zinc fingers. Each individual finger recognizes and binds to a three or four base pair sequence of DNA and multiple fingers can be linked together to recognize longer stretches of DNA, thereby improving specificity. By modifying the amino acid sequence of a ZFP, we can engineer novel ZFPs capable of recognizing the unique DNA sequences of a chosen genomic target. The engineered ZFP DNA-binding domain is then linked to a functional domain. The ZFP DNA-binding domain brings this functional domain to the target of interest. Our ability to use our highly specific ZFPs to precisely target a DNA sequence to a </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">gene of interest provides us with a range of genome editing and genome regulation functionalities that can be applied to multiple cell types.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our engineered ZFPs can be attached to a cleavage domain of a restriction endonuclease, an enzyme that cuts DNA, creating a zinc finger nuclease, or ZFN. When a pair of ZFNs binds DNA in the correct orientation and spacing, a cut is introduced into the DNA sequence between the ZFP binding sites. DNA binding by both ZFNs is necessary for cleavage, and the two halves of the endonuclease must be present in the correct orientation to interact with one another in order to mediate DNA cleavage. This break in the DNA triggers a natural process of DNA repair within the cell. This endogenous DNA repair process may be harnessed to achieve one of several outcomes that may be therapeutically useful (Figure&#160;2). If cells are treated with ZFNs alone, the repair process joins the two ends of the broken DNA together and frequently results in the loss (deletion) or addition (insertion) of a small amount of genetic material at the site of the break. These insertions and deletion events are collectively known as "indels". These disrupt the target DNA sequence and result in the expression of a truncated or non-functional protein from the targeted gene, effectively &#8220;knocking out&#8221; the gene function. ZFN-mediated genome editing can be used to disrupt genes that are involved in disease pathology. We are using ZFN-mediated genome editing of the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">BCL11A</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> erythroid specific enhancer, or ESE, in hematopoietic stem progenitor cells, or HSPCs, as the basis of a potential long-lasting and once only treatment for beta thalassemia (ST-400) and SCD (BIVV-003).</span></div><div style="text-align:center;margin-top:12pt;"><img src="sgmo-20191231_g2.jpg" alt="sgmo-20191231_g2.jpg" style="height:305px;width:490px;"/></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Figure 2:</span></div><div style="text-align:center;margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Schematic of ZFP genome editing and genome regulation</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In contrast, if cells with a mutation in a particular gene are treated not only with ZFNs, but also with an additional DNA sequence that encodes the correct gene sequence (referred to as a &#8220;donor&#8221; DNA) and with ZFNs that recognize and bind to sequences flanking the mutation, the cell&#8217;s repair machinery can use the donor DNA as a template to correct the mutated gene. This ZFN-mediated gene correction enables the corrected gene to be expressed in its natural chromosomal context and may provide a novel approach for the precise repair of DNA sequence mutations responsible for certain monogenic diseases. In addition to providing a donor sequence that encodes a complete gene, a new copy of a gene can also be precisely added into the genome at a specific location. The ability to precisely place a gene-sized segment of DNA specifically into a pre-determined location in the genome broadens the range of mutations of a gene that can be corrected in a single step. It also reduces the insertional mutagenesis concerns associated with traditional integrating gene replacement approaches such as lentiviruses, in which the insertion of a new corrective copy of the gene typically occurs at random locations in the genome. Our ZFN technology is used to insert a gene encoding a therapeutic protein into a location such as the Albumin gene, an approach that we are investigating as a single and potentially curative treatment for mucopolysaccharidosis type II (MPS II) as well as several other rare diseases.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We are also evaluating ZFP-TFs, which have the potential to regulate the expression of a target gene (Figure 2). For instance, attaching an activation domain to a ZFP will cause a target gene to be expressed at increased levels, relative to an untreated cell. Alternatively, a repression domain causes the gene to be downregulated or completely turned off. We have several preclinical programs evaluating the potential of ZFP-TFs that have been designed to down regulate the expression of genes as potential treatments for CNS diseases, including programs for Alzheimer&#8217;s disease and Parkinson&#8217;s disease (being </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">6</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">evaluated pursuant to a collaboration agreement with Biogen) and partnered programs for Huntington&#8217;s disease (being evaluated pursuant to a collaboration agreement with Takeda Pharmaceutical Company Limited, or Takeda), and amyotrophic lateral sclerosis, or ALS (being evaluated pursuant to a collaboration agreement with Pfizer Inc., or Pfizer). </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ZFPs provide the Opportunity to Develop a New Class of Human Therapeutics</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe that our ZFP technology provides a unique and proprietary basis for a broad new class of drugs that have differentiated technical advantages over small-molecule drugs, protein pharmaceuticals, RNA-based therapeutics, conventional gene therapy approaches and other gene and genome editing platforms, potentially enabling us to develop therapies that address a broad range of unmet medical needs.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We can generate highly specific ZFNs for genome editing and ZFP-TFs for genome regulation using a range of proprietary methods. We are developing delivery strategies to administer these therapeutics, including using mRNA, adeno-associated virus, or AAV, adenovirus, plasmid, lipid nanoparticles and direct injection into brain tissue or into the cerebrospinal fluid. As more genes and DNA sequences are linked to specific diseases, we believe that the clinical breadth and scope of our ZFP therapeutic reagents will continue to expand.</span></div><div style="margin-top:12pt;"><span><br/></span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">THERAPEUTIC PRODUCT DEVELOPMENT</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We focus on translating ground-breaking science into genomic medicines with the potential to transform patients&#8217; lives using our platform technologies in gene therapy, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">ex vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> gene-edited cell therapy, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> genome editing and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">in vivo </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">genome regulation. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Our Product Development Programs</span></div><div style="margin-top:12pt;"><img src="sgmo-20191231_g3.jpg" alt="sgmo-20191231_g3.jpg" style="height:371px;width:684px;"/></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Gene therapy programs</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">SB-525</span></div><div style="text-indent:39.6pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">SB-525 continues to be developed as an investigational gene therapy for severe hemophilia A, under a global collaboration with Pfizer, for the research, development and commercialization of gene therapy product candidates for severe hemophilia A. Under this agreement, we conducted the Phase 1/2 clinical trial and certain manufacturing activities for SB-525, while Pfizer is now handling the subsequent worldwide development, manufacturing, marketing and commercialization of SB-525.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="text-indent:39.6pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In 2017, we initiated the Phase 1/2 Alta study to evaluate the safety and efficacy of SB-525 in adults with severe hemophilia A.  The Alta study is an open label, ascending dose clinical trial in up to 20 adults with severe hemophilia A. In December 2019, we and Pfizer announced updated initial data from the Phase 1/2 Alta study evaluating SB-525 including data from 11 patients treated across four ascending dose cohorts: 9e11 vg/kg (2 patients), 2e12 vg/kg (2 patients), 1e13 vg/kg (2 patients) and 3e13 vg/kg (5 patients). Dose dependent increases in factor VIII, or FVIII, activity over baseline were observed across the dose cohorts. FVIII is an essential blood-clotting protein encoded by the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">F8</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> gene. A lower-dose cohort indicated durable FVIII activity with up to 52 weeks of follow-up. In the 3e13 vg/kg dose cohort, patients achieved normal range FVIII activity within 5-7 weeks of treatment with SB-525. The first two patients treated in this cohort (Patients 7 and 8) achieved stable FVIII levels, demonstrating durability in the normal range through 44 and 37 weeks, respectively, as measured by the chromogenic assay. The two patients most recently treated in this cohort (Patients 10 and 11), with 22 and 12 weeks of follow-up, respectively, demonstrated a similar pattern of FVIII expression. The FVIII expression pattern observed in Patient 9 differed from that of other patients in the cohort. Seven weeks following treatment, Patient 9 achieved normal range FVIII levels. Beginning at week 13, FVIII levels in that patient fluctuated in a range below normal, but still well above the level needed to prevent spontaneous bleeding. At week 18, FVIII levels in Patient 9 began to increase, and as of the latest measurement at week 24, continued to rise. No patient in the 3e13 vg/kg dose cohort experienced bleeding events up to 44 weeks of follow-up, and no patient in this dose cohort required factor replacement following initial use of prophylactic factor.</span></div><div style="text-indent:39.6pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">SB-525 was generally well tolerated across all dose cohorts. The treatment-related adverse events include: alanine aminotransferase, or ALT, elevation (36.4%, n=4), pyrexia (27.3%, n=3), increased aspartate aminotransferase (18.2%, n=2), tachycardia (18.2% n=2), fatigue (9.1%, n=1), hypotension (9.1%, n=1) and myalgia (9.1%, n=1). One patient in the 3e13 vg/kg cohort experienced a treatment-related serious adverse event of hypotension (grade 3), as well as a fever (grade two), six hours following dosing with SB-525 that fully resolved within 24 hours. No similar events were reported in the other patients dosed in that cohort. No patients treated with SB-525 experienced an ALT elevation associated with loss of Factor VIII expression. In the 3e13 vg/kg dose cohort, four patients experienced transient low grade ALT elevations (&gt;1.5 x baseline) that were managed with a tapering course of oral steroids. The study does not use corticosteroids prophylactically, initiating them only in the event of an ALT elevation that is greater than 1.5x baseline.</span></div><div style="text-indent:39.6pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In late December 2019, we completed the transfer to Pfizer of the SB-525 hemophilia A gene therapy IND application for which we earned a $25.0 million milestone payment under the terms of our collaboration agreement with Pfizer for the global development and commercialization of gene therapies for hemophilia A. In 2019, we also completed the manufacturing technology transfer to Pfizer. Pfizer is now advancing SB-525 into a Phase 3 registrational clinical study, which is expected to provide the basis for seeking regulatory approval as a therapeutic.</span></div><div style="text-indent:39.6pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Based on the results from the Alta study, the FDA has granted regenerative medicine advanced therapy, or RMAT, designation for SB-525 gene therapy to treat severe hemophilia A. RMAT designation is granted to regenerative medicine therapies intended to treat, modify, reverse, or cure a serious condition, for which preliminary clinical evidence indicates that the medicine has the potential to address an unmet medical need. The RMAT designation includes all the benefits of the fast track and breakthrough therapy designation programs, including early interactions with the FDA. SB-525 has also been granted Orphan Drug and Fast Track designation by the FDA, as well as Orphan Medicinal Product designation by the European Medicines Agency, or EMA.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">ST-920 and ST-101</span></div><div style="text-indent:39.6pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are also evaluating our wholly-owned investigational ST-920 gene therapy for Fabry disease, a rare inherited metabolic disease. In 2019, the IND was accepted by the FDA and a CTA was granted in the United Kingdom. The FDA also granted Orphan Drug Designation to ST-920 for the treatment of Fabry disease. We are currently evaluating ST-920 in adult males with classic Fabry disease in the Phase 1/2 STAAR study, an open-label, dose-ascending clinical trial. </span></div><div style="text-indent:39.6pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In late 2019, we announced plans to advance ST-101, a wholly-owned investigational gene therapy for phenylketonuria, or PKU, a rare inherited disorder that originates from a defect in the PAH gene and results in harmful accumulation of phenylalanine in cells throughout the body. We anticipate filing an IND for ST-101 with the FDA in 2021. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Ex vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> gene-edited cell therapy programs</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ST-400 and BIVV-003</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2014, we entered into an exclusive worldwide collaboration and license agreement with Bioverativ Inc., (now Sanofi Genzyme, a global business unit of Sanofi, or Sanofi), to develop therapeutics for hemoglobinopathies, focused on beta thalassemia and SCD. Under the agreement, we are developing ST-400 and BIVV-003, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ex vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene-edited cell therapies, for hemoglobinopathies including transfusion dependent beta thalassemia and SCD, respectively. ST-400 and BIVV-003 are related product candidates using the same technology involving gene editing of a patient's own hematopoietic stem progenitor cells using non-viral delivery of ZFN technology. We are conducting the Phase 1/2 THALES study, an open-label, single arm clinical trial to evaluate the safety and efficacy of ST-400 in up to six subjects with beta thalassemia. Recruitment of the Thales study is ongoing, with five of six patients enrolled. In August 2019 a third patient was dosed in the THALES study, and following dosing of this subject we achieved a $6.0 million milestone with Sanofi and also received $2.1 million from the </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">8</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">California Institute for Regenerative Medicine. In December 2019, the first subject was dosed in the SCD Phase 1 clinical trial, and following the dosing of this subject we achieved a $7.5 million milestone with Sanofi. Sanofi is recruiting the Phase 1/2 PRECIZN-1 study, an open-label, single arm clinical trial to evaluate the safety and efficacy of BIVV-003 in subjects with sickle cell disease. Sanofi is responsible for the subsequent development, manufacturing and commercialization of all licensed products.</span></div><div style="text-indent:39.6pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In December 2019, we presented preliminary results from the first three patients treated in the THALES study evaluating ST-400. In the THALES study, HSPCs are collected from the patient, modified using ZFN gene editing technology to disrupt the ESE of the BCL11A gene, and cryopreserved prior to infusion back into the patient following myeloablative conditioning with busulfan. </span></div><div style="text-indent:39.6pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As of the data cut date for the presentation, the three patients treated with ST-400 experienced prompt hematopoietic reconstitution, demonstrating neutrophil engraftment in 14-22 days and platelet engraftment in 22-35 days. No emerging clonal hematopoiesis had been observed as measured by on-target indel pattern monitoring in the three treated patients. Reported adverse events are consistent with the known toxicities of mobilization, apheresis, and myeloablative busulfan conditioning. Details of the date for each of three patients follows:</span></div><div style="text-indent:39.6pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">Patient 1, age 36, has a &#946;</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">0</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">/&#946;</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">0</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> genotype, the most severe form of TDT. Following ST-400 infusion, fetal hemoglobin levels increased to approximately 2.7 g/dL at Day 56 and remained elevated compared to baseline at 0.9 g/dL at week 39, the most recent measurement at the time of the data cut. After an initial transfusion-free duration of 6 weeks, the patient resumed intermittent packed red blood cell, or PRBC, transfusions, with an overall 33% reduction in annualized PRBC units transfused since engraftment. Patient 1 experienced one treatment-related serious adverse event, hypersensitivity during ST-400 infusion considered by the investigator to be likely related to the product cryoprotectant excipient, DMSO, and which resolved by the end of the infusion.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">Patient 2, age 30, is homozygous for the severe &#946;+ IVS-I-5 (G&gt;C) mutation. Following ST-400 infusion, fetal hemoglobin levels increased as compared with baseline, but have been &lt;1 g/dL through to 26 weeks, the lowest induction level observed in the three patients treated to date. The patient is currently receiving intermittent PRBC transfusions. </span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">Patient 3, age 23, has a &#946;0/&#946;+ genotype that includes the severe IVS-II-654 (C&gt;T) mutation. Following ST-400 infusion, fetal hemoglobin levels have increased as compared to baseline and were continuing to rise as of the latest measurement of 2.8 g/dL at Day 90. Following an initial transfusion-free period of seven weeks, the patient has received two PRBC transfusions commencing at 62 days post-infusion. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Not included in the presentation of the preliminary data discussed above are Patient 4, age 18 with a &#946;</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">WT</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> (&#945;&#945;)/&#946;&#186; (&#945;&#945;&#945;&#945;) genotype, and Patient 5, age 35 with a &#946;&#186;/&#946;+ (severe IVS-I-110 G&gt;A) genotype, each of which were dosed after the time of the data cut. We expect to enroll a sixth and final patient in the study in the coming months. </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Kite Collaboration and TX200</span></div><div style="text-indent:39.6pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In February 2018, we entered into a global collaboration and license agreement with Kite Pharma, Inc., or Kite, a wholly-owned subsidiary of Gilead Sciences, Inc., or Gilead, for the research, development and commercialization of engineered cell therapies for cancer. Under this agreement, which we amended and restated in September 2019, we are working together with Kite on a research program to design ZFNs and viral vectors to disrupt and insert select genes in T-cells and natural killer cells, or NK-cells, including the insertion of genes that encode chimeric antigen receptors, or CARs, T-cell receptors, or TCRs, and NK-cell receptors, or NKRs, directed  to mutually agreed targets. Kite is responsible for all clinical development and commercialization of any resulting products and has announced that they expect to initiate a clinical trial in 2020 evaluating KITE-037, an allogeneic anti-CD19 CAR-T cell therapy.</span></div><div style="text-indent:39.6pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Following the October 2018 acquisition of Sangamo Therapeutics France S.A.S., or Sangamo France (formerly TxCell, S.A.), we are evaluating the potential of CAR-Tregs (regulatory T-cells, or Tregs), genetically modified with a CAR in solid organ transplantation. We are also conducting preclinical studies to determine whether such agents have potential clinical utility in autoimmune and inflammatory diseases, such as multiple sclerosis, or MS, and inflammatory bowel diseases, or IBD. In addition, we intend to use our ZFN gene editing technology to potentially develop next-generation autologous and allogeneic CAR-Treg cell therapies for use in the treatment of autoimmune and inflammatory diseases. In late 2019, a CTA was granted in Europe for TX200, an autologous CAR-Treg cell therapy for the prevention of solid organ transplant rejection. We expect to initiate the TX200 clinical trial in 2020.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">In vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;"> genome editing programs</span></div><div style="text-indent:39.6pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We have three proprietary </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> genome editing programs being evaluated in Phase 1/2 clinical trials: SB-913 (Mucopolysaccharidosis type II, or MPS II), SB-318 (MPS I), and SB-FIX (hemophilia B). In April 2019, we announced that </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">9</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">we did not plan to treat additional patients in our SB-913, SB-318 and SB-FIX clinical trials with first generation ZFNs given that clinical benefit has not been demonstrated in the analyses conducted to date.</span></div><div style="text-indent:39.6pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We are planning a new clinical trial for SB-913 to treat MPS II to evaluate second-generation ZFNs and other potential modifications that have the potential to enhance the clinical efficacy of this product. These include modifications that have the potential to enhance the efficiency of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> delivery of the ZFNs. We expect to use data from the new study evaluating second generation ZFNs to make a Phase 3 decision for the SB-913 program and to define the next steps, if any, for the SB-318 and SB-FIX programs.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">In vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;"> genome regulation programs</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We have several ongoing preclinical programs evaluating our ZFP-TF, genome regulation technology. ZFP-TFs act at the DNA level to selectively repress or activate the expression of specific genes to achieve a desired therapeutic effect. Genome regulation differs from other genome editing approaches as it is designed to enable precise, robust, and long-term activation or repression of a selected gene following a single AVV administration and does not cut or modify the target DNA. We are developing ZFP-TFs as a novel therapeutic approach for CNS diseases. </span></div><div style="text-indent:39.6pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In March and April 2019, we presented preclinical data describing the effects of ZFP-TFs targeting the gene that encodes tau protein, delivered with AAVs in the mouse and nonhuman primate, or NHP, brain. Certain CNS diseases known as tauopathies, including dementias such as Alzheimer&#8217;s disease, are associated with tau proteins that have become dysfunctional as a result of their misfolding and accumulating in brain tissues. Intra-hippocampal ZFP-TF delivery to adult mice resulted in more than 80% tau reduction, and intravenous ZFP-TF administration reduced tau levels by 50-70% across the entire mouse brain. AAV ZFP-TFs targeting tau were administered to the adult NHP hippocampus using real-time MRI-guided stereotaxic infusion. The lowering of tau in the hippocampus and entorhinal cortex of NHP was correlated with transgene expression levels. The treatment was well-tolerated for the duration of the study. We believe that together, these preclinical data from mice and NHPs highlight the potential for a single administration of a ZFP-TF to lower tau as a treatment for tauopathies, including Alzheimer&#8217;s disease. </span></div><div style="text-indent:39.6pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In December 2019, we nominated ST-501 as a preclinical ZFP-TF product candidate for tauopathies including Alzheimer&#8217;s disease, with IND submission anticipated in 2021. We also nominated ST-502 as a preclinical ZFP-TF product candidate for alpha-synuclein related diseases, including Parkinson&#8217;s disease, with IND submission anticipated in 2022. In February 2020, we entered into a collaboration and license agreement with Biogen to further develop ST-501 and ST-502, among other targets. For more information regarding the Biogen collaboration, see &#8220;&#8212;Collaborations&#8212;Biogen.&#8221;</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In December 2017, we entered into a research collaboration and license agreement with Pfizer for the development and commercialization of potential gene therapy products that use ZFP-TFs to treat ALS, and frontotemporal lobar degeneration, or FTLD, linked to mutations in th</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">e C9ORF72</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> gene. Under this agreement, we are working with Pfizer on a research program to identify, characterize and preclinically develop ZFP-TFs that satisfy pre-agreed criteria. Pfizer is responsible for subsequent development, manufacturing and commercialization of all licensed products.</span></div><div style="text-indent:39.6pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Pursuant to a collaboration agreement with Takeda, we have a preclinical program for Huntington&#8217;s disease in which we are evaluating a ZFP-TF designed to differentially down regulate the mutated disease-causing huntingtin gene, or HTT gene, while preserving the expression of the normal version of the gene.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Legacy Clinical Research Programs</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">SB-728</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#8211; </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Human Immunodeficiency Virus, or HIV, and Acquired Immunodeficiency Syndrome, or AIDS</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">HIV infection results in the death of immune cells, particularly CD4+ T-cells, and leads to AIDS, a condition in which the body&#8217;s immune system is depleted to such a degree that the patient is unable to fight off common infections. Ultimately, these patients succumb to opportunistic infections or cancers.</span></div><div style="text-indent:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Currently, there are over 30 antiretroviral drugs approved by the FDA to treat people infected with HIV. While these drugs can suppress virus in the blood to undetectable levels, they cannot eliminate the reservoir of cells containing genomically-integrated HIV from the body. Hence, individuals infected with HIV need to take antiretroviral drugs continuously. There is no therapeutic approach available that protects CD4+ T-cells, suppresses viral load, reduces the viral reservoir and that does not require daily dosing.</span></div><div style="text-indent:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">SB-728 uses our ZFN-mediated genome editing technology to disrupt the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">CCR5</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene in cells of a patient&#8217;s immune system to make these cells permanently resistant to HIV infection. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">CCR5</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> is a co-receptor for HIV entry into T-cells and if </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">CCR5</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> is not expressed on the cell surface HIV cannot infect them or infects them with lower efficiency. The aim of this approach is to provide the patient with a population of HIV-resistant cells that can fight HIV and opportunistic infections, by mimicking the naturally occurring </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">CCR5</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">delta-32</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> mutation that renders a population of individuals largely resistant to infection </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">by the most common strains of HIV. We are evaluating this genome editing approach to disrupt the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">CCR5</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene in both T-cells and HSPCs as two potential therapeutic candidates, SB-728-T and SB-728-HSPC, respectively.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have conducted several clinical trials with SB-728-T, which were designed to evaluate safety and tolerability of SB-728-T, as well as the effect of SB-728-T on subjects&#8217; CD4 T-cell counts, levels of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">CCR5</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">-modified T-cells, viral burden during a treatment interruption from anti-retroviral therapy, or ART, and measure of the viral reservoir. The data to date have demonstrated an ability to efficiently knock out the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">CCR5</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene in T-cells by ZFN-driven genome editing and grow the cells </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ex vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, that a single infusion of SB-728-T led to proven engraftment, expansion and persistence of T-cells </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, sustained increases in CD4 T-cell counts, a significant and continuous decay of the HIV reservoir and the ability of certain subjects to control their viral loads for prolonged periods in the absence of ART. Over 100 subjects have been treated to date and the treatment appears to be well-tolerated.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, we have an ongoing investigator-sponsored Phase 1/2 clinical trial (SB-728mR-HSPC) to investigate SB-728-HSPC as a self-renewable and potentially lifelong source of HIV-resistant immune cells.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We plan to advance the SB-728 program through potential future collaborations.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">COLLABORATIONS</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We have established collaborative and strategic partnerships for several of our therapeutic programs and also for several non-therapeutic applications of our technology. We will continue to pursue further partnerships when appropriate with selected pharmaceutical and biotechnology companies to fund internal research and development activities and to assist in product development and commercialization. Decisions to partner product candidates will be based on review of our internal resources, internal know-how, and commercial considerations. We are applying our ZFP technology platform to several commercial applications in which our products provide us and our strategic partners and collaborators with potential technical, competitive and economic advantages.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Biogen</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In February 2020, we entered into a global licensing collaboration agreement with Biogen for the research, development and commercialization of gene regulation therapies for the treatment of neurological diseases. We plan to leverage our proprietary ZFP technology delivered via AAV to modulate expression of key genes involved in neurological diseases.   </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Under the Biogen collaboration agreement, we will grant to Biogen an exclusive, royalty bearing and worldwide license, under our relevant patents and know-how, to develop, manufacture and commercialize certain ZFP and/or AAV-based products directed to up to 12 neurological disease gene targets selected by Biogen. Biogen has already selected three of these: ST-501 for tauopathies including Alzheimer&#8217;s disease, ST-502 for synucleinopathies including Parkinson&#8217;s disease, and a third undisclosed neuromuscular disease target. Biogen has exclusive rights to nominate up to nine additional targets over a target selection period of five years. For each gene target selected by Biogen, we will perform early research activities, costs for which will be shared by the companies, aimed at the development of the combination of proprietary CNS delivery vectors and ZFP-TFs targeting therapeutically relevant genes. Biogen will then assume responsibility and costs for the IND-enabling studies, clinical development, related regulatory interactions, and global commercialization. We will primarily be responsible for GMP manufacturing activities for the initial clinical trials for the first three products of the collaboration and plan to leverage our in-house manufacturing capacity. Biogen will assume responsibility for GMP manufacturing activities beyond the first clinical trial for each of the first three products. Subject to certain exceptions set forth in the Biogen collaboration agreement, we will be prohibited from developing, manufacturing or commercializing any therapeutic product directed to the targets selected by Biogen.  </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">After the Biogen collaboration agreement becomes effective, Biogen will pay us an upfront payment of $125.0 million.  We are also eligible to receive research, development, regulatory and commercial milestone payments that could total up to approximately $2.37 billion if Biogen selects all of the targets allowed under the agreement and all the specified milestones set forth in the agreement are achieved, which includes up to $925.0 million in pre-approval milestone payments and up to $1,445.0 million in first commercial sale and other sales-based milestone payments.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In addition, we will also be eligible to receive tiered high single-digit to sub-teen royalties on potential net commercial sales of licensed products arising from the collaboration. These royalty payments will be subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.  </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Biogen collaboration agreement will continue, on a product-by-product and country-by-country basis, until the expiration of the applicable royalty term.  Biogen has the right to terminate the collaboration agreement, in its entirety or on target-by-target basis, for any reason after a specified notice period. Each party has the right to terminate this agreement on account of the other party&#8217;s bankruptcy or material, uncured breach.  In addition, we may terminate the collaboration agreement if Biogen challenges any patents licensed by us to Biogen. </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">11</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Concurrently with the execution of the collaboration agreement, we also entered into a stock purchase agreement with Biogen MA, Inc., pursuant to which Biogen MA, Inc. will purchase 24,420,157 shares of our common stock, or the Biogen Shares, at a price per share of $9.2137, for an aggregate purchase price of $225.0 million. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Pursuant to the terms of the stock purchase agreement, Biogen has agreed not to, without our prior written and subject to specified conditions and exceptions, directly or indirectly acquire shares of our outstanding common stock, seek or propose a tender or exchange offer or merger between the parties, solicit proxies or consents with respect to any matter, or undertake other specified actions related to the potential acquisition of additional equity interests in us.  Subject to customary exceptions, such standstill restrictions expire on the earlier of the three-year anniversary of the effectiveness of the Biogen collaboration agreement and the date that Biogen beneficially owns less than 5% of our common stock.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The stock purchase agreement also provides that until the first anniversary of the effectiveness of the Biogen collaboration agreement, Biogen will hold and not sell any of the Biogen Shares and from the first anniversary through the second anniversary, Biogen will hold and not sell at least 50% of the Biogen Shares, in addition to being subject to certain volume limitations.  The stock purchase agreement further provides that, subject to certain limitations, upon Biogen&#8217;s request, we will register for resale any of the Biogen Shares on a registration statement to be filed with the SEC, until such time as all remaining Biogen Shares may be sold pursuant to Rule 144 promulgated under the Securities Act during any 90-day period.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In addition, Biogen has agreed that, excluding specified extraordinary matters, it will vote the Biogen Shares in accordance with our recommendation and has granted us an irrevocable proxy with respect to the foregoing.  Such voting provisions expire on the earlier of (i) the two-year anniversary of the effectiveness of the Biogen collaboration agreement, (ii) the date that Biogen beneficially owns less than 5% of our common stock and (iii) the date the Biogen collaboration agreement is terminated; provided, however, that in no event shall such expiration date be prior to the one-year anniversary of the effectiveness of the Biogen collaboration agreement.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The consummation of the transactions under each of the Biogen collaboration agreement and the stock purchase agreement is subject to the satisfaction of customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Kite </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2018, we entered into a collaboration and license agreement with Kite, a wholly-owned subsidiary of Gilead, which became effective in April 2018 and was amended and restated in September 2019, for the research, development and commercialization of potential engineered cell therapies for cancer. Kite will be responsible for all clinical development and commercialization of any resulting products and has announced that it expects to initiate a clinical trial evaluating KITE-037, an allogeneic anti-CD19 CAR-T cell therapy, in 2020.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subject to the terms of this agreement, we granted Kite an exclusive, royalty-bearing, worldwide, sublicensable license, under our relevant patents and know-how, to develop, manufacture and commercialize, for the purpose of treating cancer, specific cell therapy products that may result from the research program and that are engineered </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ex vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> using selected ZFNs and AAVs developed under the research program, to express CARs, TCRs or NKRs directed to candidate targets.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the research program term and subject to certain exceptions, except pursuant to this agreement, we will be prohibited from researching, developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ex vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> genome editing, expresses a CAR, TCR or NKR that is directed to a target expressed on or in a human cancer cell. After the research program term concludes and subject to certain exceptions, except pursuant to this agreement, we will be prohibited from developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ex vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> genome editing, expresses a CAR, TCR or NKR that is directed to a candidate target.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We received a $150.0&#160;million upfront payment from Kite when the agreement became effective in April 2018. In addition, Kite reimburses our direct costs to conduct the joint research program, and Kite will be responsible for all subsequent development, manufacturing and commercialization of any licensed products. We are also eligible to receive contingent development- and sales-based milestone payments that could total up to $3.01&#160;billion if all the specified milestones set forth in this agreement are achieved.&#160;Of this amount, approximately $1.26&#160;billion relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones, and approximately $1.75&#160;billion relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels.&#160;Each development- and sales-based milestone payment is payable (i)&#160;only once for each licensed product, regardless of the number of times that the associated milestone event is achieved by such licensed product, and (ii)&#160;only for the first ten times that the associated milestone event is achieved, regardless of the number of licensed products that may achieve such milestone event. In addition, we will be entitled to receive escalating, tiered royalty payments with a percentage in the single digits based on potential future annual worldwide net sales of licensed products. These royalty payments will be subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">12</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Kite has the right to terminate this agreement, in its entirety or on a per licensed product or per candidate target basis, for any reason after a specified notice period. Each party has the right to terminate this agreement on account of the other party&#8217;s bankruptcy or material, uncured breach.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Pfizer</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have two separate collaboration agreements with Pfizer. In May 2017, we entered into an exclusive, global collaboration and license agreement with Pfizer, pursuant to which we established a collaboration for the research, development and commercialization of SB-525, our gene therapy product candidate for hemophilia A, and closely related products, which we amended in December 2019.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under this agreement, we were responsible for conducting the Phase 1/2 clinical trial and certain manufacturing activities for SB-525, while Pfizer is responsible for subsequent worldwide development, manufacturing, marketing and commercialization of SB-525. We may also collaborate in the research and development of additional AAV-based gene therapy products for hemophilia A.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We received an upfront fee of $70.0&#160;million and achieved a $25.0 million milestone in December 2019 upon completion of the transfer of the IND for SB-525 to Pfizer. We are eligible to receive further development milestone payments contingent on the achievement of specified clinical development, intellectual property, regulatory and first commercial sale milestones for SB-525 and potentially other products. The total amount of potential clinical development, intellectual property, regulatory, and first commercial sale milestone payments, assuming the achievement of all specified milestones in this agreement, is $475.0&#160;million, which includes up to $300.0&#160;million for SB-525 and up to $175.0&#160;million for other products that may be developed under the agreement, subject to reduction on account of payments made under certain licenses for third party intellectual property. In addition, Pfizer agreed to pay us royalties for each potential licensed product developed under the agreement that are an escalating tiered, double-digit percentage of the annual net sales of such product and are subject to reduction due to patent expiration, entry of biosimilar products to the market and payment made under certain licenses for third party intellectual property.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subject to the terms of the agreement, we granted Pfizer an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses, to use certain technology controlled by us for the purpose of developing, manufacturing and commercializing SB-525 and related products. Pfizer granted us a non-exclusive, worldwide, royalty free, fully paid license, with the right to grant sublicenses, to use certain manufacturing technology developed under the agreement and controlled by Pfizer to manufacture our products that utilize the AAV delivery system. During a specified period, neither we nor Pfizer will be permitted to clinically develop or commercialize, outside of the collaboration, certain AAV-based gene therapy products for hemophilia A.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unless earlier terminated, the agreement has a term that continues, on a per product and per country basis, until the later of (i)&#160;the expiration of patent claims that cover the product in a country, (ii)&#160;the expiration of regulatory exclusivity for a product in a country, and (iii)&#160;15 years after the first commercial sale of a product in a country. Pfizer has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. Upon termination for any reason, the license granted by us to Pfizer to develop, manufacture and commercialize SB-525 and related products will automatically terminate. Upon termination by us for cause or by Pfizer any country or countries, Pfizer will automatically grant us an exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize SB-525 in the terminated country or countries.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2017, we entered into a separate exclusive, global collaboration and license agreement with Pfizer for the development and commercialization of potential gene therapy products that use ZFP-TFs to treat ALS and FTLD linked to mutations of the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">C9ORF72</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene. Pursuant to this agreement, we agreed to work with Pfizer on a research program to identify, characterize and preclinically develop&#160;ZFP-TFs&#160;that bind to and specifically reduce expression of the mutant form of the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">C9ORF72</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We received a $12.0&#160;million upfront payment from Pfizer and are eligible to receive up to $60.0&#160;million in development milestone payments from Pfizer contingent on the achievement of specified preclinical development, clinical development and first commercial sale milestones, and up to $90.0&#160;million commercial milestone payments if annual worldwide net sales of the licensed products reach specified levels. In addition, Pfizer will pay us royalties based on an escalating tiered,&#160;mid-&#160;to high-single digit percentage of the annual worldwide net sales of the licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third party intellectual property. Each party will be responsible for the cost of its performance of the research program. Pfizer will be operationally and financially responsible for subsequent development, manufacturing and commercialization of the licensed products.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">13</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subject to the terms of the agreement, we granted Pfizer an exclusive, worldwide, royalty-bearing, license under our relevant patents and&#160;know-how&#160;to develop, manufacture and commercialize gene therapy products that use resulting&#160;ZFP-TFs&#160;that satisfy&#160;pre-agreed&#160;criteria. During a specified period, neither our company nor Pfizer will be permitted to research, develop, manufacture or commercialize outside of the collaboration any ZFPs that specifically bind to the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">C9ORF72</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unless earlier terminated, the agreement has a term that continues, on a per licensed product and per country basis, until the later of (i)&#160;the expiration of patent claims that cover the licensed product in a country, (ii)&#160;the expiration of regulatory exclusivity for a licensed product in a country, and (iii)&#160;15 years after the first commercial sale of a licensed product in a major market country. Pfizer has the right to terminate the agreement without cause in its entirety or on a per product or per country basis.&#160;The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party.&#160;The agreement will also terminate if we are unable to identify any lead candidates for development within a specified period of time or if Pfizer elects not to advance a lead candidate beyond a certain development milestone within a specified period of time.&#160;Upon termination for any reason, the license granted by us to Pfizer to develop, manufacture and commercialize licensed products under the agreement will automatically terminate.&#160;Upon termination by us for cause or by Pfizer without cause for any licensed product or licensed products in any country or countries, we will have the right to negotiate with Pfizer to obtain a non-exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize the licensed product or licensed products in the terminated country or countries.&#160;</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Following termination by us for Pfizer&#8217;s material breach, either party will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">C9ORF72</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene for a period of time.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Sanofi</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2014, we entered into an exclusive worldwide collaboration and license agreement with Sanofi to develop therapeutics for hemoglobinopathies, focused on beta thalassemia and SCD. Under the agreement, we are jointly conducting two research programs: the beta&#160;thalassemia program and the SCD program. In the beta thalassemia program, we are responsible for all discovery, research and development activities through the first human clinical trial. In the SCD program, both parties are responsible for research and development activities through the submission of an IND application for ZFP therapeutics intended to treat SCD. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under both programs, Sanofi is responsible for subsequent worldwide clinical development, manufacturing and commercialization of licensed products developed under the agreement. At the end of the specified research terms for each program or under certain specified circumstances, Sanofi has the right to step in and take over any of our remaining activities. Furthermore, we have an option to co-promote in the United States any licensed products to treat beta thalassemia and SCD developed under the agreement, and Sanofi will compensate us for such co-promotion activities. Subject to the terms of the agreement, we have granted Sanofi an exclusive, royalty-bearing license, with the right to grant sublicenses, to use certain ZFP and other technology controlled by us for the purpose of researching, developing, manufacturing and commercializing licensed products developed under the agreement. We have also granted Sanofi a non-exclusive, worldwide, royalty-free, fully paid license, with the right to grant sublicenses, under our interest in certain other intellectual property developed pursuant to the agreement. During the term of the agreement, we are not permitted to research, develop, manufacture or commercialize, outside of the agreement, certain gene therapy products that target genes relevant to the licensed products.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Under the agreement, we received an upfront license fee of $20.0&#160;million, a $6.0 million milestone in August 2019, upon dosing of the third subject in the ST-400 beta thalassemia Phase 1 clinical trial, a $7.5 million milestone in December 2019 upon dosing of the first subject in the SCD Phase 1 clinical trial, and are eligible to receive additional development and sales milestone payments upon the achievement of specified regulatory, clinical development and sales milestones. The total amount of potential regulatory, clinical development, and sales milestone payments, assuming the achievement of all specified milestones in the agreement, is $276.3&#160;million. In addition, we will receive royalty payments for each licensed product that are a tiered double-digit percentage of annual net sales of each product.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The agreement may be terminated by (i)&#160;us or Sanofi for the uncured material breach of the other party, (ii)&#160;us or Sanofi for the bankruptcy or other insolvency proceeding of the other party; (iii)&#160;Sanofi, upon 180 days&#8217; advance written notice to us and (iv)&#160;Sanofi, for certain safety reasons upon written notice to, and after consultation with, us. As a result, actual future milestone payments could be lower than the amounts stated above.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Takeda</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In January 2012, we entered into a collaboration and license agreement with Shire International GmbH, a wholly-owned subsidiary of Takeda, which we amended and restated in September 2015, to research, develop and commercialize human therapeutics and diagnostics for monogenic diseases based on our ZFP technology. We received an upfront license fee of $13.0&#160;million in 2012 and recognized a $1.0&#160;million milestone payment in 2014. Pursuant to the amended and restated agreement, Takeda has an exclusive, worldwide license to ZFP therapeutics for treating Huntington&#8217;s disease.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">14</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the amended and restated agreement, Takeda has full control over, and full responsibility for the costs of, the Huntington&#8217;s disease program, subject to certain obligations, including the obligation to retain us to perform ZFP design, optimization and assessment services and to reimburse us for the costs of such services. Takeda does not have any milestone payment obligations but is required to pay single digit percentage royalties to us, up to a specified maximum cap, on the commercial sales of ZFP therapeutic products for Huntington&#8217;s disease. During the term of the amended and restated agreement, we are not permitted to research, develop or commercialize, outside of the agreement, certain products that target the&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">HTT</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;gene.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the amended and restated agreement, we have full control over, and full responsibility for the costs of, the hemophilia A and B programs returned to us by Takeda, subject to certain diligence obligations. We also granted Takeda a right of first negotiation to obtain a license to such programs under certain circumstances. We are required to pay single digit percentage royalties to Takeda, up to a specified maximum cap, on commercial sales of therapeutic products from the programs returned to us by Takeda.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The amended and restated agreement may be terminated by (i)&#160;us or Takeda, in whole or in part, for the uncured material breach of the other party, (ii)&#160;us or Takeda for the bankruptcy or other insolvency proceeding of the other party and (iii)&#160;Takeda, in its entirety, effective upon at least 90 days&#8217; advance written notice.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Partnerships</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to our partnerships for the development of human therapeutic applications, we have also licensed our technology in several other areas, such as plant agriculture and research reagents, including the production of transgenic animals and cell-line engineering. These license partners include Dow AgroSciences LLC, Sigma-Aldrich Corporation, Genentech, Inc., Open Monoclonal Technology, Inc. and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">INTELLECTUAL PROPERTY</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Patents and licenses are important to our business. Our strategy is to file or license patent applications to protect technology, inventions and improvements to inventions that we consider important for the development of our genome editing and genome regulation technologies. We seek patent protection and licenses that relate to our technology and candidates in our pipeline and/or may be important to our future. We have filed numerous patents and patent applications with the U.S. Patent and Trademark Office, or U.S. PTO, and foreign jurisdictions. This proprietary intellectual property includes methods relating to the design of zinc finger proteins, Transcription Activator-Like Effector, or TALE, proteins and Clustered Regularly Interspaced Short Palindromic Repeats, or CRISPR/Cas editing systems, therapeutic applications of genome editing technology, enabling technologies related to our platform and the use of genome editing across a variety of applications. We rely on a combination of patent, copyright, trademark, proprietary know&#8211;how, continuing technological innovations, trade secret laws, as well as confidentiality agreements, materials transfer agreements, research agreements and licensing agreements, to establish and protect our proprietary rights.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">In-Licensed Technology</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have exclusively licensed intellectual property directed to the design, selection, and use of ZFPs, ZFNs and ZFP-TFs for genome editing and genome regulation from the California Institute of Technology, or Cal Tech, and the University of Utah, or Utah. These licenses grant us exclusive rights to make, use and sell ZFPs, ZFNs and ZFP-TFs under two families of patent filings. As of February 14, 2020, these patent families encompass four U.S. and over 20 foreign active granted patents, with two pending U.S. patent applications. The patent expiration dates are based on 20 years from the filing date of the earliest non-provisional patent application in each patent family, however, patents in our portfolio may be subject to patent term adjustment, or PTA (due to delays in patent prosecution by the U.S. PTO), patent term extension, or PTE (due to review of a patented product by a regulatory agency), or terminal disclaimers, or TD, each of which could positively or negatively impact the estimated expiration date. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our license agreement with Cal Tech granted us a worldwide exclusive license to certain patents related to chimeric nucleases for genome targeting for all fields of use, which expire in September 2023, absent any PTA, PTE or TD. Our license agreement with Utah granted us a worldwide exclusive license to technology and patents relating to the use of ZFNs for all fields of use, which expire in January 2023, absent any PTA, PTE or TD.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have also entered into licenses potentially useful for specific therapeutic uses of our genome editing technologies with the Regents of the University of California, or UC, and the Children&#8217;s Medical Center Corporation, or CMCC. The patents included in these licenses relate to CNS disorders and hemoglobinopathies, respectively. These licenses include three patent families, including three issued U.S. patents, 12 allowed or granted foreign patents, 25 pending foreign patent applications and three pending U.S. patent applications. The UC patents expire in May of 2021, the first CMCC patent family expires in September 2029, and the second expires in November 2033, in each case, absent any PTA, PTE or TD.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">15</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our subsidiary, Sangamo France, has a license agreement with the University of British Columbia pursuant to which it exclusively licensed the right to the CAR for use in TX200. This license includes one patent family which expires in September 2038, absent any PTA, PTE or TD.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Our Intellectual Property</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to our in-licensed patent portfolio, we have numerous issued patents and pending patent filings directed to the design, composition and use of ZFPs, ZFNs, ZFP-TFs, TALE proteins and CRISPR/Cas editing systems and other technologies related to our program.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Some of the earliest zinc finger patents in our portfolio began expiring in 2015, with the average expiration of our currently issued patents expiring late-2026. However, we have continued to build on this patent portfolio and have been issued additional patents and have applications pending that provide protection for our ZFP technology. Additionally, patents that may be issued from our pending applications will extend the patent exclusivity of our patent estate.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe that our licensed patents and patent applications, as well as our issued patents and pending patent applications, in the aggregate, will provide us with a substantial intellectual property position in our commercial development of our gene therapy, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ex vivo </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">gene-edited cell therapy, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> genome editing and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> genome regulation programs. In this regard, patents issued to us, applied for by us, or exclusively and non-exclusively licensed to us, cover the following types of inventions, processes and products:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">ZFP and ZFN design, engineered nucleases (e.g., CAS), and compositions (four patents issued with expiration dates ranging from 2029 to 2036), absent any PTA, PTE or TD):</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Includes DNA target site selection, zinc finger binding domain design, nuclease domain design, linker design, DNA nickases, ZFP libraries databases and methods of construction, as well as methods to increase zinc finger binding specificity (see, e.g., US9982245, US10066242, US10113207);</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:13.8pt;">ZFP Therapeutics (three patents issued with expiration dates ranging from 2028 to 2031, absent any PTA, PTE or TD):</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> Methods relating to activation and inhibition of endogenous genes, identification of accessible regions within chromatin, including treatment of Huntington&#8217;s disease, HIV, cancer therapeutics, modulation of cardiac contractility and methods to regulate the glucocorticoid receptor (see, e.g., US9943565);</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt;">Nuclease Therapeutics (12 patents issued with expiration dates ranging from 2031 to 2036, absent any PTA, PTE or TD):</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Treatments for HIV, beta thalassemia and SCD, hemophilia IMDs, genome editing, Parkinson&#8217;s Disease, regulation of the expression of PD1; Immunomodulatory therapeutics; Cystic Fibrosis; CNS disease; Severe combined immunodeficiency, Modified T-cells, including HLA knock out and methods of editing stem cells (see, e.g., US9877988, US9963715, US10072066, US10081661, US10143760); and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Non-Therapeutic Applications of ZFPs and Nucleases (seven patents issued with expiration dates ranging from 2028 to 2035, absent any PTA, PTE or TD):</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Identification of regulatory sequences, analysis of gene regulation, structure and biological function, methods of agricultural biotechnology, methods of altering cellular differentiation state, development of cell lines for improved protein production, methods of transgenic animal development, engineering of stem cells, methods of genome editing (see, e.g., US9890395).</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The patent positions of pharmaceutical and biotechnology firms, including our patent position, are uncertain and involve complex legal and factual questions for which important legal tenets are largely unresolved and are subject to interpretation and refinement by the court system. Patent applications may not result in the issuance of patents and the coverage claimed in a patent application may be significantly reduced before a patent is issued. Although we have filed for patents on some aspects of our technology, we cannot provide assurances that patents will be issued as a result of these pending applications or that any patent that has been or may be issued will be upheld. The laws of some foreign countries may not protect our proprietary rights to the same extent as do the laws of the United States. For example, our issued European patents EP2171052 and EP2527435 have been opposed in Europe. Our EP2281050 case was revoked during Opposition in November 2016. The claims of these patents may be amended such that claim scope is reduced or the patents may be revoked as a result of these procedures.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the U.S. PTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">we employ an outside firm and rely on our outside counsel to pay these fees due to non-U.S. patent agencies. The U.S. PTO and various non-U.S. governmental patent agencies require compliance with a </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">16</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market and this circumstance would have a material adverse effect on our business. We may not be able to protect our intellectual property rights throughout the world.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the future, third parties may assert patent, copyright trademark, and other intellectual property rights to technologies that are important to our business. The outcome following any potential legal assertions of invalidity and unenforceability is unpredictable. Any claims asserting that our products infringe or may infringe proprietary rights of third parties, if determined adversely to us, could significantly harm our business. See &#8220;Risk Factors</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#8212;Risks Relating to Our Intellectual Property</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">COMPETITION</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We, and our licensed partners, are leaders in the research, development, and commercialization of gene therapies, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">ex vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> gene-edited cell therapies,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"> in vivo </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">genome editing and i</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">n vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> genome regulation using ZFP DNA-binding proteins.  </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are aware of several companies focused on other methods for editing genes and regulating gene expression and a limited number of commercial and academic groups pursuing the development of ZFP genome regulation and genome editing technologies. The fields of gene therapy, gene-edited cell therapy, genome editing and genome regulation are highly competitive, and we expect competition to persist and intensify in the future from a number of different sources, including pharmaceutical and biotechnology companies; academic and research institutions; and government agencies that will seek to develop ZFPs as well as technologies that will compete with our ZFP technology platform, such as TALE proteins and the CRISPR/Cas9 editing system.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accordingly, our competitors may succeed in obtaining patent protection, receiving FDA approval, or commercializing competitive products before us. If we commence commercial product sales, we may be competing against companies with greater marketing, sales, distribution and manufacturing capabilities, areas in which we have limited or no experience. In addition, any product candidate that we successfully develop may compete with existing products that have long histories of safe and effective use.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Although we are in the clinical development phase of operations and have no current therapeutic product sales, we believe the following companies, products and/or technologies may potentially be competitive with our technology or our product candidates under development:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Protein pharmaceuticals under development at pharmaceutical and biotechnology companies such as Pfizer, Bayer AG, Novo Nordisk A/S, Sanofi, Takeda, BioMarin Pharmaceutical Inc., Biogen, Acceleron Pharma Inc., </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">17</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ArmaGen, Inc., Amicus Therapeutics, Inc., Protalix Biotherapeutics, Inc., F. Hoffman-LaRoche Ltd., Novartis AG, or Novartis, and numerous other pharmaceutical and biotechnology firms.</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Gene therapy companies developing gene-based products in clinical trials. Orchard Therapeutics plc&#8217;s Strimvelis&#8482; (acquired from GlaxoSmithKline plc, or GSK) is approved in Europe, Spark Therapeutics, Inc.&#8217;s LUXTURNA&#8482; is approved in the United States and Europe, and bluebird bio&#8217;s ZYNTEGLO&#8482; is approved in Europe. Other competitors in this category may include, but not be limited to, uniQure N.V., BioMarin Pharmaceutical Inc., REGENXBIO Inc., Ultragenyx Pharmaceutical Inc., Voyager Therapeutics, Inc., Takeda, Pfizer, Freeline Therapeutics, Amicus Therapeutics, Inc., and Novartis.</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Cell therapy companies developing cell-based products. Novartis&#8217; Kymriah&#8482; and Gilead&#8217;s Yescarta&#8482;, two gene-modified cell-based therapies, are approved in both the United States and Europe. Other competitors in this category may include, but not be limited to, Adaptimmune Therapeutics PLC, bluebird bio, Inc., Cellectis S.A., Sana, Lyell, Inc., Kite/Gilead, AvroBio, Inc., Medeor Therapeutics, Inc., CRISPR Therapeutics AG, Intellia Therapeutics, Inc., Casebia Therapeutics, Targazyme, Inc., ZIOPHARM Oncology, Inc., Tmunity Therapeutics, Inc., Caladrius Biosciences, Inc., TRACT Therapeutics, Inc., Cellenkos&#8482;, Inc., Regcell Co., Ltd., Allogene, Fate Therapeutics, NKarta Therapeutics and Bristol Myers Squibb.</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Nuclease technologies under development for therapeutic applications of genome modification including companies such as Editas Medicine, Inc., CRISPR Therapeutics AG, Caribou Biosciences, Inc. and Intellia Therapeutics, Inc. developing the CRISPR/Cas9 editing system, Cellectis S.A. developing TALE nucleases and meganucleases, bluebird bio, Inc. developing Homing Endonucleases and MegaTALs and Precision BioSciences, Inc. developing meganucleases.</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Antisense therapeutics and RNA interference technology, including RNAi and microRNA, which are technologies that may compete with us in the development of novel therapeutic products acting through the regulation of gene expression. These technologies are being developed by several companies including Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Moderna, Inc., Sanofi and Regulus Therapeutics Inc.</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Small molecules in development from both in-house drug discovery programs of pharmaceutical companies such as Pfizer, GSK, Novartis AG and Merck &amp; Co., Inc., as well as from biotechnology companies with expertise and capabilities in small molecule discovery and development such as Gilead, Sanofi, Bristol Myers Squibb, and Global Blood Therapeutics, Inc., which has a small molecule product in development for SCD.</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">Monoclonal antibody companies and product candidates from certain biotechnology firms such as Genentech, Inc. and Amgen Inc.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect to face intense competition from other companies for collaborative arrangements with pharmaceutical and biotechnology companies for establishing relationships with academic and research institutions, for licenses to proprietary technology and for subjects in our clinical trials of treatments for rare diseases. These competitors, either alone or with their collaborative partners, may succeed in developing technologies or products that are more effective or less costly than ours.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our ability to compete successfully will depend, in part, on our ability to:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">develop safe, efficacious and commercially attractive proprietary products;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">obtain access to gene transfer technology on commercially reasonable terms;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">obtain required regulatory approvals;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">obtain reimbursement for our products in approved indications;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">attract and retain qualified scientific and product development personnel;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">enter into collaborative and strategic partnerships with others, including our competitors, to develop our technology and product candidates;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">obtain and enforce patents, licenses or other proprietary protection for our products and technologies;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">formulate, manufacture, market and sell any product that we develop;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">develop and maintain products that reach the market first and are technologically superior to or are of lower cost than other products in the market; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">recruit subjects into our clinical trials in a timely fashion</span></div><div style="padding-left:18pt;margin-top:3pt;"><span><br/></span></div><div style="padding-left:18pt;margin-top:3pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">18</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">MANUFACTURING</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We currently rely on contract manufacturing organizations, or CMOs, to produce our preclinical and clinical product candidates in accordance with FDA and EMA mandated regulations, also known as current good manufacturing practices, or cGMPs. We employ a technical operations staff in the areas of process development, analytical development, quality control, quality assurance, project management, and manufacturing to facilitate appropriate oversight of our CMOs, support of our regulatory filings and execution of clinical trials. We are building a cGMP manufacturing facility in our new headquarters building in Brisbane, CA. This facility is being designed to manufacture Phase 1/2 clinical trial supplies for our gene therapy and cell therapy pipeline and potentially collaboration programs and is currently anticipated to become operational in 2020. We are also building a cell therapy manufacturing facility at our site in Valbonne, France. We intend to continue to rely on CMOs for the manufacture of our product candidates for any Phase 3 clinical trials, and if approved, for commercial supply. We believe this balanced approach to manufacturing, investing in internal capacity/capabilities while strengthening our commitment to external capacity, will enable us to meet our anticipated pipeline needs. Additionally, in 2019 we signed an expanded services agreement with Brammer Bio MA, a Thermo Fisher Scientific, Inc. subsidiary, or Brammer, which provided us with access to dedicated AAV manufacturing capacity up to 2000-L bioreactor scale capable of handling large-scale, commercial-grade runs for products such as ST-920, our gene therapy product candidate for Fabry disease. The agreement also allows us to leverage Brammer&#8217;s viral vector manufacturing know-how in our new Brisbane facility in order to provide a seamless transition from early development to late-stage clinical trials and commercial-scale manufacturing.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We currently leverage three distinct manufacturing platforms: AAV vector production for our genome editing and gene therapy product candidates, HSPC modification for our cell therapy product candidates and engineered T-cell therapies. We use a commercial scale baculovirus manufacturing platform to manufacture AAV vectors for genome editing and gene therapy, with each AAV vector packaging a different transgene specific to the target indication or ZFN. The manufacturing process for our HSPC cell therapy product candidates utilizes the patient&#8217;s own HSPCs. These HSPCs are transfected using mRNA to produce ZFNs that target specific DNA sites, resulting in modified HSPCs. The third platform utilizes our ZFN technology to transform CAR-Tregs for autologous and allogeneic cell therapies. With the acquisition of Sangamo France, we also added capabilities to manufacture regulatory T-cells in therapeutic quantities to be used to treat inflammatory and autoimmune disorders.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">GOVERNMENT REGULATION</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We operate within the heavily regulated pharmaceutical framework and much of our operations, including nonclinical and clinical trials, development, manufacturing, commercialization, marketing and reimbursement are subject to regulatory approvals. Relevant regulatory authorities include, but are not limited to, the FDA, the EMA, Commission of the European Union, or EU, Member State agencies, including the UK Medicines and Healthcare Products Regulatory Agency, or MHRA.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the United States, the FDA regulates biologic products including gene therapy and human cellular therapy products under the Federal Food, Drug, and Cosmetic Act, or the FDCA, the Public Health Service Act, or the PHSA, and regulations and guidance implementing these laws. The FDCA, PHSA and their corresponding regulations govern, among other things, the testing, manufacturing, safety, efficacy, labeling, packaging, storage, record keeping, distribution, reporting, advertising and other promotional practices involving biologic products. Applications to the FDA are required before conducting human clinical testing of biologic products and in the EU approval must be obtained from the EMA. FDA approval also must be obtained before marketing of biologic products. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources and we may not be able to obtain the required regulatory approvals.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accelerated Assessment</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A number of agencies, including the FDA and the EMA, have accelerated approval programs, including for innovative products and in areas of high unmet medical need, such as PRIME in the EU. These programs require a certain level of evidence demonstrating safety and efficacy in patients from early stage clinical trials. Entry into one of these accelerated schemes may result in assistance with the scientific opinion and faster approval timelines. Some of these programs may offer joint approval and reimbursement advice. It is noted that even applications in an accelerated assessment scheme may be assessed under standard timelines, where the regulatory authority deems it necessary to address more questions.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">19</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">U.S. Biologic Products Development Process</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our product candidates must be approved by the FDA before they may be legally marketed in the United States. The process required by the FDA before a biologic product candidate may be marketed in the United States generally involves the following:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">completion of preclinical laboratory tests and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> studies in accordance with the FDA&#8217;s current Good Laboratory Practice, or GLP, regulations and applicable requirements for the humane use of laboratory animals or other applicable regulations;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">submission to the FDA of an application for an IND exemption, which allows human clinical trials to begin unless FDA objects within 30&#160;days;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">approval by an independent institutional review board, or IRB, reviewing each clinical site before each clinical trial may be initiated;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">performance of adequate and well-controlled human clinical trials according to the FDA&#8217;s Good Clinical Practice, or GCP, regulations, and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed biologic product candidate for its intended use;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">preparation and submission to the FDA of a biologics license application, or BLA, for marketing approval that includes substantial evidence of safety, purity and potency from results of nonclinical testing and clinical trials;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">review of the product by an FDA advisory committee, if applicable;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biologic product candidate is produced to assess compliance with cGMP requirements and to assure that the facilities, methods and controls are adequate to preserve the biologic product candidate&#8217;s identity, safety, strength, quality, potency and purity;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">potential FDA audit of the nonclinical and clinical trial sites that generated the data in support of the BLA; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">payment of user fees and FDA review and approval, or licensure, of the BLA.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Before testing any biologic product candidate in humans, including a gene therapy product candidate, the product candidate must undergo preclinical testing. Preclinical tests, also referred to as nonclinical studies, include laboratory evaluations of product chemistry, toxicity and formulation, as well as </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> studies to assess the potential safety and activity of the product candidate and to establish a rationale for therapeutic use. The conduct of the preclinical tests must comply with federal regulations and requirements including GLPs.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Concurrent with clinical trials, companies usually must complete some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the drug in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Human gene transfer protocols are subject to the FDA&#8217;s oversight and other clinical trial regulations, and oversight at the local level as set forth in National Institutes of Health, or NIH, Guidelines. Specifically, under the NIH Guidelines, supervision of human gene transfer trials includes evaluation and assessment by an institutional biosafety committee, or IBC, a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment, and such review may result in some delay before initiation of a clinical trial. Compliance with the NIH Guidelines is mandatory for investigators at institutions receiving NIH funds for research involving recombinant DNA. However, many companies and other institutions, not otherwise subject to the NIH Guidelines, voluntarily follow them.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The clinical trial sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. Some preclinical testing may continue even after the IND is submitted. The IND automatically becomes effective 30&#160;days after receipt by the FDA, unless the FDA places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA also may impose clinical holds on a biologic product candidate at any time before or during clinical trials due to safety concerns or non-compliance. If the FDA imposes a clinical hold, trials may not recommence without FDA authorization and then only under terms authorized by the FDA. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical studies to begin, or that, once begun, issues will not arise that suspend or terminate such studies.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">20</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">EU Drug Development Process</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Similar to the United States, the EU regulatory framework sets both EU-wide and national, Member State-specific requirements for the development and approval of medicinal products. Article 8(3) of Directive 2001/83/EC sets out the contents of a marketing authorization, or MA, application and all the information that must be submitted for the evaluation of a medicinal product. Certain preclinical (also termed &#8220;non-clinical&#8221;) data is required in order to enable clinical trials and later be used in dossier for a marketing authorization application. All studies should take place in accordance with GLP and all applicable EMA, Commission and European Pharmacopoeia guidelines on preclinical studies, including guidance on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The requisite amount of preclinical data enables the design of a clinical trial, from Phase 1 (first-in-human clinical trials) through to Phases 2 and 3, which are safety and efficacy and dosing studies and similar restrictions and requirements apply as in the U.S. regarding preclinical data, approvals for trials using vectors. The preclinical tests should establish parameters such as toxicity, pharmacodynamics and pharmacokinetic properties, the quality of gene transfer medicinal products. Due to the particular nature of gene therapy medicinal products, it is recognized that that it may not always be possible for the non-clinical safety studies to be in conformity with the principles of GLP and a proper justification should be submitted where a pivotal non-clinical safety study has not been conducted under GLP rules.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Clinical studies are crucial to obtaining the required data and the requirements governing the conduct of clinical trials are further analyzed below.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">All medicinal products and advanced therapy medicinal products, or ATMPs, must be manufactured in accordance with the guidelines on Good Manufacturing Practice, or GMP, and in a GMP licensed facility, which can be subject to GMP inspections.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Human Clinical Trials Under an IND</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Clinical trials involve the administration of the biologic product candidate to healthy volunteers or patients under the supervision of qualified investigators which generally are physicians not employed by, or under, the control of the trial sponsor. Clinical trials are conducted under written study protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters to be used to monitor subject safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events should occur. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND. Clinical trials must be conducted and monitored in accordance with the FDA&#8217;s regulations comprising the GCP requirements, including the requirement that all research subjects provide informed consent.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Further, each clinical trial must be reviewed and approved by an IRB at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers items such as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed consent that must be signed by each clinical trial subject, or their legal representative, reviews and approves the study protocol, and must monitor the clinical trial until completed.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Human clinical trials typically are conducted in three sequential phases that may overlap or be combined:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Phase&#160;1.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The biologic product candidate initially is introduced into a small number of human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early understanding of its effectiveness. Phase&#160;1 clinical trials of gene therapies are typically conducted in patients rather than healthy volunteers.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Phase&#160;2.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The biologic product candidate is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product candidate for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Phase&#160;3.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Phase&#160;3 clinical trials are commonly referred to as &#8220;pivotal&#8221; studies, which typically denotes a study which presents the data that the FDA or other relevant regulatory agency will use to determine whether or not to approve a biologic product. In Phase&#160;3 studies, the biologic product candidate is administered to an expanded patient population, generally at multiple geographically dispersed clinical trial sites in adequate and &#160;&#160;well-controlled clinical trials to generate sufficient data to statistically confirm the potency and safety of the product for approval. These clinical trials are intended to establish the overall risk/benefit ratio of the product candidate and provide an adequate basis for product labeling.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Post-approval clinical trials, sometimes referred to as Phase&#160;4 clinical trials, may be conducted after initial approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">21</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">particularly for long-term safety follow-up. Sometimes approval for a product is conditional upon the completion of post-marketing clinical studies.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During all phases of clinical development, regulatory agencies (such as the FDA, the EMA and other comparable regulatory agencies) require extensive monitoring and auditing of all clinical activities, clinical data and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Written IND safety reports must be promptly submitted to the FDA, the NIH and the investigators for: serious and unexpected adverse events; any findings from other trials, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> laboratory tests or </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vitro</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> testing that suggest a significant risk for human subjects; or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#8217;s initial receipt of the information.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The FDA or the sponsor or its data safety monitoring board may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the biologic product candidate has been associated with unexpected serious harm to patients.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The FDA usually recommends that sponsors observe subjects for potential gene therapy-related delayed adverse events for up to a 15-year period, including a minimum of five years of annual examinations followed by 10&#160;years of annual queries, either in person or by questionnaire. In January 2020, the FDA issued draft guidance to elaborate on many of the factors that should be considered for this long-term observation.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the EU, clinical trials almost always require approval from a national competent authority of the relevant Member State and an approval from an Ethics Committee. If the medicinal product is considered to be a genetically modified organism, or GMO, then GMO approval must also be obtained. There is no harmonization between Member States regarding the approach to and timelines of GMO approval, which results in significant challenges and time restrictions.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The conduct of clinical trials should follow the approved clinical trial protocol and be in accordance with the principles of GCP. Gene therapy medicinal products are in addition subject to the rules of GCP for ATMPs (currently in draft form), which outline specific additional safeguards and requirements. Record retention requirements are increased for ATMPs and there are relevant long-term follow up and human safety and traceability requirements.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Compliance with cGMP Requirements</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Manufacturers of biologics must comply with applicable current Good Manufacturing Practices, or cGMP, regulations, including quality control and quality assurance and maintenance of records and documentation. Manufacturers and others involved in the manufacture and distribution of such products also must register their establishments with the FDA and certain state agencies. Both domestic and foreign manufacturing establishments must register and provide additional information to the FDA upon their initial participation in the manufacturing process. Any material changes to the manufacturing equipment, process or location of the approved manufacturing site must be reported to the relevant agency/authority. Establishments may be subject to periodic, unannounced inspections by government authorities (including regulatory agencies) to ensure compliance with cGMP requirements and other laws. Discovery of problems may result in a government entity placing restrictions on a product, manufacturer or holder of an approved BLA, and may extend to requiring withdrawal of the product from the market, issue warning or similar letters or seeking civil, criminal or administrative sanctions against the company. The FDA will not approve a BLA unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specification.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Concurrent with clinical trials, companies usually complete additional preclinical studies and must also develop additional information about the physical characteristics of the biologic product candidate as well as finalize a process for manufacturing the product candidate in commercial quantities in accordance with cGMP requirements. To help reduce the risk of the introduction of adventitious agents or of causing other adverse events with the use of biologic products, the PHSA emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other requirements, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biologic product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the biologic product candidate does not undergo unacceptable deterioration over its shelf life.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">22</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">U.S. Review and Approval Processes</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The results of the preclinical tests and clinical trials, together with detailed information relating to the product&#8217;s Chemistry, Manufacturing and Controls, or CMC, and proposed labeling, among other things, are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Prescription Drug User Fee Act, or PDUFA, as amended, each BLA must be accompanied by a significant user fee. The FDA adjusts the PDUFA user fees on an annual basis. The PDUFA also imposes an annual program fee for approved biologics. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The FDA reviews a BLA within 60&#160;days of submission to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In that event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth, substantive review of the BLA.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The FDA reviews the BLA to determine, among other things, whether the proposed product candidate is safe and potent, or effective, for its intended use, has an acceptable purity profile and whether the product candidate is being manufactured in accordance with cGMP to assure and preserve the product candidate&#8217;s identity, safety, strength, quality, potency and purity. The FDA may refer applications for novel biologic products or biologic products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the product approval process, the FDA also will determine whether a risk evaluation and mitigation strategy, or REMS, is necessary to assure the safe use of the product candidate. REMS use risk minimization strategies beyond the professional labeling to ensure that the benefits of the product outweigh the potential risks. To determine whether a REMS is needed, the FDA will consider the size of the population likely to use the product, seriousness of the disease, expected benefit of the product, expected duration of treatment, seriousness of known or potential adverse events, and whether the product is a new molecular entity. A REMS could include medication guides, physician communication plans and elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS; the FDA will not approve the BLA without a REMS, if required.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Before approving a BLA, the FDA will inspect the facilities at which the product candidate is manufactured. The FDA will not approve the product candidate unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product candidate within required specifications. Additionally, before approving a BLA, the FDA typically will inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND trial requirements and GCP requirements.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On the basis of the BLA and accompanying information, including the results of the inspection of the manufacturing facilities, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the biologic product with specific prescribing information for specific indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the BLA, the FDA will issue an approval letter.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If a product candidate receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing or dispensing in the form of a REMS, or otherwise limit the scope of any approval. In addition, the FDA may require post-marketing clinical trials, sometimes referred to as Phase&#160;4 clinical trials, designed to further assess a biologic product&#8217;s safety and effectiveness, and testing and surveillance programs to monitor the safety of approved products that have been commercialized.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The FDA has agreed to specified performance goals in the review of BLAs under the PDUFA. One such goal is to review standard BLAs in 10&#160;months after the FDA accepts the BLA for filing, and priority BLAs in six months, whereupon a review decision is to be made. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs and its review goals are subject to change from time to time. The review process and the PDUFA goal date may be extended by three months if the FDA requests or the BLA sponsor otherwise provides additional information or clarification regarding information already provided in the submission within the last three months before the PDUFA goal date.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">23</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">EU Review and Approval Process</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Before a medicinal product can be placed on the market in the EU, it must have received an MA. This could either be at national or EU level under a mutual recognition, decentralized or centralized procedure. Our product candidates are innovative treatments, which will bear the classification of ATMP and/or orphan status. As such, the appropriate authorization procedure is the centralized procedure, which involves an MA being granted by the European Commission following a positive opinion by the EMA. A centralized MA is simultaneously valid in all EU Member States and the European Economic Area, or EEA, (Iceland, Liechtenstein and Norway). A centralized MA also results in a single set of product information (patient information leaflet, labelling and summary of product characteristics) for all EU Member States.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The timeline for the grant of a centralized MA since the time of the application is 210 days for the assessment of the application (including &#8220;clock stops&#8221; for the applicant to prepare answers to the questions from the EMA). The Committee for Medicinal Products for Human Use, or the CHMP, may either provide a positive or negative opinion. Following a positive opinion, the European Commission will usually issue its legally binding MA after 67 days. A negative opinion may be appealed by the applicant who must submit a request for re-examination within 60 days. There is the possibility for accelerated timelines of drug applications for eligible applicants, which can reduce the timeline to 150 days, if the applicant can produce sufficient justification.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If the MA application contains less comprehensive than the required standard as at the time of the application, when there are public health grounds and often in the case of orphan medicinal products, the EMA may recommend to the European Commission that it issues a different type of an MA, as follows: (a)&#160;a Conditional MA (valid for one year and renewable), when the medicinal product shows a positive benefit-risk balance and targets an unmet medical need and it is expected that the applicant will be able to provide comprehensive data in due course; or (b)&#160;an MA under &#8216;exceptional circumstances&#8217;, when it is not expected that the applicant will be able to provide comprehensive efficacy and safety data (often for very rare indications).</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Post-approval Requirements</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Rigorous and extensive FDA regulation of biologic products continues after approval, particularly with respect to cGMP requirements. Manufacturers are required to comply with applicable requirements in the cGMP regulations, including quality control and quality assurance and maintenance of records and documentation. Other post-approval requirements applicable to biologic products include reporting of cGMP deviations that may affect the identity, potency, purity and overall safety of a distributed product, record-keeping requirements, reporting of adverse effects, reporting updated safety and efficacy information and complying with electronic record and signature requirements. After a BLA is approved, the product also may be subject to official lot release. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA, together with a release protocol, showing a summary of the history of manufacture of the lot and the results of all tests performed on the lot. The FDA also may perform certain confirmatory tests on lots of some products before releasing the lots for distribution. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency and effectiveness of biologic products. Failure to comply with the FDA&#8217;s post-approval regulations can result in withdrawal of product approval and licensure.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A sponsor also must comply with the FDA&#8217;s or appropriate national authority&#8217;s advertising and promotion requirements, such as the prohibition on promoting products for uses or in patient populations that are not described in the product&#8217;s approved labeling (known as &#8220;off-label use&#8221;). Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions. In addition, changes to the manufacturing process or facility generally require prior FDA approval before being implemented and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Orphan and RMAT designation</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We maintain product candidates that have obtained FDA and EU orphan designation. See the &#8220;&#8212;Therapeutic Product Development&#8221; section above. These products are intended for treating rare conditions that affect fewer than 200,000 people in the U.S., or that affect more than 200,000 persons but are not expected to recover the costs of developing and marketing a treatment drug. In the EU, these rare conditions are defined as having a prevalence of no more than five in every 10,000 people in the EU. Once a medicinal product with orphan designation obtains a marketing approval, it can benefit from a marketing exclusivity period in respect of the specific orphan indication for which the drug has been approved for a period of seven years in the U.S. and for up to ten years in the EU. This measure is intended at incentivizing the development of medicines for rare diseases. The product must be able to maintain its orphan designation, by reference to the criteria of (a)&#160;prevalence of the condition and (b)&#160;significant benefit of the product over competing products. If the manufacturer is no longer able to assert that the product meets the orphan designation criteria or is not able to provide sufficient quantities, it may lose the orphan market exclusivity.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">24</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have also received RMAT designation for our SB-525 product candidate to treat severe hemophilia A. RMAT designation is intended to expedite review of a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition and for which preliminary clinical evidence indicates the potential to address unmet medical needs for such a disease or condition. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">RMAT designation provides potential benefits that include more frequent meetings with the FDA to discuss the development plan for the product candidate, and eligibility for rolling review and priority review of the related BLA. Products granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites, including through expansion to additional sites. However, RMAT designation does not change the FDA&#8217;s standards for product approval. Additionally, RMAT designation can be revoked if the criteria for eligibility cease to be met as clinical data emerges.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Clinical Trial Data Disclosure</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Many jurisdictions have mandatory clinical trial information obligations on sponsors. In the EU this is under the Transparency Regulation No. 1049/ 2001, EMA Policy 0043, EMA Policy 0070, as well as the new Clinical Trials Regulation No. 536/2014, all of which impose on sponsors the obligation to make publicly available certain information stemming from clinical studies. In the EU, the transparency framework provides for a wide right for (EU-based at the moment) interested parties to submit an access to documents request to the EMA for information included in the marketing authorization application dossier for approved medicinal products. Only very limited information is exempted from disclosure (i.e. commercially confidential information, which is construed increasingly narrowly and protected personal data). It is possible for competitors to access and use this data in their own research and development programs anywhere in the world, once this data is in the public domain.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Additional Regulation</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Although we currently do not have any products on the market, we may be subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which we conduct our business. Such laws include, without limitation:</span></div><div style="text-indent:-31.5pt;padding-left:90pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt;">the federal healthcare Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid;</span></div><div style="text-indent:-31.5pt;padding-left:90pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt;">federal civil and criminal false claims laws, including the federal False Claims Act, and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment or approval that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></div><div style="text-indent:-31.5pt;padding-left:90pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program and also created federal criminal laws that prohibit, among other things, knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statements in connection with the delivery of or payment for healthcare benefits, items or services;</span></div><div style="text-indent:-31.5pt;padding-left:90pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, which impose obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information held by certain healthcare providers, health plans and healthcare clearinghouses, known as covered entities, and individuals and entities that perform services for them that involve individually identifiable health information, known as business associates;</span></div><div style="text-indent:-31.5pt;padding-left:90pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt;">the federal Physician Payments Sunshine Act created under the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the ACA, which  requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for Medicare and Medicaid Services, or CMS, information related to payments and other transfers of value to physicians, as defined by such law, and teaching hospitals, and ownership and investment interests held by physicians and their immediate family members;</span></div><div style="text-indent:-31.5pt;padding-left:90pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; some state laws require </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">25</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="padding-left:90pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, require drug manufacturers to report information related to payments and other transfers of value to other healthcare providers and healthcare entities, marketing expenditures; or drug pricing; and/or ensure the registration of sales personnel; and</span></div><div style="text-indent:-31.5pt;padding-left:90pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt;">state and foreign laws govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">If our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to significant penalties, including, without limitation, civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs, individual imprisonment, suspension or withdrawal of our marketing and commercialization in respect of our commercially approved products, and additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, any of which could adversely affect our ability to operate our business and our financial results. Responding to investigations can be time-and resource-consuming and can divert management&#8217;s attention from the business. Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our business.  See &#8220;Risk Factors</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">&#8212;Our current and future relationships with healthcare providers, customers and third-party payors subject us to applicable anti- kickback, fraud and abuse and other healthcare laws and regulations. If we fail to comply with federal, state and foreign laws and regulations, including healthcare, privacy and data security laws and regulations, we could face substantial penalties and our business, results of operations, financial condition and prospects could be adversely affected.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8221;</span></div><div style="margin-top:12pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Healthcare Reform </span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The U.S. and some foreign jurisdictions are considering enacting or have enacted a number of additional legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our product candidates profitably, if approved. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts, which include major legislative initiatives, such as the ACA, to reduce the cost of care through changes in the healthcare system, including limits on the pricing, coverage, and reimbursement of pharmaceutical and biopharmaceutical products, especially under government-funded health care programs, and increased governmental control of drug pricing. The ACA and its implementing regulations, among other things, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics, including products similar to our product candidates, that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program, extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations, subjected manufacturers to new annual fees and taxes for certain branded prescription drugs, created a new Patient Centered Outcomes Research Institute, which provides incentives to programs that increase the federal government&#8217;s comparative effectiveness research, established a new Medicare Part D coverage gap discount program, in which manufacturers must now agree to offer 70%</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D, and created a licensure framework for follow-on biologic products.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There remain legal and political challenges to certain aspects of the ACA, as well as efforts by the current administration to repeal or replace certain aspects of the ACA. Several bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017, or Tax Act, included a provision that repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate&#8221;. In addition, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminates the health insurer tax. In addition, the Bipartisan Budget Act of 2018, or the BBA, among other things, amended the ACA, effective January 1, 2019, to close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole.&#8221;</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Act. Additionally, on December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">26</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect in April 2013, and, due to subsequent legislative amendments to the statute, including the Bipartisan Budget Act of 2018, will remain in effect through 2029 unless additional Congressional action is taken. In January 2013, the American Taxpayer Relief Act of 2012, or the ATRA, was signed into law, which, among other things, further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Also, there has been heightened governmental scrutiny recently over pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. At the federal level, the current administration&#8217;s budget proposal for fiscal year 2020 contained further drug price control measures that could be enacted during the budget process or in other future legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs for low-income patients. Further, the current administration released a &#8220;Blueprint&#8221; to lower drug prices and reduce&#160;&#160; out-of-pocket costs of drugs that contains additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out-of-pocket costs of drug products paid by consumers. The Department of Health and Human Services, or HHS, has solicited feedback on some of these measures and, at the same, has implemented others under its existing authority. While some of these and other measures may require additional authorization to become effective, Congress and the current administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the United States, the EU and other potentially significant markets for our product candidates, government authorities and third-party payors are increasingly attempting to limit or regulate the price of medical products and services, particularly for new and innovative products and therapies, which has resulted in lower average selling prices. Furthermore, the increased emphasis on managed healthcare in the United States and on country and regional pricing and reimbursement controls in the EU will put additional pressure on product pricing, reimbursement and usage, which may adversely affect our future product sales and results of operations. These pressures can arise from rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and healthcare reform, pharmaceutical reimbursement policies and pricing in general.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See &#8220;Risk Factors&#8212;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Recently enacted and future legislation, including potentially unfavorable pricing regulations or other healthcare reform&#160;initiatives, may increase the difficulty and cost for us to obtain regulatory approval of and commercialize our product candidates and affect the prices we may obtain.&#8221;</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Pricing, Coverage and Reimbursement</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pricing and reimbursement of a therapeutic product will largely determine the affordability of the product, and whether the product is prescribed and supplied to patients and private insurance companies may take into account government reimbursement methodologies. Due to these proposed and enacted laws, as well as other actions, significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval, particularly for novel products. In both domestic and foreign markets, sales and reimbursement of any approved products will depend, in part, on the extent to which third-party payors, such as government health programs, commercial insurance and managed healthcare organizations provide coverage, and establish adequate reimbursement levels, for such products. Third-party payors are increasingly challenging the prices charged for medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the FDA-approved products for a particular indication. Additionally, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the cost-effectiveness of our products. If third-party payors do not consider our products to be cost-effective compared to other therapies, these payors may not cover our products after approved as a benefit under their plans or, if they do, the level of reimbursement may not be sufficient to allow us to sell our products on a profitable basis. See &#8220;Risk Factors&#8212;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Even if we are able to commercialize our product candidates, the products may not receive coverage and adequate reimbursement from third-party payors in the United States and in other countries in which we seek to commercialize our products, which could harm our business</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.&#8221;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">27</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the EU, pricing and reimbursement are the prerogative of Member States. Therefore, the requirements around reimbursement of medicinal products can vary widely. Each Member State can follow its own approach, subject to common rules of transparency, competition, and freedom of trade and movement in the EU. Many Member States, including France, Germany and the United Kingdom, follow a health technology assessment, or HTA, procedure for medicinal products in order to assess the cost-effectiveness of a product which could then be recommended for reimbursement under the national health services. There is increasingly exchange of information concerning HTAs on a voluntary basis among EU Member States. In the United Kingdom, the National Institute for Health and Care Excellence is the body which conducts HTAs and issues guidance to be followed by the regional health bodies called clinical commissioning groups.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Privacy Regulation</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are required to comply with privacy and data security laws in the United States and in other foreign jurisdiction in which we operate, such as the EU General Data Protection Regulation, or GDPR, and the California Consumer Privacy Act of 2018, or CCPA, which apply to the collection, use, disclosure, transfer, or other processing of personal data. The collection, use, disclosure, transfer or other processing of personal data regarding individuals in the European Union, including personal health data, is subject to GDPR, which became effective on May 25, 2018. The GDPR, which is wide-ranging in scope, imposes several requirements relating to the control over personal data by individuals to whom the personal data relates, the information provided to the individuals, the documentation we must maintain, the security and confidentiality of the personal data, data breach notification and the use of third party processors in connection with the processing of personal data. The GDPR also imposes strict rules on the transfer of personal data out of the European Union, provides an enforcement authority and authorizes the imposition of large penalties for noncompliance, including the potential for fines of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. The GDPR requirements apply not only to third-party transactions, but also to transfers of information between us and our subsidiaries such as Sangamo France, including employee information. The GDPR has increased our responsibility and potential liability in relation to personal data that we process compared to prior European Union law, particularly in light of the acquisition of Sangamo France, and we may be required to put in place additional mechanisms to ensure compliance with the GDPR, which could divert management&#8217;s attention and increase our cost of doing business. However, despite our ongoing efforts to bring our practices into compliance with the GDPR, we may not be successful either due to various factors within our control or other factors outside our control. It is also possible that local data protection authorities may have different interpretations of the GDPR, leading to potential inconsistencies amongst various European Union Member States. Any failure or alleged failure (including as a result of deficiencies in our policies, procedures or measures relating to privacy, data security, marketing or communications) by us to comply with laws, regulations, policies, legal or contractual obligations, industry standards or regulatory guidance relating to privacy or data security, may result in governmental investigations and enforcement actions, litigation, fines and penalties or adverse publicity. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the United States, California adopted the CCPA, which became effective in January 2020. The CCPA establishes a privacy framework for covered businesses, including an expansive definition of personal information and data privacy rights for California residents. The CCPA includes a framework with potentially severe statutory damages and private rights of action.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The CCPA requires covered companies to provide new disclosures to California consumers (as that word is broadly defined in the CCPA), provide such consumers new ways to opt-out of certain sales of personal information and allow for a new cause of action for data breaches.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">It remains unclear how the CCPA will be interpreted, but as currently written, it will likely impact our business activities and exemplifies the vulnerability of our business to not only cyber threats but also the evolving regulatory environment related to personal data.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As we expand our operations, the CCPA may increase our compliance costs and potential liability. Some observers have noted that the CCPA could mark the beginning of a trend toward more stringent privacy legislation in the United States.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other states are beginning to pass similar laws.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Compliance with these and any other applicable privacy and data security laws and regulations is a rigorous and time-intensive process, and we may be required to put in place additional mechanisms ensuring compliance with the new data protection rules. If we fail to comply with any such laws or regulations, we may face significant fines and penalties that could adversely affect our business, financial condition and results of operations.  Furthermore, the laws are not consistent, and compliance in the event of a widespread data breach is costly.  See &#8220;Risk Factors</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#8212;Our current and future relationships with healthcare providers, customers and third-party payors subject us to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations. If we fail to comply with federal, state and foreign laws and regulations, including healthcare, privacy and data security laws and regulations, we could face substantial penalties and our business, results of operations, financial condition and prospects could be adversely affected.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Employees</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of February 21, 2020, we had 354 full-time employees. Approximately 290 of these employees are located in California, seven of these employees are located in London, United Kingdom and the remaining 57 employees are located in </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">28</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">France. None of our employees located in California or London are represented by a collective bargaining organization or covered by a collective bargaining agreement, nor have we experienced work stoppages. Our employees located in France are represented by the Conf&#233;d&#233;ration Fran&#231;aise de l&#8217;Encadrement - Conf&#233;d&#233;ration G&#233;n&#233;rale des Cadres. We believe that our relations with our employees are good.</span></div><div style="margin-top:12pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Corporate Information</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We were incorporated in June 1995 in the state of Delaware and in January 2017, we changed our name from &#8220;Sangamo BioSciences, Inc.&#8221; to &#8220;Sangamo Therapeutics, Inc.&#8221; Our principal executive offices are located at 7000 Marina Blvd, Brisbane, California 94005. Our telephone number is (510) 970-6000. SANGAMO&#174;, Better Therapeutics By Design&#174;, ZFP Therapeutic&#174; and Engineering Genetic Cures&#174; are our registered trademarks in the United States and Sangamo Therapeutics&#8482; and Pioneering Genetic Cures&#8482; are our trademarks. All other trademarks or trade names referred to in this Annual Report on Form 10-K are the property of their respective owners.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Available information</span></div><div style="text-indent:36pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our website is located at </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">www.sangamo.com</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. This Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, are available (free of charge) on our website as soon as reasonably practicable after we electronically file this material with, or furnish it to, the Securities and Exchange Commission, or SEC. Information found on, or accessible through, our website is not a part of, and is not incorporated into, this Annual Report on Form 10-K. In addition, the SEC maintains a website at www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.</span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_19"></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM 1A &#8211; RISK FACTORS</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">An investment in our common stock involves significant risk. This Form 10-K contains forward-looking information based on our current expectations. Because our actual results may differ materially from any forward-looking statements made by or on our behalf, this section includes a discussion of important factors that could affect our actual future results, including, but not limited to, our revenues, expenses, net loss and net loss per share. You should carefully consider the information described in the following risk factors, together with the other information appearing elsewhere in this report, before making an investment decision regarding our common stock.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Relating to Research, Development, Commercialization and Regulatory Approval of our Products and Technology</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our success depends substantially on the results of clinical trials of our therapeutic programs and ability to obtain regulatory approval of our product candidates, and we may be unable to demonstrate safety and efficacy of our product candidates.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a clinical-stage biotechnology company and have ongoing clinical trials evaluating product candidates that use</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> our platform technologies in gene therapy, </span><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ex vivo</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene-edited cell therapy, </span><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> genome editing and </span><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">genome regulation.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> We do not have any products that have obtained regulatory approval and are substantially dependent on the results of clinical trials of our therapeutic programs. However, there is no guarantee that we will be able to achieve positive final safety and efficacy results in our current or future clinical trials for our product candidates. If we fail to demonstrate safety or obtain positive clinical trial results, are unable to meet the expected timeline of these clinical trials or release of data for these programs, or if we are unable to obtain regulatory approval of our product candidates, our anticipated revenue from our product candidates and our prospects for profitability would be adversely affected, which would have an adverse effect on our business operations and financial conditions, which may cause a significant decline in our stock price.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We are exposed to numerous risks associated with conducting required clinical trials for the development of our product candidates, and there is no guarantee that we will be successful in any of our clinical trials or obtain marketing approval for any of our product candidates.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We must conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates before we can obtain marketing approval for any such candidates. We have limited experience in conducting later stage clinical trials and may not possess the necessary resources and expertise to complete such trials. Clinical testing is expensive, time consuming and uncertain. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage. Events that may prevent successful or timely completion of clinical development include, among others:</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">delays in reaching a consensus with regulatory authorities on trial design;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">29</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">delays in reaching agreement on acceptable terms with prospective clinical research organizations, or CROs, and clinical trial sites;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">delays in opening clinical trial sites or obtaining required institutional review board, or IRB, or independent ethics committee approval at each clinical trial site;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">delays in recruiting and enrolling suitable subjects to participate in our clinical trials;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">imposition of a clinical hold by regulatory authorities as a result of a serious adverse event or after an inspection of our clinical trial operations or trial sites;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">failure by us, any CROs we engage or any other third parties to adhere to clinical trial requirements;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">failure to perform in accordance with the FDA, GCP, or applicable regulatory guidelines in the EU and other countries;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">delays in the testing, validation, manufacturing and delivery of our product candidates to the clinical sites, including delays by third parties with whom we have contracted to perform certain of those functions, or as a result of manufacturing or formulation changes to our product candidates;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">delays in having subjects complete participation in a trial or return for post-treatment follow-up;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">clinical trial sites or subjects dropping out of a trial;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the resulting data;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">occurrence of serious adverse events or other safety concerns associated with the product candidate that are viewed to outweigh its potential benefits, result in approval delays or other regulatory restrictions, or harm our reputation;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">occurrence of serious adverse events or other safety concerns in trials of the same class of agents conducted by other sponsors; </span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">failure to demonstrate that a product candidate is safe and effective for its proposed indication;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">unexpected costs and expenses and lack of sufficient funding for these programs; and</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">loss of licenses to critical intellectual properties.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have not yet reached agreement with regulatory authorities on the complete development pathway for certain product candidates, and such authorities have the ability to change decisions or guidance with respect to approvable endpoints, particularly as the technology continues to develop in these areas. Due to the novelty of certain programs, the endpoints needed to support regulatory approvals will likely be different from those originally anticipated. Any inability to successfully complete preclinical and clinical development of our product candidates, or complete such trials in the time frames anticipated, could result in additional costs to us or impair our ability to generate revenues from product sales, or achieve regulatory and commercialization milestones and royalties, or shorten any periods during which we may have exclusivity.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Even if a product candidate were to successfully obtain approval from the FDA and comparable foreign regulatory authorities, any approval might contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, or may be subject to burdensome post-approval study or risk management requirements. Also, any regulatory approval of our current or future product candidates, once obtained, may be withdrawn. If we are unable to obtain and maintain regulatory approval for our product candidates in one or more jurisdictions, or any approval contains significant limitations, we would not be able to generate anticipated revenues or become profitable, which would have an adverse effect on our business operations and financial conditions.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Success in research and preclinical studies or early clinical trial results may not be indicative of results obtained in later trials. Likewise, preliminary, initial or interim data from clinical trials should be considered carefully and with caution since the final data may be materially different from the preliminary, initial or interim data, particularly as more patient data become available.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Results from preclinical studies or early clinical trials are not necessarily predictive of future clinical trial results, and interim results of a clinical trial are not necessarily indicative of final results. Our product candidates may fail to show the desired safety and efficacy in clinical development despite demonstrating positive results in preclinical studies or having successfully advanced through initial clinical trials or preliminary stages of clinical trials. From time to time, we have and may in the future publish or report preliminary, initial or interim data. Preliminary, initial or interim data from our clinical trials and those of our partners may not be indicative of the final results of the trial and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and/or more patient data become available. In this regard, such data may show initial evidence of clinical benefit, but as patients continue to be followed and more patient data becomes available, there is a risk that any therapeutic effects will not be durable in patients and/or will decrease over time, or </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">30</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">cease entirely. Preliminary, initial or interim data also remain subject to audit and verification procedures that may result in the final data being materially different from such preliminary, initial or interim data. As a result, preliminary, initial or interim data should be considered carefully and with caution until the final data are available.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There is no guarantee that any of our pending clinical trials will be successful. Moreover, we have pending clinical trials involving our zinc finger nucleases, or ZFN, technology, where the clinical benefit has not been demonstrated in analyses conducted to date in the ongoing clinical trials. Although we are planning new clinical trials to evaluate updated ZFNs and other potential modifications to enhance the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> delivery of the ZFNs, there can be no assurance that we will be able to effectively deliver ZFNs to produce a clinical benefit to patients treated with our product candidates. In addition, our viral delivery systems and ZFN technologies continue to evolve and neither has been fully validated in human clinical trials for the therapeutic areas we are pursuing. If our viral delivery systems or ZFN technologies do not meet the safety criteria or cannot produce the desirable efficacy results we expect, we may be forced to suspend or terminate the affected program or seek alternative technologies to deliver ZFNs.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, there is a high failure rate for drugs, biologic products and cell therapies proceeding through clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in preclinical testing and earlier-stage clinical trials. Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit or prevent regulatory approval. Any such setbacks could adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our product candidates are subject to a lengthy and uncertain regulatory approval process in each jurisdiction where approval is sought.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A regulatory authority such as the FDA or the  EMA, must approve any human therapeutic product before it can be marketed in such jurisdiction. The process for receiving regulatory approval is long and uncertain, and a potential product may not withstand the rigors of testing under the regulatory approval processes. Before commencing clinical trials in humans in the United States, we must submit an Investigational New Drug application, or IND, to the FDA. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials. In the EU, for example, a clinical trial authorization, or CTA, must be submitted for each clinical protocol to each country&#8217;s national health authority and an independent ethics committee. Only after an IND becomes effective and/or the applicable CTA has been accepted may clinical trials begin.  See &#8220;Business&#8212;Government Regulation&#8221; for details regarding the regulatory approval processes applicable to our product candidates.  While there is some overlap, the regulatory requirements to conduct clinical trials and seek marketing approval vary by jurisdiction.  There is no guarantee that the safety studies and other data generated will be sufficient to permit us to conduct clinical trials in all jurisdictions where planned, or once generated, that such clinical trial data will be sufficient to obtain marketing approval in all jurisdictions in which we intend to seek such approval.  If we are not able to obtain the necessary regulatory approvals to conduct our clinical trials, or commercialize our products, or if such approvals are delayed or suspended, it would have an adverse effect on our business operations and trading price of our common stock.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may not be able to find suitable patients or find it difficult to enroll patients for our clinical trials, which could delay or prevent us from proceeding with clinical trials of our product candidates.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Identifying and qualifying patients to participate in clinical trials of our product candidates is critical to our success. The timing of our clinical trials depends on our ability to recruit patients to participate as well as completion of required follow-up periods. For example, hemophilia trials often take longer to enroll due to the availability of existing treatments.  There are also a number of other product candidates in development by our competitors, who compete for the same limited patient populations. We infused the first patient in the Phase 1/2 clinical trial evaluating ST-400 for the treatment of beta thalassemia in the first quarter of 2019 and have enrolled five out of the six targeted as of the date of this report. If we are not able to enroll the necessary number of patients in a timely manner, we may not be able to complete our clinical trials. We may face similar challenges or delays in our other or potential future clinical trials. If patients are unwilling to participate in our gene therapy studies because of negative publicity from adverse events related to the biotechnology or gene therapy fields, competitive clinical trials for similar patient populations or for other reasons, the timeline for recruiting patients, conducting studies and obtaining regulatory approval of our product candidates may be delayed. These delays could result in increased costs, delays in advancing our product candidates, delays in testing the effectiveness of our product candidates or termination of the clinical trials altogether.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may not be able to identify, recruit and enroll a sufficient number of patients, or those with required or desired characteristics, to complete our clinical trials in a timely manner. Patient enrollment and trial completion is affected by factors including:</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">size of the patient population and process for identifying subjects;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">design of the trial protocol;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">31</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">eligibility and exclusion criteria;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">perceived risks and benefits of the product candidate under study;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">perceived risks and benefits of gene therapy-based approaches to treatment of diseases;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">availability of competing therapies and clinical trials;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">severity of the disease under investigation;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">availability of genetic testing for potential patients;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">proximity and availability of clinical trial sites for prospective subjects;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">ability to obtain and maintain subject consent;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">risk that enrolled subjects will drop out before completion of the trial;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">patient referral practices of physicians; and</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">ability to monitor subjects adequately during and after treatment.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we have difficulty enrolling a sufficient number of patients to conduct our clinical trials as planned, we may need to delay, limit or terminate ongoing or planned clinical trials, or expand to additional jurisdictions, which could impose additional challenges on our company and expose us to risks. If we are not successful in conducting our clinical trials as planned, it would have an adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may encounter difficulties that may delay, suspend or scale back our efforts to advance additional research programs through preclinical development, IND and foreign equivalent submissions and into clinical development.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We intend to advance early research programs through preclinical development and to submit new INDs, CTAs and equivalent filings in foreign regulatory jurisdictions necessary to commence and conduct human clinical trials evaluating the preclinical candidates in our pipeline. The preparation and submission of INDs and their foreign equivalents requires us to conduct rigorous and time-consuming preclinical testing, studies, and prepare documentation relating to, among other things, the toxicity, safety, manufacturing, chemistry and clinical protocol of our product candidates. We may experience unforeseen difficulties that could delay or otherwise prevent us from executing this strategy successfully. For example, we may encounter problems in the manufacturing of our products and fail to demonstrate consistency in the formulation of the drug. Our preclinical tests may produce negative or inconclusive results, which may lead us to decide, or regulators may require us, to conduct additional preclinical testing. If we cannot obtain positive results in preclinical testing, we may decide to abandon the projects altogether. In addition, our ability to complete and submit certain IND applications and foreign equivalent filings depends on the support of our partners and the timely performance of their obligations under relevant collaboration agreements. If our partners are not able to perform such obligations or if they choose to slow down or delay the progress, we may not be able to prepare and submit the intended INDs or their foreign equivalents on a timely basis or at all. Furthermore, the submission of several INDs and their foreign equivalents involves significant cost and labor, and we may not have sufficient resources and personnel to complete the filing of all intended INDs and their foreign equivalents, which may force us to scale back the number of INDs and their foreign equivalents or forego potential INDs and foreign equivalents that we believe are promising. Any delay, suspension or reduction of our efforts to pursue our preclinical and IND strategy could have an adverse effect on our business and cause our stock price to decline.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Special regulatory designations, such as RMAT, or orphan drug designations, may not be available for our product candidates or may not lead to a faster development or regulatory review or approval process.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have received RMAT, designation for our product candidate to treat severe hemophilia A. Additionally, some of our product candidates have also been granted Orphan Drug Designation by the FDA, and some have also been designated Orphan Medicinal Products by the EMA. Regulatory authorities in some jurisdictions, including the United States and the EU, may designate drugs for relatively small patient populations as orphan drugs. For additional information regarding these special regulatory designations, see &#8220;Business&#8212;Government Regulation.&#8221;</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we request such designations for our other current or future product candidates, there can be no assurances that the FDA or the EMA will grant any of our product candidates such designations. Additionally, such designations do not guarantee that any regulatory agency will accelerate regulatory review of, or ultimately approve, those product candidates, nor does it limit the ability of any regulatory agency to grant such designations to product candidates of other companies that treat the same indications as our product candidates prior to our product candidates receiving exclusive marketing approval. Such designations can also be revoked. RMAT designation can be revoked if the criteria for eligibility cease to be met as clinical data emerges. Orphan drug exclusivity may be revoked if any regulatory agency determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition. </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">32</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the approved indications or commercial potential, or result in significant negative consequences following any potential marketing approval.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the conduct of clinical trials, patients report changes in their health, including illnesses, injuries and discomforts, to their study doctor. Often, it is not possible to determine whether or not the product candidate being studied caused these conditions, particularly as many of the diseases we are studying have complex comorbidities. If clinical experience indicates that our product candidates have side effects or cause serious or life-threatening side effects, the development of the product candidate may fail or be delayed, or, if the product candidate has received regulatory approval, such approval may be revoked, which would severely harm our business, prospects, operating results and financial condition.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There have been several significant adverse side effects in gene therapy treatments in the past, including reported cases of leukemia and death seen in other trials using other genomic therapies. Gene therapy is still a relatively new approach to disease treatment and additional adverse side effects could develop. There also is the potential risk of significantly delayed adverse events following exposure to gene therapy products due to persistent biologic activity of the genetic material or other components of products used to carry the genetic material. Possible adverse side effects that could occur with treatment with gene therapy products include an immunologic reaction early after administration that, while not necessarily adverse to the patient&#8217;s health, could substantially limit the effectiveness of the treatment. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Even if our product development efforts are successful and even if the requisite regulatory approvals are obtained, our products may not gain market acceptance among physicians, patients, healthcare payors and the medical community.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Even if we obtain regulatory approval for any of our product candidates that we may develop or acquire in the future, the applicable product may not gain market acceptance among physicians, healthcare payors, patients or the medical community. Market acceptance of any of our product candidates for which we receive approval depends on a number of factors, including:</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the efficacy and safety of such product candidates as demonstrated in clinical trials;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the clinical indications and patient populations for which the product candidate is approved;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">acceptance by physicians, major cancer treatment centers and patients of the drug as a safe and effective treatment;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the adoption of novel gene therapies by physicians, hospitals and third-party payors;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the potential and perceived advantages of product candidates over alternative treatments;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the safety of product candidates seen in a broader patient group, including its use outside the approved indications;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">any restrictions on use together with other medications;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the prevalence and severity of any side effects;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">product labeling or product insert requirements of the FDA or other regulatory authorities;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the timing of market introduction of our products as well as competitive products;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the development of manufacturing and distribution processes for our product candidates;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the cost of treatment in relation to alternative treatments;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the availability of coverage and adequate reimbursement and the willingness of patients to pay out-of-pocket in the absence of coverage or inadequacy of reimbursement by third-party payors and government authorities;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">relative convenience and ease of administration; and</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the effectiveness of our sales and marketing efforts and those of our collaborators.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If any of our product candidates are approved but fail to achieve market acceptance among physicians, patients, healthcare payors or treatment centers, we will not be able to generate significant revenues, which would compromise our ability to become profitable.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Even if we are able to commercialize our product candidates, the products may not receive coverage and adequate reimbursement from third-party payors in the United States and in other countries in which we seek to commercialize our products, which could harm our business.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our ability to commercialize any product successfully will depend, in part, on the extent to which coverage and adequate reimbursement for these products and related treatments will be available. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, determine which medications they will cover and establish reimbursement levels, which can affect demand for, or the price of, any product candidate for which we obtain regulatory approval. Given the nature of the product candidates that we are developing, some patients may require treatment </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">33</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">only one time (</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">e.g</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">., single dose administration), and there is substantial uncertainty about the pricing structure for such products, and the level of coverage and reimbursement that will be available for a shift to single-dose treatment as compared to chronic therapy over a patient&#8217;s lifetime. If other companies establish a new pricing structure or business model, including payment based on demonstration of long term efficacy, our ability to price or obtain reimbursement for our products may be adversely affected. If such pricing structure or business model do not adequately fund the costs of our research and development, manufacturing and commercialization efforts, our business may be adversely affected.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to uncertainty about the potential pricing structure for certain of our product candidates, cost containment is a recurrent trend in the healthcare industry.  Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. We cannot be sure that coverage and adequate reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be. If reimbursement is not available or is available only at limited levels, we may be unable to successfully commercialize any product candidate for which we obtain regulatory approval. Our inability to promptly obtain coverage and profitable reimbursement rates from both government-funded and private payors for any approved products that we develop could have an adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently enacted and future legislation, including potentially unfavorable pricing regulations or other healthcare reform initiatives, may increase the difficulty and cost for us to obtain regulatory approval of and commercialize our product candidates and affect the prices we may obtain.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The regulations that govern, among other things, regulatory approvals, coverage, pricing and reimbursement for new drug products vary widely from country to country. In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay regulatory approval of our product candidates, restrict or regulate post-approval activities and affect our ability to successfully sell any product candidates for which we obtain regulatory approval. Also, there has been heightened governmental scrutiny recently over pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, have been designed to encourage importation from other countries and bulk purchasing.  For a discussion of health reform activity and the current pricing framework, see &#8220;Business&#8212;Government Regulation&#8212;Healthcare Reform&#8221; and &#8220;&#8212;Pricing, Coverage and Reimbursement.&#8221;</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the demand for our product candidates, if we obtain regulatory approval;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to set a price that we believe is fair for our products;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to generate revenue and achieve or maintain profitability;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the level of taxes that we are required to pay; and</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the availability of capital.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Even if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory scrutiny.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Even if we obtain regulatory approval in a jurisdiction, the regulatory authority may still impose significant restrictions on the indicated uses or marketing of our product candidates, or impose ongoing requirements for potentially costly post-approval studies, post-market surveillance or patient or drug restrictions. For example, the FDA typically advises that patients treated with gene therapy undergo follow-up observations for potential adverse events for a 15-year period. Additionally, the holder of an approved BLA is required to comply with FDA rules and is subject to FDA review and periodic inspections, in addition to other potentially applicable federal and state laws, to ensure compliance with good manufacturing practices, or GMP, and adherence to commitments made in the BLA.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we or a regulatory agency discovers previously unknown problems with a product such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions relative to that product or the manufacturing facility, including requiring recall or withdrawal of the product </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">34</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">from the market or suspension of manufacturing. Moreover, product labeling, advertising and promotion for any approved product will be subject to regulatory requirements and continuing regulatory review. Failure to comply with such requirements, when and if applicable, could subject us to a number of actions ranging from warning letters to product seizures or significant fines, among other actions.  See &#8220;Business&#8212;Government Regulation&#8212;U.S. Review and Approval Processes&#8221; for more information.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any government investigation of alleged violations of laws or regulations could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenues.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our employees or contractors may engage in misconduct or other improper activities, including noncompliance with research, development, manufacturing or regulatory standards and requirements, which could cause significant liability for us and harm our reputation.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are exposed to the risk of  fraud or other misconduct by our employees and contractors, including intentional failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, provide accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards we have established, comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report financial information or data accurately or disclose unauthorized activities to us. Misconduct by our employees and contractors could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter such misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal and administrative penalties, damages, fines, disgorgement, personal imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may use our financial and human resources to pursue a particular research program or product candidate and fail to capitalize on programs or product candidates that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have limited resources, and may forego or delay pursuit of certain programs or product candidates that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities, or pursue partnering arrangements rather than retain sole responsibility for development. Our current and future research and development programs for product candidates may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may pursue opportunities that end up having a number of competitors that are more advance than our product candidates, or relinquish valuable rights to that product candidate through strategic collaboration, licensing or other royalty arrangements in cases where it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.  We may also allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a partnering arrangement or that do not prove to have viable commercial opportunities.  Any failure to use our financial and human resources efficiently could harm our business and operations.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Even if our technology proves to be effective, it still may not lead to commercially viable products.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Even if we, our collaborators or strategic partners are successful in using our zinc finger protein, or ZFP, technology in drug discovery, protein production, therapeutic development or other areas in which we have licensed our technology, such as plant agriculture, they may not be able to commercialize the resulting products or may decide to use other methods competitive with this technology. To date, no company has received marketing approval or has developed or commercialized any therapeutic or agricultural products based on our ZFP technology. Should our technology fail to provide safe, effective, useful or commercially viable approaches to the discovery and development of these product candidates, this would significantly limit our business and future growth and would adversely affect our value.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Relating to Manufacturing</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We are building a manufacturing facility that could support future clinical production of our product candidates. We have no experience as a company manufacturing pharmaceutical products, and there can be no assurance that we will </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">35</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">be able to build a compliant manufacturing facility or, if built, we will be able to successfully manufacture any of our product candidates.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect to utilize both contract manufacturing organizations, or CMOs, and our own facility to meet our projected needs for clinical supply. We intend to expand our manufacturing capacity by designing and building a manufacturing facility in Brisbane, California that we plan to initially use to support our clinical supply needs. To meet these objectives we will need to transition manufacturing processes and know-how of our product candidates to our own facility. Transferring manufacturing processes and know-how is complex and involves review and incorporation of both documented and undocumented processes that may have evolved over time. In addition, transferring production to different facilities may require utilization of new or different processes to meet the specific requirements of a given facility. Additional studies may also need to be conducted to support the transfer of certain manufacturing processes and process improvements. We cannot be certain that all relevant know-how and data has been adequately incorporated into the manufacturing process until the completion of studies (and the related evaluations) intended to demonstrate the comparability of material previously produced with that generated by our CMOs. Although some of our employees have experience in the manufacturing of pharmaceutical products from prior employment at other companies, we, as a company, have no prior experience in pharmaceutical product manufacturing, and operating this facility will require us to comply with complex regulations and to continue to hire and retain experienced scientific, quality control, quality assurance and manufacturing personnel. Designing and building a manufacturing facility has been and will continue to be time-consuming and expensive, and we may experience delays or cost overruns. In addition, government approvals will be required for us to operate a manufacturing facility and can be time-consuming to obtain. As a manufacturer of pharmaceutical products, we also will be required to demonstrate and maintain cGMP compliance. These requirements include, among other things, quality control, quality assurance and the maintenance of records and documentation. Furthermore, establishing manufacturing operations will require a reallocation of other resources, particularly the time and attention of our senior management. Even if we are able to establish our own manufacturing capabilities, we could encounter challenges in operating the manufacturing facility in compliance with cGMP, regulatory or other applicable requirements, resulting in potential negative consequences, including regulatory actions, which could undermine our ability to utilize this facility for our own manufacturing needs. Any failure or delay in the development of our manufacturing capabilities could adversely impact the development of our product candidates.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We operate laboratory and manufacturing as part of our facilities. If we use chemical biological and hazardous materials in a manner that causes injury or violates laws, we may be liable for damages.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There are risks associated with manufacturing our product candidates including, among others, cGMP compliance, cost overruns, technical problems with process scale-up, process reproducibility, stability issues, lot consistency, yields and timely availability of raw materials. Even if efficacy and safety data from our clinical trials would otherwise support regulatory approval for a product candidate, there is no assurance that we or any third-party manufacturer will be able to manufacture our product candidates to specifications at levels necessary to support or maintain regulatory approval by the FDA or other regulatory authorities. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For example, some of our product candidates are biologics and their manufacture involves complex processes, including the development of cell lines or cell systems to produce the biologic, with the challenge of significant variability. Further, there are difficulties in growing large quantities of such cells, consistently and sufficiently isolating certain types of cells and harvesting and purifying the biologic produced by them. The cost to manufacture biologics is generally far higher than traditional small molecule chemical compounds, and the manufacturing process can be difficult to reproduce. Additionally, our research and development activities involve the controlled use of potentially harmful biological materials as well as hazardous materials, chemicals, and various radioactive compounds typically employed in the study of molecular and cellular biology. We routinely use cells in culture and gene delivery vectors, and we employ small amounts of radioisotopes in trace experiments. Although we maintain up-to-date licensing and training programs, we cannot completely eliminate the risk of accidental contamination or injury from the use, storage, handling, or disposal of these materials. In the event of contamination or injury, we could be held liable for damages that result, and any liability could exceed our resources. We currently carry insurance covering certain claims arising from our use of these materials. However, if we are unable to maintain our insurance coverage at a reasonable cost and with adequate coverage, our insurance may not cover any liability that may arise. We are subject to federal, state, and local laws and regulations governing the use, storage, handling, and disposal of these materials and specified waste products.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Thus, there is no guarantee we will be successful in establishing a larger-scale commercial manufacturing process for our pipeline product candidates or obtaining the needed manufacturing capacity. Due to the high cost to manufacture, inherent uncertainty related to manufacturing costs, and uncertainty in our patient population, there is risk that some of our product candidates may not be commercially viable.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Supply interruptions may disrupt our inventory levels and the availability of our product candidates, and cause delays in obtaining regulatory approval, which could harm our business by reducing our potential revenues.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">36</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our product candidates are manufactured using technically complex processes requiring specialized facilities, highly specific raw materials and other production constraints. The complexity of these processes, as well as strict government standards for the manufacture and storage of our products candidates, subjects us to production risks. While product batches released for use in clinical trials undergo sample testing, some defects may only be identified following product release. In addition, process deviations or unanticipated effects of approved process changes may result in these intermediate products not complying with stability requirements or specifications. For example, our product candidates must be stored and transported at temperatures within a certain range. If these environmental conditions deviate, our product candidates&#8217; remaining shelf-lives could be impaired or their efficacy and safety could be adversely affected, making them no longer suitable for use.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The occurrence, or suspected occurrence, of production and distribution difficulties can lead to lost inventories, with consequential reputational damage and the risk of product liability. The investigation and remediation of any identified problems can cause development delays and substantial expense. Any unforeseen failure in the storage of the product or loss in supply could delay our clinical trials and, with respect to our product candidates that may be approved, result in a loss of our market share and negatively affect our business, financial condition, results of operations and prospects.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We currently rely on third parties to conduct some or all aspects of manufacturing of our product candidates for preclinical and clinical development. If one of our third-party manufacturers fails to perform adequately or fulfill our needs, we may be required to incur significant costs and devote significant efforts, to find new suppliers or manufacturers.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We currently have limited experience in clinical-scale manufacturing of our product candidates and we rely upon third-party CMOs to manufacture and supply drug product for our preclinical and clinical studies.  Although we are in the process of building out a cGMP compliant manufacturing facility in our Brisbane facility, it is not yet ready, and will only manufacture limited quantities of our product candidates for our early stage clinical trials. We intend to continue to rely on third parties for the manufacture of product candidates for later stage clinical trials, and commercial-scale manufacturing for any approved product. The manufacture of pharmaceutical products in compliance with the FDA&#8217;s cGMP requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of pharmaceutical products often encounter difficulties in production, including difficulties with production costs and yields, quality control, including stability of the product candidate and quality assurance testing, shortages of qualified personnel, as well as compliance with strictly enforced cGMP requirements, other federal and state regulatory requirements and foreign regulations. If our manufacturers were to encounter any of these difficulties or otherwise fail to comply with their obligations to us or under applicable regulations, our ability to provide study biologics in our clinical studies would be jeopardized. Any delay or interruption in the supply of clinical study materials could delay the completion of our clinical studies, increase the costs associated with maintaining our clinical study programs and, depending upon the period of delay, require us to commence new studies at significant additional expense or terminate the studies completely.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We and our CMOs must comply with cGMP requirements enforced by the FDA through its facilities inspection program. These requirements include, among other things, quality control, quality assurance and the maintenance of records and documentation. We and our CMOs may be unable to comply with these cGMP requirements and with other FDA, state and foreign regulatory requirements. The FDA or similar foreign regulatory agencies may also implement new standards at any time, or change their interpretation and enforcement of existing standards for manufacture, packaging or testing of products. We have limited control over our manufacturers&#8217; compliance with these regulations and standards. Failure to comply with these requirements may result in fines and civil penalties, suspension of production, suspension or delay in product approval, product seizure or recall or withdrawal of product approval. If the safety of any product supplied is compromised due to our manufacturers&#8217; failure to adhere to applicable laws or for other reasons, we may not be able to obtain regulatory approval for or successfully commercialize our products and we may be held liable for any injuries sustained as a result. Any of these factors could cause a delay of clinical studies, regulatory submissions, approvals or commercialization of our product candidates, entail higher costs or impair our reputation.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our current agreements with our CMOs do not provide for the entire supply of the drug product necessary for all anticipated clinical studies or for full scale commercialization. If we and our CMOs cannot agree to the terms and conditions for them to provide the drug product necessary for our clinical and commercial supply needs, we may not be able to manufacture the product candidate until a qualified alternative manufacturer is identified, which could also delay the development of, and impair our ability to commercialize our product candidates.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The number of third-party CMOs with the necessary manufacturing and regulatory expertise and facilities is limited, and it could be expensive and take a significant amount of time to arrange for alternative CMOs, which could have an adverse effect on our business. New manufacturers of any product candidate would be required to qualify under applicable regulatory requirements and would need to have sufficient rights under applicable intellectual property laws to the method of manufacturing the product candidate. Obtaining the necessary FDA approvals or other qualifications under applicable regulatory requirements and ensuring non-infringement of third-party intellectual property rights could result in a significant interruption of supply and could require the new manufacturer to bear significant additional costs which may be passed on to us.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">37</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Relating to our Industry</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our product candidates are based on novel technologies, which makes it difficult to predict the timing and costs of development and of subsequently obtaining regulatory approval.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have concentrated our research and development efforts on gene therapy, gene-edited cell therapy, genome editing and genome regulation. The regulatory approval process for novel product candidates such as ours is unclear and may be lengthier and more expensive than the process for other, better-known or more extensively studied product candidates.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Adverse developments in clinical trials of gene therapy products conducted by others may cause the FDA or other oversight bodies to change the requirements for approval of our product candidates.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These regulatory review committees and advisory groups, and any new guidelines they promulgate, may lengthen the regulatory review process, require us to perform additional preclinical studies or clinical trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our current or future product candidates or lead to significant post-approval limitations or restrictions. As we advance our product candidates, we will be required to consult with these regulatory and advisory groups and comply with applicable guidelines. If we fail to do so, we may be required to delay or discontinue development of our product candidates. These additional processes may result in a review and approval process that is longer than we otherwise would have expected. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue, and our business, financial condition, results of operations and prospects would be harmed. Even if our product candidates are approved, we expect that the FDA will require us to submit follow-up data regarding our clinical trial subjects for a number of years after any approval. If this follow-up data shows negative long-term safety or efficacy outcomes for these patients, the FDA may revoke its approval or change the label of our products in a manner that could have an adverse impact on our business.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, adverse developments in clinical trials of gene therapy or cell therapy products conducted by others may cause the FDA or other oversight bodies to change the requirements for approval of our product candidates. The FDA and EMA have only very recent and limited experience in the approval of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene therapy products. As a result, it is difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our product candidates.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we or our competitors develop, acquire, or market technologies or products that are more effective than ours, our financial condition and ability to successfully market or commercialize our product candidates or be profitable would be adversely affected.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The biotechnology and pharmaceutical industries are highly competitive and subject to significant and rapid technological change. We are aware of several companies focused on other methods for editing cells, editing genes and regulating gene expression and a limited number of commercial and academic groups pursuing the development of genome editing and genome regulation technology. The field of applied gene-edited cell therapy, genome editing and genome regulation is highly competitive and we expect competition to persist and intensify in the future from a number of different sources, including pharmaceutical and biotechnology companies, academic and research institutions, and government agencies that will seek to develop competing products as well as technologies that will compete with our ZFP technology platform. For example, in genome editing and gene therapy products, competing proprietary technologies with our product development focus include but are not limited to, recombinant proteins, other gene therapy/cDNAs, antisense, siRNA and microRNA approaches, exon skipping, small molecule drugs, monoclonal antibodies, CRISPR/Cas technology and TALE proteins, meganucleases, and MegaTALs. See &#8220;Business&#8212;Competition&#8221; for more information on the competition we may face.  </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any products that we or our collaborators or strategic partners develop by using our ZFP technology platform will enter into highly competitive markets. Even if we are able to generate products that are safe and effective for their intended use, competing technologies may prove to be more effective or less expensive, which, to the extent these competing technologies achieve market acceptance, will limit our revenue opportunities. In some cases, competing technologies have proven to be effective and less expensive. Competing technologies may include other methods of regulating gene expression or modifying genes. ZFNs and ZFP-TFs have broad application in the life sciences industry and compete with a broad array of new technologies and approaches being applied to genetic research by many companies.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to possessing competing technologies, our competitors include pharmaceutical and biotechnology companies with:</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">substantially greater capital resources than ours; </span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">larger research and development staffs and facilities than ours; and </span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">greater experience in product development and in obtaining regulatory approvals and patent protection. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These organizations also compete with us to attract qualified personnel, attract parties for acquisitions, joint ventures or other collaborations and license the proprietary technologies of academic and research institutions that are competitive with </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">38</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">our technology, which may preclude us from pursuing similar opportunities. Accordingly, our competitors may succeed in obtaining patent protection or commercializing products before us.  Even if our product candidate is more effective, it may be disadvantaged if it is not first to market. In addition, any products that we develop may compete with existing products or services that are well established in the marketplace.  Further, some of our product candidates in development are designed to use once.  Any success in developing single-dose therapeutics could cause us to lose potential recurring revenues from therapeutics that are designed to be taken over a patient&#8217;s lifetime.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Negative public opinion and increased regulatory scrutiny of gene therapy and genomic medicines may damage public perception of the safety of our product candidates and adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Genetically modified products are currently subject to public debate and heightened regulatory scrutiny, either of which could prevent or delay production of agricultural products. Gene therapy remains a novel technology, with only two </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene therapy products approved for a genetic disease to date in the United States and only a few </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene therapy products for genetic diseases approved to date in the EU. Public perception may be influenced by claims that gene therapy is unsafe, and gene therapy may not gain the acceptance of the public or the medical community. For example, reports of serious adverse events in a retroviral gene transfer trial for infants with X-linked severe combined immunodeficiency (X-linked SCID) in France and subsequent FDA actions putting related trials on hold in the United States had a significant negative impact on the public perception and stock price of certain companies involved in gene therapy, whether or not the specific company was involved with retroviral gene transfer, or whether the specific company&#8217;s clinical trials were placed on hold in connection with these events. Other adverse events could occur in the field of gene therapy and genomic medicine that could result in increased regulatory scrutiny, potential regulatory delays or negative impact on public perception of gene therapy and genomic medicines, which could cause our stock price to decline.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In particular, our success will depend upon physicians who specialize in the treatment of genetic diseases targeted by our product candidates, prescribing treatments that involve the use of our product candidates in lieu of, or in addition to, existing treatments with which they are familiar and for which greater clinical data may be available. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Even if the regulatory approval for genetically modified products developed using our technology is obtained, our success will also depend on public acceptance of the use of genetically modified products including drugs, plants, and plant products. Claims that genetically modified products are unsafe for consumption or pose a danger to the environment may influence public attitudes. Our genetically modified products may not gain public acceptance. More restrictive government regulations or negative public opinion would have an adverse effect on our business, financial condition, results of operations and prospects and may delay or impair the development and commercialization of our product candidates or demand for any products we may develop. For example, earlier gene therapy trials led to several well-publicized adverse events, including cases of leukemia and death seen in other trials using other vectors. Serious adverse events in our clinical trials, or other clinical trials involving gene therapy products or our competitors&#8217; products, even if not ultimately attributable to the relevant product candidates, and the resulting publicity, could result in increased government regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our product candidates, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our current and future relationships with healthcare providers, customers and third-party payors subject us to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations. If we fail to comply with federal, state and foreign laws and regulations, including healthcare, privacy and data security laws and regulations, we could face substantial penalties and our business, results of operations, financial condition and prospects could be adversely affected.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain regulatory approval. Arrangements with healthcare providers, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we would market, sell and distribute our products. As a biotechnology company, even though we will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, federal and state healthcare laws and regulations pertaining to fraud and abuse and patients&#8217; rights are and will be applicable to our business. For details regarding the restrictions under applicable federal and state healthcare laws and regulations that may affect our ability to operate see &#8220;Business&#8212;Government Regulation&#8212;Additional Regulation&#8221;.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Scrutiny has also increased, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Responding to investigations can be time-and resource-consuming and can divert management&#8217;s attention from the business. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. If our operations or if any physicians or other healthcare providers or entities with whom we expect to do </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">39</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">business are found to not be in compliance with applicable laws or applicable regulations, we and they could be subjected to significant civil, criminal and administrative enforcement actions, see &#8220;Business&#8212;Government Regulation&#8212;Additional Regulation&#8221;.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Further, we are required to comply with privacy and data security laws, such as the GDPR and the CCPA, which apply to the collection, use, disclosure, transfer, or other processing of personal data. For more information regarding these regulations, see &#8220;Business&#8212;Government Regulation&#8212;Privacy Regulation&#8221;. Any failure or alleged failure (including as a result of deficiencies in our policies, procedures or measures relating to privacy, data security, marketing or communications) by us to comply with laws, regulations, policies, legal or contractual obligations, industry standards or regulatory guidance relating to privacy or data security, may result in governmental investigations and enforcement actions, litigation, fines and penalties or adverse publicity. In addition, new regulation, legislative actions or changes in interpretation of existing laws or regulations regarding data privacy and security (together with applicable industry standards) may increase our costs of doing business. In this regard, we expect that there will continue to be new proposed laws, regulations and industry standards relating to privacy and data protection in the United States, the EU and other jurisdictions, and we cannot determine the impact such future laws, regulations and standards will have on our business.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk if we commercially sell any products that we may develop. Product liability claims may be brought against us by subjects enrolled in our clinical trials, patients, healthcare providers or others using, administering or selling our products. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">decreased demand for any product candidates or products that we may develop;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">termination of clinical trial sites or entire trial programs;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">injury to our reputation and significant negative media attention;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">withdrawal of clinical trial participants;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">significant costs to defend the related litigation;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">substantial monetary awards to trial subjects or patients;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">loss of revenue;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">diversion of management and scientific resources from our business operations; and</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the inability to commercialize any products that we may develop.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We currently hold product liability insurance coverage at a level that we believe is customary for similarly situated companies and adequate to provide us with insurance coverage for foreseeable risks, but which may not be adequate to cover all liabilities that we may incur. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. We intend to expand our insurance coverage for products to include the sale of commercial products if we obtain regulatory approval for our product candidates in development, but we may be unable to obtain commercially reasonable product liability insurance for any products that receive regulatory approval. Large judgments have been awarded in class action lawsuits based on drugs that had unanticipated side effects. A successful product liability claim or series of claims brought against us, particularly if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Relating to our Finances</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We have incurred significant operating losses since inception and anticipate that we will incur continued losses for the foreseeable future.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have generated operating losses since we began operations in 1995. The extent of our future losses and the timing of profitability are uncertain, and we expect to incur losses for the foreseeable future. We have been engaged in developing our ZFP technology since inception, which has and will continue to require significant research and development expenditures. To date, we have generated our funding from issuance of equity securities, revenues derived from collaboration agreements, other strategic partnerships in non-therapeutic applications of our technology, federal government research grants and grants awarded by research foundations. We expect to continue to incur additional operating losses for the next several years as we continue to advance our product candidates. If the time required to generate significant product revenues and achieve profitability is longer than we currently anticipate or if we are unable to generate liquidity through equity financing or other sources of funding, we may be forced to curtail or suspend our operations.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">40</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may be unable to raise additional capital on favorable terms, if at all, which would harm our ability to develop our technology and product candidates, and could delay or terminate some or all of our programs. Future sales and issuances could also result in dilution to our stockholders. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have incurred significant operating losses and negative operating cash flows since inception and have not achieved profitability. We expect capital outlays and operating expenditures to increase over the next several years as we expand our infrastructure and research and product development activities. While we believe our available cash resources, as well as funds received from corporate collaborators, strategic partners and research grants will enable us to maintain our currently planned operations through at least the next 12 months from the date the financial statements are issued, we will need to raise substantial additional capital to fund the development, manufacturing and potential commercialization of our product candidates.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The February 2020 collaboration agreement and stock purchase agreements with Biogen are not yet effective, and we will not receive the upfront payment or the proceeds from the sale of our common stock until they become effective and customary closing conditions are met.</span><span style="background-color:rgb(255,255,255, 0.0);color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We regularly consider fund raising opportunities and may decide, from time to time, to raise capital based on various factors, including market conditions and our plans of operation. In addition, as we focus our efforts on proprietary human therapeutics, we will need to seek FDA approvals of potential products, a process that could cost in excess of hundreds of millions of dollars per product. We may experience difficulties in accessing the capital market due to external factors beyond our control such as volatility in the equity markets for emerging biotechnology companies and general economic and market conditions both in the United States and abroad. We cannot be certain that we will be able to obtain financing on terms acceptable to us, or at all. Our failure to obtain adequate and timely funding will adversely affect our business and our ability to develop our technology and products candidates.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our ability to use net operating losses to offset future taxable income may be subject to limitations.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Although certain amount of our federal net operating loss carryforwards carry forward indefinitely (but are subject to a percentage limitation), a significant amount of our federal and all of our state net operating loss carryforwards will begin to expire, if not utilized, beginning in 2024 and 2029, respectively. The net operating loss carryforwards subject to expiration could expire unused and be unavailable to offset future income tax liabilities. In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50 percentage point change in its equity ownership value over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. We have experienced an ownership change in the past and we may also experience additional ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control. If an ownership change occurs and our ability to use our net operating loss carryforwards is materially limited, it would harm our future operating results by effectively increasing our future tax obligations. In addition, at the state level, there may be periods during which the use of net operating loss carryforwards is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. As a result, if we earn net taxable income, we may be unable to use all or a material portion of our net operating loss carryforwards and other tax attributes, which could potentially result in increased future tax liability to us and adversely affect our future cash flows.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Relating to our Reliance on Third Parties</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If conflicts arise between us and our contractors, collaborators or strategic partners, these parties may act in their self-interest, which may limit our ability to implement our strategies and otherwise harm our business and prospects.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If conflicts arise between our contractors, corporate or academic collaborators or strategic partners and us, the other party may act in its self-interest, which may limit our ability to implement our strategies. Some of our academic collaborators and strategic partners are conducting multiple product development efforts within each area that is the subject of the collaboration with us. Our collaborators or strategic partners may develop, either alone or with others, products in related fields that are competitive with the products or potential products that are the subject of these collaborations. Competing products, either developed by the collaborators or strategic partners or to which the collaborators or strategic partners have rights, may result in the withdrawal of partner support for our product candidates.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Some of our collaborators or strategic partners could also become our competitors in the future. Our collaborators or strategic partners could develop or invest in competing products, preclude us from entering into collaborations with their competitors, fail to obtain timely regulatory approvals, terminate their agreements with us prematurely, or fail to devote sufficient resources to the development and commercialization of product candidates covered by the applicable agreement.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">41</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, conflicts could arise between us and our collaborators resulting from disputes regarding our or our collaborators&#8217; or strategic partners&#8217; performance under the applicable agreement, including disputes arising from alleged breaches of our agreements with our collaborators and strategic partners. For example, we have certain confidentiality obligations to our collaborators and strategic partners under our agreements with them, and it is possible that, in connection with the data security incident we disclosed in April 2018, we could be subject to claims that we have breached our confidentiality obligations, which could result in damages payable by us and/or the affected collaborator or strategic partner seeking to terminate its agreement with us.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any of these developments could harm our product development efforts and otherwise adversely affect our business and prospects.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our collaborators and strategic partners may control aspects of our research, development and manufacturing programs, including but not limited to, our clinical trials, which could result in delays and other obstacles in the commercialization of our proposed products.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We depend on third-party collaborators and strategic partners to design and conduct our clinical trials for some of our therapeutic programs. As a result, we may not be able to conduct these programs in the manner or on the time schedule we currently contemplate, which may negatively impact our business operations. In addition, if any of these collaborators or strategic partners withdraws support for our programs or proposed products or otherwise impair their development; our business could be negatively affected.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our lack of control over the clinical development in our agreements with Biogen, Kite, Sanofi and Pfizer could cause delays or other difficulties in the development and commercialization of our product candidates, which may prevent us from completing the intended IND filings in a timely fashion and receiving any milestone, royalty payments and other benefits under the agreement. In addition, under their respective agreements, our third-party collaborators have certain rights to terminate the agreements by providing us with advance notices, therefore, the actual milestone payments that we may receive under these agreements may be substantially lower than the full amounts provided for under these agreements.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our license collaborators or strategic partners may decide to adopt alternative technologies or products, or may be unable to develop commercially viable products with our technology, which would negatively impact our revenues and our strategy to develop these products.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our collaborators or strategic partners may adopt alternative technologies, which could decrease the marketability of ZFP technology. Additionally, because many of our collaborators or strategic partners are likely to be working on more than one development project, they could choose to shift their resources to projects other than those they are working on with us. If they do so, this would delay our ability to test our technology and would delay or terminate the development of potential products based on our ZFP technology. Further, our collaborators and strategic partners may elect not to develop products arising out of our collaborative and strategic partnering arrangements or to devote sufficient resources to the development, manufacturing, marketing or sale of these products. If they terminate the collaborative relationship with us, we will be required to seek the support of other partners or collaborators. We may not have sufficient resources and expertise to develop these programs by ourselves, and we may not be able to identify a suitable partner or negotiate a favorable collaboration agreement to allow us to continue the development of these programs. If any of these events occur, we may not be able to develop our technologies or commercialize our products.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Commercialization of our technologies will depend, in part, on strategic partnering with other companies. If we are not able to find partners in the future or if our partners do not diligently pursue product development efforts, we may not be able to develop our technologies or product candidates, which could slow our growth and decrease the value of our stock.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect to rely, to some extent, on our strategic partners to provide funding in support of our research and to perform independent research and preclinical and clinical testing. Our technology is broad-based, and we do not currently possess the resources necessary to fully develop and commercialize potential products that may result from our technologies or the resources or capabilities to complete the lengthy marketing approval processes that may be required for the products. Therefore, we plan to rely on strategic partnerships to help us develop and commercialize our products. We have entered into collaborative agreements to provide funding and assistance in the development of certain product candidates through the clinical trial process. For example, we have an agreement with Biogen for ST-501, a preclinical ZFP-TF product candidate for tauopathies including Alzheimer&#8217;s disease, ST-502, a preclinical ZFP-TF product candidate for alpha-synuclein related diseases including Parkinson&#8217;s disease, among other targets for gene regulation therapies for the treatment of neurological diseases, we also have an agreement with Kite for potential engineered cell therapies for cancer, two separate agreements with Pfizer, one for SB-525 for hemophilia A, and another for amyotrophic lateral sclerosis and frontotemporal lobar degeneration linked to mutations of the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">C9ORF72</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene, and an agreement with Sanofi for our beta thalassemia and sickle cell disease product candidates.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we are unable to find additional partners or if the partners are unable or unwilling to advance our programs, or if they do not diligently pursue product approval, this may slow our progress and adversely affect our ability to generate revenues. </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">42</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, our partners may sublicense or abandon development programs or we may have disagreements or disputes with our partners, which would cause associated product development to slow or cease. In addition, the business or operations of our partners may change significantly through restructuring, acquisition or other strategic transactions or decisions that may negatively impact their ability to advance our programs.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The loss of partnering agreements or inability to find future partnering agreements may delay or terminate the potential development or commercialization of products we may derive from our technologies, but it may also delay or terminate our ability to test our product candidates. If any partner fails to conduct the collaborative activities successfully or in a timely manner, the preclinical or clinical development or commercialization of the affected product candidates or research programs could be delayed or terminated.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under typical partnering agreements, we would expect to receive revenue for the research and development of our product candidates based on achievement of specific milestones, as well as royalties based on a percentage of sales of the commercialized products. Achieving these milestones will depend, in part, on the efforts of our partner as well as our own. If we, or any partner, fail to meet specific milestones, then the partnership may be terminated, which could reduce our revenues. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Relating to our Intellectual Property</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Because it is difficult and costly to protect and maintain our proprietary rights, and third parties may have filed patent applications that are similar to ours, we may not be able to obtain or maintain proprietary protection of our technologies and products or we may only obtain protection in limited jurisdictions.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our commercial success may depend in part on obtaining and enforcing patent protection for our technology and successfully defending any of our patents that may be challenged. Obtaining and enforcing pharmaceutical and biotechnology patents is costly, time consuming and complex, and we may not be able to file and prosecute all necessary or desirable patent applications, or maintain, enforce and license any patents that may issue from such patent applications, at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and can involve complex legal and factual questions. No consistent policy regarding the breadth of claims allowed in biotechnology patents has emerged to date. Accordingly, we cannot predict the breadth of claims that may issue from any patent applications that we own or license, nor are we able to predict whether any third-party patents might issue with claims that are relevant to our product candidates or technologies.  Even if patents do successfully issue and even if such patents cover our product candidates, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed or invalidated. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Furthermore, if third parties have filed similar patent applications, an interference or derivation proceeding in the United States can be initiated by the United Stated Patent and Trademark Office, a third party, or by us to determine who was the first to invent any of the subject matter covered by the patent claims of our applications.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a party to various license agreements that grant us rights under specified patents and patent applications. We are also party to various license agreements by which we grant third parties rights under specified patents and patent applications. Our current licenses contain performance obligations. If we fail to meet those obligations, the licenses could be terminated. If we are unable to continue to license these technologies on commercially reasonable terms, or at all, we may be forced to delay or terminate aspects of our product development and research activities.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">With respect to our present and any future sublicenses, because our rights derive from those granted to our sublicensor, we are subject to the risk that our sublicensor may fail to perform its obligations under the master license or fail to inform us of useful improvements in, or additions to, the underlying intellectual property owned by the original licensor.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are unable to exercise the same degree of control over intellectual property that we license from third parties as we exercise over our internally developed intellectual property. We do not control the prosecution of certain of the patent applications that we license from third parties; therefore, the patent applications may not be prosecuted as we desire or in a timely manner.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The degree of future protection for our proprietary rights is uncertain, and we cannot ensure that:</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">we or our licensors were the first to make the inventions covered by each of our pending patent applications;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">we or our licensors were the first to file patent applications for these inventions;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the patents of others will not have an adverse effect on our ability to do business;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">others will not independently develop similar or alternative technologies or reverse engineer any of our products, processes or technologies;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">any of our pending patent applications will result in issued patents;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">43</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">any patents issued or licensed to us, our collaborators or strategic partners will provide a basis for commercially viable products or will provide us with any competitive advantages;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">any patents issued or licensed to us will not be challenged and invalidated by third parties; or</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">we will develop additional products, processes or technologies that are patentable.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Others have filed and in the future are likely to file patent applications that are similar to ours. We are aware that there are academic groups and other companies that are attempting to develop technology that is based on the use of zinc finger, TALE, CRISPR/Cas and other DNA-binding proteins, and that these groups and companies have filed patent applications. Several patents with claims directed to this technology have issued, although we have no current plans to use the claimed inventions. If these or other patent applications issue as patents, it is possible that the holder of any patent or patents granted on these applications may bring an infringement action against us, our collaborators, or strategic partners claiming damages and seeking to enjoin commercial activities relating to the affected products and processes. The costs of litigating the claim could be substantial regardless of outcome. Moreover, we cannot predict whether we, our collaborators, or strategic partners would prevail in any actions. In addition, if the relevant patent claims were upheld as valid and enforceable and our products or processes were found to infringe a patent or patents, we or our collaborators may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, and we may be prevented from making, using, or selling the relevant product or process unless we or our collaborators could obtain a license or were able to design around the patent claims. We can give no assurance that such a license would be available to us or our collaborators on commercially reasonable terms, or at all, or that we would be able to successfully design around the relevant patent claims. There may be significant litigation in the genomics or cell therapy industry regarding patent and other intellectual property rights, which could subject us to litigation. If we become involved in litigation, it could consume a substantial portion of managerial and financial resources.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We rely on trade secrets to protect technology where we believe patent protection is not appropriate or obtainable. Trade secrets, however, are difficult to protect. While we require employees, academic collaborators and consultants to enter into confidentiality agreements, we may not be able to adequately protect our trade secrets or other proprietary information or enforce these confidentiality agreements.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our collaborators, strategic partners, and scientific advisors have rights to publish data and information in which we may have rights. If we cannot maintain the confidentiality of our technology and other confidential information in connection with our collaborations and strategic partnerships, then we may not be able to receive patent protection or protect our proprietary information.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time, and may vary based on jurisdiction.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date or from the filing date of the corresponding international application. Various extensions may be available. However, the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from generic medications. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be adversely affected and our business would be harmed.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors, collaborators, partners and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures have been and may in the future be breached, and we may not have adequate remedies for any breach. See also the risk factor titled, &#8220;Significant disruptions of our information technology systems or data security incidents could result in significant financial, legal, regulatory, business and reputational harm to us.&#8221; In addition, our trade secrets may otherwise become known or be independently discovered by competitors.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Although we expect all of our employees and consultants to assign their inventions to us, and all of our employees, consultants, advisors, collaborators, partners and any third parties who have access to our proprietary know-how, information or </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">44</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed or that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Misappropriation or unauthorized disclosure of our trade secrets could impair our competitive position and may have an adverse effect on our business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. In addition, others may independently discover our trade secrets and proprietary information. For example, the FDA, as part of its Transparency Initiative, is currently considering whether to make additional information publicly available on a routine basis, including information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA&#8217;s disclosure policies may change in the future, if at all.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent material disclosure of the non-patented intellectual property related to our technologies to third parties, and there is no guarantee that we will have any such enforceable trade secret protection, we may not be able to establish or maintain a competitive advantage in our market, which could adversely affect our business, results of operations and financial condition.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may not be successful in obtaining or maintaining necessary rights to gene or cell therapy product components and processes for our development pipeline through acquisitions and in-licenses.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Presently, we believe we have rights to the intellectual property, through licenses from third parties and under patents that we own, to develop our gene and cell therapy product candidates. Because our programs may involve additional product candidates, such as TX200 and potential future CAR-Treg therapies that may require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights. In addition, our product candidates may require specific formulations to work effectively and efficiently and these rights may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify on commercially reasonable terms, if at all. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For example, we sometimes collaborate with U.S. and foreign academic institutions to accelerate our preclinical research or development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such right of first negotiation for intellectual property, we may be unable to negotiate a license within the specified time frame or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain rights to required third-party intellectual property rights, our business, financial condition and prospects for growth could suffer.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a party to a number of intellectual property license agreements that are important to our business and expect to enter into additional license agreements in the future. Our existing license agreements impose, and we expect that future license agreements will impose, various diligence, milestone, royalty and other obligations on us. If we fail to comply with our obligations under these agreements, or we are subject to a bankruptcy, the licensor may have the right to terminate the license, in which event we would not be able to market products covered by the license.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we may be required to expend significant time and resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our business significantly. We cannot provide any assurances that third-party patents do not exist that might be enforced against our current product candidates or future products, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">45</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In many cases, patent prosecution of our in-licensed technology is controlled solely by the licensor. If our licensors fail to obtain and maintain patent or other protection for the proprietary intellectual property we license from them, we could lose our rights to the intellectual property or our exclusivity with respect to those rights, and our competitors could market competing products using the intellectual property. In certain cases, we control the prosecution of patents resulting from licensed technology. In the event we breach any of our obligations related to such prosecution, we may incur significant liability to our licensing partners. Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues and is complicated by the rapid pace of scientific discovery in our industry. Disputes may arise regarding intellectual property subject to a licensing agreement, including:</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the sublicensing of patent and other rights under our collaborative development relationships;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the priority of invention of patented technology.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have an adverse effect on our business, financial condition, results of operations, and prospects. If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have an adverse effect on our business, financial conditions, results of operations, and prospects. As an example, Sangamo France has exclusively licensed the right to the CAR for use in TX200 from the University of British Columbia, or UBC. Should UBC terminate this license agreement, we may have to develop or acquire the appropriate CAR which would extend our anticipated development timeline and add expense, and which could result in our failure to realize the anticipated benefits of the acquisition of Sangamo France.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may be involved in patent or intellectual property lawsuits or similar disputes involving patents under our control or patents of third-parties claiming infringement, which lawsuits could be expensive, time-consuming and impair or prevent development and commercialization activities.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ex parte</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> reexaminations, post-grant review, and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">inter partes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> review proceedings before the U.S. Patent and Trademark Office, or U.S. PTO, and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Third parties may assert that we are employing their proprietary technology without authorization, and such parties may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. For example, we are aware of certain patents held by a third party related to certain vector manufacturing methods that are currently being used in certain of our product candidates. We have not yet finalized the commercial scale manufacturing process for any of our product candidates. If our commercial scale manufacturing process utilizes these vector manufacturing methods, and if these third-party patents are in force at the time of commercialization, we may need to use or develop a non-infringing manufacturing method or seek a license to these patents. In any event, if any third-party patents were held by a court of competent jurisdiction to cover the manufacturing methods of any of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire. Similarly, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">46</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">including combination therapy, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license, or until such patents expires. Moreover, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Competitors may also infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid, is unenforceable, in whole or in part, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly and could put our patent applications at risk of not issuing. Moreover, if we or one of our licensing partners initiated legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover our product candidate. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have an adverse impact on our business.  </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interference or derivation proceedings provoked by third parties or brought by us or declared by the U.S. PTO may be necessary to determine the priority of inventions or other matters of inventorship with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could expose us to significant monetary damages, result in the loss of valuable intellectual property, require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. Our defense of litigation, interference, derivation, or other proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have an adverse effect on our ability to raise additional funds or otherwise have an adverse effect on our business, results of operations, financial condition and prospects.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any of our employee&#8217;s former employer or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As is the case with other biotechnology companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. Changes in either the patent laws or interpretation </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">47</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">of the patent laws in the United States or in other jurisdictions in which we seek patent protection could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. The United States enacted the Leahy-Smith America Invents Act, or the America Invents Act, which includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third party submission of prior art to the U.S. PTO during patent prosecution and additional procedures to attack the validity of a patent by U.S. PTO administered post-grant proceedings, including post-grant review, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">inter partes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> review, and derivation proceedings. Because of a lower evidentiary standard in U.S. PTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a U.S. PTO proceeding sufficient for the U.S. PTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. In addition, the challenged patents are not accorded the presumption of validity as they are in Federal District Court. Accordingly, a third party may attempt to use the U.S. PTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Therefore, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our owned or in-licensed patent applications and the enforcement or defense of our owned or in-licensed issued patents, all of which could have an adverse effect on our business, financial condition, results of operations, and prospects. Moreover, recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, the U.S. PTO, and similar legislative, judicial and regulatory bodies in other jurisdictions, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may be unable to license gene transfer technologies that we may need to commercialize our zinc finger protein technology and potential products, if approved.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In order to regulate or modify a gene in a cell, the ZFP must be efficiently delivered to the cell. We have licensed certain gene transfer technologies for our ZFP in research, including AAV and mRNA technology and we are evaluating these systems and other technologies that may need to be used in the delivery of ZFP into cells for </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vitro </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> applications. We have not developed our own gene transfer technologies, and we rely on our ability to enter into license agreements to provide us with rights to the necessary gene transfer technology. Our approach has been to license appropriate technology as required. For example, we are aware of certain patents held by a third party related to certain vector manufacturing methods that are currently being used in certain of our product candidates. We have not yet finalized the commercial scale manufacturing process for any of our product candidates. If our commercial scale manufacturing process utilizes these vector manufacturing methods, and if these third-party patents are in force at the time of commercialization, we may need to use or develop a non-infringing manufacturing method or seek a license to these patents. However, we may not be able to license the gene transfer technologies on reasonable terms, if at all, required to develop and commercialize our product candidates. The inability to obtain a license to use gene transfer technologies with entities that own such technology on reasonable commercial terms, if at all, could delay or prevent the preclinical evaluation, drug development collaborations, clinical testing, and/or commercialization of our therapeutic product candidates. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We are conducting proprietary research to discover new product candidates. These programs increase our financial risk of product failure, may significantly increase our research expenditures, and may involve conflicts with future collaborators and strategic partners.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our proprietary research programs consist of research that is funded solely by us or by grant funding and in which we retain exclusive rights to therapeutic products generated by such research. This is in contrast to certain of our research programs that may be funded by corporate partners in which we may share rights to any resulting products. Conducting proprietary research programs may not generate corresponding revenue and may create conflicts with our collaborators or strategic partners over rights to our intellectual property with respect to our proprietary research activities. Any conflict with our collaborators or strategic partners could reduce our ability to enter into future collaborations or partnering agreements and negatively impact our relationship with existing collaborators and partners that could reduce our revenue and delay or terminate our product development. As we continue to focus our strategy on proprietary research and therapeutic development, we expect to experience greater business risks, expend significantly greater funds and require substantial commitments of time from our management and staff.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Relating to our Business Operations</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Significant disruptions of our information technology systems or data security incidents could result in significant financial, legal, regulatory, business and reputational harm to us.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">48</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are increasingly dependent on information technology systems and infrastructure to operate our business, which are large and complex. In the ordinary course of our business, we collect, store, process and transmit large amounts of sensitive information, including intellectual property, proprietary business information, personal information and other confidential information. It is critical that we do so in a secure manner to maintain the confidentiality, integrity and availability of such sensitive information. We have also outsourced elements of our operations (including elements of our information technology infrastructure) to third parties, and as a result, we manage a number of third-party vendors who may or could have access to our computer networks or our confidential information. Many of those third parties in turn subcontract or outsource some of their responsibilities to third parties. While all information technology operations are inherently vulnerable to inadvertent or intentional security breaches, incidents, attacks and exposures, the size, complexity, accessibility and distributed nature of our information technology systems, and the large amounts of sensitive information stored on those systems, make such systems potentially vulnerable to unintentional or malicious, internal and external attacks on our technology environment. Attacks of this nature are increasing in their frequency, levels of persistence, sophistication and intensity. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Significant disruptions of our, our third-party vendors&#8217; and/or business partners&#8217; information technology systems or other similar data security incidents could adversely affect our business operations and/or result in the loss, misappropriation, and/or unauthorized access, use or disclosure of, or the prevention of access to, sensitive information, which could result in financial and reputational harm to us. For example, in April 2018, we announced a data security incident involving the compromise of a then senior executive&#8217;s company email account. Upon learning of the incident on March 28, 2018, external network security experts were promptly engaged, and the incident response team worked diligently to investigate the incident. We also promptly notified federal law enforcement of the incident. The investigation concluded that the incident was limited to the compromise of the then senior executive&#8217;s company email account for approximately 11 weeks. The investigation did not reveal any evidence that our network or other information technology systems were otherwise compromised in connection with the incident or that the incident resulted in the disclosure of or access to personal information about patients or other individuals besides the holder of the company email account that was affected. However, proprietary, confidential and other sensitive information of ours and that of other entities was accessed and may have been compromised as a result of the incident. Unforeseen developments related to this incident could occur, which could have a further adverse impact on us. We do not maintain cyber liability insurance and will therefore have no coverage for any losses resulting from this data security incident. Any litigation or regulatory review arising from this incident could result in significant legal exposure to us. In addition, information technology system disruptions, whether from attacks on our technology environment or from computer viruses, natural disasters, terrorism, war and telecommunication and electrical failures, could result in a material disruption of our facility, development programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">While we aware of the company email incident described above, there is no way of knowing with certainty whether we have experienced any other data security incidents that have not been discovered. While we have no reason to believe this to be the case, attackers have become very sophisticated in the way they conceal access to systems, and many companies that have been attacked are not aware that they have been attacked. Any event, including the company email incident described above, that leads to unauthorized access, use or disclosure of personal information could, among other consequences, disrupt our business, harm our reputation, compel us to comply with applicable federal and/or state breach notification laws and foreign law equivalents. In addition, failure to maintain effective internal accounting controls related to security breaches and cybersecurity in general could impact our ability to produce timely and accurate financial statements and subject us to regulatory scrutiny. Moreover, data security incidents and other inappropriate access can be difficult to detect, and any delay in identifying them may lead to increased harm of the type described above. While we have implemented security measures intended to protect our information technology systems and infrastructure, there can be no assurance that such measures will successfully prevent service interruptions or further security incidents.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We plan to continue to operate the acquired Sangamo France business in France and the Sangamo UK business in the United Kingdom, which may expose us to unanticipated costs or events.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sangamo France&#8217;s historical operations have been based in France and we plan to continue to operate the acquired Sangamo France business in France. Our operation of the acquired Sangamo France business in France involves significant risks, including:</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">difficulty hiring and retaining appropriate personnel due to intense competition for such limited resources;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">disruptions in relations with our employees, including legacy Sangamo France employees; and</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">compliance with regulatory requirements, including local French employment regulations and organized labor in France.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, we have operations and conduct business through our UK subsidiary. As a result of our operations outside of the United States, we have become more exposed to fluctuations in currency exchange rates between the Euro and the U.S. </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">49</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">dollar and between the Pound Sterling and the U.S. Dollar. Given the volatility of currency exchange rates, there is no assurance that we will be able to effectively manage currency transaction and/or conversion risks. To date, we have not entered into derivative instruments to offset the impact of foreign exchange fluctuations, which fluctuations could have an adverse effect on our financial condition and results of operations. In any event, difficulties resulting from these and other risks related to our operations outside of the United States could expose us to increased expenses, impair our development efforts, adversely affect our financial condition and results of operations, and harm our competitive position.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may face difficulties as we expand our operations into countries in which we have no prior operating experience, and we may be exposed to risks associated with our operations and clinical trials in foreign jurisdictions, which could adversely affect our business.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to Sangamo France and Sangamo UK, we may expand our global footprint in order to enter into new markets. Operating in foreign jurisdictions requires significant resources and management attention and subjects us to regulatory, economic and political risks that are different from those we face in the United States. We cannot be sure that any further international expansion will be successful. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain countries in to which we may expand, may have less political, social or economic stability and less developed infrastructure and legal systems. In addition, it may be difficult for us to understand and accurately predict taste preferences and purchasing habits of consumers in these new geographic markets. It will be costly to establish, develop and maintain international operations and develop and promote our products, if and when approved, in international markets. We may also encounter regulatory, legal, personnel, technological and other difficulties that increase our expenses and/or delay our ability to become profitable in such countries, which could have an adverse effect on our business and operations. Consequently, we are, and will continue to be, subject to risks inherent with operating in foreign countries, in addition to those specific risks associated with Sangamo France and Sangamo UK, which include:</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the increased complexity and costs inherent in managing international operations, including in geographically disparate locations;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">diverse regulatory, financial and legal requirements, and any future changes to such requirements, in one or more countries where we are located or do business;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">differing payor reimbursement regimes, governmental payors or patient self-pay systems and price controls;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">adverse tax consequences, including changes in applicable tax laws and regulations;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">applicable trade laws, tariffs, export quotas, custom duties or other trade restrictions, and any changes to them;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">economic weakness, including inflation, or political or economic instability in particular foreign economies and markets;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">foreign currency fluctuations, which could result in increased operating expenses or reduced revenues, and other obligations incident to doing business or operating in another country;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">liabilities for activities of, or related to, our international operations;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">challenges inherent in efficiently managing employees in diverse geographies, including the need to adapt systems, policies, benefits and compliance programs to differing labor and other regulations;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">workforce uncertainty in countries where labor unrest is more common than in the United States; and</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">laws and regulations relating to data security and the unauthorized use of, or access to, commercial and personal information.</span></div><div style="padding-left:36pt;margin-top:3pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">The withdrawal of the United Kingdom from the European Union, commonly referred to as &#8220;Brexit,&#8221; may adversely impact our ability to obtain regulatory approvals of our product candidates in the European Union, result in restrictions or imposition of taxes and duties for importing our product candidates into the European Union, and may require us to incur additional expenses in order to develop, manufacture and commercialize our product candidates in the European Union.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Following the result of a referendum in 2016, the United Kingdom left the European Union on January 31, 2020 pursuant to formal withdrawal agreements between the United Kingdom and the European Union. Under these agreements, the United Kingdom will be subject to a transition period until December 31, 2020, during which European Union rules will continue to apply.  Negotiations between the United Kingdom and the European Union are expected to continue in relation to the customs and trading relationship between the United Kingdom and the European Union following the expiry of the transition period.   </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">50</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">A significant proportion of the regulatory framework in the United Kingdom applicable to our business and our product candidates is derived from European Union directives and regulations, and as such, following the transition period, Brexit could negatively impact the regulatory regime with respect to the development, manufacture, importation, approval and commercialization of our product candidates in the United Kingdom or the European Union. Any delay in obtaining, or an inability to obtain, any clinical trial authorizations or marketing approvals, as a result of Brexit or otherwise, would prevent us from developing or commercializing our product candidates in the United Kingdom or the European Union and restrict our ability to generate revenue and achieve and sustain profitability. In addition, we may be required to pay taxes or duties or be subjected to other hurdles in connection with the importation of our clinical trial materials and/or our product candidates into the European Union or into the United Kingdom from the European Union, or we may incur expenses in establishing a manufacturing facility in the European Union in order to circumvent such hurdles. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the United Kingdom or the European Union for our product candidates, or incur significant additional expenses to operate our business, which could significantly and significantly harm or delay our ability to generate revenues or achieve profitability of our business. Any further changes in international trade, tariff and import/export regulations as a result of Brexit or otherwise may impose unexpected duty costs or other non-tariff barriers on us. These developments, or the perception that any of them could occur, may significantly reduce global trade and, in particular, trade between the impacted nations and the United Kingdom. It is also possible that Brexit may negatively affect our ability to attract and retain employees, particularly those from the European Union.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We and third parties on which we rely may be adversely affected by natural disasters and catastrophic or other events outside of our control, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster or event.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Natural disasters could severely disrupt our facilities and our operations and have a negative impact on our business, financial condition, results of operations and prospects. If a natural disaster, pandemic or epidemic (such as the recently reported coronavirus outbreak originating in China that has resulted in global impacts on business and operations), political crisis, power outage or any other event that is out of our control occurred that prevented us or third parties on which we rely from using all or a significant portion of our or their facilities, that damaged critical infrastructure or that otherwise disrupted our or their operations, it may be difficult or, in certain cases, impossible for us to continue our business and operations for a substantial period of time. The disaster recovery and business continuity plans we have in place currently are limited and may not prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have an adverse effect on our business, financial condition, results of operations and prospects. Such disasters or events occurring at facilities of third parties on which we rely could also negatively impact our business and operations.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We will need to grow the size of our organization, and we may experience difficulties in managing this growth and attracting and retaining employees.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We will need to grow the size of our organization in order to support our continued development and potential commercialization of our product candidates. In particular, we will need to add substantial numbers of additional personnel and other resources to support our development and potential commercialization of our product candidates. As our operations expand, we will also need to manage additional relationships with various strategic partners, suppliers and other third parties. We may not be able to attract or retain employees with the appropriate levels of experience and skills to accomplish our objectives. As our development and commercialization plans and strategies continue to develop, or as a result of any future acquisitions, our need for additional managerial, operational, manufacturing, sales, marketing, financial and other resources will increase. Future growth will also impose significant added responsibilities on members of management.  </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our future financial performance and our ability to commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we must be able to manage our development efforts and preclinical studies and clinical trials effectively and hire, train and integrate additional management, research and development, manufacturing, administrative and sales and marketing personnel. Our failure to accomplish any of these tasks could prevent us from successfully growing our company. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are dependent on certain key members of our executive team and certain of our scientific and manufacturing personnel, the loss of whose services may adversely impact the achievement of our objectives. While we have entered into employment agreements with each of our executive officers, any of them could leave our employment at any time, as all of our employees are &#8220;at will&#8221; employees. We do not have &#8220;key person&#8221; insurance on any of our employees. The loss of the services of one or more of such key employees might impede the achievement of our research, development and commercialization objectives.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Recruiting and retaining other qualified employees for our business, including scientific and technical personnel is, and will continue to be, critical to our success. There currently is a shortage of skilled individuals with substantial gene therapy experience, which is likely to continue. As a result, competition for skilled personnel, including in gene therapy research and vector manufacturing, is intense and the turnover rate can be high. We may not be able to attract and retain personnel on </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">51</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">acceptable terms given the competition among numerous pharmaceutical and biotechnology companies and academic institutions for individuals with similar skill sets. In addition, failure to succeed in preclinical or clinical trials or applications for marketing approval may make it more challenging to recruit and retain qualified personnel. The inability to recruit, or loss of services of certain executives or key employees, may impede the progress of our research, development and commercialization objectives and have an adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may not successful in our efforts to identify, discover or acquire new potential product candidates</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"> and may fail to capitalize on programs or product candidates that may be a greater commercial opportunity or for which there is a greater likelihood of success</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Part of our business strategy is to expand our product candidate pipeline by identifying and validating new product candidates, which we may develop ourselves, in-license or otherwise acquire from others. In the event that our existing product candidates do not receive regulatory approval or are not successfully commercialized, then the success of our business will depend on our ability to continue to expand our product pipeline through in-licensing or other acquisitions. We may be unable to identify relevant product candidates. If we do identify such product candidates, we may be unable to reach acceptable terms with any third party from which we desire to in-license or acquire them. Further, while we seek to mitigate risks and liabilities of potential acquisitions and in-licensing transactions through, among other things, due diligence, there may be risks and liabilities that such due diligence efforts fail to discover, that are not disclosed to us, or that we inadequately assess, or that we are not able to effectively manage. Additionally, we may not realize the anticipated benefits of such transactions for a variety of reasons, including the possibility that acquired product candidates, such as TX200, prove not to be safe or effective in clinical trials, the integration of an acquired product candidate, technology or business gives rise to unforeseen difficulties and expenditures, or that the expected benefits will not otherwise be realized or will not be realized within the expected timeframe.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, because we have limited resources, we may forego or delay pursuit of opportunities with certain programs or product candidates or for indications that later prove to have greater commercial potential. Our spending on current and future research and development programs may not yield any commercially viable products. If we do not accurately evaluate the commercial potential for a particular product candidate, we may relinquish valuable rights to that product candidate through strategic collaboration, licensing or other arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. Alternatively, we may allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a partnering arrangement.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Relating to our Common Stock and Corporate Organization</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our stock price has been volatile and may continue to be volatile, which could result in substantial losses for investors, and could be influenced by public perception of genomic medicines and the biotechnology sector.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our stock price has been volatile and may continue to be volatile, which could cause stockholders to incur substantial losses. An active public market for our common stock may not be sustained, and the market price of our common stock may continue to be highly volatile. The market price of our common stock has fluctuated significantly in response to various factors, some of which are beyond our control, including but not limited to the following:</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">announcements by us or collaborators providing updates on the progress or development status of product candidates or data from clinical trials;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">initiation or termination of clinical trials;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">changes in market valuations of similar companies;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">overall market and economic conditions, including the equity markets for emerging biotechnology companies;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">deviations in our results of operations from the guidance given by us;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">announcements by us or our competitors of new or enhanced products, technologies or services or significant contracts, acquisitions, strategic relationships, joint ventures or capital commitments;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">announcement of changes in business and operations by our collaborators and partners, or changes in our existing collaboration agreements;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">changes in public opinion of gene therapy and genomic medicines;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">regulatory developments, including increased regulatory scrutiny of gene therapy and genomic medicines;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">changes, by one or more of our security analysts, in recommendations, ratings or coverage of our stock;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">additions or departures of key personnel; and</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">sales of our common stock or other securities by us, management or directors, liquidation of institutional funds that comprised large holdings of our stock and decreases in our cash balances.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">52</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These external events may have a negative impact on public perception of our business, which could cause our stock price to be volatile, and could result in a decline in the value of your investment in our company.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Actual or potential sales of significant amounts of shares of our common stock into the market could cause the market price of our common stock to fall or prevent it from increasing for numerous reasons.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. Our outstanding shares of common stock may be freely sold in the public market at any time to the extent permitted by Rules 144 and 701 under the Securities Act of 1933, as amended, or the Securities Act, or to the extent such shares have already been registered under the Securities Act and are held by non-affiliates of ours. We have filed registration statements registering all shares of common stock that we may issue under our equity compensation plans. Such shares can be freely sold in the public market upon issuance, subject to volume limitations and black-out periods applicable to affiliates.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, in accordance with the guidelines specified under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and our policies regarding stock transactions, c</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ertain of our employees, executive officers and directors </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">have adopted, and may continue to adopt, stock trading plans pursuant to which they have arranged to sell shares of our common stock from time to time in the future. Generally, sales under such plans by our executive officers and directors require public filings. Our employees, executive officers, directors and affiliated stockholders also may buy or sell additional shares outside of a Rule 10b5-1 plan when they are not in possession of material, nonpublic information. Actual or potential sales of our common stock by such persons could be viewed negatively by other investors, and could cause the price of our common stock to fall or prevent it from increasing. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. In the event securities or industry analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Anti-takeover provisions in our certificate of incorporation, Delaware law and our bylaws could make an acquisition of our company more difficult and could prevent attempts by our stockholders to remove or replace current management.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Anti-takeover provisions of Delaware law and in our certificate of incorporation and our bylaws may discourage, delay or prevent a change in control of our company, even if a change in control would be beneficial to our stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. In particular, under our certificate of incorporation our board of directors may issue up to 5,000,000 shares of preferred stock with rights and privileges that might be senior to our common stock, without the consent of the holders of the common stock. Moreover, without any further vote or action on the part of the stockholders, the board of directors would have the authority to determine the price, rights, preferences, privileges, and restrictions of the preferred stock. This preferred stock, if it is ever issued, may have preference over, and harm the rights of, the holders of common stock. Although the issuance of this preferred stock would provide us with flexibility in connection with possible acquisitions and other corporate purposes, this issuance may make it more difficult for a third party to acquire a majority of our outstanding voting stock.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Similarly, our authorized but unissued common stock is available for future issuance without stockholder approval. Our certificate of incorporation further provides that stockholders may not take action by written consent.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, our amended and restated bylaws:</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">establish advance notice requirements for nominations for election to the board of directors or proposing matters that can be acted upon at stockholders&#8217; meetings; and</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">prohibit stockholders from calling a special meeting of stockholders.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are also subject to Section 203 of the General Corporation Law of the State of Delaware, which provides, subject to certain exceptions, that if a person acquires 15% of our voting stock, the person is an &#8220;interested stockholder&#8221; and may not </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">53</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">engage in &#8220;business combinations&#8221; with us for a period of three years from the time the person acquired 15% or more or our voting stock. The application of Section 203 may, in some circumstances, deter or prevent a change in control of our company even when such change may be beneficial to our stockholders.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our amended and restated bylaws provide that a state or federal court located within the State of Delaware will be the exclusive forum for the adjudication of certain disputes, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our amended and restated bylaws provide that a state or federal court located within the State of Delaware is the sole and exclusive forum for:</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">any derivative action or proceeding brought on our behalf;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee or stockholder of Sangamo to us or our stockholders;</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">any action asserting a claim arising pursuant to any provision of the General Corporation Law of the State of Delaware, our charter or our bylaws, as to which the General Corporation Law of the State of Delaware confers jurisdiction on the Court of Chancery of the State of Delaware; and</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">any action asserting a claim governed by the internal affairs doctrine.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This provision further provides that any person or entity that acquires any interest in shares of our capital stock will be deemed to have notice of and consented to the provisions of such provision.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">While this provision does not apply to suits brought to enforce a duty or liability created by the Exchange Act or the Securities Act, or any claim for which the federal courts have exclusive jurisdiction, this provision may nonetheless limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers, and other employees. If a court were to find this provision to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could seriously harm our business.</span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_22"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160;1B &#8211; UNRESOLVED STAFF COMMENTS</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None. </span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_25"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160;2 &#8211; PROPERTIES</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our corporate headquarters occupies approximately 87,700 square feet of office and research and development laboratory facilities in Brisbane, California, pursuant to a lease that expires in May 2029. We also lease approximately 45,600 square feet of research and office space in Richmond, California, subject to leases that expire in August 2026. We also lease approximately 20,800 square feet of office, research and development space in Valbonne, France, subject to leases that expire beginning in June 2025 through March 2028. We believe that our facilities are currently adequate to meet our needs. As we continue to expand our operations, we may need to lease or purchase additional facilities.</span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_28"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160;3 &#8211; LEGAL PROCEEDINGS </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are not a party to any material pending legal proceeding. From time to time, we may be involved in legal proceedings arising in the ordinary course of business.</span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_31"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160;4 &#8211; MINE SAFETY DISCLOSURES </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Not Applicable.</span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_34"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">54</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART&#160;II</span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_37"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160;5 &#8211; MARKET FOR THE REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Market Information</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our common stock trades on the Nasdaq Global Select Market under the symbol &#8220;SGMO.&#8221;</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Holders</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of February&#160;21, 2020, there were 55 holders of record of our common stock. This number does not include &#8220;street name,&#8221; or beneficial holders, whose shares are held of record by banks, brokers, financial institutions and other nominees.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Dividends</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have not paid dividends on our common stock, and currently do not plan to pay any cash dividends in the foreseeable future.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Stock Performance Graph</span></div><div style="margin-top:6pt;"><img src="sgmo-20191231_g4.jpg" alt="sgmo-20191231_g4.jpg" style="height:572px;width:684px;"/></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The above Stock Performance Graph and related information shall not be deemed &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the SEC nor shall such information be incorporated by reference into any future filing under the Securities Act or the Exchange Act, each as amended, except to the extent that the Company specifically incorporates it by reference into such filing.</span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_40"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">55</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM 6 &#8211; SELECTED FINANCIAL DATA</span></div><div style="text-indent:36pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following Selected Financial Data should be read in conjunction with &#8220;Item&#160;7 &#8211; Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and &#8220;Item&#160;8 &#8211; Financial Statements and Supplementary Data&#8221; included elsewhere in this Annual Report on Form&#160;10-K. Historical results are not necessarily indicative of future results.</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:36.325%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.747%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.747%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.747%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.747%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.751%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2016</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2015</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands, except per share data)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Statement of Operations Data:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">102,428&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">84,452&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,567&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,389&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,539&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">145,922&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">114,866&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">65,728&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">65,618&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">67,198&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61,686&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46,736&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,200&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,330&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,197&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">207,608&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">161,602&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">92,928&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">91,948&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">86,395&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(105,180)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(77,150)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(56,361)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(72,559)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(46,856)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest and other income, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,761&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,261&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,793&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">887&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">431&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Benefit from income taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,722&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(95,419)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(68,889)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(54,568)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(71,658)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(40,703)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(233)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(555)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss attributable to Sangamo Therapeutics, Inc. stockholders</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(95,186)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(68,334)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(54,568)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(71,658)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(40,703)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.85)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.70)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.70)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.02)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.58)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares used in computing basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">112,114&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">96,941&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">78,084&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70,553&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">69,757&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:36.325%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.747%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.747%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.747%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.747%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.751%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2016</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2015</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance Sheet Data:</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Cash, cash equivalents, marketable securities, and interest receivable</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">384,988&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">400,508&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">244,560&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">142,759&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">209,307&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Working capital</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">335,601&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">332,010&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">203,538&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">136,289&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">192,485&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">637,516&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">590,395&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">286,741&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">157,891&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">217,235&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(656,985)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(562,696)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(495,479)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(440,911)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(369,253)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stockholders' equity</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">432,739&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">367,257&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">187,900&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">136,195&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">192,439&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Sangamo France was acquired in October 2018 and the results of operations have been included in the selected consolidated financial data since the date of acquisition (see </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;">Note 5 &#8211; Acquisition of Sangamo France</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"> to our Consolidated Financial Statements).</span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_43"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160;7 &#8211; MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The discussion in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; contains trend analysis, estimates and other forward-looking statements within the meaning of Section 27A of the Securities Act, as amended, and Section 21E of the Exchange Act, as amended. These forward-looking statements include, without limitation, statements containing the words &#8220;believes,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;continue,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;will,&#8221; and other words of similar import or the negative of those terms or expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties, estimates and other factors that may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially from those set forth in such forward-looking statements as a result of, but not limited to, the &#8220;Risk Factors&#8221; described in Part I, Item 1A of this Annual Report on form 10-K. You should </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">56</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">read the following discussion and analysis along with the &#8220;Selected Financial Data&#8221; and the Consolidated Financial Statements and notes attached to those statements included elsewhere in this report.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In addition, the section of this &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; generally discusses 2019 and 2018 items and year-to-year comparisons between 2019 and 2018. Discussions of 2017 items and year-to-year comparisons between 2018 and 2017 are not included in this Annual Report on Form 10-K and can be found in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in Part II, Item 7 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2018, filed with the SEC on March 1, 2019.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Overview</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a clinical stage biotechnology company focused on translating ground-breaking science into genomic medicines with the potential to transform patients&#8217; lives using our platform technologies in gene therapy, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ex vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene-edited cell therapy, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> genome editing and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> genome regulation. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our strategy is to maximize the value and therapeutic use of our technology platforms. For certain therapies, we intend to capture the value of our proprietary gene therapy, cell therapy, genome editing and genome regulation products by incorporating these technologies into our manufacturing, development and commercial operations. For other therapies, we intend to partner with biopharmaceutical companies to develop products as appropriate. Decisions to partner product candidates will be based on review of our internal resources, internal know-how, and commercial considerations. In our proprietary clinical development programs, we are focused on three therapeutic areas: IMDs, CNS diseases and immunology, which comprises inflammatory and autoimmune diseases.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a leader in the research and development of ZFPs, a naturally occurring class of transcription factor proteins found in humans and other species. We have used our internal know-how and technical expertise to develop a proprietary synthetic ZFP platform with potential clinical utility in </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ex vivo </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">gene-edited cell therapy, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> genome editing and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">genome regulation. ZFPs can be engineered to make ZFNs that can be used to specifically modify DNA sequences by knocking in or knocking out select genes, or genome editing ZFP-TFs proteins that can be used to selectively increase or decrease gene expression. In the process of developing this platform, we have additionally accrued significant scientific, manufacturing, development capabilities, and related know-how that are broadly applicable to the field of gene therapy and have used this knowledge to advance a gene therapy platform.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have a substantial intellectual property portfolio protecting our technology and product candidates. We continue to license and file new patent applications to strengthen and consolidate our existing patent portfolio. We believe that our intellectual property position is critical to our ability to research, develop, manufacture and commercialize gene therapy, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ex vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene-edited cell therapy, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> genome editing and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> genome regulation products and services.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Business Updates</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2020, we entered into a global licensing collaboration agreement with Biogen for the research, development and commercialization of gene regulation therapies for the treatment of neurological diseases, including ST-501 a preclinical ZFP-TF product candidate for tauopathies including Alzheimer&#8217;s disease, and ST-502, a preclinical ZFP-TF product candidate for alpha-synuclein related diseases including Parkinson&#8217;s disease, among other targets. After the collaboration agreement becomes effective, Biogen will pay us an upfront payment of $125.0 million.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Concurrently with the execution of the collaboration agreement, we also entered into a stock purchase agreement with Biogen MA, Inc., pursuant to which Biogen MA, Inc. agreed to acquire $225.0 million of shares of our common stock. We are also eligible to receive research, development, regulatory and commercial milestone payments that could total up to approximately $2.37 billion if Biogen selects all of the targets allowed under the agreement and all the specified milestones set forth in the agreement are achieved, which includes up to $925.0 million in pre-approval milestone payments and up to $1,445.0 million in first commercial sale and other sales-based milestone payments. The consummation of the transactions under each of the Biogen collaboration agreement and the stock purchase agreement is subject to the satisfaction of customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. For more information regarding the Biogen transactions, see &#8220;Business &#8211; Collaborations &#8211; Biogen&#8221; in Part I, Item 1 of this Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Certain Components of Results of Operations</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our revenues have consisted primarily of revenues from upfront licensing fees, reimbursements for research services, milestones achievements and research grant funding. We expect revenues to continue to fluctuate from period to period and there can be no assurance that new collaborations or partner reimbursements will continue beyond their initial terms or that we are able to meet the milestones specified in these agreements.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">57</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have incurred net losses since inception and expect to incur losses in the future as we continue our research and development activities. To date, we have funded our operations primarily through the issuance of equity securities and revenues from collaborations and research grants.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect to continue to devote substantial resources to research and development in the future and expect research and development expenses to increase in the next several years if we are successful in advancing our gene therapy and our genome editing programs in the clinic and progressing our earlier stage product candidates into clinical trials. Pursuant to the terms of the agreements with Kite, Pfizer and Sanofi, certain expenses related to research and development activities will be reimbursed to us. The reimbursement funds to be received from Kite, Pfizer and Sanofi will be recognized as revenue as the related costs are incurred and collection is reasonably assured.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">General and administrative expenses consist primarily of salaries and personnel related expenses for executive, finance and administrative personnel, stock-based compensation expenses, professional fees, allocated facilities expenses, patent prosecution expenses and other general corporate expenses. As we continue to advance our product candidates into and through the clinic, we expect the growth of our business to require increased general and administrative expenses.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Comparability</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We adopted Accounting Standards Codification, or ASC, Topic 842, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, or ASC Topic 842, on January&#160;1, 2019, resulting in changes to our accounting policy for leases. We used the modified retrospective approach and recognized the cumulative effect of initially applying ASC Topic 842 as an adjustment to the opening balances of the lease related accounts and accumulated deficit at January&#160;1, 2019. Accordingly, comparative information has not been adjusted and continues to be reported under previous accounting standards. Refer to Note 1 in Part II, Item 8 of this Annual Report on Form 10-K for additional information and details on lease related accounts impacted by ASC Topic 842.</span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_46"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Critical Accounting Policies and Estimates</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying discussion and analysis of our financial condition and results of operations are based upon our Consolidated Financial Statements and the related disclosures, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts in our Consolidated Financial Statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe the following policies to be the most critical to an understanding of our financial condition and results of operations because they require us to make estimates, assumptions and judgments about matters that are inherently uncertain.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Effective January&#160;1, 2018, we adopted the provisions of ASC Topic 606, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from Contracts with Customers,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> or ASC Topic 606, resulting in a change to our accounting policy for revenue recognition. ASC Topic 606 establishes a unified model to determine how revenue is recognized.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Contract revenues are derived from collaboration agreements and research activity grants and licensing. Research and licensing agreements typically include upfront signing or license fees, cost reimbursements, research services, minimum sublicense fees, milestone payments and royalties on future licensee&#8217;s product sales. We have both fixed and variable consideration. Non-refundable upfront fees and funding of research and development activities are considered fixed, while milestone payments are generally identified as variable consideration. Our research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenues under research grant agreements are generally recognized when the related qualified research expenses are incurred. Deferred revenue represents the portion of research or license payments received but not earned.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under our agreements, we perform the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) we satisfy each performance obligation.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic 606. Our performance obligations include license rights, development services, and services associated with the regulatory submission and approval processes. Revenues from research services earned under collaboration agreements are generally recognized as revenue as the related services are provided. Revenues from non-refundable upfront </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">58</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">fees are recognized over time either by measuring progress towards satisfaction of the relevant performance obligation, using the input method (i.e. cumulative actual costs incurred relative to total estimated costs) or on a straight-line basis when a performance obligation is expected to be satisfied evenly over a period of time (or when the entity has a stand-ready obligation). Significant management judgment is required to determine the level of effort required under an arrangement and the period over which we expect to complete our performance obligations under the arrangement which may include total internal personnel costs and external costs to be incurred as well as, in certain cases, the estimated stand-ready obligation period. Changes in these estimates can have a material effect on revenue recognized. If we cannot reasonably estimate when our performance obligations either are completed or become inconsequential, then revenue recognition is deferred until we can reasonably make such estimates. We include the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, we re-evaluate the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. The estimated period of performance and project costs, such as personnel and manufacturing cost, are reviewed quarterly and adjusted, as needed, to reflect our current assumptions regarding the timing and costs of our deliverables.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract.&#160;We used key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and&#160;probabilities of technical and regulatory success. Related costs and expenses under these arrangements have historically approximated the revenues recognized.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues from collaboration agreements and research activity grants as a percentage of total revenues were as follows:</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:58.322%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.740%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pfizer</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">47&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">47&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Kite </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sanofi</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Receivables from collaborations are typically unsecured and are concentrated in the biopharmaceutical industry. Accordingly, we may be exposed to credit risk generally associated with biopharmaceutical companies or specific to our collaboration agreements. To date, we have not experienced any losses related to these receivables.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Funds received from third parties under contract or funds received from grant arrangements are generally recorded as revenue if we are deemed to be the principal participant in the arrangements because the activities under the contracts or grants are part of our development programs. Contract funds received are not refundable and are recognized when the related qualified research and development costs are incurred and there is reasonable assurance that the funds will be received. Funds received in advance are recorded as deferred revenue.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Valuation of Long-lived Assets including Goodwill and Intangible Assets</span></div><div style="text-indent:27.35pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We allocate the fair value of purchase consideration in a business combination to the tangible assets acquired, liabilities assumed, and intangible assets acquired based on their estimated fair values. Any excess of purchase price over the fair value of net assets acquired is recorded as goodwill. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Significant estimates in valuing certain intangible assets include, but are not limited to, future expected cash flows from acquired in-process research and development, or IPR&amp;D, projects. Management&#8217;s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Allocation of purchase consideration to identifiable assets and liabilities affects our amortization expense, as acquired finite-lived intangible assets are amortized over the useful life, whereas any indefinite lived intangible assets, including goodwill, are not amortized. During the measurement period, which is not to exceed one year from the acquisition date, we may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period, any subsequent adjustments are recorded to earnings.</span></div><div style="text-indent:27.35pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We review goodwill and indefinite-lived intangible assets for impairment at least annually or more frequently if events or changes in circumstances would more likely than not reduce the fair value these assets below their carrying values. As of December&#160;31, 2019, no impairment of goodwill or indefinite-lived intangible assets has been identified.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">59</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="text-indent:27.35pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Long-lived assets, including property and equipment and finite-lived intangible assets, are reviewed for possible impairment whenever events or circumstances indicate that the carrying amount of such assets may not be recoverable. The evaluation is performed at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. Recoverability of these assets is measured by a comparison of the carrying amounts to the future undiscounted cash flows the assets are expected to generate from the use and eventual disposition. If such review indicates that the carrying amount of property and equipment and intangible assets is not recoverable, the carrying amount of such assets is reduced to fair value. We have not recorded any significant impairment charges during the years presented.</span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_49"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Results of Operations</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Years Ended December&#160;31, 2019, 2018 and 2017</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenues</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.830%;"><tr><td style="width:1.0%;"></td><td style="width:22.852%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.875%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.539%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.875%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.539%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.875%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.539%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.840%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.575%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.875%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.539%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.875%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.539%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.875%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.539%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.849%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="45" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="45" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands, except percentage values)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">102,428&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">84,452&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,976&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">84,452&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,567&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">47,885&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">131&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total revenues consisted of revenues from collaboration agreements and research grants. We anticipate revenues over the next several years will be derived primarily from our collaboration agreements with Biogen, Kite, Pfizer and Sanofi as we continue to recognize upfront and milestone payments received under such agreements over time.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The increase of $18.0 million in revenues in 2019 compared to 2018 was primarily attributed changes in the transaction prices of the Pfizer and Sanofi collaborations as a result of a $25.0 million milestone achievement upon completion of the transfer of the IND for SB-525 to Pfizer, $7.5&#160;million pertaining to a milestone achievement with Sanofi upon dosing of the first subject in the sickle cell disease Phase 1 clinical trial in December 2019, and a $6.0 million milestone achievement with Sanofi upon dosing of the third subject in the Phase 1/2 THALES study in August 2019. In addition, we recorded an increase of $8.8 million related to our agreement with Kite. Approximately $2.0 million out of the milestones achieved in 2019 was deferred and is expected to be recognized in 2020. These amounts were partially offset by a decrease in revenues due to a change in project scope related to our hemophilia A agreement with Pfizer, which resulted in a change in the measurement of proportional performance. During 2019, revenues related to our collaborative agreements with Pfizer, Kite and Sanofi represented 40%, 34% and 22%, respectively, of total revenues.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Operating Expenses</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.830%;"><tr><td style="width:1.0%;"></td><td style="width:24.035%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.875%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.539%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.875%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.391%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.875%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.539%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.840%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.539%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.875%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.539%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.875%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.539%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.875%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.539%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.850%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="45" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="45" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands, except percentage values)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">145,922&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">114,866&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31,056&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">114,866&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">65,728&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49,138&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61,686&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46,736&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,950&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46,736&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,200&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,536&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">207,608&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">161,602&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46,006&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">161,602&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">92,928&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">68,674&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and Development Expenses</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The increase of $31.1 million in research and development expenses in 2019 compared to 2018 was primarily due to a $13.7 million increase in salaries and benefits expense reflecting headcount growth in our development and technical operations teams that support clinical development trials, a $9.0 million increase in facility expense primarily related to our new Brisbane facility, a $3.7 million increase in laboratory supply expense, a $2.8 million increase in clinical, research and preclinical expenses, and a $1.9 million increase in stock compensation expense. These increases were primarily due to the growth of our business required to support the continued advancement of our product candidates into clinical trials. The main drivers of these increases were in our IMD clinical programs and preclinical and research programs, which increased approximately $24.2 million and $16.0 million, respectively.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">60</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The table below shows research and development expenses related to our clinical and preclinical programs.</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:60.609%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.732%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Programs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Human Therapeutic Programs</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Hemophilia clinical programs</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,805&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,006&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,715&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">IMD clinical programs</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61,845&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,668&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,428&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Beta thalassemia clinical program</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,634&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,317&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,354&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">HIV (SB-728) clinical programs</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,762&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,612&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,473&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Non-human Therapeutic Programs</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Preclinical and research programs</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55,762&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,779&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,414&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other clinical programs and non-therapeutic programs</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">114&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">484&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">344&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">145,922&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">114,866&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">65,728&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The length of time required to complete our development programs and our development costs for those programs may be impacted by the scope and timing of enrollment in clinical trials for our product candidates, our decisions to pursue development programs in other therapeutic areas, and whether we pursue development of our product candidates with a partner or collaborator or independently. For example, our product candidates are being developed in multiple therapeutic areas, and we do not yet know how many of those therapeutic areas we will continue to pursue. Furthermore, the scope and number of clinical trials required to obtain regulatory approval for each pursued therapeutic area is subject to the input of the applicable regulatory authorities, and we have not yet sought such input for all potential therapeutic areas that we may elect to pursue, and even after having given such input, applicable regulatory authorities may subsequently require additional clinical studies prior to granting regulatory approval based on new data generated by us or other companies, or for other reasons outside of our control. As a condition to any regulatory approval, we may also be subject to post-marketing development commitments, including additional clinical trial requirements. As a result of the uncertainties discussed above, we are unable to determine the duration of or completion costs associated with our development programs.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In any event, our potential therapeutic products are subject to a lengthy and uncertain regulatory process that may not result in our receipt of any necessary regulatory approvals. Failure to receive the necessary regulatory approvals would prevent us from commercializing the product candidates affected. In addition, clinical trials of our product candidates may fail to demonstrate safety and efficacy, which could prevent or significantly delay regulatory approval. A discussion of the risks and uncertainties with respect to our research and development activities, including completing the development of our product candidates, and the consequences to our business, financial position and growth prospects can be found in &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report on Form 10-K.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">General and Administrative Expenses</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The increase of $15.0&#160;million in 2019 compared to 2018 was primarily due to a $9.5 million increase in salaries and benefits expense related to headcount growth, a $2.7 million increase in facility expense, primarily related to our new Brisbane facility, and a $2.8 increase in stock-based compensation. The increases were primarily due to the growth of our business to support the continued advancement of our product candidates into clinical trials.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Interest and other income, net</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The increase of $1.5&#160;million in 2019 compared to 2018 was primarily due to an increase of $1.7 million in other income from Sangamo France during the year, which was partially offset by decrease of $0.3 million in foreign exchange losses.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Benefit from income taxes</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Benefit from income taxes was $0.0&#160;million for 2019, 2018, and 2017. We recognized an immaterial amount of income tax expense/benefit during each of these years.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, we had net operating loss carryforwards for federal and state income tax purposes of approximately $489.4 million and $164.7 million, respectively. The federal net operating loss generated before 2018 will begin to expire in 2024 and will keep expiring through 2037, if not utilized. Federal net operating losses generated in 2018 will carry forward indefinitely.  If not utilized, the state net operating loss carryforwards will begin to expire in 2029. We also have federal and state research tax credit carryforwards of $16.4 million and $15.2 million, respectively. The federal research credits </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">61</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">began to expire in 2018 while the state research credits have no expiration date. Utilization of our net operating loss carryforwards and research tax credit carryforwards may be subject to substantial annual limitations due to the ownership change limitations provided by the Internal Revenue Code and similar state provisions. The annual limitation could result in the expiration of the net operating loss carryforwards and research tax credit carryforwards before use. Due to the carryforwards related to the net operating losses and research and development tax credits, we do not expect to pay any taxes related to income in the near future.</span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_52"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Liquidity and Capital Resources</span></div><div style="text-indent:18pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Liquidity</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since inception, we have incurred significant net losses and we have funded our operations primarily through the issuance of equity securities and revenues from collaborations and research grants. Since the beginning of 2017, we have received significant amounts of capital as upfront payments under the following collaboration arrangements: $70.0 million received in May 2017 from Pfizer under our hemophilia A agreement, $12.0 million received in January 2018 from Pfizer under our </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">C9ORF72</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> agreement, and $150.0 million received in April 2018 under our collaboration agreement with Kite. Our collaboration agreements provide for the payment of development, regulatory, and commercial milestones. Our recent agreements with Biogen are not yet effective, as such we have not yet received the upfront payment of $125.0 million under the Biogen collaboration agreement or sold the $225.0 million of shares of our common stock under the stock purchase agreement.  For more information, see &#8220;Business &#8211; Collaborations&#8221; in Part I, Item 1 of this Annual Report on Form 10-K.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2019, we completed an underwritten public offering of our common stock, in which we sold an aggregate of 12.7 million shares of our common stock at a public offering price of $11.50 per share. The net proceeds to us from the sale of shares in this offering, after deducting underwriting discounts and commissions and other estimated offering expenses, were approximately $136.3&#160;million.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December 31, 2019, we had cash, cash equivalents, marketable securities and interest receivable totaling $385.0&#160;million compared to $400.5&#160;million as of December 31, 2018. The decrease was primarily attributable to the operating expenditures, partially offset by the proceeds from the underwritten public offering completed in April 2019, and payments received under our collaboration arrangements. Our most significant use of capital pertains to our employee compensation and external research and development expenses, such as manufacturing, clinical trials and preclinical activity related to our therapeutic programs. Cash in excess of immediate requirements is invested in accordance with our investment policy with a view toward capital preservation and liquidity.</span></div><div style="padding-left:18pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash Flows</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Operating activities. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net cash (used in) provided by operatin</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">g activities primarily reflects our net operating losses, adjusted for non-cash items including stock-based compensation expense. Net cash used in operating activities was $144.4&#160;million in 2019 compared to net cash provided by operating activities of $36.6&#160;million in 2018. N</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">et cash used in operating activities in 2019 primarily reflected our net loss of $95.4 million, a decrease in deferred revenues of $35.7 million, and an increase in accounts receivable of $32.2 million, partially offset by stock-based compensation of $19.3 million.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Investing activities.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net cash used in investing activities was $59.8&#160;million in 2019, $178.1&#160;million in 2018 and $77.4&#160;million in 2017. The decrease in net cash used in 2019 compared to 2018 reflected the 2018 acquisition of Sangamo France. Additional cash flows used in investing activities for all periods were primarily related to net purchases of marketable securities and purchases of property and equipment.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financing activities.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net cash provided by financing activities was $142.0&#160;million in</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2019, $231.7&#160;million in</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2018, and $97.5&#160;million in</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2017.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net cash</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">provided by financing activities in 2019 mainly reflected $136.3 million received related to our April 2019 underwritten public offering and $6.1 million related to proceeds from the exercise of stock options and restricted stock units and purchases under the employee stock purchase plan.</span></div><div style="text-indent:18pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Operating Capital and Capital Expenditure Requirements</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We anticipate continuing to incur operating losses for at least the next several years. While we expect our rate of cash usage to increase in the future, in particular to support our product development endeavors, we believe that the available cash resources as well as funds received from corporate collaborators, strategic partners and research grants, will enable us to maintain our currently planned operations through at least the next 12&#160;months from the date the financial statements are issued. Future capital requirements will be substantial and if our capital resources are insufficient to meet future capital requirements, we will need to raise additional capital to fund our operations through equity or debt financing. We regularly consider fund raising opportunities and may decide, from time to time, to raise capital based on various factors, including market conditions and our plans of operation.&#160;Additional capital may not be available on terms acceptable to us, or at all. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, our business and our ability to advance our product </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">62</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">candidate pipeline would be harmed. Furthermore, any sales of additional equity securities may result in dilution to our stockholders, and any debt financing may include covenants that restrict our business.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our future capital requirements will depend on many forward looking factors, including the following:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the initiation, progress, timing and completion of clinical trials for our product candidates and potential product candidates;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the outcome, timing and cost of regulatory approvals;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the success of our collaboration agreements;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">delays that may be caused by changing regulatory requirements;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the number of product candidates that we pursue;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the costs involved in filing and prosecuting patent applications and enforcing and defending patent claims;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the timing and terms of future in-licensing and out-licensing transactions;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the cost and timing of establishing sales, marketing, manufacturing and distribution capabilities;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the cost of procuring clinical and commercial supplies of our product candidates;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the extent to which we acquire or invest in businesses, products or technologies, including the costs associated with such acquisitions and investments; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the possible costs of litigation.</span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_55"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Off Balance Sheet Arrangements</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not have any off balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K.</span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_58"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Contractual Obligations and Commercial Commitments</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, we had contractual obligations and commercial commitments as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:35.591%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.747%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.747%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.747%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.747%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.751%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments Due by Period</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contractual Obligations</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less&#160;Than<br/>1 Year</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1-3<br/>Years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4-5<br/>Years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">More&#160;Than<br/>5 Years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating leases</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58,119&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,870&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,858&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,250&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,141&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">License obligations</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,176&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">223&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">363&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">260&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">330&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Manufacturing obligations</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,814&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,814&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total contractual obligations</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">69,109&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,907&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,221&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,510&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,471&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating leases consist of base rents for facilities we occupy in Brisbane, California; Richmond, California; and Valbonne, France.&#160;</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">License obligations includes an ongoing license maintenance fee associated with cancellable in-licensed patent agreements.</span></div><div style="text-indent:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Manufacturing obligations include a fee of $6.3&#160;million for dedicated capacity pursuant to the development and manufacturing services agreement with Brammer, and an option agreement with Brammer entered in 2019, which consists of $1.5&#160;million future payments to assist us in establishing our manufacturing capabilities in Brisbane, California, and a minimum purchase commitment of $2.0&#160;million through December 2021 under manufacturing-related supplier arrangements.</span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_61"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160;7A &#8211; QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our exposure to market risk relates to our cash, cash equivalents and investments. The goals of our investment policy are preservation of capital, fulfillment of liquidity needs and capturing a market rate of return based on our investment policy parameters and market conditions. We select investments that maximize interest income to the extent possible within these guidelines. To achieve our goals, we maintain a portfolio of cash equivalents and investments in securities of high credit quality and with varying maturities to match projected cash needs.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The securities in our investment portfolio are not leveraged and are classified as available-for-sale. The majority of these available-for-sale securities are short-term in nature and subject to minimal interest rate risk. Our investments currently consist of commercial paper, corporate debt securities and U.S. government-sponsored entity debt securities. Our investment policy, approved by our Board of Directors, limits the amount we may invest in any one type of investment issuer, thereby reducing credit risk concentrations. All investments have a fixed interest rate and are carried at market value, which approximates cost. We do not use derivative financial instruments in our investment portfolio. We do not believe that a change in interest rates would have a material negative impact on the value of our investment portfolio.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">63</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Foreign Currency Exchange Risk</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have operations in the United States as well as in Europe. The functional currency of each foreign subsidiary is the local currency. We are exposed to foreign currency risk, primarily through operations of our subsidiaries in Europe which conduct business primarily in Euros.&#160;We record gains and losses within our stockholders&#8217; equity due to the translation of our subsidiaries' financial statements into U.S. dollars.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A 10% strengthening/(weakening) in the rates used to translate the results of our foreign subsidiaries would have increased/(decreased) net loss for the year ended December 31, 2019 by approximately $1.8&#160;million and would not have materially impacted our operating loss.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, we incur foreign currency transaction gains and losses related to the level of activity between the United States and Europe. In 2019, we incurred foreign currency transaction losses of $0.9&#160;million.&#160;A 10% unfavorable change in the Euro and U.S. dollar exchange rate on December&#160;31, 2019 would have had an immaterial impact on foreign currency transaction losses for 2019.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December 31, 2019 and 2018, we maintained cash balances of approximately $22.6 million and $8.9 million, respectively, denominated in a foreign currency in the United States. A hypothetical 10% change in foreign exchange rates would have increased/(decreased) net loss for the year ended December 31, 2019 by approximately $2.3&#160;million and would not have materially impacted our operating loss.</span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_64"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">64</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160;8 &#8211; FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SANGAMO THERAPEUTICS, INC.</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:91.401%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:4.599%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Page</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_67">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_67">66</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_70">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_70">68</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_76">Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_76">69</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_79">Consolidated Statements of Comprehensive Loss</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_79">70</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_82">Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_82">71</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_85">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_85">72</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_88">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_88">73</a></span></div></td></tr></table></div><div><span><br/></span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_67"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">65</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To the Board of Directors and Stockholders of Sangamo Therapeutics, Inc.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Opinion on the Financial Statements</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have audited the accompanying consolidated balance sheets of Sangamo Therapeutics, Inc. (the Company) as of December&#160;31, 2019 and 2018, the related consolidated statements of operations, comprehensive loss, stockholders&#8217; equity, and cash flows for each of the three years in the period ended December 31, 2019, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2019 and 2018, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2019, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February&#160;28, 2020 expressed an unqualified opinion thereon.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Adoption of New Accounting Standards</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As discussed in Note 1 to the consolidated financial statements, the Company changed its method of accounting for leases as a result of the adoption of Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02, &#8220;Leases (Topic 842),&#8221; effective January 1, 2019 using the modified retrospective approach with a cumulative-effect adjustment. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As discussed in Note 1 to the consolidated financial statements, the Company changed its method of accounting for revenue as a result of the adoption of ASU No. 2014-09 &#8220;Revenue from Contracts with Customers (Topic 606),&#8221; as amended, effective January 1, 2018 using the modified retrospective method.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Basis for Opinion</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Critical Audit Matter</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="margin-top:12pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">66</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:11.793%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.524%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:82.483%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounting for Revenue from Collaboration Agreements</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#333333;background-color:rgb(255,255,255, 0.0);"><br/>Description of the Matter</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December 31, 2019, the Company had collaboration and license agreements with Kite Pharma, Inc., Pfizer Inc. and Sanofi Genzyme to research, develop and commercialize various research programs. As discussed in Note 1 of the consolidated financial statements, the Company recognizes revenues from research services generally as services are provided while revenues from non-refundable upfront fees are recognized over time either by measuring progress towards satisfaction of the relevant performance obligation using the input method (i.e. cumulative actual costs incurred relative to total estimated costs) or on a straight-line basis when a performance obligation is expected to be satisfied evenly over a period of time (when the entity has a stand-ready obligation).</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Auditing the Company&#8217;s estimated measure of progress was complex and involved significant judgment. In particular, the measure of revenues from upfront non-refundable fees is affected by management&#8217;s estimates of the total costs required to complete the performance obligations including the total internal personnel costs and external costs to be incurred as well as, in certain cases, the estimated stand-ready obligation period. Changes in these estimates can have a material effect on revenue recognized.</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#333333;background-color:rgb(255,255,255, 0.0);"><br/>How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the Company&#8217;s collaboration revenue recognition process. As part of our testing, we considered controls over the development of the estimates of total costs and stand-ready obligation period described above and other inputs used in the determination of the total expected inputs, as well as controls over the completeness and accuracy of the data used.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our audit procedures included, among others, gaining an understanding and testing the Company&#8217;s estimates of total expected costs (and estimated period as applicable) by project, and testing the completeness and accuracy of the underlying data used by the Company in its revenue recognition model. We performed inquiries of the research and development personnel responsible for the specific development projects to corroborate management&#8217;s assumptions used in the Company&#8217;s estimates of total expected costs (and estimated period as applicable) by project, evaluated any changes in the product development timeline and/or increases or decreases in the total expected costs by project on a quarterly basis, and examined evidence supporting key inputs of the revenue recognition model including assessing whether actual costs incurred were appropriate under the terms of the respective contracts. We compared the estimates of total expected costs by project to actual costs incurred on a quarterly basis to evaluate management&#8217;s ability to forecast costs. We also tested the amount of historical costs incurred under each project and the calculation of amounts recognized under the revenue recognition model (including recalculation of straight-line stand-ready obligation amounts).</span></div></td></tr></table></div><div style="margin-top:12pt;"><span><br/></span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">/s/&#160;ERNST&#160;&amp; YOUNG LLP</span></div><div style="margin-top:12pt;"><span><br/></span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have served as the Company&#8217;s auditor since 1997.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Redwood City, California</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">February&#160;28, 2020</span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_70"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">67</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SANGAMO THERAPEUTICS, INC.</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONSOLIDATED BALANCE SHEETS </span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(in thousands, except share and per share amounts)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:64.112%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.230%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.439%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.230%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.789%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMy0xLTEtMS0w_5b5431f1-9961-4fc6-aa0a-63d081ada5a5">80,428</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMy0zLTEtMS0w_fe3375a9-2d3b-4b4c-85a8-d8799eb2501d">140,418</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfNC0xLTEtMS0w_c21d8d37-6439-443b-9c70-c8c4a5a40e45">282,046</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfNC0zLTEtMS0w_644bee8e-186e-46b4-9fce-10366ae7b1b9">259,715</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" name="us-gaap:InterestReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfNS0xLTEtMS0w_230edf0f-57d0-4c0d-9c99-23b7dd3d0f4d">682</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" name="us-gaap:InterestReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfNS0zLTEtMS0w_4e6c90cf-d0fa-4867-a05d-24caa8886861">375</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfNi0xLTEtMS0w_270510f1-5cfc-4f82-a8b1-98eab7306f96">36,909</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfNi0zLTEtMS0w_21a76836-5108-4d98-be69-f6461bde6593">4,673</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfNy0xLTEtMS0w_99c61686-5e86-48ed-8582-1f53711afac2">5,408</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfNy0zLTEtMS0w_46714da8-e76c-4bb8-81a7-5d328a34ca5a">5,340</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfOC0xLTEtMS0w_c312d26f-2bbc-41b2-8bd3-387b242e883c">405,473</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfOC0zLTEtMS0w_16f4c018-df38-4bba-9257-23b5b1cb2dc1">410,521</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities, non-current</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMTAtMS0xLTEtMA_e3def4b4-cd7e-4fe7-b9f7-0af321a4e570">21,832</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMTAtMy0xLTEtMA_17fb2562-390b-49f3-9d40-ff1203968301">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMTEtMS0xLTEtMA_6e1cff61-cc93-4b89-995e-58c328da00db">29,926</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMTEtMy0xLTEtMA_583e0e0f-68eb-4db6-a2b4-a9e0e3f34c2a">78,723</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMTItMS0xLTEtMA_ba8c869f-35e8-4d1c-8c57-eae7ac315ad0">53,156</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMTItMy0xLTEtMA_f4ec954c-3f84-40af-a748-9594a03a306f">54,243</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMTMtMS0xLTEtMA_b3b04f60-fa09-4a75-9a4f-66c7c834d35b">39,273</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMTMtMy0xLTEtMA_6a160489-4b58-4b83-8b77-f38932a3d88b">40,044</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMTQtMS0xLTEtOTY3_47efe694-b285-486a-b7b3-912bf45e6e4b">77,289</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other non-current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMTQtMS0xLTEtMA_ec801bca-90e1-4f17-8423-e28d7e65f87f">9,067</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMTQtMy0xLTEtMA_f0a8fb60-07a4-4130-bb5a-7315f6c49bfc">3,364</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMTUtMS0xLTEtMA_72ab48b3-a477-4036-ae89-90dc6a7b6457">1,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMTUtMy0xLTEtMA_6c4111c8-7fad-4fa3-a794-5f0d60cc573f">3,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMTYtMS0xLTEtMA_af095824-e3f7-4bab-b916-1c73725757e0">637,516</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMTYtMy0xLTEtMA_d337cc18-8a8f-4456-9ff5-ccc4b40e87be">590,395</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">LIABILITIES AND STOCKHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable and accrued liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMTktMS0xLTEtMA_4993e932-eb89-4960-87da-143c4ed2edbd">17,556</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMTktMy0xLTEtMA_9f490b1f-75c4-4231-9140-82bc56444e32">21,457</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued compensation and employee benefits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMjAtMS0xLTEtMA_49a2fe65-b819-4d6c-8395-1f771c34070e">13,605</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMjAtMy0xLTEtMA_efb72e4b-ddcc-43e7-8fb8-3b20147bb575">9,490</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenues</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMjEtMS0xLTEtMA_ff8be191-b35b-4144-af05-f28feedb0e6d">38,711</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMjEtMy0xLTEtMA_08b9bded-1fcb-429b-8e2d-f75bbffa6309">47,564</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMjItMS0xLTEtMA_1d7a8a68-e674-41bc-a239-66df0a2b3978">69,872</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMjItMy0xLTEtMA_463d6f05-6ed8-452f-8bee-becdc0ffb8fa">78,511</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenues, non-current</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMjMtMS0xLTEtMA_eefb5fb4-78f5-4a26-bb76-7f65c150cbde">81,432</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMjMtMy0xLTEtMA_bf71befc-b61b-4299-8c75-b280e70408bd">108,273</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term portion of lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMjQtMS0xLTEtMA_c5fd7c00-de43-4532-a7d4-da7878bc1f6c">41,192</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:BuildToSuitLeaseObligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMjQtMy0xLTEtMA_8c31fa3c-c7c8-469d-b5ae-1cb97f4e70e6">27,689</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred income tax</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMjUtMS0xLTEtMA_f8225c7e-6af9-47a5-afdc-0e88d903f03d">6,570</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMjUtMy0xLTEtMA_edf4c2dc-d7fe-41aa-9ebc-b3316ad499dd">6,705</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other non-current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMjYtMS0xLTEtMA_fff2e510-6b58-4af4-990a-1bbaac4c128f">5,711</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMjYtMy0xLTEtMA_95910610-a195-4404-8a1f-e9fe230848a9">1,960</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMjctMS0xLTEtMA_1b8816c6-ad94-4397-a152-2713adf76858">204,777</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMjctMy0xLTEtMA_03f82874-596e-41fc-91bb-d4d92e99c098">223,138</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMjgtMS0xLTEtMA_57278f5a-fbf0-4539-8c4e-225072196542"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMjgtMy0xLTEtMA_20521eac-4581-4d19-8d68-bda342360481"></ix:nonFraction></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stockholders' equity:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzEtMC0xLTEtMTMzMDUvdGV4dHJlZ2lvbjo5YTM0NjhhYjI5Mjk0OTg1YTdiNTY5MjI3MjQ1MWJjMF84MjQ2MzM3MjA4NDcy_8b948fb8-678b-44f4-9963-1991ccc8f131"><ix:nonFraction unitRef="usdPerShare" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzEtMC0xLTEtMTMzMDUvdGV4dHJlZ2lvbjo5YTM0NjhhYjI5Mjk0OTg1YTdiNTY5MjI3MjQ1MWJjMF84MjQ2MzM3MjA4NDcy_cc0df052-63ea-453c-86ed-bcbdb1a9e79d">0.01</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzEtMC0xLTEtMTMzMDUvdGV4dHJlZ2lvbjo5YTM0NjhhYjI5Mjk0OTg1YTdiNTY5MjI3MjQ1MWJjMF8xMDQ0NTM2MDQ2Mzk2Nw_65fc5772-ae7e-49b4-bf89-1e025f5dfe5a"><ix:nonFraction unitRef="shares" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzEtMC0xLTEtMTMzMDUvdGV4dHJlZ2lvbjo5YTM0NjhhYjI5Mjk0OTg1YTdiNTY5MjI3MjQ1MWJjMF8xMDQ0NTM2MDQ2Mzk2Nw_7e25e9a3-d3bb-4b30-85da-dc80d6dca9fa">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="shares" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzEtMC0xLTEtMTMzMDUvdGV4dHJlZ2lvbjo5YTM0NjhhYjI5Mjk0OTg1YTdiNTY5MjI3MjQ1MWJjMF84MjQ2MzM3MjA4NDQz_1275b8dd-f96e-4fee-9726-0b7f33711978"><ix:nonFraction unitRef="shares" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzEtMC0xLTEtMTMzMDUvdGV4dHJlZ2lvbjo5YTM0NjhhYjI5Mjk0OTg1YTdiNTY5MjI3MjQ1MWJjMF84MjQ2MzM3MjA4NDQz_2ec37ff1-04a8-4d14-bdbf-8fbfa450415c"><ix:nonFraction unitRef="shares" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzEtMC0xLTEtMTMzMDUvdGV4dHJlZ2lvbjo5YTM0NjhhYjI5Mjk0OTg1YTdiNTY5MjI3MjQ1MWJjMF84MjQ2MzM3MjA4NDQz_85684e26-bd8d-4e25-9fba-58ed785aa015"><ix:nonFraction unitRef="shares" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzEtMC0xLTEtMTMzMDUvdGV4dHJlZ2lvbjo5YTM0NjhhYjI5Mjk0OTg1YTdiNTY5MjI3MjQ1MWJjMF84MjQ2MzM3MjA4NDQz_f041562f-766e-47c4-8e31-f19be9800763">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzEtMS0xLTEtMTU0MzQ_f661d10d-c82d-4890-b4e9-faeca18e9d39">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzEtMy0xLTEtMTU0Mzg_63248324-3646-43bc-900a-6acda09c6105">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzAtMC0xLTEtNjgvdGV4dHJlZ2lvbjoyN2NmOGY0OGFlMDg0OGU1ODQzNWY4ZGZiM2UxMmI0Zl83Njk2NTgxMzk0Njc0_17b3f855-2473-44ed-b0cd-5ccd4b08a9ea"><ix:nonFraction unitRef="usdPerShare" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzAtMC0xLTEtNjgvdGV4dHJlZ2lvbjoyN2NmOGY0OGFlMDg0OGU1ODQzNWY4ZGZiM2UxMmI0Zl83Njk2NTgxMzk0Njc0_1cb4fbd1-5069-4a37-8b7e-0fef1be6145e">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzAtMC0xLTEtNjgvdGV4dHJlZ2lvbjoyN2NmOGY0OGFlMDg0OGU1ODQzNWY4ZGZiM2UxMmI0Zl83Njk2NTgxMzk0Njg3_7e70d220-b138-4238-9f10-fa2cbf4451cc"><ix:nonFraction unitRef="shares" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzAtMC0xLTEtNjgvdGV4dHJlZ2lvbjoyN2NmOGY0OGFlMDg0OGU1ODQzNWY4ZGZiM2UxMmI0Zl83Njk2NTgxMzk0Njg3_fac48357-a102-41b7-9f1c-c57f7133e3ca">160,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzAtMC0xLTEtNjgvdGV4dHJlZ2lvbjoyN2NmOGY0OGFlMDg0OGU1ODQzNWY4ZGZiM2UxMmI0Zl83Njk2NTgxMzk0NzAw_7d2d1a9a-0931-4309-bb68-8e441b402ad8"><ix:nonFraction unitRef="shares" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzAtMC0xLTEtNjgvdGV4dHJlZ2lvbjoyN2NmOGY0OGFlMDg0OGU1ODQzNWY4ZGZiM2UxMmI0Zl83Njk2NTgxMzk0NzAw_b40cb739-c905-4b12-8cf3-1f8cc37a1753">115,972,708</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzAtMC0xLTEtNjgvdGV4dHJlZ2lvbjoyN2NmOGY0OGFlMDg0OGU1ODQzNWY4ZGZiM2UxMmI0Zl83Njk2NTgxMzk0NzEz_213eaec7-0323-4e48-b56c-a52884ceac86"><ix:nonFraction unitRef="shares" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzAtMC0xLTEtNjgvdGV4dHJlZ2lvbjoyN2NmOGY0OGFlMDg0OGU1ODQzNWY4ZGZiM2UxMmI0Zl83Njk2NTgxMzk0NzEz_619cf7d6-f587-4fe3-b802-bb7e1a9d84a3">102,187,471</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2019 and 2018, respectively</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzAtMS0xLTEtMA_0eab8a65-e12d-4957-8141-a1125ad527bc">1,160</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzAtMy0xLTEtMA_7fc57de7-4fb4-486d-97f8-b943dcbfc4d1">1,022</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional paid-in capital</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzEtMS0xLTEtMA_81591f08-93af-4a7f-b2b8-5c91d67c1d18">1,090,828</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzEtMy0xLTEtMA_50d26e70-4cf5-4d91-b798-3b180bb5356d">929,632</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzItMS0xLTEtMA_8d3440d9-c374-4888-8971-9c07bed1bd2e">656,985</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzItMy0xLTEtMA_62fa0367-54a0-4529-8e77-ed7d4d5f1335">562,696</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated other comprehensive loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzMtMS0xLTEtMA_99171b10-ede4-4d4a-8a74-6079d86eacbb">2,449</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzMtMy0xLTEtMA_989bb7e7-6f6a-4c3a-889f-6ac114263166">1,440</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Sangamo Therapeutics, Inc. stockholders' equity</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzQtMS0xLTEtMA_2b3d65bb-915e-4307-8660-2786f09bd138">432,554</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzQtMy0xLTEtMA_2f5210ed-aa9b-4cdd-9f6f-0909d9a0f2a2">366,518</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-controlling interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzUtMS0xLTEtMA_33bf6199-ebc3-4f36-a2f5-06123be94c09">185</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzUtMy0xLTEtMA_ae6a5ca9-4737-474d-bde0-eec00e4db485">739</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stockholders' equity</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzYtMS0xLTEtMA_51d7cac8-e843-4b66-9eec-8dccc24657f3">432,739</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzYtMy0xLTEtMA_d2c88160-96c7-4db8-8618-f521db828753">367,257</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities and stockholders' equity</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzctMS0xLTEtMA_dd6ee818-70ad-497c-9403-8f23e0322822">637,516</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzctMy0xLTEtMA_76dee698-36fd-488e-8510-140341644571">590,395</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See accompanying Notes to Consolidated Financial Statements.</span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_76"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">68</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SANGAMO THERAPEUTICS, INC.</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(in thousands, except per share amounts) </span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:61.343%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.731%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfNS0xLTEtMS0w_5b646f89-c05c-452c-a381-80a3b9f1bed0">102,428</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfNS0zLTEtMS0w_9cc35105-4649-49b7-bc41-de6365aeeae9">84,452</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfNS01LTEtMS0w_7fe58254-891b-45cd-b778-912b2121d0a7">36,567</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfNy0xLTEtMS0w_3ec5b0cb-8042-4dc8-a82a-878f93e6e116">145,922</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfNy0zLTEtMS0w_61d666bf-ab96-4ad2-8407-d68d7c7ef5d0">114,866</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfNy01LTEtMS0w_4d90f836-1f72-4c02-9f4f-bd9eb9b9711c">65,728</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfOC0xLTEtMS0w_10e1dcfa-cbb7-489c-bbc2-8808cf2db8a2">61,686</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfOC0zLTEtMS0w_8d67ec14-e267-4196-b91a-f3df386b4248">46,736</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfOC01LTEtMS0w_e2194c48-1605-4549-a1a4-96744828760d">27,200</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfOS0xLTEtMS0w_5c83815a-dbd2-45c1-a376-af84938f7a4d">207,608</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfOS0zLTEtMS0w_c4ad358a-64a2-47b2-add1-c6a364c14c7f">161,602</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfOS01LTEtMS0w_d75bae5c-07da-4f2f-b333-ce55a7072137">92,928</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTAtMS0xLTEtMA_94d57d53-ecd1-46c0-b1d3-4dd26e724173">105,180</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTAtMy0xLTEtMA_a401aef0-3bbc-4734-8bb6-3b256d0f9597">77,150</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTAtNS0xLTEtMA_ae513691-a09a-4a15-ac7c-48c6935b4065">56,361</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest and other income, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestAndOtherIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTEtMS0xLTEtMA_9e6dd69e-5ebe-42de-8496-054bcf47dbf5">9,761</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestAndOtherIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTEtMy0xLTEtMA_0a784928-486c-43e3-9e8a-dde44cd83cfe">8,261</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestAndOtherIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTEtNS0xLTEtMA_e5e1839d-352d-4460-ba66-f3f174f73083">1,793</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss before income taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTItMS0xLTEtMA_f06e4a9e-2be9-415c-b2eb-23a33c296b2b">95,419</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTItMy0xLTEtMA_4374c5b8-6307-482c-8d01-2a486d4eb181">68,889</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTItNS0xLTEtMA_0eee9a42-6a11-4798-b16b-d23b3a01d8b9">54,568</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Benefit from income taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTMtMS0xLTEtMA_d357dd1c-5fc4-4137-9e78-79159d2d254c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTMtMy0xLTEtMA_c6457de7-06eb-4c90-bf50-127cf2af87fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTMtNS0xLTEtMA_2573828f-2db6-474d-9254-33b62f68d7b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTQtMS0xLTEtMA_cb15ac6b-0fce-4b8c-b5c8-61b973a71e0d">95,419</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTQtMy0xLTEtMA_fe0963a4-9dfa-4f2b-a48b-ef5bca10b86e">68,889</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTQtNS0xLTEtMA_0549d2ca-50e3-4e6a-8700-811f9cfdaff0">54,568</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTUtMS0xLTEtMA_5487631a-c4a2-4253-8fcb-bb51b8df9542">233</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTUtMy0xLTEtMA_2625ee9a-f5cd-44cf-96cc-70b1d6da19a4">555</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTUtNS0xLTEtMA_cf2b94da-f497-4b7e-aa5e-283fd898e32c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss attributable to Sangamo Therapeutics, Inc. stockholders</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTYtMS0xLTEtMA_d5efbbff-57ce-4417-af9e-d8e99cfd44d2">95,186</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTYtMy0xLTEtMA_5c38618b-bf06-4e85-9187-1b4ba131a45d">68,334</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTYtNS0xLTEtMA_d7404029-f5b5-4d6b-96be-5ed9c14f05d1">54,568</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTctMS0xLTEtMA_41b3358c-cfe0-46c7-8fe9-8b0d45ea7d86">0.85</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTctMy0xLTEtMA_13c7869d-c520-429c-8b80-401e291edbef">0.70</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTctNS0xLTEtMA_314b956e-c4d6-4a37-a606-2ec030bac8ec">0.70</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares used in computing basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTgtMS0xLTEtMA_82069ab4-38ee-4963-9505-acfda748482f">112,114</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTgtMy0xLTEtMA_a17c674d-66fe-4d17-b079-39592c001cb4">96,941</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTgtNS0xLTEtMA_8e25fdcc-0e97-4f7c-bfdd-737c2ad7d6c9">78,084</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See accompanying Notes to Consolidated Financial Statements.</span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_79"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">69</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SANGAMO THERAPEUTICS, INC.</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(in thousands)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:61.343%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.731%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83OS9mcmFnOjZjYjUxMjQ5YzBlMjQxZWU4YmJkYWE2OGZiODU2M2ZlL3RhYmxlOmU1Y2Y5M2NiMDYxNDQxMmVhZDRlNjdkNDIxODA1MWEzL3RhYmxlcmFuZ2U6ZTVjZjkzY2IwNjE0NDEyZWFkNGU2N2Q0MjE4MDUxYTNfMi0xLTEtMS0w_77f52c93-30d2-4e27-a364-c0581103ff97">95,419</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83OS9mcmFnOjZjYjUxMjQ5YzBlMjQxZWU4YmJkYWE2OGZiODU2M2ZlL3RhYmxlOmU1Y2Y5M2NiMDYxNDQxMmVhZDRlNjdkNDIxODA1MWEzL3RhYmxlcmFuZ2U6ZTVjZjkzY2IwNjE0NDEyZWFkNGU2N2Q0MjE4MDUxYTNfMi0zLTEtMS0w_015b3895-6dd2-4141-acb9-0c932ac176ca">68,889</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83OS9mcmFnOjZjYjUxMjQ5YzBlMjQxZWU4YmJkYWE2OGZiODU2M2ZlL3RhYmxlOmU1Y2Y5M2NiMDYxNDQxMmVhZDRlNjdkNDIxODA1MWEzL3RhYmxlcmFuZ2U6ZTVjZjkzY2IwNjE0NDEyZWFkNGU2N2Q0MjE4MDUxYTNfMi01LTEtMS0w_761c2e19-95aa-4942-9dc0-d4ff486a20da">54,568</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency translation adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83OS9mcmFnOjZjYjUxMjQ5YzBlMjQxZWU4YmJkYWE2OGZiODU2M2ZlL3RhYmxlOmU1Y2Y5M2NiMDYxNDQxMmVhZDRlNjdkNDIxODA1MWEzL3RhYmxlcmFuZ2U6ZTVjZjkzY2IwNjE0NDEyZWFkNGU2N2Q0MjE4MDUxYTNfMy0xLTEtMS0w_5980e0d0-6b3e-45ca-9eea-e0148e9e099f">1,573</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83OS9mcmFnOjZjYjUxMjQ5YzBlMjQxZWU4YmJkYWE2OGZiODU2M2ZlL3RhYmxlOmU1Y2Y5M2NiMDYxNDQxMmVhZDRlNjdkNDIxODA1MWEzL3RhYmxlcmFuZ2U6ZTVjZjkzY2IwNjE0NDEyZWFkNGU2N2Q0MjE4MDUxYTNfMy0zLTEtMS0w_7f1c46a7-6043-4cbf-93a0-cedf2f869c69">1,148</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83OS9mcmFnOjZjYjUxMjQ5YzBlMjQxZWU4YmJkYWE2OGZiODU2M2ZlL3RhYmxlOmU1Y2Y5M2NiMDYxNDQxMmVhZDRlNjdkNDIxODA1MWEzL3RhYmxlcmFuZ2U6ZTVjZjkzY2IwNjE0NDEyZWFkNGU2N2Q0MjE4MDUxYTNfMy01LTEtMS0w_b70568c1-e34d-4289-b81d-8fa8443868d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net pension losses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83OS9mcmFnOjZjYjUxMjQ5YzBlMjQxZWU4YmJkYWE2OGZiODU2M2ZlL3RhYmxlOmU1Y2Y5M2NiMDYxNDQxMmVhZDRlNjdkNDIxODA1MWEzL3RhYmxlcmFuZ2U6ZTVjZjkzY2IwNjE0NDEyZWFkNGU2N2Q0MjE4MDUxYTNfNC0xLTEtMS0w_c62bf110-e86c-4459-92be-bb3e0d82806e">28</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83OS9mcmFnOjZjYjUxMjQ5YzBlMjQxZWU4YmJkYWE2OGZiODU2M2ZlL3RhYmxlOmU1Y2Y5M2NiMDYxNDQxMmVhZDRlNjdkNDIxODA1MWEzL3RhYmxlcmFuZ2U6ZTVjZjkzY2IwNjE0NDEyZWFkNGU2N2Q0MjE4MDUxYTNfNC0zLTEtMS0w_3c1ea55e-2728-45aa-8bd1-964509e8a1ed">21</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83OS9mcmFnOjZjYjUxMjQ5YzBlMjQxZWU4YmJkYWE2OGZiODU2M2ZlL3RhYmxlOmU1Y2Y5M2NiMDYxNDQxMmVhZDRlNjdkNDIxODA1MWEzL3RhYmxlcmFuZ2U6ZTVjZjkzY2IwNjE0NDEyZWFkNGU2N2Q0MjE4MDUxYTNfNC01LTEtMS0w_a3a8cc8f-a1c4-4747-b5db-e73228e79a8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in unrealized gain (loss) on available-for-sale securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83OS9mcmFnOjZjYjUxMjQ5YzBlMjQxZWU4YmJkYWE2OGZiODU2M2ZlL3RhYmxlOmU1Y2Y5M2NiMDYxNDQxMmVhZDRlNjdkNDIxODA1MWEzL3RhYmxlcmFuZ2U6ZTVjZjkzY2IwNjE0NDEyZWFkNGU2N2Q0MjE4MDUxYTNfNS0xLTEtMS0w_94725f39-1236-40a8-89e0-5f613d2d5cac">592</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83OS9mcmFnOjZjYjUxMjQ5YzBlMjQxZWU4YmJkYWE2OGZiODU2M2ZlL3RhYmxlOmU1Y2Y5M2NiMDYxNDQxMmVhZDRlNjdkNDIxODA1MWEzL3RhYmxlcmFuZ2U6ZTVjZjkzY2IwNjE0NDEyZWFkNGU2N2Q0MjE4MDUxYTNfNS0zLTEtMS0w_f08aeb2d-9a93-456f-ab10-fcf9daaadfdb">4</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83OS9mcmFnOjZjYjUxMjQ5YzBlMjQxZWU4YmJkYWE2OGZiODU2M2ZlL3RhYmxlOmU1Y2Y5M2NiMDYxNDQxMmVhZDRlNjdkNDIxODA1MWEzL3RhYmxlcmFuZ2U6ZTVjZjkzY2IwNjE0NDEyZWFkNGU2N2Q0MjE4MDUxYTNfNS01LTEtMS0w_567c17ac-a455-45c7-8cbc-008526fd5851">306</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Comprehensive loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83OS9mcmFnOjZjYjUxMjQ5YzBlMjQxZWU4YmJkYWE2OGZiODU2M2ZlL3RhYmxlOmU1Y2Y5M2NiMDYxNDQxMmVhZDRlNjdkNDIxODA1MWEzL3RhYmxlcmFuZ2U6ZTVjZjkzY2IwNjE0NDEyZWFkNGU2N2Q0MjE4MDUxYTNfNi0xLTEtMS0w_54d7f259-499e-4b7b-b4fc-7ed971e5dce9">96,428</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83OS9mcmFnOjZjYjUxMjQ5YzBlMjQxZWU4YmJkYWE2OGZiODU2M2ZlL3RhYmxlOmU1Y2Y5M2NiMDYxNDQxMmVhZDRlNjdkNDIxODA1MWEzL3RhYmxlcmFuZ2U6ZTVjZjkzY2IwNjE0NDEyZWFkNGU2N2Q0MjE4MDUxYTNfNi0zLTEtMS0w_de63d1fd-2d5d-4129-99bf-ec3839189ebd">70,062</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83OS9mcmFnOjZjYjUxMjQ5YzBlMjQxZWU4YmJkYWE2OGZiODU2M2ZlL3RhYmxlOmU1Y2Y5M2NiMDYxNDQxMmVhZDRlNjdkNDIxODA1MWEzL3RhYmxlcmFuZ2U6ZTVjZjkzY2IwNjE0NDEyZWFkNGU2N2Q0MjE4MDUxYTNfNi01LTEtMS0w_b1967fba-1684-4a38-871a-c6f6dffeb827">54,874</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Comprehensive loss attributable to non-controlling interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83OS9mcmFnOjZjYjUxMjQ5YzBlMjQxZWU4YmJkYWE2OGZiODU2M2ZlL3RhYmxlOmU1Y2Y5M2NiMDYxNDQxMmVhZDRlNjdkNDIxODA1MWEzL3RhYmxlcmFuZ2U6ZTVjZjkzY2IwNjE0NDEyZWFkNGU2N2Q0MjE4MDUxYTNfNy0xLTEtMS0w_09457987-13ab-45d3-9e91-9724f0100764">233</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83OS9mcmFnOjZjYjUxMjQ5YzBlMjQxZWU4YmJkYWE2OGZiODU2M2ZlL3RhYmxlOmU1Y2Y5M2NiMDYxNDQxMmVhZDRlNjdkNDIxODA1MWEzL3RhYmxlcmFuZ2U6ZTVjZjkzY2IwNjE0NDEyZWFkNGU2N2Q0MjE4MDUxYTNfNy0zLTEtMS0w_55f49090-3f45-406a-a956-4f5ca49b75f4">574</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83OS9mcmFnOjZjYjUxMjQ5YzBlMjQxZWU4YmJkYWE2OGZiODU2M2ZlL3RhYmxlOmU1Y2Y5M2NiMDYxNDQxMmVhZDRlNjdkNDIxODA1MWEzL3RhYmxlcmFuZ2U6ZTVjZjkzY2IwNjE0NDEyZWFkNGU2N2Q0MjE4MDUxYTNfNy01LTEtMS0w_d727afd4-5a39-499b-b9dd-a811396eff6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Comprehensive loss attributable to Sangamo Therapeutics, Inc.</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83OS9mcmFnOjZjYjUxMjQ5YzBlMjQxZWU4YmJkYWE2OGZiODU2M2ZlL3RhYmxlOmU1Y2Y5M2NiMDYxNDQxMmVhZDRlNjdkNDIxODA1MWEzL3RhYmxlcmFuZ2U6ZTVjZjkzY2IwNjE0NDEyZWFkNGU2N2Q0MjE4MDUxYTNfOC0xLTEtMS0w_91c7eb4a-1eac-43f9-a193-fa1122a31799">96,195</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83OS9mcmFnOjZjYjUxMjQ5YzBlMjQxZWU4YmJkYWE2OGZiODU2M2ZlL3RhYmxlOmU1Y2Y5M2NiMDYxNDQxMmVhZDRlNjdkNDIxODA1MWEzL3RhYmxlcmFuZ2U6ZTVjZjkzY2IwNjE0NDEyZWFkNGU2N2Q0MjE4MDUxYTNfOC0zLTEtMS0w_4850d5c7-f76b-49e6-936e-aac6bc26a30d">69,488</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83OS9mcmFnOjZjYjUxMjQ5YzBlMjQxZWU4YmJkYWE2OGZiODU2M2ZlL3RhYmxlOmU1Y2Y5M2NiMDYxNDQxMmVhZDRlNjdkNDIxODA1MWEzL3RhYmxlcmFuZ2U6ZTVjZjkzY2IwNjE0NDEyZWFkNGU2N2Q0MjE4MDUxYTNfOC01LTEtMS0w_c887be97-eb49-4e48-9761-e13b6f95009a">54,874</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See accompanying Notes to Consolidated Financial Statements.</span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_82"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">70</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SANGAMO THERAPEUTICS, INC.</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY </span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(in thousands, except share amounts)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:28.791%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.384%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.386%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.797%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.237%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.530%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.410%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.357%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.243%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Other<br/>Comprehensive<br/>Income/ (Loss)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-<br/>Controlling<br/>Interest</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances at December 31, 2016</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0627710456a349f7b90cec0a3f5536e8_I20161231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMi0xLTEtMS0w_29c0aa8e-eb18-4307-8424-d5cf063c1757">70,871,902</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0627710456a349f7b90cec0a3f5536e8_I20161231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMi0zLTEtMS0w_fbe9ff62-031a-46db-bf13-973cc476649b">709</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6a9e59eb89204d6cb59dbc5b2e145c09_I20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMi01LTEtMS0w_af8b67b9-9c89-4f6c-a674-71510f464c62">576,377</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5063163868264343bb3c8784a605dabf_I20161231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMi03LTEtMS0w_509dc75e-d804-48f2-b29b-d169d68c1b30">440,911</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id50e642517aa459b9ada4af0f93e6b20_I20161231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMi05LTEtMS0w_953ea09f-908a-40da-9ec3-b8437c920ee6">20</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifeb2f797e05149138caa5e72c8aa0d2b_I20161231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMi0xMS0xLTEtMA_a87d6f5a-602a-4a9e-91e4-535d84e1acd7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie9057cb83ba040218834cc92910f7361_I20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMi0xMy0xLTEtMA_fd4a3f7a-a7e5-4c11-96f9-bd6aba60ce67">136,195</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0ce63a9e5f5542dc8d3b24259ad1ee2e_D20170101-20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMy0xLTEtMS0w_ab894c3d-c1b3-4821-a389-4334376c245a">2,101,489</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0ce63a9e5f5542dc8d3b24259ad1ee2e_D20170101-20171231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMy0zLTEtMS0w_67600ee2-84e0-4845-9e9e-6dbf56b094fa">21</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibc70b211d0654544a6f9c1e9fc810641_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMy01LTEtMS0w_0cd84bed-897e-4d66-beac-715a8816e451">15,078</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMy0xMy0xLTEtMA_ee5d70b9-a4bf-4ab1-88b4-6781f7d4b18f">15,099</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Issuance of common stock under employee stock purchase plan</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0ce63a9e5f5542dc8d3b24259ad1ee2e_D20170101-20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfNC0xLTEtMS0w_9c10756b-90d6-403b-af02-8b2269f4d5f0">253,994</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0ce63a9e5f5542dc8d3b24259ad1ee2e_D20170101-20171231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfNC0zLTEtMS0w_76dd4244-f313-4f50-a132-681654c10514">2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibc70b211d0654544a6f9c1e9fc810641_D20170101-20171231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfNC01LTEtMS0w_9505956b-872f-447a-9d76-9c7c85fa597c">816</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfNC0xMy0xLTEtMA_fe47b73b-704d-430e-9122-5d1c11a35f3f">818</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Issuance of common stock under public offering, net of issuance costs</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0ce63a9e5f5542dc8d3b24259ad1ee2e_D20170101-20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfNS0xLTEtMS0xMDYw_02155fac-0534-4c19-bf5b-562f411bab89">12,371,149</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0ce63a9e5f5542dc8d3b24259ad1ee2e_D20170101-20171231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfNS0zLTEtMS0xMDYw_698f0df2-ed22-4c70-9eef-f1d44ec68507">124</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibc70b211d0654544a6f9c1e9fc810641_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfNS01LTEtMS0xMDYw_768bfdf5-bd65-4ed7-b041-5f0e1fa75ca1">81,449</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfNS0xMy0xLTEtMTA2MA_2b31786d-fc2a-4073-ae71-1102f8828722">81,573</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibc70b211d0654544a6f9c1e9fc810641_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfNS01LTEtMS0w_375ef83e-9992-48fe-9e37-df66dfd2425d">9,089</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfNS0xMy0xLTEtMA_e289d303-dce0-4735-bfa0-6f2f0c8ebf60">9,089</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Net unrealized loss on marketable securities, net of tax</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i49b4da657a834857bc1d02cc6ef16e7b_D20170101-20171231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfNy05LTEtMS0w_2236ab50-b4c3-4957-b0b0-7fb55f8b87a5">306</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfNy0xMy0xLTEtMA_11189894-d315-4572-896e-a90362b03c5b">306</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0406f7152c82421aa6b02c6472444482_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfOC03LTEtMS0w_c56a90cf-94cb-4450-ac89-278e1b8bfe39">54,568</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfOC0xMy0xLTEtMA_064332c8-acbf-4417-8330-5b9f06a390e6">54,568</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances at December 31, 2017</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i5fc1ca72aa1645a4b00f8fd2b31d8956_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTAtMS0xLTEtMA_2c476d2e-6b91-4af5-849c-b76b0e311b86">85,598,534</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5fc1ca72aa1645a4b00f8fd2b31d8956_I20171231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTAtMy0xLTEtMA_6cac4bec-aca4-4868-b301-2e16226872f7">856</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia218df6fa91f4c1fb7c308b884f2552a_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTAtNS0xLTEtMA_7d9ad35f-717d-4640-b243-cd70f1b5d305">682,809</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i81d1b464269e4be59411d5313217455a_I20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTAtNy0xLTEtMA_219a7d4b-5dde-4454-97c8-17c259e47999">495,479</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib5393cf4702d478487f5812f2284bb7d_I20171231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTAtOS0xLTEtMA_23782a8b-6605-48bb-8407-6bc320c778f9">286</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i13411b9a2fac4f62b4a1b5d13e1a6d13_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTAtMTEtMS0xLTA_b1a6a2c2-d675-4f56-9fd0-93c1cbcd71a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb7e952fbd38434585f995fe73c66a44_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTAtMTMtMS0xLTA_98e5c5d5-bf56-4b7c-ae73-f84a4045c6f3">187,900</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Cumulative-effect adjustment of ASC Topic 606 on January 1, 2018</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if6ef95d8de3d4a7d89e36708e8ad41fa_I20180101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTAtNy0xLTEtMTEwNA_a133d8c2-d37d-48dc-816f-2bd4956d9c85">1,117</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5ac2058780dd4487b64d9cea81253e0a_I20180101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTAtMTMtMS0xLTExMDQ_21b3ec2a-6665-4211-9bf9-05f7c18e1d2d">1,117</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ibc92201ce4bc4d35aac109e19e0e5a1f_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTEtMS0xLTEtMA_8dc1f096-c569-4900-8559-343e6a9b3787">2,103,727</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibc92201ce4bc4d35aac109e19e0e5a1f_D20180101-20181231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTEtMy0xLTEtMA_9ddc1221-3875-45cc-99aa-c08a5738101e">20</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5ad82eaa45484fad83417fd0c193af43_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTEtNS0xLTEtMA_935354ca-7b9d-46db-8034-dfe01c0318b0">14,447</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTEtMTMtMS0xLTA_91f99d19-60fe-4537-b5ff-fcbf44644854">14,467</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Issuance of common stock under employee stock purchase plan</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ibc92201ce4bc4d35aac109e19e0e5a1f_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTItMS0xLTEtMA_a27154f0-ada6-429d-aa37-8b0856ad706c">328,710</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibc92201ce4bc4d35aac109e19e0e5a1f_D20180101-20181231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTItMy0xLTEtMA_8712871e-51cc-4147-9860-553afff721e9">4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5ad82eaa45484fad83417fd0c193af43_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTItNS0xLTEtMA_6a084cc9-efd5-4e6b-9fc1-7a237e7fdbcc">1,480</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTItMTMtMS0xLTA_ba60fb96-9e2b-4958-8cfb-1520eb6a5fa7">1,484</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Issuance of common stock under public offering, net of issuance costs</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ibc92201ce4bc4d35aac109e19e0e5a1f_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTMtMS0xLTEtMA_4edc1a04-8296-485d-8c74-c9166b3b9241">14,156,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibc92201ce4bc4d35aac109e19e0e5a1f_D20180101-20181231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTMtMy0xLTEtMA_9b5f2132-0969-471a-a834-15e28670db27">142</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5ad82eaa45484fad83417fd0c193af43_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTMtNS0xLTEtMA_1264990f-4380-470c-a8ee-7c7570e841ac">215,616</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTMtMTMtMS0xLTA_8bcf1199-1820-4243-945e-2986f6c72807">215,758</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5ad82eaa45484fad83417fd0c193af43_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTQtNS0xLTEtMA_22bc9bfe-514c-4b4f-9500-807fb531e2f1">14,677</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTQtMTMtMS0xLTA_38839e63-10af-4bc3-92d4-252f42608d9c">14,677</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Additional paid-in capital for Acquisition of Sangamo France</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5ad82eaa45484fad83417fd0c193af43_D20180101-20181231" decimals="-3" name="sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTUtNS0xLTEtMTE2OQ_dde9df4a-1dce-4db1-b609-dffcbe46d401">603</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" name="sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTUtMTMtMS0xLTExNjk_0618a39e-4fad-428d-934d-e37b46e9b885">603</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Non-controlling interest upon Acquisition of Sangamo France</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifaf1fb068f504cafbf0b5ee6c15f15a7_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTYtMTEtMS0xLTExNjk_381c883f-694a-4d35-b6b1-a5e055335e9c">1,313</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTYtMTMtMS0xLTExNjk_3fcf4a2e-d350-4a3c-97a7-08bb48b002c2">1,313</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency translation adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaa3c4c19d5b248f48eeab6d3449c0692_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTctOS0xLTEtMTE2OQ_c400ebc2-8504-4490-9212-f6d3ba01ba5a">1,129</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifaf1fb068f504cafbf0b5ee6c15f15a7_D20180101-20181231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTctMTEtMS0xLTExNjk_28764f6c-6382-4c80-b2c3-8a2b2f3a0d42">19</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTctMTMtMS0xLTExNjk_eea70803-006c-4b04-af97-967c96fd9957">1,148</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net pension losses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaa3c4c19d5b248f48eeab6d3449c0692_D20180101-20181231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTgtOS0xLTEtMTE2OQ_b84f1c6c-c2e3-40f1-a8d5-9a3ea74501e0">21</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTgtMTMtMS0xLTExNjk_e3c365af-6121-4bc6-bf2e-3506f18ad182">21</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Net unrealized loss on marketable securities, net of tax</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaa3c4c19d5b248f48eeab6d3449c0692_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTYtOS0xLTEtMA_782f8a29-7ffb-45c2-ba91-979894ff673c">4</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTYtMTMtMS0xLTA_c0ca9c89-1698-4304-9a9a-df55a6f2e867">4</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5616295424184a8eb8bbc9e26f43ed70_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTctNy0xLTEtMA_c74294a5-bb32-431f-92db-a64b9313a176">68,334</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifaf1fb068f504cafbf0b5ee6c15f15a7_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjAtMTEtMS0xLTEwMTQz_d1aa1766-c8f7-485d-b7b0-8a6f599118b1">555</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTctMTMtMS0xLTA_1114a103-af26-43bc-9c66-c88866bc2dea">68,889</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances at December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i6b94d20f29c94303b0b5f428bcfaa12b_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTktMS0xLTEtMA_fb5757e0-b011-49ec-ae99-0d6195e4027f">102,187,471</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b94d20f29c94303b0b5f428bcfaa12b_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTktMy0xLTEtMA_6bd71c10-d459-4e59-8f6e-879cdd4f8fbf">1,022</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib9161aaed0bc4db88c75c765dcacf1d8_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTktNS0xLTEtMA_5c70f2c5-ff18-4401-a262-63fab2defa35">929,632</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifce327bcf3b8435a8b434c043c9be74b_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTktNy0xLTEtMA_090bfe52-3d8f-4967-8dc2-1320fd7b269d">562,696</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i782ffb68f66c4a7b9ab9b5592f7c00fc_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTktOS0xLTEtMA_137fec20-d325-4a48-ba42-d56246b8ef3c">1,440</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic99ff13e6b8d4ef18b9878c555ae3844_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTktMTEtMS0xLTA_9f0c3e5a-449b-4aea-b240-277444f8291b">739</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTktMTMtMS0xLTA_e957110a-c368-4a61-aa69-5846c7014e72">367,257</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Cumulative-effect adjustment of ASC Topic 842 on January 1, 2019</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5f940ceeab344a3f93e9875fa4c27245_I20190101" decimals="-3" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjAtNy0xLTEtMA_20756cb1-9b8a-4910-876b-352094e26231">897</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icbd33d4a7d834496bd26b17d12cc0d71_I20190101" decimals="-3" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjAtMTMtMS0xLTA_b81ad02d-72a8-4222-a120-ea43a2470618">897</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i10b0f55eb1164865bbf902ed106c9883_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjEtMS0xLTEtMA_8b7169bd-69d1-4970-91c9-449e2c36c66f">885,873</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i10b0f55eb1164865bbf902ed106c9883_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjEtMy0xLTEtMA_61bd80f4-7836-4b1c-9f5d-6b54a82eb69b">9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if320296fd6c04201a11aab2ec6e01e0d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjEtNS0xLTEtMA_df5968c0-2ad2-4412-a5d0-467f7370268b">3,668</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjEtMTMtMS0xLTA_81d24595-db70-4564-ab66-ac947c75ea84">3,677</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Issuance of common stock under employee stock purchase plan</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i10b0f55eb1164865bbf902ed106c9883_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjItMS0xLTEtMA_5d8670f9-ea05-4f51-8063-5e0aec565269">249,364</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i10b0f55eb1164865bbf902ed106c9883_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjItMy0xLTEtMA_e0f47b7e-1a1d-47af-a5e3-921e73ab7bab">2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if320296fd6c04201a11aab2ec6e01e0d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjItNS0xLTEtMA_2163beb8-824d-430d-8896-1a45fca3137f">2,042</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjItMTMtMS0xLTA_08474911-5243-44a0-b048-2fb9a6067bfe">2,044</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Issuance of common stock under public offering, net of issuance costs</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i10b0f55eb1164865bbf902ed106c9883_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjMtMS0xLTEtMA_952ab4f2-aa4d-4bd4-9c20-47c243cb0ba7">12,650,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i10b0f55eb1164865bbf902ed106c9883_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjMtMy0xLTEtMA_2efaf576-6a1b-45e3-b6f6-75d65b69b019">127</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if320296fd6c04201a11aab2ec6e01e0d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjMtNS0xLTEtMA_b714e720-af91-4e80-a8f3-4809c5ce7288">136,181</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjMtMTMtMS0xLTA_dcf4d1ea-ee79-48f3-9ad6-5b67cf41dc20">136,308</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if320296fd6c04201a11aab2ec6e01e0d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjQtNS0xLTEtMA_0cc101b3-862c-4052-a434-c719ecccb1d6">19,330</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjQtMTMtMS0xLTA_e2b75e1c-089a-4403-9cbf-a02ffe7076f5">19,330</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquisition of additional shares of Sangamo <br/>     France</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i700728c6360146ffb84d3df9926f1c1b_D20190101-20191231" decimals="-3" sign="-" name="sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjUtMTEtMS0xLTA_d3481a2d-13fa-415f-8987-f38b0a128446">321</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" sign="-" name="sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjUtMTMtMS0xLTA_7192b271-741b-4bac-9840-a8ee5258b3e5">321</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Issuance costs related to Sangamo France Acquisition</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if320296fd6c04201a11aab2ec6e01e0d_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjYtNS0xLTEtMA_3ee11253-b549-44d3-8a23-aa9194799def">25</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjYtMTMtMS0xLTA_1033d482-ba7e-41c7-b1a3-aecbea5a9359">25</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency translation adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib6afa72951bb45c09b9a911552d7f480_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjgtOS0xLTEtMA_b0b048bf-ef7e-4142-9f0e-243b596eabff">1,573</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span><ix:nonFraction unitRef="usd" contextRef="i700728c6360146ffb84d3df9926f1c1b_D20190101-20191231" sign="-" xsi:nil="true" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjgtMTEtMS0xLTA_7024f64e-633b-4224-ac3d-0222e99d5357"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjgtMTMtMS0xLTA_5f725343-ace5-4260-9000-c756b74136b6">1,573</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net pension losses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib6afa72951bb45c09b9a911552d7f480_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjktOS0xLTEtMA_76f4457f-a9d3-4fad-acc0-e4ac9b7a3ce1">28</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjktMTMtMS0xLTA_1f0b14ec-2ad0-4d79-b3bd-cabf865d14bb">28</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Net unrealized gain on marketable securities, net of tax</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib6afa72951bb45c09b9a911552d7f480_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMzAtOS0xLTEtMA_af373f93-4bb5-48af-9dea-b203d670066c">592</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMzAtMTMtMS0xLTA_9b2b2ef2-0974-4fc8-aa94-58f1f3f438c0">592</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id40d07a651074bf1bafbd2a12252b23a_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMzEtNy0xLTEtMA_7ddf06f1-cc89-4909-a627-9d6e0a77a85d">95,186</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i700728c6360146ffb84d3df9926f1c1b_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMzEtMTEtMS0xLTA_6f38b607-db34-4344-a119-6f81bcd393b2">233</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMzEtMTMtMS0xLTA_91d9fae2-fe38-4dfc-b4c7-6e1b63a9e741">95,419</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ife70daa8790b4a53b4ff57301234df5f_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMzMtMS0xLTEtMA_8b680394-da43-435c-ade7-a60fdde36d1b">115,972,708</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ife70daa8790b4a53b4ff57301234df5f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMzMtMy0xLTEtMA_5fd9fd3e-51b9-476d-b312-c12601b5564a">1,160</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i35c1aa897a6e445787fa8eaaa2d7f0f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMzMtNS0xLTEtMA_2669ba05-c633-494b-9726-3c516f12227f">1,090,828</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i30d904a948194419aebb5c1fd3919342_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMzMtNy0xLTEtMA_95cada81-0bff-4618-a562-ecfc34904c6f">656,985</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i96b90ecaf62c4fada95bd7bb490b3aca_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMzMtOS0xLTEtMA_ae3eab69-8c36-4bfb-a2d8-c09ec9496725">2,449</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc3f21983c41481ba4b01cd8667c5b3d_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMzMtMTEtMS0xLTA_f2bd4643-955a-4d97-b64b-3c7f09562019">185</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMzMtMTMtMS0xLTA_c40ca502-52b8-456d-be00-d9f6c2e02425">432,739</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See accompanying Notes to Consolidated Financial Statements.</span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_85"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">71</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SANGAMO THERAPEUTICS, INC.</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(in thousands)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:61.450%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.700%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating Activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMy0xLTEtMS0w_811df12f-cee1-4726-ba1f-de2f202862b0">95,419</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMy0zLTEtMS0w_986005e6-077d-4965-bd60-5eef0f90b6ed">68,889</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMy01LTEtMS0w_74a9231b-4d47-4d9d-a519-f92ad21da9b3">54,568</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNS0xLTEtMS0w_8bb52861-5c8e-417b-b93e-16ed927dffde">3,930</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNS0zLTEtMS0w_531592d4-0ecb-4356-b6d6-21bcd1b64b28">2,359</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNS01LTEtMS0w_4ddd897e-dbfd-4e05-9d75-8513a9ffb977">1,498</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of discount on marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNi0xLTEtMS0w_8fdff2b5-54ba-4512-bdf9-98711025a9f7">4,708</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNi0zLTEtMS0w_019651cb-7c88-4bfc-a738-2bc23780e01e">5,829</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNi01LTEtMS0w_1035ac04-f722-4c18-9aa3-0f6218c6862d">673</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization and other changes in right-of-use assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="sgmo:AmortizationAndOtherChangesInRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNy0xLTEtMS0xMTM4NA_60d29ed3-b2a5-4225-acad-0c50b25bd3c7">5,677</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gain on free shares</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" name="sgmo:GainOnFreeShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNy0xLTEtMS0xMjE1_7775bff5-b171-4d5d-b6b0-8de376845de6">488</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="sgmo:GainOnFreeShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNy0zLTEtMS0xMjE1_14333ac9-5ceb-4c72-90eb-bad596e7154c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="sgmo:GainOnFreeShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNy01LTEtMS0xMjE1_36c337cc-9686-456f-8a99-f2c761cb8e03">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss on disposal of property and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfOC0xLTEtMS0w_a3254e38-3121-4848-b52a-df58b2ec5abe">68</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfOC0zLTEtMS0w_214df1f8-834c-4a0f-885c-89fad0e053bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfOC01LTEtMS0w_82a13681-a394-4c1c-94df-805b02ad3b62">12</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfOS0xLTEtMS0w_dba63f68-49da-4c02-947f-905c666ffdb9">19,330</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfOS0zLTEtMS0w_2dae782e-d611-4a5e-8be0-39e59e022da2">14,677</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfOS01LTEtMS0w_d1854149-d59b-4ed7-95b7-80405731afb8">9,089</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss on lease termination</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:GainLossOnTerminationOfLease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTItMS0xLTEtMTIxOA_6d0304d4-956e-484c-b500-2ac33b74c35a">218</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnTerminationOfLease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTItMy0xLTEtMTIxOA_eea52941-d39a-4a19-aa81-0a2f7e9788ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnTerminationOfLease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTItNS0xLTEtMTIxOA_01905524-07cf-4b43-9006-5534e099163c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Build-to-suit leases</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" name="sgmo:BuildToSuitLeases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTEtMy0xLTEtMA_8a9addbf-9400-44d8-ae66-22a0fc268880">966</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" name="sgmo:BuildToSuitLeases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTEtNS0xLTEtMA_c2936154-517f-4e98-87fa-7de4b588d0c2">80</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTMtMS0xLTEtMA_96b644c5-4e3f-4491-82a9-552495e5c5f6">307</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTMtMy0xLTEtMA_4efe77ae-962a-4017-9d49-5da59dd0efc2">135</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTMtNS0xLTEtMA_f3e38e0d-59a1-4442-9441-283c31fa1286">16</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTQtMS0xLTEtMA_8c28564a-9a13-4075-9e8b-8c67a64355e5">32,236</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTQtMy0xLTEtMA_b9f3417a-b834-4333-b1fb-61fd1df9f376">1,330</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTQtNS0xLTEtMA_746e77d5-2548-4d17-bab5-6e49e453d746">1,629</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTUtMS0xLTEtMA_d805e982-ec8e-47e7-8999-81962f703839">6,660</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTUtMy0xLTEtMA_ecea793f-5dbc-449b-9e0d-f2d5edf65863">2,828</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTUtNS0xLTEtMA_f486eb07-2105-4d69-bf92-0763a8e58018">669</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable and accrued liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTYtMS0xLTEtMA_68d22552-4728-4e87-9752-c0e622cdc60d">4,192</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTYtMy0xLTEtMA_b949da49-cd5a-46a4-8945-185175dda685">6,372</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTYtNS0xLTEtMA_483232fa-dd3d-434c-ad00-305dc9fa2dc1">3,219</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued compensation and employee benefits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTctMS0xLTEtMA_72aa5d0e-65d5-4231-83cb-01e1c95ccb84">4,129</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTctMy0xLTEtMA_81312912-bdf2-493a-98b5-7a9a79892cb5">2,604</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTctNS0xLTEtMA_ba52d5c7-2f66-4a03-81e1-a0e9567bb8d0">2,594</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenues</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTgtMS0xLTEtMA_9efc20f1-ffb8-4181-8669-7435752a4337">35,693</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTgtMy0xLTEtMA_6982c226-9266-4520-9d65-d59ecb3a2037">99,364</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTgtNS0xLTEtMA_474aa066-784d-4db1-9f02-e3ed50b19fe6">48,984</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term portion of lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="sgmo:IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjItMS0xLTEtMTIyNA_8caaace3-e37a-4573-b336-9890a4bee232">1,800</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other non-current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTktMS0xLTEtMA_cbf3ec48-f156-4c6e-bedd-fd6ca96707ba">3,749</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTktMy0xLTEtMA_20ec9adf-94ab-4743-8a8e-a3efed2c4634">1,963</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTktNS0xLTEtMA_fd5ff72c-cd77-4a1d-9267-0ac0e2b87734">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash (used in) provided by operating activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjAtMS0xLTEtMA_48b44caa-7c09-49d0-8ebc-81f5a1abf003">144,402</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjAtMy0xLTEtMA_12535e62-191e-48c2-83e7-2110ddd5a7da">36,550</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjAtNS0xLTEtMA_6c71fd15-e6a3-4665-b9c9-113ca8817f33">11,179</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investing Activities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquisition, net of cash acquired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjItMS0xLTEtMA_dd7d5e38-f4bb-4757-aa66-617fcb6f39c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjItMy0xLTEtMA_ebb6301b-334a-48a4-8e0c-61dd9b00161a">75,647</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjItNS0xLTEtMA_6c7cbe8e-463d-44f3-a5e3-cfa1faf09285">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjMtMS0xLTEtMA_ddfcdd08-1e36-41aa-8309-d116703930fd">443,711</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjMtMy0xLTEtMA_3534f578-c5b5-4da2-b078-72569b627c84">451,239</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjMtNS0xLTEtMA_f38df938-5bda-4640-ad48-e3e3827c2fb4">252,328</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Maturities of marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjQtMS0xLTEtMA_854f0fb7-3523-4b37-aa2b-659beac050fe">404,847</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjQtMy0xLTEtMA_87dbfa37-49ca-402f-989b-8be0cd047319">391,845</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjQtNS0xLTEtMA_811272d3-4ce1-402b-a7c6-f1d9423f723c">178,675</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of property and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjUtMS0xLTEtMA_6a2102ac-c321-49c8-beaa-02ad5e301f64">20,675</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjUtMy0xLTEtMA_2af3f2e8-0b25-4147-8c8c-cc9009553dcd">43,065</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjUtNS0xLTEtMA_4d37ba41-e9c1-4a78-b57e-6780ba51bd70">3,751</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchase of additional Sangamo France shares</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzAtMS0xLTEtMTIyNw_88845d3a-1a03-40a1-a2c6-21a1d09df916">262</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzAtMy0xLTEtMTIyNw_19821904-8640-4f58-b33e-44269fa97de1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzAtNS0xLTEtMTIyNw_99b29f18-ac06-4824-8c5a-2ffcd1caf1b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in investing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjYtMS0xLTEtMA_de484838-c3c8-45ce-b476-02c19cb1dd18">59,801</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjYtMy0xLTEtMA_d668c579-668e-43da-ae73-32e060bc2b85">178,106</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjYtNS0xLTEtMA_a4137d5f-d735-43cb-ac5c-b821af94cfe8">77,404</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financing Activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from public offering of common stock, net of issuance costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:NetProceedsFromIssuancePublicOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjgtMS0xLTEtMA_6fade93b-a52e-43fb-99d8-eb3e2d78f2b2">136,308</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:NetProceedsFromIssuancePublicOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjgtMy0xLTEtMA_be57582a-5e10-421b-8863-8ccb62481ecf">215,758</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:NetProceedsFromIssuancePublicOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjgtNS0xLTEtMA_f29dd3db-6b6f-4937-b9ef-00c5b6bad797">81,573</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Taxes paid related to net share settlement of equity awards</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjktMS0xLTEtMA_45bee5fd-e350-4c30-b4a4-213ba77e9df6">422</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjktMy0xLTEtMA_694f813c-2a37-4526-afd4-7a4cadd2380e">254</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjktNS0xLTEtMA_6bd95da9-533a-43eb-af6f-b1eef0aed9ab">654</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzktMS0xLTEtMTEzNzQ_7bd766bd-0d58-42aa-bf7c-37a6c9400da8">2,044</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzktMy0xLTEtMTEzNzc_bd56bd08-a548-4beb-9ffc-75c8afce504a">1,484</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzktNS0xLTEtMTEzODA_dad51edb-3fe9-4f42-a76d-0eb31b66fa98">818</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from exercise of stock options and restricted stock units</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzAtMS0xLTEtMA_003ba7d4-b8c8-44db-9d55-b66413299227">4,099</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzAtMy0xLTEtMA_d92e6e34-e977-41c3-8df1-bf7b321d2d21">14,721</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzAtNS0xLTEtMA_a75afde5-c19f-4279-89de-73106fe4049a">15,753</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by financing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzEtMS0xLTEtMA_0020d590-daee-4231-9233-47db39b16633">142,029</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzEtMy0xLTEtMA_b85d1139-63c7-43c9-9896-1c2cf138ef66">231,709</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzEtNS0xLTEtMA_dd5ba316-8c70-4f9e-8c51-1434c3e9a139">97,490</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effects of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzItMS0xLTEtMA_1842073b-5474-4c04-a7ac-e334715ab6f8">184</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzItMy0xLTEtMA_216790a1-c210-4c25-abf8-b2a149e79b06">439</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzItNS0xLTEtMA_48debb3d-af14-4b80-83da-1e9d26dc89d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net (decrease) increase in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzMtMS0xLTEtMA_69665da1-27e8-4509-b9b7-e5862890f683">61,990</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzMtMy0xLTEtMA_5c69a110-19f8-42d3-bd8d-899e47c8c864">90,592</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzMtNS0xLTEtMA_890a6a3f-9c69-46a0-97b4-8fe2a837ffbe">31,265</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents, and restricted cash, beginning of period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzQtMS0xLTEtMA_a44e144a-3f52-4e66-9bac-835067d3e75c">143,918</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb7e952fbd38434585f995fe73c66a44_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzQtMy0xLTEtMA_08611366-a95c-4bec-9c3a-c44811c7d65e">53,326</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie9057cb83ba040218834cc92910f7361_I20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzQtNS0xLTEtMA_107b779c-e5d6-48e8-a4d8-be1279f68d95">22,061</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents, and restricted cash, end of period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzUtMS0xLTEtMA_604d4fae-493f-41d4-b31a-dd639dc0dc1b">81,928</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzUtMy0xLTEtMA_5119056c-b1d7-4d4b-868a-1fff07c93160">143,918</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb7e952fbd38434585f995fe73c66a44_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzUtNS0xLTEtMA_fb18fbc4-4b5b-45f7-b074-51250e068e49">53,326</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Supplemental disclosure of non-cash investing activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-controlling interest for acquisition</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="sgmo:NoncashOrPartNoncashNonControllingInterestAcquisition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNDctMS0xLTEtMTE2NDc_39d5b103-e71a-4907-9521-28c63f7abbf6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:NoncashOrPartNoncashNonControllingInterestAcquisition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNDctMy0xLTEtMTE2NTk_e2bd67ba-6957-44d8-805d-caf3b480faac">1,313</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="sgmo:NoncashOrPartNoncashNonControllingInterestAcquisition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNDctNS0xLTEtMTE2Njc_fa5795cd-8cd5-4e08-aeb5-1bb2f53a4a50">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment included in unpaid liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:3pt double #000;padding-left:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:3pt double #000;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id41b3e1cb35b4ad89ad6d22858d66005_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNDgtMS0xLTEtMTE2NDk_12e45b29-4401-4ea1-bbcc-2edae4dfd345">2,114</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:3pt double #000;padding-left:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:3pt double #000;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfc6db4e7428415f9b757be31f7ba5f9_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNDgtMy0xLTEtMTE2NjE_ef5c8094-bf42-467f-b780-e98999d6aca2">4,953</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:3pt double #000;padding-left:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:3pt double #000;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i551b7506aa0a43339495e3e41d87f7ab_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNDgtNS0xLTEtMTE2Njc_691be13b-ce03-4ae4-96eb-0ed4ed10d4c8">1,214</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Build-to-suit leases included in build-to-suit liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:3pt double #000;padding-left:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:3pt double #000;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59d1ac11e5d43868c898a5a5456c02a_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNDktMS0xLTEtMTE2NTU_966be2b8-806b-4bd0-9f17-97bde81b2ae1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:3pt double #000;padding-left:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:3pt double #000;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i49968469b9074ef393d1c026828923c4_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNDktMy0xLTEtMTE2NjM_29d82a11-089d-4221-a796-e4c0214c84ea">2,950</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:3pt double #000;padding-left:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:3pt double #000;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i00b9b5a15df54eed86abd682441fe4d1_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNDktNS0xLTEtMTE2Njc_3388ddbc-94a5-4212-b0ca-1151a521fd96">20,793</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-use assets obtained in exchange for lease obligations</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNTAtMS0xLTEtMTE2NTc_0b9296dc-7812-4663-a99e-9c2156673a06">31,291</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNTAtMy0xLTEtMTE2NjU_b6c58bca-1ee9-4029-801b-eaef3f72ccca">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNTAtNS0xLTEtMTE2Njc_24760538-eb9b-4b7e-8caa-77690a06a98f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8.4pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See accompanying Notes to Consolidated Financial Statements</span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_88"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">72</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SANGAMO THERAPEUTICS, INC.</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_91"></div><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfMjgzOTg_80451064-f17c-4b4f-a733-8aeda73c5483" continuedAt="ie44a903fc46a4803b4dda7560d3548e5" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 1 &#8211; ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Business Overview</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sangamo Therapeutics, Inc. (&#8220;Sangamo&#8221; or &#8220;the Company&#8221;) was incorporated in the State of Delaware in June 1995 and changed its name from Sangamo Biosciences, Inc. in January 2017. Sangamo is a clinical-stage biotechnology company focused on translating ground-breaking science into genomic medicines with the potential to transform patients&#8217; lives using our platform technologies in gene therapy, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ex vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene-edited cell therapy, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> genome editing and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> genome regulation. </span></div><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfMjgzOTM_f432e0c8-a930-4900-b20f-643c6cbfd8a8" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying Consolidated Financial Statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;U.S.&#160;GAAP&#8221;) and include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Consolidated Financial Statements. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net loss attributable to &#8194;non-controlling interests on our Consolidated Statements of Operations equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties.</span></div></ix:nonNumeric><div style="padding-left:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Going Concern</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sangamo is currently working on a number of long-term development projects that will involve experimental technology. The projects may require several years and substantial expenditures to complete and ultimately may be unsuccessful. The Company plans to finance operations with available cash resources, collaborations and strategic partnerships funds, research grants and from the issuance of equity or debt securities. Sangamo believes that its available cash, cash equivalents and investments as of December&#160;31, 2019, and expected revenues from collaborations, strategic partnerships and research grants, will be adequate to fund its operations at least through the next 12&#160;months from the date the financial statements are issued. Sangamo will require substantial additional financial resources to complete the development and commercialization of its products including ZFP therapeutic products. Additional capital may not be available on terms acceptable to the Company, or at all. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, the Company&#8217;s business and ability to develop its technology and therapeutic products would be harmed. Furthermore, any sales of additional equity securities may result in dilution to the Company&#8217;s stockholders, and any debt financing may include covenants that restrict the Company&#8217;s business.</span></div><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfNzY5NjU4MTQ4NTk4OA_035b3e5a-c337-4e08-8f06-98fddce39636" escape="true"><div style="padding-left:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Reclassifications</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain prior period amounts in the accompanying Consolidated Financial Statements have been reclassified to conform to the current period presentation.</span></div></ix:nonNumeric><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Summary of Significant Accounting Policies</span></div><div style="padding-left:18pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfODI0NjMzNzQwODU3MA_ab6a5604-dc6c-4bb6-adbc-daa94c7b78f9" continuedAt="i7f3f41287b074604ac328cbbfb97bbf2" escape="true">Use of Estimates</ix:nonNumeric></span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i7f3f41287b074604ac328cbbfb97bbf2">The preparation of the accompanying Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities, including from acquisitions, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. In March 2019, the Company recorded an adjustment to revenue related to a change in estimate in connection with the hemophilia A collaboration agreement with Pfizer Inc. (&#8220;Pfizer&#8221;). This adjustment was a direct result of the decision to increase the project scope during the first quarter of 2019 and the corresponding costs, both of which resulted in a decrease in the measure of proportional performance. In December 2019, the Company updated its estimated project cost and related revenues upon the transfer of the investigational new drug (&#8220;IND&#8221;) for Pfizer SB-525. This adjustment directly resulted in a decrease in project scope during the fourth quarter of 2019 and a decrease in the corresponding costs, which resulted in an increase in the measure of proportional performance.</ix:continuation> These adjustments increased revenue by $<ix:nonFraction unitRef="usd" contextRef="i45cd48c8f1eb454abb081e66040be393_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfODc5NjA5MzE5OTM3NQ_262f942f-4a0c-42db-aa9f-0cc8526e6713">5.7</ix:nonFraction>&#160;million, decreased net loss by $<ix:nonFraction unitRef="usd" contextRef="i45cd48c8f1eb454abb081e66040be393_D20190101-20191231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfODc5NjA5MzE5OTM4MQ_9e47b02f-3845-4510-b73f-1056f875555d">5.7</ix:nonFraction>&#160;million and decreased the Company&#8217;s basic net loss per share by $<ix:nonFraction unitRef="usdPerShare" contextRef="i45cd48c8f1eb454abb081e66040be393_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfODc5NjA5MzE5OTM4OA_51eb7fa0-dc31-4b78-b5d8-884e11836545">0.05</ix:nonFraction> for the year ended December&#160;31, 2019.</span></div></ix:nonNumeric><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">73</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><ix:continuation id="ie44a903fc46a4803b4dda7560d3548e5" continuedAt="i2521dc90b8c44d78a5aebef5c25a40ff"><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfODI0NjMzNzQwODU3MQ_b6d0adfe-e1cc-4e1c-949b-e23cc3c51a98" continuedAt="i4dbb652f4b2c4756988995b90afae5be" escape="true"><div style="text-indent:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Effective January&#160;1, 2018, the Company adopted the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from Contracts with Customers</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASC Topic 606&#8221;) using the modified retrospective method, resulting in a change to its accounting policy for revenue recognition. ASC Topic 606 establishes a unified model to determine how revenue is recognized.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s contract revenues are derived from collaboration agreements and research activity grants and licensing. Research and licensing agreements typically include upfront signing or license fees, cost reimbursements, research services, minimum sublicense fees, milestone payments and royalties on future licensee&#8217;s product sales. The Company has both fixed and variable consideration. Non-refundable upfront fees and funding of research and development activities are considered fixed, while milestone payments are generally identified as variable consideration. Sangamo&#8217;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenues under research grant agreements are generally recognized when the related qualified research expenses are incurred. Deferred revenue represents the portion of research or license payments received but not earned.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic 606. The Company&#8217;s performance obligations include license rights, development services and services associated with regulatory submission and approval processes. Revenues from research services earned under collaboration agreements are generally recognized as revenue as the related services are provided. Revenues from non-refundable upfront fees are recognized over time either by measuring progress towards satisfaction of the relevant performance obligation, using the input method (i.e. cumulative actual costs incurred relative to total estimated costs) or on a straight-line basis when a performance obligation is expected to be satisfied evenly over a period of time (or when the entity has a stand-ready obligation). Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement which may include total internal personnel costs and external costs to be incurred as well as, in certain cases, the estimated stand-ready obligation period. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. The estimated period of performance and project costs, such as personnel and manufacturing cost, are reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Related costs and expenses under these arrangements have historically approximated the revenues recognized.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfODI0NjMzNzQwODU4MQ_dc7f700d-296e-4613-baaa-9e887ae6e69f" escape="true"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues from collaboration agreements and research activity grants as a percentage of total revenues were as follows:</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:58.322%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.740%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pfizer Inc.</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="if75e5c9704ce446986262d7c7d8c3fab_D20190101-20191231" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjI3MTVhOTFiZTY2YTQxNWE4OTQ4N2IwM2FkMDJkMjJjL3RhYmxlcmFuZ2U6MjcxNWE5MWJlNjZhNDE1YTg5NDg3YjAzYWQwMmQyMmNfMi0xLTEtMS0xMDc3Nw_a601b464-be77-407e-8add-b2a27dc707b9">40</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i0e56cd6c5fb74bd3a43294ab0e9b6330_D20180101-20181231" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjI3MTVhOTFiZTY2YTQxNWE4OTQ4N2IwM2FkMDJkMjJjL3RhYmxlcmFuZ2U6MjcxNWE5MWJlNjZhNDE1YTg5NDg3YjAzYWQwMmQyMmNfMi0zLTEtMS0xMDc3Nw_b132aabf-d1ab-4233-b384-9b9b9f6c2dcb">47</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="id1d7fbe1eb014de78444bda067a30d18_D20170101-20171231" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjI3MTVhOTFiZTY2YTQxNWE4OTQ4N2IwM2FkMDJkMjJjL3RhYmxlcmFuZ2U6MjcxNWE5MWJlNjZhNDE1YTg5NDg3YjAzYWQwMmQyMmNfMi01LTEtMS0xMDc3Nw_8eb10019-3843-4ce0-80ae-856c9347956b">47</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Kite Pharma, Inc.</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ifeac1a9c1b7f4146b761b39496879f94_D20190101-20191231" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjI3MTVhOTFiZTY2YTQxNWE4OTQ4N2IwM2FkMDJkMjJjL3RhYmxlcmFuZ2U6MjcxNWE5MWJlNjZhNDE1YTg5NDg3YjAzYWQwMmQyMmNfMy0xLTEtMS0xMDc3Nw_b126cc00-69df-4900-a365-6e6777e302cb">34</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="icf0e324d5bd3407ea444f76424db9da6_D20180101-20181231" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjI3MTVhOTFiZTY2YTQxNWE4OTQ4N2IwM2FkMDJkMjJjL3RhYmxlcmFuZ2U6MjcxNWE5MWJlNjZhNDE1YTg5NDg3YjAzYWQwMmQyMmNfMy0zLTEtMS0xMDc3Nw_e4637922-a3ee-46b5-a514-d73959a7b668">30</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sanofi Genzyme</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i0028bf4ff4f2447683894820f58ee41f_D20190101-20191231" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjI3MTVhOTFiZTY2YTQxNWE4OTQ4N2IwM2FkMDJkMjJjL3RhYmxlcmFuZ2U6MjcxNWE5MWJlNjZhNDE1YTg5NDg3YjAzYWQwMmQyMmNfNC0xLTEtMS0xMDc3Nw_4b5eb01e-32b2-4057-b704-7d3bfed3012c">22</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i09768b80227d4cb4a5a55bae2bc04a19_D20180101-20181231" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjI3MTVhOTFiZTY2YTQxNWE4OTQ4N2IwM2FkMDJkMjJjL3RhYmxlcmFuZ2U6MjcxNWE5MWJlNjZhNDE1YTg5NDg3YjAzYWQwMmQyMmNfNC0zLTEtMS0xMDc3Nw_1f3f71fb-9af8-4842-9a8e-75aec63392eb">16</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ia9d921a5d8f94da6821ac519170255b3_D20170101-20171231" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjI3MTVhOTFiZTY2YTQxNWE4OTQ4N2IwM2FkMDJkMjJjL3RhYmxlcmFuZ2U6MjcxNWE5MWJlNjZhNDE1YTg5NDg3YjAzYWQwMmQyMmNfNC01LTEtMS0xMDc3Nw_ceb2a797-bfb6-408f-a365-015b6e7c5e15">34</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-indent:36pt;margin-top:6pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">74</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><ix:continuation id="i2521dc90b8c44d78a5aebef5c25a40ff" continuedAt="i0ca0ec0e9c0f46bcbef45f6624177df1"><ix:continuation id="i4dbb652f4b2c4756988995b90afae5be"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Receivables from collaborations are typically unsecured and are concentrated in the biopharmaceutical industry. Accordingly, the Company may be exposed to credit risk generally associated with biopharmaceutical companies or specific to its collaboration agreements. To date, the Company has not experienced any losses related to these receivables.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Funds received from third parties under contract or funds received from grant arrangements are generally recorded as revenue if the Company is deemed to be the principal participant in the arrangements because the activities under the contracts or grants are part of the Company&#8217;s development programs. Contract funds received are not refundable and are recognized when the related qualified research and development costs are incurred and there is reasonable assurance that the funds will be received. Funds received in advance are recorded as deferred revenue.</span></div></ix:continuation><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfMjgzOTQ_fc9c7ea5-ca07-4674-b41c-2d1b55a13d63" escape="true"><div style="padding-left:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Business Combinations</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for acquisitions using the acquisition method of accounting, which requires that assets acquired, including in-process research and development (&#8220;IPR&amp;D&#8221;) projects, liabilities assumed and any non-controlling interests in the acquired target in an acquisition be recorded at their fair values as of the acquisition date on the Company&#8217;s Consolidated Balance Sheets. Any excess of purchase price over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires the Company to make significant estimates and assumptions. As a result, the Company may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfODI0NjMzNzQwODU3Mw_bed72a73-3b5a-42e4-a5f8-216a3808ff9a" escape="true"><div style="padding-left:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Goodwill and Intangible Assets</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Goodwill represents the excess of the consideration transferred over the estimated fair values of assets acquired and liabilities assumed in a business combination. Intangible assets with indefinite useful lives are related to purchased IPR&amp;D projects and are measured at their respective fair values as of the acquisition date. Goodwill and intangible assets with indefinite useful lives are not amortized. Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed&#160;finite-lived&#160;and would then be amortized based on their respective estimated useful lives at that point in time. The Company tests goodwill and indefinite-lived intangible assets for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate the fair values of the assets are below their respective carrying amounts. As of December 31, 2019, no impairment of goodwill or indefinite-lived intangible assets has been identified.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfODI0NjMzNzQwODU3NA_88e7d175-2e7f-4ec5-a744-6e2b39a1a0fb" escape="true"><div style="padding-left:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Valuation of Long-Lived Assets</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Long-lived assets, including property and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may suggest that the carrying value of an asset may not be recoverable. Recoverability of these assets is measured by comparison of the carrying amount of each asset to the future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. As of December 31, 2019, no impairment of any long-lived assets has been identified.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfODI0NjMzNzQwODU3NQ_bb8a1a5d-446d-49bc-a999-d807b63e7b86" escape="true"><div style="text-indent:22.5pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Fair Value Measurements</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short maturities. Marketable securities are stated at their estimated fair values. The free share asset/liability is measured using a binomial-lattice pricing model and is reviewed each reporting period and adjusted, as needed, and is expected to approximate fair value.</span></div></ix:nonNumeric><div style="padding-left:18pt;margin-top:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfODI0NjMzNzQwODU3Ng_55ce7654-c834-40ce-bd0c-8a2c4a6a83a6" continuedAt="i5af9e430fa2d4194b5975c18fd82a5c8" escape="true">Cash, Cash Equivalents and Restricted Cash</ix:nonNumeric></span></div><div style="text-indent:36pt;margin-top:6pt;"><ix:continuation id="i5af9e430fa2d4194b5975c18fd82a5c8"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sangamo considers all highly-liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> cash, deposits in demand money market accounts, and commercial paper.</span></ix:continuation><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Restricted cash consists of a letter of credit for $<ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfMTA0NDUzNjA2MjExODU_16b018e8-6cac-44d5-a0b0-62edac88b19b">1.5</ix:nonFraction>&#160;million as a deposit for the Brisbane lease.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">75</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><ix:continuation id="i0ca0ec0e9c0f46bcbef45f6624177df1" continuedAt="idb17243d0702407c981a1aa53c8f72a6"><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfODI0NjMzNzQwODU4Mg_95aab638-e17b-464f-ba81-4e2566cfe61e" escape="true"><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfODI0NjMzNzQwODU4Mw_5fef88be-4f1c-4b54-9838-95c81710747b" escape="true"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A reconciliation of cash, cash equivalents and restricted cash reported within the Consolidated Balance Sheets to the amounts reported within the accompanying Consolidated Statements of Cash Flows is as follows (in thousands):</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:61.450%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.700%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjc2ODk3Nzg3ZjE4YjRjYTBiYmY4MTVlODYyZGQ2ZjQ4L3RhYmxlcmFuZ2U6NzY4OTc3ODdmMThiNGNhMGJiZjgxNWU4NjJkZDZmNDhfMi0xLTEtMS0xMTI3OQ_3bcaa95b-2ae1-457b-b73b-d429fc896589">80,428</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjc2ODk3Nzg3ZjE4YjRjYTBiYmY4MTVlODYyZGQ2ZjQ4L3RhYmxlcmFuZ2U6NzY4OTc3ODdmMThiNGNhMGJiZjgxNWU4NjJkZDZmNDhfMi0zLTEtMS0xMTI3OQ_1f2f052e-66fb-4915-9fd3-03c9f056a997">140,418</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb7e952fbd38434585f995fe73c66a44_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjc2ODk3Nzg3ZjE4YjRjYTBiYmY4MTVlODYyZGQ2ZjQ4L3RhYmxlcmFuZ2U6NzY4OTc3ODdmMThiNGNhMGJiZjgxNWU4NjJkZDZmNDhfMi01LTEtMS0xMTI3OQ_db234c3a-da5c-4a27-b477-33c8dc35bafb">49,826</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjc2ODk3Nzg3ZjE4YjRjYTBiYmY4MTVlODYyZGQ2ZjQ4L3RhYmxlcmFuZ2U6NzY4OTc3ODdmMThiNGNhMGJiZjgxNWU4NjJkZDZmNDhfNC0xLTEtMS0xMTI3OQ_6f3b5fb6-51fa-47aa-b9cf-c943a34a5dc8">1,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjc2ODk3Nzg3ZjE4YjRjYTBiYmY4MTVlODYyZGQ2ZjQ4L3RhYmxlcmFuZ2U6NzY4OTc3ODdmMThiNGNhMGJiZjgxNWU4NjJkZDZmNDhfNC0zLTEtMS0xMTI3OQ_55dfa4d9-35b9-4520-a0b4-7cae2e8f81c5">3,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb7e952fbd38434585f995fe73c66a44_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjc2ODk3Nzg3ZjE4YjRjYTBiYmY4MTVlODYyZGQ2ZjQ4L3RhYmxlcmFuZ2U6NzY4OTc3ODdmMThiNGNhMGJiZjgxNWU4NjJkZDZmNDhfNC01LTEtMS0xMTI3OQ_c45df9c2-722d-4400-8a2d-1ac0858a6244">3,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents and restricted cash as reported within the Consolidated Statements of Cash Flows</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjc2ODk3Nzg3ZjE4YjRjYTBiYmY4MTVlODYyZGQ2ZjQ4L3RhYmxlcmFuZ2U6NzY4OTc3ODdmMThiNGNhMGJiZjgxNWU4NjJkZDZmNDhfNS0xLTEtMS0xMTI3OQ_7d5306f7-15b2-4d10-ac1c-ada6715b6f64">81,928</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjc2ODk3Nzg3ZjE4YjRjYTBiYmY4MTVlODYyZGQ2ZjQ4L3RhYmxlcmFuZ2U6NzY4OTc3ODdmMThiNGNhMGJiZjgxNWU4NjJkZDZmNDhfNS0zLTEtMS0xMTI3OQ_9e003e3c-3957-4d43-8172-a179a7facb9d">143,918</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb7e952fbd38434585f995fe73c66a44_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjc2ODk3Nzg3ZjE4YjRjYTBiYmY4MTVlODYyZGQ2ZjQ4L3RhYmxlcmFuZ2U6NzY4OTc3ODdmMThiNGNhMGJiZjgxNWU4NjJkZDZmNDhfNS01LTEtMS0xMTI3OQ_a8d2686e-e3ae-4ad5-884b-7b0fccc462ea">53,326</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfMjgzOTk_512dc31d-655b-4f4f-9dba-1de3ae9deed2" escape="true"><div style="text-indent:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%;">Marketable Securities</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sangamo classifies its marketable securities as available-for-sale and records its investments at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in accumulated other comprehensive loss (&#8220;AOCI&#8221;). The Company classifies those investments that are not required for use in current operations and that mature in more than 12 months as non-current marketable securities in the accompanying Consolidated Balance Sheets.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s investments are subject to a periodic impairment review. The Company recognizes an impairment charge, if material, when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the fair value has been less than the Company&#8217;s cost basis, the financial condition and near-term prospects of the investee and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. Realized gains and losses on available-for-sale securities are included in other income, net, which are determined using the specific identification method.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfMjgzODE_ac3caacc-fa0d-481a-8abe-8b6303df1800" escape="true"><div style="padding-left:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Property and Equipment</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method based on the estimated useful lives of the related assets which is generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfNTczOA_d3889db1-4c3b-4768-aeb6-f18ca1502096">three</span> to <ix:nonNumeric contextRef="i213fcfde123a4b9abd25cc2767af7914_D20190101-20191231" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfNTc0NA_7a076fad-ab1f-46bf-862a-74b9fa52bc21">five years</ix:nonNumeric>. For leasehold improvements, amortization is calculated using the straight-line method based on the shorter of the useful life or the lease term. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfMjgzODI_e02f7fb5-15ad-4edb-9786-8a431a73e274" escape="true"><div style="padding-left:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development Expenses</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development expenses consist primarily of personnel costs, including salaries, benefits and stock-based compensation, clinical studies performed by contract research organizations ("CROs"), materials and supplies and overhead allocations consisting of various support and facility-related costs.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development costs are expensed as incurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfODI0NjMzNzQwODU3Nw_f66b35f0-51c7-40d0-81cc-a264f6c28767" escape="true"><div style="padding-left:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">General and Administrative Expenses</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">General and administrative expenses consist of finance, human resources, legal and other administrative activities. These expenses consist primarily of personnel costs, including salaries, benefits and stock-based compensation, facilities and overhead costs, legal expenses, and other general and administrative costs.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfMjgzODc_b8ad13ed-8bfb-4016-adf5-17263304d178" escape="true"><div style="padding-left:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-based Compensation</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company measures and recognizes compensation expense for all stock-based payment awards made to Sangamo employees and directors, including employee share options, restricted stock units (&#8220;RSUs&#8221;) and employee stock purchases related to the 2010 Employee Stock Purchase Plan (&#8220;ESPP&#8221;), as amended, based on estimated fair values at the award grant date. The fair value of stock-based awards is amortized over the vesting period of the award using a straight-line method.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To estimate the fair value of an award, the Company uses the Black-Scholes option pricing model. This model requires inputs such as expected life, expected volatility and risk-free interest rate. These inputs are subjective and generally require significant analysis and judgment to develop. While estimates of expected life and volatility are derived primarily from the Company&#8217;s historical data, the risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected life assumption. The Company accounts for forfeitures in the period they occur.</span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">76</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><ix:continuation id="idb17243d0702407c981a1aa53c8f72a6" continuedAt="i078b073c5b594312a0f58c758e7dd0c4"><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfODI0NjMzNzQwODU3OA_fdf581e3-06d3-47dd-a6c4-77616a9f47c2" escape="true"><div style="padding-left:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income Taxes</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Income tax expense has been provided using the liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities as measured by the enacted tax rates that will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets if, based upon the available evidence, it is not more likely than not that the deferred tax assets will be realized.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company recognizes a tax benefit from an&#160;uncertain&#160;tax&#160;position&#160;only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the Company&#8217;s consolidated financial statements from such positions are measured based on the largest benefit that has a greater than 50% likelihood of being realized. The Company recognizes interest and penalties associated with tax matters as part of the income tax provision and includes accrued interest and penalties with the related income tax liability within account payable and accrued liabilities on its Consolidated Balance Sheets.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfMjgzODg_06df22c8-05c2-49e9-89a7-1e9c726bf865" escape="true"><div style="padding-left:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%;">Foreign Currency Translation</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The functional currency of the Company&#8217;s foreign subsidiaries is primarily the Euro. Assets and liabilities denominated in foreign currencies are translated to U.S. dollars using the exchange rates at the balance sheet date. Foreign currency translation adjustments are recorded as a component of AOCI within stockholders&#8217; equity. Revenues and expenses from the Company&#8217;s foreign subsidiaries are translated using the monthly average exchange rates in effect during the period in which the transactions occur. Foreign currency transaction gains and losses are recorded in interest and other income, net, on the Company&#8217;s Consolidated Statements of Operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfODI0NjMzNzQwODU3OQ_a07d0ac6-86b6-47dc-9201-17fdfad38a15" continuedAt="i3aa85ca0f7e543eb83ca909d169219e1" escape="true"><div style="padding-left:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net Loss Per Share</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic net loss per share attributable to Sangamo Therapeutics, Inc. stockholders has been computed by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders is calculated by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock plus potential dilutive securities outstanding during the period.</span></div></ix:nonNumeric><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i3aa85ca0f7e543eb83ca909d169219e1">The total number of shares subject to stock options and RSUs outstanding and the ESPP shares reserved for issuance, which are all anti-dilutive, were excluded from consideration in the calculation of diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders.</ix:continuation> Stock options and RSUs outstanding and ESPP shares reserved for issuance as of December 31, 2019, 2018 and 2017 were <ix:nonFraction unitRef="shares" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="INF" format="ixt:numdotdecimal" name="sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfMjEyNTM_a561c564-4569-4731-b392-2827c61434e7">10,750,550</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="INF" format="ixt:numdotdecimal" name="sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfMjEyNTc_b73d24a7-4066-4c1e-925a-6f4a80a133eb">9,048,793</ix:nonFraction>, and <ix:nonFraction unitRef="shares" contextRef="ieb7e952fbd38434585f995fe73c66a44_I20171231" decimals="INF" format="ixt:numdotdecimal" name="sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfMjEyNjU_84dc8bf2-fcdc-4781-8f80-9f6c04c0bc50">8,367,628</ix:nonFraction>, respectively.</span></div><div style="padding-left:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfODI0NjMzNzQwODU4MA_8a7d002f-25b0-4e4e-aea3-afcc75168ab5" continuedAt="i8def21286fcb4fcead1583aba3adf0be" escape="true">Segments</ix:nonNumeric></span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i8def21286fcb4fcead1583aba3adf0be">The Company operates in <ix:nonFraction unitRef="segment" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfMjEzMTY_80bc33c5-630a-4039-a374-02aef45fedce">one</ix:nonFraction> segment. Management uses one measure of profitability and does not segregate its business for internal reporting.</ix:continuation> As of December&#160;31, 2019 and 2018, substantially all of the Company&#8217;s assets were maintained in the United States. For the years ended December&#160;31, 2019, 2018 and 2017, substantially all of the Company&#8217;s revenues and operating expenses were generated and incurred in the United States.</span></div><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfMjgzOTE_82940aea-96ff-4b0d-9e27-d030707b4984" continuedAt="ie9eb6f82b7344e15a812d59916663844" escape="true"><div style="text-indent:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Pronouncements</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Recently Adopted</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Simplified Disclosure</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the Securities and Exchange Commission ("SEC") adopted amendments to certain disclosure requirements in Securities Act Release No.&#160;33-10532, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Disclosure Update and Simplification</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, as updated. These amendments eliminate, modify, or integrate into other SEC requirements certain disclosure rules. Among the amendments is the requirement to present an analysis of changes in stockholders&#8217; equity in the interim financial statements included in quarterly reports on Form 10-Q. The analysis, which can be presented as a footnote or separate statement, is required for the current and comparative quarter and year-to-date interim periods. The amendments are effective for all filings made on or after November&#160;5, 2018. The Company&#8217;s adoption of these SEC amendments had no material effect on the Company&#8217;s reporting of financial position, results of operations, cash flows or stockholders&#8217; equity.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Accounting for Leases</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2016-2, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASC Topic 842&#8221;). ASC Topic 842 amends a number of aspects of lease accounting, including requiring lessees to recognize almost all leases with a term greater than one year as a right-of-use (&#8220;ROU&#8221;) asset and corresponding liability, measured at the present value of the lease payments. On January&#160;1, 2019, the Company adopted ASC Topic 842 using the modified retrospective </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">77</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><ix:continuation id="i078b073c5b594312a0f58c758e7dd0c4" continuedAt="if622491581f74527aa8f04356d28511b"><ix:continuation id="ie9eb6f82b7344e15a812d59916663844" continuedAt="i27b39c3ecf6f434cbcbfdabd8dcd9d06"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">approach with a cumulative-effect adjustment of $<ix:nonFraction unitRef="usd" contextRef="ie5649d96e1864877aaa84d3a06395606_I20190101" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfNzY5NjU4MTQ4NTk5Mw_b90c09f3-9a69-44d3-910f-0c9105b94fb4">0.9</ix:nonFraction> million reflected as a decrease to the opening balance of accumulated deficit as of the adoption date. Results for the year ended December&#160;31, 2019 are presented under ASC Topic 842. No prior period amounts were adjusted and continue to be reported in accordance with previous lease guidance, ASC Topic 840 &#8211; </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASC Topic 840&#8221;).</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ASC Topic 842 provides a number of optional practical expedients in transition. The Company elected the practical expedients to not reassess its prior conclusions about lease identification under the new standard, to not reassess lease classification, and to not reassess initial direct costs. The Company did not elect the practical expedient allowing the use-of-hindsight, which would require the Company to reassess the lease term of its leases based on all facts and circumstances through the effective date. The Company also did not elect the practical expedient pertaining to land easements, as this is not applicable to the current contract portfolio.</span></div><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfNzY5NjU4MTQ4NTk5MA_92b61914-9fbb-4a2d-a1d3-f39e5827e87e" escape="true"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The impact of the adoption of ASC Topic 842 on the accompanying Consolidated Balance Sheet as of January&#160;1, 2019 was as follows (in thousands):</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:60.352%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.617%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.794%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.682%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.620%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments Due to the Adoption of ASC Topic 842</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfMS0xLTEtMS00MDM1_752df9ec-8818-4034-ba25-65181c0ead27">78,723</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifb9ede9189214fb0ba40172a1dbc591a_I20190101" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfMS0zLTEtMS00MDMy_e61ae70a-e449-4e17-87e4-a364407140e8">62,500</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f20aa798c164804836d3c58f6e64322_I20190101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfMS01LTEtMS00MDI5_39a83626-d1f4-4b90-9fb5-9821d42b7ac2">16,223</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfMi0xLTEtMS00MDM1_01e432da-f057-4013-929f-26b180d4d3b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifb9ede9189214fb0ba40172a1dbc591a_I20190101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfMi0zLTEtMS00MDMy_89b19609-257c-494b-9798-fefc2a00730d">8,753</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f20aa798c164804836d3c58f6e64322_I20190101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfMi01LTEtMS00MDI5_96405b59-c499-4800-99a3-f7b91aa7b94d">8,753</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid rent</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:PrepaidRent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfMy0xLTEtMS00MDM1_78000533-41c7-47fe-a16f-f8834f9931d5"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:PrepaidRent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfMy0xLTEtMS00MDM1_de08b112-ac15-4176-86a5-8eac67b66ca4">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifb9ede9189214fb0ba40172a1dbc591a_I20190101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidRent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfMy0zLTEtMS00MDMy_7c4bc311-cf72-46c7-a0df-7717ac2315de">36,025</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f20aa798c164804836d3c58f6e64322_I20190101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidRent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfMy01LTEtMS00MDI5_b561a4e4-e984-4d01-87c5-6bcecd620491">36,025</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Operating lease liabilities - current</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfNi0xLTEtMS00MDM1_be005753-0703-4e5a-ab0d-9c584fb353dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icbd33d4a7d834496bd26b17d12cc0d71_I20190101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfNi0zLTEtMS00MDMy_f312d05e-1ee7-44e0-bec6-5c80a97b0d36">1,408</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f20aa798c164804836d3c58f6e64322_I20190101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfNi01LTEtMS00MDI5_480e5ad7-cf50-4f74-8cea-2e55f5cd0a12">1,408</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Deferred rent</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" name="sgmo:DeferredRentNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfNy0xLTEtMS00MDM1_0de402e2-87d4-4179-a639-1581a79c20b6">271</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifb9ede9189214fb0ba40172a1dbc591a_I20190101" decimals="-3" sign="-" name="sgmo:DeferredRentNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfNy0zLTEtMS00MDMy_42f34b06-87e1-497d-b360-1114ff39164c">271</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f20aa798c164804836d3c58f6e64322_I20190101" decimals="-3" format="ixt:zerodash" name="sgmo:DeferredRentNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfNy01LTEtMS00MDI5_fe79e6a6-78f1-431f-be40-fceac54dd07a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Build-to-suit lease obligation</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icbc9e04f074c44ffa8daa55bc133f128_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfOC0xLTEtMS00MDM1_05810877-0683-4aef-bc5e-85a1e14fca2f">27,689</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibf1327e2b600430586f7a8218d35f3f2_I20190101" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfOC0zLTEtMS00MDMy_4f20ac98-d973-473a-bd4d-e8ccd2bdf760">27,689</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id5dfe7b638ae41cda6e177ad875be7b5_I20190101" decimals="-3" format="ixt:zerodash" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfOC01LTEtMS00MDI5_69c2007e-d2e0-4228-b5ef-a71429f418d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Operating lease liabilities - long-term</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfOS0xLTEtMS00MDM1_fd790fa5-a1af-4f63-a288-e555880f201d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifb9ede9189214fb0ba40172a1dbc591a_I20190101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfOS0zLTEtMS00MDMy_d3088d9f-73b8-4aba-b475-9d27f0ec7241">7,933</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f20aa798c164804836d3c58f6e64322_I20190101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfOS01LTEtMS00MDI5_84dbc1d0-169b-44d0-bd47-8c04f1aa0fa8">7,933</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfMTEtMS0xLTEtNDAzNQ_a360f277-470f-4973-af5c-af32c4317e34">562,696</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifb9ede9189214fb0ba40172a1dbc591a_I20190101" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfMTEtMy0xLTEtNDAzMg_e962ac5a-42d9-4ad2-92a1-de9c20235d43">897</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3f20aa798c164804836d3c58f6e64322_I20190101" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfMTEtNS0xLTEtNDAyOQ_8377becb-f27e-4347-8070-6310457f12cb">561,799</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">___________________</span></div><div style="text-indent:-36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(1)&#160;Operating lease liabilities &#8211; current and deferred rent are included in accounts payable and accrued liabilities on the Consolidated Balance Sheets.</span></div><div style="text-indent:-36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(2)&#160;Build-to-suit lease obligation and operating lease liabilities &#8211; long-term are included in long-term portion of lease liabilities on the Consolidated Balance Sheets.</span></div></ix:nonNumeric><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The adjustments due to the adoption of ASC Topic 842 primarily related to the recognition of operating lease ROU assets and operating lease liabilities for the Company&#8217;s leases. In addition, the adoption of ASC Topic 842 resulted in a change in accounting of the build-to-suit component of two leases under ASC Topic 840 to operating leases under ASC Topic 842. As a result, the Company derecognized the estimated fair value of the building shells that were included in Property and equipment, net as of December&#160;31, 2018, as the Company had been deemed to own these buildings under ASC Topic 840. For a description of the leases, see &#8220;Note 7 &#8211; </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Commitments and Contingencies &#8211; Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; in these Consolidated Financial Statements.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Not Yet Adopted</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Collaborative Arrangements</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2018, the FASB issued ASU 2018-18, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative Arrangements (ASC Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASC Topic 808&#8221;), which clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC Topic 606 when the counterparty is a customer. In addition, ASC Topic 808 precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. This guidance will be effective for the Company beginning January&#160;1, 2020. The Company has determined the adoption of ASU 2018-18 will not have a material impact on its Consolidated Financial Statements.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Goodwill Impairment Testing</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2017, the FASB issued ASU No. 2017-4,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> Intangibles &#8211; Goodwill and Other (Topic 350): Simplifying the Test of Goodwill Impairment</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASU 2017-4&#8221;). The new guidance simplifies the subsequent measurement of goodwill by eliminating Step 2 from the goodwill impairment test. ASU 2017-4 requires goodwill impairment to be measured as the amount by which a reporting unit&#8217;s carrying amount exceeds its fair value, not to exceed the carrying amount of its goodwill. ASU </span></div></ix:continuation></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">78</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><ix:continuation id="if622491581f74527aa8f04356d28511b"><ix:continuation id="i27b39c3ecf6f434cbcbfdabd8dcd9d06"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2017-4 requires prospective application and is effective for annual periods beginning after December&#160;15, 2019. ASU 2017-4 will require the Company to amend its methodology for determining any goodwill impairment beginning in 2020. The Company does not expect the adoption of ASU 2017-4 to have a material impact on its Consolidated Financial Statements.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Credit Losses</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments &#8211; Credit Losses (Topic 326)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> ("ASU 2016-13"). ASU 2016-13 implements an impairment model, known as the current expected credit loss model that is based on expected losses rather than incurred losses. Under the new guidance, an entity will recognize as an allowance its estimate of expected credit losses. ASU 2016-13 is effective for all interim and annual reporting periods beginning after December 15, 2019 and must be adopted using a modified retrospective approach, with certain exceptions. Early adoption is permitted. The Company does not expect the adoption of ASU 2016-13 to have a material impact on its Consolidated Financial Statements.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Income Taxes</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income Taxes &#8211; Simplifying the Accounting for Income Taxes </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(&#8220;ASU 2019-12&#8221;). The guidance removes exceptions to the general principles in </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income Taxes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">(Topic 740)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> for allocating tax expense between financial statement components, accounting basis differences stemming from an ownership change in foreign investments and interim period income tax accounting for year-to-date losses that exceed projected losses. The guidance becomes effective for annual reporting periods beginning after December 15, 2020 and interim periods within those fiscal years with early adoption permitted. The Company plans to adopt ASU 2019-12 effective January 1, 2020 and does not expect this adoption to have a material impact on its Consolidated Financial Statements.</span></div></ix:continuation></ix:continuation><div id="i9a2bf9013aa44980b5a1f5846290b1a8_97"></div><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RleHRyZWdpb246MmM1Y2FkN2U3MWY3NDFkYWIyZmIzNzIzZTIxMTQ4MDlfNDQ4MQ_4d56d9f9-7d68-45a0-ac08-3b1fb671af6e" continuedAt="i9dd4fe3cb26d43fb9b934fd7980853a9" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 2 &#8211; FAIR VALUE MEASUREMENT</span></div><div style="text-indent:36pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company measures certain assets and liabilities at fair value on a recurring basis, including cash equivalents, available-for-sale securities and the free share asset/liability.&#160;The accounting guidance establishes a three-tier hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows:</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">i.e.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> supported by little or no market activity).</span></div><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RleHRyZWdpb246MmM1Y2FkN2U3MWY3NDFkYWIyZmIzNzIzZTIxMTQ4MDlfNDQ4Mg_a07d8065-6ef0-4ed9-9730-5e96cb87637f" continuedAt="ie26943bfb175481a970d50afa17c7053" escape="true"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value measurements of the Company&#8217;s cash equivalents, available-for-sale securities and the free share asset/liability are identified at the following levels within the fair value hierarchy (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:44.852%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.741%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurement</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i425b175434d04e418b20de221af1fd33_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfNC0xLTEtMS0w_5145ea1f-ead6-4058-a520-e4d1a5ba851c">30,496</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if327c6ba5afb4ee28f9cca2b391023fe_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfNC0zLTEtMS0w_9d655f44-a61d-4149-b136-133fe3a5a774">30,496</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i13e727b552f840888ab401cd0d611095_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfNC01LTEtMS0w_c7139feb-eeb2-46b1-9888-9ced1d10e5dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1916c386d59845db85c0f6b195b6c309_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfNC03LTEtMS0w_68a0565c-25a8-419b-ab91-84bae89e56f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6fedc4e1ca23438283a2d2c6f237fe8b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfNS0xLTEtMS05MTI3_f106016d-f8fc-4447-a6be-885bc4d80a11">2,999</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifedb75e8c33345abb30ce39ac8828048_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfNS0zLTEtMS05MTMw_399eb320-0690-4312-a35c-fea359a50400">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9a555374195740708b7b535422475c40_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfNS01LTEtMS05MTMz_5cbf6928-0c86-41b2-9588-8544245e1851">2,999</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9fe30ec7f787449981feb883fd8e7408_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfNS03LTEtMS05MTM2_dbc16da6-3ed5-47bb-a3f0-3d9cee40da74">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id6a8c12c301e487cab97f3ac6cb97945_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfNS0xLTEtMS0w_0e0149b9-2e63-4278-bfb3-4e7b6d758765">33,495</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d0f5ceb90cd496f91d1edf2102c57d2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfNS0zLTEtMS0w_fc8ea343-9618-45be-9dc7-bd8720c73887">30,496</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4dd1f80319a84afbb69e15090417a474_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfNS01LTEtMS0w_d40ea339-79a9-4910-8ebf-8048b9a7eb3e">2,999</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibe28cfabe6384c78b965211fe2b259d6_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfNS03LTEtMS0w_e38a7a01-4166-4875-8071-1a012e98e8ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6fedc4e1ca23438283a2d2c6f237fe8b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfNy0xLTEtMS0w_a05a39e3-c943-4117-85fe-a11698670967">155,368</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifedb75e8c33345abb30ce39ac8828048_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfNy0zLTEtMS0w_83510d71-b6c0-4364-a41b-8f96abec3040">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9a555374195740708b7b535422475c40_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfNy01LTEtMS0w_305c9683-502d-4ad6-ad2d-86d86cbf1f9f">155,368</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9fe30ec7f787449981feb883fd8e7408_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfNy03LTEtMS0w_73753ebe-67ee-4ea1-bd8e-3acae57f5153">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i70b955824d6240a6badd8bb4bbb12d0b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfOC0xLTEtMS0w_4323d803-bedd-484a-b090-38f00295ff22">95,017</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i98bf1a1fb6c946f99d2a94a5222f559e_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfOC0zLTEtMS0w_18c14ab0-82c1-4a59-8179-64173ec72b29">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i84e857a6b4d64be5bce0f89cc006035f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfOC01LTEtMS0w_cad4b385-60ed-4c2d-8637-abf643dc072e">95,017</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic69943e18c9d4e908720f488efa6db9c_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfOC03LTEtMS0w_f48b3b32-82bd-411c-ab35-257fb4e2705d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i23ea33c72d45452c8dca1b18861249d0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfOS0xLTEtMS0w_84d71f55-d708-41d2-87d2-5b5cc138b07b">53,493</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i878065655eff40a59fa226fbcc58557f_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfOS0zLTEtMS0w_8055e87e-fd6b-4734-a402-69ad278f5073">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i357038a3295843f7b8bb19efe35d46b1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfOS01LTEtMS0w_ea89848b-7bde-4a97-a7d7-a8d3bb2049e1">53,493</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia948e7072e51466fa0d1a823a8cda9e4_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfOS03LTEtMS0w_acd49d01-2467-44a6-8d4c-21e2cb095da2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id6a8c12c301e487cab97f3ac6cb97945_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfMTAtMS0xLTEtMA_6e1eff69-c7ab-4487-8457-d8fa12152d2b">303,878</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d0f5ceb90cd496f91d1edf2102c57d2_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfMTAtMy0xLTEtMA_e9e06234-fed6-451c-8287-88aa227b5f89">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4dd1f80319a84afbb69e15090417a474_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfMTAtNS0xLTEtMA_aa104d02-3a44-42de-aae7-d26fc3a0e948">303,878</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibe28cfabe6384c78b965211fe2b259d6_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfMTAtNy0xLTEtMA_94c36982-9050-42e6-9724-080017ef1948">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and marketable securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id6a8c12c301e487cab97f3ac6cb97945_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfMTEtMS0xLTEtMA_d0df4f96-e910-4d5b-a05a-cb56436d6e19">337,373</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d0f5ceb90cd496f91d1edf2102c57d2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfMTEtMy0xLTEtMA_d6fedeb8-5f8a-4bec-9884-e910437b941f">30,496</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4dd1f80319a84afbb69e15090417a474_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfMTEtNS0xLTEtMA_1ce0d8fb-d862-404c-96c3-169b2eb541cc">306,877</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibe28cfabe6384c78b965211fe2b259d6_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfMTEtNy0xLTEtMA_6afe8e68-9cae-4ddc-a725-490125f159ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Free shares asset</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55aa029ca6dd458a8a361b0d9ce3fc27_I20191231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfMTMtMS0xLTEtMA_ba610570-6534-4d6e-b9b6-1d69cad32ad9">236</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie4ed7f86404f4a6ba7c31faa2f653426_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfMTMtMy0xLTEtMA_dd520389-76ec-4314-ade3-7328462ab8f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7fd88b4bbe14d53a36b2a34dcf1fcbf_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfMTMtNS0xLTEtMA_1cd9a637-ab16-42b4-8d56-a3b49701848a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42972542d5a643f4ad2306c25b585428_I20191231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfMTMtNy0xLTEtMA_987c1e7a-08cb-4903-9c17-59c68678fe98">236</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">79</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><ix:continuation id="i9dd4fe3cb26d43fb9b934fd7980853a9" continuedAt="ie5db365f0a2045a5a41e2980e963afc9"><div><ix:continuation id="ie26943bfb175481a970d50afa17c7053"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:44.852%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.741%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> Fair Value Measurement</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9501ce5f7d6e456bb6d923b2208d2e71_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfNC0xLTEtMS0w_afa85389-7c80-446e-bdf6-19dab65ef969">103,291</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d2d295786cf43beaed8e20c63959a56_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfNC0zLTEtMS0w_2b7fd4c8-5844-4861-a4c8-4a5f05134856">103,291</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i94d4458c66c647e9ae4004aea884aea7_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfNC01LTEtMS0w_02794a93-893c-4c4a-ae8a-a73955bbb3c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia12bf2d0855544e080b1e3c549ce02c2_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfNC03LTEtMS0w_fd9d8ed0-c01e-4470-847f-f35cad38ffdc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iad708dc4322e4296b7279fb10923aa64_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfNi0xLTEtMS0w_51363672-06a4-4142-9b21-b62595993167">103,291</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0fac6e5a93cf4932b299c93b29103ee4_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfNi0zLTEtMS0w_a1febfad-3f84-4e60-9c44-32d3cf793c8b">103,291</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id07ed358181b47e991569dc03d1eca59_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfNi01LTEtMS0w_e118f81b-4bd9-461c-88e9-8da7233493f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8487d3169fa14869a2959a37cb1a1924_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfNi03LTEtMS0w_23f38198-cea0-4e45-8678-2aacbb2bd773">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i874bf2bbf8044c5ea86c5b6dec868699_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfOC0xLTEtMS0w_d404250a-a583-492c-88bd-04dc9e76b18f">177,224</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ac8366f1cf74cbda4eae920c042daef_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfOC0zLTEtMS0w_39b385aa-32d1-40ea-bf64-50e3824f96f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i329183fcaae04a14b76d777f4591b0cb_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfOC01LTEtMS0w_13af415d-085e-4dff-8117-41a608c9ba00">177,224</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibf402857bd034d28ad83a9627a535af3_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfOC03LTEtMS0w_dedd15b8-5094-4e5a-b1bb-e5badbe31168">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i604e1c483a2144499182a3abf3334884_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfOS0xLTEtMS0w_3818bff9-6e02-4e37-a1b9-8747e6678644">63,870</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i27b1fd12142f4694b5053b6268cd9c5a_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfOS0zLTEtMS0w_b3117293-83a5-4520-8a83-cbfe84a50509">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44eb81c1bb054e35a82f0ad07d8dd13a_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfOS01LTEtMS0w_6fa6726c-342d-42e0-a82e-90f1eca30ba3">63,870</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52f56fd373e54acdbc14ae1ad4e8621d_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfOS03LTEtMS0w_d77d0f40-debf-4437-9316-350c32d3ce82">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i149c7986f92344c09f4c6801f030875f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfMTAtMS0xLTEtMA_1cf7e96a-d70a-4b76-9be6-0fabc81b9bdf">18,621</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if20ea12b7bd2424fa4f0d5ddc716792c_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfMTAtMy0xLTEtMA_b4795cca-fa14-4afa-886e-4170c0524f8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5913e464612f4a46aa67a602001a2466_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfMTAtNS0xLTEtMA_a5474e3c-b152-4172-878f-487a60dfcac2">18,621</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i07c312494713484fb523d49996228eaa_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfMTAtNy0xLTEtMA_b64b1550-fb2b-469c-b6ba-9721412d4c7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iad708dc4322e4296b7279fb10923aa64_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfMTEtMS0xLTEtMA_68ce9c97-76d6-4841-bc52-14d434fbc803">259,715</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0fac6e5a93cf4932b299c93b29103ee4_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfMTEtMy0xLTEtMA_44885724-3f70-4344-b644-ab6dd6b0d0bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id07ed358181b47e991569dc03d1eca59_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfMTEtNS0xLTEtMA_7e4bfeff-8b95-4436-adf7-7ef15ce63d14">259,715</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8487d3169fa14869a2959a37cb1a1924_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfMTEtNy0xLTEtMA_026eea29-49d3-4ea7-b03a-46ef619c19a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and marketable securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iad708dc4322e4296b7279fb10923aa64_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfMTItMS0xLTEtMA_628e5d77-4827-4dea-ba3a-2d827c54d8d3">363,006</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0fac6e5a93cf4932b299c93b29103ee4_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfMTItMy0xLTEtMA_aaa93e0d-fe13-45f2-af7a-a39c7ab1a478">103,291</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id07ed358181b47e991569dc03d1eca59_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfMTItNS0xLTEtMA_b145ac0c-a79f-49b3-a647-57e8da4a8bf9">259,715</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8487d3169fa14869a2959a37cb1a1924_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfMTItNy0xLTEtMA_5257a73e-0cc0-4f97-a5ac-d5c0176ae135">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Free shares liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i64c1c287bd47404da4ea630212dedc2e_I20181231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfMTQtMS0xLTEtMTYxNA_1a2e177a-a5cc-46af-8033-1f3c490cec72">154</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i51862de68d334a6d90ced8ff154add77_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfMTQtMy0xLTEtMTYxNA_9a52c505-0165-4519-802a-cdef623c5614">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9017742317a7426b8f1655ea852cf27f_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfMTQtNS0xLTEtMTYxNA_11466d40-b124-48ef-9be4-93a6879d168c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if73c9eef08404834bb4f125b2f8334e8_I20181231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfMTQtNy0xLTEtMTYxNA_a088f105-4c74-4f84-a0d4-5dc835e3763f">154</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash Equivalents and Marketable Securities</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company generally classifies its marketable securities and some cash equivalents as Level 2. Instruments are classified as Level 2 when observable market prices for identical securities that are traded in less active markets are used. When observable market prices for identical securities are not available, such instruments are priced using benchmark curves, benchmarking of like securities, sector groupings, matrix pricing and valuation models. These valuation models are proprietary to the pricing providers or brokers and incorporate a number of inputs, including in approximate order of priority: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. For certain security types, additional inputs may be used, or some of the standard inputs may not be applicable. Evaluators may prioritize inputs differently on any given day for any security based on market conditions, and not all inputs listed are available for use in the evaluation process for each security evaluation on any given day.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Free Shares Asset/Liability</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a result of the July&#160;20, 2018 Share Purchase Agreement (&#8220;Sangamo France SPA&#8221;) to acquire Sangamo France (see Note 5 &#8211; </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Acquisition of Sangamo France</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">), the Company entered into arrangements with the holders of approximately <ix:nonFraction unitRef="shares" contextRef="ia4b36a1c4d88462a8ee8d85f748c7b16_I20180720" decimals="-3" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RleHRyZWdpb246MmM1Y2FkN2U3MWY3NDFkYWIyZmIzNzIzZTIxMTQ4MDlfNDM5ODA0NjUyNzAxMA_fe427243-c12a-4c11-ad93-4689e00b8bf5">477,000</ix:nonFraction> &#8220;free shares&#8221; of Sangamo France pursuant to which the Company has the right to purchase such shares from the holders (a call option) and such holders have the right to sell to the Company such shares from time to time through mid-2021 (a put option). The Company initially recorded a liability of $<ix:nonFraction unitRef="usd" contextRef="ia4b36a1c4d88462a8ee8d85f748c7b16_I20180720" decimals="-5" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RleHRyZWdpb246MmM1Y2FkN2U3MWY3NDFkYWIyZmIzNzIzZTIxMTQ4MDlfNDM5ODA0NjUyNjk4OA_cb8ccf64-b4b5-4dbe-8080-d3b0ce8894e8">0.2</ix:nonFraction>&#160;million on the acquisition date. The put options were classified within Level&#160;3 of the fair value hierarchy as the Company utilized a binomial-lattice pricing model (the &#8220;Monte Carlo simulation model&#8221;) that involved certain market conditions to estimate the fair value of the options. The assumptions used in this simulation model are reviewed on a quarterly basis and adjusted, as needed. Subsequent changes in the fair value of the free shares are recorded in general and administrative expenses in the Consolidated Statements of Operations. During the year, the Company purchased approximately <ix:nonFraction unitRef="shares" contextRef="i9b97713bc2a74145a84bf16db6e1a142_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RleHRyZWdpb246MmM1Y2FkN2U3MWY3NDFkYWIyZmIzNzIzZTIxMTQ4MDlfNDM5ODA0NjUyNzAyOA_d0cbed9e-d7b4-4271-8d2b-8f9048a78062">111,000</ix:nonFraction> shares of the <ix:nonFraction unitRef="shares" contextRef="ia4b36a1c4d88462a8ee8d85f748c7b16_I20180720" decimals="-3" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RleHRyZWdpb246MmM1Y2FkN2U3MWY3NDFkYWIyZmIzNzIzZTIxMTQ4MDlfNDM5ODA0NjUyNzAxOQ_fe427243-c12a-4c11-ad93-4689e00b8bf5">477,000</ix:nonFraction> total free shares for a cash payment of approximately $<ix:nonFraction unitRef="usd" contextRef="i9b97713bc2a74145a84bf16db6e1a142_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RleHRyZWdpb246MmM1Y2FkN2U3MWY3NDFkYWIyZmIzNzIzZTIxMTQ4MDlfNDM5ODA0NjUyNzA0Mg_34ac847c-28aa-434d-9f93-621f5554e5e5">0.3</ix:nonFraction>&#160;million upon exercise of the put options. As of December&#160;31, 2019, approximately <ix:nonFraction unitRef="shares" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RleHRyZWdpb246MmM1Y2FkN2U3MWY3NDFkYWIyZmIzNzIzZTIxMTQ4MDlfNDM5ODA0NjUyNzA3MA_fc611ce1-9f20-4df6-8e83-cf7601bd45a5">366,000</ix:nonFraction> free shares remain outstanding and subject to purchase by the Company.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The free shares liability was approximately $<ix:nonFraction unitRef="usd" contextRef="ifba2b3f6b5f24819b803f8b4290efdef_I20181231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RleHRyZWdpb246MmM1Y2FkN2U3MWY3NDFkYWIyZmIzNzIzZTIxMTQ4MDlfNjA0NzMxMzk2ODU5NQ_8ff56e19-6fa9-4ad0-bf1f-9f427123274a">0.2</ix:nonFraction>&#160;million at December 31, 2018 and the Company recognized a gain due to an increase in the fair value of the free shares of approximately $<ix:nonFraction unitRef="usd" contextRef="i9b97713bc2a74145a84bf16db6e1a142_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:IncreaseInFairValueOfFreeSharesAssetAndLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RleHRyZWdpb246MmM1Y2FkN2U3MWY3NDFkYWIyZmIzNzIzZTIxMTQ4MDlfODc5NjA5MzAzODI3Ng_2d1a203c-2e73-4afc-9df6-f86692a109c0">0.5</ix:nonFraction>&#160;million for the year ended December&#160;31, 2019, offset by approximately $<ix:nonFraction unitRef="usd" contextRef="i9b97713bc2a74145a84bf16db6e1a142_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionEstimatedFairValueOfFreeShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RleHRyZWdpb246MmM1Y2FkN2U3MWY3NDFkYWIyZmIzNzIzZTIxMTQ4MDlfNDM5ODA0NjUyNzA4NQ_29a8c537-d89d-4512-b4a6-3911ca4b179d">0.1</ix:nonFraction>&#160;million for the shares purchased during the year, bringing the balance to an asset of approximately $<ix:nonFraction unitRef="usd" contextRef="i2821462afaec43989ae5bb5640358bdb_I20191231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RleHRyZWdpb246MmM1Y2FkN2U3MWY3NDFkYWIyZmIzNzIzZTIxMTQ4MDlfNjA0NzMxMzk2ODYxNQ_665356ca-6053-44cf-b0ad-4165df808c5b">0.2</ix:nonFraction>&#160;million at December&#160;31, 2019.</span></div></ix:continuation><div style="text-indent:36pt;margin-top:6pt;"><span><br/></span></div><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RleHRyZWdpb246MmM1Y2FkN2U3MWY3NDFkYWIyZmIzNzIzZTIxMTQ4MDlfNDQ4MA_7d8e1fdb-f354-4189-aaf3-790f046b85ff" continuedAt="i8d4c86058a6d4a63a263e2507ea397e7" escape="true"></ix:nonNumeric><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">80</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-bottom:6pt;"><ix:continuation id="ie5db365f0a2045a5a41e2980e963afc9"><ix:continuation id="i8d4c86058a6d4a63a263e2507ea397e7"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"><tr><td style="width:1.0%;"></td><td style="width:71.784%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.812%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.389%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.815%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Free Shares valuation assumptions:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sangamo Stock Price (USD)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i8637425832d24b439a5841eb6340fe09_I20191231" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmIxZjJkZmEzOTk1MDQ3NWU4NDllNzBmZjIyMWQxNjdjL3RhYmxlcmFuZ2U6YjFmMmRmYTM5OTUwNDc1ZTg0OWU3MGZmMjIxZDE2N2NfMS0yLTEtMS0w_cfbd6ef8-b938-4eb9-bd1d-60fd6d86c124">8.68</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i5cd83c646e0741f2a6f9af0abef8b909_I20181231" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmIxZjJkZmEzOTk1MDQ3NWU4NDllNzBmZjIyMWQxNjdjL3RhYmxlcmFuZ2U6YjFmMmRmYTM5OTUwNDc1ZTg0OWU3MGZmMjIxZDE2N2NfMi0zLTEtMS0xODUx_db581f7b-10d9-4029-a94a-b666a84d4996">11.48</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sangamo France Stock Price (EUR)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8364;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="eurPerShare" contextRef="id158af407d9041baa888cbe9abf2ea9d_I20191231" decimals="INF" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmIxZjJkZmEzOTk1MDQ3NWU4NDllNzBmZjIyMWQxNjdjL3RhYmxlcmFuZ2U6YjFmMmRmYTM5OTUwNDc1ZTg0OWU3MGZmMjIxZDE2N2NfMi0yLTEtMS0w_c3ff1561-597f-4671-95f1-8d9531fa2308">2.14</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8364;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i8e015bf5f3134e418d8cb590b4182340_I20181231" decimals="INF" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmIxZjJkZmEzOTk1MDQ3NWU4NDllNzBmZjIyMWQxNjdjL3RhYmxlcmFuZ2U6YjFmMmRmYTM5OTUwNDc1ZTg0OWU3MGZmMjIxZDE2N2NfMy0zLTEtMS0xODUx_e4203da1-dcc1-449f-9679-14f4282fbd63">2.58</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">USD/ EUR Exchange Rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="INF" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmIxZjJkZmEzOTk1MDQ3NWU4NDllNzBmZjIyMWQxNjdjL3RhYmxlcmFuZ2U6YjFmMmRmYTM5OTUwNDc1ZTg0OWU3MGZmMjIxZDE2N2NfMy0yLTEtMS0w_7c62b185-d612-4112-925c-42351085ec9d">0.91</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="INF" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmIxZjJkZmEzOTk1MDQ3NWU4NDllNzBmZjIyMWQxNjdjL3RhYmxlcmFuZ2U6YjFmMmRmYTM5OTUwNDc1ZTg0OWU3MGZmMjIxZDE2N2NfNC0zLTEtMS0xODUx_57b516fd-2111-48a5-b9c0-c8c90f4a6f41">0.87</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Correlation Sangamo and Sangamo France Stock Prices</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i2ba502e8004f4a51b63eb68808f9ad0c_I20191231" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmIxZjJkZmEzOTk1MDQ3NWU4NDllNzBmZjIyMWQxNjdjL3RhYmxlcmFuZ2U6YjFmMmRmYTM5OTUwNDc1ZTg0OWU3MGZmMjIxZDE2N2NfNS0xLTEtMS0xODY5_25d27eab-ede8-4c20-a234-ec105d4dc0c3">100.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="iaa539cfd54e24b8e8f9bad28ca1ca2e2_I20181231" decimals="INF" format="ixt:zerodash" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmIxZjJkZmEzOTk1MDQ3NWU4NDllNzBmZjIyMWQxNjdjL3RhYmxlcmFuZ2U6YjFmMmRmYTM5OTUwNDc1ZTg0OWU3MGZmMjIxZDE2N2NfNS0zLTEtMS0xODY5_a11c06e3-9786-48ab-9d83-8d6cfeb6ea14">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sangamo Stock Price (USD) Volatility Estimate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i33f3835a3a9548d0bb177195bca1c91d_I20191231" decimals="INF" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmIxZjJkZmEzOTk1MDQ3NWU4NDllNzBmZjIyMWQxNjdjL3RhYmxlcmFuZ2U6YjFmMmRmYTM5OTUwNDc1ZTg0OWU3MGZmMjIxZDE2N2NfNC0yLTEtMS0w_9a5c351e-e600-42c0-94f6-b866085cafef">72.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="if0c0f4a598494b73a9f02d3c32a0337a_I20181231" decimals="INF" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmIxZjJkZmEzOTk1MDQ3NWU4NDllNzBmZjIyMWQxNjdjL3RhYmxlcmFuZ2U6YjFmMmRmYTM5OTUwNDc1ZTg0OWU3MGZmMjIxZDE2N2NfNS0zLTEtMS0xODUx_7f6ba4fb-817e-4def-8f22-5b9156f7c387">79.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sangamo France Stock Price (EUR) Volatility Estimate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i624ddabb3ed14489852a400d3c8823e6_I20191231" decimals="INF" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmIxZjJkZmEzOTk1MDQ3NWU4NDllNzBmZjIyMWQxNjdjL3RhYmxlcmFuZ2U6YjFmMmRmYTM5OTUwNDc1ZTg0OWU3MGZmMjIxZDE2N2NfNS0yLTEtMS0w_a3da3451-35b1-40cd-b49b-4f75f1208956">72.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i84d9625ccd9e40dcb299cd5ff4f2f7be_I20181231" decimals="INF" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmIxZjJkZmEzOTk1MDQ3NWU4NDllNzBmZjIyMWQxNjdjL3RhYmxlcmFuZ2U6YjFmMmRmYTM5OTUwNDc1ZTg0OWU3MGZmMjIxZDE2N2NfNi0zLTEtMS0xODUx_ce4e0cf5-eede-43df-a9bf-09b022ff4aa5">8.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">USD/ EUR Exchange Rate Volatility Estimate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="if3b6cba6a07b430f9c7d6308a92564cb_I20191231" decimals="INF" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmIxZjJkZmEzOTk1MDQ3NWU4NDllNzBmZjIyMWQxNjdjL3RhYmxlcmFuZ2U6YjFmMmRmYTM5OTUwNDc1ZTg0OWU3MGZmMjIxZDE2N2NfNi0yLTEtMS0w_9b8bda4a-a3e7-4c78-8607-41b1742391be">6.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i3aa31b7f47894ac591b3f5464dc1b173_I20181231" decimals="INF" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmIxZjJkZmEzOTk1MDQ3NWU4NDllNzBmZjIyMWQxNjdjL3RhYmxlcmFuZ2U6YjFmMmRmYTM5OTUwNDc1ZTg0OWU3MGZmMjIxZDE2N2NfNy0zLTEtMS0xODUx_0f3e31ab-df1c-4905-8476-b7221494a719">7.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk Free Rate and Cost of Debt by Expected Exercise Date</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ifdc951c6c13c4c8bb47767567ef80768_D20190101-20191231" name="sgmo:DerivativeLiabilityTerm" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmIxZjJkZmEzOTk1MDQ3NWU4NDllNzBmZjIyMWQxNjdjL3RhYmxlcmFuZ2U6YjFmMmRmYTM5OTUwNDc1ZTg0OWU3MGZmMjIxZDE2N2NfNy0yLTEtMS0w_2c8f25e6-9b00-43df-ac6a-6bc3a6951c87">Varies</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i87ef30d5e5634d03ba044c381280c504_D20180101-20181231" name="sgmo:DerivativeLiabilityTerm" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmIxZjJkZmEzOTk1MDQ3NWU4NDllNzBmZjIyMWQxNjdjL3RhYmxlcmFuZ2U6YjFmMmRmYTM5OTUwNDc1ZTg0OWU3MGZmMjIxZDE2N2NfOC0zLTEtMS0xODQx_777e5159-0743-46d6-8ecd-1e09c094c963">Varies</ix:nonNumeric></span></td></tr></table></ix:continuation></ix:continuation></div><div><span><br/></span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_100"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">81</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 3 &#8211; <ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90ZXh0cmVnaW9uOjk4OGU4MmNjMjFhNDQwMWM4Y2EzMGI4MTFlZDU2NGNhXzc2OTY1ODEzOTczMTM_e2a42cb4-d8fe-4b2b-a0ca-7043b6511e24" continuedAt="iaaaec7fc01904d7eb4d5c756a901150b" escape="true">MARKETABLE SECURITIES</ix:nonNumeric></span></div><ix:continuation id="iaaaec7fc01904d7eb4d5c756a901150b"><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:AvailableForSaleSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90ZXh0cmVnaW9uOjk4OGU4MmNjMjFhNDQwMWM4Y2EzMGI4MTFlZDU2NGNhXzc2OTY1ODEzOTczMTQ_a26fd492-04a4-4d38-8ea4-f714d4d3596c" escape="true"><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The table below summarizes the Company&#8217;s cash equivalents and available-for-sale securities (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:44.852%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.741%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8727918bfc77478d894641bf1ba39f2b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzMtMS0xLTEtMA_41b76200-f595-4114-8ea2-7c3f0a5f3b84">30,496</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8727918bfc77478d894641bf1ba39f2b_I20191231" decimals="-3" format="ixt:zerodash" name="sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzMtMy0xLTEtMA_b4eb5d4a-9dcf-4d9c-b9d8-125541a56654">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8727918bfc77478d894641bf1ba39f2b_I20191231" decimals="-3" format="ixt:zerodash" name="sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzMtNS0xLTEtMA_94538f9d-24ba-45f6-8f99-129ab25b07e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8727918bfc77478d894641bf1ba39f2b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzMtNy0xLTEtMA_25f2ec55-77f5-4ff4-bf02-2a57c7653575">30,496</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2134d5ba27be42e394846ea5e6f9bbaa_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzQtMS0xLTEtOTgxOQ_2709eead-3f7f-40a1-a0d7-c6ecfb8a1748">2,998</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2134d5ba27be42e394846ea5e6f9bbaa_I20191231" decimals="-3" name="sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzQtMy0xLTEtOTgyMQ_c8e6418f-ed83-4b1c-8b23-deb4890952fc">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2134d5ba27be42e394846ea5e6f9bbaa_I20191231" decimals="-3" format="ixt:zerodash" name="sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzQtNS0xLTEtOTgyNA_578d6682-23b5-4794-9baf-d2b86683a34e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2134d5ba27be42e394846ea5e6f9bbaa_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzQtNy0xLTEtOTgyNw_3417cc2e-a601-4b10-9fd0-1836a2cc2dbb">2,999</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i75f08675fb7643a590d56bf4bcb13e36_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzQtMS0xLTEtMA_51d4092a-6214-4e0f-9221-413eeeb9b5d9">33,494</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i75f08675fb7643a590d56bf4bcb13e36_I20191231" decimals="-3" name="sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzQtMy0xLTEtMA_a97aebb8-5377-4093-af5a-f0e4e2e7973f">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i75f08675fb7643a590d56bf4bcb13e36_I20191231" decimals="-3" format="ixt:zerodash" name="sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzQtNS0xLTEtMA_c3d87803-5ba6-4752-b68a-f831b9e44c4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i75f08675fb7643a590d56bf4bcb13e36_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzQtNy0xLTEtMA_85c14972-3b2c-4a71-ac81-9039bfba3a72">33,495</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2134d5ba27be42e394846ea5e6f9bbaa_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzYtMS0xLTEtMA_a261ba77-f96c-4061-9bd9-7d43e011b1ae">155,230</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2134d5ba27be42e394846ea5e6f9bbaa_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzYtMy0xLTEtMA_8b49b208-a9dc-4602-9dff-291e0468828e">145</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2134d5ba27be42e394846ea5e6f9bbaa_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzYtNS0xLTEtMA_835651a5-3e2e-4bc9-b2f8-81cf0ed894a5">7</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2134d5ba27be42e394846ea5e6f9bbaa_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzYtNy0xLTEtMA_ab852e45-3c51-46de-8a1b-d88024d5adef">155,368</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieeb73dab1cf94f2584bc9b78fb4369c1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzctMS0xLTEtMA_665dba77-ce45-4b7a-a4c8-6399c65fc1a5">94,905</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieeb73dab1cf94f2584bc9b78fb4369c1_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzctMy0xLTEtMA_12a2a344-dddf-4a0f-ba39-655257975b64">115</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ieeb73dab1cf94f2584bc9b78fb4369c1_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzctNS0xLTEtMA_cecca78a-d42d-457a-81de-1d9bdcfe9b53">3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieeb73dab1cf94f2584bc9b78fb4369c1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzctNy0xLTEtMA_3868a510-740f-43e6-a641-de4330faf23b">95,017</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i30cc7310d6c14807bc817509966f5218_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzgtMS0xLTEtMA_08bb1006-11f3-464b-b4d0-de7dd25061b6">53,411</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i30cc7310d6c14807bc817509966f5218_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzgtMy0xLTEtMA_b6a7c7fa-a732-44c5-a214-40de303a7de6">91</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i30cc7310d6c14807bc817509966f5218_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzgtNS0xLTEtMA_b8dd0713-e664-4776-9682-acf666cba936">9</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i30cc7310d6c14807bc817509966f5218_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzgtNy0xLTEtMA_8b7c67af-2409-4e5c-8de6-6289fb679b25">53,493</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzktMS0xLTEtMA_380bbaaf-23aa-4a01-881a-53ba81ea0331">303,546</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzktMy0xLTEtMA_4160c61b-7ed9-4658-9b51-b3eb0d5074a4">351</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzktNS0xLTEtMA_9a60c53c-8c45-406d-979a-490e3ac92673">19</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzktNy0xLTEtMA_8c76f846-7f16-4a9e-9026-d6e8441270de">303,878</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and available-for-sale securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzEwLTEtMS0xLTA_dafb283a-7119-432d-8f17-b8dc0055043a">337,040</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzEwLTMtMS0xLTA_779093e7-287a-4100-9f9c-056e5228599a">352</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzEwLTUtMS0xLTA_ae6eba2c-1d23-4ef0-8b0e-bb9ae435436b">19</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:CashEquivalentsAndAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzEwLTctMS0xLTA_794e6e08-3701-4626-83e5-1738ed81239e">337,373</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic0b60e45bbb54cb5814c2623600b05a7_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzEzLTEtMS0xLTA_fff5e664-1244-458c-8290-2145b2be52a2">103,291</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic0b60e45bbb54cb5814c2623600b05a7_I20181231" decimals="-3" format="ixt:zerodash" name="sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzEzLTMtMS0xLTA_72ee3432-e75d-44be-ba0e-953ee66d43cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic0b60e45bbb54cb5814c2623600b05a7_I20181231" decimals="-3" format="ixt:zerodash" name="sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzEzLTUtMS0xLTA_0fdbd4f4-e1f1-4ee1-a931-f1845e90c694">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic0b60e45bbb54cb5814c2623600b05a7_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzEzLTctMS0xLTA_d7f5050f-bc05-4f5a-9b10-dab07400bdfa">103,291</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iea5cd444cca1404bad4fad46fe35b1b5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzE1LTEtMS0xLTA_99bf04a3-dfb8-467d-acc2-8677552a8063">103,291</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iea5cd444cca1404bad4fad46fe35b1b5_I20181231" decimals="-3" format="ixt:zerodash" name="sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzE1LTMtMS0xLTA_312a73ab-663e-47cc-9316-150544a2add3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iea5cd444cca1404bad4fad46fe35b1b5_I20181231" decimals="-3" format="ixt:zerodash" name="sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzE1LTUtMS0xLTA_da41f887-1f4f-43df-a67e-6fd3d6414a16">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iea5cd444cca1404bad4fad46fe35b1b5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzE1LTctMS0xLTA_01b5ef84-3b06-4ce4-944a-2d37e5deb663">103,291</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Available-for-sale securities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c5421c8d9b34ac193b12f580b0e45fe_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzE3LTEtMS0xLTA_81175dc8-763a-4b7a-8b44-b5664e233631">177,353</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c5421c8d9b34ac193b12f580b0e45fe_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzE3LTMtMS0xLTA_29d84263-d541-4d78-8465-8da3fc371e41">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4c5421c8d9b34ac193b12f580b0e45fe_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzE3LTUtMS0xLTA_acf5d5ce-aadf-420a-8f16-5ae5dd517723">129</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c5421c8d9b34ac193b12f580b0e45fe_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzE3LTctMS0xLTA_b6ac9196-cfd5-4730-8321-2303aeef3061">177,224</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib6b4614c3ed0431ab9570835b20a0800_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzE4LTEtMS0xLTA_e5a1991c-c6dd-4d65-85e9-cf49bd4918ff">63,981</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib6b4614c3ed0431ab9570835b20a0800_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzE4LTMtMS0xLTA_9f7ed94b-ebe9-4f52-bba1-be44b90862aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib6b4614c3ed0431ab9570835b20a0800_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzE4LTUtMS0xLTA_82c3e20f-a150-46d8-96bd-8a4b751032bd">111</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib6b4614c3ed0431ab9570835b20a0800_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzE4LTctMS0xLTA_4e14171b-65ad-41b5-966d-f4048ab45e78">63,870</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1f19f6eef7f447ee90aa653000871c5d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzE5LTEtMS0xLTA_289ab4b9-a36b-4c72-94eb-bd292e85d506">18,640</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1f19f6eef7f447ee90aa653000871c5d_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzE5LTMtMS0xLTA_5722358e-0c0f-4f6d-a934-69c2d8c3deae">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1f19f6eef7f447ee90aa653000871c5d_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzE5LTUtMS0xLTA_ee664206-8e6e-438f-8662-69ff2f10ab6c">19</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1f19f6eef7f447ee90aa653000871c5d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzE5LTctMS0xLTA_de3c3010-442b-47ac-810a-8855a3a35b3b">18,621</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzIwLTEtMS0xLTA_fb9b08ff-b577-4485-b584-956f5bee36a3">259,974</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzIwLTMtMS0xLTA_a99ee895-52ac-48cc-aeab-3af95c342c5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzIwLTUtMS0xLTA_dff372fc-0816-4020-ae82-9f582ae3c463">259</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzIwLTctMS0xLTA_16e8d93d-3a33-4df2-aae3-7ca70638c7a7">259,715</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and available-for-sale securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzIxLTEtMS0xLTA_6d1cd510-7593-42cb-b70e-8c0601e4454f">363,265</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:zerodash" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzIxLTMtMS0xLTA_fcfcfcbc-99ad-4ca7-b838-fc9e07b06b29">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzIxLTUtMS0xLTA_398da313-cf9e-4efc-b43c-cdf15b0542dd">259</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:CashEquivalentsAndAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzIxLTctMS0xLTA_f00c0b1c-fa31-4a7c-8660-7b3fb7727f30">363,006</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of investments available-for-sale by contractual maturity were as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:57.064%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.883%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.969%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.884%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Maturing in one year or less</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo2ZjRkY2E2Yzg4YjU0MDU2YWNmYjQ4NmNjNWQ4ODU5OS90YWJsZXJhbmdlOjZmNGRjYTZjODhiNTQwNTZhY2ZiNDg2Y2M1ZDg4NTk5XzItMS0xLTEtMTEwNDA_55e4d7f0-d37b-40e5-b15f-7992f7fb6d03">282,046</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo2ZjRkY2E2Yzg4YjU0MDU2YWNmYjQ4NmNjNWQ4ODU5OS90YWJsZXJhbmdlOjZmNGRjYTZjODhiNTQwNTZhY2ZiNDg2Y2M1ZDg4NTk5XzItMy0xLTEtMTEwNDY_9d4a1ea2-b18d-4e5c-a1f0-dfa21d211ce1">259,715</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Maturing after one year through five years</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo2ZjRkY2E2Yzg4YjU0MDU2YWNmYjQ4NmNjNWQ4ODU5OS90YWJsZXJhbmdlOjZmNGRjYTZjODhiNTQwNTZhY2ZiNDg2Y2M1ZDg4NTk5XzMtMS0xLTEtMTEwNDM_0d2beba0-9bda-4b1f-9a78-80113993e287">21,832</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo2ZjRkY2E2Yzg4YjU0MDU2YWNmYjQ4NmNjNWQ4ODU5OS90YWJsZXJhbmdlOjZmNGRjYTZjODhiNTQwNTZhY2ZiNDg2Y2M1ZDg4NTk5XzMtMy0xLTEtMTEwNDk_195316b3-cf66-47b1-b21c-6e3ff45ff18e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total investments available-for-sale</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo2ZjRkY2E2Yzg4YjU0MDU2YWNmYjQ4NmNjNWQ4ODU5OS90YWJsZXJhbmdlOjZmNGRjYTZjODhiNTQwNTZhY2ZiNDg2Y2M1ZDg4NTk5XzQtMS0xLTEtMTEwNTU_a4301887-2aef-4750-9842-9b3e8028781f">303,878</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo2ZjRkY2E2Yzg4YjU0MDU2YWNmYjQ4NmNjNWQ4ODU5OS90YWJsZXJhbmdlOjZmNGRjYTZjODhiNTQwNTZhY2ZiNDg2Y2M1ZDg4NTk5XzQtMy0xLTEtMTEwNTI_0e621754-1053-436f-8e90-754f44b6c4fc">259,715</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company had <ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90ZXh0cmVnaW9uOjk4OGU4MmNjMjFhNDQwMWM4Y2EzMGI4MTFlZDU2NGNhXzI2NA_21c326a9-9753-4ada-a30b-3b5cfad5c5c7"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90ZXh0cmVnaW9uOjk4OGU4MmNjMjFhNDQwMWM4Y2EzMGI4MTFlZDU2NGNhXzI2NA_231b6234-0bdf-499f-ade4-590facf5bfd7"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90ZXh0cmVnaW9uOjk4OGU4MmNjMjFhNDQwMWM4Y2EzMGI4MTFlZDU2NGNhXzI2NA_f167d444-d5ee-4321-8616-4de7880a9307">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> material realized losses from the sale of available-for-sale securities for the years ended December&#160;31, 2019, 2018 or 2017. Sangamo has the intent and ability to hold its investments for a period of time sufficient to allow for any anticipated recovery in market value. <ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:OtherThanTemporarilyImpairedInvestment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90ZXh0cmVnaW9uOjk4OGU4MmNjMjFhNDQwMWM4Y2EzMGI4MTFlZDU2NGNhXzUxOQ_484f5d90-b581-4d5b-a238-27763592375f"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:OtherThanTemporarilyImpairedInvestment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90ZXh0cmVnaW9uOjk4OGU4MmNjMjFhNDQwMWM4Y2EzMGI4MTFlZDU2NGNhXzUxOQ_b4350391-c1e5-4701-bfb7-542ca1148267">No</ix:nonFraction></ix:nonFraction> investments were other-than-temporarily impaired at either December&#160;31, 2019 or 2018.</span></div></ix:continuation><div id="i9a2bf9013aa44980b5a1f5846290b1a8_112"></div><div style="position:relative;width:100%;height:0pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">82</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzMxMzM4_f9c979d1-0afb-4ce8-a11d-bea86faa1a20" continuedAt="id7944d296a154f098f07773a307679fb" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 4 &#8211; MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Collaboration Agreements</span></div><div style="text-indent:18pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Kite </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2018, the Company entered into a global collaboration and license agreement with Kite Pharma, Inc. (&#8220;Kite&#8221;), which became effective on April 5, 2018, and was amended and restated in September 2019, for the research, development and commercialization of potential engineered cell therapies for cancer. In this collaboration, Sangamo is working together with Kite on a research program under which the companies are designing zinc finger nucleases (&#8220;ZFNs&#8221;) and viral vectors to disrupt and insert certain genes in T-cells and natural killer cells (&#8220;NK-cells&#8221;) including the insertion of genes that encode chimeric antigen receptors (&#8220;CARs&#8221;), T-cell receptors (&#8220;TCRs&#8221;), and NK-cell receptors (&#8220;NKRs&#8221;) directed to mutually agreed targets. Kite is responsible for all clinical development and commercialization of any resulting products and has announced that they expect to initiate a clinical trial evaluating KITE-037, an allogeneic anti-CD19 CAR-T cell therapy, in 2020.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subject to the terms of this agreement, the Company granted Kite an exclusive, royalty-bearing, worldwide sublicensable license under the Company&#8217;s relevant patents and know-how to develop, manufacture and commercialize, for the purpose of treating cancer, specific cell therapy products that may result from the research program and that are engineered </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ex vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> using selected ZFNs and viral vectors developed under the research program to express CARs, TCRs or NKRs directed to candidate targets.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the research program term and subject to certain exceptions, except pursuant to this agreement, the Company is prohibited from researching, developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ex vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> genome editing, expresses a CAR, TCR or NKR that is directed to a target expressed on or in a human cancer cell. After the research program term concludes and subject to certain exceptions, except pursuant to this agreement, the Company will be prohibited from developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ex vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> genome editing, expresses a CAR, TCR or NKR that is directed to a candidate target.</span></div><div style="text-indent:36pt;margin-top:6pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Following the effective date, in April 2018, the Company received a $<ix:nonFraction unitRef="usd" contextRef="ie60f0866d78349d39fcb444b085ce632_D20180401-20180430" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestonePaymentsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzIwNzI_60538a14-24fb-4a48-aee8-6cfc4b5520b0">150.0</ix:nonFraction>&#160;million upfront payment from Kite. In addition, Kite will reimburse the Company&#8217;s direct costs to conduct service under the joint research program provisions of the agreement, and Kite will be responsible for all subsequent development, manufacturing and commercialization of any licensed products. Sangamo is also eligible to receive contingent development- and sales-based milestone payments that could total up to $<ix:nonFraction unitRef="usd" contextRef="i61fd7d98b04648caaf9d32dec4a807ec_D20180404-20180405" decimals="INF" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI0ODQ_e724bd82-72cb-4153-88c2-61bbde39d989">3.01</ix:nonFraction>&#160;billion if all of the specified milestones in this agreement are achieved.&#160;Of this amount, approximately $<ix:nonFraction unitRef="usd" contextRef="i5a2cd91a4f284017a4ef2d70e422e99c_D20180404-20180405" decimals="-7" format="ixt:numdotdecimal" name="sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI1OTQ_71ebece2-d367-4309-8c93-eaa4cce64611">1.26</ix:nonFraction>&#160;billion relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones, and approximately $<ix:nonFraction unitRef="usd" contextRef="i48416dd30d974b1aad80f204b2aabe20_D20180404-20180405" decimals="-7" format="ixt:numdotdecimal" name="sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI3MzY_f9bcbaff-e6b4-4ec6-963a-5a9e85cdd82a">1.75</ix:nonFraction>&#160;billion relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels.&#160;Each development- and sales-based milestone payment is payable (i)&#160;only once for each licensed product, regardless of the number of times that the associated milestone event is achieved by such licensed product, and (ii)&#160;only for the first ten times that the associated milestone event is achieved, regardless of the number of licensed products that may achieve such milestone event. In addition, the Company will be entitled to receive escalating, tiered royalty payments with a percentage in the single digits based on potential future annual worldwide net sales of licensed products. These royalty payments will be subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.</span></div><div style="text-indent:36pt;margin-top:6pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The initial research term of the agreement is <ix:nonNumeric contextRef="id7d82acff2b8474488fc135b1be65d92_D20190101-20191231" format="ixt-sec:durwordsen" name="sgmo:InitialResearchTermOfAgreement" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzM3MTI_dd0efe33-72c4-42af-86d2-1b9ca6f1ad7a">six years</ix:nonNumeric>. Kite has an option to extend the research term for up to <ix:nonFraction unitRef="option" contextRef="id7d82acff2b8474488fc135b1be65d92_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:NumberOfOptionsToExtendInitialResearchTerm" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzc2OTY1ODE1MDUyMjE_a71e27a5-5a6e-444e-83df-53024f477c51">two</ix:nonFraction> additional <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzc2OTY1ODE1MDUyMDY_67f3e1f2-17aa-46c8-a608-4185bf8992f1">one</span>-year periods for a separate fee of $<ix:nonFraction unitRef="usd" contextRef="id7d82acff2b8474488fc135b1be65d92_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:SeparateUpfrontFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzM4MjE_6dd3e40f-9591-48c2-8b21-a9e18c8f3d86">10.0</ix:nonFraction>&#160;million per year. All contingent payments under the agreement, when earned, will be non-refundable and non-creditable. In connection with the amendment and restatement of the agreement in September 2019, the Company entered into a new research plan with Kite, with estimated reimbursable service costs of approximately $<ix:nonFraction unitRef="usd" contextRef="i6fff5fa4d22f420dbc13bcf64a19b587_D20190901-20190930" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzE0MjkzNjUxMjU2NzM1_2b7a1fe4-86c7-4520-a98f-2c870dd722c2">3.4</ix:nonFraction>&#160;million. The Company concluded the transaction price under this agreement is $<ix:nonFraction unitRef="usd" contextRef="i6fff5fa4d22f420dbc13bcf64a19b587_D20190901-20190930" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzQwMDM_2aee23c6-bcf4-4f44-b331-4f6b311b5d14">189.3</ix:nonFraction>&#160;million and includes the upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="i6fff5fa4d22f420dbc13bcf64a19b587_D20190901-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzQwNDY_66a7ac79-69ef-4e27-bddc-c3ab9b86e0f6">150.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i6fff5fa4d22f420dbc13bcf64a19b587_D20190901-20190930" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzQwNTM_36dfe647-6662-40f7-b7be-1bff11b74540">39.3</ix:nonFraction>&#160;million estimated reimbursable service costs for identified research projects over the estimated performance period. The Company concluded that the estimated fees for the presumed exercise of the research term extension options and all milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur. None of the development and sales-based milestone payments have been included in the transaction price.</span></div><div style="text-indent:36pt;margin-top:6pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company assessed the agreement with Kite in accordance with ASC Topic 606 and concluded that Kite is a customer. Kite has the right to terminate this agreement, in its entirety or on a per licensed product or per candidate target basis, </span></div></ix:nonNumeric><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">83</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><ix:continuation id="id7944d296a154f098f07773a307679fb" continuedAt="ib81094d5098441fe93c7f1dc29ab2107"><div style="margin-top:6pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">for any reason after a specified notice period. Each party has the right to terminate this agreement on account of the other party&#8217;s bankruptcy or material, uncured breach.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has identified the primary performance obligations within the Kite agreement as: (1) a license to the technology along with the stand by ready obligation to perform research services, and (2) the on-going research services. Revenue from the upfront license fee relates to access to the license and Company&#8217;s obligation to stand-ready to perform such research services as additional targets are selected by Kite. As a result of this obligation to perform research services when and if requested throughout the duration of the contract, the fee for the license and the stand-ready obligation will be recognized over time on a straight-line basis through June 2024, the estimated period of the stand-ready obligation. Revenue from the reimbursable costs related to the integrated service deliverable is recognized as the research services are performed. Related costs and expenses under these arrangements have historically approximated the revenues recognized. The estimated period of performance and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. As of December&#160;31, 2019, and 2018 the Company had deferred revenue of $<ix:nonFraction unitRef="usd" contextRef="i0c5a81250c2e4e6992c7624e2f50a5b0_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzQ5NDc4MDIzNzY0MDE_44544706-fa52-4b0c-8007-b296e0c860a9">106.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i654a0f9976964892b5f266a6a5e30461_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzQ5NDc4MDIzNzYzNzQ_1cb8a823-c7f3-4f12-ba44-db83c7d3ba4c">131.5</ix:nonFraction>&#160;million, respectively, related to this agreement. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span><br/></span></div><ix:nonNumeric contextRef="if5e9da2152d548ad9e46e4ebe09d9cc7_D20190101-20191231" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzc2OTY1ODE0ODMyMTE_c5118510-1497-4015-be21-3a7dc6473234" escape="true"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues recognized under the agreement were as follows (in thousands):</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.538%;"><tr><td style="width:1.0%;"></td><td style="width:70.848%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.908%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.541%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.908%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.395%;"></td><td style="width:0.1%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="12" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue related to Kite agreement:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Recognition of license and stand-ready fee</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i592dd2531c234441a8b4b503c5e33bdf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTo4ZGIyMzU4NzY1YmM0ZTNhYWY5MGY2NTU3MzZkZjRmMS90YWJsZXJhbmdlOjhkYjIzNTg3NjViYzRlM2FhZjkwZjY1NTczNmRmNGYxXzMtMS0xLTEtNTA0OA_682b513b-5a2b-4d57-a9ac-dfb0123ab60c">24,977</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i88cf0e3541a3458eae231fe54f01b5e1_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTo4ZGIyMzU4NzY1YmM0ZTNhYWY5MGY2NTU3MzZkZjRmMS90YWJsZXJhbmdlOjhkYjIzNTg3NjViYzRlM2FhZjkwZjY1NTczNmRmNGYxXzMtMy0xLTEtNTA0NQ_2cca5209-07c5-4360-b55f-0c8781d1a991">18,545</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55753e9172b14060be72e0417c8e4ee5_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTo4ZGIyMzU4NzY1YmM0ZTNhYWY5MGY2NTU3MzZkZjRmMS90YWJsZXJhbmdlOjhkYjIzNTg3NjViYzRlM2FhZjkwZjY1NTczNmRmNGYxXzQtMS0xLTEtNTA0OA_a5a6e28a-5e4e-4cc9-8e9b-dcbe09e75ae6">9,373</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i60584ff2a34d45fb9afa66b5a623a4b2_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTo4ZGIyMzU4NzY1YmM0ZTNhYWY5MGY2NTU3MzZkZjRmMS90YWJsZXJhbmdlOjhkYjIzNTg3NjViYzRlM2FhZjkwZjY1NTczNmRmNGYxXzQtMy0xLTEtNTA0NQ_d1eb89cb-b222-485b-8c2f-85931ee6e898">6,972</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if5e9da2152d548ad9e46e4ebe09d9cc7_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTo4ZGIyMzU4NzY1YmM0ZTNhYWY5MGY2NTU3MzZkZjRmMS90YWJsZXJhbmdlOjhkYjIzNTg3NjViYzRlM2FhZjkwZjY1NTczNmRmNGYxXzUtMS0xLTEtNTA0OA_b0bef5f8-09c1-4fa4-a67f-49fe00813944">34,350</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ied53c137399045e198eb8eede660e8f2_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTo4ZGIyMzU4NzY1YmM0ZTNhYWY5MGY2NTU3MzZkZjRmMS90YWJsZXJhbmdlOjhkYjIzNTg3NjViYzRlM2FhZjkwZjY1NTczNmRmNGYxXzUtMy0xLTEtNTA0NQ_3becda25-74f1-43f0-be64-ca5e95bf428f">25,517</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div></ix:nonNumeric><div style="text-indent:18pt;margin-top:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Pfizer </span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">SB-525 Global Collaboration and License Agreement</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2017, the Company entered into an exclusive, global collaboration and license agreement with Pfizer, pursuant to which it established a collaboration for the research, development and commercialization of SB-525, its gene therapy product candidate for hemophilia A, and closely related products.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under this agreement, the Company is responsible for conducting the Phase 1/2 clinical trial and certain manufacturing activities for SB-525, while Pfizer is responsible for subsequent worldwide development, manufacturing, marketing and commercialization of SB-525. Sangamo may also collaborate in the research and development of additional adeno-associated virus ("AAV") based gene therapy products for hemophilia A.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company originally received an upfront fee of $<ix:nonFraction unitRef="usd" contextRef="ib08e3f2b116d4fe8846432aa9f1fb42f_D20170501-20170531" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzcwMjU_63ea5a25-2faf-4228-8d1a-935d17d2fbca">70.0</ix:nonFraction>&#160;million and is eligible to receive development milestone payments contingent on the achievement of specified clinical development, intellectual property, regulatory and first commercial sale milestones for SB-525 and potentially other products. In addition, Sangamo is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i8a64f9da293b4fb5998f17bc3ebc159f_D20170501-20170531" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzczMTU_259e4915-2fdb-4a8c-bf8f-955c8e62f325">208.5</ix:nonFraction>&#160;million in payments upon the achievement of specified clinical development, intellectual property and regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i0eb4d4a7fdf7414bbcd0bcbb337d0b56_D20170501-20170531" decimals="-5" format="ixt:numdotdecimal" name="sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzc0NDQ_131f73d4-df78-4cc0-ad26-60a3bdf3456f">266.5</ix:nonFraction>&#160;million in payments upon first commercial sale milestones for SB-525 and potentially other products. The total amount of potential clinical development, intellectual property, regulatory, and first commercial sale milestone payments, assuming the achievement of all specified milestones in the hemophilia A Pfizer agreement, is up to $<ix:nonFraction unitRef="usd" contextRef="i9107973e10124be1aa15439229671e5f_D20170501-20170531" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzc3NzM_13d6630a-ffcc-46b1-914e-33b741edfcb5">475.0</ix:nonFraction>&#160;million, which includes up to $<ix:nonFraction unitRef="usd" contextRef="i45470bac3a3d46c59bc142131a59b782_I20170531" decimals="INF" format="ixt:numdotdecimal" name="sgmo:MilestoneRevenueReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzc3OTg_1e4ecab5-a2c2-4ab6-975e-b2bff467828d">300.0</ix:nonFraction>&#160;million for SB-525 and up to $<ix:nonFraction unitRef="usd" contextRef="ibfcf378e55cd4dc89b34b84d7fc85aa2_I20170531" decimals="INF" format="ixt:numdotdecimal" name="sgmo:MilestoneRevenueReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzc4MjI_c39b0fa2-d743-46ad-9db9-62d0cd253781">175.0</ix:nonFraction>&#160;million for other products that may be developed under the agreement, subject to reduction on account of payments made under certain licenses for third party intellectual property. In addition, Pfizer agreed to pay the Company royalties for each potential licensed product developed under the agreement based on an escalating tiered, double-digit percentage of the annual net sales of such product. These royalties are subject to reduction due to patent expiration, entry of biosimilar products to the market and payment made under certain licenses for third-party intellectual property. To date, a $<ix:nonFraction unitRef="usd" contextRef="if20dd4173a934bb9bfd3c1d39c91de1b_I20191231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestoneRevenueReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzEwNDQ1MzYwNTUyNzYy_c5d77b87-3d51-4e57-ab48-346073d56802">25.0</ix:nonFraction>&#160;million milestone has been achieved, however <ix:nonFraction unitRef="product" contextRef="idc78178116cc4805a2503e4d1f1172dd_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzg0NDY_2d8319df-5439-4270-80f4-2c636938293e">no</ix:nonFraction> products have been approved and therefore <ix:nonFraction unitRef="milestone" contextRef="i9b68588d42cd47f383c50071fab098fa_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzg0OTE_dc4ddd87-87e8-404f-9613-05663c06774f">no</ix:nonFraction> royalty fees have been earned under the hemophilia A Pfizer agreement.</span></div><div style="text-indent:36pt;margin-top:6pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company assessed the agreement with Pfizer in accordance with ASC Topic 606 and concluded that Pfizer is a customer. As of December 31, 2019, the total transaction price under this agreement is $<ix:nonFraction unitRef="usd" contextRef="idc78178116cc4805a2503e4d1f1172dd_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzg3OTYwOTMxMzQyNDc_519dd27b-e3b7-48e3-9515-d46829025d1a">105.0</ix:nonFraction>&#160;million, which represents the upfront and research services fees of $<ix:nonFraction unitRef="usd" contextRef="idc78178116cc4805a2503e4d1f1172dd_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementResearchServiceFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzg3OTYwOTMxMzQzMTc_cbe27861-8039-41b9-acc2-27da27bd3b28">80.0</ix:nonFraction>&#160;million and one unconstrained milestone in the amount of $<ix:nonFraction unitRef="usd" contextRef="if20dd4173a934bb9bfd3c1d39c91de1b_I20191231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestoneRevenueReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzg3OTYwOTMxMzQzNTI_c5d77b87-3d51-4e57-ab48-346073d56802">25.0</ix:nonFraction>&#160;million. Sangamo is responsible for internal and external research costs as part of the upfront fee and has the ability to request additional reimbursement from Pfizer if certain conditions are met. None of the clinical or regulatory milestones have been included in the transaction price, as all such milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">84</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><ix:continuation id="ib81094d5098441fe93c7f1dc29ab2107" continuedAt="if3a69d42e38d435b8e300950cf083da4"><div style="margin-top:6pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subject to the terms of the agreement, the Company granted Pfizer an exclusive worldwide royalty-bearing license, with the right to grant sublicenses, to use certain technology controlled by the Company for the purpose of developing, manufacturing and commercializing SB-525 and related products. Pfizer granted the Company a non-exclusive, worldwide, royalty free, fully paid license, with the right to grant sublicenses, to use certain manufacturing technology developed under the agreement and controlled by Pfizer to manufacture the Company&#8217;s products that utilize the AAV delivery system. During a specified period, neither the Company nor Pfizer will be permitted to clinically develop or commercialize, outside of the collaboration, certain AAV-based gene therapy products for hemophilia A.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unless earlier terminated, the agreement has a term that continues on a per product and per country basis until the later of (i)&#160;the expiration of patent claims that cover the product in a country, (ii)&#160;the expiration of regulatory exclusivity for a product in a country, and (iii)&#160;<ix:nonNumeric contextRef="idc78178116cc4805a2503e4d1f1172dd_D20190101-20191231" format="ixt-sec:duryear" name="sgmo:AgreementTerminationTerm" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzc2OTY1ODE1MDQ4MDE_d3b54ce5-2367-429f-a8da-409807b32697">15</ix:nonNumeric> years after the first commercial sale of a product in a country. Pfizer has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize SB-525 and related products will automatically terminate. Upon termination by the Company for cause or by Pfizer in any country or countries, Pfizer will automatically grant the Company an exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize SB-525 in the terminated country or countries.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has identified one performance obligation within the hemophilia A Pfizer agreement as a license to the technology and on-going research services. The Company concluded that the license is not discrete, as it does not have stand-alone value to Pfizer apart from the research services to be performed by the Company pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the on-going services through 2020, the estimated period the Company will perform research services. The estimate of progress towards the satisfaction of its performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. As of December&#160;31, 2019 and 2018, the Company had deferred revenue of $<ix:nonFraction unitRef="usd" contextRef="i8bbeb9bd0c5c4a2da841e90386104e1a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzQ5NDc4MDIzNzY0MjQ_0a286c2a-8c11-41a4-aa2d-248fb240e5c5">4.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1e978c226de34436b68f163f5e4d3354_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzQ5NDc4MDIzNzY0MzA_51b7a418-74bc-4092-aea0-7146ea754b70">10.0</ix:nonFraction>&#160;million, respectively, related to this agreement.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the Company entered into an amendment to the collaboration agreement, pursuant to which the Company transferred the IND for SB-525 to Pfizer. Upon this transfer the Company achieved a $<ix:nonFraction unitRef="usd" contextRef="if20dd4173a934bb9bfd3c1d39c91de1b_I20191231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestoneRevenueReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzg3OTYwOTMxMTcwMDA_c5d77b87-3d51-4e57-ab48-346073d56802">25.0</ix:nonFraction>&#160;million milestone as the conditions for achieving the milestone were met. The Company recognized approximately $<ix:nonFraction unitRef="usd" contextRef="i842d5727afc443408e09ed5a522e2a9e_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzg3OTYwOTMxMzQxNzk_5666f5f7-a024-4ee2-8bcc-f91bdad28510">23.7</ix:nonFraction>&#160;million attributed to this milestone as revenue during the year ended December 31, 2019. The balance of this payment of $<ix:nonFraction unitRef="usd" contextRef="if20dd4173a934bb9bfd3c1d39c91de1b_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzg3OTYwOTMxMzUwMTY_275e3874-abad-49a9-adf9-00c9b5591e55">1.3</ix:nonFraction>&#160;million will be recognized as revenue commensurate with the provision of research services over the remaining term of the agreement. </span></div><ix:nonNumeric contextRef="idc78178116cc4805a2503e4d1f1172dd_D20190101-20191231" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzc2OTY1ODE1MDYxMTU_d762121d-ec88-463e-a8e9-130adf9a4b70" escape="true"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues recognized under the agreement were as follows (in thousands):</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368%;"><tr><td style="width:1.0%;"></td><td style="width:57.009%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.063%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.550%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.063%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.851%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.064%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue related to Pfizer SB-525 agreement:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Recognition of upfront fee and research services</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1ea749f7283a4e3fbab4d679c510b03b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTphMjQxNWNkZDU5MmM0ZTdhOTNmZjNjYjhhOGIwZThjYi90YWJsZXJhbmdlOmEyNDE1Y2RkNTkyYzRlN2E5M2ZmM2NiOGE4YjBlOGNiXzMtMS0xLTEtNTIxMw_31964fdf-4c7e-4848-998d-916fd3dff137">15,697</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if9de85d493b645f38a1e2fc527b2126e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTphMjQxNWNkZDU5MmM0ZTdhOTNmZjNjYjhhOGIwZThjYi90YWJsZXJhbmdlOmEyNDE1Y2RkNTkyYzRlN2E5M2ZmM2NiOGE4YjBlOGNiXzMtMy0xLTEtNTIxMA_4e42e66c-dd9a-4ffe-baf6-4b84a39f4923">37,810</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iee1c5c93e9564920af22cdeb55d9889b_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTphMjQxNWNkZDU5MmM0ZTdhOTNmZjNjYjhhOGIwZThjYi90YWJsZXJhbmdlOmEyNDE1Y2RkNTkyYzRlN2E5M2ZmM2NiOGE4YjBlOGNiXzMtNS0xLTEtOTM3Mw_a417a27a-bb63-4904-a6df-5501faba41d0">17,008</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Milestone achievement</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8eb9a2216c044b17b0ac853396d42bed_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTphMjQxNWNkZDU5MmM0ZTdhOTNmZjNjYjhhOGIwZThjYi90YWJsZXJhbmdlOmEyNDE1Y2RkNTkyYzRlN2E5M2ZmM2NiOGE4YjBlOGNiXzQtMS0xLTEtOTc1OQ_d0fd1934-dfd6-4fba-b982-cbefa94f9b38">23,662</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6f1ee4fd337946f69c2e711004e9eb21_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTphMjQxNWNkZDU5MmM0ZTdhOTNmZjNjYjhhOGIwZThjYi90YWJsZXJhbmdlOmEyNDE1Y2RkNTkyYzRlN2E5M2ZmM2NiOGE4YjBlOGNiXzQtMy0xLTEtOTg0Mg_bcab4248-11bd-407f-8727-d660d9074681">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1c6f765722544bbfaa11a0f9c28106ee_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTphMjQxNWNkZDU5MmM0ZTdhOTNmZjNjYjhhOGIwZThjYi90YWJsZXJhbmdlOmEyNDE1Y2RkNTkyYzRlN2E5M2ZmM2NiOGE4YjBlOGNiXzQtNS0xLTEtOTg0NA_40bab3bb-ab52-48f0-8114-14af8b0fc7ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc78178116cc4805a2503e4d1f1172dd_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTphMjQxNWNkZDU5MmM0ZTdhOTNmZjNjYjhhOGIwZThjYi90YWJsZXJhbmdlOmEyNDE1Y2RkNTkyYzRlN2E5M2ZmM2NiOGE4YjBlOGNiXzUtMS0xLTEtOTc2Ng_bd3e1e7d-cffb-45e6-9a47-af196b48c8a2">39,359</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i76d9c47628c147369b1a84918e870f8d_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTphMjQxNWNkZDU5MmM0ZTdhOTNmZjNjYjhhOGIwZThjYi90YWJsZXJhbmdlOmEyNDE1Y2RkNTkyYzRlN2E5M2ZmM2NiOGE4YjBlOGNiXzUtMy0xLTEtOTc2OQ_72f93d34-65eb-4d8f-8406-b89572f9c5dd">37,810</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib5b7be714d56483bab2fd4aec159f370_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTphMjQxNWNkZDU5MmM0ZTdhOTNmZjNjYjhhOGIwZThjYi90YWJsZXJhbmdlOmEyNDE1Y2RkNTkyYzRlN2E5M2ZmM2NiOGE4YjBlOGNiXzUtNS0xLTEtOTc3MQ_21d50077-3973-43d1-9bb3-16375d363282">17,008</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company adopted ASC Topic 606 effective January 1, 2018, using the modified retrospective method. The impact on the hemophilia A Pfizer agreement was to increase the amount of the recognition of the up-front payment by approximately $<ix:nonFraction unitRef="usd" contextRef="i0a295f36997b4eaf8c2fed03755d5526_I20180101" decimals="-5" sign="-" name="us-gaap:DeferredRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzg3OTYwOTMxMzM4ODE_58071a9f-3cfa-43bc-8087-444c61174905"><ix:nonFraction unitRef="usd" contextRef="i252ea1e80afe41d99972b07af7af8a3c_I20180101" decimals="-5" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzg3OTYwOTMxMzM4ODE_c1861cb3-12a0-4fc0-aa08-d8395a176fb5">5.2</ix:nonFraction></ix:nonFraction> million. This amount resulted in a decrease to the opening balance of accumulated deficit and a decrease to deferred revenues, respectively.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the first quarter of 2019, the Company updated its estimated project cost and related revenues under this program. This adjustment was a direct result of the increase in project scope during the first quarter of 2019 and the corresponding costs, which resulted in a decrease in the measure of proportional performance. In December 2019, the Company updated its estimated project cost and related revenues upon transfer of the IND for SB-525 to Pfizer. This adjustment was a direct result of the decrease in project scope during the fourth quarter of 2019 and the corresponding costs, which resulted in an increase in the measure of proportional performance. During the year ended December&#160;31, 2019, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i1ea749f7283a4e3fbab4d679c510b03b_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzQ5NDc4MDIzNzgzMDU_a4a63c57-a40e-4f80-8031-dba559fd269d">15.7</ix:nonFraction>&#160;million in revenues related to the Pfizer SB-525 agreement, which included approximately $<ix:nonFraction unitRef="usd" contextRef="id9888cd53fcb4fb4984e5cdbd778c03e_D20191001-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzE0ODQzNDA3MDcxMzI2_9744cc83-d3cc-4189-b5c4-04724118c686">8.7</ix:nonFraction> million acceleration in revenues recorded in the three months ended December 31, 2019 related to the updated estimated project cost, offset by approximately $<ix:nonFraction unitRef="usd" contextRef="icbb6596bfa944145ba083c1d73a1a730_D20190101-20190331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzQ5NDc4MDIzNzgyOTA_33b769ef-5e51-4195-8a6f-43d361284770">3.0</ix:nonFraction>&#160;million reduction in revenues recorded in the three months ended March&#160;31, 2019 related to the updated estimated project cost.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">85</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><ix:continuation id="if3a69d42e38d435b8e300950cf083da4" continuedAt="i2e1a4f93318c43e38118644a378c5410"><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">C9ORF72 Research Collaboration and License Agreement</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2017, the Company entered into a separate exclusive, global collaboration and license agreement with Pfizer for the development and commercialization of potential gene therapy products that use ZFP transcription factors (&#8220;TFs&#8221;) to treat amyotrophic lateral sclerosis (&#8220;ALS&#8221;) and frontotemporal lobar degeneration (&#8220;FTLD&#8221;) linked to mutations of the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">C9ORF72</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene. Pursuant to this agreement, the Company agreed to work with Pfizer on a research program to identify, characterize and preclinically develop ZFP-TFs that bind to and specifically reduce expression of the mutant form of the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">C9ORF72</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company received a $<ix:nonFraction unitRef="usd" contextRef="i5b20df771908439ba01919ecb4994be8_D20171201-20171231" decimals="-6" format="ixt:numdotdecimal" name="sgmo:MilestonePaymentsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzEyODc4_49e0f507-2cc6-4161-8951-33af6ae45f68">12.0</ix:nonFraction>&#160;million upfront payment from Pfizer and is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="ie5bbca9d2dbf4f0e989cbeebb1a8e942_D20171201-20171231" decimals="INF" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzEyOTQy_0cd6c361-26a3-462c-b6d1-e6b1b347061a">60.0</ix:nonFraction>&#160;million in development milestone payments from Pfizer contingent on the achievement of specified preclinical development, clinical development and first commercial sale milestones, and up to $<ix:nonFraction unitRef="usd" contextRef="i784a445513064edf8cf105a58b0207fe_D20171201-20171231" decimals="INF" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzEzMTI4_2952de68-9c12-4b6b-95f1-49e3b2c73230">90.0</ix:nonFraction>&#160;million commercial milestone payments if annual worldwide net sales of the licensed products reach specified levels. In addition, Pfizer will pay the Company royalties based on an escalating tiered, mid- to high-single digit percentage of the annual worldwide net sales of the licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third party intellectual property. Each party will be responsible for the cost of its performance of the research program. Pfizer will be operationally and financially responsible for subsequent development, manufacturing and commercialization of the licensed products.</span></div><div style="text-indent:36pt;margin-top:6pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company assessed the agreement with Pfizer in accordance with ASC Topic 606 and concluded that Pfizer is a customer. The Company concluded the total transaction price under this agreement is $<ix:nonFraction unitRef="usd" contextRef="i669f42753a6d4d3b8f142135705a640e_D20171201-20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzEzOTIz_897706d7-be73-446c-9e98-fa230de0d500">12.0</ix:nonFraction>&#160;million, which represents the upfront fee. None of the clinical or regulatory milestones have been included in the transaction price, as all milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subject to the terms of this agreement, the Company granted Pfizer an exclusive, royalty-bearing, worldwide license under the Company&#8217;s relevant patents and know-how to develop, manufacture and commercialize gene therapy products that use resulting ZFP-TFs that satisfy pre-agreed criteria. During a specified period, neither the Company nor Pfizer will be permitted to research, develop, manufacture or commercialize outside of the collaboration any ZFPs that specifically bind to the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">C9ORF7</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2 gene.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unless earlier terminated, the agreement has a term that continues on a per licensed product and per country basis until the later of (i)&#160;the expiration of patent claims that cover the licensed product in a country, (ii)&#160;the expiration of regulatory exclusivity for a licensed product in a country, and (iii)&#160;<ix:nonNumeric contextRef="i954ad6bfa1174ad180a78ff9de20535e_D20190101-20191231" format="ixt-sec:duryear" name="sgmo:AgreementTerminationTerm" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzc2OTY1ODE1MDQ3ODI_9fe24986-5388-46b5-9448-e19683f11b84">15</ix:nonNumeric> years after the first commercial sale of a licensed product in a major market country. Pfizer also has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. The agreement will also terminate if the Company is unable to identify any lead candidates for development within a specified period of time or if Pfizer elects not to advance a lead candidate beyond a certain development milestone within a specified period of time. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize licensed products under the agreement will automatically terminate. Upon termination by the Company for cause or by Pfizer without cause for any licensed product or licensed products in any country or countries, the Company will have the right to negotiate with Pfizer to obtain a non-exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize the licensed product or licensed products in the terminated country or countries.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Following termination by the Company for Pfizer&#8217;s material breach, Pfizer will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">C9ORF72 </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">gene for a period of time. Following termination by Pfizer for the Company&#8217;s material breach, the Company will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">C9ORF72</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene for a period of time.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has identified the performance obligation within this agreement as a license to the technology and on-going research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Pfizer apart from the services to be performed by the Company pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the on-going services over the estimated period the Company will perform research services. The estimation of progress towards the satisfaction of its performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. As of December&#160;31, 2019 and 2018, the Company had deferred revenue of $<ix:nonFraction unitRef="usd" contextRef="i79f178df8ea344e18c904ab658ab8f74_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzQ5NDc4MDI0MDIwODY_1571f3b1-be01-40f3-89d7-19402489c511">8.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i6c762905a0724124a285c0f906b72d49_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzQ5NDc4MDI0MDIwNjQ_d247f5c3-b393-47b9-925f-7d16d88093b1">9.8</ix:nonFraction>&#160;million, respectively, related to this agreement.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">86</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><ix:continuation id="i2e1a4f93318c43e38118644a378c5410" continuedAt="ib486cf7d6a7b4652949531506f34bba3"><ix:nonNumeric contextRef="i954ad6bfa1174ad180a78ff9de20535e_D20190101-20191231" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzc2OTY1ODE0ODMyMTM_2e0953d8-539b-43ee-956a-4f4624cbbe87" escape="true"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues recognized under the agreement were as follows (in thousands):</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:58.557%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.756%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.386%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.756%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.386%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.759%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Recognition of upfront fee related to Pfizer </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">C9ORF72</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> agreement</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1e9a9a3d68204a2f8ed5bcfe24fa0f3e_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTo0NzUwNTkyNzBmYzk0N2M3OGNmMTcxZTcwNDYwYmZmZS90YWJsZXJhbmdlOjQ3NTA1OTI3MGZjOTQ3Yzc4Y2YxNzFlNzA0NjBiZmZlXzMtMS0xLTEtNTQ1Nw_99fb3ca1-c751-44bf-8cb6-f58c090dc6b9">1,827</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6c7f53a3724d4a1ea2ce16319a2ee764_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTo0NzUwNTkyNzBmYzk0N2M3OGNmMTcxZTcwNDYwYmZmZS90YWJsZXJhbmdlOjQ3NTA1OTI3MGZjOTQ3Yzc4Y2YxNzFlNzA0NjBiZmZlXzMtMy0xLTEtNTQ1Mw_7eec5af8-e52e-429e-8b4f-d8965fc72a45">2,188</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46960a0dc45d40db8392d2fe6db2d9e9_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTo0NzUwNTkyNzBmYzk0N2M3OGNmMTcxZTcwNDYwYmZmZS90YWJsZXJhbmdlOjQ3NTA1OTI3MGZjOTQ3Yzc4Y2YxNzFlNzA0NjBiZmZlXzMtNS0xLTEtMTM5OTU_8b551e63-0a55-4f08-b0c2-46cbed43a895">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div></ix:nonNumeric><div style="text-indent:18pt;margin-top:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Sanofi</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2014, the Company entered into an exclusive worldwide collaboration and license agreement with Bioverativ Inc., (now Sanofi Genzyme, a global business unit of Sanofi S.A. (&#8220;Sanofi&#8221;)), to develop therapeutics for hemoglobinopathies, focused on beta thalassemia and sickle cell disease (&#8220;SCD&#8221;). The agreement was originally signed with Biogen MA Inc., who subsequently assigned it to Bioverativ Inc., which was later acquired by Sanofi. Under the agreement, the Company is jointly conducting <ix:nonFraction unitRef="program" contextRef="i1c5f6e7f39144671adf58c072211193c_D20140101-20140131" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:NumberOfResearchProgram" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzE4MjU1_c2277b96-d795-4a93-8911-5b49060c9258">two</ix:nonFraction> research programs: the beta thalassemia program and the SCD program. In the beta thalassemia program, the Company is responsible for all discovery, research and development activities through the first human clinical trial. In the SCD program, both parties are responsible for research and development activities through the submission of an IND application for ZFP therapeutics intended to treat SCD.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under both programs, Sanofi is responsible for subsequent worldwide clinical development, manufacturing and commercialization of licensed products developed under the agreement. At the end of the specified research terms for each program or under certain specified circumstances, Sanofi has the right to step in and take over any of the Company&#8217;s remaining activities. Furthermore, the Company has an option to co-promote in the U.S. any licensed products to treat beta thalassemia and SCD developed under the agreement, and Sanofi will compensate the Company for such co-promotion activities. Subject to the terms of the agreement, the Company has granted Sanofi an exclusive, royalty-bearing license, with the right to grant sublicenses, to use certain ZFP and other technology controlled by the Company for the purpose of researching, developing, manufacturing and commercializing licensed products developed under the agreement. The Company also granted Sanofi a non-exclusive worldwide, royalty-free fully paid license with the right to grant sublicenses, under the Company&#8217;s interest in certain other intellectual property developed pursuant to the agreement. During the term of the agreement, the Company is not permitted to research, develop, manufacture or commercialize, outside of the agreement, certain gene therapy products that target genes relevant to the licensed products.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the agreement, the Company received an upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="i1c5f6e7f39144671adf58c072211193c_D20140101-20140131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzIwMTc5_9d3f5bf6-cc79-47b1-a5a3-42fe887a8151">20.0</ix:nonFraction>&#160;million and is eligible to receive development and sales milestone payments upon the achievement of specified regulatory, clinical development and sales milestones. In addition, the Company will also be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="ide4c76d2770741e89547b697a3e8b894_D20140101-20140131" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzIwNDAz_001d9b50-dc7d-48fa-8616-8b82dd30c94c">115.8</ix:nonFraction>&#160;million in payments upon the achievement of specified clinical development and regulatory milestones, as well as up to $<ix:nonFraction unitRef="usd" contextRef="ifcd9eaedbbb14396a42bb76c734bf9f5_D20140101-20140131" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzIwNTE3_7150f758-a473-47a1-ac89-c14175b30c87">160.5</ix:nonFraction>&#160;million in payments upon the achievement of specified sales milestones. The total amount of potential regulatory, clinical development, and sales milestone payments, assuming the achievement of all specified milestones in the agreement, is up to $<ix:nonFraction unitRef="usd" contextRef="icb1c764229f147c2a7d82f2bb4a2592a_D20140101-20140131" decimals="INF" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzIwNzU4_056ddd75-f0ab-4c6c-8847-47861146ddda">276.3</ix:nonFraction>&#160;million. In addition, the Company will receive royalty payments for each licensed product that are a tiered double-digit percentage of annual net sales of each product. Sanofi reimburses Sangamo for agreed upon costs incurred in connection with research and development activities conducted by Sangamo. To date, a $<ix:nonFraction unitRef="usd" contextRef="i6b38594263d44b798c13984fcfd972f8_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="sgmo:MilestonePaymentsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzg3OTYwOTMxMTcxMTE_98f21333-5f09-492a-b0da-87b9409faf0d">6.0</ix:nonFraction>&#160;million milestone has been achieved related to ST-400 for beta thalassemia and another $<ix:nonFraction unitRef="usd" contextRef="ia2073bd7907645caa45aa97ed6850de4_I20191231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestoneRevenueReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzU0OTc1NTgyMjI1MTY_2fb2af08-0c4b-470b-97e1-34a71d6b5551">7.5</ix:nonFraction>&#160;million milestone has been achieved related to SCD, however <ix:nonFraction unitRef="product" contextRef="i468bde9877fb45c2847c91221ba681bc_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzIxMTE0_0993b003-3df9-42a8-a8fd-9943f3dfd2e9">no</ix:nonFraction> products have been approved and therefore <ix:nonFraction unitRef="milestone" contextRef="i8c872fa7b5024839a68c8f629085727c_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzIxMTU5_6c2f2b2f-121c-480b-899f-024c1823cb07">no</ix:nonFraction> royalty fees have been earned under the Sanofi agreement.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The agreement may be terminated by (i)&#160;the Company or Sanofi for the uncured material breach of the other party, (ii)&#160;the Company or Sanofi for the bankruptcy or other insolvency proceeding of the other party; (iii)&#160;Sanofi, upon <ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" format="ixt-sec:durday" name="sgmo:AgreementTerminationTerm" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzExNTQ0ODcyMjAzMzYy_91ad9bf8-a028-45f6-a008-b9f0eb015c57">180</ix:nonNumeric> days&#8217; advance written notice to the Company and (iv)&#160;Sanofi, for certain safety reasons upon written notice to, and after consultation with, the Company. As a result, actual future milestone payments could be lower than the amounts stated above.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">All contingent payments under the agreement, when earned, will be non-refundable and non-creditable. The transaction price as of December 31, 2019 of $<ix:nonFraction unitRef="usd" contextRef="i8c872fa7b5024839a68c8f629085727c_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzg3OTYwOTMxMzQ1MTA_dbad5923-72f9-43ad-9546-6c45f87f162e">89.2</ix:nonFraction>&#160;million includes the upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="i8c872fa7b5024839a68c8f629085727c_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzIxODgz_0ef3d919-0a19-4cde-aef8-fc8f7338e783">20.0</ix:nonFraction>&#160;million, milestones of $<ix:nonFraction unitRef="usd" contextRef="id798c385c8724e4b930793259339b22a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestoneRevenueReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzg3OTYwOTMxMzQ0MzU_6be9dfcc-0fa7-48ab-80cf-b2e55f97eb6e">13.5</ix:nonFraction>&#160;million achieved to date and $<ix:nonFraction unitRef="usd" contextRef="i8c872fa7b5024839a68c8f629085727c_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzIxODkw_de6fe6d0-c605-4a97-8278-85fcc9037a7e">55.7</ix:nonFraction>&#160;million of estimated research service fees for identified research projects over the estimated performance period, as all unachieved milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur. None of the clinical or regulatory milestones have been included in the transaction price.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company assessed the agreement with Sanofi in accordance with ASC Topic 606 and concluded that Sanofi is a customer. The Company has identified the performance obligations within this arrangement as a license to the technology and on-going research services activities. The Company concluded that the license is not discrete as it does not have stand-alone value to Sanofi apart from the research services to be performed pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the ongoing services through 2022, the </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">87</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><ix:continuation id="ib486cf7d6a7b4652949531506f34bba3" continuedAt="i692ed886783c4502b3cd52c9ac3f7ebb"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">estimated period the Company will perform research services. The estimate of progress towards the satisfaction of performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. Revenue from the reimbursable costs related to the integrated service deliverable is recognized as the research services are performed. Related costs and expenses under these arrangements have historically approximated the revenues recognized. As of December&#160;31, 2019 and 2018, the Company had deferred revenue of $<ix:nonFraction unitRef="usd" contextRef="i1ca1d25b473647beac3e5c4cee84dd0f_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzU0OTc1NTgyMjU3NTM_479b9c01-1c9b-4cd6-a523-32f22f0ce0ea">1.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i93e6aa3bc6514e649306cb264521204b_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzU0OTc1NTgyMjU3MzI_60ae53a9-e61a-45b2-ba3e-7de261dc9bb1">4.6</ix:nonFraction>&#160;million, respectively, related to this agreement.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2019, the Company achieved a $<ix:nonFraction unitRef="usd" contextRef="i92f62c13c94a433aa1ad8a4a8220be8f_I20190831" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestoneRevenueReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzc2OTY1ODE0ODk0MTE_d81f87a0-d4e0-4c03-a7af-4888c2c29f14">6.0</ix:nonFraction> million milestone with Sanofi upon dosing of the third subject in the ST-400 beta thalassemia Phase 1 clinical trial. The Company recognized approximately $<ix:nonFraction unitRef="usd" contextRef="id06c1dce0e884cdcba296deaf34a622e_D20190801-20190831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzg3OTYwOTMxMzQwMTg_0932f9d3-da36-4059-a76a-5c8de8a36e2b">5.7</ix:nonFraction>&#160;million attributed to this milestone as revenue during the year ended December 31, 2019.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the Company achieved a $<ix:nonFraction unitRef="usd" contextRef="ia2073bd7907645caa45aa97ed6850de4_I20191231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestoneRevenueReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzc2OTY1ODE0ODkzOTI_b9377ae2-8073-475c-91a1-b1467fc20a6d">7.5</ix:nonFraction> million milestone with Sanofi upon dosing of the first subject in the SCD Phase 1 clinical trial. The Company recognized approximately $<ix:nonFraction unitRef="usd" contextRef="i8c872fa7b5024839a68c8f629085727c_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzg3OTYwOTMxMzQwODQ_27540115-482a-4dfe-8937-10ad271e873d">7.1</ix:nonFraction>&#160;million attributed to this milestone as revenue during the year ended December 31, 2019.</span></div><ix:nonNumeric contextRef="i468bde9877fb45c2847c91221ba681bc_D20190101-20191231" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzMxMzM3_35ef29ef-6c56-4894-b71f-f7fcdcb1855a" escape="true"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues recognized under the agreement were as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:58.322%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.740%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue related to Sanofi agreement:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Recognition of upfront fee</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i39eb352d7a3a4602a414826990f703bc_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTo2N2I0NmI0ZjU0MTk0M2RiYmNiMTMyNmUwOWEzZmE3Yy90YWJsZXJhbmdlOjY3YjQ2YjRmNTQxOTQzZGJiY2IxMzI2ZTA5YTNmYTdjXzMtMS0xLTEtMA_106f255d-2edf-48f1-95a5-91141d70f1ba">3,494</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5c9ff652355349cab75acdd86216b11a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTo2N2I0NmI0ZjU0MTk0M2RiYmNiMTMyNmUwOWEzZmE3Yy90YWJsZXJhbmdlOjY3YjQ2YjRmNTQxOTQzZGJiY2IxMzI2ZTA5YTNmYTdjXzMtMy0xLTEtMA_ed6faedc-2548-4134-8738-3012b1e8ffd9">4,013</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1836a0ed76fa4e068cc55bae1f1659ca_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTo2N2I0NmI0ZjU0MTk0M2RiYmNiMTMyNmUwOWEzZmE3Yy90YWJsZXJhbmdlOjY3YjQ2YjRmNTQxOTQzZGJiY2IxMzI2ZTA5YTNmYTdjXzMtNS0xLTEtMA_ca20105e-dc8e-48c9-8525-d4ae1dcd1f06">1,769</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0bdd6ca51cf249bc84de380a836fb539_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTo2N2I0NmI0ZjU0MTk0M2RiYmNiMTMyNmUwOWEzZmE3Yy90YWJsZXJhbmdlOjY3YjQ2YjRmNTQxOTQzZGJiY2IxMzI2ZTA5YTNmYTdjXzQtMS0xLTEtMA_ac51cd8b-1381-4643-8de1-78e5bdf609b6">6,367</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibab98dee0c264ff0a13f3976dfdd1ed3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTo2N2I0NmI0ZjU0MTk0M2RiYmNiMTMyNmUwOWEzZmE3Yy90YWJsZXJhbmdlOjY3YjQ2YjRmNTQxOTQzZGJiY2IxMzI2ZTA5YTNmYTdjXzQtMy0xLTEtMA_e8c7c1b9-bf34-40fb-a9f2-3e6a249cbe13">9,503</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c1fc611498b4ec7ab651f582d24bb0b_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTo2N2I0NmI0ZjU0MTk0M2RiYmNiMTMyNmUwOWEzZmE3Yy90YWJsZXJhbmdlOjY3YjQ2YjRmNTQxOTQzZGJiY2IxMzI2ZTA5YTNmYTdjXzQtNS0xLTEtMA_ff4d43e8-657f-4bc3-9c3d-b7ed079954b9">10,489</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Milestone achievement</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iab2ce2c2494147e0a8a6070d64cfe4c8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTo2N2I0NmI0ZjU0MTk0M2RiYmNiMTMyNmUwOWEzZmE3Yy90YWJsZXJhbmdlOjY3YjQ2YjRmNTQxOTQzZGJiY2IxMzI2ZTA5YTNmYTdjXzUtMS0xLTEtOTgwMw_1be66698-25ac-4868-9922-fd924dfb605f">12,819</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c8c31caf97141fd95d9194c142029af_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTo2N2I0NmI0ZjU0MTk0M2RiYmNiMTMyNmUwOWEzZmE3Yy90YWJsZXJhbmdlOjY3YjQ2YjRmNTQxOTQzZGJiY2IxMzI2ZTA5YTNmYTdjXzUtMy0xLTEtOTgwNg_a4dbbca3-f4eb-4155-8c3b-2251b64100e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icca18901cecd47eb8ace5d534e3446cc_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTo2N2I0NmI0ZjU0MTk0M2RiYmNiMTMyNmUwOWEzZmE3Yy90YWJsZXJhbmdlOjY3YjQ2YjRmNTQxOTQzZGJiY2IxMzI2ZTA5YTNmYTdjXzUtNS0xLTEtOTgxMA_74520482-8657-4777-ac52-f927e9673da9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i468bde9877fb45c2847c91221ba681bc_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTo2N2I0NmI0ZjU0MTk0M2RiYmNiMTMyNmUwOWEzZmE3Yy90YWJsZXJhbmdlOjY3YjQ2YjRmNTQxOTQzZGJiY2IxMzI2ZTA5YTNmYTdjXzUtMS0xLTEtMA_04045d36-dadc-452a-8689-f14cc599c510">22,680</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9bf7f5b8498c4b08a82bb59829d36e28_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTo2N2I0NmI0ZjU0MTk0M2RiYmNiMTMyNmUwOWEzZmE3Yy90YWJsZXJhbmdlOjY3YjQ2YjRmNTQxOTQzZGJiY2IxMzI2ZTA5YTNmYTdjXzUtMy0xLTEtMA_f194691c-f8c1-4c20-ab2c-9ac425deea89">13,516</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7420753e3bf04bfea9bc58e19fe42eea_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTo2N2I0NmI0ZjU0MTk0M2RiYmNiMTMyNmUwOWEzZmE3Yy90YWJsZXJhbmdlOjY3YjQ2YjRmNTQxOTQzZGJiY2IxMzI2ZTA5YTNmYTdjXzUtNS0xLTEtMA_0a5a9420-7a9b-4082-9662-152e50acbd41">12,258</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:27pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company adopted ASC Topic 606 effective January 1, 2018, using the modified retrospective method. The impact on the Sanofi agreement was to reduce the amount of the recognition of the up-front payment by approximately $<ix:nonFraction unitRef="usd" contextRef="i975e5690b7e44643ac9b6ff7c837d1d5_I20180101" decimals="-5" sign="-" name="us-gaap:DeferredRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzg3OTYwOTMxMzM4ODc_10845203-0394-4de1-ab09-5df06b7fb1b5"><ix:nonFraction unitRef="usd" contextRef="idfdae914eb9f4568924b2c36819385c0_I20180101" decimals="-5" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzg3OTYwOTMxMzM4ODc_4c1a6d62-fb6a-409c-b4b0-e2201a6ead1d">4.1</ix:nonFraction></ix:nonFraction> million. This amount resulted in an increase to the opening balance of accumulated deficit and an increase to deferred revenues.</span></div><div style="text-indent:27pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">California Institute for Regenerative Medicine</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2018, the California Institute for Regenerative Medicine (&#8220;CIRM&#8221;) granted a Strategic Partnership Award for $<ix:nonFraction unitRef="usd" contextRef="i80b254e375704b6cbd33bf07e5d5a03d_D20180501-20180531" decimals="-5" format="ixt:numdotdecimal" name="sgmo:GrantFundingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzIzNzM2_aa9c02da-5f0a-441f-ad33-cc8aed2000d5">8.0</ix:nonFraction>&#160;million to fund the clinical studies of a potentially curative ZFP therapeutic for the treatment of beta thalassemia based on the application of Sangamo&#8217;s ZFN genome editing technology. The grant exists through December&#160;31, 2022 and provides matching funds to support the evaluate ST-400, a gene-edited cell therapy candidate for people with transfusion-dependent beta&#160;thalassemia. As of December&#160;31, 2019, the Company had received $<ix:nonFraction unitRef="usd" contextRef="i0b157638f47c4c3b8ec4455978598450_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzU0OTc1NTgyMjU5MDk_22857852-b53e-4b7f-ad6d-c60b62c4911b">5.2</ix:nonFraction>&#160;million under the award.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the CIRM grants, the Company is obligated to pay royalties and licensing fees based on a low single digit royalty percentage on net sales of CIRM-funded product candidates or CIRM-funded technology. The Company has the option to decline any and all amounts awarded by CIRM and as an alternative to revenue sharing, the Company has the option to convert the award to a loan. No such election has been made as of the date of the issuance of these financial statements. In the event that the Company terminates a CIRM-funded clinical trial, it will be obligated to repay the remaining CIRM funds on hand. As of December&#160;31, 2019 and 2018, $<ix:nonFraction unitRef="usd" contextRef="i37cb993a72c14f14a87486e3f9d110bb_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzU0OTc1NTgyMjcxOTU_6e21272a-8d28-4247-b2d6-e8e26d5b8a8c">5.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ide489651fbb64d8cb62d9ee459e221fc_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzU0OTc1NTgyMjcxNjg_06ea4fde-f2f1-4a64-8633-a27c90897475">1.8</ix:nonFraction>&#160;million, respectively, including accrued interest, related to this award is recorded as a loan in other long-term liabilities on the Consolidated Balance Sheets.</span></div><div style="text-indent:27pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Amended Collaboration and License Agreement with Takeda</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2012, the Company entered into a collaboration and license agreement with Shire International GmbH, a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;), to research, develop and commercialize a ZFP therapeutic for treating Huntington&#8217;s disease. The Company received an upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="ia988894eec924d3699114435116dcbb8_D20120101-20120131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI1Mjkz_901f08d4-7105-4c1f-afed-b218542494a8">13.0</ix:nonFraction>&#160;million. In 2014, Sangamo recognized a $<ix:nonFraction unitRef="usd" contextRef="i603d866010f94461ba687f9d9fc9fe07_D20140101-20141231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI1MzI3_01d06464-56a7-495a-9c87-600825cb39c3">1.0</ix:nonFraction>&#160;million milestone payment related to the hemophilia program. Takeda does not have any milestone payment obligations, but is required to pay single digit percentage royalties to the Company, up to a specified maximum cap, on the commercial sales of therapeutic products for Huntington&#8217;s disease. The Company is required to pay single digit percentage royalties to Takeda, up to a specified maximum cap, on commercial sales of therapeutic products from programs returned under the original agreement (which include blood clotting Factors VIII and IX) that use two zinc fingers.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the agreement, the Company granted Takeda an exclusive, world-wide, royalty-bearing license, with the right to grant sublicenses, to use the Company&#8217;s ZFP technology for the purpose of developing and commercializing human therapeutic and diagnostic products for the Huntingtin gene (&#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">HTT</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene&#8221;). During the term of the agreement, the Company is not permitted to research, develop or commercialize, outside of the agreement, certain products that target the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">HTT</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene. The agreement may be terminated by (i)&#160;the Company or Takeda, in whole or in part, for the uncured material breach of the other </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">88</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><ix:continuation id="i692ed886783c4502b3cd52c9ac3f7ebb"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">party, (ii)&#160;the Company or Takeda for the bankruptcy or other insolvency proceeding of the other party and (iii)&#160;Takeda, in its entirety, effective upon at least <ix:nonNumeric contextRef="i0396d61761914d09b41700c5324f9ab2_D20190101-20191231" format="ixt-sec:durday" name="sgmo:AgreementTerminationTerm" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzExNTQ0ODcyMjAzMzQz_0d6b0641-2576-48b8-88e4-5d837f4b3010">90</ix:nonNumeric> days&#8217; advance written notice.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company assessed the agreement with Takeda in accordance with ASC Topic 606 and concluded that Takeda is a customer. The Company has concluded that the license is not a separate unit of accounting as it does not have stand-alone value to Takeda apart from the research services to be performed pursuant to the Takeda agreement. The Company satisfied the deliverables and research services responsibilities within the amended arrangement which were completed in 2017. As a result, the Company recognized the remaining $<ix:nonFraction unitRef="usd" contextRef="i8ea0635e2f754a1a98f8b6ff31ee597e_I20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI3MjA3_61687f6f-7b49-4247-bb84-87890e605619">2.3</ix:nonFraction>&#160;million of deferred revenue from the upfront payment during the year ended December 31, 2017.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues recognized under the Takeda agreement for the years ended December&#160;31, 2019, 2018 and 2017, were $<ix:nonFraction unitRef="usd" contextRef="i225c2ca24fb245b1aef427d88cab0b42_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI3MzY3_4f09c55a-b2c9-41e9-8a7c-5a45d75ae09d">0.0</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="if423ade1135f4a90ba7c01bd4622b719_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI3Mzcx_7f275523-0d59-4310-b8ee-14aa4aa355dd">0.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i60cee58107b34ab3abb80c1536bbbb25_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI3Mzc4_3c6254c9-20fe-4ce3-a81b-55018e5f5312">2.4</ix:nonFraction>&#160;million, respectively.</span></div><div style="text-indent:27pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Agreement with Sigma-Aldrich Corporation</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2007, Sangamo entered into a license agreement with Sigma-Aldrich Corporation ("Sigma") to provide Sigma with access to Sangamo&#8217;s proprietary ZFP technology and the exclusive right to use the technology to develop and commercialize research reagent products and services in the research field, excluding certain agricultural research uses that Sangamo previously licensed to Dow AgroSciences LLC ("DAS"), a wholly-owned subsidiary of Dow Chemical Company. Sangamo developed laboratory research reagents using its ZFP technology over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI3OTg0_c09101db-17d8-4575-842f-cc8f133a684e">three</span>-year research services period. Sangamo has since transferred the ZFP manufacturing technology to Sigma.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2009, Sangamo expanded its license agreement with Sigma. In addition to the original terms of the license agreement, Sigma received exclusive rights to develop and distribute ZFP-modified cell lines for commercial production of protein pharmaceuticals and certain ZFP-engineered transgenic animals for commercial applications. Under the terms of the agreement, Sigma made an upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="ic7e8b05b2b84429ea591ae9027f2f01c_I20091031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI4NTAx_4bb7baa3-166b-4958-a3d4-9bfcb2efb32a">20.0</ix:nonFraction>&#160;million consisting of a $<ix:nonFraction unitRef="usd" contextRef="i19ed0c7322dc4072986f0f09203dc043_D20091001-20091031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI4NTIw_ccf2fb18-3e2f-4c0a-9a6a-c63362506811">4.9</ix:nonFraction>&#160;million purchase of <ix:nonFraction unitRef="shares" contextRef="i19ed0c7322dc4072986f0f09203dc043_D20091001-20091031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI4NTM1_68b661ce-4f1d-4d98-97ca-68e23c33567e">636,133</ix:nonFraction> shares of Sangamo common stock, valued at $<ix:nonFraction unitRef="usd" contextRef="i19ed0c7322dc4072986f0f09203dc043_D20091001-20091031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI4NTgw_94e4f027-804d-4c65-afcd-686a48c65b4e">4.9</ix:nonFraction>&#160;million, and a $<ix:nonFraction unitRef="usd" contextRef="i2d0454da729b48fc9e22bda7f76d2ad5_I20091031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI4NTkw_4f837c9f-745b-4031-a7d5-ed44a367957a">15.1</ix:nonFraction>&#160;million upfront license fee. Sangamo is also eligible to receive commercial license fees of $<ix:nonFraction unitRef="usd" contextRef="i278e40ede357423c89bdc1aee03bef48_D20091001-20091031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI4Njc3_d3f2705a-6ac0-4d3b-a06e-e8e30a6935cd">5.0</ix:nonFraction>&#160;million based upon a percentage of net sales and sublicensing revenue and thereafter a reduced royalty rate of <ix:nonFraction unitRef="number" contextRef="i19ed0c7322dc4072986f0f09203dc043_D20091001-20091031" decimals="3" name="sgmo:ReducedRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI4Nzgz_9514ee6b-1a3d-4e98-b274-f6b920d6e1e3">10.5</ix:nonFraction>% of net sales and sublicensing revenue. In addition, upon the achievement of certain cumulative commercial milestones, Sigma will make milestone payments to Sangamo up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i19ed0c7322dc4072986f0f09203dc043_D20091001-20091031" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI4OTcy_35083ec9-d248-4a25-a742-14b2bea847a8">25.0</ix:nonFraction>&#160;million. Sangamo does not have additional ongoing performance obligations under the agreement.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues recognized under the agreement with Sigma for the years ended December&#160;31, 2019, 2018 and 2017, were $<ix:nonFraction unitRef="usd" contextRef="i12a07f5e2768459da813de50c58f1b60_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI5MTUz_0d170848-f2c6-440e-ba3f-ca629ab43703">0.6</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i7e4cd48445e44370bba7e39d5af5ce52_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI5MTU2_3f882910-b2f9-4502-ab5c-9c5f33e645b8">0.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i3087b4ee5afa4f2dabb514f4cf15f16c_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI5MTYz_7333e704-163b-483e-8637-d73fcfe3b9ea">0.7</ix:nonFraction>&#160;million, respectively.</span></div><div style="text-indent:27pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Agreement with DAS</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2005, Sangamo entered into an exclusive commercial license with DAS, with an initial <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI5MzIy_7d482839-f2da-4dcc-a0a2-fb576c2847cb">three</span>-year research term. Under this agreement, Sangamo is providing DAS with access to its proprietary ZFP technology and the exclusive right to use the technology to modify the genomes or alter the nucleic acid or protein expression of plant cells, plants, or plant cell cultures. Sangamo has retained rights to use plants or plant-derived products to deliver ZFP-TFs or ZFNs into humans or animals for diagnostic, therapeutic or prophylactic purposes. In 2008, DAS exercised its option and obtained a commercial license to sell products incorporating or derived from plant cells generated using the Company&#8217;s ZFP technology. The exercise of the option triggered a one-time commercial license fee of $<ix:nonFraction unitRef="usd" contextRef="id1d7e675aff548549bda7f384c0b71fe_I20051231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:OneTimeLicenseFeeEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzMwMDIw_4385ca99-273f-4cb5-a6ab-0f1c64b86aed">6.0</ix:nonFraction>&#160;million, payment of the remaining $<ix:nonFraction unitRef="usd" contextRef="i6d6e0b311090479699df435b03b0f9b4_D20050101-20051231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzMwMDQ5_0a01e32a-8072-45ff-acf4-7d2e6eaaa1d4">2.3</ix:nonFraction>&#160;million of the previously agreed upon $<ix:nonFraction unitRef="usd" contextRef="if0b4d17d3d8d4ebc977872aa77c541e2_D20050101-20051231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzMwMDgy_228c37e2-f193-4b59-80a5-cbd97dfe450b">4.0</ix:nonFraction>&#160;million in research milestones, development and commercialization milestone payments for each product, and royalties on sales of products. Furthermore, DAS has the right to sublicense Sangamo&#8217;s ZFP technology to third parties for use in plant cells, plants, or plant cell cultures, and Sangamo will be entitled to <ix:nonFraction unitRef="number" contextRef="if0b4d17d3d8d4ebc977872aa77c541e2_D20050101-20051231" decimals="2" name="sgmo:PercentageOfRoyaltiesToBeReceivedFromSublicensing" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzMwMzkx_5e809f63-c8e6-4e77-9529-442ed0fbbdad">25</ix:nonFraction>% of any cash consideration received by DAS under such sublicenses. In December 2010, the Company amended its agreement with DAS to extend the period of reagent manufacturing services and research services through December&#160;31, 2012.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The agreement with DAS also provides for minimum sublicense fees each year due to Sangamo every October, provided the agreement is not terminated by DAS. Annual fees range from $<ix:nonFraction unitRef="usd" contextRef="i9b2070f38ef740d580ee67b0026687db_D20050101-20051231" decimals="INF" format="ixt:numdotdecimal" name="sgmo:AnnualFeesRelatedToAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzMwODAx_d73c76d0-ed55-44e3-a34a-8ce0e3271a19">0.3</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="i700b128806b74604a574c5a9d52798f4_D20050101-20051231" decimals="INF" format="ixt:numdotdecimal" name="sgmo:AnnualFeesRelatedToAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzMwODA3_734b491d-cafc-43b2-ab72-b1f353a40311">3.0</ix:nonFraction>&#160;million and total $<ix:nonFraction unitRef="usd" contextRef="if0b4d17d3d8d4ebc977872aa77c541e2_D20050101-20051231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:FeeDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzMwODIw_b8137729-c63b-4148-9687-615c5d29fb01">25.3</ix:nonFraction>&#160;million over <ix:nonNumeric contextRef="if0b4d17d3d8d4ebc977872aa77c541e2_D20050101-20051231" format="ixt-sec:duryear" name="sgmo:MinimumSublicenseAnnualFeesSpecificReckoningPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzMwODI4_f5e87216-e760-4329-9805-d6df453434a0">11</ix:nonNumeric> years unless terminated at any time by DAS. The Company has identified the performance obligation within this arrangement as a license to the technology. In the event of any termination of the agreement, all rights to use the Company&#8217;s ZFP technology will revert to Sangamo, and DAS will no longer be permitted to practice Sangamo&#8217;s ZFP technology or to develop or, except in limited circumstances, commercialize any products derived from the Company&#8217;s ZFP technology.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues under the agreement with DAS were $<ix:nonFraction unitRef="usd" contextRef="i5b28cb60703942d78f84fa70547f2d7a_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzMxMjg4_a78d1b19-03e0-4f9c-960e-ce3366edb41c">3.0</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i35e0ebbeae2040128ef7a7deb5f4d32f_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzMxMjky_6a11ea07-fe43-411b-b7e1-cebc89a69e6b">3.0</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="i6c13afb7fbda4eb8bf0c38bac4d2c1ff_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzMxMzAw_36fe978a-10c7-4a1e-96c7-959d4152c371">3.0</ix:nonFraction>&#160;million during 2019, 2018 and 2017, respectively.</span></div></ix:continuation><div id="i9a2bf9013aa44980b5a1f5846290b1a8_118"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">89</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzkxMjY_62bbfce0-b861-4f00-bcac-def5dbe44d99" continuedAt="i853a2d91d85543f4b3907fa40587682b" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 5 &#8211; ACQUISITION OF SANGAMO FRANCE</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On July&#160;20, 2018, Sangamo entered into various agreements with the goal of eventually acquiring <ix:nonFraction unitRef="number" contextRef="ia4b36a1c4d88462a8ee8d85f748c7b16_I20180720" decimals="INF" name="sgmo:BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzI2MA_3b4ed0cf-fc86-4c0d-90a2-98ad6bf95907">100</ix:nonFraction>% of Sangamo France&#8217;s share capital. The Company entered into the Sangamo France SPA with certain shareholders of Sangamo France, pursuant to which it acquired <ix:nonFraction unitRef="shares" contextRef="i38f5aec47ea84bc295354a823c8a5831_D20181001-20181001" decimals="INF" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzM3MQ_3dfcd88b-3d03-4ea9-9abe-c52055c980b6">13,519,036</ix:nonFraction> ordinary shares of Sangamo France (&#8220;Ordinary Shares&#8221;) as part of a block transaction that closed on October&#160;1, 2018 (the &#8220;Acquisition Date&#8221;). Additionally, the Company and Sangamo France entered into a Tender Offer Agreement pursuant to which Sangamo agreed to acquire <ix:nonFraction unitRef="shares" contextRef="i3a6b4067c84e43e1bdc883068436bfa7_D20181001-20181123" decimals="INF" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzQzOTgwNDY1MjI2MjE_c9c51035-fa07-47c4-94cd-fdea82e64df2">11,528,635</ix:nonFraction> Ordinary Shares for the same price per share as the Sangamo France SPA via a cash tender offer that closed on November&#160;23, 2018. Following the block transaction, cash tender offer, and other open market purchases of shares, the Company owned <ix:nonFraction unitRef="number" contextRef="i86361484bbe7475eadd2f54f1495c9bc_I20181231" decimals="3" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzQzOTgwNDY1MjI2Mjg_03a30acd-be35-4aaf-adc6-3fe8b4d7da34">98.2</ix:nonFraction>% of the Ordinary Shares as of December&#160;31, 2018 (or <ix:nonFraction unitRef="shares" contextRef="i5253724c8c7745708c6743fc72b1bd23_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzcxNDY4MjU2MDAwMTA_946bf9a1-29ab-40bb-91c7-38ca04864ace">25,047,671</ix:nonFraction> Ordinary Shares). In addition to the Sangamo France SPA and the tender offer agreement, the Company also entered into arrangements with the holders of approximately <ix:nonFraction unitRef="shares" contextRef="ia4b36a1c4d88462a8ee8d85f748c7b16_I20180720" decimals="-3" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzcxNDY4MjU2MDAwMjI_fe427243-c12a-4c11-ad93-4689e00b8bf5">477,000</ix:nonFraction> &#8220;free shares&#8221; of Sangamo France pursuant to which the Company has the right to purchase such shares from the holders (a call option) and such holders have the right to sell to the Company such shares from time to time through mid-2021 (a put option) (collectively the &#8220;Free Shares Options&#8221;). In June 2019, Sangamo France became a </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">soci&#233;t&#233; par actions simplifi&#233;e </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(&#8220;S.A.S.&#8221;) and was renamed from &#8220;TxCell&#8221; to &#8220;Sangamo Therapeutics France.&#8221; During 2019, the Company acquired approximately <ix:nonFraction unitRef="shares" contextRef="i9b97713bc2a74145a84bf16db6e1a142_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzcxNDY4MjU2MDAwMTk_d0cbed9e-d7b4-4271-8d2b-8f9048a78062">111,000</ix:nonFraction> vested free shares, increasing its ownership of the Ordinary Shares to <ix:nonFraction unitRef="number" contextRef="ie44e76842d7f4cde88a0228bac132b9e_I20191231" decimals="3" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzQzOTgwNDY1MzA2MzA_3a107ec7-8f53-4cab-9545-3c316261f8c4">98.7</ix:nonFraction>% as of December&#160;31, 2019.</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At the Acquisition Date, the fair value of the Free Shares Options was estimated to be a liability of $<ix:nonFraction unitRef="usd" contextRef="ifba2b3f6b5f24819b803f8b4290efdef_I20181231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzQzOTgwNDY1MzA4MjU_8ff56e19-6fa9-4ad0-bf1f-9f427123274a">0.2</ix:nonFraction>&#160;million. See Note 2 - </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair Value Measurement</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8211; </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Free Shares Asset/Liability</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> for information regarding the valuation method. The fair value of the Free Shares Options will vary based on future changes in the Company&#8217;s stock price during the option period. The fair value of the Free Shares Options was estimated to be an asset of $<ix:nonFraction unitRef="usd" contextRef="i2821462afaec43989ae5bb5640358bdb_I20191231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzYwNDczMTM5NzIxODY_665356ca-6053-44cf-b0ad-4165df808c5b">0.2</ix:nonFraction>&#160;million as of December&#160;31, 2019.</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The acquisition of Sangamo France was accounted for as a business combination in accordance with ASC Topic 805, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Business Combinations</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The operating results of Sangamo France after the Acquisition Date have been included in the Company&#8217;s Consolidated Statements of Operations. There were no purchase price adjustments subsequent to the acquisition.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There were <ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzQzOTgwNDY1MzIwNjA_22178f36-9a28-476a-aec1-36a18b78a3a1"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzQzOTgwNDY1MzIwNjA_dce684e2-f90d-4f8c-86bf-f9b48f0d75db">no</ix:nonFraction></ix:nonFraction> goodwill impairments during the years ended December&#160;31, 2019 or 2018 and, as noted below, substantially all of the non-controlling interest on the Acquisition Date was subsequently acquired by the Company and, accordingly, substantially all of the goodwill is allocated to the Company as of December&#160;31, 2019 and 2018.</span></div><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzkxMjM_3c4421c3-9f76-45cd-b10c-b598cf8ba991" escape="true"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the estimated consideration transferred and the fair value of the net assets acquired as of the Acquisition Date (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:85.262%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.738%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">October 1, 2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Consideration transferred</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i38f5aec47ea84bc295354a823c8a5831_D20181001-20181001" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90YWJsZTo2NjM3ZGQ0NWFiNDQ0ZTJkYjJlNDMxYjYwZmRjYTNiZS90YWJsZXJhbmdlOjY2MzdkZDQ1YWI0NDRlMmRiMmU0MzFiNjBmZGNhM2JlXzEtMS0xLTEtMA_cfa16cab-1fc3-4db4-a720-6e5c7508ab40">45,911</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of non-controlling interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib79220f5f92f424dbf1bd1416f1d62af_I20181001" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90YWJsZTo2NjM3ZGQ0NWFiNDQ0ZTJkYjJlNDMxYjYwZmRjYTNiZS90YWJsZXJhbmdlOjY2MzdkZDQ1YWI0NDRlMmRiMmU0MzFiNjBmZGNhM2JlXzItMS0xLTEtMA_09b01ef9-02f8-497c-86c5-95b46b22a2cd">35,829</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of Sangamo France</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib79220f5f92f424dbf1bd1416f1d62af_I20181001" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90YWJsZTo2NjM3ZGQ0NWFiNDQ0ZTJkYjJlNDMxYjYwZmRjYTNiZS90YWJsZXJhbmdlOjY2MzdkZDQ1YWI0NDRlMmRiMmU0MzFiNjBmZGNhM2JlXzMtMS0xLTEtMA_72b90eb1-0dc1-4723-92b7-643a91fd0e66">81,740</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib79220f5f92f424dbf1bd1416f1d62af_I20181001" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90YWJsZTo2NjM3ZGQ0NWFiNDQ0ZTJkYjJlNDMxYjYwZmRjYTNiZS90YWJsZXJhbmdlOjY2MzdkZDQ1YWI0NDRlMmRiMmU0MzFiNjBmZGNhM2JlXzUtMS0xLTEtMA_996b77a5-2203-4e09-b560-a4b125e6b33f">4,779</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib79220f5f92f424dbf1bd1416f1d62af_I20181001" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90YWJsZTo2NjM3ZGQ0NWFiNDQ0ZTJkYjJlNDMxYjYwZmRjYTNiZS90YWJsZXJhbmdlOjY2MzdkZDQ1YWI0NDRlMmRiMmU0MzFiNjBmZGNhM2JlXzYtMS0xLTEtMA_c4ec4880-21a1-4f02-947d-0e88ae6dfc25">2,427</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib79220f5f92f424dbf1bd1416f1d62af_I20181001" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90YWJsZTo2NjM3ZGQ0NWFiNDQ0ZTJkYjJlNDMxYjYwZmRjYTNiZS90YWJsZXJhbmdlOjY2MzdkZDQ1YWI0NDRlMmRiMmU0MzFiNjBmZGNhM2JlXzctMS0xLTEtMA_9483fe23-61f7-497b-9a76-df37b16c47c7">1,857</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">IPR&amp;D</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib79220f5f92f424dbf1bd1416f1d62af_I20181001" decimals="-3" format="ixt:numdotdecimal" name="sgmo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90YWJsZTo2NjM3ZGQ0NWFiNDQ0ZTJkYjJlNDMxYjYwZmRjYTNiZS90YWJsZXJhbmdlOjY2MzdkZDQ1YWI0NDRlMmRiMmU0MzFiNjBmZGNhM2JlXzgtMS0xLTEtMA_417270d6-dfbb-4e5c-9113-5881039d35b0">55,019</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib79220f5f92f424dbf1bd1416f1d62af_I20181001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90YWJsZTo2NjM3ZGQ0NWFiNDQ0ZTJkYjJlNDMxYjYwZmRjYTNiZS90YWJsZXJhbmdlOjY2MzdkZDQ1YWI0NDRlMmRiMmU0MzFiNjBmZGNhM2JlXzktMS0xLTEtMA_4495759a-05b6-4de9-b2ae-7f62e25348e4">155</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib79220f5f92f424dbf1bd1416f1d62af_I20181001" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90YWJsZTo2NjM3ZGQ0NWFiNDQ0ZTJkYjJlNDMxYjYwZmRjYTNiZS90YWJsZXJhbmdlOjY2MzdkZDQ1YWI0NDRlMmRiMmU0MzFiNjBmZGNhM2JlXzEwLTEtMS0xLTA_f73ff1a2-c7f3-4bda-8d39-b9e6ca711ddb">9,761</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assumed debt liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib79220f5f92f424dbf1bd1416f1d62af_I20181001" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90YWJsZTo2NjM3ZGQ0NWFiNDQ0ZTJkYjJlNDMxYjYwZmRjYTNiZS90YWJsZXJhbmdlOjY2MzdkZDQ1YWI0NDRlMmRiMmU0MzFiNjBmZGNhM2JlXzExLTEtMS0xLTA_500a9c57-b24f-40fb-88de-408172c554de">4,933</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liability, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib79220f5f92f424dbf1bd1416f1d62af_I20181001" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90YWJsZTo2NjM3ZGQ0NWFiNDQ0ZTJkYjJlNDMxYjYwZmRjYTNiZS90YWJsZXJhbmdlOjY2MzdkZDQ1YWI0NDRlMmRiMmU0MzFiNjBmZGNhM2JlXzEyLTEtMS0xLTA_93870dd4-1dd6-474a-aa5a-3b7a2f7714e6">6,798</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of net identifiable assets acquired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib79220f5f92f424dbf1bd1416f1d62af_I20181001" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90YWJsZTo2NjM3ZGQ0NWFiNDQ0ZTJkYjJlNDMxYjYwZmRjYTNiZS90YWJsZXJhbmdlOjY2MzdkZDQ1YWI0NDRlMmRiMmU0MzFiNjBmZGNhM2JlXzEzLTEtMS0xLTA_216590ca-86a6-42c4-82f5-e7f29166ee9c">42,745</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib79220f5f92f424dbf1bd1416f1d62af_I20181001" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90YWJsZTo2NjM3ZGQ0NWFiNDQ0ZTJkYjJlNDMxYjYwZmRjYTNiZS90YWJsZXJhbmdlOjY2MzdkZDQ1YWI0NDRlMmRiMmU0MzFiNjBmZGNhM2JlXzE1LTEtMS0xLTA_e7b469b1-26b9-45db-9c5e-165caf391468">38,995</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total fair value of net assets acquired</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib79220f5f92f424dbf1bd1416f1d62af_I20181001" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90YWJsZTo2NjM3ZGQ0NWFiNDQ0ZTJkYjJlNDMxYjYwZmRjYTNiZS90YWJsZXJhbmdlOjY2MzdkZDQ1YWI0NDRlMmRiMmU0MzFiNjBmZGNhM2JlXzE2LTEtMS0xLTA_cdcb3e1c-f9d0-4a2f-89ed-674434145b1f">81,740</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Non-controlling Interest</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the non-controlling interest at the Acquisition Date was based on the $<ix:nonFraction unitRef="usdPerShare" contextRef="ib79220f5f92f424dbf1bd1416f1d62af_I20181001" decimals="INF" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzU3NTY_32be82cf-8753-45bc-8274-38c8ea00a31f">2.99</ix:nonFraction> acquisition price per share for the <ix:nonFraction unitRef="shares" contextRef="ib79220f5f92f424dbf1bd1416f1d62af_I20181001" decimals="INF" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzU3OTU_a6b431c0-e469-46b4-8447-150074cbfb34">11,981,867</ix:nonFraction> Ordinary Shares that were not purchased by the Company in the block transaction on the Acquisition Date. Subsequent to the Acquisition Date and through December&#160;31, 2018, the Company acquired <ix:nonFraction unitRef="shares" contextRef="i3a6b4067c84e43e1bdc883068436bfa7_D20181001-20181123" decimals="INF" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzY0NTQ_c9c51035-fa07-47c4-94cd-fdea82e64df2">11,528,635</ix:nonFraction> Ordinary Shares, which when aggregated with the <ix:nonFraction unitRef="shares" contextRef="i68a40c6357a5417c8e40fc23122e7423_D20181001-20181001" decimals="INF" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzY1MTI_dd320b9f-c471-43b1-ad85-bee6236f61b5">13,519,036</ix:nonFraction> Ordinary Shares acquired at the Acquisition Date, resulted in the Company owning <ix:nonFraction unitRef="number" contextRef="i86361484bbe7475eadd2f54f1495c9bc_I20181231" decimals="3" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzY1OTY_03a30acd-be35-4aaf-adc6-3fe8b4d7da34">98.2</ix:nonFraction>% of all Ordinary Shares as of December&#160;31, 2018. During 2019, the Company acquired approximately <ix:nonFraction unitRef="shares" contextRef="i9b97713bc2a74145a84bf16db6e1a142_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzU0OTc1NTgxNjIwMjM_d0cbed9e-d7b4-4271-8d2b-8f9048a78062">111,000</ix:nonFraction> vested free </span></div></ix:nonNumeric><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">90</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><ix:continuation id="i853a2d91d85543f4b3907fa40587682b"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">shares for approximately $<ix:nonFraction unitRef="usd" contextRef="i9b97713bc2a74145a84bf16db6e1a142_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzU0OTc1NTgxNjIwMzc_34ac847c-28aa-434d-9f93-621f5554e5e5">0.3</ix:nonFraction>&#160;million of cash, pursuant to the exercise of the Free Shares Options, increasing its ownership of the Ordinary Shares to <ix:nonFraction unitRef="number" contextRef="ie44e76842d7f4cde88a0228bac132b9e_I20191231" decimals="3" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzU0OTc1NTgxNjIwNjU_3a107ec7-8f53-4cab-9545-3c316261f8c4">98.7</ix:nonFraction>% as of December&#160;31, 2019.</span></div><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="sgmo:ScheduleOfNoncontrollingInterestTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzkxMjQ_9c6f543e-3753-439f-b8ae-ddbabf75649b" escape="true"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Non-controlling interest as of December&#160;31, 2019 was as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:85.262%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.738%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, beginning of year</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic99ff13e6b8d4ef18b9878c555ae3844_I20181231" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90YWJsZToyNTAwZmNhNGJmZDA0YTkzOWViZGJkN2E1N2IyOTg0Yy90YWJsZXJhbmdlOjI1MDBmY2E0YmZkMDRhOTM5ZWJkYmQ3YTU3YjI5ODRjXzctMS0xLTEtMA_b467b38c-2c83-4971-bcf1-966c27e8a995">739</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of additional shares acquired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90YWJsZToyNTAwZmNhNGJmZDA0YTkzOWViZGJkN2E1N2IyOTg0Yy90YWJsZXJhbmdlOjI1MDBmY2E0YmZkMDRhOTM5ZWJkYmQ3YTU3YjI5ODRjXzgtMS0xLTEtNzg3MQ_6003d0c2-81cc-457c-be56-1c270f49e457">321</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss attributable to non-controlling interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90YWJsZToyNTAwZmNhNGJmZDA0YTkzOWViZGJkN2E1N2IyOTg0Yy90YWJsZXJhbmdlOjI1MDBmY2E0YmZkMDRhOTM5ZWJkYmQ3YTU3YjI5ODRjXzktMS0xLTEtNzg3MQ_e31a13d0-bf5d-4fbc-ac3f-2af15d0deaa3">233</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, end of year</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc3f21983c41481ba4b01cd8667c5b3d_I20191231" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90YWJsZToyNTAwZmNhNGJmZDA0YTkzOWViZGJkN2E1N2IyOTg0Yy90YWJsZXJhbmdlOjI1MDBmY2E0YmZkMDRhOTM5ZWJkYmQ3YTU3YjI5ODRjXzEwLTEtMS0xLTc4NzE_170dfe02-06e5-4ebe-94c1-19e787e5f333">185</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;"><span><br/></span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_124"></div><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90ZXh0cmVnaW9uOjNjMjgxYjg5MWNkODRlZGM5MzNhODYwMmFjNzgyNDllXzgzMQ_d4758078-7647-41ac-8984-465822ce8f7b" continuedAt="i80720666126a4e29a6a7541fb5b14080" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 6 &#8211; OTHER BALANCE SHEET DETAILS</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Property and Equipment, Net</span></div><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90ZXh0cmVnaW9uOjNjMjgxYjg5MWNkODRlZGM5MzNhODYwMmFjNzgyNDllXzgzMg_c5bba676-2089-4bdb-ae98-367947995798" escape="true"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Property and equipment, net consist of the following (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:71.792%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.739%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Laboratory equipment</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if8a9cbb45d2746dcb48a28a379d261b4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTpiYTQ0MWM1ODI5NmM0NTQ3YTUwMDViMGU5NmI0ZGZhNy90YWJsZXJhbmdlOmJhNDQxYzU4Mjk2YzQ1NDdhNTAwNWIwZTk2YjRkZmE3XzItMS0xLTEtMA_c889bed0-034a-463c-8149-ccac2bc0afed">17,179</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0638fbc591ba4ce589a9cfe88a114e95_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTpiYTQ0MWM1ODI5NmM0NTQ3YTUwMDViMGU5NmI0ZGZhNy90YWJsZXJhbmdlOmJhNDQxYzU4Mjk2YzQ1NDdhNTAwNWIwZTk2YjRkZmE3XzItMy0xLTEtMA_6779b5c1-47ce-4430-a80a-9853ba51cfcc">11,466</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Furniture and fixtures</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibe70b54fab8e46b4bea40c2b35ede19a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTpiYTQ0MWM1ODI5NmM0NTQ3YTUwMDViMGU5NmI0ZGZhNy90YWJsZXJhbmdlOmJhNDQxYzU4Mjk2YzQ1NDdhNTAwNWIwZTk2YjRkZmE3XzMtMS0xLTEtMA_3f60c06e-71bb-4711-b6c8-42bca4c85d64">4,639</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iac226c28c7fb4c64920cad2ca7e259a1_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTpiYTQ0MWM1ODI5NmM0NTQ3YTUwMDViMGU5NmI0ZGZhNy90YWJsZXJhbmdlOmJhNDQxYzU4Mjk2YzQ1NDdhNTAwNWIwZTk2YjRkZmE3XzMtMy0xLTEtMA_19d69232-4a76-4e52-b4a0-d38af1378654">3,840</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie3c60a720f6b4df19f3f92b51be623e5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTpiYTQ0MWM1ODI5NmM0NTQ3YTUwMDViMGU5NmI0ZGZhNy90YWJsZXJhbmdlOmJhNDQxYzU4Mjk2YzQ1NDdhNTAwNWIwZTk2YjRkZmE3XzQtMS0xLTEtMA_3c7bcaa2-f26e-4a95-8944-10b915c2dc30">13,888</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iac6944dea140420e82c37c6b728de97a_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTpiYTQ0MWM1ODI5NmM0NTQ3YTUwMDViMGU5NmI0ZGZhNy90YWJsZXJhbmdlOmJhNDQxYzU4Mjk2YzQ1NDdhNTAwNWIwZTk2YjRkZmE3XzQtMy0xLTEtMA_bb5cf320-49dc-4148-901b-9d15b4d4deb5">3,640</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Buildings</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic4483a2719984476afd6ceb188081fda_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTpiYTQ0MWM1ODI5NmM0NTQ3YTUwMDViMGU5NmI0ZGZhNy90YWJsZXJhbmdlOmJhNDQxYzU4Mjk2YzQ1NDdhNTAwNWIwZTk2YjRkZmE3XzUtMS0xLTEtMA_88714802-5e76-4939-b4e4-9fd56c738c48">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2471a22261164bf78fea22576f465fb3_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTpiYTQ0MWM1ODI5NmM0NTQ3YTUwMDViMGU5NmI0ZGZhNy90YWJsZXJhbmdlOmJhNDQxYzU4Mjk2YzQ1NDdhNTAwNWIwZTk2YjRkZmE3XzUtMy0xLTEtMA_4adeb0bb-8135-4f35-847e-8f161fb13524">3,876</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Construction in progress</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icf9dff888e724c4fbe02ba474671d5fe_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTpiYTQ0MWM1ODI5NmM0NTQ3YTUwMDViMGU5NmI0ZGZhNy90YWJsZXJhbmdlOmJhNDQxYzU4Mjk2YzQ1NDdhNTAwNWIwZTk2YjRkZmE3XzYtMS0xLTEtMTEwODc_925eb936-9d87-4b65-a204-63a82cd9b763">5,901</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5620868d7a3f4744aeeaa72cb2948e05_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTpiYTQ0MWM1ODI5NmM0NTQ3YTUwMDViMGU5NmI0ZGZhNy90YWJsZXJhbmdlOmJhNDQxYzU4Mjk2YzQ1NDdhNTAwNWIwZTk2YjRkZmE3XzYtMy0xLTEtMTExMDA_1a791dbf-71a8-456b-82dc-b864f1d11f8c">65,211</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTpiYTQ0MWM1ODI5NmM0NTQ3YTUwMDViMGU5NmI0ZGZhNy90YWJsZXJhbmdlOmJhNDQxYzU4Mjk2YzQ1NDdhNTAwNWIwZTk2YjRkZmE3XzYtMS0xLTEtMA_6dcf3177-3036-4044-8a8e-1c69e72fec2b">41,607</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTpiYTQ0MWM1ODI5NmM0NTQ3YTUwMDViMGU5NmI0ZGZhNy90YWJsZXJhbmdlOmJhNDQxYzU4Mjk2YzQ1NDdhNTAwNWIwZTk2YjRkZmE3XzYtMy0xLTEtMA_5cf1c73b-d682-476a-9d29-43b3be30a663">88,033</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTpiYTQ0MWM1ODI5NmM0NTQ3YTUwMDViMGU5NmI0ZGZhNy90YWJsZXJhbmdlOmJhNDQxYzU4Mjk2YzQ1NDdhNTAwNWIwZTk2YjRkZmE3XzctMS0xLTEtMA_0b2a9afa-0cbe-4573-9f12-febdd682902e">11,681</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTpiYTQ0MWM1ODI5NmM0NTQ3YTUwMDViMGU5NmI0ZGZhNy90YWJsZXJhbmdlOmJhNDQxYzU4Mjk2YzQ1NDdhNTAwNWIwZTk2YjRkZmE3XzctMy0xLTEtMA_dc39ebdd-b2d0-4906-86cc-f0d26c65ac77">9,310</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTpiYTQ0MWM1ODI5NmM0NTQ3YTUwMDViMGU5NmI0ZGZhNy90YWJsZXJhbmdlOmJhNDQxYzU4Mjk2YzQ1NDdhNTAwNWIwZTk2YjRkZmE3XzktMS0xLTEtMA_4606b17a-233b-48d3-9a44-8001d8fe06cb">29,926</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTpiYTQ0MWM1ODI5NmM0NTQ3YTUwMDViMGU5NmI0ZGZhNy90YWJsZXJhbmdlOmJhNDQxYzU4Mjk2YzQ1NDdhNTAwNWIwZTk2YjRkZmE3XzktMy0xLTEtMA_7861bbef-7001-4911-8e66-c6a3cdca2f3b">78,723</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Depreciation and amortization expense was $<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90ZXh0cmVnaW9uOjNjMjgxYjg5MWNkODRlZGM5MzNhODYwMmFjNzgyNDllXzE1NQ_8effbb8b-cca7-40be-a1fc-e515d8fbb6ab">3.9</ix:nonFraction>&#160;million in 2019, $<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90ZXh0cmVnaW9uOjNjMjgxYjg5MWNkODRlZGM5MzNhODYwMmFjNzgyNDllXzE2NQ_6ef6f2d5-6438-454e-9743-8c630f352d62">2.4</ix:nonFraction>&#160;million in 2018 and $<ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90ZXh0cmVnaW9uOjNjMjgxYjg5MWNkODRlZGM5MzNhODYwMmFjNzgyNDllXzE3OA_4d9ec318-97b6-4b6f-9333-7686cddf706b">1.5</ix:nonFraction>&#160;million in 2017.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Intangible Assets</span></div><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90ZXh0cmVnaW9uOjNjMjgxYjg5MWNkODRlZGM5MzNhODYwMmFjNzgyNDllXzc2OTY1ODEzOTY5MjI_b1d37c1d-65e7-4d3b-b0ae-ea8b3ca1974a" continuedAt="ia072eaf9b37c489fa7b0317e2c352f6e" escape="true"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The changes in intangible assets were as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:71.245%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.719%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.452%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, beginning of year</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplMTE0MjQ5OGEwNzM0ZmMyYTgzODhiMTRmOTJiZDNkOC90YWJsZXJhbmdlOmUxMTQyNDk4YTA3MzRmYzJhODM4OGIxNGY5MmJkM2Q4XzItMS0xLTEtNzExNQ_c9b9a398-4830-4bdd-9cf6-9cb2f7968aef">54,243</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb7e952fbd38434585f995fe73c66a44_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplMTE0MjQ5OGEwNzM0ZmMyYTgzODhiMTRmOTJiZDNkOC90YWJsZXJhbmdlOmUxMTQyNDk4YTA3MzRmYzJhODM4OGIxNGY5MmJkM2Q4XzItMy0xLTEtNzEwNg_fd914552-78f1-476e-ae70-ead1c847a293">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Indefinite-lived assets - IPR&amp;D</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:IndefinitelivedIntangibleAssetsAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplMTE0MjQ5OGEwNzM0ZmMyYTgzODhiMTRmOTJiZDNkOC90YWJsZXJhbmdlOmUxMTQyNDk4YTA3MzRmYzJhODM4OGIxNGY5MmJkM2Q4XzMtMS0xLTEtNzExNQ_e83183d2-b5be-4373-abde-3ff9c2f7ac6e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IndefinitelivedIntangibleAssetsAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplMTE0MjQ5OGEwNzM0ZmMyYTgzODhiMTRmOTJiZDNkOC90YWJsZXJhbmdlOmUxMTQyNDk4YTA3MzRmYzJhODM4OGIxNGY5MmJkM2Q4XzMtMy0xLTEtNzEwNg_9580fe1d-9b18-45b8-a1b2-24306e280b07">55,019</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency translation adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplMTE0MjQ5OGEwNzM0ZmMyYTgzODhiMTRmOTJiZDNkOC90YWJsZXJhbmdlOmUxMTQyNDk4YTA3MzRmYzJhODM4OGIxNGY5MmJkM2Q4XzQtMS0xLTEtNzExNQ_1c329a43-54c2-42d6-87b8-b2eed29e494a">1,087</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplMTE0MjQ5OGEwNzM0ZmMyYTgzODhiMTRmOTJiZDNkOC90YWJsZXJhbmdlOmUxMTQyNDk4YTA3MzRmYzJhODM4OGIxNGY5MmJkM2Q4XzQtMy0xLTEtNzEwNg_44647a19-1633-4509-94a3-4f307346657b">776</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, end of year</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplMTE0MjQ5OGEwNzM0ZmMyYTgzODhiMTRmOTJiZDNkOC90YWJsZXJhbmdlOmUxMTQyNDk4YTA3MzRmYzJhODM4OGIxNGY5MmJkM2Q4XzUtMS0xLTEtNzExNQ_23706826-25cc-4b19-a161-91b57234b5e4">53,156</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplMTE0MjQ5OGEwNzM0ZmMyYTgzODhiMTRmOTJiZDNkOC90YWJsZXJhbmdlOmUxMTQyNDk4YTA3MzRmYzJhODM4OGIxNGY5MmJkM2Q4XzUtMy0xLTEtNzEwNg_17ba5094-8c24-4c58-94d0-2ec59f66b0f4">54,243</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Goodwill</span></div><ix:continuation id="ia072eaf9b37c489fa7b0317e2c352f6e"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The changes in goodwill were as follows (in thousands):</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:70.660%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.719%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.823%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.598%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, beginning of year</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTo1NTc5ZGNmMTllMzY0MDg2YWI0MzI1MzgyNjFjYWI5OS90YWJsZXJhbmdlOjU1NzlkY2YxOWUzNjQwODZhYjQzMjUzODI2MWNhYjk5XzItMS0xLTEtNzEyMQ_36ffd26e-8462-499e-b916-f56c5e069bfc">40,044</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb7e952fbd38434585f995fe73c66a44_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTo1NTc5ZGNmMTllMzY0MDg2YWI0MzI1MzgyNjFjYWI5OS90YWJsZXJhbmdlOjU1NzlkY2YxOWUzNjQwODZhYjQzMjUzODI2MWNhYjk5XzItMy0xLTEtNzExOA_82c58abc-5724-4b63-b611-d90cf5eb06fa">1,585</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill acquired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTo1NTc5ZGNmMTllMzY0MDg2YWI0MzI1MzgyNjFjYWI5OS90YWJsZXJhbmdlOjU1NzlkY2YxOWUzNjQwODZhYjQzMjUzODI2MWNhYjk5XzMtMS0xLTEtNzEyMQ_048dfea7-2521-4346-86b0-bfd3f5ec40cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTo1NTc5ZGNmMTllMzY0MDg2YWI0MzI1MzgyNjFjYWI5OS90YWJsZXJhbmdlOjU1NzlkY2YxOWUzNjQwODZhYjQzMjUzODI2MWNhYjk5XzMtMy0xLTEtNzExOA_ee30facf-dca0-4efd-a790-242e2f6f9d4c">38,995</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency translation adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTo1NTc5ZGNmMTllMzY0MDg2YWI0MzI1MzgyNjFjYWI5OS90YWJsZXJhbmdlOjU1NzlkY2YxOWUzNjQwODZhYjQzMjUzODI2MWNhYjk5XzQtMS0xLTEtNzEyMQ_890d7c22-578c-4165-91f6-afbfb617d1a5">771</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTo1NTc5ZGNmMTllMzY0MDg2YWI0MzI1MzgyNjFjYWI5OS90YWJsZXJhbmdlOjU1NzlkY2YxOWUzNjQwODZhYjQzMjUzODI2MWNhYjk5XzQtMy0xLTEtNzExOA_04e696d2-6901-4393-855c-072a9f8e7fae">536</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, end of year</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTo1NTc5ZGNmMTllMzY0MDg2YWI0MzI1MzgyNjFjYWI5OS90YWJsZXJhbmdlOjU1NzlkY2YxOWUzNjQwODZhYjQzMjUzODI2MWNhYjk5XzUtMS0xLTEtNzEyMQ_b8ff7ae1-6367-44d4-a53d-ebde795f7b8d">39,273</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTo1NTc5ZGNmMTllMzY0MDg2YWI0MzI1MzgyNjFjYWI5OS90YWJsZXJhbmdlOjU1NzlkY2YxOWUzNjQwODZhYjQzMjUzODI2MWNhYjk5XzUtMy0xLTEtNzExOA_35c48126-d5bd-4afb-b68d-2ec91f780126">40,044</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:continuation></ix:nonNumeric><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">91</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><ix:continuation id="i80720666126a4e29a6a7541fb5b14080"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounts Payable and Accrued Liabilities</span></div><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90ZXh0cmVnaW9uOjNjMjgxYjg5MWNkODRlZGM5MzNhODYwMmFjNzgyNDllXzc2OTY1ODEzOTY5MjQ_7beaa069-8487-474c-aca2-c854d2c33540" escape="true"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accounts payable and accrued liabilities consist of the following (in thousands):</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:70.474%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.117%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.472%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplZDFkNjNkYWQ2NDg0NzJjOWRlZjY5ZmFjOTc5MjNkNy90YWJsZXJhbmdlOmVkMWQ2M2RhZDY0ODQ3MmM5ZGVmNjlmYWM5NzkyM2Q3XzItMS0xLTEtNzIyMA_ce867f3c-c44b-449f-a8fd-a0b828acb235">6,671</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplZDFkNjNkYWQ2NDg0NzJjOWRlZjY5ZmFjOTc5MjNkNy90YWJsZXJhbmdlOmVkMWQ2M2RhZDY0ODQ3MmM5ZGVmNjlmYWM5NzkyM2Q3XzItMy0xLTEtNzIyMA_45476fe7-f93c-4814-a3b6-c7ac7b3408f1">3,355</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued research and development expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:AccruedResearchAndDevelopmentExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplZDFkNjNkYWQ2NDg0NzJjOWRlZjY5ZmFjOTc5MjNkNy90YWJsZXJhbmdlOmVkMWQ2M2RhZDY0ODQ3MmM5ZGVmNjlmYWM5NzkyM2Q3XzMtMS0xLTEtNzIyMA_7d6b0358-a3db-44ae-a608-883503214a9c">4,102</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:AccruedResearchAndDevelopmentExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplZDFkNjNkYWQ2NDg0NzJjOWRlZjY5ZmFjOTc5MjNkNy90YWJsZXJhbmdlOmVkMWQ2M2RhZDY0ODQ3MmM5ZGVmNjlmYWM5NzkyM2Q3XzMtMy0xLTEtNzIyMA_d1475878-b5c3-4bf1-ac59-8ecb12f59998">10,999</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities - current</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplZDFkNjNkYWQ2NDg0NzJjOWRlZjY5ZmFjOTc5MjNkNy90YWJsZXJhbmdlOmVkMWQ2M2RhZDY0ODQ3MmM5ZGVmNjlmYWM5NzkyM2Q3XzQtMS0xLTEtMTQyMDU_a1df79da-9010-47e2-84c9-ec04233b8676">3,214</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplZDFkNjNkYWQ2NDg0NzJjOWRlZjY5ZmFjOTc5MjNkNy90YWJsZXJhbmdlOmVkMWQ2M2RhZDY0ODQ3MmM5ZGVmNjlmYWM5NzkyM2Q3XzQtMy0xLTEtMTQyMDc_b468c714-7dde-469b-bf06-32993bcbd087">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued professional fees</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplZDFkNjNkYWQ2NDg0NzJjOWRlZjY5ZmFjOTc5MjNkNy90YWJsZXJhbmdlOmVkMWQ2M2RhZDY0ODQ3MmM5ZGVmNjlmYWM5NzkyM2Q3XzQtMS0xLTEtNzIyMA_f2580c4d-93a4-41d6-84f4-21060e2c1fd7">1,118</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplZDFkNjNkYWQ2NDg0NzJjOWRlZjY5ZmFjOTc5MjNkNy90YWJsZXJhbmdlOmVkMWQ2M2RhZDY0ODQ3MmM5ZGVmNjlmYWM5NzkyM2Q3XzQtMy0xLTEtNzIyMA_6afdd311-9e3a-4ff4-85bf-c1311a35bd3d">1,930</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred rent</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredRentCreditCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplZDFkNjNkYWQ2NDg0NzJjOWRlZjY5ZmFjOTc5MjNkNy90YWJsZXJhbmdlOmVkMWQ2M2RhZDY0ODQ3MmM5ZGVmNjlmYWM5NzkyM2Q3XzUtMS0xLTEtNzIyMA_52afa974-1bb7-40dd-b8a7-33428d25c597">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" name="us-gaap:DeferredRentCreditCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplZDFkNjNkYWQ2NDg0NzJjOWRlZjY5ZmFjOTc5MjNkNy90YWJsZXJhbmdlOmVkMWQ2M2RhZDY0ODQ3MmM5ZGVmNjlmYWM5NzkyM2Q3XzUtMy0xLTEtNzIyMA_0ecbee2f-1271-468a-9920-2e1926ca7f4f">204</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplZDFkNjNkYWQ2NDg0NzJjOWRlZjY5ZmFjOTc5MjNkNy90YWJsZXJhbmdlOmVkMWQ2M2RhZDY0ODQ3MmM5ZGVmNjlmYWM5NzkyM2Q3XzYtMS0xLTEtNzIyMA_38e4d619-c7e3-448a-80d2-af3b531545d7">2,451</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplZDFkNjNkYWQ2NDg0NzJjOWRlZjY5ZmFjOTc5MjNkNy90YWJsZXJhbmdlOmVkMWQ2M2RhZDY0ODQ3MmM5ZGVmNjlmYWM5NzkyM2Q3XzYtMy0xLTEtNzIyMA_87517caf-2474-4615-8927-4e420f9dc112">4,969</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total accounts payable and accrued liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplZDFkNjNkYWQ2NDg0NzJjOWRlZjY5ZmFjOTc5MjNkNy90YWJsZXJhbmdlOmVkMWQ2M2RhZDY0ODQ3MmM5ZGVmNjlmYWM5NzkyM2Q3XzctMS0xLTEtNzIyMA_af93019f-fbec-4f0e-a25c-bfa64d949524">17,556</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplZDFkNjNkYWQ2NDg0NzJjOWRlZjY5ZmFjOTc5MjNkNy90YWJsZXJhbmdlOmVkMWQ2M2RhZDY0ODQ3MmM5ZGVmNjlmYWM5NzkyM2Q3XzctMy0xLTEtNzIyMA_db8bc027-0a95-4f51-988d-ac486f363180">21,457</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;"><span><br/></span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_127"></div><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzEzODU_485412a4-c287-446c-90e9-326b4a5a57b0" continuedAt="i6b111b0ab4254286acb1cf4b2780b22b" escape="true"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 7 &#8211; COMMITMENTS AND CONTINGENCIES</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Leases</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sangamo occupies approximately <ix:nonFraction unitRef="sqft" contextRef="iaf513274ee0c43639e9c1500db2d7963_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LandSubjectToGroundLeases" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzYwNDczMTM5NjQ5MjY_687f31c2-9af0-4366-826f-452ce062bc29">87,700</ix:nonFraction> square feet of office and research and development laboratory facilities in Brisbane, California pursuant to a lease that expires in May 2029. Sangamo also occupies approximately <ix:nonFraction unitRef="sqft" contextRef="i61974f1d85ab49f78df77bf7c87828b4_I20191231" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:LandSubjectToGroundLeases" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzYwNDczMTM5NjQ5NjU_3954b1ac-4917-4639-8cac-8209ebff4dda">45,600</ix:nonFraction> square feet of research and office space in Richmond, California pursuant to leases that expire in August 2026. In addition, the Company leases approximately <ix:nonFraction unitRef="sqft" contextRef="i545fe0f072c9408797e00f296a4a44dd_I20191231" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:LandSubjectToGroundLeases" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzc2OTY1ODE0MTAxMzY_9d2b2bc3-3340-4fa8-935b-17e3c259d274">20,800</ix:nonFraction> square feet of office and research space in Valbonne, France subject to leases that expire beginning in June 2025 through March 2028.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain of these leases also include renewal options at the election of the Company to renew or extend the lease for an additional <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzc2OTY1ODE0MDcwOTQ_38c04c15-1abf-4f53-8e13-ebfe9bb10579">five</span> to <ix:nonNumeric contextRef="i83dc1a1104c8410f962b75bd5a2646f0_I20191231" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzc2OTY1ODE0MDcwNzk_e7af62b1-b666-4910-94db-d3da2add664f">ten years</ix:nonNumeric>. These optional periods have not been considered in the determination of the ROU assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain it would exercise the options.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">With respect to the Brisbane lease, the commencement date for approximately <ix:nonFraction unitRef="sqft" contextRef="iebf52cf79a6041878e2eb875ad9b53ba_I20191231" decimals="-1" format="ixt:numdotdecimal" name="us-gaap:LandSubjectToGroundLeases" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzYwNDczMTM5NjQ5MzQ_0a501eb5-1d1e-46a6-9a08-2817240f542a">35,080</ix:nonFraction> square feet of the office space occurred in January 2019 while the commencement date for the remaining approximately <ix:nonFraction unitRef="sqft" contextRef="i38763d7e12814008b53fbac4a892782d_I20191231" decimals="-1" format="ixt:numdotdecimal" name="us-gaap:LandSubjectToGroundLeases" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzYwNDczMTM5NjQ5NTc_a939df97-7307-45ef-9167-0fa349999fca">52,620</ix:nonFraction> square feet occurred in June 2019. The Company has the right and exercised that right to make tenant improvements, including the addition of laboratory space, with a lease incentive allowance of $<ix:nonFraction unitRef="usd" contextRef="i38763d7e12814008b53fbac4a892782d_I20191231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:LesseeOperatingLeaseLiabilityTenantImprovementAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzYwNDczMTM5NjUyMTk_3c5a1d3f-c4b8-48a7-bd4d-eca2ccce4ec4">6.8</ix:nonFraction>&#160;million on the first portion of the space occupied and $<ix:nonFraction unitRef="usd" contextRef="i38763d7e12814008b53fbac4a892782d_I20191231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzYwNDczMTM5NjUyMzg_daf4646b-898f-44ae-bd3b-4de6b651ab3c">10.2</ix:nonFraction>&#160;million on the portion of the lease that commenced in June 2019. As of December 31, 2019, these incentives have been received and used.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company performed evaluations of its contracts and determined each of its identified leases are operating leases. For the year ended December&#160;31, 2019, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzYwNDczMTM5NjUyNTM_e1406aa6-ab6b-48fd-96e6-ce1c78505aff">7.9</ix:nonFraction>&#160;million of lease costs included in operating expenses in the Consolidated Statement of Operations in relation to these operating leases. Variable lease expense was $<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzYwNDczMTM5NjUyNzY_fbdc1bdb-1f80-4aae-b97c-6b70b010c74f">1.9</ix:nonFraction>&#160;million for the year ended December&#160;31, 2019 and was not included in the measurement of the Company&#8217;s operating ROU assets and lease liabilities. The variable expense consists primarily of the Company&#8217;s proportionate share of operating expenses, property taxes and insurance and is classified as lease expense due to the Company&#8217;s election to not separate lease and non-lease components.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash paid for amounts included in the measurement of operating lease liabilities for the year ended December&#160;31, 2019 was $<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzYwNDczMTM5NjUyOTM_44169a9a-1b94-4966-a4fb-40d861495ec2">3.5</ix:nonFraction>&#160;million and was included in net cash used in operating activities in the Company&#8217;s Consolidated Statement of Cash Flow.</span></div></ix:nonNumeric><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">92</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><ix:continuation id="i6b111b0ab4254286acb1cf4b2780b22b"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Rent expense related to lease agreements was $<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzk3MQ_3f971ad3-dff9-41e7-85af-0d34de94a371">7.9</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzk3NQ_7518c3e0-6ee6-4684-abd7-bd7382ab962c">2.3</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzk4Mw_6934224d-a21a-4654-b9ee-8e8ee8d6cc5e">1.1</ix:nonFraction>&#160;million for 2019, 2018 and 2017, respectively. <ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzEzODY_10a3b359-0864-4d76-af10-05926678a7c1" continuedAt="i86ddd671e48b4032a4c2056e97855330" escape="true">Future minimum payments under lease obligations at December&#160;31, 2019 consist of the following (in thousands):</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:continuation id="i86ddd671e48b4032a4c2056e97855330" continuedAt="i9a30b49ae72c4cfd8a157d76e91d0df4">&#160;</ix:continuation></span></div><div style="margin-top:6pt;margin-bottom:6pt;"><ix:continuation id="i9a30b49ae72c4cfd8a157d76e91d0df4"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:85.262%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.738%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90YWJsZTo0MmY2ZWEyZjVkM2M0YjZlYjM1OTA2YzM2ZWVhZTBmMy90YWJsZXJhbmdlOjQyZjZlYTJmNWQzYzRiNmViMzU5MDZjMzZlZWFlMGYzXzEtMS0xLTEtMA_7701510d-ec01-4888-a5e7-652c4431d028">5,870</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90YWJsZTo0MmY2ZWEyZjVkM2M0YjZlYjM1OTA2YzM2ZWVhZTBmMy90YWJsZXJhbmdlOjQyZjZlYTJmNWQzYzRiNmViMzU5MDZjMzZlZWFlMGYzXzItMS0xLTEtMA_6846eddc-f3d8-41c2-854b-6f564922d65f">6,390</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90YWJsZTo0MmY2ZWEyZjVkM2M0YjZlYjM1OTA2YzM2ZWVhZTBmMy90YWJsZXJhbmdlOjQyZjZlYTJmNWQzYzRiNmViMzU5MDZjMzZlZWFlMGYzXzMtMS0xLTEtMA_87a08819-45c2-43c6-873a-614bcfbde898">6,468</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90YWJsZTo0MmY2ZWEyZjVkM2M0YjZlYjM1OTA2YzM2ZWVhZTBmMy90YWJsZXJhbmdlOjQyZjZlYTJmNWQzYzRiNmViMzU5MDZjMzZlZWFlMGYzXzQtMS0xLTEtMA_f9682292-28ce-40d9-b720-95730d4daef1">6,556</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90YWJsZTo0MmY2ZWEyZjVkM2M0YjZlYjM1OTA2YzM2ZWVhZTBmMy90YWJsZXJhbmdlOjQyZjZlYTJmNWQzYzRiNmViMzU5MDZjMzZlZWFlMGYzXzUtMS0xLTEtMA_532c9ebc-91f4-44b9-9cd8-acc3277ca1d9">6,694</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90YWJsZTo0MmY2ZWEyZjVkM2M0YjZlYjM1OTA2YzM2ZWVhZTBmMy90YWJsZXJhbmdlOjQyZjZlYTJmNWQzYzRiNmViMzU5MDZjMzZlZWFlMGYzXzYtMS0xLTEtMA_0f7192b9-8b06-4e7b-81f4-d50e1419c629">26,141</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90YWJsZTo0MmY2ZWEyZjVkM2M0YjZlYjM1OTA2YzM2ZWVhZTBmMy90YWJsZXJhbmdlOjQyZjZlYTJmNWQzYzRiNmViMzU5MDZjMzZlZWFlMGYzXzctMS0xLTEtMA_35dc6092-71ae-493c-8535-116a9f15e7bf">58,119</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Imputed interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90YWJsZTo0MmY2ZWEyZjVkM2M0YjZlYjM1OTA2YzM2ZWVhZTBmMy90YWJsZXJhbmdlOjQyZjZlYTJmNWQzYzRiNmViMzU5MDZjMzZlZWFlMGYzXzktMS0xLTEtNDE2MQ_96e7627d-11bb-4c57-ae81-76cc415fc1c7">13,713</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90YWJsZTo0MmY2ZWEyZjVkM2M0YjZlYjM1OTA2YzM2ZWVhZTBmMy90YWJsZXJhbmdlOjQyZjZlYTJmNWQzYzRiNmViMzU5MDZjMzZlZWFlMGYzXzEwLTEtMS0xLTQxNjE_37e934fd-dea3-49bd-8952-fcc7541ed97b">44,406</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Reported as of December 31, 2019:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities - current (included in Accounts payable and accrued liabilities on the Consolidated Balance Sheet)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90YWJsZTo0MmY2ZWEyZjVkM2M0YjZlYjM1OTA2YzM2ZWVhZTBmMy90YWJsZXJhbmdlOjQyZjZlYTJmNWQzYzRiNmViMzU5MDZjMzZlZWFlMGYzXzEyLTEtMS0xLTQxNjE_d78d1bb8-bc2d-4ca4-9183-7d3c40d21133">3,214</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities - long-term</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90YWJsZTo0MmY2ZWEyZjVkM2M0YjZlYjM1OTA2YzM2ZWVhZTBmMy90YWJsZXJhbmdlOjQyZjZlYTJmNWQzYzRiNmViMzU5MDZjMzZlZWFlMGYzXzEzLTEtMS0xLTQxNjE_5e11be0b-8332-4e37-99cb-9e62c26f2ef6">41,192</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90YWJsZTo0MmY2ZWEyZjVkM2M0YjZlYjM1OTA2YzM2ZWVhZTBmMy90YWJsZXJhbmdlOjQyZjZlYTJmNWQzYzRiNmViMzU5MDZjMzZlZWFlMGYzXzE0LTEtMS0xLTQxNjE_5743342c-4459-4f07-b42b-996f9ece6135">44,406</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, the weighted-average remaining lease term is <ix:nonNumeric contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzYwNDczMTM5NjUzMDU_e1d573c8-176b-453b-b560-263ea2f57b5d">8.8</ix:nonNumeric> years and the weighted-average incremental borrowing rate used to determine the operating lease liability was <ix:nonFraction unitRef="number" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzYwNDczMTM5NjUzMTM_ffff0e96-eb82-48b5-aaa9-e8dc783cda89">6.2</ix:nonFraction>% for the Company&#8217;s operating leases.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Contractual Commitments</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December 31, 2019, the Company has manufacturing obligations that include a fee of $<ix:nonFraction unitRef="usd" contextRef="i37d7eb43c08a471b816747e6c8de433d_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherCommitment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzg3OTYwOTMwMzg3MTI_fcb020d6-c3cd-4328-81a8-61f16048dc40">6.3</ix:nonFraction>&#160;million for dedicated capacity pursuant to the Development and Manufacturing Services Agreement with Brammer Bio MA, now a </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Thermo Fisher</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Scientific Inc. subsidiary ("Brammer"). The Company also has an Option Agreement ("Option") with Brammer, entered in April 2019, whereby Brammer granted the Company an option to secure dedicated capacity for manufacturing in Brammer&#8217;s facilities. The Company paid $<ix:nonFraction unitRef="usd" contextRef="i7e239f59de424eaeb896378613c4c2fc_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:PaymentsForOtherCommitment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzE0MjkzNjUxMTc1MDI0_e42fdc36-1d61-4896-8b57-d620c4120930">3.0</ix:nonFraction>&#160;million for the Option, which expires on December&#160;31, 2021. In addition, the Company agreed to pay Brammer $<ix:nonFraction unitRef="usd" contextRef="i30aa48009d514a9694cf66cf00207e2e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherCommitment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzg3OTYwOTMwMzcyNjA_8a49b977-4002-426f-8a64-d5082fb2ba4e">2.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i22655d04f591458ebb9c3737889fcaa1_D20190401-20190430" decimals="-5" format="ixt:numdotdecimal" name="sgmo:PaymentsForOtherCommitment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzg3OTYwOTMwMzcyNjQ_ab9fa899-8581-4b9b-b8df-04bdbc1c2420">0.5</ix:nonFraction> million of which was paid upon execution of the agreement, to assist it in establishing its manufacturing capabilities in Brisbane, California, which may increase Sangamo's contractual commitments in the future. Furthermore, the Company has non-cancelable contractual commitments under manufacturing-related supplier arrangements with Brammer, which requires minimum purchase commitments totaling approximately $<ix:nonFraction unitRef="usd" contextRef="i2fba1b8b532b45cc848f39f189b1366e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractualObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzE0MjkzNjUxMTc1NDYz_68271a17-ef1f-4e23-81dc-dec03c69c9a7">2.5</ix:nonFraction>&#160;million through December 2021, $<ix:nonFraction unitRef="usd" contextRef="i4c3d46edbdfc47afb7a1080ab7235f2a_I20190430" decimals="-5" format="ixt:numdotdecimal" name="sgmo:ContractualObligationPaidUponExecution" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzE0MjkzNjUxMTc1NDk4_949b43c5-a853-43ec-8a57-175a94cf339b">0.5</ix:nonFraction>&#160;million of which was paid upon execution of the agreement.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company also has $<ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:LicenseObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzIxOTkwMjMyNzExMDY_df4966f3-1f00-4f4d-881e-f8b447366fd1">1.2</ix:nonFraction>&#160;million of license obligations related to its intellectual property.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Contingencies</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sangamo is not party to any material pending legal proceeding. From time to time, Sangamo may be involved in legal proceedings arising in the ordinary course of business.</span></div></ix:continuation><div id="i9a2bf9013aa44980b5a1f5846290b1a8_133"></div><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzExODA4_6a25e3b7-daea-4975-98dd-16fd0870d89f" continuedAt="i7b99a64f68a04a6d8e69ad7437e67e54" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 8 &#8211; STOCKHOLDERS&#8217; EQUITY</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Preferred Stock</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has <ix:nonFraction unitRef="shares" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzY3_4cad8adf-a444-47ef-b54b-548fd5e19790">5,000,000</ix:nonFraction> preferred shares authorized, which may be issued at the discretion of the Company&#8217;s Board of Director&#8217;s discretion.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Common Stock</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2019, Sangamo completed an underwritten public offering of its common stock, in which the Company sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="icb4b35fddcc442cb8c1b62aa13aad983_D20190401-20190430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzYwNDczMTM5NjQ5NzE_7aaedcc6-f89e-4d13-95ca-15110437192e">12.7</ix:nonFraction>&#160;million shares of its common stock at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ie4f08396a6674db59b83934997d376ca_I20190430" decimals="INF" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzYwNDczMTM5NjQ5ODA_dd582a1a-4bd2-4d9e-b568-0d1ba54972c1">11.50</ix:nonFraction> per share. The net proceeds to Sangamo from the sale of shares in this offering, after deducting underwriting discounts and commissions and other offering expenses, were approximately $<ix:nonFraction unitRef="usd" contextRef="icb4b35fddcc442cb8c1b62aa13aad983_D20190401-20190430" decimals="-5" format="ixt:numdotdecimal" name="sgmo:NetProceedsFromIssuancePublicOffering" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzYwNDczMTM5NjQ5ODM_649f442c-2846-49cf-92e3-60ef04efcf20">136.3</ix:nonFraction>&#160;million.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2018, Sangamo completed an underwritten public offering of its common stock, in which the Company sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="i17fa15d6fbd948fcbb752fa955283c6b_D20180401-20180430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzMyNw_279d8267-7f3b-4a33-b6dd-7ec573e2f459">14.2</ix:nonFraction>&#160;million shares of its common stock at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib60221bf695b4b5c95ff088c3caaf236_I20180430" decimals="INF" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzM4Nw_c7cbe13b-c16e-49fa-91e3-9ad8bef546d9">16.25</ix:nonFraction> per share. The net proceeds to Sangamo from the sale of shares in this offering, after deducting underwriting discounts and commissions and other offering expenses, were approximately $<ix:nonFraction unitRef="usd" contextRef="i17fa15d6fbd948fcbb752fa955283c6b_D20180401-20180430" decimals="-5" format="ixt:numdotdecimal" name="sgmo:NetProceedsFromIssuancePublicOffering" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzU3NA_fd3030b1-fc3b-4977-8c8c-42453a233e8f">215.8</ix:nonFraction>&#160;million.</span></div></ix:nonNumeric><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">93</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><ix:continuation id="i7b99a64f68a04a6d8e69ad7437e67e54" continuedAt="i50431469146649c6916c485362414921"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2017, Sangamo completed an underwritten public offering of its common stock, in which the Company sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="if150961a5ee14928826e68c655e5d53f_D20170601-20170630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzcwNQ_fe337829-3c3c-43ee-bd18-2b1bb027d273">11.5</ix:nonFraction>&#160;million shares of its common stock at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i70ff8798b92448c0b579928fa54468cd_I20170630" decimals="INF" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzc2NQ_0249e658-44f3-4413-9f2e-98fad154e237">7.25</ix:nonFraction> per share. The net proceeds to Sangamo from the sale of shares in this offering, after deducting underwriting discounts and commissions and other offering expenses, were approximately $<ix:nonFraction unitRef="usd" contextRef="if150961a5ee14928826e68c655e5d53f_D20170601-20170630" decimals="-5" format="ixt:numdotdecimal" name="sgmo:NetProceedsFromIssuancePublicOffering" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzk1Mg_bf150e0e-d8e0-48de-8a5b-3e5d2ade8f12">78.1</ix:nonFraction>&#160;million.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock Incentive Plan</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2018, the Compensation Committee of the Company&#8217;s Board of Directors approved the Sangamo Therapeutics, Inc. 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;), subject to approval by the Company&#8217;s stockholders. The 2018 Plan became effective on June&#160;11, 2018 upon approval at the Company&#8217;s Annual Meeting of Stockholders. In connection with the approval of the 2018 Plan, <ix:nonFraction unitRef="shares" contextRef="i37807fd639dc45328330120e8b98348c_D20180401-20180430" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzY4NjE_cd6870d5-184f-47ae-8088-e6d7fe6ece1c">no</ix:nonFraction> additional equity awards will be granted under the 2013 Plan, however all outstanding equity awards under the 2013 Plan will continue to be subject to the terms and conditions as set forth in the agreements evidencing such awards and the terms of the 2013 Plan.</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The exercise price of a stock option granted under the 2018 Plan may not be less than <ix:nonFraction unitRef="number" contextRef="ic0f7d9825feb4e208361c4ad02284de8_D20190101-20191231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzcyMTA_05b97402-a08d-4b31-941b-1bc36e38cd12">100</ix:nonFraction>% of the fair market value of the Company's common stock subject to the stock option on the date of grant, and the option term will not exceed <ix:nonNumeric contextRef="i86e7f798089c4c66a4e5b968d764d534_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzczNDQ_0e408012-4fac-469b-b838-2a199eac52ef">10</ix:nonNumeric> years. If the person to whom the stock option is granted is a <ix:nonFraction unitRef="number" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="INF" name="sgmo:SpecifiedStockholderOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzc0MDU_bdb47443-08c3-4993-8135-9fd720908179">10</ix:nonFraction>% stockholder of the Company, and the stock option granted qualifies as an incentive stock option, then the exercise price per share will not be less than <ix:nonFraction unitRef="number" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="INF" name="sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzc1NzU_5de2d371-5115-411a-b716-2d97a2bbd9c8">110</ix:nonFraction>% of the fair market value of the Company&#8217;s common stock on the date of grant, and the option term will not exceed <ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" format="ixt-sec:durwordsen" name="sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzc2OTE_a1b062a9-ae58-41e6-ac49-f9985161d7aa">five years</ix:nonNumeric>. Generally, stock options granted under the 2018 Plan vest over <ix:nonNumeric contextRef="ic0f7d9825feb4e208361c4ad02284de8_D20190101-20191231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzc3NTg_8e12248e-85e0-440c-a70e-d51de388e15f">four years</ix:nonNumeric> at a rate of <ix:nonFraction unitRef="number" contextRef="i2c7aa74b5db84179b2918daa34c73c69_D20190101-20191231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzc3OTQ_7506fa0f-4c6f-472e-8ba3-9196a4bf5234">25</ix:nonFraction>% on the one year anniversary of the date of grant and 1/48 per month thereafter and expire <ix:nonNumeric contextRef="ic0f7d9825feb4e208361c4ad02284de8_D20190101-20191231" format="ixt-sec:duryear" name="sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzc5MDA_ec353e14-bc7a-423c-ac71-b724c2f2949e">10</ix:nonNumeric> years after the date of grant, or earlier upon termination of employment or services to the Company.</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The number of shares of common stock reserved for issuance under the 2018 Plan will be reduced: (i)&#160;on a <ix:nonFraction unitRef="number" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="INF" name="sgmo:CommonStockExchangeRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzc2OTY1ODE0MTk2Mjk_489a15c3-2f1e-4173-9ebb-b19a4ea190da">1</ix:nonFraction>-for-1 basis for each share of common stock subject to a stock option or stock appreciation right granted under the plan, (ii)&#160;by a fixed ratio of <ix:nonFraction unitRef="number" contextRef="ic0f7d9825feb4e208361c4ad02284de8_D20190101-20191231" decimals="2" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzgyNTE_dc4485fb-83d7-4e04-8886-7600c70bf398">1.33</ix:nonFraction> shares of common stock for each share of common stock issued pursuant to a full-value award granted under the plan.</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Shares subject to any outstanding stock options or other awards under the 2018 Plan that expire or otherwise terminate prior to the issuance of the shares subject to those stock options or awards will be available for subsequent issuance under the 2018 Plan. Any unvested shares issued under the 2018 Plan that the Company subsequently purchases, pursuant to repurchase rights under the 2018 Plan, will be added back to the number of shares reserved for issuance under the 2018 Plan on a <ix:nonFraction unitRef="number" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="INF" name="sgmo:CommonStockExchangeRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzc2OTY1ODE0MTk2MzU_443a7dc0-9cf7-47df-b984-f6d4e4ff8be7">1</ix:nonFraction>-for-1 basis or a <ix:nonFraction unitRef="number" contextRef="ic0f7d9825feb4e208361c4ad02284de8_D20190101-20191231" decimals="2" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzg4NzA_dc4485fb-83d7-4e04-8886-7600c70bf398">1.33</ix:nonFraction>-for-1 basis (depending on the ratio at which the share reserve was debited for the original award) and will accordingly be available for subsequent issuance in accordance with the terms of the 2018 Plan.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Employee Stock Purchase Plan</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2018, the Company&#8217;s stockholders approved the amendment and restatement of the ESPP. As amended, the ESPP provides a total reserve of <ix:nonFraction unitRef="shares" contextRef="i38ea9f2d9931428fba1f41e0b36e7bea_I20180630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzg3OTYwOTMwNDA5NDE_44756444-7c83-4134-b1ff-6b668779d6fb">4.6</ix:nonFraction>&#160;million&#160;shares of common stock for issuance under the ESPP. Eligible employees may purchase common stock at <ix:nonFraction unitRef="number" contextRef="i57406eb823ae4dcba23a5c69e7941851_D20180601-20180630" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzkzNTE_a7ea9237-4205-4d0d-a626-46aeff2f8bec">85</ix:nonFraction>% of the lesser of the fair market value of the Company&#8217;s common stock on the first day of the applicable <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzk0NTg_a01f06c3-4780-4e1a-a835-8d6a1d1c86ad">two</span>-year offering period or the last day of the applicable <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzk1MTY_14ef30bf-8a48-4b2c-8cc7-f55e130f23b6">six</span>-month purchase period.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock Option Activity</span></div><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzExODA5_5e24d1e9-94a3-4345-b6fd-66749005c292" escape="true"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of Sangamo&#8217;s stock option activity is as follows:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:46.680%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.929%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.732%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number of<br/>Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-<br/>Average<br/>Exercise per<br/>Share Price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average<br/>Remaining<br/>Contractual&#160;Term</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In&#160;thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options outstanding at December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTpmMmZlNDNkY2U2MGE0YmQ3YWRmNmUwM2JkZmZlZDQ2NS90YWJsZXJhbmdlOmYyZmU0M2RjZTYwYTRiZDdhZGY2ZTAzYmRmZmVkNDY1XzItMS0xLTEtMA_f2976f4b-16f0-4e9b-a2ad-0f31542e624b">8,726,092</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTpmMmZlNDNkY2U2MGE0YmQ3YWRmNmUwM2JkZmZlZDQ2NS90YWJsZXJhbmdlOmYyZmU0M2RjZTYwYTRiZDdhZGY2ZTAzYmRmZmVkNDY1XzItMy0xLTEtMA_45e8a6d8-bbfd-4103-becf-1f2ab4ba87df">11.23</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTpmMmZlNDNkY2U2MGE0YmQ3YWRmNmUwM2JkZmZlZDQ2NS90YWJsZXJhbmdlOmYyZmU0M2RjZTYwYTRiZDdhZGY2ZTAzYmRmZmVkNDY1XzMtMS0xLTEtMA_5c2d2697-1cc7-4ee0-9b0c-5f1478dff833">4,530,288</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTpmMmZlNDNkY2U2MGE0YmQ3YWRmNmUwM2JkZmZlZDQ2NS90YWJsZXJhbmdlOmYyZmU0M2RjZTYwYTRiZDdhZGY2ZTAzYmRmZmVkNDY1XzMtMy0xLTEtMA_ecbde3f2-0a5b-4d74-96fb-856388a223a0">9.68</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTpmMmZlNDNkY2U2MGE0YmQ3YWRmNmUwM2JkZmZlZDQ2NS90YWJsZXJhbmdlOmYyZmU0M2RjZTYwYTRiZDdhZGY2ZTAzYmRmZmVkNDY1XzQtMS0xLTEtMA_00ab107d-23e7-400c-92a4-0db99405ba5f">806,226</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTpmMmZlNDNkY2U2MGE0YmQ3YWRmNmUwM2JkZmZlZDQ2NS90YWJsZXJhbmdlOmYyZmU0M2RjZTYwYTRiZDdhZGY2ZTAzYmRmZmVkNDY1XzQtMy0xLTEtMA_f24a209d-fa46-4d8e-b473-b5e7e85f8284">5.08</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options canceled</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTpmMmZlNDNkY2U2MGE0YmQ3YWRmNmUwM2JkZmZlZDQ2NS90YWJsZXJhbmdlOmYyZmU0M2RjZTYwYTRiZDdhZGY2ZTAzYmRmZmVkNDY1XzUtMS0xLTEtMA_fdd0b2a5-62f6-4964-b7c2-eaa2f485bbbd">2,620,867</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTpmMmZlNDNkY2U2MGE0YmQ3YWRmNmUwM2JkZmZlZDQ2NS90YWJsZXJhbmdlOmYyZmU0M2RjZTYwYTRiZDdhZGY2ZTAzYmRmZmVkNDY1XzUtMy0xLTEtMA_6e6652fb-de28-4b9b-85bc-759113ff5bfc">12.39</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options outstanding at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTpmMmZlNDNkY2U2MGE0YmQ3YWRmNmUwM2JkZmZlZDQ2NS90YWJsZXJhbmdlOmYyZmU0M2RjZTYwYTRiZDdhZGY2ZTAzYmRmZmVkNDY1XzYtMS0xLTEtMA_799c6360-34c0-4726-8ad2-e3006b0bc884">9,829,287</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTpmMmZlNDNkY2U2MGE0YmQ3YWRmNmUwM2JkZmZlZDQ2NS90YWJsZXJhbmdlOmYyZmU0M2RjZTYwYTRiZDdhZGY2ZTAzYmRmZmVkNDY1XzYtMy0xLTEtMA_f9cf6248-30bd-4e2b-b2dc-f81a233f9d8b">10.71</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTpmMmZlNDNkY2U2MGE0YmQ3YWRmNmUwM2JkZmZlZDQ2NS90YWJsZXJhbmdlOmYyZmU0M2RjZTYwYTRiZDdhZGY2ZTAzYmRmZmVkNDY1XzYtNS0xLTEtMA_01cf798f-b8e8-48db-8290-adadec8f7d64">7.91</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTpmMmZlNDNkY2U2MGE0YmQ3YWRmNmUwM2JkZmZlZDQ2NS90YWJsZXJhbmdlOmYyZmU0M2RjZTYwYTRiZDdhZGY2ZTAzYmRmZmVkNDY1XzYtNy0xLTEtMA_09fa8e74-62ac-47e0-a28a-3e2483f0a83e">7,472</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options vested and expected to vest at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTpmMmZlNDNkY2U2MGE0YmQ3YWRmNmUwM2JkZmZlZDQ2NS90YWJsZXJhbmdlOmYyZmU0M2RjZTYwYTRiZDdhZGY2ZTAzYmRmZmVkNDY1XzctMS0xLTEtMA_393634d1-e1a5-45f9-85e3-db9a2a38de04">9,829,287</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTpmMmZlNDNkY2U2MGE0YmQ3YWRmNmUwM2JkZmZlZDQ2NS90YWJsZXJhbmdlOmYyZmU0M2RjZTYwYTRiZDdhZGY2ZTAzYmRmZmVkNDY1XzctMy0xLTEtMA_3b18b7e7-a513-4ccc-9ac1-55db4eee553f">10.71</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTpmMmZlNDNkY2U2MGE0YmQ3YWRmNmUwM2JkZmZlZDQ2NS90YWJsZXJhbmdlOmYyZmU0M2RjZTYwYTRiZDdhZGY2ZTAzYmRmZmVkNDY1XzctNS0xLTEtMA_75633d12-45ed-4899-b37a-bd4182c1304c">7.91</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTpmMmZlNDNkY2U2MGE0YmQ3YWRmNmUwM2JkZmZlZDQ2NS90YWJsZXJhbmdlOmYyZmU0M2RjZTYwYTRiZDdhZGY2ZTAzYmRmZmVkNDY1XzctNy0xLTEtMA_d1c8f9a0-c2f9-4d5a-8c22-2344ce5f4352">7,472</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options exercisable at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTpmMmZlNDNkY2U2MGE0YmQ3YWRmNmUwM2JkZmZlZDQ2NS90YWJsZXJhbmdlOmYyZmU0M2RjZTYwYTRiZDdhZGY2ZTAzYmRmZmVkNDY1XzgtMS0xLTEtMA_31193cff-fdcb-4f81-a1e4-a89cb29cff1a">3,993,645</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTpmMmZlNDNkY2U2MGE0YmQ3YWRmNmUwM2JkZmZlZDQ2NS90YWJsZXJhbmdlOmYyZmU0M2RjZTYwYTRiZDdhZGY2ZTAzYmRmZmVkNDY1XzgtMy0xLTEtMA_bc7d66a2-6801-4a0d-9efa-123365c02cb7">10.43</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTpmMmZlNDNkY2U2MGE0YmQ3YWRmNmUwM2JkZmZlZDQ2NS90YWJsZXJhbmdlOmYyZmU0M2RjZTYwYTRiZDdhZGY2ZTAzYmRmZmVkNDY1XzgtNS0xLTEtMA_73b9a0a7-0840-4f69-a657-ab23b069b6cb">6.54</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTpmMmZlNDNkY2U2MGE0YmQ3YWRmNmUwM2JkZmZlZDQ2NS90YWJsZXJhbmdlOmYyZmU0M2RjZTYwYTRiZDdhZGY2ZTAzYmRmZmVkNDY1XzgtNy0xLTEtMA_3eaf44e4-9a4b-4b65-9e82-dd96b7a3468a">5,442</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Newly created shares are issued upon exercises of options. There were no shares subject to Sangamo&#8217;s right of repurchase as of December&#160;31, 2019. The intrinsic value of options exercised was $<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzk4MDI_6c6bfe43-0d6c-4fc6-b52f-8a0b16634688">4.7</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzk4MDY_bf4af03d-e24c-4ef8-a574-8b3022763b24">27.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzk4MTM_c2aab8f5-c73a-4cf9-af6b-6d7726a90bec">12.3</ix:nonFraction>&#160;million during 2019, 2018 and 2017, respectively.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">94</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><ix:continuation id="i50431469146649c6916c485362414921"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At December&#160;31, 2019, the aggregate intrinsic values of outstanding and exercisable options were $<ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzk5MzQ_d4fce347-b105-4ca0-96a9-d907157ec250">7.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzk5NDE_6a6b7247-7da5-405a-9f56-46cb3b09f4ac">5.4</ix:nonFraction> million, respectively. The aggregate intrinsic value of options vested and expected to vest as of December&#160;31, 2019, 2018 and 2017 was $<ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzEwMDUy_d8ed90f2-acd4-4430-a5fa-4603d7529015">7.5</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzEwMDU2_38138f58-9eb5-4b65-9f8a-c2d320669972">24.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ieb7e952fbd38434585f995fe73c66a44_I20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzEwMDYz_69025db3-6257-455b-952f-c038415dbaaa">71.7</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Restricted Stock Units</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During 2019, 2018 and 2017, the Company awarded <ix:nonFraction unitRef="shares" contextRef="i413bd4488b904c0eb127a3a7f3af5412_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzEwMjQw_17aaf444-4dbc-486f-a665-fb95ec8d4b8f">834,745</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="i91e4fec1d21b4176925e0d7555154914_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzEwMjQ0_d1c74da2-a84c-474b-8abf-0d6d498133f0">346,055</ix:nonFraction>, and <ix:nonFraction unitRef="shares" contextRef="i7afd1bb162e74f8188a0eebdfa207e9c_D20170101-20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzEwMjUy_fd84cbe8-a2e8-4f57-a893-1ad033f162ef">12,600</ix:nonFraction> RSUs, respectively. The RSUs awarded in 2019, 2018 and 2017 had an average grant date fair value per award of $<ix:nonFraction unitRef="usdPerShare" contextRef="i413bd4488b904c0eb127a3a7f3af5412_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzEwMzU5_c1434acd-65a3-4cf0-9ac5-ed5c5687004d">9.49</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i91e4fec1d21b4176925e0d7555154914_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzEwMzYz_4fccf640-c948-48a5-852a-e06b564cac0d">17.87</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i7afd1bb162e74f8188a0eebdfa207e9c_D20170101-20171231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzEwMzcw_590fd47c-3fae-42a8-8498-265a2f9c11e4">15.85</ix:nonFraction>, respectively. These awards generally vest in a series of <ix:nonFraction unitRef="installment" contextRef="i413bd4488b904c0eb127a3a7f3af5412_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzEwNDc2_1930a00e-4286-400b-a523-21f3a729c4bc">three</ix:nonFraction> successive equal annual installments. The aggregate fair value of RSUs vested during 2019, 2018 and 2017 was $<ix:nonFraction unitRef="usd" contextRef="i413bd4488b904c0eb127a3a7f3af5412_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzEwNTgy_7ab80eed-14f0-4b03-a82c-5bec9108d632">2.0</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i91e4fec1d21b4176925e0d7555154914_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzEwNTk0_ebe43988-0d29-4e0c-83fb-883a6ab11a2a">0.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i7afd1bb162e74f8188a0eebdfa207e9c_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzEwNjAx_f419a938-1acb-4879-8268-735ca790a689">1.2</ix:nonFraction>&#160;million, respectively.</span></div><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzExODEx_d2ecb868-5a81-4fb8-8a47-9c133674c2f1" escape="true"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of Sangamo&#8217;s RSU activity is as follows:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:54.451%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.756%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.662%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.665%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number of<br/>Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average<br/>Remaining<br/>Contractual&#160;Term</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate&#160;Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">RSUs outstanding at December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTplOWY5YTI3ZWIxYjY0ZWVjYjk2NWQxMDNhMzRlMjhkNi90YWJsZXJhbmdlOmU5ZjlhMjdlYjFiNjRlZWNiOTY1ZDEwM2EzNGUyOGQ2XzItMS0xLTEtMA_ae4440fa-f117-4f9f-ad47-b9ccc35ff7d2">322,701</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">RSUs awarded</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTplOWY5YTI3ZWIxYjY0ZWVjYjk2NWQxMDNhMzRlMjhkNi90YWJsZXJhbmdlOmU5ZjlhMjdlYjFiNjRlZWNiOTY1ZDEwM2EzNGUyOGQ2XzMtMS0xLTEtMA_836d1b9c-f420-46a7-9fd7-eb5abd4cc0f4">834,745</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">RSUs released</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTplOWY5YTI3ZWIxYjY0ZWVjYjk2NWQxMDNhMzRlMjhkNi90YWJsZXJhbmdlOmU5ZjlhMjdlYjFiNjRlZWNiOTY1ZDEwM2EzNGUyOGQ2XzQtMS0xLTEtMA_2fd09729-e06d-4f65-aa71-1d9a9555778d">118,807</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">RSUs forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTplOWY5YTI3ZWIxYjY0ZWVjYjk2NWQxMDNhMzRlMjhkNi90YWJsZXJhbmdlOmU5ZjlhMjdlYjFiNjRlZWNiOTY1ZDEwM2EzNGUyOGQ2XzUtMS0xLTEtMA_a097a622-d44a-42b6-8339-f0ea613e4903">175,789</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">RSUs outstanding at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTplOWY5YTI3ZWIxYjY0ZWVjYjk2NWQxMDNhMzRlMjhkNi90YWJsZXJhbmdlOmU5ZjlhMjdlYjFiNjRlZWNiOTY1ZDEwM2EzNGUyOGQ2XzYtMS0xLTEtMA_997d88d5-86ad-4568-8072-e601d99f6f3d">862,850</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTplOWY5YTI3ZWIxYjY0ZWVjYjk2NWQxMDNhMzRlMjhkNi90YWJsZXJhbmdlOmU5ZjlhMjdlYjFiNjRlZWNiOTY1ZDEwM2EzNGUyOGQ2XzYtMy0xLTEtMA_ebdf48cc-646a-4f54-a034-8009c9ae6fe9">1.22</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTplOWY5YTI3ZWIxYjY0ZWVjYjk2NWQxMDNhMzRlMjhkNi90YWJsZXJhbmdlOmU5ZjlhMjdlYjFiNjRlZWNiOTY1ZDEwM2EzNGUyOGQ2XzYtNS0xLTEtMA_95b972a7-33c2-44d5-96bb-bcc4487ee011">7,222</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">RSUs vested and expected to vest at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="INF" format="ixt:numdotdecimal" name="sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTplOWY5YTI3ZWIxYjY0ZWVjYjk2NWQxMDNhMzRlMjhkNi90YWJsZXJhbmdlOmU5ZjlhMjdlYjFiNjRlZWNiOTY1ZDEwM2EzNGUyOGQ2XzctMS0xLTEtMA_b2f0d9e9-14e9-4cd1-a90c-bd67256e38bb">862,850</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" format="ixt-sec:duryear" name="sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTplOWY5YTI3ZWIxYjY0ZWVjYjk2NWQxMDNhMzRlMjhkNi90YWJsZXJhbmdlOmU5ZjlhMjdlYjFiNjRlZWNiOTY1ZDEwM2EzNGUyOGQ2XzctMy0xLTEtMA_579eb72f-2172-47b4-b453-808a04e54709">1.22</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTplOWY5YTI3ZWIxYjY0ZWVjYjk2NWQxMDNhMzRlMjhkNi90YWJsZXJhbmdlOmU5ZjlhMjdlYjFiNjRlZWNiOTY1ZDEwM2EzNGUyOGQ2XzctNS0xLTEtMA_be9eab51-fb67-4b26-82a1-f224e61cb981">7,222</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">RSUs that vested in 2019, 2018 and 2017 were net-share settled such that the Company withheld shares with value equivalent to the employees&#8217; minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. The total shares withheld were approximately <ix:nonFraction unitRef="shares" contextRef="i413bd4488b904c0eb127a3a7f3af5412_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzEwOTk2_ceff72c3-f037-4036-9231-a0ca959efca4">39,160</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="i91e4fec1d21b4176925e0d7555154914_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzExMDAw_5e826b37-2be5-4b67-8102-231c76b22910">20,193</ix:nonFraction>, and <ix:nonFraction unitRef="shares" contextRef="i7afd1bb162e74f8188a0eebdfa207e9c_D20170101-20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzExMDA4_abd7d098-f2b9-4401-bc0c-394e3cffa7c1">42,243</ix:nonFraction> for 2019, 2018 and 2017, respectively, and were based on the value of the RSUs on their respective issuance dates as determined by the Company&#8217;s closing stock price. Total payments for the employees&#8217; tax obligations to taxing authorities </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">were $<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzExMjQ4_48990781-e720-4923-9456-198acebb8110">0.4</ix:nonFraction>&#160;million</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, $<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzExMjUy_3191f580-9d21-45ae-980a-89a266124dfa">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzExMjU4_15ce1633-a89a-4809-abf3-d1cc58e89265">0.7</ix:nonFraction>&#160;million in 2019, 2018 and 2017, respectively and are reflected as a financing activity within the accompanying Consolidated Statements of Cash Flows.&#160;These net-share settlements had the effect of share repurchases by the Company as they reduced and retired the number of shares that would have otherwise been issued as a result of the vesting and did not represent an expense to the Company.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, there were <ix:nonFraction unitRef="shares" contextRef="i6a1a6094e01242c48030234e32514b5b_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzExNjYw_88a728bd-2f97-413a-926f-580a224616dd">6,691,209</ix:nonFraction> shares reserved for future awards under the Company&#8217;s 2018 Plan and <ix:nonFraction unitRef="shares" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzYwNDczMTM5NjYwOTk_2acafd96-aafc-41a1-b8cb-ef103e6beee8">2,757,600</ix:nonFraction> shares of common stock reserved for future issuance under the ESPP.</span></div></ix:continuation><div id="i9a2bf9013aa44980b5a1f5846290b1a8_106"></div><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzIwMTQ_a6739eba-2807-4156-a9a7-f52eb3d7cdf2" continuedAt="idb740e645d3e4788b165f3de36e0f309" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 9 &#8211; STOCK-BASED COMPENSATION</span></div><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzIwMTU_d35e26bf-9a67-4be2-9b62-4a97423ac32e" escape="true"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table shows total stock-based compensation expense recognized in the accompanying Consolidated Statements of Operations (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:58.322%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.740%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id5101aded6334b1c9c3a881011b6abae_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90YWJsZTphMGU0YTA0MzAxZTU0YzJmOWFlYzdlOTRkOTZhNjU0OC90YWJsZXJhbmdlOmEwZTRhMDQzMDFlNTRjMmY5YWVjN2U5NGQ5NmE2NTQ4XzItMS0xLTEtMA_bf3ba541-f254-4308-bdbd-630cb584a31e">10,135</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i277c3b7360f04d3780bef6a633da1c71_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90YWJsZTphMGU0YTA0MzAxZTU0YzJmOWFlYzdlOTRkOTZhNjU0OC90YWJsZXJhbmdlOmEwZTRhMDQzMDFlNTRjMmY5YWVjN2U5NGQ5NmE2NTQ4XzItMy0xLTEtMA_9681eeef-8bee-4273-9ba7-c2a4f6e6274f">8,249</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia4360f72084d45c580dd59abd6150a88_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90YWJsZTphMGU0YTA0MzAxZTU0YzJmOWFlYzdlOTRkOTZhNjU0OC90YWJsZXJhbmdlOmEwZTRhMDQzMDFlNTRjMmY5YWVjN2U5NGQ5NmE2NTQ4XzItNS0xLTEtMA_8f888b14-37dc-4038-8a43-45008d8a0dd3">5,031</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib25eb7ae48804546b9f361611f4966bb_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90YWJsZTphMGU0YTA0MzAxZTU0YzJmOWFlYzdlOTRkOTZhNjU0OC90YWJsZXJhbmdlOmEwZTRhMDQzMDFlNTRjMmY5YWVjN2U5NGQ5NmE2NTQ4XzMtMS0xLTEtMA_bfa52156-a069-4866-a231-0b8fa35b285c">9,195</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6f39fb4590c1429f8543e94bc2f27f17_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90YWJsZTphMGU0YTA0MzAxZTU0YzJmOWFlYzdlOTRkOTZhNjU0OC90YWJsZXJhbmdlOmEwZTRhMDQzMDFlNTRjMmY5YWVjN2U5NGQ5NmE2NTQ4XzMtMy0xLTEtMA_747b1b09-ac88-42ee-b3e5-198fca53e62d">6,428</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if9d63f212ff549b3a6d95bbdc6243555_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90YWJsZTphMGU0YTA0MzAxZTU0YzJmOWFlYzdlOTRkOTZhNjU0OC90YWJsZXJhbmdlOmEwZTRhMDQzMDFlNTRjMmY5YWVjN2U5NGQ5NmE2NTQ4XzMtNS0xLTEtMA_9659ce93-be62-47e7-a2ed-70f67b6512c3">4,058</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90YWJsZTphMGU0YTA0MzAxZTU0YzJmOWFlYzdlOTRkOTZhNjU0OC90YWJsZXJhbmdlOmEwZTRhMDQzMDFlNTRjMmY5YWVjN2U5NGQ5NmE2NTQ4XzQtMS0xLTEtMA_1059be01-9cb9-4a53-bff3-d08702a90d18">19,330</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90YWJsZTphMGU0YTA0MzAxZTU0YzJmOWFlYzdlOTRkOTZhNjU0OC90YWJsZXJhbmdlOmEwZTRhMDQzMDFlNTRjMmY5YWVjN2U5NGQ5NmE2NTQ4XzQtMy0xLTEtMA_b1c3d286-ea6f-47da-b3c6-a5a0613094cf">14,677</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90YWJsZTphMGU0YTA0MzAxZTU0YzJmOWFlYzdlOTRkOTZhNjU0OC90YWJsZXJhbmdlOmEwZTRhMDQzMDFlNTRjMmY5YWVjN2U5NGQ5NmE2NTQ4XzQtNS0xLTEtMA_5a59f224-242f-4f94-9596-48f25b56f485">9,089</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, total stock-based compensation expense to be recognized in future periods related to unvested stock options was $<ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzMxMw_02ddce33-a27a-45ff-a7d1-ec909a3a5f9b">37.4</ix:nonFraction>&#160;million, which is expected to be expensed over a weighted-average period of <ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzM4NA_5ca358f8-31e6-497a-a0ba-9b72f7454353">2.76</ix:nonNumeric> years. As of December&#160;31, 2019, total stock-based compensation expense to be recognized in future periods related to unvested RSUs was $<ix:nonFraction unitRef="usd" contextRef="i11cbad67c18a49ca910e920c1e2d9646_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzUwMg_bd3ec0a8-ef78-4769-a27a-b20ae1d6c5a7">7.0</ix:nonFraction>&#160;million, which is expected to be expensed over a weighted-average period of <ix:nonNumeric contextRef="i413bd4488b904c0eb127a3a7f3af5412_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzU3Mw_e3d8aff4-d00f-414e-8cfd-a0097a192c0e">2.11</ix:nonNumeric> years. There was <ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzU4Nw_14451ecf-0525-4f28-a6bc-af32b2389540"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzU4Nw_87d8beff-197a-4af5-a47d-b685fa210e8a"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzU4Nw_f9d3c00a-23f9-4cd2-87ec-02d375a542c0">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> capitalized stock-based employee compensation expense as of December&#160;31, 2019, 2018 or 2017.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Valuation Assumptions</span></div><div style="text-indent:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Employee stock-based compensation expense was determined using the Black-Scholes option valuation model for stock options and employee share purchases under the ESPP. Option valuation models require the input of subjective assumptions and these assumptions can vary over time. The fair value of RSUs was based on the closing price of the underlying common stock on the date of grant.</span></div></ix:nonNumeric><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">95</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><ix:continuation id="idb740e645d3e4788b165f3de36e0f309"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company bases its determination of expected volatility through its assessment of the historical volatility of its common stock. The Company relied on its historical exercise and post-vested termination activity for estimating its expected term for use in determining the fair value of these options.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The weighted-average estimated fair value per share of options granted during 2019, 2018 and 2017 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzEzMDg_e4ae4763-d18c-4988-b8f5-29bf0907458c">6.37</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzEzMTI_aa7df587-213d-48dc-aa12-9e816f0fe218">11.39</ix:nonFraction>, and $<ix:nonFraction unitRef="usdPerShare" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzEzMjA_3217d15c-7ee4-4fda-9a27-cdca33eb7226">4.10</ix:nonFraction>, respectively, based upon the assumptions used in the Black-Scholes valuation model. <ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzIwMTY_6d5f9d4a-0cb2-4d6e-8bda-d058a1e1afed" continuedAt="i7c3bf91ec2fa4aedbc407adfc8ee2369" escape="true">The assumptions used for estimating the fair value of the employee stock options were as follows:</ix:nonNumeric></span></div><div style="margin-bottom:6pt;"><ix:continuation id="i7c3bf91ec2fa4aedbc407adfc8ee2369"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:54.158%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.929%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.929%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.518%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.68-2.25%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.53-2.96%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.81-2.28%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term (in years)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.50-5.62</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.59-5.61</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.73-5.83</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield of stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i280d0aff0b424211b1e87b1cc76e27a7_D20190101-20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90YWJsZTo2YWEwNDRiZmRiOGU0MDQxYmM5ZmU1Y2VkZmI0YTRkZi90YWJsZXJhbmdlOjZhYTA0NGJmZGI4ZTQwNDFiYzlmZTVjZWRmYjRhNGRmXzQtMS0xLTEtMA_f7a4dd8b-55a8-4e16-a391-cc12829a28a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ia0b92851791b4e9e8a15edb926cc2b4e_D20180101-20181231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90YWJsZTo2YWEwNDRiZmRiOGU0MDQxYmM5ZmU1Y2VkZmI0YTRkZi90YWJsZXJhbmdlOjZhYTA0NGJmZGI4ZTQwNDFiYzlmZTVjZWRmYjRhNGRmXzQtMy0xLTEtMA_17c202d8-e3cc-4039-bc73-5c40ece065ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i6568a8c2edac4a3c89060b40650283bd_D20170101-20171231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90YWJsZTo2YWEwNDRiZmRiOGU0MDQxYmM5ZmU1Y2VkZmI0YTRkZi90YWJsZXJhbmdlOjZhYTA0NGJmZGI4ZTQwNDFiYzlmZTVjZWRmYjRhNGRmXzQtNS0xLTEtMA_5fea366b-daa3-4d44-8568-f482ffe9be08">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">76.46-78.39%</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72.33-75.49%</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">71.11-72.30%</span></td></tr></table></ix:continuation></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Employees purchased <ix:nonFraction unitRef="shares" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzE1NDE_d4d2cb3a-b5ac-4c59-896f-ff8cc17c7c49">249,364</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzE1NDU_f1792845-12ee-4a2e-94ae-b689b73efd97">328,710</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzE1NTI_dd75c6e1-1443-48ff-936c-2fc736aa721b">253,994</ix:nonFraction> shares of common stock through the ESPP at an average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="2" name="sgmo:StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzE2Mjc_0b8f26ba-6d00-46bd-839a-fc38e4394573">8.53</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="2" name="sgmo:StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzE2MzE_b018a22b-de6c-40ae-bf8b-dce1ad2dee7b">4.51</ix:nonFraction>, and $<ix:nonFraction unitRef="usdPerShare" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="2" name="sgmo:StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzE2Mzk_b43cd491-fb81-48f9-952b-dbf3b360f126">3.22</ix:nonFraction> per share during 2019, 2018 and 2017, respectively. The weighted-average estimated fair values of shares purchased under the Company&#8217;s ESPP during 2019, 2018 and 2017 were $<ix:nonFraction unitRef="usdPerShare" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="2" name="sgmo:EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzE4MDE_d49ac7e8-a86e-410f-9c14-6d5ca7212e83">4.70</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="2" name="sgmo:EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzE4MDU_834bb94a-d62a-417a-afdd-7b48a686b30c">7.07</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="2" name="sgmo:EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzE4MTI_731016d3-aba5-4d3a-80c4-b060928ee04d">2.37</ix:nonFraction>, respectively, based upon the assumptions used in the Black-Scholes valuation model.</span></div><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzIwMTM_40c270eb-8da1-4310-bbef-11a2fcbcab34" escape="true"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The weighted&#8211;average assumptions used for estimating the fair value of the ESPP purchase rights are as follows:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:53.701%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.035%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.181%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.623%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.53-2.42%</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.16-2.80%</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.44-0.76%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term (in years)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 &#8211; 2.0</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5-2.0</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5-2.0</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield of stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ibf6eda356cbb4886a9bc71ebb4c979a6_D20190101-20191231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90YWJsZTpjZmY1NWYyNjlmMWU0YzAyYjNkY2Y3MzFjMzFjYzgxMC90YWJsZXJhbmdlOmNmZjU1ZjI2OWYxZTRjMDJiM2RjZjczMWMzMWNjODEwXzQtMS0xLTEtMA_fd20f79a-652b-432c-a522-9bb3c8553d70">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i12f6a30ee0794a7a8c75e504690f5c2c_D20180101-20181231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90YWJsZTpjZmY1NWYyNjlmMWU0YzAyYjNkY2Y3MzFjMzFjYzgxMC90YWJsZXJhbmdlOmNmZjU1ZjI2OWYxZTRjMDJiM2RjZjczMWMzMWNjODEwXzQtMy0xLTEtMA_daa9e24a-0997-4342-a099-3781a59b398a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ib7ba96e253094ecbb1f17619de72a1e5_D20170101-20171231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90YWJsZTpjZmY1NWYyNjlmMWU0YzAyYjNkY2Y3MzFjMzFjYzgxMC90YWJsZXJhbmdlOmNmZjU1ZjI2OWYxZTRjMDJiM2RjZjczMWMzMWNjODEwXzQtNS0xLTEtMA_4d0414db-1d49-4ede-b35f-47769843bb96">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51.02-91.96%</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73.21-83.25%</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66.39-82.19%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_148"></div><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNDgvZnJhZzo0YzJlZmNmNjJhNzI0M2U3YTRmM2FlMjE0ODNmOGJlZS90ZXh0cmVnaW9uOjRjMmVmY2Y2MmE3MjQzZTdhNGYzYWUyMTQ4M2Y4YmVlXzU5OA_8d6bc1c1-8e1c-48bb-8151-e359cbe17243" escape="true"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 10 &#8211; EMPLOYEE BENEFIT PLAN</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company sponsors a defined-contribution savings plan under Section&#160;401(k) of the Internal Revenue Code covering all full-time employees (&#8220;Sangamo 401(k) Plan&#8221;). The Sangamo 401(k) Plan is intended to qualify under Section&#160;401 of the Internal Revenue Code.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company matched employee contributions equal to <ix:nonFraction unitRef="number" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNDgvZnJhZzo0YzJlZmNmNjJhNzI0M2U3YTRmM2FlMjE0ODNmOGJlZS90ZXh0cmVnaW9uOjRjMmVmY2Y2MmE3MjQzZTdhNGYzYWUyMTQ4M2Y4YmVlXzQ5NDc4MDIzMjU2MTA_0b52a11d-6d01-427e-aa36-cc89831c6ee9"><ix:nonFraction unitRef="number" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNDgvZnJhZzo0YzJlZmNmNjJhNzI0M2U3YTRmM2FlMjE0ODNmOGJlZS90ZXh0cmVnaW9uOjRjMmVmY2Y2MmE3MjQzZTdhNGYzYWUyMTQ4M2Y4YmVlXzQ5NDc4MDIzMjU2MTA_ec7ac6f5-5d78-49f0-af47-3d401ae3bbc2"><ix:nonFraction unitRef="number" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNDgvZnJhZzo0YzJlZmNmNjJhNzI0M2U3YTRmM2FlMjE0ODNmOGJlZS90ZXh0cmVnaW9uOjRjMmVmY2Y2MmE3MjQzZTdhNGYzYWUyMTQ4M2Y4YmVlXzQ5NDc4MDIzMjU2MTA_f0c07e03-2316-4041-80be-f775c07b7094">50</ix:nonFraction></ix:nonFraction></ix:nonFraction>% for the first <ix:nonFraction unitRef="number" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNDgvZnJhZzo0YzJlZmNmNjJhNzI0M2U3YTRmM2FlMjE0ODNmOGJlZS90ZXh0cmVnaW9uOjRjMmVmY2Y2MmE3MjQzZTdhNGYzYWUyMTQ4M2Y4YmVlXzQ5NDc4MDIzMjU2MTM_20c15a2c-c6e1-4bae-a798-e70ffccfd34c"><ix:nonFraction unitRef="number" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNDgvZnJhZzo0YzJlZmNmNjJhNzI0M2U3YTRmM2FlMjE0ODNmOGJlZS90ZXh0cmVnaW9uOjRjMmVmY2Y2MmE3MjQzZTdhNGYzYWUyMTQ4M2Y4YmVlXzQ5NDc4MDIzMjU2MTM_754739f1-e1ec-4323-a502-c5eaefa57e19"><ix:nonFraction unitRef="number" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNDgvZnJhZzo0YzJlZmNmNjJhNzI0M2U3YTRmM2FlMjE0ODNmOGJlZS90ZXh0cmVnaW9uOjRjMmVmY2Y2MmE3MjQzZTdhNGYzYWUyMTQ4M2Y4YmVlXzQ5NDc4MDIzMjU2MTM_fc0aa7cc-6822-42e7-877a-0c5e65f4edc9">8</ix:nonFraction></ix:nonFraction></ix:nonFraction>% in 2019, 2018 and 2017, up to a limit of $<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNDgvZnJhZzo0YzJlZmNmNjJhNzI0M2U3YTRmM2FlMjE0ODNmOGJlZS90ZXh0cmVnaW9uOjRjMmVmY2Y2MmE3MjQzZTdhNGYzYWUyMTQ4M2Y4YmVlXzM5NA_c1d67471-7000-4053-b43c-1bfb5ecc0c95">4,000</ix:nonFraction> in 2019, 2018 and 2017. Matching funds are fully vested when contributed. Contributions to the Sangamo 401(k) Plan by the Company were $<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNDgvZnJhZzo0YzJlZmNmNjJhNzI0M2U3YTRmM2FlMjE0ODNmOGJlZS90ZXh0cmVnaW9uOjRjMmVmY2Y2MmE3MjQzZTdhNGYzYWUyMTQ4M2Y4YmVlXzUzNg_bfd11135-343c-458f-a01c-2863120f3700">0.9</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNDgvZnJhZzo0YzJlZmNmNjJhNzI0M2U3YTRmM2FlMjE0ODNmOGJlZS90ZXh0cmVnaW9uOjRjMmVmY2Y2MmE3MjQzZTdhNGYzYWUyMTQ4M2Y4YmVlXzU0MA_9faae97b-e3e0-46b7-93d6-3bc623646877">0.8</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNDgvZnJhZzo0YzJlZmNmNjJhNzI0M2U3YTRmM2FlMjE0ODNmOGJlZS90ZXh0cmVnaW9uOjRjMmVmY2Y2MmE3MjQzZTdhNGYzYWUyMTQ4M2Y4YmVlXzU0OA_44952aaf-7fc3-4a3b-bb74-59c96c3fbb87">0.5</ix:nonFraction>&#160;million for the years ended December&#160;31, 2019, 2018 and 2017, respectively.</span></div></ix:nonNumeric><div id="i9a2bf9013aa44980b5a1f5846290b1a8_139"></div><div style="margin-top:3pt;"><span><br/></span></div><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90ZXh0cmVnaW9uOmU1ZTQ2NmFmOGMxZjRhMjE5OTAyMTIwZmRkMDc4ZDc5XzY4NTc_cd150003-8bbc-4ccf-b74c-3452728e537c" continuedAt="i6d8786c3a5834983b2b5e7939863b162" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 11 &#8211; INCOME TAXES </span></div><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90ZXh0cmVnaW9uOmU1ZTQ2NmFmOGMxZjRhMjE5OTAyMTIwZmRkMDc4ZDc5XzY4NTI_59120dca-788b-4126-b030-08c07e21163c" escape="true"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The domestic and foreign components of loss before income taxes were as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:61.343%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.731%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Domestic</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZToyYzMxYzE0MGIxMjU0ODRiODAzOWViYTAwY2MwNzFmMy90YWJsZXJhbmdlOjJjMzFjMTQwYjEyNTQ4NGI4MDM5ZWJhMDBjYzA3MWYzXzItMS0xLTEtMA_af04ce59-2972-44b5-9917-f2f430264f84">77,354</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZToyYzMxYzE0MGIxMjU0ODRiODAzOWViYTAwY2MwNzFmMy90YWJsZXJhbmdlOjJjMzFjMTQwYjEyNTQ4NGI4MDM5ZWJhMDBjYzA3MWYzXzItMy0xLTEtMA_7fbd9a40-8408-4709-9592-320cffe1654a">65,695</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZToyYzMxYzE0MGIxMjU0ODRiODAzOWViYTAwY2MwNzFmMy90YWJsZXJhbmdlOjJjMzFjMTQwYjEyNTQ4NGI4MDM5ZWJhMDBjYzA3MWYzXzItNS0xLTEtMA_fbe79e08-e406-4f7b-91a5-8fee51b53448">54,568</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZToyYzMxYzE0MGIxMjU0ODRiODAzOWViYTAwY2MwNzFmMy90YWJsZXJhbmdlOjJjMzFjMTQwYjEyNTQ4NGI4MDM5ZWJhMDBjYzA3MWYzXzMtMS0xLTEtMA_61d4fcb3-22f2-43fd-9d0b-d54307272728">18,065</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZToyYzMxYzE0MGIxMjU0ODRiODAzOWViYTAwY2MwNzFmMy90YWJsZXJhbmdlOjJjMzFjMTQwYjEyNTQ4NGI4MDM5ZWJhMDBjYzA3MWYzXzMtMy0xLTEtMA_a53e988a-a6b4-4fac-b395-8099dfc4191d">3,194</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZToyYzMxYzE0MGIxMjU0ODRiODAzOWViYTAwY2MwNzFmMy90YWJsZXJhbmdlOjJjMzFjMTQwYjEyNTQ4NGI4MDM5ZWJhMDBjYzA3MWYzXzMtNS0xLTEtMA_177238ab-7a11-4f2d-ab02-cf21a2d0ae20">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss before income taxes</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZToyYzMxYzE0MGIxMjU0ODRiODAzOWViYTAwY2MwNzFmMy90YWJsZXJhbmdlOjJjMzFjMTQwYjEyNTQ4NGI4MDM5ZWJhMDBjYzA3MWYzXzQtMS0xLTEtMA_c51aa813-b33b-4e37-9864-e11c5ac1528a">95,419</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZToyYzMxYzE0MGIxMjU0ODRiODAzOWViYTAwY2MwNzFmMy90YWJsZXJhbmdlOjJjMzFjMTQwYjEyNTQ4NGI4MDM5ZWJhMDBjYzA3MWYzXzQtMy0xLTEtMA_e912b330-9c1f-4016-9e23-412f7e71e8ce">68,889</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZToyYzMxYzE0MGIxMjU0ODRiODAzOWViYTAwY2MwNzFmMy90YWJsZXJhbmdlOjJjMzFjMTQwYjEyNTQ4NGI4MDM5ZWJhMDBjYzA3MWYzXzQtNS0xLTEtMA_752c1a1d-7728-49b6-8b10-09c91c436b39">54,568</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">96</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><ix:continuation id="i6d8786c3a5834983b2b5e7939863b162" continuedAt="i2a4422be77484eeca865ab2e2a60ddcd"><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90ZXh0cmVnaW9uOmU1ZTQ2NmFmOGMxZjRhMjE5OTAyMTIwZmRkMDc4ZDc5XzY4NTM_224bece4-5798-4206-b7cb-637c2d7d3b45" escape="true"><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The benefit for income taxes consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:61.343%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.731%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Benefit for income taxes:</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Federal</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzQtMS0xLTEtMA_524e74a7-4fdb-4ed4-bebd-9969996c1c73">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzQtMy0xLTEtMA_3c7ae08d-79ee-4333-bb3f-67e73f8f5764">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzQtNS0xLTEtMA_75520391-2932-46e4-8024-69ce02fdec4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzUtMS0xLTEtMA_84b90953-08b9-4e8f-a676-ab290ffb77aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzUtMy0xLTEtMA_38a1ad35-391a-411f-83d4-68ed0ea371f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzUtNS0xLTEtMA_29f1711f-d378-4958-9005-6aa5e70b9c05">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzYtMS0xLTEtMA_cd5b9f9a-b37a-472a-8d32-304d5ad07f24">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzYtMy0xLTEtMA_70942325-fea5-42ee-afd5-c25763e92f6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzYtNS0xLTEtMA_2d299333-24cc-4a26-851d-a58c86aceaa7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Subtotal</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzctMS0xLTEtMA_0a3d967d-4ea4-4cf0-b934-a819826640a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzctMy0xLTEtMA_4551dd94-b957-4484-817b-82fcb3fd057f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzctNS0xLTEtMA_e57cda2d-ab52-46ba-baa9-bde1141b625c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred:</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Federal</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzktMS0xLTEtMA_6d2bab09-037f-4c14-9c7f-15876f888e6e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzktMy0xLTEtMA_ce2a663e-9978-4655-994e-708efeb2bbbb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzktNS0xLTEtMA_83e12766-f053-4654-a465-362356e9f044">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzEwLTEtMS0xLTA_e2db9a0b-3632-4800-96c3-dd610a7f6528">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzEwLTMtMS0xLTA_9a28b9bf-fadc-4397-bbad-5864a9443127">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzEwLTUtMS0xLTA_62823e6d-18d6-49db-9e58-2f708a49b2f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzExLTEtMS0xLTA_805aa502-3606-47c4-94c4-afc28766f06f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzExLTMtMS0xLTA_5e63028b-c2ef-4f44-82b9-80b24aad1913">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzExLTUtMS0xLTA_d549e7a5-1112-437f-b357-5cb41ac29e9d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Subtotal</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzEyLTEtMS0xLTA_94cc6af1-b74d-4e26-8152-27993b9ca6ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzEyLTMtMS0xLTA_dad6bb14-1cea-4934-80c5-979aefd3d986">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzEyLTUtMS0xLTA_5e5fc1be-ee79-4909-ba11-ba88fa7f0a24">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax benefit</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzEzLTEtMS0xLTA_b4f2255f-2a1f-4494-8f87-904d157317f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzEzLTMtMS0xLTA_f5bfdf78-1bb4-4512-a213-b48cade41bf4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzEzLTUtMS0xLTA_f7b3f53c-6411-4d6e-952e-1c292b530746">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90ZXh0cmVnaW9uOmU1ZTQ2NmFmOGMxZjRhMjE5OTAyMTIwZmRkMDc4ZDc5Xzc2OTY1ODE0MDIyMzY_b0e7ecda-66d0-47b2-a708-8d5c409bf427" escape="true"><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The difference between the benefit for income taxes and the amount computed by applying the federal statutory income tax rate to loss before taxes is explained as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:60.848%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.894%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.894%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.896%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Tax at federal statutory rate</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzItMS0xLTEtMA_502148dd-38e2-49f5-a401-67f736015f2d">20,038</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzItMy0xLTEtMA_c9778374-f7be-4810-92bb-e56e8c5cbee7">14,467</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzItNS0xLTEtMA_dce8ad90-3918-46cc-8b25-35a9e1bc5f73">18,553</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State taxes, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzMtMS0xLTEtMA_fa7037bf-6753-41cb-a332-5714d8d6eb4f">9,597</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzMtMy0xLTEtMA_5b3731ca-d81d-47eb-bd72-b214f85f20ea">2,849</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzMtNS0xLTEtMA_587cd78d-cf3e-458e-a15f-40914f32e47e">795</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Federal rate change</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzQtMS0xLTEtMA_175202e5-c042-4475-8690-a824c18ca791">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzQtMy0xLTEtMA_1504d724-bd57-4e22-a992-9dc42d90e15f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzQtNS0xLTEtMA_1e42d817-bd36-4b9d-b301-182b96a7edc7">53,045</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign rate differential</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzUtMS0xLTEtMA_5575b7a6-a4c1-4e7d-8c8d-fe138db6b41e">665</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzUtMy0xLTEtMA_0f625b00-0aba-42e9-a6dd-e03d9e1278b0">177</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzUtNS0xLTEtMA_b92f3f9e-f35d-44bf-bb6c-b534db5843f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-deductible stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzYtMS0xLTEtMA_791fa3ac-f1c5-415c-bafa-327792e92c2d">2,817</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="sgmo:IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzYtMy0xLTEtMA_995719e7-a338-4d45-9c90-620104650e15">2,729</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzYtNS0xLTEtMA_b43a6b23-2f1c-410e-9c35-deba0f3a174f">2,120</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research credits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzctMS0xLTEtMA_302490ed-4f04-4993-8b36-d534020085e5">3,429</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzctMy0xLTEtMA_57867961-00be-40f4-93c7-0ce2aeacdba8">1,005</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzctNS0xLTEtMA_fec83c4e-99d9-4b33-8a4f-1c77b9517555">869</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in valuation allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzgtMS0xLTEtMA_96c09646-07ed-4291-adc6-44670632aca8">29,655</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzgtMy0xLTEtMA_a752299c-d4d1-429a-b196-9380d6d4f1a9">20,271</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzgtNS0xLTEtMA_67d39f4d-44ec-4fb9-9e2c-ec0fb0e40a58">36,575</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzktMS0xLTEtMA_0215e937-6980-4b3f-ab92-a519daf8db2e">1,257</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzktMy0xLTEtMA_cce2fb62-17d4-43a5-886b-6966c0ddfc4c">956</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzktNS0xLTEtMA_07880771-6a1c-4592-a905-a11ef7fef985">37</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax benefit</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzEwLTEtMS0xLTA_25d84bae-f288-46a2-80ad-c430974415a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzEwLTMtMS0xLTA_b60f2d01-219b-4c72-9027-e41c17fbf45a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzEwLTUtMS0xLTA_3d23ff14-d8b8-4e1b-83f5-75f7f41e51ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">___________________</span></div><div style="text-indent:-36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(1)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt;">For the year ended December&#160;31, 2017 the statutory tax rate was <ix:nonFraction unitRef="number" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90ZXh0cmVnaW9uOmU1ZTQ2NmFmOGMxZjRhMjE5OTAyMTIwZmRkMDc4ZDc5XzQ5NDc4MDIzMzE5MDQ_764c711a-4552-46fc-80b5-371a444166a2">35</ix:nonFraction>%. For the years ended December&#160;31, 2018 and 2019, as a result of Tax Reform, the statutory tax rate was decreased to <ix:nonFraction unitRef="number" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90ZXh0cmVnaW9uOmU1ZTQ2NmFmOGMxZjRhMjE5OTAyMTIwZmRkMDc4ZDc5XzU2NQ_53615296-0189-4005-9922-17cdf83bbda4"><ix:nonFraction unitRef="number" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90ZXh0cmVnaW9uOmU1ZTQ2NmFmOGMxZjRhMjE5OTAyMTIwZmRkMDc4ZDc5XzU2NQ_6d4c8a72-c25d-49e0-b02c-eddbf96d897a">21</ix:nonFraction></ix:nonFraction>%.</span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">97</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><ix:continuation id="i2a4422be77484eeca865ab2e2a60ddcd" continuedAt="i4330da4104864ab5beff341725c32fcf"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. <ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90ZXh0cmVnaW9uOmU1ZTQ2NmFmOGMxZjRhMjE5OTAyMTIwZmRkMDc4ZDc5XzY4NTU_d73aee2c-8f27-46a7-ba35-7d623b5c7b3c" continuedAt="ie5475f353ce046eca9aa44b2b849274c" escape="true">Significant components of the Company&#8217;s deferred tax assets are as follows (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:6pt;"><ix:continuation id="ie5475f353ce046eca9aa44b2b849274c"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:73.806%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.731%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax assets:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net operating loss carryforwards</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzQtMS0xLTEtMA_e4f920a7-e170-43ec-afae-b0f4e5f6a7d2">133,765</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzQtMy0xLTEtMA_6a3a027c-04bc-43dc-84f9-055057267a98">138,896</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development tax credit carryforwards</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzUtMS0xLTEtMA_0a6e06c8-c78a-442a-b450-6733d16c6f68">21,459</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzUtMy0xLTEtMA_b468fb62-187f-4878-b17f-8f0a53279837">16,829</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzYtMS0xLTEtMA_51856f22-fafc-400c-87f9-dad458a481b9">4,194</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzYtMy0xLTEtMA_85856380-eaf6-4382-8278-7568f174ee09">3,801</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzctMS0xLTEtMA_8819dca6-3aab-4fab-9e26-4781cfd73b34">32,171</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzctMy0xLTEtMA_759bc0bd-22a8-43dc-b528-fd9c5016ac12">3,191</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fixed assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzgtMS0xLTEtMTUwMTg_96e00a51-273f-4b67-b103-fd542aa6ab6f">11,282</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzgtMy0xLTEtMTUwMjE_d2968cf3-b27b-4272-bc75-0ad7c58ad49c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lease liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:DeferredTaxAssetsLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzktMS0xLTEtMTUwMTI_3e35606d-3546-4246-b9c2-5d3384e53009">11,722</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:zerodash" name="sgmo:DeferredTaxAssetsLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzktMy0xLTEtMTUwMTU_495bf6aa-83f2-4239-a8bb-f29753aeb67c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Build to suit lease liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:zerodash" name="sgmo:DeferredTaxAssetsBuildToSuitLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzgtMS0xLTEtMA_b3878636-0700-43e5-8606-e042ca77dfa6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:DeferredTaxAssetsBuildToSuitLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzgtMy0xLTEtMA_5d4c6c50-faeb-4a3a-ba53-7bf3a8bbd355">6,400</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accruals and reserves</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzExLTEtMS0xLTE1MTAx_1f114e25-33a5-4d4b-b4e8-e570db9c63e1">675</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzExLTMtMS0xLTE1MTA0_b96a9919-7ef9-496a-bfde-22f71cbf920d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzktMS0xLTEtMA_40981d9c-827f-4c2b-aef0-814f65a94542">151</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzktMy0xLTEtMA_fac6a64e-faa1-49d8-a47e-e53037d181fd">604</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total deferred tax asset</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzEwLTEtMS0xLTA_4f47bdec-502d-4388-a437-d89655f3d999">215,419</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzEwLTMtMS0xLTA_e10dea67-468f-4217-999a-303d49fd957b">169,721</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Valuation allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzExLTEtMS0xLTA_c8a7dbd7-5d6e-4e55-8c67-55476b807caa">187,724</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzExLTMtMS0xLTA_003befcf-7791-4ff9-b0d1-de9bbb973f96">158,150</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net deferred tax assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzEyLTEtMS0xLTA_ac72e818-4e02-4617-a5b0-a47685c7fb94">27,695</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzEyLTMtMS0xLTA_f795e806-cede-4c15-90f6-9fb8984f89af">11,571</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzE0LTEtMS0xLTA_8aac447a-bbcf-4f55-8877-e3c949065f81">13,609</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzE0LTMtMS0xLTA_ff67a815-288e-447d-a37b-151537ee57bb">14,100</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzE3LTEtMS0xLTE1MDMw_b4e1dcb8-d007-44d3-bee8-c407a8d4f1eb">20,656</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fixed assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzE1LTEtMS0xLTA_1fea8c5b-ccc4-439d-b692-3755001211b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzE1LTMtMS0xLTA_d5d38ad0-887e-4d8f-b4bc-84bfd48e44bf">4,176</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net deferred tax liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzE2LTEtMS0xLTA_54c0bd7b-ef51-421e-914a-d1b764c84035">34,265</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzE2LTMtMS0xLTA_d7826a1c-9093-4a4e-b744-9385f4374f60">18,276</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total deferred tax liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzE3LTEtMS0xLTA_36c936ac-b3a9-4130-8751-242c86d41575">6,570</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzE3LTMtMS0xLTA_19cfb23b-a7bb-4124-86a1-8433b3da351e">6,705</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2018, the Company acquired Sangamo France. The Company recorded goodwill and intangible assets as part of accounting for the acquisition of Sangamo France. There is no corresponding tax basis for the goodwill or intangible assets. A portion of the intangible assets acquired were for the use in a particular research and development project IPR&amp;D and are considered indefinite-lived assets with no tax basis.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The changes in the fair value of the unrealized gain/loss on securities investment are recorded as a component of accumulated other comprehensive income, net of a provision for income taxes.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A valuation allowance is recorded when it is more likely than not that all or some portion of the deferred income tax assets will not be realized. The Company regularly assesses the need for a valuation allowance against its deferred income tax assets by considering both positive and negative evidence related to whether it is more likely than not that the Company&#8217;s deferred income tax assets will be realized. In evaluating the Company&#8217;s ability to recover its deferred income tax assets within the jurisdiction from which they arise, the Company considers all available positive and negative evidence, including scheduled reversals of deferred income tax liabilities, projected future taxable income, tax-planning strategies, and results of recent operations. Accordingly, based upon the Company&#8217;s analysis of these factors the net deferred tax assets have been substantially offset by a valuation allowance. The valuation allowance (decreased) increased by $(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90ZXh0cmVnaW9uOmU1ZTQ2NmFmOGMxZjRhMjE5OTAyMTIwZmRkMDc4ZDc5XzI0NTM_86f86cfe-8524-43ac-ae4d-198b88517d24">29.6</ix:nonFraction>)&#160;million, $<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90ZXh0cmVnaW9uOmU1ZTQ2NmFmOGMxZjRhMjE5OTAyMTIwZmRkMDc4ZDc5XzI0NTc_0e85893d-ca39-43be-83b1-633870032308">45.3</ix:nonFraction>&#160;million and $(<ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-5" sign="-" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90ZXh0cmVnaW9uOmU1ZTQ2NmFmOGMxZjRhMjE5OTAyMTIwZmRkMDc4ZDc5XzI0NjQ_b063db8e-0f53-42a8-ae3e-68ae1116591d">28.9</ix:nonFraction>)&#160;million for the years ended December&#160;31, 2019, 2018 and 2017, respectively. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, Sangamo had net operating loss carryforwards for federal and state income tax purposes of approximately $<ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90ZXh0cmVnaW9uOmU1ZTQ2NmFmOGMxZjRhMjE5OTAyMTIwZmRkMDc4ZDc5XzI2MzA_3a26383d-d6b3-41a2-bcbb-3a1996226c84">489.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90ZXh0cmVnaW9uOmU1ZTQ2NmFmOGMxZjRhMjE5OTAyMTIwZmRkMDc4ZDc5XzI2Mzc_769a6166-d1d4-494d-b2a4-2a6dbd94b684">164.7</ix:nonFraction>&#160;million, respectively. The federal net operating loss generated before 2018 will begin to expire in 2024 and will keep expiring through 2037, if not utilized. Federal net operating loss generated in 2018 will carry forward indefinitely. If not utilized, the state net operating loss carryforwards will begin to expire in 2029, respectively. The Company&#8217;s French net operating loss carryforward balance is $<ix:nonFraction unitRef="usd" contextRef="ic95b30c3bdb047e09c97a070b92d9bd5_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90ZXh0cmVnaW9uOmU1ZTQ2NmFmOGMxZjRhMjE5OTAyMTIwZmRkMDc4ZDc5XzI3OTU_cad090ec-a2a5-4acb-94e7-6825cfd7aee8">147.9</ix:nonFraction>&#160;million, which carries over indefinitely. The Company also has federal and state research tax credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90ZXh0cmVnaW9uOmU1ZTQ2NmFmOGMxZjRhMjE5OTAyMTIwZmRkMDc4ZDc5XzI5MDc_b93ec417-21b0-4e6d-870a-1013f0d93bca">16.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90ZXh0cmVnaW9uOmU1ZTQ2NmFmOGMxZjRhMjE5OTAyMTIwZmRkMDc4ZDc5XzI5MTQ_cbb36661-5dd1-4b00-b48a-48a5fab691d8">15.2</ix:nonFraction>&#160;million, respectively. The federal research credits began to expire in 2018 while the state research credits have no expiration date. Utilization of the Company&#8217;s net operating loss carryforwards and research tax credit carryforwards may be subject to substantial annual limitations due to the ownership change limitations provided by the Internal Revenue Code and similar state provisions. The annual limitation could result in the expiration of the net operating loss carryforwards and research tax credit carryforwards before utilization.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On December&#160;22, 2017, the current administration signed the Tax Cuts and Jobs Act (&#8220;Tax Reform&#8221;) into legislation. The Tax Reform makes significant changes to the U.S. corporate income tax law including, but not limited to, (1) reducing the </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">98</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><ix:continuation id="i4330da4104864ab5beff341725c32fcf"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">U.S. federal corporate tax rate to 35% from 21% and (2) requiring a one-time mandatory transition tax on previously deferred foreign earnings of U.S. subsidiaries. Under ASC Topic 740, the effects of changes in tax rates and laws are recognized in the period in which the new legislation is enacted. In the case of U.S. federal income taxes, the enactment date is the date the bill becomes law.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On December 22, 2017, the SEC staff issued Staff Accounting Bulletin No. 118 (&#8220;SAB 118&#8221;), which provides guidance on accounting for the tax effects of the Tax Reform. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Reform enactment date for companies to complete the accounting under ASC Topic 740 for the year ended December&#160;31, 2018. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Tax Reform for which the accounting under ASC Topic 740 is complete. The Company has finished their analysis as of the measurement period closing of December 22, 2018 after application of law changes were reviewed by the Company. There were no subsequent adjustments as the conclusions have remained the same.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s policy is to reinvest the earnings of its non-U.S. subsidiaries in those operations. The Company does not provide for U.S. taxes on the earnings of foreign subsidiaries because the Company intends to reinvest such earnings offshore indefinitely. However, if these funds were repatriated, the Company would be required to accrue and pay applicable U.S. taxes and withholding taxes. Due to the losses generated in foreign countries there are no earnings to repatriate.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company files federal and state income tax returns with varying statutes of limitations. The tax years from 2002 forward remain open to examination due to the carryover of net operating losses or tax credits. The Company also files United Kingdom and French income tax returns, and the tax years from 2008 and thereafter remain open in the United Kingdom and 2016 and thereafter in France are still subject to examination.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. As of December&#160;31, 2019, the Company had <ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90ZXh0cmVnaW9uOmU1ZTQ2NmFmOGMxZjRhMjE5OTAyMTIwZmRkMDc4ZDc5XzY0NzQ_2206131c-cc14-4e67-93b2-c99867f2e50c">no</ix:nonFraction> accrued interest and/or penalties. The unrecognized tax benefits may change during the next year for items that arise in the ordinary course of business. In the event that any unrecognized tax benefits are recognized, the effective tax rate will not be affected.</span></div><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90ZXh0cmVnaW9uOmU1ZTQ2NmFmOGMxZjRhMjE5OTAyMTIwZmRkMDc4ZDc5XzY4NTY_0ba3d87e-5d87-4e6a-b7b9-6965baaa5210" escape="true"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the activity related to the Company&#8217;s unrecognized tax benefits (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:61.343%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.731%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Beginning balance</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozZmUzM2U1N2I0NzQ0ZTRkYjg0ZTMyMWJmZDc0MmE0ZS90YWJsZXJhbmdlOjNmZTMzZTU3YjQ3NDRlNGRiODRlMzIxYmZkNzQyYTRlXzItMS0xLTEtMA_28efb193-1b85-4f8e-a802-319edc822407">6,288</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb7e952fbd38434585f995fe73c66a44_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozZmUzM2U1N2I0NzQ0ZTRkYjg0ZTMyMWJmZDc0MmE0ZS90YWJsZXJhbmdlOjNmZTMzZTU3YjQ3NDRlNGRiODRlMzIxYmZkNzQyYTRlXzItMy0xLTEtMA_a393d7bf-32e3-4880-933d-f1c9637865ed">5,659</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie9057cb83ba040218834cc92910f7361_I20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozZmUzM2U1N2I0NzQ0ZTRkYjg0ZTMyMWJmZDc0MmE0ZS90YWJsZXJhbmdlOjNmZTMzZTU3YjQ3NDRlNGRiODRlMzIxYmZkNzQyYTRlXzItNS0xLTEtMA_0d8a87f1-b8d8-4923-bfa8-83bcc52a41dd">5,045</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions based on tax positions related to the current year</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozZmUzM2U1N2I0NzQ0ZTRkYjg0ZTMyMWJmZDc0MmE0ZS90YWJsZXJhbmdlOjNmZTMzZTU3YjQ3NDRlNGRiODRlMzIxYmZkNzQyYTRlXzMtMS0xLTEtMA_44ce048b-789a-4325-8a1c-ed23179dc1e9">5,393</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozZmUzM2U1N2I0NzQ0ZTRkYjg0ZTMyMWJmZDc0MmE0ZS90YWJsZXJhbmdlOjNmZTMzZTU3YjQ3NDRlNGRiODRlMzIxYmZkNzQyYTRlXzMtMy0xLTEtMA_f722c4b6-6bd9-4811-916f-6894c5eb55c0">636</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozZmUzM2U1N2I0NzQ0ZTRkYjg0ZTMyMWJmZDc0MmE0ZS90YWJsZXJhbmdlOjNmZTMzZTU3YjQ3NDRlNGRiODRlMzIxYmZkNzQyYTRlXzMtNS0xLTEtMA_9aacfb49-5075-49ef-bc86-8f264c313de0">622</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions for tax positions of prior years</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" sign="-" name="sgmo:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozZmUzM2U1N2I0NzQ0ZTRkYjg0ZTMyMWJmZDc0MmE0ZS90YWJsZXJhbmdlOjNmZTMzZTU3YjQ3NDRlNGRiODRlMzIxYmZkNzQyYTRlXzQtMS0xLTEtMA_12e3614b-592d-41eb-ba87-8ed11891f1c4">51</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" sign="-" name="sgmo:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozZmUzM2U1N2I0NzQ0ZTRkYjg0ZTMyMWJmZDc0MmE0ZS90YWJsZXJhbmdlOjNmZTMzZTU3YjQ3NDRlNGRiODRlMzIxYmZkNzQyYTRlXzQtMy0xLTEtMA_afd8dc87-4655-4787-87d4-6bdba599e182">7</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" sign="-" name="sgmo:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozZmUzM2U1N2I0NzQ0ZTRkYjg0ZTMyMWJmZDc0MmE0ZS90YWJsZXJhbmdlOjNmZTMzZTU3YjQ3NDRlNGRiODRlMzIxYmZkNzQyYTRlXzQtNS0xLTEtMA_90265e9a-9341-48f8-bd3a-297e738fd0e3">8</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Reductions for tax positions of prior years</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozZmUzM2U1N2I0NzQ0ZTRkYjg0ZTMyMWJmZDc0MmE0ZS90YWJsZXJhbmdlOjNmZTMzZTU3YjQ3NDRlNGRiODRlMzIxYmZkNzQyYTRlXzUtMS0xLTEtMA_24ee2c3c-6ba6-42bc-b8aa-c6f698c2830c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozZmUzM2U1N2I0NzQ0ZTRkYjg0ZTMyMWJmZDc0MmE0ZS90YWJsZXJhbmdlOjNmZTMzZTU3YjQ3NDRlNGRiODRlMzIxYmZkNzQyYTRlXzUtMy0xLTEtMA_8236e677-6f9f-41d8-b6d1-812e3a93d2fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozZmUzM2U1N2I0NzQ0ZTRkYjg0ZTMyMWJmZDc0MmE0ZS90YWJsZXJhbmdlOjNmZTMzZTU3YjQ3NDRlNGRiODRlMzIxYmZkNzQyYTRlXzUtNS0xLTEtMA_7b2dfbed-01a0-4e85-bebe-bacd347a9b3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ending balance</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozZmUzM2U1N2I0NzQ0ZTRkYjg0ZTMyMWJmZDc0MmE0ZS90YWJsZXJhbmdlOjNmZTMzZTU3YjQ3NDRlNGRiODRlMzIxYmZkNzQyYTRlXzYtMS0xLTEtMA_6ad9fef9-359b-4643-9556-db3d0b7fb469">11,630</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafee69bb5c304299817c47783c041381_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozZmUzM2U1N2I0NzQ0ZTRkYjg0ZTMyMWJmZDc0MmE0ZS90YWJsZXJhbmdlOjNmZTMzZTU3YjQ3NDRlNGRiODRlMzIxYmZkNzQyYTRlXzYtMy0xLTEtMA_1e4e713b-60d5-468f-a1fa-da0de68d5f25">6,288</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb7e952fbd38434585f995fe73c66a44_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozZmUzM2U1N2I0NzQ0ZTRkYjg0ZTMyMWJmZDc0MmE0ZS90YWJsZXJhbmdlOjNmZTMzZTU3YjQ3NDRlNGRiODRlMzIxYmZkNzQyYTRlXzYtNS0xLTEtMA_042b82ef-4d31-4d32-8ccf-0f83f142aeef">5,659</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_1965"></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 12 &#8211; <ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTY1L2ZyYWc6MmJjNjFmOTUxOGFlNDgwYzg5NWIyNmI1YzRiODc1YmYvdGV4dHJlZ2lvbjoyYmM2MWY5NTE4YWU0ODBjODk1YjI2YjVjNGI4NzViZl84MjQ2MzM3MjA4NzY3_51df043e-0455-4e78-8ae3-bc3a7301a98c" continuedAt="i5b69c65cba0742c4b33be005b629d884" escape="true">RELATED PARTY TRANSACTION</ix:nonNumeric></span></div><div style="text-indent:36pt;margin-top:6pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i5b69c65cba0742c4b33be005b629d884">During the year, the Company acquired <ix:nonFraction unitRef="shares" contextRef="i52834b9e08624c8bacef183387dd51ed_D20190701-20190930" decimals="INF" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTY1L2ZyYWc6MmJjNjFmOTUxOGFlNDgwYzg5NWIyNmI1YzRiODc1YmYvdGV4dHJlZ2lvbjoyYmM2MWY5NTE4YWU0ODBjODk1YjI2YjVjNGI4NzViZl84Nzk2MDkzMDIyMzU4_c07d524d-bcb6-47f6-8c98-b3144f01c664">52,700</ix:nonFraction> vested free shares from a former executive of Sangamo France who is now an executive of Sangamo, pursuant to the exercise of the Free Shares Options for approximately $<ix:nonFraction unitRef="usd" contextRef="i7904976381aa418691f37a32d64b07c0_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTY1L2ZyYWc6MmJjNjFmOTUxOGFlNDgwYzg5NWIyNmI1YzRiODc1YmYvdGV4dHJlZ2lvbjoyYmM2MWY5NTE4YWU0ODBjODk1YjI2YjVjNGI4NzViZl84MjQ2MzM3MjA4Nzc1_8d2faf70-3ae0-489f-934b-08c07d61ba71">0.1</ix:nonFraction>&#160;million of cash.</ix:continuation></span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_154"></div><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:QuarterlyFinancialInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90ZXh0cmVnaW9uOmFmNGFkZGZkZTg5OTRiNGQ5NTMzNzg5YTI1OTA1N2IwXzUwNg_ea36a779-83a0-4bcb-ba65-cfaca76ef3c9" continuedAt="i078cb9f8667f40f28c5d997cecd7ab86" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 13 &#8211; QUARTERLY FINANCIAL DATA (UNAUDITED)</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90ZXh0cmVnaW9uOmFmNGFkZGZkZTg5OTRiNGQ5NTMzNzg5YTI1OTA1N2IwXzc2OTY1ODEzOTQ5OTA_fadb5da0-77c9-4844-83b2-067a091f365a" continuedAt="if05feeee89974f4e83e18e253d4b934c" escape="true">The following table sets forth certain unaudited quarterly financial data for the eight quarters ended December&#160;31, 2019. The unaudited information set forth below has been prepared on the same basis as the audited information contained herein and includes all adjustments necessary to present fairly the information set forth. The operating results for any quarter are not indicative of results for any future period. All amounts are in thousands except per share amounts.</ix:nonNumeric></span></div></ix:nonNumeric><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">99</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-bottom:6pt;"><ix:continuation id="i078cb9f8667f40f28c5d997cecd7ab86"><ix:continuation id="if05feeee89974f4e83e18e253d4b934c"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:22.264%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.823%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.823%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.823%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.823%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.823%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.823%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.823%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.830%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Q1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Q2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Q3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Q4</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Q1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Q2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Q3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Q4</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i650fabb9fd3342b194a201cbf6d40308_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzItMS0xLTEtMA_a614f01a-3e4d-41c3-86c5-4e91de1383dc">8,071</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7d3836ab6ab8497ea22f279a0bfeb107_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzItMy0xLTEtMA_e8df0ecf-4e3e-4b00-a9e1-62606f8c0b7f">17,548</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id2195a0eb53f457697e901d30824c2b3_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzItNS0xLTEtMA_ab6da33e-1ffd-4157-833f-3fc88eade9ef">21,958</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iecf9c60eda6d47d4a66bc7797840c1d5_D20191001-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzItNy0xLTEtMA_af356e16-0c0d-4187-b58c-f04de82d791a">54,851</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iad063cfae7ac486cb8c7a7931ccbc02e_D20180101-20180331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzItOS0xLTEtMA_c9f95a2f-7f7a-4008-8cb4-ef8220270664">12,637</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if2cf250af72b4f33993772a39178733a_D20180401-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzItMTEtMS0xLTA_c07c5e56-7801-4adf-8a76-bf76b017dd13">21,416</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibac9f542f2ce4f519e06c7aabb195095_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzItMTMtMS0xLTA_af1c139f-bdae-48d0-b56f-13a2129bc5ed">23,562</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibbad735aad064fe6bda84e11e1e8baab_D20181001-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzItMTUtMS0xLTA_02d597d9-abe0-45c1-960f-0c642b7cfc1a">26,837</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i650fabb9fd3342b194a201cbf6d40308_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzMtMS0xLTEtMA_0bd87fae-6dc8-40d5-b38f-e1d774ee20af">51,968</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7d3836ab6ab8497ea22f279a0bfeb107_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzMtMy0xLTEtMA_98560fd1-84ee-4854-bc6b-f4e709495394">51,052</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id2195a0eb53f457697e901d30824c2b3_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzMtNS0xLTEtMA_bad5528e-f9d3-4f1c-aad7-8b6febaba96e">51,206</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iecf9c60eda6d47d4a66bc7797840c1d5_D20191001-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzMtNy0xLTEtMA_ace46951-31dd-4771-9b35-543a10dc7e73">53,382</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iad063cfae7ac486cb8c7a7931ccbc02e_D20180101-20180331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzMtOS0xLTEtMA_f9a27e2a-e451-4562-a8ac-8ddbeeb3730c">33,634</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if2cf250af72b4f33993772a39178733a_D20180401-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzMtMTEtMS0xLTA_e4d2e284-52a4-4351-926d-3aa299e1e08f">40,556</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibac9f542f2ce4f519e06c7aabb195095_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzMtMTMtMS0xLTA_9d2acad8-6fa9-4579-b732-cc58aa4dd6c5">39,803</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibbad735aad064fe6bda84e11e1e8baab_D20181001-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzMtMTUtMS0xLTA_155dc1ad-ed93-478c-abc0-0527385029a2">47,609</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net (loss) income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i650fabb9fd3342b194a201cbf6d40308_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzQtMS0xLTEtMA_89419bbb-6825-4e31-a17b-5f168c5aef3b">42,203</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7d3836ab6ab8497ea22f279a0bfeb107_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzQtMy0xLTEtMA_166d2398-c7c9-497f-b534-24ebe40f7a42">30,356</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id2195a0eb53f457697e901d30824c2b3_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzQtNS0xLTEtMA_99a6f024-8fd9-43a3-b82b-a9d8df175dfa">27,361</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iecf9c60eda6d47d4a66bc7797840c1d5_D20191001-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzQtNy0xLTEtMA_ee225bc6-4d0a-4020-9cc0-9b6e7ddae9f8">4,501</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iad063cfae7ac486cb8c7a7931ccbc02e_D20180101-20180331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzQtOS0xLTEtMA_a4950fad-e593-4ba0-8ef4-52efafd1f960">20,187</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if2cf250af72b4f33993772a39178733a_D20180401-20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzQtMTEtMS0xLTA_db828562-2817-4e05-8f6f-7e7e33528f00">16,640</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibac9f542f2ce4f519e06c7aabb195095_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzQtMTMtMS0xLTA_c22acb9e-bb54-4caa-811a-053116af3525">12,843</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibbad735aad064fe6bda84e11e1e8baab_D20181001-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzQtMTUtMS0xLTA_1d1a6d96-56e1-4b02-9971-adddf79a3318">19,219</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i650fabb9fd3342b194a201cbf6d40308_D20190101-20190331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzUtMS0xLTEtMA_7d37849e-3ad4-47dd-b904-3b98d1b532ce">53</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7d3836ab6ab8497ea22f279a0bfeb107_D20190401-20190630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzUtMy0xLTEtMA_7cee9991-cbe2-42e9-97c2-cf859b41d4b3">72</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id2195a0eb53f457697e901d30824c2b3_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzUtNS0xLTEtMA_8363b8fb-3d9b-4ee6-a086-3f993053bb09">54</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iecf9c60eda6d47d4a66bc7797840c1d5_D20191001-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzUtNy0xLTEtMA_9a4c881f-3066-4423-930f-730083e409bb">54</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iad063cfae7ac486cb8c7a7931ccbc02e_D20180101-20180331" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzUtOS0xLTEtMA_6559ec6d-9cd3-48da-8ad8-ca42dcd2d2f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if2cf250af72b4f33993772a39178733a_D20180401-20180630" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzUtMTEtMS0xLTA_914de789-80ec-4197-9dad-52d53fd2669a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibac9f542f2ce4f519e06c7aabb195095_D20180701-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzUtMTMtMS0xLTA_efc941b4-061b-4560-94d8-15805c1eadc0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibbad735aad064fe6bda84e11e1e8baab_D20181001-20181231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzUtMTUtMS0xLTA_e6df3d09-65d5-4ebb-9086-ce717c7bbd2e">555</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net (loss) income attributable to Sangamo Therapeutics, Inc.</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i650fabb9fd3342b194a201cbf6d40308_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzYtMS0xLTEtMA_36d4a91e-c537-4353-b57f-2eaa96335088">42,150</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7d3836ab6ab8497ea22f279a0bfeb107_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzYtMy0xLTEtMA_26bd5d57-3a6c-40e1-85d8-e44a66881857">30,284</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id2195a0eb53f457697e901d30824c2b3_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzYtNS0xLTEtMA_676b5c31-1d0e-41f5-90d6-ea23c4cd663a">27,307</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iecf9c60eda6d47d4a66bc7797840c1d5_D20191001-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzYtNy0xLTEtMA_4666210c-ce9d-4a02-9f48-51cbfe44ba4c">4,555</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iad063cfae7ac486cb8c7a7931ccbc02e_D20180101-20180331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzYtOS0xLTEtMA_007a316a-2fc8-429d-b039-5c8bdff78813">20,187</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if2cf250af72b4f33993772a39178733a_D20180401-20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzYtMTEtMS0xLTA_5276900b-2942-4e91-8f44-eb9d9e0555a2">16,640</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibac9f542f2ce4f519e06c7aabb195095_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzYtMTMtMS0xLTA_a4754850-6d9b-4fca-9d7d-9a5f43c7b559">12,843</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibbad735aad064fe6bda84e11e1e8baab_D20181001-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzYtMTUtMS0xLTA_3e26795a-f48f-46b1-a060-f4fefc7666e0">18,664</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted net (loss) income per share attributable to Sangamo Therapeutics, Inc.</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i650fabb9fd3342b194a201cbf6d40308_D20190101-20190331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzctMS0xLTEtMA_e3c0b2bf-89bb-4a20-bd97-9237667255b8">0.41</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7d3836ab6ab8497ea22f279a0bfeb107_D20190401-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzctMy0xLTEtMA_27c706b3-6b98-46a3-9719-d4bf0539309d">0.26</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="id2195a0eb53f457697e901d30824c2b3_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzctNS0xLTEtMA_299e6318-67e1-4166-8bcf-ce3a8d0b463c">0.24</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="iecf9c60eda6d47d4a66bc7797840c1d5_D20191001-20191231" decimals="2" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzctNy0xLTEtMA_1c8e98a4-9b74-4d12-abd6-470841e6b165">0.04</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="iad063cfae7ac486cb8c7a7931ccbc02e_D20180101-20180331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzctOS0xLTEtMA_74acff7e-a5dc-4cf2-88de-35931f31b7f8">0.23</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="if2cf250af72b4f33993772a39178733a_D20180401-20180630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzctMTEtMS0xLTA_8948e92e-15dc-48a0-9427-178ec2a1dc6b">0.17</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ibac9f542f2ce4f519e06c7aabb195095_D20180701-20180930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzctMTMtMS0xLTA_969f9a7f-3943-48c5-b4be-3bd33e50f24d">0.13</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ibbad735aad064fe6bda84e11e1e8baab_D20181001-20181231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzctMTUtMS0xLTA_f24e6065-3ed5-4877-858d-78f5de5d69c0">0.18</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></ix:continuation></div><div><span><br/></span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_1972"></div><div style="margin-top:21pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 14 &#8211; <ix:nonNumeric contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV83Njk2NTgxNDE2MDY1_f9189503-c0eb-4c10-8576-fac0095f6565" continuedAt="i847eac3f31c348cf8a1da7d222814652" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><ix:continuation id="i847eac3f31c348cf8a1da7d222814652" continuedAt="i869db9fefd294449ba1fe8dcfac97cd5"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2020, the Company entered into a global licensing collaboration agreement with Biogen MA, Inc. and its affiliate, Biogen International GmbH, for the research, development and commercialization of gene regulation therapies for the treatment of neurological diseases. The companies plan to leverage the Company&#8217;s proprietary ZFP technology delivered via AAV to modulate expression of key genes involved in neurological diseases.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Biogen collaboration agreement, the Company will grant to Biogen an exclusive, royalty bearing and worldwide license, under its relevant patents and know-how, to develop, manufacture and commercialize certain ZFP and/or  AAV-based products directed to up to <ix:nonFraction unitRef="product_target" contextRef="i815aed8f3ed04efa8895ee3a5a249f46_D20200201-20200228" decimals="INF" name="sgmo:CollaborativeArrangementNumberOfProductTargets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV83Njk2NTgxNDE1MzAz_ada8f3f1-b39e-4861-91b2-04594043630a">12</ix:nonFraction> neurological disease gene targets selected by Biogen. Biogen has already selected <ix:nonFraction unitRef="product_target" contextRef="id2fcb8b96ce04f23aa5b97d6cacdf777_I20200228" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:CollaborativeArrangementNumberOfProductTargetsSelected" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV84MjQ2MzM3MjMwMDMy_f1d2a6df-a6e3-4d7c-90c3-66f5c75a6be3">three</ix:nonFraction> of these: ST-501 for tauopathies including Alzheimer&#8217;s disease, ST-502 for synucleinopathies including Parkinson&#8217;s disease, and a third undisclosed neuromuscular disease target. Biogen has exclusive rights to nominate up to <ix:nonFraction unitRef="product_target" contextRef="i815aed8f3ed04efa8895ee3a5a249f46_D20200201-20200228" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:CollaborationAgreementNumberOfAdditionalProductTargets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV83Njk2NTgxNDE1MzE0_8ac4c0a1-340f-4063-a7b4-1b4c4284c163">nine</ix:nonFraction> additional targets over a target selection period of <ix:nonNumeric contextRef="i815aed8f3ed04efa8895ee3a5a249f46_D20200201-20200228" format="ixt-sec:durwordsen" name="sgmo:CollaborationAgreementTargetSelectionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV83Njk2NTgxNDE1MzMx_49b83e20-f738-4b9c-a8f7-e2192742c64a">five years</ix:nonNumeric>. For each gene target selected by Biogen, the Company will perform early research activities, costs for which will be shared by the companies, aimed at the development of the combination of proprietary CNS delivery vectors and ZFP-TFs (or potential other ZFP products) targeting therapeutically relevant genes. Biogen will then assume responsibility and costs for the IND-enabling studies, clinical development, related regulatory interactions, and global commercialization. The Company will be responsible for GMP manufacturing activities for the initial clinical trials for the first <ix:nonFraction unitRef="product_target" contextRef="id2fcb8b96ce04f23aa5b97d6cacdf777_I20200228" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:CollaborativeArrangementNumberOfProductTargetsSelected" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV83Njk2NTgxNDE1MzQz_be3c3b47-41a0-41a9-aa40-4c4763a36a55">three</ix:nonFraction> products of the collaboration and plans to leverage its in-house manufacturing capacity. Biogen will assume responsibility for GMP manufacturing activities beyond the first clinical trial for each of the first <ix:nonFraction unitRef="product_target" contextRef="id2fcb8b96ce04f23aa5b97d6cacdf777_I20200228" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:CollaborativeArrangementNumberOfProductTargetsSelected" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV83Njk2NTgxNDE1MzUz_f183def7-4fcc-4f73-bb51-9e50e39f490e">three</ix:nonFraction> products. Subject to certain exceptions set forth in the Biogen collaboration agreement, the Company will be prohibited from developing, manufacturing or commercializing any therapeutic product directed to the targets selected by Biogen.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">After the Biogen collaboration agreement becomes effective, Biogen will pay the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i68abcab0cf41405fae245c20e792bbf2_D20200201-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCollaborators" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV83Njk2NTgxNDE1OTU2_a81acf4d-4979-45d8-8bec-8c22d2fd91f9">125.0</ix:nonFraction>&#160;million. The Company is also eligible to receive research, development, regulatory and commercial milestone payments that could total up to approximately $<ix:nonFraction unitRef="usd" contextRef="i7c5278bbcb4141f78ac8881b4edfac94_I20200228" decimals="7" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV83Njk2NTgxNDE1OTcy_e12887d1-b2cf-49b5-9a2b-8c76ea3c7179">2.37</ix:nonFraction>&#160;billion if Biogen selects all of the targets allowed under the agreement and all the specified milestones set forth in the agreement are achieved, which includes up to $<ix:nonFraction unitRef="usd" contextRef="i1640dffb6cb34c52994dcc5099a67ffd_I20200228" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV83Njk2NTgxNDE1OTg3_4fba908d-466f-42e6-8bdb-4f580a42c7a5">925.0</ix:nonFraction>&#160;million in pre-approval milestone payments and up to $<ix:nonFraction unitRef="usd" contextRef="i21a4261ff2844d9d957100ee0d0f8fa3_I20200228" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV83Njk2NTgxNDE2MTA2_de32d922-d5f7-4945-816e-bb9053dee949">1,445.0</ix:nonFraction> million in first commercial sale and other sales-based milestone payments.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"> I</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">n addition, the Company will also be eligible to receive tiered high single-digit to sub-teen royalties on potential net commercial sales of licensed products arising from the collaboration. These royalty payments will be subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Biogen collaboration agreement will continue, on a product-by-product and country-by-country basis, until the expiration of the applicable royalty term. Biogen has the right to terminate the collaboration agreement, in its entirety or on target-by-target basis, for any reason after a specified notice period. Each party has the right to terminate this agreement on account of the other party&#8217;s bankruptcy or material, uncured breach. In addition, the Company may terminate the collaboration agreement if Biogen challenges any patents licensed by the Company to Biogen.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Concurrently with the execution of the collaboration agreement, the Company also entered into a stock purchase agreement with Biogen MA, Inc., pursuant to which Biogen will purchase <ix:nonFraction unitRef="shares" contextRef="i908ad6d97bab414e84166e66b25274be_D20200201-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV83Njk2NTgxNDE2MDEx_e29580be-2be6-4b77-9fc5-d27063157b47">24,420,157</ix:nonFraction> shares of the Company&#8217;s common stock (the &#8220;Biogen Shares&#8221;), at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i2be6d9a350e04b98992adc724912b287_I20200228" decimals="4" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV83Njk2NTgxNDE2ODcz_37e11695-ef79-45cd-90b7-3809cfb0cb43">9.2137</ix:nonFraction>, for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i908ad6d97bab414e84166e66b25274be_D20200201-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV83Njk2NTgxNDE2MDIz_d6cf5073-9a1f-4bad-9ca5-985edf40b54a">225.0</ix:nonFraction>&#160;million.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the terms of the stock purchase agreement, Biogen has agreed not to, without the Company&#8217;s prior written and subject to specified conditions and exceptions, directly or indirectly acquire shares of the Company&#8217;s outstanding common stock, seek or propose a tender or exchange offer or merger between the parties, solicit proxies or consents with respect to any </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">100</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><ix:continuation id="i869db9fefd294449ba1fe8dcfac97cd5"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">matter, or undertake other specified actions related to the potential acquisition of additional equity interests in the Company. Such standstill restrictions expire on the earlier of the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV83Njk2NTgxNDE2MDUx_0d84836a-c95f-4eb8-a58e-c4a119cbf42f">three</span>-year anniversary of the effectiveness of the Biogen collaboration agreement and the date that Biogen beneficially owns less than <ix:nonFraction unitRef="number" contextRef="i5dbb06595ef34d1581373015fa20fc10_I20200228" decimals="2" name="sgmo:CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV83Njk2NTgxNDE2MDM5_0bd8dc82-da26-4b1f-b9a4-17e868818298">5</ix:nonFraction>% of the Company&#8217;s common stock.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The stock purchase agreement also provides that until the first anniversary of the effectiveness of the Biogen collaboration agreement, Biogen will hold and not sell any of the Biogen Shares and from the first anniversary through the second anniversary, Biogen will hold and not sell at least <ix:nonFraction unitRef="number" contextRef="if7c1080eb5384ad88c89d65e002242e1_I20200228" decimals="2" name="sgmo:CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV83Njk2NTgxNDE2MDU3_25eda8de-ca01-4ba8-ab51-7db993946cdf">50</ix:nonFraction>% of the Biogen Shares, in addition to being subject to certain volume limitations. The stock purchase agreement further provides that, subject to certain limitations, upon Biogen&#8217;s request, the Company will register for resale any of the Biogen Shares on a registration statement to be filed with the SEC, until such time as all remaining Biogen Shares may be sold pursuant to Rule 144 promulgated under the Securities Act during any 90-day period.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, Biogen has agreed that, excluding specified extraordinary matters, it will vote the Biogen Shares in accordance with the Company&#8217;s recommendation and has granted the Company an irrevocable proxy with respect to the foregoing. Such voting provisions expire on the earlier of (i) the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV83Njk2NTgxNDE2MTM1_d2c3c96b-72c7-45db-9430-d8a812b9fc92">two</span>-year anniversary of the effectiveness of the Biogen collaboration agreement, (ii) the date that Biogen beneficially owns less than <ix:nonFraction unitRef="number" contextRef="if7c1080eb5384ad88c89d65e002242e1_I20200228" decimals="2" name="sgmo:CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV83Njk2NTgxNDE2MDYy_443f7495-8a4a-4aef-b807-289e341cc7e6">5</ix:nonFraction>% of the Company&#8217;s common stock and (iii) the date the Biogen collaboration agreement is terminated; provided, however, that in no event shall such expiration date be prior to the one-year anniversary of the effectiveness of the Biogen collaboration agreement.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The consummation of the transactions under each of the Biogen collaboration agreement and the stock purchase agreement is subject to the satisfaction of customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.</span></div></ix:continuation><div id="i9a2bf9013aa44980b5a1f5846290b1a8_163"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160;9 &#8211; CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_166"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160;9A &#8211; CONTROLS AND PROCEDURES</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Evaluation of Disclosure Controls and Procedures</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the supervision of our principal executive officer and principal financial officer, we evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of December&#160;31, 2019. Based on that evaluation, as of December&#160;31, 2019, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Inherent Limitations on Controls and Procedures</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our management, including the principal executive officer and principal financial officer, does not expect that our disclosure controls and procedures and our internal control over financial reporting will prevent all error and all fraud. A control system, no matter how well designed and operated, can only provide reasonable assurances that the objectives of the control system are met. The design of a control system reflects resource constraints; the benefits of controls must be considered relative to their costs. Because there are inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, for our company have been or will be detected. As these inherent limitations are known features of the disclosure and financial reporting processes, it is possible to design into the processes safeguards to reduce, though not eliminate, these risks. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events. While our disclosure controls and procedures and our internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives, there can be no assurance that any design will succeed in achieving its stated goals under all future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with the policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">101</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Management&#8217;s Report on Internal Control over Financial Reporting</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our management is responsible for establishing and maintaining an adequate internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) for our company. Our management, including our principal executive officer and principal financial officer, conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework set forth in the &#8220;Internal Control&#8212;Integrated Framework&#8221; issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Based on an evaluation under that framework, our management concluded that our internal control over financial reporting was effective at the reasonable assurance level as of December&#160;31, 2019.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The effectiveness of our internal control over financial reporting as of December&#160;31, 2019 has been audited by Ernst&#160;&amp; Young LLP, an independent registered public accounting firm, as stated in their report, which is included herein.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Changes in Internal Control over Financial Reporting</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There have been no changes in our internal control over financial reporting identified in connection with the evaluation required by Rules&#160;13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the three months ended December&#160;31, 2019 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">102</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%;">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;">To the Board of Directors and Stockholders of Sangamo Therapeutics, Inc.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%;">Opinion on Internal Control over Financial Reporting</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;">We have audited Sangamo Therapeutics, Inc.&#8217;s internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control &#8211; Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Sangamo Therapeutics, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2019, based on the COSO criteria.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the 2019 consolidated financial statements of the Company and our report dated February&#160;28, 2020 expressed an unqualified opinion thereon.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%;">Basis for Opinion</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%;">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;">/s/&#160;ERNST&#160;&amp; YOUNG LLP</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;">Redwood City, California</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;">February&#160;28, 2020</span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_169"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">103</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160;9B &#8211; OTHER INFORMATION</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Item 1.01 Entry into a Material Definitive Agreement.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaboration and License Agreement</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On February 26, 2020, we entered into a Collaboration and License Agreement (the &#8220;Biogen collaboration agreement&#8221;) with Biogen MA, Inc. (&#8220;BIMA&#8221;) and Biogen International GmbH (&#8220;BIG&#8221; and, together with BIMA, collectively &#8220;Biogen&#8221;) for the research, development and commercialization of gene regulation therapies for the treatment of neurological diseases. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Biogen collaboration agreement, we will grant to Biogen an exclusive, royalty bearing and worldwide license, under our relevant patents and know-how, to develop, manufacture and commercialize certain ZFP and/or AAV-based products directed to up to 12 neurological disease gene targets selected by Biogen. Biogen has already selected three of these: ST-501 for tauopathies including Alzheimer&#8217;s disease, ST-502 for synucleinopathies including Parkinson&#8217;s disease, and a third undisclosed neuromuscular disease target. Biogen has exclusive rights to nominate up to nine additional targets over a target selection period of five years. For each gene target selected by Biogen, we will perform early research activities, costs for which will be shared by the companies, aimed at the development of the combination of proprietary CNS delivery vectors and ZFP-TFs targeting therapeutically relevant genes. Biogen will then assume responsibility and costs for the IND-enabling studies, clinical development, related regulatory interactions, and global commercialization. We will be responsible for GMP manufacturing activities for the initial clinical trials for the first three products of the collaboration and plan to leverage our in-house manufacturing capacity. Biogen will assume responsibility for GMP manufacturing activities beyond the first clinical trial for each of the first three products. Subject to certain exceptions set forth in the Biogen collaboration agreement, we will be prohibited from developing, manufacturing or commercializing any therapeutic product directed to the targets selected by Biogen.  </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">After the Biogen collaboration agreement becomes effective, Biogen will pay us an upfront payment of $125.0 million.  We are also eligible to receive research, development, regulatory and commercial milestone payments that could total up to approximately $2.37 billion if Biogen selects all of the targets allowed under the Biogen collaboration agreement and all the specified milestones set forth in the Biogen collaboration agreement are achieved, which includes up to $925.0 million in pre-approval milestone payments and up to $1,445.0 million in first commercial sale and other sales-based milestone payments.  In addition, we will also be eligible to receive tiered high single-digit to sub-teen royalties on potential net commercial sales of licensed products arising from the collaboration. These royalty payments will be subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.  </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Biogen collaboration agreement will continue, on a product-by-product and country-by-country basis, until the expiration of the applicable royalty term.  Biogen has the right to terminate the Biogen collaboration agreement, in its entirety or on target-by-target basis, for any reason after a specified notice period. Each party has the right to terminate the Biogen collaboration agreement on account of the other party&#8217;s bankruptcy or material, uncured breach.  In addition, we may terminate the Biogen collaboration agreement if Biogen challenges any patents licensed by us to Biogen. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Stock Purchase Agreement</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Concurrently with the execution of the Biogen collaboration agreement, we entered into a stock purchase agreement with BIMA, pursuant to which BIMA will purchase 24,420,157 shares of our common stock (the &#8220;Biogen Shares&#8221;), at a price per Biogen Share of $9.2137, for an aggregate purchase price of approximately $225.0 million.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the terms of the stock purchase agreement, BIMA has agreed not to, without our prior written and subject to specified conditions and exceptions, directly or indirectly acquire shares of our outstanding common stock, seek or propose a tender or exchange offer or merger between the parties, solicit proxies or consents with respect to any matter, or undertake other specified actions related to the potential acquisition of additional equity interests in us.  Such standstill restrictions expire on the earlier of the three-year anniversary of the effectiveness of the Biogen collaboration agreement and the date that BIMA beneficially owns less than 5% of our common stock.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The stock purchase agreement also provides that until the first anniversary of the effectiveness of the Biogen collaboration agreement, BIMA will hold and not sell any of the Biogen Shares and from the first anniversary through the second anniversary, BIMS will hold and not sell at least 50% of the Biogen Shares, in addition to being subject to certain volume limitations.  The stock purchase agreement further provides that, subject to certain limitations, upon BIMA&#8217;s request, we will register for resale any of the Biogen Shares on a registration statement to be filed with the SEC, until such time as all remaining Biogen Shares may be sold pursuant to Rule 144 promulgated under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) during any 90-day period.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, BIMA has agreed that, excluding specified extraordinary matters, it will vote the Biogen Shares in accordance with our recommendation and has granted us an irrevocable proxy with respect to the foregoing.  Such voting </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">104</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">provisions expire on the earlier of (i) the two-year anniversary of the effectiveness of the Biogen collaboration agreement, (ii)&#160;the date that BIMA beneficially owns less than 5% of our common stock and (iii) the date the Biogen collaboration agreement is terminated; provided, however, that in no event shall such expiration date be prior to the one-year anniversary of the effectiveness of the Biogen collaboration agreement.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The consummation of the transactions under each of the Biogen collaboration agreement and the stock purchase agreement are subject to the satisfaction of customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The foregoing is only a brief description of the material terms of the Biogen collaboration agreement and the stock purchase agreement, does not purport to be a complete statement of the rights and obligations of the parties under these agreements and the transactions contemplated thereby, and is qualified in its entirety by the full text of such agreements, copies of which will be filed with the Securities and Exchange Commission as exhibits to our Quarterly Report on Form 10-Q for the three months ending March 31, 2020.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Item 3.02. Unregistered Sales of Equity Securities</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See the description set forth under Item 1.01 above with respect to the stock purchase agreement, which is incorporated into this Item 3.02 by reference. The Biogen Shares are being offered and sold to BIMA pursuant to the exemption from the registration requirements provided in Section 4(a)(2) of the Securities Act for transactions by an issuer not involving any public offering. Accordingly, the Biogen Shares have not been registered the Securities Act and may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. </span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_172"></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART&#160;III</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain information required by Part&#160;III is omitted from this Report on Form&#160;10-K because we intend to file our definitive Proxy Statement for our next Annual Meeting of Stockholders, pursuant to Regulation&#160;14A of the Securities Exchange Act of 1934, as amended, or the 2020 Proxy Statement, no later than April&#160;29, 2020, and certain information to be included in the 2020 Proxy Statement is incorporated herein by reference.</span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_175"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160;10 &#8211; DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The information required by this item is to be included in our 2020 Proxy Statement as follows:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The information relating to our directors and nominees for director is to be included in the section entitled &#8220;Election of Directors;&#8221;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The information relating to our executive officers is to be included in the section entitled &#8220;Executive Officers;&#8221;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The information relating to our audit committee and audit committee financial expert is to be included in the section entitled &#8220;Election of Directors &#8211; Audit Committee;&#8221;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The information relating to the procedures by which stockholders may recommend nominees to our Board of Directors is to be included in the section entitled &#8220;Questions and Answers About These Proxy Materials and Voting;&#8221; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The information regarding compliance with Section 16(a) of the Exchange Act is to be included in the section entitled &#8220;Delinquent Section 16(a) Reporting.&#8221;</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Such information is incorporated herein by reference to our 2020 Proxy Statement, provided that if the 2020 Proxy Statement is not filed within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, the omitted information will be included in an amendment to this Annual Report on Form 10-K filed not later than the end of such 120-day period.</span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_178"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160;11 &#8211; EXECUTIVE COMPENSATION </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The information required by this item is to be included in our 2020 Proxy Statement under the sections entitled &#8220;Executive Compensation,&#8221; &#8220;Director Compensation,&#8221; &#8220;Election of Directors&#8212;Compensation Committee Interlocks and Insider Participation&#8221; and &#8220;Report of the Compensation Committee of the Board of Directors&#8221; and is incorporated herein by reference, provided that if the 2020 Proxy Statement is not filed within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, the omitted information will be included in an amendment to this Annual Report on Form 10-K filed not later than the end of such 120-day period.</span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_181"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">105</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160;12 &#8211; SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The information required by this item with respect to equity compensation plans is to be included in our 2020 Proxy Statement under the section entitled &#8220;Equity Compensation Plan Information&#8221; and the information required by this item with respect to security ownership of certain beneficial owners and management is to be included in our 2020 Proxy Statement under the section entitled &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and in each case is incorporated herein by reference, provided that if the 2020 Proxy Statement is not filed within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, the omitted information will be included in an amendment to this Annual Report on Form 10-K filed not later than the end of such 120-day period.</span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_184"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160;13 &#8211; CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The information required by this item is to be included in our 2020 Proxy Statement under the sections entitled &#8220;Certain Relationships and Related Transactions&#8221; and &#8220;Election of Directors&#8212;Board Independence&#8221; and is incorporated herein by reference, provided that if the 2020 Proxy Statement is not filed within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, the omitted information will be included in an amendment to this Annual Report on Form 10-K filed not later than the end of such 120-day period.</span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_187"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160;14 &#8211; PRINCIPAL ACCOUNTING FEES AND SERVICES</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The information required by this item is to be included in our 2020 Proxy Statement under the section entitled &#8220;Ratification of Independent Registered Public Accounting Firm&#8221; and is incorporated herein by reference, provided that if the 2020 Proxy Statement is not filed within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, the omitted information will be included in an amendment to this Annual Report on Form 10-K filed not later than the end of such 120-day period.</span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_190"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">106</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART&#160;IV</span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_193"></div><div style="margin-top:12pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160;15 &#8211; EXHIBITS, FINANCIAL STATEMENT SCHEDULES</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a) The following documents are included as part of this Annual Report on Form 10-K:</span></div><div style="padding-left:72pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1. Financial Statements&#8212;See Index to Consolidated Financial Statements in Item&#160;8.</span></div><div style="padding-left:72pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2. Financial Statement Schedules&#8212;Not Applicable.</span></div><div style="padding-left:72pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3. Exhibits</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:9.713%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:86.287%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Exhibit</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration: underline;">Number</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Description of Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000119312518223059/d558251dex21.htm">Share Purchase Agreement dated July 20, 2018 among the Company and the Selling TxCell Shareholders named on the signature page thereto (incorporated by reference to Exhibit 2.1 to the Company&#8217;s Current Report on Form 8-K filed July 23, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000119312518319603/d651511dex22.htm">Amendment Agreement to the Share Purchase Agreement dated October 1, 2018 between the Company and TxCell S.A. (incorporated by reference to Exhibit 2.2 to the Company&#8217;s Current Report on Form 8-K filed November 6, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000119312518223059/d558251dex22.htm">Tender Offer Agreement dated July 20, 2018 between the Company and TxCell S.A. (incorporated by reference to Exhibit 2.2 to the Company&#8217;s Current Report on Form 8-K filed July 23, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.4</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000119312518319603/d651511dex24.htm">Amendment No. 1 to the Tender Offer Agreement dated October 1, 2018 between the Company and TxCell S.A. (incorporated by reference to Exhibit 2.4 to the Company&#8217;s Current Report on Form 8-K filed November&#160;6, 2</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000119312518319603/d651511dex24.htm">018).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459017017005/sgmo-ex31_651.htm">Seventh Amended and Restated Certificate of Incorporation, as amended (incorporated by reference to Exhibit&#160;3.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed August 9, 2017).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.2</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459018015648/sgmo-ex31_6.htm">Third Amended and Restated Bylaws (incorporated by reference to Exhibit&#160;3.1 to the Company&#8217;s Current Report on Form 8-K filed June 15, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="sgmo-20191231xexx41.htm">Description of Securities of the Company.</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.2</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000119312517003781/d304900dex41.htm">Form of Specimen Common Stock Certificate (incorporated by reference to Exhibit&#160;4.1 to the Company&#8217;s Current Report on Form&#160;8-K filed January 6, 2017).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1(+)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459018012641/sgmo-ex102_123.htm">Amended and Restated 2013 Stock Incentive Plan (the &#8220;2013 Plan&#8221;) (incorporated by reference to Exhibit&#160;10.2 to the Company&#8217;s Quarterly Report on Form&#160;10-Q filed May 10, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2(+)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000119312518189435/d603403dex991.htm">2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;) (incorporated by reference to Exhibit 99.1 to the Company&#8217;s Registration Statement on Form S-8 (File No. 333-225552) filed June 11, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3(+)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex103_614.htm">2018 Equity Incentive Plan French Stock-Options Sub-Plan (the &#8220;French Options Sub-Plan&#8221;)</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex103_614.htm"> </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex103_614.htm">(incorporated by reference to Exhibit 10.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex103_614.htm">3</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex103_614.htm"> to the Company&#8217;s Annual Report on Form 10-K (File No. 000-30171), filed with the SEC on March 1, 2019)</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex103_614.htm">.</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.4(+)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex104_439.htm">2018 Equity Incentive Plan French Restricted Stock Unit Award Sub-Plan (the &#8220;French RSU Sub-Plan&#8221;)</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex104_439.htm"> </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex104_439.htm">(incorporated by reference to Exhibit 10.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex104_439.htm">4</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex104_439.htm"> to the Company&#8217;s Annual Report on Form 10-K (File No. 000-30171), filed with the SEC on March 1, 201</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex104_439.htm">9</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex104_439.htm">)</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex104_439.htm">.</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.5(+)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000119312513259487/d554133dex102.htm">Form of Restricted Stock Unit Award Agreement under the 2013 Plan (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed June 14, 2013).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.6(+)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000119312513259487/d554133dex103.htm">Form of Notice of Grant of Stock Option under the 2013 Plan (incorporated by reference to Exhibit&#160;10.3 to the Company&#8217;s Current Report on Form 8-K filed June 14, 2013).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.7(+)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000119312513259487/d554133dex104.htm">Form of Stock Option Agreement under the 2013 Plan (incorporated by reference to Exhibit&#160;10.4 to the Company&#8217;s Current Report on Form 8-K filed June 14, 2013).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.8(+)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000119312513259487/d554133dex105.htm">Form of Notice of Grant of Stock Option &#8211; Director Initial Grant under the 2013 Plan (incorporated by reference to Exhibit&#160;10.5 to the Company&#8217;s Current Report on Form 8-K filed June 14, 2013).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.9(+)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000119312513259487/d554133dex106.htm">Form of Notice of Grant of Stock Option &#8211; Director Annual Grant under the 2013 Plan (incorporated by reference to Exhibit&#160;10.6 to the Company&#8217;s Current Report on Form 8-K filed June 14, 2013).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.10(+)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000119312513259487/d554133dex107.htm">Form of Automatic Stock Option Agreement under the 2013 Plan (incorporated by reference to Exhibit&#160;10.7 to the Company&#8217;s Current Report on Form 8-K filed June 14, 2013).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.11(+)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459018015648/sgmo-ex992_12.htm">Form of Stock Option Grant Notice and Form of Option Agreement (U.S. employees) under the 2018 Plan (incorporated by reference to Exhibit 99.2 to the Company&#8217;s Current Report on Form 8-K filed June 15, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.12(+)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459018015648/sgmo-ex993_11.htm">Form of Stock Option Grant Notice and Form of Option Agreement (non-employee directors) under the 2018 Plan (incorporated by reference to Exhibit 99.3 to the Company&#8217;s Current Report on Form 8-K filed June 15, 2018).</a></span></div></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">107</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:9.713%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:86.287%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Exhibit</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration: underline;">Number</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Description of Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.13(+)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459018015648/sgmo-ex994_10.htm">Form of Stock Option Grant Notice and Form of Option Agreement (U.K. employees) under the 2018 Plan (incorporated by reference to Exhibit 99.4 to the Company&#8217;s Current Report on Form 8-K filed June 15, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.14(+)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1014_438.htm">Form of Stock Option Grant Notice (French employees) under the 2018 Plan and the French Options Sub-Plan</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1014_438.htm"> </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1014_438.htm">(incorporated by reference to Exhibit 10.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1014_438.htm">14</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1014_438.htm"> to the Company&#8217;s Annual Report on Form 10-K (File No. 000-30171), filed with the SEC on March 1, 2019)</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1014_438.htm">.</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.15(+)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1015_613.htm">Form of Stock Option Agreement (French Employees) under the 2018 Plan and the French Options Sub-Plan</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1015_613.htm"> </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1015_613.htm">(incorporated by reference to Exhibit 10.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1015_613.htm">15</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1015_613.htm"> to the Company&#8217;s Annual Report on Form 10-K (File No. 000-30171), filed with the SEC on March 1, 2019)</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1015_613.htm">.</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.16(+)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459018015648/sgmo-ex995_9.htm">Form of Restricted Stock Unit Grant Notice and Form of Restricted Stock Unit Award Agreement (U.S. employees) under the 2018 Plan (incorporated by reference to Exhibit 99.5 to the Company&#8217;s Current Report on Form 8-K filed June 15, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.17(+)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459018015648/sgmo-ex996_7.htm">Form of Restricted Stock Unit Grant Notice and Form of Restricted Stock Unit Award Agreement (non-employee directors) under the 2018 Plan (incorporated by reference to Exhibit 99.6 to the Company&#8217;s Current Report on Form 8-K filed June 15, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.18(+)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459018015648/sgmo-ex997_8.htm">Form of Restricted Stock Unit Grant Notice and Form of Restricted Stock Unit Award Agreement (U.K. employees) under the 2018 Plan (incorporated by reference to Exhibit 99.7 to the Company&#8217;s Current Report on Form 8-K filed June 15, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.19(+)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1019_437.htm">Form of Restricted Stock Unit Grant Notice and Form of Restricted Stock Unit Award Agreement (French employees) under the 2018 Plan and the French RSU Sub-Plan.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1019_437.htm"> </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1019_437.htm">(incorporated by reference to Exhibit 10.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1019_437.htm">19</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1019_437.htm"> to the Company&#8217;s Annual Report on Form 10-K (File No. 000-30171), filed with the SEC on March 1, 2019)</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1019_437.htm">.</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.20(+)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1020_436.htm">Amended and Restated Severance Plan</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1020_436.htm"> </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1020_436.htm">(incorporated by reference to Exhibit 10.20 to the Company&#8217;s Annual Report on Form 10-K (File No. 000-30171), filed with the SEC on March 1, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.21(+)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459018012641/sgmo-ex102_123.htm">Amended and Restated Incentive Compensation Plan (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed May 10, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.22(+)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459015006479/sgmo-ex102_19.htm">Form of Indemnification Agreement (incorporated by reference to Exhibit&#160;10.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed August 6, 2015).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.23(+)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459016022708/sgmo-ex101_285.htm">Employment Agreement between the Company and Alexander (Sandy) Macrae, dated May 17, 2016 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed August 4, 2016).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.24(+)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="sgmo-20191231xexx1024.htm">Employment Agreement between the Company and Sung Lee effective as of October 31, 2019.</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.25(+)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="sgmo-20191231xexx1025.htm">Employment Agreement between the Company and Gary Loeb effective as of June 6, 2019</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.26(+)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="sgmo-20191231xexx1026.htm">Employment Agreement between the Company and Rolf Andrew (Andy) Ramelmeier effective as of November 1, 2017.</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.27(+)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1027_724.htm">Employment Agreement between the Company and St&#233;phane Boissel, effective October 1, 2018</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1027_724.htm"> </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1027_724.htm">(incorporated by reference to Exhibit 10.2</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1027_724.htm">7</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1027_724.htm"> to the Company&#8217;s Annual Report on Form 10-K (File No. 000-30171), filed with the SEC on March 1, 2019)</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1027_724.htm">.</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.28(+)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1028_725.htm">Employment Agreement between the Company and Adrian Woolfson, effective January 21 2019</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1028_725.htm"> </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1028_725.htm">(incorporated by reference to Exhibit 10.28 to the Company&#8217;s Annual Report on Form 10-K (File No. 000-30171), filed with the SEC on March 1, 2019)</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1028_725.htm">.</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.29(+)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459017010305/sgmo-ex101_7.htm">Employment Agreement between the Company and Kathy Yi, dated February 28, 2017 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed May 10, 2017).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.30(+)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="http://www.sec.gov/Archives/edgar/data/1001233/000095014900000384/0000950149-00-000384.txt">Triple Net Laboratory Lease between the Company and Point Richmond R&amp;D Associates II, LLC, dated May&#160;23, 1997 (incorporated by reference to Exhibit 10.5 to the Company&#8217;s Registration Statement on Form&#160;S-1 (Reg. No.&#160;333-30314), as amended, filed February 24, 2000).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.31</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000095014905000054/f05860exv10w20.htm">First Amendment to Triple Net Laboratory Lease between the Company and Point Richmond R&amp;D Associates II, LLC, dated March&#160;12, 2004 (incorporated by reference to Exhibit 10.20 to the Company&#8217;s Annual Report on Form&#160;10-K filed February 23, 2005).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.32</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000119312513425338/d595389dex101.htm">Second Amendment to Triple Net Laboratory Lease between the Company and Point Richmond R&amp;D Associates II, LLC, dated March&#160;15, 2007 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form&#160;10-Q filed November 4, 2013).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.33</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000119312513425338/d595389dex102.htm">Third Amendment to Triple Net Laboratory Lease between the Company and Point Richmond R&amp;D Associates II, LLC, dated August 1, 2013 (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form&#160;10-Q filed November 4, 2013).</a></span></div></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">108</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:9.713%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:86.287%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Exhibit</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration: underline;">Number</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Description of Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.34</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1033_728.htm">Fourth Amendment to Triple Net Laboratory Lease between the Company and Point Richmond R&amp;D Associates II, LLC, dated June 10, 2016 (incorporated by reference to Exhibit 10.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1033_728.htm">33</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1033_728.htm"> to the Company&#8217;s Annual Report on Form 10-K (File No. 000-30171), filed with the SEC on March 1, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.35</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1034_727.htm">Fifth Amendment to Triple Net Laboratory Lease between the Company and Point Richmond R&amp;D Associates II, LLC, dated July 10, 2017</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1034_727.htm"> </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1034_727.htm">(incorporated by reference to Exhibit 10.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1034_727.htm">34</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1034_727.htm"> to the Company&#8217;s Annual Report on Form 10-K (File No. 000-30171), filed with the SEC on March 1, 2019)</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1034_727.htm">.</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.36</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459018020536/sgmo-ex109_61.htm">Sixth Amendment to Triple Net Laboratory Lease between the Company and Point Richmond R&amp;D Associates II, LLC, dated May 11, 2018 (incorporated by reference to Exhibit 10.9 to the Company&#8217;s Quarterly Report on Form&#160;10-Q filed August 8, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.37</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459018004163/sgmo-ex1021_830.htm">Lease Agreement between the Company and Marina Boulevard Property, LLC dated November 3, 2017 (incorporated by reference to Exhibit 10.21 to the Company&#8217;s Annual Report on Form 10-K filed March 1, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.38</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1037_729.htm">First Amendment to Lease Agreement between the Company and Marina Boulevard Property, LLC dated January 1, 2019 (incorporated by reference to Exhibit 10.37 to the Company&#8217;s Annual Report on Form 10-K (File No. 000-30171), filed with the SEC on March 1, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.39</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000119312517185733/d261905dex11.htm">Amended and Restated Sales Agreement between the Company and Cowen LLC, dated May 26, 2017 (incorporated by reference to Exhibit 1.1 to the Company&#8217;s Current Report on Form 8-K filed May 26, 2017).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.40&#8224;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459015009009/sgmo-ex101_99.htm">Amended and Restated Collaboration and License Agreement between the Company and Shire International GmbH, dated September 1, 2015 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed October 30, 2015).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.41&#8224;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000119312514187386/d699448dex101.htm">Global Research, Development and Commercialization Collaboration and License Agreement between the Company and Biogen MA Inc. (Bioverativ Inc.), dated January 8, 2014 (incorporated by reference to Exhibit&#160;10.1 to the Company&#8217;s Quarterly Report on Form&#160;10-Q filed May 7, 2014).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.42&#8224;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459016012882/sgmo-ex1063_373.htm">Letter Amendment to Global Research, Development and Commercialization Collaboration and License Agreement between the Company and Biogen MA Inc. (Bioverativ Inc.), dated December 14, 2015 (incorporated by reference to Exhibit 10.63 to the Company&#8217;s Annual Report on Form 10-K filed February 18, 2016).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.43&#8224;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459016018000/sgmo-ex101_333.htm">Letter Agreement and Waiver between the Company and Biogen MA Inc. (Bioverativ Inc.), dated March 24, 2016 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed May&#160;5, 2016).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.44&#8224;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459017017005/sgmo-ex101_575.htm">Collaboration and License Agreement between the Company and Pfizer Inc., dated May 10, 2017 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed August 9, 2017).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.45&#8273;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="sgmo-20191231xexx1045.htm">Letter Amendment, dated December 17, 2019, to the Collaboration and License Agreement between the Company and Pfizer Inc., dated May 10, 2017.</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.46&#8224;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459018004163/sgmo-ex1040_689.htm">Research Collaboration and License Agreement between the Company and Pfizer Inc., dated December 28, 2017 (incorporated by reference to Exhibit 10.40 to the Company&#8217;s Annual Report on Form 10-K filed March&#160;1, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.47&#8224;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459018012641/sgmo-ex101_180.htm">Collaboration and License Agreement between the Company and Kite Pharma, Inc., dated February 20, 2018 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed May </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459018012641/sgmo-ex101_180.htm">10</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459018012641/sgmo-ex101_180.htm">, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.48&#8273;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019017255/sgmo-ex103_230.htm">Amendment No. 1 to Research Collaboration and License Agreement between the Company and Pfizer Inc., dated as of December 27, 2017, dated as of March 21, 2019 (incorporated by reference to Exhibit 10.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019017255/sgmo-ex103_230.htm">3</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019017255/sgmo-ex103_230.htm"> to the Company&#8217;s Quarterly Report on Form 10-Q filed May 8, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.49&#8224;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000162828019013510/sgmo-20190930xex101.htm">Amended and Restated Collaboration and License Agreement between the Company and Kite Pharma, Inc., dated September 11, 2019 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed November 6, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="sgmo-20191231xexx211.htm">Subsidiaries of the Company</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23.1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="sgmo-20191231xexx231.htm">Consent of Independent Registered Public Accounting Firm.</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24.1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_199">Power of Attorney (included on signature page).</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="sgmo-20191231xex311.htm">Rule&#160;13a-14(a) Certification of Principal Executive Officer.</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.2</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="sgmo-20191231xex312.htm">Rule&#160;13a-14(a) Certification of Principal Financial Officer.</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32.1*</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="sgmo-20191231xex321.htm">Certification Pursuant to 18 U.S.C. Section&#160;1350.</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">109</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:9.713%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:86.287%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Exhibit</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration: underline;">Number</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Description of Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.INS</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.SCH</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.CAL</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.DEF</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.LAB</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.PRE</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">104</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">The cover page from Sangamo&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019, is formatted in Inline XBRL and it is contained in Exhibit 101</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">________________________</span></div><div style="text-indent:-36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8224;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Confidential treatment has been granted for certain information contained in this document pursuant to an order of the SEC. Such information has been omitted and filed separately with the SEC.</span></div><div style="text-indent:-36pt;padding-left:36pt;"><span><br/></span></div><div style="text-indent:-36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8273;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">         </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Certain portions of this exhibit (indicated by &#8220;[*]&#8221;) have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed.</span></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(+)&#160;Indicates management contract or compensatory plan or arrangement.</span></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">*&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The certifications attached as Exhibit 32.1 accompany this Annual Report on Form 10-K pursuant to 18 U.S.C. Section</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">1350, as adopted</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed &#8220;filed&#8221; by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.</span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_196"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM 16 &#8211; FORM 10-K SUMMARY</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div id="i9a2bf9013aa44980b5a1f5846290b1a8_199"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">110</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">Tabl</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i9a2bf9013aa44980b5a1f5846290b1a8_7">e of Contents</a></span></div></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SIGNATURES</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on February&#160;28, 2020.</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:20.076%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:40.836%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.093%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:28.995%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date: February 28, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SANGAMO THERAPEUTICS, INC.</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">/ </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">S</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> /&#160;&#160;&#160;&#160;A</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">LEXANDER</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> M</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">ACRAE</span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Alexander Macrae</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%;">President, and Chief Executive Officer</span></div></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Alexander Macrae, Sung H. Lee, and Gary Loeb, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:40.836%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.935%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.229%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Signature</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Title</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Date</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">/ S /&#160;&#160;&#160;&#160;ALEXANDER MACRAE</span></div></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">President,&#160;Chief&#160;Executive&#160;Officer<br/>(Principal&#160;Executive Officer) and Director</span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">February 28, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Alexander Macrae</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">/ S /&#160;&#160;&#160;&#160;SUNG H. LEE</span></div></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Executive&#160;Vice&#160;President&#160;and<br/>Chief&#160;Financial&#160;Officer&#160;(Principal&#160;Financial Officer)</span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">February 28, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sung H. Lee</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/ S /&#160;&#160;&#160;&#160;PRATHYUSHA DURAIBABU</span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vice President, Finance (Principal Accounting Officer)</span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">February 28, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prathyusha Duraibabu</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">/ S /&#160;&#160;&#160;&#160;H. STEWART PARKER</span></div></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Director and Chairwoman of the Board</span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">February 28, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">H. Stewart Parker</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">/ S /&#160;&#160;&#160;ROBERT F. CAREY</span></div></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Director</span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">February 28, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Robert F Carey</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">/&#160;S&#160;/&#160;&#160;&#160;&#160;STEPHEN&#160; G.&#160;DILLY,&#160;M.B.B.S,&#160;P</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">H</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">.D.</span></div></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Director</span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">February 28, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stephen G. Dilly, M.B.B.S, Ph.D.</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">/&#160;S&#160;/&#160;&#160;&#160;&#160;JAMES R. MEYERS</span></div></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Director</span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">February 28, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">James R. Myers</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">/&#160;S&#160;/&#160;&#160;&#160;&#160;JOHN MARKELS,&#160;P</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">H</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">.D.</span></div></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Director</span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">February 28, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">John Markels, Ph.D.</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">/&#160;S&#160;/&#160;&#160;&#160;&#160;SAIRA RAMASASTRY</span></div></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Director</span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">February 28, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Saira Ramasastry</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">/ </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">S</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> /&#160;&#160;&#160;&#160;KAREN SMITH, M.D, P</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">H</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">.D., M.B.A., L.L.M.</span></div></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Director</span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">February 28, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Karen Smith, M.D., Ph.D., M.B.A., L.L.M.</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">/ </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">S</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> /&#160;&#160;&#160;&#160;JOSEPH S. ZAKRZEWSKI</span></div></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Director</span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">February 28, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Joseph S. Zakrzewski</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>sgmo-20191231xexx41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ia262bbed737443e495e25bb9b8949852_1"></div><div style="height:72pt;width:100%;"><div style="text-align:right;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:138%;">Exhibit 4.1</font></div></div><div style="text-align:center;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">DESCRIPTION OF CAPITAL STOCK</font></div><div style="margin-top:12pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">References herein to &#8220;Sangamo,&#8221; &#8220;our,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and the &#8220;Company&#8221; refer only to Sangamo Therapeutics,&#160;Inc. and not to any of our subsidiaries. </font></div><div style="margin-top:12pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">General</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our seventh amended and restated certificate of incorporation, as amended, or the Restated Certificate, authorizes us to issue 160,000,000 shares of common stock, par value $0.01 per share, and 5,000,000 shares of preferred stock, par value $0.01 per share. </font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following summary description of our capital stock is based on the provisions of the Restated Certificate, our second amended and restated bylaws, as amended, or the Bylaws, and the applicable provisions of the General Corporation Law of the State of Delaware, or DGCL. This information may not be complete in all respects and is qualified entirely by reference to the provisions of the Restated Certificate, the Bylaws and the DGCL.  The Restated Certificate and the Bylaws are filed as exhibits to this Annual Report on Form 10-K to which this Description of Capital Stock is an exhibit. </font></div><div style="text-align:justify;margin-top:12pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Common Stock</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Shares of our common stock are the only security of the Company registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended, or the Exchange Act. The holders of common stock are entitled to one vote per share on all matters to be voted on by the stockholders. Stockholders have no cumulative voting rights. Subject to the preferences of any outstanding shares of preferred stock, the holders of common stock are entitled to receive ratably any dividends our board of directors declares out of funds legally available for the payment of dividends. If we are liquidated, dissolved or wound up, the holders of common stock are entitled to share pro rata all assets remaining after payment of liabilities and liquidation preferences of any outstanding shares of preferred stock. Holders of common stock have no preemptive rights or rights to convert their common stock into any other securities. There are no redemption or sinking fund provisions applicable to the common stock.&#160;</font></div><div style="margin-top:18pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Preferred Stock</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the Restated Certificate, our board of directors has the authority, without further action by the stockholders, to issue shares of preferred stock in one or more series. Our board of directors also has the authority to determine or alter the designation, rights, preferences, privileges and restrictions granted to or imposed upon any unissued series of preferred stock, any or all of which may be greater than the rights of the common stock. Our board of directors, without stockholder approval, may issue preferred stock with voting, conversion or other rights that are superior to the voting and other rights of the holders of common stock. The issuance of preferred stock may have the effect of delaying, deferring or preventing a change of control of Sangamo without further action by the stockholders, and may have the effect of delaying or preventing changes in management of Sangamo. In addition, the issuance of preferred stock may have the effect of decreasing the market price of the common stock and may adversely affect the voting power of holders of common stock and reduce the likelihood that common stockholders will receive dividend payments and payments upon liquidation.</font></div><div style="margin-top:18pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Antitakeover Effects of Provisions of our Restated Certificate, Bylaws and Delaware Law</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Our Restated Certificate and Bylaws</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As noted above, our board of directors, without stockholder approval, has the authority under our Restated Certificate to issue preferred stock with rights superior to the rights of the holders of common stock. As a result, the issuance of preferred stock may have the effect of delaying, deferring or preventing a change of control of Sangamo without further action by the stockholders and may adversely affect the voting and other rights of the holders of common stock. Our Restated Certificate also requires that any action required or permitted to be taken by our stockholders must be effected at a duly called annual or special meeting of the stockholders and may not be effected </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">by a consent in writing. Further, our Restated Certificate provides that a special meeting of the stockholders may be called only by our board of directors.</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to the provisions noted above, our Bylaws further establish advance notice procedures with respect to stockholder proposals and nomination of candidates for election as directors other than nominations made by or at the direction of the board of directors or a committee of the board of directors. Although our stockholders may amend, repeal or alter our Bylaws by a vote of at least a majority</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">of the outstanding shares of our capital stock entitled to vote, our board of directors may also unilaterally adopt, repeal, alter, amend and rescind our Bylaws by a vote of at least a majority of board of directors. Finally, our board of directors has the ability to elect a director to fill a vacancy created by the expansion of the board of directors or due to the resignation or departure of an existing board member.</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These provisions may have the effect of delaying, deferring or preventing a change in control and may also delay or prevent changes in management of Sangamo, which could have an adverse effect on the market price of our stock. These and other provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and to discourage certain types of transactions that may involve an actual or threatened change of control. However, such provisions could have the effect of discouraging others from making tender offers for our shares and, as a consequence, such provisions also may inhibit fluctuations in the market price of our shares that could result from actual or rumored takeover attempts.</font></div><div style="padding-left:24.75pt;margin-top:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:138%;">Section&#160;203 of the General Corporation Law of the State of Delaware</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">We are subject to Section&#160;203 of the DGCL which regulates acquisitions of some Delaware corporations. In general, Section&#160;203 prohibits, with some exceptions, a publicly held Delaware corporation such as us from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a period of three years following the time that the stockholder became an interested stockholder, unless&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:2.960%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.720%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.920%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:90.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">prior to the time the stockholder became an interested stockholder, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder&#59;</font></td></tr></table></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:2.960%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.720%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.920%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:90.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned by (a)&#160;persons who are directors and also officers and (b)&#160;employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer&#59; or</font></td></tr></table></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:2.960%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.720%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.920%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:90.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">at or subsequent to the time the stockholder became an interested stockholder, the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">2</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8260;</font><sub style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:bottom;">3</sub><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">% of the outstanding voting stock which is not owned by the interested stockholder.</font></div></td></tr></table></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">Section&#160;203 of the DGCL generally defines a &#8220;business combination&#8221; to include any of the following&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:2.960%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.720%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.920%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:90.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">any merger or consolidation involving the corporation and the interested stockholder&#59;</font></td></tr></table></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:2.960%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.720%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.920%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:90.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">any sale, lease, exchange, mortgage, transfer, pledge or other disposition involving the interested stockholder (in one transaction or a series of transactions) of assets of the corporation having an aggregate market value equal to 10% or more of the aggregate market value of either all of the assets of the corporation or its outstanding stock&#59;<br></font></td></tr></table></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:2.960%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.720%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.920%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:90.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder&#59;</font></td></tr></table></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:2.960%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.720%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.920%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:90.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">subject to exceptions, any transaction involving the corporation that has the effect, directly or indirectly, of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder&#59; and</font></td></tr></table></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">&#160;</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:2.960%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.720%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.920%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:90.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8226;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">the receipt by the interested stockholder of the benefit, directly or indirectly (except proportionately as a stockholder of such corporation), of any loans, advances, guarantees, pledges or other financial benefits, other than certain benefits set forth in Section&#160;203, provided by or through the corporation.</font></td></tr></table></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">In general, Section&#160;203 defines an &#8220;interested stockholder&#8221; as an entity or person who, together with the person&#8217;s affiliates and associates, beneficially owns, or within three years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the corporation.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">Section&#160;203 of the DGCL could depress our stock price and delay, discourage or prohibit transactions not approved in advance by our board of directors, such as takeover attempts that might otherwise involve the payment to our stockholders of a premium over the market price of our common stock.</font></div><div style="margin-top:18pt;margin-bottom:6pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Forum Selection Bylaw</font></div><div style="text-indent:27pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the sole and exclusive forum for (1) any derivative action or proceeding brought on behalf of Sangamo, (2) any action asserting a claim of breach of a fiduciary duty owed by any current or former director, officer, other employee or stockholder of Sangamo to Sangamo or to our stockholders, (3) any action asserting a claim arising pursuant to any provision of the DGCL, Restated Certificate, Bylaws, or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware, or (4) any action asserting a claim governed by the internal affairs doctrine shall be a state or federal court located within the state of Delaware. Any person or entity purchasing or otherwise acquiring or holding any interest in shares of capital stock of Sangamo is deemed to have notice of and consented to the forum selection provisions of the Bylaws. However, this provision does not apply to actions arising under the Securities Act of 1933, as amended, or the Exchange Act, or any claim for which the federal courts have exclusive jurisdiction.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.24
<SEQUENCE>3
<FILENAME>sgmo-20191231xexx1024.htm
<DESCRIPTION>EX-10.24
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i768970e7c95d4e8eaf4bfb6f88489095_1"></div><div style="height:72pt;width:100%;"><div style="text-indent:36pt;padding-left:396pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 10.24</font></div></div><div style="text-align:center;margin-bottom:24pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">EXECUTIVE EMPLOYMENT AGREEMENT</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Employment Agreement (&#8220;Agreement&#8221;) made as of the 21</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">st</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> day of October by and between Sangamo Therapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221;), and Sung Lee  (&#8220;Executive&#8221;) (collectively, the &#8220;Parties&#8221;).</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">R E C I T A L S</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">WHEREAS</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, the Company desires to employ Executive, and Executive desires to be employed by the Company, on the terms and conditions set forth in this Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">NOW, THEREFORE</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, in consideration of the mutual promises set forth herein, the Parties agree follows&#58;</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;">Employment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The Company hereby agrees to employ Executive and Executive hereby agrees to accept such employment, on the terms and conditions set forth in this Agreement, with a start date of  October 31</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">st</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> 2019 (the &#8220;Effective Date&#8221;).</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">At-Will Employment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Executive shall be employed on an at-will basis.  Either Executive or the Company may terminate employment at any time, with or without cause, and with or without advance notice.  </font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Position, Duties and Obligations</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Executive shall be appointed as the Executive Vice President and Chief Financial Officer and shall serve in such position, and in such other positions as the Board and the Company may from time to time reasonably determine, subject at all times to the direction, supervision and authority of the Chief Executive Officer.  </font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">During Executive&#8217;s employment, Executive shall perform Executive&#8217;s duties faithfully and to the best of Executive&#8217;s ability, and shall devote substantially all of Executive&#8217;s business time, attention, knowledge, skills and interests to the business of the Company (and its affiliates or subsidiaries).  </font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">During Executive&#8217;s employment, Executive shall not, whether directly or indirectly, render any services of a commercial or professional nature to any other person or organization, whether for compensation or otherwise, without the prior written consent of the Chief Executive Officer. </font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The foregoing in this Section 3 shall not preclude Executive from serving on any corporate, civic or charitable boards or committees on which Executive is serving as of the Effective Date and discloses to the Chief Executive Officer prior to the Effective Date or on which Executive commences service following such date with the Chief Executive Officer&#8217;s </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div style="text-indent:36pt;padding-left:396pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 10.24</font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">prior written approval, so long as such activities do not interfere with the performance of Executive&#8217;s responsibilities hereunder.  </font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Executive&#8217;s principal place of business will be located in Brisbane,  California.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Executive represents that Executive may enter into this Agreement, and as of the Effective Date, 1) accept employment with the Company under the terms of this Agreement, and 2) perform the duties and responsibilities contemplated by this Agreement without violating any other agreement or agreements with other parties including but not limited to and any prior employers.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Compensation and Benefits</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Base Compensation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Company shall pay to Executive an annual base salary of $435,000 Dollars, prorated for any partial employment period and payable in equal monthly installments in accordance with the Company&#8217;s payroll schedule.  The Compensation Committee of the Board shall annually review the then-current level of Executive&#8217;s base salary (for increase only) to determine the amount, if any, of change to such salary.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Annual Performance Bonus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Executive is eligible to earn an annual performance bonus commencing with the 2019 calendar year performance period.  The target amount of Executive&#8217;s annual cash bonus shall be 40% percent of Executive&#8217;s annual base salary.  The Board shall have sole discretion to determine whether any annual cash bonus will be paid based upon achievement of both corporate objectives and Executive&#8217;s personal objectives, and the reasonable discretion to determine that actual amount of any such bonus.  Executive must be an employee in good standing on the date that the Board makes such determination in order to earn any such bonus, which determination shall be made by the Board no later than March 31 of the calendar year first following the performance period calendar year.  The actual bonus may be more or less than the target amount based upon the Company&#8217;s achievement over the year.  Any bonus to which Executive becomes entitled for a particular calendar year shall be paid in accordance with the terms of the applicable bonus plan, but in no event later than the second payroll period following such Board determination.  The Compensation Committee of the Board shall annually review Executive&#8217;s then target amount for the annual cash bonus (for increase only) to determine the amount, if any, of change to such target amount.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Executive Severance Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Executive shall be deemed an Eligible Employee and an Executive Officer and entitled to receive certain severance benefits under the Sangamo Therapeutics, Inc. Executive Severance Plan dated February 6, 2019 (the &#8220;Severance Plan&#8221;) subject to the terms and conditions of the Severance Plan.  A copy of the Severance Plan has been provided to Executive concurrently with this Agreement.  Notwithstanding the foregoing, in the event that the Company withdraws this offer after it is signed by Executive or terminates this Agreement prior to the Effective Date for any reason other than Executive&#8217;s failure to successfully pass the requirements for a background check clearance, satisfactory reference check, and satisfactory proof of Executive&#8217;s legal right to work in the United States required under Section 8(a) herein, then Executive shall be entitled to severance under the </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2 </font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div style="text-indent:36pt;padding-left:396pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 10.24</font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Severance Plan as though his employment was terminated by the Company other than for Cause to the same extent as he would otherwise be entitled had such termination occurred after the Effective Date&#59; provided, however, that Executive shall not be entitled to such severance if he has not notified his current employer of his intent to resign his employment at the time the Company informs him of the withdrawal or termination of this Agreement.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Benefits</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Executive will be entitled to the employee benefits generally provided to other executive officers of the Company pursuant to the terms of the applicable benefit plans.  Executive will not be subject to a formal paid time off program.  Executive is free to take paid time off from work for vacation, medical appointments, and other short-term absences due to illnesses or other personal reasons.  If Executive desires to take time off for a duration longer than two (2) weeks manager approval is required.  Unlimited paid time off is available from the first day of employment.  </font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Retention Bonus Advance. Executive shall be advanced a retention bonus (the &#8220;Retention Bonus&#8221;) in the amount of two hundred thousand dollars  ($200,000), payable in the first regularly rescheduled payroll after the Effective Date.  Although the Retention Bonus is advanced at the beginning of Executive&#8217;s employment, it is expressly conditioned on Executive not terminating employment prior to the first (1st) anniversary of the Effective Date under any circumstances other than a termination that would entitle Executive to receive benefits under the Severance Plan, and such advanced Retention Bonus shall not be deemed earned by Executive until such service condition has been met.  If Executive&#8217;s employment terminates at any time prior to the first (1st) anniversary of the Effective Date and Executive is not entitled to receive benefits under the Severance Plan (such termination, a &#8220;Disqualifying Termination&#8221;), then, Executive shall at the time of such Disqualifying Termination promptly repay the full Retention Bonus to the Company.  In the event Executive does not earn and fails to promptly repay the Retention Bonus in connection with a Disqualifying Termination, then the Company shall be further entitled to recover from Executive its costs and expenses incurred in enforcing Executive&#8217;s repayment obligation, including reasonable attorney&#8217;s fees and costs. </font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Equity</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Subject to approval by the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) or a committee or individual to whom the Board has delegated authority to grant stock options, we intend to grant you a stock option to purchase 262,500 shares of the Company&#8217;s common stock (the &#8220;Option&#8221;) under the Company&#8217;s equity plan (the &#8220;Plan&#8221;), subject to the terms and conditions in the Plan and the Stock Option Agreement that will subsequently be delivered.  The per share exercise price of your Option will be equal to the closing selling price per share of the Company&#8217;s common stock on the grant date (or if there is no closing selling price on the grant date, then the closing selling price on the last preceding date for which such quotation exists).  Unless otherwise specified in your Stock Option Agreement, your Option will be subject to a four-year vesting provision pursuant to which 25% of the total number of Option shares will vest one year from the grant date (the &#8220;Vesting Commencement Date&#8221;) and the remaining 75% will vest in thirty-six successive equal monthly installments following the first anniversary of the Vesting Commencement date, provided you remain employed or are providing other qualifying services through each applicable vesting date.  Following the grant of your Option, you will be </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3 </font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div style="text-indent:36pt;padding-left:396pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 10.24</font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">eligible to participate in the Company&#8217;s equity award program under which you will be considered for additional equity awards under the Plan on an annual basis. </font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(g)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Also, subject to approval by the Board, we intend to grant you 43,750 restricted stock units (&#8220;Restricted Stock Units&#8221;) under the Plan.  Each Restricted Stock Unit represents the right to receive one share of the Company&#8217;s common stock upon the specified issuance date following vesting.  Your Restricted Stock Units will vest in a series of three (3) successive equal annual installments upon your completion of each year of service to the Company measured from the Vesting Commencement Date.  The issuance of the underlying shares of common stock in settlement of vested Restricted Stock Units will be subject to the Company&#8217;s collection of all applicable withholding taxes.  The Restricted Stock Units will be evidenced by the Plan&#8217;s form of Restricted Stock Unit Issuance Agreement and will be subject to its terms and conditions and the Plan.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(h)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">You may be eligible to participate in an annual corporate bonus program under the Company&#8217;s Employee Cash Bonus Plan (the &#8220;Bonus Plan&#8221;) based on individual and Company performance. An employee&#8217;s first date of employment must be on or before October 31st to be eligible for a performance bonus.  If you start employment anytime in the year before October 31st, you will be eligible for a pro-rated bonus.  While the Company reserves the right to amend and rescind both your eligibility for a bonus and your bonus target any time in accordance with the terms and conditions of the Bonus Plan, your target bonus is currently 40% of annual salary, less taxes. Whether or not you receive a bonus, and the amount of any such bonus, shall be determined in the sole discretion of the Company, and you must remain an employee of the Company in good standing on the date any such bonus is determined and paid in order to earn and receive the bonus.  </font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Clawback</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Notwithstanding anything to the contrary in this Agreement, all compensation paid to Executive by the Company (whether payable pursuant to this Agreement or otherwise) will be subject to reduction, recovery and&#47;or recoupment to the extent required by any present or future law, government regulation or stock exchange listing requirement (or any policy adopted by the Company which ensures compliance with the requirements of any such law, government regulation or stock exchange listing requirement).</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(j)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Resignation from Positions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Notwithstanding any other provision of this Agreement to the contrary, upon any termination of employment (whether voluntary or involuntary), Executive, upon written request from the Board, shall immediately resign from any positions Executive has with the Company (or any subsidiary), whether as an executive, officer, employee, consultant, director, trustee, fiduciary or otherwise.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Confidentiality</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Executive agrees to abide by the terms and conditions of the Employee Confidential Information and Invention Assignment Agreement between Executive and the Company, a copy of which is attached as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibit A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Executive further agrees that at all times both during Executive&#8217;s employment by the Company and after Executive&#8217;s employment ends, Executive will keep in confidence and trust, and will not use or disclose, except as directed by the Company, any confidential or proprietary information of the Company.  </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4 </font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div style="text-indent:36pt;padding-left:396pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 10.24</font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Tax Withholdings</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Any and all cash compensation and other benefits (including without limitation, base salary, annual bonus and sign-on bonus) paid to Executive under this Agreement shall be subject to all applicable tax withholding requirements, and the Company shall make such other deductions as may be required and&#47;or allowed by applicable law and&#47;or as authorized in writing by Executive.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">7.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Arbitration</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Any dispute, controversy, or claim, whether contractual or non-contractual, between Executive and the Company shall be resolved by binding arbitration before the Judicial Arbitration and Mediation Service (the &#8220;JAMS&#8221;), in accordance with the JAMS Employment Arbitration Rules and Procedures, available at www.jamsadr.com.  Executive and the Company each agree that before proceeding to arbitration, they will mediate disputes before the JAMS by a mediator approved by the JAMS.  If mediation fails to resolve the matter, any subsequent arbitration shall be conducted by an arbitrator approved by the JAMS and mutually acceptable to Executive and the Company.  All disputes, controversies, and claims shall be conducted by a single arbitrator, who shall&#58; (i) allow discovery authorized by California Code of Civil Procedure Section 1282, et seq., or any other discovery required by applicable law&#59; and (ii) issue a written award that sets forth the essential findings of fact and conclusions of law on which the award is based.  The arbitrator shall have the authority to award any relief authorized by law in connection with the asserted claims or disputes.   Judgment upon the arbitrator&#8217;s award may be entered in any court having jurisdiction thereof.  If Executive and the Company are unable to agree on the mediator or the arbitrator, then the JAMS shall select the mediator&#47;arbitrator.  The resolution of the dispute by the arbitrator shall be final, binding, non-appealable, and fully enforceable by a court of competent jurisdiction under the Federal Arbitration Act.  The arbitration award shall be in writing and shall include a statement of the reasons for the award.  The arbitration shall be held in San Francisco, California.  The Company shall pay all JAMS, mediation, and arbitrator&#8217;s fees and costs, irrespective of who raised the claim and the outcome of arbitration.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Miscellaneous</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Conditions to Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Agreement is contingent upon a background check clearance, satisfactory reference check, and satisfactory proof of Executive&#8217;s legal right to work in the United States.  Executive agrees to provide any documentation or information at the Company&#8217;s request to facilitate these processes.  </font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Governing Law</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Agreement shall be interpreted, construed, governed and enforced according to the laws of the State of California.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Attorneys&#8217; Fees</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  In the event of any controversy, claim or dispute between the parties, arising out of or relating to this Agreement or the breach hereof, or the interpretation hereof, each party shall bear its own legal fees and expenses.  Notwithstanding the foregoing, in the event of a finding by any court having jurisdiction over such matter that any party initiating an action under this Agreement failed to have a reasonable prospect of prevailing on its claim, the arbitrator shall have discretion to award the prevailing party attorneys&#8217; fees and costs incurred by it with respect to such claim or action.  The &#34;prevailing party&#34; means the party determined by the arbitrator to have most nearly prevailed, even if such party did not prevail in all matters, not necessarily the one in whose favor a judgment is rendered.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5 </font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div style="text-indent:36pt;padding-left:396pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 10.24</font></div></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Amendments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  No amendment or modification of the terms or conditions of this Agreement shall be valid unless in writing and signed by the Parties hereto.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Severability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  If any provision of this Agreement as applied to any party or to any circumstance should be adjudged by a court of competent jurisdiction (or determined by the arbitrator) to be void or unenforceable for any reason, the invalidity of that provision shall in no way affect (to the maximum extent permissible by law) the application of such provision under circumstances different from those adjudicated by the court or determined by the arbitrator, the application of any other provision of this Agreement, or the enforceability or invalidity of this Agreement as a whole.  Should any provision of this Agreement become or be deemed invalid, illegal or unenforceable in any jurisdiction by reason of the scope, extent or duration of its coverage, then such provision shall be deemed amended to the extent necessary to conform to applicable law so as to be valid and enforceable or, if such provision cannot be so amended without materially altering the intention of the parties, then such provision will be stricken, and the remainder of this Agreement shall continue in full force and effect.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Successors and Assigns</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The rights and obligations of the Company under this Agreement shall inure to the benefit of and shall be binding upon the successors and assigns of the Company.  Executive shall not be entitled to assign any of Executive&#8217;s rights or obligations under this Agreement.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(g)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Entire Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Agreement, along with any other agreements set forth herein, including without limitation, the Proprietary Information and Inventions Agreement, constitutes the entire agreement between the parties with respect to the employment of Executive.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(h)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div id="i768970e7c95d4e8eaf4bfb6f88489095_4"></div><div style="padding-left:216pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6 </font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="padding-left:216pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:49.198%;"><tr><td style="width:1.0%;"></td><td style="width:12.006%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:5.817%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:74.547%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.430%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">SANGAMO THERAPEUTICS, INC.</font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="6" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">By&#58;</font></div></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><br>Name&#58;  <br> <br>Title&#58;  <br></font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">SUNG LEE</font></div><div style="margin-bottom:12pt;"><font><br></font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><br></font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="padding-left:36pt;padding-right:49.5pt;text-align:center;margin-bottom:6pt;"><font><br></font></div><div id="i768970e7c95d4e8eaf4bfb6f88489095_7"></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:54pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="padding-left:36pt;padding-right:49.5pt;text-align:center;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">EXHIBIT A</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">EMPLOYEE CONFIDENTIAL INFORMATION AND </font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">INVENTION ASSIGNMENT AGREEMENT</font></div><div style="text-indent:36pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">In consideration of my employment or continued employment by Sangamo Therapeutics, Inc. (&#8220;Sangamo&#8221;), its direct and indirect subsidiaries, parents, affiliates, predecessors, successors and assigns (together with Sangamo, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Company</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#8221;), and the compensation and benefits provided to me now and during my employment with the Company, I hereby enter into this Employee Confidential Information and Invention Assignment Agreement (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#8221;), which will be deemed effective as of the first day of my employment with the Company&#58;</font></div><div style="margin-bottom:6pt;"><font><br></font></div><div id="i768970e7c95d4e8eaf4bfb6f88489095_10"></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;">CONFIDENTIAL INFORMATION PROTECTIONS.</font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Recognition of Company&#8217;s Rights&#59;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Nondisclosure.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  I understand and acknowledge that my employment by Company creates a relationship of confidence and trust with respect to Company&#8217;s Confidential Information (as defined below) and that Company has a protectable interest therein.  At all times during and after my employment, I will hold in confidence and will not disclose, use, lecture upon, or publish any of Company&#8217;s Confidential Information, except as such disclosure, use or publication may be required in connection with my work for Company, or unless an officer of Company expressly authorizes such disclosure.  I will obtain Company&#8217;s written approval before publishing or submitting for publication any material (written, oral, or otherwise) that discloses and&#47;or incorporates any Confidential Information.  I hereby assign to Sangamo any rights I may have or acquire in such Confidential Information and recognize that all Confidential Information shall be the sole and exclusive property of Sangamo and its assigns.  I will take all reasonable precautions to prevent the inadvertent accidental disclosure of Confidential Information.  Notwithstanding the foregoing, pursuant to 18 U.S.C. Section 1833(b), I shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that&#58;  (1) is made in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law&#59; or (2) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.</font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Confidential Information.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  The term </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#8220;Confidential Information&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> shall mean any and all confidential knowledge, data or information of Company.  By way of illustration but not limitation, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#8220;Confidential Information&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> includes (a)&#160;trade secrets, inventions, mask works, ideas, processes, formulas, software in source or object code versions, data, programs, other works of authorship, know-how, improvements, discoveries, developments, designs and techniques and any other proprietary technology and all Intellectual Property Rights therein (collectively, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#8220;Inventions&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">)&#59; (b)&#160;information regarding research, development, new products, marketing and selling, business plans, budgets and unpublished financial statements, licenses, prices and costs, margins, discounts, credit terms, pricing and billing policies, quoting procedures, methods of obtaining business, forecasts, future plans and potential strategies, financial projections and business strategies, operational plans, financing and capital-raising plans, activities and agreements, internal services and operational manuals, methods of conducting Company business, suppliers and supplier information, and purchasing&#59; (c) information regarding customers and potential customers of Company, including customer lists, names, representatives, their needs or desires with respect to the types of products or services offered by Company, proposals, bids, contracts and their contents and parties, the type and quantity of products and services provided or sought to be provided to customers and potential customers of Company and other non-public information relating to customers and potential customers&#59; (d) information regarding any of Company&#8217;s business partners and their services, including names, representatives, proposals, bids, contracts and their contents and parties, the type and quantity of products and services received by Company, and other non-public information relating to business partners&#59; (e) information regarding personnel, employee lists, compensation, and employee skills&#59; and (f) any other non-public information which a competitor of Company could use to the competitive disadvantage of Company.  Notwithstanding the foregoing, it is understood that, at all such times, I am free to use information which is generally known in the trade or industry through no breach of this Agreement or other act or omission by me.  Further, notwithstanding the foregoing or anything to the contrary in this Agreement or any other agreement between the Company and me, nothing in this Agreement shall limit my right to discuss my employment or report possible violations of law or regulation with any federal government agency or similar </font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">1</font></div></div></div><hr style="page-break-after:always"><div style="height:54pt;width:100%;"><div style="text-indent:36pt;padding-left:396pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 10.24</font></div></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">state or local agency or to discuss the terms and conditions of my employment with others to the extent expressly permitted by Section 7 of the National Labor Relations Act. </font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Third Party Information.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">I understand, in addition, that Company has received, and in the future will receive, from third parties their confidential and&#47;or proprietary knowledge, data or information (</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#8220;Third Party Information&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">) subject to a duty on Company&#8217;s part to maintain the confidentiality of such information and to use it only for certain limited purposes.  During my employment and thereafter, I will hold Third Party Information in confidence and will not disclose to anyone (other than Company personnel who need to know such information in connection with their work for Company) or use, except in connection with my work for Company, Third Party Information unless expressly authorized by an officer of Company in writing.</font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">No Improper Use of Information of Prior Employers and Others.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  During my employment by Company, I will not improperly use or disclose confidential information or trade secrets, if any, of any former employer or any other person to whom I have an obligation of confidentiality, and I will not bring onto the premises of Company any unpublished documents or any property belonging to any former employer or any other person to whom I have an obligation of confidentiality unless consented to in writing by that former employer or person.</font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;">ASSIGNMENTS OF INVENTIONS.</font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Definitions.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">As used in this Agreement, the term </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#8220;Intellectual Property Rights&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> means all trade secrets, Copyrights, trademarks, mask work rights, patents and other intellectual property rights recognized by the laws of any jurisdiction or country&#59; the term </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#8220;Copyright&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> means the exclusive legal right to reproduce, perform, display, distribute and make derivative works of a work of authorship (as a literary, musical, or artistic work) recognized by the laws of any jurisdiction or country&#59; and the term </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#8220;Moral Rights&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> means all paternity, integrity, disclosure, withdrawal, special and any other similar rights recognized by the laws of any jurisdiction or country.</font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Excluded Inventions and Other Inventions.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  Attached hereto as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Attachment 1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> is a list describing all existing Inventions, if any, that may relate to Company&#8217;s business or actual or demonstrably anticipated research or development and that were made by me or acquired by me prior to the commencement of my employment with, and which are not to be assigned to, Company (</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#8220;Excluded Inventions&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">).  If no such list is attached, I represent and agree that it is because I have no rights in any existing Inventions that may relate to Company&#8217;s business or actual or demonstrably anticipated research or development.  For purposes of this Agreement, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#8220;Other Inventions&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> means Inventions in which I have or may have an interest, as of the commencement of my employment, other than Company Inventions (defined below) and Excluded Inventions.  I acknowledge and agree that if I use any Excluded Inventions or any Other Inventions in the scope of my employment, or if I include any Excluded Inventions or Other Inventions in any product or service of Company, or if my rights in any Excluded Inventions or Other Inventions may block or interfere with, or may otherwise be required for, the exercise by Company of any rights assigned to Company under this Agreement, I will immediately so notify Company in writing.  Unless Company and I agree otherwise in writing as to particular Excluded Inventions or Other Inventions, I hereby grant to Company, in such circumstances (whether or not I give Company notice as required above), a non-exclusive, perpetual, transferable, fully-paid and royalty-free, irrevocable and worldwide license, with rights to sublicense through multiple levels of sublicensees, to reproduce, make derivative works of, distribute, publicly perform, and publicly display in any form or medium, whether now known or later developed, make, have made, use, sell, import, offer for sale, and exercise any and all present or future rights in, such Excluded Inventions and Other Inventions.  To the extent that any third parties have rights in any such Excluded Inventions or Other Inventions, I hereby represent and warrant that such third party or parties have validly and irrevocably granted to me the right to grant the license stated above.</font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Assignment of Company Inventions.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> Inventions assigned to Sangamo, or to a third party as directed by Sangamo pursuant to Section 2.6, are referred to in this Agreement as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#8220;Company Inventions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  Subject to Section 2.4 (Unassigned or Nonassignable Inventions) and except for Excluded Inventions set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Attachment 1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> and Other Inventions, I hereby assign to</font><font style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Sangamo all my right, title, and interest in and to any and all Inventions (and all Intellectual Property Rights with respect thereto) made, conceived, reduced to practice, or learned by me, either alone or with others, during the period of my employment by Company.  To the extent required by applicable Copyright laws, I agree to assign in the future (when any copyrightable Inventions are first fixed in a tangible medium of expression) my Copyright rights in and to such Inventions.  Any assignment of Company Inventions (and all Intellectual Property Rights with respect </font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;">2</font></div></div></div><hr style="page-break-after:always"><div style="height:54pt;width:100%;"><div style="text-indent:36pt;padding-left:396pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 10.24</font></div></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">thereto) hereunder includes an assignment of all Moral Rights.  To the extent such Moral Rights cannot be assigned to Sangamo and to the extent the following is allowed by the laws in any country where Moral Rights exist, I hereby unconditionally and irrevocably waive the enforcement of such Moral Rights, and all claims and causes of action of any kind against Company or related to Company&#8217;s customers, with respect to such rights.  I further acknowledge and agree that neither my successors-in-interest nor legal heirs retain any Moral Rights in any Company Inventions (and any Intellectual Property Rights with respect thereto).</font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Unassigned or Nonassignable Inventions.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  I recognize that this Agreement will not be deemed to require assignment of any Invention that is covered under California Labor Code section 2870(a) (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Specific Inventions Law</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#8221;), as detailed on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Attachment 2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Obligation to Keep Company Informed.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  During the period of my employment and for one (1) year after termination of my employment, I will promptly and fully disclose to Company in writing all Inventions authored, conceived, or reduced to practice by me, either alone or jointly with others.  In addition, I will promptly disclose to Company all patent applications filed by me or on my behalf within one (1) year after termination of employment.  At the time of each such disclosure, I will advise Company in writing of any Inventions that I believe fully qualify for protection under the provisions of the Specific Inventions Law&#59; and I will at that time provide to Company in writing all evidence necessary to substantiate that belief.  Company will keep in confidence and will not use for any purpose or disclose to third parties without my consent any confidential information disclosed in writing to Company pursuant to this Agreement relating to Inventions that qualify fully for protection under the Specific Inventions Law.  I will preserve the confidentiality of any Invention that does not fully qualify for protection under the Specific Inventions Law.</font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Government or Third Party. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> I agree that, as directed by Company, I will assign to a third party, including without limitation the United States, all my right, title, and interest in and to any particular Company Invention.</font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.7</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Ownership of Work Product.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  I agree that Sangamo will exclusively own all work product that is made by me (solely or jointly with others) within the scope of my employment, and I hereby irrevocably and unconditionally assign to Sangamo all right, title, and interest worldwide in and to such work product.  I acknowledge that all original works of authorship which are made by me (solely or jointly with others) within the scope of my employment and which are protectable by Copyright are &#8220;works made for hire,&#8221; pursuant to United States Copyright Act (17 U.S.C., Section 101).  I understand and agree that I have no right to publish on, submit for publishing, or use for any publication any work product protected by this Section, except as necessary to perform services for Company.</font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.8</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Enforcement of Intellectual Property Rights and Assistance.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  I will assist Company in every proper way to obtain, and from time to time enforce, United States and foreign Intellectual Property Rights and Moral Rights relating to Company Inventions in any and all countries.  To that end I will execute, verify and deliver such documents and perform such other acts (including appearances as a witness) as Company may reasonably request for use in applying for, obtaining, perfecting, evidencing, sustaining and enforcing such Intellectual Property Rights and the assignment thereof.  In addition, I will execute, verify and deliver assignments of such Intellectual Property Rights to Sangamo or its designee, including the United States or any third party designated by Sangamo.  My obligation to assist Company with respect to Intellectual Property Rights relating to such Company Inventions in any and all countries will continue beyond the termination of my employment, but Company will compensate me at a reasonable rate after my termination for the time actually spent by me at Company's request on such assistance. In the event Company is unable for any reason, after reasonable effort, to secure my signature on any document needed in connection with the actions specified in this paragraph, I hereby irrevocably designate and appoint Company and its duly authorized officers and agents as my agent and attorney in fact, which appointment is coupled with an interest, to act for and in my behalf to execute, verify and file any such documents and to do all other lawfully permitted acts to further the purposes of this Agreement with the same legal force and effect as if executed by me.  I hereby waive and quitclaim to Company any and all claims, of any nature whatsoever, which I now or may hereafter have for infringement of any Intellectual Property Rights assigned under this Agreement to Sangamo. </font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.9</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Incorporation of Software Code.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  I agree that I will not incorporate into any Company software or otherwise deliver to Company any software code licensed under the GNU General Public License or Lesser General Public License or any other license that, by its terms, requires or conditions the use or distribution of such code on the disclosure, </font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;">3</font></div></div></div><hr style="page-break-after:always"><div style="height:54pt;width:100%;"><div style="text-indent:36pt;padding-left:396pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 10.24</font></div></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">licensing, or distribution of any source code owned or licensed by Company </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">except</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> in strict compliance with Company&#8217;s policies regarding the use of such software.</font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;">RECORDS.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  I agree to keep and maintain adequate and current records (in the form of notes, sketches, drawings and in any other form that is required by Company) of all Confidential Information developed by me and all Company Inventions made by me during the period of my employment at Company, which records will be available to and remain the sole property of Company at all times.</font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;">DUTY OF LOYALTY DURING EMPLOYMENT.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  I agree that during the period of my employment by Company I will not, without Company's express written consent, directly or indirectly (a) engage in any other employment or (b) engage in any other activities that are competitive with, or would otherwise conflict with, my employment by Company.</font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;">NO SOLICITATION OF EMPLOYEES, CONSULTANTS, OR CONTRACTORS.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">I agree that during the period of my employment and for the one (1) year period after the date my employment ends for any reason, including but not limited to voluntary termination by me or involuntary termination by Company, I will not, as an officer, director, employee, consultant, owner, partner, or in any other capacity, either directly or through others, except on behalf of Company, solicit, induce, encourage, or participate in soliciting, inducing or encouraging any employee, consultant, or independent contractor of Company to terminate his, her or its relationship with Company, even if I did not initiate the discussion or seek out the contact. </font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;">REASONABLENESS OF RESTRICTIONS.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">I agree that I have read this entire Agreement and understand it.  I agree that this Agreement does not prevent me from earning a living or pursuing my career.  I agree that the restrictions contained in this Agreement are reasonable, proper, and necessitated by Company&#8217;s legitimate business interests.  I represent and agree that I am entering into this Agreement freely and with knowledge of its contents with the intent to be bound by the Agreement and the restrictions contained in it.</font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">7.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;">NO CONFLICTING AGREEMENT OR OBLIGATION.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  I represent that my employment by Company does not and will not breach any agreement with any former employer or third party, including any noncompete agreement or any agreement to keep in confidence or refrain from using information acquired by me prior to my employment by Company.  I further represent that I have not entered into, and will not enter into, any agreement, either written or oral, in conflict with my obligations under this Agreement.</font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">8.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;">RETURN OF COMPANY PROPERTY. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> Subject to the nondisclosure requirements of Section 1.1 above, upon termination of my employment or upon Company&#8217;s request at any other time, I will deliver to Company any and all of Company&#8217;s property and equipment and any and all drawings, notes, memoranda, specifications, devices, formulas and documents, together with all copies thereof, and any other material containing or disclosing any Company Inventions, Third Party Information or Confidential Information of Company.  I agree that I will not copy, delete, or alter any information contained upon my Company computer or Company equipment before I return it to Company.  In addition, if I have used any personal computer, server, or e-mail system to receive, store, review, prepare or transmit any Company information, including but not limited to, Confidential Information, I agree to provide Company with a computer-useable copy of all such Confidential Information and then permanently delete and expunge such Confidential Information from those systems&#59; and I agree to provide Company access to my system as reasonably requested to verify that the necessary copying and&#47;or deletion is completed.  I further agree that any property situated on Company&#8217;s premises and owned by Company, including disks and other storage media, filing cabinets or other work areas, is subject to inspection by Company&#8217;s personnel at any time with or without notice.</font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">9.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;">LEGAL AND EQUITABLE REMEDIES.</font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">I agree that it may be impossible to assess the damages caused by my violation of this Agreement or any of its terms.  I agree that any threatened or actual violation of this Agreement or any of its terms will constitute immediate and irreparable injury to Company, and Company will have the right to enforce this Agreement and any of its provisions by injunction, specific performance or other equitable relief, without bond and without prejudice to any other rights and remedies that Company may have for a breach or threatened breach of this Agreement.</font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;">4</font></div></div></div><hr style="page-break-after:always"><div style="height:54pt;width:100%;"><div style="text-indent:36pt;padding-left:396pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 10.24</font></div></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">In the event Company enforces this Agreement through a court or arbitration order, I agree that the restrictions of Sections 5 will remain in effect for a period of twelve (12) months from the effective date of the order enforcing the Agreement. </font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">10.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt;">NOTICES.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  Any notices required or permitted under this Agreement will be given to Company at its headquarters location at the time notice is given, and to me at my address as listed on Company payroll, or at such other address as Company or I may designate by written notice to the other.  Notice will be effective upon receipt or refusal of delivery.  If delivered by certified or registered mail, notice will be considered to have been given five (5) business days after it was mailed, as evidenced by the postmark.  If delivered by courier or express mail service, notice will be considered to have been given on the delivery date reflected by the courier or express mail service receipt.</font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">11.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt;">NOTIFICATION OF NEW EMPLOYER.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">If I leave the employ of Company, I consent to the notification of my new employer of my rights and obligations under this Agreement, by Company providing a copy of this Agreement or otherwise. </font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">12.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt;">GENERAL PROVISIONS.</font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Governing Law.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  This Agreement will be governed by and construed according to the laws of the State of California as such laws are applied to agreements entered into and to be performed entirely within California between California residents. </font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Severability.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  In case any one or more of the provisions, subsections, or sentences contained in this Agreement will, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect the other provisions of this Agreement, and this Agreement will be construed as if such invalid, illegal or unenforceable provision had never been contained in this Agreement.  If moreover, any one or more of the provisions contained in this Agreement will for any reason be held to be excessively broad as to duration, geographical scope, activity or subject, it will be construed by limiting and reducing it, so as to be enforceable to the extent compatible with the applicable law as it will then appear. </font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Successors and Assigns.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  This Agreement is for my benefit and the benefit of Company, its successors, assigns, parent corporations, direct and indirect subsidiaries, affiliates, and purchasers, and will be binding upon my heirs, executors, administrators and other legal representatives.</font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Survival.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  This Agreement shall survive the termination of my employment, regardless of the reason, and the assignment of this Agreement by Company to any successor in interest or other assignee.</font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Employment At-Will.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  I agree and understand that nothing in this Agreement will change my at-will employment status or confer any right with respect to continuation of employment by Company, nor will it interfere in any way with my right or Company's right to terminate my employment at any time, with or without cause or advance notice.</font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Waiver.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  No waiver by Company of any breach of this Agreement will be a waiver of any preceding or succeeding breach.  No waiver by Company of any right under this Agreement will be construed as a waiver of any other right.  Company will not be required to give notice to enforce strict adherence to all terms of this Agreement.</font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.7</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Export.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  I agree not to export, reexport, or transfer, directly or indirectly, any U.S. technical data acquired from Company or any products utilizing such data, in violation of the United States export laws or regulations.</font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.8</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Entire Agreement.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  This Agreement is the final, complete and exclusive agreement of the parties with respect to the subject matter of this Agreement and supersedes and merges all prior discussions between the parties&#59; provided, however, prior to the execution of this Agreement, if Company and I were parties to any agreement regarding the subject matter hereof, that agreement will be superseded by this Agreement prospectively only.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">No modification of or amendment to this Agreement, or any waiver of any rights under this Agreement, will be effective unless in writing and signed by me and an authorized officer of the Company.  Any subsequent change or changes in my duties, salary or compensation will not affect the validity or scope of this Agreement.  If no other agreement governs nondisclosure and assignment of inventions during any period in which I was previously engaged or am in the future engaged by Company </font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;">5</font></div></div></div><hr style="page-break-after:always"><div style="height:54pt;width:100%;"><div style="text-indent:36pt;padding-left:396pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 10.24</font></div></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">as an independent contractor, the obligations pursuant to sections of this Agreement titled &#8220;Confidential Information Protections&#8221; and &#8220;Assignment of Inventions&#8221; shall apply.</font></div><div style="text-indent:36pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> </font></div><div id="i768970e7c95d4e8eaf4bfb6f88489095_13"></div><div style="margin-top:12pt;margin-bottom:12pt;"><font><br></font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:96.666%;"><tr><td style="width:1.0%;"></td><td style="width:48.000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:48.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:222pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:5pt;"><font><br></font></div><div style="margin-bottom:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;">SUNG LEE&#58;</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;">I HAVE READ, UNDERSTAND, AND ACCEPT THIS AGREEMENT.</font></div><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration: underline;">&#160;&#160;&#160;</font></div><div style="text-align:center;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;">(Signature)</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;">By&#58;__________________________________________   </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;">Title&#58;________________________________________   </font></div><div><font><br></font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;">Date&#58; ________________________________________</font></div><div style="margin-bottom:10pt;"><font><br></font></div></td><td colspan="3" style="height:222pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:5pt;"><font><br></font></div><div style="margin-bottom:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;">SANGAMO THERAPEUTICS, INC.&#58;</font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;">ACCEPTED AND AGREED&#58;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration: underline;">&#160;&#160;&#160;</font></div><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;">(Signature)</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;">By&#58; __________________________________________   </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;">Title&#58; ________________________________________   </font></div><div><font><br></font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;">Date&#58; ________________________________________   </font></div><div style="margin-bottom:10pt;"><font><br></font></div></td></tr></table></div><div><font><br></font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font><br></font></div><div id="i768970e7c95d4e8eaf4bfb6f88489095_16"></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;">6</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ATTACHMENT 1</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">PRIOR INVENTIONS</font></div><div style="text-indent:-54pt;padding-left:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">TO&#58;&#160;Sangamo Therapeutics, Inc. </font></div><div style="text-indent:-54pt;padding-left:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">FROM&#58;&#160;Sung Lee </font></div><div style="text-indent:-54pt;padding-left:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">DATE&#58;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">&#160;</font></div><div style="text-indent:-56.25pt;padding-left:58.5pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">SUBJECT&#58;&#160;Prior Inventions </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;Except as listed in Section 2 below, the following is a complete list of all inventions or improvements relevant to the subject matter of my employment by Sangamo Therapeutics, Inc. (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Company</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) that have been made or conceived or first reduced to practice by me alone or jointly with others prior to my engagement by Company&#58;</font></div><div style="text-indent:29.25pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No inventions or improvements.</font></div><div style="text-indent:29.25pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;See below&#58;</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-indent:-27pt;padding-left:29.25pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Additional sheets attached.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">2.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Due to a prior confidentiality agreement, I cannot complete the disclosure under Section&#160;1 above with respect to inventions or improvements generally listed below, the intellectual property rights and duty of confidentiality with respect to which I owe to the following party(ies)&#58;</font></div><div style="text-indent:29.25pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Invention or Improvement&#160;Party(ies)&#160; Relationship</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</font></div><div style="text-indent:-27pt;padding-left:29.25pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Additional sheets attached.</font></div><div><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div style="text-indent:36pt;padding-left:396pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 10.24</font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ATTACHMENT 2</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">LIMITED EXCLUSION NOTIFICATION</font></div><div><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">This is to notify you in accordance with Section 2872 of the California Labor Code that the foregoing Agreement between you and Company does not require you to assign or offer to assign to Company any Invention that you develop entirely on your own time without using Company&#8217;s equipment, supplies, facilities or trade secret information, except for those Inventions that either&#58;</font></div><div><font><br></font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Relate at the time of conception or reduction to practice to Company&#8217;s business, or actual or demonstrably anticipated research or development&#59; or</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Result from any work performed by you for Company.</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">To the extent a provision in the foregoing Agreement purports to require you to assign an Invention otherwise excluded from the preceding paragraph, the provision is against the public policy of this state and is unenforceable.</font></div><div><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">This limited exclusion does not apply to any patent or Invention covered by a contract between Company and the United States or any of its agencies requiring full title to such patent or Invention to be in the United States.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">A-2</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.25
<SEQUENCE>4
<FILENAME>sgmo-20191231xexx1025.htm
<DESCRIPTION>EX-10.25
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i5822bb9995eb4fea855b4ed69b1efe03_1"></div><div style="height:72pt;width:100%;"><div style="text-indent:36pt;padding-left:396pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 10.25</font></div></div><div style="text-align:center;margin-bottom:24pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">EXECUTIVE EMPLOYMENT AGREEMENT</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Employment Agreement (&#8220;Agreement&#8221;) made as of the 6</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">th</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> day of June 2019 by and between Sangamo Therapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221;), and Gary Loeb (&#8220;Executive&#8221;) (collectively, the &#8220;Parties&#8221;).</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">R E C I T A L S</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">WHEREAS</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, the Company desires to employ Executive, and Executive desires to be employed by the Company, on the terms and conditions set forth in this Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">NOW, THEREFORE</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, in consideration of the mutual promises set forth herein, the Parties agree follows&#58;</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;">Employment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The Company hereby agrees to employ Executive and Executive hereby agrees to accept such employment, on the terms and conditions set forth in this Agreement, with a start date of  July 29</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">th</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  2019 (the &#8220;Effective Date&#8221;).</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">At-Will Employment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Executive shall be employed on an at-will basis.  Either Executive or the Company may terminate employment at any time, with or without cause, and with or without advance notice.  </font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Position, Duties and Obligations</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Executive shall be appointed as the Executive Vice President and Chief Legal Counsel and shall serve in such position, and in such other positions as the Board and the Company may from time to time reasonably determine, subject at all times to the direction, supervision and authority of the Chief Executive Officer.  </font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">During Executive&#8217;s employment, Executive shall perform Executive&#8217;s duties faithfully and to the best of Executive&#8217;s ability, and shall devote substantially all of Executive&#8217;s business time, attention, knowledge, skills and interests to the business of the Company (and its affiliates or subsidiaries).  </font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">During Executive&#8217;s employment, Executive shall not, whether directly or indirectly, render any services of a commercial or professional nature to any other person or organization, whether for compensation or otherwise, without the prior written consent of the Chief Executive Officer. </font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The foregoing in this Section 3 shall not preclude Executive from serving on any corporate, civic or charitable boards or committees on which Executive is serving as of the Effective Date and discloses to the Chief Executive Officer prior to the Effective Date or on which Executive commences service following such date with the Chief Executive Officer&#8217;s </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div style="text-indent:36pt;padding-left:396pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 10.25</font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">prior written approval, so long as such activities do not interfere with the performance of Executive&#8217;s responsibilities hereunder.  </font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Executive&#8217;s principal place of business will be located in Brisbane,  California.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Executive represents that Executive may enter into this Agreement, and as of the Effective Date, 1) accept employment with the Company under the terms of this Agreement, and 2) perform the duties and responsibilities contemplated by this Agreement without violating any other agreement or agreements with other parties including but not limited to and any prior employers.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Compensation and Benefits</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Base Compensation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Company shall pay to Executive an annual base salary of $400,000 Dollars, prorated for any partial employment period and payable in equal monthly installments in accordance with the Company&#8217;s payroll schedule.  The Compensation Committee of the Board shall annually review the then-current level of Executive&#8217;s base salary (for increase only) to determine the amount, if any, of change to such salary.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Annual Performance Bonus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Executive is eligible to earn an annual performance bonus commencing with the 2019 calendar year performance period.  The target amount of Executive&#8217;s annual cash bonus shall be 40% percent of Executive&#8217;s annual base salary.  The Board shall have sole discretion to determine whether any annual cash bonus will be paid based upon achievement of both corporate objectives and Executive&#8217;s personal objectives, and the reasonable discretion to determine that actual amount of any such bonus.  Executive must be an employee in good standing on the date that the Board makes such determination in order to earn any such bonus, which determination shall be made by the Board no later than March 31 of the calendar year first following the performance period calendar year.  The actual bonus may be more or less than the target amount based upon the Company&#8217;s achievement over the year.  Any bonus to which Executive becomes entitled for a particular calendar year shall be paid in accordance with the terms of the applicable bonus plan, but in no event later than the second payroll period following such Board determination.  The Compensation Committee of the Board shall annually review Executive&#8217;s then target amount for the annual cash bonus (for increase only) to determine the amount, if any, of change to such target amount.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Executive Severance Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Executive shall be deemed an Eligible Employee and an Executive Officer and entitled to receive certain severance benefits under the Sangamo Therapeutics, Inc. Executive Severance Plan dated February 6, 2019 (the &#8220;Severance Plan&#8221;) subject to the terms and conditions of the Severance Plan.  A copy of the Severance Plan has been provided to Executive concurrently with this Agreement.  Notwithstanding the foregoing, in the event that the Company withdraws this offer after it is signed by Executive or terminates this Agreement prior to the Effective Date for any reason other than Executive&#8217;s failure to successfully pass the requirements for a background check clearance, satisfactory reference check, and satisfactory proof of Executive&#8217;s legal right to work in the United States required under Section 8(a) herein, then Executive shall be entitled to severance under the </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2 </font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div style="text-indent:36pt;padding-left:396pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 10.25</font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Severance Plan as though his employment was terminated by the Company other than for Cause to the same extent as he would otherwise be entitled had such termination occurred after the Effective Date&#59; provided, however, that Executive shall not be entitled to such severance if he has not notified his current employer of his intent to resign his employment at the time the Company informs him of the withdrawal or termination of this Agreement.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Benefits</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Executive will be entitled to the employee benefits generally provided to other executive officers of the Company pursuant to the terms of the applicable benefit plans.  Executive will not be subject to a formal paid time off program.  Executive is free to take paid time off from work for vacation, medical appointments, and other short-term absences due to illnesses or other personal reasons.  If Executive desires to take time off for a duration longer than two (2) weeks manager approval is required.  Unlimited paid time off is available from the first day of employment.  </font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Equity</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Effective as of August 25</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">th</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> 2019 or the trading day immediately preceding in the event August 25</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">th</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> is not a trading day (the &#8220;Grant Date&#8221;), the Compensation Committee of the Board</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">shall grant Executive a non-statutory stock option to purchase up to 250,000 shares of the Company&#8217;s Common Stock with an exercise price per share equal to the fair market value of the Company&#8217;s Common Stock on the Grant Date (the &#8220;Option&#8221;) under the Company&#8217;s 2018 Equity Incentive Plan (the &#8220;Plan&#8221;).  The Option will be evidenced by the standard stock option agreement under the Plan and will be subject to the terms and conditions of that agreement and the Plan, with one-quarter of the Option shares vesting twelve (12) months from the Grant Date and the remainder vesting in equal monthly installments for thirty-six (36) months thereafter, provided Executive remains a full-time employee through each such vesting date.  Vesting of the Option and any subsequent equity grants will cease upon termination of Executive&#8217;s service by either party for any reason.  </font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Clawback</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Notwithstanding anything to the contrary in this Agreement, all compensation paid to Executive by the Company (whether payable pursuant to this Agreement or otherwise) will be subject to reduction, recovery and&#47;or recoupment to the extent required by any present or future law, government regulation or stock exchange listing requirement (or any policy adopted by the Company which ensures compliance with the requirements of any such law, government regulation or stock exchange listing requirement).</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(g)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Resignation from Positions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Notwithstanding any other provision of this Agreement to the contrary, upon any termination of employment (whether voluntary or involuntary), Executive, upon written request from the Board, shall immediately resign from any positions Executive has with the Company (or any subsidiary), whether as an executive, officer, employee, consultant, director, trustee, fiduciary or otherwise.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Confidentiality</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Executive agrees to abide by the terms and conditions of the Employee Confidential Information and Invention Assignment Agreement between Executive and the Company, a copy of which is attached as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibit A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Executive further agrees that at all times both during Executive&#8217;s employment by the Company and after Executive&#8217;s employment ends, Executive will keep in confidence and trust, and will not use or disclose, except as directed by the Company, any confidential or proprietary information of the Company.  </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3 </font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div style="text-indent:36pt;padding-left:396pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 10.25</font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Tax Withholdings</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Any and all cash compensation and other benefits (including without limitation, base salary, annual bonus and sign-on bonus) paid to Executive under this Agreement shall be subject to all applicable tax withholding requirements, and the Company shall make such other deductions as may be required and&#47;or allowed by applicable law and&#47;or as authorized in writing by Executive.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">7.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Arbitration</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Any dispute, controversy, or claim, whether contractual or non-contractual, between Executive and the Company shall be resolved by binding arbitration before the Judicial Arbitration and Mediation Service (the &#8220;JAMS&#8221;), in accordance with the JAMS Employment Arbitration Rules and Procedures, available at www.jamsadr.com.  Executive and the Company each agree that before proceeding to arbitration, they will mediate disputes before the JAMS by a mediator approved by the JAMS.  If mediation fails to resolve the matter, any subsequent arbitration shall be conducted by an arbitrator approved by the JAMS and mutually acceptable to Executive and the Company.  All disputes, controversies, and claims shall be conducted by a single arbitrator, who shall&#58; (i) allow discovery authorized by California Code of Civil Procedure Section 1282, et seq., or any other discovery required by applicable law&#59; and (ii) issue a written award that sets forth the essential findings of fact and conclusions of law on which the award is based.  The arbitrator shall have the authority to award any relief authorized by law in connection with the asserted claims or disputes.   Judgment upon the arbitrator&#8217;s award may be entered in any court having jurisdiction thereof.  If Executive and the Company are unable to agree on the mediator or the arbitrator, then the JAMS shall select the mediator&#47;arbitrator.  The resolution of the dispute by the arbitrator shall be final, binding, non-appealable, and fully enforceable by a court of competent jurisdiction under the Federal Arbitration Act.  The arbitration award shall be in writing and shall include a statement of the reasons for the award.  The arbitration shall be held in San Francisco, California.  The Company shall pay all JAMS, mediation, and arbitrator&#8217;s fees and costs, irrespective of who raised the claim and the outcome of arbitration.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Miscellaneous</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Conditions to Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Agreement is contingent upon a background check clearance, satisfactory reference check, and satisfactory proof of Executive&#8217;s legal right to work in the United States.  Executive agrees to provide any documentation or information at the Company&#8217;s request to facilitate these processes.  </font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Governing Law</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Agreement shall be interpreted, construed, governed and enforced according to the laws of the State of California.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Attorneys&#8217; Fees</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  In the event of any controversy, claim or dispute between the parties, arising out of or relating to this Agreement or the breach hereof, or the interpretation hereof, each party shall bear its own legal fees and expenses.  Notwithstanding the foregoing, in the event of a finding by any court having jurisdiction over such matter that any party initiating an action under this Agreement failed to have a reasonable prospect of prevailing on its claim, the arbitrator shall have discretion to award the prevailing party attorneys&#8217; fees and costs incurred by it with respect to such claim or action.  The &#34;prevailing party&#34; means the party determined by the arbitrator to have most nearly prevailed, even if such party did not prevail in all matters, not necessarily the one in whose favor a judgment is rendered.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4 </font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div style="text-indent:36pt;padding-left:396pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 10.25</font></div></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Amendments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  No amendment or modification of the terms or conditions of this Agreement shall be valid unless in writing and signed by the Parties hereto.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Severability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  If any provision of this Agreement as applied to any party or to any circumstance should be adjudged by a court of competent jurisdiction (or determined by the arbitrator) to be void or unenforceable for any reason, the invalidity of that provision shall in no way affect (to the maximum extent permissible by law) the application of such provision under circumstances different from those adjudicated by the court or determined by the arbitrator, the application of any other provision of this Agreement, or the enforceability or invalidity of this Agreement as a whole.  Should any provision of this Agreement become or be deemed invalid, illegal or unenforceable in any jurisdiction by reason of the scope, extent or duration of its coverage, then such provision shall be deemed amended to the extent necessary to conform to applicable law so as to be valid and enforceable or, if such provision cannot be so amended without materially altering the intention of the parties, then such provision will be stricken, and the remainder of this Agreement shall continue in full force and effect.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Successors and Assigns</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The rights and obligations of the Company under this Agreement shall inure to the benefit of and shall be binding upon the successors and assigns of the Company.  Executive shall not be entitled to assign any of Executive&#8217;s rights or obligations under this Agreement.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(g)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Entire Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Agreement, along with any other agreements set forth herein, including without limitation, the Proprietary Information and Inventions Agreement, constitutes the entire agreement between the parties with respect to the employment of Executive.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(h)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div id="i5822bb9995eb4fea855b4ed69b1efe03_4"></div><div style="padding-left:216pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5 </font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="padding-left:216pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:49.198%;"><tr><td style="width:1.0%;"></td><td style="width:12.006%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:5.817%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:74.547%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.430%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">SANGAMO THERAPEUTICS, INC.</font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="6" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">By&#58;</font></div></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><br>Name&#58;  <br> <br>Title&#58;  <br></font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">GARY LOEB</font></div><div style="margin-bottom:12pt;"><font><br></font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><br></font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="padding-left:36pt;padding-right:49.5pt;text-align:center;margin-bottom:6pt;"><font><br></font></div><div id="i5822bb9995eb4fea855b4ed69b1efe03_7"></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:54pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="padding-left:36pt;padding-right:49.5pt;text-align:center;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">EXHIBIT A</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">EMPLOYEE CONFIDENTIAL INFORMATION AND </font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">INVENTION ASSIGNMENT AGREEMENT</font></div><div style="text-indent:36pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">In consideration of my employment or continued employment by Sangamo Therapeutics, Inc. (&#8220;Sangamo&#8221;), its direct and indirect subsidiaries, parents, affiliates, predecessors, successors and assigns (together with Sangamo, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Company</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#8221;), and the compensation and benefits provided to me now and during my employment with the Company, I hereby enter into this Employee Confidential Information and Invention Assignment Agreement (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#8221;), which will be deemed effective as of the first day of my employment with the Company&#58;</font></div><div style="margin-bottom:6pt;"><font><br></font></div><div id="i5822bb9995eb4fea855b4ed69b1efe03_10"></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;">CONFIDENTIAL INFORMATION PROTECTIONS.</font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Recognition of Company&#8217;s Rights&#59;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Nondisclosure.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  I understand and acknowledge that my employment by Company creates a relationship of confidence and trust with respect to Company&#8217;s Confidential Information (as defined below) and that Company has a protectable interest therein.  At all times during and after my employment, I will hold in confidence and will not disclose, use, lecture upon, or publish any of Company&#8217;s Confidential Information, except as such disclosure, use or publication may be required in connection with my work for Company, or unless an officer of Company expressly authorizes such disclosure.  I will obtain Company&#8217;s written approval before publishing or submitting for publication any material (written, oral, or otherwise) that discloses and&#47;or incorporates any Confidential Information.  I hereby assign to Sangamo any rights I may have or acquire in such Confidential Information and recognize that all Confidential Information shall be the sole and exclusive property of Sangamo and its assigns.  I will take all reasonable precautions to prevent the inadvertent accidental disclosure of Confidential Information.  Notwithstanding the foregoing, pursuant to 18 U.S.C. Section 1833(b), I shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that&#58;  (1) is made in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law&#59; or (2) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.</font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Confidential Information.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  The term </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#8220;Confidential Information&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> shall mean any and all confidential knowledge, data or information of Company.  By way of illustration but not limitation, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#8220;Confidential Information&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> includes (a)&#160;trade secrets, inventions, mask works, ideas, processes, formulas, software in source or object code versions, data, programs, other works of authorship, know-how, improvements, discoveries, developments, designs and techniques and any other proprietary technology and all Intellectual Property Rights therein (collectively, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#8220;Inventions&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">)&#59; (b)&#160;information regarding research, development, new products, marketing and selling, business plans, budgets and unpublished financial statements, licenses, prices and costs, margins, discounts, credit terms, pricing and billing policies, quoting procedures, methods of obtaining business, forecasts, future plans and potential strategies, financial projections and business strategies, operational plans, financing and capital-raising plans, activities and agreements, internal services and operational manuals, methods of conducting Company business, suppliers and supplier information, and purchasing&#59; (c) information regarding customers and potential customers of Company, including customer lists, names, representatives, their needs or desires with respect to the types of products or services offered by Company, proposals, bids, contracts and their contents and parties, the type and quantity of products and services provided or sought to be provided to customers and potential customers of Company and other non-public information relating to customers and potential customers&#59; (d) information regarding any of Company&#8217;s business partners and their services, including names, representatives, proposals, bids, contracts and their contents and parties, the type and quantity of products and services received by Company, and other non-public information relating to business partners&#59; (e) information regarding personnel, employee lists, compensation, and employee skills&#59; and (f) any other non-public information which a competitor of Company could use to the competitive disadvantage of Company.  Notwithstanding the foregoing, it is understood that, at all such times, I am free to use information which is generally known in the trade or industry through no breach of this Agreement or other act or omission by me.  Further, notwithstanding the foregoing or anything to the contrary in this Agreement or any other agreement between the Company and me, nothing in this Agreement shall limit my right to discuss my employment or report possible violations of law or regulation with any federal government agency or similar </font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">1</font></div></div></div><hr style="page-break-after:always"><div style="height:54pt;width:100%;"><div style="text-indent:36pt;padding-left:396pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 10.25</font></div></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">state or local agency or to discuss the terms and conditions of my employment with others to the extent expressly permitted by Section 7 of the National Labor Relations Act. </font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Third Party Information.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">I understand, in addition, that Company has received, and in the future will receive, from third parties their confidential and&#47;or proprietary knowledge, data or information (</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#8220;Third Party Information&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">) subject to a duty on Company&#8217;s part to maintain the confidentiality of such information and to use it only for certain limited purposes.  During my employment and thereafter, I will hold Third Party Information in confidence and will not disclose to anyone (other than Company personnel who need to know such information in connection with their work for Company) or use, except in connection with my work for Company, Third Party Information unless expressly authorized by an officer of Company in writing.</font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">No Improper Use of Information of Prior Employers and Others.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  During my employment by Company, I will not improperly use or disclose confidential information or trade secrets, if any, of any former employer or any other person to whom I have an obligation of confidentiality, and I will not bring onto the premises of Company any unpublished documents or any property belonging to any former employer or any other person to whom I have an obligation of confidentiality unless consented to in writing by that former employer or person.</font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;">ASSIGNMENTS OF INVENTIONS.</font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Definitions.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">As used in this Agreement, the term </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#8220;Intellectual Property Rights&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> means all trade secrets, Copyrights, trademarks, mask work rights, patents and other intellectual property rights recognized by the laws of any jurisdiction or country&#59; the term </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#8220;Copyright&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> means the exclusive legal right to reproduce, perform, display, distribute and make derivative works of a work of authorship (as a literary, musical, or artistic work) recognized by the laws of any jurisdiction or country&#59; and the term </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#8220;Moral Rights&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> means all paternity, integrity, disclosure, withdrawal, special and any other similar rights recognized by the laws of any jurisdiction or country.</font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Excluded Inventions and Other Inventions.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  Attached hereto as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Attachment 1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> is a list describing all existing Inventions, if any, that may relate to Company&#8217;s business or actual or demonstrably anticipated research or development and that were made by me or acquired by me prior to the commencement of my employment with, and which are not to be assigned to, Company (</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#8220;Excluded Inventions&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">).  If no such list is attached, I represent and agree that it is because I have no rights in any existing Inventions that may relate to Company&#8217;s business or actual or demonstrably anticipated research or development.  For purposes of this Agreement, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#8220;Other Inventions&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> means Inventions in which I have or may have an interest, as of the commencement of my employment, other than Company Inventions (defined below) and Excluded Inventions.  I acknowledge and agree that if I use any Excluded Inventions or any Other Inventions in the scope of my employment, or if I include any Excluded Inventions or Other Inventions in any product or service of Company, or if my rights in any Excluded Inventions or Other Inventions may block or interfere with, or may otherwise be required for, the exercise by Company of any rights assigned to Company under this Agreement, I will immediately so notify Company in writing.  Unless Company and I agree otherwise in writing as to particular Excluded Inventions or Other Inventions, I hereby grant to Company, in such circumstances (whether or not I give Company notice as required above), a non-exclusive, perpetual, transferable, fully-paid and royalty-free, irrevocable and worldwide license, with rights to sublicense through multiple levels of sublicensees, to reproduce, make derivative works of, distribute, publicly perform, and publicly display in any form or medium, whether now known or later developed, make, have made, use, sell, import, offer for sale, and exercise any and all present or future rights in, such Excluded Inventions and Other Inventions.  To the extent that any third parties have rights in any such Excluded Inventions or Other Inventions, I hereby represent and warrant that such third party or parties have validly and irrevocably granted to me the right to grant the license stated above.</font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Assignment of Company Inventions.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> Inventions assigned to Sangamo, or to a third party as directed by Sangamo pursuant to Section 2.6, are referred to in this Agreement as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#8220;Company Inventions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  Subject to Section 2.4 (Unassigned or Nonassignable Inventions) and except for Excluded Inventions set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Attachment 1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> and Other Inventions, I hereby assign to</font><font style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Sangamo all my right, title, and interest in and to any and all Inventions (and all Intellectual Property Rights with respect thereto) made, conceived, reduced to practice, or learned by me, either alone or with others, during the period of my employment by Company.  To the extent required by applicable Copyright laws, I agree to assign in the future (when any copyrightable Inventions are first fixed in a tangible medium of expression) my Copyright rights in and to such Inventions.  Any assignment of Company Inventions (and all Intellectual Property Rights with respect </font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;">2</font></div></div></div><hr style="page-break-after:always"><div style="height:54pt;width:100%;"><div style="text-indent:36pt;padding-left:396pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 10.25</font></div></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">thereto) hereunder includes an assignment of all Moral Rights.  To the extent such Moral Rights cannot be assigned to Sangamo and to the extent the following is allowed by the laws in any country where Moral Rights exist, I hereby unconditionally and irrevocably waive the enforcement of such Moral Rights, and all claims and causes of action of any kind against Company or related to Company&#8217;s customers, with respect to such rights.  I further acknowledge and agree that neither my successors-in-interest nor legal heirs retain any Moral Rights in any Company Inventions (and any Intellectual Property Rights with respect thereto).</font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Unassigned or Nonassignable Inventions.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  I recognize that this Agreement will not be deemed to require assignment of any Invention that is covered under California Labor Code section 2870(a) (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Specific Inventions Law</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#8221;), as detailed on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Attachment 2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Obligation to Keep Company Informed.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  During the period of my employment and for one (1) year after termination of my employment, I will promptly and fully disclose to Company in writing all Inventions authored, conceived, or reduced to practice by me, either alone or jointly with others.  In addition, I will promptly disclose to Company all patent applications filed by me or on my behalf within one (1) year after termination of employment.  At the time of each such disclosure, I will advise Company in writing of any Inventions that I believe fully qualify for protection under the provisions of the Specific Inventions Law&#59; and I will at that time provide to Company in writing all evidence necessary to substantiate that belief.  Company will keep in confidence and will not use for any purpose or disclose to third parties without my consent any confidential information disclosed in writing to Company pursuant to this Agreement relating to Inventions that qualify fully for protection under the Specific Inventions Law.  I will preserve the confidentiality of any Invention that does not fully qualify for protection under the Specific Inventions Law.</font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Government or Third Party. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> I agree that, as directed by Company, I will assign to a third party, including without limitation the United States, all my right, title, and interest in and to any particular Company Invention.</font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.7</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Ownership of Work Product.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  I agree that Sangamo will exclusively own all work product that is made by me (solely or jointly with others) within the scope of my employment, and I hereby irrevocably and unconditionally assign to Sangamo all right, title, and interest worldwide in and to such work product.  I acknowledge that all original works of authorship which are made by me (solely or jointly with others) within the scope of my employment and which are protectable by Copyright are &#8220;works made for hire,&#8221; pursuant to United States Copyright Act (17 U.S.C., Section 101).  I understand and agree that I have no right to publish on, submit for publishing, or use for any publication any work product protected by this Section, except as necessary to perform services for Company.</font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.8</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Enforcement of Intellectual Property Rights and Assistance.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  I will assist Company in every proper way to obtain, and from time to time enforce, United States and foreign Intellectual Property Rights and Moral Rights relating to Company Inventions in any and all countries.  To that end I will execute, verify and deliver such documents and perform such other acts (including appearances as a witness) as Company may reasonably request for use in applying for, obtaining, perfecting, evidencing, sustaining and enforcing such Intellectual Property Rights and the assignment thereof.  In addition, I will execute, verify and deliver assignments of such Intellectual Property Rights to Sangamo or its designee, including the United States or any third party designated by Sangamo.  My obligation to assist Company with respect to Intellectual Property Rights relating to such Company Inventions in any and all countries will continue beyond the termination of my employment, but Company will compensate me at a reasonable rate after my termination for the time actually spent by me at Company's request on such assistance. In the event Company is unable for any reason, after reasonable effort, to secure my signature on any document needed in connection with the actions specified in this paragraph, I hereby irrevocably designate and appoint Company and its duly authorized officers and agents as my agent and attorney in fact, which appointment is coupled with an interest, to act for and in my behalf to execute, verify and file any such documents and to do all other lawfully permitted acts to further the purposes of this Agreement with the same legal force and effect as if executed by me.  I hereby waive and quitclaim to Company any and all claims, of any nature whatsoever, which I now or may hereafter have for infringement of any Intellectual Property Rights assigned under this Agreement to Sangamo. </font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.9</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Incorporation of Software Code.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  I agree that I will not incorporate into any Company software or otherwise deliver to Company any software code licensed under the GNU General Public License or Lesser General Public License or any other license that, by its terms, requires or conditions the use or distribution of such code on the disclosure, </font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;">3</font></div></div></div><hr style="page-break-after:always"><div style="height:54pt;width:100%;"><div style="text-indent:36pt;padding-left:396pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 10.25</font></div></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">licensing, or distribution of any source code owned or licensed by Company </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">except</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> in strict compliance with Company&#8217;s policies regarding the use of such software.</font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;">RECORDS.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  I agree to keep and maintain adequate and current records (in the form of notes, sketches, drawings and in any other form that is required by Company) of all Confidential Information developed by me and all Company Inventions made by me during the period of my employment at Company, which records will be available to and remain the sole property of Company at all times.</font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;">DUTY OF LOYALTY DURING EMPLOYMENT.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  I agree that during the period of my employment by Company I will not, without Company's express written consent, directly or indirectly (a) engage in any other employment or (b) engage in any other activities that are competitive with, or would otherwise conflict with, my employment by Company.</font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;">NO SOLICITATION OF EMPLOYEES, CONSULTANTS, OR CONTRACTORS.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">I agree that during the period of my employment and for the one (1) year period after the date my employment ends for any reason, including but not limited to voluntary termination by me or involuntary termination by Company, I will not, as an officer, director, employee, consultant, owner, partner, or in any other capacity, either directly or through others, except on behalf of Company, solicit, induce, encourage, or participate in soliciting, inducing or encouraging any employee, consultant, or independent contractor of Company to terminate his, her or its relationship with Company, even if I did not initiate the discussion or seek out the contact. </font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;">REASONABLENESS OF RESTRICTIONS.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">I agree that I have read this entire Agreement and understand it.  I agree that this Agreement does not prevent me from earning a living or pursuing my career.  I agree that the restrictions contained in this Agreement are reasonable, proper, and necessitated by Company&#8217;s legitimate business interests.  I represent and agree that I am entering into this Agreement freely and with knowledge of its contents with the intent to be bound by the Agreement and the restrictions contained in it.</font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">7.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;">NO CONFLICTING AGREEMENT OR OBLIGATION.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  I represent that my employment by Company does not and will not breach any agreement with any former employer or third party, including any noncompete agreement or any agreement to keep in confidence or refrain from using information acquired by me prior to my employment by Company.  I further represent that I have not entered into, and will not enter into, any agreement, either written or oral, in conflict with my obligations under this Agreement.</font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">8.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;">RETURN OF COMPANY PROPERTY. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> Subject to the nondisclosure requirements of Section 1.1 above, upon termination of my employment or upon Company&#8217;s request at any other time, I will deliver to Company any and all of Company&#8217;s property and equipment and any and all drawings, notes, memoranda, specifications, devices, formulas and documents, together with all copies thereof, and any other material containing or disclosing any Company Inventions, Third Party Information or Confidential Information of Company.  I agree that I will not copy, delete, or alter any information contained upon my Company computer or Company equipment before I return it to Company.  In addition, if I have used any personal computer, server, or e-mail system to receive, store, review, prepare or transmit any Company information, including but not limited to, Confidential Information, I agree to provide Company with a computer-useable copy of all such Confidential Information and then permanently delete and expunge such Confidential Information from those systems&#59; and I agree to provide Company access to my system as reasonably requested to verify that the necessary copying and&#47;or deletion is completed.  I further agree that any property situated on Company&#8217;s premises and owned by Company, including disks and other storage media, filing cabinets or other work areas, is subject to inspection by Company&#8217;s personnel at any time with or without notice.</font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">9.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;">LEGAL AND EQUITABLE REMEDIES.</font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">I agree that it may be impossible to assess the damages caused by my violation of this Agreement or any of its terms.  I agree that any threatened or actual violation of this Agreement or any of its terms will constitute immediate and irreparable injury to Company, and Company will have the right to enforce this Agreement and any of its provisions by injunction, specific performance or other equitable relief, without bond and without prejudice to any other rights and remedies that Company may have for a breach or threatened breach of this Agreement.</font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;">4</font></div></div></div><hr style="page-break-after:always"><div style="height:54pt;width:100%;"><div style="text-indent:36pt;padding-left:396pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 10.25</font></div></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">In the event Company enforces this Agreement through a court or arbitration order, I agree that the restrictions of Sections 5 will remain in effect for a period of twelve (12) months from the effective date of the order enforcing the Agreement. </font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">10.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt;">NOTICES.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  Any notices required or permitted under this Agreement will be given to Company at its headquarters location at the time notice is given, and to me at my address as listed on Company payroll, or at such other address as Company or I may designate by written notice to the other.  Notice will be effective upon receipt or refusal of delivery.  If delivered by certified or registered mail, notice will be considered to have been given five (5) business days after it was mailed, as evidenced by the postmark.  If delivered by courier or express mail service, notice will be considered to have been given on the delivery date reflected by the courier or express mail service receipt.</font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">11.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt;">NOTIFICATION OF NEW EMPLOYER.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">If I leave the employ of Company, I consent to the notification of my new employer of my rights and obligations under this Agreement, by Company providing a copy of this Agreement or otherwise. </font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">12.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt;">GENERAL PROVISIONS.</font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Governing Law.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  This Agreement will be governed by and construed according to the laws of the State of California as such laws are applied to agreements entered into and to be performed entirely within California between California residents. </font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Severability.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  In case any one or more of the provisions, subsections, or sentences contained in this Agreement will, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect the other provisions of this Agreement, and this Agreement will be construed as if such invalid, illegal or unenforceable provision had never been contained in this Agreement.  If moreover, any one or more of the provisions contained in this Agreement will for any reason be held to be excessively broad as to duration, geographical scope, activity or subject, it will be construed by limiting and reducing it, so as to be enforceable to the extent compatible with the applicable law as it will then appear. </font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Successors and Assigns.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  This Agreement is for my benefit and the benefit of Company, its successors, assigns, parent corporations, direct and indirect subsidiaries, affiliates, and purchasers, and will be binding upon my heirs, executors, administrators and other legal representatives.</font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Survival.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  This Agreement shall survive the termination of my employment, regardless of the reason, and the assignment of this Agreement by Company to any successor in interest or other assignee.</font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Employment At-Will.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  I agree and understand that nothing in this Agreement will change my at-will employment status or confer any right with respect to continuation of employment by Company, nor will it interfere in any way with my right or Company's right to terminate my employment at any time, with or without cause or advance notice.</font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Waiver.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  No waiver by Company of any breach of this Agreement will be a waiver of any preceding or succeeding breach.  No waiver by Company of any right under this Agreement will be construed as a waiver of any other right.  Company will not be required to give notice to enforce strict adherence to all terms of this Agreement.</font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.7</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Export.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  I agree not to export, reexport, or transfer, directly or indirectly, any U.S. technical data acquired from Company or any products utilizing such data, in violation of the United States export laws or regulations.</font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.8</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Entire Agreement.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  This Agreement is the final, complete and exclusive agreement of the parties with respect to the subject matter of this Agreement and supersedes and merges all prior discussions between the parties&#59; provided, however, prior to the execution of this Agreement, if Company and I were parties to any agreement regarding the subject matter hereof, that agreement will be superseded by this Agreement prospectively only.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">No modification of or amendment to this Agreement, or any waiver of any rights under this Agreement, will be effective unless in writing and signed by me and an authorized officer of the Company.  Any subsequent change or changes in my duties, salary or compensation will not affect the validity or scope of this Agreement.  If no other agreement governs nondisclosure and assignment of inventions during any period in which I was previously engaged or am in the future engaged by Company </font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;">5</font></div></div></div><hr style="page-break-after:always"><div style="height:54pt;width:100%;"><div style="text-indent:36pt;padding-left:396pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 10.25</font></div></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">as an independent contractor, the obligations pursuant to sections of this Agreement titled &#8220;Confidential Information Protections&#8221; and &#8220;Assignment of Inventions&#8221; shall apply.</font></div><div style="text-indent:36pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> </font></div><div id="i5822bb9995eb4fea855b4ed69b1efe03_13"></div><div style="margin-top:12pt;margin-bottom:12pt;"><font><br></font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:96.666%;"><tr><td style="width:1.0%;"></td><td style="width:48.000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:48.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:222pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:5pt;"><font><br></font></div><div style="margin-bottom:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;">GARY LOEB&#58;</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;">I HAVE READ, UNDERSTAND, AND ACCEPT THIS AGREEMENT.</font></div><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration: underline;">&#160;&#160;&#160;</font></div><div style="text-align:center;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;">(Signature)</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;">By&#58;__________________________________________   </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;">Title&#58;________________________________________   </font></div><div><font><br></font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;">Date&#58; ________________________________________</font></div><div style="margin-bottom:10pt;"><font><br></font></div></td><td colspan="3" style="height:222pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:5pt;"><font><br></font></div><div style="margin-bottom:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;">SANGAMO THERAPEUTICS, INC.&#58;</font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;">ACCEPTED AND AGREED&#58;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration: underline;">&#160;&#160;&#160;</font></div><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;">(Signature)</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;">By&#58; __________________________________________   </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;">Title&#58; ________________________________________   </font></div><div><font><br></font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;">Date&#58; ________________________________________   </font></div><div style="margin-bottom:10pt;"><font><br></font></div></td></tr></table></div><div><font><br></font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font><br></font></div><div id="i5822bb9995eb4fea855b4ed69b1efe03_16"></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;">6</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ATTACHMENT 1</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">PRIOR INVENTIONS</font></div><div style="text-indent:-54pt;padding-left:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">TO&#58;&#160;Sangamo Therapeutics, Inc. </font></div><div style="text-indent:-54pt;padding-left:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">FROM&#58;&#160;Gary Loeb</font></div><div style="text-indent:-54pt;padding-left:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">DATE&#58;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">&#160;</font></div><div style="text-indent:-56.25pt;padding-left:58.5pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">SUBJECT&#58;&#160;Prior Inventions </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;Except as listed in Section 2 below, the following is a complete list of all inventions or improvements relevant to the subject matter of my employment by Sangamo Therapeutics, Inc. (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Company</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) that have been made or conceived or first reduced to practice by me alone or jointly with others prior to my engagement by Company&#58;</font></div><div style="text-indent:29.25pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No inventions or improvements.</font></div><div style="text-indent:29.25pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;See below&#58;</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-indent:-27pt;padding-left:29.25pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Additional sheets attached.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">2.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Due to a prior confidentiality agreement, I cannot complete the disclosure under Section&#160;1 above with respect to inventions or improvements generally listed below, the intellectual property rights and duty of confidentiality with respect to which I owe to the following party(ies)&#58;</font></div><div style="text-indent:29.25pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Invention or Improvement&#160;Party(ies)&#160; Relationship</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</font></div><div style="text-indent:-27pt;padding-left:29.25pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Additional sheets attached.</font></div><div><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div style="text-indent:36pt;padding-left:396pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 10.25</font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ATTACHMENT 2</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">LIMITED EXCLUSION NOTIFICATION</font></div><div><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">This is to notify you in accordance with Section 2872 of the California Labor Code that the foregoing Agreement between you and Company does not require you to assign or offer to assign to Company any Invention that you develop entirely on your own time without using Company&#8217;s equipment, supplies, facilities or trade secret information, except for those Inventions that either&#58;</font></div><div><font><br></font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Relate at the time of conception or reduction to practice to Company&#8217;s business, or actual or demonstrably anticipated research or development&#59; or</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Result from any work performed by you for Company.</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">To the extent a provision in the foregoing Agreement purports to require you to assign an Invention otherwise excluded from the preceding paragraph, the provision is against the public policy of this state and is unenforceable.</font></div><div><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">This limited exclusion does not apply to any patent or Invention covered by a contract between Company and the United States or any of its agencies requiring full title to such patent or Invention to be in the United States.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">A-2</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.26
<SEQUENCE>5
<FILENAME>sgmo-20191231xexx1026.htm
<DESCRIPTION>EX-10.26
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ib9ebbd63ba52453b8bed7388d9fa3b19_1"></div><div style="height:72pt;width:100%;"><div style="text-indent:36pt;padding-left:396pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 10.26</font></div></div><div style="text-align:center;margin-bottom:24pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">EXECUTIVE EMPLOYMENT AGREEMENT</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Employment Agreement (&#8220;Agreement&#8221;) made as of the 1st day of November, 2017 by and between Sangamo Therapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221;), and Andy Ramelmeier (&#8220;Executive&#8221;) (collectively, the &#8220;Parties&#8221;).</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">R E C I T A L S</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">WHEREAS</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, the Company desires to employ Executive, and Executive desires to be employed by the Company, on the terms and conditions set forth in this Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">NOW, THEREFORE</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, in consideration of the mutual promises set forth herein, the Parties agree follows&#58;</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;">Employment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The Company hereby agrees to employ Executive and Executive hereby agrees to accept such employment, on the terms and conditions set forth in this Agreement, with a start date of January 1, 2018 (the &#8220;Effective Date&#8221;).</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">At-Will Employment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Executive shall be employed on an at-will basis.  Either Executive or the Company may terminate employment at any time, with or without cause, and with or without advance notice.  </font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Position, Duties and Obligations</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Executive shall be appointed as the Company&#8217;s Senior Vice President, Technical Operations.  Executive shall serve in such position, and in such other positions as the Board and the Company may from time to time reasonably determine, subject at all times to the direction, supervision and authority of the Chief Executive Officer or such other officer as designated by the Chief Executive Officer.  </font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">During Executive&#8217;s employment, Executive shall perform Executive&#8217;s  duties faithfully and to the best of Executive&#8217;s ability and shall devote substantially all of Executive&#8217;s business time, attention, knowledge, skills and interests to the business of the Company (and its subsidiaries).  </font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">During Executive&#8217;s employment, Executive shall not, whether directly or indirectly, render any services of a commercial or professional nature to any other person or organization, whether for compensation or otherwise, without the prior written consent of the Chief Executive Officer.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The foregoing in this Section 1 shall not preclude Executive from serving on any corporate, civic or charitable boards or committees on which Executive is serving as of the Effective Date and discloses to the Chief Executive Officer prior to the Effective Date or on </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">152273479 v4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div style="text-indent:36pt;padding-left:396pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 10.26</font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">which Executive commences service following such date with the Chief Executive Officer&#8217;s prior written approval, so long as such activities do not interfere with the performance of Executive&#8217;s responsibilities hereunder.  </font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Executive&#8217;s principal place of business will initially be located in Richmond, California and is anticipated to transition to Brisbane, California in connection with the Company&#8217;s planned relocation to a new facility.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Executive represents that Executive may enter into this Agreement, accept employment with the Company under the terms of this Agreement, and perform the duties and responsibilities contemplated by this Agreement without violating any other agreement or agreements with other parties including but not limited to prior employers.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Compensation and Benefits</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Base Compensation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Company shall pay to Executive an annual base salary of three hundred sixty five thousand dollars ($365,000), prorated for any partial employment period and payable in equal monthly installments in accordance with the Company&#8217;s payroll schedule.  The Compensation Committee of the Board shall annually review the then-current level of Executive&#8217;s base salary to determine the amount, if any, of change to such salary.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Annual Performance Bonus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Executive is not eligible to earn any performance bonus for the 2017 calendar year performance period.  Commencing with the 2018 calendar year performance period, the target amount of Executive&#8217;s annual cash bonus shall be thirty five percent (35%) of Executive&#8217;s annual base salary.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The Board shall have sole discretion to determine whether any annual cash bonus will be paid based upon achievement of both corporate objectives and Executive&#8217;s personal objectives, and the sole discretion to determine that actual amount of any such bonus.  Executive must be an employee in good standing on the date that the Board makes such determination in order to earn any such bonus, which determination shall be made by the Board between January 1 and March 31 of the calendar year first following the performance period calendar year.  Any bonus to which Executive becomes entitled for a particular calendar year shall be paid in accordance with the terms of the applicable bonus plan, but in no event later than the second payroll period following such Board determination.  The Compensation Committee of the Board shall annually review Executive&#8217;s then target amount for the annual cash bonus to determine the amount, if any, of change to such target amount.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Benefits</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Executive will be entitled to the employee benefits generally provided to other executive officers of the Company.  Under the Company&#8217;s vacation policy, Executive will have 10 sick days, 15 vacation days and 10 Company holidays per year.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Executive Severance Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Executive shall be deemed an Eligible Employee and entitled to receive certain severance benefits under the Sangamo Therapeutics, Inc. Executive Severance Plan dated March 14, 2017 (the &#8220;Plan&#8221;) subject to the terms and </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">152273479 v4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div style="text-indent:36pt;padding-left:396pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 10.26</font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">conditions of the Plan.  A copy of the Plan has been provided to Executive concurrently with this Agreement.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Equity</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  As an inducement to Executive&#8217;s commencement of employment, effective as of the last business day of the month in which the Effective Date occurs, the Compensation Committee of the Board</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">shall grant Executive a stock option to purchase up to 120,000 shares of the Company&#8217;s Common Stock with an exercise price per share equal to the fair market value of the Company&#8217;s Common Stock on the applicable date of grant (the &#8220;Option&#8221;) under the Company&#8217;s 2013 Stock Incentive Plan (the &#8220;Plan&#8221;).  The Option will be evidenced by the standard stock option agreement under the Plan and will be subject to the terms and conditions of that agreement and the Plan, with one-quarter of the Option shares vesting twelve (12) months from the Effective Date and the remainder vesting in equal monthly installments for thirty-six (36) months thereafter, provided Executive remains a full-time employee through each such vesting date.  Vesting of the Option and any subsequent equity grants will cease upon termination of Executive&#8217;s service by either party for any reason.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Clawback</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Notwithstanding anything to the contrary in this Agreement, all compensation paid to Executive by the Company (whether payable pursuant to this Agreement or otherwise) will be subject to reduction, recovery and&#47;or recoupment to the extent required and allowed by any present or future law, government regulation or stock exchange listing requirement (or any policy adopted by the Company which ensures compliance with the requirements of any such law, government regulation or stock exchange listing requirement).</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(g)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Resignation from Positions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Notwithstanding any other provision of this Agreement to the contrary, upon any termination of employment (whether voluntary or involuntary), Executive, upon written request from the Board, shall immediately resign from any positions Executive has with the Company (or any subsidiary), whether as an executive, officer, employee, consultant, director, trustee, fiduciary or otherwise.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Confidentiality</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Executive agrees to abide by the terms and conditions of the  Proprietary Information, Inventions and Materials Agreement between Executive and the Company, a copy of which is attached as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibit A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Executive further agrees that at all times both during Executive&#8217;s employment by the Company and after Executive&#8217;s employment ends, Executive will keep in confidence and trust, and will not use or disclose, except as directed by the Company, any confidential or proprietary information of the Company.  </font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Tax Withholdings</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Any and all cash compensation and other benefits (including without limitation, base salary and annual bonus) paid to Executive under this Agreement shall be subject to all applicable tax withholding requirements, and the Company shall make such other deductions as may be required and&#47;or allowed by applicable law and&#47;or as authorized in writing by Executive.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">7.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Arbitration</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Any dispute, controversy, or claim, whether contractual or non-contractual, between Executive and the Company shall be resolved by binding arbitration before the Judicial Arbitration and Mediation Service (the &#8220;JAMS&#8221;), in accordance with the JAMS Employment Arbitration Rules and Procedures, available at www.jamsadr.com.  Executive and the Company </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">152273479 v4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div style="text-indent:36pt;padding-left:396pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 10.26</font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">each agree that before proceeding to arbitration, they will mediate disputes before the JAMS by a mediator approved by the JAMS.  If mediation fails to resolve the matter, any subsequent arbitration shall be conducted by an arbitrator approved by the JAMS and mutually acceptable to Executive and the Company.  All disputes, controversies, and claims shall be conducted by a single arbitrator, who shall&#58; (i) allow discovery authorized by California Code of Civil Procedure Section 1282, et seq., or any other discovery required by applicable law&#59; and (ii) issue a written award that sets forth the essential findings of fact and conclusions of law on which the award is based.  The arbitrator shall have the authority to award any relief authorized by law in connection with the asserted claims or disputes.   Judgment upon the arbitrator&#8217;s award may be entered in any court having jurisdiction thereof.  If Executive and the Company are unable to agree on the mediator or the arbitrator, then the JAMS shall select the mediator&#47;arbitrator.  The resolution of the dispute by the arbitrator shall be final, binding, non-appealable, and fully enforceable by a court of competent jurisdiction under the Federal Arbitration Act.  The arbitration award shall be in writing and shall include a statement of the reasons for the award.  The arbitration shall be held in San Francisco, California.  The Company shall pay all JAMS, mediation, and arbitrator&#8217;s fees and costs, irrespective of who raised the claim and the outcome of arbitration.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Miscellaneous</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Conditions to Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Agreement is contingent upon a background check clearance, satisfactory reference check, and satisfactory proof of Executive&#8217;s  legal right to work in the United States.  Executive agrees to provide any documentation or information at the Company&#8217;s request to facilitate these processes.  </font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Governing Law</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Agreement shall be interpreted, construed, governed and enforced according to the laws of the State of California.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Attorneys&#8217; Fees</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  In the event of any controversy, claim or dispute between the parties, arising out of or relating to this Agreement or the breach hereof, or the interpretation hereof, each party shall bear its own legal fees and expenses.  Notwithstanding the foregoing, in the event of a finding by any court having jurisdiction over such matter that any party initiating an action under this Agreement failed to have a reasonable prospect of prevailing on its claim, the court shall have discretion to award the prevailing party attorneys&#8217; fees and costs incurred by it with respect to such claim or action.  The &#34;prevailing party&#34; means the party determined by the court to have most nearly prevailed, even if such party did not prevail in all matters, not necessarily the one in whose favor a judgment is rendered.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Amendments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  No amendment or modification of the terms or conditions of this Agreement shall be valid unless in writing and signed by the Parties hereto.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Severability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  If any provision of this Agreement as applied to any party or to any circumstance should be adjudged by a court of competent jurisdiction (or determined by the arbitrator) to be void or unenforceable for any reason, the invalidity of that provision shall in no way affect (to the maximum extent permissible by law) the application of such provision under circumstances different from those adjudicated by the court or determined by the arbitrator, the application of any other provision of this Agreement, or the enforceability or </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">152273479 v4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div style="text-indent:36pt;padding-left:396pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 10.26</font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">invalidity of this Agreement as a whole.  Should any provision of this Agreement become or be deemed invalid, illegal or unenforceable in any jurisdiction by reason of the scope, extent or duration of its coverage, then such provision shall be deemed amended to the extent necessary to conform to applicable law so as to be valid and enforceable or, if such provision cannot be so amended without materially altering the intention of the parties, then such provision will be stricken, and the remainder of this Agreement shall continue in full force and effect.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Successors and Assigns</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The rights and obligations of the Company under this Agreement shall inure to the benefit of and shall be binding upon the successors and assigns of the Company.  Executive shall not be entitled to assign any of her rights or obligations under this Agreement.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(g)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Entire Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Agreement, along with any other agreements set forth herein, including without limitation, the Proprietary Information and Inventions Agreement, constitutes the entire agreement between the parties with respect to the employment of Executive.</font></div><div style="text-indent:72pt;text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(h)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#91;signature page follows&#93;</font></div><div id="ib9ebbd63ba52453b8bed7388d9fa3b19_4"></div><div style="padding-left:216pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">152273479 v4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="padding-left:216pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:49.198%;"><tr><td style="width:1.0%;"></td><td style="width:12.006%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:5.817%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:74.547%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.430%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">SANGAMO THERAPEUTICS, INC.</font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="6" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">By&#58;</font></div></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><br>Name&#58;<br> <br>Title&#58;<br></font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">ANDY RAMELMEIER</font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><br></font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="padding-left:36pt;padding-right:49.5pt;text-align:center;margin-bottom:6pt;"><font><br></font></div><div id="ib9ebbd63ba52453b8bed7388d9fa3b19_7"></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">152273479 v4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="padding-left:36pt;padding-right:49.5pt;text-align:center;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">EXHIBIT A</font></div><div style="text-align:center;margin-bottom:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Proprietary Information, Inventions and Materials Agreement</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">152273479 v4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.45
<SEQUENCE>6
<FILENAME>sgmo-20191231xexx1045.htm
<DESCRIPTION>EX-10.45
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ifc7106f34a534be6925084427c7a0959_1"></div><div style="height:72pt;width:100%;"><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 10.45</font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;*&#93;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></div><div><font><br></font></div><div><img alt="picture11.jpg" src="picture11.jpg" style="height:110px;width:198px;"></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">December 17, 2019</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Sandy Macrae, Ph.D.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Chief Executive Officer</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Sangamo Therapeutics, Inc. </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">7000 Marina Blvd</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Brisbane, CA 94804</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Re&#58; SB-525 IND transfer and &#91;*&#93; milestone under the Collaboration and License Agreement between Sangamo Therapeutics, Inc. (&#8220;Sangamo&#8221;) and Pfizer Inc. (&#8220;Pfizer&#8221;), dated May 10, 2017 (&#8220;Collaboration Agreement&#8221;).  </font></div><div><font><br></font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Dear Dr. Macrae,       </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">This letter (&#8220;Letter Amendment&#8221;) sets forth Sangamo&#8217;s and Pfizer&#8217;s understanding and agreement related to transferring the IND for SB-525 and Pfizer potentially paying the &#91;*&#93; milestone for SB-525 ahead of &#91;*&#93; for SB-525.  This Letter Amendment is an amendment to the Collaboration Agreement and capitalized terms used herein but not otherwise defined shall have the meaning ascribed to them in the Collaboration Agreement.  </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 5.2 of the Collaboration Agreement sets forth that Sangamo would retain ownership of the IND for SB-525 and shall be responsible for all regulatory activities for SB-525 in the U.S., in each case through the IND Transition Date.  Although the IND Transition Date has not yet been reached, in order to advance the SB-525 development, Pfizer would like to begin the process of Sangamo transferring ownership of the IND for SB-25, namely IND 17250 (the &#8220;IND&#8221;) and transferring responsibility for all regulatory activities for SB-525.  Before Pfizer can approve the IND and responsibility transfer, Pfizer must ensure the readiness of transfer of the IND, which includes but is not limited to &#91;*&#93; (collectively, the &#8220;Transfer Preparation Activities&#8221;), and Sangamo is willing to cooperate reasonably with and provide reasonable assistance to Pfizer in order to complete these Transfer Preparation Activities on or before &#91;*&#93;.  Once the Transfer Preparation Activities are complete, Pfizer will promptly seek internal approval to provide written authorization to Sangamo to instruct the U.S. FDA to transfer ownership of the IND for SB-525 to Pfizer, and such approval shall not be unreasonably withheld.  Immediately after </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Pfizer receives such internal approval, it will inform Sangamo and Sangamo shall instruct the U.S. FDA to transfer ownership of the IND&#59; provided that Sangamo will allow Pfizer to review and approve the instructions it intends to provide to the U.S. FDA prior to delivering such instructions to the U.S. FDA.  Upon Sangamo&#8217;s submission, Pfizer will timely submit to the U.S. FDA its acceptance of ownership of the IND as to effectuate its acceptance of the IND transfer by &#91;*&#93;, or such other date as mutually agreed in writing by the Parties.  The date on which Pfizer submits its acceptance of the ownership of the IND to the U.S. FDA will be the IND Transition Date under the Collaboration Agreement.  In the event the Transfer Preparation Activities are not completed by &#91;*&#93;, Sangamo and Pfizer will reasonably discuss extending such deadline, with both parties recognizing time is of the essence and that such Transfer Preparation Activities should be completed as soon as reasonably practicable.  In no event will the transfer of the IND cancel the obligations of each of Sangamo and Pfizer to cooperate reasonably and provide reasonable assistance to the other party with regards to preparation of Regulatory Materials for any Product, as set forth in the Collaboration Agreement.  </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 9.4 of the Collaboration Agreement sets forth certain development milestones to be paid by Pfizer to Sangamo following the achievement of defined milestone events.  The &#91;*&#93; would be paid &#91;*&#93;.  Although the &#91;*&#93; has not yet been achieved, at &#91;*&#93;.  As such, if Sangamo &#91;*&#93; as set forth in this letter, then upon Pfizer&#8217;s submission of its acceptance of the ownership of the IND, the &#91;*&#93; milestone payment for &#91;*&#93; shall be due, &#91;*&#93;.  Sangamo and Pfizer recognize and agree that &#91;*&#93;.  In the event that &#91;*&#93; in accordance with the terms and conditions set forth by the Collaboration Agreement prior to this Letter Amendment.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Your signature below and return of this letter will serve as Sangamo&#8217;s agreement to the content of this letter and the terms and conditions set forth herein.  </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Sincerely,</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#91;*&#93;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#91;*&#93;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#91;*&#93;</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;..</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Read, Understood, and Agreed On behalf of Sangamo Therapeutics, Inc.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">__&#47;s Alexander Macrae____________</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Signature</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">______Alexander Macrae______________</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Printed Name &#38; Title</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">_____Dec 17, 2019___________________________</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Date</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Page </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exhibit A</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#91;*&#93; </font></div><div style="padding-left:36pt;"><font><br></font></div><div style="padding-left:18pt;margin-bottom:10pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Page </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">3</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>7
<FILENAME>sgmo-20191231xexx211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="iba726d18d7a649ff8dd6c4c4d32b52d7_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 21.1</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Subsidiaries of the Company</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Gendaq Limited (U.K.)</font></div><div style="margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ceregene Inc. (Delaware)</font></div><div style="margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">Sangamo Therapeutics France S.A.S. (France)</font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>8
<FILENAME>sgmo-20191231xexx231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ie39c6fb0f18d47cabb255e12a8f69fbc_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 23.1</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="text-indent:27pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:4.442%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:91.558%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Registration Statements (Forms S-8 No.&#160;333-166220, 333-189621, 333-206173, 333-221827, and 333-225552) pertaining to the Amended and Restated 2013 Stock Incentive Plan, 2010 Employee Stock Purchase Plan, and 2018 Equity Incentive Plan of Sangamo Therapeutics, Inc., and</font></td></tr><tr><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Registration Statements (Forms S-3 No.&#160;333-218294 and 333-224418) and related prospectuses of Sangamo Therapeutics, Inc.&#59;</font></td></tr></table></div><div style="margin-top:15pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">of our reports dated February&#160;28, 2020, with respect to the consolidated financial statements of Sangamo Therapeutics, Inc. and the effectiveness of internal control over financial reporting of Sangamo Therapeutics, Inc. included in this Annual Report (Form 10-K) of Sangamo Therapeutics, Inc. for the year ended December&#160;31, 2019.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#47;s&#47;&#160;Ernst&#160;&#38; Young LLP&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Redwood City, California</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">February&#160;28, 2020</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>9
<FILENAME>sgmo-20191231xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i6b55af98d96b4f238b98e163a62cee93_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 31.1</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">CERTIFICATION</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Alexander D. Macrae, certify that&#58;</font></div><div style="text-indent:-54pt;padding-left:54pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt;">I have reviewed this annual report on Form 10-K of Sangamo Therapeutics, Inc.&#59;</font></div><div style="text-indent:-54pt;padding-left:54pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-54pt;padding-left:54pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-54pt;padding-left:54pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:-54pt;padding-left:108pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-54pt;padding-left:108pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt;">Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-54pt;padding-left:108pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-54pt;padding-left:108pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:-54pt;padding-left:54pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-54pt;padding-left:108pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-54pt;padding-left:108pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:48.000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:48.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; February 28, 2020</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; ALEXANDER D. MACRAE</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Alexander D. Macrae</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">President and Chief Executive Officer</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Executive Officer)</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>10
<FILENAME>sgmo-20191231xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i6a569ecb59f04251aea43731a042f02d_1"></div><div style="height:42.75pt;width:100%;"><div style="margin-top:6pt;"><font><br></font></div></div><div style="text-align:right;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 31.2</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">CERTIFICATION</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Sung Lee, certify that&#58;</font></div><div style="text-indent:-54pt;padding-left:54pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt;">I have reviewed this annual report on Form 10-K of Sangamo Therapeutics, Inc.&#59;</font></div><div style="text-indent:-54pt;padding-left:54pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-54pt;padding-left:54pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-54pt;padding-left:54pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:-54pt;padding-left:108pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-54pt;padding-left:108pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt;">Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-54pt;padding-left:108pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-54pt;padding-left:108pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:-54pt;padding-left:54pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-54pt;padding-left:108pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="text-indent:-54pt;padding-left:108pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:73.219%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:22.781%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; February 28, 2020</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; SUNG LEE</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sung Lee</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Executive Vice&#160;President and Chief&#160;Financial&#160;Officer</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Financial Officer)</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="margin-top:6pt;"><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="margin-top:6pt;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>11
<FILENAME>sgmo-20191231xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i743ed33215904f40996b296e2d335797_1"></div><div style="height:42.75pt;width:100%;"><div style="margin-top:6pt;"><font><br></font></div></div><div style="text-align:right;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 32.1</font></div><div style="text-align:center;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Certifications Pursuant to 18 U.S.C. &#167;1350, as Adopted</font></div><div style="text-align:center;margin-top:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), 18 U.S.C. &#167;1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002, Alexander Macrae, Chief Executive Officer of Sangamo Therapeutics, Inc. (the &#8220;Company&#8221;), and Sung Lee, Chief Financial Officer of the Company, each hereby certifies in his or her capacity, that, to the best of his or her knowledge&#58;</font></div><div style="margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1)&#160;the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2019, to which this Certification is attached as Exhibit 32.1 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section 15(d) of the Exchange Act&#59; and</font></div><div style="margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2)&#160;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:78.234%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.766%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; ALEXANDER D. MACRAE</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Alexander D. Macrae</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">President and Chief Executive Officer</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Executive Officer)</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; February 28, 2020</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; SUNG LEE</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sung Lee</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Executive Vice&#160;President and Chief&#160;Financial&#160;Officer</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Financial Officer)</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; February 28, 2020</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">This certification accompanies the Annual Report on Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Sangamo Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form&#160;10-K), irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by Section&#160;906 of the Sarbanes-Oxley Act of 2002 has been provided to Sangamo Therapeutics, Inc. and will be retained by Sangamo Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="margin-top:6pt;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>sgmo-20191231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:6b105dfa-4da0-4f89-a738-1fa68397e7a0,g:da741c8d-9db4-444a-b42c-06c4caf6626c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sgmo="http://www.sangamo.com/20191231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.sangamo.com/20191231">
  <xs:import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20191231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20191231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20191231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20191231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.sangamo.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.sangamo.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.sangamo.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.sangamo.com/role/ConsolidatedStatementsofOperations">
        <link:definition>1003004 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss">
        <link:definition>1004005 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>1005006 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1006007 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPolicies" roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>2303301 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>2404401 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail" roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail">
        <link:definition>2405402 - Disclosure - Organization and Summary of Significant Accounting Policies - Revenues from Strategic Partnering Collaboration Agreements and Research Activity Grants (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofCashandCashEquivalentsDetails" roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofCashandCashEquivalentsDetails">
        <link:definition>2406403 - Disclosure - Organization and Summary of Significant Accounting Policies - Reconciliation of Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesImpactofAdoptionofASConCondensedConsolidatedBalanceSheetDetail" roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesImpactofAdoptionofASConCondensedConsolidatedBalanceSheetDetail">
        <link:definition>2407404 - Disclosure - Organization and Summary of Significant Accounting Policies - Impact of Adoption of ASC on Condensed Consolidated Balance Sheet (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurement" roleURI="http://www.sangamo.com/role/FairValueMeasurement">
        <link:definition>2108102 - Disclosure - Fair Value Measurement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementTables" roleURI="http://www.sangamo.com/role/FairValueMeasurementTables">
        <link:definition>2309302 - Disclosure - Fair Value Measurement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail" roleURI="http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail">
        <link:definition>2410405 - Disclosure - Fair Value Measurement - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Securities and Free Share Liability (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail">
        <link:definition>2411406 - Disclosure - Fair Value Measurement - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail" roleURI="http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail">
        <link:definition>2412407 - Disclosure - Fair Value Measurement - Summary of Estimated Fair Value of Free Share Liability Assumptions (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://www.sangamo.com/role/MarketableSecurities">
        <link:definition>2113103 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://www.sangamo.com/role/MarketableSecuritiesTables">
        <link:definition>2314303 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail" roleURI="http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail">
        <link:definition>2415408 - Disclosure - Marketable Securities - Summary of Cash Equivalents and Available-for-Sale Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetail" roleURI="http://www.sangamo.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetail">
        <link:definition>2416409 - Disclosure - Marketable Securities - Summary of Available-for-Sale Securities by Contractual Maturity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/MarketableSecuritiesAdditionalInformationDetail">
        <link:definition>2417410 - Disclosure - Marketable Securities - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MajorCustomersPartnershipsandStrategicAlliances" roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliances">
        <link:definition>2118104 - Disclosure - Major Customers, Partnerships and Strategic Alliances</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MajorCustomersPartnershipsandStrategicAlliancesTables" roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesTables">
        <link:definition>2319304 - Disclosure - Major Customers, Partnerships and Strategic Alliances (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail">
        <link:definition>2420411 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail" roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail">
        <link:definition>2421412 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Revenues Recognized under Agreement (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationAdditionalInformationDetail">
        <link:definition>2422413 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Agreement with Sigma-Aldrich Corporation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDowAgroSciencesinPlantAgricultureAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDowAgroSciencesinPlantAgricultureAdditionalInformationDetail">
        <link:definition>2423414 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Agreement with Dow AgroSciences in Plant Agriculture - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionofSangamoFrance" roleURI="http://www.sangamo.com/role/AcquisitionofSangamoFrance">
        <link:definition>2124105 - Disclosure - Acquisition of Sangamo France</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionofAcquisitionofSangamoFranceTables" roleURI="http://www.sangamo.com/role/AcquisitionofAcquisitionofSangamoFranceTables">
        <link:definition>2325305 - Disclosure - Acquisition of Acquisition of Sangamo France (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionofSangamoFranceAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail">
        <link:definition>2426415 - Disclosure - Acquisition of Sangamo France - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionofSangamoFranceSummaryofEstimatedFairValueofNetAssetsAcquiredDetail" roleURI="http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofEstimatedFairValueofNetAssetsAcquiredDetail">
        <link:definition>2427416 - Disclosure - Acquisition of Sangamo France - Summary of Estimated Fair Value of Net Assets Acquired (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail" roleURI="http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail">
        <link:definition>2428417 - Disclosure - Acquisition of Sangamo France - Summary of Non-controlling Interest (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetDetails" roleURI="http://www.sangamo.com/role/OtherBalanceSheetDetails">
        <link:definition>2129106 - Disclosure - Other Balance Sheet Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetDetailsTables" roleURI="http://www.sangamo.com/role/OtherBalanceSheetDetailsTables">
        <link:definition>2330306 - Disclosure - Other Balance Sheet Details (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetDetailsDetail" roleURI="http://www.sangamo.com/role/OtherBalanceSheetDetailsDetail">
        <link:definition>2431418 - Disclosure - Other Balance Sheet Details (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetDetailsScheduleofIntangibleAssetsandGoodwillDetail" roleURI="http://www.sangamo.com/role/OtherBalanceSheetDetailsScheduleofIntangibleAssetsandGoodwillDetail">
        <link:definition>2432419 - Disclosure - Other Balance Sheet Details - Schedule of Intangible Assets and Goodwill (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail" roleURI="http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail">
        <link:definition>2433420 - Disclosure - Other Balance Sheet Details - Summary of Accounts Payable and Accrued Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.sangamo.com/role/CommitmentsandContingencies">
        <link:definition>2134107 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.sangamo.com/role/CommitmentsandContingenciesTables">
        <link:definition>2335307 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail">
        <link:definition>2436421 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail" roleURI="http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail">
        <link:definition>2437422 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Payments under Contractual Obligations (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail_1" roleURI="http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail_1">
        <link:definition>2437422 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Payments under Contractual Obligations (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.sangamo.com/role/StockholdersEquity">
        <link:definition>2138108 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.sangamo.com/role/StockholdersEquityTables">
        <link:definition>2339308 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail">
        <link:definition>2440423 - Disclosure - Stockholders' Equity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySummaryofStockOptionActivityDetail" roleURI="http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail">
        <link:definition>2441424 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySummaryofRestrictedStockUnitActivityDetail" roleURI="http://www.sangamo.com/role/StockholdersEquitySummaryofRestrictedStockUnitActivityDetail">
        <link:definition>2442425 - Disclosure - Stockholders' Equity - Summary of Restricted Stock Unit Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.sangamo.com/role/StockBasedCompensation">
        <link:definition>2143109 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.sangamo.com/role/StockBasedCompensationTables">
        <link:definition>2344309 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationExpenseDetail" roleURI="http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail">
        <link:definition>2445426 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/StockBasedCompensationAdditionalInformationDetail">
        <link:definition>2446427 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail" roleURI="http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail">
        <link:definition>2447428 - Disclosure - Stock-Based Compensation - Assumptions Used for Estimating Fair Value of Employee Stock Options (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail" roleURI="http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail">
        <link:definition>2448429 - Disclosure - Stock-Based Compensation - Weighted-Average Assumptions Used for Estimating Fair Value of ESPP Purchased Rights (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlan" roleURI="http://www.sangamo.com/role/EmployeeBenefitPlan">
        <link:definition>2149110 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlanAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/EmployeeBenefitPlanAdditionalInformationDetail">
        <link:definition>2450430 - Disclosure - Employee Benefit Plan - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.sangamo.com/role/IncomeTaxes">
        <link:definition>2151111 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.sangamo.com/role/IncomeTaxesTables">
        <link:definition>2352310 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetail" roleURI="http://www.sangamo.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetail">
        <link:definition>2453431 - Disclosure - Income Taxes - Summary of Domestic and Foreign Components of Loss Before Income Taxes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofBenefitforIncomeTaxesDetail" roleURI="http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail">
        <link:definition>2454432 - Disclosure - Income Taxes - Summary of Benefit for Income Taxes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/IncomeTaxesAdditionalInformationDetail">
        <link:definition>2455433 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail" roleURI="http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail">
        <link:definition>2456434 - Disclosure - Income Taxes - Schedule of Difference Between Benefit for Income Taxes and Federal Statutory Income Tax Rate (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateAdditionalInformationDetail">
        <link:definition>2457435 - Disclosure - Income Taxes - Schedule of Difference Between Benefit for Income Taxes and Federal Statutory Income Tax Rate, Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail" roleURI="http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail">
        <link:definition>2458436 - Disclosure - Income Taxes - Schedule of Company's Deferred Tax Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofActivityRelatedtoCompanysUnrecognizedTaxBenefitsDetail" roleURI="http://www.sangamo.com/role/IncomeTaxesSummaryofActivityRelatedtoCompanysUnrecognizedTaxBenefitsDetail">
        <link:definition>2459437 - Disclosure - Income Taxes - Summary of Activity Related to Company's Unrecognized Tax Benefits (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyDisclosures" roleURI="http://www.sangamo.com/role/RelatedPartyDisclosures">
        <link:definition>2160112 - Disclosure - Related Party Disclosures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyDisclosuresDetails" roleURI="http://www.sangamo.com/role/RelatedPartyDisclosuresDetails">
        <link:definition>2461438 - Disclosure - Related Party Disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnaudited" roleURI="http://www.sangamo.com/role/QuarterlyFinancialDataUnaudited">
        <link:definition>2162113 - Disclosure - Quarterly Financial Data (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnauditedTables" roleURI="http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedTables">
        <link:definition>2363311 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnauditedSummaryofQuarterlyFinancialDataDetail" roleURI="http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedSummaryofQuarterlyFinancialDataDetail">
        <link:definition>2464439 - Disclosure - Quarterly Financial Data (Unaudited) - Summary of Quarterly Financial Data (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.sangamo.com/role/SubsequentEvents">
        <link:definition>2165114 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.sangamo.com/role/SubsequentEventsDetails">
        <link:definition>2466440 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" abstract="false" name="CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementTransactionPrice" abstract="false" name="CollaborativeArrangementTransactionPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" abstract="true" name="AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod" abstract="false" name="CollaborativeArrangementVotingProvisionsExpirationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_BuildToSuitLeases" abstract="false" name="BuildToSuitLeases" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_MilestoneThreeMember" abstract="true" name="MilestoneThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" abstract="true" name="SharePurchaseAgreementAndTenderOfferAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_ResearchServicesMember" abstract="true" name="ResearchServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_PropertyAndEquipmentMember" abstract="true" name="PropertyAndEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" abstract="true" name="OrganizationAndSummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sgmo_AmortizationAndOtherChangesInRightOfUseAssets" abstract="false" name="AmortizationAndOtherChangesInRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_DeferredRentNoncurrent" abstract="false" name="DeferredRentNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_MilestoneOneMember" abstract="true" name="MilestoneOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_ContractualObligationPaidUponExecution" abstract="false" name="ContractualObligationPaidUponExecution" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_BusinessAcquisitionEstimatedFairValueOfFreeShares" abstract="false" name="BusinessAcquisitionEstimatedFairValueOfFreeShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_SpecifiedStockholderOwnershipPercentage" abstract="false" name="SpecifiedStockholderOwnershipPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sgmo_CollaborativeAgreementMilestoneDomain" abstract="true" name="CollaborativeAgreementMilestoneDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_GrantFundingAmount" abstract="false" name="GrantFundingAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" abstract="false" name="CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_BusinessAcquisitionNumberOfSharesAcquired" abstract="false" name="BusinessAcquisitionNumberOfSharesAcquired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sgmo_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" abstract="false" name="LesseeOperatingLeaseLiabilityTenantImprovementAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_MilestoneTwoMember" abstract="true" name="MilestoneTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" abstract="false" name="NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_MilestoneRevenueReceivable" abstract="false" name="MilestoneRevenueReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" abstract="false" name="BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" abstract="true" name="AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CommonStockExchangeRatio" abstract="false" name="CommonStockExchangeRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" abstract="false" name="IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_StockPurchaseAgreementMember" abstract="true" name="StockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementNumberOfProductTargetsSelected" abstract="false" name="CollaborativeArrangementNumberOfProductTargetsSelected" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_AmendedCollaborationAndLicenseAgreementMember" abstract="true" name="AmendedCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" abstract="false" name="CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CNineORFSevenTwoMember" abstract="true" name="CNineORFSevenTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_ChangeInCollaborationAgreementScopeMember" abstract="true" name="ChangeInCollaborationAgreementScopeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_NumberOfOptionsToExtendInitialResearchTerm" abstract="false" name="NumberOfOptionsToExtendInitialResearchTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sgmo_BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction" abstract="false" name="BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sgmo_PfizerC9ORF72Member" abstract="true" name="PfizerC9ORF72Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" abstract="false" name="CollaborationAgreementNumberOfAdditionalProductTargets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_BrisbaneCaliforniaMember" abstract="true" name="BrisbaneCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_RichmondCaliforniaMember" abstract="true" name="RichmondCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_TwoThousandThirteenStockIncentivePlanMember" abstract="true" name="TwoThousandThirteenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_OtherProductsMember" abstract="true" name="OtherProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_SigmaAldrichCorporationMember" abstract="true" name="SigmaAldrichCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_ManufacturingCapacityMember" abstract="true" name="ManufacturingCapacityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_ExtendedResearchTermOfAgreement" abstract="false" name="ExtendedResearchTermOfAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" abstract="true" name="AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_NonCancelableContractualCommitmentMember" abstract="true" name="NonCancelableContractualCommitmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_SalesBasedMilestoneMember" abstract="true" name="SalesBasedMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_LicenseObligations" abstract="false" name="LicenseObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" abstract="false" name="CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" abstract="false" name="CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" abstract="true" name="RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" abstract="false" name="CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CommitmentsAndContingenciesLineItems" abstract="true" name="CommitmentsAndContingenciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sgmo_FormerExecutiveOfSangamoFranceMember" abstract="true" name="FormerExecutiveOfSangamoFranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" abstract="false" name="ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="sgmo_ResearchServicesPeriod" abstract="false" name="ResearchServicesPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_MeasurementInputStockPriceCorrelationMember" abstract="true" name="MeasurementInputStockPriceCorrelationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CollaborativeAgreementMilestoneAxis" abstract="true" name="CollaborativeAgreementMilestoneAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue" abstract="false" name="EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="sgmo_SanofiMember" abstract="true" name="SanofiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_DeferredTaxAssetsBuildToSuitLeaseLiability" abstract="false" name="DeferredTaxAssetsBuildToSuitLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_LeaseArrangementsDomain" abstract="true" name="LeaseArrangementsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability" abstract="false" name="IncreaseInFairValueOfFreeSharesAssetAndLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember" abstract="true" name="AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" abstract="true" name="AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_PurchasePlanPurchasePeriod" abstract="false" name="PurchasePlanPurchasePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal" abstract="false" name="DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" abstract="false" name="BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" abstract="true" name="AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_FeeDue" abstract="false" name="FeeDue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_FreeSharesLiabilityMember" abstract="true" name="FreeSharesLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice" abstract="false" name="StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" abstract="false" name="DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sgmo_SeparateUpfrontFee" abstract="false" name="SeparateUpfrontFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement" abstract="false" name="MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" abstract="false" name="MinimumSublicenseAnnualFeesSpecificReckoningPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_OfficeAndLaboratoryMember" abstract="true" name="OfficeAndLaboratoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_OfficeSpaceMember" abstract="true" name="OfficeSpaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_OtherThanTemporarilyImpairedInvestment" abstract="false" name="OtherThanTemporarilyImpairedInvestment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_ValbonneFranceMember" abstract="true" name="ValbonneFranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_ManufacturingObligationsMember" abstract="true" name="ManufacturingObligationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_TwoThousandEighteenStockIncentivePlanMember" abstract="true" name="TwoThousandEighteenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_ScheduleOfNoncontrollingInterestTableTextBlock" abstract="false" name="ScheduleOfNoncontrollingInterestTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" abstract="false" name="ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_ShireAgMember" abstract="true" name="ShireAgMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_DerivativeLiabilityTerm" abstract="false" name="DerivativeLiabilityTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sgmo_NumberOfResearchProgram" abstract="false" name="NumberOfResearchProgram" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable" abstract="false" name="CollaborativeArrangementMaximumMilestonePaymentReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" abstract="false" name="CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders" abstract="false" name="BusinessAcquisitionNumberOfFreeSharesHeldByHolders" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" abstract="false" name="CustomerContractLiabilityMilestonePaymentEligibleToReceive" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" abstract="false" name="PercentageOfRoyaltiesToBeReceivedFromSublicensing" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sgmo_AchievementOfCommercialMilestonesMember" abstract="true" name="AchievementOfCommercialMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" abstract="false" name="CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_FreeSharesAssetMember" abstract="true" name="FreeSharesAssetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_DowAgroSciencesMember" abstract="true" name="DowAgroSciencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_AnnualFeesRelatedToAgreement" abstract="false" name="AnnualFeesRelatedToAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_OneTimeLicenseFeeEarned" abstract="false" name="OneTimeLicenseFeeEarned" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_BuildToSuitLeaseObligations" abstract="false" name="BuildToSuitLeaseObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_PurchasePlanOfferingPeriod" abstract="false" name="PurchasePlanOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_LeaseArrangementsAxis" abstract="true" name="LeaseArrangementsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sgmo_InitialResearchTermOfAgreement" abstract="false" name="InitialResearchTermOfAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_SBFiveTwoFiveMember" abstract="true" name="SBFiveTwoFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_PreApprovalMilestoneMember" abstract="true" name="PreApprovalMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares" abstract="false" name="BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborationAndLicenseAgreementMember" abstract="true" name="CollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_ReducedRoyaltyRate" abstract="false" name="ReducedRoyaltyRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sgmo_BuildToSuitLeaseMember" abstract="true" name="BuildToSuitLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_IncomeTaxesTable" abstract="true" name="IncomeTaxesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" abstract="false" name="CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sgmo_PaymentsForOtherCommitment" abstract="false" name="PaymentsForOtherCommitment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" abstract="false" name="BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" abstract="false" name="AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_NoncashOrPartNoncashNonControllingInterestAcquisition" abstract="false" name="NoncashOrPartNoncashNonControllingInterestAcquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_AchievementOfFirstCommercialSaleMilestonesMember" abstract="true" name="AchievementOfFirstCommercialSaleMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CollaborationAgreementTargetSelectionPeriod" abstract="false" name="CollaborationAgreementTargetSelectionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_MilestoneAchievementMember" abstract="true" name="MilestoneAchievementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedSalesMilestonesMember" abstract="true" name="AchievementOfSpecifiedSalesMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_SangamoFranceMember" abstract="true" name="SangamoFranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_PfizerMember" abstract="true" name="PfizerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" abstract="false" name="CollaborativeArrangementEstimatedReimbursableServiceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_AccruedResearchAndDevelopmentExpenses" abstract="false" name="AccruedResearchAndDevelopmentExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_KitePharmaIncMember" abstract="true" name="KitePharmaIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_BiogenMAIncMember" abstract="true" name="BiogenMAIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CommitmentsAndContingenciesTable" abstract="true" name="CommitmentsAndContingenciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sgmo_AgreementTerminationTerm" abstract="false" name="AgreementTerminationTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sgmo_MilestonePaymentsReceived" abstract="false" name="MilestonePaymentsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_ResearchAndOfficeSpaceMember" abstract="true" name="ResearchAndOfficeSpaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" abstract="false" name="UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CashEquivalentsAndAvailableForSaleSecurities" abstract="false" name="CashEquivalentsAndAvailableForSaleSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation" abstract="false" name="IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_GainOnFreeShares" abstract="false" name="GainOnFreeShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" abstract="true" name="CaliforniaInstituteForRegenerativeMedicineAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_SharePurchaseAgreementMember" abstract="true" name="SharePurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementResearchServiceFees" abstract="false" name="CollaborativeArrangementResearchServiceFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_PfizerSB525Member" abstract="true" name="PfizerSB525Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementStandstillRestrictionPeriod" abstract="false" name="CollaborativeArrangementStandstillRestrictionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_IntangibleAssetsExcludingGoodwillRollForward" abstract="true" name="IntangibleAssetsExcludingGoodwillRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sgmo_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance" abstract="false" name="LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" abstract="false" name="CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_IncomeTaxesLineItems" abstract="true" name="IncomeTaxesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sgmo_NetProceedsFromIssuancePublicOffering" abstract="false" name="NetProceedsFromIssuancePublicOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementNumberOfProductTargets" abstract="false" name="CollaborativeArrangementNumberOfProductTargets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_DeferredTaxAssetsLeaseLiability" abstract="false" name="DeferredTaxAssetsLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>sgmo-20191231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:6b105dfa-4da0-4f89-a738-1fa68397e7a0,g:da741c8d-9db4-444a-b42c-06c4caf6626c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sangamo.com/role/Cover" xlink:type="simple" xlink:href="sgmo-20191231.xsd#Cover"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/Cover" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="sgmo-20191231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6604447e-54ba-4e10-a6bd-f3ed7cbe0963" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6391bae5-c61e-43b4-9ec0-779bcebd431d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6604447e-54ba-4e10-a6bd-f3ed7cbe0963" xlink:to="loc_us-gaap_LiabilitiesCurrent_6391bae5-c61e-43b4-9ec0-779bcebd431d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_95d120bb-3829-417b-9477-a1ca043b9535" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6604447e-54ba-4e10-a6bd-f3ed7cbe0963" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_95d120bb-3829-417b-9477-a1ca043b9535" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ada4277c-3ac7-4d70-84bd-e62768323d15" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6604447e-54ba-4e10-a6bd-f3ed7cbe0963" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ada4277c-3ac7-4d70-84bd-e62768323d15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BuildToSuitLeaseObligations_d204a459-1ce7-44b4-91ea-ec0398d706a6" xlink:href="sgmo-20191231.xsd#sgmo_BuildToSuitLeaseObligations"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6604447e-54ba-4e10-a6bd-f3ed7cbe0963" xlink:to="loc_sgmo_BuildToSuitLeaseObligations_d204a459-1ce7-44b4-91ea-ec0398d706a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_46c39b26-937a-43d6-ab50-546944cbf814" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6604447e-54ba-4e10-a6bd-f3ed7cbe0963" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_46c39b26-937a-43d6-ab50-546944cbf814" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_4241e769-b3e1-4f0c-a31e-35442108fe07" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6604447e-54ba-4e10-a6bd-f3ed7cbe0963" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_4241e769-b3e1-4f0c-a31e-35442108fe07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9f37b753-69a4-4bc1-a6c9-873b7f3b1ea2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ea11b941-f7d3-4075-acc5-eae27dd79e93" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9f37b753-69a4-4bc1-a6c9-873b7f3b1ea2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ea11b941-f7d3-4075-acc5-eae27dd79e93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_543bbe87-296b-4866-b6ce-eb4926b36c3e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9f37b753-69a4-4bc1-a6c9-873b7f3b1ea2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_543bbe87-296b-4866-b6ce-eb4926b36c3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_2a2bd983-a6f4-40df-8be7-83878c7c3ba6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9f37b753-69a4-4bc1-a6c9-873b7f3b1ea2" xlink:to="loc_us-gaap_InterestReceivableCurrent_2a2bd983-a6f4-40df-8be7-83878c7c3ba6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a99aab51-5b5e-417c-8651-b375fe3fadc5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9f37b753-69a4-4bc1-a6c9-873b7f3b1ea2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a99aab51-5b5e-417c-8651-b375fe3fadc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d50a63c2-1ec1-4e2b-b358-400e30cb4a59" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9f37b753-69a4-4bc1-a6c9-873b7f3b1ea2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d50a63c2-1ec1-4e2b-b358-400e30cb4a59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_58453111-0f76-4398-96b9-2e98bcb5c832" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_451d4c8a-1ab8-47fa-984f-09f523eef0c8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_58453111-0f76-4398-96b9-2e98bcb5c832" xlink:to="loc_us-gaap_AssetsCurrent_451d4c8a-1ab8-47fa-984f-09f523eef0c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_f40cc043-aba0-412f-bb8e-5685a01a7c7c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_58453111-0f76-4398-96b9-2e98bcb5c832" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_f40cc043-aba0-412f-bb8e-5685a01a7c7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_49a55a7e-e87e-4f28-8681-217b1321ca43" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_58453111-0f76-4398-96b9-2e98bcb5c832" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_49a55a7e-e87e-4f28-8681-217b1321ca43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_79a2fca7-c54b-493a-be85-e0e705ad33dc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_58453111-0f76-4398-96b9-2e98bcb5c832" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_79a2fca7-c54b-493a-be85-e0e705ad33dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_592918a4-cb94-4743-a12f-d704ac044e4a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_58453111-0f76-4398-96b9-2e98bcb5c832" xlink:to="loc_us-gaap_Goodwill_592918a4-cb94-4743-a12f-d704ac044e4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7b32d78f-8aae-434b-8c3d-252ca5eb69e0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_58453111-0f76-4398-96b9-2e98bcb5c832" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7b32d78f-8aae-434b-8c3d-252ca5eb69e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_4c77baf2-6b45-44b8-b074-e5aeaea5e3e6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_58453111-0f76-4398-96b9-2e98bcb5c832" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_4c77baf2-6b45-44b8-b074-e5aeaea5e3e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_5c418303-6964-495f-91b3-32a7ffb0b709" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_58453111-0f76-4398-96b9-2e98bcb5c832" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_5c418303-6964-495f-91b3-32a7ffb0b709" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6ecc6171-4988-49f2-9e8a-bc73db20f8bd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ead32581-67cf-4fa5-84b4-83d39152581e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6ecc6171-4988-49f2-9e8a-bc73db20f8bd" xlink:to="loc_us-gaap_StockholdersEquity_ead32581-67cf-4fa5-84b4-83d39152581e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_d31c30fa-8b71-4da2-b733-73c3c2ded369" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6ecc6171-4988-49f2-9e8a-bc73db20f8bd" xlink:to="loc_us-gaap_MinorityInterest_d31c30fa-8b71-4da2-b733-73c3c2ded369" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_180436ca-dd38-498d-812c-b1740a612e23" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d1bb186d-bfa5-4ef2-bdd8-b00a7a4a129a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_180436ca-dd38-498d-812c-b1740a612e23" xlink:to="loc_us-gaap_Liabilities_d1bb186d-bfa5-4ef2-bdd8-b00a7a4a129a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_00642423-c3e0-4373-ad8e-b3571a30d516" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_180436ca-dd38-498d-812c-b1740a612e23" xlink:to="loc_us-gaap_CommitmentsAndContingencies_00642423-c3e0-4373-ad8e-b3571a30d516" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_150541ca-94fa-4825-83cb-79bd6af890db" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_180436ca-dd38-498d-812c-b1740a612e23" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_150541ca-94fa-4825-83cb-79bd6af890db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_69d9b456-b9c8-4de3-b26c-16adcb74e821" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_2799e24d-b360-4ffd-9973-43ce4a80f614" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_69d9b456-b9c8-4de3-b26c-16adcb74e821" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_2799e24d-b360-4ffd-9973-43ce4a80f614" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_ac2d30b3-f082-41da-8a11-1b3a1e246b0f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_69d9b456-b9c8-4de3-b26c-16adcb74e821" xlink:to="loc_us-gaap_CommonStockValue_ac2d30b3-f082-41da-8a11-1b3a1e246b0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_9712593e-0622-4c17-ba3e-2b95476316ab" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_69d9b456-b9c8-4de3-b26c-16adcb74e821" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_9712593e-0622-4c17-ba3e-2b95476316ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ee9c29a4-b202-4339-8729-b699b122f009" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_69d9b456-b9c8-4de3-b26c-16adcb74e821" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ee9c29a4-b202-4339-8729-b699b122f009" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f30f4da6-a2d5-446d-bb66-24af445f82f7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_69d9b456-b9c8-4de3-b26c-16adcb74e821" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f30f4da6-a2d5-446d-bb66-24af445f82f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e67c932e-5b48-40d5-88c4-9b45dcf3e87c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_933e4cf7-354d-4518-954d-c0a3b1568781" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e67c932e-5b48-40d5-88c4-9b45dcf3e87c" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_933e4cf7-354d-4518-954d-c0a3b1568781" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_3c209d09-cece-4790-b9e4-dc797a282e63" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e67c932e-5b48-40d5-88c4-9b45dcf3e87c" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_3c209d09-cece-4790-b9e4-dc797a282e63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c1c6b34f-51f5-47af-8c9b-238d041b17f4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e67c932e-5b48-40d5-88c4-9b45dcf3e87c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c1c6b34f-51f5-47af-8c9b-238d041b17f4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="sgmo-20191231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="sgmo-20191231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1c035bc2-58a9-4936-bd71-13ebd71f2106" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d8e23a17-5897-4e1b-85d3-1bd4a18b7106" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_1c035bc2-58a9-4936-bd71-13ebd71f2106" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d8e23a17-5897-4e1b-85d3-1bd4a18b7106" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8dd50600-f6d4-4b36-9687-cfbce5b585b3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_1c035bc2-58a9-4936-bd71-13ebd71f2106" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8dd50600-f6d4-4b36-9687-cfbce5b585b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_5a0efa3e-a651-4153-a53f-951367bec40d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_20dbe3ab-e826-410f-99c7-9d77cbde1ece" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_5a0efa3e-a651-4153-a53f-951367bec40d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_20dbe3ab-e826-410f-99c7-9d77cbde1ece" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_04b52314-5b5b-4606-a618-b52dfd930c02" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_5a0efa3e-a651-4153-a53f-951367bec40d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_04b52314-5b5b-4606-a618-b52dfd930c02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cec4a0c9-7fbb-4f2f-ae48-fedc7a83cca9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9b4d90ec-1fea-4c7f-841d-5d2e434c3308" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cec4a0c9-7fbb-4f2f-ae48-fedc7a83cca9" xlink:to="loc_us-gaap_OperatingIncomeLoss_9b4d90ec-1fea-4c7f-841d-5d2e434c3308" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome_3fa74bd4-485b-42eb-8f67-e8f15bcd4f24" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cec4a0c9-7fbb-4f2f-ae48-fedc7a83cca9" xlink:to="loc_us-gaap_InterestAndOtherIncome_3fa74bd4-485b-42eb-8f67-e8f15bcd4f24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d13cc374-73c5-406d-a035-8198a21e20d8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_19e0a7b2-f472-428c-b49e-3ade68984f80" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_d13cc374-73c5-406d-a035-8198a21e20d8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_19e0a7b2-f472-428c-b49e-3ade68984f80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_497fc70c-3e46-4727-8f1e-884ad2f0ad0f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_d13cc374-73c5-406d-a035-8198a21e20d8" xlink:to="loc_us-gaap_OperatingExpenses_497fc70c-3e46-4727-8f1e-884ad2f0ad0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_74a245aa-7fed-49e0-a083-7ad3babfff2c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_189a6094-c483-4b49-b6ba-086fe51dcdcf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_74a245aa-7fed-49e0-a083-7ad3babfff2c" xlink:to="loc_us-gaap_ProfitLoss_189a6094-c483-4b49-b6ba-086fe51dcdcf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f0acbcc5-b237-4745-a7ec-b8c0a5c3f502" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_74a245aa-7fed-49e0-a083-7ad3babfff2c" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f0acbcc5-b237-4745-a7ec-b8c0a5c3f502" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="sgmo-20191231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_5964002a-9095-411f-80de-e5bdc917187c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_567dca90-b538-4581-8258-d2777b08e906" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_5964002a-9095-411f-80de-e5bdc917187c" xlink:to="loc_us-gaap_ProfitLoss_567dca90-b538-4581-8258-d2777b08e906" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_9c520712-0451-4abd-bb3f-4405ba973349" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_5964002a-9095-411f-80de-e5bdc917187c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_9c520712-0451-4abd-bb3f-4405ba973349" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_82999997-6547-458c-bdc9-e8058164ba64" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_5964002a-9095-411f-80de-e5bdc917187c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_82999997-6547-458c-bdc9-e8058164ba64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_06b40111-a7b3-4764-989e-f54ebcdef321" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_5964002a-9095-411f-80de-e5bdc917187c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_06b40111-a7b3-4764-989e-f54ebcdef321" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_d07e94a6-3af4-41c6-adb3-46d58dce31ae" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_47e32735-e7a9-44c3-adb6-0be5a826691b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d07e94a6-3af4-41c6-adb3-46d58dce31ae" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_47e32735-e7a9-44c3-adb6-0be5a826691b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_faf87770-d7ce-4670-ab5e-468f5d530a87" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d07e94a6-3af4-41c6-adb3-46d58dce31ae" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_faf87770-d7ce-4670-ab5e-468f5d530a87" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="sgmo-20191231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="sgmo-20191231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_54315469-6f9b-4114-8269-9e599e65d50a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_9d710067-47ff-42d8-ad04-f325ba685c2f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_54315469-6f9b-4114-8269-9e599e65d50a" xlink:to="loc_us-gaap_ProfitLoss_9d710067-47ff-42d8-ad04-f325ba685c2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4be49d8f-3554-4c7d-94b2-2d99cfcc866b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_54315469-6f9b-4114-8269-9e599e65d50a" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_4be49d8f-3554-4c7d-94b2-2d99cfcc866b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4fef2a04-0fbc-4155-8a78-6ef629dacf05" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_54315469-6f9b-4114-8269-9e599e65d50a" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4fef2a04-0fbc-4155-8a78-6ef629dacf05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_4239120b-e481-4833-b45d-7d020d0959b9" xlink:href="sgmo-20191231.xsd#sgmo_AmortizationAndOtherChangesInRightOfUseAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_54315469-6f9b-4114-8269-9e599e65d50a" xlink:to="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_4239120b-e481-4833-b45d-7d020d0959b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GainOnFreeShares_3691f66a-97ec-4562-b564-259c3581f594" xlink:href="sgmo-20191231.xsd#sgmo_GainOnFreeShares"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_54315469-6f9b-4114-8269-9e599e65d50a" xlink:to="loc_sgmo_GainOnFreeShares_3691f66a-97ec-4562-b564-259c3581f594" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ab8b3a58-5791-4129-8afa-d79742957868" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_54315469-6f9b-4114-8269-9e599e65d50a" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ab8b3a58-5791-4129-8afa-d79742957868" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_85305bcb-5275-4b78-91db-0105529104a7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_54315469-6f9b-4114-8269-9e599e65d50a" xlink:to="loc_us-gaap_ShareBasedCompensation_85305bcb-5275-4b78-91db-0105529104a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease_94b6b2b7-7bb9-4662-a456-b125359cc0b3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_54315469-6f9b-4114-8269-9e599e65d50a" xlink:to="loc_us-gaap_GainLossOnTerminationOfLease_94b6b2b7-7bb9-4662-a456-b125359cc0b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BuildToSuitLeases_b28c4021-87d9-4e50-b016-3d68b8b20532" xlink:href="sgmo-20191231.xsd#sgmo_BuildToSuitLeases"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_54315469-6f9b-4114-8269-9e599e65d50a" xlink:to="loc_sgmo_BuildToSuitLeases_b28c4021-87d9-4e50-b016-3d68b8b20532" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_cb36c3a7-5f07-4565-bdb9-7d0d24c7cb73" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_54315469-6f9b-4114-8269-9e599e65d50a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_cb36c3a7-5f07-4565-bdb9-7d0d24c7cb73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_18a14921-db47-4169-9720-eeda73ee3c9e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_54315469-6f9b-4114-8269-9e599e65d50a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_18a14921-db47-4169-9720-eeda73ee3c9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_50f444af-3427-45b4-8235-2a03064241e4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_54315469-6f9b-4114-8269-9e599e65d50a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_50f444af-3427-45b4-8235-2a03064241e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_4790cdb7-10f5-42fa-bf59-c043ebbb637e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_54315469-6f9b-4114-8269-9e599e65d50a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_4790cdb7-10f5-42fa-bf59-c043ebbb637e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_eeb6fdc9-e322-45d8-8578-77890ef9136d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_54315469-6f9b-4114-8269-9e599e65d50a" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_eeb6fdc9-e322-45d8-8578-77890ef9136d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_778ad515-5395-4850-a7c8-b679317aea98" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_54315469-6f9b-4114-8269-9e599e65d50a" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_778ad515-5395-4850-a7c8-b679317aea98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_fef939c7-5963-4fcd-b3d7-c2639b3603e9" xlink:href="sgmo-20191231.xsd#sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_54315469-6f9b-4114-8269-9e599e65d50a" xlink:to="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_fef939c7-5963-4fcd-b3d7-c2639b3603e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_25b6b4c0-760c-4404-8264-1d6abdde0c71" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_54315469-6f9b-4114-8269-9e599e65d50a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_25b6b4c0-760c-4404-8264-1d6abdde0c71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_369fdc05-fede-4065-b417-a14e516574b2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NetProceedsFromIssuancePublicOffering_c207df7f-7789-4174-8150-856964661e36" xlink:href="sgmo-20191231.xsd#sgmo_NetProceedsFromIssuancePublicOffering"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_369fdc05-fede-4065-b417-a14e516574b2" xlink:to="loc_sgmo_NetProceedsFromIssuancePublicOffering_c207df7f-7789-4174-8150-856964661e36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_a2c2349d-3e58-4350-a658-cb066895658b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_369fdc05-fede-4065-b417-a14e516574b2" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_a2c2349d-3e58-4350-a658-cb066895658b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_15f48f35-58cb-46c7-b5ba-ceec50253f6f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_369fdc05-fede-4065-b417-a14e516574b2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_15f48f35-58cb-46c7-b5ba-ceec50253f6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_5adf3cba-5e94-4295-a1e0-8bf96531cc18" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_369fdc05-fede-4065-b417-a14e516574b2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_5adf3cba-5e94-4295-a1e0-8bf96531cc18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_53c59eb9-6630-4ec4-b520-718680c03bc8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9889e281-79bd-4c39-833b-31126a0bfdbc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_53c59eb9-6630-4ec4-b520-718680c03bc8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9889e281-79bd-4c39-833b-31126a0bfdbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_13ae933d-05ad-407d-8eb2-44ffc289c082" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_53c59eb9-6630-4ec4-b520-718680c03bc8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_13ae933d-05ad-407d-8eb2-44ffc289c082" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_29571717-ea41-4d2c-a70e-56da5b74b4e7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_53c59eb9-6630-4ec4-b520-718680c03bc8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_29571717-ea41-4d2c-a70e-56da5b74b4e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_51794707-8c5d-4216-8874-92b0180e2694" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_53c59eb9-6630-4ec4-b520-718680c03bc8" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_51794707-8c5d-4216-8874-92b0180e2694" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_54add522-6de7-4a2d-833c-1cce02aca95e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_53485d6f-1e2d-4735-8fa4-0eef7a865115" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_54add522-6de7-4a2d-833c-1cce02aca95e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_53485d6f-1e2d-4735-8fa4-0eef7a865115" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_71a41cea-6f60-46ff-829b-6254a9de1a21" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_54add522-6de7-4a2d-833c-1cce02aca95e" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_71a41cea-6f60-46ff-829b-6254a9de1a21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_6580b48e-e7d1-47ef-a785-23969118e235" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_54add522-6de7-4a2d-833c-1cce02aca95e" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_6580b48e-e7d1-47ef-a785-23969118e235" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3025cbcd-c11f-45bd-9b80-981ab2b07dfc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_54add522-6de7-4a2d-833c-1cce02aca95e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3025cbcd-c11f-45bd-9b80-981ab2b07dfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_c1b25afd-9b34-4dcc-82f2-b211855f5914" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_54add522-6de7-4a2d-833c-1cce02aca95e" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_c1b25afd-9b34-4dcc-82f2-b211855f5914" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="sgmo-20191231.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="sgmo-20191231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="sgmo-20191231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="sgmo-20191231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofCashandCashEquivalentsDetails"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_29a9fe15-ee87-4c99-8d06-2a827bb31ea4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_15676f43-f56b-4756-98a5-3c62aee94beb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_29a9fe15-ee87-4c99-8d06-2a827bb31ea4" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_15676f43-f56b-4756-98a5-3c62aee94beb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_6bd502dc-df84-4acf-9f76-55aa99edabf2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_29a9fe15-ee87-4c99-8d06-2a827bb31ea4" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_6bd502dc-df84-4acf-9f76-55aa99edabf2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesImpactofAdoptionofASConCondensedConsolidatedBalanceSheetDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesImpactofAdoptionofASConCondensedConsolidatedBalanceSheetDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesImpactofAdoptionofASConCondensedConsolidatedBalanceSheetDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurement" xlink:type="simple" xlink:href="sgmo-20191231.xsd#FairValueMeasurement"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/FairValueMeasurement" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurementTables" xlink:type="simple" xlink:href="sgmo-20191231.xsd#FairValueMeasurementTables"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/FairValueMeasurementTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_105ae78d-da6e-4376-b3dd-e43f0b2d9802" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9433d38f-5910-4251-b22b-12f5baef0b85" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_105ae78d-da6e-4376-b3dd-e43f0b2d9802" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9433d38f-5910-4251-b22b-12f5baef0b85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cd38a2a6-6b0f-4976-a11f-1e14684ed6e1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_105ae78d-da6e-4376-b3dd-e43f0b2d9802" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cd38a2a6-6b0f-4976-a11f-1e14684ed6e1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#FairValueMeasurementAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/MarketableSecurities" xlink:type="simple" xlink:href="sgmo-20191231.xsd#MarketableSecurities"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/MarketableSecurities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="sgmo-20191231.xsd#MarketableSecuritiesTables"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/MarketableSecuritiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e7559dfe-fe8c-4115-bec1-24e7d4cab793" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_f7316824-6b53-46c4-a9e7-e796c51efa31" xlink:href="sgmo-20191231.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e7559dfe-fe8c-4115-bec1-24e7d4cab793" xlink:to="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_f7316824-6b53-46c4-a9e7-e796c51efa31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_2df02ace-7d69-4a82-941d-c94d9270f66f" xlink:href="sgmo-20191231.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e7559dfe-fe8c-4115-bec1-24e7d4cab793" xlink:to="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_2df02ace-7d69-4a82-941d-c94d9270f66f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f792d950-9b1f-4732-891e-11d417b67741" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e7559dfe-fe8c-4115-bec1-24e7d4cab793" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f792d950-9b1f-4732-891e-11d417b67741" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_970b7cc6-46ba-4934-a679-71dfb03f0f48" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2cbf585d-1a3c-4784-8561-d4035a071863" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_970b7cc6-46ba-4934-a679-71dfb03f0f48" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2cbf585d-1a3c-4784-8561-d4035a071863" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2fe8d782-e3e8-4b4c-8caa-fd53a5cef6ee" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_970b7cc6-46ba-4934-a679-71dfb03f0f48" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2fe8d782-e3e8-4b4c-8caa-fd53a5cef6ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5289aab3-1e68-4fd5-b7ca-1a5f8459335d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_970b7cc6-46ba-4934-a679-71dfb03f0f48" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5289aab3-1e68-4fd5-b7ca-1a5f8459335d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_88f33a55-c8aa-46c8-8525-8761d015e4ed" xlink:href="sgmo-20191231.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_2a39d9aa-f8f5-4fa2-8960-4b4909e68ecb" xlink:href="sgmo-20191231.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_88f33a55-c8aa-46c8-8525-8761d015e4ed" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_2a39d9aa-f8f5-4fa2-8960-4b4909e68ecb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_e694de59-43a9-4e74-af8c-23d288eebab8" xlink:href="sgmo-20191231.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_88f33a55-c8aa-46c8-8525-8761d015e4ed" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_e694de59-43a9-4e74-af8c-23d288eebab8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_792cf132-bb51-4442-bbb1-4e79cd509f51" xlink:href="sgmo-20191231.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_88f33a55-c8aa-46c8-8525-8761d015e4ed" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_792cf132-bb51-4442-bbb1-4e79cd509f51" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#MarketableSecuritiesSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6b3c9c2f-61a3-489f-820e-5ddbb19bf8c9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_3edada90-1c9d-47cd-acc9-d7b10a8a709c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6b3c9c2f-61a3-489f-820e-5ddbb19bf8c9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_3edada90-1c9d-47cd-acc9-d7b10a8a709c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_7c990177-f259-477d-93e1-f5dd281c121b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6b3c9c2f-61a3-489f-820e-5ddbb19bf8c9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_7c990177-f259-477d-93e1-f5dd281c121b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MarketableSecuritiesAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#MarketableSecuritiesAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/MarketableSecuritiesAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliances" xlink:type="simple" xlink:href="sgmo-20191231.xsd#MajorCustomersPartnershipsandStrategicAlliances"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliances" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesTables" xlink:type="simple" xlink:href="sgmo-20191231.xsd#MajorCustomersPartnershipsandStrategicAlliancesTables"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDowAgroSciencesinPlantAgricultureAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDowAgroSciencesinPlantAgricultureAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDowAgroSciencesinPlantAgricultureAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/AcquisitionofSangamoFrance" xlink:type="simple" xlink:href="sgmo-20191231.xsd#AcquisitionofSangamoFrance"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/AcquisitionofSangamoFrance" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/AcquisitionofAcquisitionofSangamoFranceTables" xlink:type="simple" xlink:href="sgmo-20191231.xsd#AcquisitionofAcquisitionofSangamoFranceTables"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/AcquisitionofAcquisitionofSangamoFranceTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#AcquisitionofSangamoFranceAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofEstimatedFairValueofNetAssetsAcquiredDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#AcquisitionofSangamoFranceSummaryofEstimatedFairValueofNetAssetsAcquiredDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofEstimatedFairValueofNetAssetsAcquiredDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1dc33081-8499-4e60-a379-a278f17fb3d7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6535386a-88ed-4088-b558-93f385fb87a3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1dc33081-8499-4e60-a379-a278f17fb3d7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6535386a-88ed-4088-b558-93f385fb87a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_938291be-0f6d-4e58-96bd-5e0144e59530" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1dc33081-8499-4e60-a379-a278f17fb3d7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_938291be-0f6d-4e58-96bd-5e0144e59530" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_f04597ce-9ad1-42c7-898e-66af9893a6b0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1dc33081-8499-4e60-a379-a278f17fb3d7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_f04597ce-9ad1-42c7-898e-66af9893a6b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_20c5ca18-43a6-4c34-bdb0-1a5cb7e3fbb1" xlink:href="sgmo-20191231.xsd#sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1dc33081-8499-4e60-a379-a278f17fb3d7" xlink:to="loc_sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_20c5ca18-43a6-4c34-bdb0-1a5cb7e3fbb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_b3920362-0505-418f-96ac-216503fb1701" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1dc33081-8499-4e60-a379-a278f17fb3d7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_b3920362-0505-418f-96ac-216503fb1701" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_088a6155-bfeb-4f7d-8d5a-f431cba0cd87" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1dc33081-8499-4e60-a379-a278f17fb3d7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_088a6155-bfeb-4f7d-8d5a-f431cba0cd87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_bba64f77-91d4-4ff1-b95d-d4ffd1215c55" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1dc33081-8499-4e60-a379-a278f17fb3d7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_bba64f77-91d4-4ff1-b95d-d4ffd1215c55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_8e344f14-e6ef-4e69-9e77-676ba077b897" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1dc33081-8499-4e60-a379-a278f17fb3d7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_8e344f14-e6ef-4e69-9e77-676ba077b897" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_1fce31dd-044d-4ba7-8003-260f863634e4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_2153c914-386f-4b6b-9ec8-e5de48291b7a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_1fce31dd-044d-4ba7-8003-260f863634e4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_2153c914-386f-4b6b-9ec8-e5de48291b7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_efe2223e-52bb-4957-9dfa-5b0f5d71ff7c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_1fce31dd-044d-4ba7-8003-260f863634e4" xlink:to="loc_us-gaap_Goodwill_efe2223e-52bb-4957-9dfa-5b0f5d71ff7c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/OtherBalanceSheetDetails" xlink:type="simple" xlink:href="sgmo-20191231.xsd#OtherBalanceSheetDetails"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/OtherBalanceSheetDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/OtherBalanceSheetDetailsTables" xlink:type="simple" xlink:href="sgmo-20191231.xsd#OtherBalanceSheetDetailsTables"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/OtherBalanceSheetDetailsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/OtherBalanceSheetDetailsDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#OtherBalanceSheetDetailsDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/OtherBalanceSheetDetailsDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/OtherBalanceSheetDetailsScheduleofIntangibleAssetsandGoodwillDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#OtherBalanceSheetDetailsScheduleofIntangibleAssetsandGoodwillDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/OtherBalanceSheetDetailsScheduleofIntangibleAssetsandGoodwillDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_881df225-4bcd-44ae-a572-d534f67c3844" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_fb95f09d-6fe9-4a66-b88e-8bb5de45e934" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_881df225-4bcd-44ae-a572-d534f67c3844" xlink:to="loc_us-gaap_DeferredRentCreditCurrent_fb95f09d-6fe9-4a66-b88e-8bb5de45e934" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilities_a120b7fd-5c16-4d7f-aad2-14649c693272" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_881df225-4bcd-44ae-a572-d534f67c3844" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilities_a120b7fd-5c16-4d7f-aad2-14649c693272" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_d929a124-0a2a-48e8-8039-0ad680a9538d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_881df225-4bcd-44ae-a572-d534f67c3844" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_d929a124-0a2a-48e8-8039-0ad680a9538d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AccruedResearchAndDevelopmentExpenses_79740698-e54a-4699-8d72-acc365168ae5" xlink:href="sgmo-20191231.xsd#sgmo_AccruedResearchAndDevelopmentExpenses"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_881df225-4bcd-44ae-a572-d534f67c3844" xlink:to="loc_sgmo_AccruedResearchAndDevelopmentExpenses_79740698-e54a-4699-8d72-acc365168ae5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_42f6c949-d6e5-4ed7-a00d-570cc43be7b9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_881df225-4bcd-44ae-a572-d534f67c3844" xlink:to="loc_us-gaap_AccountsPayableCurrent_42f6c949-d6e5-4ed7-a00d-570cc43be7b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2f4de35a-7158-42b2-8847-5e72d605da11" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_881df225-4bcd-44ae-a572-d534f67c3844" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2f4de35a-7158-42b2-8847-5e72d605da11" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="sgmo-20191231.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="sgmo-20191231.xsd#CommitmentsandContingenciesTables"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CommitmentsandContingenciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_37fc7a52-c80f-4042-8854-0617816118ea" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6b1ba897-5697-4cdb-89cb-b5f548ff3dba" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_37fc7a52-c80f-4042-8854-0617816118ea" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6b1ba897-5697-4cdb-89cb-b5f548ff3dba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d5507c2e-1df9-4f75-8d44-c5fd38288a62" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_37fc7a52-c80f-4042-8854-0617816118ea" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d5507c2e-1df9-4f75-8d44-c5fd38288a62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f8e63f99-1d21-440d-b7c7-fa1432df7f11" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a123592e-9214-44b7-997f-e06d0fbb321f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f8e63f99-1d21-440d-b7c7-fa1432df7f11" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a123592e-9214-44b7-997f-e06d0fbb321f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_54a898fa-8749-49da-a072-c294d8892c35" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f8e63f99-1d21-440d-b7c7-fa1432df7f11" xlink:to="loc_us-gaap_OperatingLeaseLiability_54a898fa-8749-49da-a072-c294d8892c35" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail_1" xlink:type="simple" xlink:href="sgmo-20191231.xsd#CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail_1"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_879f0f72-1cb7-4b04-970b-97ea4cc99017" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3f82e92d-c906-4bd2-94c0-99c79fbea45e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_879f0f72-1cb7-4b04-970b-97ea4cc99017" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3f82e92d-c906-4bd2-94c0-99c79fbea45e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_16514313-893c-4cfa-a446-56e75cf0b7f4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_879f0f72-1cb7-4b04-970b-97ea4cc99017" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_16514313-893c-4cfa-a446-56e75cf0b7f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_15a6069a-8a7a-4d14-8960-a34fbb6e84a7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_879f0f72-1cb7-4b04-970b-97ea4cc99017" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_15a6069a-8a7a-4d14-8960-a34fbb6e84a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_fc202d03-9b17-4695-835f-0a27bd57d8d8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_879f0f72-1cb7-4b04-970b-97ea4cc99017" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_fc202d03-9b17-4695-835f-0a27bd57d8d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_3cd9f698-95a3-4eeb-99aa-85c6d999f304" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_879f0f72-1cb7-4b04-970b-97ea4cc99017" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_3cd9f698-95a3-4eeb-99aa-85c6d999f304" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_ff9e70a3-ceb3-473a-9a01-8ab314bbf621" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_879f0f72-1cb7-4b04-970b-97ea4cc99017" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_ff9e70a3-ceb3-473a-9a01-8ab314bbf621" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockholdersEquity" xlink:type="simple" xlink:href="sgmo-20191231.xsd#StockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/StockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="sgmo-20191231.xsd#StockholdersEquityTables"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/StockholdersEquityTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#StockholdersEquityAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#StockholdersEquitySummaryofStockOptionActivityDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockholdersEquitySummaryofRestrictedStockUnitActivityDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#StockholdersEquitySummaryofRestrictedStockUnitActivityDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/StockholdersEquitySummaryofRestrictedStockUnitActivityDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="sgmo-20191231.xsd#StockBasedCompensation"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/StockBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="sgmo-20191231.xsd#StockBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/StockBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#StockBasedCompensationStockBasedCompensationExpenseDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#StockBasedCompensationAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="sgmo-20191231.xsd#EmployeeBenefitPlan"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/EmployeeBenefitPlan" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/EmployeeBenefitPlanAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#EmployeeBenefitPlanAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/EmployeeBenefitPlanAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxes" xlink:type="simple" xlink:href="sgmo-20191231.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="sgmo-20191231.xsd#IncomeTaxesTables"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/IncomeTaxesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#IncomeTaxesSummaryofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a599c946-e866-4ca3-9632-8efdc2f02907" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_a5920d9c-2a0c-4eec-8ce7-7a1ccf3100f9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a599c946-e866-4ca3-9632-8efdc2f02907" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_a5920d9c-2a0c-4eec-8ce7-7a1ccf3100f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2bc0a56e-4c03-4710-8710-e1bea815f0f0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a599c946-e866-4ca3-9632-8efdc2f02907" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2bc0a56e-4c03-4710-8710-e1bea815f0f0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#IncomeTaxesSummaryofBenefitforIncomeTaxesDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_e4b6cbe0-7de9-456e-995d-aceb3eed8ce0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_0aac2f0e-76b2-4b82-bdf3-5666cd84698c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_e4b6cbe0-7de9-456e-995d-aceb3eed8ce0" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_0aac2f0e-76b2-4b82-bdf3-5666cd84698c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_ff5db730-425a-4689-88e1-ecdb729398b9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_e4b6cbe0-7de9-456e-995d-aceb3eed8ce0" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_ff5db730-425a-4689-88e1-ecdb729398b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_648545a4-b2d4-4cb3-8396-4e80ec32587b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_e4b6cbe0-7de9-456e-995d-aceb3eed8ce0" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_648545a4-b2d4-4cb3-8396-4e80ec32587b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_a6cffb43-c3ac-4839-b29b-4f0e69e01ae0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_e4b6cbe0-7de9-456e-995d-aceb3eed8ce0" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_a6cffb43-c3ac-4839-b29b-4f0e69e01ae0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_b45de088-dbf5-4e81-bdbb-91ec53ec4916" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_7ad2b382-2d15-4d54-aa14-4c4a8daaced7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_b45de088-dbf5-4e81-bdbb-91ec53ec4916" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_7ad2b382-2d15-4d54-aa14-4c4a8daaced7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_f20c5d3f-5672-4d53-8bff-8e55ab39fd6c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_b45de088-dbf5-4e81-bdbb-91ec53ec4916" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_f20c5d3f-5672-4d53-8bff-8e55ab39fd6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_67979e27-e553-45c2-9543-e3a4722f351b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_b45de088-dbf5-4e81-bdbb-91ec53ec4916" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_67979e27-e553-45c2-9543-e3a4722f351b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1b6bf57b-a6c6-4bfd-8481-08f153898d3c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_3339339c-a74c-4458-aa04-78155c4b73df" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_1b6bf57b-a6c6-4bfd-8481-08f153898d3c" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_3339339c-a74c-4458-aa04-78155c4b73df" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#IncomeTaxesAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7d7a58bb-ad03-401f-a82f-841209fd1662" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_85acc79d-3e6a-426b-9c30-687f90a995b5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_7d7a58bb-ad03-401f-a82f-841209fd1662" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_85acc79d-3e6a-426b-9c30-687f90a995b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_ee28c46a-a6d0-4886-8387-b867416fee9a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_7d7a58bb-ad03-401f-a82f-841209fd1662" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_ee28c46a-a6d0-4886-8387-b867416fee9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_566caa55-92b1-4310-b7ab-1638b0d6cc1e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_7d7a58bb-ad03-401f-a82f-841209fd1662" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_566caa55-92b1-4310-b7ab-1638b0d6cc1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_39649a56-fb76-467f-9e3f-f64ab547fb0a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_7d7a58bb-ad03-401f-a82f-841209fd1662" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_39649a56-fb76-467f-9e3f-f64ab547fb0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation_b0e972cb-5e5c-478c-b7bc-1ec69a3b5c42" xlink:href="sgmo-20191231.xsd#sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_7d7a58bb-ad03-401f-a82f-841209fd1662" xlink:to="loc_sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation_b0e972cb-5e5c-478c-b7bc-1ec69a3b5c42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_d111f8fd-49e7-4dbd-b33d-910e1acbe917" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_7d7a58bb-ad03-401f-a82f-841209fd1662" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_d111f8fd-49e7-4dbd-b33d-910e1acbe917" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_ec51bb65-42b3-4a07-9de3-967557094d4f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_7d7a58bb-ad03-401f-a82f-841209fd1662" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_ec51bb65-42b3-4a07-9de3-967557094d4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_b52a76d5-e773-4997-90f9-79a02b2710aa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_7d7a58bb-ad03-401f-a82f-841209fd1662" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_b52a76d5-e773-4997-90f9-79a02b2710aa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_4d0ae0b4-29b7-4aac-bc3b-7d3d3fb3c4bc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_46bbb1db-dc76-411a-9bf2-06e553f5cf51" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_4d0ae0b4-29b7-4aac-bc3b-7d3d3fb3c4bc" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_46bbb1db-dc76-411a-9bf2-06e553f5cf51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9fe30971-3ec2-4772-8781-7dd784d918ce" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_4d0ae0b4-29b7-4aac-bc3b-7d3d3fb3c4bc" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9fe30971-3ec2-4772-8781-7dd784d918ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_d63c529e-fe28-483f-874d-da8276d162be" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2d1d2248-f45d-4c89-b1ca-47e0441f5e47" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d63c529e-fe28-483f-874d-da8276d162be" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2d1d2248-f45d-4c89-b1ca-47e0441f5e47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_032a5675-7aaf-44c1-9d88-bef8e0806592" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d63c529e-fe28-483f-874d-da8276d162be" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_032a5675-7aaf-44c1-9d88-bef8e0806592" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_c3fb69b9-e90f-4803-b6f7-f5f39a476de6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d63c529e-fe28-483f-874d-da8276d162be" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_c3fb69b9-e90f-4803-b6f7-f5f39a476de6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_dc4f88af-3224-43db-a6ec-f132330d010c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d63c529e-fe28-483f-874d-da8276d162be" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_dc4f88af-3224-43db-a6ec-f132330d010c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_a9b21f29-3902-4c53-84ec-77d317474240" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d63c529e-fe28-483f-874d-da8276d162be" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_a9b21f29-3902-4c53-84ec-77d317474240" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DeferredTaxAssetsLeaseLiability_0c358d1a-ae84-48af-8c58-9cbfc84bd6a7" xlink:href="sgmo-20191231.xsd#sgmo_DeferredTaxAssetsLeaseLiability"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d63c529e-fe28-483f-874d-da8276d162be" xlink:to="loc_sgmo_DeferredTaxAssetsLeaseLiability_0c358d1a-ae84-48af-8c58-9cbfc84bd6a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DeferredTaxAssetsBuildToSuitLeaseLiability_64cfa2b6-0331-4a1b-9206-a9b6970b9e07" xlink:href="sgmo-20191231.xsd#sgmo_DeferredTaxAssetsBuildToSuitLeaseLiability"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d63c529e-fe28-483f-874d-da8276d162be" xlink:to="loc_sgmo_DeferredTaxAssetsBuildToSuitLeaseLiability_64cfa2b6-0331-4a1b-9206-a9b6970b9e07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_c10e1b99-258a-4558-b051-3fb2ff2fd51b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d63c529e-fe28-483f-874d-da8276d162be" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_c10e1b99-258a-4558-b051-3fb2ff2fd51b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_b662d04e-b37d-437a-88b1-25ffe8df9d7f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d63c529e-fe28-483f-874d-da8276d162be" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_b662d04e-b37d-437a-88b1-25ffe8df9d7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_7f14149c-0776-402c-9f53-9fa374f764b6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_5038f370-e01e-4b67-9e3c-248d69afa973" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_7f14149c-0776-402c-9f53-9fa374f764b6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_5038f370-e01e-4b67-9e3c-248d69afa973" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_8b65d1d8-1179-457e-8c6c-5ea012ac2d4e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_7f14149c-0776-402c-9f53-9fa374f764b6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_8b65d1d8-1179-457e-8c6c-5ea012ac2d4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_87e9dc79-f33d-4708-b6bf-526d3ea8e2a4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_7f14149c-0776-402c-9f53-9fa374f764b6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_87e9dc79-f33d-4708-b6bf-526d3ea8e2a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_74ea544c-44a4-413b-af23-8da4aff0c557" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_7d49bd39-b290-4c52-a011-df5985093ce4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_74ea544c-44a4-413b-af23-8da4aff0c557" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_7d49bd39-b290-4c52-a011-df5985093ce4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_5ca502b1-fa74-4b62-a14a-13aee1981032" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_74ea544c-44a4-413b-af23-8da4aff0c557" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_5ca502b1-fa74-4b62-a14a-13aee1981032" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesSummaryofActivityRelatedtoCompanysUnrecognizedTaxBenefitsDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#IncomeTaxesSummaryofActivityRelatedtoCompanysUnrecognizedTaxBenefitsDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/IncomeTaxesSummaryofActivityRelatedtoCompanysUnrecognizedTaxBenefitsDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/RelatedPartyDisclosures" xlink:type="simple" xlink:href="sgmo-20191231.xsd#RelatedPartyDisclosures"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/RelatedPartyDisclosures" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/RelatedPartyDisclosuresDetails" xlink:type="simple" xlink:href="sgmo-20191231.xsd#RelatedPartyDisclosuresDetails"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/RelatedPartyDisclosuresDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/QuarterlyFinancialDataUnaudited" xlink:type="simple" xlink:href="sgmo-20191231.xsd#QuarterlyFinancialDataUnaudited"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/QuarterlyFinancialDataUnaudited" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="simple" xlink:href="sgmo-20191231.xsd#QuarterlyFinancialDataUnauditedTables"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedSummaryofQuarterlyFinancialDataDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#QuarterlyFinancialDataUnauditedSummaryofQuarterlyFinancialDataDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedSummaryofQuarterlyFinancialDataDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/SubsequentEvents" xlink:type="simple" xlink:href="sgmo-20191231.xsd#SubsequentEvents"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/SubsequentEvents" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="sgmo-20191231.xsd#SubsequentEventsDetails"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/SubsequentEventsDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>sgmo-20191231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:6b105dfa-4da0-4f89-a738-1fa68397e7a0,g:da741c8d-9db4-444a-b42c-06c4caf6626c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/Cover" xlink:type="simple" xlink:href="sgmo-20191231.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/Cover" xlink:type="extended" id="i0d72d377e9504b7faa450122f9ca95fe_b0a11068-af24-4535-9473-a30c42eae5f0"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="sgmo-20191231.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/ConsolidatedBalanceSheets" xlink:type="extended" id="if0848b1eba974ffab082602fa996f47f_5c9d13a3-caba-461b-a584-f554384529d1"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="sgmo-20191231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="ib834c753522f46ccaae1095ad0d7f5ba_dabd15ce-3411-47fc-8d5f-868ef2263d56"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="sgmo-20191231.xsd#ConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/ConsolidatedStatementsofOperations" xlink:type="extended" id="id279bd3ed18942ad90529164270a8075_56956da4-0e6d-44b5-af26-4c4d173462c6"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="sgmo-20191231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended" id="if907c9e2c8784950b406ae7f33e62db3_73b5aa28-ab2b-441a-a4ac-af3140e75e02"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="sgmo-20191231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i2e83adf206a0470a84e399b29672a46a_cdcbdd68-8ff1-4779-83f0-8eb4748a0fdb">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_33165dfb-d019-423e-8f08-37f83ee10624" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_bdd0ed6e-c7ec-4bb2-b87b-0876ac5090e5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_33165dfb-d019-423e-8f08-37f83ee10624" xlink:to="loc_us-gaap_CommonStockSharesIssued_bdd0ed6e-c7ec-4bb2-b87b-0876ac5090e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c518e192-afff-4170-9857-0998111fc206" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_33165dfb-d019-423e-8f08-37f83ee10624" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c518e192-afff-4170-9857-0998111fc206" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_d46b317c-f9a8-48a8-9dc6-ec160c295668" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_33165dfb-d019-423e-8f08-37f83ee10624" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_d46b317c-f9a8-48a8-9dc6-ec160c295668" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1449246e-aece-49bf-93f7-036195c935d6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_33165dfb-d019-423e-8f08-37f83ee10624" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1449246e-aece-49bf-93f7-036195c935d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_19e2790e-cdf8-48ba-8973-e512ea76f0e7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_33165dfb-d019-423e-8f08-37f83ee10624" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_19e2790e-cdf8-48ba-8973-e512ea76f0e7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a3f39ce2-5cea-46bd-8fc2-ac59d8589c84" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_33165dfb-d019-423e-8f08-37f83ee10624" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a3f39ce2-5cea-46bd-8fc2-ac59d8589c84" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_c9738d2e-94b7-44f3-9ee5-5a5f28a0dbe1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_33165dfb-d019-423e-8f08-37f83ee10624" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_c9738d2e-94b7-44f3-9ee5-5a5f28a0dbe1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_14fca906-2eb7-408b-8c8f-297d5a670934" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_33165dfb-d019-423e-8f08-37f83ee10624" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_14fca906-2eb7-408b-8c8f-297d5a670934" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_27ad8301-0168-4106-9810-e3f375caffcf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_33165dfb-d019-423e-8f08-37f83ee10624" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_27ad8301-0168-4106-9810-e3f375caffcf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_33615ad4-59fa-40d6-b15c-251a347c6337" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_33165dfb-d019-423e-8f08-37f83ee10624" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_33615ad4-59fa-40d6-b15c-251a347c6337" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest_c4377f9d-f777-465b-a89f-1dfe08dd7c4b" xlink:href="sgmo-20191231.xsd#sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_33165dfb-d019-423e-8f08-37f83ee10624" xlink:to="loc_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest_c4377f9d-f777-465b-a89f-1dfe08dd7c4b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_1e49e1a1-9431-4e3a-83ae-791666389420" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_33165dfb-d019-423e-8f08-37f83ee10624" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_1e49e1a1-9431-4e3a-83ae-791666389420" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_61ec60c2-7b7e-4704-98c8-0bdc6377d1b3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_33165dfb-d019-423e-8f08-37f83ee10624" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_61ec60c2-7b7e-4704-98c8-0bdc6377d1b3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_16d511c1-2fa9-4116-9ad7-4811d4d04885" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_33165dfb-d019-423e-8f08-37f83ee10624" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_16d511c1-2fa9-4116-9ad7-4811d4d04885" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_d1289b18-7462-427c-aa54-2638ea381542" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_33165dfb-d019-423e-8f08-37f83ee10624" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_d1289b18-7462-427c-aa54-2638ea381542" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8b87a6f0-7e46-401a-ab61-80e3ed3bc4bb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_33165dfb-d019-423e-8f08-37f83ee10624" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8b87a6f0-7e46-401a-ab61-80e3ed3bc4bb" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0fca3b85-3eae-44b3-b7e6-498814c91fe9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_33165dfb-d019-423e-8f08-37f83ee10624" xlink:to="loc_us-gaap_ProfitLoss_0fca3b85-3eae-44b3-b7e6-498814c91fe9" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4d09dfed-3c41-4f0c-8a69-766c5ffdefd1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_33d739dd-8774-488e-a60c-af847e4e17e0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_37f41f03-be8e-4067-abd0-b222f9a92ca4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_33165dfb-d019-423e-8f08-37f83ee10624" xlink:to="loc_us-gaap_StatementTable_37f41f03-be8e-4067-abd0-b222f9a92ca4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_68cbf42f-6f35-4e29-ae8a-362720b5669c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_37f41f03-be8e-4067-abd0-b222f9a92ca4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_68cbf42f-6f35-4e29-ae8a-362720b5669c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_68cbf42f-6f35-4e29-ae8a-362720b5669c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_68cbf42f-6f35-4e29-ae8a-362720b5669c" xlink:to="loc_us-gaap_EquityComponentDomain_68cbf42f-6f35-4e29-ae8a-362720b5669c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2093c801-9b2f-4d5b-9a4f-b4d8309cbe34" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_68cbf42f-6f35-4e29-ae8a-362720b5669c" xlink:to="loc_us-gaap_EquityComponentDomain_2093c801-9b2f-4d5b-9a4f-b4d8309cbe34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_be5894c3-6c13-4086-acb8-3624fa779637" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2093c801-9b2f-4d5b-9a4f-b4d8309cbe34" xlink:to="loc_us-gaap_CommonStockMember_be5894c3-6c13-4086-acb8-3624fa779637" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2e9f0775-d93b-4ad0-8ce7-98e7268b2bfb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2093c801-9b2f-4d5b-9a4f-b4d8309cbe34" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2e9f0775-d93b-4ad0-8ce7-98e7268b2bfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_95adbfec-39c7-44fe-9d7d-5c1ec8060b56" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2093c801-9b2f-4d5b-9a4f-b4d8309cbe34" xlink:to="loc_us-gaap_RetainedEarningsMember_95adbfec-39c7-44fe-9d7d-5c1ec8060b56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e9b758d5-e1ea-4404-b66c-5d775d88c9fe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2093c801-9b2f-4d5b-9a4f-b4d8309cbe34" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e9b758d5-e1ea-4404-b66c-5d775d88c9fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_e5b011e6-719a-4e33-8695-24da00c2cadd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2093c801-9b2f-4d5b-9a4f-b4d8309cbe34" xlink:to="loc_us-gaap_NoncontrollingInterestMember_e5b011e6-719a-4e33-8695-24da00c2cadd" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="sgmo-20191231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="i8bba0b0af9a5441b8dd4fb532b02147a_6e68e5b3-96a7-4f43-b4a1-79ec2e79e54e">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a8161f6d-496c-470f-a45d-6ce7143e3d35" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_81b1070b-6bcb-4ad7-bd92-dc9167c027e9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a8161f6d-496c-470f-a45d-6ce7143e3d35" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_81b1070b-6bcb-4ad7-bd92-dc9167c027e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_dec578f6-ecd9-4227-a51f-72e06741cd96" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_81b1070b-6bcb-4ad7-bd92-dc9167c027e9" xlink:to="loc_us-gaap_ProfitLoss_dec578f6-ecd9-4227-a51f-72e06741cd96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_99552de7-6c5e-4bd0-a72c-d95c92fadade" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_81b1070b-6bcb-4ad7-bd92-dc9167c027e9" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_99552de7-6c5e-4bd0-a72c-d95c92fadade" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_6a72df24-c225-4f7a-85c4-83df292686bb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_99552de7-6c5e-4bd0-a72c-d95c92fadade" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_6a72df24-c225-4f7a-85c4-83df292686bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_21bd16df-ea73-4222-8c30-5dc91ebacb9c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_99552de7-6c5e-4bd0-a72c-d95c92fadade" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_21bd16df-ea73-4222-8c30-5dc91ebacb9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_aee6c07d-fcb2-4f95-9979-0804bb1ed30f" xlink:href="sgmo-20191231.xsd#sgmo_AmortizationAndOtherChangesInRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_99552de7-6c5e-4bd0-a72c-d95c92fadade" xlink:to="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_aee6c07d-fcb2-4f95-9979-0804bb1ed30f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GainOnFreeShares_83e04e6a-1361-41b3-b887-f45aee15aee0" xlink:href="sgmo-20191231.xsd#sgmo_GainOnFreeShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_99552de7-6c5e-4bd0-a72c-d95c92fadade" xlink:to="loc_sgmo_GainOnFreeShares_83e04e6a-1361-41b3-b887-f45aee15aee0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_a27fd3d7-55a0-4e50-9bc4-6b55665c4a69" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_99552de7-6c5e-4bd0-a72c-d95c92fadade" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_a27fd3d7-55a0-4e50-9bc4-6b55665c4a69" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_76e235cf-d794-4f03-915e-eb924a6eb377" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_99552de7-6c5e-4bd0-a72c-d95c92fadade" xlink:to="loc_us-gaap_ShareBasedCompensation_76e235cf-d794-4f03-915e-eb924a6eb377" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease_884e1fb4-f283-4a5f-bd04-216114b888f4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_99552de7-6c5e-4bd0-a72c-d95c92fadade" xlink:to="loc_us-gaap_GainLossOnTerminationOfLease_884e1fb4-f283-4a5f-bd04-216114b888f4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BuildToSuitLeases_7198fbd6-f76b-460d-81a8-f59ce8005214" xlink:href="sgmo-20191231.xsd#sgmo_BuildToSuitLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_99552de7-6c5e-4bd0-a72c-d95c92fadade" xlink:to="loc_sgmo_BuildToSuitLeases_7198fbd6-f76b-460d-81a8-f59ce8005214" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b91b2505-14b6-4642-80c2-c2637ec15ea6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_81b1070b-6bcb-4ad7-bd92-dc9167c027e9" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b91b2505-14b6-4642-80c2-c2637ec15ea6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_d8ba01f6-054f-4a92-9605-e893270b4dae" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b91b2505-14b6-4642-80c2-c2637ec15ea6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_d8ba01f6-054f-4a92-9605-e893270b4dae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1288ea94-686c-4edd-bf0a-3df7d2cacd56" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b91b2505-14b6-4642-80c2-c2637ec15ea6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1288ea94-686c-4edd-bf0a-3df7d2cacd56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a0a4b330-045f-4d90-b0cf-39aefff6428d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b91b2505-14b6-4642-80c2-c2637ec15ea6" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a0a4b330-045f-4d90-b0cf-39aefff6428d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ab2b359e-7f57-4897-ad0c-64fe88314f1b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b91b2505-14b6-4642-80c2-c2637ec15ea6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ab2b359e-7f57-4897-ad0c-64fe88314f1b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_173c16cb-4efe-4388-949f-4e841250a0fe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b91b2505-14b6-4642-80c2-c2637ec15ea6" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_173c16cb-4efe-4388-949f-4e841250a0fe" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_5582b4f5-fbb9-4009-b9a3-d454318736c3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b91b2505-14b6-4642-80c2-c2637ec15ea6" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_5582b4f5-fbb9-4009-b9a3-d454318736c3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_df1a56bd-68e7-4212-bf16-039ce49f3e8f" xlink:href="sgmo-20191231.xsd#sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b91b2505-14b6-4642-80c2-c2637ec15ea6" xlink:to="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_df1a56bd-68e7-4212-bf16-039ce49f3e8f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_009c2483-077d-4708-90b1-3c98a3cc3ce7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b91b2505-14b6-4642-80c2-c2637ec15ea6" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_009c2483-077d-4708-90b1-3c98a3cc3ce7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_53d8b31f-bcb0-45ae-98d1-fe9cf317017c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_81b1070b-6bcb-4ad7-bd92-dc9167c027e9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_53d8b31f-bcb0-45ae-98d1-fe9cf317017c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bec2b79b-8a82-4fb2-8acf-7f32f951770b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a8161f6d-496c-470f-a45d-6ce7143e3d35" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bec2b79b-8a82-4fb2-8acf-7f32f951770b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_5425c29b-4a63-473b-b644-4f252459cc57" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bec2b79b-8a82-4fb2-8acf-7f32f951770b" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_5425c29b-4a63-473b-b644-4f252459cc57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_06f7e9e8-5dc6-44ae-b8f6-ae9f4353e528" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bec2b79b-8a82-4fb2-8acf-7f32f951770b" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_06f7e9e8-5dc6-44ae-b8f6-ae9f4353e528" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_c64083db-d1aa-40ab-b2be-eb6541456833" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bec2b79b-8a82-4fb2-8acf-7f32f951770b" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_c64083db-d1aa-40ab-b2be-eb6541456833" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6a0b147e-7a8b-4de3-9c0a-4055ec5075e0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bec2b79b-8a82-4fb2-8acf-7f32f951770b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6a0b147e-7a8b-4de3-9c0a-4055ec5075e0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_b84ccd0e-586a-42a5-a5ab-a35a25a439ed" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bec2b79b-8a82-4fb2-8acf-7f32f951770b" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_b84ccd0e-586a-42a5-a5ab-a35a25a439ed" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7ba302a0-ab56-4ee7-a2c0-38e62d5dbe16" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bec2b79b-8a82-4fb2-8acf-7f32f951770b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7ba302a0-ab56-4ee7-a2c0-38e62d5dbe16" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc640db6-4472-407d-aeca-4fcafa268dd4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a8161f6d-496c-470f-a45d-6ce7143e3d35" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc640db6-4472-407d-aeca-4fcafa268dd4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NetProceedsFromIssuancePublicOffering_f6ee6b08-8602-4c8a-a824-682f16b48246" xlink:href="sgmo-20191231.xsd#sgmo_NetProceedsFromIssuancePublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc640db6-4472-407d-aeca-4fcafa268dd4" xlink:to="loc_sgmo_NetProceedsFromIssuancePublicOffering_f6ee6b08-8602-4c8a-a824-682f16b48246" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1086c965-b196-4a77-a083-329cad69a08c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc640db6-4472-407d-aeca-4fcafa268dd4" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1086c965-b196-4a77-a083-329cad69a08c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1506c519-2023-4ca5-8b27-802fc12a3c76" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc640db6-4472-407d-aeca-4fcafa268dd4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1506c519-2023-4ca5-8b27-802fc12a3c76" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_8dbf47a5-0667-4206-b3e6-b8cc2ab35edf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc640db6-4472-407d-aeca-4fcafa268dd4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_8dbf47a5-0667-4206-b3e6-b8cc2ab35edf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_92077fe6-945f-40b4-92d9-8cd1bbbf8070" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc640db6-4472-407d-aeca-4fcafa268dd4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_92077fe6-945f-40b4-92d9-8cd1bbbf8070" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_eac93210-1d53-4263-94e3-c93c1e8ac9b3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a8161f6d-496c-470f-a45d-6ce7143e3d35" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_eac93210-1d53-4263-94e3-c93c1e8ac9b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_448a9029-d0ea-4cd5-b631-e5d0082f8e77" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a8161f6d-496c-470f-a45d-6ce7143e3d35" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_448a9029-d0ea-4cd5-b631-e5d0082f8e77" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f27d3732-7872-424c-b94f-9b755cb08ad1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a8161f6d-496c-470f-a45d-6ce7143e3d35" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f27d3732-7872-424c-b94f-9b755cb08ad1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f39e40d3-a8d4-4d06-bda7-2d9c23251a5e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2238aac0-772f-4735-a5db-b9aac35d522c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a8161f6d-496c-470f-a45d-6ce7143e3d35" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2238aac0-772f-4735-a5db-b9aac35d522c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NoncashOrPartNoncashNonControllingInterestAcquisition_0d96abe0-01ac-4c09-9960-ab1d9aa9fb64" xlink:href="sgmo-20191231.xsd#sgmo_NoncashOrPartNoncashNonControllingInterestAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2238aac0-772f-4735-a5db-b9aac35d522c" xlink:to="loc_sgmo_NoncashOrPartNoncashNonControllingInterestAcquisition_0d96abe0-01ac-4c09-9960-ab1d9aa9fb64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_2f5164d7-6687-42b2-86db-15b2dc37a1fa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2238aac0-772f-4735-a5db-b9aac35d522c" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_2f5164d7-6687-42b2-86db-15b2dc37a1fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_37fa16bc-7e5f-4d67-8a1c-80a14a26de08" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2238aac0-772f-4735-a5db-b9aac35d522c" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_37fa16bc-7e5f-4d67-8a1c-80a14a26de08" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_92742e04-1105-4c4e-bc2e-7c2fed56fdd5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_a8161f6d-496c-470f-a45d-6ce7143e3d35" xlink:to="loc_us-gaap_StatementTable_92742e04-1105-4c4e-bc2e-7c2fed56fdd5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_ca54cfeb-b088-4d09-92e5-0c44f18d9c96" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_92742e04-1105-4c4e-bc2e-7c2fed56fdd5" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_ca54cfeb-b088-4d09-92e5-0c44f18d9c96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_ca54cfeb-b088-4d09-92e5-0c44f18d9c96_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_ca54cfeb-b088-4d09-92e5-0c44f18d9c96" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_ca54cfeb-b088-4d09-92e5-0c44f18d9c96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_78a2b0be-c9a6-4956-bf50-c38e8fe381ed" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_ca54cfeb-b088-4d09-92e5-0c44f18d9c96" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_78a2b0be-c9a6-4956-bf50-c38e8fe381ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BuildToSuitLeaseMember_a03a1910-f9e4-4bce-a8ad-0cbe4bcdaa56" xlink:href="sgmo-20191231.xsd#sgmo_BuildToSuitLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_78a2b0be-c9a6-4956-bf50-c38e8fe381ed" xlink:to="loc_sgmo_BuildToSuitLeaseMember_a03a1910-f9e4-4bce-a8ad-0cbe4bcdaa56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f481aa1c-0ec2-46e0-a9df-e87122bd922d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_92742e04-1105-4c4e-bc2e-7c2fed56fdd5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f481aa1c-0ec2-46e0-a9df-e87122bd922d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f481aa1c-0ec2-46e0-a9df-e87122bd922d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f481aa1c-0ec2-46e0-a9df-e87122bd922d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f481aa1c-0ec2-46e0-a9df-e87122bd922d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_324d8305-60e3-4b6a-a51e-f0444bc4cda7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f481aa1c-0ec2-46e0-a9df-e87122bd922d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_324d8305-60e3-4b6a-a51e-f0444bc4cda7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PropertyAndEquipmentMember_ff8d18f2-58ba-4562-a502-d90fc2666de9" xlink:href="sgmo-20191231.xsd#sgmo_PropertyAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_324d8305-60e3-4b6a-a51e-f0444bc4cda7" xlink:to="loc_sgmo_PropertyAndEquipmentMember_ff8d18f2-58ba-4562-a502-d90fc2666de9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="sgmo-20191231.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended" id="ia0ffc7841cdb421ea2c5f6d7bf51aba4_5adc454a-5813-4854-86ee-dc113ee58f8f"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="sgmo-20191231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="ibc19b88c203c4afba79550b15ae16045_71b6b9a6-e4f3-4acc-9986-d75048451565"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="sgmo-20191231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended" id="i2b22ebeb502940339392bf2e469de027_f794850a-b2d8-421f-8163-5d17f0b36871"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended" id="i30eeff2a9d5946bcb12c3a11bf5c1252_a5850ddc-9ae3-44cc-85f7-841daff9094f">
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_4ca58e0d-2655-4807-9fe0-1261e228eb63" xlink:href="sgmo-20191231.xsd#sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_88967291-d4af-461a-ab15-bcd78bc8255d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_4ca58e0d-2655-4807-9fe0-1261e228eb63" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_88967291-d4af-461a-ab15-bcd78bc8255d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8b24aaaa-854c-471b-8f90-f293b7fcbf15" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_4ca58e0d-2655-4807-9fe0-1261e228eb63" xlink:to="loc_us-gaap_ProfitLoss_8b24aaaa-854c-471b-8f90-f293b7fcbf15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_b79432dd-cd2c-4b8b-9b59-7e588b141a3e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_4ca58e0d-2655-4807-9fe0-1261e228eb63" xlink:to="loc_us-gaap_EarningsPerShareBasic_b79432dd-cd2c-4b8b-9b59-7e588b141a3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_659f9a6a-4e30-4775-9743-d5f828c67dc8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_4ca58e0d-2655-4807-9fe0-1261e228eb63" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_659f9a6a-4e30-4775-9743-d5f828c67dc8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_e87f72a4-1357-433b-83bb-8fb971a5ff48" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_4ca58e0d-2655-4807-9fe0-1261e228eb63" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_e87f72a4-1357-433b-83bb-8fb971a5ff48" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber_4c3fbba5-1436-4219-848a-541067e7642c" xlink:href="sgmo-20191231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_4ca58e0d-2655-4807-9fe0-1261e228eb63" xlink:to="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber_4c3fbba5-1436-4219-848a-541067e7642c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_04377e8d-644b-4afa-8d26-a4e2ebb46e55" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_4ca58e0d-2655-4807-9fe0-1261e228eb63" xlink:to="loc_us-gaap_NumberOfOperatingSegments_04377e8d-644b-4afa-8d26-a4e2ebb46e55" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_90d5319f-ec2b-46cb-a9c3-0b8e8e17ce02" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_4ca58e0d-2655-4807-9fe0-1261e228eb63" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_90d5319f-ec2b-46cb-a9c3-0b8e8e17ce02" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_2b9325ac-e99c-451a-af3f-eabee68ca1ce" xlink:href="sgmo-20191231.xsd#sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_4ca58e0d-2655-4807-9fe0-1261e228eb63" xlink:to="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_2b9325ac-e99c-451a-af3f-eabee68ca1ce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4878ecae-c94e-4416-829c-c66102046728" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_2b9325ac-e99c-451a-af3f-eabee68ca1ce" xlink:to="loc_srt_RangeAxis_4878ecae-c94e-4416-829c-c66102046728" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4878ecae-c94e-4416-829c-c66102046728_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4878ecae-c94e-4416-829c-c66102046728" xlink:to="loc_srt_RangeMember_4878ecae-c94e-4416-829c-c66102046728_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9494fe0b-e64c-4faf-b90a-61b888adb654" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4878ecae-c94e-4416-829c-c66102046728" xlink:to="loc_srt_RangeMember_9494fe0b-e64c-4faf-b90a-61b888adb654" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_66a4c7f0-3de3-4c9d-82ee-087ef1c72a22" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9494fe0b-e64c-4faf-b90a-61b888adb654" xlink:to="loc_srt_MinimumMember_66a4c7f0-3de3-4c9d-82ee-087ef1c72a22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ef5da891-4707-4c14-9f3c-08dcd528de1f" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9494fe0b-e64c-4faf-b90a-61b888adb654" xlink:to="loc_srt_MaximumMember_ef5da891-4707-4c14-9f3c-08dcd528de1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_abe025db-f307-4e93-97e5-75b14e981a41" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_2b9325ac-e99c-451a-af3f-eabee68ca1ce" xlink:to="loc_srt_CounterpartyNameAxis_abe025db-f307-4e93-97e5-75b14e981a41" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_abe025db-f307-4e93-97e5-75b14e981a41_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_abe025db-f307-4e93-97e5-75b14e981a41" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_abe025db-f307-4e93-97e5-75b14e981a41_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_83bb8a30-207b-431f-9eb1-9ae8c9c5c5c2" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_abe025db-f307-4e93-97e5-75b14e981a41" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_83bb8a30-207b-431f-9eb1-9ae8c9c5c5c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_5ddb3fad-aa47-434f-97b9-0c5552ccd795" xlink:href="sgmo-20191231.xsd#sgmo_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_83bb8a30-207b-431f-9eb1-9ae8c9c5c5c2" xlink:to="loc_sgmo_SanofiMember_5ddb3fad-aa47-434f-97b9-0c5552ccd795" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember_71ff2577-c2b4-4335-8d05-f14e678970ae" xlink:href="sgmo-20191231.xsd#sgmo_PfizerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_83bb8a30-207b-431f-9eb1-9ae8c9c5c5c2" xlink:to="loc_sgmo_PfizerMember_71ff2577-c2b4-4335-8d05-f14e678970ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member_fe53e2be-57d1-41b1-a8ce-2d2788386388" xlink:href="sgmo-20191231.xsd#sgmo_PfizerSB525Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_83bb8a30-207b-431f-9eb1-9ae8c9c5c5c2" xlink:to="loc_sgmo_PfizerSB525Member_fe53e2be-57d1-41b1-a8ce-2d2788386388" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_9edab184-ee07-46e6-ba78-b601ade114cd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_2b9325ac-e99c-451a-af3f-eabee68ca1ce" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_9edab184-ee07-46e6-ba78-b601ade114cd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_9edab184-ee07-46e6-ba78-b601ade114cd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_9edab184-ee07-46e6-ba78-b601ade114cd" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_9edab184-ee07-46e6-ba78-b601ade114cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_bd41f2c8-41b3-4bd0-aac4-564ebf1211e8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_9edab184-ee07-46e6-ba78-b601ade114cd" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_bd41f2c8-41b3-4bd0-aac4-564ebf1211e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ChangeInCollaborationAgreementScopeMember_e0ce7236-fcc0-4e02-a34d-95a1a6aef8e1" xlink:href="sgmo-20191231.xsd#sgmo_ChangeInCollaborationAgreementScopeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_bd41f2c8-41b3-4bd0-aac4-564ebf1211e8" xlink:to="loc_sgmo_ChangeInCollaborationAgreementScopeMember_e0ce7236-fcc0-4e02-a34d-95a1a6aef8e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_436757f2-2b7b-4b76-8878-1b3fb0ed6bdb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_2b9325ac-e99c-451a-af3f-eabee68ca1ce" xlink:to="loc_us-gaap_TypeOfArrangementAxis_436757f2-2b7b-4b76-8878-1b3fb0ed6bdb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_436757f2-2b7b-4b76-8878-1b3fb0ed6bdb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_436757f2-2b7b-4b76-8878-1b3fb0ed6bdb" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_436757f2-2b7b-4b76-8878-1b3fb0ed6bdb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a3c58e81-0c62-422a-b633-9a0103ae3040" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_436757f2-2b7b-4b76-8878-1b3fb0ed6bdb" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a3c58e81-0c62-422a-b633-9a0103ae3040" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_8d44465b-fc5f-4351-a08f-828c4cbfd835" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a3c58e81-0c62-422a-b633-9a0103ae3040" xlink:to="loc_us-gaap_CollaborativeArrangementMember_8d44465b-fc5f-4351-a08f-828c4cbfd835" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_ba3e9fa1-7647-4204-96a8-13560c49e231" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_2b9325ac-e99c-451a-af3f-eabee68ca1ce" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_ba3e9fa1-7647-4204-96a8-13560c49e231" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_ba3e9fa1-7647-4204-96a8-13560c49e231_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_ba3e9fa1-7647-4204-96a8-13560c49e231" xlink:to="loc_us-gaap_TypeOfAdoptionMember_ba3e9fa1-7647-4204-96a8-13560c49e231_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_0c82d276-7b49-4c6f-9faf-bed299645c04" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_ba3e9fa1-7647-4204-96a8-13560c49e231" xlink:to="loc_us-gaap_TypeOfAdoptionMember_0c82d276-7b49-4c6f-9faf-bed299645c04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_42ed601d-dd52-4f98-8161-e77f0113f590" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_0c82d276-7b49-4c6f-9faf-bed299645c04" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_42ed601d-dd52-4f98-8161-e77f0113f590" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_eef122c3-9539-4c2f-8529-734a1ef8fbfd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_2b9325ac-e99c-451a-af3f-eabee68ca1ce" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_eef122c3-9539-4c2f-8529-734a1ef8fbfd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_eef122c3-9539-4c2f-8529-734a1ef8fbfd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_eef122c3-9539-4c2f-8529-734a1ef8fbfd" xlink:to="loc_us-gaap_EquityComponentDomain_eef122c3-9539-4c2f-8529-734a1ef8fbfd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_48004c28-4c38-475d-9ebd-c56c292f1f12" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_eef122c3-9539-4c2f-8529-734a1ef8fbfd" xlink:to="loc_us-gaap_EquityComponentDomain_48004c28-4c38-475d-9ebd-c56c292f1f12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_16e120ed-d4f0-481b-a5e3-a6caf3846020" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_48004c28-4c38-475d-9ebd-c56c292f1f12" xlink:to="loc_us-gaap_RetainedEarningsMember_16e120ed-d4f0-481b-a5e3-a6caf3846020" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail" xlink:type="extended" id="i953c235326134c928cdfc82f4198f4e0_028e2c46-dea7-4275-a62c-036024bf1287">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_16c9764f-ae62-492e-a9e7-62eaaf54bc98" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_4b84947c-2d3b-4b75-a8f5-5e810dff240d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_16c9764f-ae62-492e-a9e7-62eaaf54bc98" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_4b84947c-2d3b-4b75-a8f5-5e810dff240d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_a17fa785-0542-4cda-bf00-3b620c561cb8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_16c9764f-ae62-492e-a9e7-62eaaf54bc98" xlink:to="loc_us-gaap_ConcentrationRiskTable_a17fa785-0542-4cda-bf00-3b620c561cb8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_35ff2c47-c804-488b-9b4f-b71666cf1331" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_a17fa785-0542-4cda-bf00-3b620c561cb8" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_35ff2c47-c804-488b-9b4f-b71666cf1331" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_35ff2c47-c804-488b-9b4f-b71666cf1331_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_35ff2c47-c804-488b-9b4f-b71666cf1331" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_35ff2c47-c804-488b-9b4f-b71666cf1331_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bc56065b-9c68-4754-a152-56f03bff625f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_35ff2c47-c804-488b-9b4f-b71666cf1331" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bc56065b-9c68-4754-a152-56f03bff625f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_6188cd1f-a05d-41d9-90ed-5deb3e365970" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bc56065b-9c68-4754-a152-56f03bff625f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_6188cd1f-a05d-41d9-90ed-5deb3e365970" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_bd61c287-67c0-4bb8-8a0c-645cf44d47d6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_a17fa785-0542-4cda-bf00-3b620c561cb8" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_bd61c287-67c0-4bb8-8a0c-645cf44d47d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_bd61c287-67c0-4bb8-8a0c-645cf44d47d6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_bd61c287-67c0-4bb8-8a0c-645cf44d47d6" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_bd61c287-67c0-4bb8-8a0c-645cf44d47d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a4dce865-ec74-4c8d-8b6f-b42c1ea7759b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_bd61c287-67c0-4bb8-8a0c-645cf44d47d6" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a4dce865-ec74-4c8d-8b6f-b42c1ea7759b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_0f2d35c6-6d41-415d-ab7b-4a9e803c098b" xlink:href="sgmo-20191231.xsd#sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_a4dce865-ec74-4c8d-8b6f-b42c1ea7759b" xlink:to="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_0f2d35c6-6d41-415d-ab7b-4a9e803c098b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_55ba0613-f3f1-4d92-b9aa-328ce066275b" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_a17fa785-0542-4cda-bf00-3b620c561cb8" xlink:to="loc_srt_CounterpartyNameAxis_55ba0613-f3f1-4d92-b9aa-328ce066275b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_55ba0613-f3f1-4d92-b9aa-328ce066275b_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_55ba0613-f3f1-4d92-b9aa-328ce066275b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_55ba0613-f3f1-4d92-b9aa-328ce066275b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_50a80ea4-2b75-4b68-85c4-3cccbf96636a" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_55ba0613-f3f1-4d92-b9aa-328ce066275b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_50a80ea4-2b75-4b68-85c4-3cccbf96636a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember_3bc2b4c0-afd4-4981-810a-cf899fc81fc0" xlink:href="sgmo-20191231.xsd#sgmo_PfizerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_50a80ea4-2b75-4b68-85c4-3cccbf96636a" xlink:to="loc_sgmo_PfizerMember_3bc2b4c0-afd4-4981-810a-cf899fc81fc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_3d412b34-edc0-44f4-a7a6-6dd56dab6c55" xlink:href="sgmo-20191231.xsd#sgmo_KitePharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_50a80ea4-2b75-4b68-85c4-3cccbf96636a" xlink:to="loc_sgmo_KitePharmaIncMember_3d412b34-edc0-44f4-a7a6-6dd56dab6c55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_4070ba52-3dd9-4fb8-9031-df8fbb301d01" xlink:href="sgmo-20191231.xsd#sgmo_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_50a80ea4-2b75-4b68-85c4-3cccbf96636a" xlink:to="loc_sgmo_SanofiMember_4070ba52-3dd9-4fb8-9031-df8fbb301d01" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="sgmo-20191231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofCashandCashEquivalentsDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofCashandCashEquivalentsDetails" xlink:type="extended" id="i5da2d862ba7543cfb3ee69d16182ee85_4f796822-cc11-4716-81be-dd362c94532c"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesImpactofAdoptionofASConCondensedConsolidatedBalanceSheetDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesImpactofAdoptionofASConCondensedConsolidatedBalanceSheetDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesImpactofAdoptionofASConCondensedConsolidatedBalanceSheetDetail" xlink:type="extended" id="if422c1395d0a42df98cf96c884b33e84_b96ce355-85b8-494c-a38a-9089c5c8b5f1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_885c44ec-d2b6-4c4d-a817-fb20cf34b46c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_46441963-d685-4e1e-8677-1ecf6f2f9443" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_885c44ec-d2b6-4c4d-a817-fb20cf34b46c" xlink:to="loc_us-gaap_AssetsAbstract_46441963-d685-4e1e-8677-1ecf6f2f9443" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2ec40f91-45d9-4c63-84eb-3f569c3682da" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_46441963-d685-4e1e-8677-1ecf6f2f9443" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2ec40f91-45d9-4c63-84eb-3f569c3682da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b641799c-1d95-4845-b21a-ccf5d199ed48" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_46441963-d685-4e1e-8677-1ecf6f2f9443" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b641799c-1d95-4845-b21a-ccf5d199ed48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidRent_5a47e9eb-b994-48a2-97cb-f42c2d459c05" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_46441963-d685-4e1e-8677-1ecf6f2f9443" xlink:to="loc_us-gaap_PrepaidRent_5a47e9eb-b994-48a2-97cb-f42c2d459c05" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_8d0f5914-922f-4d8c-a43c-25efc5327616" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_885c44ec-d2b6-4c4d-a817-fb20cf34b46c" xlink:to="loc_us-gaap_LiabilitiesAbstract_8d0f5914-922f-4d8c-a43c-25efc5327616" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5377ec9f-05ea-41e5-a5de-258107e60eea" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_8d0f5914-922f-4d8c-a43c-25efc5327616" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_5377ec9f-05ea-41e5-a5de-258107e60eea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DeferredRentNoncurrent_d781d6d6-78ee-498d-bcdd-5f4f39531329" xlink:href="sgmo-20191231.xsd#sgmo_DeferredRentNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_8d0f5914-922f-4d8c-a43c-25efc5327616" xlink:to="loc_sgmo_DeferredRentNoncurrent_d781d6d6-78ee-498d-bcdd-5f4f39531329" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8a12bb92-aa4d-4a84-b407-8b9a50b7be35" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_8d0f5914-922f-4d8c-a43c-25efc5327616" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8a12bb92-aa4d-4a84-b407-8b9a50b7be35" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f6e12d3e-9512-4aad-8261-25c91304c4ad" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_8d0f5914-922f-4d8c-a43c-25efc5327616" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f6e12d3e-9512-4aad-8261-25c91304c4ad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_659196c3-6ea6-4d0a-b2de-d7b1aeea92a2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_885c44ec-d2b6-4c4d-a817-fb20cf34b46c" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_659196c3-6ea6-4d0a-b2de-d7b1aeea92a2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LeaseArrangementsAxis_12ab6a2c-3270-4e51-bef1-cbf7e0be9ca7" xlink:href="sgmo-20191231.xsd#sgmo_LeaseArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_659196c3-6ea6-4d0a-b2de-d7b1aeea92a2" xlink:to="loc_sgmo_LeaseArrangementsAxis_12ab6a2c-3270-4e51-bef1-cbf7e0be9ca7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LeaseArrangementsDomain_12ab6a2c-3270-4e51-bef1-cbf7e0be9ca7_default" xlink:href="sgmo-20191231.xsd#sgmo_LeaseArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sgmo_LeaseArrangementsAxis_12ab6a2c-3270-4e51-bef1-cbf7e0be9ca7" xlink:to="loc_sgmo_LeaseArrangementsDomain_12ab6a2c-3270-4e51-bef1-cbf7e0be9ca7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LeaseArrangementsDomain_ac74bcca-b4a7-4763-b9d6-015d3eaa0ca5" xlink:href="sgmo-20191231.xsd#sgmo_LeaseArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sgmo_LeaseArrangementsAxis_12ab6a2c-3270-4e51-bef1-cbf7e0be9ca7" xlink:to="loc_sgmo_LeaseArrangementsDomain_ac74bcca-b4a7-4763-b9d6-015d3eaa0ca5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BuildToSuitLeaseMember_f4dee5e0-50b9-47bf-bf0e-ad6fa1282cc9" xlink:href="sgmo-20191231.xsd#sgmo_BuildToSuitLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_LeaseArrangementsDomain_ac74bcca-b4a7-4763-b9d6-015d3eaa0ca5" xlink:to="loc_sgmo_BuildToSuitLeaseMember_f4dee5e0-50b9-47bf-bf0e-ad6fa1282cc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1f6360cd-d677-4d8a-b40a-f78043072d08" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_659196c3-6ea6-4d0a-b2de-d7b1aeea92a2" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1f6360cd-d677-4d8a-b40a-f78043072d08" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_1f6360cd-d677-4d8a-b40a-f78043072d08_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1f6360cd-d677-4d8a-b40a-f78043072d08" xlink:to="loc_us-gaap_TypeOfAdoptionMember_1f6360cd-d677-4d8a-b40a-f78043072d08_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_a3be318b-d46a-4fea-9138-15b7f1e33f7e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1f6360cd-d677-4d8a-b40a-f78043072d08" xlink:to="loc_us-gaap_TypeOfAdoptionMember_a3be318b-d46a-4fea-9138-15b7f1e33f7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_1e8493b5-db7a-4706-b391-3ddbcaff2482" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_a3be318b-d46a-4fea-9138-15b7f1e33f7e" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_1e8493b5-db7a-4706-b391-3ddbcaff2482" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_34b84c20-647b-4e0f-8817-6aee80f01d4c" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_659196c3-6ea6-4d0a-b2de-d7b1aeea92a2" xlink:to="loc_srt_RestatementAxis_34b84c20-647b-4e0f-8817-6aee80f01d4c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_34b84c20-647b-4e0f-8817-6aee80f01d4c_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_34b84c20-647b-4e0f-8817-6aee80f01d4c" xlink:to="loc_srt_RestatementDomain_34b84c20-647b-4e0f-8817-6aee80f01d4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_151f850a-e988-4af4-9d7e-5d47e22dce22" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_34b84c20-647b-4e0f-8817-6aee80f01d4c" xlink:to="loc_srt_RestatementDomain_151f850a-e988-4af4-9d7e-5d47e22dce22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember_ae1112cf-db75-4dcc-b44a-493e02fefdb9" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_151f850a-e988-4af4-9d7e-5d47e22dce22" xlink:to="loc_srt_RestatementAdjustmentMember_ae1112cf-db75-4dcc-b44a-493e02fefdb9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurement" xlink:type="simple" xlink:href="sgmo-20191231.xsd#FairValueMeasurement"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/FairValueMeasurement" xlink:type="extended" id="i5b483bd123954730a47ad7c0f00a5f52_2586b959-5066-4f07-88bd-05ce43408ee1"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurementTables" xlink:type="simple" xlink:href="sgmo-20191231.xsd#FairValueMeasurementTables"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/FairValueMeasurementTables" xlink:type="extended" id="i3619c36251cd4c62bc49b0b83609ec31_7581e964-9d41-43f1-9fb6-7cba0cd891c7"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail" xlink:type="extended" id="i1c8ce697912e425d84250dc2210c3ad7_5630641f-07b0-4bb3-aa40-6a4b774c4fdc">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ab851ab4-8040-46d0-8deb-6eda29de763a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_463ac8a6-d9b2-422a-8fbb-126cc1b0c18c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ab851ab4-8040-46d0-8deb-6eda29de763a" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_463ac8a6-d9b2-422a-8fbb-126cc1b0c18c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_50119692-da0c-47b1-b4bd-dc4a0d8b0b49" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ab851ab4-8040-46d0-8deb-6eda29de763a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_50119692-da0c-47b1-b4bd-dc4a0d8b0b49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_b093dd8d-6a0a-4bdd-8b21-8fd65f932a10" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ab851ab4-8040-46d0-8deb-6eda29de763a" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_b093dd8d-6a0a-4bdd-8b21-8fd65f932a10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_71d3629a-ddbd-483d-9c59-e0787c8c5436" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ab851ab4-8040-46d0-8deb-6eda29de763a" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_71d3629a-ddbd-483d-9c59-e0787c8c5436" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2a4c3294-41f7-467c-a02b-0a6594e0712b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ab851ab4-8040-46d0-8deb-6eda29de763a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2a4c3294-41f7-467c-a02b-0a6594e0712b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c1862955-f9d0-45ea-9fb2-b6c3d3054569" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2a4c3294-41f7-467c-a02b-0a6594e0712b" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c1862955-f9d0-45ea-9fb2-b6c3d3054569" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c1862955-f9d0-45ea-9fb2-b6c3d3054569_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c1862955-f9d0-45ea-9fb2-b6c3d3054569" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c1862955-f9d0-45ea-9fb2-b6c3d3054569_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7a00bb2f-f186-4681-b6f6-8cb11f7893ee" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c1862955-f9d0-45ea-9fb2-b6c3d3054569" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7a00bb2f-f186-4681-b6f6-8cb11f7893ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_bc39ce1a-339d-4fe9-932c-38a7d1ce6316" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7a00bb2f-f186-4681-b6f6-8cb11f7893ee" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_bc39ce1a-339d-4fe9-932c-38a7d1ce6316" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c4dfac57-d18a-4af1-85dc-6f9736015644" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2a4c3294-41f7-467c-a02b-0a6594e0712b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c4dfac57-d18a-4af1-85dc-6f9736015644" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c4dfac57-d18a-4af1-85dc-6f9736015644_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c4dfac57-d18a-4af1-85dc-6f9736015644" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c4dfac57-d18a-4af1-85dc-6f9736015644_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_81bd3daf-3bcf-4da5-b252-3292ef0fdb8c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c4dfac57-d18a-4af1-85dc-6f9736015644" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_81bd3daf-3bcf-4da5-b252-3292ef0fdb8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_c3b8772b-832e-4b70-bbe6-794e8d943602" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_81bd3daf-3bcf-4da5-b252-3292ef0fdb8c" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_c3b8772b-832e-4b70-bbe6-794e8d943602" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_ec4bbb20-a8db-4eb7-914b-fee5f28f5454" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_81bd3daf-3bcf-4da5-b252-3292ef0fdb8c" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_ec4bbb20-a8db-4eb7-914b-fee5f28f5454" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FreeSharesAssetMember_d5b0c731-68b8-468f-b31e-a0b6ff14b704" xlink:href="sgmo-20191231.xsd#sgmo_FreeSharesAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_81bd3daf-3bcf-4da5-b252-3292ef0fdb8c" xlink:to="loc_sgmo_FreeSharesAssetMember_d5b0c731-68b8-468f-b31e-a0b6ff14b704" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FreeSharesLiabilityMember_c62d8ac9-8499-4888-918a-78bc040e2c63" xlink:href="sgmo-20191231.xsd#sgmo_FreeSharesLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_81bd3daf-3bcf-4da5-b252-3292ef0fdb8c" xlink:to="loc_sgmo_FreeSharesLiabilityMember_c62d8ac9-8499-4888-918a-78bc040e2c63" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0cbf3f15-f868-4439-abe7-cf47d61874f0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2a4c3294-41f7-467c-a02b-0a6594e0712b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0cbf3f15-f868-4439-abe7-cf47d61874f0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0cbf3f15-f868-4439-abe7-cf47d61874f0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0cbf3f15-f868-4439-abe7-cf47d61874f0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0cbf3f15-f868-4439-abe7-cf47d61874f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_151c568d-6fa1-45a9-b369-3f32154d3f9c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0cbf3f15-f868-4439-abe7-cf47d61874f0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_151c568d-6fa1-45a9-b369-3f32154d3f9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_7fdb6529-d004-4fbb-bf4d-e32a60268852" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_151c568d-6fa1-45a9-b369-3f32154d3f9c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_7fdb6529-d004-4fbb-bf4d-e32a60268852" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4d4f561f-b4e2-40af-b228-15c1406d4539" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_151c568d-6fa1-45a9-b369-3f32154d3f9c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_4d4f561f-b4e2-40af-b228-15c1406d4539" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_03c2213b-7ac1-449c-a302-83b28c0e13db" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_151c568d-6fa1-45a9-b369-3f32154d3f9c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_03c2213b-7ac1-449c-a302-83b28c0e13db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_7cda0bb9-9a17-4f60-9f8d-6cdc4dfa29d4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2a4c3294-41f7-467c-a02b-0a6594e0712b" xlink:to="loc_us-gaap_InvestmentTypeAxis_7cda0bb9-9a17-4f60-9f8d-6cdc4dfa29d4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_7cda0bb9-9a17-4f60-9f8d-6cdc4dfa29d4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_7cda0bb9-9a17-4f60-9f8d-6cdc4dfa29d4" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_7cda0bb9-9a17-4f60-9f8d-6cdc4dfa29d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_a6c784a0-d066-435a-8ed7-c43a8b6018da" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_7cda0bb9-9a17-4f60-9f8d-6cdc4dfa29d4" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_a6c784a0-d066-435a-8ed7-c43a8b6018da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_3530bb5d-7cef-41fa-a3e7-f9a6dd08fb89" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_a6c784a0-d066-435a-8ed7-c43a8b6018da" xlink:to="loc_us-gaap_MoneyMarketFundsMember_3530bb5d-7cef-41fa-a3e7-f9a6dd08fb89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_1ead6ca7-35e2-4074-990f-4d13f569099d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_a6c784a0-d066-435a-8ed7-c43a8b6018da" xlink:to="loc_us-gaap_CommercialPaperMember_1ead6ca7-35e2-4074-990f-4d13f569099d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#FairValueMeasurementAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail" xlink:type="extended" id="ie3289081a5da488c9393107088ccba80_528ed84e-908d-459f-a258-ee17d2327fee">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f55eddde-f8a0-4af3-853a-5a4b7a84b42f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_85f0ba06-b462-4b98-8966-a108d84ce16f" xlink:href="sgmo-20191231.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f55eddde-f8a0-4af3-853a-5a4b7a84b42f" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_85f0ba06-b462-4b98-8966-a108d84ce16f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_92ace64c-3353-49a4-9b9b-7ae22230a156" xlink:href="sgmo-20191231.xsd#sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f55eddde-f8a0-4af3-853a-5a4b7a84b42f" xlink:to="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_92ace64c-3353-49a4-9b9b-7ae22230a156" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_8931f328-8bd2-4ae2-b4d8-7ed1d85cc575" xlink:href="sgmo-20191231.xsd#sgmo_BusinessAcquisitionNumberOfSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f55eddde-f8a0-4af3-853a-5a4b7a84b42f" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_8931f328-8bd2-4ae2-b4d8-7ed1d85cc575" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_46111261-afbb-4b3f-83e5-153d8bc95c6a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f55eddde-f8a0-4af3-853a-5a4b7a84b42f" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_46111261-afbb-4b3f-83e5-153d8bc95c6a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase_999f8058-897b-4240-b215-f8761feb6729" xlink:href="sgmo-20191231.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f55eddde-f8a0-4af3-853a-5a4b7a84b42f" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase_999f8058-897b-4240-b215-f8761feb6729" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability_0f05ea4e-e47e-482e-a466-55f4897c1921" xlink:href="sgmo-20191231.xsd#sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f55eddde-f8a0-4af3-853a-5a4b7a84b42f" xlink:to="loc_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability_0f05ea4e-e47e-482e-a466-55f4897c1921" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueOfFreeShares_b1a2601b-8ac7-4377-b10b-56bfc4fe0b00" xlink:href="sgmo-20191231.xsd#sgmo_BusinessAcquisitionEstimatedFairValueOfFreeShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f55eddde-f8a0-4af3-853a-5a4b7a84b42f" xlink:to="loc_sgmo_BusinessAcquisitionEstimatedFairValueOfFreeShares_b1a2601b-8ac7-4377-b10b-56bfc4fe0b00" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_613f57b9-f88d-4cf6-a1e6-78b55996eb4f" xlink:href="sgmo-20191231.xsd#sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f55eddde-f8a0-4af3-853a-5a4b7a84b42f" xlink:to="loc_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_613f57b9-f88d-4cf6-a1e6-78b55996eb4f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_447554ad-034c-40f9-a969-3b89558fb0bf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f55eddde-f8a0-4af3-853a-5a4b7a84b42f" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_447554ad-034c-40f9-a969-3b89558fb0bf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3c808ba2-fe1a-4a66-8769-8634fd851212" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_447554ad-034c-40f9-a969-3b89558fb0bf" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3c808ba2-fe1a-4a66-8769-8634fd851212" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3c808ba2-fe1a-4a66-8769-8634fd851212_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3c808ba2-fe1a-4a66-8769-8634fd851212" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3c808ba2-fe1a-4a66-8769-8634fd851212_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0fbe82b7-276b-4395-be89-21bbf13381e0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3c808ba2-fe1a-4a66-8769-8634fd851212" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0fbe82b7-276b-4395-be89-21bbf13381e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_817703ec-1fdb-4297-9433-dc4285054e4b" xlink:href="sgmo-20191231.xsd#sgmo_SangamoFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0fbe82b7-276b-4395-be89-21bbf13381e0" xlink:to="loc_sgmo_SangamoFranceMember_817703ec-1fdb-4297-9433-dc4285054e4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_72217974-f72c-4783-a3e7-7ecdfaeefa5a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_447554ad-034c-40f9-a969-3b89558fb0bf" xlink:to="loc_us-gaap_TypeOfArrangementAxis_72217974-f72c-4783-a3e7-7ecdfaeefa5a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_72217974-f72c-4783-a3e7-7ecdfaeefa5a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_72217974-f72c-4783-a3e7-7ecdfaeefa5a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_72217974-f72c-4783-a3e7-7ecdfaeefa5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c8cb35e8-cf2a-4765-b056-0eab5e8eb96b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_72217974-f72c-4783-a3e7-7ecdfaeefa5a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c8cb35e8-cf2a-4765-b056-0eab5e8eb96b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_67853941-32df-45ea-9197-47fcbf9b5b4f" xlink:href="sgmo-20191231.xsd#sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c8cb35e8-cf2a-4765-b056-0eab5e8eb96b" xlink:to="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_67853941-32df-45ea-9197-47fcbf9b5b4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_d9b3472a-82d3-4318-b81c-0868337eb83e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_447554ad-034c-40f9-a969-3b89558fb0bf" xlink:to="loc_us-gaap_ValuationTechniqueAxis_d9b3472a-82d3-4318-b81c-0868337eb83e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_d9b3472a-82d3-4318-b81c-0868337eb83e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_d9b3472a-82d3-4318-b81c-0868337eb83e" xlink:to="loc_us-gaap_ValuationTechniqueDomain_d9b3472a-82d3-4318-b81c-0868337eb83e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_1116aca2-cc27-4099-9ca6-aa9adc603034" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_d9b3472a-82d3-4318-b81c-0868337eb83e" xlink:to="loc_us-gaap_ValuationTechniqueDomain_1116aca2-cc27-4099-9ca6-aa9adc603034" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_f92371fc-84ea-492f-bc1a-1b69a588e8cb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_1116aca2-cc27-4099-9ca6-aa9adc603034" xlink:to="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_f92371fc-84ea-492f-bc1a-1b69a588e8cb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail" xlink:type="extended" id="i1d6f7f8087b7445eb4e835d9f294dbfb_004623ab-f182-4e05-9b78-c4fd5acef6fb">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_3554a2b9-179b-4897-95f5-fedaa0c8cc67" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_a8842398-dedf-4c4c-be02-6245b822db56" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_3554a2b9-179b-4897-95f5-fedaa0c8cc67" xlink:to="loc_us-gaap_SharePrice_a8842398-dedf-4c4c-be02-6245b822db56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_a7b3ba12-dcfd-4f19-ad1a-dddf012a3d6e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_3554a2b9-179b-4897-95f5-fedaa0c8cc67" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_a7b3ba12-dcfd-4f19-ad1a-dddf012a3d6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_29fccf29-d6f8-4655-8350-63e4621e1cd9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_3554a2b9-179b-4897-95f5-fedaa0c8cc67" xlink:to="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_29fccf29-d6f8-4655-8350-63e4621e1cd9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_54c7c893-08e6-43ce-b38e-2c921ed587b2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_3554a2b9-179b-4897-95f5-fedaa0c8cc67" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_54c7c893-08e6-43ce-b38e-2c921ed587b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput_c3daa093-ebf0-4cb1-9fc5-bb28e0e2d262" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_3554a2b9-179b-4897-95f5-fedaa0c8cc67" xlink:to="loc_us-gaap_DerivativeLiabilityMeasurementInput_c3daa093-ebf0-4cb1-9fc5-bb28e0e2d262" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DerivativeLiabilityTerm_e43c1625-eff1-41f1-a413-d4460a2a7c28" xlink:href="sgmo-20191231.xsd#sgmo_DerivativeLiabilityTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_3554a2b9-179b-4897-95f5-fedaa0c8cc67" xlink:to="loc_sgmo_DerivativeLiabilityTerm_e43c1625-eff1-41f1-a413-d4460a2a7c28" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d7437218-8b26-41d6-842c-ea784433d37b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_3554a2b9-179b-4897-95f5-fedaa0c8cc67" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d7437218-8b26-41d6-842c-ea784433d37b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_47b54aa9-7f56-4690-aeb6-f728f966a325" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d7437218-8b26-41d6-842c-ea784433d37b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_47b54aa9-7f56-4690-aeb6-f728f966a325" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_47b54aa9-7f56-4690-aeb6-f728f966a325_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_47b54aa9-7f56-4690-aeb6-f728f966a325" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_47b54aa9-7f56-4690-aeb6-f728f966a325_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7531eae3-39df-4069-b1f1-be1fe8fc03e3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_47b54aa9-7f56-4690-aeb6-f728f966a325" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7531eae3-39df-4069-b1f1-be1fe8fc03e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_d3de5f2c-a74e-4617-856b-fb6b348ab238" xlink:href="sgmo-20191231.xsd#sgmo_SangamoFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7531eae3-39df-4069-b1f1-be1fe8fc03e3" xlink:to="loc_sgmo_SangamoFranceMember_d3de5f2c-a74e-4617-856b-fb6b348ab238" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_ee0a6cb8-cefd-4acf-8584-872a9a040478" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d7437218-8b26-41d6-842c-ea784433d37b" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_ee0a6cb8-cefd-4acf-8584-872a9a040478" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_ee0a6cb8-cefd-4acf-8584-872a9a040478_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_ee0a6cb8-cefd-4acf-8584-872a9a040478" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_ee0a6cb8-cefd-4acf-8584-872a9a040478_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_a2367fdf-2ccd-4ae4-9215-fb8abf9dfead" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_ee0a6cb8-cefd-4acf-8584-872a9a040478" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_a2367fdf-2ccd-4ae4-9215-fb8abf9dfead" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember_a9d022f6-bdc1-47d5-9390-d2a8f395c9cb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_a2367fdf-2ccd-4ae4-9215-fb8abf9dfead" xlink:to="loc_us-gaap_MeasurementInputSharePriceMember_a9d022f6-bdc1-47d5-9390-d2a8f395c9cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember_ecb6086b-88b1-43d8-a55f-79112c4ffdf9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputOptionVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_a2367fdf-2ccd-4ae4-9215-fb8abf9dfead" xlink:to="loc_us-gaap_MeasurementInputOptionVolatilityMember_ecb6086b-88b1-43d8-a55f-79112c4ffdf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_7494030f-2541-4f05-b34e-92858e377635" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_a2367fdf-2ccd-4ae4-9215-fb8abf9dfead" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_7494030f-2541-4f05-b34e-92858e377635" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_d1add0ad-5e9f-4f6e-9d22-3873d04c8e10" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_a2367fdf-2ccd-4ae4-9215-fb8abf9dfead" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_d1add0ad-5e9f-4f6e-9d22-3873d04c8e10" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MeasurementInputStockPriceCorrelationMember_8833865f-41c5-46c3-a35f-365c29779b65" xlink:href="sgmo-20191231.xsd#sgmo_MeasurementInputStockPriceCorrelationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_a2367fdf-2ccd-4ae4-9215-fb8abf9dfead" xlink:to="loc_sgmo_MeasurementInputStockPriceCorrelationMember_8833865f-41c5-46c3-a35f-365c29779b65" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MarketableSecurities" xlink:type="simple" xlink:href="sgmo-20191231.xsd#MarketableSecurities"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MarketableSecurities" xlink:type="extended" id="ib6b7d89756a94ac2b45bfb9d176d07bf_a918224b-87b2-43b6-8b22-2ffdd1eadd3c"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="sgmo-20191231.xsd#MarketableSecuritiesTables"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MarketableSecuritiesTables" xlink:type="extended" id="i49ae727290d44b418c44bc2393adbd64_41ddc5d8-6eb7-4c1c-af2c-f4dd8aafd326"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="extended" id="i855fdd38c03d48cb9c31cc68f0931e53_935e4900-5f7d-4af3-972f-444877bf6136">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_525b3db8-e8d8-4384-acae-081fb532049e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_272dc21a-a461-4d3d-8bad-a0ed5576d5ac" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_525b3db8-e8d8-4384-acae-081fb532049e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_272dc21a-a461-4d3d-8bad-a0ed5576d5ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_b2637cf9-8f24-4dfa-9fd0-75435a8a164b" xlink:href="sgmo-20191231.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_525b3db8-e8d8-4384-acae-081fb532049e" xlink:to="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_b2637cf9-8f24-4dfa-9fd0-75435a8a164b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_9d1282e8-61d4-4b17-8e78-f3bf528fa371" xlink:href="sgmo-20191231.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_525b3db8-e8d8-4384-acae-081fb532049e" xlink:to="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_9d1282e8-61d4-4b17-8e78-f3bf528fa371" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0f5f4720-7607-4248-bd15-7a5ab7fc3b16" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_525b3db8-e8d8-4384-acae-081fb532049e" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0f5f4720-7607-4248-bd15-7a5ab7fc3b16" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0ade0b7-18e6-4934-b6e9-43ada7069c63" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_525b3db8-e8d8-4384-acae-081fb532049e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0ade0b7-18e6-4934-b6e9-43ada7069c63" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b513a559-cddd-4acc-abc5-e6d432374bf3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_525b3db8-e8d8-4384-acae-081fb532049e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b513a559-cddd-4acc-abc5-e6d432374bf3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2fc0c1cc-60fe-4c68-8d5a-02b3da8f3083" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_525b3db8-e8d8-4384-acae-081fb532049e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2fc0c1cc-60fe-4c68-8d5a-02b3da8f3083" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6359cd4e-73a1-49a3-82c1-3998751a178b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_525b3db8-e8d8-4384-acae-081fb532049e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6359cd4e-73a1-49a3-82c1-3998751a178b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_bfe3aecb-9ca7-4a80-b430-be25e896fcf1" xlink:href="sgmo-20191231.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_525b3db8-e8d8-4384-acae-081fb532049e" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_bfe3aecb-9ca7-4a80-b430-be25e896fcf1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_fa919198-386a-44dc-a01d-989ad4b81d27" xlink:href="sgmo-20191231.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_525b3db8-e8d8-4384-acae-081fb532049e" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_fa919198-386a-44dc-a01d-989ad4b81d27" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_b723052e-b0aa-4104-9313-692b9a34a167" xlink:href="sgmo-20191231.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_525b3db8-e8d8-4384-acae-081fb532049e" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_b723052e-b0aa-4104-9313-692b9a34a167" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_b700a816-71c9-48be-9d57-18bbcd782f75" xlink:href="sgmo-20191231.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_525b3db8-e8d8-4384-acae-081fb532049e" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_b700a816-71c9-48be-9d57-18bbcd782f75" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_d9401ce7-4db1-4d80-a84a-3885632a2929" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_525b3db8-e8d8-4384-acae-081fb532049e" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_d9401ce7-4db1-4d80-a84a-3885632a2929" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_56b7b793-94f4-4c40-be58-2748d28bd416" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_d9401ce7-4db1-4d80-a84a-3885632a2929" xlink:to="loc_us-gaap_FinancialInstrumentAxis_56b7b793-94f4-4c40-be58-2748d28bd416" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_56b7b793-94f4-4c40-be58-2748d28bd416_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_56b7b793-94f4-4c40-be58-2748d28bd416" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_56b7b793-94f4-4c40-be58-2748d28bd416_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2bf93bdd-d5b9-4f91-80dd-be9b677febdb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_56b7b793-94f4-4c40-be58-2748d28bd416" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2bf93bdd-d5b9-4f91-80dd-be9b677febdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_04717db8-2d59-432e-b6d0-c36a4f82f5ea" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2bf93bdd-d5b9-4f91-80dd-be9b677febdb" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_04717db8-2d59-432e-b6d0-c36a4f82f5ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_80f28fce-40aa-4b37-ac5d-0bd81230e8b3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2bf93bdd-d5b9-4f91-80dd-be9b677febdb" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_80f28fce-40aa-4b37-ac5d-0bd81230e8b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_4b38efb6-5df4-41e1-a3b7-e9a67d1c5e85" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_d9401ce7-4db1-4d80-a84a-3885632a2929" xlink:to="loc_us-gaap_InvestmentTypeAxis_4b38efb6-5df4-41e1-a3b7-e9a67d1c5e85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_4b38efb6-5df4-41e1-a3b7-e9a67d1c5e85_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_4b38efb6-5df4-41e1-a3b7-e9a67d1c5e85" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_4b38efb6-5df4-41e1-a3b7-e9a67d1c5e85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_3e62b3eb-7dd8-41a0-8ef6-3002b5db4a6e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_4b38efb6-5df4-41e1-a3b7-e9a67d1c5e85" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_3e62b3eb-7dd8-41a0-8ef6-3002b5db4a6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_54da57df-3cbd-492d-a32e-1cac5eea0100" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_3e62b3eb-7dd8-41a0-8ef6-3002b5db4a6e" xlink:to="loc_us-gaap_MoneyMarketFundsMember_54da57df-3cbd-492d-a32e-1cac5eea0100" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_61937654-f080-4f39-9e43-d6b4b2f1ec25" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_3e62b3eb-7dd8-41a0-8ef6-3002b5db4a6e" xlink:to="loc_us-gaap_CommercialPaperMember_61937654-f080-4f39-9e43-d6b4b2f1ec25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_9f57abed-6fec-4e77-9bc2-6984b31ab4e1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_3e62b3eb-7dd8-41a0-8ef6-3002b5db4a6e" xlink:to="loc_us-gaap_CashEquivalentsMember_9f57abed-6fec-4e77-9bc2-6984b31ab4e1" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#MarketableSecuritiesSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetail" xlink:type="extended" id="i4a4c2167351a48469aa844268895c006_f2154d06-6372-4660-a924-addcb270ab8a"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/MarketableSecuritiesAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#MarketableSecuritiesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MarketableSecuritiesAdditionalInformationDetail" xlink:type="extended" id="i9923feaffcce45afaf4146c1656f17a2_de1bacb8-1f22-4331-855b-8295ab3e3330"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliances" xlink:type="simple" xlink:href="sgmo-20191231.xsd#MajorCustomersPartnershipsandStrategicAlliances"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliances" xlink:type="extended" id="i8868fbba7121494bb1f56f2df2c101bf_67f5436f-faf4-426b-8654-dee6c91c8e2a"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesTables" xlink:type="simple" xlink:href="sgmo-20191231.xsd#MajorCustomersPartnershipsandStrategicAlliancesTables"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesTables" xlink:type="extended" id="i2c0544e646364c8e8ced6cdfedb641f2_3ed6af54-9729-4d84-9a0a-8078c0dcd80f">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_976c792d-7572-4fa1-a99b-9c803adca5ed" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_7214bfaa-59c0-4279-a85e-60abe7481085" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_976c792d-7572-4fa1-a99b-9c803adca5ed" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_7214bfaa-59c0-4279-a85e-60abe7481085" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_3aedf717-e976-4a60-807f-a85a965b6f88" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_976c792d-7572-4fa1-a99b-9c803adca5ed" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_3aedf717-e976-4a60-807f-a85a965b6f88" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ad244963-2f38-48d7-a3e5-d8f0b78b44d0" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_3aedf717-e976-4a60-807f-a85a965b6f88" xlink:to="loc_srt_CounterpartyNameAxis_ad244963-2f38-48d7-a3e5-d8f0b78b44d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ad244963-2f38-48d7-a3e5-d8f0b78b44d0_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_ad244963-2f38-48d7-a3e5-d8f0b78b44d0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ad244963-2f38-48d7-a3e5-d8f0b78b44d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88d93616-18cd-49ba-9abd-8a641d05fa57" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_ad244963-2f38-48d7-a3e5-d8f0b78b44d0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88d93616-18cd-49ba-9abd-8a641d05fa57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_1937cde3-173a-4839-b352-95f6949e9784" xlink:href="sgmo-20191231.xsd#sgmo_KitePharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88d93616-18cd-49ba-9abd-8a641d05fa57" xlink:to="loc_sgmo_KitePharmaIncMember_1937cde3-173a-4839-b352-95f6949e9784" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member_bb1adfe1-3774-45e3-892e-0b37c8673166" xlink:href="sgmo-20191231.xsd#sgmo_PfizerSB525Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88d93616-18cd-49ba-9abd-8a641d05fa57" xlink:to="loc_sgmo_PfizerSB525Member_bb1adfe1-3774-45e3-892e-0b37c8673166" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerC9ORF72Member_890df488-9323-4e60-b4dc-16efa27c4d59" xlink:href="sgmo-20191231.xsd#sgmo_PfizerC9ORF72Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88d93616-18cd-49ba-9abd-8a641d05fa57" xlink:to="loc_sgmo_PfizerC9ORF72Member_890df488-9323-4e60-b4dc-16efa27c4d59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_9123817d-9696-4848-9dc7-7c7284951eed" xlink:href="sgmo-20191231.xsd#sgmo_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88d93616-18cd-49ba-9abd-8a641d05fa57" xlink:to="loc_sgmo_SanofiMember_9123817d-9696-4848-9dc7-7c7284951eed" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail" xlink:type="extended" id="i1724812996a6466399ab0b5a8bfdcc21_6fc8d2d9-097e-4230-b238-526208342beb">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestonePaymentsReceived_fd090dbf-9581-4720-996c-c9bd8c044656" xlink:href="sgmo-20191231.xsd#sgmo_MilestonePaymentsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_sgmo_MilestonePaymentsReceived_fd090dbf-9581-4720-996c-c9bd8c044656" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_bd0345bf-648a-46f6-90fb-55be293890b4" xlink:href="sgmo-20191231.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_bd0345bf-648a-46f6-90fb-55be293890b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_5d24da54-3ce4-460e-9043-1c237905ba85" xlink:href="sgmo-20191231.xsd#sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_5d24da54-3ce4-460e-9043-1c237905ba85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_InitialResearchTermOfAgreement_be88c287-90d7-43c9-a7da-9d3d6884b031" xlink:href="sgmo-20191231.xsd#sgmo_InitialResearchTermOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_sgmo_InitialResearchTermOfAgreement_be88c287-90d7-43c9-a7da-9d3d6884b031" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfOptionsToExtendInitialResearchTerm_ca658785-9893-4c90-af56-d21c3e107fa4" xlink:href="sgmo-20191231.xsd#sgmo_NumberOfOptionsToExtendInitialResearchTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_sgmo_NumberOfOptionsToExtendInitialResearchTerm_ca658785-9893-4c90-af56-d21c3e107fa4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ExtendedResearchTermOfAgreement_44d80f94-4783-4e3b-ac6b-e259ace14957" xlink:href="sgmo-20191231.xsd#sgmo_ExtendedResearchTermOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_sgmo_ExtendedResearchTermOfAgreement_44d80f94-4783-4e3b-ac6b-e259ace14957" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SeparateUpfrontFee_2937c20e-519f-46d8-bda3-a3f5d5db24f8" xlink:href="sgmo-20191231.xsd#sgmo_SeparateUpfrontFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_sgmo_SeparateUpfrontFee_2937c20e-519f-46d8-bda3-a3f5d5db24f8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan_dd14cfce-5f37-4860-828c-484c054ccc7c" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan_dd14cfce-5f37-4860-828c-484c054ccc7c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementTransactionPrice_57aaedcb-88b4-455e-b154-784ed2ce17ca" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeArrangementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_sgmo_CollaborativeArrangementTransactionPrice_57aaedcb-88b4-455e-b154-784ed2ce17ca" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c7ea2fac-379c-45c6-8767-ea86fdaff10e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c7ea2fac-379c-45c6-8767-ea86fdaff10e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_956727dc-1d7e-4f6b-b356-6ccdea9a770e" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_956727dc-1d7e-4f6b-b356-6ccdea9a770e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AgreementTerminationTerm_6315be00-1737-40da-96f5-749910c79c68" xlink:href="sgmo-20191231.xsd#sgmo_AgreementTerminationTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_sgmo_AgreementTerminationTerm_6315be00-1737-40da-96f5-749910c79c68" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_8307fee4-7ff4-4f3e-9f8b-7252f235b426" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_us-gaap_ContractWithCustomerLiability_8307fee4-7ff4-4f3e-9f8b-7252f235b426" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_40a29834-865b-4575-b34e-7ed7959b4301" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_40a29834-865b-4575-b34e-7ed7959b4301" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue_0382bc72-2736-406c-b746-d27902adcac0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_us-gaap_DeferredRevenue_0382bc72-2736-406c-b746-d27902adcac0" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneRevenueReceivable_a08e47df-3351-4e77-805e-88a09970373e" xlink:href="sgmo-20191231.xsd#sgmo_MilestoneRevenueReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_sgmo_MilestoneRevenueReceivable_a08e47df-3351-4e77-805e-88a09970373e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7a20761c-3eea-4001-b50c-50f6c31c444d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7a20761c-3eea-4001-b50c-50f6c31c444d" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_237f1280-7231-44f4-a6a3-0c861f1c06e6" xlink:href="sgmo-20191231.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_237f1280-7231-44f4-a6a3-0c861f1c06e6" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_c5b8e22d-c2aa-4085-a3fc-0ea3230326c7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_c5b8e22d-c2aa-4085-a3fc-0ea3230326c7" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_91fcf04c-ef54-4aae-95a8-169a9edaae5f" xlink:href="sgmo-20191231.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_91fcf04c-ef54-4aae-95a8-169a9edaae5f" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_d6ff7c12-1ad4-4edf-b241-aaeb161ff27e" xlink:href="sgmo-20191231.xsd#sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_d6ff7c12-1ad4-4edf-b241-aaeb161ff27e" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementResearchServiceFees_92b32dbd-2dec-4f20-b54a-949e73b1a7cb" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeArrangementResearchServiceFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_sgmo_CollaborativeArrangementResearchServiceFees_92b32dbd-2dec-4f20-b54a-949e73b1a7cb" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GrantFundingAmount_56a23fab-a414-4d3c-8ba1-c1660fd2c0d7" xlink:href="sgmo-20191231.xsd#sgmo_GrantFundingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_sgmo_GrantFundingAmount_56a23fab-a414-4d3c-8ba1-c1660fd2c0d7" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_6b82dc80-0b2a-4932-9d7d-456af2c718ee" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_6b82dc80-0b2a-4932-9d7d-456af2c718ee" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_274cea36-ba60-42f9-aff4-7ebc4b06063a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_274cea36-ba60-42f9-aff4-7ebc4b06063a" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfResearchProgram_94692a40-2308-4a47-9a5e-322ec9f1610e" xlink:href="sgmo-20191231.xsd#sgmo_NumberOfResearchProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_sgmo_NumberOfResearchProgram_94692a40-2308-4a47-9a5e-322ec9f1610e" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_4113f95a-aa20-4688-847d-414469bdfd56" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_4113f95a-aa20-4688-847d-414469bdfd56" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2aa66d5c-9c20-4af7-a231-25397f1e3d9b" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_4113f95a-aa20-4688-847d-414469bdfd56" xlink:to="loc_srt_CounterpartyNameAxis_2aa66d5c-9c20-4af7-a231-25397f1e3d9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2aa66d5c-9c20-4af7-a231-25397f1e3d9b_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_2aa66d5c-9c20-4af7-a231-25397f1e3d9b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2aa66d5c-9c20-4af7-a231-25397f1e3d9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_17965fe2-b41b-4cc5-8fa6-89ecee7fc34f" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_2aa66d5c-9c20-4af7-a231-25397f1e3d9b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_17965fe2-b41b-4cc5-8fa6-89ecee7fc34f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_f6a99f99-5b78-4fa8-bf5d-6f5dca3c1876" xlink:href="sgmo-20191231.xsd#sgmo_KitePharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_17965fe2-b41b-4cc5-8fa6-89ecee7fc34f" xlink:to="loc_sgmo_KitePharmaIncMember_f6a99f99-5b78-4fa8-bf5d-6f5dca3c1876" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member_3e39fc4f-1f0d-40d1-9249-53b0d97369b9" xlink:href="sgmo-20191231.xsd#sgmo_PfizerSB525Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_17965fe2-b41b-4cc5-8fa6-89ecee7fc34f" xlink:to="loc_sgmo_PfizerSB525Member_3e39fc4f-1f0d-40d1-9249-53b0d97369b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerC9ORF72Member_8d56ad73-eb44-460e-b25e-fd24c5c5743b" xlink:href="sgmo-20191231.xsd#sgmo_PfizerC9ORF72Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_17965fe2-b41b-4cc5-8fa6-89ecee7fc34f" xlink:to="loc_sgmo_PfizerC9ORF72Member_8d56ad73-eb44-460e-b25e-fd24c5c5743b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_f5038442-f1b2-4131-a7e7-b0becbbfa1ce" xlink:href="sgmo-20191231.xsd#sgmo_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_17965fe2-b41b-4cc5-8fa6-89ecee7fc34f" xlink:to="loc_sgmo_SanofiMember_f5038442-f1b2-4131-a7e7-b0becbbfa1ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShireAgMember_86cc8cff-b928-430a-b8a5-88c61e3aefe9" xlink:href="sgmo-20191231.xsd#sgmo_ShireAgMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_17965fe2-b41b-4cc5-8fa6-89ecee7fc34f" xlink:to="loc_sgmo_ShireAgMember_86cc8cff-b928-430a-b8a5-88c61e3aefe9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_804907e7-908b-4e76-944f-88729bc2a5b4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_4113f95a-aa20-4688-847d-414469bdfd56" xlink:to="loc_us-gaap_TypeOfArrangementAxis_804907e7-908b-4e76-944f-88729bc2a5b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_804907e7-908b-4e76-944f-88729bc2a5b4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_804907e7-908b-4e76-944f-88729bc2a5b4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_804907e7-908b-4e76-944f-88729bc2a5b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_edcd489f-86e7-4916-bda5-ac084b95be7f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_804907e7-908b-4e76-944f-88729bc2a5b4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_edcd489f-86e7-4916-bda5-ac084b95be7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementMember_d5ed78ad-135b-48de-8305-a6e8987fdd7a" xlink:href="sgmo-20191231.xsd#sgmo_CollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_edcd489f-86e7-4916-bda5-ac084b95be7f" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementMember_d5ed78ad-135b-48de-8305-a6e8987fdd7a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AmendedCollaborationAndLicenseAgreementMember_13ffccc6-46d5-4fdf-b11b-74883b4aa2d8" xlink:href="sgmo-20191231.xsd#sgmo_AmendedCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_edcd489f-86e7-4916-bda5-ac084b95be7f" xlink:to="loc_sgmo_AmendedCollaborationAndLicenseAgreementMember_13ffccc6-46d5-4fdf-b11b-74883b4aa2d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_75453625-9b6e-4bdb-89bb-e071495320b7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_4113f95a-aa20-4688-847d-414469bdfd56" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_75453625-9b6e-4bdb-89bb-e071495320b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_75453625-9b6e-4bdb-89bb-e071495320b7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_75453625-9b6e-4bdb-89bb-e071495320b7" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_75453625-9b6e-4bdb-89bb-e071495320b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7cec9716-7d72-446f-953d-2f7c15f3aa56" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_75453625-9b6e-4bdb-89bb-e071495320b7" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7cec9716-7d72-446f-953d-2f7c15f3aa56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_572e8634-771d-44c1-bf3e-ae8bc871f860" xlink:href="sgmo-20191231.xsd#sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7cec9716-7d72-446f-953d-2f7c15f3aa56" xlink:to="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_572e8634-771d-44c1-bf3e-ae8bc871f860" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_9cfe866f-3746-4544-be26-56cab94aa415" xlink:href="sgmo-20191231.xsd#sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7cec9716-7d72-446f-953d-2f7c15f3aa56" xlink:to="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_9cfe866f-3746-4544-be26-56cab94aa415" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_27da2e50-bef7-40d6-90f0-617632d37817" xlink:href="sgmo-20191231.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7cec9716-7d72-446f-953d-2f7c15f3aa56" xlink:to="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_27da2e50-bef7-40d6-90f0-617632d37817" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_dc3369b4-6d34-4dc7-9fe0-38141708eb01" xlink:href="sgmo-20191231.xsd#sgmo_AchievementOfFirstCommercialSaleMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7cec9716-7d72-446f-953d-2f7c15f3aa56" xlink:to="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_dc3369b4-6d34-4dc7-9fe0-38141708eb01" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_60107ac4-814a-4346-af9d-67b73f03fd2f" xlink:href="sgmo-20191231.xsd#sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7cec9716-7d72-446f-953d-2f7c15f3aa56" xlink:to="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_60107ac4-814a-4346-af9d-67b73f03fd2f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfCommercialMilestonesMember_e88d9315-47be-4782-8344-bad8c53c0384" xlink:href="sgmo-20191231.xsd#sgmo_AchievementOfCommercialMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7cec9716-7d72-446f-953d-2f7c15f3aa56" xlink:to="loc_sgmo_AchievementOfCommercialMilestonesMember_e88d9315-47be-4782-8344-bad8c53c0384" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_a50fecc1-5100-4349-87a3-686bf2f551ed" xlink:href="sgmo-20191231.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7cec9716-7d72-446f-953d-2f7c15f3aa56" xlink:to="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_a50fecc1-5100-4349-87a3-686bf2f551ed" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesMilestonesMember_dd4dd2cc-98ec-4238-8915-858ec4b0f2d3" xlink:href="sgmo-20191231.xsd#sgmo_AchievementOfSpecifiedSalesMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7cec9716-7d72-446f-953d-2f7c15f3aa56" xlink:to="loc_sgmo_AchievementOfSpecifiedSalesMilestonesMember_dd4dd2cc-98ec-4238-8915-858ec4b0f2d3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_0f0095fa-a739-42b0-a9e4-48db53343543" xlink:href="sgmo-20191231.xsd#sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7cec9716-7d72-446f-953d-2f7c15f3aa56" xlink:to="loc_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_0f0095fa-a739-42b0-a9e4-48db53343543" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b84e2a93-0ece-4964-900a-6344a1162b7b" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_4113f95a-aa20-4688-847d-414469bdfd56" xlink:to="loc_srt_RangeAxis_b84e2a93-0ece-4964-900a-6344a1162b7b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b84e2a93-0ece-4964-900a-6344a1162b7b_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b84e2a93-0ece-4964-900a-6344a1162b7b" xlink:to="loc_srt_RangeMember_b84e2a93-0ece-4964-900a-6344a1162b7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1a543950-aaf3-42af-a41f-99bf567bfe4f" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b84e2a93-0ece-4964-900a-6344a1162b7b" xlink:to="loc_srt_RangeMember_1a543950-aaf3-42af-a41f-99bf567bfe4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6dd18c35-1848-4186-b479-d7f056bf54aa" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1a543950-aaf3-42af-a41f-99bf567bfe4f" xlink:to="loc_srt_MaximumMember_6dd18c35-1848-4186-b479-d7f056bf54aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4c0c49d6-5452-4636-97da-1a210a059e50" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1a543950-aaf3-42af-a41f-99bf567bfe4f" xlink:to="loc_srt_MinimumMember_4c0c49d6-5452-4636-97da-1a210a059e50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_488dca1e-eb25-492c-b521-91256bf48501" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_4113f95a-aa20-4688-847d-414469bdfd56" xlink:to="loc_srt_ProductOrServiceAxis_488dca1e-eb25-492c-b521-91256bf48501" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_488dca1e-eb25-492c-b521-91256bf48501_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_488dca1e-eb25-492c-b521-91256bf48501" xlink:to="loc_srt_ProductsAndServicesDomain_488dca1e-eb25-492c-b521-91256bf48501_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cdd81eec-180f-4ce0-8ca5-a36335ec0755" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_488dca1e-eb25-492c-b521-91256bf48501" xlink:to="loc_srt_ProductsAndServicesDomain_cdd81eec-180f-4ce0-8ca5-a36335ec0755" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SBFiveTwoFiveMember_ec3cfcc5-fc2f-49d8-a0bb-768acfae64da" xlink:href="sgmo-20191231.xsd#sgmo_SBFiveTwoFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cdd81eec-180f-4ce0-8ca5-a36335ec0755" xlink:to="loc_sgmo_SBFiveTwoFiveMember_ec3cfcc5-fc2f-49d8-a0bb-768acfae64da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OtherProductsMember_d37637dd-b371-4d61-8ca3-69d2e8137434" xlink:href="sgmo-20191231.xsd#sgmo_OtherProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cdd81eec-180f-4ce0-8ca5-a36335ec0755" xlink:to="loc_sgmo_OtherProductsMember_d37637dd-b371-4d61-8ca3-69d2e8137434" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_db62b136-c28f-41eb-b97d-b82257e2c000" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cdd81eec-180f-4ce0-8ca5-a36335ec0755" xlink:to="loc_us-gaap_LicenseAndServiceMember_db62b136-c28f-41eb-b97d-b82257e2c000" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CNineORFSevenTwoMember_2b6065ff-e49a-477e-881f-5a2508bc4984" xlink:href="sgmo-20191231.xsd#sgmo_CNineORFSevenTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cdd81eec-180f-4ce0-8ca5-a36335ec0755" xlink:to="loc_sgmo_CNineORFSevenTwoMember_2b6065ff-e49a-477e-881f-5a2508bc4984" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_fef20fdc-ff20-47b7-b50f-eb594ebd9ca0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cdd81eec-180f-4ce0-8ca5-a36335ec0755" xlink:to="loc_us-gaap_GrantMember_fef20fdc-ff20-47b7-b50f-eb594ebd9ca0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_d22fdf3e-c687-4a69-83ef-e41f6207a337" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_4113f95a-aa20-4688-847d-414469bdfd56" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_d22fdf3e-c687-4a69-83ef-e41f6207a337" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_d22fdf3e-c687-4a69-83ef-e41f6207a337_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_d22fdf3e-c687-4a69-83ef-e41f6207a337" xlink:to="loc_us-gaap_TypeOfAdoptionMember_d22fdf3e-c687-4a69-83ef-e41f6207a337_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_c05dd667-eb4c-4815-aed3-622b19e03fd6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_d22fdf3e-c687-4a69-83ef-e41f6207a337" xlink:to="loc_us-gaap_TypeOfAdoptionMember_c05dd667-eb4c-4815-aed3-622b19e03fd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_f7d54d04-45ed-4388-9c67-b5facfde1682" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_c05dd667-eb4c-4815-aed3-622b19e03fd6" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_f7d54d04-45ed-4388-9c67-b5facfde1682" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_14eb2aae-18ae-4d8b-a984-8f9aed2ea769" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_4113f95a-aa20-4688-847d-414469bdfd56" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_14eb2aae-18ae-4d8b-a984-8f9aed2ea769" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_14eb2aae-18ae-4d8b-a984-8f9aed2ea769_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_14eb2aae-18ae-4d8b-a984-8f9aed2ea769" xlink:to="loc_us-gaap_EquityComponentDomain_14eb2aae-18ae-4d8b-a984-8f9aed2ea769_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ae731456-4608-40ce-823a-9c7befaf60b1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_14eb2aae-18ae-4d8b-a984-8f9aed2ea769" xlink:to="loc_us-gaap_EquityComponentDomain_ae731456-4608-40ce-823a-9c7befaf60b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_59e656e4-e8a0-4efb-a071-84bb31ce3f36" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ae731456-4608-40ce-823a-9c7befaf60b1" xlink:to="loc_us-gaap_RetainedEarningsMember_59e656e4-e8a0-4efb-a071-84bb31ce3f36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneAxis_d28d0830-f0e2-4c1a-abea-9a8343462bea" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeAgreementMilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_4113f95a-aa20-4688-847d-414469bdfd56" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneAxis_d28d0830-f0e2-4c1a-abea-9a8343462bea" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneDomain_d28d0830-f0e2-4c1a-abea-9a8343462bea_default" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeAgreementMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneAxis_d28d0830-f0e2-4c1a-abea-9a8343462bea" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneDomain_d28d0830-f0e2-4c1a-abea-9a8343462bea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneDomain_f5493af6-13a5-48f4-bf3e-21c3bf8a7f04" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeAgreementMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneAxis_d28d0830-f0e2-4c1a-abea-9a8343462bea" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneDomain_f5493af6-13a5-48f4-bf3e-21c3bf8a7f04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneOneMember_9a3293c0-f074-4cf0-886e-9985d188696b" xlink:href="sgmo-20191231.xsd#sgmo_MilestoneOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_f5493af6-13a5-48f4-bf3e-21c3bf8a7f04" xlink:to="loc_sgmo_MilestoneOneMember_9a3293c0-f074-4cf0-886e-9985d188696b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneTwoMember_fc64e975-4da0-4c87-92e7-01f43aa0f6ec" xlink:href="sgmo-20191231.xsd#sgmo_MilestoneTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_f5493af6-13a5-48f4-bf3e-21c3bf8a7f04" xlink:to="loc_sgmo_MilestoneTwoMember_fc64e975-4da0-4c87-92e7-01f43aa0f6ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneThreeMember_4ab15779-808a-4e8e-b84b-281f6edb206c" xlink:href="sgmo-20191231.xsd#sgmo_MilestoneThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_f5493af6-13a5-48f4-bf3e-21c3bf8a7f04" xlink:to="loc_sgmo_MilestoneThreeMember_4ab15779-808a-4e8e-b84b-281f6edb206c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail" xlink:type="extended" id="i992250f0cb2c4210b33e32ff4a40e50f_e3cde8de-ad12-4042-8b7e-2cc9fbc21439">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d6ef5281-0dff-4f26-a69a-f94ae60abeae" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_2e73d0fc-03c9-4713-9b5d-c48bd91929b5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d6ef5281-0dff-4f26-a69a-f94ae60abeae" xlink:to="loc_us-gaap_RevenuesAbstract_2e73d0fc-03c9-4713-9b5d-c48bd91929b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ec89dd9b-cbc7-4f96-93dc-a1fa80020f85" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_2e73d0fc-03c9-4713-9b5d-c48bd91929b5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ec89dd9b-cbc7-4f96-93dc-a1fa80020f85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_ef965f37-394a-4f1b-bf0f-c01677306144" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d6ef5281-0dff-4f26-a69a-f94ae60abeae" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_ef965f37-394a-4f1b-bf0f-c01677306144" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f3950e5c-f403-4242-8d7a-fd110a1e9660" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_ef965f37-394a-4f1b-bf0f-c01677306144" xlink:to="loc_srt_CounterpartyNameAxis_f3950e5c-f403-4242-8d7a-fd110a1e9660" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f3950e5c-f403-4242-8d7a-fd110a1e9660_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_f3950e5c-f403-4242-8d7a-fd110a1e9660" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f3950e5c-f403-4242-8d7a-fd110a1e9660_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_62aafcc3-9e3b-4ff1-bf6d-4a78eae3c5d4" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_f3950e5c-f403-4242-8d7a-fd110a1e9660" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_62aafcc3-9e3b-4ff1-bf6d-4a78eae3c5d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_bd377872-2396-4db3-a300-2d108f9279cd" xlink:href="sgmo-20191231.xsd#sgmo_KitePharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_62aafcc3-9e3b-4ff1-bf6d-4a78eae3c5d4" xlink:to="loc_sgmo_KitePharmaIncMember_bd377872-2396-4db3-a300-2d108f9279cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_ce2ff98d-7256-4cb8-be7e-a0e01d99f3de" xlink:href="sgmo-20191231.xsd#sgmo_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_62aafcc3-9e3b-4ff1-bf6d-4a78eae3c5d4" xlink:to="loc_sgmo_SanofiMember_ce2ff98d-7256-4cb8-be7e-a0e01d99f3de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member_1a110246-40e7-4774-80c7-75704a254a19" xlink:href="sgmo-20191231.xsd#sgmo_PfizerSB525Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_62aafcc3-9e3b-4ff1-bf6d-4a78eae3c5d4" xlink:to="loc_sgmo_PfizerSB525Member_1a110246-40e7-4774-80c7-75704a254a19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4935563f-c1fa-4133-8281-68a03d67523e" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_ef965f37-394a-4f1b-bf0f-c01677306144" xlink:to="loc_srt_ProductOrServiceAxis_4935563f-c1fa-4133-8281-68a03d67523e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4935563f-c1fa-4133-8281-68a03d67523e_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4935563f-c1fa-4133-8281-68a03d67523e" xlink:to="loc_srt_ProductsAndServicesDomain_4935563f-c1fa-4133-8281-68a03d67523e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_329f6b52-cd91-43b9-a339-13198f28e15b" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4935563f-c1fa-4133-8281-68a03d67523e" xlink:to="loc_srt_ProductsAndServicesDomain_329f6b52-cd91-43b9-a339-13198f28e15b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_c25b69ff-acdd-4880-a270-d75e57517159" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_329f6b52-cd91-43b9-a339-13198f28e15b" xlink:to="loc_us-gaap_LicenseAndServiceMember_c25b69ff-acdd-4880-a270-d75e57517159" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_64f80bb9-1615-43fa-9f56-291ca0ded56e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchServicesMember_472a6723-739e-4e9d-a7cd-36cdf3651f36" xlink:href="sgmo-20191231.xsd#sgmo_ResearchServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_329f6b52-cd91-43b9-a339-13198f28e15b" xlink:to="loc_sgmo_ResearchServicesMember_472a6723-739e-4e9d-a7cd-36cdf3651f36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneAchievementMember_4a6af99d-57bb-43c0-acdc-b3f55f8c60e4" xlink:href="sgmo-20191231.xsd#sgmo_MilestoneAchievementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_329f6b52-cd91-43b9-a339-13198f28e15b" xlink:to="loc_sgmo_MilestoneAchievementMember_4a6af99d-57bb-43c0-acdc-b3f55f8c60e4" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationAdditionalInformationDetail" xlink:type="extended" id="ie393ab98ea1442dea83ca8c331ee41d9_9ce1da9f-c4f0-49c8-9f91-3c63614ea7bb">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b6811e70-657c-42be-b1dc-dc2493f6607b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchServicesPeriod_c5081ab1-2aa3-4484-96ed-9e70051fa135" xlink:href="sgmo-20191231.xsd#sgmo_ResearchServicesPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b6811e70-657c-42be-b1dc-dc2493f6607b" xlink:to="loc_sgmo_ResearchServicesPeriod_c5081ab1-2aa3-4484-96ed-9e70051fa135" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_b5bbcb6a-f1c2-4a8c-9825-633c1a0c4c9f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b6811e70-657c-42be-b1dc-dc2493f6607b" xlink:to="loc_us-gaap_ContractWithCustomerLiability_b5bbcb6a-f1c2-4a8c-9825-633c1a0c4c9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7eebd405-33a3-4408-9804-612783679bb8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b6811e70-657c-42be-b1dc-dc2493f6607b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7eebd405-33a3-4408-9804-612783679bb8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_97467c8d-5c63-42da-b767-db865e1d8d3e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b6811e70-657c-42be-b1dc-dc2493f6607b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_97467c8d-5c63-42da-b767-db865e1d8d3e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_6dae22fe-af03-4bde-950f-946a211bf2be" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b6811e70-657c-42be-b1dc-dc2493f6607b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_6dae22fe-af03-4bde-950f-946a211bf2be" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ReducedRoyaltyRate_7f08e70a-99f7-41e8-9d89-35f649a0ae22" xlink:href="sgmo-20191231.xsd#sgmo_ReducedRoyaltyRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b6811e70-657c-42be-b1dc-dc2493f6607b" xlink:to="loc_sgmo_ReducedRoyaltyRate_7f08e70a-99f7-41e8-9d89-35f649a0ae22" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_2ebbe23a-fe21-48d6-b666-e86d0c6200a2" xlink:href="sgmo-20191231.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b6811e70-657c-42be-b1dc-dc2493f6607b" xlink:to="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_2ebbe23a-fe21-48d6-b666-e86d0c6200a2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8e3a1c2b-6a8f-48aa-8257-e611beb06275" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b6811e70-657c-42be-b1dc-dc2493f6607b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8e3a1c2b-6a8f-48aa-8257-e611beb06275" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_bb915f2e-860f-4bd7-adf4-6f923a690c44" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b6811e70-657c-42be-b1dc-dc2493f6607b" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_bb915f2e-860f-4bd7-adf4-6f923a690c44" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_dc4250d9-5b97-4879-8330-1466499219a7" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_bb915f2e-860f-4bd7-adf4-6f923a690c44" xlink:to="loc_srt_CounterpartyNameAxis_dc4250d9-5b97-4879-8330-1466499219a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc4250d9-5b97-4879-8330-1466499219a7_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_dc4250d9-5b97-4879-8330-1466499219a7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc4250d9-5b97-4879-8330-1466499219a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ed3a1d58-4785-4127-873e-a6d6fdef2f70" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_dc4250d9-5b97-4879-8330-1466499219a7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ed3a1d58-4785-4127-873e-a6d6fdef2f70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SigmaAldrichCorporationMember_2ed57d2f-f76d-4662-bb42-d7675e10a397" xlink:href="sgmo-20191231.xsd#sgmo_SigmaAldrichCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ed3a1d58-4785-4127-873e-a6d6fdef2f70" xlink:to="loc_sgmo_SigmaAldrichCorporationMember_2ed57d2f-f76d-4662-bb42-d7675e10a397" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b13afad3-3b7a-41da-8554-c9694872f64a" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_bb915f2e-860f-4bd7-adf4-6f923a690c44" xlink:to="loc_srt_ProductOrServiceAxis_b13afad3-3b7a-41da-8554-c9694872f64a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b13afad3-3b7a-41da-8554-c9694872f64a_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b13afad3-3b7a-41da-8554-c9694872f64a" xlink:to="loc_srt_ProductsAndServicesDomain_b13afad3-3b7a-41da-8554-c9694872f64a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a5b81730-a34c-4deb-81c0-c3271a1d4179" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b13afad3-3b7a-41da-8554-c9694872f64a" xlink:to="loc_srt_ProductsAndServicesDomain_a5b81730-a34c-4deb-81c0-c3271a1d4179" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_9b5573c2-8941-4046-82fd-332a5a59890a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a5b81730-a34c-4deb-81c0-c3271a1d4179" xlink:to="loc_us-gaap_LicenseMember_9b5573c2-8941-4046-82fd-332a5a59890a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_7b556415-e0f2-4343-b18e-db9f3f0903a9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_bb915f2e-860f-4bd7-adf4-6f923a690c44" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_7b556415-e0f2-4343-b18e-db9f3f0903a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7b556415-e0f2-4343-b18e-db9f3f0903a9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_7b556415-e0f2-4343-b18e-db9f3f0903a9" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7b556415-e0f2-4343-b18e-db9f3f0903a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d15fcb56-d5b1-4548-96ad-db84cb9cdde4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_7b556415-e0f2-4343-b18e-db9f3f0903a9" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d15fcb56-d5b1-4548-96ad-db84cb9cdde4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_5963980a-4705-46c7-9df0-477de08acc39" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d15fcb56-d5b1-4548-96ad-db84cb9cdde4" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_5963980a-4705-46c7-9df0-477de08acc39" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDowAgroSciencesinPlantAgricultureAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDowAgroSciencesinPlantAgricultureAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDowAgroSciencesinPlantAgricultureAdditionalInformationDetail" xlink:type="extended" id="i3954cd9a67a34c48ad438b365ba26c0d_9d916694-af5c-474c-94ea-fb1c6dc511d5">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a861defa-59a1-4e7d-b0dd-327d6f9f887e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_InitialResearchTermOfAgreement_856f02f1-a569-498c-b8ff-1d6cb1e8730b" xlink:href="sgmo-20191231.xsd#sgmo_InitialResearchTermOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a861defa-59a1-4e7d-b0dd-327d6f9f887e" xlink:to="loc_sgmo_InitialResearchTermOfAgreement_856f02f1-a569-498c-b8ff-1d6cb1e8730b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OneTimeLicenseFeeEarned_be28d3d0-ccf1-4e44-a419-70c529f405ad" xlink:href="sgmo-20191231.xsd#sgmo_OneTimeLicenseFeeEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a861defa-59a1-4e7d-b0dd-327d6f9f887e" xlink:to="loc_sgmo_OneTimeLicenseFeeEarned_be28d3d0-ccf1-4e44-a419-70c529f405ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_91dd600c-3545-43eb-b25f-ca7c98ba8e1d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a861defa-59a1-4e7d-b0dd-327d6f9f887e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_91dd600c-3545-43eb-b25f-ca7c98ba8e1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement_78ee5270-01aa-4a1c-87e8-ff9b30fa8c0e" xlink:href="sgmo-20191231.xsd#sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a861defa-59a1-4e7d-b0dd-327d6f9f887e" xlink:to="loc_sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement_78ee5270-01aa-4a1c-87e8-ff9b30fa8c0e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing_2344905a-9dd9-40db-ac33-3382f03e5a17" xlink:href="sgmo-20191231.xsd#sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a861defa-59a1-4e7d-b0dd-327d6f9f887e" xlink:to="loc_sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing_2344905a-9dd9-40db-ac33-3382f03e5a17" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AnnualFeesRelatedToAgreement_273356cd-d39a-41f8-aa70-f613a6cea05c" xlink:href="sgmo-20191231.xsd#sgmo_AnnualFeesRelatedToAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a861defa-59a1-4e7d-b0dd-327d6f9f887e" xlink:to="loc_sgmo_AnnualFeesRelatedToAgreement_273356cd-d39a-41f8-aa70-f613a6cea05c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FeeDue_c8ecd242-de17-4dbb-ae0f-271f5718b61d" xlink:href="sgmo-20191231.xsd#sgmo_FeeDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a861defa-59a1-4e7d-b0dd-327d6f9f887e" xlink:to="loc_sgmo_FeeDue_c8ecd242-de17-4dbb-ae0f-271f5718b61d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod_18becc2b-96fe-4bba-a046-6cb2a85a513e" xlink:href="sgmo-20191231.xsd#sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a861defa-59a1-4e7d-b0dd-327d6f9f887e" xlink:to="loc_sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod_18becc2b-96fe-4bba-a046-6cb2a85a513e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_268d3562-e832-4114-b3dd-250d74cb2c04" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a861defa-59a1-4e7d-b0dd-327d6f9f887e" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_268d3562-e832-4114-b3dd-250d74cb2c04" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_829b6bfe-8076-4a57-a465-ff89c3196bd7" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_268d3562-e832-4114-b3dd-250d74cb2c04" xlink:to="loc_srt_CounterpartyNameAxis_829b6bfe-8076-4a57-a465-ff89c3196bd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_829b6bfe-8076-4a57-a465-ff89c3196bd7_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_829b6bfe-8076-4a57-a465-ff89c3196bd7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_829b6bfe-8076-4a57-a465-ff89c3196bd7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_be038c91-756c-42a8-9703-2fe00fa93e08" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_829b6bfe-8076-4a57-a465-ff89c3196bd7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_be038c91-756c-42a8-9703-2fe00fa93e08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DowAgroSciencesMember_18e07110-3ce0-4739-80dd-1923db9fc7dd" xlink:href="sgmo-20191231.xsd#sgmo_DowAgroSciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_be038c91-756c-42a8-9703-2fe00fa93e08" xlink:to="loc_sgmo_DowAgroSciencesMember_18e07110-3ce0-4739-80dd-1923db9fc7dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_336fe979-ce35-4d8f-9250-6e1eaac1f51c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_268d3562-e832-4114-b3dd-250d74cb2c04" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_336fe979-ce35-4d8f-9250-6e1eaac1f51c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_336fe979-ce35-4d8f-9250-6e1eaac1f51c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_336fe979-ce35-4d8f-9250-6e1eaac1f51c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_336fe979-ce35-4d8f-9250-6e1eaac1f51c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f824e69c-4d5d-4ed2-bfcc-68ddb5a6adeb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_336fe979-ce35-4d8f-9250-6e1eaac1f51c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f824e69c-4d5d-4ed2-bfcc-68ddb5a6adeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_86c5c09e-f3b0-46bc-b88d-4342f6610a18" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f824e69c-4d5d-4ed2-bfcc-68ddb5a6adeb" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_86c5c09e-f3b0-46bc-b88d-4342f6610a18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9c5937d4-7eb6-4283-8ae5-afcd2938e1b1" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_268d3562-e832-4114-b3dd-250d74cb2c04" xlink:to="loc_srt_ProductOrServiceAxis_9c5937d4-7eb6-4283-8ae5-afcd2938e1b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9c5937d4-7eb6-4283-8ae5-afcd2938e1b1_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9c5937d4-7eb6-4283-8ae5-afcd2938e1b1" xlink:to="loc_srt_ProductsAndServicesDomain_9c5937d4-7eb6-4283-8ae5-afcd2938e1b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4d253378-c350-4928-aeb9-2406dff0443b" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9c5937d4-7eb6-4283-8ae5-afcd2938e1b1" xlink:to="loc_srt_ProductsAndServicesDomain_4d253378-c350-4928-aeb9-2406dff0443b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_255f3fdf-db31-4582-a0a7-c4590070564a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4d253378-c350-4928-aeb9-2406dff0443b" xlink:to="loc_us-gaap_RoyaltyMember_255f3fdf-db31-4582-a0a7-c4590070564a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_f7bbe043-2144-414c-9236-f274a9d8eb62" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4d253378-c350-4928-aeb9-2406dff0443b" xlink:to="loc_us-gaap_LicenseMember_f7bbe043-2144-414c-9236-f274a9d8eb62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0d23cbd5-3d7f-4d58-b823-0ed12a1d3660" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_268d3562-e832-4114-b3dd-250d74cb2c04" xlink:to="loc_srt_RangeAxis_0d23cbd5-3d7f-4d58-b823-0ed12a1d3660" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0d23cbd5-3d7f-4d58-b823-0ed12a1d3660_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0d23cbd5-3d7f-4d58-b823-0ed12a1d3660" xlink:to="loc_srt_RangeMember_0d23cbd5-3d7f-4d58-b823-0ed12a1d3660_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_74f796ed-69f5-46de-9a93-4cf614e6b560" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0d23cbd5-3d7f-4d58-b823-0ed12a1d3660" xlink:to="loc_srt_RangeMember_74f796ed-69f5-46de-9a93-4cf614e6b560" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e4c2a78e-def9-4a0b-a636-bd6763187a96" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_74f796ed-69f5-46de-9a93-4cf614e6b560" xlink:to="loc_srt_MinimumMember_e4c2a78e-def9-4a0b-a636-bd6763187a96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1e53e5bb-7822-48c3-b733-b706eaca1311" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_74f796ed-69f5-46de-9a93-4cf614e6b560" xlink:to="loc_srt_MaximumMember_1e53e5bb-7822-48c3-b733-b706eaca1311" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/AcquisitionofSangamoFrance" xlink:type="simple" xlink:href="sgmo-20191231.xsd#AcquisitionofSangamoFrance"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/AcquisitionofSangamoFrance" xlink:type="extended" id="i8bb66160eb554b988072f04fe5ecb0a3_8ab31053-2543-4cae-a7a7-cb9e9b6adb50"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/AcquisitionofAcquisitionofSangamoFranceTables" xlink:type="simple" xlink:href="sgmo-20191231.xsd#AcquisitionofAcquisitionofSangamoFranceTables"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/AcquisitionofAcquisitionofSangamoFranceTables" xlink:type="extended" id="if94f6296fcf44bc68edddc55489683a9_4e073dd3-d254-4433-bd8f-54c6f2f06189"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#AcquisitionofSangamoFranceAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail" xlink:type="extended" id="icde6408029b845878e66988aca225881_42032347-3374-4eb9-9394-0d45f0436fb4">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_5d2e24b2-46b4-4c02-8092-202608f85230" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_31521002-d70f-401d-b7de-685c4185a638" xlink:href="sgmo-20191231.xsd#sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5d2e24b2-46b4-4c02-8092-202608f85230" xlink:to="loc_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_31521002-d70f-401d-b7de-685c4185a638" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_d2d83b06-d54d-4d35-8c9e-c5bd08e9009b" xlink:href="sgmo-20191231.xsd#sgmo_BusinessAcquisitionNumberOfSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5d2e24b2-46b4-4c02-8092-202608f85230" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_d2d83b06-d54d-4d35-8c9e-c5bd08e9009b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_c698601c-3567-422d-bbc7-677a3a0e872f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5d2e24b2-46b4-4c02-8092-202608f85230" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_c698601c-3567-422d-bbc7-677a3a0e872f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_8031edad-5a09-46af-b6f5-391805fddc31" xlink:href="sgmo-20191231.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5d2e24b2-46b4-4c02-8092-202608f85230" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_8031edad-5a09-46af-b6f5-391805fddc31" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_72068dbd-0cfc-4f0e-ac45-6e8cbc34e2db" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5d2e24b2-46b4-4c02-8092-202608f85230" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_72068dbd-0cfc-4f0e-ac45-6e8cbc34e2db" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_c9e75e79-2b9e-4086-851e-26c891de435b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5d2e24b2-46b4-4c02-8092-202608f85230" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_c9e75e79-2b9e-4086-851e-26c891de435b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_7d47347d-2e54-488d-a13c-25bb0a65db96" xlink:href="sgmo-20191231.xsd#sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5d2e24b2-46b4-4c02-8092-202608f85230" xlink:to="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_7d47347d-2e54-488d-a13c-25bb0a65db96" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_a081103d-353b-46a0-9ec9-c82954e84645" xlink:href="sgmo-20191231.xsd#sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5d2e24b2-46b4-4c02-8092-202608f85230" xlink:to="loc_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_a081103d-353b-46a0-9ec9-c82954e84645" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_c7ea0cb6-d508-409c-89d6-7acdd615751b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5d2e24b2-46b4-4c02-8092-202608f85230" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_c7ea0cb6-d508-409c-89d6-7acdd615751b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_eba44c82-16b4-4cb5-b7f4-477731e7a156" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5d2e24b2-46b4-4c02-8092-202608f85230" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_eba44c82-16b4-4cb5-b7f4-477731e7a156" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction_6c4f627b-f354-40d4-82f8-a03eada4acdf" xlink:href="sgmo-20191231.xsd#sgmo_BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5d2e24b2-46b4-4c02-8092-202608f85230" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction_6c4f627b-f354-40d4-82f8-a03eada4acdf" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b7ac5c3-70ad-4a8f-bf28-a086eee23199" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5d2e24b2-46b4-4c02-8092-202608f85230" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b7ac5c3-70ad-4a8f-bf28-a086eee23199" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_4e4ae090-f060-476d-8469-b61c18c6d59d" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b7ac5c3-70ad-4a8f-bf28-a086eee23199" xlink:to="loc_srt_OwnershipAxis_4e4ae090-f060-476d-8469-b61c18c6d59d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_4e4ae090-f060-476d-8469-b61c18c6d59d_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_4e4ae090-f060-476d-8469-b61c18c6d59d" xlink:to="loc_srt_OwnershipDomain_4e4ae090-f060-476d-8469-b61c18c6d59d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_9b4b8706-d3de-468e-b6a8-4671cbb63685" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_4e4ae090-f060-476d-8469-b61c18c6d59d" xlink:to="loc_srt_OwnershipDomain_9b4b8706-d3de-468e-b6a8-4671cbb63685" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_ff0cb910-588a-4d7a-8ace-3245f71ab908" xlink:href="sgmo-20191231.xsd#sgmo_SangamoFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_9b4b8706-d3de-468e-b6a8-4671cbb63685" xlink:to="loc_sgmo_SangamoFranceMember_ff0cb910-588a-4d7a-8ace-3245f71ab908" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_87d6e342-3635-47b8-8ddc-2fd87af5b700" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b7ac5c3-70ad-4a8f-bf28-a086eee23199" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_87d6e342-3635-47b8-8ddc-2fd87af5b700" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_87d6e342-3635-47b8-8ddc-2fd87af5b700_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_87d6e342-3635-47b8-8ddc-2fd87af5b700" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_87d6e342-3635-47b8-8ddc-2fd87af5b700_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5c90bd72-0cc0-4e5f-8fc1-9aa06a7dd372" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_87d6e342-3635-47b8-8ddc-2fd87af5b700" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5c90bd72-0cc0-4e5f-8fc1-9aa06a7dd372" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_a5e15c31-a22f-47eb-a3f1-e2b0b11a9110" xlink:href="sgmo-20191231.xsd#sgmo_SangamoFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5c90bd72-0cc0-4e5f-8fc1-9aa06a7dd372" xlink:to="loc_sgmo_SangamoFranceMember_a5e15c31-a22f-47eb-a3f1-e2b0b11a9110" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e255f130-eb2e-4648-934a-fa557b83d3d1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b7ac5c3-70ad-4a8f-bf28-a086eee23199" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e255f130-eb2e-4648-934a-fa557b83d3d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e255f130-eb2e-4648-934a-fa557b83d3d1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e255f130-eb2e-4648-934a-fa557b83d3d1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e255f130-eb2e-4648-934a-fa557b83d3d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_df0fafe7-02ef-48b6-aca5-6968176ef3c9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e255f130-eb2e-4648-934a-fa557b83d3d1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_df0fafe7-02ef-48b6-aca5-6968176ef3c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_777db76e-edd5-4055-9ae0-9aa734b9a951" xlink:href="sgmo-20191231.xsd#sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_df0fafe7-02ef-48b6-aca5-6968176ef3c9" xlink:to="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_777db76e-edd5-4055-9ae0-9aa734b9a951" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SharePurchaseAgreementMember_d74f66f2-6d87-4b40-a779-230e7620c1bd" xlink:href="sgmo-20191231.xsd#sgmo_SharePurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_df0fafe7-02ef-48b6-aca5-6968176ef3c9" xlink:to="loc_sgmo_SharePurchaseAgreementMember_d74f66f2-6d87-4b40-a779-230e7620c1bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_98a9fd16-a39b-4046-a989-c8c7f2c6e342" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b7ac5c3-70ad-4a8f-bf28-a086eee23199" xlink:to="loc_srt_CounterpartyNameAxis_98a9fd16-a39b-4046-a989-c8c7f2c6e342" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_98a9fd16-a39b-4046-a989-c8c7f2c6e342_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_98a9fd16-a39b-4046-a989-c8c7f2c6e342" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_98a9fd16-a39b-4046-a989-c8c7f2c6e342_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9bd1814c-c497-4c67-9f51-e39fbe4d3887" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_98a9fd16-a39b-4046-a989-c8c7f2c6e342" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9bd1814c-c497-4c67-9f51-e39fbe4d3887" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FormerExecutiveOfSangamoFranceMember_0dfca530-5933-48c4-9559-4841d655085d" xlink:href="sgmo-20191231.xsd#sgmo_FormerExecutiveOfSangamoFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9bd1814c-c497-4c67-9f51-e39fbe4d3887" xlink:to="loc_sgmo_FormerExecutiveOfSangamoFranceMember_0dfca530-5933-48c4-9559-4841d655085d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_7e9ba9e1-22b0-45aa-a5e2-a56239924f2c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b7ac5c3-70ad-4a8f-bf28-a086eee23199" xlink:to="loc_us-gaap_ValuationTechniqueAxis_7e9ba9e1-22b0-45aa-a5e2-a56239924f2c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_7e9ba9e1-22b0-45aa-a5e2-a56239924f2c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_7e9ba9e1-22b0-45aa-a5e2-a56239924f2c" xlink:to="loc_us-gaap_ValuationTechniqueDomain_7e9ba9e1-22b0-45aa-a5e2-a56239924f2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_eb425fd4-4f97-48c5-a699-5bcf41d77bf4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_7e9ba9e1-22b0-45aa-a5e2-a56239924f2c" xlink:to="loc_us-gaap_ValuationTechniqueDomain_eb425fd4-4f97-48c5-a699-5bcf41d77bf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_3536cc9e-50c3-4a0f-b15d-b3d8994f4ef9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_eb425fd4-4f97-48c5-a699-5bcf41d77bf4" xlink:to="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_3536cc9e-50c3-4a0f-b15d-b3d8994f4ef9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofEstimatedFairValueofNetAssetsAcquiredDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#AcquisitionofSangamoFranceSummaryofEstimatedFairValueofNetAssetsAcquiredDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofEstimatedFairValueofNetAssetsAcquiredDetail" xlink:type="extended" id="i69148ab613004b49a192354d18a8238b_0b6f553b-3abd-44bd-87e0-dbe61761bc8b">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_d3690929-cd9b-4818-98bc-cba1fdddfde3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_79ebafe9-236e-46ee-9b9b-0ff763233471" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d3690929-cd9b-4818-98bc-cba1fdddfde3" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_79ebafe9-236e-46ee-9b9b-0ff763233471" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_50f446b1-b63f-428b-a194-8f0ef6f9d23a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d3690929-cd9b-4818-98bc-cba1fdddfde3" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_50f446b1-b63f-428b-a194-8f0ef6f9d23a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_d87dadf7-ed69-45df-8cc5-842f9028b9fc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d3690929-cd9b-4818-98bc-cba1fdddfde3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_d87dadf7-ed69-45df-8cc5-842f9028b9fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_9ecce745-3140-42b0-baba-ce37f81f226f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d3690929-cd9b-4818-98bc-cba1fdddfde3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_9ecce745-3140-42b0-baba-ce37f81f226f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_3deac9fc-611f-4b22-9b98-b05b98713476" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d3690929-cd9b-4818-98bc-cba1fdddfde3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_3deac9fc-611f-4b22-9b98-b05b98713476" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_dcf15336-4af3-4a47-8c3d-e575aca85625" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d3690929-cd9b-4818-98bc-cba1fdddfde3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_dcf15336-4af3-4a47-8c3d-e575aca85625" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_7b358a40-fd09-4b52-a4e9-200619e7106a" xlink:href="sgmo-20191231.xsd#sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d3690929-cd9b-4818-98bc-cba1fdddfde3" xlink:to="loc_sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_7b358a40-fd09-4b52-a4e9-200619e7106a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_b308c3e9-fc73-4f21-93ba-abe0aa744518" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d3690929-cd9b-4818-98bc-cba1fdddfde3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_b308c3e9-fc73-4f21-93ba-abe0aa744518" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_d5aad161-c125-49c6-b9d3-8aa6234b0114" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d3690929-cd9b-4818-98bc-cba1fdddfde3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_d5aad161-c125-49c6-b9d3-8aa6234b0114" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1f06be0a-541d-4c6d-a1f3-cad252334ad6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d3690929-cd9b-4818-98bc-cba1fdddfde3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1f06be0a-541d-4c6d-a1f3-cad252334ad6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_a12f6f8b-7ae5-46d6-84ba-7a48d874cbe5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d3690929-cd9b-4818-98bc-cba1fdddfde3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_a12f6f8b-7ae5-46d6-84ba-7a48d874cbe5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_275c3d35-83d6-47e1-8dab-6b21f8c0c007" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d3690929-cd9b-4818-98bc-cba1fdddfde3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_275c3d35-83d6-47e1-8dab-6b21f8c0c007" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0cbc90f9-9c60-420a-abe3-257481017141" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d3690929-cd9b-4818-98bc-cba1fdddfde3" xlink:to="loc_us-gaap_Goodwill_0cbc90f9-9c60-420a-abe3-257481017141" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_26ae6830-4f00-4934-81b6-d0d909a51cf3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3b3fe61b-bc5c-4e9c-8f5b-37c383e64bcf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d3690929-cd9b-4818-98bc-cba1fdddfde3" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3b3fe61b-bc5c-4e9c-8f5b-37c383e64bcf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9899ee57-1f39-4c9c-ac9e-37069e12dbf4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3b3fe61b-bc5c-4e9c-8f5b-37c383e64bcf" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9899ee57-1f39-4c9c-ac9e-37069e12dbf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9899ee57-1f39-4c9c-ac9e-37069e12dbf4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9899ee57-1f39-4c9c-ac9e-37069e12dbf4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9899ee57-1f39-4c9c-ac9e-37069e12dbf4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b722756e-2c95-46a3-94c9-10bd13cde758" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9899ee57-1f39-4c9c-ac9e-37069e12dbf4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b722756e-2c95-46a3-94c9-10bd13cde758" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_bca927d2-f3e3-4849-8167-296e030496a3" xlink:href="sgmo-20191231.xsd#sgmo_SangamoFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b722756e-2c95-46a3-94c9-10bd13cde758" xlink:to="loc_sgmo_SangamoFranceMember_bca927d2-f3e3-4849-8167-296e030496a3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail" xlink:type="extended" id="i9bb3dceced6741aca7d1c47209319cbc_6bd2c3ab-db2e-49d6-ab14-fc53536ce756">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_0312f60c-f5a3-4917-ba5a-c667728cff86" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward_ea4a56a1-020e-49da-8e55-6a6130828504" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_0312f60c-f5a3-4917-ba5a-c667728cff86" xlink:to="loc_us-gaap_MovementInMinorityInterestRollForward_ea4a56a1-020e-49da-8e55-6a6130828504" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_0eb9e648-f0a7-4908-ac33-cd4c82a2105f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_ea4a56a1-020e-49da-8e55-6a6130828504" xlink:to="loc_us-gaap_MinorityInterest_0eb9e648-f0a7-4908-ac33-cd4c82a2105f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_c9b96495-b72f-4366-bc72-8e7199a5fa11" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_ea4a56a1-020e-49da-8e55-6a6130828504" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_c9b96495-b72f-4366-bc72-8e7199a5fa11" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_30f88f6e-fa56-4316-8f7e-322d6494cbdc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_ea4a56a1-020e-49da-8e55-6a6130828504" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_30f88f6e-fa56-4316-8f7e-322d6494cbdc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_15faf4d5-4f41-43a1-8fdd-c28aec8923c8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_782d2743-1627-4324-8111-b23005a0f150" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_0312f60c-f5a3-4917-ba5a-c667728cff86" xlink:to="loc_us-gaap_MinorityInterestTable_782d2743-1627-4324-8111-b23005a0f150" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2e31641f-a3e1-41a8-b57c-118579e989bd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_782d2743-1627-4324-8111-b23005a0f150" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2e31641f-a3e1-41a8-b57c-118579e989bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2e31641f-a3e1-41a8-b57c-118579e989bd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2e31641f-a3e1-41a8-b57c-118579e989bd" xlink:to="loc_us-gaap_EquityComponentDomain_2e31641f-a3e1-41a8-b57c-118579e989bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_27819fac-ac97-4599-b8cc-432b23de0bc3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2e31641f-a3e1-41a8-b57c-118579e989bd" xlink:to="loc_us-gaap_EquityComponentDomain_27819fac-ac97-4599-b8cc-432b23de0bc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_ba0cd24e-ec83-4a4c-855b-3ff857a925dc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_27819fac-ac97-4599-b8cc-432b23de0bc3" xlink:to="loc_us-gaap_NoncontrollingInterestMember_ba0cd24e-ec83-4a4c-855b-3ff857a925dc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/OtherBalanceSheetDetails" xlink:type="simple" xlink:href="sgmo-20191231.xsd#OtherBalanceSheetDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/OtherBalanceSheetDetails" xlink:type="extended" id="id2b3a093764d4ac1aaac2802cba91e63_58a6a64e-6aaf-4c8d-a7b0-f3d73ee3bcd5"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/OtherBalanceSheetDetailsTables" xlink:type="simple" xlink:href="sgmo-20191231.xsd#OtherBalanceSheetDetailsTables"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/OtherBalanceSheetDetailsTables" xlink:type="extended" id="idc943c93b5484cb0b9824a9f275493d0_fbb61a47-af53-4296-8453-69ed60c19f8d"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/OtherBalanceSheetDetailsDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#OtherBalanceSheetDetailsDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/OtherBalanceSheetDetailsDetail" xlink:type="extended" id="i0ae127706e684080846ae53f60677902_f0bfbf72-5f8a-4f80-a175-331498556152">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6e44026a-c967-4328-b508-b1bf062d3277" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_e3eaee29-7ea0-4e8c-880c-b298af3c1639" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6e44026a-c967-4328-b508-b1bf062d3277" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_e3eaee29-7ea0-4e8c-880c-b298af3c1639" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c628c473-56a7-4783-ac3d-6b5e588f29ce" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6e44026a-c967-4328-b508-b1bf062d3277" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c628c473-56a7-4783-ac3d-6b5e588f29ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_58c5e657-ca3c-4c03-b9fe-b3e44ff9669a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6e44026a-c967-4328-b508-b1bf062d3277" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_58c5e657-ca3c-4c03-b9fe-b3e44ff9669a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1d2b9a1f-413e-4178-af78-0ab2dd7641c6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6e44026a-c967-4328-b508-b1bf062d3277" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1d2b9a1f-413e-4178-af78-0ab2dd7641c6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_83626b33-895b-4805-bb4b-b56164ae552e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1d2b9a1f-413e-4178-af78-0ab2dd7641c6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_83626b33-895b-4805-bb4b-b56164ae552e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_83626b33-895b-4805-bb4b-b56164ae552e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_83626b33-895b-4805-bb4b-b56164ae552e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_83626b33-895b-4805-bb4b-b56164ae552e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1766ee5c-1fc6-4a5e-9706-11b93be529ff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_83626b33-895b-4805-bb4b-b56164ae552e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1766ee5c-1fc6-4a5e-9706-11b93be529ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_601007e1-8e49-4a35-b988-bb2d68231e4d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1766ee5c-1fc6-4a5e-9706-11b93be529ff" xlink:to="loc_us-gaap_EquipmentMember_601007e1-8e49-4a35-b988-bb2d68231e4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_0fd26654-8d99-4b4b-a4fb-c0ad97463424" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1766ee5c-1fc6-4a5e-9706-11b93be529ff" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_0fd26654-8d99-4b4b-a4fb-c0ad97463424" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_cf4a41f6-fd85-4ce5-8d22-288ee08f6a65" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1766ee5c-1fc6-4a5e-9706-11b93be529ff" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_cf4a41f6-fd85-4ce5-8d22-288ee08f6a65" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_6e5af103-fa67-48d3-be66-6f6528a7b589" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1766ee5c-1fc6-4a5e-9706-11b93be529ff" xlink:to="loc_us-gaap_BuildingMember_6e5af103-fa67-48d3-be66-6f6528a7b589" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_d2087de6-0a59-4d9c-b6ff-bfd8cdcd2334" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1766ee5c-1fc6-4a5e-9706-11b93be529ff" xlink:to="loc_us-gaap_ConstructionInProgressMember_d2087de6-0a59-4d9c-b6ff-bfd8cdcd2334" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/OtherBalanceSheetDetailsScheduleofIntangibleAssetsandGoodwillDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#OtherBalanceSheetDetailsScheduleofIntangibleAssetsandGoodwillDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/OtherBalanceSheetDetailsScheduleofIntangibleAssetsandGoodwillDetail" xlink:type="extended" id="i08c2dbad88ff4850a567ffc79487825a_5f14423d-6826-41c3-9f69-c2ff98d0ad02"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail" xlink:type="extended" id="ifb5e2d3b179b41768df9bb835ed1d99d_6e70b9c7-fa10-42a5-bb72-6d5677ef86b5"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="sgmo-20191231.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CommitmentsandContingencies" xlink:type="extended" id="i5cf2c47640df4b1796170464b89e2d62_36c0c752-8663-476b-8bf5-9e8c5e1ed40b"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="sgmo-20191231.xsd#CommitmentsandContingenciesTables"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CommitmentsandContingenciesTables" xlink:type="extended" id="i1a2dd7835d86495db2f1f10ee7cd54b8_9a0e0258-ff39-4445-ace2-d737e78509a8"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended" id="ia9ab2014b9374466816c1fc680d54497_9d3649ae-1043-4147-a241-b5a9258f486c">
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommitmentsAndContingenciesLineItems_b5171e1d-1982-4aa8-84ed-3b72558c99df" xlink:href="sgmo-20191231.xsd#sgmo_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_ba10b1dc-4a6d-45a5-9416-fb83115d0bbd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b5171e1d-1982-4aa8-84ed-3b72558c99df" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_ba10b1dc-4a6d-45a5-9416-fb83115d0bbd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_1fe6bf11-83f9-4c3c-beae-6f6cf13fd5d7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b5171e1d-1982-4aa8-84ed-3b72558c99df" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_1fe6bf11-83f9-4c3c-beae-6f6cf13fd5d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseLiabilityTenantImprovementAllowance_b715f825-a2e7-4464-a13e-ea027a96a618" xlink:href="sgmo-20191231.xsd#sgmo_LesseeOperatingLeaseLiabilityTenantImprovementAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b5171e1d-1982-4aa8-84ed-3b72558c99df" xlink:to="loc_sgmo_LesseeOperatingLeaseLiabilityTenantImprovementAllowance_b715f825-a2e7-4464-a13e-ea027a96a618" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance_f2b2f0e7-1124-4e6f-9e1e-0cb633a90877" xlink:href="sgmo-20191231.xsd#sgmo_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b5171e1d-1982-4aa8-84ed-3b72558c99df" xlink:to="loc_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance_f2b2f0e7-1124-4e6f-9e1e-0cb633a90877" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_5565c401-b790-4be2-b5e4-9fd0970b39a5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b5171e1d-1982-4aa8-84ed-3b72558c99df" xlink:to="loc_us-gaap_OperatingLeaseCost_5565c401-b790-4be2-b5e4-9fd0970b39a5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_54ac3108-af95-441a-8d4c-20433c37714f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b5171e1d-1982-4aa8-84ed-3b72558c99df" xlink:to="loc_us-gaap_VariableLeaseCost_54ac3108-af95-441a-8d4c-20433c37714f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_9dbdb7f7-6721-4815-880b-22734a22b817" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b5171e1d-1982-4aa8-84ed-3b72558c99df" xlink:to="loc_us-gaap_OperatingLeasePayments_9dbdb7f7-6721-4815-880b-22734a22b817" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_6b52e94e-f131-4218-8b4a-2e0f38139755" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b5171e1d-1982-4aa8-84ed-3b72558c99df" xlink:to="loc_us-gaap_OperatingLeaseExpense_6b52e94e-f131-4218-8b4a-2e0f38139755" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_80262df9-76b2-4369-b758-dc1674b2df1b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b5171e1d-1982-4aa8-84ed-3b72558c99df" xlink:to="loc_us-gaap_LeaseAndRentalExpense_80262df9-76b2-4369-b758-dc1674b2df1b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1e19fb40-6622-4014-ab1e-b8844befec4b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b5171e1d-1982-4aa8-84ed-3b72558c99df" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1e19fb40-6622-4014-ab1e-b8844befec4b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_dfd0a88d-4c1f-415c-a41b-21d98c15a36a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b5171e1d-1982-4aa8-84ed-3b72558c99df" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_dfd0a88d-4c1f-415c-a41b-21d98c15a36a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LicenseObligations_e089cd50-24bd-47e0-8457-327370bd3521" xlink:href="sgmo-20191231.xsd#sgmo_LicenseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b5171e1d-1982-4aa8-84ed-3b72558c99df" xlink:to="loc_sgmo_LicenseObligations_e089cd50-24bd-47e0-8457-327370bd3521" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PaymentsForOtherCommitment_1babb612-3e75-4235-8a14-e4aad56315b0" xlink:href="sgmo-20191231.xsd#sgmo_PaymentsForOtherCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b5171e1d-1982-4aa8-84ed-3b72558c99df" xlink:to="loc_sgmo_PaymentsForOtherCommitment_1babb612-3e75-4235-8a14-e4aad56315b0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_07b25a43-fccc-48ff-a2c8-96ce92c95d4b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b5171e1d-1982-4aa8-84ed-3b72558c99df" xlink:to="loc_us-gaap_OtherCommitment_07b25a43-fccc-48ff-a2c8-96ce92c95d4b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_36b71455-0af3-4b66-b44c-663dc4fe899a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b5171e1d-1982-4aa8-84ed-3b72558c99df" xlink:to="loc_us-gaap_ContractualObligation_36b71455-0af3-4b66-b44c-663dc4fe899a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContractualObligationPaidUponExecution_29fb1914-7b8b-406a-9dc8-7338c55f5169" xlink:href="sgmo-20191231.xsd#sgmo_ContractualObligationPaidUponExecution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b5171e1d-1982-4aa8-84ed-3b72558c99df" xlink:to="loc_sgmo_ContractualObligationPaidUponExecution_29fb1914-7b8b-406a-9dc8-7338c55f5169" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommitmentsAndContingenciesTable_9493d59d-8549-409b-8603-29fe0647fc13" xlink:href="sgmo-20191231.xsd#sgmo_CommitmentsAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b5171e1d-1982-4aa8-84ed-3b72558c99df" xlink:to="loc_sgmo_CommitmentsAndContingenciesTable_9493d59d-8549-409b-8603-29fe0647fc13" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e15a72b6-8109-4bda-9ccd-2757c8c2b9bd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_9493d59d-8549-409b-8603-29fe0647fc13" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e15a72b6-8109-4bda-9ccd-2757c8c2b9bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e15a72b6-8109-4bda-9ccd-2757c8c2b9bd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e15a72b6-8109-4bda-9ccd-2757c8c2b9bd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e15a72b6-8109-4bda-9ccd-2757c8c2b9bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e8ae0080-5213-40dc-b397-c7b56df26d02" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e15a72b6-8109-4bda-9ccd-2757c8c2b9bd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e8ae0080-5213-40dc-b397-c7b56df26d02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchAndOfficeSpaceMember_7aaf14ce-e913-4d80-9b0e-475820687e42" xlink:href="sgmo-20191231.xsd#sgmo_ResearchAndOfficeSpaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e8ae0080-5213-40dc-b397-c7b56df26d02" xlink:to="loc_sgmo_ResearchAndOfficeSpaceMember_7aaf14ce-e913-4d80-9b0e-475820687e42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OfficeAndLaboratoryMember_b88f7146-a273-4e4d-a58a-e906a0ac3abf" xlink:href="sgmo-20191231.xsd#sgmo_OfficeAndLaboratoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e8ae0080-5213-40dc-b397-c7b56df26d02" xlink:to="loc_sgmo_OfficeAndLaboratoryMember_b88f7146-a273-4e4d-a58a-e906a0ac3abf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OfficeSpaceMember_fef6687a-b097-4995-bfa1-e60a830e4a00" xlink:href="sgmo-20191231.xsd#sgmo_OfficeSpaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e8ae0080-5213-40dc-b397-c7b56df26d02" xlink:to="loc_sgmo_OfficeSpaceMember_fef6687a-b097-4995-bfa1-e60a830e4a00" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f7beab08-78f7-4010-afc4-046e7d0cd124" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_9493d59d-8549-409b-8603-29fe0647fc13" xlink:to="loc_srt_StatementGeographicalAxis_f7beab08-78f7-4010-afc4-046e7d0cd124" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f7beab08-78f7-4010-afc4-046e7d0cd124_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_f7beab08-78f7-4010-afc4-046e7d0cd124" xlink:to="loc_srt_SegmentGeographicalDomain_f7beab08-78f7-4010-afc4-046e7d0cd124_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3847e7ab-4ab9-4fae-bea7-b57e07d40d16" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_f7beab08-78f7-4010-afc4-046e7d0cd124" xlink:to="loc_srt_SegmentGeographicalDomain_3847e7ab-4ab9-4fae-bea7-b57e07d40d16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BrisbaneCaliforniaMember_8b5ca85a-aaac-41c6-bab3-33c1dd8f0620" xlink:href="sgmo-20191231.xsd#sgmo_BrisbaneCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_3847e7ab-4ab9-4fae-bea7-b57e07d40d16" xlink:to="loc_sgmo_BrisbaneCaliforniaMember_8b5ca85a-aaac-41c6-bab3-33c1dd8f0620" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RichmondCaliforniaMember_fb8a6dda-85b7-4d15-b0cc-b7a9e0019e90" xlink:href="sgmo-20191231.xsd#sgmo_RichmondCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_3847e7ab-4ab9-4fae-bea7-b57e07d40d16" xlink:to="loc_sgmo_RichmondCaliforniaMember_fb8a6dda-85b7-4d15-b0cc-b7a9e0019e90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ValbonneFranceMember_e9a126d1-afde-4b5f-a1ad-c9464fd976f8" xlink:href="sgmo-20191231.xsd#sgmo_ValbonneFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_3847e7ab-4ab9-4fae-bea7-b57e07d40d16" xlink:to="loc_sgmo_ValbonneFranceMember_e9a126d1-afde-4b5f-a1ad-c9464fd976f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5c9b142d-17bb-441e-9d84-23abc4bc8a62" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_9493d59d-8549-409b-8603-29fe0647fc13" xlink:to="loc_srt_RangeAxis_5c9b142d-17bb-441e-9d84-23abc4bc8a62" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5c9b142d-17bb-441e-9d84-23abc4bc8a62_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5c9b142d-17bb-441e-9d84-23abc4bc8a62" xlink:to="loc_srt_RangeMember_5c9b142d-17bb-441e-9d84-23abc4bc8a62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_61d4c283-5456-4ddb-99b8-b848ad498555" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5c9b142d-17bb-441e-9d84-23abc4bc8a62" xlink:to="loc_srt_RangeMember_61d4c283-5456-4ddb-99b8-b848ad498555" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_90f1c922-ab1d-4111-bd53-4627583dcc0a" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_61d4c283-5456-4ddb-99b8-b848ad498555" xlink:to="loc_srt_MinimumMember_90f1c922-ab1d-4111-bd53-4627583dcc0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2c180360-a1e1-4045-a55c-126b922d7327" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_61d4c283-5456-4ddb-99b8-b848ad498555" xlink:to="loc_srt_MaximumMember_2c180360-a1e1-4045-a55c-126b922d7327" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_1c88a1f6-40c3-4932-a31f-5a2897052cf5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_9493d59d-8549-409b-8603-29fe0647fc13" xlink:to="loc_us-gaap_OtherCommitmentsAxis_1c88a1f6-40c3-4932-a31f-5a2897052cf5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_1c88a1f6-40c3-4932-a31f-5a2897052cf5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_1c88a1f6-40c3-4932-a31f-5a2897052cf5" xlink:to="loc_us-gaap_OtherCommitmentsDomain_1c88a1f6-40c3-4932-a31f-5a2897052cf5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_98efa02e-3f2a-4c70-a5bf-28623acb614f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_1c88a1f6-40c3-4932-a31f-5a2897052cf5" xlink:to="loc_us-gaap_OtherCommitmentsDomain_98efa02e-3f2a-4c70-a5bf-28623acb614f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ManufacturingCapacityMember_e7c83631-a621-4124-9623-ea0fc9e0f954" xlink:href="sgmo-20191231.xsd#sgmo_ManufacturingCapacityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_98efa02e-3f2a-4c70-a5bf-28623acb614f" xlink:to="loc_sgmo_ManufacturingCapacityMember_e7c83631-a621-4124-9623-ea0fc9e0f954" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ManufacturingObligationsMember_7cf27c96-953c-4be8-8c36-c38ce7e7aa26" xlink:href="sgmo-20191231.xsd#sgmo_ManufacturingObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_98efa02e-3f2a-4c70-a5bf-28623acb614f" xlink:to="loc_sgmo_ManufacturingObligationsMember_7cf27c96-953c-4be8-8c36-c38ce7e7aa26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NonCancelableContractualCommitmentMember_a25a29ba-542c-4b8f-8ef9-de9634c47c8e" xlink:href="sgmo-20191231.xsd#sgmo_NonCancelableContractualCommitmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_98efa02e-3f2a-4c70-a5bf-28623acb614f" xlink:to="loc_sgmo_NonCancelableContractualCommitmentMember_a25a29ba-542c-4b8f-8ef9-de9634c47c8e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail" xlink:type="extended" id="i09fe56fa6ab44faba36c1a54b49d2b46_4bfc43de-8f6d-49e9-a2df-6b4d0b2cd727"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockholdersEquity" xlink:type="simple" xlink:href="sgmo-20191231.xsd#StockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/StockholdersEquity" xlink:type="extended" id="i22a0d450cef445d0bb52dd941cc48ab1_fde526c7-48fd-4f5a-a990-18d9a8cee8b5"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="sgmo-20191231.xsd#StockholdersEquityTables"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/StockholdersEquityTables" xlink:type="extended" id="id3303f37c6e240dba50b812f084e9198_d64608c3-a9c3-4e02-b972-fcea2f21a680"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#StockholdersEquityAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail" xlink:type="extended" id="i193f5e9f0e8646078568ea3f00fcbc86_941c035a-1725-4b0f-9c17-de9da0dbdd3d">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_451b7b4e-0c60-4b01-9640-dcb6485e0ae0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_451b7b4e-0c60-4b01-9640-dcb6485e0ae0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2414e421-2466-4690-99c1-f033714f77e8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2414e421-2466-4690-99c1-f033714f77e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_d040cabc-4db6-4d35-8b56-0d695261ec24" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_d040cabc-4db6-4d35-8b56-0d695261ec24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NetProceedsFromIssuancePublicOffering_ccf0e745-8b63-45eb-8caf-be6227c96f90" xlink:href="sgmo-20191231.xsd#sgmo_NetProceedsFromIssuancePublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_sgmo_NetProceedsFromIssuancePublicOffering_ccf0e745-8b63-45eb-8caf-be6227c96f90" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_1c3d4711-4cbb-485e-8484-fd11c0bb8cef" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_1c3d4711-4cbb-485e-8484-fd11c0bb8cef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7758ba53-5f9b-45ab-89af-ac228cc6b106" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7758ba53-5f9b-45ab-89af-ac228cc6b106" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SpecifiedStockholderOwnershipPercentage_a8198b5d-ef1a-4ea9-95c9-f972aa0d446a" xlink:href="sgmo-20191231.xsd#sgmo_SpecifiedStockholderOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_sgmo_SpecifiedStockholderOwnershipPercentage_a8198b5d-ef1a-4ea9-95c9-f972aa0d446a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder_5f6eed9e-691d-465e-b215-71898ddc8e65" xlink:href="sgmo-20191231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder_5f6eed9e-691d-465e-b215-71898ddc8e65" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder_7e24ca0b-491f-49a3-84ee-12ddc128ff92" xlink:href="sgmo-20191231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder_7e24ca0b-491f-49a3-84ee-12ddc128ff92" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4cdc7f4c-4b6d-4dc3-a705-8108af00366a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4cdc7f4c-4b6d-4dc3-a705-8108af00366a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0c10af8d-e4f2-4898-8b98-a64ae0dbe203" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0c10af8d-e4f2-4898-8b98-a64ae0dbe203" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm_2edc649e-af16-44ff-8565-1ccaccec62f4" xlink:href="sgmo-20191231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm_2edc649e-af16-44ff-8565-1ccaccec62f4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommonStockExchangeRatio_33e7167e-75b5-4c39-8952-f19e22c370e2" xlink:href="sgmo-20191231.xsd#sgmo_CommonStockExchangeRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_sgmo_CommonStockExchangeRatio_33e7167e-75b5-4c39-8952-f19e22c370e2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_e185cbf5-1f4e-49f7-9b4a-1a00bade3231" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_e185cbf5-1f4e-49f7-9b4a-1a00bade3231" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_aaaa5471-da73-41c2-b1fb-0f6827615f6e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_aaaa5471-da73-41c2-b1fb-0f6827615f6e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_492dbb24-f683-48b8-996f-36d51d159c99" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_492dbb24-f683-48b8-996f-36d51d159c99" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PurchasePlanOfferingPeriod_d70a8fb2-2d30-4dd5-84a9-116fefc7f325" xlink:href="sgmo-20191231.xsd#sgmo_PurchasePlanOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_sgmo_PurchasePlanOfferingPeriod_d70a8fb2-2d30-4dd5-84a9-116fefc7f325" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PurchasePlanPurchasePeriod_eab717ec-b083-4200-88ba-7b9f35f5d38d" xlink:href="sgmo-20191231.xsd#sgmo_PurchasePlanPurchasePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_sgmo_PurchasePlanPurchasePeriod_eab717ec-b083-4200-88ba-7b9f35f5d38d" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_23a12722-456a-4f41-8348-a95cb0e42af2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_23a12722-456a-4f41-8348-a95cb0e42af2" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_a3f81435-c81f-4093-9dfd-4afb7596c93f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_a3f81435-c81f-4093-9dfd-4afb7596c93f" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c0371959-2477-4951-9d70-cf26b237e899" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c0371959-2477-4951-9d70-cf26b237e899" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cfe56e50-899a-42ef-b671-8a9e3adfdd41" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cfe56e50-899a-42ef-b671-8a9e3adfdd41" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7ba8c519-2fd7-40bd-8848-9c2ae62cd646" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7ba8c519-2fd7-40bd-8848-9c2ae62cd646" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment_1ebacd36-8142-4654-b5d1-fbe365c273fc" xlink:href="sgmo-20191231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment_1ebacd36-8142-4654-b5d1-fbe365c273fc" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_077c94ba-34c0-414f-a7b3-e31deec53718" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_077c94ba-34c0-414f-a7b3-e31deec53718" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_7a88a5ce-50b6-4a96-bf93-5c79dc2413b9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_7a88a5ce-50b6-4a96-bf93-5c79dc2413b9" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_18039db9-d09e-4403-a422-a819f4dc216c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_18039db9-d09e-4403-a422-a819f4dc216c" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_72020a0f-b822-455f-a75a-7d134449beb1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_72020a0f-b822-455f-a75a-7d134449beb1" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7898ec6d-5b2e-420e-b894-6c6dedb15058" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7898ec6d-5b2e-420e-b894-6c6dedb15058" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d3bcedaa-f418-4926-b32e-a29d23246944" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7898ec6d-5b2e-420e-b894-6c6dedb15058" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d3bcedaa-f418-4926-b32e-a29d23246944" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d3bcedaa-f418-4926-b32e-a29d23246944_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d3bcedaa-f418-4926-b32e-a29d23246944" xlink:to="loc_us-gaap_EquityComponentDomain_d3bcedaa-f418-4926-b32e-a29d23246944_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d6a11994-cc4c-401d-8636-888ee939a781" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d3bcedaa-f418-4926-b32e-a29d23246944" xlink:to="loc_us-gaap_EquityComponentDomain_d6a11994-cc4c-401d-8636-888ee939a781" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9eb656b5-ea33-4c25-898b-311fa6458d7f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d6a11994-cc4c-401d-8636-888ee939a781" xlink:to="loc_us-gaap_CommonStockMember_9eb656b5-ea33-4c25-898b-311fa6458d7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2a12894f-513c-4443-9836-58580460017b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7898ec6d-5b2e-420e-b894-6c6dedb15058" xlink:to="loc_us-gaap_AwardTypeAxis_2a12894f-513c-4443-9836-58580460017b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2a12894f-513c-4443-9836-58580460017b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2a12894f-513c-4443-9836-58580460017b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2a12894f-513c-4443-9836-58580460017b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2b9530ca-a1c0-4ac8-8060-4fd59552acaa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2a12894f-513c-4443-9836-58580460017b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2b9530ca-a1c0-4ac8-8060-4fd59552acaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9a693d85-7835-4475-9975-f4ae255207a7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2b9530ca-a1c0-4ac8-8060-4fd59552acaa" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9a693d85-7835-4475-9975-f4ae255207a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1e79e448-e25c-4863-b2e2-3dc87e1c32f1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2b9530ca-a1c0-4ac8-8060-4fd59552acaa" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1e79e448-e25c-4863-b2e2-3dc87e1c32f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b1cf6d3f-784d-498f-97e6-3b2ae9fc0901" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7898ec6d-5b2e-420e-b894-6c6dedb15058" xlink:to="loc_srt_RangeAxis_b1cf6d3f-784d-498f-97e6-3b2ae9fc0901" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b1cf6d3f-784d-498f-97e6-3b2ae9fc0901_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b1cf6d3f-784d-498f-97e6-3b2ae9fc0901" xlink:to="loc_srt_RangeMember_b1cf6d3f-784d-498f-97e6-3b2ae9fc0901_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b68a6f4f-2be8-4978-8a16-8ea80b9fe6e9" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b1cf6d3f-784d-498f-97e6-3b2ae9fc0901" xlink:to="loc_srt_RangeMember_b68a6f4f-2be8-4978-8a16-8ea80b9fe6e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_12d4136e-5d23-4b40-a5f9-e52de0b19589" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b68a6f4f-2be8-4978-8a16-8ea80b9fe6e9" xlink:to="loc_srt_MaximumMember_12d4136e-5d23-4b40-a5f9-e52de0b19589" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_596b7871-d802-4e5b-86d7-6df767b17c9f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7898ec6d-5b2e-420e-b894-6c6dedb15058" xlink:to="loc_us-gaap_PlanNameAxis_596b7871-d802-4e5b-86d7-6df767b17c9f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_596b7871-d802-4e5b-86d7-6df767b17c9f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_596b7871-d802-4e5b-86d7-6df767b17c9f" xlink:to="loc_us-gaap_PlanNameDomain_596b7871-d802-4e5b-86d7-6df767b17c9f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d68ecd7c-7477-4854-9f77-a8aa1074f7a7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_596b7871-d802-4e5b-86d7-6df767b17c9f" xlink:to="loc_us-gaap_PlanNameDomain_d68ecd7c-7477-4854-9f77-a8aa1074f7a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_TwoThousandThirteenStockIncentivePlanMember_0d37eb04-d085-4e1c-a448-f943119615ca" xlink:href="sgmo-20191231.xsd#sgmo_TwoThousandThirteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d68ecd7c-7477-4854-9f77-a8aa1074f7a7" xlink:to="loc_sgmo_TwoThousandThirteenStockIncentivePlanMember_0d37eb04-d085-4e1c-a448-f943119615ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember_865a4487-14d3-4efc-98b5-024268158689" xlink:href="sgmo-20191231.xsd#sgmo_AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d68ecd7c-7477-4854-9f77-a8aa1074f7a7" xlink:to="loc_sgmo_AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember_865a4487-14d3-4efc-98b5-024268158689" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_TwoThousandEighteenStockIncentivePlanMember_6f22ccb0-0b2e-484d-8bf2-7142b063daf7" xlink:href="sgmo-20191231.xsd#sgmo_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d68ecd7c-7477-4854-9f77-a8aa1074f7a7" xlink:to="loc_sgmo_TwoThousandEighteenStockIncentivePlanMember_6f22ccb0-0b2e-484d-8bf2-7142b063daf7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_EmployeeStockPurchasePlanMember_794be2ca-c7e3-4536-813b-6705d4480f7b" xlink:href="sgmo-20191231.xsd#sgmo_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d68ecd7c-7477-4854-9f77-a8aa1074f7a7" xlink:to="loc_sgmo_EmployeeStockPurchasePlanMember_794be2ca-c7e3-4536-813b-6705d4480f7b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_77ed3560-8e63-4399-9089-8a773caeb92a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7898ec6d-5b2e-420e-b894-6c6dedb15058" xlink:to="loc_us-gaap_VestingAxis_77ed3560-8e63-4399-9089-8a773caeb92a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_77ed3560-8e63-4399-9089-8a773caeb92a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_77ed3560-8e63-4399-9089-8a773caeb92a" xlink:to="loc_us-gaap_VestingDomain_77ed3560-8e63-4399-9089-8a773caeb92a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_832fec71-0cab-475f-94a7-7211ae524d72" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_77ed3560-8e63-4399-9089-8a773caeb92a" xlink:to="loc_us-gaap_VestingDomain_832fec71-0cab-475f-94a7-7211ae524d72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_092ea44c-01ef-4eac-9850-a08658d14dcc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_832fec71-0cab-475f-94a7-7211ae524d72" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_092ea44c-01ef-4eac-9850-a08658d14dcc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_4350db19-8775-4f9a-b551-dc91b553f570" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_832fec71-0cab-475f-94a7-7211ae524d72" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_4350db19-8775-4f9a-b551-dc91b553f570" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_c30fdbeb-b023-46f8-8a5b-c59b20ecdb53" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_832fec71-0cab-475f-94a7-7211ae524d72" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_c30fdbeb-b023-46f8-8a5b-c59b20ecdb53" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#StockholdersEquitySummaryofStockOptionActivityDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail" xlink:type="extended" id="i46a17af9291f4610a0cb4d2712d540ce_930511a4-a582-417b-a992-8fc022879113"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockholdersEquitySummaryofRestrictedStockUnitActivityDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#StockholdersEquitySummaryofRestrictedStockUnitActivityDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/StockholdersEquitySummaryofRestrictedStockUnitActivityDetail" xlink:type="extended" id="i637a8169f2c344aba3e5c763cd391b15_51f17bda-3f01-4cf5-b7e3-a6177157b1ba"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="sgmo-20191231.xsd#StockBasedCompensation"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/StockBasedCompensation" xlink:type="extended" id="i61c97cf084a2455590f0454a7b69a96a_2c07cb87-b735-45d1-be1e-e38671b7f680"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="sgmo-20191231.xsd#StockBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/StockBasedCompensationTables" xlink:type="extended" id="id27f9bc5a6594abd8ed1c364441171b6_266f4dfa-a86a-43f2-99a2-aab7feaf2ce4"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#StockBasedCompensationStockBasedCompensationExpenseDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="extended" id="iedcfc95e4d214467935d56311b0b83ca_297141c1-de04-47fc-8ecb-38e77bf3172a">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e7041b4e-319e-410e-b67b-089ba77cc107" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0effda14-a0e1-4ea7-8386-0bd95b978e12" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e7041b4e-319e-410e-b67b-089ba77cc107" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0effda14-a0e1-4ea7-8386-0bd95b978e12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_bac44f3f-ae9f-4870-b540-a915d446a5d5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e7041b4e-319e-410e-b67b-089ba77cc107" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_bac44f3f-ae9f-4870-b540-a915d446a5d5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_60a7feb2-0a19-4bbe-a489-0eda268422c7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_bac44f3f-ae9f-4870-b540-a915d446a5d5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_60a7feb2-0a19-4bbe-a489-0eda268422c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_60a7feb2-0a19-4bbe-a489-0eda268422c7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_60a7feb2-0a19-4bbe-a489-0eda268422c7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_60a7feb2-0a19-4bbe-a489-0eda268422c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9e54e227-3eb1-4e01-9d5d-d084d1e9ac90" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_60a7feb2-0a19-4bbe-a489-0eda268422c7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9e54e227-3eb1-4e01-9d5d-d084d1e9ac90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_15fba1e3-cae3-4906-b973-85cd34b1c4bf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9e54e227-3eb1-4e01-9d5d-d084d1e9ac90" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_15fba1e3-cae3-4906-b973-85cd34b1c4bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_cc3beab7-1e3f-43c0-9701-3c38bf14a186" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9e54e227-3eb1-4e01-9d5d-d084d1e9ac90" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_cc3beab7-1e3f-43c0-9701-3c38bf14a186" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#StockBasedCompensationAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended" id="iec670f2c42264ef4a5ad77cf5ce007f9_6f08ced2-8617-4314-9af4-0ade7bea45ea">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_964d185d-3895-4199-9d39-ee659c4ccfb0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_e2fcd9da-db99-4300-826f-702c9a8e145d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_964d185d-3895-4199-9d39-ee659c4ccfb0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_e2fcd9da-db99-4300-826f-702c9a8e145d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6358ffa5-ca30-4095-b820-34cdf0247a4d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_964d185d-3895-4199-9d39-ee659c4ccfb0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6358ffa5-ca30-4095-b820-34cdf0247a4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_0fee1133-d979-4c9d-98b5-a27c51ad2a82" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_964d185d-3895-4199-9d39-ee659c4ccfb0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_0fee1133-d979-4c9d-98b5-a27c51ad2a82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9e3fe1ee-9f60-4e4d-9008-77396a742e17" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_964d185d-3895-4199-9d39-ee659c4ccfb0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9e3fe1ee-9f60-4e4d-9008-77396a742e17" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e7c682d6-88af-4962-a7e2-3db30bc98d9b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_964d185d-3895-4199-9d39-ee659c4ccfb0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e7c682d6-88af-4962-a7e2-3db30bc98d9b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice_20a70792-6449-4eb1-97b9-be9f2158cbad" xlink:href="sgmo-20191231.xsd#sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_964d185d-3895-4199-9d39-ee659c4ccfb0" xlink:to="loc_sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice_20a70792-6449-4eb1-97b9-be9f2158cbad" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue_2711c2a7-f394-44cc-9100-9388c0f6f44b" xlink:href="sgmo-20191231.xsd#sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_964d185d-3895-4199-9d39-ee659c4ccfb0" xlink:to="loc_sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue_2711c2a7-f394-44cc-9100-9388c0f6f44b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a41f76fa-211b-4d4f-a933-da90948f9291" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_964d185d-3895-4199-9d39-ee659c4ccfb0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a41f76fa-211b-4d4f-a933-da90948f9291" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e3b0046e-bdda-488d-bcf9-bd5d6f9e9a94" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a41f76fa-211b-4d4f-a933-da90948f9291" xlink:to="loc_us-gaap_AwardTypeAxis_e3b0046e-bdda-488d-bcf9-bd5d6f9e9a94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e3b0046e-bdda-488d-bcf9-bd5d6f9e9a94_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e3b0046e-bdda-488d-bcf9-bd5d6f9e9a94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e3b0046e-bdda-488d-bcf9-bd5d6f9e9a94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f089d009-d6e5-4cad-99f9-f1bed3e403a4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e3b0046e-bdda-488d-bcf9-bd5d6f9e9a94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f089d009-d6e5-4cad-99f9-f1bed3e403a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d407acf6-5946-4bf9-962b-b43a966f8f05" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f089d009-d6e5-4cad-99f9-f1bed3e403a4" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d407acf6-5946-4bf9-962b-b43a966f8f05" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail" xlink:type="extended" id="i8d16b566b2fa43edb69c05b62a794831_b6f40067-4ab1-4c38-9f99-25557d2e09f5">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37a9901c-5dfe-4d9f-bc18-35b6e3a1cddb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_17e64fe8-a3e9-4c23-a93f-3ae632502b87" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37a9901c-5dfe-4d9f-bc18-35b6e3a1cddb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_17e64fe8-a3e9-4c23-a93f-3ae632502b87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0fd963f7-375c-4325-a3c1-3c9b6e519655" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37a9901c-5dfe-4d9f-bc18-35b6e3a1cddb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0fd963f7-375c-4325-a3c1-3c9b6e519655" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4424ffeb-792e-4581-9fbb-14e5fd060453" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37a9901c-5dfe-4d9f-bc18-35b6e3a1cddb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4424ffeb-792e-4581-9fbb-14e5fd060453" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_08d7dc2b-26be-489d-a64b-06529b115dfc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37a9901c-5dfe-4d9f-bc18-35b6e3a1cddb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_08d7dc2b-26be-489d-a64b-06529b115dfc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff92dca4-1e3c-4f6e-adbf-ddb94c7ae738" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37a9901c-5dfe-4d9f-bc18-35b6e3a1cddb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff92dca4-1e3c-4f6e-adbf-ddb94c7ae738" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_da63ec2f-3dea-4ce6-a1aa-9cc0551c6d89" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff92dca4-1e3c-4f6e-adbf-ddb94c7ae738" xlink:to="loc_srt_RangeAxis_da63ec2f-3dea-4ce6-a1aa-9cc0551c6d89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_da63ec2f-3dea-4ce6-a1aa-9cc0551c6d89_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_da63ec2f-3dea-4ce6-a1aa-9cc0551c6d89" xlink:to="loc_srt_RangeMember_da63ec2f-3dea-4ce6-a1aa-9cc0551c6d89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e981d583-9cbc-489b-8c43-9747de605426" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_da63ec2f-3dea-4ce6-a1aa-9cc0551c6d89" xlink:to="loc_srt_RangeMember_e981d583-9cbc-489b-8c43-9747de605426" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5df25971-fdd3-4c3f-aa75-a18422f88e81" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e981d583-9cbc-489b-8c43-9747de605426" xlink:to="loc_srt_MinimumMember_5df25971-fdd3-4c3f-aa75-a18422f88e81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_131b79a0-e91a-48d6-9039-50faa3abf6c8" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e981d583-9cbc-489b-8c43-9747de605426" xlink:to="loc_srt_MaximumMember_131b79a0-e91a-48d6-9039-50faa3abf6c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_4cdc837f-a568-460c-929e-2f08d04ee65b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff92dca4-1e3c-4f6e-adbf-ddb94c7ae738" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_4cdc837f-a568-460c-929e-2f08d04ee65b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_4cdc837f-a568-460c-929e-2f08d04ee65b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_4cdc837f-a568-460c-929e-2f08d04ee65b" xlink:to="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_4cdc837f-a568-460c-929e-2f08d04ee65b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_c2eb8717-e355-49fc-949c-458eeaf36e51" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_4cdc837f-a568-460c-929e-2f08d04ee65b" xlink:to="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_c2eb8717-e355-49fc-949c-458eeaf36e51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_57770b0d-fd68-4581-8ae8-aa41805d578a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_c2eb8717-e355-49fc-949c-458eeaf36e51" xlink:to="loc_us-gaap_EmployeeStockOptionMember_57770b0d-fd68-4581-8ae8-aa41805d578a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail" xlink:type="extended" id="i2fe3a448bc7f4a40a379be36b25c58a1_326555eb-f69c-45b9-8ff0-93492408b4cc">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a3d54b8d-ebd6-4b54-9f03-a46b8d406799" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f635bd40-1e4d-442e-85ba-1c61a6b61c95" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a3d54b8d-ebd6-4b54-9f03-a46b8d406799" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f635bd40-1e4d-442e-85ba-1c61a6b61c95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_76c0ba7b-13ed-42ee-995f-e19a8fbc6284" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a3d54b8d-ebd6-4b54-9f03-a46b8d406799" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_76c0ba7b-13ed-42ee-995f-e19a8fbc6284" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_240e6929-49c0-4ee8-97e6-af1bf03f8478" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a3d54b8d-ebd6-4b54-9f03-a46b8d406799" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_240e6929-49c0-4ee8-97e6-af1bf03f8478" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_913e2584-34fc-487d-8382-91031fb06695" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a3d54b8d-ebd6-4b54-9f03-a46b8d406799" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_913e2584-34fc-487d-8382-91031fb06695" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5715f7b1-e288-40ec-a4b8-156f364f9d63" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a3d54b8d-ebd6-4b54-9f03-a46b8d406799" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5715f7b1-e288-40ec-a4b8-156f364f9d63" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b5883099-1e9c-434d-98db-22c2fb9178d9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5715f7b1-e288-40ec-a4b8-156f364f9d63" xlink:to="loc_us-gaap_PlanNameAxis_b5883099-1e9c-434d-98db-22c2fb9178d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b5883099-1e9c-434d-98db-22c2fb9178d9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_b5883099-1e9c-434d-98db-22c2fb9178d9" xlink:to="loc_us-gaap_PlanNameDomain_b5883099-1e9c-434d-98db-22c2fb9178d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e1c4a4a9-129e-4a37-95ac-80afb84a78ab" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_b5883099-1e9c-434d-98db-22c2fb9178d9" xlink:to="loc_us-gaap_PlanNameDomain_e1c4a4a9-129e-4a37-95ac-80afb84a78ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_EmployeeStockPurchasePlanMember_88f0fb96-ff4b-43a6-a68d-d55af83fa295" xlink:href="sgmo-20191231.xsd#sgmo_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e1c4a4a9-129e-4a37-95ac-80afb84a78ab" xlink:to="loc_sgmo_EmployeeStockPurchasePlanMember_88f0fb96-ff4b-43a6-a68d-d55af83fa295" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cd089d24-c04e-4ef1-8568-3be3e602ed51" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5715f7b1-e288-40ec-a4b8-156f364f9d63" xlink:to="loc_srt_RangeAxis_cd089d24-c04e-4ef1-8568-3be3e602ed51" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cd089d24-c04e-4ef1-8568-3be3e602ed51_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_cd089d24-c04e-4ef1-8568-3be3e602ed51" xlink:to="loc_srt_RangeMember_cd089d24-c04e-4ef1-8568-3be3e602ed51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4e76b7dc-9e83-49f6-8388-7691f6ad9f2e" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_cd089d24-c04e-4ef1-8568-3be3e602ed51" xlink:to="loc_srt_RangeMember_4e76b7dc-9e83-49f6-8388-7691f6ad9f2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_72b4d219-8c46-474b-9b26-6ca4123d0890" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4e76b7dc-9e83-49f6-8388-7691f6ad9f2e" xlink:to="loc_srt_MinimumMember_72b4d219-8c46-474b-9b26-6ca4123d0890" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_dfa1cabf-9db1-4fb6-b5f4-810d991a3856" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4e76b7dc-9e83-49f6-8388-7691f6ad9f2e" xlink:to="loc_srt_MaximumMember_dfa1cabf-9db1-4fb6-b5f4-810d991a3856" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="sgmo-20191231.xsd#EmployeeBenefitPlan"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/EmployeeBenefitPlan" xlink:type="extended" id="i61df77cc3ecf4bd885d3b0b8f3a9bf1f_4ab4fe28-5100-472f-8dfd-eee367fc7958"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/EmployeeBenefitPlanAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#EmployeeBenefitPlanAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/EmployeeBenefitPlanAdditionalInformationDetail" xlink:type="extended" id="i1d164ea6186b416a9d1a733bd5c4d209_02dd616d-f729-4c57-87b9-d876d05359cc"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxes" xlink:type="simple" xlink:href="sgmo-20191231.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/IncomeTaxes" xlink:type="extended" id="ieb5e1ba01f594eddb96bb8987a806489_9d461a83-f343-44ee-b965-59f5e0315a2f"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="sgmo-20191231.xsd#IncomeTaxesTables"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/IncomeTaxesTables" xlink:type="extended" id="idf56f906cde849ab85f4d0e3616d5b74_af876ec9-3aaa-4ed8-ae28-c0c97ab06b82"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#IncomeTaxesSummaryofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetail" xlink:type="extended" id="ic7b0fdd5a0b6480eaaa01cb03d091ef0_198be40d-b601-428c-80f0-a9b7c8eaa1ed"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#IncomeTaxesSummaryofBenefitforIncomeTaxesDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail" xlink:type="extended" id="i8e344ef76865408bbfa137d9b91f2657_8b81bd41-3059-4326-af81-0ad084c6bf71"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#IncomeTaxesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="extended" id="iff6e816834904e4e9be28899a3afe466_05891552-7b69-413b-9586-fecbdcfab8e5">
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncomeTaxesLineItems_700d01b2-3ce1-4ad5-b0d7-911b17e5989a" xlink:href="sgmo-20191231.xsd#sgmo_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_7dce5ee9-d7bd-4e16-9d1a-d101a4c6d7b6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_IncomeTaxesLineItems_700d01b2-3ce1-4ad5-b0d7-911b17e5989a" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_7dce5ee9-d7bd-4e16-9d1a-d101a4c6d7b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_cd8b6132-8203-4665-85ea-c4bb1c6ebd1e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_IncomeTaxesLineItems_700d01b2-3ce1-4ad5-b0d7-911b17e5989a" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_cd8b6132-8203-4665-85ea-c4bb1c6ebd1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_14cb1e88-625a-4699-9ea8-7201c0d0ba3d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_IncomeTaxesLineItems_700d01b2-3ce1-4ad5-b0d7-911b17e5989a" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_14cb1e88-625a-4699-9ea8-7201c0d0ba3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_dbe7bfc4-441e-4f3f-8c08-f9ffe363cede" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_IncomeTaxesLineItems_700d01b2-3ce1-4ad5-b0d7-911b17e5989a" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_dbe7bfc4-441e-4f3f-8c08-f9ffe363cede" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal_afbab5bd-86ce-4af0-8feb-9793e2e1d23f" xlink:href="sgmo-20191231.xsd#sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_IncomeTaxesLineItems_700d01b2-3ce1-4ad5-b0d7-911b17e5989a" xlink:to="loc_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal_afbab5bd-86ce-4af0-8feb-9793e2e1d23f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal_2b8a5441-074a-4eba-a2ca-0a10a641d96c" xlink:href="sgmo-20191231.xsd#sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_IncomeTaxesLineItems_700d01b2-3ce1-4ad5-b0d7-911b17e5989a" xlink:to="loc_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal_2b8a5441-074a-4eba-a2ca-0a10a641d96c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_8e077a75-7930-4eff-b01f-9f5ebfec70b8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_IncomeTaxesLineItems_700d01b2-3ce1-4ad5-b0d7-911b17e5989a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_8e077a75-7930-4eff-b01f-9f5ebfec70b8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncomeTaxesTable_d34d1073-468f-494a-9325-dd791a13981b" xlink:href="sgmo-20191231.xsd#sgmo_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sgmo_IncomeTaxesLineItems_700d01b2-3ce1-4ad5-b0d7-911b17e5989a" xlink:to="loc_sgmo_IncomeTaxesTable_d34d1073-468f-494a-9325-dd791a13981b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_6708ec01-0dfa-45a4-a403-8eb50e635d04" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_IncomeTaxesTable_d34d1073-468f-494a-9325-dd791a13981b" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_6708ec01-0dfa-45a4-a403-8eb50e635d04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_6708ec01-0dfa-45a4-a403-8eb50e635d04_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6708ec01-0dfa-45a4-a403-8eb50e635d04" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_6708ec01-0dfa-45a4-a403-8eb50e635d04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_cfc78d8e-1951-4762-ba7b-e663ff216f5e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6708ec01-0dfa-45a4-a403-8eb50e635d04" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_cfc78d8e-1951-4762-ba7b-e663ff216f5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinistryOfTheEconomyFinanceAndIndustryFranceMember_ab5d3bdc-89f1-4e8f-855e-06df150942f2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinistryOfTheEconomyFinanceAndIndustryFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_cfc78d8e-1951-4762-ba7b-e663ff216f5e" xlink:to="loc_us-gaap_MinistryOfTheEconomyFinanceAndIndustryFranceMember_ab5d3bdc-89f1-4e8f-855e-06df150942f2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail" xlink:type="extended" id="i4c8c3f19d8694745b68ad645325bc138_57dae209-b252-4cc0-b199-7fb906684dbe"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateAdditionalInformationDetail" xlink:type="extended" id="i960ef1acfded42749bd95bbab184af75_a3c77003-ce02-4c60-98e1-a920c8a24fe7"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail" xlink:type="extended" id="i457f06ff970144ae9d16a0a8789dd21f_f7018c15-d89d-42ec-8891-ba27f2a7ad24"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesSummaryofActivityRelatedtoCompanysUnrecognizedTaxBenefitsDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#IncomeTaxesSummaryofActivityRelatedtoCompanysUnrecognizedTaxBenefitsDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/IncomeTaxesSummaryofActivityRelatedtoCompanysUnrecognizedTaxBenefitsDetail" xlink:type="extended" id="idcdd09fdb8d440b0a25cc617188cebc2_9bfb5c73-aee4-450f-8da2-d56ef3bda6c3"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/RelatedPartyDisclosures" xlink:type="simple" xlink:href="sgmo-20191231.xsd#RelatedPartyDisclosures"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/RelatedPartyDisclosures" xlink:type="extended" id="i4bddcb11791849efb577da93992b74b8_7191cc6e-3d49-4884-b4bc-ce55a7d6a02a"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/RelatedPartyDisclosuresDetails" xlink:type="simple" xlink:href="sgmo-20191231.xsd#RelatedPartyDisclosuresDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/RelatedPartyDisclosuresDetails" xlink:type="extended" id="i62e75729682646f2a16cecf38e76c8c1_9bdd0acf-3cbb-495e-ba1a-c908101857fc">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0b35bad4-c3c9-4e26-9289-56c6854925a6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_8e67ee35-824b-4c36-b3b9-17401e6d7888" xlink:href="sgmo-20191231.xsd#sgmo_BusinessAcquisitionNumberOfSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0b35bad4-c3c9-4e26-9289-56c6854925a6" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_8e67ee35-824b-4c36-b3b9-17401e6d7888" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_ce81ef93-afdf-4069-9c45-2b872fa8c97f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0b35bad4-c3c9-4e26-9289-56c6854925a6" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_ce81ef93-afdf-4069-9c45-2b872fa8c97f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e8338ebe-c149-4b3e-9534-fad686d15d83" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0b35bad4-c3c9-4e26-9289-56c6854925a6" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e8338ebe-c149-4b3e-9534-fad686d15d83" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_db7c30eb-9210-45a0-9852-1f64e5486794" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e8338ebe-c149-4b3e-9534-fad686d15d83" xlink:to="loc_srt_CounterpartyNameAxis_db7c30eb-9210-45a0-9852-1f64e5486794" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_db7c30eb-9210-45a0-9852-1f64e5486794_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_db7c30eb-9210-45a0-9852-1f64e5486794" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_db7c30eb-9210-45a0-9852-1f64e5486794_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcc41059-937d-48f3-895b-a492be5c0998" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_db7c30eb-9210-45a0-9852-1f64e5486794" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcc41059-937d-48f3-895b-a492be5c0998" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FormerExecutiveOfSangamoFranceMember_e9ba06f7-a54b-471c-9b7a-ccbcec441f45" xlink:href="sgmo-20191231.xsd#sgmo_FormerExecutiveOfSangamoFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcc41059-937d-48f3-895b-a492be5c0998" xlink:to="loc_sgmo_FormerExecutiveOfSangamoFranceMember_e9ba06f7-a54b-471c-9b7a-ccbcec441f45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_cdc09077-f3ae-44ef-9321-2c6eb65292a4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e8338ebe-c149-4b3e-9534-fad686d15d83" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_cdc09077-f3ae-44ef-9321-2c6eb65292a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cdc09077-f3ae-44ef-9321-2c6eb65292a4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_cdc09077-f3ae-44ef-9321-2c6eb65292a4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cdc09077-f3ae-44ef-9321-2c6eb65292a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b353b66c-fcec-4860-a6fd-1eeb84889646" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_cdc09077-f3ae-44ef-9321-2c6eb65292a4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b353b66c-fcec-4860-a6fd-1eeb84889646" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_faf49be3-f061-4229-b005-388d18590287" xlink:href="sgmo-20191231.xsd#sgmo_SangamoFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b353b66c-fcec-4860-a6fd-1eeb84889646" xlink:to="loc_sgmo_SangamoFranceMember_faf49be3-f061-4229-b005-388d18590287" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ead44829-b993-4dde-ac3e-bc5ca63b112c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e8338ebe-c149-4b3e-9534-fad686d15d83" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ead44829-b993-4dde-ac3e-bc5ca63b112c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ead44829-b993-4dde-ac3e-bc5ca63b112c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ead44829-b993-4dde-ac3e-bc5ca63b112c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ead44829-b993-4dde-ac3e-bc5ca63b112c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2ec86977-0746-41f4-a019-0c882c7f17d4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ead44829-b993-4dde-ac3e-bc5ca63b112c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2ec86977-0746-41f4-a019-0c882c7f17d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_5f1b2d58-b3be-4b5b-b324-fedaadcabc58" xlink:href="sgmo-20191231.xsd#sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2ec86977-0746-41f4-a019-0c882c7f17d4" xlink:to="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_5f1b2d58-b3be-4b5b-b324-fedaadcabc58" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/QuarterlyFinancialDataUnaudited" xlink:type="simple" xlink:href="sgmo-20191231.xsd#QuarterlyFinancialDataUnaudited"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/QuarterlyFinancialDataUnaudited" xlink:type="extended" id="ib80b9bad345244bf8056ff50b6ca607e_fc827cb7-af7c-46e7-bff7-6e3b0ebe5441"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="simple" xlink:href="sgmo-20191231.xsd#QuarterlyFinancialDataUnauditedTables"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="extended" id="ia10388ff00bf4e1fb03709d7db06bb4e_3f30d305-12cb-47f4-a51f-738a48e0ca1f"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedSummaryofQuarterlyFinancialDataDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#QuarterlyFinancialDataUnauditedSummaryofQuarterlyFinancialDataDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedSummaryofQuarterlyFinancialDataDetail" xlink:type="extended" id="i937e6ee6782c48da8a334e7ae6f79280_28875b2e-9921-4b76-80e2-056c15d20012"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/SubsequentEvents" xlink:type="simple" xlink:href="sgmo-20191231.xsd#SubsequentEvents"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/SubsequentEvents" xlink:type="extended" id="i70a0a46676b941bcad19af1da97c0e5f_48e525ae-7ad5-4821-9b6b-2424fbdd4a16"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="sgmo-20191231.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/SubsequentEventsDetails" xlink:type="extended" id="i7cddad1d947747e1b160f499f24ee2a6_ff1f7d69-85f5-4968-b960-edae1442aa3c">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_c8933d18-3cf2-4584-80fc-d6be28f552b9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfProductTargets_264bccc5-ab2a-4829-acd6-26add1816546" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeArrangementNumberOfProductTargets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c8933d18-3cf2-4584-80fc-d6be28f552b9" xlink:to="loc_sgmo_CollaborativeArrangementNumberOfProductTargets_264bccc5-ab2a-4829-acd6-26add1816546" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected_5074ea70-1221-4b56-81e1-071f73fb5e02" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeArrangementNumberOfProductTargetsSelected"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c8933d18-3cf2-4584-80fc-d6be28f552b9" xlink:to="loc_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected_5074ea70-1221-4b56-81e1-071f73fb5e02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_1c0114ce-1cee-43ef-949f-f33a3aaae88f" xlink:href="sgmo-20191231.xsd#sgmo_CollaborationAgreementNumberOfAdditionalProductTargets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c8933d18-3cf2-4584-80fc-d6be28f552b9" xlink:to="loc_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_1c0114ce-1cee-43ef-949f-f33a3aaae88f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementTargetSelectionPeriod_941fb392-97b9-4cae-8125-e65662220896" xlink:href="sgmo-20191231.xsd#sgmo_CollaborationAgreementTargetSelectionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c8933d18-3cf2-4584-80fc-d6be28f552b9" xlink:to="loc_sgmo_CollaborationAgreementTargetSelectionPeriod_941fb392-97b9-4cae-8125-e65662220896" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_9f678694-b179-470b-b9db-6999f433b97a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c8933d18-3cf2-4584-80fc-d6be28f552b9" xlink:to="loc_us-gaap_ProceedsFromCollaborators_9f678694-b179-470b-b9db-6999f433b97a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable_69429449-234e-43a2-b168-9c972ab56e7a" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c8933d18-3cf2-4584-80fc-d6be28f552b9" xlink:to="loc_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable_69429449-234e-43a2-b168-9c972ab56e7a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_384d1c7c-c8e0-4d17-9e32-bb3e44ddb659" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c8933d18-3cf2-4584-80fc-d6be28f552b9" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_384d1c7c-c8e0-4d17-9e32-bb3e44ddb659" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_c814b23a-4cbb-4715-87b0-45fb680f98e9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c8933d18-3cf2-4584-80fc-d6be28f552b9" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_c814b23a-4cbb-4715-87b0-45fb680f98e9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9b93b7db-a8f8-4a6a-969a-68601f387991" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c8933d18-3cf2-4584-80fc-d6be28f552b9" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9b93b7db-a8f8-4a6a-969a-68601f387991" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementStandstillRestrictionPeriod_4cc92e21-003b-40e9-a07d-964d5cc2f82e" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeArrangementStandstillRestrictionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c8933d18-3cf2-4584-80fc-d6be28f552b9" xlink:to="loc_sgmo_CollaborativeArrangementStandstillRestrictionPeriod_4cc92e21-003b-40e9-a07d-964d5cc2f82e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage_03075a61-40fc-4d9f-b8fb-b2b7347a195f" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c8933d18-3cf2-4584-80fc-d6be28f552b9" xlink:to="loc_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage_03075a61-40fc-4d9f-b8fb-b2b7347a195f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld_e5abf5d7-21d6-4676-ae66-37d15a82fb87" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c8933d18-3cf2-4584-80fc-d6be28f552b9" xlink:to="loc_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld_e5abf5d7-21d6-4676-ae66-37d15a82fb87" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod_5dfdf3a7-a7a3-4a9b-ab06-748d9a351335" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c8933d18-3cf2-4584-80fc-d6be28f552b9" xlink:to="loc_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod_5dfdf3a7-a7a3-4a9b-ab06-748d9a351335" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage_3c099248-ab28-40ae-9bae-63106c486d50" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c8933d18-3cf2-4584-80fc-d6be28f552b9" xlink:to="loc_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage_3c099248-ab28-40ae-9bae-63106c486d50" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_f5527470-e514-4ba6-b76e-fda8be4ff440" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_c8933d18-3cf2-4584-80fc-d6be28f552b9" xlink:to="loc_us-gaap_SubsequentEventTable_f5527470-e514-4ba6-b76e-fda8be4ff440" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_fa55564b-64e3-484f-b41f-bfed62c01d9e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_f5527470-e514-4ba6-b76e-fda8be4ff440" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_fa55564b-64e3-484f-b41f-bfed62c01d9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fa55564b-64e3-484f-b41f-bfed62c01d9e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fa55564b-64e3-484f-b41f-bfed62c01d9e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fa55564b-64e3-484f-b41f-bfed62c01d9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e2af638d-898e-4fe2-9d21-10ac204a3ef6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fa55564b-64e3-484f-b41f-bfed62c01d9e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e2af638d-898e-4fe2-9d21-10ac204a3ef6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_686f9cf4-7a35-40b8-a5d2-cfd594294459" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e2af638d-898e-4fe2-9d21-10ac204a3ef6" xlink:to="loc_us-gaap_SubsequentEventMember_686f9cf4-7a35-40b8-a5d2-cfd594294459" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9ae7eeec-1209-4390-a41e-e35904dd80f0" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_f5527470-e514-4ba6-b76e-fda8be4ff440" xlink:to="loc_srt_CounterpartyNameAxis_9ae7eeec-1209-4390-a41e-e35904dd80f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9ae7eeec-1209-4390-a41e-e35904dd80f0_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_9ae7eeec-1209-4390-a41e-e35904dd80f0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9ae7eeec-1209-4390-a41e-e35904dd80f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0a5aa716-12cb-4608-8699-8e2c0434c546" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_9ae7eeec-1209-4390-a41e-e35904dd80f0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0a5aa716-12cb-4608-8699-8e2c0434c546" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_1c872e08-b85b-45db-a1b0-f4b1275661ba" xlink:href="sgmo-20191231.xsd#sgmo_BiogenMAIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0a5aa716-12cb-4608-8699-8e2c0434c546" xlink:to="loc_sgmo_BiogenMAIncMember_1c872e08-b85b-45db-a1b0-f4b1275661ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2afc63fb-cbb0-4e23-a51c-d6ee0612aae6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_f5527470-e514-4ba6-b76e-fda8be4ff440" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2afc63fb-cbb0-4e23-a51c-d6ee0612aae6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2afc63fb-cbb0-4e23-a51c-d6ee0612aae6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2afc63fb-cbb0-4e23-a51c-d6ee0612aae6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2afc63fb-cbb0-4e23-a51c-d6ee0612aae6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f32df3a4-63ff-44f4-960f-983e9e0bc3b7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2afc63fb-cbb0-4e23-a51c-d6ee0612aae6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f32df3a4-63ff-44f4-960f-983e9e0bc3b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementMember_cb70819d-3c35-4398-949f-2c4aaef13ca4" xlink:href="sgmo-20191231.xsd#sgmo_CollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f32df3a4-63ff-44f4-960f-983e9e0bc3b7" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementMember_cb70819d-3c35-4398-949f-2c4aaef13ca4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockPurchaseAgreementMember_c8703daf-76c5-4ca9-87d0-06547446f1a4" xlink:href="sgmo-20191231.xsd#sgmo_StockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f32df3a4-63ff-44f4-960f-983e9e0bc3b7" xlink:to="loc_sgmo_StockPurchaseAgreementMember_c8703daf-76c5-4ca9-87d0-06547446f1a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a9e5a05c-fc5d-4530-8717-d4a666761827" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_f5527470-e514-4ba6-b76e-fda8be4ff440" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a9e5a05c-fc5d-4530-8717-d4a666761827" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a9e5a05c-fc5d-4530-8717-d4a666761827_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a9e5a05c-fc5d-4530-8717-d4a666761827" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a9e5a05c-fc5d-4530-8717-d4a666761827_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_789e7eae-1ca4-4fca-b5a7-ce8d4930ae25" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a9e5a05c-fc5d-4530-8717-d4a666761827" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_789e7eae-1ca4-4fca-b5a7-ce8d4930ae25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_5fcbf5eb-2c64-40f1-8d06-3cb3e16e5abe" xlink:href="sgmo-20191231.xsd#sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_789e7eae-1ca4-4fca-b5a7-ce8d4930ae25" xlink:to="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_5fcbf5eb-2c64-40f1-8d06-3cb3e16e5abe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneAxis_3bc0cffc-cb1d-4c85-9244-6ce95f6e8323" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeAgreementMilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_f5527470-e514-4ba6-b76e-fda8be4ff440" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneAxis_3bc0cffc-cb1d-4c85-9244-6ce95f6e8323" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneDomain_3bc0cffc-cb1d-4c85-9244-6ce95f6e8323_default" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeAgreementMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneAxis_3bc0cffc-cb1d-4c85-9244-6ce95f6e8323" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneDomain_3bc0cffc-cb1d-4c85-9244-6ce95f6e8323_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneDomain_8d1ea13b-fa44-4d0c-bc5b-96af8085a0f2" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeAgreementMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneAxis_3bc0cffc-cb1d-4c85-9244-6ce95f6e8323" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneDomain_8d1ea13b-fa44-4d0c-bc5b-96af8085a0f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PreApprovalMilestoneMember_22e7d5c8-4374-45c6-a1a1-d21b9669e23c" xlink:href="sgmo-20191231.xsd#sgmo_PreApprovalMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_8d1ea13b-fa44-4d0c-bc5b-96af8085a0f2" xlink:to="loc_sgmo_PreApprovalMilestoneMember_22e7d5c8-4374-45c6-a1a1-d21b9669e23c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SalesBasedMilestoneMember_68fba673-9708-4801-8986-af0f4338dd3d" xlink:href="sgmo-20191231.xsd#sgmo_SalesBasedMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_8d1ea13b-fa44-4d0c-bc5b-96af8085a0f2" xlink:to="loc_sgmo_SalesBasedMilestoneMember_68fba673-9708-4801-8986-af0f4338dd3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementScenarioAxis_86e689f9-3648-47f0-9914-50ee333c1b8c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_f5527470-e514-4ba6-b76e-fda8be4ff440" xlink:to="loc_us-gaap_StatementScenarioAxis_86e689f9-3648-47f0-9914-50ee333c1b8c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_86e689f9-3648-47f0-9914-50ee333c1b8c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_86e689f9-3648-47f0-9914-50ee333c1b8c" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_86e689f9-3648-47f0-9914-50ee333c1b8c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_ad24cf3e-8347-48ff-8a7e-5c3dccb6fb07" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_86e689f9-3648-47f0-9914-50ee333c1b8c" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_ad24cf3e-8347-48ff-8a7e-5c3dccb6fb07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScenarioForecastMember_58319062-2a2b-46de-a6dc-480cd4afeac3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_ad24cf3e-8347-48ff-8a7e-5c3dccb6fb07" xlink:to="loc_us-gaap_ScenarioForecastMember_58319062-2a2b-46de-a6dc-480cd4afeac3" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>sgmo-20191231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:6b105dfa-4da0-4f89-a738-1fa68397e7a0,g:da741c8d-9db4-444a-b42c-06c4caf6626c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_bc032650-f1ce-41df-91e6-f61744289bb0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Topic 606</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2014-09 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201409Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201409Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bfb12898-ad0c-41fa-bb8d-0e26ddbb443c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_2fb96b9c-b426-470e-ae02-d725df7bcb67_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Specified Sales Based Milestones If Annual Worldwide Net Sales Of Licensed Products Reach Specified Levels [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified sales based milestones if annual worldwide net sales of licensed products reach specified levels.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:href="sgmo-20191231.xsd#sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:to="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_LeaseArrangementsDomain_0a61fbdd-53fd-4ac5-a12a-b60eb97680d3_terseLabel_en-US" xlink:label="lab_sgmo_LeaseArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Domain]</link:label>
    <link:label id="lab_sgmo_LeaseArrangementsDomain_label_en-US" xlink:label="lab_sgmo_LeaseArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Domain]</link:label>
    <link:label id="lab_sgmo_LeaseArrangementsDomain_documentation_en-US" xlink:label="lab_sgmo_LeaseArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LeaseArrangementsDomain" xlink:href="sgmo-20191231.xsd#sgmo_LeaseArrangementsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_LeaseArrangementsDomain" xlink:to="lab_sgmo_LeaseArrangementsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_8004445b-b712-443f-ad4e-48164741cc72_terseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares withheld from issuance in order to pay employee taxes (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Paid for Tax Withholding for Share Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_7f2f222a-6caa-4855-977d-68f364d31b54_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_9ec1fca1-2f6e-4564-b587-35c43fb8098b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue_512414ac-f469-4531-995e-5db5cc8dc92c_terseLabel_en-US" xlink:label="lab_sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average estimated fair value of shares purchased under ESPP plan (in dollars per share)</link:label>
    <link:label id="lab_sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue_label_en-US" xlink:label="lab_sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan Rights Weighted Average Estimated Fair Value</link:label>
    <link:label id="lab_sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue_documentation_en-US" xlink:label="lab_sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan rights weighted average estimated fair value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue" xlink:href="sgmo-20191231.xsd#sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue" xlink:to="lab_sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_a998cc5d-4740-45f2-af08-25129599fb00_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, weighted average discount rate, percent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_5707f5c8-a921-4ace-8dcf-6183c7075337_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_96694b11-4a27-4980-ba5f-f0de5cac95fa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units awarded (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_498ea0f1-d641-44ff-b0cb-a34ea9ab1625_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs awarded (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_cde5bba7-df0c-40b3-a6c6-581c3525ecb0_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government-sponsored entity debt securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_0f7c2ca4-7cc6-4d2f-ace5-14e8897206e5_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_fa9ba319-7d7f-4d82-861c-6ae40d3c1263_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_dccd0daf-649e-4222-b849-1f677a9321e6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cfea288b-150f-40a1-8d08-0698b2f70436_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_02a31747-e226-44a6-a86e-35703bd894f2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average period of unvested stock options and RSU</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_279a7ad7-9e97-4a17-8f68-5f8b0523c2f4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted net (loss) income per share attributable to Sangamo Therapeutics, Inc. (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MeasurementInputStockPriceCorrelationMember_c194c958-10b9-4644-8c85-a5004c4e8fab_terseLabel_en-US" xlink:label="lab_sgmo_MeasurementInputStockPriceCorrelationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Stock Price Correlation</link:label>
    <link:label id="lab_sgmo_MeasurementInputStockPriceCorrelationMember_label_en-US" xlink:label="lab_sgmo_MeasurementInputStockPriceCorrelationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Stock Price Correlation [Member]</link:label>
    <link:label id="lab_sgmo_MeasurementInputStockPriceCorrelationMember_documentation_en-US" xlink:label="lab_sgmo_MeasurementInputStockPriceCorrelationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Stock Price Correlation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MeasurementInputStockPriceCorrelationMember" xlink:href="sgmo-20191231.xsd#sgmo_MeasurementInputStockPriceCorrelationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MeasurementInputStockPriceCorrelationMember" xlink:to="lab_sgmo_MeasurementInputStockPriceCorrelationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ea8efa87-cd08-4893-b73b-423c4ba91bc0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_ffa5b556-f5a2-4dbe-9329-e536fc4dec3e_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate by Type</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:to="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_OtherProductsMember_aebc7147-1563-4fb6-9806-170e9e029297_terseLabel_en-US" xlink:label="lab_sgmo_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other products</link:label>
    <link:label id="lab_sgmo_OtherProductsMember_label_en-US" xlink:label="lab_sgmo_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products [Member]</link:label>
    <link:label id="lab_sgmo_OtherProductsMember_documentation_en-US" xlink:label="lab_sgmo_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OtherProductsMember" xlink:href="sgmo-20191231.xsd#sgmo_OtherProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_OtherProductsMember" xlink:to="lab_sgmo_OtherProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_83bd75e1-dad3-42dd-92c4-bc3492b79eed_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under public offering, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_6626d8ce-3bae-43e7-9ef1-38a7d5e6c834_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued under license agreement</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_a70d0d39-72a7-4c32-9222-74160809962b_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward" xlink:to="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_5d456c16-d5b5-48d3-802d-3633f6a539ff_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_9eb2cba9-2ad6-4eca-a094-4204847666cd_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_38484ff0-43f5-44bc-bb9c-12b4fb7a5eae_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share, basic</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_0be6842c-fbbe-4b9d-a5c9-b756b736254f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_6d7231a3-c98a-441a-9560-5f59d5da5d06_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BuildToSuitLeaseObligations_017195ff-5307-416a-9289-6c289fc0f06e_terseLabel_en-US" xlink:label="lab_sgmo_BuildToSuitLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of lease liabilities</link:label>
    <link:label id="lab_sgmo_BuildToSuitLeaseObligations_label_en-US" xlink:label="lab_sgmo_BuildToSuitLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Build To Suit Lease Obligations</link:label>
    <link:label id="lab_sgmo_BuildToSuitLeaseObligations_documentation_en-US" xlink:label="lab_sgmo_BuildToSuitLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Build-to-suit lease obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BuildToSuitLeaseObligations" xlink:href="sgmo-20191231.xsd#sgmo_BuildToSuitLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BuildToSuitLeaseObligations" xlink:to="lab_sgmo_BuildToSuitLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod_d4b2dd3d-3027-4924-8af4-3c9daeb25c56_terseLabel_en-US" xlink:label="lab_sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum license annual fees specific reckoning period</link:label>
    <link:label id="lab_sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod_label_en-US" xlink:label="lab_sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Sublicense Annual Fees Specific Reckoning Period</link:label>
    <link:label id="lab_sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod_documentation_en-US" xlink:label="lab_sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum sublicense annual fees specific reckoning period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" xlink:href="sgmo-20191231.xsd#sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" xlink:to="lab_sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_cdcef95a-d1ab-4c2f-85dd-397bb18b2ec7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful lives of related assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_56700035-69fb-43b1-9351-b0f65fcbf101_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_a136e2ef-0124-4144-a9f1-589e562c40a3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable at end of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAdjustmentMember_7383ce12-a5d2-4e51-8a4d-db14b4530cef_terseLabel_en-US" xlink:label="lab_srt_RestatementAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments Due to the Adoption of ASC Topic 842</link:label>
    <link:label id="lab_srt_RestatementAdjustmentMember_label_en-US" xlink:label="lab_srt_RestatementAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAdjustmentMember" xlink:to="lab_srt_RestatementAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_f5b05d5f-6855-4027-ba41-ac31768e2192_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions for tax positions of prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_c4ad7385-86b1-4394-94fa-1ff78962fabe_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_33c6302d-6cc7-4728-bbdd-ddb5e9c2208e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_d070bb49-32e3-428c-b2d7-9512f55c2f33_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_12cf4289-682a-4283-90d4-cb3b3b9168a3_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk Free Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SanofiMember_69088922-d1fa-4f92-9f69-6d0506defa36_terseLabel_en-US" xlink:label="lab_sgmo_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi</link:label>
    <link:label id="lab_sgmo_SanofiMember_label_en-US" xlink:label="lab_sgmo_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi [Member]</link:label>
    <link:label id="lab_sgmo_SanofiMember_documentation_en-US" xlink:label="lab_sgmo_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember" xlink:href="sgmo-20191231.xsd#sgmo_SanofiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SanofiMember" xlink:to="lab_sgmo_SanofiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_22b5ecd8-343a-4620-87d3-e411b8d90ce3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fba43369-a0b1-4e68-a07d-1fb4990ba8c8_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_6ab4f856-8400-4ae8-bd4c-f8c4d95bb73f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_03f8ae9f-f675-4d70-bc7c-2feac6e0e937_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_e722e9f2-ea8e-4374-be32-6ca23d2e73f7_terseLabel_en-US" xlink:label="lab_sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions for tax positions of prior years</link:label>
    <link:label id="lab_sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions</link:label>
    <link:label id="lab_sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_documentation_en-US" xlink:label="lab_sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits increase decrease resulting from prior period tax positions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:href="sgmo-20191231.xsd#sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:to="lab_sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitment_dd6438b6-0d80-45ab-aa5a-392eb4c29309_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other commitment</link:label>
    <link:label id="lab_us-gaap_OtherCommitment_label_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment" xlink:to="lab_us-gaap_OtherCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_2c5675d6-692c-4136-8f69-955e37334753_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_033c4750-091b-41a1-8ca7-9c11ce3738d8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_10adf2c3-cf67-4eee-a551-746408ddb384_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_797729a0-23e4-4f85-ae2b-548f2c5696b8_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill acquired</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_560fc553-c3c9-49d1-a73e-09fe8a554ae2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net operating loss carryforwards for foreign</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_91be2ef2-86d1-4c1a-aa32-ba108aa6ddad_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_05259faf-2ed5-4491-b751-95ea68be36c2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber_59c9ceec-1396-461b-98c9-45b33a770492_terseLabel_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options and RSUs outstanding (in shares)</link:label>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber_label_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options And Restricted Stock Units Outstanding Number</link:label>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber_documentation_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award options and restricted stock units outstanding number.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber" xlink:href="sgmo-20191231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber" xlink:to="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_86dfb456-9601-4bc3-9dd4-854e51c772cf_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_8a38bf59-72f2-40af-b4cb-2ec669dd2d1a_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_eaa7e711-79f0-40b3-ac1f-e523df5b8994_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_ac48ca47-7284-4032-a419-5e80127b179e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_6a0718a5-386e-4ccc-a245-79c6bd490d89_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue related to Sanofi agreement:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability_51478e38-91bb-4bec-b79d-ed2c9ca9ce47_terseLabel_en-US" xlink:label="lab_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in fair value of free shares asset and liability</link:label>
    <link:label id="lab_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability_label_en-US" xlink:label="lab_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase In Fair Value Of Free Shares Asset And Liability</link:label>
    <link:label id="lab_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability_documentation_en-US" xlink:label="lab_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase In Fair Value Of Free Shares Asset And Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability" xlink:href="sgmo-20191231.xsd#sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability" xlink:to="lab_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_81b191cd-395f-4a84-b965-13ec3c0144fb_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and marketable securities</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder_0ca428b4-60b3-4af3-b21e-7ad8b949fd5a_terseLabel_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of common stock percent under stock incentive plans for specified stockholder</link:label>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder_label_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Purchase Price Of Common Stock Percent For Specified Stockholder</link:label>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder_documentation_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award purchase price of common stock percent for specified stockholder.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder" xlink:href="sgmo-20191231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder" xlink:to="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_34f97f65-5e92-4826-b2e5-2d5ad51caf62_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_142da121-4536-492c-9214-1350b2b6af6f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2e0a167a-6792-48e4-bd0a-87b78fa7f9d1_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_RichmondCaliforniaMember_5805bf4e-d45a-49dc-9556-c10e1036b06e_terseLabel_en-US" xlink:label="lab_sgmo_RichmondCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Richmond, California</link:label>
    <link:label id="lab_sgmo_RichmondCaliforniaMember_label_en-US" xlink:label="lab_sgmo_RichmondCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Richmond, California [Member]</link:label>
    <link:label id="lab_sgmo_RichmondCaliforniaMember_documentation_en-US" xlink:label="lab_sgmo_RichmondCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Richmond, California</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RichmondCaliforniaMember" xlink:href="sgmo-20191231.xsd#sgmo_RichmondCaliforniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_RichmondCaliforniaMember" xlink:to="lab_sgmo_RichmondCaliforniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_72552b59-eb8c-4e48-a44f-cec8926589fe_verboseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable_6a64f13f-187e-4142-ac8b-74457cdb1ce5_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum milestone payment receivable</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Milestone Payment Receivable</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Milestone Payment Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable" xlink:to="lab_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_4bc2e694-4812-460d-8898-a35e70dd9935_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_b0258d39-4f0a-4358-a445-c00bb0d85fc6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of share capital and voting rights acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_1a561c31-1df4-4f8e-a3ab-7c474264e646_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3c0782e5-cfe9-43d4-b659-1e4515149694_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7c97d8a3-32da-4d14-af49-0f1b449b0416_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1b572ff1-dd43-4202-b588-63515855ee97_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total investments available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_04bbeb93-6b26-417d-ab58-febf298efdf4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_bd65fefa-374a-4957-915b-c40babee2bea_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_LesseeOperatingLeaseLiabilityTenantImprovementAllowance_7781bce3-6181-4f9d-bc72-63cc58540e3e_terseLabel_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee operating lease liability tenant improvement allowance</link:label>
    <link:label id="lab_sgmo_LesseeOperatingLeaseLiabilityTenantImprovementAllowance_label_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Liability Tenant Improvement Allowance</link:label>
    <link:label id="lab_sgmo_LesseeOperatingLeaseLiabilityTenantImprovementAllowance_documentation_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Liability Tenant Improvement Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" xlink:href="sgmo-20191231.xsd#sgmo_LesseeOperatingLeaseLiabilityTenantImprovementAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" xlink:to="lab_sgmo_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementTransactionPrice_ee42c24a-7d9b-4aa0-a472-15fa47557c49_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement transaction price</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementTransactionPrice_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Transaction Price</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementTransactionPrice_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement transaction price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementTransactionPrice" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeArrangementTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementTransactionPrice" xlink:to="lab_sgmo_CollaborativeArrangementTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0b7528ec-d71b-4b06-96ed-12e2887e7d84_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_f2ea5b1b-a9d6-407c-a9e5-e10f06fc028d_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3fa27cee-373c-4319-9ad0-43ba4b56196b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_62b3a769-8e67-4dbb-bd61-7a5c08e7ad1b_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate, Type</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:to="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_3374e382-dcfb-48ab-aea3-0518c5ad2860_terseLabel_en-US" xlink:label="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential amount to be funded for achievement of specified commercialized and sales milestones</link:label>
    <link:label id="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_label_en-US" xlink:label="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Additional Revenue Recognition Milestone Method Revenue Eligible To Receive</link:label>
    <link:label id="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_documentation_en-US" xlink:label="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate additional revenue recognition milestone method revenue eligible to receive.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:href="sgmo-20191231.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:to="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired_431fd276-8be1-45fe-be2d-0a5dcd06f293_terseLabel_en-US" xlink:label="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived assets - IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired_label_en-US" xlink:label="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:to="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_6a0a22b7-c1f0-4ad0-a7ac-b0f8c2864f59_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate employer's contributions to defined contribution plan</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_ef31d746-478f-47c7-afee-974ebaba230a_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper securities</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_368a3928-9d02-41fb-b4bd-16c9e9440874_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_b7fcc283-fda0-46fe-a943-7944ef56f3c2_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to Sangamo Therapeutics, Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest_3ed1f536-f231-4eed-b1bb-0904ee1e699b_terseLabel_en-US" xlink:label="lab_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of additional shares of Sangamo France</link:label>
    <link:label id="lab_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest_label_en-US" xlink:label="lab_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital Acquisition Of Noncontrolling Interest</link:label>
    <link:label id="lab_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest_documentation_en-US" xlink:label="lab_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to additional paid in capital acquisition of non-controlling interest.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" xlink:href="sgmo-20191231.xsd#sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" xlink:to="lab_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PurchasePlanPurchasePeriod_909c927d-4930-4346-a6b9-09a7cc2cc747_terseLabel_en-US" xlink:label="lab_sgmo_PurchasePlanPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase plan purchase period</link:label>
    <link:label id="lab_sgmo_PurchasePlanPurchasePeriod_label_en-US" xlink:label="lab_sgmo_PurchasePlanPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Plan Purchase Period</link:label>
    <link:label id="lab_sgmo_PurchasePlanPurchasePeriod_documentation_en-US" xlink:label="lab_sgmo_PurchasePlanPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase plan purchase period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PurchasePlanPurchasePeriod" xlink:href="sgmo-20191231.xsd#sgmo_PurchasePlanPurchasePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PurchasePlanPurchasePeriod" xlink:to="lab_sgmo_PurchasePlanPurchasePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_5a310b48-d1cc-481b-b79c-fc530af7e9b9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_c0f5451c-e14c-4169-af00-4ad194bfbe78_terseLabel_en-US" xlink:label="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents accumulated gross unrealized loss before tax</link:label>
    <link:label id="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:label id="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents accumulated gross unrealized loss before tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="sgmo-20191231.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BuildToSuitLeases_b9e2fac7-c86c-47b2-808e-75b170c5e60e_verboseLabel_en-US" xlink:label="lab_sgmo_BuildToSuitLeases" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Build-to-suit leases</link:label>
    <link:label id="lab_sgmo_BuildToSuitLeases_label_en-US" xlink:label="lab_sgmo_BuildToSuitLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Build To Suit Leases</link:label>
    <link:label id="lab_sgmo_BuildToSuitLeases_documentation_en-US" xlink:label="lab_sgmo_BuildToSuitLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Build to suit leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BuildToSuitLeases" xlink:href="sgmo-20191231.xsd#sgmo_BuildToSuitLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BuildToSuitLeases" xlink:to="lab_sgmo_BuildToSuitLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember_86af5e07-9858-4fa1-bb1b-768cf37c56ac_terseLabel_en-US" xlink:label="lab_sgmo_AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated 2013 Stock Incentive Plan</link:label>
    <link:label id="lab_sgmo_AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember_label_en-US" xlink:label="lab_sgmo_AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended And Restated Two Thousand Thirteen Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_sgmo_AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember_documentation_en-US" xlink:label="lab_sgmo_AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and restated 2013 stock incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember" xlink:href="sgmo-20191231.xsd#sgmo_AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember" xlink:to="lab_sgmo_AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_d980296d-ec96-45a5-8bcb-b209143cf1b4_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified preclinical development clinical development and first commercial sale milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Specified Preclinical Development Clinical Development And First Commercial Sale Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified preclinical development clinical development and first commercial sale milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:href="sgmo-20191231.xsd#sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:to="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MilestoneThreeMember_80b900a6-9bdb-498b-bd02-1bf83d6ea65f_terseLabel_en-US" xlink:label="lab_sgmo_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Three</link:label>
    <link:label id="lab_sgmo_MilestoneThreeMember_label_en-US" xlink:label="lab_sgmo_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Three [Member]</link:label>
    <link:label id="lab_sgmo_MilestoneThreeMember_documentation_en-US" xlink:label="lab_sgmo_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneThreeMember" xlink:href="sgmo-20191231.xsd#sgmo_MilestoneThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestoneThreeMember" xlink:to="lab_sgmo_MilestoneThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_265073be-87eb-4c1b-b352-0520624bad89_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield of stock</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_fcc2244b-7b73-4bc4-be5b-5afff0ee2c12_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional equity award (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_448eed39-d88f-4357-9bc5-828c36225f44_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ShireAgMember_00386a0c-d3b3-43bd-bbdf-b4614f1e33fc_terseLabel_en-US" xlink:label="lab_sgmo_ShireAgMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shire AG</link:label>
    <link:label id="lab_sgmo_ShireAgMember_label_en-US" xlink:label="lab_sgmo_ShireAgMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shire Ag [Member]</link:label>
    <link:label id="lab_sgmo_ShireAgMember_documentation_en-US" xlink:label="lab_sgmo_ShireAgMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shire ag.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShireAgMember" xlink:href="sgmo-20191231.xsd#sgmo_ShireAgMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ShireAgMember" xlink:to="lab_sgmo_ShireAgMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_1dd29604-7cbf-4b1a-a09c-b7e59ea42436_terseLabel_en-US" xlink:label="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of milestones included in transaction price</link:label>
    <link:label id="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_label_en-US" xlink:label="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Clinical Or Regulatory Milestones Included In Transaction Price</link:label>
    <link:label id="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_documentation_en-US" xlink:label="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of clinical or regulatory milestones included in transaction price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:href="sgmo-20191231.xsd#sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:to="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_06e5ac29-bf35-4724-986f-79c651d4bc81_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_f4143ec4-6ade-49b5-adef-d8dcc24b7d37_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_6bdcf84a-8d50-406d-b06c-d8b49f6c5571_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of fair value per share of common stock on option grant date</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_85daeac7-4d7f-4874-bf1c-ec84abba07ad_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0880a834-f851-44ec-8cd3-fbdbd1213e49_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options granted vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_9d8e3b22-7e59-4bce-bda4-7477fae1660c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_6a2df06d-b6f7-4108-864d-0a392255e18a_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_8f90feb7-8eb9-4f82-aa71-d3eab0cf1a5e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_c8928903-cce9-430e-82b6-13b6a09b12ff_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cc613ae9-b63e-4c3c-8751-e9fe69e7f941_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6bffb196-9603-4b5d-9d86-2117c086079b_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_c59a6d55-25f2-4522-86f0-f2ed5ace3b87_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of milestone</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_dde0ba77-54f9-4118-b69e-49d079629026_negatedLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and available-for-sale securities, gross unrealized (losses)</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Available For Sale Securities Gross Unrealized Loss Before Tax</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and available for sale securities, gross unrealized loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:href="sgmo-20191231.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:to="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_fa36bb3e-575c-415c-ad0a-34fa2134fc7b_totalLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and available-for-sale securities, amortized cost</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_label_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Available For Sale Securities Amortized Cost</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and available for Sale Securities Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:href="sgmo-20191231.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:to="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_320b8f5d-961d-4209-be2d-ce5e9df39a21_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_3a49036e-c5ee-4ec4-8d61-81228ee649f4_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_72a2a4f5-f56e-4b68-979a-0077213bdf02_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_38dd9e25-1433-4765-bf18-284884e82541_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_70dde88b-3812-4bbe-90d7-5e48b2b149a9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of non-controlling interest</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ece02a3f-947f-4fb0-bc32-83e63e15f9ae_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease) increase in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_DeferredTaxAssetsBuildToSuitLeaseLiability_6e043b26-fdd3-44c9-b616-73e66e8d930e_terseLabel_en-US" xlink:label="lab_sgmo_DeferredTaxAssetsBuildToSuitLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Build to suit lease liability</link:label>
    <link:label id="lab_sgmo_DeferredTaxAssetsBuildToSuitLeaseLiability_label_en-US" xlink:label="lab_sgmo_DeferredTaxAssetsBuildToSuitLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Build To Suit Lease Liability</link:label>
    <link:label id="lab_sgmo_DeferredTaxAssetsBuildToSuitLeaseLiability_documentation_en-US" xlink:label="lab_sgmo_DeferredTaxAssetsBuildToSuitLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets build to suit lease liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DeferredTaxAssetsBuildToSuitLeaseLiability" xlink:href="sgmo-20191231.xsd#sgmo_DeferredTaxAssetsBuildToSuitLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_DeferredTaxAssetsBuildToSuitLeaseLiability" xlink:to="lab_sgmo_DeferredTaxAssetsBuildToSuitLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_NumberOfResearchProgram_5f41b470-39ac-4501-ba7e-1ddd3c1dfb69_terseLabel_en-US" xlink:label="lab_sgmo_NumberOfResearchProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of research programs</link:label>
    <link:label id="lab_sgmo_NumberOfResearchProgram_label_en-US" xlink:label="lab_sgmo_NumberOfResearchProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Research Program</link:label>
    <link:label id="lab_sgmo_NumberOfResearchProgram_documentation_en-US" xlink:label="lab_sgmo_NumberOfResearchProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of research program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfResearchProgram" xlink:href="sgmo-20191231.xsd#sgmo_NumberOfResearchProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NumberOfResearchProgram" xlink:to="lab_sgmo_NumberOfResearchProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_242225b1-c2b1-4ae3-bbb2-615e9f6c4673_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_84d41fe8-5669-4181-8507-7db1147fab05_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_d7c2f610-4cf9-423f-b834-f9291b16809a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value; 160,000,000 shares authorized, 115,972,708 and 102,187,471 shares issued and outstanding at December 31, 2019 and 2018, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_efd0c0c3-e6b0-4e70-aca4-bc13fc0ffcb4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate fair value of RSUs vested in period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_85e85abf-1d2b-443e-8098-b83258fa4ced_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinistryOfTheEconomyFinanceAndIndustryFranceMember_b2d140e8-06cd-4b93-a328-17fd001d7963_terseLabel_en-US" xlink:label="lab_us-gaap_MinistryOfTheEconomyFinanceAndIndustryFranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">French</link:label>
    <link:label id="lab_us-gaap_MinistryOfTheEconomyFinanceAndIndustryFranceMember_label_en-US" xlink:label="lab_us-gaap_MinistryOfTheEconomyFinanceAndIndustryFranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ministry of the Economy, Finance and Industry, France [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinistryOfTheEconomyFinanceAndIndustryFranceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinistryOfTheEconomyFinanceAndIndustryFranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinistryOfTheEconomyFinanceAndIndustryFranceMember" xlink:to="lab_us-gaap_MinistryOfTheEconomyFinanceAndIndustryFranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2b9bcd7d-4ed3-48cc-b836-224c4efc59c6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options canceled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e8b5af26-48f3-4a6d-b9d6-1225e3d93353_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise per Share Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_108152eb-aa4b-4665-9e8b-a1ef3a73cf66_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_6c63934e-4938-4da4-b871-8dac616fedc0_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_465c546a-ed91-48e1-b970-1eece1657cf4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_08254824-5109-49ae-9e3e-374cacfbed33_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_DerivativeLiabilityTerm_b9646ed8-fa9e-4d8e-a960-53a75f77e578_terseLabel_en-US" xlink:label="lab_sgmo_DerivativeLiabilityTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk Free Rate and Cost of Debt by Expected Exercise Date</link:label>
    <link:label id="lab_sgmo_DerivativeLiabilityTerm_label_en-US" xlink:label="lab_sgmo_DerivativeLiabilityTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability Term</link:label>
    <link:label id="lab_sgmo_DerivativeLiabilityTerm_documentation_en-US" xlink:label="lab_sgmo_DerivativeLiabilityTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DerivativeLiabilityTerm" xlink:href="sgmo-20191231.xsd#sgmo_DerivativeLiabilityTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_DerivativeLiabilityTerm" xlink:to="lab_sgmo_DerivativeLiabilityTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_c8c01e9c-6092-4ad1-b01f-84c68801e752_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_04bb919a-fce3-4ba3-a404-56e149e8d430_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_d4613b32-228e-4003-b047-fbf7b8a13ff3_terseLabel_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs vested and expected to vest at end of period (in shares)</link:label>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Number</link:label>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_documentation_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options vested and expected to vest outstanding number.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="sgmo-20191231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_036971ef-8b86-4d86-a509-4b262b0aaa1d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Securities and Free Share Liability</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_66d86d08-c211-4f48-8ca7-63702aaed095_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenues</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8fc36bcc-0068-438a-ab25-2d74c33c4c70_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_66211a07-2ab7-4544-90ae-486c41ce7e58_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_b856a7c3-a424-410d-97e6-39f89ac22418_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_54463484-421a-467e-a3d2-eef6e6d933f4_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_f9175c43-cef6-428f-b765-585d241d1409_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement, Type</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis" xlink:to="lab_us-gaap_LeaseArrangementTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1bd933a4-2ce2-49ec-b36d-755c030fb100_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant date fair value per award of restricted stock units (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_6c837498-a2a8-43a5-a8d3-e55ec17cdf63_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis" xlink:to="lab_us-gaap_OtherCommitmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_55eee8e1-4704-4077-ac00-ca95a511a023_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_2f20e746-8466-4c6c-a327-da47e00f0a0a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Estimated Fair Value of Free Share Liability Assumptions</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_d93e6351-138e-4231-a3f5-00bea2acfab9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_55016b49-34fb-46eb-8278-b036fdd66b62_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_a1116b33-1734-4dcd-82e0-654b2d2d9d9d_terseLabel_en-US" xlink:label="lab_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition estimated fair value liabilities of free shares</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_label_en-US" xlink:label="lab_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Estimated Fair Value Liabilities Of Free Shares</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_documentation_en-US" xlink:label="lab_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Estimated Fair Value Liabilities Of Free Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" xlink:href="sgmo-20191231.xsd#sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" xlink:to="lab_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6166222a-b61d-49d0-967f-f66fbdf9a1dc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_78ce5551-137d-4313-9059-9796ad674969_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PfizerSB525Member_68191f75-b30a-498e-8d40-9d3e61f3c874_terseLabel_en-US" xlink:label="lab_sgmo_PfizerSB525Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer SB-525</link:label>
    <link:label id="lab_sgmo_PfizerSB525Member_label_en-US" xlink:label="lab_sgmo_PfizerSB525Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer SB-525 [Member]</link:label>
    <link:label id="lab_sgmo_PfizerSB525Member_documentation_en-US" xlink:label="lab_sgmo_PfizerSB525Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer SB-525</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member" xlink:href="sgmo-20191231.xsd#sgmo_PfizerSB525Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PfizerSB525Member" xlink:to="lab_sgmo_PfizerSB525Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6328b7a6-85b1-4266-be98-d3f136fda6cc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_8d67a9ac-22e4-46b4-aac4-d797e7b267db_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_0be55979-38af-4fda-a68b-c47808b36f3b_terseLabel_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of free shares held by the holders (in shares)</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_label_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Number Of Free Shares Held By Holders</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_documentation_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, number of free shares held by the holders.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders" xlink:href="sgmo-20191231.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders" xlink:to="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_65eb0868-b447-431a-9a89-d260002753b5_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3efd4f8d-0278-405f-a664-592bcf677d61_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balances</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5af2bbae-e746-4399-8bd8-e32b1907ff64_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balances</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_52cd22e0-ecad-44c3-aa20-43cbe8273762_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_2964ba27-1424-486c-8596-2b155b463d73_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_54afd608-78d7-4a3b-99f8-735f5994bf28_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_3385ec63-b745-47dc-b061-3e6ad963e1ff_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_TwoThousandThirteenStockIncentivePlanMember_a5a987d1-1286-4cd4-b1c7-e185f2a98171_terseLabel_en-US" xlink:label="lab_sgmo_TwoThousandThirteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2013 Stock Incentive Plan</link:label>
    <link:label id="lab_sgmo_TwoThousandThirteenStockIncentivePlanMember_label_en-US" xlink:label="lab_sgmo_TwoThousandThirteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Thirteen Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_sgmo_TwoThousandThirteenStockIncentivePlanMember_documentation_en-US" xlink:label="lab_sgmo_TwoThousandThirteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand thirteen stock incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_TwoThousandThirteenStockIncentivePlanMember" xlink:href="sgmo-20191231.xsd#sgmo_TwoThousandThirteenStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_TwoThousandThirteenStockIncentivePlanMember" xlink:to="lab_sgmo_TwoThousandThirteenStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_7191d2d6-dfb8-4c86-a988-cf24e2e2ffa6_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_aa0be1ff-1a05-4e51-80ee-d90e92d12812_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease agreement, extendable lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_86ac8ffc-7aa6-4b9e-96ef-e0a13006a0bd_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction_7c0da297-86e8-4db2-97d7-e333012478fb_terseLabel_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares not purchased by the acquirer</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction_label_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Number Of Shares Owned By Sellers Under Block Transaction</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction_documentation_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition number of shares owned by sellers under block transaction.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction" xlink:href="sgmo-20191231.xsd#sgmo_BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction" xlink:to="lab_sgmo_BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing_d2e4e27f-8801-47dd-9385-4e23e584e4cc_terseLabel_en-US" xlink:label="lab_sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of royalties to be received from sublicensing</link:label>
    <link:label id="lab_sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing_label_en-US" xlink:label="lab_sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Royalties To Be Received From Sublicensing</link:label>
    <link:label id="lab_sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing_documentation_en-US" xlink:label="lab_sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of royalties to be received from sublicensing.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" xlink:href="sgmo-20191231.xsd#sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" xlink:to="lab_sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SpecifiedStockholderOwnershipPercentage_7348c9f4-43c4-4dbf-a69e-f38a3c91f1ef_terseLabel_en-US" xlink:label="lab_sgmo_SpecifiedStockholderOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specified stockholder ownership percentage</link:label>
    <link:label id="lab_sgmo_SpecifiedStockholderOwnershipPercentage_label_en-US" xlink:label="lab_sgmo_SpecifiedStockholderOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specified Stockholder Ownership Percentage</link:label>
    <link:label id="lab_sgmo_SpecifiedStockholderOwnershipPercentage_documentation_en-US" xlink:label="lab_sgmo_SpecifiedStockholderOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specified stockholder ownership percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SpecifiedStockholderOwnershipPercentage" xlink:href="sgmo-20191231.xsd#sgmo_SpecifiedStockholderOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SpecifiedStockholderOwnershipPercentage" xlink:to="lab_sgmo_SpecifiedStockholderOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_a34b9705-685c-406b-bcf9-9e13dd8b284c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Cash Equivalents and Available-for-Sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_76bd8fd0-29d1-4a4a-99f7-74951aec43be_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_8cb9b100-6bfd-4dbe-8506-e05716c76208_terseLabel_en-US" xlink:label="lab_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of equity interests agreed to acquire</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_label_en-US" xlink:label="lab_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Percentage Of Equity Interests Agreed To Acquire</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_documentation_en-US" xlink:label="lab_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, percentage of equity interests agreed to acquire.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" xlink:href="sgmo-20191231.xsd#sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" xlink:to="lab_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_5cc834ba-a267-494e-8b65-caf81522ee9d_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_908f748b-31c2-4d20-9c75-f5440fc7eabe_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs related to Sangamo France Acquisition</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_7dc63030-714f-4fbd-8cac-2f84bd832c13_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_DeferredTaxAssetsLeaseLiability_72edb59c-f65e-42ac-b6f2-3d009b224858_terseLabel_en-US" xlink:label="lab_sgmo_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liability</link:label>
    <link:label id="lab_sgmo_DeferredTaxAssetsLeaseLiability_label_en-US" xlink:label="lab_sgmo_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liability</link:label>
    <link:label id="lab_sgmo_DeferredTaxAssetsLeaseLiability_documentation_en-US" xlink:label="lab_sgmo_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DeferredTaxAssetsLeaseLiability" xlink:href="sgmo-20191231.xsd#sgmo_DeferredTaxAssetsLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_DeferredTaxAssetsLeaseLiability" xlink:to="lab_sgmo_DeferredTaxAssetsLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_IncomeTaxesTable_7b8930c4-9d38-4291-a390-92c746ba93d9_terseLabel_en-US" xlink:label="lab_sgmo_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_sgmo_IncomeTaxesTable_label_en-US" xlink:label="lab_sgmo_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_sgmo_IncomeTaxesTable_documentation_en-US" xlink:label="lab_sgmo_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncomeTaxesTable" xlink:href="sgmo-20191231.xsd#sgmo_IncomeTaxesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_IncomeTaxesTable" xlink:to="lab_sgmo_IncomeTaxesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_0dbba081-d01c-47f8-ac8d-fa646f16a1a7_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement estimated reimbursable service costs</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Estimated Reimbursable Service Costs</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement estimated reimbursable service costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:to="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_5b196b71-e9ad-4645-98ce-1ad1e55122bb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_26de2b14-a16c-45f7-9afd-7a1b13724eaf_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo Stock Price (USD) (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_4ba2c54b-c27b-4e31-8101-c18e2c2e0850_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Accounts Payable and Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_f4143c95-9112-42ef-9307-ef919cdd0a6b_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Customers, Partnerships and Strategic Alliances</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e3cf6ba0-0b88-409d-988a-2c7abc419d30_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_e649ad42-e872-4895-8e01-fb6f0357d3ca_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1bbe8627-b5d1-4eeb-b273-1c845f741f1d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_03fd8cf6-821e-45d9-bcac-de22a9a5fa18_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_f8b4a1b8-4ec2-43a4-b262-70b791a87709_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_14d022ca-a501-4da0-b1f6-2a5f9e145ba3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from collaborators</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Collaborators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollaborators" xlink:to="lab_us-gaap_ProceedsFromCollaborators" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_00c5ca74-0388-47ac-b580-6ee1431457f1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Benefit for Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputSharePriceMember_2925b81c-8fbe-47ab-b96e-079d21e81844_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputSharePriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Share Price</link:label>
    <link:label id="lab_us-gaap_MeasurementInputSharePriceMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputSharePriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Share Price [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputSharePriceMember" xlink:to="lab_us-gaap_MeasurementInputSharePriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_5aa6c25f-db3a-4c9c-ad23-412c268c9fce_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_e11e0f39-7899-4603-ac4b-82fe54be7c77_periodStartLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity attributable to noncontrolling interest, beginning balance</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_61ce3d01-f93c-4463-8a11-0e85a1916701_periodEndLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity attributable to noncontrolling interest, ending balance</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_4c9e9271-a11d-487d-9414-37d282a12e5d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_36b1505d-641d-4b63-bd53-3a65fd185a5b_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_ec957b5f-4c8a-4063-b11a-d8660f3222f5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_35e96e87-d727-47e2-aaf9-ab6361d9fc90_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_a9c555ea-c13b-4fa6-9228-25f1d1b2e099_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AmendedCollaborationAndLicenseAgreementMember_3e89bba3-4cfe-4cd4-86ba-0844d050b37e_terseLabel_en-US" xlink:label="lab_sgmo_AmendedCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended collaboration and license agreement</link:label>
    <link:label id="lab_sgmo_AmendedCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_sgmo_AmendedCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_sgmo_AmendedCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_sgmo_AmendedCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AmendedCollaborationAndLicenseAgreementMember" xlink:href="sgmo-20191231.xsd#sgmo_AmendedCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AmendedCollaborationAndLicenseAgreementMember" xlink:to="lab_sgmo_AmendedCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_FeeDue_af5ef56d-b1e5-4627-9979-0e214e482894_terseLabel_en-US" xlink:label="lab_sgmo_FeeDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fee due</link:label>
    <link:label id="lab_sgmo_FeeDue_label_en-US" xlink:label="lab_sgmo_FeeDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fee Due</link:label>
    <link:label id="lab_sgmo_FeeDue_documentation_en-US" xlink:label="lab_sgmo_FeeDue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fee due.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FeeDue" xlink:href="sgmo-20191231.xsd#sgmo_FeeDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_FeeDue" xlink:to="lab_sgmo_FeeDue" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_NetProceedsFromIssuancePublicOffering_13b4bd6e-eb52-4174-a777-7dc5b13f3c2f_terseLabel_en-US" xlink:label="lab_sgmo_NetProceedsFromIssuancePublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from public offering of common stock, net of issuance costs</link:label>
    <link:label id="lab_sgmo_NetProceedsFromIssuancePublicOffering_b0335c59-7367-4ca7-b90c-093de348e2ef_verboseLabel_en-US" xlink:label="lab_sgmo_NetProceedsFromIssuancePublicOffering" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issuance of common stock, after deducting offering expenses</link:label>
    <link:label id="lab_sgmo_NetProceedsFromIssuancePublicOffering_label_en-US" xlink:label="lab_sgmo_NetProceedsFromIssuancePublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Proceeds From Issuance Public Offering</link:label>
    <link:label id="lab_sgmo_NetProceedsFromIssuancePublicOffering_documentation_en-US" xlink:label="lab_sgmo_NetProceedsFromIssuancePublicOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issuance public offering.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NetProceedsFromIssuancePublicOffering" xlink:href="sgmo-20191231.xsd#sgmo_NetProceedsFromIssuancePublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NetProceedsFromIssuancePublicOffering" xlink:to="lab_sgmo_NetProceedsFromIssuancePublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_daea7fd8-9f44-4d90-a51b-5e81bd369f79_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_b1d2553b-0c31-4112-8025-270cdb690a91_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1046cdf8-7c08-4d66-9288-f163b50081b8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_8d02909b-faa2-4145-957c-a90955e8e683_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_096f4236-bf28-42d7-87cd-ac96e4eb3ac3_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage limit of employee contributions</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_ae31000a-79c0-4845-a79c-04c56ce43483_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_de0c49af-1a6f-4501-bc41-acaeb014686b_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net pension losses</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_bbf712fc-2200-42fb-9781-0158e7a7e6ec_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm_94236a0b-336c-45ea-a588-b8e289ee01c2_terseLabel_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options expiration term</link:label>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm_label_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Expiration Term</link:label>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm_documentation_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award options expiration term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" xlink:href="sgmo-20191231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" xlink:to="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_adc16923-8953-45a7-9a5f-ce59fb662997_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_8e0b6e61-0bd6-4e96-8087-ce4dcedad2cb_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_09192361-67c7-4b9d-9604-7480a934e222_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues, non-current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_9c6cabbf-6971-4047-8ee0-36b6138e708b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6268536e-7141-4d96-aefa-7cfd0fb1e9c4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance_d37f9eea-439f-4cd0-aafb-5ccdbc960333_terseLabel_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee operating lease, lease not yet commenced tenant improvement allowance</link:label>
    <link:label id="lab_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance_label_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease, Lease Not Yet Commenced Tenant Improvement Allowance</link:label>
    <link:label id="lab_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance_documentation_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease, Lease Not Yet Commenced Tenant Improvement Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance" xlink:href="sgmo-20191231.xsd#sgmo_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance" xlink:to="lab_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_cb888a32-71f3-428c-986d-e9dbe8970b35_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Sangamo Therapeutics, Inc. stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9b24a108-4441-429c-ad97-1b6d1fd21204_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_FreeSharesLiabilityMember_45c28af7-8cca-4b37-9175-44f8ffd8b7f5_terseLabel_en-US" xlink:label="lab_sgmo_FreeSharesLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Free shares liability</link:label>
    <link:label id="lab_sgmo_FreeSharesLiabilityMember_label_en-US" xlink:label="lab_sgmo_FreeSharesLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Free Shares Liability [Member]</link:label>
    <link:label id="lab_sgmo_FreeSharesLiabilityMember_documentation_en-US" xlink:label="lab_sgmo_FreeSharesLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Free Shares Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FreeSharesLiabilityMember" xlink:href="sgmo-20191231.xsd#sgmo_FreeSharesLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_FreeSharesLiabilityMember" xlink:to="lab_sgmo_FreeSharesLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0a8d2291-b4e2-47a1-a900-062bf29a7818_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_a4b14185-87de-476d-9706-496537599812_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_c3cfa8be-d06d-4780-81c6-232c31c87f29_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_089e0847-cbc3-45c5-916c-dbf661050e29_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities - long-term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c517604b-8815-4373-bc40-ad3dae345152_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_79651219-0511-49be-8981-05cd5e136c44_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_9174f9a7-470d-4fae-af30-86c6630e5671_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ResearchServicesPeriod_4402909c-5671-4689-8b87-850d0e00f765_terseLabel_en-US" xlink:label="lab_sgmo_ResearchServicesPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed laboratory research reagents, research services period</link:label>
    <link:label id="lab_sgmo_ResearchServicesPeriod_label_en-US" xlink:label="lab_sgmo_ResearchServicesPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Services Period</link:label>
    <link:label id="lab_sgmo_ResearchServicesPeriod_documentation_en-US" xlink:label="lab_sgmo_ResearchServicesPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research services period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchServicesPeriod" xlink:href="sgmo-20191231.xsd#sgmo_ResearchServicesPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ResearchServicesPeriod" xlink:to="lab_sgmo_ResearchServicesPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_18f7da20-c798-43d3-89f8-0b39ebc6ee95_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_02b87824-9992-453f-b2f4-9b25a4a1aebb_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional neurological disease gene targets</link:label>
    <link:label id="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_label_en-US" xlink:label="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Number Of Additional Product Targets</link:label>
    <link:label id="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_documentation_en-US" xlink:label="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Number Of Additional Product Targets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" xlink:href="sgmo-20191231.xsd#sgmo_CollaborationAgreementNumberOfAdditionalProductTargets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" xlink:to="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValueOutstanding_bb88bf1e-d445-49f9-9569-8f88f9777a7c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.01 par value, 5,000,000 shares authorized and no shares issued or outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValueOutstanding" xlink:to="lab_us-gaap_PreferredStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_48464f8c-cb97-41bf-8f2e-0679b7054b54_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_9fa060b6-bce9-4612-84bc-ea0c7d3abf63_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accruals and reserves</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_7d270dcd-1f39-4cea-8db9-1c7a86252039_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest at end of period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_ec5d9c3d-c17d-4e5a-8477-5901cbe798a3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Domestic and Foreign Components of Loss Before Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_3982fec4-4a86-4bef-8088-2fe920aeea1f_terseLabel_en-US" xlink:label="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Summary of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:href="sgmo-20191231.xsd#sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage_13b79c78-4c3e-4d07-bb56-e3e65209d6c9_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement provision, ownership percentage (less than)</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Voting Provisions, Ownership Threshold Percentage</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Voting Provisions, Ownership Threshold Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" xlink:to="lab_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_af21c773-47f5-4817-9ecc-c782c6adab84_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_cfed8b18-f36f-4ab3-97ae-17a78ec035d5_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_c92dd0ad-e9dc-4eb4-a053-0e6fe23a7eb5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_ee566f7c-6610-4fbc-be53-af8b5e05a23d_terseLabel_en-US" xlink:label="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and other changes in right-of-use assets</link:label>
    <link:label id="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_label_en-US" xlink:label="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization And Other Changes In Right-of-Use Assets</link:label>
    <link:label id="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_documentation_en-US" xlink:label="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization And Other Changes In Right-of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets" xlink:href="sgmo-20191231.xsd#sgmo_AmortizationAndOtherChangesInRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets" xlink:to="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_c7d40785-b0e8-42f8-90fc-a1e8b695197d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3cc1fbe0-03d3-458a-b813-34965b0e5aff_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_e873953e-9b64-489e-b4e8-569b9f88dbb1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8335b806-148b-4b75-8e84-94cf48870de8_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_40fed1a0-4d7b-4aa7-abfd-f60c7b0582e3_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest and/or penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_f12d7114-d5ca-4d92-aa69-179df5dae220_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_2bd0079e-b31f-4370-be72-42717bde3185_terseLabel_en-US" xlink:label="lab_sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D</link:label>
    <link:label id="lab_sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed In Process Research And Development</link:label>
    <link:label id="lab_sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_documentation_en-US" xlink:label="lab_sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination recognized identifiable assets acquired and liabilities assumed in process research and development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" xlink:href="sgmo-20191231.xsd#sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" xlink:to="lab_sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_6654704f-2ba7-454d-9220-536c422a99f2_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_OfficeAndLaboratoryMember_033d1098-12f5-4ae7-b078-2dd61b51c643_terseLabel_en-US" xlink:label="lab_sgmo_OfficeAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office And Laboratory</link:label>
    <link:label id="lab_sgmo_OfficeAndLaboratoryMember_label_en-US" xlink:label="lab_sgmo_OfficeAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office And Laboratory [Member]</link:label>
    <link:label id="lab_sgmo_OfficeAndLaboratoryMember_documentation_en-US" xlink:label="lab_sgmo_OfficeAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office And Laboratory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OfficeAndLaboratoryMember" xlink:href="sgmo-20191231.xsd#sgmo_OfficeAndLaboratoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_OfficeAndLaboratoryMember" xlink:to="lab_sgmo_OfficeAndLaboratoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PaymentsForOtherCommitment_634014c9-c6a1-4a01-9022-7ad39df2dee9_terseLabel_en-US" xlink:label="lab_sgmo_PaymentsForOtherCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment to secure manufacturing capacity</link:label>
    <link:label id="lab_sgmo_PaymentsForOtherCommitment_label_en-US" xlink:label="lab_sgmo_PaymentsForOtherCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Other Commitment</link:label>
    <link:label id="lab_sgmo_PaymentsForOtherCommitment_documentation_en-US" xlink:label="lab_sgmo_PaymentsForOtherCommitment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Other Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PaymentsForOtherCommitment" xlink:href="sgmo-20191231.xsd#sgmo_PaymentsForOtherCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PaymentsForOtherCommitment" xlink:to="lab_sgmo_PaymentsForOtherCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_a3db0638-c997-4393-b7c0-6729583c7920_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_8a8e46fc-e9cf-45e7-a08a-71a2e0326ab6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain" xlink:to="lab_us-gaap_OtherCommitmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MilestoneRevenueReceivable_764db588-eaa5-44f5-b32b-25196806ca77_terseLabel_en-US" xlink:label="lab_sgmo_MilestoneRevenueReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone revenue receivable</link:label>
    <link:label id="lab_sgmo_MilestoneRevenueReceivable_label_en-US" xlink:label="lab_sgmo_MilestoneRevenueReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Revenue Receivable</link:label>
    <link:label id="lab_sgmo_MilestoneRevenueReceivable_documentation_en-US" xlink:label="lab_sgmo_MilestoneRevenueReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone&#8203; revenue receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneRevenueReceivable" xlink:href="sgmo-20191231.xsd#sgmo_MilestoneRevenueReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestoneRevenueReceivable" xlink:to="lab_sgmo_MilestoneRevenueReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_b76872b4-2acd-4816-85fa-909d95f63a58_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_a63fdd13-abba-4abb-ba11-4534688de051_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BusinessAcquisitionEstimatedFairValueOfFreeShares_262b668c-db31-4190-b2b2-7dd5b975fa7a_terseLabel_en-US" xlink:label="lab_sgmo_BusinessAcquisitionEstimatedFairValueOfFreeShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value of free shares</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionEstimatedFairValueOfFreeShares_label_en-US" xlink:label="lab_sgmo_BusinessAcquisitionEstimatedFairValueOfFreeShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Estimated Fair Value Of Free Shares</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionEstimatedFairValueOfFreeShares_documentation_en-US" xlink:label="lab_sgmo_BusinessAcquisitionEstimatedFairValueOfFreeShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, estimated fair value of free shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueOfFreeShares" xlink:href="sgmo-20191231.xsd#sgmo_BusinessAcquisitionEstimatedFairValueOfFreeShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessAcquisitionEstimatedFairValueOfFreeShares" xlink:to="lab_sgmo_BusinessAcquisitionEstimatedFairValueOfFreeShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_f671fbb9-36a3-489d-8573-325f02e473ff_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License fee revenues</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationAgreementTargetSelectionPeriod_7883d360-6c81-4780-b481-02cf216b41ad_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationAgreementTargetSelectionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Target selection period</link:label>
    <link:label id="lab_sgmo_CollaborationAgreementTargetSelectionPeriod_label_en-US" xlink:label="lab_sgmo_CollaborationAgreementTargetSelectionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Target Selection Period</link:label>
    <link:label id="lab_sgmo_CollaborationAgreementTargetSelectionPeriod_documentation_en-US" xlink:label="lab_sgmo_CollaborationAgreementTargetSelectionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Target Selection Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementTargetSelectionPeriod" xlink:href="sgmo-20191231.xsd#sgmo_CollaborationAgreementTargetSelectionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationAgreementTargetSelectionPeriod" xlink:to="lab_sgmo_CollaborationAgreementTargetSelectionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRentCreditCurrent_481c7a37-89dc-4f12-8b9f-76ab4409756e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_us-gaap_DeferredRentCreditCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRentCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Rent Credit, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditCurrent" xlink:to="lab_us-gaap_DeferredRentCreditCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_fc98ebe7-8fb1-4830-a4d0-8a13a9133bd7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod_109158ba-bf79-4753-a016-319e5dec78c1_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement provision, expiration period</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Voting Provisions Expiration Period</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Voting Provisions Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod" xlink:to="lab_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PreApprovalMilestoneMember_d0688ae2-2d33-42a2-9bf2-e3f3fd73c446_terseLabel_en-US" xlink:label="lab_sgmo_PreApprovalMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-approval Milestone</link:label>
    <link:label id="lab_sgmo_PreApprovalMilestoneMember_label_en-US" xlink:label="lab_sgmo_PreApprovalMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-approval Milestone [Member]</link:label>
    <link:label id="lab_sgmo_PreApprovalMilestoneMember_documentation_en-US" xlink:label="lab_sgmo_PreApprovalMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-approval Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PreApprovalMilestoneMember" xlink:href="sgmo-20191231.xsd#sgmo_PreApprovalMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PreApprovalMilestoneMember" xlink:to="lab_sgmo_PreApprovalMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeAgreementMilestoneAxis_0f3e88d8-d37a-4662-9cb7-f4a318e2190f_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeAgreementMilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone [Axis]</link:label>
    <link:label id="lab_sgmo_CollaborativeAgreementMilestoneAxis_label_en-US" xlink:label="lab_sgmo_CollaborativeAgreementMilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone [Axis]</link:label>
    <link:label id="lab_sgmo_CollaborativeAgreementMilestoneAxis_documentation_en-US" xlink:label="lab_sgmo_CollaborativeAgreementMilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneAxis" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeAgreementMilestoneAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneAxis" xlink:to="lab_sgmo_CollaborativeAgreementMilestoneAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ResearchServicesMember_77d854d7-bd15-4a74-8673-b515878c2aa6_terseLabel_en-US" xlink:label="lab_sgmo_ResearchServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research services</link:label>
    <link:label id="lab_sgmo_ResearchServicesMember_label_en-US" xlink:label="lab_sgmo_ResearchServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Services [Member]</link:label>
    <link:label id="lab_sgmo_ResearchServicesMember_documentation_en-US" xlink:label="lab_sgmo_ResearchServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchServicesMember" xlink:href="sgmo-20191231.xsd#sgmo_ResearchServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ResearchServicesMember" xlink:to="lab_sgmo_ResearchServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfProductTargets_14f0d32b-4392-46f1-8c66-7997ee7f88a1_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfProductTargets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of neurological disease gene targets</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfProductTargets_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfProductTargets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Product Targets</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfProductTargets_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfProductTargets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Product Targets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfProductTargets" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeArrangementNumberOfProductTargets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementNumberOfProductTargets" xlink:to="lab_sgmo_CollaborativeArrangementNumberOfProductTargets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_261f9408-7501-4c51-b610-11be4c0865b6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_81dbf3f5-14e2-40db-9769-383011bca57f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in unrealized gain (loss) on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_d9c81ae4-9e19-4060-8eeb-07ed6ac8fb4c_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized loss on marketable securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d5707953-93f1-428d-b8bb-7cbe28f0b369_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_4481ba7e-e4ec-4beb-bd4a-b24f6c2b3594_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_42bb1c7a-2faa-47d7-b2a9-d9dfadee19e0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_a8f0c6ae-3117-427c-b33c-04215c20d520_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_ffccb1ba-1787-4627-8a4f-45a16f409de8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Awards, Tranche 2</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Award, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_5342868d-9561-475e-a8a0-dde409407e71_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Topic 842</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_a6c1ec45-988a-4637-b67b-6041f9537240_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_378d4b61-6adf-42d1-9367-7a49df70b802_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired_73944865-6bf1-4707-a4fa-ab4a8e97ecff_terseLabel_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of ordinary shares acquired (in shares)</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired_label_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Number Of Shares Acquired</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired_documentation_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, number of shares acquired.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired" xlink:href="sgmo-20191231.xsd#sgmo_BusinessAcquisitionNumberOfSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired" xlink:to="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_FreeSharesAssetMember_dd48ef12-7884-4366-9d9a-15c75889521d_terseLabel_en-US" xlink:label="lab_sgmo_FreeSharesAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Free shares asset</link:label>
    <link:label id="lab_sgmo_FreeSharesAssetMember_label_en-US" xlink:label="lab_sgmo_FreeSharesAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Free Shares Asset [Member]</link:label>
    <link:label id="lab_sgmo_FreeSharesAssetMember_documentation_en-US" xlink:label="lab_sgmo_FreeSharesAssetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Free Shares Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FreeSharesAssetMember" xlink:href="sgmo-20191231.xsd#sgmo_FreeSharesAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_FreeSharesAssetMember" xlink:to="lab_sgmo_FreeSharesAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_513e0643-c2c2-4fb9-9747-396442ee6a33_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_b19a7ba3-8234-486e-ae38-b8b0ead03eed_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain" xlink:to="lab_us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8040800c-05af-4251-8d2d-0c8a90b96c90_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e7a40bcc-f43c-4e70-83c8-cc57e211e4e5_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_3da98810-32f2-4e69-a496-d96e9fefc642_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_b4c01e77-c627-410b-9ecf-2da9baa8a520_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a29dccd-009e-4cbe-b6c2-fdc5be1ea2cf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_23e84304-b22d-4c63-82c4-db5f75e29602_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues recognized under agreement</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_eb69b3e1-339a-47b0-acb4-06970b3de476_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax at federal statutory rate(1)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_068188cd-c595-475b-b76a-836415ed3c15_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8b843042-6792-4c82-b7ee-b4744749eda0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_03c77352-5143-4259-8423-02fc193f7a12_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_5af98d3e-2fee-410c-91d2-889b251effd1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_FormerExecutiveOfSangamoFranceMember_964731ee-725e-43c8-8ff8-0dad33bba1cc_terseLabel_en-US" xlink:label="lab_sgmo_FormerExecutiveOfSangamoFranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Executive of TxCell</link:label>
    <link:label id="lab_sgmo_FormerExecutiveOfSangamoFranceMember_label_en-US" xlink:label="lab_sgmo_FormerExecutiveOfSangamoFranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Executive Of Sangamo France [Member]</link:label>
    <link:label id="lab_sgmo_FormerExecutiveOfSangamoFranceMember_documentation_en-US" xlink:label="lab_sgmo_FormerExecutiveOfSangamoFranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Executive Of Sangamo France</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FormerExecutiveOfSangamoFranceMember" xlink:href="sgmo-20191231.xsd#sgmo_FormerExecutiveOfSangamoFranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_FormerExecutiveOfSangamoFranceMember" xlink:to="lab_sgmo_FormerExecutiveOfSangamoFranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_77ea377c-bc6b-4a1b-9a2c-975648ebf3d0_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, gross unrealized (Losses)</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_953b58d1-0a88-4130-bfe9-63e8602fa470_terseLabel_en-US" xlink:label="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and sales-based milestone payments to be received</link:label>
    <link:label id="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_label_en-US" xlink:label="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Contract Liability Milestone Payment Eligible To Receive</link:label>
    <link:label id="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_documentation_en-US" xlink:label="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer contract liability milestone payment eligible to receive.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:href="sgmo-20191231.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:to="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_a5d3e60c-68b4-4c8b-beeb-191e8da99744_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty revenues</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseAgreementTermsMember_bf7fe691-a2d3-432c-91dd-5c6bfe096d3d_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement terms</link:label>
    <link:label id="lab_us-gaap_LicenseAgreementTermsMember_label_en-US" xlink:label="lab_us-gaap_LicenseAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Terms [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAgreementTermsMember" xlink:to="lab_us-gaap_LicenseAgreementTermsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_5d8a5335-b770-4da8-bc20-c040586760cf_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_2822a7bb-6d1c-41b3-b6c5-a24d9342313b_terseLabel_en-US" xlink:label="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement and Tender Offer Agreement</link:label>
    <link:label id="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_3b476586-bb50-4c96-8fca-3d6c09d62f76_verboseLabel_en-US" xlink:label="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPA and TOA</link:label>
    <link:label id="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_label_en-US" xlink:label="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement And Tender Offer Agreement [Member]</link:label>
    <link:label id="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_documentation_en-US" xlink:label="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share purchase agreement and tender offer agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" xlink:href="sgmo-20191231.xsd#sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" xlink:to="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_7e32a33c-075b-45e5-a319-f7afd87eefed_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_e3249c46-d43e-4621-93a4-3453a90fe79f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_f7ec980c-e3ac-42bc-b39f-c4be690f4dfc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_c1e79f5f-d8fd-4f9b-84b4-b9b4d5c794ff_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidRent_044aaf75-8708-49e8-a6b3-78f70727ab29_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid rent</link:label>
    <link:label id="lab_us-gaap_PrepaidRent_label_en-US" xlink:label="lab_us-gaap_PrepaidRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidRent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidRent" xlink:to="lab_us-gaap_PrepaidRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_961b3653-dc95-4971-8762-36da0f2b156e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_302a4e83-5d93-45cb-b21b-075255408721_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_27d255a4-7c1f-49d1-82d6-49ce75fb9643_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_0497354f-b3e4-4220-a316-1427c3e8decf_terseLabel_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs vested and expected to vest at end of period</link:label>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_label_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Aggregate Intrinsic Value</link:label>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options vested and expected to vest aggregate intrinsic value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" xlink:href="sgmo-20191231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" xlink:to="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_2126c1ee-6359-479b-8d64-26ad0387f135_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified clinical development and regulatory milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Specified Clinical Development And Regulatory Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Specified Clinical Development and Regulatory Milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" xlink:href="sgmo-20191231.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" xlink:to="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_41f64bf3-d4f6-4a74-8593-6de38b354abb_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_74e8f538-3722-458f-922a-23176e352aef_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_4bde30cf-aff3-4109-b306-703354aa8e77_negatedLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer, liability, cumulative catch-up adjustment to revenue, change in measure of progress</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_85d97a7c-b115-44d4-9eae-d5d42b070b4f_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_9463b61b-c17e-434f-b560-edb6446b2e14_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivableCurrent" xlink:to="lab_us-gaap_InterestReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld_9002a717-5d29-477d-8304-734727064afa_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement restriction, percentage of shares held</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Agreement Restriction, Percentage Of Shares Held</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Agreement Restriction, Percentage Of Shares Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" xlink:to="lab_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_ff2aa329-0000-4a88-a709-8b7569d8096a_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_9ddcb785-5260-4334-82ad-3a61dd36c29f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Awards, Tranche 1</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Award, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_13065fed-10fb-43c3-94ab-5602e179b124_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net operating loss carryforwards for state</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_a3411aba-ad73-444f-803c-cc2edc0e15a0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_7d54a61e-6a40-4532-bac5-a5032b7c799b_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_ae7968b6-e501-43d1-aa5e-630eea6d23f7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_65c012cd-7b0d-47db-8f04-a1d0e06d097a_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total payments for the employees' tax obligations to taxing authorities</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Related to Tax Withholding for Share-based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BiogenMAIncMember_6a54dd11-e72d-4d06-9a82-419fbd5885ed_terseLabel_en-US" xlink:label="lab_sgmo_BiogenMAIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen MA Inc</link:label>
    <link:label id="lab_sgmo_BiogenMAIncMember_label_en-US" xlink:label="lab_sgmo_BiogenMAIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen MA Inc [Member]</link:label>
    <link:label id="lab_sgmo_BiogenMAIncMember_documentation_en-US" xlink:label="lab_sgmo_BiogenMAIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen MA Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember" xlink:href="sgmo-20191231.xsd#sgmo_BiogenMAIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BiogenMAIncMember" xlink:to="lab_sgmo_BiogenMAIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_1212b41d-97f1-468e-a18c-12527f342ae7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Awards, Tranche 3</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Award, Tranche Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_345c6bf1-999d-4e23-9f8c-3285a625cf02_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income/ (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_f1950fb1-ac1e-414d-9a3f-45e2a77a3eab_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SeparateUpfrontFee_ea19da09-cac0-4133-93b9-632a07b0d854_terseLabel_en-US" xlink:label="lab_sgmo_SeparateUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate fee for additional term</link:label>
    <link:label id="lab_sgmo_SeparateUpfrontFee_label_en-US" xlink:label="lab_sgmo_SeparateUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate Upfront Fee</link:label>
    <link:label id="lab_sgmo_SeparateUpfrontFee_documentation_en-US" xlink:label="lab_sgmo_SeparateUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate upfront fee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SeparateUpfrontFee" xlink:href="sgmo-20191231.xsd#sgmo_SeparateUpfrontFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SeparateUpfrontFee" xlink:to="lab_sgmo_SeparateUpfrontFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_89ead8b0-b763-4fa8-b376-35d230973e3b_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo France Stock Price (EUR) (in Euro per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_60127e33-69c2-4151-82bc-4dfe40c01e80_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_a9c8a9b8-6020-42d1-8582-f6725c0f57b8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_58383419-84a9-4ec3-896d-6e6867f0e54e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_800f8b19-3782-4902-8ea8-a51c7f6409e1_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_32b585cf-3475-4bac-9b93-143128dff331_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_49b5a04e-b9b7-4503-b231-375a94a01ed7_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of credit</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3cbefd77-f132-49fc-979c-d84232d9b2c6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_647ac249-6c07-47cc-959c-4d1eb073ebd5_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_8681389f-2ea6-4417-aa04-5d726cdc3345_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligation_b5aa55c8-f18c-4ff2-b1ef-55af43be368c_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual obligation</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_label_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="lab_us-gaap_ContractualObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ScheduleOfNoncontrollingInterestTableTextBlock_7d84f53b-4bc2-460f-8c2c-baf8c7a628a6_terseLabel_en-US" xlink:label="lab_sgmo_ScheduleOfNoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Non-controlling Interest</link:label>
    <link:label id="lab_sgmo_ScheduleOfNoncontrollingInterestTableTextBlock_label_en-US" xlink:label="lab_sgmo_ScheduleOfNoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Noncontrolling Interest Table [Text Block]</link:label>
    <link:label id="lab_sgmo_ScheduleOfNoncontrollingInterestTableTextBlock_documentation_en-US" xlink:label="lab_sgmo_ScheduleOfNoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of noncontrolling interest.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ScheduleOfNoncontrollingInterestTableTextBlock" xlink:href="sgmo-20191231.xsd#sgmo_ScheduleOfNoncontrollingInterestTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ScheduleOfNoncontrollingInterestTableTextBlock" xlink:to="lab_sgmo_ScheduleOfNoncontrollingInterestTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantMember_3c6bf29a-3978-4fbf-81e0-bc3431360a18_terseLabel_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research grants</link:label>
    <link:label id="lab_us-gaap_GrantMember_label_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember" xlink:to="lab_us-gaap_GrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_e6fa4396-5380-4f25-86e7-24ce3fb93451_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase_a2927225-e8a2-4762-95de-24a035236c6b_terseLabel_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, number of free shares outstanding subject to purchase (in shares)</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase_label_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Number Of Free Shares Outstanding Subject To Purchase</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase_documentation_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Number Of Free Shares Outstanding Subject To Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" xlink:href="sgmo-20191231.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" xlink:to="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_eb9632c6-15b6-4559-a914-7bba9532b085_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5e293dca-3f5d-4374-8d63-c3e878066089_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_89d3a1c3-8952-4828-aa87-742e4205919f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_aba3799a-4e57-40d9-b530-a68e39b2c2a1_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balances (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_31aeab06-760f-4c2c-ba16-ac2a968084e6_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balances (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_87ee6bcc-8313-4a1f-a600-c07eecdd28b4_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_251ff65b-3e9e-4285-b7a3-c05238f03de1_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AccruedResearchAndDevelopmentExpenses_afed91ff-3af5-4100-b3dc-5fc6607610df_terseLabel_en-US" xlink:label="lab_sgmo_AccruedResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development expenses</link:label>
    <link:label id="lab_sgmo_AccruedResearchAndDevelopmentExpenses_label_en-US" xlink:label="lab_sgmo_AccruedResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Expenses</link:label>
    <link:label id="lab_sgmo_AccruedResearchAndDevelopmentExpenses_documentation_en-US" xlink:label="lab_sgmo_AccruedResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AccruedResearchAndDevelopmentExpenses" xlink:href="sgmo-20191231.xsd#sgmo_AccruedResearchAndDevelopmentExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AccruedResearchAndDevelopmentExpenses" xlink:to="lab_sgmo_AccruedResearchAndDevelopmentExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_001c9b85-4876-4364-8551-f5fa286cf3ec_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Estimated Fair Value of Net Assets Acquired</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_OneTimeLicenseFeeEarned_50c2048d-2ba8-4fc6-a92d-9b426b2a876f_terseLabel_en-US" xlink:label="lab_sgmo_OneTimeLicenseFeeEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-time license fee earned on exercise of option</link:label>
    <link:label id="lab_sgmo_OneTimeLicenseFeeEarned_label_en-US" xlink:label="lab_sgmo_OneTimeLicenseFeeEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Time License Fee Earned</link:label>
    <link:label id="lab_sgmo_OneTimeLicenseFeeEarned_documentation_en-US" xlink:label="lab_sgmo_OneTimeLicenseFeeEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One time license fee earned.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OneTimeLicenseFeeEarned" xlink:href="sgmo-20191231.xsd#sgmo_OneTimeLicenseFeeEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_OneTimeLicenseFeeEarned" xlink:to="lab_sgmo_OneTimeLicenseFeeEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_3b1c88ae-9c27-464c-a897-7d482784ce8e_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of additional Sangamo France shares</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_6373466d-f127-409d-ac68-ac6552ecd426_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire additional interest in subsidiaries</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Additional Interest in Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:to="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_36a56a51-1c7d-408b-854d-478acb5dc858_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_a255f97f-561c-436d-aeb4-85b47f5c4dd6_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease, cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_67028849-af65-473a-bd68-3b2aed283e1f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized stock-based employee compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_3e71e972-0166-48b0-a9f3-19e089aa84de_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit for income taxes:</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9edf313b-ddbb-46be-8856-331f12d68588_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_52fe9d71-85ad-4ce9-9622-b300f79198b6_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation_a14875fb-8e61-41b8-9200-06845b94f828_terseLabel_en-US" xlink:label="lab_sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible stock-based compensation</link:label>
    <link:label id="lab_sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation_label_en-US" xlink:label="lab_sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation Nondeductible Expense Income Share Based Compensation</link:label>
    <link:label id="lab_sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation_documentation_en-US" xlink:label="lab_sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax reconciliation nondeductible expense income share based compensation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation" xlink:href="sgmo-20191231.xsd#sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation" xlink:to="lab_sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_971a5956-be90-4513-8624-c7fdf7580eb9_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non- Controlling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_28a0b687-00ca-451e-ac9f-701e44112e0d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_fa8e89d9-71b1-4316-aa1c-20865268a5e4_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_df8f5093-2d87-4e7b-90e1-efe21ccd6994_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm_aece6a92-1bdc-4fcc-af01-0ec8242ff2f1_terseLabel_en-US" xlink:label="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options to extend initial research term</link:label>
    <link:label id="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm_label_en-US" xlink:label="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Options To Extend Initial Research Term</link:label>
    <link:label id="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm_documentation_en-US" xlink:label="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Options To Extend Initial Research Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfOptionsToExtendInitialResearchTerm" xlink:href="sgmo-20191231.xsd#sgmo_NumberOfOptionsToExtendInitialResearchTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NumberOfOptionsToExtendInitialResearchTerm" xlink:to="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember_17e3c7e5-ef3b-402c-bca1-bdb1de8908ec_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified sales milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Specified Sales Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Specified Sales Milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesMilestonesMember" xlink:href="sgmo-20191231.xsd#sgmo_AchievementOfSpecifiedSalesMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedSalesMilestonesMember" xlink:to="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BuildToSuitLeaseMember_469f1c2a-c360-48cb-a1b1-136c8dddd7d4_terseLabel_en-US" xlink:label="lab_sgmo_BuildToSuitLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Build-to-Suit Leases</link:label>
    <link:label id="lab_sgmo_BuildToSuitLeaseMember_label_en-US" xlink:label="lab_sgmo_BuildToSuitLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Build To Suit Lease [Member]</link:label>
    <link:label id="lab_sgmo_BuildToSuitLeaseMember_documentation_en-US" xlink:label="lab_sgmo_BuildToSuitLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Build-to-suit lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BuildToSuitLeaseMember" xlink:href="sgmo-20191231.xsd#sgmo_BuildToSuitLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BuildToSuitLeaseMember" xlink:to="lab_sgmo_BuildToSuitLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_2a9653a2-a747-4869-bcf2-96624933d85e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_bd43742a-96cc-4293-8092-4eaf1d97b464_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_aba428fc-8040-4d18-a39a-86b80b446a84_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_359da25e-881a-415f-9489-9c274e247711_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_98505843-897d-41e0-bdf5-5a19cef3eae3_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_GainOnFreeShares_28ca0c07-d6b2-47c2-90bf-5136f3185169_negatedLabel_en-US" xlink:label="lab_sgmo_GainOnFreeShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on free shares</link:label>
    <link:label id="lab_sgmo_GainOnFreeShares_label_en-US" xlink:label="lab_sgmo_GainOnFreeShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain On Free Shares</link:label>
    <link:label id="lab_sgmo_GainOnFreeShares_documentation_en-US" xlink:label="lab_sgmo_GainOnFreeShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain On Free Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GainOnFreeShares" xlink:href="sgmo-20191231.xsd#sgmo_GainOnFreeShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_GainOnFreeShares" xlink:to="lab_sgmo_GainOnFreeShares" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_b775966b-3a91-40b1-a5f0-6a8998f80b83_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AnnualFeesRelatedToAgreement_6918f9dc-2a60-47ed-a28a-332dc4a5f164_terseLabel_en-US" xlink:label="lab_sgmo_AnnualFeesRelatedToAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual fees</link:label>
    <link:label id="lab_sgmo_AnnualFeesRelatedToAgreement_label_en-US" xlink:label="lab_sgmo_AnnualFeesRelatedToAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Fees Related To Agreement</link:label>
    <link:label id="lab_sgmo_AnnualFeesRelatedToAgreement_documentation_en-US" xlink:label="lab_sgmo_AnnualFeesRelatedToAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual fees related to agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AnnualFeesRelatedToAgreement" xlink:href="sgmo-20191231.xsd#sgmo_AnnualFeesRelatedToAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AnnualFeesRelatedToAgreement" xlink:to="lab_sgmo_AnnualFeesRelatedToAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1c34fe28-e850-4edc-8eff-0334826537ef_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SharePurchaseAgreementMember_452097a0-b9fa-4e72-9230-6e81e62f1e64_terseLabel_en-US" xlink:label="lab_sgmo_SharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPA</link:label>
    <link:label id="lab_sgmo_SharePurchaseAgreementMember_label_en-US" xlink:label="lab_sgmo_SharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement [Member]</link:label>
    <link:label id="lab_sgmo_SharePurchaseAgreementMember_documentation_en-US" xlink:label="lab_sgmo_SharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SharePurchaseAgreementMember" xlink:href="sgmo-20191231.xsd#sgmo_SharePurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SharePurchaseAgreementMember" xlink:to="lab_sgmo_SharePurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_fbd1a844-4133-4b07-9158-3edebeabc2aa_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_725d1b39-f65b-44e4-8462-c7ef95750f84_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_3fa3ee84-299a-457c-8199-cf6d6410c541_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_0ab26739-8654-472d-a3c9-e873a5b43f87_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice_bf645659-2269-4263-b9b3-b34327acd598_terseLabel_en-US" xlink:label="lab_sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued under employee stock purchase plans, average exercise price (in dollars per share)</link:label>
    <link:label id="lab_sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice_label_en-US" xlink:label="lab_sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued Under Employee Stock Purchase Plans Average Exercise Price</link:label>
    <link:label id="lab_sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice_documentation_en-US" xlink:label="lab_sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued under employee stock purchase plans average exercise price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice" xlink:href="sgmo-20191231.xsd#sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice" xlink:to="lab_sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_df6299ee-e8cd-41bd-9c56-98ee973ec6c2_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs outstanding at end of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_77e9af2d-13c8-434b-abf8-eb81af700203_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_StockPurchaseAgreementMember_de620db3-3d6d-4448-bc20-9dfe4cfca243_terseLabel_en-US" xlink:label="lab_sgmo_StockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement</link:label>
    <link:label id="lab_sgmo_StockPurchaseAgreementMember_label_en-US" xlink:label="lab_sgmo_StockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement [Member]</link:label>
    <link:label id="lab_sgmo_StockPurchaseAgreementMember_documentation_en-US" xlink:label="lab_sgmo_StockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockPurchaseAgreementMember" xlink:href="sgmo-20191231.xsd#sgmo_StockPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_StockPurchaseAgreementMember" xlink:to="lab_sgmo_StockPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_IntangibleAssetsExcludingGoodwillRollForward_9e7c3b06-efea-4dd3-b1ba-0f2753a67bb2_terseLabel_en-US" xlink:label="lab_sgmo_IntangibleAssetsExcludingGoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets (Excluding Goodwill)</link:label>
    <link:label id="lab_sgmo_IntangibleAssetsExcludingGoodwillRollForward_label_en-US" xlink:label="lab_sgmo_IntangibleAssetsExcludingGoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets (Excluding Goodwill) [Roll Forward]</link:label>
    <link:label id="lab_sgmo_IntangibleAssetsExcludingGoodwillRollForward_documentation_en-US" xlink:label="lab_sgmo_IntangibleAssetsExcludingGoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IntangibleAssetsExcludingGoodwillRollForward" xlink:href="sgmo-20191231.xsd#sgmo_IntangibleAssetsExcludingGoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_IntangibleAssetsExcludingGoodwillRollForward" xlink:to="lab_sgmo_IntangibleAssetsExcludingGoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_DowAgroSciencesMember_2fd09a48-ee9c-447f-bdf6-5ff23e7064cc_terseLabel_en-US" xlink:label="lab_sgmo_DowAgroSciencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dow Agro Sciences</link:label>
    <link:label id="lab_sgmo_DowAgroSciencesMember_label_en-US" xlink:label="lab_sgmo_DowAgroSciencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dow Agro Sciences [Member]</link:label>
    <link:label id="lab_sgmo_DowAgroSciencesMember_documentation_en-US" xlink:label="lab_sgmo_DowAgroSciencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dow agro sciences.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DowAgroSciencesMember" xlink:href="sgmo-20191231.xsd#sgmo_DowAgroSciencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_DowAgroSciencesMember" xlink:to="lab_sgmo_DowAgroSciencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeAgreementMilestoneDomain_08b0dd9c-816b-4a1f-94e1-a61f8c7c12b7_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeAgreementMilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone</link:label>
    <link:label id="lab_sgmo_CollaborativeAgreementMilestoneDomain_label_en-US" xlink:label="lab_sgmo_CollaborativeAgreementMilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone [Domain]</link:label>
    <link:label id="lab_sgmo_CollaborativeAgreementMilestoneDomain_documentation_en-US" xlink:label="lab_sgmo_CollaborativeAgreementMilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneDomain" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeAgreementMilestoneDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain" xlink:to="lab_sgmo_CollaborativeAgreementMilestoneDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_048b005b-c2d3-4005-86a4-1c9d4dac647d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Quarterly Financial Data</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementStandstillRestrictionPeriod_0e5935de-5811-4f50-88ed-24ccacef4856_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementStandstillRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement restriction expiration period</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementStandstillRestrictionPeriod_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementStandstillRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Standstill Restriction Period</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementStandstillRestrictionPeriod_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementStandstillRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Standstill Restriction Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementStandstillRestrictionPeriod" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeArrangementStandstillRestrictionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementStandstillRestrictionPeriod" xlink:to="lab_sgmo_CollaborativeArrangementStandstillRestrictionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_7edd47ea-5ae8-4326-b283-b49272825803_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_66369db1-da71-4a64-8100-4a3994c6b295_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cef7bb5c-4fa5-4282-bad1-73fa2e6f41e2_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d9fc5d25-f049-471e-bc5d-e26bdc0e07db_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash as reported within the Consolidated Statements of Cash Flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_28364714-2c01-40d7-b983-bf0886dae565_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_c6926c2d-575f-4d7c-8857-74fad8c429ee_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_a8297f73-bb00-4f73-8fd3-9d3ad3908e56_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairments</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_943de9af-f6a2-4dd9-872f-438c2a81e857_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_7700b53a-a118-4c8d-93fe-9935c74e65da_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_be5b04fc-9501-4326-8c0a-b8f6c48c6033_terseLabel_en-US" xlink:label="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaboration Agreements, Grants And Licensing Concentration Risk [Member]</link:label>
    <link:label id="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_label_en-US" xlink:label="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaboration Agreements, Grants And Licensing Concentration Risk [Member]</link:label>
    <link:label id="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_documentation_en-US" xlink:label="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaboration Agreements, Grants And Licensing Concentration Risk</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:href="sgmo-20191231.xsd#sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:to="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_87e012c3-fe2f-4a74-96bc-0c5296fa6fe8_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage_9ba29305-93a4-44b6-82fe-7506460eadaa_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement restriction, ownership percentage (less than)</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Standstill Restriction, Ownership Threshold Percentage Ownership Percentage</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Standstill Restriction, Ownership Threshold Percentage Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" xlink:to="lab_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bd9d4dff-4169-4389-803c-0d5c6d1641b7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_ca2fc818-6225-4c07-bd83-84f4925ebc7b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityMeasurementInput_19afdd7f-78ce-4b0a-b5da-7d98d36eb239_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility Estimate</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="lab_us-gaap_DerivativeLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_0a7f73bc-5c31-4285-b079-5b5d17cad497_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual&#160;Term</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_4e5a9274-938d-4241-8a92-f1cee1ca1599_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_7e3bed1d-10e0-4f35-8dbd-f554189b54b8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities, non-current</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_535d6cd0-7324-48af-b340-468980c14b62_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_daaf8eae-98d7-4f30-bfb8-29452514a850_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_58a52932-979a-4624-bebc-703d3c730fdf_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_61367205-c0bd-441e-b9f9-008c4c61d7a1_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c7e80c16-f310-4978-aa89-41f82fa3a117_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents, estimated fair value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_372e6902-62f7-48ab-a2a0-363ebdbd4ba2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign rate differential</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1aa62259-cd97-4d88-96af-14f04628d19e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_5782ad11-8326-49e2-9eaa-685801f2dc9b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_cccba46e-896c-4644-9c65-81eae5c1910d_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnTerminationOfLease_c99b7205-d65c-47af-bc7c-0fe22cd73a72_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnTerminationOfLease" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss on lease termination</link:label>
    <link:label id="lab_us-gaap_GainLossOnTerminationOfLease_label_en-US" xlink:label="lab_us-gaap_GainLossOnTerminationOfLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Termination of Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnTerminationOfLease" xlink:to="lab_us-gaap_GainLossOnTerminationOfLease" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_KitePharmaIncMember_1509a780-6b8f-40f5-802c-a7dd4be5c0e7_terseLabel_en-US" xlink:label="lab_sgmo_KitePharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kite Pharma, Inc. ("Kite")</link:label>
    <link:label id="lab_sgmo_KitePharmaIncMember_label_en-US" xlink:label="lab_sgmo_KitePharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kite Pharma Inc [Member]</link:label>
    <link:label id="lab_sgmo_KitePharmaIncMember_documentation_en-US" xlink:label="lab_sgmo_KitePharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kite Pharma Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember" xlink:href="sgmo-20191231.xsd#sgmo_KitePharmaIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_KitePharmaIncMember" xlink:to="lab_sgmo_KitePharmaIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_fb19d9d6-6a56-47fc-aee3-ceed34346ca7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_3a61bf6b-c39d-47b5-a79c-891214178459_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_806a856d-fb41-4d33-99c5-3d27b40c0e8a_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_7529f323-1106-4501-8a14-8f1b1d445a56_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_f7896bc6-c6af-486b-acf2-d881fd449d48_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_7dc453e9-90b9-4c15-aac6-0624e027b047_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_1e3ef704-fbb2-469f-8736-49322ffa2fb7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Assumptions Used for Estimating Fair Value of ESPP Purchase Rights</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_d7936b7f-45c2-4525-b6cb-5589df071af6_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_dcb13b77-3208-4c9e-b58d-8d98605baff3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_51cf4c52-30db-4802-9359-f45ebbdd1391_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_95d0627e-72ec-490b-9e23-14f7bd197556_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, maximum employer's contribution per employee</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_08eeae07-5307-48a3-b2fe-3d9451fefada_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues under agreement</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_2c8e253a-3ea8-437a-a336-d38dcadbb362_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_c2b7b305-0611-43d0-9e07-12a70eafa374_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_c5542bbe-5a1b-4477-a68d-4139a40590c9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal rate change</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_a2e06045-432e-424c-812e-1d4108cd4d1d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest at end of period (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_42101d47-5416-4090-af7a-447b792cee4b_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_064f6b26-db23-4f7c-8689-c1ba0303c850_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_1e1407cc-096a-497a-8c90-324b39de7ac1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs outstanding at end of period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_f56d021f-f064-43fb-b811-b2998f4f3eae_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_d0855f89-7f5e-44c5-bd44-40df3c505e9c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for issuance of future awards (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_bdde91d6-5526-416c-80a4-ce6fa3ac9f53_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_40d0fd7a-b03e-414c-8208-b43155d582fb_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_5d6adfe8-e4fe-4d4c-b073-66d4428e7882_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_53431c2d-793a-44e9-a2b7-b7bfa8502be9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_7d2ce29f-3b31-4c18-8282-0f523539047b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder_1729d975-8dbf-4370-8da4-70bfd6cdb61f_terseLabel_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option maximum term for specified stockholder</link:label>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder_label_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Maximum Term For Specified Stock Holder</link:label>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder_documentation_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award options maximum term for specified stock holder.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder" xlink:href="sgmo-20191231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder" xlink:to="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_bc3140ea-b4f4-4fed-8d1f-9ff5dbf61b8e_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Correlation Sangamo and Sangamo France Stock Prices</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_adba966e-9991-4987-9c99-01d374fbeb49_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures included in unpaid liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_dbd6e7dc-3a82-4cac-bb80-2e9d784fbcef_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_5611cc99-c8ca-4cad-8e75-26b031e7f84b_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_52619c8a-4f45-44af-8b7a-99d50651e23d_terseLabel_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative-effect adjustment</link:label>
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_c9cd096f-663d-4aa5-8e80-4bec6a17234d_negatedLabel_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative effect of new accounting principle in period of adoption</link:label>
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_label_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect of New Accounting Principle in Period of Adoption</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:to="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_1d407c96-ad1d-4494-ae6d-b295086e1dfb_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_3eeb14e2-6910-4044-b792-d8443b232b22_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate&#160;Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_1bebf95a-35e4-4de2-b6ba-ba289c5ba811_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_d80de02d-4aa1-4025-b633-2dabb93cc185_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_369c1236-67ae-454d-812f-007518addfb9_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized losses from the sale of available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Gross Realized Losses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_def7623b-32b5-47c6-9f5a-9e62774a5670_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_f381de66-113e-4438-a73b-0ea51edfcabb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of Sangamo France</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_eff4cbfc-85c1-4c97-979f-20c66d1096ae_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of net assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_0e053252-a5e1-4ae2-9ee4-23ec4d691ffb_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_9c611c29-3a5c-420b-81df-a560a3460248_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestTable_52b87565-23ac-45db-a811-7a3b3664ad75_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestTable_label_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestTable" xlink:to="lab_us-gaap_MinorityInterestTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_39e06860-c610-4690-a4c9-d43f1fa66dc0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes, net</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseAndServiceMember_85017ae4-9c7c-4759-918c-26a0a5bfe6b5_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreements</link:label>
    <link:label id="lab_us-gaap_LicenseAndServiceMember_6989f42e-e929-4088-9b18-3b14f6f44a73_verboseLabel_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of upfront fee</link:label>
    <link:label id="lab_us-gaap_LicenseAndServiceMember_label_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAndServiceMember" xlink:to="lab_us-gaap_LicenseAndServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_c965a1f8-0914-452a-ba56-fe6bd2075b6d_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_0549d347-a8c2-42eb-b75a-ab66d0bb6c4e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_37371490-7fc8-41c9-8129-80d02da720de_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_cda833f1-09d0-472d-b08a-5b720676440f_terseLabel_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_label_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:href="sgmo-20191231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities_2feac2f1-e9f9-4e62-bc9b-87c41e6b879b_terseLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and available-for-sale securities, estimated fair value</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities_label_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Available For Sale Securities</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and available for sale securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:href="sgmo-20191231.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:to="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_225f1075-5782-4958-8bdf-9a040e629c40_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_62a3b5ba-6716-4470-b90a-293cd62adb4e_terseLabel_en-US" xlink:label="lab_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition estimated fair value assets of free shares</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_label_en-US" xlink:label="lab_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Estimated Fair Value Assets Of Free Shares</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_documentation_en-US" xlink:label="lab_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Estimated Fair Value Assets Of Free Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares" xlink:href="sgmo-20191231.xsd#sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares" xlink:to="lab_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_5677e91d-edde-48e7-a0d9-2265d9f5d2ea_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_36ce8b03-a680-4168-ad74-9f1c0a1a5e2e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_ae09fcaa-b4b2-4017-b8b4-4cd6a730e5cc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_EmployeeStockPurchasePlanMember_ce6669c0-d223-4374-943b-84a8cdae93a3_terseLabel_en-US" xlink:label="lab_sgmo_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2010 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_sgmo_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_sgmo_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_sgmo_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_sgmo_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_EmployeeStockPurchasePlanMember" xlink:href="sgmo-20191231.xsd#sgmo_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_EmployeeStockPurchasePlanMember" xlink:to="lab_sgmo_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_066f051c-22a7-440e-b0e8-cfc4e801142f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_f19b43ba-893e-4609-a047-8782c9799acb_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ResearchAndOfficeSpaceMember_1cfce917-d7a3-44be-8fcf-d3a792d75dee_terseLabel_en-US" xlink:label="lab_sgmo_ResearchAndOfficeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Office Space</link:label>
    <link:label id="lab_sgmo_ResearchAndOfficeSpaceMember_label_en-US" xlink:label="lab_sgmo_ResearchAndOfficeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Office Space [Member]</link:label>
    <link:label id="lab_sgmo_ResearchAndOfficeSpaceMember_documentation_en-US" xlink:label="lab_sgmo_ResearchAndOfficeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and office space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchAndOfficeSpaceMember" xlink:href="sgmo-20191231.xsd#sgmo_ResearchAndOfficeSpaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ResearchAndOfficeSpaceMember" xlink:to="lab_sgmo_ResearchAndOfficeSpaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_LicenseObligations_d18c8e23-c016-48a8-b33a-a7b7723c6bab_terseLabel_en-US" xlink:label="lab_sgmo_LicenseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License obligations</link:label>
    <link:label id="lab_sgmo_LicenseObligations_label_en-US" xlink:label="lab_sgmo_LicenseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Obligations</link:label>
    <link:label id="lab_sgmo_LicenseObligations_documentation_en-US" xlink:label="lab_sgmo_LicenseObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LicenseObligations" xlink:href="sgmo-20191231.xsd#sgmo_LicenseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_LicenseObligations" xlink:to="lab_sgmo_LicenseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_098bdd65-36c8-4d1a-a999-0c42fc320aed_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_23cf5e85-1320-49e4-adde-97690d311484_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_InitialResearchTermOfAgreement_f5b903d5-a904-41e0-af8d-b3a377327c9a_terseLabel_en-US" xlink:label="lab_sgmo_InitialResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial research term of agreement</link:label>
    <link:label id="lab_sgmo_InitialResearchTermOfAgreement_6f9ceee9-cabc-4330-8503-f142ae28f030_verboseLabel_en-US" xlink:label="lab_sgmo_InitialResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research program to develop laboratory research reagents</link:label>
    <link:label id="lab_sgmo_InitialResearchTermOfAgreement_label_en-US" xlink:label="lab_sgmo_InitialResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Research Term Of Agreement</link:label>
    <link:label id="lab_sgmo_InitialResearchTermOfAgreement_documentation_en-US" xlink:label="lab_sgmo_InitialResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial research term of agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_InitialResearchTermOfAgreement" xlink:href="sgmo-20191231.xsd#sgmo_InitialResearchTermOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_InitialResearchTermOfAgreement" xlink:to="lab_sgmo_InitialResearchTermOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_a8451554-b47f-45a9-9883-ccdeb89effa4_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_label_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestLineItems" xlink:to="lab_us-gaap_MinorityInterestLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_487564a6-19c6-4104-8caf-ba63e40d20a4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_TwoThousandEighteenStockIncentivePlanMember_27fa38cc-831b-4d1a-9b21-37edb27fda68_terseLabel_en-US" xlink:label="lab_sgmo_TwoThousandEighteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Stock Incentive Plan</link:label>
    <link:label id="lab_sgmo_TwoThousandEighteenStockIncentivePlanMember_label_en-US" xlink:label="lab_sgmo_TwoThousandEighteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Eighteen Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_sgmo_TwoThousandEighteenStockIncentivePlanMember_documentation_en-US" xlink:label="lab_sgmo_TwoThousandEighteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand eighteen stock incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_TwoThousandEighteenStockIncentivePlanMember" xlink:href="sgmo-20191231.xsd#sgmo_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_TwoThousandEighteenStockIncentivePlanMember" xlink:to="lab_sgmo_TwoThousandEighteenStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_4c4acddb-cd48-4867-b652-13aa74f36953_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_4bc77e98-4258-4225-b52e-dcd6cd046ce0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value on recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_85fe8f28-92cc-432f-8479-24589e3ccd1e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_d0faa759-c532-491f-b5f8-976f10fbeb26_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ad1ea100-3664-48db-80e4-4899826b10e0_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_1b11129d-af23-4ae1-ad80-cc4c80ba3ceb_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenue_5e2104ae-197d-48c4-a07d-47c83eb536d3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenue_label_en-US" xlink:label="lab_us-gaap_DeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenue" xlink:to="lab_us-gaap_DeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan_f376a494-0e04-420c-9319-75e51cd6dc2b_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement estimated reimbursable service costs for new research plan</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Estimated Reimbursable Service Costs For New Research Plan</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Estimated Reimbursable Service Costs For New Research Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" xlink:to="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_86366e06-6fd8-4f0a-a31c-c3f11dd01b94_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities - current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_31ac1092-f42f-4a31-88c3-163cebc3f8a3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities - current (included in Accounts payable and accrued liabilities on the Consolidated Balance Sheet)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_41d7e90a-0155-4d4d-91cb-256aa8e8a2a2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected_658bb193-7693-4c8f-bdf3-ee00b7bb59c8_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of product targets selected</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Product Targets Selected</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Product Targets Selected</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeArrangementNumberOfProductTargetsSelected"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected" xlink:to="lab_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_8b2d2035-274d-43ba-9735-6791672abe76_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total compensation cost related to unvested stock options and RSU</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PfizerC9ORF72Member_aea3fd20-07ee-4c20-9b04-bdd110192cdb_terseLabel_en-US" xlink:label="lab_sgmo_PfizerC9ORF72Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer C9ORF72</link:label>
    <link:label id="lab_sgmo_PfizerC9ORF72Member_label_en-US" xlink:label="lab_sgmo_PfizerC9ORF72Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer C9ORF72 [Member]</link:label>
    <link:label id="lab_sgmo_PfizerC9ORF72Member_documentation_en-US" xlink:label="lab_sgmo_PfizerC9ORF72Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer C9ORF72</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerC9ORF72Member" xlink:href="sgmo-20191231.xsd#sgmo_PfizerC9ORF72Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PfizerC9ORF72Member" xlink:to="lab_sgmo_PfizerC9ORF72Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ValbonneFranceMember_d184ce59-c87d-4bd3-b092-e317d173ec3b_terseLabel_en-US" xlink:label="lab_sgmo_ValbonneFranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valbonne, France</link:label>
    <link:label id="lab_sgmo_ValbonneFranceMember_label_en-US" xlink:label="lab_sgmo_ValbonneFranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valbonne, France [Member]</link:label>
    <link:label id="lab_sgmo_ValbonneFranceMember_documentation_en-US" xlink:label="lab_sgmo_ValbonneFranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valbonne, France</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ValbonneFranceMember" xlink:href="sgmo-20191231.xsd#sgmo_ValbonneFranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ValbonneFranceMember" xlink:to="lab_sgmo_ValbonneFranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_9f13d152-c842-43ad-96eb-6c594b1b9f8a_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfCommercialMilestonesMember_7a64e0ff-59f9-4333-890b-2baff4869935_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of commercial milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfCommercialMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Commercial Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfCommercialMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Commercial Milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfCommercialMilestonesMember" xlink:href="sgmo-20191231.xsd#sgmo_AchievementOfCommercialMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfCommercialMilestonesMember" xlink:to="lab_sgmo_AchievementOfCommercialMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1a9c487c-3f88-4941-835d-338a3daa8924_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal_bb4b2c29-3a4f-452c-a104-487dfe63be5c_terseLabel_en-US" xlink:label="lab_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State research tax credit carryforwards</link:label>
    <link:label id="lab_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal_label_en-US" xlink:label="lab_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Tax Credit Carryforwards Research State And Local</link:label>
    <link:label id="lab_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal_documentation_en-US" xlink:label="lab_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets tax credit carryforwards research state and local.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" xlink:href="sgmo-20191231.xsd#sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" xlink:to="lab_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_14932b78-df32-4d7f-ad1a-eee0ecb52a90_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement, Type</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain" xlink:to="lab_us-gaap_LeaseArrangementTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_fe762bbf-1dab-42c0-8726-e6eea3e66fbd_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_50b6b26a-bb64-4f2a-9508-81f4d3e0a483_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_9e7dd903-19f6-4007-9e6e-89ab354373ec_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a7c652e3-a961-495c-9417-4149e8bffde8_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_a204152f-1d0e-480f-9a97-8ff84ea4aac1_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementScenarioAxis_39dcda90-0172-48da-9443-fc7a47ddf207_terseLabel_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementScenarioAxis_label_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementScenarioAxis" xlink:to="lab_us-gaap_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9740ad2e-da48-45a1-b7d6-c8bbb87b6450_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding at end of period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_793b1757-1904-4241-b6e7-b576ef8fa2d7_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option maximum term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_d63e2c40-7df5-4b3e-9b7d-bb8429668069_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable at end of period (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_aca39f3c-bdcf-4109-8d8e-d47de704e17c_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed debt liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PfizerMember_019bdd14-b789-4ed1-8f16-92cd431bdd5b_terseLabel_en-US" xlink:label="lab_sgmo_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer</link:label>
    <link:label id="lab_sgmo_PfizerMember_label_en-US" xlink:label="lab_sgmo_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer [Member]</link:label>
    <link:label id="lab_sgmo_PfizerMember_documentation_en-US" xlink:label="lab_sgmo_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember" xlink:href="sgmo-20191231.xsd#sgmo_PfizerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PfizerMember" xlink:to="lab_sgmo_PfizerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_74d15f42-acd4-4ea1-83ab-888c5844263a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_47d61a6a-dec0-42f2-b85a-2b41aac38401_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Data (Unaudited)</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_b1cf64c2-7343-4664-942e-a15ed35d9778_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified research, clinical development, regulatory and first commercial sale milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Specified Research Clinical Development Regulatory And First Commercial Sale Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified research, clinical development, regulatory and first commercial sale milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:href="sgmo-20191231.xsd#sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:to="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_0e4a849f-d3ee-45dd-9598-2393876bdb15_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9037a1a4-731f-4539-baa8-52560d5c74ad_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_87d33188-437d-49d0-865b-5271fd063ef1_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, employer's matching contribution percent</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SangamoFranceMember_9e99c0cf-3eec-47ad-9ffa-b1abaac88eba_terseLabel_en-US" xlink:label="lab_sgmo_SangamoFranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TxCell S.A.</link:label>
    <link:label id="lab_sgmo_SangamoFranceMember_label_en-US" xlink:label="lab_sgmo_SangamoFranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo France [Member]</link:label>
    <link:label id="lab_sgmo_SangamoFranceMember_documentation_en-US" xlink:label="lab_sgmo_SangamoFranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo France</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember" xlink:href="sgmo-20191231.xsd#sgmo_SangamoFranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SangamoFranceMember" xlink:to="lab_sgmo_SangamoFranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3b529d9a-ef03-4231-aa42-0b04774665ce_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_be92a291-2461-4a4e-948f-3b7e81eed6b5_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, at carrying value, total</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_cf447a80-8549-40de-8940-57a39c4d1339_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement_9aadfeaf-cf23-4ff7-86f3-9ee7226060a3_verboseLabel_en-US" xlink:label="lab_sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Previously agreed research, development and commercialization milestone payments, and royalties on sales of products</link:label>
    <link:label id="lab_sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement_label_en-US" xlink:label="lab_sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment And Royalty Revenue Of Previous Agreement</link:label>
    <link:label id="lab_sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement_documentation_en-US" xlink:label="lab_sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment and royalty revenue of previous agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement" xlink:href="sgmo-20191231.xsd#sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement" xlink:to="lab_sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_5456de7b-eb5c-45a2-904b-306bed4f770f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Company's Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_de157565-b89a-4ef8-9445-21932dabaa67_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_de0e51b3-fa66-4c2f-8550-4a756169aa0b_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_1a030feb-4e90-41f2-a118-3334776840e7_terseLabel_en-US" xlink:label="lab_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Institute for Regenerative Medicine ("CIRM")</link:label>
    <link:label id="lab_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_label_en-US" xlink:label="lab_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Institute For Regenerative Medicine Agreement [Member]</link:label>
    <link:label id="lab_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_documentation_en-US" xlink:label="lab_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California institute for regenerative medicine agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" xlink:href="sgmo-20191231.xsd#sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" xlink:to="lab_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_201de7df-6f8f-4f3a-b1af-8654bf93596c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1_bd3de4cb-2616-4cb7-8e7a-5bf188baec3b_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">USD/ EUR Exchange Rate</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Exchange Rate, Translation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:to="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BrisbaneCaliforniaMember_99306255-0c84-4eaa-bfea-0e9feb11eb76_terseLabel_en-US" xlink:label="lab_sgmo_BrisbaneCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brisbane, California</link:label>
    <link:label id="lab_sgmo_BrisbaneCaliforniaMember_label_en-US" xlink:label="lab_sgmo_BrisbaneCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brisbane, California [Member]</link:label>
    <link:label id="lab_sgmo_BrisbaneCaliforniaMember_documentation_en-US" xlink:label="lab_sgmo_BrisbaneCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brisbane, California</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BrisbaneCaliforniaMember" xlink:href="sgmo-20191231.xsd#sgmo_BrisbaneCaliforniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BrisbaneCaliforniaMember" xlink:to="lab_sgmo_BrisbaneCaliforniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_1ec711e6-ba3e-46f5-9b6f-4228dc421c06_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CNineORFSevenTwoMember_01ea12b0-45a2-467f-91c0-afdb87742747_terseLabel_en-US" xlink:label="lab_sgmo_CNineORFSevenTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C9ORF72</link:label>
    <link:label id="lab_sgmo_CNineORFSevenTwoMember_label_en-US" xlink:label="lab_sgmo_CNineORFSevenTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C Nine O R F Seven Two [Member]</link:label>
    <link:label id="lab_sgmo_CNineORFSevenTwoMember_documentation_en-US" xlink:label="lab_sgmo_CNineORFSevenTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C nine ORF seven two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CNineORFSevenTwoMember" xlink:href="sgmo-20191231.xsd#sgmo_CNineORFSevenTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CNineORFSevenTwoMember" xlink:to="lab_sgmo_CNineORFSevenTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_27571290-40cf-476b-9e7d-35172a69b080_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_9988fb00-8461-4fe3-9e4f-b826a08629b5_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm_467b187a-43ef-40e1-9683-4f60c23f6edc_terseLabel_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs vested and expected to vest at end of period (in years)</link:label>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options vested and expected to vest weighted average remaining contractual term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" xlink:href="sgmo-20191231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" xlink:to="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ChangeInCollaborationAgreementScopeMember_f2a1fdce-1cbb-49c4-88be-6b0c951069e0_terseLabel_en-US" xlink:label="lab_sgmo_ChangeInCollaborationAgreementScopeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in collaboration agreement scope</link:label>
    <link:label id="lab_sgmo_ChangeInCollaborationAgreementScopeMember_label_en-US" xlink:label="lab_sgmo_ChangeInCollaborationAgreementScopeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Collaboration Agreement Scope [Member]</link:label>
    <link:label id="lab_sgmo_ChangeInCollaborationAgreementScopeMember_documentation_en-US" xlink:label="lab_sgmo_ChangeInCollaborationAgreementScopeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Collaboration Agreement Scope</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ChangeInCollaborationAgreementScopeMember" xlink:href="sgmo-20191231.xsd#sgmo_ChangeInCollaborationAgreementScopeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ChangeInCollaborationAgreementScopeMember" xlink:to="lab_sgmo_ChangeInCollaborationAgreementScopeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_acde37d7-8256-438c-a950-664038a22971_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash investing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_76b55634-ac8e-45e5-a268-9350b21cf442_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of net identifiable assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_66486d88-84f6-40f2-88fb-8ab3f3abf302_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_b4c28737-91b9-431a-8047-f2f892e53452_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of products approved</link:label>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_label_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreements Number Of Products Approved Under Agreement</link:label>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_documentation_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and license agreements number of products approved under agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:href="sgmo-20191231.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:to="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_fe34ba44-dcd3-474b-9e29-36b304051e0e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MilestoneOneMember_d72a5e6f-0fd4-4bfb-8338-e051d7c81eea_terseLabel_en-US" xlink:label="lab_sgmo_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One</link:label>
    <link:label id="lab_sgmo_MilestoneOneMember_label_en-US" xlink:label="lab_sgmo_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One [Member]</link:label>
    <link:label id="lab_sgmo_MilestoneOneMember_documentation_en-US" xlink:label="lab_sgmo_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneOneMember" xlink:href="sgmo-20191231.xsd#sgmo_MilestoneOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestoneOneMember" xlink:to="lab_sgmo_MilestoneOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_43ec6452-55ca-4d01-8dfe-0ff639bce29d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueOptionPricingModelMember_2ba8c562-e227-49ad-b313-b1671d52f12c_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Pricing Method</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueOptionPricingModelMember_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Technique, Option Pricing Model [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:to="lab_us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_f3ff101d-5c02-4115-8638-63a58391aed2_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PropertyAndEquipmentMember_77b0c3b8-be58-4156-9657-3d57757cb436_terseLabel_en-US" xlink:label="lab_sgmo_PropertyAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_sgmo_PropertyAndEquipmentMember_label_en-US" xlink:label="lab_sgmo_PropertyAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property And Equipment [Member]</link:label>
    <link:label id="lab_sgmo_PropertyAndEquipmentMember_documentation_en-US" xlink:label="lab_sgmo_PropertyAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PropertyAndEquipmentMember" xlink:href="sgmo-20191231.xsd#sgmo_PropertyAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PropertyAndEquipmentMember" xlink:to="lab_sgmo_PropertyAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_ed3d9179-13d6-479a-a0e6-3c1f2f124f40_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_2ed2a387-9f83-4038-96f7-000fdaf5e505_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScenarioForecastMember_affe145b-a47f-4766-93f7-df18fd5d8bc1_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_us-gaap_ScenarioForecastMember_label_en-US" xlink:label="lab_us-gaap_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScenarioForecastMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioForecastMember" xlink:to="lab_us-gaap_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_1df04d80-4ad0-4547-b298-fa5f775e683e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_d4f7a019-c886-4db4-b97b-fd40f9f1c1dd_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_30398a32-6214-4ec3-9bbd-71ac7c6c416f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a5b4a1a4-663f-49b2-8474-7e06a4924e7a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_0991402c-8939-499c-8398-8b71cf13573f_terseLabel_en-US" xlink:label="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent development - and sales-based milestone payments to be received</link:label>
    <link:label id="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_label_en-US" xlink:label="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Development And Sales Based Milestone Payments To Be Received</link:label>
    <link:label id="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_documentation_en-US" xlink:label="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent development and sales based milestone payments to be received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:href="sgmo-20191231.xsd#sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:to="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_bd852a6a-cd87-4c57-be5a-1b6c7170ff10_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified clinical development intellectual property and regulatory milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Specified Clinical Development Intellectual Property And Regulatory Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified clinical development intellectual property and regulatory milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:href="sgmo-20191231.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:to="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_1fde519e-d97b-466f-a757-bb458bdc8bd8_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_260e6164-7a11-48af-9770-c83afdc343ab_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_06b7b990-6526-4750-91dd-ac192327995c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_OfficeSpaceMember_e8eb0195-4524-42e9-a19f-4594c69e6c19_terseLabel_en-US" xlink:label="lab_sgmo_OfficeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Space</link:label>
    <link:label id="lab_sgmo_OfficeSpaceMember_label_en-US" xlink:label="lab_sgmo_OfficeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Space [Member]</link:label>
    <link:label id="lab_sgmo_OfficeSpaceMember_documentation_en-US" xlink:label="lab_sgmo_OfficeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OfficeSpaceMember" xlink:href="sgmo-20191231.xsd#sgmo_OfficeSpaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_OfficeSpaceMember" xlink:to="lab_sgmo_OfficeSpaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_GrantFundingAmount_b3eb2f9d-09f3-45fe-8b14-504607ea55b8_terseLabel_en-US" xlink:label="lab_sgmo_GrantFundingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funds due under the agreement</link:label>
    <link:label id="lab_sgmo_GrantFundingAmount_label_en-US" xlink:label="lab_sgmo_GrantFundingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Funding Amount</link:label>
    <link:label id="lab_sgmo_GrantFundingAmount_documentation_en-US" xlink:label="lab_sgmo_GrantFundingAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funding amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GrantFundingAmount" xlink:href="sgmo-20191231.xsd#sgmo_GrantFundingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_GrantFundingAmount" xlink:to="lab_sgmo_GrantFundingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1941d2f2-16d4-443e-a792-864e67c81c95_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock_7462ab04-f976-4fe8-b33a-507f2ea9b9b3_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Company's Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Positions for which Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" xlink:to="lab_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_e2126a88-02ab-4a88-b68c-7f8a1ebee74a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_3dfc3770-6032-4a68-af9a-73ee3c33e351_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expenses</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense" xlink:to="lab_us-gaap_LeaseAndRentalExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_3567f475-5c57-4639-a603-39623cbbd31f_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of first commercial sale milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of First Commercial Sale Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of first commercial sale milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:href="sgmo-20191231.xsd#sgmo_AchievementOfFirstCommercialSaleMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:to="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_3db878c4-6103-4fdb-a9b1-6ac95ae369da_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options and restricted stock units</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_ca3848e4-bf46-4474-9cfb-0d326ee1d68b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c6be27cb-2d2c-4311-85df-ea2c7414be22_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual&#160;Term</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_04932de2-132d-43b6-a5ff-a0cb881c7193_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_f06f213c-de91-4317-aa98-defe0cfee917_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_6462102d-62b2-4a7d-a7e0-01dbe1ab04fe_negatedLabel_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs released (in shares)</link:label>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_label_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Released In Period</link:label>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_documentation_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options released in period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xlink:href="sgmo-20191231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xlink:to="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_c0acd05d-1b12-4407-8b9b-19e7a124773e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_742bd6cf-fa94-44d0-9554-be7a82b9aaa4_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MilestoneTwoMember_eb443e7a-5df2-44c5-b66b-f1c7efa798f0_terseLabel_en-US" xlink:label="lab_sgmo_MilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Two</link:label>
    <link:label id="lab_sgmo_MilestoneTwoMember_label_en-US" xlink:label="lab_sgmo_MilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Two [Member]</link:label>
    <link:label id="lab_sgmo_MilestoneTwoMember_documentation_en-US" xlink:label="lab_sgmo_MilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneTwoMember" xlink:href="sgmo-20191231.xsd#sgmo_MilestoneTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestoneTwoMember" xlink:to="lab_sgmo_MilestoneTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_d85487a1-cc22-4fc6-901e-341da3136f74_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_a63bfb2d-0c16-4a27-9504-3a32eb9c6de1_terseLabel_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of lease liabilities</link:label>
    <link:label id="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_label_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Long Term Portion Of Lease Liabilities</link:label>
    <link:label id="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_documentation_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Long Term Portion Of Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" xlink:href="sgmo-20191231.xsd#sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" xlink:to="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_634f1859-9664-4c96-8e7b-44c0d8466221_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_aff037b1-aa44-4153-8905-14b15704ce4d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CommonStockExchangeRatio_b5886fc7-ca84-488e-be65-6b2ecf9815e7_terseLabel_en-US" xlink:label="lab_sgmo_CommonStockExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of common stock subject to a stock option or stock appreciation right (in shares)</link:label>
    <link:label id="lab_sgmo_CommonStockExchangeRatio_label_en-US" xlink:label="lab_sgmo_CommonStockExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Exchange Ratio</link:label>
    <link:label id="lab_sgmo_CommonStockExchangeRatio_documentation_en-US" xlink:label="lab_sgmo_CommonStockExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock exchange ratio.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommonStockExchangeRatio" xlink:href="sgmo-20191231.xsd#sgmo_CommonStockExchangeRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CommonStockExchangeRatio" xlink:to="lab_sgmo_CommonStockExchangeRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_e2e87355-c6c8-4a37-8299-9a74cc48b0f7_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Rate Volatility Estimate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_86be04cf-05bd-4a08-b120-2e5f6215e426_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_82a6b146-1323-44b2-915d-51e7a6a40d03_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f93fa398-2a61-4665-bac3-c51faf2884ad_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_0a6dfdb5-b33e-46cd-979f-51b1d6ba29fb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_d8d4c3c3-048b-47af-a64b-9f6bf502c7ab_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_403c1705-7eeb-4953-88e7-b1833dbd38e9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_NonCancelableContractualCommitmentMember_d412e59e-0c05-48c3-bd93-cc44dc59b5fd_terseLabel_en-US" xlink:label="lab_sgmo_NonCancelableContractualCommitmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cancelable Contractual Commitment</link:label>
    <link:label id="lab_sgmo_NonCancelableContractualCommitmentMember_label_en-US" xlink:label="lab_sgmo_NonCancelableContractualCommitmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cancelable Contractual Commitment [Member]</link:label>
    <link:label id="lab_sgmo_NonCancelableContractualCommitmentMember_documentation_en-US" xlink:label="lab_sgmo_NonCancelableContractualCommitmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cancelable Contractual Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NonCancelableContractualCommitmentMember" xlink:href="sgmo-20191231.xsd#sgmo_NonCancelableContractualCommitmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NonCancelableContractualCommitmentMember" xlink:to="lab_sgmo_NonCancelableContractualCommitmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CommitmentsAndContingenciesTable_345888ab-82a9-4687-b10c-79fe7d27f7ec_terseLabel_en-US" xlink:label="lab_sgmo_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_sgmo_CommitmentsAndContingenciesTable_label_en-US" xlink:label="lab_sgmo_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_sgmo_CommitmentsAndContingenciesTable_documentation_en-US" xlink:label="lab_sgmo_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommitmentsAndContingenciesTable" xlink:href="sgmo-20191231.xsd#sgmo_CommitmentsAndContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable" xlink:to="lab_sgmo_CommitmentsAndContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8a07c5b6-5c21-4f9e-bf20-15fc8807d8f8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_7cde7680-d080-47f8-8a38-838dc4b2992b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_6fb81388-7cda-44e2-b601-7ebc1b1b8e56_negatedLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of additional shares acquired</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_dbbad906-1c30-46fc-ad1e-4f55c1f9b1c9_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interest upon Acquisition of Sangamo France</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Business Combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_6b00c914-2ae2-4437-8685-d6f67bdf70a2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_46e912d0-c79b-42ba-b710-4ba3fe795f32_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_e0a545f6-ca01-4172-a160-04d9aaa85b3a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8c1e8bb8-5981-4682-9ddd-bf1786c295c6_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_65760572-9647-4cf7-8956-8e40d0b4d9e6_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_1474ebfd-2337-48e6-818a-333f018fabd3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2608d507-de6e-48dd-aea2-11e793b33b9b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average estimated fair value per share of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_LeaseArrangementsAxis_14a52895-d0f8-427d-8ed6-c535e0e4cf8e_terseLabel_en-US" xlink:label="lab_sgmo_LeaseArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Axis]</link:label>
    <link:label id="lab_sgmo_LeaseArrangementsAxis_label_en-US" xlink:label="lab_sgmo_LeaseArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Axis]</link:label>
    <link:label id="lab_sgmo_LeaseArrangementsAxis_documentation_en-US" xlink:label="lab_sgmo_LeaseArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LeaseArrangementsAxis" xlink:href="sgmo-20191231.xsd#sgmo_LeaseArrangementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_LeaseArrangementsAxis" xlink:to="lab_sgmo_LeaseArrangementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b06d20ea-6661-4f94-a5ea-0b299cede746_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_5d8b8c9b-9117-4538-9d65-b9e8ea7ba37d_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_02fdf18b-36df-473f-8f63-35e0bcd289ea_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_60d1b6e5-e40a-4cfb-b277-2092e49207c3_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AgreementTerminationTerm_91eb84ef-8d7d-4abc-be18-d6cff358a19a_terseLabel_en-US" xlink:label="lab_sgmo_AgreementTerminationTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement termination, term</link:label>
    <link:label id="lab_sgmo_AgreementTerminationTerm_label_en-US" xlink:label="lab_sgmo_AgreementTerminationTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement Termination, Term</link:label>
    <link:label id="lab_sgmo_AgreementTerminationTerm_documentation_en-US" xlink:label="lab_sgmo_AgreementTerminationTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement Termination, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AgreementTerminationTerm" xlink:href="sgmo-20191231.xsd#sgmo_AgreementTerminationTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AgreementTerminationTerm" xlink:to="lab_sgmo_AgreementTerminationTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_9f10651a-6678-45bc-ba59-1413ebc2e88c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment_2352fae8-22cc-4688-88e3-6503fb836af1_terseLabel_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, number of vesting installment</link:label>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment_label_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Vesting Installment</link:label>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment_documentation_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award number of vesting installment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment" xlink:href="sgmo-20191231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment" xlink:to="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a6902faa-99f4-473c-b0aa-5dcd2d115472_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_cc1f0aa6-a2a8-4166-b012-7f033bd62a20_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net operating loss carryforwards for federal</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_a9b602df-aaf0-4031-b782-5ee9f123a6d4_terseLabel_en-US" xlink:label="lab_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation</link:label>
    <link:label id="lab_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_label_en-US" xlink:label="lab_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="lab_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_03169089-c961-44d4-9ec1-d36e16679da9_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_e506ac0c-535a-4a16-b3a9-90f7d44e6f73_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_8555b801-0ef0-472c-aed7-00264ebfb49c_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9c2bd486-e593-4c8b-aa88-4965dda62e5e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumptions Used for Estimating Fair Value of Employee Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3380557f-e7fe-4af6-9130-8300a83fec37_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CommitmentsAndContingenciesLineItems_94f0b156-343e-43ad-aa3e-3059bd8f3762_terseLabel_en-US" xlink:label="lab_sgmo_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_sgmo_CommitmentsAndContingenciesLineItems_label_en-US" xlink:label="lab_sgmo_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_sgmo_CommitmentsAndContingenciesLineItems_documentation_en-US" xlink:label="lab_sgmo_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommitmentsAndContingenciesLineItems" xlink:href="sgmo-20191231.xsd#sgmo_CommitmentsAndContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems" xlink:to="lab_sgmo_CommitmentsAndContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e796ae35-260c-4016-b44f-c7093aa4fe77_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under public offering, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_16895946-0a73-4207-a276-ac3d431bd645_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public offering, common stock shares issued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_9aad745e-32a9-4d83-8d96-c60b922440f4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Restricted Stock Unit Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_c17acfc6-58bc-47db-9093-f3f5b446f482_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Sangamo France</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilities_da00a8d7-c286-4f32-b435-b51eb552438d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_OtherThanTemporarilyImpairedInvestment_3d650210-3e64-4c43-bce4-18f09f6e10c6_terseLabel_en-US" xlink:label="lab_sgmo_OtherThanTemporarilyImpairedInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments other-than-temporarily impaired</link:label>
    <link:label id="lab_sgmo_OtherThanTemporarilyImpairedInvestment_label_en-US" xlink:label="lab_sgmo_OtherThanTemporarilyImpairedInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Than Temporarily Impaired Investment</link:label>
    <link:label id="lab_sgmo_OtherThanTemporarilyImpairedInvestment_documentation_en-US" xlink:label="lab_sgmo_OtherThanTemporarilyImpairedInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than temporarily impaired investment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OtherThanTemporarilyImpairedInvestment" xlink:href="sgmo-20191231.xsd#sgmo_OtherThanTemporarilyImpairedInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_OtherThanTemporarilyImpairedInvestment" xlink:to="lab_sgmo_OtherThanTemporarilyImpairedInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_b5ef8ad4-53c5-4c0e-8bf2-33e1eca36871_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_371abf32-de28-43cc-8de9-8640ae1f8896_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementMember_e84eab91-8ebc-4eff-87a7-8c081e775279_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and license agreement</link:label>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementMember" xlink:href="sgmo-20191231.xsd#sgmo_CollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationAndLicenseAgreementMember" xlink:to="lab_sgmo_CollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0c104eae-956c-41d7-bc21-b46d19475f55_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_2df09325-f823-4b61-a05a-8e6c3c8468e5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_f41e4416-7c16-4293-8d52-700a4043db44_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_827aa35a-83cb-47e5-a8ea-1d055856a1ea_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_af4fb632-62ab-457d-b846-4b56f68c8a08_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest, ownership percentage by parent</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_06012711-1cda-4a6d-9269-b07741d3b49b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_IncomeTaxesLineItems_368675bd-9230-4f8b-9503-22d58629d914_terseLabel_en-US" xlink:label="lab_sgmo_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_sgmo_IncomeTaxesLineItems_label_en-US" xlink:label="lab_sgmo_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_sgmo_IncomeTaxesLineItems_documentation_en-US" xlink:label="lab_sgmo_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncomeTaxesLineItems" xlink:href="sgmo-20191231.xsd#sgmo_IncomeTaxesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_IncomeTaxesLineItems" xlink:to="lab_sgmo_IncomeTaxesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_d75570e9-9358-4f53-b6fd-891bbbcbc3d1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ad76e764-7181-48b9-8d6a-4db023fbb872_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_361b4ed6-fa91-4b9c-8caa-062daf3d4504_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_10989f93-17f0-4af1-88a6-5f59d41df315_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Future Minimum Payments under Contractual Obligations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_16736a5b-afab-4318-b190-4f67a7a2dd60_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_8f82a22c-13dd-4298-a2c5-0f4e4456f4cf_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_ef7d1d36-27c8-4edc-b0ff-c7eeab3e1142_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_db8d32ea-6500-4783-afc5-79bd886d1a1e_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in deferred tax assets valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_0b82d0ee-7c85-4aa1-a466-6960352acb0e_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ReducedRoyaltyRate_3dbaaf4e-b8b2-4a50-a9a8-ffb485bfe233_terseLabel_en-US" xlink:label="lab_sgmo_ReducedRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduced royalty rate</link:label>
    <link:label id="lab_sgmo_ReducedRoyaltyRate_label_en-US" xlink:label="lab_sgmo_ReducedRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduced Royalty Rate</link:label>
    <link:label id="lab_sgmo_ReducedRoyaltyRate_documentation_en-US" xlink:label="lab_sgmo_ReducedRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduced royalty rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ReducedRoyaltyRate" xlink:href="sgmo-20191231.xsd#sgmo_ReducedRoyaltyRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ReducedRoyaltyRate" xlink:to="lab_sgmo_ReducedRoyaltyRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2794d61a-ff05-4080-aee2-182fe00bfcfb_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration received from sale of stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementResearchServiceFees_890b6653-88c0-47af-b68d-ac2dffa3bfac_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementResearchServiceFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research service fees</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementResearchServiceFees_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementResearchServiceFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Research Service Fees</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementResearchServiceFees_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementResearchServiceFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Research Service Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementResearchServiceFees" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeArrangementResearchServiceFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementResearchServiceFees" xlink:to="lab_sgmo_CollaborativeArrangementResearchServiceFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_57aca5c2-c64d-4e24-a6df-f813b8592104_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_99326f03-690c-4978-b4c8-396db812fc7c_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_f2b04894-0db1-4caf-a285-87fd18f5bfd4_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SalesBasedMilestoneMember_75c4bb4f-e4ad-429a-b9b5-ab81ba74a7a9_terseLabel_en-US" xlink:label="lab_sgmo_SalesBasedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based Milestone</link:label>
    <link:label id="lab_sgmo_SalesBasedMilestoneMember_label_en-US" xlink:label="lab_sgmo_SalesBasedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based Milestone [Member]</link:label>
    <link:label id="lab_sgmo_SalesBasedMilestoneMember_documentation_en-US" xlink:label="lab_sgmo_SalesBasedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SalesBasedMilestoneMember" xlink:href="sgmo-20191231.xsd#sgmo_SalesBasedMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SalesBasedMilestoneMember" xlink:to="lab_sgmo_SalesBasedMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_e2f9551c-7121-4955-9d16-e5d6f1ca47a3_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed ratio shares of common stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_f763dd77-d80e-404f-9a86-2d4b889f7eff_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in computing basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7d00a043-8e10-434d-8ee3-8965bb8ccac3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_d903428b-f2ee-457a-bf41-4211895f5ea2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_42564e79-f892-4b30-b5c3-3b91724b0524_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MilestonePaymentsReceived_50244449-39df-4892-afa7-3b8f690ce982_terseLabel_en-US" xlink:label="lab_sgmo_MilestonePaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments received</link:label>
    <link:label id="lab_sgmo_MilestonePaymentsReceived_label_en-US" xlink:label="lab_sgmo_MilestonePaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Received</link:label>
    <link:label id="lab_sgmo_MilestonePaymentsReceived_documentation_en-US" xlink:label="lab_sgmo_MilestonePaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestonePaymentsReceived" xlink:href="sgmo-20191231.xsd#sgmo_MilestonePaymentsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestonePaymentsReceived" xlink:to="lab_sgmo_MilestonePaymentsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_60cf912d-b0b7-48e5-8ba3-6f4b6f19455a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Interest Receivable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e078a5ee-1267-4210-96e1-dc23e32b59b5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock reserved for issuance under plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_af51402d-1d47-4620-b7a0-76ad6acaa9d4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ManufacturingObligationsMember_2fdad19c-b576-40c1-a42d-6c9d20e78006_terseLabel_en-US" xlink:label="lab_sgmo_ManufacturingObligationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Obligations</link:label>
    <link:label id="lab_sgmo_ManufacturingObligationsMember_label_en-US" xlink:label="lab_sgmo_ManufacturingObligationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Obligations [Member]</link:label>
    <link:label id="lab_sgmo_ManufacturingObligationsMember_documentation_en-US" xlink:label="lab_sgmo_ManufacturingObligationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ManufacturingObligationsMember" xlink:href="sgmo-20191231.xsd#sgmo_ManufacturingObligationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ManufacturingObligationsMember" xlink:to="lab_sgmo_ManufacturingObligationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_feae1219-635d-4ea6-bd71-fdb3e456887e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_6e58d585-129e-4b15-9134-79f384f15ed5_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public offering price of common stock issued (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_DeferredRentNoncurrent_6bcc587c-e434-48c0-aa73-909da28b959c_terseLabel_en-US" xlink:label="lab_sgmo_DeferredRentNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_sgmo_DeferredRentNoncurrent_label_en-US" xlink:label="lab_sgmo_DeferredRentNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Rent Noncurrent</link:label>
    <link:label id="lab_sgmo_DeferredRentNoncurrent_documentation_en-US" xlink:label="lab_sgmo_DeferredRentNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Rent Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DeferredRentNoncurrent" xlink:href="sgmo-20191231.xsd#sgmo_DeferredRentNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_DeferredRentNoncurrent" xlink:to="lab_sgmo_DeferredRentNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_34f965b5-286f-417f-b580-52ba82171f1e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_68c8c049-c4f2-4834-a517-30b2a723c447_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding at end of period (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_136068d1-e669-4949-9cce-f56bbb2a803d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_bb88a1a1-dc30-45ea-a953-d5cd38e402e3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_f36ddcc4-9b63-457c-8a1f-eed123cdff1a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_b5f1fcce-a194-4b35-b35e-2e7a1179a70f_terseLabel_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of space leased (in sqft)</link:label>
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_label_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land Subject to Ground Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandSubjectToGroundLeases" xlink:to="lab_us-gaap_LandSubjectToGroundLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_aec51018-3b0a-4ff6-8a87-f7d812ab9f75_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c958e899-3815-47e4-bf5b-d9553d9448d9_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_b9699de1-4c1a-4b1f-ad55-4b6c1b2526e1_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_a48def7d-5a94-4415-a191-84670bcbd7ea_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of New Accounting Pronouncements and Changes in Accounting Principles</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_NoncashOrPartNoncashNonControllingInterestAcquisition_ad07625f-cbce-4579-8269-f5bf649ce449_terseLabel_en-US" xlink:label="lab_sgmo_NoncashOrPartNoncashNonControllingInterestAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interest for acquisition</link:label>
    <link:label id="lab_sgmo_NoncashOrPartNoncashNonControllingInterestAcquisition_label_en-US" xlink:label="lab_sgmo_NoncashOrPartNoncashNonControllingInterestAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Or Part Noncash Non Controlling Interest Acquisition</link:label>
    <link:label id="lab_sgmo_NoncashOrPartNoncashNonControllingInterestAcquisition_documentation_en-US" xlink:label="lab_sgmo_NoncashOrPartNoncashNonControllingInterestAcquisition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or part noncash non-controlling interest acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NoncashOrPartNoncashNonControllingInterestAcquisition" xlink:href="sgmo-20191231.xsd#sgmo_NoncashOrPartNoncashNonControllingInterestAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NoncashOrPartNoncashNonControllingInterestAcquisition" xlink:to="lab_sgmo_NoncashOrPartNoncashNonControllingInterestAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_78018676-f83e-4267-8e7a-dd9eab949812_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Difference Between Benefit for Income Taxes and Federal Statutory Income Tax Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_fbc81398-09dc-40ec-984f-5a3261f2cc2f_terseLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and available-for-sale securities, gross unrealized gains</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Available For Sale Securities Gross Unrealized Gain Before Tax</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and available for sale securities, gross unrealized gain, before tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:href="sgmo-20191231.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:to="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e14d8c8-fec4-45ed-a18d-f0b5b7467455_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1f20572b-1323-4b20-bbbf-1a1c0ea4e9f2_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_bb97e493-da4e-4e8f-a870-d7d9a440a08d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SBFiveTwoFiveMember_14cbaa6f-17a6-4f29-ba08-8aca1f631daf_terseLabel_en-US" xlink:label="lab_sgmo_SBFiveTwoFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SB-525</link:label>
    <link:label id="lab_sgmo_SBFiveTwoFiveMember_label_en-US" xlink:label="lab_sgmo_SBFiveTwoFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">S B Five Two Five [Member]</link:label>
    <link:label id="lab_sgmo_SBFiveTwoFiveMember_documentation_en-US" xlink:label="lab_sgmo_SBFiveTwoFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SB five two five.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SBFiveTwoFiveMember" xlink:href="sgmo-20191231.xsd#sgmo_SBFiveTwoFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SBFiveTwoFiveMember" xlink:to="lab_sgmo_SBFiveTwoFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_90202734-f982-41f9-a143-51a2de583465_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SigmaAldrichCorporationMember_88ff0123-1ed4-4d5e-8b6c-1bff985a6323_terseLabel_en-US" xlink:label="lab_sgmo_SigmaAldrichCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sigma-Aldrich Corporation</link:label>
    <link:label id="lab_sgmo_SigmaAldrichCorporationMember_label_en-US" xlink:label="lab_sgmo_SigmaAldrichCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sigma Aldrich Corporation [Member]</link:label>
    <link:label id="lab_sgmo_SigmaAldrichCorporationMember_documentation_en-US" xlink:label="lab_sgmo_SigmaAldrichCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sigma-Aldrich corporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SigmaAldrichCorporationMember" xlink:href="sgmo-20191231.xsd#sgmo_SigmaAldrichCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SigmaAldrichCorporationMember" xlink:to="lab_sgmo_SigmaAldrichCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_033d3ab5-5673-4efb-ae0b-d17d04de0e64_terseLabel_en-US" xlink:label="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:href="sgmo-20191231.xsd#sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_03ad6008-c05e-46af-bcb0-c13da05aa36e_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of discount on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputOptionVolatilityMember_c84937db-d728-4397-8b11-12cca134aafe_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputOptionVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price Volatility Estimate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputOptionVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputOptionVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Option Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputOptionVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputOptionVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputOptionVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_7b9b9eec-c34a-4705-b466-98a580934051_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_dfc4ba65-f61d-40aa-811d-a85fd007306c_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ContractualObligationPaidUponExecution_001246e5-7ddd-4479-94c4-ffd46b8a2d91_terseLabel_en-US" xlink:label="lab_sgmo_ContractualObligationPaidUponExecution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual obligation, paid upon execution</link:label>
    <link:label id="lab_sgmo_ContractualObligationPaidUponExecution_label_en-US" xlink:label="lab_sgmo_ContractualObligationPaidUponExecution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation, Paid Upon Execution</link:label>
    <link:label id="lab_sgmo_ContractualObligationPaidUponExecution_documentation_en-US" xlink:label="lab_sgmo_ContractualObligationPaidUponExecution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation, Paid Upon Execution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContractualObligationPaidUponExecution" xlink:href="sgmo-20191231.xsd#sgmo_ContractualObligationPaidUponExecution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ContractualObligationPaidUponExecution" xlink:to="lab_sgmo_ContractualObligationPaidUponExecution" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_5099e336-ead2-47cd-b86c-3572646c4390_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_ed5cb3e4-6ce7-48ac-963c-05f7643f0055_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_18971234-fa44-4056-8b36-6ad89df2a6d2_terseLabel_en-US" xlink:label="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from Strategic Partnering Collaboration Agreements and Research Activity Grants as a Percentage of Total Revenues</link:label>
    <link:label id="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_label_en-US" xlink:label="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues [Table Text Block]</link:label>
    <link:label id="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_documentation_en-US" xlink:label="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:href="sgmo-20191231.xsd#sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:to="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_d9b7fc43-15c5-4ae3-ab69-8f0515880a15_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_9f52d69d-6b79-412a-a8fe-d9371522483e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_60281d59-b25d-4a64-97c0-8ac51a00588c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal_964b1bf4-93e3-44f1-bb97-9b7885b9f8fd_terseLabel_en-US" xlink:label="lab_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal research tax credit carryforwards</link:label>
    <link:label id="lab_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal_label_en-US" xlink:label="lab_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Tax Credit Carryforwards Research Federal</link:label>
    <link:label id="lab_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal_documentation_en-US" xlink:label="lab_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets tax credit carryforwards research federal.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal" xlink:href="sgmo-20191231.xsd#sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal" xlink:to="lab_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAxis_6578e430-e58d-40a4-95ea-b1d3bd5ee6e6_terseLabel_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement [Axis]</link:label>
    <link:label id="lab_srt_RestatementAxis_label_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_9a2c5397-a5c6-4e79-8c6a-5beb2d94c253_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_66a787ed-7570-4eaf-be95-23c7fe10ac0d_periodStartLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of year</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_7a609f84-4edd-458a-a62c-8c9cca5b8700_periodEndLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of year</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_9788f914-a674-4ef1-b283-23e381c4bd5b_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_93fa336e-ddad-4df6-9a9e-0b7222fc2095_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_5e209fa8-a1cf-4a15-87b4-8ced14507ba2_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MilestoneAchievementMember_f9d40814-5e34-4c73-ac4c-2a04b909915a_terseLabel_en-US" xlink:label="lab_sgmo_MilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone achievement</link:label>
    <link:label id="lab_sgmo_MilestoneAchievementMember_label_en-US" xlink:label="lab_sgmo_MilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Achievement [Member]</link:label>
    <link:label id="lab_sgmo_MilestoneAchievementMember_documentation_en-US" xlink:label="lab_sgmo_MilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Achievement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneAchievementMember" xlink:href="sgmo-20191231.xsd#sgmo_MilestoneAchievementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestoneAchievementMember" xlink:to="lab_sgmo_MilestoneAchievementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_15812d16-b629-49bb-a678-c676b7101647_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_da58d894-65be-47b7-8d9c-f8d65bb4a2db_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestAndOtherIncome_72d0cd73-858d-414c-a53d-190a2ca3d9a6_terseLabel_en-US" xlink:label="lab_us-gaap_InterestAndOtherIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income, net</link:label>
    <link:label id="lab_us-gaap_InterestAndOtherIncome_label_en-US" xlink:label="lab_us-gaap_InterestAndOtherIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and Other Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndOtherIncome" xlink:to="lab_us-gaap_InterestAndOtherIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_d35384ee-ca6e-4554-b48f-bd09924d6966_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_63647017-0002-4be8-8fef-2b952e64ebcc_terseLabel_en-US" xlink:label="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents, gross unrealized gains</link:label>
    <link:label id="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:label id="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents accumulated gross unrealized gain before tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="sgmo-20191231.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_c4cb1417-033d-44e5-9e3f-6d7e29c37a47_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_a399896b-df0a-45b1-ba6f-87459a7c801e_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0ab6323b-99f7-4f33-bb66-472aab85dfe0_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_afa9d211-3058-4d18-aa75-6a7b8df5ee30_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_0932b100-f2ff-4504-9ec3-bda8d58ea2be_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ExtendedResearchTermOfAgreement_4aae4abd-4361-4b82-807a-cba239119433_terseLabel_en-US" xlink:label="lab_sgmo_ExtendedResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended research term of agreement</link:label>
    <link:label id="lab_sgmo_ExtendedResearchTermOfAgreement_label_en-US" xlink:label="lab_sgmo_ExtendedResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended Research Term Of Agreement</link:label>
    <link:label id="lab_sgmo_ExtendedResearchTermOfAgreement_documentation_en-US" xlink:label="lab_sgmo_ExtendedResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended Research Term Of Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ExtendedResearchTermOfAgreement" xlink:href="sgmo-20191231.xsd#sgmo_ExtendedResearchTermOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ExtendedResearchTermOfAgreement" xlink:to="lab_sgmo_ExtendedResearchTermOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_25cda022-bfcd-488f-a7f1-aa59f029d9ee_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions based on tax positions related to the current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PurchasePlanOfferingPeriod_7f61b797-c0ed-46a8-8780-c6ab64270ec2_terseLabel_en-US" xlink:label="lab_sgmo_PurchasePlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase plan offering period</link:label>
    <link:label id="lab_sgmo_PurchasePlanOfferingPeriod_label_en-US" xlink:label="lab_sgmo_PurchasePlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Plan Offering Period</link:label>
    <link:label id="lab_sgmo_PurchasePlanOfferingPeriod_documentation_en-US" xlink:label="lab_sgmo_PurchasePlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase plan offering period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PurchasePlanOfferingPeriod" xlink:href="sgmo-20191231.xsd#sgmo_PurchasePlanOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PurchasePlanOfferingPeriod" xlink:to="lab_sgmo_PurchasePlanOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_91f36925-c6d9-4c6b-9e6a-4884a1b26cb7_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsMember_0919aaa2-cc51-43cf-8392-9cc4b7db700c_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents:</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember" xlink:to="lab_us-gaap_CashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_17c967b1-a0da-428f-8381-b073e85fe958_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Sangamo Therapeutics, Inc. stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_e585dd06-ff51-49a9-9c41-45edef0d5006_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income attributable to Sangamo Therapeutics, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_05800615-9084-4c7a-b42b-05753d732b08_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_68762ba1-39b5-4b28-a1ba-7441fd0e7fe2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_791e26ba-b77a-411d-b8b9-69e696d519f5_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_d20111fd-d73e-4de9-ba57-d8dff6e3a0f7_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementDomain_52d02ce1-b486-4265-9902-8cac081f35d2_terseLabel_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement [Domain]</link:label>
    <link:label id="lab_srt_RestatementDomain_label_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ManufacturingCapacityMember_b66f596d-1323-4368-8b22-de99e5907795_terseLabel_en-US" xlink:label="lab_sgmo_ManufacturingCapacityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Capacity</link:label>
    <link:label id="lab_sgmo_ManufacturingCapacityMember_label_en-US" xlink:label="lab_sgmo_ManufacturingCapacityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Capacity [Member]</link:label>
    <link:label id="lab_sgmo_ManufacturingCapacityMember_documentation_en-US" xlink:label="lab_sgmo_ManufacturingCapacityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ManufacturingCapacityMember" xlink:href="sgmo-20191231.xsd#sgmo_ManufacturingCapacityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ManufacturingCapacityMember" xlink:to="lab_sgmo_ManufacturingCapacityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d5a31da0-3a8d-40c0-8be3-4c593fdff60c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>sgmo-20191231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:6b105dfa-4da0-4f89-a738-1fa68397e7a0,g:da741c8d-9db4-444a-b42c-06c4caf6626c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sangamo.com/role/Cover" xlink:type="simple" xlink:href="sgmo-20191231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_5bd1eec3-429f-412b-b9dc-2a898230d0d7" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_14eadda0-6cb8-461d-8a25-f08a3319560f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5bd1eec3-429f-412b-b9dc-2a898230d0d7" xlink:to="loc_dei_DocumentType_14eadda0-6cb8-461d-8a25-f08a3319560f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_7f734184-519c-47fa-8a53-73334a2f4e3d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5bd1eec3-429f-412b-b9dc-2a898230d0d7" xlink:to="loc_dei_DocumentAnnualReport_7f734184-519c-47fa-8a53-73334a2f4e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_9959fc6e-4e4c-494f-ae46-a6e80ee8b6a2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5bd1eec3-429f-412b-b9dc-2a898230d0d7" xlink:to="loc_dei_DocumentPeriodEndDate_9959fc6e-4e4c-494f-ae46-a6e80ee8b6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_7d18ffc6-c4b1-4adb-869a-d6968d962964" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5bd1eec3-429f-412b-b9dc-2a898230d0d7" xlink:to="loc_dei_DocumentTransitionReport_7d18ffc6-c4b1-4adb-869a-d6968d962964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_2a637d34-575d-4580-a6f3-09e33ee65697" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5bd1eec3-429f-412b-b9dc-2a898230d0d7" xlink:to="loc_dei_EntityFileNumber_2a637d34-575d-4580-a6f3-09e33ee65697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_a2236b1a-922d-4afa-9170-20cd26b88f83" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5bd1eec3-429f-412b-b9dc-2a898230d0d7" xlink:to="loc_dei_EntityRegistrantName_a2236b1a-922d-4afa-9170-20cd26b88f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_8af6d7b5-fd39-4cb2-8a5d-d8b2c513bb40" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5bd1eec3-429f-412b-b9dc-2a898230d0d7" xlink:to="loc_dei_EntityIncorporationStateCountryCode_8af6d7b5-fd39-4cb2-8a5d-d8b2c513bb40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_46465c0d-ff06-46c7-afc7-3eec8d17ba18" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5bd1eec3-429f-412b-b9dc-2a898230d0d7" xlink:to="loc_dei_EntityTaxIdentificationNumber_46465c0d-ff06-46c7-afc7-3eec8d17ba18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_2f491980-2f51-4d05-8e2e-0c7cee5ca0f7" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5bd1eec3-429f-412b-b9dc-2a898230d0d7" xlink:to="loc_dei_EntityAddressAddressLine1_2f491980-2f51-4d05-8e2e-0c7cee5ca0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_0641d8b6-b987-439e-ad1f-0ad52c962449" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5bd1eec3-429f-412b-b9dc-2a898230d0d7" xlink:to="loc_dei_EntityAddressCityOrTown_0641d8b6-b987-439e-ad1f-0ad52c962449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_de5f97a4-d2cb-4990-92ea-1c045c289cd8" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5bd1eec3-429f-412b-b9dc-2a898230d0d7" xlink:to="loc_dei_EntityAddressStateOrProvince_de5f97a4-d2cb-4990-92ea-1c045c289cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_deee961d-ee62-4a24-aa64-3f13729a3693" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5bd1eec3-429f-412b-b9dc-2a898230d0d7" xlink:to="loc_dei_EntityAddressPostalZipCode_deee961d-ee62-4a24-aa64-3f13729a3693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_5aa7b708-e5f6-4c92-93a4-a0716c478b87" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5bd1eec3-429f-412b-b9dc-2a898230d0d7" xlink:to="loc_dei_CityAreaCode_5aa7b708-e5f6-4c92-93a4-a0716c478b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_d2c2e943-a452-434f-8b21-6c0cec634be3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5bd1eec3-429f-412b-b9dc-2a898230d0d7" xlink:to="loc_dei_LocalPhoneNumber_d2c2e943-a452-434f-8b21-6c0cec634be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_0e66140f-14d5-420e-a9c1-b2a46c3acd20" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5bd1eec3-429f-412b-b9dc-2a898230d0d7" xlink:to="loc_dei_Security12bTitle_0e66140f-14d5-420e-a9c1-b2a46c3acd20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ad6f76de-b4c3-44a8-b7ca-5145fb5f904a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5bd1eec3-429f-412b-b9dc-2a898230d0d7" xlink:to="loc_dei_TradingSymbol_ad6f76de-b4c3-44a8-b7ca-5145fb5f904a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_5da76a61-3aa0-4c2d-8fb8-23d79dbb09e4" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5bd1eec3-429f-412b-b9dc-2a898230d0d7" xlink:to="loc_dei_SecurityExchangeName_5da76a61-3aa0-4c2d-8fb8-23d79dbb09e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_908c6c61-5adc-4812-ad51-584a633d0b6e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5bd1eec3-429f-412b-b9dc-2a898230d0d7" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_908c6c61-5adc-4812-ad51-584a633d0b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_f76d91de-7bbe-44a5-802b-7f50995d1d52" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5bd1eec3-429f-412b-b9dc-2a898230d0d7" xlink:to="loc_dei_EntityVoluntaryFilers_f76d91de-7bbe-44a5-802b-7f50995d1d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_5a99ead3-c8ba-4b79-8074-28725833d861" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5bd1eec3-429f-412b-b9dc-2a898230d0d7" xlink:to="loc_dei_EntityCurrentReportingStatus_5a99ead3-c8ba-4b79-8074-28725833d861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_f40788dc-b30b-418a-96d3-27e13a73807a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5bd1eec3-429f-412b-b9dc-2a898230d0d7" xlink:to="loc_dei_EntityInteractiveDataCurrent_f40788dc-b30b-418a-96d3-27e13a73807a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_83e6ae02-6c2f-4035-973c-5a7e0e25b1e1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5bd1eec3-429f-412b-b9dc-2a898230d0d7" xlink:to="loc_dei_EntityFilerCategory_83e6ae02-6c2f-4035-973c-5a7e0e25b1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_b859c87c-8712-4f47-9801-a7284f928b54" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5bd1eec3-429f-412b-b9dc-2a898230d0d7" xlink:to="loc_dei_EntitySmallBusiness_b859c87c-8712-4f47-9801-a7284f928b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_cbc94d97-8e94-4069-8231-00990b91bddf" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5bd1eec3-429f-412b-b9dc-2a898230d0d7" xlink:to="loc_dei_EntityEmergingGrowthCompany_cbc94d97-8e94-4069-8231-00990b91bddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_a0b04a38-2290-4a56-bad1-604556755cd1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5bd1eec3-429f-412b-b9dc-2a898230d0d7" xlink:to="loc_dei_EntityShellCompany_a0b04a38-2290-4a56-bad1-604556755cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_68cc25b8-ef00-402d-aec5-3dfcb64b66fa" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5bd1eec3-429f-412b-b9dc-2a898230d0d7" xlink:to="loc_dei_EntityPublicFloat_68cc25b8-ef00-402d-aec5-3dfcb64b66fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_e4e852f1-80a4-47d9-b0c1-b1b826f21658" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5bd1eec3-429f-412b-b9dc-2a898230d0d7" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_e4e852f1-80a4-47d9-b0c1-b1b826f21658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_b3024bcf-5da4-4b64-9d3e-512333ab2dc5" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5bd1eec3-429f-412b-b9dc-2a898230d0d7" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_b3024bcf-5da4-4b64-9d3e-512333ab2dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_9c4b30b7-4f60-470e-9f86-2906a530e32e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5bd1eec3-429f-412b-b9dc-2a898230d0d7" xlink:to="loc_dei_AmendmentFlag_9c4b30b7-4f60-470e-9f86-2906a530e32e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_d3590c80-1f80-4f3b-809d-d32da0172263" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5bd1eec3-429f-412b-b9dc-2a898230d0d7" xlink:to="loc_dei_DocumentFiscalYearFocus_d3590c80-1f80-4f3b-809d-d32da0172263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9f5f1ae7-66be-4fe8-862f-cf30d48ac92d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5bd1eec3-429f-412b-b9dc-2a898230d0d7" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9f5f1ae7-66be-4fe8-862f-cf30d48ac92d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_1a98c513-3ca5-4d76-8575-a7e4eeb713bc" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5bd1eec3-429f-412b-b9dc-2a898230d0d7" xlink:to="loc_dei_EntityCentralIndexKey_1a98c513-3ca5-4d76-8575-a7e4eeb713bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_e31cc8f5-4bd6-4fea-95f4-21951fffcd95" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5bd1eec3-429f-412b-b9dc-2a898230d0d7" xlink:to="loc_dei_CurrentFiscalYearEndDate_e31cc8f5-4bd6-4fea-95f4-21951fffcd95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="sgmo-20191231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_4355c9dc-d2af-4b3c-ad98-6f1bdb54305f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_1040ad91-809b-45fe-ad40-8d3425922eeb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4355c9dc-d2af-4b3c-ad98-6f1bdb54305f" xlink:to="loc_us-gaap_AssetsAbstract_1040ad91-809b-45fe-ad40-8d3425922eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_98f828b3-a97c-4a54-bedf-92de70c531ac" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1040ad91-809b-45fe-ad40-8d3425922eeb" xlink:to="loc_us-gaap_AssetsCurrentAbstract_98f828b3-a97c-4a54-bedf-92de70c531ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_75c8cee7-b79b-4d7f-adbc-e2afc4b47211" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_98f828b3-a97c-4a54-bedf-92de70c531ac" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_75c8cee7-b79b-4d7f-adbc-e2afc4b47211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_1115b786-fdc8-4479-84f7-c4ca61ac8475" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_98f828b3-a97c-4a54-bedf-92de70c531ac" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_1115b786-fdc8-4479-84f7-c4ca61ac8475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_a9e318bc-089a-4957-a4b9-68fc105b7add" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_98f828b3-a97c-4a54-bedf-92de70c531ac" xlink:to="loc_us-gaap_InterestReceivableCurrent_a9e318bc-089a-4957-a4b9-68fc105b7add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a96a7579-add7-465a-96f2-af8ca98b1d37" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_98f828b3-a97c-4a54-bedf-92de70c531ac" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a96a7579-add7-465a-96f2-af8ca98b1d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6ea81bd8-f0bd-4fe7-b2ec-a22597d24aec" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_98f828b3-a97c-4a54-bedf-92de70c531ac" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6ea81bd8-f0bd-4fe7-b2ec-a22597d24aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1f07b185-ddb2-4139-aca6-266f72e8b6e6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_98f828b3-a97c-4a54-bedf-92de70c531ac" xlink:to="loc_us-gaap_AssetsCurrent_1f07b185-ddb2-4139-aca6-266f72e8b6e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_a43c1d89-3fa9-48c5-9cf2-b440d99fa81d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1040ad91-809b-45fe-ad40-8d3425922eeb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_a43c1d89-3fa9-48c5-9cf2-b440d99fa81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_16e34668-9b68-420f-a031-98a319b04295" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1040ad91-809b-45fe-ad40-8d3425922eeb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_16e34668-9b68-420f-a031-98a319b04295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_fe60e3d6-ad70-4a8b-986f-097afe107ff7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1040ad91-809b-45fe-ad40-8d3425922eeb" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_fe60e3d6-ad70-4a8b-986f-097afe107ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4fc17f14-313b-464c-b5ee-a35f2fec0ca3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1040ad91-809b-45fe-ad40-8d3425922eeb" xlink:to="loc_us-gaap_Goodwill_4fc17f14-313b-464c-b5ee-a35f2fec0ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_5d266366-17de-4a7c-9c5b-d5f76316d82c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1040ad91-809b-45fe-ad40-8d3425922eeb" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_5d266366-17de-4a7c-9c5b-d5f76316d82c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b3ac6cde-a312-465c-a287-aa372ef04408" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1040ad91-809b-45fe-ad40-8d3425922eeb" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b3ac6cde-a312-465c-a287-aa372ef04408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_51a5a90d-9ee4-4421-bbe8-e06bcb90a91b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1040ad91-809b-45fe-ad40-8d3425922eeb" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_51a5a90d-9ee4-4421-bbe8-e06bcb90a91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_edf1399b-de46-40bb-ae39-4b5001580a94" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1040ad91-809b-45fe-ad40-8d3425922eeb" xlink:to="loc_us-gaap_Assets_edf1399b-de46-40bb-ae39-4b5001580a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96595913-a6a8-478e-aa67-f8f941f84732" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4355c9dc-d2af-4b3c-ad98-6f1bdb54305f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96595913-a6a8-478e-aa67-f8f941f84732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_3917a4bf-ec7b-4afa-874e-83dcc7084984" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96595913-a6a8-478e-aa67-f8f941f84732" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_3917a4bf-ec7b-4afa-874e-83dcc7084984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_93af159b-e308-47a3-8e11-f4b97fedadc3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3917a4bf-ec7b-4afa-874e-83dcc7084984" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_93af159b-e308-47a3-8e11-f4b97fedadc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_51d8989a-327e-451e-9d38-74545973fea1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3917a4bf-ec7b-4afa-874e-83dcc7084984" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_51d8989a-327e-451e-9d38-74545973fea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_fc96fb50-9f60-4114-88b1-34677a274088" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3917a4bf-ec7b-4afa-874e-83dcc7084984" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_fc96fb50-9f60-4114-88b1-34677a274088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9bd0ddd9-c69a-4938-9082-546d517f72b1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3917a4bf-ec7b-4afa-874e-83dcc7084984" xlink:to="loc_us-gaap_LiabilitiesCurrent_9bd0ddd9-c69a-4938-9082-546d517f72b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_76039eb0-491f-4215-8881-3202dbfe1410" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96595913-a6a8-478e-aa67-f8f941f84732" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_76039eb0-491f-4215-8881-3202dbfe1410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_da553823-14e6-4043-9226-56a2ebfe67db" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96595913-a6a8-478e-aa67-f8f941f84732" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_da553823-14e6-4043-9226-56a2ebfe67db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BuildToSuitLeaseObligations_a9336a57-c0f2-4773-bd65-dda4a89d9f86" xlink:href="sgmo-20191231.xsd#sgmo_BuildToSuitLeaseObligations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96595913-a6a8-478e-aa67-f8f941f84732" xlink:to="loc_sgmo_BuildToSuitLeaseObligations_a9336a57-c0f2-4773-bd65-dda4a89d9f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_4041093c-2197-4435-b5df-f178717ca5dc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96595913-a6a8-478e-aa67-f8f941f84732" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_4041093c-2197-4435-b5df-f178717ca5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_832b46e7-d824-42ba-95b7-f23152f65704" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96595913-a6a8-478e-aa67-f8f941f84732" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_832b46e7-d824-42ba-95b7-f23152f65704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ffe7ca49-55d3-4556-a941-60ff3363ddf8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96595913-a6a8-478e-aa67-f8f941f84732" xlink:to="loc_us-gaap_Liabilities_ffe7ca49-55d3-4556-a941-60ff3363ddf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_9c993802-2c0f-444f-9c3b-b9e1f1feba50" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96595913-a6a8-478e-aa67-f8f941f84732" xlink:to="loc_us-gaap_CommitmentsAndContingencies_9c993802-2c0f-444f-9c3b-b9e1f1feba50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_86c30132-949e-4f45-bcb0-ace5002115c7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96595913-a6a8-478e-aa67-f8f941f84732" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_86c30132-949e-4f45-bcb0-ace5002115c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_cd477051-0d59-4826-8385-b6a5a0f1cfb8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_86c30132-949e-4f45-bcb0-ace5002115c7" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_cd477051-0d59-4826-8385-b6a5a0f1cfb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_8ff3eb5d-51d8-46b0-9b21-4fb54ea23c36" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_86c30132-949e-4f45-bcb0-ace5002115c7" xlink:to="loc_us-gaap_CommonStockValue_8ff3eb5d-51d8-46b0-9b21-4fb54ea23c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_07602bfb-80c7-4867-9689-b98fb9fcffed" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_86c30132-949e-4f45-bcb0-ace5002115c7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_07602bfb-80c7-4867-9689-b98fb9fcffed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_347e5482-9712-4164-a1d9-e1f6819a4047" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_86c30132-949e-4f45-bcb0-ace5002115c7" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_347e5482-9712-4164-a1d9-e1f6819a4047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0d6e38d6-1221-4dee-876a-13119ea148f0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_86c30132-949e-4f45-bcb0-ace5002115c7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0d6e38d6-1221-4dee-876a-13119ea148f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a78e64ba-0fee-4ecd-a6fb-877b5261fb6c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_86c30132-949e-4f45-bcb0-ace5002115c7" xlink:to="loc_us-gaap_StockholdersEquity_a78e64ba-0fee-4ecd-a6fb-877b5261fb6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_e0d4b551-0d74-40e1-a0fe-38e4d5d4fdf7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_86c30132-949e-4f45-bcb0-ace5002115c7" xlink:to="loc_us-gaap_MinorityInterest_e0d4b551-0d74-40e1-a0fe-38e4d5d4fdf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4cae7062-e909-490b-ad3c-cc442777eeb2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_86c30132-949e-4f45-bcb0-ace5002115c7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4cae7062-e909-490b-ad3c-cc442777eeb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_efa18b33-3d0d-4401-86ea-32a0c75438bb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96595913-a6a8-478e-aa67-f8f941f84732" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_efa18b33-3d0d-4401-86ea-32a0c75438bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="sgmo-20191231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_dfe1103e-a582-42a6-b729-943b32003a34" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_377f115e-e9da-4e36-8814-cd3a05684ef8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dfe1103e-a582-42a6-b729-943b32003a34" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_377f115e-e9da-4e36-8814-cd3a05684ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6a08db65-f99d-4e43-87f3-bcb54b190ab3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dfe1103e-a582-42a6-b729-943b32003a34" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_6a08db65-f99d-4e43-87f3-bcb54b190ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_eec85c41-bf2f-4ca7-bffa-4beac572e12d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dfe1103e-a582-42a6-b729-943b32003a34" xlink:to="loc_us-gaap_CommonStockSharesIssued_eec85c41-bf2f-4ca7-bffa-4beac572e12d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f2d5e934-4f17-4879-abd8-97a85a23f5be" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dfe1103e-a582-42a6-b729-943b32003a34" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f2d5e934-4f17-4879-abd8-97a85a23f5be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_da70e3a0-ea35-4f68-b143-0cfbe5d6d74e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dfe1103e-a582-42a6-b729-943b32003a34" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_da70e3a0-ea35-4f68-b143-0cfbe5d6d74e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_0dd40877-820d-43bb-aa3f-4c6dc3e183b8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dfe1103e-a582-42a6-b729-943b32003a34" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_0dd40877-820d-43bb-aa3f-4c6dc3e183b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_11540c93-3c85-4666-80fd-94102d787a0d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dfe1103e-a582-42a6-b729-943b32003a34" xlink:to="loc_us-gaap_PreferredStockSharesIssued_11540c93-3c85-4666-80fd-94102d787a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_24f00630-bc45-4cc9-a1c4-37b97d15bd34" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dfe1103e-a582-42a6-b729-943b32003a34" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_24f00630-bc45-4cc9-a1c4-37b97d15bd34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="sgmo-20191231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_8b592216-b814-480b-ab95-8822fce3eb56" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_1317efb2-1b3e-48c3-b3f8-ff287ada4e7b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8b592216-b814-480b-ab95-8822fce3eb56" xlink:to="loc_us-gaap_RevenuesAbstract_1317efb2-1b3e-48c3-b3f8-ff287ada4e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_74cdf7b8-3510-4636-be5e-c77f82c6ca18" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_1317efb2-1b3e-48c3-b3f8-ff287ada4e7b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_74cdf7b8-3510-4636-be5e-c77f82c6ca18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_f19d3545-13c6-46b7-b004-c7b1b4e83c74" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8b592216-b814-480b-ab95-8822fce3eb56" xlink:to="loc_us-gaap_OperatingExpensesAbstract_f19d3545-13c6-46b7-b004-c7b1b4e83c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4dedd214-3f37-43de-9000-2569a1661f8b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f19d3545-13c6-46b7-b004-c7b1b4e83c74" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4dedd214-3f37-43de-9000-2569a1661f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_0a01012a-df90-4b52-a445-30a3c3863cca" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f19d3545-13c6-46b7-b004-c7b1b4e83c74" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_0a01012a-df90-4b52-a445-30a3c3863cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_812560bd-702e-4138-91b0-54d573e468e9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f19d3545-13c6-46b7-b004-c7b1b4e83c74" xlink:to="loc_us-gaap_OperatingExpenses_812560bd-702e-4138-91b0-54d573e468e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_79b1d897-51e6-475d-8e45-2c29ce1744ab" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8b592216-b814-480b-ab95-8822fce3eb56" xlink:to="loc_us-gaap_OperatingIncomeLoss_79b1d897-51e6-475d-8e45-2c29ce1744ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome_d076e55b-f85a-42be-9570-7e2838770d0f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8b592216-b814-480b-ab95-8822fce3eb56" xlink:to="loc_us-gaap_InterestAndOtherIncome_d076e55b-f85a-42be-9570-7e2838770d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5a12f8e2-2c3d-4bde-9e8c-dc71d89e5be4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8b592216-b814-480b-ab95-8822fce3eb56" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5a12f8e2-2c3d-4bde-9e8c-dc71d89e5be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8ed23782-1cde-47a7-9c72-a75c9eccada3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8b592216-b814-480b-ab95-8822fce3eb56" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8ed23782-1cde-47a7-9c72-a75c9eccada3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6ea14fca-89ea-4495-9906-0c8d551d2489" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8b592216-b814-480b-ab95-8822fce3eb56" xlink:to="loc_us-gaap_ProfitLoss_6ea14fca-89ea-4495-9906-0c8d551d2489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_40ca1135-eea3-4687-85d6-0fc7ba326569" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8b592216-b814-480b-ab95-8822fce3eb56" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_40ca1135-eea3-4687-85d6-0fc7ba326569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_530bee6f-1cc5-4077-8349-9250c0ab52a7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8b592216-b814-480b-ab95-8822fce3eb56" xlink:to="loc_us-gaap_NetIncomeLoss_530bee6f-1cc5-4077-8349-9250c0ab52a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_047791d3-90dd-47ef-9bef-79af55529177" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8b592216-b814-480b-ab95-8822fce3eb56" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_047791d3-90dd-47ef-9bef-79af55529177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_01b0b176-d369-46f3-a9de-a87542138291" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8b592216-b814-480b-ab95-8822fce3eb56" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_01b0b176-d369-46f3-a9de-a87542138291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="sgmo-20191231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_036a73ca-eabf-4c36-923b-fb4932b10b30" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_fa0fa6f1-c7f4-43af-9854-be10aa0a7d42" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_036a73ca-eabf-4c36-923b-fb4932b10b30" xlink:to="loc_us-gaap_ProfitLoss_fa0fa6f1-c7f4-43af-9854-be10aa0a7d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_98f5d72f-fc13-4d43-bcab-30865a07cfe2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_036a73ca-eabf-4c36-923b-fb4932b10b30" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_98f5d72f-fc13-4d43-bcab-30865a07cfe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_410c27f9-e804-43b2-9fad-6e4b6aa59ed9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_036a73ca-eabf-4c36-923b-fb4932b10b30" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_410c27f9-e804-43b2-9fad-6e4b6aa59ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_d835145a-f73d-4441-a543-b37382d9c1da" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_036a73ca-eabf-4c36-923b-fb4932b10b30" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_d835145a-f73d-4441-a543-b37382d9c1da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_271530ef-db2d-4389-9712-75eb03798e7b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_036a73ca-eabf-4c36-923b-fb4932b10b30" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_271530ef-db2d-4389-9712-75eb03798e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_51c996e9-1e5a-4372-ba57-29069d45655e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_036a73ca-eabf-4c36-923b-fb4932b10b30" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_51c996e9-1e5a-4372-ba57-29069d45655e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_02a51489-9dc0-449f-af5e-da339e77b04b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_036a73ca-eabf-4c36-923b-fb4932b10b30" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_02a51489-9dc0-449f-af5e-da339e77b04b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="sgmo-20191231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_ac650eba-6f2f-433e-ab0a-7ce5b73a3f59" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_37f41f03-be8e-4067-abd0-b222f9a92ca4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_ac650eba-6f2f-433e-ab0a-7ce5b73a3f59" xlink:to="loc_us-gaap_StatementTable_37f41f03-be8e-4067-abd0-b222f9a92ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_68cbf42f-6f35-4e29-ae8a-362720b5669c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_37f41f03-be8e-4067-abd0-b222f9a92ca4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_68cbf42f-6f35-4e29-ae8a-362720b5669c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2093c801-9b2f-4d5b-9a4f-b4d8309cbe34" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_68cbf42f-6f35-4e29-ae8a-362720b5669c" xlink:to="loc_us-gaap_EquityComponentDomain_2093c801-9b2f-4d5b-9a4f-b4d8309cbe34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_be5894c3-6c13-4086-acb8-3624fa779637" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2093c801-9b2f-4d5b-9a4f-b4d8309cbe34" xlink:to="loc_us-gaap_CommonStockMember_be5894c3-6c13-4086-acb8-3624fa779637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2e9f0775-d93b-4ad0-8ce7-98e7268b2bfb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2093c801-9b2f-4d5b-9a4f-b4d8309cbe34" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2e9f0775-d93b-4ad0-8ce7-98e7268b2bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_95adbfec-39c7-44fe-9d7d-5c1ec8060b56" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2093c801-9b2f-4d5b-9a4f-b4d8309cbe34" xlink:to="loc_us-gaap_RetainedEarningsMember_95adbfec-39c7-44fe-9d7d-5c1ec8060b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e9b758d5-e1ea-4404-b66c-5d775d88c9fe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2093c801-9b2f-4d5b-9a4f-b4d8309cbe34" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e9b758d5-e1ea-4404-b66c-5d775d88c9fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_e5b011e6-719a-4e33-8695-24da00c2cadd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2093c801-9b2f-4d5b-9a4f-b4d8309cbe34" xlink:to="loc_us-gaap_NoncontrollingInterestMember_e5b011e6-719a-4e33-8695-24da00c2cadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_33165dfb-d019-423e-8f08-37f83ee10624" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_37f41f03-be8e-4067-abd0-b222f9a92ca4" xlink:to="loc_us-gaap_StatementLineItems_33165dfb-d019-423e-8f08-37f83ee10624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_bdd0ed6e-c7ec-4bb2-b87b-0876ac5090e5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_33165dfb-d019-423e-8f08-37f83ee10624" xlink:to="loc_us-gaap_CommonStockSharesIssued_bdd0ed6e-c7ec-4bb2-b87b-0876ac5090e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c518e192-afff-4170-9857-0998111fc206" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_33165dfb-d019-423e-8f08-37f83ee10624" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c518e192-afff-4170-9857-0998111fc206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_d46b317c-f9a8-48a8-9dc6-ec160c295668" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_33165dfb-d019-423e-8f08-37f83ee10624" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_d46b317c-f9a8-48a8-9dc6-ec160c295668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1449246e-aece-49bf-93f7-036195c935d6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_33165dfb-d019-423e-8f08-37f83ee10624" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1449246e-aece-49bf-93f7-036195c935d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_19e2790e-cdf8-48ba-8973-e512ea76f0e7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_33165dfb-d019-423e-8f08-37f83ee10624" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_19e2790e-cdf8-48ba-8973-e512ea76f0e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a3f39ce2-5cea-46bd-8fc2-ac59d8589c84" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_33165dfb-d019-423e-8f08-37f83ee10624" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a3f39ce2-5cea-46bd-8fc2-ac59d8589c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_c9738d2e-94b7-44f3-9ee5-5a5f28a0dbe1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_33165dfb-d019-423e-8f08-37f83ee10624" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_c9738d2e-94b7-44f3-9ee5-5a5f28a0dbe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_14fca906-2eb7-408b-8c8f-297d5a670934" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_33165dfb-d019-423e-8f08-37f83ee10624" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_14fca906-2eb7-408b-8c8f-297d5a670934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_27ad8301-0168-4106-9810-e3f375caffcf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_33165dfb-d019-423e-8f08-37f83ee10624" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_27ad8301-0168-4106-9810-e3f375caffcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_33615ad4-59fa-40d6-b15c-251a347c6337" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_33165dfb-d019-423e-8f08-37f83ee10624" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_33615ad4-59fa-40d6-b15c-251a347c6337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest_c4377f9d-f777-465b-a89f-1dfe08dd7c4b" xlink:href="sgmo-20191231.xsd#sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_33165dfb-d019-423e-8f08-37f83ee10624" xlink:to="loc_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest_c4377f9d-f777-465b-a89f-1dfe08dd7c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_1e49e1a1-9431-4e3a-83ae-791666389420" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_33165dfb-d019-423e-8f08-37f83ee10624" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_1e49e1a1-9431-4e3a-83ae-791666389420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_61ec60c2-7b7e-4704-98c8-0bdc6377d1b3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_33165dfb-d019-423e-8f08-37f83ee10624" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_61ec60c2-7b7e-4704-98c8-0bdc6377d1b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_16d511c1-2fa9-4116-9ad7-4811d4d04885" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_33165dfb-d019-423e-8f08-37f83ee10624" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_16d511c1-2fa9-4116-9ad7-4811d4d04885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_d1289b18-7462-427c-aa54-2638ea381542" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_33165dfb-d019-423e-8f08-37f83ee10624" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_d1289b18-7462-427c-aa54-2638ea381542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8b87a6f0-7e46-401a-ab61-80e3ed3bc4bb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_33165dfb-d019-423e-8f08-37f83ee10624" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8b87a6f0-7e46-401a-ab61-80e3ed3bc4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0fca3b85-3eae-44b3-b7e6-498814c91fe9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_33165dfb-d019-423e-8f08-37f83ee10624" xlink:to="loc_us-gaap_ProfitLoss_0fca3b85-3eae-44b3-b7e6-498814c91fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4d09dfed-3c41-4f0c-8a69-766c5ffdefd1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_33165dfb-d019-423e-8f08-37f83ee10624" xlink:to="loc_us-gaap_CommonStockSharesIssued_4d09dfed-3c41-4f0c-8a69-766c5ffdefd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_33d739dd-8774-488e-a60c-af847e4e17e0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_33165dfb-d019-423e-8f08-37f83ee10624" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_33d739dd-8774-488e-a60c-af847e4e17e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="sgmo-20191231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_f65507ba-acb3-4d6f-8c60-9f0349930ab2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_92742e04-1105-4c4e-bc2e-7c2fed56fdd5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f65507ba-acb3-4d6f-8c60-9f0349930ab2" xlink:to="loc_us-gaap_StatementTable_92742e04-1105-4c4e-bc2e-7c2fed56fdd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_ca54cfeb-b088-4d09-92e5-0c44f18d9c96" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_92742e04-1105-4c4e-bc2e-7c2fed56fdd5" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_ca54cfeb-b088-4d09-92e5-0c44f18d9c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_78a2b0be-c9a6-4956-bf50-c38e8fe381ed" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_ca54cfeb-b088-4d09-92e5-0c44f18d9c96" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_78a2b0be-c9a6-4956-bf50-c38e8fe381ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BuildToSuitLeaseMember_a03a1910-f9e4-4bce-a8ad-0cbe4bcdaa56" xlink:href="sgmo-20191231.xsd#sgmo_BuildToSuitLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_78a2b0be-c9a6-4956-bf50-c38e8fe381ed" xlink:to="loc_sgmo_BuildToSuitLeaseMember_a03a1910-f9e4-4bce-a8ad-0cbe4bcdaa56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f481aa1c-0ec2-46e0-a9df-e87122bd922d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_92742e04-1105-4c4e-bc2e-7c2fed56fdd5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f481aa1c-0ec2-46e0-a9df-e87122bd922d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_324d8305-60e3-4b6a-a51e-f0444bc4cda7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f481aa1c-0ec2-46e0-a9df-e87122bd922d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_324d8305-60e3-4b6a-a51e-f0444bc4cda7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PropertyAndEquipmentMember_ff8d18f2-58ba-4562-a502-d90fc2666de9" xlink:href="sgmo-20191231.xsd#sgmo_PropertyAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_324d8305-60e3-4b6a-a51e-f0444bc4cda7" xlink:to="loc_sgmo_PropertyAndEquipmentMember_ff8d18f2-58ba-4562-a502-d90fc2666de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a8161f6d-496c-470f-a45d-6ce7143e3d35" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_92742e04-1105-4c4e-bc2e-7c2fed56fdd5" xlink:to="loc_us-gaap_StatementLineItems_a8161f6d-496c-470f-a45d-6ce7143e3d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_81b1070b-6bcb-4ad7-bd92-dc9167c027e9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a8161f6d-496c-470f-a45d-6ce7143e3d35" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_81b1070b-6bcb-4ad7-bd92-dc9167c027e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_dec578f6-ecd9-4227-a51f-72e06741cd96" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_81b1070b-6bcb-4ad7-bd92-dc9167c027e9" xlink:to="loc_us-gaap_ProfitLoss_dec578f6-ecd9-4227-a51f-72e06741cd96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_99552de7-6c5e-4bd0-a72c-d95c92fadade" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_81b1070b-6bcb-4ad7-bd92-dc9167c027e9" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_99552de7-6c5e-4bd0-a72c-d95c92fadade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_6a72df24-c225-4f7a-85c4-83df292686bb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_99552de7-6c5e-4bd0-a72c-d95c92fadade" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_6a72df24-c225-4f7a-85c4-83df292686bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_21bd16df-ea73-4222-8c30-5dc91ebacb9c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_99552de7-6c5e-4bd0-a72c-d95c92fadade" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_21bd16df-ea73-4222-8c30-5dc91ebacb9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_aee6c07d-fcb2-4f95-9979-0804bb1ed30f" xlink:href="sgmo-20191231.xsd#sgmo_AmortizationAndOtherChangesInRightOfUseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_99552de7-6c5e-4bd0-a72c-d95c92fadade" xlink:to="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_aee6c07d-fcb2-4f95-9979-0804bb1ed30f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GainOnFreeShares_83e04e6a-1361-41b3-b887-f45aee15aee0" xlink:href="sgmo-20191231.xsd#sgmo_GainOnFreeShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_99552de7-6c5e-4bd0-a72c-d95c92fadade" xlink:to="loc_sgmo_GainOnFreeShares_83e04e6a-1361-41b3-b887-f45aee15aee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_a27fd3d7-55a0-4e50-9bc4-6b55665c4a69" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_99552de7-6c5e-4bd0-a72c-d95c92fadade" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_a27fd3d7-55a0-4e50-9bc4-6b55665c4a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_76e235cf-d794-4f03-915e-eb924a6eb377" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_99552de7-6c5e-4bd0-a72c-d95c92fadade" xlink:to="loc_us-gaap_ShareBasedCompensation_76e235cf-d794-4f03-915e-eb924a6eb377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease_884e1fb4-f283-4a5f-bd04-216114b888f4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_99552de7-6c5e-4bd0-a72c-d95c92fadade" xlink:to="loc_us-gaap_GainLossOnTerminationOfLease_884e1fb4-f283-4a5f-bd04-216114b888f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BuildToSuitLeases_7198fbd6-f76b-460d-81a8-f59ce8005214" xlink:href="sgmo-20191231.xsd#sgmo_BuildToSuitLeases"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_99552de7-6c5e-4bd0-a72c-d95c92fadade" xlink:to="loc_sgmo_BuildToSuitLeases_7198fbd6-f76b-460d-81a8-f59ce8005214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b91b2505-14b6-4642-80c2-c2637ec15ea6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_81b1070b-6bcb-4ad7-bd92-dc9167c027e9" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b91b2505-14b6-4642-80c2-c2637ec15ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_d8ba01f6-054f-4a92-9605-e893270b4dae" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b91b2505-14b6-4642-80c2-c2637ec15ea6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_d8ba01f6-054f-4a92-9605-e893270b4dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1288ea94-686c-4edd-bf0a-3df7d2cacd56" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b91b2505-14b6-4642-80c2-c2637ec15ea6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1288ea94-686c-4edd-bf0a-3df7d2cacd56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a0a4b330-045f-4d90-b0cf-39aefff6428d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b91b2505-14b6-4642-80c2-c2637ec15ea6" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a0a4b330-045f-4d90-b0cf-39aefff6428d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ab2b359e-7f57-4897-ad0c-64fe88314f1b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b91b2505-14b6-4642-80c2-c2637ec15ea6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ab2b359e-7f57-4897-ad0c-64fe88314f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_173c16cb-4efe-4388-949f-4e841250a0fe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b91b2505-14b6-4642-80c2-c2637ec15ea6" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_173c16cb-4efe-4388-949f-4e841250a0fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_5582b4f5-fbb9-4009-b9a3-d454318736c3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b91b2505-14b6-4642-80c2-c2637ec15ea6" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_5582b4f5-fbb9-4009-b9a3-d454318736c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_df1a56bd-68e7-4212-bf16-039ce49f3e8f" xlink:href="sgmo-20191231.xsd#sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b91b2505-14b6-4642-80c2-c2637ec15ea6" xlink:to="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_df1a56bd-68e7-4212-bf16-039ce49f3e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_009c2483-077d-4708-90b1-3c98a3cc3ce7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b91b2505-14b6-4642-80c2-c2637ec15ea6" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_009c2483-077d-4708-90b1-3c98a3cc3ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_53d8b31f-bcb0-45ae-98d1-fe9cf317017c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_81b1070b-6bcb-4ad7-bd92-dc9167c027e9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_53d8b31f-bcb0-45ae-98d1-fe9cf317017c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bec2b79b-8a82-4fb2-8acf-7f32f951770b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a8161f6d-496c-470f-a45d-6ce7143e3d35" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bec2b79b-8a82-4fb2-8acf-7f32f951770b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_5425c29b-4a63-473b-b644-4f252459cc57" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bec2b79b-8a82-4fb2-8acf-7f32f951770b" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_5425c29b-4a63-473b-b644-4f252459cc57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_06f7e9e8-5dc6-44ae-b8f6-ae9f4353e528" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bec2b79b-8a82-4fb2-8acf-7f32f951770b" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_06f7e9e8-5dc6-44ae-b8f6-ae9f4353e528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_c64083db-d1aa-40ab-b2be-eb6541456833" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bec2b79b-8a82-4fb2-8acf-7f32f951770b" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_c64083db-d1aa-40ab-b2be-eb6541456833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6a0b147e-7a8b-4de3-9c0a-4055ec5075e0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bec2b79b-8a82-4fb2-8acf-7f32f951770b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6a0b147e-7a8b-4de3-9c0a-4055ec5075e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_b84ccd0e-586a-42a5-a5ab-a35a25a439ed" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bec2b79b-8a82-4fb2-8acf-7f32f951770b" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_b84ccd0e-586a-42a5-a5ab-a35a25a439ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7ba302a0-ab56-4ee7-a2c0-38e62d5dbe16" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bec2b79b-8a82-4fb2-8acf-7f32f951770b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7ba302a0-ab56-4ee7-a2c0-38e62d5dbe16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc640db6-4472-407d-aeca-4fcafa268dd4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a8161f6d-496c-470f-a45d-6ce7143e3d35" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc640db6-4472-407d-aeca-4fcafa268dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NetProceedsFromIssuancePublicOffering_f6ee6b08-8602-4c8a-a824-682f16b48246" xlink:href="sgmo-20191231.xsd#sgmo_NetProceedsFromIssuancePublicOffering"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc640db6-4472-407d-aeca-4fcafa268dd4" xlink:to="loc_sgmo_NetProceedsFromIssuancePublicOffering_f6ee6b08-8602-4c8a-a824-682f16b48246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1086c965-b196-4a77-a083-329cad69a08c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc640db6-4472-407d-aeca-4fcafa268dd4" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1086c965-b196-4a77-a083-329cad69a08c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1506c519-2023-4ca5-8b27-802fc12a3c76" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc640db6-4472-407d-aeca-4fcafa268dd4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1506c519-2023-4ca5-8b27-802fc12a3c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_8dbf47a5-0667-4206-b3e6-b8cc2ab35edf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc640db6-4472-407d-aeca-4fcafa268dd4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_8dbf47a5-0667-4206-b3e6-b8cc2ab35edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_92077fe6-945f-40b4-92d9-8cd1bbbf8070" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc640db6-4472-407d-aeca-4fcafa268dd4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_92077fe6-945f-40b4-92d9-8cd1bbbf8070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_eac93210-1d53-4263-94e3-c93c1e8ac9b3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a8161f6d-496c-470f-a45d-6ce7143e3d35" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_eac93210-1d53-4263-94e3-c93c1e8ac9b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_448a9029-d0ea-4cd5-b631-e5d0082f8e77" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a8161f6d-496c-470f-a45d-6ce7143e3d35" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_448a9029-d0ea-4cd5-b631-e5d0082f8e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f27d3732-7872-424c-b94f-9b755cb08ad1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a8161f6d-496c-470f-a45d-6ce7143e3d35" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f27d3732-7872-424c-b94f-9b755cb08ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f39e40d3-a8d4-4d06-bda7-2d9c23251a5e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a8161f6d-496c-470f-a45d-6ce7143e3d35" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f39e40d3-a8d4-4d06-bda7-2d9c23251a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2238aac0-772f-4735-a5db-b9aac35d522c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a8161f6d-496c-470f-a45d-6ce7143e3d35" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2238aac0-772f-4735-a5db-b9aac35d522c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NoncashOrPartNoncashNonControllingInterestAcquisition_0d96abe0-01ac-4c09-9960-ab1d9aa9fb64" xlink:href="sgmo-20191231.xsd#sgmo_NoncashOrPartNoncashNonControllingInterestAcquisition"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2238aac0-772f-4735-a5db-b9aac35d522c" xlink:to="loc_sgmo_NoncashOrPartNoncashNonControllingInterestAcquisition_0d96abe0-01ac-4c09-9960-ab1d9aa9fb64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_2f5164d7-6687-42b2-86db-15b2dc37a1fa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2238aac0-772f-4735-a5db-b9aac35d522c" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_2f5164d7-6687-42b2-86db-15b2dc37a1fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_37fa16bc-7e5f-4d67-8a1c-80a14a26de08" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2238aac0-772f-4735-a5db-b9aac35d522c" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_37fa16bc-7e5f-4d67-8a1c-80a14a26de08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="sgmo-20191231.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e5f07ec3-7b76-4828-8352-ff2153d671ec" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_6cfbea76-cd16-4ffd-ab25-3effc24f1bd7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e5f07ec3-7b76-4828-8352-ff2153d671ec" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_6cfbea76-cd16-4ffd-ab25-3effc24f1bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="sgmo-20191231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_754468c4-ea4e-4fca-bac8-a164b00fb89a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0e0fb13b-6bad-4e9d-8bea-26831a6d81bc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_754468c4-ea4e-4fca-bac8-a164b00fb89a" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0e0fb13b-6bad-4e9d-8bea-26831a6d81bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_9ce7ec16-6a21-4356-a693-91d8abd54b9f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_754468c4-ea4e-4fca-bac8-a164b00fb89a" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_9ce7ec16-6a21-4356-a693-91d8abd54b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_b2cbd8a8-f2a8-4c82-8f08-2a4a875a1cb7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_754468c4-ea4e-4fca-bac8-a164b00fb89a" xlink:to="loc_us-gaap_UseOfEstimates_b2cbd8a8-f2a8-4c82-8f08-2a4a875a1cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_b7a6e389-3f75-43b6-adf3-eef67be01242" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_754468c4-ea4e-4fca-bac8-a164b00fb89a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_b7a6e389-3f75-43b6-adf3-eef67be01242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_2f792e3a-eeb7-4fd8-bffb-0d06ee80c467" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_754468c4-ea4e-4fca-bac8-a164b00fb89a" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_2f792e3a-eeb7-4fd8-bffb-0d06ee80c467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_d09edd55-e3c4-4c9d-8725-eea52557a5d2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_754468c4-ea4e-4fca-bac8-a164b00fb89a" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_d09edd55-e3c4-4c9d-8725-eea52557a5d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_94fec7ef-cc4c-49da-bbc0-bcabb8eb7be5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_754468c4-ea4e-4fca-bac8-a164b00fb89a" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_94fec7ef-cc4c-49da-bbc0-bcabb8eb7be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_78481f10-5018-4a89-a3e0-05df062c19e7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_754468c4-ea4e-4fca-bac8-a164b00fb89a" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_78481f10-5018-4a89-a3e0-05df062c19e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_02a2e21e-a2af-4ba0-a34a-5f735b9b4432" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_754468c4-ea4e-4fca-bac8-a164b00fb89a" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_02a2e21e-a2af-4ba0-a34a-5f735b9b4432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_ac6c2690-36cf-4a8d-9cb7-bc7105d60083" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_754468c4-ea4e-4fca-bac8-a164b00fb89a" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_ac6c2690-36cf-4a8d-9cb7-bc7105d60083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_41a2106c-63f0-4634-be9c-93dc7f5006cd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_754468c4-ea4e-4fca-bac8-a164b00fb89a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_41a2106c-63f0-4634-be9c-93dc7f5006cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_6beee679-01f3-4b22-9726-8abfa336ebab" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_754468c4-ea4e-4fca-bac8-a164b00fb89a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_6beee679-01f3-4b22-9726-8abfa336ebab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_112b4940-4dc5-43eb-9d02-43dd60ca1337" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_754468c4-ea4e-4fca-bac8-a164b00fb89a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_112b4940-4dc5-43eb-9d02-43dd60ca1337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_6bb02c87-13fd-4f5d-9547-ecc3690917dd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_754468c4-ea4e-4fca-bac8-a164b00fb89a" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_6bb02c87-13fd-4f5d-9547-ecc3690917dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_48b987cf-e22e-4062-a758-05374f0a2f51" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_754468c4-ea4e-4fca-bac8-a164b00fb89a" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_48b987cf-e22e-4062-a758-05374f0a2f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_340d69a4-fcb4-41ae-9446-f3f7727a61db" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_754468c4-ea4e-4fca-bac8-a164b00fb89a" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_340d69a4-fcb4-41ae-9446-f3f7727a61db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_621304c0-5320-4504-b533-5ea6a98de51c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_754468c4-ea4e-4fca-bac8-a164b00fb89a" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_621304c0-5320-4504-b533-5ea6a98de51c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_a603a153-90cf-4968-8795-fcef9b97b182" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_754468c4-ea4e-4fca-bac8-a164b00fb89a" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_a603a153-90cf-4968-8795-fcef9b97b182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f1513a85-bd28-486a-b557-31485031f446" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_754468c4-ea4e-4fca-bac8-a164b00fb89a" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f1513a85-bd28-486a-b557-31485031f446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="sgmo-20191231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_264e7d72-c61f-47aa-988e-c95c7365ddea" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_1108b0d0-4f4c-4c1a-ad7a-a62e68f19c88" xlink:href="sgmo-20191231.xsd#sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_264e7d72-c61f-47aa-988e-c95c7365ddea" xlink:to="loc_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_1108b0d0-4f4c-4c1a-ad7a-a62e68f19c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_1a9447e9-40cd-43c5-b446-ffc72dd2c6a5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_264e7d72-c61f-47aa-988e-c95c7365ddea" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_1a9447e9-40cd-43c5-b446-ffc72dd2c6a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_1c7830b4-a920-4fef-9608-e9f5ec1da6aa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_264e7d72-c61f-47aa-988e-c95c7365ddea" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_1c7830b4-a920-4fef-9608-e9f5ec1da6aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_76515a29-95c1-4adb-bfb3-9155fa3bd9e4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_264e7d72-c61f-47aa-988e-c95c7365ddea" xlink:to="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_76515a29-95c1-4adb-bfb3-9155fa3bd9e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_fcf12e1a-a4b0-45ef-b03e-34fcd94e64c8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_2b9325ac-e99c-451a-af3f-eabee68ca1ce" xlink:href="sgmo-20191231.xsd#sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fcf12e1a-a4b0-45ef-b03e-34fcd94e64c8" xlink:to="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_2b9325ac-e99c-451a-af3f-eabee68ca1ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4878ecae-c94e-4416-829c-c66102046728" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_2b9325ac-e99c-451a-af3f-eabee68ca1ce" xlink:to="loc_srt_RangeAxis_4878ecae-c94e-4416-829c-c66102046728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9494fe0b-e64c-4faf-b90a-61b888adb654" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4878ecae-c94e-4416-829c-c66102046728" xlink:to="loc_srt_RangeMember_9494fe0b-e64c-4faf-b90a-61b888adb654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_66a4c7f0-3de3-4c9d-82ee-087ef1c72a22" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9494fe0b-e64c-4faf-b90a-61b888adb654" xlink:to="loc_srt_MinimumMember_66a4c7f0-3de3-4c9d-82ee-087ef1c72a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ef5da891-4707-4c14-9f3c-08dcd528de1f" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9494fe0b-e64c-4faf-b90a-61b888adb654" xlink:to="loc_srt_MaximumMember_ef5da891-4707-4c14-9f3c-08dcd528de1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_abe025db-f307-4e93-97e5-75b14e981a41" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_2b9325ac-e99c-451a-af3f-eabee68ca1ce" xlink:to="loc_srt_CounterpartyNameAxis_abe025db-f307-4e93-97e5-75b14e981a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_83bb8a30-207b-431f-9eb1-9ae8c9c5c5c2" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_abe025db-f307-4e93-97e5-75b14e981a41" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_83bb8a30-207b-431f-9eb1-9ae8c9c5c5c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_5ddb3fad-aa47-434f-97b9-0c5552ccd795" xlink:href="sgmo-20191231.xsd#sgmo_SanofiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_83bb8a30-207b-431f-9eb1-9ae8c9c5c5c2" xlink:to="loc_sgmo_SanofiMember_5ddb3fad-aa47-434f-97b9-0c5552ccd795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember_71ff2577-c2b4-4335-8d05-f14e678970ae" xlink:href="sgmo-20191231.xsd#sgmo_PfizerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_83bb8a30-207b-431f-9eb1-9ae8c9c5c5c2" xlink:to="loc_sgmo_PfizerMember_71ff2577-c2b4-4335-8d05-f14e678970ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member_fe53e2be-57d1-41b1-a8ce-2d2788386388" xlink:href="sgmo-20191231.xsd#sgmo_PfizerSB525Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_83bb8a30-207b-431f-9eb1-9ae8c9c5c5c2" xlink:to="loc_sgmo_PfizerSB525Member_fe53e2be-57d1-41b1-a8ce-2d2788386388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_9edab184-ee07-46e6-ba78-b601ade114cd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_2b9325ac-e99c-451a-af3f-eabee68ca1ce" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_9edab184-ee07-46e6-ba78-b601ade114cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_bd41f2c8-41b3-4bd0-aac4-564ebf1211e8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_9edab184-ee07-46e6-ba78-b601ade114cd" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_bd41f2c8-41b3-4bd0-aac4-564ebf1211e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ChangeInCollaborationAgreementScopeMember_e0ce7236-fcc0-4e02-a34d-95a1a6aef8e1" xlink:href="sgmo-20191231.xsd#sgmo_ChangeInCollaborationAgreementScopeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_bd41f2c8-41b3-4bd0-aac4-564ebf1211e8" xlink:to="loc_sgmo_ChangeInCollaborationAgreementScopeMember_e0ce7236-fcc0-4e02-a34d-95a1a6aef8e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_436757f2-2b7b-4b76-8878-1b3fb0ed6bdb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_2b9325ac-e99c-451a-af3f-eabee68ca1ce" xlink:to="loc_us-gaap_TypeOfArrangementAxis_436757f2-2b7b-4b76-8878-1b3fb0ed6bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a3c58e81-0c62-422a-b633-9a0103ae3040" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_436757f2-2b7b-4b76-8878-1b3fb0ed6bdb" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a3c58e81-0c62-422a-b633-9a0103ae3040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_8d44465b-fc5f-4351-a08f-828c4cbfd835" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a3c58e81-0c62-422a-b633-9a0103ae3040" xlink:to="loc_us-gaap_CollaborativeArrangementMember_8d44465b-fc5f-4351-a08f-828c4cbfd835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_ba3e9fa1-7647-4204-96a8-13560c49e231" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_2b9325ac-e99c-451a-af3f-eabee68ca1ce" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_ba3e9fa1-7647-4204-96a8-13560c49e231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_0c82d276-7b49-4c6f-9faf-bed299645c04" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_ba3e9fa1-7647-4204-96a8-13560c49e231" xlink:to="loc_us-gaap_TypeOfAdoptionMember_0c82d276-7b49-4c6f-9faf-bed299645c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_42ed601d-dd52-4f98-8161-e77f0113f590" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_0c82d276-7b49-4c6f-9faf-bed299645c04" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_42ed601d-dd52-4f98-8161-e77f0113f590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_eef122c3-9539-4c2f-8529-734a1ef8fbfd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_2b9325ac-e99c-451a-af3f-eabee68ca1ce" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_eef122c3-9539-4c2f-8529-734a1ef8fbfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_48004c28-4c38-475d-9ebd-c56c292f1f12" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_eef122c3-9539-4c2f-8529-734a1ef8fbfd" xlink:to="loc_us-gaap_EquityComponentDomain_48004c28-4c38-475d-9ebd-c56c292f1f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_16e120ed-d4f0-481b-a5e3-a6caf3846020" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_48004c28-4c38-475d-9ebd-c56c292f1f12" xlink:to="loc_us-gaap_RetainedEarningsMember_16e120ed-d4f0-481b-a5e3-a6caf3846020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_4ca58e0d-2655-4807-9fe0-1261e228eb63" xlink:href="sgmo-20191231.xsd#sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_2b9325ac-e99c-451a-af3f-eabee68ca1ce" xlink:to="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_4ca58e0d-2655-4807-9fe0-1261e228eb63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_88967291-d4af-461a-ab15-bcd78bc8255d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_4ca58e0d-2655-4807-9fe0-1261e228eb63" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_88967291-d4af-461a-ab15-bcd78bc8255d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8b24aaaa-854c-471b-8f90-f293b7fcbf15" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_4ca58e0d-2655-4807-9fe0-1261e228eb63" xlink:to="loc_us-gaap_ProfitLoss_8b24aaaa-854c-471b-8f90-f293b7fcbf15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_b79432dd-cd2c-4b8b-9b59-7e588b141a3e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_4ca58e0d-2655-4807-9fe0-1261e228eb63" xlink:to="loc_us-gaap_EarningsPerShareBasic_b79432dd-cd2c-4b8b-9b59-7e588b141a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_659f9a6a-4e30-4775-9743-d5f828c67dc8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_4ca58e0d-2655-4807-9fe0-1261e228eb63" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_659f9a6a-4e30-4775-9743-d5f828c67dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_e87f72a4-1357-433b-83bb-8fb971a5ff48" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_4ca58e0d-2655-4807-9fe0-1261e228eb63" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_e87f72a4-1357-433b-83bb-8fb971a5ff48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber_4c3fbba5-1436-4219-848a-541067e7642c" xlink:href="sgmo-20191231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_4ca58e0d-2655-4807-9fe0-1261e228eb63" xlink:to="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber_4c3fbba5-1436-4219-848a-541067e7642c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_04377e8d-644b-4afa-8d26-a4e2ebb46e55" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_4ca58e0d-2655-4807-9fe0-1261e228eb63" xlink:to="loc_us-gaap_NumberOfOperatingSegments_04377e8d-644b-4afa-8d26-a4e2ebb46e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_90d5319f-ec2b-46cb-a9c3-0b8e8e17ce02" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_4ca58e0d-2655-4807-9fe0-1261e228eb63" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_90d5319f-ec2b-46cb-a9c3-0b8e8e17ce02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0ae85960-3f76-422e-a6fc-bc8120f2750f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_a17fa785-0542-4cda-bf00-3b620c561cb8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0ae85960-3f76-422e-a6fc-bc8120f2750f" xlink:to="loc_us-gaap_ConcentrationRiskTable_a17fa785-0542-4cda-bf00-3b620c561cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_35ff2c47-c804-488b-9b4f-b71666cf1331" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_a17fa785-0542-4cda-bf00-3b620c561cb8" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_35ff2c47-c804-488b-9b4f-b71666cf1331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bc56065b-9c68-4754-a152-56f03bff625f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_35ff2c47-c804-488b-9b4f-b71666cf1331" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bc56065b-9c68-4754-a152-56f03bff625f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_6188cd1f-a05d-41d9-90ed-5deb3e365970" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bc56065b-9c68-4754-a152-56f03bff625f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_6188cd1f-a05d-41d9-90ed-5deb3e365970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_bd61c287-67c0-4bb8-8a0c-645cf44d47d6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_a17fa785-0542-4cda-bf00-3b620c561cb8" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_bd61c287-67c0-4bb8-8a0c-645cf44d47d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a4dce865-ec74-4c8d-8b6f-b42c1ea7759b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_bd61c287-67c0-4bb8-8a0c-645cf44d47d6" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a4dce865-ec74-4c8d-8b6f-b42c1ea7759b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_0f2d35c6-6d41-415d-ab7b-4a9e803c098b" xlink:href="sgmo-20191231.xsd#sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_a4dce865-ec74-4c8d-8b6f-b42c1ea7759b" xlink:to="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_0f2d35c6-6d41-415d-ab7b-4a9e803c098b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_55ba0613-f3f1-4d92-b9aa-328ce066275b" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_a17fa785-0542-4cda-bf00-3b620c561cb8" xlink:to="loc_srt_CounterpartyNameAxis_55ba0613-f3f1-4d92-b9aa-328ce066275b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_50a80ea4-2b75-4b68-85c4-3cccbf96636a" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_55ba0613-f3f1-4d92-b9aa-328ce066275b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_50a80ea4-2b75-4b68-85c4-3cccbf96636a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember_3bc2b4c0-afd4-4981-810a-cf899fc81fc0" xlink:href="sgmo-20191231.xsd#sgmo_PfizerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_50a80ea4-2b75-4b68-85c4-3cccbf96636a" xlink:to="loc_sgmo_PfizerMember_3bc2b4c0-afd4-4981-810a-cf899fc81fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_3d412b34-edc0-44f4-a7a6-6dd56dab6c55" xlink:href="sgmo-20191231.xsd#sgmo_KitePharmaIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_50a80ea4-2b75-4b68-85c4-3cccbf96636a" xlink:to="loc_sgmo_KitePharmaIncMember_3d412b34-edc0-44f4-a7a6-6dd56dab6c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_4070ba52-3dd9-4fb8-9031-df8fbb301d01" xlink:href="sgmo-20191231.xsd#sgmo_SanofiMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_50a80ea4-2b75-4b68-85c4-3cccbf96636a" xlink:to="loc_sgmo_SanofiMember_4070ba52-3dd9-4fb8-9031-df8fbb301d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_16c9764f-ae62-492e-a9e7-62eaaf54bc98" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_a17fa785-0542-4cda-bf00-3b620c561cb8" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_16c9764f-ae62-492e-a9e7-62eaaf54bc98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_4b84947c-2d3b-4b75-a8f5-5e810dff240d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_16c9764f-ae62-492e-a9e7-62eaaf54bc98" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_4b84947c-2d3b-4b75-a8f5-5e810dff240d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="sgmo-20191231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofCashandCashEquivalentsDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3d396329-20da-4a67-9877-a6dead5981d9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_6b2ed78d-9648-4c3d-a01b-c42f86c77c9f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3d396329-20da-4a67-9877-a6dead5981d9" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_6b2ed78d-9648-4c3d-a01b-c42f86c77c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_9d576546-3ab6-42cb-bd3c-e99cbc4dac62" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3d396329-20da-4a67-9877-a6dead5981d9" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_9d576546-3ab6-42cb-bd3c-e99cbc4dac62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_23afc17e-3842-40b7-89e3-2616fe768eb5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3d396329-20da-4a67-9877-a6dead5981d9" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_23afc17e-3842-40b7-89e3-2616fe768eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesImpactofAdoptionofASConCondensedConsolidatedBalanceSheetDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesImpactofAdoptionofASConCondensedConsolidatedBalanceSheetDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesImpactofAdoptionofASConCondensedConsolidatedBalanceSheetDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9b88ded2-a600-4897-ad6a-60cdddd6abe2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_659196c3-6ea6-4d0a-b2de-d7b1aeea92a2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b88ded2-a600-4897-ad6a-60cdddd6abe2" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_659196c3-6ea6-4d0a-b2de-d7b1aeea92a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LeaseArrangementsAxis_12ab6a2c-3270-4e51-bef1-cbf7e0be9ca7" xlink:href="sgmo-20191231.xsd#sgmo_LeaseArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_659196c3-6ea6-4d0a-b2de-d7b1aeea92a2" xlink:to="loc_sgmo_LeaseArrangementsAxis_12ab6a2c-3270-4e51-bef1-cbf7e0be9ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LeaseArrangementsDomain_ac74bcca-b4a7-4763-b9d6-015d3eaa0ca5" xlink:href="sgmo-20191231.xsd#sgmo_LeaseArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_LeaseArrangementsAxis_12ab6a2c-3270-4e51-bef1-cbf7e0be9ca7" xlink:to="loc_sgmo_LeaseArrangementsDomain_ac74bcca-b4a7-4763-b9d6-015d3eaa0ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BuildToSuitLeaseMember_f4dee5e0-50b9-47bf-bf0e-ad6fa1282cc9" xlink:href="sgmo-20191231.xsd#sgmo_BuildToSuitLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_LeaseArrangementsDomain_ac74bcca-b4a7-4763-b9d6-015d3eaa0ca5" xlink:to="loc_sgmo_BuildToSuitLeaseMember_f4dee5e0-50b9-47bf-bf0e-ad6fa1282cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1f6360cd-d677-4d8a-b40a-f78043072d08" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_659196c3-6ea6-4d0a-b2de-d7b1aeea92a2" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1f6360cd-d677-4d8a-b40a-f78043072d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_a3be318b-d46a-4fea-9138-15b7f1e33f7e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1f6360cd-d677-4d8a-b40a-f78043072d08" xlink:to="loc_us-gaap_TypeOfAdoptionMember_a3be318b-d46a-4fea-9138-15b7f1e33f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_1e8493b5-db7a-4706-b391-3ddbcaff2482" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_a3be318b-d46a-4fea-9138-15b7f1e33f7e" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_1e8493b5-db7a-4706-b391-3ddbcaff2482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_34b84c20-647b-4e0f-8817-6aee80f01d4c" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_659196c3-6ea6-4d0a-b2de-d7b1aeea92a2" xlink:to="loc_srt_RestatementAxis_34b84c20-647b-4e0f-8817-6aee80f01d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_151f850a-e988-4af4-9d7e-5d47e22dce22" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_34b84c20-647b-4e0f-8817-6aee80f01d4c" xlink:to="loc_srt_RestatementDomain_151f850a-e988-4af4-9d7e-5d47e22dce22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember_ae1112cf-db75-4dcc-b44a-493e02fefdb9" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_151f850a-e988-4af4-9d7e-5d47e22dce22" xlink:to="loc_srt_RestatementAdjustmentMember_ae1112cf-db75-4dcc-b44a-493e02fefdb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_885c44ec-d2b6-4c4d-a817-fb20cf34b46c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_659196c3-6ea6-4d0a-b2de-d7b1aeea92a2" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_885c44ec-d2b6-4c4d-a817-fb20cf34b46c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_46441963-d685-4e1e-8677-1ecf6f2f9443" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_885c44ec-d2b6-4c4d-a817-fb20cf34b46c" xlink:to="loc_us-gaap_AssetsAbstract_46441963-d685-4e1e-8677-1ecf6f2f9443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2ec40f91-45d9-4c63-84eb-3f569c3682da" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_46441963-d685-4e1e-8677-1ecf6f2f9443" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2ec40f91-45d9-4c63-84eb-3f569c3682da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b641799c-1d95-4845-b21a-ccf5d199ed48" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_46441963-d685-4e1e-8677-1ecf6f2f9443" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b641799c-1d95-4845-b21a-ccf5d199ed48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidRent_5a47e9eb-b994-48a2-97cb-f42c2d459c05" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidRent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_46441963-d685-4e1e-8677-1ecf6f2f9443" xlink:to="loc_us-gaap_PrepaidRent_5a47e9eb-b994-48a2-97cb-f42c2d459c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_8d0f5914-922f-4d8c-a43c-25efc5327616" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_885c44ec-d2b6-4c4d-a817-fb20cf34b46c" xlink:to="loc_us-gaap_LiabilitiesAbstract_8d0f5914-922f-4d8c-a43c-25efc5327616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5377ec9f-05ea-41e5-a5de-258107e60eea" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_8d0f5914-922f-4d8c-a43c-25efc5327616" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_5377ec9f-05ea-41e5-a5de-258107e60eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DeferredRentNoncurrent_d781d6d6-78ee-498d-bcdd-5f4f39531329" xlink:href="sgmo-20191231.xsd#sgmo_DeferredRentNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_8d0f5914-922f-4d8c-a43c-25efc5327616" xlink:to="loc_sgmo_DeferredRentNoncurrent_d781d6d6-78ee-498d-bcdd-5f4f39531329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8a12bb92-aa4d-4a84-b407-8b9a50b7be35" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_8d0f5914-922f-4d8c-a43c-25efc5327616" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8a12bb92-aa4d-4a84-b407-8b9a50b7be35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f6e12d3e-9512-4aad-8261-25c91304c4ad" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_8d0f5914-922f-4d8c-a43c-25efc5327616" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f6e12d3e-9512-4aad-8261-25c91304c4ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurement" xlink:type="simple" xlink:href="sgmo-20191231.xsd#FairValueMeasurement"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/FairValueMeasurement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0d6edb73-d948-43ba-965d-fa81625d82ed" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_e5fcecdd-ea2a-4d29-a24b-e484111a64c9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0d6edb73-d948-43ba-965d-fa81625d82ed" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_e5fcecdd-ea2a-4d29-a24b-e484111a64c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurementTables" xlink:type="simple" xlink:href="sgmo-20191231.xsd#FairValueMeasurementTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/FairValueMeasurementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_55bcdb6e-afc7-47cb-9f73-d6d08e0f39e3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_f38ca942-5a1c-4f3c-834d-3a8491477055" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_55bcdb6e-afc7-47cb-9f73-d6d08e0f39e3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_f38ca942-5a1c-4f3c-834d-3a8491477055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_802e2fb3-9c48-435d-ab91-9dfe35be141a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_55bcdb6e-afc7-47cb-9f73-d6d08e0f39e3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_802e2fb3-9c48-435d-ab91-9dfe35be141a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2fa29ecc-be34-40f5-a5b3-04c6fd1a367d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2a4c3294-41f7-467c-a02b-0a6594e0712b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2fa29ecc-be34-40f5-a5b3-04c6fd1a367d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2a4c3294-41f7-467c-a02b-0a6594e0712b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c1862955-f9d0-45ea-9fb2-b6c3d3054569" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2a4c3294-41f7-467c-a02b-0a6594e0712b" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c1862955-f9d0-45ea-9fb2-b6c3d3054569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7a00bb2f-f186-4681-b6f6-8cb11f7893ee" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c1862955-f9d0-45ea-9fb2-b6c3d3054569" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7a00bb2f-f186-4681-b6f6-8cb11f7893ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_bc39ce1a-339d-4fe9-932c-38a7d1ce6316" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7a00bb2f-f186-4681-b6f6-8cb11f7893ee" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_bc39ce1a-339d-4fe9-932c-38a7d1ce6316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c4dfac57-d18a-4af1-85dc-6f9736015644" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2a4c3294-41f7-467c-a02b-0a6594e0712b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c4dfac57-d18a-4af1-85dc-6f9736015644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_81bd3daf-3bcf-4da5-b252-3292ef0fdb8c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c4dfac57-d18a-4af1-85dc-6f9736015644" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_81bd3daf-3bcf-4da5-b252-3292ef0fdb8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_c3b8772b-832e-4b70-bbe6-794e8d943602" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_81bd3daf-3bcf-4da5-b252-3292ef0fdb8c" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_c3b8772b-832e-4b70-bbe6-794e8d943602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_ec4bbb20-a8db-4eb7-914b-fee5f28f5454" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_81bd3daf-3bcf-4da5-b252-3292ef0fdb8c" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_ec4bbb20-a8db-4eb7-914b-fee5f28f5454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FreeSharesAssetMember_d5b0c731-68b8-468f-b31e-a0b6ff14b704" xlink:href="sgmo-20191231.xsd#sgmo_FreeSharesAssetMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_81bd3daf-3bcf-4da5-b252-3292ef0fdb8c" xlink:to="loc_sgmo_FreeSharesAssetMember_d5b0c731-68b8-468f-b31e-a0b6ff14b704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FreeSharesLiabilityMember_c62d8ac9-8499-4888-918a-78bc040e2c63" xlink:href="sgmo-20191231.xsd#sgmo_FreeSharesLiabilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_81bd3daf-3bcf-4da5-b252-3292ef0fdb8c" xlink:to="loc_sgmo_FreeSharesLiabilityMember_c62d8ac9-8499-4888-918a-78bc040e2c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0cbf3f15-f868-4439-abe7-cf47d61874f0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2a4c3294-41f7-467c-a02b-0a6594e0712b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0cbf3f15-f868-4439-abe7-cf47d61874f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_151c568d-6fa1-45a9-b369-3f32154d3f9c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0cbf3f15-f868-4439-abe7-cf47d61874f0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_151c568d-6fa1-45a9-b369-3f32154d3f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_7fdb6529-d004-4fbb-bf4d-e32a60268852" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_151c568d-6fa1-45a9-b369-3f32154d3f9c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_7fdb6529-d004-4fbb-bf4d-e32a60268852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4d4f561f-b4e2-40af-b228-15c1406d4539" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_151c568d-6fa1-45a9-b369-3f32154d3f9c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_4d4f561f-b4e2-40af-b228-15c1406d4539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_03c2213b-7ac1-449c-a302-83b28c0e13db" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_151c568d-6fa1-45a9-b369-3f32154d3f9c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_03c2213b-7ac1-449c-a302-83b28c0e13db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_7cda0bb9-9a17-4f60-9f8d-6cdc4dfa29d4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2a4c3294-41f7-467c-a02b-0a6594e0712b" xlink:to="loc_us-gaap_InvestmentTypeAxis_7cda0bb9-9a17-4f60-9f8d-6cdc4dfa29d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_a6c784a0-d066-435a-8ed7-c43a8b6018da" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_7cda0bb9-9a17-4f60-9f8d-6cdc4dfa29d4" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_a6c784a0-d066-435a-8ed7-c43a8b6018da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_3530bb5d-7cef-41fa-a3e7-f9a6dd08fb89" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_a6c784a0-d066-435a-8ed7-c43a8b6018da" xlink:to="loc_us-gaap_MoneyMarketFundsMember_3530bb5d-7cef-41fa-a3e7-f9a6dd08fb89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_1ead6ca7-35e2-4074-990f-4d13f569099d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_a6c784a0-d066-435a-8ed7-c43a8b6018da" xlink:to="loc_us-gaap_CommercialPaperMember_1ead6ca7-35e2-4074-990f-4d13f569099d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ab851ab4-8040-46d0-8deb-6eda29de763a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2a4c3294-41f7-467c-a02b-0a6594e0712b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ab851ab4-8040-46d0-8deb-6eda29de763a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_463ac8a6-d9b2-422a-8fbb-126cc1b0c18c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ab851ab4-8040-46d0-8deb-6eda29de763a" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_463ac8a6-d9b2-422a-8fbb-126cc1b0c18c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_50119692-da0c-47b1-b4bd-dc4a0d8b0b49" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ab851ab4-8040-46d0-8deb-6eda29de763a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_50119692-da0c-47b1-b4bd-dc4a0d8b0b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_b093dd8d-6a0a-4bdd-8b21-8fd65f932a10" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ab851ab4-8040-46d0-8deb-6eda29de763a" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_b093dd8d-6a0a-4bdd-8b21-8fd65f932a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_71d3629a-ddbd-483d-9c59-e0787c8c5436" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ab851ab4-8040-46d0-8deb-6eda29de763a" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_71d3629a-ddbd-483d-9c59-e0787c8c5436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#FairValueMeasurementAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7082314c-5ba6-4b32-b7b4-73ef6145571e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_447554ad-034c-40f9-a969-3b89558fb0bf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7082314c-5ba6-4b32-b7b4-73ef6145571e" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_447554ad-034c-40f9-a969-3b89558fb0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3c808ba2-fe1a-4a66-8769-8634fd851212" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_447554ad-034c-40f9-a969-3b89558fb0bf" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3c808ba2-fe1a-4a66-8769-8634fd851212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0fbe82b7-276b-4395-be89-21bbf13381e0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3c808ba2-fe1a-4a66-8769-8634fd851212" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0fbe82b7-276b-4395-be89-21bbf13381e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_817703ec-1fdb-4297-9433-dc4285054e4b" xlink:href="sgmo-20191231.xsd#sgmo_SangamoFranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0fbe82b7-276b-4395-be89-21bbf13381e0" xlink:to="loc_sgmo_SangamoFranceMember_817703ec-1fdb-4297-9433-dc4285054e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_72217974-f72c-4783-a3e7-7ecdfaeefa5a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_447554ad-034c-40f9-a969-3b89558fb0bf" xlink:to="loc_us-gaap_TypeOfArrangementAxis_72217974-f72c-4783-a3e7-7ecdfaeefa5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c8cb35e8-cf2a-4765-b056-0eab5e8eb96b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_72217974-f72c-4783-a3e7-7ecdfaeefa5a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c8cb35e8-cf2a-4765-b056-0eab5e8eb96b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_67853941-32df-45ea-9197-47fcbf9b5b4f" xlink:href="sgmo-20191231.xsd#sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c8cb35e8-cf2a-4765-b056-0eab5e8eb96b" xlink:to="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_67853941-32df-45ea-9197-47fcbf9b5b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_d9b3472a-82d3-4318-b81c-0868337eb83e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_447554ad-034c-40f9-a969-3b89558fb0bf" xlink:to="loc_us-gaap_ValuationTechniqueAxis_d9b3472a-82d3-4318-b81c-0868337eb83e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_1116aca2-cc27-4099-9ca6-aa9adc603034" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_d9b3472a-82d3-4318-b81c-0868337eb83e" xlink:to="loc_us-gaap_ValuationTechniqueDomain_1116aca2-cc27-4099-9ca6-aa9adc603034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_f92371fc-84ea-492f-bc1a-1b69a588e8cb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_1116aca2-cc27-4099-9ca6-aa9adc603034" xlink:to="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_f92371fc-84ea-492f-bc1a-1b69a588e8cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f55eddde-f8a0-4af3-853a-5a4b7a84b42f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_447554ad-034c-40f9-a969-3b89558fb0bf" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f55eddde-f8a0-4af3-853a-5a4b7a84b42f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_85f0ba06-b462-4b98-8966-a108d84ce16f" xlink:href="sgmo-20191231.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f55eddde-f8a0-4af3-853a-5a4b7a84b42f" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_85f0ba06-b462-4b98-8966-a108d84ce16f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_92ace64c-3353-49a4-9b9b-7ae22230a156" xlink:href="sgmo-20191231.xsd#sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f55eddde-f8a0-4af3-853a-5a4b7a84b42f" xlink:to="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_92ace64c-3353-49a4-9b9b-7ae22230a156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_8931f328-8bd2-4ae2-b4d8-7ed1d85cc575" xlink:href="sgmo-20191231.xsd#sgmo_BusinessAcquisitionNumberOfSharesAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f55eddde-f8a0-4af3-853a-5a4b7a84b42f" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_8931f328-8bd2-4ae2-b4d8-7ed1d85cc575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_46111261-afbb-4b3f-83e5-153d8bc95c6a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f55eddde-f8a0-4af3-853a-5a4b7a84b42f" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_46111261-afbb-4b3f-83e5-153d8bc95c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase_999f8058-897b-4240-b215-f8761feb6729" xlink:href="sgmo-20191231.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f55eddde-f8a0-4af3-853a-5a4b7a84b42f" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase_999f8058-897b-4240-b215-f8761feb6729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability_0f05ea4e-e47e-482e-a466-55f4897c1921" xlink:href="sgmo-20191231.xsd#sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f55eddde-f8a0-4af3-853a-5a4b7a84b42f" xlink:to="loc_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability_0f05ea4e-e47e-482e-a466-55f4897c1921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueOfFreeShares_b1a2601b-8ac7-4377-b10b-56bfc4fe0b00" xlink:href="sgmo-20191231.xsd#sgmo_BusinessAcquisitionEstimatedFairValueOfFreeShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f55eddde-f8a0-4af3-853a-5a4b7a84b42f" xlink:to="loc_sgmo_BusinessAcquisitionEstimatedFairValueOfFreeShares_b1a2601b-8ac7-4377-b10b-56bfc4fe0b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_613f57b9-f88d-4cf6-a1e6-78b55996eb4f" xlink:href="sgmo-20191231.xsd#sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f55eddde-f8a0-4af3-853a-5a4b7a84b42f" xlink:to="loc_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_613f57b9-f88d-4cf6-a1e6-78b55996eb4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c8902d67-5181-4f86-a622-6de4804651b7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d7437218-8b26-41d6-842c-ea784433d37b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c8902d67-5181-4f86-a622-6de4804651b7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d7437218-8b26-41d6-842c-ea784433d37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_47b54aa9-7f56-4690-aeb6-f728f966a325" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d7437218-8b26-41d6-842c-ea784433d37b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_47b54aa9-7f56-4690-aeb6-f728f966a325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7531eae3-39df-4069-b1f1-be1fe8fc03e3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_47b54aa9-7f56-4690-aeb6-f728f966a325" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7531eae3-39df-4069-b1f1-be1fe8fc03e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_d3de5f2c-a74e-4617-856b-fb6b348ab238" xlink:href="sgmo-20191231.xsd#sgmo_SangamoFranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7531eae3-39df-4069-b1f1-be1fe8fc03e3" xlink:to="loc_sgmo_SangamoFranceMember_d3de5f2c-a74e-4617-856b-fb6b348ab238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_ee0a6cb8-cefd-4acf-8584-872a9a040478" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d7437218-8b26-41d6-842c-ea784433d37b" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_ee0a6cb8-cefd-4acf-8584-872a9a040478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_a2367fdf-2ccd-4ae4-9215-fb8abf9dfead" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_ee0a6cb8-cefd-4acf-8584-872a9a040478" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_a2367fdf-2ccd-4ae4-9215-fb8abf9dfead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember_a9d022f6-bdc1-47d5-9390-d2a8f395c9cb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_a2367fdf-2ccd-4ae4-9215-fb8abf9dfead" xlink:to="loc_us-gaap_MeasurementInputSharePriceMember_a9d022f6-bdc1-47d5-9390-d2a8f395c9cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember_ecb6086b-88b1-43d8-a55f-79112c4ffdf9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputOptionVolatilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_a2367fdf-2ccd-4ae4-9215-fb8abf9dfead" xlink:to="loc_us-gaap_MeasurementInputOptionVolatilityMember_ecb6086b-88b1-43d8-a55f-79112c4ffdf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_7494030f-2541-4f05-b34e-92858e377635" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_a2367fdf-2ccd-4ae4-9215-fb8abf9dfead" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_7494030f-2541-4f05-b34e-92858e377635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_d1add0ad-5e9f-4f6e-9d22-3873d04c8e10" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_a2367fdf-2ccd-4ae4-9215-fb8abf9dfead" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_d1add0ad-5e9f-4f6e-9d22-3873d04c8e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MeasurementInputStockPriceCorrelationMember_8833865f-41c5-46c3-a35f-365c29779b65" xlink:href="sgmo-20191231.xsd#sgmo_MeasurementInputStockPriceCorrelationMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_a2367fdf-2ccd-4ae4-9215-fb8abf9dfead" xlink:to="loc_sgmo_MeasurementInputStockPriceCorrelationMember_8833865f-41c5-46c3-a35f-365c29779b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_3554a2b9-179b-4897-95f5-fedaa0c8cc67" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d7437218-8b26-41d6-842c-ea784433d37b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_3554a2b9-179b-4897-95f5-fedaa0c8cc67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_a8842398-dedf-4c4c-be02-6245b822db56" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_3554a2b9-179b-4897-95f5-fedaa0c8cc67" xlink:to="loc_us-gaap_SharePrice_a8842398-dedf-4c4c-be02-6245b822db56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_a7b3ba12-dcfd-4f19-ad1a-dddf012a3d6e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_3554a2b9-179b-4897-95f5-fedaa0c8cc67" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_a7b3ba12-dcfd-4f19-ad1a-dddf012a3d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_29fccf29-d6f8-4655-8350-63e4621e1cd9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_3554a2b9-179b-4897-95f5-fedaa0c8cc67" xlink:to="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_29fccf29-d6f8-4655-8350-63e4621e1cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_54c7c893-08e6-43ce-b38e-2c921ed587b2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_3554a2b9-179b-4897-95f5-fedaa0c8cc67" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_54c7c893-08e6-43ce-b38e-2c921ed587b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput_c3daa093-ebf0-4cb1-9fc5-bb28e0e2d262" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_3554a2b9-179b-4897-95f5-fedaa0c8cc67" xlink:to="loc_us-gaap_DerivativeLiabilityMeasurementInput_c3daa093-ebf0-4cb1-9fc5-bb28e0e2d262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DerivativeLiabilityTerm_e43c1625-eff1-41f1-a413-d4460a2a7c28" xlink:href="sgmo-20191231.xsd#sgmo_DerivativeLiabilityTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_3554a2b9-179b-4897-95f5-fedaa0c8cc67" xlink:to="loc_sgmo_DerivativeLiabilityTerm_e43c1625-eff1-41f1-a413-d4460a2a7c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MarketableSecurities" xlink:type="simple" xlink:href="sgmo-20191231.xsd#MarketableSecurities"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b1529251-959c-4f84-9b64-9c48df6fbb81" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_c42362c3-7241-4783-b3c7-9797fb3996e5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b1529251-959c-4f84-9b64-9c48df6fbb81" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_c42362c3-7241-4783-b3c7-9797fb3996e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="sgmo-20191231.xsd#MarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3c313384-3b82-4aa1-90ea-639346136e25" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_4ac022e2-59a3-4774-94cb-a5610e70bbb6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3c313384-3b82-4aa1-90ea-639346136e25" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_4ac022e2-59a3-4774-94cb-a5610e70bbb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_81400984-8918-49b5-8383-a880d7de604a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_d9401ce7-4db1-4d80-a84a-3885632a2929" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_81400984-8918-49b5-8383-a880d7de604a" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_d9401ce7-4db1-4d80-a84a-3885632a2929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_56b7b793-94f4-4c40-be58-2748d28bd416" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_d9401ce7-4db1-4d80-a84a-3885632a2929" xlink:to="loc_us-gaap_FinancialInstrumentAxis_56b7b793-94f4-4c40-be58-2748d28bd416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2bf93bdd-d5b9-4f91-80dd-be9b677febdb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_56b7b793-94f4-4c40-be58-2748d28bd416" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2bf93bdd-d5b9-4f91-80dd-be9b677febdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_04717db8-2d59-432e-b6d0-c36a4f82f5ea" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2bf93bdd-d5b9-4f91-80dd-be9b677febdb" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_04717db8-2d59-432e-b6d0-c36a4f82f5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_80f28fce-40aa-4b37-ac5d-0bd81230e8b3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2bf93bdd-d5b9-4f91-80dd-be9b677febdb" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_80f28fce-40aa-4b37-ac5d-0bd81230e8b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_4b38efb6-5df4-41e1-a3b7-e9a67d1c5e85" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_d9401ce7-4db1-4d80-a84a-3885632a2929" xlink:to="loc_us-gaap_InvestmentTypeAxis_4b38efb6-5df4-41e1-a3b7-e9a67d1c5e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_3e62b3eb-7dd8-41a0-8ef6-3002b5db4a6e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_4b38efb6-5df4-41e1-a3b7-e9a67d1c5e85" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_3e62b3eb-7dd8-41a0-8ef6-3002b5db4a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_54da57df-3cbd-492d-a32e-1cac5eea0100" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_3e62b3eb-7dd8-41a0-8ef6-3002b5db4a6e" xlink:to="loc_us-gaap_MoneyMarketFundsMember_54da57df-3cbd-492d-a32e-1cac5eea0100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_61937654-f080-4f39-9e43-d6b4b2f1ec25" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_3e62b3eb-7dd8-41a0-8ef6-3002b5db4a6e" xlink:to="loc_us-gaap_CommercialPaperMember_61937654-f080-4f39-9e43-d6b4b2f1ec25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_9f57abed-6fec-4e77-9bc2-6984b31ab4e1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_3e62b3eb-7dd8-41a0-8ef6-3002b5db4a6e" xlink:to="loc_us-gaap_CashEquivalentsMember_9f57abed-6fec-4e77-9bc2-6984b31ab4e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_525b3db8-e8d8-4384-acae-081fb532049e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_d9401ce7-4db1-4d80-a84a-3885632a2929" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_525b3db8-e8d8-4384-acae-081fb532049e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_272dc21a-a461-4d3d-8bad-a0ed5576d5ac" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_525b3db8-e8d8-4384-acae-081fb532049e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_272dc21a-a461-4d3d-8bad-a0ed5576d5ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_b2637cf9-8f24-4dfa-9fd0-75435a8a164b" xlink:href="sgmo-20191231.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_525b3db8-e8d8-4384-acae-081fb532049e" xlink:to="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_b2637cf9-8f24-4dfa-9fd0-75435a8a164b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_9d1282e8-61d4-4b17-8e78-f3bf528fa371" xlink:href="sgmo-20191231.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_525b3db8-e8d8-4384-acae-081fb532049e" xlink:to="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_9d1282e8-61d4-4b17-8e78-f3bf528fa371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0f5f4720-7607-4248-bd15-7a5ab7fc3b16" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_525b3db8-e8d8-4384-acae-081fb532049e" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0f5f4720-7607-4248-bd15-7a5ab7fc3b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0ade0b7-18e6-4934-b6e9-43ada7069c63" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_525b3db8-e8d8-4384-acae-081fb532049e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0ade0b7-18e6-4934-b6e9-43ada7069c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b513a559-cddd-4acc-abc5-e6d432374bf3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_525b3db8-e8d8-4384-acae-081fb532049e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b513a559-cddd-4acc-abc5-e6d432374bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2fc0c1cc-60fe-4c68-8d5a-02b3da8f3083" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_525b3db8-e8d8-4384-acae-081fb532049e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2fc0c1cc-60fe-4c68-8d5a-02b3da8f3083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6359cd4e-73a1-49a3-82c1-3998751a178b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_525b3db8-e8d8-4384-acae-081fb532049e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6359cd4e-73a1-49a3-82c1-3998751a178b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_bfe3aecb-9ca7-4a80-b430-be25e896fcf1" xlink:href="sgmo-20191231.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_525b3db8-e8d8-4384-acae-081fb532049e" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_bfe3aecb-9ca7-4a80-b430-be25e896fcf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_fa919198-386a-44dc-a01d-989ad4b81d27" xlink:href="sgmo-20191231.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_525b3db8-e8d8-4384-acae-081fb532049e" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_fa919198-386a-44dc-a01d-989ad4b81d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_b723052e-b0aa-4104-9313-692b9a34a167" xlink:href="sgmo-20191231.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_525b3db8-e8d8-4384-acae-081fb532049e" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_b723052e-b0aa-4104-9313-692b9a34a167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_b700a816-71c9-48be-9d57-18bbcd782f75" xlink:href="sgmo-20191231.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_525b3db8-e8d8-4384-acae-081fb532049e" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_b700a816-71c9-48be-9d57-18bbcd782f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#MarketableSecuritiesSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3e314b15-3ba8-46d1-9976-74d94b3e2646" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_578a14a4-0001-46a3-97cd-02ad7111f6ab" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3e314b15-3ba8-46d1-9976-74d94b3e2646" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_578a14a4-0001-46a3-97cd-02ad7111f6ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_140ce4d3-7c6e-40f5-bc5f-62ef57703c7c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3e314b15-3ba8-46d1-9976-74d94b3e2646" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_140ce4d3-7c6e-40f5-bc5f-62ef57703c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_abb4eb76-60b7-442e-8b8f-9110a1cb6625" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3e314b15-3ba8-46d1-9976-74d94b3e2646" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_abb4eb76-60b7-442e-8b8f-9110a1cb6625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MarketableSecuritiesAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#MarketableSecuritiesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MarketableSecuritiesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f7d39ade-53ce-447b-af86-89a4861cffa6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_fd4ebed9-1c7c-431f-92d0-f27e879a0dcf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f7d39ade-53ce-447b-af86-89a4861cffa6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_fd4ebed9-1c7c-431f-92d0-f27e879a0dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OtherThanTemporarilyImpairedInvestment_d5a03b65-3523-43a8-8c50-895f5bf37829" xlink:href="sgmo-20191231.xsd#sgmo_OtherThanTemporarilyImpairedInvestment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f7d39ade-53ce-447b-af86-89a4861cffa6" xlink:to="loc_sgmo_OtherThanTemporarilyImpairedInvestment_d5a03b65-3523-43a8-8c50-895f5bf37829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliances" xlink:type="simple" xlink:href="sgmo-20191231.xsd#MajorCustomersPartnershipsandStrategicAlliances"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliances" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_199412dd-5a06-46fa-bbb7-9638ec759289" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_935a7867-bd5a-4b34-bc60-1a37ef67f5d0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_199412dd-5a06-46fa-bbb7-9638ec759289" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_935a7867-bd5a-4b34-bc60-1a37ef67f5d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesTables" xlink:type="simple" xlink:href="sgmo-20191231.xsd#MajorCustomersPartnershipsandStrategicAlliancesTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3ce82c47-799e-4345-861a-32344345d55f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_3aedf717-e976-4a60-807f-a85a965b6f88" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3ce82c47-799e-4345-861a-32344345d55f" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_3aedf717-e976-4a60-807f-a85a965b6f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ad244963-2f38-48d7-a3e5-d8f0b78b44d0" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_3aedf717-e976-4a60-807f-a85a965b6f88" xlink:to="loc_srt_CounterpartyNameAxis_ad244963-2f38-48d7-a3e5-d8f0b78b44d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88d93616-18cd-49ba-9abd-8a641d05fa57" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_ad244963-2f38-48d7-a3e5-d8f0b78b44d0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88d93616-18cd-49ba-9abd-8a641d05fa57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_1937cde3-173a-4839-b352-95f6949e9784" xlink:href="sgmo-20191231.xsd#sgmo_KitePharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88d93616-18cd-49ba-9abd-8a641d05fa57" xlink:to="loc_sgmo_KitePharmaIncMember_1937cde3-173a-4839-b352-95f6949e9784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member_bb1adfe1-3774-45e3-892e-0b37c8673166" xlink:href="sgmo-20191231.xsd#sgmo_PfizerSB525Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88d93616-18cd-49ba-9abd-8a641d05fa57" xlink:to="loc_sgmo_PfizerSB525Member_bb1adfe1-3774-45e3-892e-0b37c8673166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerC9ORF72Member_890df488-9323-4e60-b4dc-16efa27c4d59" xlink:href="sgmo-20191231.xsd#sgmo_PfizerC9ORF72Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88d93616-18cd-49ba-9abd-8a641d05fa57" xlink:to="loc_sgmo_PfizerC9ORF72Member_890df488-9323-4e60-b4dc-16efa27c4d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_9123817d-9696-4848-9dc7-7c7284951eed" xlink:href="sgmo-20191231.xsd#sgmo_SanofiMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88d93616-18cd-49ba-9abd-8a641d05fa57" xlink:to="loc_sgmo_SanofiMember_9123817d-9696-4848-9dc7-7c7284951eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_976c792d-7572-4fa1-a99b-9c803adca5ed" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_3aedf717-e976-4a60-807f-a85a965b6f88" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_976c792d-7572-4fa1-a99b-9c803adca5ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_7214bfaa-59c0-4279-a85e-60abe7481085" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_976c792d-7572-4fa1-a99b-9c803adca5ed" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_7214bfaa-59c0-4279-a85e-60abe7481085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e775ddce-4049-4d52-8315-f64d28a22712" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_4113f95a-aa20-4688-847d-414469bdfd56" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e775ddce-4049-4d52-8315-f64d28a22712" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_4113f95a-aa20-4688-847d-414469bdfd56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2aa66d5c-9c20-4af7-a231-25397f1e3d9b" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_4113f95a-aa20-4688-847d-414469bdfd56" xlink:to="loc_srt_CounterpartyNameAxis_2aa66d5c-9c20-4af7-a231-25397f1e3d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_17965fe2-b41b-4cc5-8fa6-89ecee7fc34f" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_2aa66d5c-9c20-4af7-a231-25397f1e3d9b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_17965fe2-b41b-4cc5-8fa6-89ecee7fc34f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_f6a99f99-5b78-4fa8-bf5d-6f5dca3c1876" xlink:href="sgmo-20191231.xsd#sgmo_KitePharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_17965fe2-b41b-4cc5-8fa6-89ecee7fc34f" xlink:to="loc_sgmo_KitePharmaIncMember_f6a99f99-5b78-4fa8-bf5d-6f5dca3c1876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member_3e39fc4f-1f0d-40d1-9249-53b0d97369b9" xlink:href="sgmo-20191231.xsd#sgmo_PfizerSB525Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_17965fe2-b41b-4cc5-8fa6-89ecee7fc34f" xlink:to="loc_sgmo_PfizerSB525Member_3e39fc4f-1f0d-40d1-9249-53b0d97369b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerC9ORF72Member_8d56ad73-eb44-460e-b25e-fd24c5c5743b" xlink:href="sgmo-20191231.xsd#sgmo_PfizerC9ORF72Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_17965fe2-b41b-4cc5-8fa6-89ecee7fc34f" xlink:to="loc_sgmo_PfizerC9ORF72Member_8d56ad73-eb44-460e-b25e-fd24c5c5743b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_f5038442-f1b2-4131-a7e7-b0becbbfa1ce" xlink:href="sgmo-20191231.xsd#sgmo_SanofiMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_17965fe2-b41b-4cc5-8fa6-89ecee7fc34f" xlink:to="loc_sgmo_SanofiMember_f5038442-f1b2-4131-a7e7-b0becbbfa1ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShireAgMember_86cc8cff-b928-430a-b8a5-88c61e3aefe9" xlink:href="sgmo-20191231.xsd#sgmo_ShireAgMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_17965fe2-b41b-4cc5-8fa6-89ecee7fc34f" xlink:to="loc_sgmo_ShireAgMember_86cc8cff-b928-430a-b8a5-88c61e3aefe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_804907e7-908b-4e76-944f-88729bc2a5b4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_4113f95a-aa20-4688-847d-414469bdfd56" xlink:to="loc_us-gaap_TypeOfArrangementAxis_804907e7-908b-4e76-944f-88729bc2a5b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_edcd489f-86e7-4916-bda5-ac084b95be7f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_804907e7-908b-4e76-944f-88729bc2a5b4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_edcd489f-86e7-4916-bda5-ac084b95be7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementMember_d5ed78ad-135b-48de-8305-a6e8987fdd7a" xlink:href="sgmo-20191231.xsd#sgmo_CollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_edcd489f-86e7-4916-bda5-ac084b95be7f" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementMember_d5ed78ad-135b-48de-8305-a6e8987fdd7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AmendedCollaborationAndLicenseAgreementMember_13ffccc6-46d5-4fdf-b11b-74883b4aa2d8" xlink:href="sgmo-20191231.xsd#sgmo_AmendedCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_edcd489f-86e7-4916-bda5-ac084b95be7f" xlink:to="loc_sgmo_AmendedCollaborationAndLicenseAgreementMember_13ffccc6-46d5-4fdf-b11b-74883b4aa2d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_75453625-9b6e-4bdb-89bb-e071495320b7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_4113f95a-aa20-4688-847d-414469bdfd56" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_75453625-9b6e-4bdb-89bb-e071495320b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7cec9716-7d72-446f-953d-2f7c15f3aa56" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_75453625-9b6e-4bdb-89bb-e071495320b7" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7cec9716-7d72-446f-953d-2f7c15f3aa56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_572e8634-771d-44c1-bf3e-ae8bc871f860" xlink:href="sgmo-20191231.xsd#sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7cec9716-7d72-446f-953d-2f7c15f3aa56" xlink:to="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_572e8634-771d-44c1-bf3e-ae8bc871f860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_9cfe866f-3746-4544-be26-56cab94aa415" xlink:href="sgmo-20191231.xsd#sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7cec9716-7d72-446f-953d-2f7c15f3aa56" xlink:to="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_9cfe866f-3746-4544-be26-56cab94aa415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_27da2e50-bef7-40d6-90f0-617632d37817" xlink:href="sgmo-20191231.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7cec9716-7d72-446f-953d-2f7c15f3aa56" xlink:to="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_27da2e50-bef7-40d6-90f0-617632d37817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_dc3369b4-6d34-4dc7-9fe0-38141708eb01" xlink:href="sgmo-20191231.xsd#sgmo_AchievementOfFirstCommercialSaleMilestonesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7cec9716-7d72-446f-953d-2f7c15f3aa56" xlink:to="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_dc3369b4-6d34-4dc7-9fe0-38141708eb01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_60107ac4-814a-4346-af9d-67b73f03fd2f" xlink:href="sgmo-20191231.xsd#sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7cec9716-7d72-446f-953d-2f7c15f3aa56" xlink:to="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_60107ac4-814a-4346-af9d-67b73f03fd2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfCommercialMilestonesMember_e88d9315-47be-4782-8344-bad8c53c0384" xlink:href="sgmo-20191231.xsd#sgmo_AchievementOfCommercialMilestonesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7cec9716-7d72-446f-953d-2f7c15f3aa56" xlink:to="loc_sgmo_AchievementOfCommercialMilestonesMember_e88d9315-47be-4782-8344-bad8c53c0384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_a50fecc1-5100-4349-87a3-686bf2f551ed" xlink:href="sgmo-20191231.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7cec9716-7d72-446f-953d-2f7c15f3aa56" xlink:to="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_a50fecc1-5100-4349-87a3-686bf2f551ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesMilestonesMember_dd4dd2cc-98ec-4238-8915-858ec4b0f2d3" xlink:href="sgmo-20191231.xsd#sgmo_AchievementOfSpecifiedSalesMilestonesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7cec9716-7d72-446f-953d-2f7c15f3aa56" xlink:to="loc_sgmo_AchievementOfSpecifiedSalesMilestonesMember_dd4dd2cc-98ec-4238-8915-858ec4b0f2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_0f0095fa-a739-42b0-a9e4-48db53343543" xlink:href="sgmo-20191231.xsd#sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7cec9716-7d72-446f-953d-2f7c15f3aa56" xlink:to="loc_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_0f0095fa-a739-42b0-a9e4-48db53343543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b84e2a93-0ece-4964-900a-6344a1162b7b" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_4113f95a-aa20-4688-847d-414469bdfd56" xlink:to="loc_srt_RangeAxis_b84e2a93-0ece-4964-900a-6344a1162b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1a543950-aaf3-42af-a41f-99bf567bfe4f" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b84e2a93-0ece-4964-900a-6344a1162b7b" xlink:to="loc_srt_RangeMember_1a543950-aaf3-42af-a41f-99bf567bfe4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6dd18c35-1848-4186-b479-d7f056bf54aa" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1a543950-aaf3-42af-a41f-99bf567bfe4f" xlink:to="loc_srt_MaximumMember_6dd18c35-1848-4186-b479-d7f056bf54aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4c0c49d6-5452-4636-97da-1a210a059e50" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1a543950-aaf3-42af-a41f-99bf567bfe4f" xlink:to="loc_srt_MinimumMember_4c0c49d6-5452-4636-97da-1a210a059e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_488dca1e-eb25-492c-b521-91256bf48501" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_4113f95a-aa20-4688-847d-414469bdfd56" xlink:to="loc_srt_ProductOrServiceAxis_488dca1e-eb25-492c-b521-91256bf48501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cdd81eec-180f-4ce0-8ca5-a36335ec0755" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_488dca1e-eb25-492c-b521-91256bf48501" xlink:to="loc_srt_ProductsAndServicesDomain_cdd81eec-180f-4ce0-8ca5-a36335ec0755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SBFiveTwoFiveMember_ec3cfcc5-fc2f-49d8-a0bb-768acfae64da" xlink:href="sgmo-20191231.xsd#sgmo_SBFiveTwoFiveMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cdd81eec-180f-4ce0-8ca5-a36335ec0755" xlink:to="loc_sgmo_SBFiveTwoFiveMember_ec3cfcc5-fc2f-49d8-a0bb-768acfae64da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OtherProductsMember_d37637dd-b371-4d61-8ca3-69d2e8137434" xlink:href="sgmo-20191231.xsd#sgmo_OtherProductsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cdd81eec-180f-4ce0-8ca5-a36335ec0755" xlink:to="loc_sgmo_OtherProductsMember_d37637dd-b371-4d61-8ca3-69d2e8137434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_db62b136-c28f-41eb-b97d-b82257e2c000" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cdd81eec-180f-4ce0-8ca5-a36335ec0755" xlink:to="loc_us-gaap_LicenseAndServiceMember_db62b136-c28f-41eb-b97d-b82257e2c000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CNineORFSevenTwoMember_2b6065ff-e49a-477e-881f-5a2508bc4984" xlink:href="sgmo-20191231.xsd#sgmo_CNineORFSevenTwoMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cdd81eec-180f-4ce0-8ca5-a36335ec0755" xlink:to="loc_sgmo_CNineORFSevenTwoMember_2b6065ff-e49a-477e-881f-5a2508bc4984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_fef20fdc-ff20-47b7-b50f-eb594ebd9ca0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cdd81eec-180f-4ce0-8ca5-a36335ec0755" xlink:to="loc_us-gaap_GrantMember_fef20fdc-ff20-47b7-b50f-eb594ebd9ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_d22fdf3e-c687-4a69-83ef-e41f6207a337" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_4113f95a-aa20-4688-847d-414469bdfd56" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_d22fdf3e-c687-4a69-83ef-e41f6207a337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_c05dd667-eb4c-4815-aed3-622b19e03fd6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_d22fdf3e-c687-4a69-83ef-e41f6207a337" xlink:to="loc_us-gaap_TypeOfAdoptionMember_c05dd667-eb4c-4815-aed3-622b19e03fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_f7d54d04-45ed-4388-9c67-b5facfde1682" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_c05dd667-eb4c-4815-aed3-622b19e03fd6" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_f7d54d04-45ed-4388-9c67-b5facfde1682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_14eb2aae-18ae-4d8b-a984-8f9aed2ea769" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_4113f95a-aa20-4688-847d-414469bdfd56" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_14eb2aae-18ae-4d8b-a984-8f9aed2ea769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ae731456-4608-40ce-823a-9c7befaf60b1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_14eb2aae-18ae-4d8b-a984-8f9aed2ea769" xlink:to="loc_us-gaap_EquityComponentDomain_ae731456-4608-40ce-823a-9c7befaf60b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_59e656e4-e8a0-4efb-a071-84bb31ce3f36" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ae731456-4608-40ce-823a-9c7befaf60b1" xlink:to="loc_us-gaap_RetainedEarningsMember_59e656e4-e8a0-4efb-a071-84bb31ce3f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneAxis_d28d0830-f0e2-4c1a-abea-9a8343462bea" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeAgreementMilestoneAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_4113f95a-aa20-4688-847d-414469bdfd56" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneAxis_d28d0830-f0e2-4c1a-abea-9a8343462bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneDomain_f5493af6-13a5-48f4-bf3e-21c3bf8a7f04" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeAgreementMilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneAxis_d28d0830-f0e2-4c1a-abea-9a8343462bea" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneDomain_f5493af6-13a5-48f4-bf3e-21c3bf8a7f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneOneMember_9a3293c0-f074-4cf0-886e-9985d188696b" xlink:href="sgmo-20191231.xsd#sgmo_MilestoneOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_f5493af6-13a5-48f4-bf3e-21c3bf8a7f04" xlink:to="loc_sgmo_MilestoneOneMember_9a3293c0-f074-4cf0-886e-9985d188696b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneTwoMember_fc64e975-4da0-4c87-92e7-01f43aa0f6ec" xlink:href="sgmo-20191231.xsd#sgmo_MilestoneTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_f5493af6-13a5-48f4-bf3e-21c3bf8a7f04" xlink:to="loc_sgmo_MilestoneTwoMember_fc64e975-4da0-4c87-92e7-01f43aa0f6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneThreeMember_4ab15779-808a-4e8e-b84b-281f6edb206c" xlink:href="sgmo-20191231.xsd#sgmo_MilestoneThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_f5493af6-13a5-48f4-bf3e-21c3bf8a7f04" xlink:to="loc_sgmo_MilestoneThreeMember_4ab15779-808a-4e8e-b84b-281f6edb206c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_4113f95a-aa20-4688-847d-414469bdfd56" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestonePaymentsReceived_fd090dbf-9581-4720-996c-c9bd8c044656" xlink:href="sgmo-20191231.xsd#sgmo_MilestonePaymentsReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_sgmo_MilestonePaymentsReceived_fd090dbf-9581-4720-996c-c9bd8c044656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_bd0345bf-648a-46f6-90fb-55be293890b4" xlink:href="sgmo-20191231.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_bd0345bf-648a-46f6-90fb-55be293890b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_5d24da54-3ce4-460e-9043-1c237905ba85" xlink:href="sgmo-20191231.xsd#sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_5d24da54-3ce4-460e-9043-1c237905ba85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_InitialResearchTermOfAgreement_be88c287-90d7-43c9-a7da-9d3d6884b031" xlink:href="sgmo-20191231.xsd#sgmo_InitialResearchTermOfAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_sgmo_InitialResearchTermOfAgreement_be88c287-90d7-43c9-a7da-9d3d6884b031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfOptionsToExtendInitialResearchTerm_ca658785-9893-4c90-af56-d21c3e107fa4" xlink:href="sgmo-20191231.xsd#sgmo_NumberOfOptionsToExtendInitialResearchTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_sgmo_NumberOfOptionsToExtendInitialResearchTerm_ca658785-9893-4c90-af56-d21c3e107fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ExtendedResearchTermOfAgreement_44d80f94-4783-4e3b-ac6b-e259ace14957" xlink:href="sgmo-20191231.xsd#sgmo_ExtendedResearchTermOfAgreement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_sgmo_ExtendedResearchTermOfAgreement_44d80f94-4783-4e3b-ac6b-e259ace14957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SeparateUpfrontFee_2937c20e-519f-46d8-bda3-a3f5d5db24f8" xlink:href="sgmo-20191231.xsd#sgmo_SeparateUpfrontFee"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_sgmo_SeparateUpfrontFee_2937c20e-519f-46d8-bda3-a3f5d5db24f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan_dd14cfce-5f37-4860-828c-484c054ccc7c" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan_dd14cfce-5f37-4860-828c-484c054ccc7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementTransactionPrice_57aaedcb-88b4-455e-b154-784ed2ce17ca" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeArrangementTransactionPrice"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_sgmo_CollaborativeArrangementTransactionPrice_57aaedcb-88b4-455e-b154-784ed2ce17ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c7ea2fac-379c-45c6-8767-ea86fdaff10e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c7ea2fac-379c-45c6-8767-ea86fdaff10e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_956727dc-1d7e-4f6b-b356-6ccdea9a770e" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_956727dc-1d7e-4f6b-b356-6ccdea9a770e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AgreementTerminationTerm_6315be00-1737-40da-96f5-749910c79c68" xlink:href="sgmo-20191231.xsd#sgmo_AgreementTerminationTerm"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_sgmo_AgreementTerminationTerm_6315be00-1737-40da-96f5-749910c79c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_8307fee4-7ff4-4f3e-9f8b-7252f235b426" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_us-gaap_ContractWithCustomerLiability_8307fee4-7ff4-4f3e-9f8b-7252f235b426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_40a29834-865b-4575-b34e-7ed7959b4301" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_40a29834-865b-4575-b34e-7ed7959b4301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue_0382bc72-2736-406c-b746-d27902adcac0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_us-gaap_DeferredRevenue_0382bc72-2736-406c-b746-d27902adcac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneRevenueReceivable_a08e47df-3351-4e77-805e-88a09970373e" xlink:href="sgmo-20191231.xsd#sgmo_MilestoneRevenueReceivable"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_sgmo_MilestoneRevenueReceivable_a08e47df-3351-4e77-805e-88a09970373e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7a20761c-3eea-4001-b50c-50f6c31c444d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7a20761c-3eea-4001-b50c-50f6c31c444d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_237f1280-7231-44f4-a6a3-0c861f1c06e6" xlink:href="sgmo-20191231.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_237f1280-7231-44f4-a6a3-0c861f1c06e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_c5b8e22d-c2aa-4085-a3fc-0ea3230326c7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_c5b8e22d-c2aa-4085-a3fc-0ea3230326c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_91fcf04c-ef54-4aae-95a8-169a9edaae5f" xlink:href="sgmo-20191231.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_91fcf04c-ef54-4aae-95a8-169a9edaae5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_d6ff7c12-1ad4-4edf-b241-aaeb161ff27e" xlink:href="sgmo-20191231.xsd#sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_d6ff7c12-1ad4-4edf-b241-aaeb161ff27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementResearchServiceFees_92b32dbd-2dec-4f20-b54a-949e73b1a7cb" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeArrangementResearchServiceFees"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_sgmo_CollaborativeArrangementResearchServiceFees_92b32dbd-2dec-4f20-b54a-949e73b1a7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GrantFundingAmount_56a23fab-a414-4d3c-8ba1-c1660fd2c0d7" xlink:href="sgmo-20191231.xsd#sgmo_GrantFundingAmount"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_sgmo_GrantFundingAmount_56a23fab-a414-4d3c-8ba1-c1660fd2c0d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_6b82dc80-0b2a-4932-9d7d-456af2c718ee" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_6b82dc80-0b2a-4932-9d7d-456af2c718ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_274cea36-ba60-42f9-aff4-7ebc4b06063a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_274cea36-ba60-42f9-aff4-7ebc4b06063a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfResearchProgram_94692a40-2308-4a47-9a5e-322ec9f1610e" xlink:href="sgmo-20191231.xsd#sgmo_NumberOfResearchProgram"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d277e5f2-e95f-41cf-be3b-c3687edecb9b" xlink:to="loc_sgmo_NumberOfResearchProgram_94692a40-2308-4a47-9a5e-322ec9f1610e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_121ad555-b513-42df-aa49-13ef45129dfe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_ef965f37-394a-4f1b-bf0f-c01677306144" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_121ad555-b513-42df-aa49-13ef45129dfe" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_ef965f37-394a-4f1b-bf0f-c01677306144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f3950e5c-f403-4242-8d7a-fd110a1e9660" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_ef965f37-394a-4f1b-bf0f-c01677306144" xlink:to="loc_srt_CounterpartyNameAxis_f3950e5c-f403-4242-8d7a-fd110a1e9660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_62aafcc3-9e3b-4ff1-bf6d-4a78eae3c5d4" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_f3950e5c-f403-4242-8d7a-fd110a1e9660" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_62aafcc3-9e3b-4ff1-bf6d-4a78eae3c5d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_bd377872-2396-4db3-a300-2d108f9279cd" xlink:href="sgmo-20191231.xsd#sgmo_KitePharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_62aafcc3-9e3b-4ff1-bf6d-4a78eae3c5d4" xlink:to="loc_sgmo_KitePharmaIncMember_bd377872-2396-4db3-a300-2d108f9279cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_ce2ff98d-7256-4cb8-be7e-a0e01d99f3de" xlink:href="sgmo-20191231.xsd#sgmo_SanofiMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_62aafcc3-9e3b-4ff1-bf6d-4a78eae3c5d4" xlink:to="loc_sgmo_SanofiMember_ce2ff98d-7256-4cb8-be7e-a0e01d99f3de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member_1a110246-40e7-4774-80c7-75704a254a19" xlink:href="sgmo-20191231.xsd#sgmo_PfizerSB525Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_62aafcc3-9e3b-4ff1-bf6d-4a78eae3c5d4" xlink:to="loc_sgmo_PfizerSB525Member_1a110246-40e7-4774-80c7-75704a254a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4935563f-c1fa-4133-8281-68a03d67523e" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_ef965f37-394a-4f1b-bf0f-c01677306144" xlink:to="loc_srt_ProductOrServiceAxis_4935563f-c1fa-4133-8281-68a03d67523e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_329f6b52-cd91-43b9-a339-13198f28e15b" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4935563f-c1fa-4133-8281-68a03d67523e" xlink:to="loc_srt_ProductsAndServicesDomain_329f6b52-cd91-43b9-a339-13198f28e15b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_c25b69ff-acdd-4880-a270-d75e57517159" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_329f6b52-cd91-43b9-a339-13198f28e15b" xlink:to="loc_us-gaap_LicenseAndServiceMember_c25b69ff-acdd-4880-a270-d75e57517159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_64f80bb9-1615-43fa-9f56-291ca0ded56e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_329f6b52-cd91-43b9-a339-13198f28e15b" xlink:to="loc_us-gaap_LicenseAndServiceMember_64f80bb9-1615-43fa-9f56-291ca0ded56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchServicesMember_472a6723-739e-4e9d-a7cd-36cdf3651f36" xlink:href="sgmo-20191231.xsd#sgmo_ResearchServicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_329f6b52-cd91-43b9-a339-13198f28e15b" xlink:to="loc_sgmo_ResearchServicesMember_472a6723-739e-4e9d-a7cd-36cdf3651f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneAchievementMember_4a6af99d-57bb-43c0-acdc-b3f55f8c60e4" xlink:href="sgmo-20191231.xsd#sgmo_MilestoneAchievementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_329f6b52-cd91-43b9-a339-13198f28e15b" xlink:to="loc_sgmo_MilestoneAchievementMember_4a6af99d-57bb-43c0-acdc-b3f55f8c60e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d6ef5281-0dff-4f26-a69a-f94ae60abeae" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_ef965f37-394a-4f1b-bf0f-c01677306144" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d6ef5281-0dff-4f26-a69a-f94ae60abeae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_2e73d0fc-03c9-4713-9b5d-c48bd91929b5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d6ef5281-0dff-4f26-a69a-f94ae60abeae" xlink:to="loc_us-gaap_RevenuesAbstract_2e73d0fc-03c9-4713-9b5d-c48bd91929b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ec89dd9b-cbc7-4f96-93dc-a1fa80020f85" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_2e73d0fc-03c9-4713-9b5d-c48bd91929b5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ec89dd9b-cbc7-4f96-93dc-a1fa80020f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_27471f8c-3e7e-46a8-ba81-e646a7ab2090" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_bb915f2e-860f-4bd7-adf4-6f923a690c44" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_27471f8c-3e7e-46a8-ba81-e646a7ab2090" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_bb915f2e-860f-4bd7-adf4-6f923a690c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_dc4250d9-5b97-4879-8330-1466499219a7" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_bb915f2e-860f-4bd7-adf4-6f923a690c44" xlink:to="loc_srt_CounterpartyNameAxis_dc4250d9-5b97-4879-8330-1466499219a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ed3a1d58-4785-4127-873e-a6d6fdef2f70" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_dc4250d9-5b97-4879-8330-1466499219a7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ed3a1d58-4785-4127-873e-a6d6fdef2f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SigmaAldrichCorporationMember_2ed57d2f-f76d-4662-bb42-d7675e10a397" xlink:href="sgmo-20191231.xsd#sgmo_SigmaAldrichCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ed3a1d58-4785-4127-873e-a6d6fdef2f70" xlink:to="loc_sgmo_SigmaAldrichCorporationMember_2ed57d2f-f76d-4662-bb42-d7675e10a397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b13afad3-3b7a-41da-8554-c9694872f64a" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_bb915f2e-860f-4bd7-adf4-6f923a690c44" xlink:to="loc_srt_ProductOrServiceAxis_b13afad3-3b7a-41da-8554-c9694872f64a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a5b81730-a34c-4deb-81c0-c3271a1d4179" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b13afad3-3b7a-41da-8554-c9694872f64a" xlink:to="loc_srt_ProductsAndServicesDomain_a5b81730-a34c-4deb-81c0-c3271a1d4179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_9b5573c2-8941-4046-82fd-332a5a59890a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a5b81730-a34c-4deb-81c0-c3271a1d4179" xlink:to="loc_us-gaap_LicenseMember_9b5573c2-8941-4046-82fd-332a5a59890a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_7b556415-e0f2-4343-b18e-db9f3f0903a9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_bb915f2e-860f-4bd7-adf4-6f923a690c44" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_7b556415-e0f2-4343-b18e-db9f3f0903a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d15fcb56-d5b1-4548-96ad-db84cb9cdde4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_7b556415-e0f2-4343-b18e-db9f3f0903a9" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d15fcb56-d5b1-4548-96ad-db84cb9cdde4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_5963980a-4705-46c7-9df0-477de08acc39" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d15fcb56-d5b1-4548-96ad-db84cb9cdde4" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_5963980a-4705-46c7-9df0-477de08acc39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b6811e70-657c-42be-b1dc-dc2493f6607b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_bb915f2e-860f-4bd7-adf4-6f923a690c44" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b6811e70-657c-42be-b1dc-dc2493f6607b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchServicesPeriod_c5081ab1-2aa3-4484-96ed-9e70051fa135" xlink:href="sgmo-20191231.xsd#sgmo_ResearchServicesPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b6811e70-657c-42be-b1dc-dc2493f6607b" xlink:to="loc_sgmo_ResearchServicesPeriod_c5081ab1-2aa3-4484-96ed-9e70051fa135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_b5bbcb6a-f1c2-4a8c-9825-633c1a0c4c9f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b6811e70-657c-42be-b1dc-dc2493f6607b" xlink:to="loc_us-gaap_ContractWithCustomerLiability_b5bbcb6a-f1c2-4a8c-9825-633c1a0c4c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7eebd405-33a3-4408-9804-612783679bb8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b6811e70-657c-42be-b1dc-dc2493f6607b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7eebd405-33a3-4408-9804-612783679bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_97467c8d-5c63-42da-b767-db865e1d8d3e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b6811e70-657c-42be-b1dc-dc2493f6607b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_97467c8d-5c63-42da-b767-db865e1d8d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_6dae22fe-af03-4bde-950f-946a211bf2be" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b6811e70-657c-42be-b1dc-dc2493f6607b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_6dae22fe-af03-4bde-950f-946a211bf2be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ReducedRoyaltyRate_7f08e70a-99f7-41e8-9d89-35f649a0ae22" xlink:href="sgmo-20191231.xsd#sgmo_ReducedRoyaltyRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b6811e70-657c-42be-b1dc-dc2493f6607b" xlink:to="loc_sgmo_ReducedRoyaltyRate_7f08e70a-99f7-41e8-9d89-35f649a0ae22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_2ebbe23a-fe21-48d6-b666-e86d0c6200a2" xlink:href="sgmo-20191231.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b6811e70-657c-42be-b1dc-dc2493f6607b" xlink:to="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_2ebbe23a-fe21-48d6-b666-e86d0c6200a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8e3a1c2b-6a8f-48aa-8257-e611beb06275" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b6811e70-657c-42be-b1dc-dc2493f6607b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8e3a1c2b-6a8f-48aa-8257-e611beb06275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDowAgroSciencesinPlantAgricultureAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDowAgroSciencesinPlantAgricultureAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDowAgroSciencesinPlantAgricultureAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a1fa14ea-c1c5-49c6-9903-f6f7517d843f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_268d3562-e832-4114-b3dd-250d74cb2c04" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a1fa14ea-c1c5-49c6-9903-f6f7517d843f" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_268d3562-e832-4114-b3dd-250d74cb2c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_829b6bfe-8076-4a57-a465-ff89c3196bd7" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_268d3562-e832-4114-b3dd-250d74cb2c04" xlink:to="loc_srt_CounterpartyNameAxis_829b6bfe-8076-4a57-a465-ff89c3196bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_be038c91-756c-42a8-9703-2fe00fa93e08" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_829b6bfe-8076-4a57-a465-ff89c3196bd7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_be038c91-756c-42a8-9703-2fe00fa93e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DowAgroSciencesMember_18e07110-3ce0-4739-80dd-1923db9fc7dd" xlink:href="sgmo-20191231.xsd#sgmo_DowAgroSciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_be038c91-756c-42a8-9703-2fe00fa93e08" xlink:to="loc_sgmo_DowAgroSciencesMember_18e07110-3ce0-4739-80dd-1923db9fc7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_336fe979-ce35-4d8f-9250-6e1eaac1f51c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_268d3562-e832-4114-b3dd-250d74cb2c04" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_336fe979-ce35-4d8f-9250-6e1eaac1f51c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f824e69c-4d5d-4ed2-bfcc-68ddb5a6adeb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_336fe979-ce35-4d8f-9250-6e1eaac1f51c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f824e69c-4d5d-4ed2-bfcc-68ddb5a6adeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_86c5c09e-f3b0-46bc-b88d-4342f6610a18" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f824e69c-4d5d-4ed2-bfcc-68ddb5a6adeb" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_86c5c09e-f3b0-46bc-b88d-4342f6610a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9c5937d4-7eb6-4283-8ae5-afcd2938e1b1" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_268d3562-e832-4114-b3dd-250d74cb2c04" xlink:to="loc_srt_ProductOrServiceAxis_9c5937d4-7eb6-4283-8ae5-afcd2938e1b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4d253378-c350-4928-aeb9-2406dff0443b" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9c5937d4-7eb6-4283-8ae5-afcd2938e1b1" xlink:to="loc_srt_ProductsAndServicesDomain_4d253378-c350-4928-aeb9-2406dff0443b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_255f3fdf-db31-4582-a0a7-c4590070564a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4d253378-c350-4928-aeb9-2406dff0443b" xlink:to="loc_us-gaap_RoyaltyMember_255f3fdf-db31-4582-a0a7-c4590070564a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_f7bbe043-2144-414c-9236-f274a9d8eb62" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4d253378-c350-4928-aeb9-2406dff0443b" xlink:to="loc_us-gaap_LicenseMember_f7bbe043-2144-414c-9236-f274a9d8eb62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0d23cbd5-3d7f-4d58-b823-0ed12a1d3660" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_268d3562-e832-4114-b3dd-250d74cb2c04" xlink:to="loc_srt_RangeAxis_0d23cbd5-3d7f-4d58-b823-0ed12a1d3660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_74f796ed-69f5-46de-9a93-4cf614e6b560" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0d23cbd5-3d7f-4d58-b823-0ed12a1d3660" xlink:to="loc_srt_RangeMember_74f796ed-69f5-46de-9a93-4cf614e6b560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e4c2a78e-def9-4a0b-a636-bd6763187a96" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_74f796ed-69f5-46de-9a93-4cf614e6b560" xlink:to="loc_srt_MinimumMember_e4c2a78e-def9-4a0b-a636-bd6763187a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1e53e5bb-7822-48c3-b733-b706eaca1311" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_74f796ed-69f5-46de-9a93-4cf614e6b560" xlink:to="loc_srt_MaximumMember_1e53e5bb-7822-48c3-b733-b706eaca1311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a861defa-59a1-4e7d-b0dd-327d6f9f887e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_268d3562-e832-4114-b3dd-250d74cb2c04" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a861defa-59a1-4e7d-b0dd-327d6f9f887e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_InitialResearchTermOfAgreement_856f02f1-a569-498c-b8ff-1d6cb1e8730b" xlink:href="sgmo-20191231.xsd#sgmo_InitialResearchTermOfAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a861defa-59a1-4e7d-b0dd-327d6f9f887e" xlink:to="loc_sgmo_InitialResearchTermOfAgreement_856f02f1-a569-498c-b8ff-1d6cb1e8730b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OneTimeLicenseFeeEarned_be28d3d0-ccf1-4e44-a419-70c529f405ad" xlink:href="sgmo-20191231.xsd#sgmo_OneTimeLicenseFeeEarned"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a861defa-59a1-4e7d-b0dd-327d6f9f887e" xlink:to="loc_sgmo_OneTimeLicenseFeeEarned_be28d3d0-ccf1-4e44-a419-70c529f405ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_91dd600c-3545-43eb-b25f-ca7c98ba8e1d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a861defa-59a1-4e7d-b0dd-327d6f9f887e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_91dd600c-3545-43eb-b25f-ca7c98ba8e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement_78ee5270-01aa-4a1c-87e8-ff9b30fa8c0e" xlink:href="sgmo-20191231.xsd#sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a861defa-59a1-4e7d-b0dd-327d6f9f887e" xlink:to="loc_sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement_78ee5270-01aa-4a1c-87e8-ff9b30fa8c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing_2344905a-9dd9-40db-ac33-3382f03e5a17" xlink:href="sgmo-20191231.xsd#sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a861defa-59a1-4e7d-b0dd-327d6f9f887e" xlink:to="loc_sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing_2344905a-9dd9-40db-ac33-3382f03e5a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AnnualFeesRelatedToAgreement_273356cd-d39a-41f8-aa70-f613a6cea05c" xlink:href="sgmo-20191231.xsd#sgmo_AnnualFeesRelatedToAgreement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a861defa-59a1-4e7d-b0dd-327d6f9f887e" xlink:to="loc_sgmo_AnnualFeesRelatedToAgreement_273356cd-d39a-41f8-aa70-f613a6cea05c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FeeDue_c8ecd242-de17-4dbb-ae0f-271f5718b61d" xlink:href="sgmo-20191231.xsd#sgmo_FeeDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a861defa-59a1-4e7d-b0dd-327d6f9f887e" xlink:to="loc_sgmo_FeeDue_c8ecd242-de17-4dbb-ae0f-271f5718b61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod_18becc2b-96fe-4bba-a046-6cb2a85a513e" xlink:href="sgmo-20191231.xsd#sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a861defa-59a1-4e7d-b0dd-327d6f9f887e" xlink:to="loc_sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod_18becc2b-96fe-4bba-a046-6cb2a85a513e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/AcquisitionofSangamoFrance" xlink:type="simple" xlink:href="sgmo-20191231.xsd#AcquisitionofSangamoFrance"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/AcquisitionofSangamoFrance" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_53f6c4aa-87a8-491d-b639-497ce6187d37" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_ede4c68a-d9bc-4221-9485-dd4026ee1efa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_53f6c4aa-87a8-491d-b639-497ce6187d37" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_ede4c68a-d9bc-4221-9485-dd4026ee1efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/AcquisitionofAcquisitionofSangamoFranceTables" xlink:type="simple" xlink:href="sgmo-20191231.xsd#AcquisitionofAcquisitionofSangamoFranceTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/AcquisitionofAcquisitionofSangamoFranceTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_f58c79b3-f582-44e6-8cb4-2f317103f8a4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_556c3624-eab4-4873-bf54-ae03dc4f31ed" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_f58c79b3-f582-44e6-8cb4-2f317103f8a4" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_556c3624-eab4-4873-bf54-ae03dc4f31ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ScheduleOfNoncontrollingInterestTableTextBlock_87c01c29-4fc4-4560-aef9-dbd94a51a9d4" xlink:href="sgmo-20191231.xsd#sgmo_ScheduleOfNoncontrollingInterestTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_f58c79b3-f582-44e6-8cb4-2f317103f8a4" xlink:to="loc_sgmo_ScheduleOfNoncontrollingInterestTableTextBlock_87c01c29-4fc4-4560-aef9-dbd94a51a9d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#AcquisitionofSangamoFranceAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_0052e171-5cd0-4451-bb34-01af08068f89" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b7ac5c3-70ad-4a8f-bf28-a086eee23199" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_0052e171-5cd0-4451-bb34-01af08068f89" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b7ac5c3-70ad-4a8f-bf28-a086eee23199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_4e4ae090-f060-476d-8469-b61c18c6d59d" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b7ac5c3-70ad-4a8f-bf28-a086eee23199" xlink:to="loc_srt_OwnershipAxis_4e4ae090-f060-476d-8469-b61c18c6d59d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_9b4b8706-d3de-468e-b6a8-4671cbb63685" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_4e4ae090-f060-476d-8469-b61c18c6d59d" xlink:to="loc_srt_OwnershipDomain_9b4b8706-d3de-468e-b6a8-4671cbb63685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_ff0cb910-588a-4d7a-8ace-3245f71ab908" xlink:href="sgmo-20191231.xsd#sgmo_SangamoFranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_9b4b8706-d3de-468e-b6a8-4671cbb63685" xlink:to="loc_sgmo_SangamoFranceMember_ff0cb910-588a-4d7a-8ace-3245f71ab908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_87d6e342-3635-47b8-8ddc-2fd87af5b700" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b7ac5c3-70ad-4a8f-bf28-a086eee23199" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_87d6e342-3635-47b8-8ddc-2fd87af5b700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5c90bd72-0cc0-4e5f-8fc1-9aa06a7dd372" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_87d6e342-3635-47b8-8ddc-2fd87af5b700" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5c90bd72-0cc0-4e5f-8fc1-9aa06a7dd372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_a5e15c31-a22f-47eb-a3f1-e2b0b11a9110" xlink:href="sgmo-20191231.xsd#sgmo_SangamoFranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5c90bd72-0cc0-4e5f-8fc1-9aa06a7dd372" xlink:to="loc_sgmo_SangamoFranceMember_a5e15c31-a22f-47eb-a3f1-e2b0b11a9110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e255f130-eb2e-4648-934a-fa557b83d3d1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b7ac5c3-70ad-4a8f-bf28-a086eee23199" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e255f130-eb2e-4648-934a-fa557b83d3d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_df0fafe7-02ef-48b6-aca5-6968176ef3c9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e255f130-eb2e-4648-934a-fa557b83d3d1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_df0fafe7-02ef-48b6-aca5-6968176ef3c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_777db76e-edd5-4055-9ae0-9aa734b9a951" xlink:href="sgmo-20191231.xsd#sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_df0fafe7-02ef-48b6-aca5-6968176ef3c9" xlink:to="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_777db76e-edd5-4055-9ae0-9aa734b9a951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SharePurchaseAgreementMember_d74f66f2-6d87-4b40-a779-230e7620c1bd" xlink:href="sgmo-20191231.xsd#sgmo_SharePurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_df0fafe7-02ef-48b6-aca5-6968176ef3c9" xlink:to="loc_sgmo_SharePurchaseAgreementMember_d74f66f2-6d87-4b40-a779-230e7620c1bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_98a9fd16-a39b-4046-a989-c8c7f2c6e342" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b7ac5c3-70ad-4a8f-bf28-a086eee23199" xlink:to="loc_srt_CounterpartyNameAxis_98a9fd16-a39b-4046-a989-c8c7f2c6e342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9bd1814c-c497-4c67-9f51-e39fbe4d3887" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_98a9fd16-a39b-4046-a989-c8c7f2c6e342" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9bd1814c-c497-4c67-9f51-e39fbe4d3887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FormerExecutiveOfSangamoFranceMember_0dfca530-5933-48c4-9559-4841d655085d" xlink:href="sgmo-20191231.xsd#sgmo_FormerExecutiveOfSangamoFranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9bd1814c-c497-4c67-9f51-e39fbe4d3887" xlink:to="loc_sgmo_FormerExecutiveOfSangamoFranceMember_0dfca530-5933-48c4-9559-4841d655085d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_7e9ba9e1-22b0-45aa-a5e2-a56239924f2c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b7ac5c3-70ad-4a8f-bf28-a086eee23199" xlink:to="loc_us-gaap_ValuationTechniqueAxis_7e9ba9e1-22b0-45aa-a5e2-a56239924f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_eb425fd4-4f97-48c5-a699-5bcf41d77bf4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_7e9ba9e1-22b0-45aa-a5e2-a56239924f2c" xlink:to="loc_us-gaap_ValuationTechniqueDomain_eb425fd4-4f97-48c5-a699-5bcf41d77bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_3536cc9e-50c3-4a0f-b15d-b3d8994f4ef9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_eb425fd4-4f97-48c5-a699-5bcf41d77bf4" xlink:to="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_3536cc9e-50c3-4a0f-b15d-b3d8994f4ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_5d2e24b2-46b4-4c02-8092-202608f85230" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b7ac5c3-70ad-4a8f-bf28-a086eee23199" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_5d2e24b2-46b4-4c02-8092-202608f85230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_31521002-d70f-401d-b7de-685c4185a638" xlink:href="sgmo-20191231.xsd#sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5d2e24b2-46b4-4c02-8092-202608f85230" xlink:to="loc_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_31521002-d70f-401d-b7de-685c4185a638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_d2d83b06-d54d-4d35-8c9e-c5bd08e9009b" xlink:href="sgmo-20191231.xsd#sgmo_BusinessAcquisitionNumberOfSharesAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5d2e24b2-46b4-4c02-8092-202608f85230" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_d2d83b06-d54d-4d35-8c9e-c5bd08e9009b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_c698601c-3567-422d-bbc7-677a3a0e872f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5d2e24b2-46b4-4c02-8092-202608f85230" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_c698601c-3567-422d-bbc7-677a3a0e872f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_8031edad-5a09-46af-b6f5-391805fddc31" xlink:href="sgmo-20191231.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5d2e24b2-46b4-4c02-8092-202608f85230" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_8031edad-5a09-46af-b6f5-391805fddc31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_72068dbd-0cfc-4f0e-ac45-6e8cbc34e2db" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5d2e24b2-46b4-4c02-8092-202608f85230" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_72068dbd-0cfc-4f0e-ac45-6e8cbc34e2db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_c9e75e79-2b9e-4086-851e-26c891de435b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5d2e24b2-46b4-4c02-8092-202608f85230" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_c9e75e79-2b9e-4086-851e-26c891de435b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_7d47347d-2e54-488d-a13c-25bb0a65db96" xlink:href="sgmo-20191231.xsd#sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5d2e24b2-46b4-4c02-8092-202608f85230" xlink:to="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_7d47347d-2e54-488d-a13c-25bb0a65db96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_a081103d-353b-46a0-9ec9-c82954e84645" xlink:href="sgmo-20191231.xsd#sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5d2e24b2-46b4-4c02-8092-202608f85230" xlink:to="loc_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_a081103d-353b-46a0-9ec9-c82954e84645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_c7ea0cb6-d508-409c-89d6-7acdd615751b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5d2e24b2-46b4-4c02-8092-202608f85230" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_c7ea0cb6-d508-409c-89d6-7acdd615751b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_eba44c82-16b4-4cb5-b7f4-477731e7a156" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5d2e24b2-46b4-4c02-8092-202608f85230" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_eba44c82-16b4-4cb5-b7f4-477731e7a156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction_6c4f627b-f354-40d4-82f8-a03eada4acdf" xlink:href="sgmo-20191231.xsd#sgmo_BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5d2e24b2-46b4-4c02-8092-202608f85230" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction_6c4f627b-f354-40d4-82f8-a03eada4acdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofEstimatedFairValueofNetAssetsAcquiredDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#AcquisitionofSangamoFranceSummaryofEstimatedFairValueofNetAssetsAcquiredDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofEstimatedFairValueofNetAssetsAcquiredDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_f43c6c22-b6c2-412c-93f8-f2137e0c4b59" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3b3fe61b-bc5c-4e9c-8f5b-37c383e64bcf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_f43c6c22-b6c2-412c-93f8-f2137e0c4b59" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3b3fe61b-bc5c-4e9c-8f5b-37c383e64bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9899ee57-1f39-4c9c-ac9e-37069e12dbf4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3b3fe61b-bc5c-4e9c-8f5b-37c383e64bcf" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9899ee57-1f39-4c9c-ac9e-37069e12dbf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b722756e-2c95-46a3-94c9-10bd13cde758" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9899ee57-1f39-4c9c-ac9e-37069e12dbf4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b722756e-2c95-46a3-94c9-10bd13cde758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_bca927d2-f3e3-4849-8167-296e030496a3" xlink:href="sgmo-20191231.xsd#sgmo_SangamoFranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b722756e-2c95-46a3-94c9-10bd13cde758" xlink:to="loc_sgmo_SangamoFranceMember_bca927d2-f3e3-4849-8167-296e030496a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_d3690929-cd9b-4818-98bc-cba1fdddfde3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3b3fe61b-bc5c-4e9c-8f5b-37c383e64bcf" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_d3690929-cd9b-4818-98bc-cba1fdddfde3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_79ebafe9-236e-46ee-9b9b-0ff763233471" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d3690929-cd9b-4818-98bc-cba1fdddfde3" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_79ebafe9-236e-46ee-9b9b-0ff763233471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_50f446b1-b63f-428b-a194-8f0ef6f9d23a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d3690929-cd9b-4818-98bc-cba1fdddfde3" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_50f446b1-b63f-428b-a194-8f0ef6f9d23a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_d87dadf7-ed69-45df-8cc5-842f9028b9fc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d3690929-cd9b-4818-98bc-cba1fdddfde3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_d87dadf7-ed69-45df-8cc5-842f9028b9fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_9ecce745-3140-42b0-baba-ce37f81f226f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d3690929-cd9b-4818-98bc-cba1fdddfde3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_9ecce745-3140-42b0-baba-ce37f81f226f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_3deac9fc-611f-4b22-9b98-b05b98713476" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d3690929-cd9b-4818-98bc-cba1fdddfde3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_3deac9fc-611f-4b22-9b98-b05b98713476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_dcf15336-4af3-4a47-8c3d-e575aca85625" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d3690929-cd9b-4818-98bc-cba1fdddfde3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_dcf15336-4af3-4a47-8c3d-e575aca85625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_7b358a40-fd09-4b52-a4e9-200619e7106a" xlink:href="sgmo-20191231.xsd#sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d3690929-cd9b-4818-98bc-cba1fdddfde3" xlink:to="loc_sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_7b358a40-fd09-4b52-a4e9-200619e7106a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_b308c3e9-fc73-4f21-93ba-abe0aa744518" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d3690929-cd9b-4818-98bc-cba1fdddfde3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_b308c3e9-fc73-4f21-93ba-abe0aa744518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_d5aad161-c125-49c6-b9d3-8aa6234b0114" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d3690929-cd9b-4818-98bc-cba1fdddfde3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_d5aad161-c125-49c6-b9d3-8aa6234b0114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1f06be0a-541d-4c6d-a1f3-cad252334ad6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d3690929-cd9b-4818-98bc-cba1fdddfde3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1f06be0a-541d-4c6d-a1f3-cad252334ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_a12f6f8b-7ae5-46d6-84ba-7a48d874cbe5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d3690929-cd9b-4818-98bc-cba1fdddfde3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_a12f6f8b-7ae5-46d6-84ba-7a48d874cbe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_275c3d35-83d6-47e1-8dab-6b21f8c0c007" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d3690929-cd9b-4818-98bc-cba1fdddfde3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_275c3d35-83d6-47e1-8dab-6b21f8c0c007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0cbc90f9-9c60-420a-abe3-257481017141" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d3690929-cd9b-4818-98bc-cba1fdddfde3" xlink:to="loc_us-gaap_Goodwill_0cbc90f9-9c60-420a-abe3-257481017141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_26ae6830-4f00-4934-81b6-d0d909a51cf3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d3690929-cd9b-4818-98bc-cba1fdddfde3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_26ae6830-4f00-4934-81b6-d0d909a51cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_89bd3891-e5ad-4a09-be24-2cbbfadc23e3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_782d2743-1627-4324-8111-b23005a0f150" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_89bd3891-e5ad-4a09-be24-2cbbfadc23e3" xlink:to="loc_us-gaap_MinorityInterestTable_782d2743-1627-4324-8111-b23005a0f150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2e31641f-a3e1-41a8-b57c-118579e989bd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_782d2743-1627-4324-8111-b23005a0f150" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2e31641f-a3e1-41a8-b57c-118579e989bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_27819fac-ac97-4599-b8cc-432b23de0bc3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2e31641f-a3e1-41a8-b57c-118579e989bd" xlink:to="loc_us-gaap_EquityComponentDomain_27819fac-ac97-4599-b8cc-432b23de0bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_ba0cd24e-ec83-4a4c-855b-3ff857a925dc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_27819fac-ac97-4599-b8cc-432b23de0bc3" xlink:to="loc_us-gaap_NoncontrollingInterestMember_ba0cd24e-ec83-4a4c-855b-3ff857a925dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_0312f60c-f5a3-4917-ba5a-c667728cff86" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_782d2743-1627-4324-8111-b23005a0f150" xlink:to="loc_us-gaap_MinorityInterestLineItems_0312f60c-f5a3-4917-ba5a-c667728cff86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward_ea4a56a1-020e-49da-8e55-6a6130828504" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_0312f60c-f5a3-4917-ba5a-c667728cff86" xlink:to="loc_us-gaap_MovementInMinorityInterestRollForward_ea4a56a1-020e-49da-8e55-6a6130828504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_0eb9e648-f0a7-4908-ac33-cd4c82a2105f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_ea4a56a1-020e-49da-8e55-6a6130828504" xlink:to="loc_us-gaap_MinorityInterest_0eb9e648-f0a7-4908-ac33-cd4c82a2105f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_c9b96495-b72f-4366-bc72-8e7199a5fa11" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_ea4a56a1-020e-49da-8e55-6a6130828504" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_c9b96495-b72f-4366-bc72-8e7199a5fa11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_30f88f6e-fa56-4316-8f7e-322d6494cbdc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_ea4a56a1-020e-49da-8e55-6a6130828504" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_30f88f6e-fa56-4316-8f7e-322d6494cbdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_15faf4d5-4f41-43a1-8fdd-c28aec8923c8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_ea4a56a1-020e-49da-8e55-6a6130828504" xlink:to="loc_us-gaap_MinorityInterest_15faf4d5-4f41-43a1-8fdd-c28aec8923c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/OtherBalanceSheetDetails" xlink:type="simple" xlink:href="sgmo-20191231.xsd#OtherBalanceSheetDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/OtherBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_913180bd-c041-401e-9249-e9aea7f2185c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_f944f854-579e-4993-b6f8-62afadd713c5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_913180bd-c041-401e-9249-e9aea7f2185c" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_f944f854-579e-4993-b6f8-62afadd713c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/OtherBalanceSheetDetailsTables" xlink:type="simple" xlink:href="sgmo-20191231.xsd#OtherBalanceSheetDetailsTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/OtherBalanceSheetDetailsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_d6691fa6-742d-437b-9dbe-f37fc269c995" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_5e104cbf-1eb1-4aab-be85-109f1ef23e7e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_d6691fa6-742d-437b-9dbe-f37fc269c995" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_5e104cbf-1eb1-4aab-be85-109f1ef23e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_bec33435-314f-4626-8200-d85b7a413559" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_d6691fa6-742d-437b-9dbe-f37fc269c995" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_bec33435-314f-4626-8200-d85b7a413559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_b2789271-2a97-4bbd-96c2-37e3fca06714" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_d6691fa6-742d-437b-9dbe-f37fc269c995" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_b2789271-2a97-4bbd-96c2-37e3fca06714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/OtherBalanceSheetDetailsDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#OtherBalanceSheetDetailsDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/OtherBalanceSheetDetailsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_fea85036-2e20-4fc8-83cf-e44161c5dd04" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1d2b9a1f-413e-4178-af78-0ab2dd7641c6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_fea85036-2e20-4fc8-83cf-e44161c5dd04" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1d2b9a1f-413e-4178-af78-0ab2dd7641c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_83626b33-895b-4805-bb4b-b56164ae552e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1d2b9a1f-413e-4178-af78-0ab2dd7641c6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_83626b33-895b-4805-bb4b-b56164ae552e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1766ee5c-1fc6-4a5e-9706-11b93be529ff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_83626b33-895b-4805-bb4b-b56164ae552e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1766ee5c-1fc6-4a5e-9706-11b93be529ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_601007e1-8e49-4a35-b988-bb2d68231e4d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1766ee5c-1fc6-4a5e-9706-11b93be529ff" xlink:to="loc_us-gaap_EquipmentMember_601007e1-8e49-4a35-b988-bb2d68231e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_0fd26654-8d99-4b4b-a4fb-c0ad97463424" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1766ee5c-1fc6-4a5e-9706-11b93be529ff" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_0fd26654-8d99-4b4b-a4fb-c0ad97463424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_cf4a41f6-fd85-4ce5-8d22-288ee08f6a65" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1766ee5c-1fc6-4a5e-9706-11b93be529ff" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_cf4a41f6-fd85-4ce5-8d22-288ee08f6a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_6e5af103-fa67-48d3-be66-6f6528a7b589" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1766ee5c-1fc6-4a5e-9706-11b93be529ff" xlink:to="loc_us-gaap_BuildingMember_6e5af103-fa67-48d3-be66-6f6528a7b589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_d2087de6-0a59-4d9c-b6ff-bfd8cdcd2334" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1766ee5c-1fc6-4a5e-9706-11b93be529ff" xlink:to="loc_us-gaap_ConstructionInProgressMember_d2087de6-0a59-4d9c-b6ff-bfd8cdcd2334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6e44026a-c967-4328-b508-b1bf062d3277" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1d2b9a1f-413e-4178-af78-0ab2dd7641c6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6e44026a-c967-4328-b508-b1bf062d3277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_e3eaee29-7ea0-4e8c-880c-b298af3c1639" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6e44026a-c967-4328-b508-b1bf062d3277" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_e3eaee29-7ea0-4e8c-880c-b298af3c1639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c628c473-56a7-4783-ac3d-6b5e588f29ce" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6e44026a-c967-4328-b508-b1bf062d3277" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c628c473-56a7-4783-ac3d-6b5e588f29ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_58c5e657-ca3c-4c03-b9fe-b3e44ff9669a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6e44026a-c967-4328-b508-b1bf062d3277" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_58c5e657-ca3c-4c03-b9fe-b3e44ff9669a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/OtherBalanceSheetDetailsScheduleofIntangibleAssetsandGoodwillDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#OtherBalanceSheetDetailsScheduleofIntangibleAssetsandGoodwillDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/OtherBalanceSheetDetailsScheduleofIntangibleAssetsandGoodwillDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_cb367198-4815-4bde-b03f-e9f3f5322ebf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IntangibleAssetsExcludingGoodwillRollForward_047e3298-59f5-41c4-b496-8b2d9662092e" xlink:href="sgmo-20191231.xsd#sgmo_IntangibleAssetsExcludingGoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_cb367198-4815-4bde-b03f-e9f3f5322ebf" xlink:to="loc_sgmo_IntangibleAssetsExcludingGoodwillRollForward_047e3298-59f5-41c4-b496-8b2d9662092e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1f745788-9242-4eac-b413-fb2df2934ac1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_IntangibleAssetsExcludingGoodwillRollForward_047e3298-59f5-41c4-b496-8b2d9662092e" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1f745788-9242-4eac-b413-fb2df2934ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_6f287343-7bb2-4ba5-a7ec-43aca8037023" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_IntangibleAssetsExcludingGoodwillRollForward_047e3298-59f5-41c4-b496-8b2d9662092e" xlink:to="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_6f287343-7bb2-4ba5-a7ec-43aca8037023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_a87491ac-9e36-46fb-a9e2-65ae27e3779b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_IntangibleAssetsExcludingGoodwillRollForward_047e3298-59f5-41c4-b496-8b2d9662092e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_a87491ac-9e36-46fb-a9e2-65ae27e3779b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d3e3c28d-f3a2-4b60-9e5a-5569a74d4015" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_IntangibleAssetsExcludingGoodwillRollForward_047e3298-59f5-41c4-b496-8b2d9662092e" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d3e3c28d-f3a2-4b60-9e5a-5569a74d4015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_932c4925-b940-4e0f-a635-dbf48201cd6f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_cb367198-4815-4bde-b03f-e9f3f5322ebf" xlink:to="loc_us-gaap_GoodwillRollForward_932c4925-b940-4e0f-a635-dbf48201cd6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_32893cc1-e335-4351-a8c6-6c2e1d34db6c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_932c4925-b940-4e0f-a635-dbf48201cd6f" xlink:to="loc_us-gaap_Goodwill_32893cc1-e335-4351-a8c6-6c2e1d34db6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_3152c2c6-19b0-4f40-9618-5835ff752b0d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_932c4925-b940-4e0f-a635-dbf48201cd6f" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_3152c2c6-19b0-4f40-9618-5835ff752b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_aefc8373-47b4-4a49-9827-8b45a09412c6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_932c4925-b940-4e0f-a635-dbf48201cd6f" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_aefc8373-47b4-4a49-9827-8b45a09412c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c523098f-1777-4b02-9ea9-300e789beef1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_932c4925-b940-4e0f-a635-dbf48201cd6f" xlink:to="loc_us-gaap_Goodwill_c523098f-1777-4b02-9ea9-300e789beef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f8d0758a-faec-4538-9d07-ebb44e5b8108" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_39de7123-ffea-4f5d-a88d-80ce8ef03861" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_39349e59-1885-47c3-bf47-07561839b02a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_39de7123-ffea-4f5d-a88d-80ce8ef03861" xlink:to="loc_us-gaap_AccountsPayableCurrent_39349e59-1885-47c3-bf47-07561839b02a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AccruedResearchAndDevelopmentExpenses_764c5a6d-c978-4190-9f1a-34ddb446ff37" xlink:href="sgmo-20191231.xsd#sgmo_AccruedResearchAndDevelopmentExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_39de7123-ffea-4f5d-a88d-80ce8ef03861" xlink:to="loc_sgmo_AccruedResearchAndDevelopmentExpenses_764c5a6d-c978-4190-9f1a-34ddb446ff37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_2b77bf16-eaf1-4e94-aba2-d3ade35b4cd4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_39de7123-ffea-4f5d-a88d-80ce8ef03861" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_2b77bf16-eaf1-4e94-aba2-d3ade35b4cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_267216ef-6ac5-4ea9-ae45-9e2a9c52b01e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_39de7123-ffea-4f5d-a88d-80ce8ef03861" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_267216ef-6ac5-4ea9-ae45-9e2a9c52b01e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_22a7c35d-58f4-4ec7-88f0-c9754d50b46f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_39de7123-ffea-4f5d-a88d-80ce8ef03861" xlink:to="loc_us-gaap_DeferredRentCreditCurrent_22a7c35d-58f4-4ec7-88f0-c9754d50b46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilities_12ba8e1c-b5d1-4e74-989e-9bd28e5d2dba" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_39de7123-ffea-4f5d-a88d-80ce8ef03861" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilities_12ba8e1c-b5d1-4e74-989e-9bd28e5d2dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1b4feedc-9624-4f89-9859-c5aa9e0aad7b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_39de7123-ffea-4f5d-a88d-80ce8ef03861" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1b4feedc-9624-4f89-9859-c5aa9e0aad7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="sgmo-20191231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ceb9a634-f85e-4456-834e-6a27c91cd19b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_16323ac6-74b5-4989-9050-e23cb800b3d2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ceb9a634-f85e-4456-834e-6a27c91cd19b" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_16323ac6-74b5-4989-9050-e23cb800b3d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="sgmo-20191231.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8d5f22a8-eaa1-4709-9b57-3edda0245188" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_81637cf1-e3c1-43e1-8571-6392f44a11a6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8d5f22a8-eaa1-4709-9b57-3edda0245188" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_81637cf1-e3c1-43e1-8571-6392f44a11a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_69c9efc6-8c38-43db-8032-e38bf6b556fc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommitmentsAndContingenciesTable_9493d59d-8549-409b-8603-29fe0647fc13" xlink:href="sgmo-20191231.xsd#sgmo_CommitmentsAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_69c9efc6-8c38-43db-8032-e38bf6b556fc" xlink:to="loc_sgmo_CommitmentsAndContingenciesTable_9493d59d-8549-409b-8603-29fe0647fc13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e15a72b6-8109-4bda-9ccd-2757c8c2b9bd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_9493d59d-8549-409b-8603-29fe0647fc13" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e15a72b6-8109-4bda-9ccd-2757c8c2b9bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e8ae0080-5213-40dc-b397-c7b56df26d02" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e15a72b6-8109-4bda-9ccd-2757c8c2b9bd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e8ae0080-5213-40dc-b397-c7b56df26d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchAndOfficeSpaceMember_7aaf14ce-e913-4d80-9b0e-475820687e42" xlink:href="sgmo-20191231.xsd#sgmo_ResearchAndOfficeSpaceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e8ae0080-5213-40dc-b397-c7b56df26d02" xlink:to="loc_sgmo_ResearchAndOfficeSpaceMember_7aaf14ce-e913-4d80-9b0e-475820687e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OfficeAndLaboratoryMember_b88f7146-a273-4e4d-a58a-e906a0ac3abf" xlink:href="sgmo-20191231.xsd#sgmo_OfficeAndLaboratoryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e8ae0080-5213-40dc-b397-c7b56df26d02" xlink:to="loc_sgmo_OfficeAndLaboratoryMember_b88f7146-a273-4e4d-a58a-e906a0ac3abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OfficeSpaceMember_fef6687a-b097-4995-bfa1-e60a830e4a00" xlink:href="sgmo-20191231.xsd#sgmo_OfficeSpaceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e8ae0080-5213-40dc-b397-c7b56df26d02" xlink:to="loc_sgmo_OfficeSpaceMember_fef6687a-b097-4995-bfa1-e60a830e4a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f7beab08-78f7-4010-afc4-046e7d0cd124" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_9493d59d-8549-409b-8603-29fe0647fc13" xlink:to="loc_srt_StatementGeographicalAxis_f7beab08-78f7-4010-afc4-046e7d0cd124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3847e7ab-4ab9-4fae-bea7-b57e07d40d16" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_f7beab08-78f7-4010-afc4-046e7d0cd124" xlink:to="loc_srt_SegmentGeographicalDomain_3847e7ab-4ab9-4fae-bea7-b57e07d40d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BrisbaneCaliforniaMember_8b5ca85a-aaac-41c6-bab3-33c1dd8f0620" xlink:href="sgmo-20191231.xsd#sgmo_BrisbaneCaliforniaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_3847e7ab-4ab9-4fae-bea7-b57e07d40d16" xlink:to="loc_sgmo_BrisbaneCaliforniaMember_8b5ca85a-aaac-41c6-bab3-33c1dd8f0620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RichmondCaliforniaMember_fb8a6dda-85b7-4d15-b0cc-b7a9e0019e90" xlink:href="sgmo-20191231.xsd#sgmo_RichmondCaliforniaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_3847e7ab-4ab9-4fae-bea7-b57e07d40d16" xlink:to="loc_sgmo_RichmondCaliforniaMember_fb8a6dda-85b7-4d15-b0cc-b7a9e0019e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ValbonneFranceMember_e9a126d1-afde-4b5f-a1ad-c9464fd976f8" xlink:href="sgmo-20191231.xsd#sgmo_ValbonneFranceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_3847e7ab-4ab9-4fae-bea7-b57e07d40d16" xlink:to="loc_sgmo_ValbonneFranceMember_e9a126d1-afde-4b5f-a1ad-c9464fd976f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5c9b142d-17bb-441e-9d84-23abc4bc8a62" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_9493d59d-8549-409b-8603-29fe0647fc13" xlink:to="loc_srt_RangeAxis_5c9b142d-17bb-441e-9d84-23abc4bc8a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_61d4c283-5456-4ddb-99b8-b848ad498555" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5c9b142d-17bb-441e-9d84-23abc4bc8a62" xlink:to="loc_srt_RangeMember_61d4c283-5456-4ddb-99b8-b848ad498555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_90f1c922-ab1d-4111-bd53-4627583dcc0a" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_61d4c283-5456-4ddb-99b8-b848ad498555" xlink:to="loc_srt_MinimumMember_90f1c922-ab1d-4111-bd53-4627583dcc0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2c180360-a1e1-4045-a55c-126b922d7327" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_61d4c283-5456-4ddb-99b8-b848ad498555" xlink:to="loc_srt_MaximumMember_2c180360-a1e1-4045-a55c-126b922d7327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_1c88a1f6-40c3-4932-a31f-5a2897052cf5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_9493d59d-8549-409b-8603-29fe0647fc13" xlink:to="loc_us-gaap_OtherCommitmentsAxis_1c88a1f6-40c3-4932-a31f-5a2897052cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_98efa02e-3f2a-4c70-a5bf-28623acb614f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_1c88a1f6-40c3-4932-a31f-5a2897052cf5" xlink:to="loc_us-gaap_OtherCommitmentsDomain_98efa02e-3f2a-4c70-a5bf-28623acb614f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ManufacturingCapacityMember_e7c83631-a621-4124-9623-ea0fc9e0f954" xlink:href="sgmo-20191231.xsd#sgmo_ManufacturingCapacityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_98efa02e-3f2a-4c70-a5bf-28623acb614f" xlink:to="loc_sgmo_ManufacturingCapacityMember_e7c83631-a621-4124-9623-ea0fc9e0f954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ManufacturingObligationsMember_7cf27c96-953c-4be8-8c36-c38ce7e7aa26" xlink:href="sgmo-20191231.xsd#sgmo_ManufacturingObligationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_98efa02e-3f2a-4c70-a5bf-28623acb614f" xlink:to="loc_sgmo_ManufacturingObligationsMember_7cf27c96-953c-4be8-8c36-c38ce7e7aa26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NonCancelableContractualCommitmentMember_a25a29ba-542c-4b8f-8ef9-de9634c47c8e" xlink:href="sgmo-20191231.xsd#sgmo_NonCancelableContractualCommitmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_98efa02e-3f2a-4c70-a5bf-28623acb614f" xlink:to="loc_sgmo_NonCancelableContractualCommitmentMember_a25a29ba-542c-4b8f-8ef9-de9634c47c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommitmentsAndContingenciesLineItems_b5171e1d-1982-4aa8-84ed-3b72558c99df" xlink:href="sgmo-20191231.xsd#sgmo_CommitmentsAndContingenciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_9493d59d-8549-409b-8603-29fe0647fc13" xlink:to="loc_sgmo_CommitmentsAndContingenciesLineItems_b5171e1d-1982-4aa8-84ed-3b72558c99df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_ba10b1dc-4a6d-45a5-9416-fb83115d0bbd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b5171e1d-1982-4aa8-84ed-3b72558c99df" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_ba10b1dc-4a6d-45a5-9416-fb83115d0bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_1fe6bf11-83f9-4c3c-beae-6f6cf13fd5d7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b5171e1d-1982-4aa8-84ed-3b72558c99df" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_1fe6bf11-83f9-4c3c-beae-6f6cf13fd5d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseLiabilityTenantImprovementAllowance_b715f825-a2e7-4464-a13e-ea027a96a618" xlink:href="sgmo-20191231.xsd#sgmo_LesseeOperatingLeaseLiabilityTenantImprovementAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b5171e1d-1982-4aa8-84ed-3b72558c99df" xlink:to="loc_sgmo_LesseeOperatingLeaseLiabilityTenantImprovementAllowance_b715f825-a2e7-4464-a13e-ea027a96a618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance_f2b2f0e7-1124-4e6f-9e1e-0cb633a90877" xlink:href="sgmo-20191231.xsd#sgmo_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b5171e1d-1982-4aa8-84ed-3b72558c99df" xlink:to="loc_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance_f2b2f0e7-1124-4e6f-9e1e-0cb633a90877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_5565c401-b790-4be2-b5e4-9fd0970b39a5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b5171e1d-1982-4aa8-84ed-3b72558c99df" xlink:to="loc_us-gaap_OperatingLeaseCost_5565c401-b790-4be2-b5e4-9fd0970b39a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_54ac3108-af95-441a-8d4c-20433c37714f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b5171e1d-1982-4aa8-84ed-3b72558c99df" xlink:to="loc_us-gaap_VariableLeaseCost_54ac3108-af95-441a-8d4c-20433c37714f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_9dbdb7f7-6721-4815-880b-22734a22b817" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b5171e1d-1982-4aa8-84ed-3b72558c99df" xlink:to="loc_us-gaap_OperatingLeasePayments_9dbdb7f7-6721-4815-880b-22734a22b817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_6b52e94e-f131-4218-8b4a-2e0f38139755" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b5171e1d-1982-4aa8-84ed-3b72558c99df" xlink:to="loc_us-gaap_OperatingLeaseExpense_6b52e94e-f131-4218-8b4a-2e0f38139755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_80262df9-76b2-4369-b758-dc1674b2df1b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b5171e1d-1982-4aa8-84ed-3b72558c99df" xlink:to="loc_us-gaap_LeaseAndRentalExpense_80262df9-76b2-4369-b758-dc1674b2df1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1e19fb40-6622-4014-ab1e-b8844befec4b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b5171e1d-1982-4aa8-84ed-3b72558c99df" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1e19fb40-6622-4014-ab1e-b8844befec4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_dfd0a88d-4c1f-415c-a41b-21d98c15a36a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b5171e1d-1982-4aa8-84ed-3b72558c99df" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_dfd0a88d-4c1f-415c-a41b-21d98c15a36a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LicenseObligations_e089cd50-24bd-47e0-8457-327370bd3521" xlink:href="sgmo-20191231.xsd#sgmo_LicenseObligations"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b5171e1d-1982-4aa8-84ed-3b72558c99df" xlink:to="loc_sgmo_LicenseObligations_e089cd50-24bd-47e0-8457-327370bd3521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PaymentsForOtherCommitment_1babb612-3e75-4235-8a14-e4aad56315b0" xlink:href="sgmo-20191231.xsd#sgmo_PaymentsForOtherCommitment"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b5171e1d-1982-4aa8-84ed-3b72558c99df" xlink:to="loc_sgmo_PaymentsForOtherCommitment_1babb612-3e75-4235-8a14-e4aad56315b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_07b25a43-fccc-48ff-a2c8-96ce92c95d4b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitment"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b5171e1d-1982-4aa8-84ed-3b72558c99df" xlink:to="loc_us-gaap_OtherCommitment_07b25a43-fccc-48ff-a2c8-96ce92c95d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_36b71455-0af3-4b66-b44c-663dc4fe899a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b5171e1d-1982-4aa8-84ed-3b72558c99df" xlink:to="loc_us-gaap_ContractualObligation_36b71455-0af3-4b66-b44c-663dc4fe899a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContractualObligationPaidUponExecution_29fb1914-7b8b-406a-9dc8-7338c55f5169" xlink:href="sgmo-20191231.xsd#sgmo_ContractualObligationPaidUponExecution"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b5171e1d-1982-4aa8-84ed-3b72558c99df" xlink:to="loc_sgmo_ContractualObligationPaidUponExecution_29fb1914-7b8b-406a-9dc8-7338c55f5169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_91cfccc6-e793-4c59-8a77-ac082156d667" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f4286a13-632b-403f-8f9b-2c3c1aee221d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_91cfccc6-e793-4c59-8a77-ac082156d667" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f4286a13-632b-403f-8f9b-2c3c1aee221d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d8c01703-dc9f-4e1a-84c7-d85a7507c178" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_91cfccc6-e793-4c59-8a77-ac082156d667" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d8c01703-dc9f-4e1a-84c7-d85a7507c178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7e0d1504-c2e5-42cc-ac46-7b644a4221ef" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_91cfccc6-e793-4c59-8a77-ac082156d667" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7e0d1504-c2e5-42cc-ac46-7b644a4221ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8d12177f-a6dd-4744-bdad-7ba8cb8f03b3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_91cfccc6-e793-4c59-8a77-ac082156d667" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8d12177f-a6dd-4744-bdad-7ba8cb8f03b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e56655a7-8d64-4fc3-a0bc-8ea1c8207f2b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_91cfccc6-e793-4c59-8a77-ac082156d667" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e56655a7-8d64-4fc3-a0bc-8ea1c8207f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_597d14df-78bd-485b-a840-63630417220e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_91cfccc6-e793-4c59-8a77-ac082156d667" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_597d14df-78bd-485b-a840-63630417220e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1fd691fc-ed81-439e-96ff-c046c27e4065" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_91cfccc6-e793-4c59-8a77-ac082156d667" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1fd691fc-ed81-439e-96ff-c046c27e4065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e9b20887-dcf7-4fa2-8858-e7ba0a726554" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_91cfccc6-e793-4c59-8a77-ac082156d667" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e9b20887-dcf7-4fa2-8858-e7ba0a726554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_6e27ff45-5290-4847-926b-9bbd7265a078" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_91cfccc6-e793-4c59-8a77-ac082156d667" xlink:to="loc_us-gaap_OperatingLeaseLiability_6e27ff45-5290-4847-926b-9bbd7265a078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ec508dba-0cf4-401b-bba3-23193909a3b5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_91cfccc6-e793-4c59-8a77-ac082156d667" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ec508dba-0cf4-401b-bba3-23193909a3b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_97418643-7263-4c74-868b-262b9d91fe19" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_91cfccc6-e793-4c59-8a77-ac082156d667" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_97418643-7263-4c74-868b-262b9d91fe19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockholdersEquity" xlink:type="simple" xlink:href="sgmo-20191231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f09507db-7169-40e6-8323-1fee76a37a50" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_cf0431ec-4ae3-48d1-b646-c62b887f5353" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f09507db-7169-40e6-8323-1fee76a37a50" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_cf0431ec-4ae3-48d1-b646-c62b887f5353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="sgmo-20191231.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6b60dd4b-3588-4ea2-b9a9-5a9e0bd8877b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f9d4cc56-8ffd-4a8f-9f3b-d9365f7daf20" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6b60dd4b-3588-4ea2-b9a9-5a9e0bd8877b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f9d4cc56-8ffd-4a8f-9f3b-d9365f7daf20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_d50bfe92-5341-4e1f-b3b4-9bac84ce6be0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6b60dd4b-3588-4ea2-b9a9-5a9e0bd8877b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_d50bfe92-5341-4e1f-b3b4-9bac84ce6be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#StockholdersEquityAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_62295bb4-b6fa-468f-9b45-9e85211057bc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7898ec6d-5b2e-420e-b894-6c6dedb15058" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_62295bb4-b6fa-468f-9b45-9e85211057bc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7898ec6d-5b2e-420e-b894-6c6dedb15058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d3bcedaa-f418-4926-b32e-a29d23246944" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7898ec6d-5b2e-420e-b894-6c6dedb15058" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d3bcedaa-f418-4926-b32e-a29d23246944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d6a11994-cc4c-401d-8636-888ee939a781" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d3bcedaa-f418-4926-b32e-a29d23246944" xlink:to="loc_us-gaap_EquityComponentDomain_d6a11994-cc4c-401d-8636-888ee939a781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9eb656b5-ea33-4c25-898b-311fa6458d7f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d6a11994-cc4c-401d-8636-888ee939a781" xlink:to="loc_us-gaap_CommonStockMember_9eb656b5-ea33-4c25-898b-311fa6458d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2a12894f-513c-4443-9836-58580460017b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7898ec6d-5b2e-420e-b894-6c6dedb15058" xlink:to="loc_us-gaap_AwardTypeAxis_2a12894f-513c-4443-9836-58580460017b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2b9530ca-a1c0-4ac8-8060-4fd59552acaa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2a12894f-513c-4443-9836-58580460017b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2b9530ca-a1c0-4ac8-8060-4fd59552acaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9a693d85-7835-4475-9975-f4ae255207a7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2b9530ca-a1c0-4ac8-8060-4fd59552acaa" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9a693d85-7835-4475-9975-f4ae255207a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1e79e448-e25c-4863-b2e2-3dc87e1c32f1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2b9530ca-a1c0-4ac8-8060-4fd59552acaa" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1e79e448-e25c-4863-b2e2-3dc87e1c32f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b1cf6d3f-784d-498f-97e6-3b2ae9fc0901" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7898ec6d-5b2e-420e-b894-6c6dedb15058" xlink:to="loc_srt_RangeAxis_b1cf6d3f-784d-498f-97e6-3b2ae9fc0901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b68a6f4f-2be8-4978-8a16-8ea80b9fe6e9" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b1cf6d3f-784d-498f-97e6-3b2ae9fc0901" xlink:to="loc_srt_RangeMember_b68a6f4f-2be8-4978-8a16-8ea80b9fe6e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_12d4136e-5d23-4b40-a5f9-e52de0b19589" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b68a6f4f-2be8-4978-8a16-8ea80b9fe6e9" xlink:to="loc_srt_MaximumMember_12d4136e-5d23-4b40-a5f9-e52de0b19589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_596b7871-d802-4e5b-86d7-6df767b17c9f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7898ec6d-5b2e-420e-b894-6c6dedb15058" xlink:to="loc_us-gaap_PlanNameAxis_596b7871-d802-4e5b-86d7-6df767b17c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d68ecd7c-7477-4854-9f77-a8aa1074f7a7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_596b7871-d802-4e5b-86d7-6df767b17c9f" xlink:to="loc_us-gaap_PlanNameDomain_d68ecd7c-7477-4854-9f77-a8aa1074f7a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_TwoThousandThirteenStockIncentivePlanMember_0d37eb04-d085-4e1c-a448-f943119615ca" xlink:href="sgmo-20191231.xsd#sgmo_TwoThousandThirteenStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d68ecd7c-7477-4854-9f77-a8aa1074f7a7" xlink:to="loc_sgmo_TwoThousandThirteenStockIncentivePlanMember_0d37eb04-d085-4e1c-a448-f943119615ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember_865a4487-14d3-4efc-98b5-024268158689" xlink:href="sgmo-20191231.xsd#sgmo_AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d68ecd7c-7477-4854-9f77-a8aa1074f7a7" xlink:to="loc_sgmo_AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember_865a4487-14d3-4efc-98b5-024268158689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_TwoThousandEighteenStockIncentivePlanMember_6f22ccb0-0b2e-484d-8bf2-7142b063daf7" xlink:href="sgmo-20191231.xsd#sgmo_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d68ecd7c-7477-4854-9f77-a8aa1074f7a7" xlink:to="loc_sgmo_TwoThousandEighteenStockIncentivePlanMember_6f22ccb0-0b2e-484d-8bf2-7142b063daf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_EmployeeStockPurchasePlanMember_794be2ca-c7e3-4536-813b-6705d4480f7b" xlink:href="sgmo-20191231.xsd#sgmo_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d68ecd7c-7477-4854-9f77-a8aa1074f7a7" xlink:to="loc_sgmo_EmployeeStockPurchasePlanMember_794be2ca-c7e3-4536-813b-6705d4480f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_77ed3560-8e63-4399-9089-8a773caeb92a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7898ec6d-5b2e-420e-b894-6c6dedb15058" xlink:to="loc_us-gaap_VestingAxis_77ed3560-8e63-4399-9089-8a773caeb92a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_832fec71-0cab-475f-94a7-7211ae524d72" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_77ed3560-8e63-4399-9089-8a773caeb92a" xlink:to="loc_us-gaap_VestingDomain_832fec71-0cab-475f-94a7-7211ae524d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_092ea44c-01ef-4eac-9850-a08658d14dcc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_832fec71-0cab-475f-94a7-7211ae524d72" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_092ea44c-01ef-4eac-9850-a08658d14dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_4350db19-8775-4f9a-b551-dc91b553f570" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_832fec71-0cab-475f-94a7-7211ae524d72" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_4350db19-8775-4f9a-b551-dc91b553f570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_c30fdbeb-b023-46f8-8a5b-c59b20ecdb53" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_832fec71-0cab-475f-94a7-7211ae524d72" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_c30fdbeb-b023-46f8-8a5b-c59b20ecdb53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7898ec6d-5b2e-420e-b894-6c6dedb15058" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_451b7b4e-0c60-4b01-9640-dcb6485e0ae0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_451b7b4e-0c60-4b01-9640-dcb6485e0ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2414e421-2466-4690-99c1-f033714f77e8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2414e421-2466-4690-99c1-f033714f77e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_d040cabc-4db6-4d35-8b56-0d695261ec24" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_d040cabc-4db6-4d35-8b56-0d695261ec24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NetProceedsFromIssuancePublicOffering_ccf0e745-8b63-45eb-8caf-be6227c96f90" xlink:href="sgmo-20191231.xsd#sgmo_NetProceedsFromIssuancePublicOffering"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_sgmo_NetProceedsFromIssuancePublicOffering_ccf0e745-8b63-45eb-8caf-be6227c96f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_1c3d4711-4cbb-485e-8484-fd11c0bb8cef" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_1c3d4711-4cbb-485e-8484-fd11c0bb8cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7758ba53-5f9b-45ab-89af-ac228cc6b106" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7758ba53-5f9b-45ab-89af-ac228cc6b106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SpecifiedStockholderOwnershipPercentage_a8198b5d-ef1a-4ea9-95c9-f972aa0d446a" xlink:href="sgmo-20191231.xsd#sgmo_SpecifiedStockholderOwnershipPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_sgmo_SpecifiedStockholderOwnershipPercentage_a8198b5d-ef1a-4ea9-95c9-f972aa0d446a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder_5f6eed9e-691d-465e-b215-71898ddc8e65" xlink:href="sgmo-20191231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder_5f6eed9e-691d-465e-b215-71898ddc8e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder_7e24ca0b-491f-49a3-84ee-12ddc128ff92" xlink:href="sgmo-20191231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder_7e24ca0b-491f-49a3-84ee-12ddc128ff92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4cdc7f4c-4b6d-4dc3-a705-8108af00366a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4cdc7f4c-4b6d-4dc3-a705-8108af00366a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0c10af8d-e4f2-4898-8b98-a64ae0dbe203" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0c10af8d-e4f2-4898-8b98-a64ae0dbe203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm_2edc649e-af16-44ff-8565-1ccaccec62f4" xlink:href="sgmo-20191231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm_2edc649e-af16-44ff-8565-1ccaccec62f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommonStockExchangeRatio_33e7167e-75b5-4c39-8952-f19e22c370e2" xlink:href="sgmo-20191231.xsd#sgmo_CommonStockExchangeRatio"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_sgmo_CommonStockExchangeRatio_33e7167e-75b5-4c39-8952-f19e22c370e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_e185cbf5-1f4e-49f7-9b4a-1a00bade3231" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_e185cbf5-1f4e-49f7-9b4a-1a00bade3231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_aaaa5471-da73-41c2-b1fb-0f6827615f6e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_aaaa5471-da73-41c2-b1fb-0f6827615f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_492dbb24-f683-48b8-996f-36d51d159c99" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_492dbb24-f683-48b8-996f-36d51d159c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PurchasePlanOfferingPeriod_d70a8fb2-2d30-4dd5-84a9-116fefc7f325" xlink:href="sgmo-20191231.xsd#sgmo_PurchasePlanOfferingPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_sgmo_PurchasePlanOfferingPeriod_d70a8fb2-2d30-4dd5-84a9-116fefc7f325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PurchasePlanPurchasePeriod_eab717ec-b083-4200-88ba-7b9f35f5d38d" xlink:href="sgmo-20191231.xsd#sgmo_PurchasePlanPurchasePeriod"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_sgmo_PurchasePlanPurchasePeriod_eab717ec-b083-4200-88ba-7b9f35f5d38d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_23a12722-456a-4f41-8348-a95cb0e42af2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_23a12722-456a-4f41-8348-a95cb0e42af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_a3f81435-c81f-4093-9dfd-4afb7596c93f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_a3f81435-c81f-4093-9dfd-4afb7596c93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c0371959-2477-4951-9d70-cf26b237e899" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c0371959-2477-4951-9d70-cf26b237e899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cfe56e50-899a-42ef-b671-8a9e3adfdd41" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cfe56e50-899a-42ef-b671-8a9e3adfdd41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7ba8c519-2fd7-40bd-8848-9c2ae62cd646" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7ba8c519-2fd7-40bd-8848-9c2ae62cd646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment_1ebacd36-8142-4654-b5d1-fbe365c273fc" xlink:href="sgmo-20191231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment_1ebacd36-8142-4654-b5d1-fbe365c273fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_077c94ba-34c0-414f-a7b3-e31deec53718" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_077c94ba-34c0-414f-a7b3-e31deec53718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_7a88a5ce-50b6-4a96-bf93-5c79dc2413b9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_7a88a5ce-50b6-4a96-bf93-5c79dc2413b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_18039db9-d09e-4403-a422-a819f4dc216c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_18039db9-d09e-4403-a422-a819f4dc216c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_72020a0f-b822-455f-a75a-7d134449beb1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa9a7c0f-460c-48d9-a32b-bec602be6a42" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_72020a0f-b822-455f-a75a-7d134449beb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#StockholdersEquitySummaryofStockOptionActivityDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f37564a5-5193-445e-bfda-82a198d6335d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d3b19ef9-bb90-4b20-ac87-398830757221" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f37564a5-5193-445e-bfda-82a198d6335d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d3b19ef9-bb90-4b20-ac87-398830757221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_58245bc5-bf64-49eb-8e55-256379fc135a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d3b19ef9-bb90-4b20-ac87-398830757221" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_58245bc5-bf64-49eb-8e55-256379fc135a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a394afb3-c28c-4474-992f-2574632c76cf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d3b19ef9-bb90-4b20-ac87-398830757221" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a394afb3-c28c-4474-992f-2574632c76cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_212cbd18-6193-45f8-9952-c41b1a713d5b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d3b19ef9-bb90-4b20-ac87-398830757221" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_212cbd18-6193-45f8-9952-c41b1a713d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6f561d6f-d144-47d6-949e-090d5a352633" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d3b19ef9-bb90-4b20-ac87-398830757221" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6f561d6f-d144-47d6-949e-090d5a352633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9664f79c-ac8b-4285-af26-e6122a4a8635" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d3b19ef9-bb90-4b20-ac87-398830757221" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9664f79c-ac8b-4285-af26-e6122a4a8635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_66317014-8915-4418-bb9b-01fb6bfe9701" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d3b19ef9-bb90-4b20-ac87-398830757221" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_66317014-8915-4418-bb9b-01fb6bfe9701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1a1d923c-fbf4-4de9-b50e-8dee09e009d7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d3b19ef9-bb90-4b20-ac87-398830757221" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1a1d923c-fbf4-4de9-b50e-8dee09e009d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e0d0d53e-cc01-442a-9e2d-ca4015f2f2f2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f37564a5-5193-445e-bfda-82a198d6335d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e0d0d53e-cc01-442a-9e2d-ca4015f2f2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a63ab40b-3814-4477-8104-0fe45f878b44" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e0d0d53e-cc01-442a-9e2d-ca4015f2f2f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a63ab40b-3814-4477-8104-0fe45f878b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3e0c08e8-2206-4297-83de-f572b6b8665b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e0d0d53e-cc01-442a-9e2d-ca4015f2f2f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3e0c08e8-2206-4297-83de-f572b6b8665b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2e952ac7-6c0d-4bfc-82fe-4b0306dab7a9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e0d0d53e-cc01-442a-9e2d-ca4015f2f2f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2e952ac7-6c0d-4bfc-82fe-4b0306dab7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_5f88bd98-493f-4e70-ab52-d991490a2a6f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e0d0d53e-cc01-442a-9e2d-ca4015f2f2f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_5f88bd98-493f-4e70-ab52-d991490a2a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_244929e3-5b3a-4d4c-8816-e0c139daed03" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e0d0d53e-cc01-442a-9e2d-ca4015f2f2f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_244929e3-5b3a-4d4c-8816-e0c139daed03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2a887d5f-df9a-4d4d-ad68-b407e33a44ef" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e0d0d53e-cc01-442a-9e2d-ca4015f2f2f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2a887d5f-df9a-4d4d-ad68-b407e33a44ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_64752429-357b-483f-83ba-8be9fcdd3cf8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e0d0d53e-cc01-442a-9e2d-ca4015f2f2f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_64752429-357b-483f-83ba-8be9fcdd3cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e3cd2564-28f1-439b-abda-163ecca8f9d2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f37564a5-5193-445e-bfda-82a198d6335d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e3cd2564-28f1-439b-abda-163ecca8f9d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d5850c39-dcba-4b21-9b01-fa65dd46f82d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e3cd2564-28f1-439b-abda-163ecca8f9d2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d5850c39-dcba-4b21-9b01-fa65dd46f82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_622365c3-1e72-4661-b44e-fb133b592db5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e3cd2564-28f1-439b-abda-163ecca8f9d2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_622365c3-1e72-4661-b44e-fb133b592db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_55ab49d9-60cd-4337-965d-336c73a9be9f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e3cd2564-28f1-439b-abda-163ecca8f9d2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_55ab49d9-60cd-4337-965d-336c73a9be9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_66683617-a13e-48e1-ae8a-75bfc76842b4" xlink:href="sgmo-20191231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f37564a5-5193-445e-bfda-82a198d6335d" xlink:to="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_66683617-a13e-48e1-ae8a-75bfc76842b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_49ee3275-5134-428c-bd6c-ee3d4bf9b714" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_66683617-a13e-48e1-ae8a-75bfc76842b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_49ee3275-5134-428c-bd6c-ee3d4bf9b714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_f6f6780d-995d-4247-be30-60a970e73f41" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_66683617-a13e-48e1-ae8a-75bfc76842b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_f6f6780d-995d-4247-be30-60a970e73f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7ca73fde-f50c-4704-8f43-4b1f28b9e273" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_66683617-a13e-48e1-ae8a-75bfc76842b4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7ca73fde-f50c-4704-8f43-4b1f28b9e273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockholdersEquitySummaryofRestrictedStockUnitActivityDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#StockholdersEquitySummaryofRestrictedStockUnitActivityDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/StockholdersEquitySummaryofRestrictedStockUnitActivityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_94499dc0-269e-4a54-b86e-e70bce4ac3c6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_06a18800-d695-4a63-b097-d81bf73aa11a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_94499dc0-269e-4a54-b86e-e70bce4ac3c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_06a18800-d695-4a63-b097-d81bf73aa11a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_06ccc273-2fd2-4452-9609-697bc6702060" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_06a18800-d695-4a63-b097-d81bf73aa11a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_06ccc273-2fd2-4452-9609-697bc6702060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_134ed89d-df87-4c38-985f-ce81a6f8f54b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_06a18800-d695-4a63-b097-d81bf73aa11a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_134ed89d-df87-4c38-985f-ce81a6f8f54b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_2d20570e-4000-4ac4-9313-e79a1c541eb3" xlink:href="sgmo-20191231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_06a18800-d695-4a63-b097-d81bf73aa11a" xlink:to="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_2d20570e-4000-4ac4-9313-e79a1c541eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7829fd76-283b-45cf-9811-ec2d266343e2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_06a18800-d695-4a63-b097-d81bf73aa11a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7829fd76-283b-45cf-9811-ec2d266343e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9add23df-2731-45cb-9b77-575495a3e179" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_06a18800-d695-4a63-b097-d81bf73aa11a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9add23df-2731-45cb-9b77-575495a3e179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_9af90f0e-419c-4e1b-b1c7-b40dde4a49a4" xlink:href="sgmo-20191231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_06a18800-d695-4a63-b097-d81bf73aa11a" xlink:to="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_9af90f0e-419c-4e1b-b1c7-b40dde4a49a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_c0418dce-d23e-40f6-a7a9-773b0a42bb5e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_94499dc0-269e-4a54-b86e-e70bce4ac3c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_c0418dce-d23e-40f6-a7a9-773b0a42bb5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_2a545c51-f01e-43d2-9c9d-ff2a1982e925" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_c0418dce-d23e-40f6-a7a9-773b0a42bb5e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_2a545c51-f01e-43d2-9c9d-ff2a1982e925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm_42c3ff0e-f041-48d9-a218-9aeafbeb3649" xlink:href="sgmo-20191231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_c0418dce-d23e-40f6-a7a9-773b0a42bb5e" xlink:to="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm_42c3ff0e-f041-48d9-a218-9aeafbeb3649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_857cb31f-7228-4ce1-840d-5b651af66896" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_94499dc0-269e-4a54-b86e-e70bce4ac3c6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_857cb31f-7228-4ce1-840d-5b651af66896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_a652e300-f802-49d4-85e6-e60c8f6db81f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_857cb31f-7228-4ce1-840d-5b651af66896" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_a652e300-f802-49d4-85e6-e60c8f6db81f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_dc8c3513-48d0-4644-902b-0ee2574cd2f2" xlink:href="sgmo-20191231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_857cb31f-7228-4ce1-840d-5b651af66896" xlink:to="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_dc8c3513-48d0-4644-902b-0ee2574cd2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="sgmo-20191231.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3e0970b5-f290-4039-8cbb-fd16fd2a9693" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1fd50d68-0f15-459d-ba56-f8067ff9a16e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3e0970b5-f290-4039-8cbb-fd16fd2a9693" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1fd50d68-0f15-459d-ba56-f8067ff9a16e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="sgmo-20191231.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0b0e471b-538e-49e9-81d6-edd6fea0966c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_20e801e6-c070-4e92-bf1b-b072f55673ae" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0b0e471b-538e-49e9-81d6-edd6fea0966c" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_20e801e6-c070-4e92-bf1b-b072f55673ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4906f233-abd2-4924-bf30-4b87a82fd634" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0b0e471b-538e-49e9-81d6-edd6fea0966c" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4906f233-abd2-4924-bf30-4b87a82fd634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_ab90e8b7-861c-4c2b-9da8-71d2587fe09a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0b0e471b-538e-49e9-81d6-edd6fea0966c" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_ab90e8b7-861c-4c2b-9da8-71d2587fe09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#StockBasedCompensationStockBasedCompensationExpenseDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_866322d1-4420-45d6-ad41-1f4a985fa316" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_bac44f3f-ae9f-4870-b540-a915d446a5d5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_866322d1-4420-45d6-ad41-1f4a985fa316" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_bac44f3f-ae9f-4870-b540-a915d446a5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_60a7feb2-0a19-4bbe-a489-0eda268422c7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_bac44f3f-ae9f-4870-b540-a915d446a5d5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_60a7feb2-0a19-4bbe-a489-0eda268422c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9e54e227-3eb1-4e01-9d5d-d084d1e9ac90" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_60a7feb2-0a19-4bbe-a489-0eda268422c7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9e54e227-3eb1-4e01-9d5d-d084d1e9ac90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_15fba1e3-cae3-4906-b973-85cd34b1c4bf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9e54e227-3eb1-4e01-9d5d-d084d1e9ac90" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_15fba1e3-cae3-4906-b973-85cd34b1c4bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_cc3beab7-1e3f-43c0-9701-3c38bf14a186" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9e54e227-3eb1-4e01-9d5d-d084d1e9ac90" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_cc3beab7-1e3f-43c0-9701-3c38bf14a186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e7041b4e-319e-410e-b67b-089ba77cc107" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_bac44f3f-ae9f-4870-b540-a915d446a5d5" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e7041b4e-319e-410e-b67b-089ba77cc107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0effda14-a0e1-4ea7-8386-0bd95b978e12" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e7041b4e-319e-410e-b67b-089ba77cc107" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0effda14-a0e1-4ea7-8386-0bd95b978e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#StockBasedCompensationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2f9b2dfc-ddaf-4ac5-8ea1-8627b802e853" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a41f76fa-211b-4d4f-a933-da90948f9291" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2f9b2dfc-ddaf-4ac5-8ea1-8627b802e853" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a41f76fa-211b-4d4f-a933-da90948f9291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e3b0046e-bdda-488d-bcf9-bd5d6f9e9a94" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a41f76fa-211b-4d4f-a933-da90948f9291" xlink:to="loc_us-gaap_AwardTypeAxis_e3b0046e-bdda-488d-bcf9-bd5d6f9e9a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f089d009-d6e5-4cad-99f9-f1bed3e403a4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e3b0046e-bdda-488d-bcf9-bd5d6f9e9a94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f089d009-d6e5-4cad-99f9-f1bed3e403a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d407acf6-5946-4bf9-962b-b43a966f8f05" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f089d009-d6e5-4cad-99f9-f1bed3e403a4" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d407acf6-5946-4bf9-962b-b43a966f8f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_964d185d-3895-4199-9d39-ee659c4ccfb0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a41f76fa-211b-4d4f-a933-da90948f9291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_964d185d-3895-4199-9d39-ee659c4ccfb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_e2fcd9da-db99-4300-826f-702c9a8e145d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_964d185d-3895-4199-9d39-ee659c4ccfb0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_e2fcd9da-db99-4300-826f-702c9a8e145d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6358ffa5-ca30-4095-b820-34cdf0247a4d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_964d185d-3895-4199-9d39-ee659c4ccfb0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6358ffa5-ca30-4095-b820-34cdf0247a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_0fee1133-d979-4c9d-98b5-a27c51ad2a82" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_964d185d-3895-4199-9d39-ee659c4ccfb0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_0fee1133-d979-4c9d-98b5-a27c51ad2a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9e3fe1ee-9f60-4e4d-9008-77396a742e17" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_964d185d-3895-4199-9d39-ee659c4ccfb0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9e3fe1ee-9f60-4e4d-9008-77396a742e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e7c682d6-88af-4962-a7e2-3db30bc98d9b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_964d185d-3895-4199-9d39-ee659c4ccfb0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e7c682d6-88af-4962-a7e2-3db30bc98d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice_20a70792-6449-4eb1-97b9-be9f2158cbad" xlink:href="sgmo-20191231.xsd#sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_964d185d-3895-4199-9d39-ee659c4ccfb0" xlink:to="loc_sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice_20a70792-6449-4eb1-97b9-be9f2158cbad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue_2711c2a7-f394-44cc-9100-9388c0f6f44b" xlink:href="sgmo-20191231.xsd#sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_964d185d-3895-4199-9d39-ee659c4ccfb0" xlink:to="loc_sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue_2711c2a7-f394-44cc-9100-9388c0f6f44b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7c231dbe-ef55-4f7f-86d4-4f4202c7465e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff92dca4-1e3c-4f6e-adbf-ddb94c7ae738" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7c231dbe-ef55-4f7f-86d4-4f4202c7465e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff92dca4-1e3c-4f6e-adbf-ddb94c7ae738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_da63ec2f-3dea-4ce6-a1aa-9cc0551c6d89" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff92dca4-1e3c-4f6e-adbf-ddb94c7ae738" xlink:to="loc_srt_RangeAxis_da63ec2f-3dea-4ce6-a1aa-9cc0551c6d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e981d583-9cbc-489b-8c43-9747de605426" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_da63ec2f-3dea-4ce6-a1aa-9cc0551c6d89" xlink:to="loc_srt_RangeMember_e981d583-9cbc-489b-8c43-9747de605426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5df25971-fdd3-4c3f-aa75-a18422f88e81" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e981d583-9cbc-489b-8c43-9747de605426" xlink:to="loc_srt_MinimumMember_5df25971-fdd3-4c3f-aa75-a18422f88e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_131b79a0-e91a-48d6-9039-50faa3abf6c8" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e981d583-9cbc-489b-8c43-9747de605426" xlink:to="loc_srt_MaximumMember_131b79a0-e91a-48d6-9039-50faa3abf6c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_4cdc837f-a568-460c-929e-2f08d04ee65b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff92dca4-1e3c-4f6e-adbf-ddb94c7ae738" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_4cdc837f-a568-460c-929e-2f08d04ee65b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_c2eb8717-e355-49fc-949c-458eeaf36e51" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_4cdc837f-a568-460c-929e-2f08d04ee65b" xlink:to="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_c2eb8717-e355-49fc-949c-458eeaf36e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_57770b0d-fd68-4581-8ae8-aa41805d578a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_c2eb8717-e355-49fc-949c-458eeaf36e51" xlink:to="loc_us-gaap_EmployeeStockOptionMember_57770b0d-fd68-4581-8ae8-aa41805d578a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37a9901c-5dfe-4d9f-bc18-35b6e3a1cddb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff92dca4-1e3c-4f6e-adbf-ddb94c7ae738" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37a9901c-5dfe-4d9f-bc18-35b6e3a1cddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_17e64fe8-a3e9-4c23-a93f-3ae632502b87" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37a9901c-5dfe-4d9f-bc18-35b6e3a1cddb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_17e64fe8-a3e9-4c23-a93f-3ae632502b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0fd963f7-375c-4325-a3c1-3c9b6e519655" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37a9901c-5dfe-4d9f-bc18-35b6e3a1cddb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0fd963f7-375c-4325-a3c1-3c9b6e519655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4424ffeb-792e-4581-9fbb-14e5fd060453" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37a9901c-5dfe-4d9f-bc18-35b6e3a1cddb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4424ffeb-792e-4581-9fbb-14e5fd060453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_08d7dc2b-26be-489d-a64b-06529b115dfc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37a9901c-5dfe-4d9f-bc18-35b6e3a1cddb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_08d7dc2b-26be-489d-a64b-06529b115dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_86968229-85d9-498a-9228-5871ea97ca62" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5715f7b1-e288-40ec-a4b8-156f364f9d63" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_86968229-85d9-498a-9228-5871ea97ca62" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5715f7b1-e288-40ec-a4b8-156f364f9d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b5883099-1e9c-434d-98db-22c2fb9178d9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5715f7b1-e288-40ec-a4b8-156f364f9d63" xlink:to="loc_us-gaap_PlanNameAxis_b5883099-1e9c-434d-98db-22c2fb9178d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e1c4a4a9-129e-4a37-95ac-80afb84a78ab" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_b5883099-1e9c-434d-98db-22c2fb9178d9" xlink:to="loc_us-gaap_PlanNameDomain_e1c4a4a9-129e-4a37-95ac-80afb84a78ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_EmployeeStockPurchasePlanMember_88f0fb96-ff4b-43a6-a68d-d55af83fa295" xlink:href="sgmo-20191231.xsd#sgmo_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e1c4a4a9-129e-4a37-95ac-80afb84a78ab" xlink:to="loc_sgmo_EmployeeStockPurchasePlanMember_88f0fb96-ff4b-43a6-a68d-d55af83fa295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cd089d24-c04e-4ef1-8568-3be3e602ed51" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5715f7b1-e288-40ec-a4b8-156f364f9d63" xlink:to="loc_srt_RangeAxis_cd089d24-c04e-4ef1-8568-3be3e602ed51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4e76b7dc-9e83-49f6-8388-7691f6ad9f2e" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_cd089d24-c04e-4ef1-8568-3be3e602ed51" xlink:to="loc_srt_RangeMember_4e76b7dc-9e83-49f6-8388-7691f6ad9f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_72b4d219-8c46-474b-9b26-6ca4123d0890" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4e76b7dc-9e83-49f6-8388-7691f6ad9f2e" xlink:to="loc_srt_MinimumMember_72b4d219-8c46-474b-9b26-6ca4123d0890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_dfa1cabf-9db1-4fb6-b5f4-810d991a3856" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4e76b7dc-9e83-49f6-8388-7691f6ad9f2e" xlink:to="loc_srt_MaximumMember_dfa1cabf-9db1-4fb6-b5f4-810d991a3856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a3d54b8d-ebd6-4b54-9f03-a46b8d406799" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5715f7b1-e288-40ec-a4b8-156f364f9d63" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a3d54b8d-ebd6-4b54-9f03-a46b8d406799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f635bd40-1e4d-442e-85ba-1c61a6b61c95" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a3d54b8d-ebd6-4b54-9f03-a46b8d406799" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f635bd40-1e4d-442e-85ba-1c61a6b61c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_76c0ba7b-13ed-42ee-995f-e19a8fbc6284" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a3d54b8d-ebd6-4b54-9f03-a46b8d406799" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_76c0ba7b-13ed-42ee-995f-e19a8fbc6284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_240e6929-49c0-4ee8-97e6-af1bf03f8478" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a3d54b8d-ebd6-4b54-9f03-a46b8d406799" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_240e6929-49c0-4ee8-97e6-af1bf03f8478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_913e2584-34fc-487d-8382-91031fb06695" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a3d54b8d-ebd6-4b54-9f03-a46b8d406799" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_913e2584-34fc-487d-8382-91031fb06695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="sgmo-20191231.xsd#EmployeeBenefitPlan"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/EmployeeBenefitPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_697b5352-778f-4037-93f2-332f59684dd4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_0deafde1-8f5f-472e-8381-cc62e6326977" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_697b5352-778f-4037-93f2-332f59684dd4" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_0deafde1-8f5f-472e-8381-cc62e6326977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/EmployeeBenefitPlanAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#EmployeeBenefitPlanAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/EmployeeBenefitPlanAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f7a9f2b3-0bdf-48c7-b4a7-1d9ce7c35a2f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_9392642e-dcfb-4e9c-ab8c-bd3d89fa8afd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f7a9f2b3-0bdf-48c7-b4a7-1d9ce7c35a2f" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_9392642e-dcfb-4e9c-ab8c-bd3d89fa8afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_2731200f-49b8-4847-b2d7-b1e4d483c605" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f7a9f2b3-0bdf-48c7-b4a7-1d9ce7c35a2f" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_2731200f-49b8-4847-b2d7-b1e4d483c605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_5296bb72-b7b6-43e6-94b3-93ee93843876" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f7a9f2b3-0bdf-48c7-b4a7-1d9ce7c35a2f" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_5296bb72-b7b6-43e6-94b3-93ee93843876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_c764f454-7d0d-477e-89f6-de2c77e0b7f1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f7a9f2b3-0bdf-48c7-b4a7-1d9ce7c35a2f" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_c764f454-7d0d-477e-89f6-de2c77e0b7f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxes" xlink:type="simple" xlink:href="sgmo-20191231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_83723cce-ea66-4627-9a2f-5b9d1bf697a7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_741eead7-694f-4426-824c-18fc0e3f31fd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_83723cce-ea66-4627-9a2f-5b9d1bf697a7" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_741eead7-694f-4426-824c-18fc0e3f31fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="sgmo-20191231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_656c8765-bbfd-407a-ad71-d171c8a094a9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_05fe0dd9-9a6b-4944-87d4-fb702a5ef975" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_656c8765-bbfd-407a-ad71-d171c8a094a9" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_05fe0dd9-9a6b-4944-87d4-fb702a5ef975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_9dfde76e-47bd-401e-9e55-03d9ee32e778" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_656c8765-bbfd-407a-ad71-d171c8a094a9" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_9dfde76e-47bd-401e-9e55-03d9ee32e778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_e72c5867-da37-4d21-a8fc-a86d9a557f39" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_656c8765-bbfd-407a-ad71-d171c8a094a9" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_e72c5867-da37-4d21-a8fc-a86d9a557f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_9b12a965-4101-4da4-b413-276e6253c794" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_656c8765-bbfd-407a-ad71-d171c8a094a9" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_9b12a965-4101-4da4-b413-276e6253c794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock_e3ff3ed7-2746-4f1e-b879-df3174aa89ab" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_656c8765-bbfd-407a-ad71-d171c8a094a9" xlink:to="loc_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock_e3ff3ed7-2746-4f1e-b879-df3174aa89ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#IncomeTaxesSummaryofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5105a4bc-d552-4229-aeea-e8f478910d20" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_62e5f02d-452c-450e-84a5-d042ea6cfe0c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5105a4bc-d552-4229-aeea-e8f478910d20" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_62e5f02d-452c-450e-84a5-d042ea6cfe0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_5d6c315a-aa80-45d3-87b3-f5d907c9dfe0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5105a4bc-d552-4229-aeea-e8f478910d20" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_5d6c315a-aa80-45d3-87b3-f5d907c9dfe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e4d137f9-05d2-45c9-95f5-417275790c3d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5105a4bc-d552-4229-aeea-e8f478910d20" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e4d137f9-05d2-45c9-95f5-417275790c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#IncomeTaxesSummaryofBenefitforIncomeTaxesDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c09fb311-7b18-4bbd-88a0-190af74efb79" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_96641839-4e62-48d1-aca1-e161667af44f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c09fb311-7b18-4bbd-88a0-190af74efb79" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_96641839-4e62-48d1-aca1-e161667af44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_bc4b9467-50ad-4d3b-9a95-8739ea180c4b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_96641839-4e62-48d1-aca1-e161667af44f" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_bc4b9467-50ad-4d3b-9a95-8739ea180c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_d2d514b3-16c0-44ea-a587-e1706018f6aa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_bc4b9467-50ad-4d3b-9a95-8739ea180c4b" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_d2d514b3-16c0-44ea-a587-e1706018f6aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1537d1b8-77de-423c-b11f-baa34aa76206" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_bc4b9467-50ad-4d3b-9a95-8739ea180c4b" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1537d1b8-77de-423c-b11f-baa34aa76206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_cfc6a2e2-f5b4-4070-bfef-cfbb861e43e3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_bc4b9467-50ad-4d3b-9a95-8739ea180c4b" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_cfc6a2e2-f5b4-4070-bfef-cfbb861e43e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_1c653b26-8b41-4b0c-b254-7e99fffc5ad0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_bc4b9467-50ad-4d3b-9a95-8739ea180c4b" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_1c653b26-8b41-4b0c-b254-7e99fffc5ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_f67d96ee-17bf-4acb-bf30-62deaddbb5e2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_96641839-4e62-48d1-aca1-e161667af44f" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_f67d96ee-17bf-4acb-bf30-62deaddbb5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_b1d7afb7-f6ec-456e-8bcd-32f38e95d5d1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_f67d96ee-17bf-4acb-bf30-62deaddbb5e2" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_b1d7afb7-f6ec-456e-8bcd-32f38e95d5d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_72c5ceb4-dd97-4dd3-a06f-7f12c68ca404" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_f67d96ee-17bf-4acb-bf30-62deaddbb5e2" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_72c5ceb4-dd97-4dd3-a06f-7f12c68ca404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_9bb3d872-320d-4295-aa1a-e311acc007b5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_f67d96ee-17bf-4acb-bf30-62deaddbb5e2" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_9bb3d872-320d-4295-aa1a-e311acc007b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_9772fd8f-2ff9-40cd-9a60-ec291b56e2df" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_f67d96ee-17bf-4acb-bf30-62deaddbb5e2" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_9772fd8f-2ff9-40cd-9a60-ec291b56e2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f2d27604-c8f4-4776-8597-0c76d7ac9236" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_96641839-4e62-48d1-aca1-e161667af44f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f2d27604-c8f4-4776-8597-0c76d7ac9236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#IncomeTaxesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ebe65015-b58d-4184-9540-d4e6faead36b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncomeTaxesTable_d34d1073-468f-494a-9325-dd791a13981b" xlink:href="sgmo-20191231.xsd#sgmo_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ebe65015-b58d-4184-9540-d4e6faead36b" xlink:to="loc_sgmo_IncomeTaxesTable_d34d1073-468f-494a-9325-dd791a13981b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_6708ec01-0dfa-45a4-a403-8eb50e635d04" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_IncomeTaxesTable_d34d1073-468f-494a-9325-dd791a13981b" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_6708ec01-0dfa-45a4-a403-8eb50e635d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_cfc78d8e-1951-4762-ba7b-e663ff216f5e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6708ec01-0dfa-45a4-a403-8eb50e635d04" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_cfc78d8e-1951-4762-ba7b-e663ff216f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinistryOfTheEconomyFinanceAndIndustryFranceMember_ab5d3bdc-89f1-4e8f-855e-06df150942f2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinistryOfTheEconomyFinanceAndIndustryFranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_cfc78d8e-1951-4762-ba7b-e663ff216f5e" xlink:to="loc_us-gaap_MinistryOfTheEconomyFinanceAndIndustryFranceMember_ab5d3bdc-89f1-4e8f-855e-06df150942f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncomeTaxesLineItems_700d01b2-3ce1-4ad5-b0d7-911b17e5989a" xlink:href="sgmo-20191231.xsd#sgmo_IncomeTaxesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_IncomeTaxesTable_d34d1073-468f-494a-9325-dd791a13981b" xlink:to="loc_sgmo_IncomeTaxesLineItems_700d01b2-3ce1-4ad5-b0d7-911b17e5989a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_7dce5ee9-d7bd-4e16-9d1a-d101a4c6d7b6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_IncomeTaxesLineItems_700d01b2-3ce1-4ad5-b0d7-911b17e5989a" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_7dce5ee9-d7bd-4e16-9d1a-d101a4c6d7b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_cd8b6132-8203-4665-85ea-c4bb1c6ebd1e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_IncomeTaxesLineItems_700d01b2-3ce1-4ad5-b0d7-911b17e5989a" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_cd8b6132-8203-4665-85ea-c4bb1c6ebd1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_14cb1e88-625a-4699-9ea8-7201c0d0ba3d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_IncomeTaxesLineItems_700d01b2-3ce1-4ad5-b0d7-911b17e5989a" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_14cb1e88-625a-4699-9ea8-7201c0d0ba3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_dbe7bfc4-441e-4f3f-8c08-f9ffe363cede" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_IncomeTaxesLineItems_700d01b2-3ce1-4ad5-b0d7-911b17e5989a" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_dbe7bfc4-441e-4f3f-8c08-f9ffe363cede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal_afbab5bd-86ce-4af0-8feb-9793e2e1d23f" xlink:href="sgmo-20191231.xsd#sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_IncomeTaxesLineItems_700d01b2-3ce1-4ad5-b0d7-911b17e5989a" xlink:to="loc_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal_afbab5bd-86ce-4af0-8feb-9793e2e1d23f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal_2b8a5441-074a-4eba-a2ca-0a10a641d96c" xlink:href="sgmo-20191231.xsd#sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_IncomeTaxesLineItems_700d01b2-3ce1-4ad5-b0d7-911b17e5989a" xlink:to="loc_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal_2b8a5441-074a-4eba-a2ca-0a10a641d96c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_8e077a75-7930-4eff-b01f-9f5ebfec70b8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_IncomeTaxesLineItems_700d01b2-3ce1-4ad5-b0d7-911b17e5989a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_8e077a75-7930-4eff-b01f-9f5ebfec70b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f01da565-521b-41fb-8ce4-d7b50361b6eb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_73f62f9d-df42-45f4-9010-275af8e48808" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f01da565-521b-41fb-8ce4-d7b50361b6eb" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_73f62f9d-df42-45f4-9010-275af8e48808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_97314487-5963-4dd0-a6e7-cf9cb8f16321" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f01da565-521b-41fb-8ce4-d7b50361b6eb" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_97314487-5963-4dd0-a6e7-cf9cb8f16321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_aee466f0-3546-4d3d-9cb1-4754cc6b0509" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f01da565-521b-41fb-8ce4-d7b50361b6eb" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_aee466f0-3546-4d3d-9cb1-4754cc6b0509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_36b75e93-fc05-44d6-8c62-19322bac9d10" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f01da565-521b-41fb-8ce4-d7b50361b6eb" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_36b75e93-fc05-44d6-8c62-19322bac9d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation_a75da86c-5ed3-4c5c-aa1c-bdeedf94ebd7" xlink:href="sgmo-20191231.xsd#sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f01da565-521b-41fb-8ce4-d7b50361b6eb" xlink:to="loc_sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation_a75da86c-5ed3-4c5c-aa1c-bdeedf94ebd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_f307aa31-5317-4b59-8cd3-aecc75a3a1be" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f01da565-521b-41fb-8ce4-d7b50361b6eb" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_f307aa31-5317-4b59-8cd3-aecc75a3a1be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_7236308f-54f6-45cd-8954-80d1ed08f0f5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f01da565-521b-41fb-8ce4-d7b50361b6eb" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_7236308f-54f6-45cd-8954-80d1ed08f0f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_513b53db-2128-489b-9491-f731fa285998" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f01da565-521b-41fb-8ce4-d7b50361b6eb" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_513b53db-2128-489b-9491-f731fa285998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_fb6fe864-297c-4bab-9d27-317115158854" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f01da565-521b-41fb-8ce4-d7b50361b6eb" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_fb6fe864-297c-4bab-9d27-317115158854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_cdd66446-b6ff-4d3b-8be8-bd1e204119bf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_7f0eea56-7401-48c9-a8a2-6521cd52e44f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cdd66446-b6ff-4d3b-8be8-bd1e204119bf" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_7f0eea56-7401-48c9-a8a2-6521cd52e44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_fb618791-a04b-4501-b80f-12f4eab5c8bc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_8328d73e-12b8-4043-aae0-24c331f53cef" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fb618791-a04b-4501-b80f-12f4eab5c8bc" xlink:to="loc_us-gaap_AssetsAbstract_8328d73e-12b8-4043-aae0-24c331f53cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_2c6fbe60-f9fb-47bc-8889-04b6ebdd4cfd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8328d73e-12b8-4043-aae0-24c331f53cef" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_2c6fbe60-f9fb-47bc-8889-04b6ebdd4cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_5feeae38-8f01-458f-80bb-8cd0fc26644b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_2c6fbe60-f9fb-47bc-8889-04b6ebdd4cfd" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_5feeae38-8f01-458f-80bb-8cd0fc26644b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_e5dfa147-aac0-4be5-a0bd-2b2f99f8912d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_2c6fbe60-f9fb-47bc-8889-04b6ebdd4cfd" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_e5dfa147-aac0-4be5-a0bd-2b2f99f8912d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1e7a079d-989e-494f-8023-f17c33b45b72" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_2c6fbe60-f9fb-47bc-8889-04b6ebdd4cfd" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1e7a079d-989e-494f-8023-f17c33b45b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_86edae7e-f04a-4cb0-b5ef-04f317c3a5cd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_2c6fbe60-f9fb-47bc-8889-04b6ebdd4cfd" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_86edae7e-f04a-4cb0-b5ef-04f317c3a5cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_6f2e4902-8650-4b1d-976b-fa0f1715acb2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_2c6fbe60-f9fb-47bc-8889-04b6ebdd4cfd" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_6f2e4902-8650-4b1d-976b-fa0f1715acb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DeferredTaxAssetsLeaseLiability_50478791-0764-49c4-ab57-0bd3514e5036" xlink:href="sgmo-20191231.xsd#sgmo_DeferredTaxAssetsLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_2c6fbe60-f9fb-47bc-8889-04b6ebdd4cfd" xlink:to="loc_sgmo_DeferredTaxAssetsLeaseLiability_50478791-0764-49c4-ab57-0bd3514e5036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DeferredTaxAssetsBuildToSuitLeaseLiability_24bd8a38-6a37-4b4c-85cb-ff5c73fef2ad" xlink:href="sgmo-20191231.xsd#sgmo_DeferredTaxAssetsBuildToSuitLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_2c6fbe60-f9fb-47bc-8889-04b6ebdd4cfd" xlink:to="loc_sgmo_DeferredTaxAssetsBuildToSuitLeaseLiability_24bd8a38-6a37-4b4c-85cb-ff5c73fef2ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_5675c8ea-0c48-4017-a0e0-4b545bc0de56" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_2c6fbe60-f9fb-47bc-8889-04b6ebdd4cfd" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_5675c8ea-0c48-4017-a0e0-4b545bc0de56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_08ac7ea8-a8c9-48f1-b041-cf03f7bb0600" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_2c6fbe60-f9fb-47bc-8889-04b6ebdd4cfd" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_08ac7ea8-a8c9-48f1-b041-cf03f7bb0600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_f08b794c-8827-4120-b07d-5be041024dbf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_2c6fbe60-f9fb-47bc-8889-04b6ebdd4cfd" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_f08b794c-8827-4120-b07d-5be041024dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_3e71f8c3-43f8-40c3-8374-94d2dbcdcea9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_2c6fbe60-f9fb-47bc-8889-04b6ebdd4cfd" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_3e71f8c3-43f8-40c3-8374-94d2dbcdcea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_80869161-5fd8-4ab2-85bd-1ddf1f7324ee" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_2c6fbe60-f9fb-47bc-8889-04b6ebdd4cfd" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_80869161-5fd8-4ab2-85bd-1ddf1f7324ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_2fd387a1-ef07-4083-94e5-61189ded2190" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fb618791-a04b-4501-b80f-12f4eab5c8bc" xlink:to="loc_us-gaap_LiabilitiesAbstract_2fd387a1-ef07-4083-94e5-61189ded2190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_90ed63b7-4f02-462c-8a8b-c936f16ae7ce" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_2fd387a1-ef07-4083-94e5-61189ded2190" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_90ed63b7-4f02-462c-8a8b-c936f16ae7ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_21af996c-4d1a-4bdf-9206-da1e53565f91" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_2fd387a1-ef07-4083-94e5-61189ded2190" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_21af996c-4d1a-4bdf-9206-da1e53565f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_fd7ea934-b76d-43f2-b0ab-14ec5e83e932" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_2fd387a1-ef07-4083-94e5-61189ded2190" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_fd7ea934-b76d-43f2-b0ab-14ec5e83e932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_ac6eac31-02b4-4a34-ae99-7d80ec534635" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_2fd387a1-ef07-4083-94e5-61189ded2190" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_ac6eac31-02b4-4a34-ae99-7d80ec534635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_a52adaaa-cf20-42af-89b4-1ddcf1265cc6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_2fd387a1-ef07-4083-94e5-61189ded2190" xlink:to="loc_us-gaap_DeferredTaxLiabilities_a52adaaa-cf20-42af-89b4-1ddcf1265cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesSummaryofActivityRelatedtoCompanysUnrecognizedTaxBenefitsDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#IncomeTaxesSummaryofActivityRelatedtoCompanysUnrecognizedTaxBenefitsDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/IncomeTaxesSummaryofActivityRelatedtoCompanysUnrecognizedTaxBenefitsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_674e4eea-b8bf-44ce-a765-0a8c9ad1225f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6519ee4a-caee-4eaf-b3fb-3fbec19a5fcf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_674e4eea-b8bf-44ce-a765-0a8c9ad1225f" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6519ee4a-caee-4eaf-b3fb-3fbec19a5fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_bd7e2266-c50d-4fb3-9789-c965254cbf43" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6519ee4a-caee-4eaf-b3fb-3fbec19a5fcf" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_bd7e2266-c50d-4fb3-9789-c965254cbf43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_1940a9bb-426d-4b20-915e-c507716ca7bf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6519ee4a-caee-4eaf-b3fb-3fbec19a5fcf" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_1940a9bb-426d-4b20-915e-c507716ca7bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_a55ce079-1fd1-431e-8ae0-ff1a293dffc7" xlink:href="sgmo-20191231.xsd#sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6519ee4a-caee-4eaf-b3fb-3fbec19a5fcf" xlink:to="loc_sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_a55ce079-1fd1-431e-8ae0-ff1a293dffc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_533fbe61-8928-4453-83e6-6127fd38dd96" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6519ee4a-caee-4eaf-b3fb-3fbec19a5fcf" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_533fbe61-8928-4453-83e6-6127fd38dd96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_c3927990-29f3-4dc1-92bf-4280319cb19d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6519ee4a-caee-4eaf-b3fb-3fbec19a5fcf" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_c3927990-29f3-4dc1-92bf-4280319cb19d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/RelatedPartyDisclosures" xlink:type="simple" xlink:href="sgmo-20191231.xsd#RelatedPartyDisclosures"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/RelatedPartyDisclosures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_4521c7c5-f116-43a7-8c26-d76712d9756e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_63b90221-4b8a-4682-a8b8-74a608e22ae1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_4521c7c5-f116-43a7-8c26-d76712d9756e" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_63b90221-4b8a-4682-a8b8-74a608e22ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/RelatedPartyDisclosuresDetails" xlink:type="simple" xlink:href="sgmo-20191231.xsd#RelatedPartyDisclosuresDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/RelatedPartyDisclosuresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0158250e-fe02-4daa-85e1-ef4eb9ee55ff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e8338ebe-c149-4b3e-9534-fad686d15d83" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0158250e-fe02-4daa-85e1-ef4eb9ee55ff" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e8338ebe-c149-4b3e-9534-fad686d15d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_db7c30eb-9210-45a0-9852-1f64e5486794" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e8338ebe-c149-4b3e-9534-fad686d15d83" xlink:to="loc_srt_CounterpartyNameAxis_db7c30eb-9210-45a0-9852-1f64e5486794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcc41059-937d-48f3-895b-a492be5c0998" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_db7c30eb-9210-45a0-9852-1f64e5486794" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcc41059-937d-48f3-895b-a492be5c0998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FormerExecutiveOfSangamoFranceMember_e9ba06f7-a54b-471c-9b7a-ccbcec441f45" xlink:href="sgmo-20191231.xsd#sgmo_FormerExecutiveOfSangamoFranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcc41059-937d-48f3-895b-a492be5c0998" xlink:to="loc_sgmo_FormerExecutiveOfSangamoFranceMember_e9ba06f7-a54b-471c-9b7a-ccbcec441f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_cdc09077-f3ae-44ef-9321-2c6eb65292a4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e8338ebe-c149-4b3e-9534-fad686d15d83" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_cdc09077-f3ae-44ef-9321-2c6eb65292a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b353b66c-fcec-4860-a6fd-1eeb84889646" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_cdc09077-f3ae-44ef-9321-2c6eb65292a4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b353b66c-fcec-4860-a6fd-1eeb84889646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_faf49be3-f061-4229-b005-388d18590287" xlink:href="sgmo-20191231.xsd#sgmo_SangamoFranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b353b66c-fcec-4860-a6fd-1eeb84889646" xlink:to="loc_sgmo_SangamoFranceMember_faf49be3-f061-4229-b005-388d18590287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ead44829-b993-4dde-ac3e-bc5ca63b112c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e8338ebe-c149-4b3e-9534-fad686d15d83" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ead44829-b993-4dde-ac3e-bc5ca63b112c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2ec86977-0746-41f4-a019-0c882c7f17d4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ead44829-b993-4dde-ac3e-bc5ca63b112c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2ec86977-0746-41f4-a019-0c882c7f17d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_5f1b2d58-b3be-4b5b-b324-fedaadcabc58" xlink:href="sgmo-20191231.xsd#sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2ec86977-0746-41f4-a019-0c882c7f17d4" xlink:to="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_5f1b2d58-b3be-4b5b-b324-fedaadcabc58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0b35bad4-c3c9-4e26-9289-56c6854925a6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e8338ebe-c149-4b3e-9534-fad686d15d83" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_0b35bad4-c3c9-4e26-9289-56c6854925a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_8e67ee35-824b-4c36-b3b9-17401e6d7888" xlink:href="sgmo-20191231.xsd#sgmo_BusinessAcquisitionNumberOfSharesAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0b35bad4-c3c9-4e26-9289-56c6854925a6" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_8e67ee35-824b-4c36-b3b9-17401e6d7888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_ce81ef93-afdf-4069-9c45-2b872fa8c97f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0b35bad4-c3c9-4e26-9289-56c6854925a6" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_ce81ef93-afdf-4069-9c45-2b872fa8c97f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/QuarterlyFinancialDataUnaudited" xlink:type="simple" xlink:href="sgmo-20191231.xsd#QuarterlyFinancialDataUnaudited"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/QuarterlyFinancialDataUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_790d6db1-23ca-4cd9-956f-14e49f90bf23" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_6d8d2528-860c-4f58-8eb4-dd986db64560" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_790d6db1-23ca-4cd9-956f-14e49f90bf23" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_6d8d2528-860c-4f58-8eb4-dd986db64560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="simple" xlink:href="sgmo-20191231.xsd#QuarterlyFinancialDataUnauditedTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_9ac253e2-ca36-4e9a-a204-b0d41df6c436" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_b197f329-1032-4881-bebb-fbd7a4559b79" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_9ac253e2-ca36-4e9a-a204-b0d41df6c436" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_b197f329-1032-4881-bebb-fbd7a4559b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedSummaryofQuarterlyFinancialDataDetail" xlink:type="simple" xlink:href="sgmo-20191231.xsd#QuarterlyFinancialDataUnauditedSummaryofQuarterlyFinancialDataDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedSummaryofQuarterlyFinancialDataDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_bddb2e26-b421-4d9d-bc2d-cc48ad4ebcc6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5c8bcf56-a145-4e3d-af73-12f34942cd6b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_bddb2e26-b421-4d9d-bc2d-cc48ad4ebcc6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5c8bcf56-a145-4e3d-af73-12f34942cd6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_56184163-09f1-4c3a-b50b-1084f9917133" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_bddb2e26-b421-4d9d-bc2d-cc48ad4ebcc6" xlink:to="loc_us-gaap_OperatingExpenses_56184163-09f1-4c3a-b50b-1084f9917133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_572064e3-fe86-4393-b925-2a9c2d9c52fb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_bddb2e26-b421-4d9d-bc2d-cc48ad4ebcc6" xlink:to="loc_us-gaap_ProfitLoss_572064e3-fe86-4393-b925-2a9c2d9c52fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4df070b4-baf7-4257-bdb9-f725244925fa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_bddb2e26-b421-4d9d-bc2d-cc48ad4ebcc6" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4df070b4-baf7-4257-bdb9-f725244925fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d16bc4f3-e27b-4eeb-95d7-6649e8acec02" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_bddb2e26-b421-4d9d-bc2d-cc48ad4ebcc6" xlink:to="loc_us-gaap_NetIncomeLoss_d16bc4f3-e27b-4eeb-95d7-6649e8acec02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_8d027a70-d3c1-461d-9381-81d5d32c3071" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_bddb2e26-b421-4d9d-bc2d-cc48ad4ebcc6" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_8d027a70-d3c1-461d-9381-81d5d32c3071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/SubsequentEvents" xlink:type="simple" xlink:href="sgmo-20191231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_34a79183-8ef4-48c5-b119-76670b8872d3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_9d7da2e5-ec43-4a6a-88fa-aec32fae46d0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_34a79183-8ef4-48c5-b119-76670b8872d3" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_9d7da2e5-ec43-4a6a-88fa-aec32fae46d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="sgmo-20191231.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_82f54d2d-3dd3-4482-9f63-08bb2adb4219" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_f5527470-e514-4ba6-b76e-fda8be4ff440" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_82f54d2d-3dd3-4482-9f63-08bb2adb4219" xlink:to="loc_us-gaap_SubsequentEventTable_f5527470-e514-4ba6-b76e-fda8be4ff440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_fa55564b-64e3-484f-b41f-bfed62c01d9e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f5527470-e514-4ba6-b76e-fda8be4ff440" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_fa55564b-64e3-484f-b41f-bfed62c01d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e2af638d-898e-4fe2-9d21-10ac204a3ef6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fa55564b-64e3-484f-b41f-bfed62c01d9e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e2af638d-898e-4fe2-9d21-10ac204a3ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_686f9cf4-7a35-40b8-a5d2-cfd594294459" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e2af638d-898e-4fe2-9d21-10ac204a3ef6" xlink:to="loc_us-gaap_SubsequentEventMember_686f9cf4-7a35-40b8-a5d2-cfd594294459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9ae7eeec-1209-4390-a41e-e35904dd80f0" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f5527470-e514-4ba6-b76e-fda8be4ff440" xlink:to="loc_srt_CounterpartyNameAxis_9ae7eeec-1209-4390-a41e-e35904dd80f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0a5aa716-12cb-4608-8699-8e2c0434c546" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_9ae7eeec-1209-4390-a41e-e35904dd80f0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0a5aa716-12cb-4608-8699-8e2c0434c546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_1c872e08-b85b-45db-a1b0-f4b1275661ba" xlink:href="sgmo-20191231.xsd#sgmo_BiogenMAIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0a5aa716-12cb-4608-8699-8e2c0434c546" xlink:to="loc_sgmo_BiogenMAIncMember_1c872e08-b85b-45db-a1b0-f4b1275661ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2afc63fb-cbb0-4e23-a51c-d6ee0612aae6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f5527470-e514-4ba6-b76e-fda8be4ff440" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2afc63fb-cbb0-4e23-a51c-d6ee0612aae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f32df3a4-63ff-44f4-960f-983e9e0bc3b7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2afc63fb-cbb0-4e23-a51c-d6ee0612aae6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f32df3a4-63ff-44f4-960f-983e9e0bc3b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementMember_cb70819d-3c35-4398-949f-2c4aaef13ca4" xlink:href="sgmo-20191231.xsd#sgmo_CollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f32df3a4-63ff-44f4-960f-983e9e0bc3b7" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementMember_cb70819d-3c35-4398-949f-2c4aaef13ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockPurchaseAgreementMember_c8703daf-76c5-4ca9-87d0-06547446f1a4" xlink:href="sgmo-20191231.xsd#sgmo_StockPurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f32df3a4-63ff-44f4-960f-983e9e0bc3b7" xlink:to="loc_sgmo_StockPurchaseAgreementMember_c8703daf-76c5-4ca9-87d0-06547446f1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a9e5a05c-fc5d-4530-8717-d4a666761827" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f5527470-e514-4ba6-b76e-fda8be4ff440" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a9e5a05c-fc5d-4530-8717-d4a666761827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_789e7eae-1ca4-4fca-b5a7-ce8d4930ae25" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a9e5a05c-fc5d-4530-8717-d4a666761827" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_789e7eae-1ca4-4fca-b5a7-ce8d4930ae25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_5fcbf5eb-2c64-40f1-8d06-3cb3e16e5abe" xlink:href="sgmo-20191231.xsd#sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_789e7eae-1ca4-4fca-b5a7-ce8d4930ae25" xlink:to="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_5fcbf5eb-2c64-40f1-8d06-3cb3e16e5abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneAxis_3bc0cffc-cb1d-4c85-9244-6ce95f6e8323" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeAgreementMilestoneAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f5527470-e514-4ba6-b76e-fda8be4ff440" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneAxis_3bc0cffc-cb1d-4c85-9244-6ce95f6e8323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneDomain_8d1ea13b-fa44-4d0c-bc5b-96af8085a0f2" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeAgreementMilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneAxis_3bc0cffc-cb1d-4c85-9244-6ce95f6e8323" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneDomain_8d1ea13b-fa44-4d0c-bc5b-96af8085a0f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PreApprovalMilestoneMember_22e7d5c8-4374-45c6-a1a1-d21b9669e23c" xlink:href="sgmo-20191231.xsd#sgmo_PreApprovalMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_8d1ea13b-fa44-4d0c-bc5b-96af8085a0f2" xlink:to="loc_sgmo_PreApprovalMilestoneMember_22e7d5c8-4374-45c6-a1a1-d21b9669e23c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SalesBasedMilestoneMember_68fba673-9708-4801-8986-af0f4338dd3d" xlink:href="sgmo-20191231.xsd#sgmo_SalesBasedMilestoneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_8d1ea13b-fa44-4d0c-bc5b-96af8085a0f2" xlink:to="loc_sgmo_SalesBasedMilestoneMember_68fba673-9708-4801-8986-af0f4338dd3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementScenarioAxis_86e689f9-3648-47f0-9914-50ee333c1b8c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f5527470-e514-4ba6-b76e-fda8be4ff440" xlink:to="loc_us-gaap_StatementScenarioAxis_86e689f9-3648-47f0-9914-50ee333c1b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_ad24cf3e-8347-48ff-8a7e-5c3dccb6fb07" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_86e689f9-3648-47f0-9914-50ee333c1b8c" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_ad24cf3e-8347-48ff-8a7e-5c3dccb6fb07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScenarioForecastMember_58319062-2a2b-46de-a6dc-480cd4afeac3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_ad24cf3e-8347-48ff-8a7e-5c3dccb6fb07" xlink:to="loc_us-gaap_ScenarioForecastMember_58319062-2a2b-46de-a6dc-480cd4afeac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_c8933d18-3cf2-4584-80fc-d6be28f552b9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f5527470-e514-4ba6-b76e-fda8be4ff440" xlink:to="loc_us-gaap_SubsequentEventLineItems_c8933d18-3cf2-4584-80fc-d6be28f552b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfProductTargets_264bccc5-ab2a-4829-acd6-26add1816546" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeArrangementNumberOfProductTargets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c8933d18-3cf2-4584-80fc-d6be28f552b9" xlink:to="loc_sgmo_CollaborativeArrangementNumberOfProductTargets_264bccc5-ab2a-4829-acd6-26add1816546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected_5074ea70-1221-4b56-81e1-071f73fb5e02" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeArrangementNumberOfProductTargetsSelected"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c8933d18-3cf2-4584-80fc-d6be28f552b9" xlink:to="loc_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected_5074ea70-1221-4b56-81e1-071f73fb5e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_1c0114ce-1cee-43ef-949f-f33a3aaae88f" xlink:href="sgmo-20191231.xsd#sgmo_CollaborationAgreementNumberOfAdditionalProductTargets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c8933d18-3cf2-4584-80fc-d6be28f552b9" xlink:to="loc_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_1c0114ce-1cee-43ef-949f-f33a3aaae88f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementTargetSelectionPeriod_941fb392-97b9-4cae-8125-e65662220896" xlink:href="sgmo-20191231.xsd#sgmo_CollaborationAgreementTargetSelectionPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c8933d18-3cf2-4584-80fc-d6be28f552b9" xlink:to="loc_sgmo_CollaborationAgreementTargetSelectionPeriod_941fb392-97b9-4cae-8125-e65662220896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_9f678694-b179-470b-b9db-6999f433b97a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c8933d18-3cf2-4584-80fc-d6be28f552b9" xlink:to="loc_us-gaap_ProceedsFromCollaborators_9f678694-b179-470b-b9db-6999f433b97a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable_69429449-234e-43a2-b168-9c972ab56e7a" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c8933d18-3cf2-4584-80fc-d6be28f552b9" xlink:to="loc_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable_69429449-234e-43a2-b168-9c972ab56e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_384d1c7c-c8e0-4d17-9e32-bb3e44ddb659" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c8933d18-3cf2-4584-80fc-d6be28f552b9" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_384d1c7c-c8e0-4d17-9e32-bb3e44ddb659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_c814b23a-4cbb-4715-87b0-45fb680f98e9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c8933d18-3cf2-4584-80fc-d6be28f552b9" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_c814b23a-4cbb-4715-87b0-45fb680f98e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9b93b7db-a8f8-4a6a-969a-68601f387991" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c8933d18-3cf2-4584-80fc-d6be28f552b9" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9b93b7db-a8f8-4a6a-969a-68601f387991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementStandstillRestrictionPeriod_4cc92e21-003b-40e9-a07d-964d5cc2f82e" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeArrangementStandstillRestrictionPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c8933d18-3cf2-4584-80fc-d6be28f552b9" xlink:to="loc_sgmo_CollaborativeArrangementStandstillRestrictionPeriod_4cc92e21-003b-40e9-a07d-964d5cc2f82e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage_03075a61-40fc-4d9f-b8fb-b2b7347a195f" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c8933d18-3cf2-4584-80fc-d6be28f552b9" xlink:to="loc_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage_03075a61-40fc-4d9f-b8fb-b2b7347a195f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld_e5abf5d7-21d6-4676-ae66-37d15a82fb87" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c8933d18-3cf2-4584-80fc-d6be28f552b9" xlink:to="loc_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld_e5abf5d7-21d6-4676-ae66-37d15a82fb87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod_5dfdf3a7-a7a3-4a9b-ab06-748d9a351335" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c8933d18-3cf2-4584-80fc-d6be28f552b9" xlink:to="loc_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod_5dfdf3a7-a7a3-4a9b-ab06-748d9a351335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage_3c099248-ab28-40ae-9bae-63106c486d50" xlink:href="sgmo-20191231.xsd#sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c8933d18-3cf2-4584-80fc-d6be28f552b9" xlink:to="loc_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage_3c099248-ab28-40ae-9bae-63106c486d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>picture11.jpg
<TEXT>
begin 644 picture11.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !3 )4# 2(  A$! Q$!_\0
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M:^U_(^%S7B#$48_\)U)3TYKMK9NUU&]VK]=#N]<_:D\MG72-%WJ.DEW)C/\
MP%>GYUQ5_P#M/>,&9F@73[=>R^06_F:T?%FNZ=\+O%ND:#;6T<FGZ>J2:DRQ
M(TMV[#)#%ATZ<>]>1?$/Q!IVJ^(=3O\ 3+0:?8SR;HK;@;1CT' R><#UKZW
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-HH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>sgmo-20191231_g1.jpg
<TEXT>
begin 644 sgmo-20191231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#B17AI9@  34T *@    @ ! $[  (
M   (   (2H=I  0    !   (4IR=  $    0   0RNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %=D97-K,C,
M  60 P "    %   $*"0!  "    %   $+22D0 "     S@T  "2D@ "
M S@T  #J'  '   (#   ")0     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M[YA K GCCDGIBN'N?&7CU/!&I^,4\4_NM'UI[1+#[*F)T\T#YV_X$ ,=@>]
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MXGPA_P G!>.3_P!.MI_Z"*I^(;"QU/\ :3T>WU&T@NX3HDA,<\8=3\S8X/%
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M:ZRB@##T+PII?AR\U*XTQ)%DU.Y-U<;W+9D/IZ5N444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 '
MI6/H&OQZ\-0\J!XOL-[)9MN(^9D )(]N:V*XOX<_<\3?]A^Y_DE ':4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117'>(/
M'$WAVY(N_#VHR6S3+"ES$T1$C,<#:N_<?RH [&BL:UUF-S=?;$%DD$WEJ\TJ
MD/QG/!X^AJW%JMC+8M>17D+VJC+3AP5&.O/2@"]156#4+:ZLS=6D\=Q#@D/$
MX93CW%<QHWC6;7+62[M- OX[,)(T=S*\863:2/[V1DCN* .QHK)CUZR2Q@FO
M[B&R:1%8QRS+E<]L@X/U%3W6L:=8*C7M];VZR?ZLRRA=P]LGF@"_16?)K.FP
M^29KZW3S_P#4EI5'F?3GFGS:G96]PEO+=PQRN0%C:0!F)Z#'O0!=HKF_$7BO
M^P]1L;"#2[O4KJ]#M'%;;> HR<EB!6==?$K2;/PO>:Q/;7JM93""ZLFB GB<
M]BN?Z\T =K17.V_B[3[O4-(MK4/*-4@>>"4#Y0JXR#[\]*98>--/U'QE>^'8
M4F6XLT!\QE^27^\%/<CO0!TM%8WB;7HO#6B2:E/!-.J.J"*$ LS,< #/N:RK
M3QNEY#J"'2+NVU"P"-+97!16VOC#!MQ7'XT ==16:^L6$#(EQ>6\,KX7RWE4
M-N(Z=>M5O$/B*R\/Z;<7,\L1FBA:5+=I0K28';- &W16%IVOB[DS-;_9H/LT
M<_G22J1\_P##UR,>XK0M]5L+I)C;7D$PA.)"D@;9]?2@"[16?::SIVH,RZ?>
MP7+*,LL4BL0/H#7-:Q\1+?2-8O[632-0G@TP(UY>0*C1PA@""1NW'KS@4 =K
M16;'K6G22PQK>P^;. 8T+@,V1D8'7IS3H]9TR9YHXK^W=[<$S!)03'CUYXH
MT**P]*\6:+K.CG5+&_A:U7[TA8#9VY]*DGUN/%C)IZI>PW<WE^;%,F%&#SR>
M>G0<T ;%%9Z:QITMTMK%>V[3MDB(2#<<>@S5/Q)K9T.VM6BB\^>\NX[:&+.,
MENI_  G\* -RBN.U3QS/I&IP6UYX=U+R[FZ%K#.C1E9&)X8#?NQC)/%2Z=XR
M?5-=NM/LM#OY8+6[>UFO@8Q&KKU/W]V/PH ZRBN'L/B1:7M];I+I>H6EG=7;
MV=O?2JIBDE4D8X8D9VG&1VK<\.:[_;D%UYL/D7-E=R6L\>[.UE/!'L1@_0T
M;E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M17@EM/M#VR;B20N05.!^-?0/:L35?">B:U=K<ZGIL<\P79YFXJ67T.",CV-
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M6*QGLQ2-58C_ ($"/PKLV&:K6-A:Z? L%E"D,2DL%0<9)))^N2?SH M4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7&?#K[
MGB;_ +#]S_)*[.N,^'7W/$W_ &'[G^24 =G1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M110 4444 %%%% !1110 457BOK6XFDB@N(I)(SAT5P2OU%6* "BBB@ HHHH
M**** "BBD+!5))  ')- "T57MKZUO%+6D\<P4X8QL&P:L4 %%%% !1110 44
M44 %%%([JB,SD*JC))/04 +15>VO;:\C#VD\<R9QNC8,,U8H **** "BBB@
MHHHH ***CFFCMX6EGD6.-1EF8X % $E%0P7,-S$LEO*DJ-T=&W _C4U !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &'XRT5/$7@O5=)<9
M^UVKQK_O$?*?SQ7SS^R]X>>3Q=K&KW49!T^$6RY[2.>?QPI_.OJ(C(P:Y+P/
MX,A\(KK(A"_\3'4I;SY>RMC _#G\Z .MHHHH *YW5?$ZVMTUAIMNU]?*,NBG
M:D(]7;H/YFK'B34Y-/TU4M K7MT_DVRL>-QZL?8#)/TKS:VLKGQ5KD_AW1;J
M6#2;,AM4U!3^\N)3U4'^\>OL* -^[\;W%M+MO-=T>S<=8E5I,?CQ5FQ\8WLZ
ME[>YTS5HU&66"3RY /8'C]:U-.^'_A?3(0D&BVKD+R\R"5V]R6S7 _$/P_X:
M36+#2M+LDL[^=O.N)K5C'Y< Z@@'!W'Y1]30!IMH5M\3-43Q+=6DMM:6<;0Z
M>X)CF=\_-)D'[H(POODUT'AC7KR#4#X=\1/NOXUW6UT1@7D8[^SCN/QK7\-W
M<#:;%;0*L<<*!4C48"J. *K>*O#JZQ8!H&,%W;L);:=!AHI!T/N.Q'<4 =(.
ME%<[X2\0/K>GLM[&L&I6;^3>0#^!QW'^RPP1714 %%)FE!S0 4444 %5;Z\A
MT^RENKJ18H8E+NS<  5:KS/QEKL>K^)H?#T;@V=F5FO\'B0]4B_J?:@"&+PA
M_P )+J%SXQE633=0N5 L7A)5XHU/RNX[ENX/:NK\+>(Y=2\[3-7C6'5[+ FC
M'25>TB>JG]*UM)O$O;)<8R!@@#@"L'Q9H,\GDZOHQ$>IV)WQ-T$B]XV]5(X^
MM '7CI163X?UN#Q!HT-]; INRLD;=8W'#*?<&M;- !11FB@ HHHH *SM9U6V
MT32IK^[;;'$,X'5CV4>Y-:)KRW5M?BU[QNL".'T[2).F>)KCU]PO\Z &6O@2
M]7[1XGMS_9GB&]D^T 1D^6@[1NO0Y'4^M=KX6\0C7;)UN(S;:A;-LN[9CS&_
M]0>H-:EC<I>6:L#GCG-<IXGTRZTJ^C\2:*A-U;KBY@7_ )>8>ZGW'4&@#MZ*
MH:7J-OJNFV]]:.'AG0.I']:OYH **3-+0 4444 %8GB76DT72R_E_:+JX;R;
M:W'6:0]!]/7VK8DD6.-G=@JJ"2QZ 5Y=I_B)/$'C*36RV;6V)M]/1N@&?GD^
MIZ?2@!;+P->^#;-=4\/-C5"QGN[<,1%=9.60+T&.Q%=YH&MV_B#2HKZU)7<=
MLD9X:)QU5AV(K0B=+NU5N"&%<3K$,O@W7SK]FA.GW)":E"G0=A,!ZCO[4 =[
M14,,R2PI)&P='&Y6'.0>]2YQ0 M%)FEH ****  ]*YWQ7K8TS34M[>%;N_OC
MY-K;'D2,1R6']T#DUNW$\=M;R33N$BC4L[L<!0.IKS'0==&N>*YO$$_^K;,%
MBC?\LX0?O>Q8\_3% "V'@R[^']A%=^&M\LT?SWUH&.R[!Y;:#]UAV]<8KT'1
M=8M->TN&_L9 \,HS[J>ZGW%6QLNK8'J&&17#WH;P1XC_ +4A4_V/J#A;Z-?N
MP2$X64#L#T;\#0!WU%,1@Z*RD%2,@@]13\T %%)FEH ***#TH #P/6N2\:7S
MW-HGARPABN+_ %5&C"2#<D47\<KCT';U.*Z'4]2MM(TRYO[YQ';V\9DD8GL!
MFO/O!FK/=ZI<Z[J.!>:BP(4_\L(1]R,?0'GW- #;?0I_AG!#<>'EGN-)A0+?
M6+,6)4=9H_\ :'=>XKT/3[Z#4;&*[M)4FAF4.CH<A@>]321I<0]N1D&N(LV/
M@?Q*EFPVZ%JDN(?[MI.>=OLK\X]#D4 =[11FC- !129I: "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH ***HZKJ4.DZ7<WUT=L4"%S[^WYT <'X
MYUT6+:MJ9Y72[<6T ]9I!EOQ"[1_P*N@^'GAX^'/!MG;SC-W,IN;MCU:5^3^
M60/PK@]1M9M:\1>'?#4XW3W5T=4U->RJ"'*G\E3\*]F'2@!'8)&S'HH)KY#;
MX@2:O\1=8OKAB/.N2D8/\,:DA5_+GZFOKQ@&4@]",&OC3XO> ;WP%XUFU&VC
M9M+OYVE@E X1B<E#Z8)_&@#W#PCXCPT;A\_CUKU2WN([JU653E6'-?)_@KQ*
M3'%E^*].F\=10VMOHG]HQV,NHG:]Q(V/L\7\;?7L/<T =MX6C34/%VM:Y:#;
M9%5LH6'2=HR2S^^"=H/L:J^.?'?_  CY-I9;C/E5)1-[%VZ1HO=B/P%;UM?:
M5I7A-IM&DBFL;&V)01.&&%&>W?\ QKPG0;U_%^I3ZWJ=_P#9KB1S<1;6QY1P
M -OO@ 9H [&&U^)&HQ_:X]+: -\P2[U'9(1] ,"KVF>.];T;4DTWQ+9SP3-]
MV*YQF0=_+D'RO]#@UN?#/Q+<ZYI][:7TOGS6$BH)CU=3G&??BND\0>'['Q+I
M,VGZE$'C=?E;^*-NS*>Q'M0!/IFIV^JV:W-F_F1L<9/!![@CL0>U:%>1?#W4
M+_1O$EUH&KREYX)_LTKM_P M>,Q2X]2,J?4XKUP?=H S]<U$:1H-]J##(M8'
MDP/89KY-\)>-Y;W4;BXO7S/<SM+(2?XF.?Y<#Z5]<W]E%J.G3V=P-T4\;1N/
M8C%?$7C+PEJ/PU\9/9W*O]E9RUM/CB1,\?B.AH ^FO"/B,*Z;F^4]:]$FN8!
M8O<3.HA5"S,3T KYA\'^(\QQY?TKT(^,=/U6]M_#-_J4-I9MB6]DD?;N3M$#
MZMW]J .U\"6SM;:EJVPPPZI=F>WB(QA ,!OJV,_E6'XQ\?W%I??V7H<4T]Q(
MYCC2W7=+,X^]M[ #NQKH_%GB>#PYX O=8TXQ3);0X@\L@KGH.G:O%O#J-=6T
MNM2ZJT.H(K,KAN1DY('MDT =A'8?$N2,77]FB,?>\IM3_>_RQGVK1T+XB7]M
M?_V?X@MIXIT_UD,\>V91_>&.)!].:Z?X?^(9?$GA:.ZNB&N(Y&AE8#[Q'?\
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M*[&"47%K'*HXD0,/Q%>9?%#P['I:_P#"6Z7%Y?E,JZI%&,":$G'F8_OH>0:
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M$^P KV/2M4M-:TR&_P!.E$UO,NY&'\C[^U>6/FV^-UX)NCWEM(N?[I0J/UH
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M%%% !1110 4444 %&:*YKQ]JTNC^"[Z:T.+N8+;6^.TDC!%/X%LT <K?W?\
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M#'F.>6;\ZZ#485EA(90RL,,&'6O&O#OB KM*/^M>CV/B&.6S9KF3"(I9F)Z
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M(?#%_I4QVBZA9%;^ZW\+?@<'\*UZ0\B@#Q+1M0EN+-1=+Y=Y Q@NH_[DJG#
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M'\4D8)_.N5^'GB+3Y? .C".93BV16RZ@A@.003ZYKJO[9ML<'/\ P)?\: .
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M'P?X@ETO5HGMYH7V,K=O_K=\UZ;I6IW_ (A@&G:9:W5TDN%NI+>/=Y:?W<]
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M;QVFEWM[IT#":1H(OEGE4Y5-Q(& >3]!7I7C'X&>'?&'BF#6IC):/N_TN.#
M%P!TSZ'U/>O0M,TNST?3H+#38$@MH%"I&@P * /.O WPVLCH<R>)O#T,$@NI
M#;AFS((2=P#$=P21] *Z=?AIX44Y&E+]"[8_G75T4 9FE^']*T;_ )!>GP6Q
M/5D7!/XUIT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 QYXH
MB!)*B$]-S 9IJW$+S-"LJ&1 "R!AE0>A(KSWQYIDD&N/XBDMK#4+.SL"LEI=
M2E67#;MR]LD#%=5H-A:^;+KD"R^;JT4,A$IYC0+\J8[8R?Q)H GUB[FMI(A
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MA@ZJR'<K ,".X/0T =GI^M7\]BCR3Y9O858_M>\S@S 'L..:R=*_Y!L>/>N
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M<&DEU>]6%V6;D*2./:N&\":58VW]JSP6R)-'J=S"D@.2$#\*/:NLF_X]I/\
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M/1#69=>$X[ZZ6YN]&,LR?QM"<GZUZR=6TY6(:\A!'7+BD_M?3?\ G]@_[[%
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MK0!H<5#=W4%E9S75T_EPPH7D;T ZU-]:S/$6G3:KX=O;*W*K/*@*;ONEE8,
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M (0-O^?_ /\ (?\ ]>D_X01\8^W_ /D/_P"O7:4478'&?\(&W_/_ /\ D/\
M^O1_P@;?\_\ _P"0_P#Z]=G11=@<9_P@C_\ /_\ ^0__ *]'_"!G_G__ /(?
M_P!>NSHHNP.>M/#)MK58C<!MO?94W]@?]-__ !RMNB@#$_L _P#/<?\ ?%']
M@'_GN/\ OBMNB@#$_L _\]Q_WQ2_V ?^>_\ XY6U10!B?V ?^>X_[XH_L _\
M]Q_WQ6W10!B_V ?^>^/^ 4?V ?\ GN/^^*VJ* ..F\#M+,\GVW!8YQY?_P!>
MF?\ "!O_ ,_^/^V?_P!>NTHHN!QG_"!M_P __P#Y#_\ KT?\(&W_ #__ /D/
M_P"O79T478'&?\(&W_/_ /\ D/\ ^O2'P(YY^W_^0_\ Z]=I11=@<9_P@;?\
M_P#_ .0__KT?\(&W_/\ _P#D/_Z]=G11=@<7_P ((_\ S_\ _D/_ .O1_P (
M&XP?M_\ Y#_^O7:4478&&N@$* 9P<#'W*7^P/^F__CE;=% &)_8!_P">X_[X
MH_L _P#/<?\ ?%;=% &)_8'_ $W_ /'*/[ _Z;_^.5MT4 8G]@'_ )[C_OBC
M^P/^F_\ XY6W10!B?V!_TW_\<ILGAXO$Z"<#<I&=G2MVB@#B_P#A W_Y_P <
M_P#3/_Z]'_""/_S_ /\ Y#_^O7:447 XS_A V_Y__P#R'_\ 7H_X0-O^?_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
BHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>sgmo-20191231_g2.jpg
<TEXT>
begin 644 sgmo-20191231_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#B17AI9@  34T *@    @ ! $[  (
M   (   (2H=I  0    !   (4IR=  $    0   0RNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %=D97-K,C,
M  60 P "    %   $*"0!  "    %   $+22D0 "     S Q  "2D@ "
M S Q  #J'  '   (#   ")0     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M_P )M/\ ]"EK_P#WS;?_ !ZM#_/^>*/\_P">*8C/_P"$VG_Z%+7_ /OFV_\
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MW>LZ-::]I[6.HJ[P,RL0K8Y!R*@3PWIT>K3:DL;_ &F>V%JYW\&,# &.WUH
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M+?XC6,DO"W5A)#&?5PZMCZX!_*@#7HHQU]NM%,04444 %%%% !1110 4444
M%%%% !Z_X4444 %%%% !1110 4444 %%%% !1110 4444 %%%'UH S-!_P"1
M]UC_ *]8/ZUUM<AX:;[1XSUVXBYBC6&W+?[8&2/PR*Z^D,**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K'\0^'XM?T]
M87E,$\+B6WN$'S1..C#_  K8HH XE+GQ/88AU#0VU';TN=/FC ?W*.P*G\Z=
M_;&L?]"GJG_?R#_XY79X/8T8H XS^V-8_P"A3U3_ +^0?_'*/[8UC_H4]4_[
M^0?_ !RNSQ1B@#C/[8UC_H4]4_[^0?\ QRC^V-8_Z%/5/^_D'_QRNSQ1B@#C
M/[8UC_H4]4_[^0?_ !RC^V-8_P"A3U3_ +^0?_'*[/%&* .,_MC6/^A3U3_O
MY!_\<H_MC6/^A3U3_OY!_P#'*[/%&* .,_MC6/\ H4]4_P"_D'_QRC^V-8_Z
M%/5/^_D'_P <KL\48H XS^V-8_Z%/5/^_D'_ ,<JO?>)[_3;*2ZN_"VJ1PQ@
M%FWP<9./^>GO7=XKG?'2X\$ZC_N+_P"AK0!G+K.K,H*^$]4((R/G@_\ CE']
ML:Q_T*>J?]_(/_CE=? /]'C_ -P?RJ3% '&?VQK'_0IZI_W\@_\ CE']L:Q_
MT*>J?]_(/_CE=GBC% '&?VQK'_0IZI_W\@_^.4?VQK'_ $*>J?\ ?R#_ ..5
MV>*,4 <9_;&L?]"GJG_?R#_XY1_;&L?]"GJG_?R#_P".5V>*,4 <9_;&L?\
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M?^?/5O\ P63?_$T =)17-_\ "<Z;_P ^>K?^"R;_ .)H_P"$YTW_ )\]6_\
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M:,T %>2ZIX.\_P#:%T[41'FWDM_M;G'\<?RY_/97K6:B,,9N%G*+YJJ4#XY
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MT.0><=?P-/S0!A_\(E9?\_>H_P#@6]'_  B5E_S]ZC_X%O6[10!A?\(E9?\
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M9:]'H?B!UG:=2]E?*NWS]HRR,.S <\=:["N'\4#8NC3IQ)#K%H%/IOF6-O\
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M.G6>I.7NHH0),G./:GZ;X;M=+\0:EJ\#R&?4=OFJQX&W/3\ZV.H /XT ?/\
MX4EG\,VRZT79M-U9Y[.Y'4)("P1OZ?B:Z3P_X@OM%\'^#HK%T5+Z^DAF)7.Y
M=_Z5VL/@/2H_",WAZ0R26LKM(6)^96+;LC\:@G^'>FS>%K+14N+B);"3S;>X
M0_.C9SG]: ,^Z\9WUAJWC 2[)8-(@@>V3;CYF!!R?K4,B>(I? .J:AKFHV]S
M!=Z8\HB2/:8F*YP#W&.*V]/\ Z98IJ:R23W?]J1+'<F=\E\9YSZ\U'I_@&"R
MT^YLI-5OKF":W:V1)7XB0^@_ 4#.17Q7>Z;HOA30[*X:S$ND1W$MPD!E<#&
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M\C>+1M@;..6Z"L#P3=6NO:Q>>*-5NX/MUYNBL;4R M#$,XP/4]_QJK\+K;Q
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M.FW,=S"3@/&V1GT^M6=WM0!S?_"O]#_N7/\ X$O_ (T?\*_T/^Y<_P#@2_\
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MK)=PNZHLB%V7>$W#.WUQZ4 8'_"O]#_N7/\ X$O_ (T?\*_T/^Y<_P#@2_\
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M9^)]5OM8N])FU 2V%^UO:V=O:AX'5#C]XV<Y->EOX'TEUT(%9<:$1]C^<\8
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M'$>=A W$KZ=,?C6#)XB\9Q>#M9UE_$ QX=OS:E/)&;DB15)<_P# Q^5>M?\
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M!S@^AJ2@ HHHH :%Q3J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF[Q3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "DQ[TM% '@OQC^&E\]]/XFT<RW:.-US
M3N:/ ZK_ +/MVKEOAC\,9_&-\+[4E>'1XG^9N09S_='MZFOJ QA@0<$$8P1V
MJ.VLX;.%8;6-88D&%1!@#\* &V=C!I]I':V<:Q6\2A4C48 %<#\3?AE;^,+(
MWNG*L6KQ)\C=!,/[K?XUZ/2;: /D7PQ\/=:\1^)VTCR)+7[.V+J652!"/ZGT
M%?5&@:%;>'=#M=+LMQAMDVAF.2Q[D_4U?2WCCD9T10SX+$* 6/O4E !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 -*9[T!,4ZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH ***3=0 M%%)F@!:*0L "3T%(&SB@!U%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%137,<$
M+RS,L<:*69V.  .I)H );F."%Y9F6.-%+,S'  '4DU4TG7-/UVP6]TBZCN[=
MF*^9&<C([5\]_%7XJ/XDFDT?09&CTJ,_O91P;DCO_NC]:YCP%X]U#P-K GMC
MYUE,0+FV).)!Z^S#L: /KNBLS0O$&G^)-'AU/29A-;RCCU0_W6'8UIT %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:_7S#_A0!\U8YZ\_SHK6\3Q06_BK4X;.%8+=+EUCB7HJ@\"LF@#JO ?CN_\
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M% 'S_P#"WPMKVE_VC_:&CWEMYA39YL1&>M>A_P!EW_\ SZ3?]\&N\*\]:7%
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M _\ DY/_ /%UW-% %>PL+;3-/@L;&/RK>W01Q)N)VJ!@#)Y/XU8HHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>sgmo-20191231_g3.jpg
<TEXT>
begin 644 sgmo-20191231_g3.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#^17AI9@  34T *@    @ ! $[  (
M   1   (2H=I  0    !   (7)R=  $    B   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %9E<F]N:6-A
M(%-A;F-H97H    %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,U
M-@  DI(  @    ,U-@  ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M0T__ $+4?_@<?_C='_#0T_\ T+4?_@<?_C='U2MV_(/K%+N>X45X?_PT-/\
M]"U'_P"!Q_\ C='_  T-/_T+4?\ X''_ .-T?5*W;\@^L4NY[A17A_\ PT-/
M_P!"U'_X''_XW1_PT-/_ -"U'_X''_XW1]4K=OR#ZQ2[GN%%>'_\-#3_ /0M
M1_\ @<?_ (W1_P -#3_]"U'_ .!Q_P#C='U2MV_(/K%+N>X45X?_ ,-#3_\
M0M1_^!Q_^-T?\-#3_P#0M1_^!Q_^-T?5*W;\@^L4NY[A17A__#0T_P#T+4?_
M (''_P"-T?\ #0T__0M1_P#@<?\ XW1]4K=OR#ZQ2[GN%%>'_P##0T__ $+4
M?_@<?_C='_#0T_\ T+4?_@<?_C='U2MV_(/K%+N>X45X?_PT-/\ ]"U'_P"!
MQ_\ C='_  T-/_T+4?\ X''_ .-T?5*W;\@^L4NY[A17A_\ PT-/_P!"U'_X
M''_XW1_PT-/_ -"U'_X''_XW1]4K=OR#ZQ2[GN%%>'_\-#3_ /0M1_\ @<?_
M (W1_P -#3_]"U'_ .!Q_P#C='U2MV_(/K%+N>X45X?_ ,-#3_\ 0M1_^!Q_
M^-T?\-#3_P#0M1_^!Q_^-T?5*W;\@^L4NY[A17A__#0T_P#T+4?_ (''_P"-
MT?\ #0T__0M1_P#@<?\ XW1]4K=OR#ZQ2[GN%%>'_P##0T__ $+4?_@<?_C=
M'_#0T_\ T+4?_@<?_C='U2MV_(/K%+N>X45X?_PT-/\ ]"U'_P"!Q_\ C='_
M  T-/_T+4?\ X''_ .-T?5*W;\@^L4NY[A17A_\ PT-/_P!"U'_X''_XW1_P
MT-/_ -"U'_X''_XW1]4K=OR#ZQ2[GN%%>'_\-#3_ /0M1_\ @<?_ (W1_P -
M#3_]"U'_ .!Q_P#C='U2MV_(/K%+N>X45X?_ ,-#3_\ 0M1_^!Q_^-T?\-#3
M_P#0M1_^!Q_^-T?5*W;\@^L4NY[A17A__#0T_P#T+4?_ (''_P"-T?\ #0T_
M_0M1_P#@<?\ XW1]4K=OR#ZQ2[GN%%>'_P##0T__ $+4?_@<?_C='_#0T_\
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M^-T?5*W;\@^L4NY[A17A_P#PT-/_ -"U'_X''_XW1_PT-/\ ]"U'_P"!Q_\
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M_0M1_P#@<?\ XW1_PT-/_P!"U'_X''_XW1]4K=OR#ZQ2[GN%%>'_ /#0T_\
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MG>)-@Q'GG ],9I>W;5[6_P"''[*SW/&RP'WB!]32[AC.1CUKTZ]OY/!/PO\
M#5UX>@ABN=65I;N^>%)&+#&$RP('4_\ ?/UJ/PS?:WKVL:OX@*Z/I*6EFGVR
M\EL01$"#AT3!RYP3Z?I5^U=G*VA'LU>U]3SFV"RW,2$Y5I%4X/8FNF^)&@V/
MAKQQ=:9I2-';1QQLJNY8Y903R:Z[QB;35/ASH&LBYCU"Z_M3R!?BS^S-(GS<
M%?JHY]JP_C-_R5"^_P"N,/\ Z *F-1SFOG^A4H*,7\C@Z***Z3 **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MPH'Q+_T$M)_[^2?_ !%'UBE_,'L:G8\LHKU/_A0/B7_H):3_ -_)/_B*/^%
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MD_\ ?R3_ .(HC6H1V:!TJKW1Y917J?\ PH'Q+_T$M)_[^2?_ !%'_"@?$O\
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M (BCZQ2_F#V-3L>645ZG_P *!\2_]!+2?^_DG_Q%'_"@?$O_ $$M)_[^2?\
MQ%'UBE_,'L:G8\LHKU/_ (4#XE_Z"6D_]_)/_B*/^% ^)?\ H):3_P!_)/\
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M*/\ A-M!_P"?QO\ OR_^%>645?\ 9U'N_P"OD1_;^*[1^Y_YGJ?_  FV@_\
M/XW_ 'Y?_"C_ (3;0?\ G\;_ +\O_A7EE%']G4>[_KY!_;^*[1^Y_P"9ZG_P
MFV@_\_C?]^7_ ,*/^$VT'_G\;_OR_P#A7EE%']G4>[_KY!_;^*[1^Y_YGLNF
M:O9:Q"\FGRF1(VVL2A7!QGN*EO[^WTRQDN[QRD,>-S!2<9..@]S7+?#G_D%W
MG_7<?^@BM/QO_P B;?\ T3_T-:\''+ZNJG)]E/\ (^QRJ;QD*3J?::O;UL1?
M\)[X>_Y_7_[\/_A1_P )[X>_Y_7_ ._#_P"%>1T5\A_;6)[+[G_F?=?V%A>\
MOO7^1ZY_PGOA[_G]?_OP_P#A1_PGOA[_ )_7_P"_#_X5Y'11_;6)[+[G_F']
MA87O+[U_D>N?\)[X>_Y_7_[\/_A1_P )[X>_Y_7_ ._#_P"%>1T4?VUB>R^Y
M_P"8?V%A>\OO7^1ZY_PGOA[_ )_7_P"_#_X4?\)[X>_Y_7_[\/\ X5Y)UZ5<
M;2YHE;[0\<,B@_NF/SDC'&!TSGC-4LXQ4MHK[G_F1+),)'>3^]?Y'I__  GO
MA[_G]?\ [\/_ (4?\)[X>_Y_7_[\/_A7ET>GO+"K1RQ&1@3Y).'Z@ 8/4G/
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MP3V^AJY7)_$/_D 6_P#U\C_T%J^CH052HHOJ?)XRM*AAY58[I%W_ (3;0?\
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MJ5K%WBF<U1*,VEW"BBBJ("BBB@#T'X<_\@N\_P"NX_\ 016GXW_Y$V_^B?\
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MN4OE^:.[K'\5_P#(JW__ %S_ *BMBL?Q7_R*M_\ ]<_ZBONJ/\6/JC\[Q?\
MN]3T?Y'DM%%%?5GYB%%%% !1110!J6%I:)I[7]\&E42&-(@< D '+=\<C@4D
MM\+Z:-9C(88SD1(!&B >@&:<CA/#L.[[IO'#?0HM4Y(7MHBC*0\GM_#_ /7K
M!*[;9VRDX148K2RO_P $M_;TM+R22S,L44WS;&(=6![,#UIUW;6=UILE_9J8
M7C91)&/N')(RH/(Z=.15&**2XC\I48NIR@QU'<?U_.KT3 Z+J2+]U#"H_P"^
MCG]:4DHM-;Z#A)S34EI9_)V;T,FBBBN@X0HHHH **** /6?"/_(IV/\ N'_T
M(UR'Q._Y"=A_UQ?^8KK_  C_ ,BG8_[A_P#0C7(?$[_D)V'_ %Q?^8KX#//X
M-3U_4_9.&_XE'_#_ .VG$4445\,?H@4444 %2V\)GF"Y"J 2S$'"@=SBHJLV
MF_$NV/<A #OS\BDC^?3FJBKO4F3M'0T;:V>[>1 L<%G&@=FE?Y8UR<;\#YFY
MX'7I3_.T8-L^V79Y_P!8+5-GUVYSCBDU)F3P];A.%FNY6E^J[0H_ $UAUU3G
M[-\J5SDIT_:IR;M_P/4VKFV>U\O8([BSF5F5XF^64<9V@_=?CGO67<P^1-A3
MN1AN1AG!'X@?3\*U-*9FT*^1ON130R1^SEMI_,$_E6?=[]D8,6$!<1R<_.-W
M3TX]JFJDXJ2ZZ_H52;4W%]-/PN5:***Y3K"BBB@ KH? O_(YV7TD_P#1;5SU
M=#X%_P"1SLOI)_Z+:NG"?[Q3]5^9RXS_ ':I_A?Y'KU>%:G_ ,AB]_Z^)/\
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MZG#*PP0?2FUU>HZ;IUM<+<Z@EQ.^H7DJJ(G"B)1(5_$Y[5'>^'['1+>[GO\
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M(>^,#M[UA4J2B[15SLH4(5(<TY6UM^%_ET.9BCO8]_D)<)D%'V!AGU!Q_*F
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MRN<L['))J.BDYSDK-Z#C3A%\T4DPHHHJ"PHHHH *1ONGZ4M(WW3]* />-/\
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M*& ,S%B01GC=^/3-.D%_$!)+]I3S$\L.VX;E_NY[CVK9L9AIWA6"Y1/,\[4
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MU]IF/^XR^7YH^$RS_?X_/\F>?4445\6?=A1110 4444 %%%% !1110 4444
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M<EM_7Z(V(/$^H026L@$$DUJA2.61"6VD8P3GD51M=0FM+:Z@AV[+M DFX9.
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M !1110 4C?=/TI:1ONGZ4 >\:?\ \@VV_P"N*?R%<3\4/]7IGUE_]EKMM/\
M^0;;?]<4_D*XGXH?ZO3/K+_[+7VF8_[C+Y?FCX3+/]_C\_R9Y]1117Q9]V%%
M%% !1110 4444 %%%% !1110 4444 %:_A7_ )&S3?\ KN/Y&LBM?PK_ ,C9
MIO\ UW'\C6V'_C0]5^9AB?X$_1_D>T5Y%X[_ .1RO/\ =C_] %>NUY%X[_Y'
M*\_W8_\ T 5]1G7^[KU7Y,^3R+_>G_A?YHYVBBBOD3[,**** "BBB@ HHHH
M**** "BBB@ HHHH *]$^&'_'IJ/_ %T3^1KSNO1/AA_QZ:C_ -=$_D:]/*O]
M[C\_R9Y.<?[E+Y?FCNZQ_%?_ "*M_P#]<_ZBMBL?Q7_R*M__ -<_ZBONJ/\
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MFN>IEU"$W&--.WDCKIYAB913E4:_[>97_P"$'\._] X?]_I/_BJ/^$'\._\
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MVB>VA+I&1D$^IQV'6FJU9NRD_O$\'A4KNG'[D,_X0W0?^?#_ ,C/_P#%4?\
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M-)G$T#DC.,%2.H([$>E:%0ZU9.SD_O9:P>%:NJ<?N1A_\(;H/_/A_P"1G_\
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MP^I87_GW'[D8?_"&Z#_SX?\ D9__ (JHY_"OANUA:6YM8XHUZN\[@#\=U/\
M$OB:'0(8HU7S[ZX8)! #U).,GT&:Y#6]*7Q#XFNM*FU2[DO;>#SLLJ^0AP#M
MP.G4<UVT(5JGO3FU'Y]#S<5+"4KPI48REHK62U>WY#]1U?P!8,52V>Z<=H7D
M(_,MBL*?QCX60_NO#4S#_:NF']:L_P!GW/A_0]%EL=+EO)[IA<W;)%N)CXVQ
MYP< C\ZY+6+*_P!4OKC4;'1+BWM9F+HD<)**/KC%>U0H49;R;7=R_0^>KU:J
M2M"*>FB@NJONT_F=);^./!1D"WOA^Z@'=EF9P/\ QZNTT*T\$^)(#)HZQS[1
M\\?G2!T^JDYKP>73-0;3VOEL;@VB]9Q$=@_&DL1XA\.Z@FKV-G>0/: 2L_E,
M%V'^]_LFBO@HM/V51I^ITX3$*Z]K1BU_A7^1]'_\(;H/_/A_Y&?_ .*JA>Z%
MINDZSHTFGVWDN]WM8[V;(V,>Y-='870OM-MKL+M$\2R 'MD9_K69KW_(4T/_
M *_#_P"BVKYVG5JN?+*3Z]?(^BQ&%P\:?/""3O'HNZ-NBBBN0],**** "BBB
M@#%\'_\ (J6?T?\ ]#:MJL7P?_R*EG]'_P#0VK:K6O\ Q9>K.7!_[M3_ ,*_
M(*K:D;T:9<'2UB:\$9\E9L["W8'':K-%9'4>)Z[IFI>)=/\ L0^'1L->=E#:
MG'MCC1L\N&')'L:Z*PB\0>";[5K<:!/KRZE*)X[N!EY<J 5DR> ".ON:]*HK
MH==M6MI\S%4K.]]3RCX9>&=9TKQ%!<ZMICVJ+IDL9+ 81S<LVT?\!.?I447A
M[6M+\4S:Y;:>MQ+;ZS=RQ:?)(J-<02(@\R//<8KURN?\3>%?[?FLKRTU";3-
M2L2QM[N%0VT,,,I4\$' IJLW-M]1.DE&RZ'FSV.I^*]=\07PTX6>L6L]I.ND
M3G!EBCR<LW0ENWN*M^+1XC\8W=I)%X2O;&.UMKE"TY7>SO'@ 8/W<CCU)KN?
M#_@_^R;B\OM3U*?5M2O=BS74J!,*OW551P!6RVF1-G=),<C'^L/KFFZZ4O=6
MW^01HIQ]YV.3L]%O8_%?ABY>S98;72'AF? Q&^%PI]^M<8/ >KQ:.M_):7C2
MM%-:FU@P)8P;AG#C)Q@C QWS7K[:9$V=TLQ))Y+],G-/%C'U+R$\X.[D9Q_A
M6?MI6M_77_,WIQC":GVU.4\ >&KK2)M0U.\62%M16$"VEP7C\M2,L1P2<]?I
M7:5#!:K;LQ5F.Y0""?2IJRE)R=V-VNV@HHHI",2R_P"1TU3_ *]X/_9JM^(/
M^1:U/_KTE_\ 0#52R_Y'35/^O>#_ -FJWX@_Y%K4_P#KTE_] -/%_ _\*_(R
MR_XE_C?_ *4Q^C?\@&P_Z]H__015VJ6C?\@&P_Z]H_\ T$5=K*G\$?0Z:O\
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M85_X,O1_D;X?^-#U7YE[3_\ D&VW_7%/Y"LK5O\ D;_#_P#V\_\ HL5JZ?\
M\@VV_P"N*?R%96K?\C?X?_[>?_18K*M_"CZQ_P#2D:T?XTO27_I+-VBBBNLX
MPKB?&D^JQ:E$LOA2#Q'HC1_-&BAIHY/7#<8Q_P#KKMJ*J,N5W)DN96/$[;P/
MK5[_ &GJ>F:'_8]H+BWN;71II!B9HF);(Z+D&KOBX>(_&5Y8O#X2O;&.UM[I
M&><IO9W@90HP?NYQCW->OT5O]8=[M&7L5:USS[6- OY_ ?A*R@LW%Q9W=D]P
MJ@!H54?.Q^G>N5U;^V= ^&DWAJ?1TGTT2;#K4+B2+R3)GS"HYW"O:F 92K#(
M(P17!-\,9A:MI,/B6]B\/NY8Z:(ER%+9*"3J%SVQ3IU5]KO<4Z;^R4]/&L>#
M=0U2.P\/SZ[9ZFZSVMU;NO0H!MDST'OZ5G^ O#.LZ?-.=2TN2WWZ3+" 0,;S
M*QVC\"*]/_LR 1A(]\2JH4"-L8 & /RI!IL:])9AR"</UP,5'MG9JVYHJ,;I
MW/-W\):I>^%_!^FFUEMWABN(KEL?\>^^)@"WXD5DCX?ZI=O)HK6M[ GD16_V
MQROV<>7CYU .03@D=P3GOQZ^FG11D;))0..-^>G:AM.B*; \BC;M&&Z=/\*3
MK2=C:FH4U);W5BTB[45<YP,9I:!Q16)(5@^(_P#D(Z#_ -A ?^@-6]6#XC_Y
M".@_]A ?^@-7/B?X?S7YHZ<+_%^3_)F]6%I7_(X:_P#2V_\ 0#6[6%I7_(X:
M_P#2V_\ 0#16^.GZ_P#ML@H_PZG^'_VZ)C3^ ?M'C;6O$5PZ2R3K;/IT1GE5
M(IH48!Y$!VMAF!!(..<8KFO^%-7L=G'8?VK'>V-Q]CDOX[L ;I(9=S;-B#(9
M6<9;+<+D^GK=%=!S' :7X U#3X?#-K]IM#;Z!>W+H5#!I8'C=$SQ]\;QN/?!
M.>:Y.3X'ZG'8206E_8NLUA'%-;3%_*:X6YBE=Q\I(5TB /'7G'->UT4 >4ZQ
M\)[G7+N.\-KHVF26>G^396UL6DBBG6X\U6.47*,,JPQW/6O4XO,\E/."B3:-
MX0Y4''./:GT4 %<_XNT-=6TIG@BW7<1!C(')&<$?UKH**N$W"2DC.I3C4@X2
MZGBNJRW.@0,NE:9<:A?J/FN?L[-!;G_9X^=O?H/>N!L;._\ $WB:&TD>2:\O
M)@KO(22/4GZ#)_"OJBL=/"^F1^*/[>B@5+SR3$2H !R?O?7'&?2O4IY@HIWC
MKW.)X)*RB]#G_&^@R?\ "*:-I.CI*BPW]NBO"N6B49&_\.N:Q((-3L-"L_#X
MT^YMKNSU>'S[BV5MMS$6.9=WT/.>E>H2F0!?*"D[ANW>G>LP2ZYQF"WZC)#=
ML\]_3I7%'$N,.5J_4[5AU.5T['F,5AK.DZ1JEKIJ:HCKJK-<[B^'MRQVLI7D
MD_Q%>37H?@8:B/"L']K2R2REV*&96#A,_*#NY_/MBM"V?5CG[7%;K@#_ %;9
MR?;/;I4WF7V1^XBYZG?TIU*[JQLT)4?92WN6ZPM%_P"1G\0?]=H?_10K;C+M
M&ID4*Q'(!SBL31?^1G\0?]=H?_10KS*W\2GZ_P#MK.ZC_#J>B_\ 2HF[6/XM
M_P"13U#_ *Y?U%;%8_BW_D4]0_ZY?U%=M'^+'U1YN+_W:I_A?Y&M'_JD_P!T
M4ZFQ_P"J3_=%.K(Z%L%9OB%M430;EM!@M[B^"_NXKC[C^H/X5I44T[.X/5'B
MVH:/?>)+NP33/ ,GA_4X[J.6;4LK&B '+8*_>S[UKV\7B'POHFJ^&XO#,^K&
MYEF>"^B9?+D$F3F3)R",_H*]2HK=UVU:VGS,O8I.]]3S;X6>'=3T:]O7U:P>
MV#Z?9Q(T@')5"'7\#C-8_AW0]>\,7]IJ\.E?;;A$NH)M.,JK-'&T[.DJ ]CG
M%>PUS7B+PC+JVK0:OI.K3Z/JD,)@^T1QB17C)SM9#P>>::K<TGS=1.G9*W0\
M[TNQU/5+J\\16NG;]4L=<-Q=:*WRLJ;-HP3P6[@T_P 56?B/Q=K$M_'X6O+*
M$:?Y"";:9)&\Y&Y /'&<?2O1O#OA*+0K>Y,]Y/?WMW.)[F[EPK2.!@8 Z #M
M6H-,B# ^;,2"I&9,\CI_.FZ]I72"-%.-I.QS$FCWA\;ZK=BS;R)M$6W23 PS
MY/R_6N%'@76+/1;2Z>SOYIKFUMHY(+4J);=H@<AB3T.>@],]J]A&F1#:?,F)
M4CDOGH<T[^SX]I!>0DC!;=SCG_&LO:RY>4Z:2C3J*HM;'/\ @3P[/H-C?271
M*OJ%T;KR3UA!4#:<<9XY(KJJBA@6#?M9CO.3GMQCBI:SE)R=V39+8*1ONGZ4
MM(WW3]*0&/X1_P"13L?]P_\ H1J*Y_Y'ZP_Z\9O_ $-:E\(_\BG8_P"X?_0C
M45S_ ,C]8?\ 7C-_Z&M1COC?^)?F&5?P(_X/_;3,\1> X?$WC6SU/5&\S38=
M/DM9;59Y(S*S2*PW;" R?+RK9!]*Y;5OA)K5[9ZI+;ZU"U]K$=Y'>1S*!"@E
M8-'L*H'.T(@^8GIQBO6J*L#SA?AG<V>FW&E:9+90Z?\ V[;ZK;##!D565I(S
M@<\K\OL0. !6;K/P@O[_ %F_U*RU"V@EOIKXSJV[;(DL16+/'WD9C^#&O6:*
M /)I_A#+J^D:9I>I6.C:;:V:2K*=/=V:9VAV++S&N&# 'OWYKTK0K:\LO#]C
M:ZE]G^UP0)'*;4$1%E&,J"!@<=.U7Z* .1\5Z=>:A/+$=$COT:+%G=12".2V
MD[EF)SC.#D4V7PUJ>JZK$=0OI[:*SLEMTFA*DSNX_>$Y!XX KL**W5:222)Y
M4<9;:)J@TW0[*ZA\T:;?%7=F!WP!656/U!'%16'A&\BUC5K.X/\ Q*I;#[+:
M2[LLJEF;;C_9S^6*[C%%/ZQ/7^NMPY4<>[>)9=%.AG2HUF:+[.U_YP\G9C&_
M;][..WK2S>#X;KQ!:+=P-+86NF+;JXD*G>&/H<]*Z^C%+VTE\.@<J,%-*E@\
M86MS!%BRATXVX8MG#;P0/7I4.K7&H:1JHNHI4%A,P\SS6PJ'OSVKI,4V2-)8
MRDJ*Z'JK#(-<6*H_65%.3C9[K<N+Y3Q7Q[K,GCOQ-:Z+X<W7=O"<;H^49SU8
MGT [UZ)IMD-.\66%D#N^SZ-Y>?7$BBNAMK&TL\_9+:&#/7RT"Y_*LEO^2A1_
M]@MO_1HK?&UE.%.G%62:-L+&SFW_ "LVIO\ 42?[I_E6/X/&?!NG#_IC_4UL
M3?ZB3_=/\JR/!W_(GZ;_ -<1_,US2_WB/H_SB5'_ ':7^)?E(XNU^$C0^%XM
M/-YLOI[D"^O%F>3;;"=I_+A20,B9;;D;0IYSGOG7GP9OKMP);^TG%A;2)I<L
MZDNLGVGSXS(H4+MZHP QM/ KU^BN@YCS_6_A_?ZW<:_)/-9A=8&G Q'<RK]G
MD5Y >.00"!^N*Y^T^#^H:9J4$VW2=<M+:XN3%;:F[J!%((UB!(1OF18]O3FO
M8** /./#WPVO-#\:_P#"2*]@;FXO+MKI0&.8)=I0*2/OJRX[ AC7H]%% !7,
M^,M _M2R2>TA!NT8#(XRIZY^E=-16E.HZ<E)&=6G&K!PD>(ZS=WFA6[)H6FW
M5U=#B34#;L8XO^N8(Y/^T?P]:XKP[I-SXJ\66UE([R/<2[IY&))"CEB3]*^H
MZQ[/POIEAXCN=:M(%BN;F(1N% "]<E@/4\9^E>E#,%&+]W7N<?U))I)Z'._$
M#0KG48?#^GZ3YENJ71030J?W"^4P!..@[?C65:1Z@]CX?T0:==Z9)97Y@O?L
MP94=-C#S0_<$\Y]:]*G,X4?9PA/.=Y]N/UK.$NN8'[BWSD<ENV.<\^N*XXXE
MQ@HM;?\ !_S.Q8=3DY)V/*[2TUO3?",%I91ZI"(KR0:@C>8,#+;-FWG:>IV]
M\9KU'PD+]?"MB-6E>6Z\OYVD4AB,G&0><XQ5FV?52K&ZB@!&,!&ZG'//IT]Z
ME,E^#_Q[Q$>OF4ZM=UHVM;6Y,:/LI;W+=87AG_7ZW_V$Y/\ T%:W%)* N,-C
MD ]*P_#/^OUO_L)R?^@K7F5/XL/G^1WTOX-3Y?F;M8OB/_7:/_V$8_\ T%JV
MJQ?$?^NT?_L(Q_\ H+5VT?C1YF+_ (+^7YHVJYWQSX;G\5^&QIEM.L#?:[>=
MG+LA"QRJ[89>0<*<$=ZZ*BLCJ/-M:^%3WET7T?46TZ*RM@-.C#>:3<&;SWDF
M>16<Y=(N58-\O7M1X;^&E[H'B<ZZ)+!KJ[>]2^VAN8YG$D90D9#*1M/8J?85
MZ310!Y#>_!K4+[PSI]BVHVT5[IVE-:V]PF[Y)_,+9Z?<*,R'OACQ4Q^%NIC3
M_$EF+70WEUB.98]39W\^(/&%"%?+Y7*_WN_2O6** .5\$>$7\'+J5E!]G_LZ
M>X%Q;+&"'C)4!U;CD!A\OL<=JZJBB@#R*>[CNOC!)+J]PD%O9S9!E;  0?*/
MSP:SCXIU#6M>ELM.2WM!J=QY4DD$6))$+8^9CD]/3%=EX[^'S:].=2TAD2]V
M@21.<++CH<]C7)^"?#FI:5XO-UK5A-;Q:?!).69<AB!@8(Z]37U-*MAYT/:7
MUC&UO-?YL^*K8;%PQ'LK-1E)MR75/SZ61N7WB"WL/%6O7)NUB&G6(M+.#S,;
MI,=A[&L>>2WT/P[#9V.LV<T<VQM4F%UF1DW#=%&O88)]S7 7TEY?ZA/<O;S-
M)/(TC 1D\DY]*DLO"/B+5G LM'NF!_B>/8H_$XKH^JTZ<5S3MM?Y+_AWZF<<
M35J3?+"^]M^K_P K+T/0/$>J6TFJ.EE?:9#IU\(;03?;"["WR-RI$!B/@')-
M4I6U?Q_\2[ZTT6]EC\/1(MK<2Q']VT(QE1V)8YZ=JE\/? ^:619_%%VL<?4V
MML<LWL7[?AGZUZYI>E6.BV$=EI=M';6\8^5(QC\3ZGWKR*V(HT5:D^9VM?IT
MU]=#W\/AZU7WJJY5>]NOIZ:EF.-88DCC 5$4*H'8"L;7O^0IH?\ U^'_ -%M
M6W6)KW_(4T/_ *_#_P"BVKRZ/Q_?^1Z&+_A?./\ Z4C;HHHK$Z@HHHH ****
M .?M- U6PM5MK/7?+@3.Q39HV,G/4GWJ;^S-=_Z&'_R13_&O.]9^+6MZ=KU_
M90V>GM';7,D*%T?)"L0,_/UXJE_PN;7_ /GQTW_OW)_\77I>QQ$O>LM?)?Y'
M-' TXI)7M_BE_F>H_P!F:[_T,/\ Y(I_C1_9FN_]##_Y(I_C7EW_  N;7_\
MGQTW_OW)_P#%T?\ "YM?_P"?'3?^_<G_ ,71[#$=E]R_R']3AWE_X%+_ #/4
M?[,UW_H8?_)%/\:/[,UW_H8?_)%/\:\N_P"%S:__ ,^.F_\ ?N3_ .+H_P"%
MS:__ ,^.F_\ ?N3_ .+H]AB.R^Y?Y!]3AWE_X%+_ #/4?[,UW_H8?_)%/\:/
M[,UW_H8?_)%/\:\N_P"%S:__ ,^.F_\ ?N3_ .+H_P"%S:__ ,^.F_\ ?N3_
M .+H]AB.R^Y?Y!]3AWE_X%+_ #/4?[,UW_H8?_)%/\:/[,UW_H8?_)%/\:\N
M_P"%S:__ ,^.F_\ ?N3_ .+H_P"%S:__ ,^.F_\ ?N3_ .+H]AB.R^Y?Y!]3
MAWE_X%+_ #/4?[,UW_H8?_)%/\:/[,UW_H8?_)%/\:\N_P"%S:__ ,^.F_\
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M)_\ %T?V2^WXL7UBOW_!'IW_  C#_P#0?UG_ ,"1_P#$T?\ ",/_ -!_6?\
MP)'_ ,37F/\ PN;7_P#GQTW_ +]R?_%T?\+FU_\ Y\=-_P"_<G_Q=']DOM^+
M#ZQ7[_@CT[_A&'_Z#^L_^!(_^)H_X1A_^@_K/_@2/_B:\Q_X7-K_ /SXZ;_W
M[D_^+H_X7-K_ /SXZ;_W[D_^+H_LE]OQ8?6*_?\ !'IW_",/_P!!_6?_  )'
M_P 31_PC#_\ 0?UG_P "1_\ $UYC_P +FU__ )\=-_[]R?\ Q='_  N;7_\
MGQTW_OW)_P#%T?V2^WXL/K%?O^"/3O\ A&'_ .@_K/\ X$C_ .)H_P"$8?\
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M?\+N/_0 '_@9_P#857]ES[/_ ,"?^9M]8J]H_P#@,?\ ([O^RO$'_0RC_P
M(_\ &C^RO$'_ $,H_P# "/\ QKA/^%W'_H #_P #/_L*/^%W'_H #_P,_P#L
M*/[+GV?_ ($_\P^L5>T?_ 8_Y'=_V5X@_P"AE'_@!'_C1_97B#_H91_X 1_X
MUPG_  NX_P#0 '_@9_\ 84?\+N/_ $ !_P"!G_V%']ES[/\ \"?^8?6*O:/_
M (#'_([O^RO$'_0RC_P C_QH_LKQ!_T,H_\  "/_ !KA/^%W'_H #_P,_P#L
M*/\ A=Q_Z  _\#/_ +"C^RY]G_X$_P#,/K%7M'_P&/\ D=W_ &5X@_Z&4?\
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M\-L!QK>K?^! _P#B:7_A''_Z#FK?^! _^)KBA\2]7Q_QZV7_ 'P__P 52_\
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MFE]\O\P_L_'_ ,L?NC_D=C_97B#_ *&4?^ $?^-']E>(/^AE'_@!'_C7'?\
M"R]7_P"?6R_[X?\ ^*H_X67J_P#SZV7_ 'P__P 51]?P7\TOOE_F']GX_P#E
MC]T?\CL?[*\0?]#*/_ "/_&C^RO$'_0RC_P C_QKCO\ A9>K_P#/K9?]\/\
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MPNWQ#_SXZ9_W[D_^+H^K0[O_ ,"E_F'U?%]H_P#@,?\ (]5_LKQ!_P!#*/\
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MC.T**** "BBB@#U7X=?\BK_VW?\ I6#\3O\ D)V'_7%_YBM[X=?\BK_VW?\
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M''H1T/H:RQI6I+8("5D>*[6>*!YBVU /N[R.>OI13C3:O(=>I74FH+2W:_\
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M>G7-1W.DF#2=.N$$K7%V\J-%M^Z48  #KGFCV-2.MNE_R_S#VU.6E^MONO\
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ML,@C!'K3888[>%(H4"1H,*JC@"GT4"LKW"BBB@84444 %%%% !1110 4444
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M2@#ZDTK_ ) UE_U[Q_\ H(KR'XT?\C38_P#7D/\ T-J]>TK_ ) UE_U[Q_\
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M_P#?F_\ 1K5\\U]#?"?_ ))OI_\ OS?^C6I,\O-/X"]?T9V=%%%(^;"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^9_%/\
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M!OQ%TKQ>3;Q!K6_5=S6TAY8=RI[C]:QK_6:"YI0T\F=>&S3#XE\L'KYGB/\
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MQI^L0>=IEY#=(.IC;)7ZCJ/QJY5+,&U=(PES0?+)69\Q_P#".ZW_ - ;4?\
MP$D_PKJ?ACI][:?$2W6[L[B!EMY'82Q,I"D8!Y'3/&:]SKET_P"2M3?]@1/_
M $>U-XMU(RC;H3S7.HKYV\3Z5J-]XRUJ2QT^ZN8Q?2J7A@9P#GID#KR*^B:Y
M?P5_KO$G_8;G_P#04KGP]5TN:20D['A?_".ZW_T!M1_\!)/\*/\ A'=;_P"@
M-J/_ ("2?X5].45T?7Y?RCYSYC_X1W6_^@-J/_@))_A1_P ([K?_ $!M1_\
M 23_  KZ<HH^OR_E#G/F/_A'=;_Z VH_^ DG^%'_  CNM_\ 0&U'_P !)/\
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M_P" [_X5[E11_8</YW]P?V_4_D7WGAO]C:I_T#;S_P !W_PH_L;5/^@;>?\
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M_P#%5])447#^U:W\J_'_ #/FW_A7'B__ * <_P#W\C_^*H_X5QXO_P"@'/\
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MK;WL9\L3[3C++_$IQUJGX=^)5S9:R?#OCR);/4$(5+M>(Y<]"?3/KT^E5Y_
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M!.S_ / A/\:HZH_AG6K<0ZG=:?.JG*EIURI]0<Y%._X0WPU_T --_P# 5/\
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M_P#"&^&O^@!IO_@*G^%'_"&^&O\ H :;_P" J?X4?N_,-"Y_;FD_]!.S_P#
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M_&JW_"-Z)_T"++_P'7_"C_A&]$_Z!%E_X#K_ (47Q'9?C_D%L-WE]R_S+/\
M:NG_ //];?\ ?Y?\:1M4T\J?].MNG_/9?\:K_P#"-Z)_T"++_P !U_PH_P"$
M;T3_ *!%E_X#K_A1_M'9?C_D/_9N\ON7^96\%_\ (G:?_N'_ -"-5=7U"UTS
MQI87%_.L$/V*5=[],EEX_2NCA@BMH5AMXUBC085$& !["E:-'^^JM]1FI]C+
MV,::>JM^ _K$?;RJ-:2O^)C_ /"8>'_^@M;_ /?5'_"8>'_^@M;_ /?5:_D1
M?\\D_P"^11Y$7_/)/^^15<N(_F7W/_,7-AOY9?>O_D3(_P"$P\/_ /06M_\
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MK;?G6QY$7_/)/^^11Y$7_/)/^^11RXC^9?<_\PYL-_++[U_\B9'_  F'A_\
MZ"UO_P!]4?\ "8>'_P#H+6__ 'U6OY$7_/)/^^11Y$7_ #R3_OD4<N(_F7W/
M_,.;#?RR^]?_ ")D?\)AX?\ ^@M;_P#?54;+4[+5?'BS:=<)<1IIK*S(<@'S
M <5TOD1?\\D_[Y%*L:(?D15^@Q4NG6DUS25D[[/_ #&JM&"?)%W:MJU_D-N?
M^/67_</\J\^\#>./#6E^!]*LM0UFV@N88 LD3L04.3P>*]%J+[+;_P#/"/\
M[X%=1E"<5%QDOZU\O,Y[_A8_A#_H/V?_ 'T?\*/^%C^$/^@_9_\ ?1_PKH?L
MMO\ \\(_^^!1]EM_^>$?_? H'>CV?WK_ ".>_P"%C^$/^@_9_P#?1_PH_P"%
MC^$/^@_9_P#?1_PKH?LMO_SPC_[X%'V6W_YX1_\ ? H"]'L_O7^1SW_"Q_"'
M_0?L_P#OH_X4?\+'\(?]!^S_ .^C_A70_9;?_GA'_P!\"C[+;_\ /"/_ +X%
M 7H]G]Z_R.=/Q%\'LI#:]9D'J"Q_PI$^(G@V-<)KMDH] <?TKH_LMO\ \\(_
M^^!1]EM_^>$?_? H"]'L_O7^1SW_  L?PA_T'[/_ +Z/^%'_  L?PA_T'[/_
M +Z/^%=#]EM_^>$?_? H^RV__/"/_O@4!>CV?WK_ ".>_P"%C^$/^@_9_P#?
M1_PH_P"%C^$/^@_9_P#?1_PKH?LMO_SPC_[X%'V6W_YX1_\ ? H"]'L_O7^1
MSW_"Q_"'_0?L_P#OH_X4?\+'\(?]!^S_ .^C_A70_9;?_GA'_P!\"C[+;_\
M/"/_ +X% 7H]G]Z_R.>_X6/X0_Z#]G_WT?\ "H?AFP?P+;NARKW%PRGU!F<@
MUT_V6W_YX1_]\"I%544*BA0.@ Q0$IPY'&*>MNO:_EYBT444& 4444 %%%%
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M\_$W_?PT?:KC_GXF_P"_AJ&BO<LC4F^U7'_/Q-_W\-'VJX_Y^)O^_AJ&BBR
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV1.<^P'I6?>7+7M]/=2*JO-(TC!1P"3GBH**:BEL,**,YZ450!1110 4444
M>[_"/_D08O\ KXE_]"J[\2_^2=:I](__ $:E4OA'_P B#%_U\2_^A5=^)?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)2<6@@($BJO)W#@$UE+X3N=9&G2*;:UM_P"RDNY9883E5W,!E1RSG';%4O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;J&S@-M8P0,0QBC5"1WP,5-7@/<R"BBBD 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW_84N_\ T::7XC_\D_U+_ME_Z-2D\ ?\@2^_["EW_P"C32_$?_DG^I?]LO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ_SQC_6C_A(+C_GC'^M95%!QFK_PD%Q_SQC_ %H_X2"X_P">,?ZUE44 :O\
MPD%Q_P \8_UH_P"$@N/^>,?ZUE44 :O_  D%Q_SQC_6C_A(+C_GC'^M95% &
MK_PD%Q_SQC_6C_A(+C_GC'^M95% &K_PD%Q_SQC_ %H_X2"X_P">,?ZUE44
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M3C3=HRN%%%%;& 4444 %%%% !1110 4444 %%%% !1110 5C>)]=3P_HSW.
MT[G9"A[MZ_0=:V:\N^)MXTNN6]IGY((=V,]V/7\L4'7@Z*K5E%[%#3M(AURQ
MN-3UG4S;W%S<?9[:2095Y<;CO/\ "O09[9K!OK&YTV]EM+Z)H9XCAT;M_P#6
M]ZT]$U2T6UETC6E9M.N7#^8@R]M)C D7U'J.XK6U&-?LPTGQ-*HEAAWZ9JR
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MT**UMEM5O+M[55V>1(R%2OH?ES^M E*FE)?U8SY=4N[K5-))MIK2WF\U@WF
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %9NO?\ (/'_ %T'\C6E6?K44DUB%B1G;>#A1GUH
M YNBI_L-W_S[2_\ ?!H^PW?_ #[2_P#?!IB(**G^PW?_ #[2_P#?!H^PW?\
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M&>*CUMI[#4K;Q?\ $"ZTG2[;18IAI]C;W;2B6X=""QD=(RSE RK&JYY)R>@
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MYP<<ZFI?#".#Q+:WVFZ!H&O:?#I,.FI8ZVQ7[-Y+'8\;>3+G*L01@'(!R<X
M!4UOQ2/'7A30K-;=;=]1\31V%Q''-YL<B6TK22M')M&]"(>&P.O2KEQXPTO0
M3XM\4VFA-->)JUMH[&.Z9GOW38@"J1A-OFN-H^\5.3DUN_\ "+W\_B3PI?7'
M]GPVNA6DX>"T#(HG>-8U$:8P$5/, R<\CBL>P^'^JQZ5X>M;Z>S9[;7YM;U1
MHY7/FNS2NBIE1NPSIG=C[E &M:>.9H/$&HZ7XHTV'2/L6EC5_.CN_M"K;[W5
MO,^1=CKLSA2X/.&..:ME\0KR;5O#T5_H26=GXD9_[/S>[[O:L9D#R0!,*NT
MG#MMW*#@DXBUSX?7FOW7C9[J]AA77K&"QL70%F@CC1B=XP.LCMP"> .AJ]X.
M\-7&B7ADD\,>%]#4VWERR:-EY+A\K@EO)CVJ,-\IWY+#D;?F +OC#Q;_ ,(J
MNDI%ITVIW.J7Z645M X5SE68L-W'&WN0.<DBLF7XB3:99^*QK^E06M]X<LTO
M&BMKTS17".C,@61HT()9"I!7C@\U3\62:K?_ !@\/6N@I9S7&CZ=<ZB\%Y(T
M<<GFLD"C>JL4;;YI!VMG!&.<A-0^'NK:MH>LF^N;,ZKXAOK1]0*.XBAM(9%(
M@C.W+$(&&2%W%V.%H TY?'.HVND6=U>^'Q%>:O(D.D:<MYNGG=D9SYWR 0JH
M7)(+X'49PI8?B(-(GUNV\7Z?'IMQI%G'?'['<FZCN(9"578Q2,[RZE=I4<E<
M$YXN^*_#^IW^OZ!KVA_9);O1I)_]%O)6BCF26/8WSJKE6&!CY3U(KD_%GA&X
M_P"$>US7O$NI6-KJNH75DR-^\-G9Q03*T4+R;=VPMN+RE5 +YV@+B@#H(/&N
MN1^)]"T;6?#$-D^MK)+$\>I"4P1QQEW$B^6N'!,:X7<N6/S\<LTOXBOJ%CJV
MLS:7'9^'M(N+N*XU&:[):582PWQ1B,[P=O()7!.!N(K$\,7>I>+OBI>>(4N=
M.O+/2]'-I:_8)FGLXKF5PS*MQM'FMMC4L0HVAU7&1N;3;X=74OP.7P5)=PK?
MFU423G+Q//Y@E;.0"49\@\9P>G:@"U9^/;X^(](T_6="CL(=:AGGM-E[YUQ&
MD:[P9X1& F5_NN^&PO.<U)X;\=W&OZ"?$;Z3'#X?DMIKF"ZAO1--LC8C$D6T
M!6(!X5GP00<&CP]X>U'1H[^33O#/A/P_-)"HB73=SBXD!)_>,(HBJCH  Q^8
MGMAJFB^$=9TK7=9\16-EHNE7U_%%&-,M)I'MIV60N\LLGEH1(P9E#",[?O'?
MDK0!L^$/$NI>)K"#4I](M[73;VW6YLYX+\3L5/\ #(NQ=CX(.%+CA@6&!FMK
M5WIEQ\2M$T^\T]9[FPLKG5$NVN&06:C;%GRQPY;>P!/W=I(J/P5X/F\/:QK6
MJ36UAI:ZHT1&EZ7(SV\)12#)DH@+OGG"+]T=3DU#K7A+6;[6?%>IVD]HEQJ.
MBQZ9I9>5QY1Q(7:3"G'S2*1MS]V@"CI/Q1OM1TSP[J\_AK['I.NWJ6,4CWN9
MP[[MKB+R\-&=HY+*W4[2 ">_O+=[JRE@CN9K1I%*B>#;OC]UW C/U!KE)O!<
MYN?!-O;R0+IGAL%I8V)WNZV_E1;>,8&YB<D=!5[QO:>*-0T(6?@Z>SM;B>0+
M<7%Q<-"\</\ %Y3+&^'/0,0=O7!.* .-M-6_X1OX@>*+G3;_ %*[\,Z%HF_4
M4O+^:Z5;U27"1O*S$-Y?W@#C)4$9J'58]:TOP3HWBRZU?4?^$DO;^Q>2W%[(
MML1-*B&V%OGRMH1B,[=V5W;L\UT</@ZYO?ASJGA"XTO3=!M)[-K>V:PO9+OY
MF!R[[XHR3NP2<DMDY(/)+?PWXBUJ]T-_%JZ9;VNALMQ';6%S),+RY5"JR.6C
M38J9+!1NR2,GY>0"A\6('T_P[=:C8:MK2Z]=R16VC6MG?R1+YY(PBQ(0D@.&
M9C(&.-W( 4"V\M]XJ\>3>'KF^N8-/T.PADU$V%P]LUS=S9*KYB$.$5%+85AD
MNN>!@P:+H/C*'Q5+KWB'3-!U"^D<QPS+JTP6QMR>4AC-MU(Y9BP+'N!@"[-X
M?\3:3XO\0:KX:_LN>/7D@9FOIY(VLYHX_*W!%C82K@*=NY.01GG- $GPTO;R
MYTG6;:[NYKR'3];N[*TGGE,DC0HPVAG.2Q!++DDD[:[*L?PKX=@\*^&;32+>
M5K@PAFEN'&&GE9BSR'W9B3CMG%;% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
-10 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>sgmo-20191231_g4.jpg
<TEXT>
begin 644 sgmo-20191231_g4.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1"<17AI9@  34T *@    @ ! $[  (
M   .   (2H=I  0    !   (6)R=  $    <   0>.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %-A<6EB(%-H
M96AZ860   'J'  '   (#   "&H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*BHJ*BK_P  1" *J R\# 2(  A$! Q$!_\0 'P   04! 0$! 0$
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MG_:_2CR?]K]*EHH B\G_ &OTH\G_ &OTJ6B@"+R?]K]*/)_VOTJ6B@"+R?\
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MXCGE21F+,N^,!2H).W &%VC Q@ &[1110 4444 %%%% !1110 4444 %%%%
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M)),S",,-N22 3CCTKS73? _Q\TC2K33=/\;>'X;2SA2""/RE;8B*%49-L2<
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M@>=O*CGO7;V'Q+TZ_P#L;_V3JUM:W<\EJEU/%&$6XC5R\) D+;AY;C< 4)&
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M%!(DD$Z[7AEC)5XW /564@X)!QD$@@D \]T;X7Z_X:3QAH6C7UBWA76[6?\
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MM-)\'M6\'^(I[1[JZOYKVTN+=F=8)"!Y;'<H.>"",="1FO7J* .'^$7@K4?
M/P_AT/6)K6:ZCGDD+VKLR88Y'+*IS^%=Q110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 57E_P!8:L57E_UAH G7[B_2EI%^XOTI: "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\\
M;X5PZKX;U5->O+L:SJTDUQ<266J7*6Z3,?W1$094;RU6( LF3Y8S7H=% 'G,
MO@?Q%J'A;Q);:G<:?_:>M"T;?'*YC#Q0Q(Y)* @%HV(X/!%7-<\%:I>>,Y_$
M6GS6?FPO8S6<,[L!(\(NDD1R%.P,ER0& ;!&2IQ@]U10!P4'@O6;GQ/9>(M4
MEL8[S^UA>7-M!([QPPI:2P1HCE 9&S)N)(4<D ?*,XNI63>!?%4>O7>IZ/;W
M%YJ%^T,>I7,EM;RP3+"Q5KCRV6.4-"I"D'<-V.F1ZO10!Q7PTM;\_#C_ $J7
M[/=7MU?7"3Q18XEN)7255?/!#!E!SP1G-5;SPIX@U^XTH>(;+0EN=-N895UZ
MVE<W;+'('(2(Q 1>9MPP$C !FX;BN_HH \LM?AOK0U[2K^^ATF>[T_5!=3:O
M-=33WEY%\ZA1O3]PH5@?*5F3(XV]39N/AY>/X-\+Z7J%Q#Y6C6UU%?M;AY&9
M9+.:']TH7+',@., G'&3Q7I5% 'BMC=ZOXYU73;31=;TAFL_#UY NI:-</-Y
M$DJPK')+E5,+MM)6+)8;'.3CBW<?"K5[J;4;BVL-!TI[W1KG3W$-W-<2S2R2
MQ2":6X>,/(248'<"5X.YMV%]?HH Y#5O"5]?Z]XEO89;=8]6T)--@#,VY9%,
M^2W'"_O5Y&3P>/7&D\!^((]!U7PU:3Z=_96MJGVF[>5Q/:[HDCG5(]A60$(2
MK%DVE^0=O/0:AXXBTS45AO-"UB.Q:^CL!J;0QK 978*N%,@E*[R%W^7M)Y!(
MYJ"P^(UA?W=N@TO5+>TN;^;3H[^9(A";B,R KQ(7P?*;#;=O0$@Y  .IN(/,
ML);>+ W1%%R>!Q@5RD'A&_B\%^#M(::V-QH3V37+!FV/Y,>UMAVY.3TR!^%5
M/^%CR7WB#PS;:5I5TFFZW=2I'?W<2B.YA2&1P\6U]RY*J1YBKN4D@'J)O%'C
M75-$\3W&FVFDF:WCT*ZU$7+;-HDBQMS^\#;.<$!<Y9<<;B #*UGX9W6H:_J&
ML/;:/J;/JRWMOI^I*6@GB-K' Z2$HVQP4W*P5_N@$?,<:>C>"[FPU;1[Y=-T
M'2([2>ZEEL](B*(HDC5$^;:OF-\N2Q5."!@XR9=,^)%E-9B36K"^TIO[-_M)
M9)XE*W,(*AGC5'9^KIA'"O\ .O&<XU]'\4)J>I-IMYI=_I%^(/M*6U\(BTD6
M=I=3$[KP2 02&&1D<B@#B#\-M:FURQOKR'2+F[L]82]?6+FZFFNIX!,S")%9
M,0*$;[B,4)7HN21#X6\/:SXM\%Z-8:M]AAT*WGEG$\$SFYG ,BK&8RFU,%B2
MVYL[1\HW''16OCNX3XH:CX;U6UCAT\2QV^GWR _/.8%F:&0DXW%6)7IG8PY-
M0MXVUBX\$V]SIMO9R:_J.JW.G6$#JWDDQ7,J%V&[.%AA9S@C)';(% %#0OAI
M+96\5A<Z!X1M!!:2VIUFRL\WESF,QJ^W8HA8@[F^>3/*CKN$=UX"\4:S906V
MJOI%J+?PW>:*K6T\LN]YHXE64AHUVCY#E>2./F;/&I?_ !!?_A!]!UJU^RZ<
M-6F2&YO-05FM],;:V_S0"N<.GE#+*-S#+#&#!=>,/$5OX9FO+6?0]2CEO;*W
MT_6K-2]I<":X6&0&%9BP:,D_\M,'CD$$  67P3KESJ$NKNVGPW\8T^:W@$[R
M1F6V$P=&?8"%99<!@I(/.TXP;'B#P_X@\36*1Z]H/A;4HM[_ .@37$ZM;@J
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M?5H/%$7B'PV+*>X>U^Q7=I?2O"DT:L7C99%5RC*S/QL8,'[8!K+\0_$NWLM
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MFA9+?^S\$.I.PE9&+>8, A2BIDC<Q[ZB@ HHHH **** "BBB@ HHHH ****
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M P4O&<EAGG(]1HH X+_A#-<'C1/%HN+ :C;NME!9J66 :=SN3=LR)"Q\S."
M5"9QECWM%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5Y?\ 6&K%5Y?]8: )
MU^XOTI:1?N+]*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *KR_P"L-6*KR_ZPT 3K]Q?I
M2TB_<7Z4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 57E_UAJQ5>7_ %AH G7[B_2EI%^X
MOTI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ JO+_K#5BJ\O\ K#0!.OW%^E+2+]Q?I2T
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JO
M+_K#5BJ\O^L- $Z_<7Z4M(OW%^E+0 4444 %%%% !1110 4444 %%%% !111
M0 5G:Y_R#XO^ORU_]'QUHUG:Y_R#XO\ K\M?_1\= &C1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !5>7_6&K%5Y?\ 6&@"=?N+]*6D7[B_2EH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>6/)P,#)[ 5T7AC0CX;T"'2S>/=K"SE'= FU68L$ '11G '8 "M>B@ HHHH
M**** "BBB@ HHHH **** "BBB@ JO+_K#5BJ\O\ K#0!.OW%^E+2+]Q?I2T
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M%UOXD\37%U>&W2-[329)<VUE* ,L ,;VR,Y/^&.SHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ JO+_K#5BJ\O\ K#0!.OW%^E+2+]Q?I2T
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M:NZY_P @^+_K\M?_ $?'0!HT444 %%%% !1110 4444 %%%% !1110 4444
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M]8:L57E_UAH G7[B_2EI%^XOTI: "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **IZEJ^G:-:_:=7O[6P@SCS;F98US]6(KE?%?Q2\/\
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M6L3&ZD.9& 6(( PPN=_W1E6)K7/PQ\37H_XG7Q1\0R_]@^..S_\ 00:])HH
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M7(&R9/3$BX8?3.*Y/_A"_'O@[YO WBK^V;%>FE>(LR$#T2=?F'H >!Q7I]%
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M1R12+]UT=2&5AV(-7Z* ,;1_"]CHU[-?))=7E],@C>[O;AII!&#D(I/"KGG
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M+JW23_T(&N-O/@;X$GG-Q8:9-I%SVGTR[D@8?0 [?TH ]#HKS7_A67BC2_\
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M_1\=:-9VN?\ (/B_Z_+7_P!'QT :-%%% !1110 4444 %%%% !1110 4444
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M9OYNB:-,.9SVN9Q_Z"O]/O>K4 8&!P** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JO+_K#5BJ\O\
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M@ HHHH **** "BBB@ HHHH **K:EJ%MI.E7>HW\GE6MG"\\SX)VHBEF.!R<
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M1110 4444 %5Y?\ 6&K%5Y?]8: )U^XOTI:1?N+]*6@ HHHH **** "BBB@
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MO_H-W_\ WQ!_\:K1HH SO[,N_P#H-W__ 'Q!_P#&J/[,N_\ H-W_ /WQ!_\
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M_P"-4?V9=_\ 0;O_ /OB#_XU6C10!G?V9=_]!N__ .^(/_C5']F7?_0;O_\
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MQ';:;9-=/J,X,:2E)3&X12,LJLK+OSRR, " "0#H_P"S+O\ Z#=__P!\0?\
MQJC^S+O_ *#=_P#]\0?_ !JN<\"?$%O'%Q,]M8V:6(MTGCGMM4CN)(P[,%CG
MA #0R%1NQ\R]1NR*[2@#._LR[_Z#=_\ ]\0?_&J/[,N_^@W?_P#?$'_QJM&B
M@#._LR[_ .@W?_\ ?$'_ ,:H_LR[_P"@W?\ _?$'_P :K1HH SO[,N_^@W?_
M /?$'_QJC^S+O_H-W_\ WQ!_\:K1HH SO[,N_P#H-W__ 'Q!_P#&J/[,N_\
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M_P#[X@_^-4?V9=_]!N__ .^(/_C5:-% &=_9EW_T&[__ +X@_P#C5']F7?\
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MIK'RM)T8:/:FR9RUVGF[_-E#*-AP%^0%^68[NE>C444 %%%% !1110 4444
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MXM?(@BNULM0>_NYI-TKY3_1RPAA&"0Y7?NX/RG)KVRB@#'T%O$DAN7\3QZ5
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 57E_UAJQ5>7_6&@"=?N+]*6D7[B_2EH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=R02!8T>9P1@!NC9!R,Y.W%2R\7?VIX(LK'5O'.O6^J-<7UQ!>#6%T^&:-)
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MM(U_Q1J&NWE]#+LN+3Q#!J6GS%5\QV\H('MP!@+G&2"!Q7M@\.Z(-=.MC1[
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JO+_K#5BJ\O\
MK#0!.OW%^E+2+]Q?I2T %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5>7_6&K%5Y?]8: )U^
MXOTI:1?N+]*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MWNA_;8K?4K6Z-L+:XE1)+AA$DI,2[MS*%<9..Q^M>=1_#W6E\)I:-I$?VI?
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M)("W*\G/7GJ_ASJ<6O\ B/Q5KME:""SO)[98W66*7S&2'#$O$S1L1D?=9L#
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M%\X '&"<D#-T_P"%UIIWB:;4;:73XH7N+BYCDCTF(7RO-N+ W9R=H9V*X56
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M=:K<W\I>W/W)I'D\L8?@@L!N.<X/R\\ &[1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 57E_UAJQ5>7_6&@"=?N+]*6D7[B_2EH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "J\O^L-6*KR_ZPT 3K]Q?I2TB_<7Z4M !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 57E_UAJQ5>7_6&@"=?N+]*6D7[B_2EH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MJ\O^L-6*KR_ZPT 3K]Q?I2TB_<7Z4M !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 57E_P!8
M:L57E_UAH G7[B_2EI%^XOTI: "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JO+_ *PU8JO+
M_K#0!*LBA0">WI2^:GK^E5Z* +'FIZ_I1YJ>OZ57HH L>:GK^E'FIZ_I5>B@
M"QYJ>OZ4>:GK^E5Z* +'FIZ_I1YJ>OZ57HH L>:GK^E'FIZ_I5>B@"QYJ>OZ
M4>:GK^E5Z* +'FIZ_I1YJ>OZ57HH L>:GK^E'FIZ_I5>B@"QYJ>OZ4>:GK^E
M5Z* +'FIZ_I1YJ>OZ57HH L>:GK^E'FIZ_I5>B@"QYJ>OZ4>:GK^E5Z* +'F
MIZ_I1YJ>OZ57HH L>:GK^E'FIZ_I5>B@"QYJ>OZ4>:GK^E5Z* +'FIZ_I1YJ
M>OZ57HH L>:GK^E'FIZ_I5>B@"QYJ>OZ4>:GK^E5Z* +'FIZ_I1YJ>OZ57HH
M L>:GK^E'FIZ_I5>B@"QYJ>OZ4>:GK^E5Z* +'FIZ_I1YJ>OZ57HH L>:GK^
ME'FIZ_I5>B@"QYJ>OZ4>:GK^E5Z* +'FIZ_I1YJ>OZ57HH L>:GK^E'FIZ_I
M5>B@"QYJ>OZ4>:GK^E5Z* +'FIZ_I1YJ>OZ57HH L>:GK^E'FIZ_I5>B@"QY
MJ>OZ4>:GK^E5Z* +'FIZ_I1YJ>OZ57HH L>:GK^E'FIZ_I5>B@"QYJ>OZ4>:
MGK^E5Z* +'FIZ_I1YJ>OZ57HH L>:GK^E'FIZ_I5>B@"QYJ>OZ4>:GK^E5Z*
M +'FIZ_I1YJ>OZ57HH L>:GK^E'FIZ_I5>B@"QYJ>OZ4>:GK^E5Z* +'FIZ_
MI1YJ>OZ57HH L>:GK^E'FIZ_I5>B@"QYJ>OZ4>:GK^E5Z* +'FIZ_I1YJ>OZ
M57HH L>:GK^E'FIZ_I5>B@"QYJ>OZ4>:GK^E5Z* +'FIZ_I1YJ>OZ57HH L>
M:GK^E'FIZ_I5>B@"QYJ>OZ4>:GK^E5Z* +'FIZ_I1YJ>OZ57HH L>:GK^E0N
)07)'2FT4 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6843033840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2020 </div>
<div>USD ($) </div>
<div>product_target </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage', window );">Agreement restriction, ownership percentage (less than)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Biogen MA Inc | Collaboration and license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementNumberOfProductTargets', window );">Number of neurological disease gene targets | product_target</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected', window );">Number of product targets selected | product_target</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets', window );">Number of additional neurological disease gene targets | product_target</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAgreementTargetSelectionPeriod', window );">Target selection period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Biogen MA Inc | Collaboration and license agreement | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds from collaborators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Biogen MA Inc | Collaboration and license agreement | Pre-approval Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable', window );">Maximum milestone payment receivable</a></td>
<td class="nump">$ 925,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Biogen MA Inc | Collaboration and license agreement | Sales-based Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable', window );">Maximum milestone payment receivable</a></td>
<td class="nump">1,445,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Biogen MA Inc | Collaboration and license agreement | Achievement of specified research, clinical development, regulatory and first commercial sale milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable', window );">Maximum milestone payment receivable</a></td>
<td class="nump">$ 2,370,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Biogen MA Inc | Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementStandstillRestrictionPeriod', window );">Agreement restriction expiration period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld', window );">Agreement restriction, percentage of shares held</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod', window );">Agreement provision, expiration period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage', window );">Agreement provision, ownership percentage (less than)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Biogen MA Inc | Stock Purchase Agreement | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,420,157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 9.2137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Number Of Additional Product Targets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationAgreementNumberOfAdditionalProductTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAgreementTargetSelectionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Target Selection Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationAgreementTargetSelectionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Agreement Restriction, Percentage Of Shares Held</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Maximum Milestone Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementNumberOfProductTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Number Of Product Targets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementNumberOfProductTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Number Of Product Targets Selected</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementNumberOfProductTargetsSelected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Standstill Restriction, Ownership Threshold Percentage Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementStandstillRestrictionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Standstill Restriction Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementStandstillRestrictionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Voting Provisions Expiration Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Voting Provisions, Ownership Threshold Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeAgreementMilestoneAxis=sgmo_PreApprovalMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeAgreementMilestoneAxis=sgmo_PreApprovalMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeAgreementMilestoneAxis=sgmo_SalesBasedMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeAgreementMilestoneAxis=sgmo_SalesBasedMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6855383936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Sangamo France - Summary of Non-controlling Interest (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Stockholders' equity attributable to noncontrolling interest, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Fair value of additional shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(321)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
<td class="num">$ (54)<span></span>
</td>
<td class="num">$ (54)<span></span>
</td>
<td class="num">$ (72)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="num">$ (555)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(233)<span></span>
</td>
<td class="num">$ (555)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Stockholders' equity attributable to noncontrolling interest, ending balance</a></td>
<td class="nump">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="nump">739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember', window );">Non- Controlling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Stockholders' equity attributable to noncontrolling interest, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Stockholders' equity attributable to noncontrolling interest, ending balance</a></td>
<td class="nump">$ 185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185<span></span>
</td>
<td class="nump">$ 739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4616395-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInMinorityInterestRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInMinorityInterestRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6861614704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease, cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease, cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease, payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, weighted average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease, weighted average discount rate, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_LicenseObligations', window );">License obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=sgmo_ManufacturingCapacityMember', window );">Manufacturing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_PaymentsForOtherCommitment', window );">Payment to secure manufacturing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Other commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=sgmo_ManufacturingObligationsMember', window );">Manufacturing Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_PaymentsForOtherCommitment', window );">Payment to secure manufacturing capacity</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Other commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=sgmo_NonCancelableContractualCommitmentMember', window );">Non-cancelable Contractual Commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ContractualObligationPaidUponExecution', window );">Contractual obligation, paid upon execution</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease agreement, extendable lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Non-cancelable Contractual Commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease agreement, extendable lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=sgmo_BrisbaneCaliforniaMember', window );">Brisbane, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Area of space leased (in sqft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_LesseeOperatingLeaseLiabilityTenantImprovementAllowance', window );">Lessee operating lease liability tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance', window );">Lessee operating lease, lease not yet commenced tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_ResearchAndOfficeSpaceMember', window );">Research and Office Space | Valbonne, France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Area of space leased (in sqft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_OfficeAndLaboratoryMember', window );">Office And Laboratory | Brisbane, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Area of space leased (in sqft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_OfficeAndLaboratoryMember', window );">Office And Laboratory | Richmond, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Area of space leased (in sqft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_OfficeSpaceMember', window );">Office Space | Brisbane, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Area of space leased (in sqft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ContractualObligationPaidUponExecution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Obligation, Paid Upon Execution</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ContractualObligationPaidUponExecution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease, Lease Not Yet Commenced Tenant Improvement Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_LesseeOperatingLeaseLiabilityTenantImprovementAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease Liability Tenant Improvement Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_LesseeOperatingLeaseLiabilityTenantImprovementAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_LicenseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_LicenseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_PaymentsForOtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Other Commitment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_PaymentsForOtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandSubjectToGroundLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land subject to a ground lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandSubjectToGroundLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=sgmo_ManufacturingCapacityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=sgmo_ManufacturingCapacityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=sgmo_ManufacturingObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=sgmo_ManufacturingObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=sgmo_NonCancelableContractualCommitmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=sgmo_NonCancelableContractualCommitmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=sgmo_BrisbaneCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=sgmo_BrisbaneCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_ResearchAndOfficeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_ResearchAndOfficeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=sgmo_ValbonneFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=sgmo_ValbonneFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_OfficeAndLaboratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_OfficeAndLaboratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=sgmo_RichmondCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=sgmo_RichmondCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_OfficeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_OfficeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6607577024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Restricted Stock Unit Activity (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs outstanding at beginning of period (in shares)</a></td>
<td class="nump">322,701<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs awarded (in shares)</a></td>
<td class="nump">834,745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod', window );">RSUs released (in shares)</a></td>
<td class="num">(118,807)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">RSUs forfeited (in shares)</a></td>
<td class="num">(175,789)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs outstanding at end of period (in shares)</a></td>
<td class="nump">862,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber', window );">RSUs vested and expected to vest at end of period (in shares)</a></td>
<td class="nump">862,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining Contractual&#160;Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">RSUs outstanding at end of period (in years)</a></td>
<td class="text">1 year 2 months 19 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm', window );">RSUs vested and expected to vest at end of period (in years)</a></td>
<td class="text">1 year 2 months 19 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate&#160;Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">RSUs outstanding at end of period | $</a></td>
<td class="nump">$ 7,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue', window );">RSUs vested and expected to vest at end of period | $</a></td>
<td class="nump">$ 7,222<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options released in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options vested and expected to vest aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options vested and expected to vest outstanding number.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options vested and expected to vest weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of equity-based compensation awards outstanding. Excludes stock and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6855856288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2018</div></th>
<th class="th"><div>Nov. 23, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jul. 20, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Payments to acquire additional interest in subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 262<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase', window );">Business acquisition, number of free shares outstanding subject to purchase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">366,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">TxCell S.A.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfSharesAcquired', window );">Number of ordinary shares acquired (in shares)</a></td>
<td class="nump">13,519,036<span></span>
</td>
<td class="nump">11,528,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">TxCell S.A. | Share Purchase Agreement and Tender Offer Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders', window );">Number of free shares held by the holders (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">477,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares', window );">Business acquisition estimated fair value liabilities of free shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfSharesAcquired', window );">Number of ordinary shares acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,000<span></span>
</td>
<td class="nump">25,047,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Payments to acquire additional interest in subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability', window );">Increase in fair value of free shares asset and liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionEstimatedFairValueOfFreeShares', window );">Estimated fair value of free shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares', window );">Business acquisition estimated fair value assets of free shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">TxCell S.A. | Share Purchase Agreement and Tender Offer Agreement | Option Pricing Method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares', window );">Business acquisition estimated fair value liabilities of free shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition Estimated Fair Value Assets Of Free Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition Estimated Fair Value Liabilities Of Free Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionEstimatedFairValueOfFreeShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition, estimated fair value of free shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionEstimatedFairValueOfFreeShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition, number of free shares held by the holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Number Of Free Shares Outstanding Subject To Purchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionNumberOfSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition, number of shares acquired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionNumberOfSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase In Fair Value Of Free Shares Asset And Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of noncontrolling interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6861524688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Revenues from Strategic Partnering Collaboration Agreements and Research Activity Grants (Detail) - Revenue from Contract with Customer - Revenue From Collaboration Agreements, Grants And Licensing Concentration Risk [Member]<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Kite Pharma, Inc. ("Kite")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">22.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6850209008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table shows total stock-based compensation expense recognized in the accompanying Consolidated Statements of Operations (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:58.322%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.740%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,135&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,249&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,031&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,195&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,428&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,058&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,330&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,677&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,089&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions Used for Estimating Fair Value of Employee Stock Options</a></td>
<td class="text">The assumptions used for estimating the fair value of the employee stock options were as follows:<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:54.158%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.929%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.929%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.518%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.68-2.25%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.53-2.96%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.81-2.28%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term (in years)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.50-5.62</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.59-5.61</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.73-5.83</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield of stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">76.46-78.39%</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72.33-75.49%</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">71.11-72.30%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Weighted-Average Assumptions Used for Estimating Fair Value of ESPP Purchase Rights</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The weighted&#8211;average assumptions used for estimating the fair value of the ESPP purchase rights are as follows:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:53.701%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.035%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.181%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.623%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.53-2.42%</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.16-2.80%</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.44-0.76%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term (in years)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 &#8211; 2.0</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5-2.0</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5-2.0</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield of stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51.02-91.96%</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73.21-83.25%</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66.39-82.19%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6841734256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Sangamo France<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisition of Sangamo France</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 5 &#8211; ACQUISITION OF SANGAMO FRANCE</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On July&#160;20, 2018, Sangamo entered into various agreements with the goal of eventually acquiring 100% of Sangamo France&#8217;s share capital. The Company entered into the Sangamo France SPA with certain shareholders of Sangamo France, pursuant to which it acquired 13,519,036 ordinary shares of Sangamo France (&#8220;Ordinary Shares&#8221;) as part of a block transaction that closed on October&#160;1, 2018 (the &#8220;Acquisition Date&#8221;). Additionally, the Company and Sangamo France entered into a Tender Offer Agreement pursuant to which Sangamo agreed to acquire 11,528,635 Ordinary Shares for the same price per share as the Sangamo France SPA via a cash tender offer that closed on November&#160;23, 2018. Following the block transaction, cash tender offer, and other open market purchases of shares, the Company owned 98.2% of the Ordinary Shares as of December&#160;31, 2018 (or 25,047,671 Ordinary Shares). In addition to the Sangamo France SPA and the tender offer agreement, the Company also entered into arrangements with the holders of approximately 477,000 &#8220;free shares&#8221; of Sangamo France pursuant to which the Company has the right to purchase such shares from the holders (a call option) and such holders have the right to sell to the Company such shares from time to time through mid-2021 (a put option) (collectively the &#8220;Free Shares Options&#8221;). In June 2019, Sangamo France became a </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">soci&#233;t&#233; par actions simplifi&#233;e </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(&#8220;S.A.S.&#8221;) and was renamed from &#8220;TxCell&#8221; to &#8220;Sangamo Therapeutics France.&#8221; During 2019, the Company acquired approximately 111,000 vested free shares, increasing its ownership of the Ordinary Shares to 98.7% as of December&#160;31, 2019.</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At the Acquisition Date, the fair value of the Free Shares Options was estimated to be a liability of $0.2&#160;million. See Note 2 - </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair Value Measurement</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8211; </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Free Shares Asset/Liability</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> for information regarding the valuation method. The fair value of the Free Shares Options will vary based on future changes in the Company&#8217;s stock price during the option period. The fair value of the Free Shares Options was estimated to be an asset of $0.2&#160;million as of December&#160;31, 2019.</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The acquisition of Sangamo France was accounted for as a business combination in accordance with ASC Topic 805, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Business Combinations</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The operating results of Sangamo France after the Acquisition Date have been included in the Company&#8217;s Consolidated Statements of Operations. There were no purchase price adjustments subsequent to the acquisition.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There were no goodwill impairments during the years ended December&#160;31, 2019 or 2018 and, as noted below, substantially all of the non-controlling interest on the Acquisition Date was subsequently acquired by the Company and, accordingly, substantially all of the goodwill is allocated to the Company as of December&#160;31, 2019 and 2018.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the estimated consideration transferred and the fair value of the net assets acquired as of the Acquisition Date (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:85.262%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.738%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">October 1, 2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Consideration transferred</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45,911&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of non-controlling interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,829&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of Sangamo France</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81,740&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,779&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,427&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,857&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">IPR&amp;D</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55,019&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">155&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,761)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assumed debt liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,933)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liability, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,798)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of net identifiable assets acquired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42,745&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,995&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total fair value of net assets acquired</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81,740&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Non-controlling Interest</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the non-controlling interest at the Acquisition Date was based on the $2.99 acquisition price per share for the 11,981,867 Ordinary Shares that were not purchased by the Company in the block transaction on the Acquisition Date. Subsequent to the Acquisition Date and through December&#160;31, 2018, the Company acquired 11,528,635 Ordinary Shares, which when aggregated with the 13,519,036 Ordinary Shares acquired at the Acquisition Date, resulted in the Company owning 98.2% of all Ordinary Shares as of December&#160;31, 2018. During 2019, the Company acquired approximately 111,000 vested free </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">shares for approximately $0.3&#160;million of cash, pursuant to the exercise of the Free Shares Options, increasing its ownership of the Ordinary Shares to 98.7% as of December&#160;31, 2019.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Non-controlling interest as of December&#160;31, 2019 was as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:85.262%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.738%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, beginning of year</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">739&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of additional shares acquired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(321)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss attributable to non-controlling interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(233)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, end of year</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">185&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6849992208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 9 &#8211; STOCK-BASED COMPENSATION</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table shows total stock-based compensation expense recognized in the accompanying Consolidated Statements of Operations (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:58.322%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.740%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,135&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,249&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,031&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,195&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,428&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,058&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,330&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,677&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,089&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, total stock-based compensation expense to be recognized in future periods related to unvested stock options was $37.4&#160;million, which is expected to be expensed over a weighted-average period of 2.76 years. As of December&#160;31, 2019, total stock-based compensation expense to be recognized in future periods related to unvested RSUs was $7.0&#160;million, which is expected to be expensed over a weighted-average period of 2.11 years. There was no capitalized stock-based employee compensation expense as of December&#160;31, 2019, 2018 or 2017.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Valuation Assumptions</span></div><div style="text-indent:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Employee stock-based compensation expense was determined using the Black-Scholes option valuation model for stock options and employee share purchases under the ESPP. Option valuation models require the input of subjective assumptions and these assumptions can vary over time. The fair value of RSUs was based on the closing price of the underlying common stock on the date of grant.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company bases its determination of expected volatility through its assessment of the historical volatility of its common stock. The Company relied on its historical exercise and post-vested termination activity for estimating its expected term for use in determining the fair value of these options.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The weighted-average estimated fair value per share of options granted during 2019, 2018 and 2017 was $6.37, $11.39, and $4.10, respectively, based upon the assumptions used in the Black-Scholes valuation model. The assumptions used for estimating the fair value of the employee stock options were as follows:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:54.158%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.929%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.929%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.518%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.68-2.25%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.53-2.96%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.81-2.28%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term (in years)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.50-5.62</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.59-5.61</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.73-5.83</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield of stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">76.46-78.39%</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72.33-75.49%</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">71.11-72.30%</span></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Employees purchased 249,364, 328,710 and 253,994 shares of common stock through the ESPP at an average exercise price of $8.53, $4.51, and $3.22 per share during 2019, 2018 and 2017, respectively. The weighted-average estimated fair values of shares purchased under the Company&#8217;s ESPP during 2019, 2018 and 2017 were $4.70, $7.07 and $2.37, respectively, based upon the assumptions used in the Black-Scholes valuation model.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The weighted&#8211;average assumptions used for estimating the fair value of the ESPP purchase rights are as follows:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:53.701%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.035%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.181%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.623%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.53-2.42%</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.16-2.80%</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.44-0.76%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term (in years)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 &#8211; 2.0</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5-2.0</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5-2.0</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield of stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51.02-91.96%</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73.21-83.25%</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66.39-82.19%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6850031056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Financial Data (Unaudited)</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 13 &#8211; QUARTERLY FINANCIAL DATA (UNAUDITED)</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth certain unaudited quarterly financial data for the eight quarters ended December&#160;31, 2019. The unaudited information set forth below has been prepared on the same basis as the audited information contained herein and includes all adjustments necessary to present fairly the information set forth. The operating results for any quarter are not indicative of results for any future period. All amounts are in thousands except per share amounts.</span></div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:22.264%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:6.823%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.823%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.823%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.823%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.823%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.823%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.823%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.830%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Q1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Q2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Q3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Q4</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Q1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Q2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Q3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Q4</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,071&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,548&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,958&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">54,851&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,637&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,416&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,562&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,837&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51,968&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51,052&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51,206&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,382&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,634&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40,556&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,803&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">47,609&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net (loss) income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(42,203)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(30,356)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(27,361)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,501&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(20,187)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16,640)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(12,843)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(19,219)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(53)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(72)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(54)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(54)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(555)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net (loss) income attributable to Sangamo Therapeutics, Inc.</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(42,150)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(30,284)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(27,307)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,555&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(20,187)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16,640)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(12,843)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18,664)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted net (loss) income per share attributable to Sangamo Therapeutics, Inc.</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.41)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.26)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.24)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.04&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.23)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.17)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.13)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.18)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6845636112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Securities and Free Share Liability</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value measurements of the Company&#8217;s cash equivalents, available-for-sale securities and the free share asset/liability are identified at the following levels within the fair value hierarchy (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:44.852%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.741%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurement</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,496&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,496&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,999&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,999&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,495&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,496&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,999&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">155,368&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">155,368&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">95,017&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">95,017&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,493&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,493&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">303,878&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">303,878&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and marketable securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">337,373&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,496&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">306,877&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Free shares asset</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">236&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">236&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:44.852%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.741%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> Fair Value Measurement</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103,291&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103,291&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103,291&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103,291&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">177,224&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">177,224&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63,870&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63,870&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,621&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,621&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">259,715&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">259,715&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and marketable securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">363,006&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103,291&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">259,715&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Free shares liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">154&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">154&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Summary of Estimated Fair Value of Free Share Liability Assumptions</a></td>
<td class="text"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"><tr><td style="width:1.0%;"/><td style="width:71.784%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.812%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.389%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.815%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Free Shares valuation assumptions:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sangamo Stock Price (USD)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.68&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.48&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sangamo France Stock Price (EUR)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8364;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.14&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8364;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.58&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">USD/ EUR Exchange Rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.91&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.87&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Correlation Sangamo and Sangamo France Stock Prices</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sangamo Stock Price (USD) Volatility Estimate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">79.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sangamo France Stock Price (EUR) Volatility Estimate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">USD/ EUR Exchange Rate Volatility Estimate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk Free Rate and Cost of Debt by Expected Exercise Date</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Varies</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Varies</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19190-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6850046464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Balance Sheet Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment, Net</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Property and equipment, net consist of the following (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.792%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Laboratory equipment</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,179&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,466&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Furniture and fixtures</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,639&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,840&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,888&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,640&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Buildings</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,876&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Construction in progress</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,901&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">65,211&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41,607&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">88,033&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,681)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,310)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,926&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">78,723&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Intangible Assets and Goodwill</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The changes in intangible assets were as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:71.245%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.452%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, beginning of year</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">54,243&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Indefinite-lived assets - IPR&amp;D</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55,019&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency translation adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,087)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(776)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, end of year</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,156&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">54,243&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The changes in goodwill were as follows (in thousands):</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:70.660%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, beginning of year</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40,044&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,585&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill acquired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,995&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency translation adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(771)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(536)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, end of year</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,273&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40,044&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Summary of Accounts Payable and Accrued Liabilities</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accounts payable and accrued liabilities consist of the following (in thousands):</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:70.474%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.117%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.472%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,671&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,355&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued research and development expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,102&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,999&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities - current</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,214&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued professional fees</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,118&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,930&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred rent</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">204&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,451&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,969&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total accounts payable and accrued liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,556&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,457&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6853101808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (95,419)<span></span>
</td>
<td class="num">$ (68,889)<span></span>
</td>
<td class="num">$ (54,568)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(1,573)<span></span>
</td>
<td class="num">(1,148)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Net pension losses</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Change in unrealized gain (loss) on available-for-sale securities</a></td>
<td class="nump">592<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(306)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">(96,428)<span></span>
</td>
<td class="num">(70,062)<span></span>
</td>
<td class="num">(54,874)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive loss attributable to non-controlling interest</a></td>
<td class="num">(233)<span></span>
</td>
<td class="num">(574)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Sangamo Therapeutics, Inc.</a></td>
<td class="num">$ (96,195)<span></span>
</td>
<td class="num">$ (69,488)<span></span>
</td>
<td class="num">$ (54,874)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613674-111683<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109240241&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6861140880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Feb. 21, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover page.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SANGAMO THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">68-0359556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7000 Marina Blvd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Brisbane<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">970-6000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value  $0.01&#160;per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SGMO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,244,723,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,022,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;">Certain information required by Part III, Items 10-14 of this Form 10-K is incorporated by reference to the registrant&#8217;s definitive Proxy Statement for the 2020 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Form 10-K, provided that if such Proxy Statement is not filed within such period, such information will be included in an amendment to this Form 10-K to be filed within such 120-day period</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%;">.</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001001233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 20-F, 40-F<br> -Number 240<br> -Section 15<br> -Subsection d-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6622373344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Weighted-Average Assumptions Used for Estimating Fair Value of ESPP Purchased Rights (Detail) - 2010 Employee Stock Purchase Plan<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield of stock</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sgmo_EmployeeStockPurchasePlanMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.16%<span></span>
</td>
<td class="nump">0.44%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">0.73%<span></span>
</td>
<td class="nump">0.66%<span></span>
</td>
<td class="nump">0.71%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sgmo_EmployeeStockPurchasePlanMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">0.76%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">0.83%<span></span>
</td>
<td class="nump">0.82%<span></span>
</td>
<td class="nump">0.76%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sgmo_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sgmo_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6850019248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 2 &#8211; FAIR VALUE MEASUREMENT</span></div><div style="text-indent:36pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company measures certain assets and liabilities at fair value on a recurring basis, including cash equivalents, available-for-sale securities and the free share asset/liability.&#160;The accounting guidance establishes a three-tier hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows:</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">i.e.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> supported by little or no market activity).</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value measurements of the Company&#8217;s cash equivalents, available-for-sale securities and the free share asset/liability are identified at the following levels within the fair value hierarchy (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:44.852%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.741%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurement</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,496&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,496&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,999&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,999&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,495&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,496&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,999&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">155,368&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">155,368&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">95,017&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">95,017&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,493&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,493&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">303,878&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">303,878&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and marketable securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">337,373&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,496&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">306,877&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Free shares asset</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">236&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">236&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:44.852%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.741%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> Fair Value Measurement</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103,291&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103,291&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103,291&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103,291&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">177,224&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">177,224&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63,870&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63,870&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,621&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,621&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">259,715&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">259,715&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and marketable securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">363,006&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103,291&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">259,715&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Free shares liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">154&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">154&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash Equivalents and Marketable Securities</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company generally classifies its marketable securities and some cash equivalents as Level 2. Instruments are classified as Level 2 when observable market prices for identical securities that are traded in less active markets are used. When observable market prices for identical securities are not available, such instruments are priced using benchmark curves, benchmarking of like securities, sector groupings, matrix pricing and valuation models. These valuation models are proprietary to the pricing providers or brokers and incorporate a number of inputs, including in approximate order of priority: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. For certain security types, additional inputs may be used, or some of the standard inputs may not be applicable. Evaluators may prioritize inputs differently on any given day for any security based on market conditions, and not all inputs listed are available for use in the evaluation process for each security evaluation on any given day.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Free Shares Asset/Liability</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a result of the July&#160;20, 2018 Share Purchase Agreement (&#8220;Sangamo France SPA&#8221;) to acquire Sangamo France (see Note 5 &#8211; </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Acquisition of Sangamo France</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">), the Company entered into arrangements with the holders of approximately 477,000 &#8220;free shares&#8221; of Sangamo France pursuant to which the Company has the right to purchase such shares from the holders (a call option) and such holders have the right to sell to the Company such shares from time to time through mid-2021 (a put option). The Company initially recorded a liability of $0.2&#160;million on the acquisition date. The put options were classified within Level&#160;3 of the fair value hierarchy as the Company utilized a binomial-lattice pricing model (the &#8220;Monte Carlo simulation model&#8221;) that involved certain market conditions to estimate the fair value of the options. The assumptions used in this simulation model are reviewed on a quarterly basis and adjusted, as needed. Subsequent changes in the fair value of the free shares are recorded in general and administrative expenses in the Consolidated Statements of Operations. During the year, the Company purchased approximately 111,000 shares of the 477,000 total free shares for a cash payment of approximately $0.3&#160;million upon exercise of the put options. As of December&#160;31, 2019, approximately 366,000 free shares remain outstanding and subject to purchase by the Company.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The free shares liability was approximately $0.2&#160;million at December 31, 2018 and the Company recognized a gain due to an increase in the fair value of the free shares of approximately $0.5&#160;million for the year ended December&#160;31, 2019, offset by approximately $0.1&#160;million for the shares purchased during the year, bringing the balance to an asset of approximately $0.2&#160;million at December&#160;31, 2019.</span></div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"><tr><td style="width:1.0%;"/><td style="width:71.784%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.812%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.389%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.815%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Free Shares valuation assumptions:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sangamo Stock Price (USD)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.68&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.48&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sangamo France Stock Price (EUR)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8364;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.14&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8364;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.58&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">USD/ EUR Exchange Rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.91&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.87&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Correlation Sangamo and Sangamo France Stock Prices</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sangamo Stock Price (USD) Volatility Estimate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">79.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sangamo France Stock Price (EUR) Volatility Estimate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">USD/ EUR Exchange Rate Volatility Estimate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk Free Rate and Cost of Debt by Expected Exercise Date</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Varies</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Varies</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6711653632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase (decrease) in deferred tax assets valuation allowance</a></td>
<td class="num">$ (29,600,000)<span></span>
</td>
<td class="nump">$ 45,300,000<span></span>
</td>
<td class="num">$ (28,900,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Deferred tax assets, net operating loss carryforwards for federal</a></td>
<td class="nump">489,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Deferred tax assets, net operating loss carryforwards for state</a></td>
<td class="nump">164,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal', window );">Federal research tax credit carryforwards</a></td>
<td class="nump">16,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal', window );">State research tax credit carryforwards</a></td>
<td class="nump">15,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest and/or penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_MinistryOfTheEconomyFinanceAndIndustryFranceMember', window );">French</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Deferred tax assets, net operating loss carryforwards for foreign</a></td>
<td class="nump">$ 147,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets tax credit carryforwards research federal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets tax credit carryforwards research state and local.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_MinistryOfTheEconomyFinanceAndIndustryFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_MinistryOfTheEconomyFinanceAndIndustryFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6856214768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisition of Sangamo France - Summary of Estimated Fair Value of Net Assets Acquired (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Oct. 01, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,273<span></span>
</td>
<td class="nump">$ 40,044<span></span>
</td>
<td class="nump">$ 1,585<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">TxCell S.A.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="nump">$ 45,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue', window );">Fair value of non-controlling interest</a></td>
<td class="nump">35,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Fair value of Sangamo France</a></td>
<td class="nump">81,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="nump">4,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets', window );">Current assets</a></td>
<td class="nump">2,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">1,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment', window );">IPR&amp;D</a></td>
<td class="nump">55,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Current liabilities</a></td>
<td class="num">(9,761)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Assumed debt liabilities</a></td>
<td class="num">(4,933)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent', window );">Deferred tax liability, net</a></td>
<td class="num">(6,798)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Fair value of net identifiable assets acquired</a></td>
<td class="nump">42,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">38,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total fair value of net assets acquired</a></td>
<td class="nump">$ 81,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination recognized identifiable assets acquired and liabilities assumed in process research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary difference assumed at the acquisition date that are classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=108330185&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=108330185&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6863709904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Major Customers, Partnerships and Strategic Alliances - Revenues Recognized under Agreement (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total</a></td>
<td class="nump">$ 54,851<span></span>
</td>
<td class="nump">$ 21,958<span></span>
</td>
<td class="nump">$ 17,548<span></span>
</td>
<td class="nump">$ 8,071<span></span>
</td>
<td class="nump">$ 26,837<span></span>
</td>
<td class="nump">$ 23,562<span></span>
</td>
<td class="nump">$ 21,416<span></span>
</td>
<td class="nump">$ 12,637<span></span>
</td>
<td class="nump">$ 102,428<span></span>
</td>
<td class="nump">$ 84,452<span></span>
</td>
<td class="nump">$ 36,567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. ("Kite")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,350<span></span>
</td>
<td class="nump">25,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. ("Kite") | Recognition of upfront fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,977<span></span>
</td>
<td class="nump">18,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. ("Kite") | Research services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,373<span></span>
</td>
<td class="nump">6,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,680<span></span>
</td>
<td class="nump">13,516<span></span>
</td>
<td class="nump">12,258<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Recognition of upfront fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,494<span></span>
</td>
<td class="nump">4,013<span></span>
</td>
<td class="nump">1,769<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Research services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,367<span></span>
</td>
<td class="nump">9,503<span></span>
</td>
<td class="nump">10,489<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Milestone achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,819<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,359<span></span>
</td>
<td class="nump">37,810<span></span>
</td>
<td class="nump">17,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525 | Recognition of upfront fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total</a></td>
<td class="nump">$ 8,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,697<span></span>
</td>
<td class="nump">37,810<span></span>
</td>
<td class="nump">17,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525 | Milestone achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,662<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_ResearchServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_ResearchServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_MilestoneAchievementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_MilestoneAchievementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerSB525Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6862549520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Summary of Cash Equivalents and Available-for-Sale Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, at carrying value, total</a></td>
<td class="nump">$ 80,428<span></span>
</td>
<td class="nump">$ 140,418<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, amortized cost</a></td>
<td class="nump">303,546<span></span>
</td>
<td class="nump">259,974<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, gross unrealized gains</a></td>
<td class="nump">351<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, gross unrealized (Losses)</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(259)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, estimated fair value</a></td>
<td class="nump">303,878<span></span>
</td>
<td class="nump">259,715<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost', window );">Total cash equivalents and available-for-sale securities, amortized cost</a></td>
<td class="nump">337,040<span></span>
</td>
<td class="nump">363,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax', window );">Total cash equivalents and available-for-sale securities, gross unrealized gains</a></td>
<td class="nump">352<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax', window );">Total cash equivalents and available-for-sale securities, gross unrealized (losses)</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(259)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsAndAvailableForSaleSecurities', window );">Total cash equivalents and available-for-sale securities, estimated fair value</a></td>
<td class="nump">337,373<span></span>
</td>
<td class="nump">363,006<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, at carrying value, total</a></td>
<td class="nump">30,496<span></span>
</td>
<td class="nump">103,291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax', window );">Cash equivalents, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax', window );">Cash and cash equivalents accumulated gross unrealized loss before tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, estimated fair value</a></td>
<td class="nump">30,496<span></span>
</td>
<td class="nump">103,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, at carrying value, total</a></td>
<td class="nump">2,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax', window );">Cash equivalents, gross unrealized gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax', window );">Cash and cash equivalents accumulated gross unrealized loss before tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, estimated fair value</a></td>
<td class="nump">2,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, amortized cost</a></td>
<td class="nump">155,230<span></span>
</td>
<td class="nump">177,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, gross unrealized gains</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, gross unrealized (Losses)</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(129)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, estimated fair value</a></td>
<td class="nump">155,368<span></span>
</td>
<td class="nump">177,224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CashEquivalentsMember', window );">Cash equivalents:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, at carrying value, total</a></td>
<td class="nump">33,494<span></span>
</td>
<td class="nump">103,291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax', window );">Cash equivalents, gross unrealized gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax', window );">Cash and cash equivalents accumulated gross unrealized loss before tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, estimated fair value</a></td>
<td class="nump">33,495<span></span>
</td>
<td class="nump">103,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, amortized cost</a></td>
<td class="nump">94,905<span></span>
</td>
<td class="nump">63,981<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, gross unrealized gains</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, gross unrealized (Losses)</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(111)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, estimated fair value</a></td>
<td class="nump">95,017<span></span>
</td>
<td class="nump">63,870<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, amortized cost</a></td>
<td class="nump">53,411<span></span>
</td>
<td class="nump">18,640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, gross unrealized gains</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, gross unrealized (Losses)</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, estimated fair value</a></td>
<td class="nump">$ 53,493<span></span>
</td>
<td class="nump">$ 18,621<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents accumulated gross unrealized gain before tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents accumulated gross unrealized loss before tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsAndAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsAndAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for Sale Securities Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for sale securities, gross unrealized gain, before tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for sale securities, gross unrealized loss, before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6843181888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Summary of Future Minimum Payments under Contractual Obligations</a></td>
<td class="text">Future minimum payments under lease obligations at December&#160;31, 2019 consist of the following (in thousands):&#160;<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:85.262%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.738%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,870&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,390&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,468&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,556&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,694&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,141&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58,119&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Imputed interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13,713)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,406&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Reported as of December 31, 2019:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities - current (included in Accounts payable and accrued liabilities on the Consolidated Balance Sheet)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,214&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities - long-term</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41,192&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,406&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6849970144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">SUBSEQUENT EVENTS<div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2020, the Company entered into a global licensing collaboration agreement with Biogen MA, Inc. and its affiliate, Biogen International GmbH, for the research, development and commercialization of gene regulation therapies for the treatment of neurological diseases. The companies plan to leverage the Company&#8217;s proprietary ZFP technology delivered via AAV to modulate expression of key genes involved in neurological diseases.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Biogen collaboration agreement, the Company will grant to Biogen an exclusive, royalty bearing and worldwide license, under its relevant patents and know-how, to develop, manufacture and commercialize certain ZFP and/or  AAV-based products directed to up to 12 neurological disease gene targets selected by Biogen. Biogen has already selected three of these: ST-501 for tauopathies including Alzheimer&#8217;s disease, ST-502 for synucleinopathies including Parkinson&#8217;s disease, and a third undisclosed neuromuscular disease target. Biogen has exclusive rights to nominate up to nine additional targets over a target selection period of five years. For each gene target selected by Biogen, the Company will perform early research activities, costs for which will be shared by the companies, aimed at the development of the combination of proprietary CNS delivery vectors and ZFP-TFs (or potential other ZFP products) targeting therapeutically relevant genes. Biogen will then assume responsibility and costs for the IND-enabling studies, clinical development, related regulatory interactions, and global commercialization. The Company will be responsible for GMP manufacturing activities for the initial clinical trials for the first three products of the collaboration and plans to leverage its in-house manufacturing capacity. Biogen will assume responsibility for GMP manufacturing activities beyond the first clinical trial for each of the first three products. Subject to certain exceptions set forth in the Biogen collaboration agreement, the Company will be prohibited from developing, manufacturing or commercializing any therapeutic product directed to the targets selected by Biogen.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">After the Biogen collaboration agreement becomes effective, Biogen will pay the Company an upfront payment of $125.0&#160;million. The Company is also eligible to receive research, development, regulatory and commercial milestone payments that could total up to approximately $2.37&#160;billion if Biogen selects all of the targets allowed under the agreement and all the specified milestones set forth in the agreement are achieved, which includes up to $925.0&#160;million in pre-approval milestone payments and up to $1,445.0 million in first commercial sale and other sales-based milestone payments.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"> I</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">n addition, the Company will also be eligible to receive tiered high single-digit to sub-teen royalties on potential net commercial sales of licensed products arising from the collaboration. These royalty payments will be subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Biogen collaboration agreement will continue, on a product-by-product and country-by-country basis, until the expiration of the applicable royalty term. Biogen has the right to terminate the collaboration agreement, in its entirety or on target-by-target basis, for any reason after a specified notice period. Each party has the right to terminate this agreement on account of the other party&#8217;s bankruptcy or material, uncured breach. In addition, the Company may terminate the collaboration agreement if Biogen challenges any patents licensed by the Company to Biogen.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Concurrently with the execution of the collaboration agreement, the Company also entered into a stock purchase agreement with Biogen MA, Inc., pursuant to which Biogen will purchase 24,420,157 shares of the Company&#8217;s common stock (the &#8220;Biogen Shares&#8221;), at a price per share of $9.2137, for an aggregate purchase price of $225.0&#160;million.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the terms of the stock purchase agreement, Biogen has agreed not to, without the Company&#8217;s prior written and subject to specified conditions and exceptions, directly or indirectly acquire shares of the Company&#8217;s outstanding common stock, seek or propose a tender or exchange offer or merger between the parties, solicit proxies or consents with respect to any </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">matter, or undertake other specified actions related to the potential acquisition of additional equity interests in the Company. Such standstill restrictions expire on the earlier of the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV83Njk2NTgxNDE2MDUx_0d84836a-c95f-4eb8-a58e-c4a119cbf42f">three</span>-year anniversary of the effectiveness of the Biogen collaboration agreement and the date that Biogen beneficially owns less than 5% of the Company&#8217;s common stock.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The stock purchase agreement also provides that until the first anniversary of the effectiveness of the Biogen collaboration agreement, Biogen will hold and not sell any of the Biogen Shares and from the first anniversary through the second anniversary, Biogen will hold and not sell at least 50% of the Biogen Shares, in addition to being subject to certain volume limitations. The stock purchase agreement further provides that, subject to certain limitations, upon Biogen&#8217;s request, the Company will register for resale any of the Biogen Shares on a registration statement to be filed with the SEC, until such time as all remaining Biogen Shares may be sold pursuant to Rule 144 promulgated under the Securities Act during any 90-day period.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, Biogen has agreed that, excluding specified extraordinary matters, it will vote the Biogen Shares in accordance with the Company&#8217;s recommendation and has granted the Company an irrevocable proxy with respect to the foregoing. Such voting provisions expire on the earlier of (i) the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV83Njk2NTgxNDE2MTM1_d2c3c96b-72c7-45db-9430-d8a812b9fc92">two</span>-year anniversary of the effectiveness of the Biogen collaboration agreement, (ii) the date that Biogen beneficially owns less than 5% of the Company&#8217;s common stock and (iii) the date the Biogen collaboration agreement is terminated; provided, however, that in no event shall such expiration date be prior to the one-year anniversary of the effectiveness of the Biogen collaboration agreement.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The consummation of the transactions under each of the Biogen collaboration agreement and the stock purchase agreement is subject to the satisfaction of customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6850025056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Summary of Cash Equivalents and Available-for-Sale Securities</a></td>
<td class="text"><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The table below summarizes the Company&#8217;s cash equivalents and available-for-sale securities (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:44.852%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.741%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,496&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,496&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,998&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,999&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,494&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,495&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">155,230&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">145&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">155,368&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">94,905&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">115&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">95,017&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,411&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">91&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,493&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">303,546&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">351&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(19)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">303,878&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and available-for-sale securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">337,040&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">352&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(19)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">337,373&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103,291&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103,291&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103,291&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103,291&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Available-for-sale securities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">177,353&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(129)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">177,224&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63,981&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(111)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63,870&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,640&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(19)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,621&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">259,974&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(259)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">259,715&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and available-for-sale securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">363,265&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(259)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">363,006&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of investments available-for-sale by contractual maturity were as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:57.064%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.883%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.969%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.884%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Maturing in one year or less</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">282,046&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">259,715&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Maturing after one year through five years</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,832&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total investments available-for-sale</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">303,878&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">259,715&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6622427632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Defined contribution plan, employer's matching contribution percent</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum percentage limit of employee contributions</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount', window );">Defined contribution plan, maximum employer's contribution per employee</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Aggregate employer's contributions to defined contribution plan</a></td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6842358640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 1 &#8211; ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Business Overview</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sangamo Therapeutics, Inc. (&#8220;Sangamo&#8221; or &#8220;the Company&#8221;) was incorporated in the State of Delaware in June 1995 and changed its name from Sangamo Biosciences, Inc. in January 2017. Sangamo is a clinical-stage biotechnology company focused on translating ground-breaking science into genomic medicines with the potential to transform patients&#8217; lives using our platform technologies in gene therapy, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ex vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene-edited cell therapy, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> genome editing and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> genome regulation. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying Consolidated Financial Statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;U.S.&#160;GAAP&#8221;) and include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Consolidated Financial Statements. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net loss attributable to &#8194;non-controlling interests on our Consolidated Statements of Operations equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties.</span></div><div style="padding-left:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Going Concern</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sangamo is currently working on a number of long-term development projects that will involve experimental technology. The projects may require several years and substantial expenditures to complete and ultimately may be unsuccessful. The Company plans to finance operations with available cash resources, collaborations and strategic partnerships funds, research grants and from the issuance of equity or debt securities. Sangamo believes that its available cash, cash equivalents and investments as of December&#160;31, 2019, and expected revenues from collaborations, strategic partnerships and research grants, will be adequate to fund its operations at least through the next 12&#160;months from the date the financial statements are issued. Sangamo will require substantial additional financial resources to complete the development and commercialization of its products including ZFP therapeutic products. Additional capital may not be available on terms acceptable to the Company, or at all. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, the Company&#8217;s business and ability to develop its technology and therapeutic products would be harmed. Furthermore, any sales of additional equity securities may result in dilution to the Company&#8217;s stockholders, and any debt financing may include covenants that restrict the Company&#8217;s business.</span></div><div style="padding-left:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Reclassifications</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain prior period amounts in the accompanying Consolidated Financial Statements have been reclassified to conform to the current period presentation.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Summary of Significant Accounting Policies</span></div><div style="padding-left:18pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of the accompanying Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities, including from acquisitions, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. In March 2019, the Company recorded an adjustment to revenue related to a change in estimate in connection with the hemophilia A collaboration agreement with Pfizer Inc. (&#8220;Pfizer&#8221;). This adjustment was a direct result of the decision to increase the project scope during the first quarter of 2019 and the corresponding costs, both of which resulted in a decrease in the measure of proportional performance. In December 2019, the Company updated its estimated project cost and related revenues upon the transfer of the investigational new drug (&#8220;IND&#8221;) for Pfizer SB-525. This adjustment directly resulted in a decrease in project scope during the fourth quarter of 2019 and a decrease in the corresponding costs, which resulted in an increase in the measure of proportional performance. These adjustments increased revenue by $5.7&#160;million, decreased net loss by $5.7&#160;million and decreased the Company&#8217;s basic net loss per share by $0.05 for the year ended December&#160;31, 2019.</span></div><div style="text-indent:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Effective January&#160;1, 2018, the Company adopted the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from Contracts with Customers</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASC Topic 606&#8221;) using the modified retrospective method, resulting in a change to its accounting policy for revenue recognition. ASC Topic 606 establishes a unified model to determine how revenue is recognized.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s contract revenues are derived from collaboration agreements and research activity grants and licensing. Research and licensing agreements typically include upfront signing or license fees, cost reimbursements, research services, minimum sublicense fees, milestone payments and royalties on future licensee&#8217;s product sales. The Company has both fixed and variable consideration. Non-refundable upfront fees and funding of research and development activities are considered fixed, while milestone payments are generally identified as variable consideration. Sangamo&#8217;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenues under research grant agreements are generally recognized when the related qualified research expenses are incurred. Deferred revenue represents the portion of research or license payments received but not earned.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic 606. The Company&#8217;s performance obligations include license rights, development services and services associated with regulatory submission and approval processes. Revenues from research services earned under collaboration agreements are generally recognized as revenue as the related services are provided. Revenues from non-refundable upfront fees are recognized over time either by measuring progress towards satisfaction of the relevant performance obligation, using the input method (i.e. cumulative actual costs incurred relative to total estimated costs) or on a straight-line basis when a performance obligation is expected to be satisfied evenly over a period of time (or when the entity has a stand-ready obligation). Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement which may include total internal personnel costs and external costs to be incurred as well as, in certain cases, the estimated stand-ready obligation period. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. The estimated period of performance and project costs, such as personnel and manufacturing cost, are reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Related costs and expenses under these arrangements have historically approximated the revenues recognized.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues from collaboration agreements and research activity grants as a percentage of total revenues were as follows:</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:58.322%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.740%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pfizer Inc.</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">47&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">47&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Kite Pharma, Inc.</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sanofi Genzyme</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Receivables from collaborations are typically unsecured and are concentrated in the biopharmaceutical industry. Accordingly, the Company may be exposed to credit risk generally associated with biopharmaceutical companies or specific to its collaboration agreements. To date, the Company has not experienced any losses related to these receivables.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Funds received from third parties under contract or funds received from grant arrangements are generally recorded as revenue if the Company is deemed to be the principal participant in the arrangements because the activities under the contracts or grants are part of the Company&#8217;s development programs. Contract funds received are not refundable and are recognized when the related qualified research and development costs are incurred and there is reasonable assurance that the funds will be received. Funds received in advance are recorded as deferred revenue.</span></div><div style="padding-left:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Business Combinations</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for acquisitions using the acquisition method of accounting, which requires that assets acquired, including in-process research and development (&#8220;IPR&amp;D&#8221;) projects, liabilities assumed and any non-controlling interests in the acquired target in an acquisition be recorded at their fair values as of the acquisition date on the Company&#8217;s Consolidated Balance Sheets. Any excess of purchase price over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires the Company to make significant estimates and assumptions. As a result, the Company may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.</span></div><div style="padding-left:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Goodwill and Intangible Assets</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Goodwill represents the excess of the consideration transferred over the estimated fair values of assets acquired and liabilities assumed in a business combination. Intangible assets with indefinite useful lives are related to purchased IPR&amp;D projects and are measured at their respective fair values as of the acquisition date. Goodwill and intangible assets with indefinite useful lives are not amortized. Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed&#160;finite-lived&#160;and would then be amortized based on their respective estimated useful lives at that point in time. The Company tests goodwill and indefinite-lived intangible assets for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate the fair values of the assets are below their respective carrying amounts. As of December 31, 2019, no impairment of goodwill or indefinite-lived intangible assets has been identified.</span></div><div style="padding-left:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Valuation of Long-Lived Assets</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Long-lived assets, including property and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may suggest that the carrying value of an asset may not be recoverable. Recoverability of these assets is measured by comparison of the carrying amount of each asset to the future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. As of December 31, 2019, no impairment of any long-lived assets has been identified.</span></div><div style="text-indent:22.5pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Fair Value Measurements</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short maturities. Marketable securities are stated at their estimated fair values. The free share asset/liability is measured using a binomial-lattice pricing model and is reviewed each reporting period and adjusted, as needed, and is expected to approximate fair value.</span></div><div style="padding-left:18pt;margin-top:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash, Cash Equivalents and Restricted Cash</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sangamo considers all highly-liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> cash, deposits in demand money market accounts, and commercial paper.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Restricted cash consists of a letter of credit for $1.5&#160;million as a deposit for the Brisbane lease.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A reconciliation of cash, cash equivalents and restricted cash reported within the Consolidated Balance Sheets to the amounts reported within the accompanying Consolidated Statements of Cash Flows is as follows (in thousands):</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:61.450%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.700%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80,428&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">140,418&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49,826&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents and restricted cash as reported within the Consolidated Statements of Cash Flows</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81,928&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">143,918&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,326&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-indent:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%;">Marketable Securities</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sangamo classifies its marketable securities as available-for-sale and records its investments at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in accumulated other comprehensive loss (&#8220;AOCI&#8221;). The Company classifies those investments that are not required for use in current operations and that mature in more than 12 months as non-current marketable securities in the accompanying Consolidated Balance Sheets.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s investments are subject to a periodic impairment review. The Company recognizes an impairment charge, if material, when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the fair value has been less than the Company&#8217;s cost basis, the financial condition and near-term prospects of the investee and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. Realized gains and losses on available-for-sale securities are included in other income, net, which are determined using the specific identification method.</span></div><div style="padding-left:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Property and Equipment</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method based on the estimated useful lives of the related assets which is generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfNTczOA_d3889db1-4c3b-4768-aeb6-f18ca1502096">three</span> to five years. For leasehold improvements, amortization is calculated using the straight-line method based on the shorter of the useful life or the lease term. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.</span></div><div style="padding-left:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development Expenses</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development expenses consist primarily of personnel costs, including salaries, benefits and stock-based compensation, clinical studies performed by contract research organizations ("CROs"), materials and supplies and overhead allocations consisting of various support and facility-related costs.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development costs are expensed as incurred.</span></div><div style="padding-left:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">General and Administrative Expenses</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">General and administrative expenses consist of finance, human resources, legal and other administrative activities. These expenses consist primarily of personnel costs, including salaries, benefits and stock-based compensation, facilities and overhead costs, legal expenses, and other general and administrative costs.</span></div><div style="padding-left:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-based Compensation</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company measures and recognizes compensation expense for all stock-based payment awards made to Sangamo employees and directors, including employee share options, restricted stock units (&#8220;RSUs&#8221;) and employee stock purchases related to the 2010 Employee Stock Purchase Plan (&#8220;ESPP&#8221;), as amended, based on estimated fair values at the award grant date. The fair value of stock-based awards is amortized over the vesting period of the award using a straight-line method.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To estimate the fair value of an award, the Company uses the Black-Scholes option pricing model. This model requires inputs such as expected life, expected volatility and risk-free interest rate. These inputs are subjective and generally require significant analysis and judgment to develop. While estimates of expected life and volatility are derived primarily from the Company&#8217;s historical data, the risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected life assumption. The Company accounts for forfeitures in the period they occur.</span></div><div style="padding-left:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income Taxes</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Income tax expense has been provided using the liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities as measured by the enacted tax rates that will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets if, based upon the available evidence, it is not more likely than not that the deferred tax assets will be realized.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company recognizes a tax benefit from an&#160;uncertain&#160;tax&#160;position&#160;only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the Company&#8217;s consolidated financial statements from such positions are measured based on the largest benefit that has a greater than 50% likelihood of being realized. The Company recognizes interest and penalties associated with tax matters as part of the income tax provision and includes accrued interest and penalties with the related income tax liability within account payable and accrued liabilities on its Consolidated Balance Sheets.</span></div><div style="padding-left:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%;">Foreign Currency Translation</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The functional currency of the Company&#8217;s foreign subsidiaries is primarily the Euro. Assets and liabilities denominated in foreign currencies are translated to U.S. dollars using the exchange rates at the balance sheet date. Foreign currency translation adjustments are recorded as a component of AOCI within stockholders&#8217; equity. Revenues and expenses from the Company&#8217;s foreign subsidiaries are translated using the monthly average exchange rates in effect during the period in which the transactions occur. Foreign currency transaction gains and losses are recorded in interest and other income, net, on the Company&#8217;s Consolidated Statements of Operations.</span></div><div style="padding-left:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net Loss Per Share</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic net loss per share attributable to Sangamo Therapeutics, Inc. stockholders has been computed by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders is calculated by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock plus potential dilutive securities outstanding during the period.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The total number of shares subject to stock options and RSUs outstanding and the ESPP shares reserved for issuance, which are all anti-dilutive, were excluded from consideration in the calculation of diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders. Stock options and RSUs outstanding and ESPP shares reserved for issuance as of December 31, 2019, 2018 and 2017 were 10,750,550, 9,048,793, and 8,367,628, respectively.</span></div><div style="padding-left:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Segments</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company operates in one segment. Management uses one measure of profitability and does not segregate its business for internal reporting. As of December&#160;31, 2019 and 2018, substantially all of the Company&#8217;s assets were maintained in the United States. For the years ended December&#160;31, 2019, 2018 and 2017, substantially all of the Company&#8217;s revenues and operating expenses were generated and incurred in the United States.</span></div><div style="text-indent:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Pronouncements</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Recently Adopted</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Simplified Disclosure</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the Securities and Exchange Commission ("SEC") adopted amendments to certain disclosure requirements in Securities Act Release No.&#160;33-10532, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Disclosure Update and Simplification</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, as updated. These amendments eliminate, modify, or integrate into other SEC requirements certain disclosure rules. Among the amendments is the requirement to present an analysis of changes in stockholders&#8217; equity in the interim financial statements included in quarterly reports on Form 10-Q. The analysis, which can be presented as a footnote or separate statement, is required for the current and comparative quarter and year-to-date interim periods. The amendments are effective for all filings made on or after November&#160;5, 2018. The Company&#8217;s adoption of these SEC amendments had no material effect on the Company&#8217;s reporting of financial position, results of operations, cash flows or stockholders&#8217; equity.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Accounting for Leases</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2016-2, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASC Topic 842&#8221;). ASC Topic 842 amends a number of aspects of lease accounting, including requiring lessees to recognize almost all leases with a term greater than one year as a right-of-use (&#8220;ROU&#8221;) asset and corresponding liability, measured at the present value of the lease payments. On January&#160;1, 2019, the Company adopted ASC Topic 842 using the modified retrospective </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">approach with a cumulative-effect adjustment of $0.9 million reflected as a decrease to the opening balance of accumulated deficit as of the adoption date. Results for the year ended December&#160;31, 2019 are presented under ASC Topic 842. No prior period amounts were adjusted and continue to be reported in accordance with previous lease guidance, ASC Topic 840 &#8211; </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASC Topic 840&#8221;).</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ASC Topic 842 provides a number of optional practical expedients in transition. The Company elected the practical expedients to not reassess its prior conclusions about lease identification under the new standard, to not reassess lease classification, and to not reassess initial direct costs. The Company did not elect the practical expedient allowing the use-of-hindsight, which would require the Company to reassess the lease term of its leases based on all facts and circumstances through the effective date. The Company also did not elect the practical expedient pertaining to land easements, as this is not applicable to the current contract portfolio.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The impact of the adoption of ASC Topic 842 on the accompanying Consolidated Balance Sheet as of January&#160;1, 2019 was as follows (in thousands):</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:60.352%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.617%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.794%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.682%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.620%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments Due to the Adoption of ASC Topic 842</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">78,723&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(62,500)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,223&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,753&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,753&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid rent</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,025&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,025&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Operating lease liabilities - current</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,408&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,408&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Deferred rent</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">271&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(271)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Build-to-suit lease obligation</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,689&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(27,689)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Operating lease liabilities - long-term</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,933&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,933&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(562,696)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">897&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(561,799)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">___________________</span></div><div style="text-indent:-36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(1)&#160;Operating lease liabilities &#8211; current and deferred rent are included in accounts payable and accrued liabilities on the Consolidated Balance Sheets.</span></div><div style="text-indent:-36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(2)&#160;Build-to-suit lease obligation and operating lease liabilities &#8211; long-term are included in long-term portion of lease liabilities on the Consolidated Balance Sheets.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The adjustments due to the adoption of ASC Topic 842 primarily related to the recognition of operating lease ROU assets and operating lease liabilities for the Company&#8217;s leases. In addition, the adoption of ASC Topic 842 resulted in a change in accounting of the build-to-suit component of two leases under ASC Topic 840 to operating leases under ASC Topic 842. As a result, the Company derecognized the estimated fair value of the building shells that were included in Property and equipment, net as of December&#160;31, 2018, as the Company had been deemed to own these buildings under ASC Topic 840. For a description of the leases, see &#8220;Note 7 &#8211; </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Commitments and Contingencies &#8211; Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; in these Consolidated Financial Statements.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Not Yet Adopted</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Collaborative Arrangements</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2018, the FASB issued ASU 2018-18, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative Arrangements (ASC Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASC Topic 808&#8221;), which clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC Topic 606 when the counterparty is a customer. In addition, ASC Topic 808 precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. This guidance will be effective for the Company beginning January&#160;1, 2020. The Company has determined the adoption of ASU 2018-18 will not have a material impact on its Consolidated Financial Statements.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Goodwill Impairment Testing</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2017, the FASB issued ASU No. 2017-4,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> Intangibles &#8211; Goodwill and Other (Topic 350): Simplifying the Test of Goodwill Impairment</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASU 2017-4&#8221;). The new guidance simplifies the subsequent measurement of goodwill by eliminating Step 2 from the goodwill impairment test. ASU 2017-4 requires goodwill impairment to be measured as the amount by which a reporting unit&#8217;s carrying amount exceeds its fair value, not to exceed the carrying amount of its goodwill. ASU </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2017-4 requires prospective application and is effective for annual periods beginning after December&#160;15, 2019. ASU 2017-4 will require the Company to amend its methodology for determining any goodwill impairment beginning in 2020. The Company does not expect the adoption of ASU 2017-4 to have a material impact on its Consolidated Financial Statements.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Credit Losses</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments &#8211; Credit Losses (Topic 326)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> ("ASU 2016-13"). ASU 2016-13 implements an impairment model, known as the current expected credit loss model that is based on expected losses rather than incurred losses. Under the new guidance, an entity will recognize as an allowance its estimate of expected credit losses. ASU 2016-13 is effective for all interim and annual reporting periods beginning after December 15, 2019 and must be adopted using a modified retrospective approach, with certain exceptions. Early adoption is permitted. The Company does not expect the adoption of ASU 2016-13 to have a material impact on its Consolidated Financial Statements.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Income Taxes</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income Taxes &#8211; Simplifying the Accounting for Income Taxes </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(&#8220;ASU 2019-12&#8221;). The guidance removes exceptions to the general principles in </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income Taxes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">(Topic 740)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> for allocating tax expense between financial statement components, accounting basis differences stemming from an ownership change in foreign investments and interim period income tax accounting for year-to-date losses that exceed projected losses. The guidance becomes effective for annual reporting periods beginning after December 15, 2020 and interim periods within those fiscal years with early adoption permitted. The Company plans to adopt ASU 2019-12 effective January 1, 2020 and does not expect this adoption to have a material impact on its Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6707822064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Difference Between Benefit for Income Taxes and Federal Statutory Income Tax Rate (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax at federal statutory rate(1)</a></td>
<td class="num">$ (20,038)<span></span>
</td>
<td class="num">$ (14,467)<span></span>
</td>
<td class="num">$ (18,553)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net</a></td>
<td class="num">(9,597)<span></span>
</td>
<td class="num">(2,849)<span></span>
</td>
<td class="nump">795<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Federal rate change</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">53,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="num">(665)<span></span>
</td>
<td class="num">(177)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation', window );">Non-deductible stock-based compensation</a></td>
<td class="nump">2,817<span></span>
</td>
<td class="num">(2,729)<span></span>
</td>
<td class="nump">2,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research credits</a></td>
<td class="num">(3,429)<span></span>
</td>
<td class="num">(1,005)<span></span>
</td>
<td class="num">(869)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">29,655<span></span>
</td>
<td class="nump">20,271<span></span>
</td>
<td class="num">(36,575)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">1,257<span></span>
</td>
<td class="nump">956<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation nondeductible expense income share based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32059-109318<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6861243360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 102,428<span></span>
</td>
<td class="nump">$ 84,452<span></span>
</td>
<td class="nump">$ 36,567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">145,922<span></span>
</td>
<td class="nump">114,866<span></span>
</td>
<td class="nump">65,728<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">61,686<span></span>
</td>
<td class="nump">46,736<span></span>
</td>
<td class="nump">27,200<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">207,608<span></span>
</td>
<td class="nump">161,602<span></span>
</td>
<td class="nump">92,928<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(105,180)<span></span>
</td>
<td class="num">(77,150)<span></span>
</td>
<td class="num">(56,361)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income, net</a></td>
<td class="nump">9,761<span></span>
</td>
<td class="nump">8,261<span></span>
</td>
<td class="nump">1,793<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(95,419)<span></span>
</td>
<td class="num">(68,889)<span></span>
</td>
<td class="num">(54,568)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(95,419)<span></span>
</td>
<td class="num">(68,889)<span></span>
</td>
<td class="num">(54,568)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
<td class="num">(233)<span></span>
</td>
<td class="num">(555)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Sangamo Therapeutics, Inc. stockholders</a></td>
<td class="num">$ (95,186)<span></span>
</td>
<td class="num">$ (68,334)<span></span>
</td>
<td class="num">$ (54,568)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net (loss) income per share attributable to Sangamo Therapeutics, Inc. (in dollars per share)</a></td>
<td class="num">$ (0.85)<span></span>
</td>
<td class="num">$ (0.70)<span></span>
</td>
<td class="num">$ (0.70)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Shares used in computing basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares)</a></td>
<td class="nump">112,114<span></span>
</td>
<td class="nump">96,941<span></span>
</td>
<td class="nump">78,084<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6976040848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="8">1 Months Ended</th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 05, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2014 </div>
<div>USD ($) </div>
<div>program</div>
</th>
<th class="th">
<div>Jan. 31, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>milestone </div>
<div>product </div>
<div>option</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AgreementTerminationTerm', window );">Agreement termination, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative-effect adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 897,000<span></span>
</td>
<td class="nump">$ 1,117,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,851,000<span></span>
</td>
<td class="nump">$ 21,958,000<span></span>
</td>
<td class="nump">$ 17,548,000<span></span>
</td>
<td class="nump">$ 8,071,000<span></span>
</td>
<td class="nump">$ 26,837,000<span></span>
</td>
<td class="nump">$ 23,562,000<span></span>
</td>
<td class="nump">$ 21,416,000<span></span>
</td>
<td class="nump">$ 12,637,000<span></span>
</td>
<td class="nump">$ 102,428,000<span></span>
</td>
<td class="nump">$ 84,452,000<span></span>
</td>
<td class="nump">$ 36,567,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,711,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,960,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,711,000<span></span>
</td>
<td class="nump">1,960,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative-effect adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 897,000<span></span>
</td>
<td class="nump">1,117,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember', window );">California Institute for Regenerative Medicine ("CIRM")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_GrantFundingAmount', window );">Funds due under the agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700,000<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember', window );">California Institute for Regenerative Medicine ("CIRM") | Research grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. ("Kite")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,350,000<span></span>
</td>
<td class="nump">25,517,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. ("Kite") | Collaboration agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,977,000<span></span>
</td>
<td class="nump">18,545,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. ("Kite") | Collaboration and license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_InitialResearchTermOfAgreement', window );">Initial research term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfOptionsToExtendInitialResearchTerm', window );">Number of options to extend initial research term | option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ExtendedResearchTermOfAgreement', window );">Extended research term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_SeparateUpfrontFee', window );">Separate fee for additional term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan', window );">Collaborative arrangement estimated reimbursable service costs for new research plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementTransactionPrice', window );">Collaborative arrangement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts', window );">Collaborative arrangement estimated reimbursable service costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,500,000<span></span>
</td>
<td class="nump">131,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. ("Kite") | Collaboration and license agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="nump">$ 3,010,000,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. ("Kite") | Collaboration and license agreement | Achievement of specified research, clinical development, regulatory and first commercial sale milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived', window );">Contingent development - and sales-based milestone payments to be received</a></td>
<td class="nump">1,260,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. ("Kite") | Collaboration and license agreement | Achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived', window );">Contingent development - and sales-based milestone payments to be received</a></td>
<td class="nump">$ 1,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementTransactionPrice', window );">Collaborative arrangement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AgreementTerminationTerm', window );">Agreement termination, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,359,000<span></span>
</td>
<td class="nump">37,810,000<span></span>
</td>
<td class="nump">17,008,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement', window );">Number of products approved | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementResearchServiceFees', window );">Research service fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525 | Topic 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,200,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525 | Topic 606 | Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative-effect adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525 | SB-525</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice', window );">Number of milestones included in transaction price | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525 | Collaboration agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,697,000<span></span>
</td>
<td class="nump">37,810,000<span></span>
</td>
<td class="nump">17,008,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">Contract with customer, liability, cumulative catch-up adjustment to revenue, change in measure of progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525 | Maximum | SB-525</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive', window );">Potential amount to be funded for achievement of specified commercialized and sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525 | Maximum | Other products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525 | Achievement of specified clinical development intellectual property and regulatory milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525 | Achievement of first commercial sale milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 475,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525 | Amended collaboration and license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Recognition of milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member', window );">Pfizer C9ORF72</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AgreementTerminationTerm', window );">Agreement termination, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member', window );">Pfizer C9ORF72 | Collaboration agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,827,000<span></span>
</td>
<td class="nump">2,188,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member', window );">Pfizer C9ORF72 | C9ORF72</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000.0<span></span>
</td>
<td class="nump">9,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member', window );">Pfizer C9ORF72 | Achievement of specified preclinical development clinical development and first commercial sale milestones | Maximum | C9ORF72</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member', window );">Pfizer C9ORF72 | Achievement of commercial milestones | Maximum | C9ORF72</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,680,000<span></span>
</td>
<td class="nump">13,516,000<span></span>
</td>
<td class="nump">12,258,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement', window );">Number of products approved | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfResearchProgram', window );">Number of research programs | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Topic 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,100,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Topic 606 | Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative-effect adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Collaboration agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,494,000<span></span>
</td>
<td class="nump">4,013,000<span></span>
</td>
<td class="nump">1,769,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Collaboration and license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementTransactionPrice', window );">Collaborative arrangement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts', window );">Collaborative arrangement estimated reimbursable service costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice', window );">Number of milestones included in transaction price | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Recognition of milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Collaboration and license agreement | Milestone One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Collaboration and license agreement | Milestone Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Collaboration and license agreement | Milestone Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Collaboration and license agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 276,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Collaboration and license agreement | Achievement of specified clinical development and regulatory milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Collaboration and license agreement | Achievement of specified sales milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_ShireAgMember', window );">Shire AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_ShireAgMember', window );">Shire AG | Collaboration and license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AgreementTerminationTerm', window );">Agreement termination, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Recognition of milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate additional revenue recognition milestone method revenue eligible to receive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AgreementTerminationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement Termination, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AgreementTerminationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreements number of products approved under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement estimated reimbursable service costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement Estimated Reimbursable Service Costs For New Research Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementResearchServiceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Research Service Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementResearchServiceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent development and sales based milestone payments to be received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Customer contract liability milestone payment eligible to receive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ExtendedResearchTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Extended Research Term Of Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ExtendedResearchTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_GrantFundingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant funding amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_GrantFundingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_InitialResearchTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial research term of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_InitialResearchTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_MilestonePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_MilestonePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_MilestoneRevenueReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone&#8203; revenue receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_MilestoneRevenueReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of clinical or regulatory milestones included in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NumberOfOptionsToExtendInitialResearchTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Options To Extend Initial Research Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NumberOfOptionsToExtendInitialResearchTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NumberOfResearchProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of research program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NumberOfResearchProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_SeparateUpfrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Separate upfront fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_SeparateUpfrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerSB525Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_SBFiveTwoFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_SBFiveTwoFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_OtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_OtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfFirstCommercialSaleMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfFirstCommercialSaleMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_AmendedCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_AmendedCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_CNineORFSevenTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_CNineORFSevenTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfCommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfCommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeAgreementMilestoneAxis=sgmo_MilestoneOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeAgreementMilestoneAxis=sgmo_MilestoneOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeAgreementMilestoneAxis=sgmo_MilestoneTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeAgreementMilestoneAxis=sgmo_MilestoneTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeAgreementMilestoneAxis=sgmo_MilestoneThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeAgreementMilestoneAxis=sgmo_MilestoneThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedSalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedSalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_ShireAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_ShireAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3.a.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>344</ContextCount>
  <ElementCount>509</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>104</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>13</UnitCount>
  <MyReports>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2108102 - Disclosure - Fair Value Measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/FairValueMeasurement</Role>
      <ShortName>Fair Value Measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2113103 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2118104 - Disclosure - Major Customers, Partnerships and Strategic Alliances</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliances</Role>
      <ShortName>Major Customers, Partnerships and Strategic Alliances</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2124105 - Disclosure - Acquisition of Sangamo France</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/AcquisitionofSangamoFrance</Role>
      <ShortName>Acquisition of Sangamo France</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2129106 - Disclosure - Other Balance Sheet Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/OtherBalanceSheetDetails</Role>
      <ShortName>Other Balance Sheet Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2134107 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2138108 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2143109 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2149110 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2151111 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2160112 - Disclosure - Related Party Disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/RelatedPartyDisclosures</Role>
      <ShortName>Related Party Disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2162113 - Disclosure - Quarterly Financial Data (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/QuarterlyFinancialDataUnaudited</Role>
      <ShortName>Quarterly Financial Data (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2165114 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2309302 - Disclosure - Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/FairValueMeasurementTables</Role>
      <ShortName>Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/FairValueMeasurement</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2314303 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/MarketableSecurities</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2319304 - Disclosure - Major Customers, Partnerships and Strategic Alliances (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesTables</Role>
      <ShortName>Major Customers, Partnerships and Strategic Alliances (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliances</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2325305 - Disclosure - Acquisition of Acquisition of Sangamo France (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/AcquisitionofAcquisitionofSangamoFranceTables</Role>
      <ShortName>Acquisition of Acquisition of Sangamo France (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2330306 - Disclosure - Other Balance Sheet Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/OtherBalanceSheetDetailsTables</Role>
      <ShortName>Other Balance Sheet Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/OtherBalanceSheetDetails</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2335307 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/CommitmentsandContingencies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2339308 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/StockholdersEquity</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2344309 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/StockBasedCompensation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2352310 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/IncomeTaxes</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2363311 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedTables</Role>
      <ShortName>Quarterly Financial Data (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/QuarterlyFinancialDataUnaudited</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Organization and Summary of Significant Accounting Policies - Revenues from Strategic Partnering Collaboration Agreements and Research Activity Grants (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Revenues from Strategic Partnering Collaboration Agreements and Research Activity Grants (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Organization and Summary of Significant Accounting Policies - Reconciliation of Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofCashandCashEquivalentsDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Reconciliation of Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - Organization and Summary of Significant Accounting Policies - Impact of Adoption of ASC on Condensed Consolidated Balance Sheet (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesImpactofAdoptionofASConCondensedConsolidatedBalanceSheetDetail</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Impact of Adoption of ASC on Condensed Consolidated Balance Sheet (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Fair Value Measurement - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Securities and Free Share Liability (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail</Role>
      <ShortName>Fair Value Measurement - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Securities and Free Share Liability (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2411406 - Disclosure - Fair Value Measurement - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurement - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2412407 - Disclosure - Fair Value Measurement - Summary of Estimated Fair Value of Free Share Liability Assumptions (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail</Role>
      <ShortName>Fair Value Measurement - Summary of Estimated Fair Value of Free Share Liability Assumptions (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2415408 - Disclosure - Marketable Securities - Summary of Cash Equivalents and Available-for-Sale Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail</Role>
      <ShortName>Marketable Securities - Summary of Cash Equivalents and Available-for-Sale Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2416409 - Disclosure - Marketable Securities - Summary of Available-for-Sale Securities by Contractual Maturity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetail</Role>
      <ShortName>Marketable Securities - Summary of Available-for-Sale Securities by Contractual Maturity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2417410 - Disclosure - Marketable Securities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MarketableSecuritiesAdditionalInformationDetail</Role>
      <ShortName>Marketable Securities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2420411 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail</Role>
      <ShortName>Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2421412 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Revenues Recognized under Agreement (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail</Role>
      <ShortName>Major Customers, Partnerships and Strategic Alliances - Revenues Recognized under Agreement (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2422413 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Agreement with Sigma-Aldrich Corporation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationAdditionalInformationDetail</Role>
      <ShortName>Major Customers, Partnerships and Strategic Alliances - Agreement with Sigma-Aldrich Corporation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2423414 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Agreement with Dow AgroSciences in Plant Agriculture - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDowAgroSciencesinPlantAgricultureAdditionalInformationDetail</Role>
      <ShortName>Major Customers, Partnerships and Strategic Alliances - Agreement with Dow AgroSciences in Plant Agriculture - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2426415 - Disclosure - Acquisition of Sangamo France - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail</Role>
      <ShortName>Acquisition of Sangamo France - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2427416 - Disclosure - Acquisition of Sangamo France - Summary of Estimated Fair Value of Net Assets Acquired (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofEstimatedFairValueofNetAssetsAcquiredDetail</Role>
      <ShortName>Acquisition of Sangamo France - Summary of Estimated Fair Value of Net Assets Acquired (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2428417 - Disclosure - Acquisition of Sangamo France - Summary of Non-controlling Interest (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail</Role>
      <ShortName>Acquisition of Sangamo France - Summary of Non-controlling Interest (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2431418 - Disclosure - Other Balance Sheet Details (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/OtherBalanceSheetDetailsDetail</Role>
      <ShortName>Other Balance Sheet Details (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/OtherBalanceSheetDetailsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2432419 - Disclosure - Other Balance Sheet Details - Schedule of Intangible Assets and Goodwill (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/OtherBalanceSheetDetailsScheduleofIntangibleAssetsandGoodwillDetail</Role>
      <ShortName>Other Balance Sheet Details - Schedule of Intangible Assets and Goodwill (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2433420 - Disclosure - Other Balance Sheet Details - Summary of Accounts Payable and Accrued Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail</Role>
      <ShortName>Other Balance Sheet Details - Summary of Accounts Payable and Accrued Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2436421 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2437422 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Payments under Contractual Obligations (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail</Role>
      <ShortName>Commitments and Contingencies - Summary of Future Minimum Payments under Contractual Obligations (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2440423 - Disclosure - Stockholders' Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2441424 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail</Role>
      <ShortName>Stockholders' Equity - Summary of Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2442425 - Disclosure - Stockholders' Equity - Summary of Restricted Stock Unit Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/StockholdersEquitySummaryofRestrictedStockUnitActivityDetail</Role>
      <ShortName>Stockholders' Equity - Summary of Restricted Stock Unit Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2445426 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2446427 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/StockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2447428 - Disclosure - Stock-Based Compensation - Assumptions Used for Estimating Fair Value of Employee Stock Options (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail</Role>
      <ShortName>Stock-Based Compensation - Assumptions Used for Estimating Fair Value of Employee Stock Options (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2448429 - Disclosure - Stock-Based Compensation - Weighted-Average Assumptions Used for Estimating Fair Value of ESPP Purchased Rights (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail</Role>
      <ShortName>Stock-Based Compensation - Weighted-Average Assumptions Used for Estimating Fair Value of ESPP Purchased Rights (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2450430 - Disclosure - Employee Benefit Plan - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/EmployeeBenefitPlanAdditionalInformationDetail</Role>
      <ShortName>Employee Benefit Plan - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2453431 - Disclosure - Income Taxes - Summary of Domestic and Foreign Components of Loss Before Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetail</Role>
      <ShortName>Income Taxes - Summary of Domestic and Foreign Components of Loss Before Income Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2454432 - Disclosure - Income Taxes - Summary of Benefit for Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail</Role>
      <ShortName>Income Taxes - Summary of Benefit for Income Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2455433 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/IncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2456434 - Disclosure - Income Taxes - Schedule of Difference Between Benefit for Income Taxes and Federal Statutory Income Tax Rate (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail</Role>
      <ShortName>Income Taxes - Schedule of Difference Between Benefit for Income Taxes and Federal Statutory Income Tax Rate (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2457435 - Disclosure - Income Taxes - Schedule of Difference Between Benefit for Income Taxes and Federal Statutory Income Tax Rate, Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Schedule of Difference Between Benefit for Income Taxes and Federal Statutory Income Tax Rate, Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2458436 - Disclosure - Income Taxes - Schedule of Company's Deferred Tax Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail</Role>
      <ShortName>Income Taxes - Schedule of Company's Deferred Tax Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2459437 - Disclosure - Income Taxes - Summary of Activity Related to Company's Unrecognized Tax Benefits (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/IncomeTaxesSummaryofActivityRelatedtoCompanysUnrecognizedTaxBenefitsDetail</Role>
      <ShortName>Income Taxes - Summary of Activity Related to Company's Unrecognized Tax Benefits (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2461438 - Disclosure - Related Party Disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/RelatedPartyDisclosuresDetails</Role>
      <ShortName>Related Party Disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/RelatedPartyDisclosures</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2464439 - Disclosure - Quarterly Financial Data (Unaudited) - Summary of Quarterly Financial Data (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedSummaryofQuarterlyFinancialDataDetail</Role>
      <ShortName>Quarterly Financial Data (Unaudited) - Summary of Quarterly Financial Data (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="sgmo-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2466440 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/SubsequentEvents</ParentRole>
      <Position>73</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="sgmo-20191231.htm">sgmo-20191231.htm</File>
    <File>sgmo-20191231.xsd</File>
    <File>sgmo-20191231_cal.xml</File>
    <File>sgmo-20191231_def.xml</File>
    <File>sgmo-20191231_lab.xml</File>
    <File>sgmo-20191231_pre.xml</File>
    <File>sgmo-20191231xex311.htm</File>
    <File>sgmo-20191231xex312.htm</File>
    <File>sgmo-20191231xex321.htm</File>
    <File>sgmo-20191231xexx1024.htm</File>
    <File>sgmo-20191231xexx1025.htm</File>
    <File>sgmo-20191231xexx1026.htm</File>
    <File>sgmo-20191231xexx1045.htm</File>
    <File>sgmo-20191231xexx211.htm</File>
    <File>sgmo-20191231xexx231.htm</File>
    <File>sgmo-20191231xexx41.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>sgmo-20191231_g1.jpg</File>
    <File>sgmo-20191231_g2.jpg</File>
    <File>sgmo-20191231_g3.jpg</File>
    <File>sgmo-20191231_g4.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6855851680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement - Summary of Estimated Fair Value of Free Share Liability Assumptions (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Oct. 01, 2018 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">USD/ EUR Exchange Rate</a></td>
<td class="nump">0.91<span></span>
</td>
<td class="nump">0.87<span></span>
</td>
<td class="nump">0.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Sangamo Stock Price (USD) (in usd per share)</a></td>
<td class="nump">$ 8.68<span></span>
</td>
<td class="nump">$ 11.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember', window );">Stock Price Volatility Estimate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Volatility Estimate</a></td>
<td class="nump">0.725<span></span>
</td>
<td class="nump">0.799<span></span>
</td>
<td class="nump">0.725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Exchange Rate Volatility Estimate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Volatility Estimate</a></td>
<td class="nump">0.066<span></span>
</td>
<td class="nump">0.077<span></span>
</td>
<td class="nump">0.066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk Free Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_DerivativeLiabilityTerm', window );">Risk Free Rate and Cost of Debt by Expected Exercise Date</a></td>
<td class="text">Varies<span></span>
</td>
<td class="text">Varies<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">TxCell S.A.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Sangamo France Stock Price (EUR) (in Euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.99<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">TxCell S.A. | Measurement Input, Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Sangamo France Stock Price (EUR) (in Euro per share) | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.58<span></span>
</td>
<td class="nump">&#8364; 2.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">TxCell S.A. | Stock Price Volatility Estimate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Volatility Estimate</a></td>
<td class="nump">0.725<span></span>
</td>
<td class="nump">0.086<span></span>
</td>
<td class="nump">0.725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">TxCell S.A. | Measurement Input Stock Price Correlation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Estimated Correlation Sangamo and Sangamo France Stock Prices</a></td>
<td class="nump">1.000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1.000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_DerivativeLiabilityTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative liability term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_DerivativeLiabilityTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyExchangeRateTranslation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6897108&amp;loc=SL6897125-166521<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyExchangeRateTranslation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=sgmo_MeasurementInputStockPriceCorrelationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=sgmo_MeasurementInputStockPriceCorrelationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6855322368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Sangamo France - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2018</div></th>
<th class="th"><div>Nov. 23, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jul. 20, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Payments to acquire additional interest in subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 262,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">TxCell S.A.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfSharesAcquired', window );">Number of ordinary shares acquired (in shares)</a></td>
<td class="nump">13,519,036<span></span>
</td>
<td class="nump">11,528,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of share capital and voting rights acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Purchase price per share (in dollars per share)</a></td>
<td class="nump">$ 2.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction', window );">Number of shares not purchased by the acquirer</a></td>
<td class="nump">11,981,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">TxCell S.A. | SPA and TOA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire', window );">Percentage of equity interests agreed to acquire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfSharesAcquired', window );">Number of ordinary shares acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,000<span></span>
</td>
<td class="nump">25,047,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders', window );">Number of free shares held by the holders (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">477,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Payments to acquire additional interest in subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares', window );">Business acquisition estimated fair value liabilities of free shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares', window );">Business acquisition estimated fair value assets of free shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">TxCell S.A. | SPA and TOA | Option Pricing Method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares', window );">Business acquisition estimated fair value liabilities of free shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">TxCell S.A. | SPA and TOA | Former Executive of TxCell</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfSharesAcquired', window );">Number of ordinary shares acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Payments to acquire additional interest in subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">TxCell S.A. | SPA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfSharesAcquired', window );">Number of ordinary shares acquired (in shares)</a></td>
<td class="nump">13,519,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=sgmo_SangamoFranceMember', window );">TxCell S.A. | SPA and TOA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Noncontrolling interest, ownership percentage by parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition Estimated Fair Value Assets Of Free Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition Estimated Fair Value Liabilities Of Free Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition, number of free shares held by the holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionNumberOfSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition, number of shares acquired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionNumberOfSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition number of shares owned by sellers under block transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition, percentage of equity interests agreed to acquire.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of noncontrolling interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_FormerExecutiveOfSangamoFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_FormerExecutiveOfSangamoFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_SharePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_SharePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=sgmo_SangamoFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=sgmo_SangamoFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6841551600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited) - Summary of Quarterly Financial Data (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 54,851<span></span>
</td>
<td class="nump">$ 21,958<span></span>
</td>
<td class="nump">$ 17,548<span></span>
</td>
<td class="nump">$ 8,071<span></span>
</td>
<td class="nump">$ 26,837<span></span>
</td>
<td class="nump">$ 23,562<span></span>
</td>
<td class="nump">$ 21,416<span></span>
</td>
<td class="nump">$ 12,637<span></span>
</td>
<td class="nump">$ 102,428<span></span>
</td>
<td class="nump">$ 84,452<span></span>
</td>
<td class="nump">$ 36,567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">53,382<span></span>
</td>
<td class="nump">51,206<span></span>
</td>
<td class="nump">51,052<span></span>
</td>
<td class="nump">51,968<span></span>
</td>
<td class="nump">47,609<span></span>
</td>
<td class="nump">39,803<span></span>
</td>
<td class="nump">40,556<span></span>
</td>
<td class="nump">33,634<span></span>
</td>
<td class="nump">207,608<span></span>
</td>
<td class="nump">161,602<span></span>
</td>
<td class="nump">92,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="nump">4,501<span></span>
</td>
<td class="num">(27,361)<span></span>
</td>
<td class="num">(30,356)<span></span>
</td>
<td class="num">(42,203)<span></span>
</td>
<td class="num">(19,219)<span></span>
</td>
<td class="num">(12,843)<span></span>
</td>
<td class="num">(16,640)<span></span>
</td>
<td class="num">(20,187)<span></span>
</td>
<td class="num">(95,419)<span></span>
</td>
<td class="num">(68,889)<span></span>
</td>
<td class="num">(54,568)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
<td class="num">(54)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="num">(72)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="num">(555)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(233)<span></span>
</td>
<td class="num">(555)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income attributable to Sangamo Therapeutics, Inc.</a></td>
<td class="nump">$ 4,555<span></span>
</td>
<td class="num">$ (27,307)<span></span>
</td>
<td class="num">$ (30,284)<span></span>
</td>
<td class="num">$ (42,150)<span></span>
</td>
<td class="num">$ (18,664)<span></span>
</td>
<td class="num">$ (12,843)<span></span>
</td>
<td class="num">$ (16,640)<span></span>
</td>
<td class="num">$ (20,187)<span></span>
</td>
<td class="num">$ (95,186)<span></span>
</td>
<td class="num">$ (68,334)<span></span>
</td>
<td class="num">$ (54,568)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net (loss) income per share attributable to Sangamo Therapeutics, Inc. (in dollars per share)</a></td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.41)<span></span>
</td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.85)<span></span>
</td>
<td class="num">$ (0.70)<span></span>
</td>
<td class="num">$ (0.70)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6607560208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 19,330<span></span>
</td>
<td class="nump">$ 14,677<span></span>
</td>
<td class="nump">$ 9,089<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">10,135<span></span>
</td>
<td class="nump">8,249<span></span>
</td>
<td class="nump">5,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 9,195<span></span>
</td>
<td class="nump">$ 6,428<span></span>
</td>
<td class="nump">$ 4,058<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6862994416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Balance Sheet Details (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 41,607<span></span>
</td>
<td class="nump">$ 88,033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(11,681)<span></span>
</td>
<td class="num">(9,310)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">29,926<span></span>
</td>
<td class="nump">78,723<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">17,179<span></span>
</td>
<td class="nump">11,466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">4,639<span></span>
</td>
<td class="nump">3,840<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">13,888<span></span>
</td>
<td class="nump">3,640<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,876<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 5,901<span></span>
</td>
<td class="nump">$ 65,211<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6854156016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Future Minimum Payments under Contractual Obligations (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2020</a></td>
<td class="nump">$ 5,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2021</a></td>
<td class="nump">6,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2022</a></td>
<td class="nump">6,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2023</a></td>
<td class="nump">6,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2024</a></td>
<td class="nump">6,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">26,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">58,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Imputed interest</a></td>
<td class="num">(13,713)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">44,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities - current (included in Accounts payable and accrued liabilities on the Consolidated Balance Sheet)</a></td>
<td class="nump">3,214<span></span>
</td>
<td class="nump">$ 1,408<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - long-term</a></td>
<td class="nump">$ 41,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6861497488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Additional Information (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>segment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 54,851<span></span>
</td>
<td class="nump">$ 21,958<span></span>
</td>
<td class="nump">$ 17,548<span></span>
</td>
<td class="nump">$ 8,071<span></span>
</td>
<td class="nump">$ 26,837<span></span>
</td>
<td class="nump">$ 23,562<span></span>
</td>
<td class="nump">$ 21,416<span></span>
</td>
<td class="nump">$ 12,637<span></span>
</td>
<td class="nump">$ 102,428<span></span>
</td>
<td class="nump">$ 84,452<span></span>
</td>
<td class="nump">$ 36,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="nump">4,501<span></span>
</td>
<td class="num">$ (27,361)<span></span>
</td>
<td class="num">$ (30,356)<span></span>
</td>
<td class="num">$ (42,203)<span></span>
</td>
<td class="num">$ (19,219)<span></span>
</td>
<td class="num">$ (12,843)<span></span>
</td>
<td class="num">$ (16,640)<span></span>
</td>
<td class="num">$ (20,187)<span></span>
</td>
<td class="num">(95,419)<span></span>
</td>
<td class="num">$ (68,889)<span></span>
</td>
<td class="num">$ (54,568)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber', window );">Stock options and RSUs outstanding (in shares) | shares</a></td>
<td class="nump">10,750,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,048,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,750,550<span></span>
</td>
<td class="nump">9,048,793<span></span>
</td>
<td class="nump">8,367,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (897)<span></span>
</td>
<td class="num">$ (1,117)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (95,186)<span></span>
</td>
<td class="num">$ (68,334)<span></span>
</td>
<td class="num">$ (54,568)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(897)<span></span>
</td>
<td class="num">$ (1,117)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Topic 842 | Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,680<span></span>
</td>
<td class="nump">13,516<span></span>
</td>
<td class="nump">12,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,359<span></span>
</td>
<td class="nump">$ 37,810<span></span>
</td>
<td class="nump">$ 17,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525 | Change in collaboration agreement scope | Collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share, basic | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of related assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of related assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization and summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options and restricted stock units outstanding number.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=109256448&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerSB525Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=sgmo_ChangeInCollaborationAgreementScopeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateByTypeAxis=sgmo_ChangeInCollaborationAgreementScopeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6709880320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of Sangamo&#8217;s stock option activity is as follows:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:46.680%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.929%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.732%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number of<br/>Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-<br/>Average<br/>Exercise per<br/>Share Price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average<br/>Remaining<br/>Contractual&#160;Term</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In&#160;thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options outstanding at December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,726,092&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.23&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,530,288&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.68&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(806,226)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.08&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options canceled</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,620,867)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.39&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options outstanding at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,829,287&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.71&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.91</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,472&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options vested and expected to vest at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,829,287&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.71&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.91</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,472&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options exercisable at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,993,645&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.43&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.54</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,442&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Restricted Stock Unit Activity</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of Sangamo&#8217;s RSU activity is as follows:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:54.451%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.756%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.662%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.665%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number of<br/>Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average<br/>Remaining<br/>Contractual&#160;Term</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate&#160;Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">RSUs outstanding at December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">322,701&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">RSUs awarded</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">834,745&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">RSUs released</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(118,807)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">RSUs forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(175,789)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">RSUs outstanding at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">862,850&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.22</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,222&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">RSUs vested and expected to vest at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">862,850&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.22</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,222&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6860696688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Securities and Free Share Liability (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">$ 303,878<span></span>
</td>
<td class="nump">$ 259,715<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">30,496<span></span>
</td>
<td class="nump">103,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">2,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">155,368<span></span>
</td>
<td class="nump">177,224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">95,017<span></span>
</td>
<td class="nump">63,870<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">53,493<span></span>
</td>
<td class="nump">18,621<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">33,495<span></span>
</td>
<td class="nump">103,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">303,878<span></span>
</td>
<td class="nump">259,715<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">337,373<span></span>
</td>
<td class="nump">363,006<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">30,496<span></span>
</td>
<td class="nump">103,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">2,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">155,368<span></span>
</td>
<td class="nump">177,224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">30,496<span></span>
</td>
<td class="nump">103,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">30,496<span></span>
</td>
<td class="nump">103,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">30,496<span></span>
</td>
<td class="nump">103,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">2,999<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">303,878<span></span>
</td>
<td class="nump">259,715<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">306,877<span></span>
</td>
<td class="nump">259,715<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">2,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">155,368<span></span>
</td>
<td class="nump">177,224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">95,017<span></span>
</td>
<td class="nump">63,870<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Corporate debt securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Corporate debt securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">95,017<span></span>
</td>
<td class="nump">63,870<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Corporate debt securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">53,493<span></span>
</td>
<td class="nump">18,621<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | U.S. government-sponsored entity debt securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | U.S. government-sponsored entity debt securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">53,493<span></span>
</td>
<td class="nump">18,621<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | U.S. government-sponsored entity debt securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Free shares asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Free shares asset | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Free shares asset | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Free shares asset | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">$ 236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Free shares liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Free shares liability | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Free shares liability | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Free shares liability | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=sgmo_FreeSharesAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=sgmo_FreeSharesAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=sgmo_FreeSharesLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=sgmo_FreeSharesLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6849970144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Balance Sheet Details<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Supplemental Balance Sheet Disclosures</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 6 &#8211; OTHER BALANCE SHEET DETAILS</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Property and Equipment, Net</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Property and equipment, net consist of the following (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.792%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Laboratory equipment</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,179&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,466&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Furniture and fixtures</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,639&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,840&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,888&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,640&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Buildings</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,876&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Construction in progress</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,901&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">65,211&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41,607&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">88,033&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,681)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,310)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,926&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">78,723&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Depreciation and amortization expense was $3.9&#160;million in 2019, $2.4&#160;million in 2018 and $1.5&#160;million in 2017.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Intangible Assets</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The changes in intangible assets were as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:71.245%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.452%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, beginning of year</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">54,243&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Indefinite-lived assets - IPR&amp;D</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55,019&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency translation adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,087)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(776)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, end of year</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,156&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">54,243&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Goodwill</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The changes in goodwill were as follows (in thousands):</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:70.660%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, beginning of year</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40,044&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,585&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill acquired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,995&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency translation adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(771)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(536)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, end of year</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,273&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40,044&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounts Payable and Accrued Liabilities</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accounts payable and accrued liabilities consist of the following (in thousands):</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:70.474%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.117%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.472%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,671&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,355&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued research and development expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,102&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,999&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities - current</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,214&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued professional fees</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,118&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,930&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred rent</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">204&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,451&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,969&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total accounts payable and accrued liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,556&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,457&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6842479664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 10 &#8211; EMPLOYEE BENEFIT PLAN</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company sponsors a defined-contribution savings plan under Section&#160;401(k) of the Internal Revenue Code covering all full-time employees (&#8220;Sangamo 401(k) Plan&#8221;). The Sangamo 401(k) Plan is intended to qualify under Section&#160;401 of the Internal Revenue Code.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company matched employee contributions equal to 50% for the first 8% in 2019, 2018 and 2017, up to a limit of $4,000 in 2019, 2018 and 2017. Matching funds are fully vested when contributed. Contributions to the Sangamo 401(k) Plan by the Company were $0.9&#160;million, $0.8&#160;million, and $0.5&#160;million for the years ended December&#160;31, 2019, 2018 and 2017, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6850017568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock', window );">Schedule of Revenue from Strategic Partnering Collaboration Agreements and Research Activity Grants as a Percentage of Total Revenues</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues from collaboration agreements and research activity grants as a percentage of total revenues were as follows:</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:58.322%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.740%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pfizer Inc.</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">47&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">47&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Kite Pharma, Inc.</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sanofi Genzyme</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A reconciliation of cash, cash equivalents and restricted cash reported within the Consolidated Balance Sheets to the amounts reported within the accompanying Consolidated Statements of Cash Flows is as follows (in thousands):</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:61.450%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.700%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80,428&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">140,418&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49,826&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents and restricted cash as reported within the Consolidated Statements of Cash Flows</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81,928&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">143,918&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,326&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Restrictions on Cash and Cash Equivalents</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A reconciliation of cash, cash equivalents and restricted cash reported within the Consolidated Balance Sheets to the amounts reported within the accompanying Consolidated Statements of Cash Flows is as follows (in thousands):</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:61.450%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.700%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80,428&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">140,418&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49,826&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents and restricted cash as reported within the Consolidated Statements of Cash Flows</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81,928&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">143,918&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,326&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Schedule of New Accounting Pronouncements and Changes in Accounting Principles</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The impact of the adoption of ASC Topic 842 on the accompanying Consolidated Balance Sheet as of January&#160;1, 2019 was as follows (in thousands):</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:60.352%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.617%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.794%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.682%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.620%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments Due to the Adoption of ASC Topic 842</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">78,723&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(62,500)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,223&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,753&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,753&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid rent</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,025&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,025&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Operating lease liabilities - current</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,408&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,408&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Deferred rent</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">271&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(271)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Build-to-suit lease obligation</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,689&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(27,689)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Operating lease liabilities - long-term</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,933&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,933&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(562,696)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">897&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(561,799)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">___________________</span></div><div style="text-indent:-36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(1)&#160;Operating lease liabilities &#8211; current and deferred rent are included in accounts payable and accrued liabilities on the Consolidated Balance Sheets.</span></div><div style="text-indent:-36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(2)&#160;Build-to-suit lease obligation and operating lease liabilities &#8211; long-term are included in long-term portion of lease liabilities on the Consolidated Balance Sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109236672&amp;loc=d3e765-108305<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.10-01.(b)(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=27015980&amp;loc=d3e46468-122699<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22580-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109236672&amp;loc=d3e725-108305<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6850254064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Acquisition of Sangamo France (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Summary of Estimated Fair Value of Net Assets Acquired</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the estimated consideration transferred and the fair value of the net assets acquired as of the Acquisition Date (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:85.262%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.738%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">October 1, 2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Consideration transferred</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45,911&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of non-controlling interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,829&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of Sangamo France</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81,740&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,779&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,427&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,857&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">IPR&amp;D</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55,019&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">155&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,761)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assumed debt liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,933)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liability, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,798)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of net identifiable assets acquired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42,745&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,995&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total fair value of net assets acquired</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81,740&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ScheduleOfNoncontrollingInterestTableTextBlock', window );">Summary of Non-controlling Interest</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Non-controlling interest as of December&#160;31, 2019 was as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:85.262%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.738%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, beginning of year</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">739&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of additional shares acquired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(321)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss attributable to non-controlling interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(233)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, end of year</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">185&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ScheduleOfNoncontrollingInterestTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ScheduleOfNoncontrollingInterestTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6856660768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Major Customers, Partnerships and Strategic Alliances - Agreement with Sigma-Aldrich Corporation - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2009</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2007</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136,308<span></span>
</td>
<td class="nump">$ 215,758<span></span>
</td>
<td class="nump">$ 81,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,851<span></span>
</td>
<td class="nump">$ 21,958<span></span>
</td>
<td class="nump">$ 17,548<span></span>
</td>
<td class="nump">$ 8,071<span></span>
</td>
<td class="nump">$ 26,837<span></span>
</td>
<td class="nump">$ 23,562<span></span>
</td>
<td class="nump">$ 21,416<span></span>
</td>
<td class="nump">$ 12,637<span></span>
</td>
<td class="nump">102,428<span></span>
</td>
<td class="nump">84,452<span></span>
</td>
<td class="nump">36,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember', window );">Sigma-Aldrich Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ResearchServicesPeriod', window );">Developed laboratory research reagents, research services period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued under license agreement</a></td>
<td class="nump">$ 4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Public offering, common stock shares issued</a></td>
<td class="nump">636,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ReducedRoyaltyRate', window );">Reduced royalty rate</a></td>
<td class="nump">10.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember', window );">Sigma-Aldrich Corporation | License agreement terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember', window );">Sigma-Aldrich Corporation | License fee revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 15,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Customer contract liability milestone payment eligible to receive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ReducedRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduced royalty rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ReducedRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ResearchServicesPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research services period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ResearchServicesPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6847740032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Summary of Available-for-Sale Securities by Contractual Maturity (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturing in one year or less</a></td>
<td class="nump">$ 282,046<span></span>
</td>
<td class="nump">$ 259,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Maturing after one year through five years</a></td>
<td class="nump">21,832<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">$ 303,878<span></span>
</td>
<td class="nump">$ 259,715<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6845710592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Assumptions Used for Estimating Fair Value of Employee Stock Options (Detail) - Employee Stock Options<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield of stock</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.53%<span></span>
</td>
<td class="nump">1.81%<span></span>
</td>
<td class="nump">1.13%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 7 months 2 days<span></span>
</td>
<td class="text">5 years 8 months 23 days<span></span>
</td>
<td class="text">5 years 3 months 10 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">0.72%<span></span>
</td>
<td class="nump">0.71%<span></span>
</td>
<td class="nump">0.68%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.96%<span></span>
</td>
<td class="nump">2.28%<span></span>
</td>
<td class="nump">1.61%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 7 months 9 days<span></span>
</td>
<td class="text">5 years 9 months 29 days<span></span>
</td>
<td class="text">5 years 3 months 14 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="nump">0.72%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6707300416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Benefit for Income Taxes (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit', window );">Subtotal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit', window );">Subtotal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6862570352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income/ (Loss)</div></th>
<th class="th"><div>Non- Controlling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning Balances (in shares) at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,871,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balances at Dec. 31, 2016</a></td>
<td class="nump">$ 136,195<span></span>
</td>
<td class="nump">$ 709<span></span>
</td>
<td class="nump">$ 576,377<span></span>
</td>
<td class="num">$ (440,911)<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,101,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</a></td>
<td class="nump">$ 15,099<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">15,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="nump">253,994<span></span>
</td>
<td class="nump">253,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">$ 818<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under public offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,371,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under public offering, net of issuance costs</a></td>
<td class="nump">81,573<span></span>
</td>
<td class="nump">$ 124<span></span>
</td>
<td class="nump">81,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">9,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Net pension losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized loss on marketable securities, net of tax</a></td>
<td class="num">(306)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(306)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(54,568)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54,568)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balances (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,598,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balances at Dec. 31, 2017</a></td>
<td class="nump">187,900<span></span>
</td>
<td class="nump">$ 856<span></span>
</td>
<td class="nump">682,809<span></span>
</td>
<td class="num">(495,479)<span></span>
</td>
<td class="num">(286)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,103,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</a></td>
<td class="nump">$ 14,467<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">14,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="nump">328,710<span></span>
</td>
<td class="nump">328,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">$ 1,484<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">1,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under public offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,156,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under public offering, net of issuance costs</a></td>
<td class="nump">215,758<span></span>
</td>
<td class="nump">$ 142<span></span>
</td>
<td class="nump">215,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">14,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest', window );">Acquisition of additional shares of Sangamo France</a></td>
<td class="nump">603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination', window );">Non-controlling interest upon Acquisition of Sangamo France</a></td>
<td class="nump">1,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(1,148)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,129)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Net pension losses</a></td>
<td class="num">(21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized loss on marketable securities, net of tax</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (68,889)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(68,334)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(555)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balances (in shares) at Dec. 31, 2018</a></td>
<td class="nump">102,187,471<span></span>
</td>
<td class="nump">102,187,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balances at Dec. 31, 2018</a></td>
<td class="nump">$ 367,257<span></span>
</td>
<td class="nump">$ 1,022<span></span>
</td>
<td class="nump">929,632<span></span>
</td>
<td class="num">(562,696)<span></span>
</td>
<td class="num">(1,440)<span></span>
</td>
<td class="nump">739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">885,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</a></td>
<td class="nump">$ 3,677<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">3,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="nump">249,364<span></span>
</td>
<td class="nump">249,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">$ 2,044<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">2,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under public offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under public offering, net of issuance costs</a></td>
<td class="nump">136,308<span></span>
</td>
<td class="nump">$ 127<span></span>
</td>
<td class="nump">136,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">19,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest', window );">Acquisition of additional shares of Sangamo France</a></td>
<td class="num">(321)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(321)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs related to Sangamo France Acquisition</a></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(1,573)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,573)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Net pension losses</a></td>
<td class="num">(28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized loss on marketable securities, net of tax</a></td>
<td class="nump">592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (95,419)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(95,186)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(233)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balances (in shares) at Dec. 31, 2019</a></td>
<td class="nump">115,972,708<span></span>
</td>
<td class="nump">115,972,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balances at Dec. 31, 2019</a></td>
<td class="nump">$ 432,739<span></span>
</td>
<td class="nump">$ 1,160<span></span>
</td>
<td class="nump">$ 1,090,828<span></span>
</td>
<td class="num">$ (656,985)<span></span>
</td>
<td class="num">$ (2,449)<span></span>
</td>
<td class="nump">$ 185<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital acquisition of non-controlling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6672952992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Company's Deferred Tax Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 133,765<span></span>
</td>
<td class="nump">$ 138,896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">21,459<span></span>
</td>
<td class="nump">16,829<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">4,194<span></span>
</td>
<td class="nump">3,801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">32,171<span></span>
</td>
<td class="nump">3,191<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="nump">11,282<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_DeferredTaxAssetsLeaseLiability', window );">Deferred Tax Assets, Lease Liability</a></td>
<td class="nump">11,722<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_DeferredTaxAssetsBuildToSuitLeaseLiability', window );">Build to suit lease liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accruals and reserves</a></td>
<td class="nump">675<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">151<span></span>
</td>
<td class="nump">604<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax asset</a></td>
<td class="nump">215,419<span></span>
</td>
<td class="nump">169,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">187,724<span></span>
</td>
<td class="nump">158,150<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">27,695<span></span>
</td>
<td class="nump">11,571<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">(13,609)<span></span>
</td>
<td class="num">(14,100)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Operating lease right-of-use assets</a></td>
<td class="nump">20,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,176)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Net deferred tax liability</a></td>
<td class="num">(34,265)<span></span>
</td>
<td class="num">(18,276)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liability</a></td>
<td class="num">$ (6,570)<span></span>
</td>
<td class="num">$ (6,705)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_DeferredTaxAssetsBuildToSuitLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets build to suit lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_DeferredTaxAssetsBuildToSuitLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Lease Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6861837920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 80,428<span></span>
</td>
<td class="nump">$ 140,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">282,046<span></span>
</td>
<td class="nump">259,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable</a></td>
<td class="nump">682<span></span>
</td>
<td class="nump">375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">36,909<span></span>
</td>
<td class="nump">4,673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,408<span></span>
</td>
<td class="nump">5,340<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">405,473<span></span>
</td>
<td class="nump">410,521<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Marketable securities, non-current</a></td>
<td class="nump">21,832<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">29,926<span></span>
</td>
<td class="nump">78,723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">53,156<span></span>
</td>
<td class="nump">54,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">39,273<span></span>
</td>
<td class="nump">40,044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">77,289<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">9,067<span></span>
</td>
<td class="nump">3,364<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Non-current restricted cash</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">637,516<span></span>
</td>
<td class="nump">590,395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts Payable and Accrued Liabilities, Current</a></td>
<td class="nump">17,556<span></span>
</td>
<td class="nump">21,457<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation and employee benefits</a></td>
<td class="nump">13,605<span></span>
</td>
<td class="nump">9,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenues</a></td>
<td class="nump">38,711<span></span>
</td>
<td class="nump">47,564<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">69,872<span></span>
</td>
<td class="nump">78,511<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenues, non-current</a></td>
<td class="nump">81,432<span></span>
</td>
<td class="nump">108,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of lease liabilities</a></td>
<td class="nump">41,192<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BuildToSuitLeaseObligations', window );">Long-term portion of lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNoncurrent', window );">Deferred income tax</a></td>
<td class="nump">6,570<span></span>
</td>
<td class="nump">6,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">5,711<span></span>
</td>
<td class="nump">1,960<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">204,777<span></span>
</td>
<td class="nump">223,138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValueOutstanding', window );">Preferred stock, $0.01 par value, 5,000,000 shares authorized and no shares issued or outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value; 160,000,000 shares authorized, 115,972,708 and 102,187,471 shares issued and outstanding at December 31, 2019 and 2018, respectively</a></td>
<td class="nump">1,160<span></span>
</td>
<td class="nump">1,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,090,828<span></span>
</td>
<td class="nump">929,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(656,985)<span></span>
</td>
<td class="num">(562,696)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(2,449)<span></span>
</td>
<td class="num">(1,440)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Sangamo Therapeutics, Inc. stockholders' equity</a></td>
<td class="nump">432,554<span></span>
</td>
<td class="nump">366,518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
<td class="nump">185<span></span>
</td>
<td class="nump">739<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders' equity</a></td>
<td class="nump">432,739<span></span>
</td>
<td class="nump">367,257<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 637,516<span></span>
</td>
<td class="nump">$ 590,395<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BuildToSuitLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Build-to-suit lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BuildToSuitLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in net income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31958-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 305<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84242212&amp;loc=d3e2352-115587<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6712633600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Balance Sheet Details - Summary of Accounts Payable and Accrued Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 6,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AccruedResearchAndDevelopmentExpenses', window );">Accrued research and development expenses</a></td>
<td class="nump">4,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">1,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities - current (included in Accounts payable and accrued liabilities on the Consolidated Balance Sheet)</a></td>
<td class="nump">3,214<span></span>
</td>
<td class="nump">$ 1,408<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities', window );">Other</a></td>
<td class="nump">2,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,969<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total accounts payable and accrued liabilities</a></td>
<td class="nump">$ 17,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,457<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6709880320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Stock Option Activity (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at beginning of period (in shares) | shares</a></td>
<td class="nump">8,726,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares) | shares</a></td>
<td class="nump">4,530,288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares) | shares</a></td>
<td class="num">(806,226)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options canceled (in shares) | shares</a></td>
<td class="num">(2,620,867)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at end of period (in shares) | shares</a></td>
<td class="nump">9,829,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested and expected to vest at end of period (in shares) | shares</a></td>
<td class="nump">9,829,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable at end of period (in shares) | shares</a></td>
<td class="nump">3,993,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise per Share Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 11.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in dollars per share) | $ / shares</a></td>
<td class="nump">9.68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">5.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options canceled (in dollars per share) | $ / shares</a></td>
<td class="nump">12.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">10.71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options vested and expected to vest at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">10.71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 10.43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining Contractual&#160;Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding at end of period (in years)</a></td>
<td class="text">7 years 10 months 28 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options vested and expected to vest at end of period (in years)</a></td>
<td class="text">7 years 10 months 28 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable at end of period (in years)</a></td>
<td class="text">6 years 6 months 14 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding at end of period | $</a></td>
<td class="nump">$ 7,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options vested and expected to vest at end of period | $</a></td>
<td class="nump">7,472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable at end of period | $</a></td>
<td class="nump">$ 5,442<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6841491040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Activity Related to Company's Unrecognized Tax Benefits (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 6,288<span></span>
</td>
<td class="nump">$ 5,659<span></span>
</td>
<td class="nump">$ 5,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to the current year</a></td>
<td class="nump">5,393<span></span>
</td>
<td class="nump">636<span></span>
</td>
<td class="nump">622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions', window );">Additions for tax positions of prior years</a></td>
<td class="num">(51)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions for tax positions of prior years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 11,630<span></span>
</td>
<td class="nump">$ 6,288<span></span>
</td>
<td class="nump">$ 5,659<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized tax benefits increase decrease resulting from prior period tax positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6850113456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Major Customers, Partnerships and Strategic Alliances<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Major Customers, Partnerships and Strategic Alliances</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 4 &#8211; MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Collaboration Agreements</span></div><div style="text-indent:18pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Kite </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2018, the Company entered into a global collaboration and license agreement with Kite Pharma, Inc. (&#8220;Kite&#8221;), which became effective on April 5, 2018, and was amended and restated in September 2019, for the research, development and commercialization of potential engineered cell therapies for cancer. In this collaboration, Sangamo is working together with Kite on a research program under which the companies are designing zinc finger nucleases (&#8220;ZFNs&#8221;) and viral vectors to disrupt and insert certain genes in T-cells and natural killer cells (&#8220;NK-cells&#8221;) including the insertion of genes that encode chimeric antigen receptors (&#8220;CARs&#8221;), T-cell receptors (&#8220;TCRs&#8221;), and NK-cell receptors (&#8220;NKRs&#8221;) directed to mutually agreed targets. Kite is responsible for all clinical development and commercialization of any resulting products and has announced that they expect to initiate a clinical trial evaluating KITE-037, an allogeneic anti-CD19 CAR-T cell therapy, in 2020.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subject to the terms of this agreement, the Company granted Kite an exclusive, royalty-bearing, worldwide sublicensable license under the Company&#8217;s relevant patents and know-how to develop, manufacture and commercialize, for the purpose of treating cancer, specific cell therapy products that may result from the research program and that are engineered </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ex vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> using selected ZFNs and viral vectors developed under the research program to express CARs, TCRs or NKRs directed to candidate targets.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the research program term and subject to certain exceptions, except pursuant to this agreement, the Company is prohibited from researching, developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ex vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> genome editing, expresses a CAR, TCR or NKR that is directed to a target expressed on or in a human cancer cell. After the research program term concludes and subject to certain exceptions, except pursuant to this agreement, the Company will be prohibited from developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ex vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> genome editing, expresses a CAR, TCR or NKR that is directed to a candidate target.</span></div><div style="text-indent:36pt;margin-top:6pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Following the effective date, in April 2018, the Company received a $150.0&#160;million upfront payment from Kite. In addition, Kite will reimburse the Company&#8217;s direct costs to conduct service under the joint research program provisions of the agreement, and Kite will be responsible for all subsequent development, manufacturing and commercialization of any licensed products. Sangamo is also eligible to receive contingent development- and sales-based milestone payments that could total up to $3.01&#160;billion if all of the specified milestones in this agreement are achieved.&#160;Of this amount, approximately $1.26&#160;billion relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones, and approximately $1.75&#160;billion relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels.&#160;Each development- and sales-based milestone payment is payable (i)&#160;only once for each licensed product, regardless of the number of times that the associated milestone event is achieved by such licensed product, and (ii)&#160;only for the first ten times that the associated milestone event is achieved, regardless of the number of licensed products that may achieve such milestone event. In addition, the Company will be entitled to receive escalating, tiered royalty payments with a percentage in the single digits based on potential future annual worldwide net sales of licensed products. These royalty payments will be subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.</span></div><div style="text-indent:36pt;margin-top:6pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The initial research term of the agreement is six years. Kite has an option to extend the research term for up to two additional <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzc2OTY1ODE1MDUyMDY_67f3e1f2-17aa-46c8-a608-4185bf8992f1">one</span>-year periods for a separate fee of $10.0&#160;million per year. All contingent payments under the agreement, when earned, will be non-refundable and non-creditable. In connection with the amendment and restatement of the agreement in September 2019, the Company entered into a new research plan with Kite, with estimated reimbursable service costs of approximately $3.4&#160;million. The Company concluded the transaction price under this agreement is $189.3&#160;million and includes the upfront license fee of $150.0&#160;million and $39.3&#160;million estimated reimbursable service costs for identified research projects over the estimated performance period. The Company concluded that the estimated fees for the presumed exercise of the research term extension options and all milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur. None of the development and sales-based milestone payments have been included in the transaction price.</span></div><div style="text-indent:36pt;margin-top:6pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company assessed the agreement with Kite in accordance with ASC Topic 606 and concluded that Kite is a customer. Kite has the right to terminate this agreement, in its entirety or on a per licensed product or per candidate target basis, </span></div><div style="margin-top:6pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">for any reason after a specified notice period. Each party has the right to terminate this agreement on account of the other party&#8217;s bankruptcy or material, uncured breach.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has identified the primary performance obligations within the Kite agreement as: (1) a license to the technology along with the stand by ready obligation to perform research services, and (2) the on-going research services. Revenue from the upfront license fee relates to access to the license and Company&#8217;s obligation to stand-ready to perform such research services as additional targets are selected by Kite. As a result of this obligation to perform research services when and if requested throughout the duration of the contract, the fee for the license and the stand-ready obligation will be recognized over time on a straight-line basis through June 2024, the estimated period of the stand-ready obligation. Revenue from the reimbursable costs related to the integrated service deliverable is recognized as the research services are performed. Related costs and expenses under these arrangements have historically approximated the revenues recognized. The estimated period of performance and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. As of December&#160;31, 2019, and 2018 the Company had deferred revenue of $106.5&#160;million and $131.5&#160;million, respectively, related to this agreement. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span><br/></span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues recognized under the agreement were as follows (in thousands):</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.538%;"><tr><td style="width:1.0%;"/><td style="width:70.848%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.908%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.541%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.908%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.395%;"/><td style="width:0.1%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="12" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue related to Kite agreement:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Recognition of license and stand-ready fee</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,977&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,545&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,373&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,972&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,350&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,517&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-indent:18pt;margin-top:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Pfizer </span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">SB-525 Global Collaboration and License Agreement</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2017, the Company entered into an exclusive, global collaboration and license agreement with Pfizer, pursuant to which it established a collaboration for the research, development and commercialization of SB-525, its gene therapy product candidate for hemophilia A, and closely related products.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under this agreement, the Company is responsible for conducting the Phase 1/2 clinical trial and certain manufacturing activities for SB-525, while Pfizer is responsible for subsequent worldwide development, manufacturing, marketing and commercialization of SB-525. Sangamo may also collaborate in the research and development of additional adeno-associated virus ("AAV") based gene therapy products for hemophilia A.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company originally received an upfront fee of $70.0&#160;million and is eligible to receive development milestone payments contingent on the achievement of specified clinical development, intellectual property, regulatory and first commercial sale milestones for SB-525 and potentially other products. In addition, Sangamo is eligible to receive up to $208.5&#160;million in payments upon the achievement of specified clinical development, intellectual property and regulatory milestones and up to $266.5&#160;million in payments upon first commercial sale milestones for SB-525 and potentially other products. The total amount of potential clinical development, intellectual property, regulatory, and first commercial sale milestone payments, assuming the achievement of all specified milestones in the hemophilia A Pfizer agreement, is up to $475.0&#160;million, which includes up to $300.0&#160;million for SB-525 and up to $175.0&#160;million for other products that may be developed under the agreement, subject to reduction on account of payments made under certain licenses for third party intellectual property. In addition, Pfizer agreed to pay the Company royalties for each potential licensed product developed under the agreement based on an escalating tiered, double-digit percentage of the annual net sales of such product. These royalties are subject to reduction due to patent expiration, entry of biosimilar products to the market and payment made under certain licenses for third-party intellectual property. To date, a $25.0&#160;million milestone has been achieved, however no products have been approved and therefore no royalty fees have been earned under the hemophilia A Pfizer agreement.</span></div><div style="text-indent:36pt;margin-top:6pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company assessed the agreement with Pfizer in accordance with ASC Topic 606 and concluded that Pfizer is a customer. As of December 31, 2019, the total transaction price under this agreement is $105.0&#160;million, which represents the upfront and research services fees of $80.0&#160;million and one unconstrained milestone in the amount of $25.0&#160;million. Sangamo is responsible for internal and external research costs as part of the upfront fee and has the ability to request additional reimbursement from Pfizer if certain conditions are met. None of the clinical or regulatory milestones have been included in the transaction price, as all such milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the </span></div><div style="margin-top:6pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subject to the terms of the agreement, the Company granted Pfizer an exclusive worldwide royalty-bearing license, with the right to grant sublicenses, to use certain technology controlled by the Company for the purpose of developing, manufacturing and commercializing SB-525 and related products. Pfizer granted the Company a non-exclusive, worldwide, royalty free, fully paid license, with the right to grant sublicenses, to use certain manufacturing technology developed under the agreement and controlled by Pfizer to manufacture the Company&#8217;s products that utilize the AAV delivery system. During a specified period, neither the Company nor Pfizer will be permitted to clinically develop or commercialize, outside of the collaboration, certain AAV-based gene therapy products for hemophilia A.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unless earlier terminated, the agreement has a term that continues on a per product and per country basis until the later of (i)&#160;the expiration of patent claims that cover the product in a country, (ii)&#160;the expiration of regulatory exclusivity for a product in a country, and (iii)&#160;15 years after the first commercial sale of a product in a country. Pfizer has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize SB-525 and related products will automatically terminate. Upon termination by the Company for cause or by Pfizer in any country or countries, Pfizer will automatically grant the Company an exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize SB-525 in the terminated country or countries.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has identified one performance obligation within the hemophilia A Pfizer agreement as a license to the technology and on-going research services. The Company concluded that the license is not discrete, as it does not have stand-alone value to Pfizer apart from the research services to be performed by the Company pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the on-going services through 2020, the estimated period the Company will perform research services. The estimate of progress towards the satisfaction of its performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. As of December&#160;31, 2019 and 2018, the Company had deferred revenue of $4.0&#160;million and $10.0&#160;million, respectively, related to this agreement.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the Company entered into an amendment to the collaboration agreement, pursuant to which the Company transferred the IND for SB-525 to Pfizer. Upon this transfer the Company achieved a $25.0&#160;million milestone as the conditions for achieving the milestone were met. The Company recognized approximately $23.7&#160;million attributed to this milestone as revenue during the year ended December 31, 2019. The balance of this payment of $1.3&#160;million will be recognized as revenue commensurate with the provision of research services over the remaining term of the agreement. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues recognized under the agreement were as follows (in thousands):</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368%;"><tr><td style="width:1.0%;"/><td style="width:57.009%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.063%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.550%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.063%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.851%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.064%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue related to Pfizer SB-525 agreement:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Recognition of upfront fee and research services</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,697&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,810&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,008&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Milestone achievement</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,662&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,359&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,810&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,008&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company adopted ASC Topic 606 effective January 1, 2018, using the modified retrospective method. The impact on the hemophilia A Pfizer agreement was to increase the amount of the recognition of the up-front payment by approximately $5.2 million. This amount resulted in a decrease to the opening balance of accumulated deficit and a decrease to deferred revenues, respectively.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the first quarter of 2019, the Company updated its estimated project cost and related revenues under this program. This adjustment was a direct result of the increase in project scope during the first quarter of 2019 and the corresponding costs, which resulted in a decrease in the measure of proportional performance. In December 2019, the Company updated its estimated project cost and related revenues upon transfer of the IND for SB-525 to Pfizer. This adjustment was a direct result of the decrease in project scope during the fourth quarter of 2019 and the corresponding costs, which resulted in an increase in the measure of proportional performance. During the year ended December&#160;31, 2019, the Company recognized $15.7&#160;million in revenues related to the Pfizer SB-525 agreement, which included approximately $8.7 million acceleration in revenues recorded in the three months ended December 31, 2019 related to the updated estimated project cost, offset by approximately $3.0&#160;million reduction in revenues recorded in the three months ended March&#160;31, 2019 related to the updated estimated project cost.</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">C9ORF72 Research Collaboration and License Agreement</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2017, the Company entered into a separate exclusive, global collaboration and license agreement with Pfizer for the development and commercialization of potential gene therapy products that use ZFP transcription factors (&#8220;TFs&#8221;) to treat amyotrophic lateral sclerosis (&#8220;ALS&#8221;) and frontotemporal lobar degeneration (&#8220;FTLD&#8221;) linked to mutations of the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">C9ORF72</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene. Pursuant to this agreement, the Company agreed to work with Pfizer on a research program to identify, characterize and preclinically develop ZFP-TFs that bind to and specifically reduce expression of the mutant form of the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">C9ORF72</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company received a $12.0&#160;million upfront payment from Pfizer and is eligible to receive up to $60.0&#160;million in development milestone payments from Pfizer contingent on the achievement of specified preclinical development, clinical development and first commercial sale milestones, and up to $90.0&#160;million commercial milestone payments if annual worldwide net sales of the licensed products reach specified levels. In addition, Pfizer will pay the Company royalties based on an escalating tiered, mid- to high-single digit percentage of the annual worldwide net sales of the licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third party intellectual property. Each party will be responsible for the cost of its performance of the research program. Pfizer will be operationally and financially responsible for subsequent development, manufacturing and commercialization of the licensed products.</span></div><div style="text-indent:36pt;margin-top:6pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company assessed the agreement with Pfizer in accordance with ASC Topic 606 and concluded that Pfizer is a customer. The Company concluded the total transaction price under this agreement is $12.0&#160;million, which represents the upfront fee. None of the clinical or regulatory milestones have been included in the transaction price, as all milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subject to the terms of this agreement, the Company granted Pfizer an exclusive, royalty-bearing, worldwide license under the Company&#8217;s relevant patents and know-how to develop, manufacture and commercialize gene therapy products that use resulting ZFP-TFs that satisfy pre-agreed criteria. During a specified period, neither the Company nor Pfizer will be permitted to research, develop, manufacture or commercialize outside of the collaboration any ZFPs that specifically bind to the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">C9ORF7</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2 gene.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unless earlier terminated, the agreement has a term that continues on a per licensed product and per country basis until the later of (i)&#160;the expiration of patent claims that cover the licensed product in a country, (ii)&#160;the expiration of regulatory exclusivity for a licensed product in a country, and (iii)&#160;15 years after the first commercial sale of a licensed product in a major market country. Pfizer also has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. The agreement will also terminate if the Company is unable to identify any lead candidates for development within a specified period of time or if Pfizer elects not to advance a lead candidate beyond a certain development milestone within a specified period of time. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize licensed products under the agreement will automatically terminate. Upon termination by the Company for cause or by Pfizer without cause for any licensed product or licensed products in any country or countries, the Company will have the right to negotiate with Pfizer to obtain a non-exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize the licensed product or licensed products in the terminated country or countries.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Following termination by the Company for Pfizer&#8217;s material breach, Pfizer will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">C9ORF72 </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">gene for a period of time. Following termination by Pfizer for the Company&#8217;s material breach, the Company will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">C9ORF72</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene for a period of time.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has identified the performance obligation within this agreement as a license to the technology and on-going research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Pfizer apart from the services to be performed by the Company pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the on-going services over the estimated period the Company will perform research services. The estimation of progress towards the satisfaction of its performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. As of December&#160;31, 2019 and 2018, the Company had deferred revenue of $8.0&#160;million and $9.8&#160;million, respectively, related to this agreement.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues recognized under the agreement were as follows (in thousands):</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:58.557%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.756%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.386%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.756%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.386%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.759%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Recognition of upfront fee related to Pfizer </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">C9ORF72</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> agreement</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,827&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,188&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-indent:18pt;margin-top:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Sanofi</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2014, the Company entered into an exclusive worldwide collaboration and license agreement with Bioverativ Inc., (now Sanofi Genzyme, a global business unit of Sanofi S.A. (&#8220;Sanofi&#8221;)), to develop therapeutics for hemoglobinopathies, focused on beta thalassemia and sickle cell disease (&#8220;SCD&#8221;). The agreement was originally signed with Biogen MA Inc., who subsequently assigned it to Bioverativ Inc., which was later acquired by Sanofi. Under the agreement, the Company is jointly conducting two research programs: the beta thalassemia program and the SCD program. In the beta thalassemia program, the Company is responsible for all discovery, research and development activities through the first human clinical trial. In the SCD program, both parties are responsible for research and development activities through the submission of an IND application for ZFP therapeutics intended to treat SCD.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under both programs, Sanofi is responsible for subsequent worldwide clinical development, manufacturing and commercialization of licensed products developed under the agreement. At the end of the specified research terms for each program or under certain specified circumstances, Sanofi has the right to step in and take over any of the Company&#8217;s remaining activities. Furthermore, the Company has an option to co-promote in the U.S. any licensed products to treat beta thalassemia and SCD developed under the agreement, and Sanofi will compensate the Company for such co-promotion activities. Subject to the terms of the agreement, the Company has granted Sanofi an exclusive, royalty-bearing license, with the right to grant sublicenses, to use certain ZFP and other technology controlled by the Company for the purpose of researching, developing, manufacturing and commercializing licensed products developed under the agreement. The Company also granted Sanofi a non-exclusive worldwide, royalty-free fully paid license with the right to grant sublicenses, under the Company&#8217;s interest in certain other intellectual property developed pursuant to the agreement. During the term of the agreement, the Company is not permitted to research, develop, manufacture or commercialize, outside of the agreement, certain gene therapy products that target genes relevant to the licensed products.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the agreement, the Company received an upfront license fee of $20.0&#160;million and is eligible to receive development and sales milestone payments upon the achievement of specified regulatory, clinical development and sales milestones. In addition, the Company will also be eligible to receive up to $115.8&#160;million in payments upon the achievement of specified clinical development and regulatory milestones, as well as up to $160.5&#160;million in payments upon the achievement of specified sales milestones. The total amount of potential regulatory, clinical development, and sales milestone payments, assuming the achievement of all specified milestones in the agreement, is up to $276.3&#160;million. In addition, the Company will receive royalty payments for each licensed product that are a tiered double-digit percentage of annual net sales of each product. Sanofi reimburses Sangamo for agreed upon costs incurred in connection with research and development activities conducted by Sangamo. To date, a $6.0&#160;million milestone has been achieved related to ST-400 for beta thalassemia and another $7.5&#160;million milestone has been achieved related to SCD, however no products have been approved and therefore no royalty fees have been earned under the Sanofi agreement.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The agreement may be terminated by (i)&#160;the Company or Sanofi for the uncured material breach of the other party, (ii)&#160;the Company or Sanofi for the bankruptcy or other insolvency proceeding of the other party; (iii)&#160;Sanofi, upon 180 days&#8217; advance written notice to the Company and (iv)&#160;Sanofi, for certain safety reasons upon written notice to, and after consultation with, the Company. As a result, actual future milestone payments could be lower than the amounts stated above.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">All contingent payments under the agreement, when earned, will be non-refundable and non-creditable. The transaction price as of December 31, 2019 of $89.2&#160;million includes the upfront license fee of $20.0&#160;million, milestones of $13.5&#160;million achieved to date and $55.7&#160;million of estimated research service fees for identified research projects over the estimated performance period, as all unachieved milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur. None of the clinical or regulatory milestones have been included in the transaction price.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company assessed the agreement with Sanofi in accordance with ASC Topic 606 and concluded that Sanofi is a customer. The Company has identified the performance obligations within this arrangement as a license to the technology and on-going research services activities. The Company concluded that the license is not discrete as it does not have stand-alone value to Sanofi apart from the research services to be performed pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the ongoing services through 2022, the </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">estimated period the Company will perform research services. The estimate of progress towards the satisfaction of performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. Revenue from the reimbursable costs related to the integrated service deliverable is recognized as the research services are performed. Related costs and expenses under these arrangements have historically approximated the revenues recognized. As of December&#160;31, 2019 and 2018, the Company had deferred revenue of $1.7&#160;million and $4.6&#160;million, respectively, related to this agreement.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2019, the Company achieved a $6.0 million milestone with Sanofi upon dosing of the third subject in the ST-400 beta thalassemia Phase 1 clinical trial. The Company recognized approximately $5.7&#160;million attributed to this milestone as revenue during the year ended December 31, 2019.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the Company achieved a $7.5 million milestone with Sanofi upon dosing of the first subject in the SCD Phase 1 clinical trial. The Company recognized approximately $7.1&#160;million attributed to this milestone as revenue during the year ended December 31, 2019.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues recognized under the agreement were as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:58.322%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.740%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue related to Sanofi agreement:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Recognition of upfront fee</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,494&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,013&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,769&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,367&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,503&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,489&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Milestone achievement</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,819&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,680&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,516&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,258&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:27pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company adopted ASC Topic 606 effective January 1, 2018, using the modified retrospective method. The impact on the Sanofi agreement was to reduce the amount of the recognition of the up-front payment by approximately $4.1 million. This amount resulted in an increase to the opening balance of accumulated deficit and an increase to deferred revenues.</span></div><div style="text-indent:27pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">California Institute for Regenerative Medicine</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2018, the California Institute for Regenerative Medicine (&#8220;CIRM&#8221;) granted a Strategic Partnership Award for $8.0&#160;million to fund the clinical studies of a potentially curative ZFP therapeutic for the treatment of beta thalassemia based on the application of Sangamo&#8217;s ZFN genome editing technology. The grant exists through December&#160;31, 2022 and provides matching funds to support the evaluate ST-400, a gene-edited cell therapy candidate for people with transfusion-dependent beta&#160;thalassemia. As of December&#160;31, 2019, the Company had received $5.2&#160;million under the award.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the CIRM grants, the Company is obligated to pay royalties and licensing fees based on a low single digit royalty percentage on net sales of CIRM-funded product candidates or CIRM-funded technology. The Company has the option to decline any and all amounts awarded by CIRM and as an alternative to revenue sharing, the Company has the option to convert the award to a loan. No such election has been made as of the date of the issuance of these financial statements. In the event that the Company terminates a CIRM-funded clinical trial, it will be obligated to repay the remaining CIRM funds on hand. As of December&#160;31, 2019 and 2018, $5.7&#160;million and $1.8&#160;million, respectively, including accrued interest, related to this award is recorded as a loan in other long-term liabilities on the Consolidated Balance Sheets.</span></div><div style="text-indent:27pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Amended Collaboration and License Agreement with Takeda</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2012, the Company entered into a collaboration and license agreement with Shire International GmbH, a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;), to research, develop and commercialize a ZFP therapeutic for treating Huntington&#8217;s disease. The Company received an upfront license fee of $13.0&#160;million. In 2014, Sangamo recognized a $1.0&#160;million milestone payment related to the hemophilia program. Takeda does not have any milestone payment obligations, but is required to pay single digit percentage royalties to the Company, up to a specified maximum cap, on the commercial sales of therapeutic products for Huntington&#8217;s disease. The Company is required to pay single digit percentage royalties to Takeda, up to a specified maximum cap, on commercial sales of therapeutic products from programs returned under the original agreement (which include blood clotting Factors VIII and IX) that use two zinc fingers.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the agreement, the Company granted Takeda an exclusive, world-wide, royalty-bearing license, with the right to grant sublicenses, to use the Company&#8217;s ZFP technology for the purpose of developing and commercializing human therapeutic and diagnostic products for the Huntingtin gene (&#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">HTT</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene&#8221;). During the term of the agreement, the Company is not permitted to research, develop or commercialize, outside of the agreement, certain products that target the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">HTT</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene. The agreement may be terminated by (i)&#160;the Company or Takeda, in whole or in part, for the uncured material breach of the other </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">party, (ii)&#160;the Company or Takeda for the bankruptcy or other insolvency proceeding of the other party and (iii)&#160;Takeda, in its entirety, effective upon at least 90 days&#8217; advance written notice.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company assessed the agreement with Takeda in accordance with ASC Topic 606 and concluded that Takeda is a customer. The Company has concluded that the license is not a separate unit of accounting as it does not have stand-alone value to Takeda apart from the research services to be performed pursuant to the Takeda agreement. The Company satisfied the deliverables and research services responsibilities within the amended arrangement which were completed in 2017. As a result, the Company recognized the remaining $2.3&#160;million of deferred revenue from the upfront payment during the year ended December 31, 2017.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues recognized under the Takeda agreement for the years ended December&#160;31, 2019, 2018 and 2017, were $0.0&#160;million, $0.0&#160;million and $2.4&#160;million, respectively.</span></div><div style="text-indent:27pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Agreement with Sigma-Aldrich Corporation</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2007, Sangamo entered into a license agreement with Sigma-Aldrich Corporation ("Sigma") to provide Sigma with access to Sangamo&#8217;s proprietary ZFP technology and the exclusive right to use the technology to develop and commercialize research reagent products and services in the research field, excluding certain agricultural research uses that Sangamo previously licensed to Dow AgroSciences LLC ("DAS"), a wholly-owned subsidiary of Dow Chemical Company. Sangamo developed laboratory research reagents using its ZFP technology over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI3OTg0_c09101db-17d8-4575-842f-cc8f133a684e">three</span>-year research services period. Sangamo has since transferred the ZFP manufacturing technology to Sigma.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2009, Sangamo expanded its license agreement with Sigma. In addition to the original terms of the license agreement, Sigma received exclusive rights to develop and distribute ZFP-modified cell lines for commercial production of protein pharmaceuticals and certain ZFP-engineered transgenic animals for commercial applications. Under the terms of the agreement, Sigma made an upfront cash payment of $20.0&#160;million consisting of a $4.9&#160;million purchase of 636,133 shares of Sangamo common stock, valued at $4.9&#160;million, and a $15.1&#160;million upfront license fee. Sangamo is also eligible to receive commercial license fees of $5.0&#160;million based upon a percentage of net sales and sublicensing revenue and thereafter a reduced royalty rate of 10.5% of net sales and sublicensing revenue. In addition, upon the achievement of certain cumulative commercial milestones, Sigma will make milestone payments to Sangamo up to an aggregate of $25.0&#160;million. Sangamo does not have additional ongoing performance obligations under the agreement.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues recognized under the agreement with Sigma for the years ended December&#160;31, 2019, 2018 and 2017, were $0.6&#160;million, $0.5&#160;million and $0.7&#160;million, respectively.</span></div><div style="text-indent:27pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Agreement with DAS</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2005, Sangamo entered into an exclusive commercial license with DAS, with an initial <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI5MzIy_7d482839-f2da-4dcc-a0a2-fb576c2847cb">three</span>-year research term. Under this agreement, Sangamo is providing DAS with access to its proprietary ZFP technology and the exclusive right to use the technology to modify the genomes or alter the nucleic acid or protein expression of plant cells, plants, or plant cell cultures. Sangamo has retained rights to use plants or plant-derived products to deliver ZFP-TFs or ZFNs into humans or animals for diagnostic, therapeutic or prophylactic purposes. In 2008, DAS exercised its option and obtained a commercial license to sell products incorporating or derived from plant cells generated using the Company&#8217;s ZFP technology. The exercise of the option triggered a one-time commercial license fee of $6.0&#160;million, payment of the remaining $2.3&#160;million of the previously agreed upon $4.0&#160;million in research milestones, development and commercialization milestone payments for each product, and royalties on sales of products. Furthermore, DAS has the right to sublicense Sangamo&#8217;s ZFP technology to third parties for use in plant cells, plants, or plant cell cultures, and Sangamo will be entitled to 25% of any cash consideration received by DAS under such sublicenses. In December 2010, the Company amended its agreement with DAS to extend the period of reagent manufacturing services and research services through December&#160;31, 2012.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The agreement with DAS also provides for minimum sublicense fees each year due to Sangamo every October, provided the agreement is not terminated by DAS. Annual fees range from $0.3&#160;million to $3.0&#160;million and total $25.3&#160;million over 11 years unless terminated at any time by DAS. The Company has identified the performance obligation within this arrangement as a license to the technology. In the event of any termination of the agreement, all rights to use the Company&#8217;s ZFP technology will revert to Sangamo, and DAS will no longer be permitted to practice Sangamo&#8217;s ZFP technology or to develop or, except in limited circumstances, commercialize any products derived from the Company&#8217;s ZFP technology.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues under the agreement with DAS were $3.0&#160;million, $3.0&#160;million, and $3.0&#160;million during 2019, 2018 and 2017, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6850000368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 8 &#8211; STOCKHOLDERS&#8217; EQUITY</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Preferred Stock</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has 5,000,000 preferred shares authorized, which may be issued at the discretion of the Company&#8217;s Board of Director&#8217;s discretion.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Common Stock</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2019, Sangamo completed an underwritten public offering of its common stock, in which the Company sold an aggregate of 12.7&#160;million shares of its common stock at a public offering price of $11.50 per share. The net proceeds to Sangamo from the sale of shares in this offering, after deducting underwriting discounts and commissions and other offering expenses, were approximately $136.3&#160;million.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2018, Sangamo completed an underwritten public offering of its common stock, in which the Company sold an aggregate of 14.2&#160;million shares of its common stock at a public offering price of $16.25 per share. The net proceeds to Sangamo from the sale of shares in this offering, after deducting underwriting discounts and commissions and other offering expenses, were approximately $215.8&#160;million.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2017, Sangamo completed an underwritten public offering of its common stock, in which the Company sold an aggregate of 11.5&#160;million shares of its common stock at a public offering price of $7.25 per share. The net proceeds to Sangamo from the sale of shares in this offering, after deducting underwriting discounts and commissions and other offering expenses, were approximately $78.1&#160;million.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock Incentive Plan</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2018, the Compensation Committee of the Company&#8217;s Board of Directors approved the Sangamo Therapeutics, Inc. 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;), subject to approval by the Company&#8217;s stockholders. The 2018 Plan became effective on June&#160;11, 2018 upon approval at the Company&#8217;s Annual Meeting of Stockholders. In connection with the approval of the 2018 Plan, no additional equity awards will be granted under the 2013 Plan, however all outstanding equity awards under the 2013 Plan will continue to be subject to the terms and conditions as set forth in the agreements evidencing such awards and the terms of the 2013 Plan.</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The exercise price of a stock option granted under the 2018 Plan may not be less than 100% of the fair market value of the Company's common stock subject to the stock option on the date of grant, and the option term will not exceed 10 years. If the person to whom the stock option is granted is a 10% stockholder of the Company, and the stock option granted qualifies as an incentive stock option, then the exercise price per share will not be less than 110% of the fair market value of the Company&#8217;s common stock on the date of grant, and the option term will not exceed five years. Generally, stock options granted under the 2018 Plan vest over four years at a rate of 25% on the one year anniversary of the date of grant and 1/48 per month thereafter and expire 10 years after the date of grant, or earlier upon termination of employment or services to the Company.</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The number of shares of common stock reserved for issuance under the 2018 Plan will be reduced: (i)&#160;on a 1-for-1 basis for each share of common stock subject to a stock option or stock appreciation right granted under the plan, (ii)&#160;by a fixed ratio of 1.33 shares of common stock for each share of common stock issued pursuant to a full-value award granted under the plan.</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Shares subject to any outstanding stock options or other awards under the 2018 Plan that expire or otherwise terminate prior to the issuance of the shares subject to those stock options or awards will be available for subsequent issuance under the 2018 Plan. Any unvested shares issued under the 2018 Plan that the Company subsequently purchases, pursuant to repurchase rights under the 2018 Plan, will be added back to the number of shares reserved for issuance under the 2018 Plan on a 1-for-1 basis or a 1.33-for-1 basis (depending on the ratio at which the share reserve was debited for the original award) and will accordingly be available for subsequent issuance in accordance with the terms of the 2018 Plan.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Employee Stock Purchase Plan</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2018, the Company&#8217;s stockholders approved the amendment and restatement of the ESPP. As amended, the ESPP provides a total reserve of 4.6&#160;million&#160;shares of common stock for issuance under the ESPP. Eligible employees may purchase common stock at 85% of the lesser of the fair market value of the Company&#8217;s common stock on the first day of the applicable <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzk0NTg_a01f06c3-4780-4e1a-a835-8d6a1d1c86ad">two</span>-year offering period or the last day of the applicable <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzk1MTY_14ef30bf-8a48-4b2c-8cc7-f55e130f23b6">six</span>-month purchase period.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock Option Activity</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of Sangamo&#8217;s stock option activity is as follows:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:46.680%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.929%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.732%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number of<br/>Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-<br/>Average<br/>Exercise per<br/>Share Price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average<br/>Remaining<br/>Contractual&#160;Term</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In&#160;thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options outstanding at December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,726,092&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.23&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,530,288&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.68&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(806,226)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.08&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options canceled</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,620,867)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.39&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options outstanding at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,829,287&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.71&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.91</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,472&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options vested and expected to vest at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,829,287&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.71&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.91</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,472&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options exercisable at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,993,645&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.43&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.54</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,442&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Newly created shares are issued upon exercises of options. There were no shares subject to Sangamo&#8217;s right of repurchase as of December&#160;31, 2019. The intrinsic value of options exercised was $4.7&#160;million, $27.0&#160;million and $12.3&#160;million during 2019, 2018 and 2017, respectively.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At December&#160;31, 2019, the aggregate intrinsic values of outstanding and exercisable options were $7.5 million and $5.4 million, respectively. The aggregate intrinsic value of options vested and expected to vest as of December&#160;31, 2019, 2018 and 2017 was $7.5&#160;million, $24.5&#160;million and $71.7&#160;million, respectively.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Restricted Stock Units</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During 2019, 2018 and 2017, the Company awarded 834,745, 346,055, and 12,600 RSUs, respectively. The RSUs awarded in 2019, 2018 and 2017 had an average grant date fair value per award of $9.49, $17.87 and $15.85, respectively. These awards generally vest in a series of three successive equal annual installments. The aggregate fair value of RSUs vested during 2019, 2018 and 2017 was $2.0&#160;million, $0.6&#160;million and $1.2&#160;million, respectively.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of Sangamo&#8217;s RSU activity is as follows:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:54.451%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.756%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.662%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.665%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number of<br/>Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average<br/>Remaining<br/>Contractual&#160;Term</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate&#160;Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">RSUs outstanding at December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">322,701&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">RSUs awarded</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">834,745&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">RSUs released</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(118,807)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">RSUs forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(175,789)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">RSUs outstanding at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">862,850&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.22</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,222&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">RSUs vested and expected to vest at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">862,850&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.22</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,222&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">RSUs that vested in 2019, 2018 and 2017 were net-share settled such that the Company withheld shares with value equivalent to the employees&#8217; minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. The total shares withheld were approximately 39,160, 20,193, and 42,243 for 2019, 2018 and 2017, respectively, and were based on the value of the RSUs on their respective issuance dates as determined by the Company&#8217;s closing stock price. Total payments for the employees&#8217; tax obligations to taxing authorities </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">were $0.4&#160;million</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, $0.3&#160;million and $0.7&#160;million in 2019, 2018 and 2017, respectively and are reflected as a financing activity within the accompanying Consolidated Statements of Cash Flows.&#160;These net-share settlements had the effect of share repurchases by the Company as they reduced and retired the number of shares that would have otherwise been issued as a result of the vesting and did not represent an expense to the Company.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, there were 6,691,209 shares reserved for future awards under the Company&#8217;s 2018 Plan and 2,757,600 shares of common stock reserved for future issuance under the ESPP.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6842644784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Disclosures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transaction</a></td>
<td class="text">RELATED PARTY TRANSACTIONDuring the year, the Company acquired 52,700 vested free shares from a former executive of Sangamo France who is now an executive of Sangamo, pursuant to the exercise of the Free Shares Options for approximately $0.1&#160;million of cash.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6850541632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Reconciliation of Cash and Cash Equivalents (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 80,428<span></span>
</td>
<td class="nump">$ 140,418<span></span>
</td>
<td class="nump">$ 49,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Non-current restricted cash</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash as reported within the Consolidated Statements of Cash Flows</a></td>
<td class="nump">$ 81,928<span></span>
</td>
<td class="nump">$ 143,918<span></span>
</td>
<td class="nump">$ 53,326<span></span>
</td>
<td class="nump">$ 22,061<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 305<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84242212&amp;loc=d3e2352-115587<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>81
<FILENAME>0001628280-20-002582-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-20-002582-xbrl.zip
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MVI_/LOM3[GPGER ;(UE%C9(.0J2(2>7BR2FKD(2N*RYUD$OY/)<<6.LLQ5Y
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MN(O/KE( *E9R+9,D3"A.Y*WM0EW]BOO=Y_Y<E&[1)51B449*0^$0 <0$4/F
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M1>X8,BX5OR+02G9\8YL$2LY% \4;4.@)2XE$0$3:%+4:N?HA O6'.&QJ^)D
M,SXXJS8YT\OC]VW5 C]BVG_5+M_?[W-7YI52I*I15_(Y@:B>5 PF0&>,J<ZE
MU63HHLJ>%8&/"1R!HPOB[,3K ;&CS*K&E+-27MDN;$"PB 2^&<ZL9-\E!,X^
M);"L8TX%.*D8C*H0(U?TA5)>$?B.$K@KLM-81FMS, 4<.)-CR:A)Q^BU@516
MLPHW0N#7KYZ./O!XV#YY]7XTG(S&7!Y/EXR.^Q.>=#.8AZB\\\YQK9+!N%31
M&%\I9Q>="ZM@OOQJ="EY;5U0-J(UR46P-9"DY3IQ9>L*>-(K7B\\E5;:]1)>
MMUVK.*A@V&GPOJ(J&J.Q&'/!Q*LQ[Q6O.REIG4-4)F7)P$341A37[36IDC+;
MFDU8\7J6O)XNB9);XU<[..;)_<F$O[5D;U&(PL EU.A!084VXAZRU1715.\L
MF-6<S?(*U@ZS5BA;8FP30ZRA."O>C0Q:*+GJFFF59BVJ[KO3K 63@G%@BD,O
M211@,5;Y;!RY*&^O*@$75=7=:=8FIW1F5T/Q#,X3^9*,)6-4+(:#7MRN%PO,
MVH59X#F[7ARZF&*2"]'G"I88N40V*K<V6@F=7_&DZTIR"4F;H(#DQ]G[["%P
M0@:E !EC;/\.*]+>H06>-SMH.3O2HC9435'1.0? *BK2;+.#E%F9;%:DO4.D
MO=D1R1F2M@01C+FUN6-)A#P%$U(EK41,HN1#*](N'F:J8O;L,%F1=,D:,BGE
M)-H_:6695Y@MJJ1;% (5%;A8%X4DU.15TLZGDI4MFC.ZM"+02NI\HS@VAF*U
M3Q4U1)_0M&32ADP:=3(K#[22'=\JR +1RD0U*H#L)+'SV9$OG*,7/JT\T'Q7
M7R\*30+F:+VO.M< F0H"(R>CL@)3D.N*)@NJ=.XP9ZW(\&AK1N2VIQ10\"6$
M4,$E32K3BK-SI<E*SUW"6:J@3'2!BK)03,02+29O CKKL-H59^\.9[LB(;UJ
MS?2@M='3T#KXZ&C0(M76."W&50ZR0.N;%H4S)I"N10MA3 6?@)QREKSQ,9>4
M':XXTW4]N>0$!F"*.FLBY8 E-D=3%1852BQ%VQ6!%X@S*Z5Y"8&=J<[78H-E
M!Y@+90W(&@MP]$:7%8'O*(&[(CLUI!Q2]#49"Y!5JI!]5+HJJV)PJR&IQ5^:
MM"A4JD9Q*QJ1M-N @8I057&EY*!]2":OJ+3T:G0I>>V2M@P>O)8L"\$C^H!>
M&>$?&O"KDM/%I])*NU[":]46X1E($+2%")6<L0522MZ8R+A*OE:\[J2D]9!U
M-E%D" 10,)UE]589;0J7;'C%ZQM<<_1''ZF_)P^S(V1Q6O+TPCX6:P%]22IS
MB;5J2>=+":O2_$4@RT*IY45A;E(Z!!!B!I3_>(I5MXY0&)W)U815YG[GF-L5
MX5F#S8FYJ@AM=WH@@JJ-(U.C.&%>X!W.5\R]V](2@:Q'G:'$"-Y@9(XENAH@
MYD#Z9"A !:,6E;D/#B;](4\F]_-_#_H3R3%&PW,T>87#MS@8/1D+E6:VVW8K
M%]FHY[;X/G_!QLGG!T*5M@OX6V'I](!AV>1AX?%&K3S^_/8-DT2%GE&S",R4
M@J34E(T$9@T.(Y#$YD*>-6HP?STZW9"]M^B=&%9L.<\68<1X_Q'N\R4;LI]]
M]AG)<G;H!?]S^LF/1$YJ&W!73ZX:B#I15+9& I,4U]*% N(E9M25;ZA%/VR_
M?)/SSK OFN%BA/SZ\XWW[>7SL9Q7%,.H\%Y' J:)1K= 69$SV!03LB-R'I1U
MD4H']MI88L)>CR0S;&?LK62P+EI3#)#0!%T$S>0MJ,I=V/_ZG+*?JMI+%G=_
M<<0QCF+0WV+-HH#D<HDV>_"L1-54@[XFK J))0 EU8$E3@L+TK7<[<&P?XP0
M'XR?\WAZRY\1*/T/\N3.'[HNF>$8]T>?G^/@^#?_UI^,P.CPZ^/7+T^O=/K1
MZ>M+O]_>?,3#T4#RSTM.>_)@IJGG/YWWPBE^N7CWYPZ[E)I%NX@55"AM%SE"
MC#%FXH14#6,JB^\_YA!D%M8:9AA76&E'U56K+3!H2=4SN:1(_C3V9!_GA799
M*U[<B"@E=,IP5--NM$Z+T!"Q$:.*$M**ZL!6,@O%B^DUOR+%_BB_FY+BX6@\
MYKUI/M,1OX'H;,JU.&#1HY&%%H3%Q(PZH^$.=#Y:\>,F_8>UU4;KT&)R$(LB
MTB'HY*@1).D.Z(WO=_+'(Q!_CAI0-SZ]/SM3KBJKYN-3A 04!+&J3+'9&E36
MA@[4."TX5#,LVS%0"A)9+AH@IN@,@E("5A2UQAWH$;]07G<AV#'+_2M+\L;E
M7!*#*GG:)*RX6J&:&J@#15TK=MR<[ZB6?";TJ *!537E4+Q5$9-Q'G('AIF_
M'ZJI>.J<'5M$JRE4"#$!YM9$Q%8''DK6(J,ZT)IAL9&:H4V5G)S./FN;(;<-
MTD/PP?G -:K@8X>FL;\?LI?]R;M6,_.L%6;S9/\E[M_ Z,;\)Y2CH&E5<>R\
MA:(L86M@9L4 H\I.P13D> KRDMGE'$".5P<YSA!D$Y*.5',(XG>+>%X/FJHF
MM*F:#D3'A>D)/\/M@+48G",T(E[!L$T0P3,Z]C41G:R^Z2PHM]GK;':8!%=5
ME!A7*7BPZ))X1D\5*).V;#N0@OXC)CC9>2RYQP?<D\^[8B?,%&Q!TKDFR?5<
M%#02A5A%Z/N4N[ G["+V<)FAHE<Y!ZM5$:4(H@PI1QV<2LG[ZHSNPGY3'5K6
M/#O<LB*O&!P1.4F17=20C3?6*T7*=6%3DH51!;-+ND0 Y (BP3-J4$!8H,K_
M?=L"FS2Y;H-RFQ%HADVJL@.C<RR)+&#6R9(VU44Q$S&?VH&AQT51:C/L\.D)
MO#@LRT6!U4C)!17%1HQ"%54'2CL64A7,L*]0U:EZYAHJ0&!."M$[*\\R!IU=
M%QIC=4@5S#  >=5R(%]"M)"*3363Q"-2T67VUIP,",')@) 8W\(N=?JG,NJ'
MH[T]I&9>;1IF6/[H9_DZSZS4?S+>EVL<3,F X_W#=1R<KX;XW_X^/]_!\0"?
M#?/-#SG!E8><Y%"KSB[QPT-.7M<22HJDP$/,B%6X9 IG0$D1.'^F$9S02+D5
MC6Z41E>ZULOV&T\N("_7\%-_<#"X%8+"E0FJW P(ZM#DDC1"-5&<64#@:DH0
M16<,I[0BZ.(1]/3WON0)M\7%\G,>M<7#H_?3'WWV^Q\*T&/,^YNCYSRNH_'@
MR6B\L;_#X\F#PR_*TN[GG;Z<HWUKH[YZS[EA44ZO\'"O/^QGW#MWF9?\]F"O
M5:D?RN6?],>3_3,!_4K2FK7^GDAM23YO(.#/WVH@@O:E6%52 -*():IJ)$\U
MB,1&=<AJ;IY%C0Z3!SCA<D:*9_7^<'B >V]&<IL?Y7>L\_[TN(UZ8IKE^7A4
M#G+K$(!YY_/)ILOD9]8.:DE<1B=M2'11-)AK-10A ,18LYZ.[K!W)75I>?B*
M1K<Z<_]YJ==H6J7UF16GZZFF/_SXL],S7+;4ZG+!7FMU%:$84\&HULC:4JX>
M4"=R,9RP,IVP4J55WK?XK$Q79J4<.I.\3V6'41NGLF%@GY+)P1M@4YU"1VKQ
M)X/N+GMN9);).T!54PH^>8C)M,X5WJ-'QU:!UXL_#K@BQ&S+"AVG@D8[4QQ$
M;.7<7EP%L4HEY1PZ('\6R\G??M&@2Z84XZS.;<\ T!BI;3UDL]BTI5([ N%)
MHK4Q?L7C#V*X%T?W3TUY6$X^[K8MSY\U,>:JV#KABP47&5EX4=E!59H<ZPZ4
MFMYMULRE=M6YX"PG'0QI4%X1!\,*=,A1H@:[COB:VQS$OYRATVN=#GJ=?'+3
M8Y1S\3->N0BU&O$R!5REA!6])X?>6 0R'?$S=Y,Q<_$Q7)S-V@:;D@*)1"DR
M1>;"WBN.]8XQII,0DHILJ\0([0M4;MU9P1K$5'4E,,>2-"AW#*'\T3D(G]?^
M$8]?/7#&W3" H:?<%0&<'CH;=8@>:DL,DZ6V%4E*L>I V3)E[5(7 +R]F:5+
MYB7;&J:]/<[[![@G[ER>_'Z;H3R;KKSRQ.3M$?5*5YI+2<)<3$ QB6+!4$MM
M?8.)<E&4B:P-\H?S'3"!;XB)5P^>]#_PYL=1^\^*AHM)PZ152,&RR!T#Q!I1
M.[#)F.2#9K?RQ.*)KU/XL2+VG(@-#H(BS!9M 9]=:IOU&FTUNK:@[+BMUT+R
M>>569SB5\06AKK,(H>9J0V37UNR4'-OZ$(I00LW1(2XXH6X/Y'^@[M39GE8\
MW7E"5:-* =W:E+5=<1+58K,N-K6N<JP7>*'^[1'J*M.R]P>M&7JYYNSL'*?0
M/U?ZO#\VC<M+?4X^/#W'E6M]2@Y1RS_:YPQ1.31.68:BJ];!E-+],?7;&RRY
M]=JOP:G.O)P3GS_^;E8D\M'%6,!(- NMPV5V2@5=D52*%>\2*VY3D76%@1>'
MZXA8XE-1V65 4[!MV)"4C5XKD)SQ#D2J.8:'BRLM.868C?&%+8#U8L95>UN=
M>'1K'2QNA=6"0#&[VJ8(IKA@ M8L2("*K!(7A\X8-IAXY4*[(N3F[V$U8X!4
M@XD6@6TE)"@^I.RT(F6I(UQ:K'*9Y=.%%_/'5#BZ LF2!R<2#C6;FIT)9+3Q
MW)&)[+O*F?D4/[ 6#9<L)^<A&8752 + Y%Q),28Z&>X_X4Q8<6:Q.!.NSIDP
M._4OVA^-T3XK -*!%.;HK$U>LD?B.S6 <-U4\?.\T;D)IF6,3;YJ9JB2DH0$
MOOJ4#0<MB (GEO#4D=AT5SDSE]BDLZ_!2T9EG/@9JHA:M]5$V42M/'-'8M-=
MY<Q<8E/P)64(WL2L(5B?2&.$I"/'H&HL=\G/=-+HR5$@"0U01)!&*WFOJ060
MIV6 -JB[9/2=M$"%)DGRZ5,*!(PU9E.Y*!LDI7#.''=1GEK@TN+VS2N=)B;W
MR^[!<6?&R9/1>)T_WL^YW4!_^%9\^5#^S%-//;F8SYP=]6H?AP7'9?+Z?1&\
MY,F"2C<\7'J!4]=I@>X,H^8H.2>#+DD(8T@%K/)/1)L7ERBG.,C3WY_BT[J:
M[A\^' W>2X3]"JZ7O(_](9?'.!X*9AVJ$%OQM,V7I[:A<'&V]4*L!"D"NURH
MA!"SLB?#^HU>"YWNWM4A$LEAU:VGNYG(N^0E9TD &ARABJV6)UC4&*SZ8HA$
MV15G%HLSWS%$HNR,UKJ24:6VK415!)N$,N),$HO320F(CW=<$L';=>7[,&V\
M?!+,C6M?L>7;UK[LB#*F8@I5J(I33)F8J26AG,!T!,)_&$=XN"Y*1O![Q1]X
MN/EQ-"N%<?.KIIZ/.7^]<.J2M537[.QXFT9RI6O-J<1_#N87(B" <]HJ#UPD
M]:Q:.721E%&A\LK\;MW\SHQH94"+;T#>IPHF.(N^0+$4ZW2)C MB11[4RH!6
MBN?+LF$'6%J>HW60OW14&&)ME2A&.>N6IN;M=B"<R]1L2%6'*-&2T0*PCCDI
M0,E?(XH#"+#8Q;QWQM9OIC]CZ\^9Q+NK8$ ;0!-=5C4I3\$42(M=/7P7L9_A
M'CV<,*$M/AJQ=R/V7QSER@8JJFJ[XKH7<8QJB:.%>(PJ^M"*ORB FM%DUM[J
MA(8Y^"YL&7VW63.767WPR2M4)8,KH I%FTPQE7TA4Q*GCLSJWUW6W%8IP?FE
MKV_'./C;I:_MP]-S7'F1H\ZN>@[5)@W@@\927<RB?8S6.MGC;7_@E(;RQV+2
M\!\X\0J'H]J_83+ U<DP/70F+J0PB%@M)@050'.4S#.03P$M1XH).H#=(O04
MGVN;LAML2?9#@W0K:_O;M419PC)R(2(--GD$0Q1$_%F@FJI;6=N"6=MT&ZF5
M22VP2672$L# F%0UA&RP[015Q:PD^7;)X,JD5LR<#S,]V>@2&&\+ (44L[8I
M0LVUI&!J[,!(T$(P\XN+?#AWZL_++RY9DK$QO.E,\5:H.Y?A*#0J6"HA*7&M
M+B."0TR!BX].2<JPN),776;LS0^HWQ1C;V06!7RDPBF&4$E(:**$=^&<T80^
M:LH=\)]WUH'$'"7$82"G#$2;!+$<:YL4BZV72Q>P6PA/<E?Y4YI<$OG4: 0,
ME*P*R8J@MS:1,0O<"FLA:/.C 6A'CNHH9V^F#5A&78RCMN85 C%FRRY#9HY0
MBJHK&MX5)B3+'M%2]DX#>Q"'Y#,94<=&M[W:%[>D8\6$V19X)",Z1E+YG #!
M6D2-)2)@-$81QQ.?H.**":ML_BMWI.)L2%C$^^B26;5=F7+)A";YPE@MH#?F
MM,HHGJZ$6[%QD2CQI;Z.5U\5%V>CKVUBLLZ4@!;!*X.@(1J?DJI!V<[DUHM5
M.;*\Z9C+J5;OC'7.0LI(P6$N)7JC/6F-J_*T1:7+?%I,1>M1<0F^(K#R,6?G
M"%E7[9W09U67MJATF4]O&RK%9W0Z5P.)LN36;*-"85$E9U.G@]&/;/C:":K,
M)1 14HJ%665)O6M5J&VU*?A22]%<;*<#T=)293[%T5G7[+6&% DXA[;V2E<7
M33% I+K=@W=IJ3*7 (1D,ILLP4?2H, 2>="KH(J'7!ER%RHU9M^HLA-TF4L0
M$D9DJS/6%#3H6I(K22=H&Q\JD[!V/P@M*UWF$HAR1AW%>V1N>T Q1<SLBB32
M;6L9GW/W ]&RTF4NP2A1#=51%-V2@53$:(A<BB85Z]G$CGB7>6,W%U,/$@&"
MLVRI*J#**-FLBZR3R C#W)6!CWEC-Q^["XZ=3XH"BUL&BSF1KS7D:$/1Q2U^
MX]2Y]!-=5$+=3-/26I"3!J94P?F8))4TV?JH4RM64HO/D3DUUUU1]+8H&A49
M)](RN" AR&<JMD6CT"0G*GO:JM^=R(=%W$C[)I9W/<2]OAPQ[.,S>;;]_8-]
MEH-?\EL>\G$=PAH7N9WAK6V %]L.UU<5*!<VP[[64+MVP=M8(63(EB+GUMHO
MA2@*$]R7'7075:#\\\S,4R'(0JXQ7#P2SF7\Q(9,*5D,)FNH&C &B)YM345K
M10N\(_O2DN)&:B8+0TQMT)W(0XF9?.M*PN 2&Z-K7OR:R67&>785D=A:^2=@
MSJ*'2]NC1&L Z[3V)1,=CUB8TZ!B5DMP?TR%[O3'<K$;#@CFZ@'!S&ZEK.C2
MZ+T 6I/DWM,%7D&B0:HY55;ABS7<B^PQ[CR!OFNI]<PJ2-HNF5X'+[(!BDH$
M.BB5G350$Y+I@*Q=$6BNZQ49E;>.30T.4$M$J[&-_EG-+-D13Z7*0H[7WF7>
MG%,S869JQAB734;Q'&3 D49NS;M+C!E)$73!E]Q=.Q:H+!;6VKH*F!1AR$I3
M 6\,!9V68/+L5L";R^R95UF\;=0JD 4DBY([J*R=]23_,VX)9L]N!;RY3)]Q
M6Z =N#5H*,#.($\UO/SI%.<XM3QU"I[J)'C]MP.\OU?&_;SS<#1^?Q)/;Q9,
M=74PU>S S($C*4>&(H!)C"Y)'$S*A&JJTM.1&Y6T6F'X;6FBIEOES68Y>N*B
M<K!B8AE4,"GZJJI*1O+GK&!:_:Q.]TQ<X7-E&[OZ9H9?@GD-&S-%@8." B-!
MK+D-BI*\K*T=*Q[7&]PA#*]TU2NMR.F(,9L0&107MBZ(:I40226+EV5E25*.
M>%>-^<H9[XP&Y[]<SW6:%&_R>/"MNH=..AYM4(7JV 0?P:6"4=O"3F47JR;?
ME3G@18LB<]IFB"$7$)7F&, &19+QLDW%87599/@2)+QS 7,N";!5,1!(#HP5
MH9HB";#34"%7[:KV7:D47S@PYY(05T50="BV1$F(*:<08C"((60'FJ>6V<JP
MCN.[ZR"8CT8?)5J.7N4^#V>P_&R)XKJ[>M+N9M<S3Y? /HCSJ ZB@S3-)FR$
MK"CH.IW#6/&LZSP[EXNXF<UY^.)9D=5:)04A^91*!>M(4A%5)3WMB*_ZY_3P
MY>@0]_8/;WBR:T76A7**B8P*2KP@UP"JN*A8?"0I9;R/H5!'F/UE:_[^\!9:
M\Z^HO%!4#DJ1-C&V743!*T 7(#N47,^$%&M7G/2=)-P/&?EM[(@^'RH[,JT<
M6#RS36!*B#5"Q: <A-J:TG5D"&H6P]$KFUFJ\3CK6#$1(QL%0K:F.S 4)E>A
M6-/MWA K9B\&L^=3G9.UQ4JA4D%@BE15MI$P0S%9U]J1P<D5LQ>9V7,9J;6Q
M.N0,@3$"99.<=:V?M\T17;3ZV&>?S,0>_[%HS#[%[,'!I#_DR>1^_N]!?]*?
MUOM>6,C\%@>C)T*(;[:KO+Z/NNK4YI>'7@=)] 3*AQR!P;*FDF.TRD>PGD1@
M?HFD//X5DK-%4IZLG0&2T5NO0<R1.$!PC*68ZMIJT>1RH@ZL'9PK@#>RSL\9
M9X-IW<]" !=4S#Z K3D8$DLS76B^.7MPKGS)?UJ@\6H'Q_S\0&(WG@NX$L<W
MQ81XO%$KCV^Q+\'MBTL&X%:.(LE_A5PX1E3&-'6IK:'$B[\D_+;@O9+VW/@X
M%%&WTW\_%X\SNQ7D%)(QJKJ:3 4#A:HX&@W:5UV\P7H2!5:"["I1X'P0O\Y<
M8410V5L7T($6J<6@:A;+-(9;(>.=5,LWZ"862MW-2*?7B"D3@2LF0&L2 !%-
M1!M2,5Y3!_:7?3X>R>_=/WR^AU-/WMII3=/MRS+ISQ]VQ.VJUB&(LDN:$#*[
MF 2NVH*RUL#)+;[X7D!X9J?#)252)+D0DOA>27B)FT<V9!T7UJD#FV-^%SQ/
M#L;#_O[!N&VU\:3_J?UUHW4U,S0DS,;X;"1AJ@390S(J8S$9 QN74"^9(=TZ
M4K.S*;;9*PPB-L6@2M6I6A&=Y#2Q-Y;=DMG4'RP28V>T5YX-WH]'QQV;NV-4
M/@$41@T*C.)HL@W94S"Q< JX9$9U^U#-SJHR0+1H@DXI @2/M?C,I&-44=>R
M;)'JP4%?SCJ\V4X7LS,D T&CD0BEM0>J(5:6ER[X"MY5LDMF2+>"S@QMIZ92
M:XR1VY@K5&)E1(Y+OA1T<;4#0V+?A<[#D3RJ\4%N2?BSH7Q5\M])5T*2\T9%
M']MVFE40 F3&UMZ23(+(:MD2ICE@=2V[.A!5.@5J\M^Z_QF!@0164:B_'>R/
M?VT?G'[Y]/W3U^W;EPN1ZK0U =IV9&"]39RR=DH5,B4D;Q?70ML8\>=.X$]9
M\,/W._V,>^=&HQZ,^Q/"(9_UK9S5&-B5N#:]AXU:6XG&L/QQW+YJ-/Y6^?ZB
M> 2O4X"J2W1(D"2VEAH"M=T$0C1QD4>XKL*-E_V\,Q@-RXH;/Q0M0,*WJDH"
M1 (50PJL5#7)(Z D-J7;W/@3]V@T'/)LQ\VOSHMS55#'%'GU'CLSX27*.R/8
M BXWY9"BE=3)2#AQWJ&XD<6FQ@^M4EF41Q]M:[^AM8(<H76B]8:"H^+0>/!5
M=>O1W]3:@1MY]$S5F5Q#0J] 2X1DPQ2#PY+(65K@88)N":DN>4(;@[<EL#91
M@U)1B%!;L3'&9$1"=3Q(?C<G%@:6()@0V*PB0M 4M0\0V.=8&*Q=8%A.C69:
M\/QP-!CTC_<A.K^/(0X/*N;]@W%_^/8ABK7TO[E>>%& "6QLJBX)# 88Q7]*
M!AJBUS9#-C5W8$G5XB"T .N(%")$I5)Q&C#Y!+EZGZM21@G4'1C]NRJ*&[37
M?SOM M.5T3YCO'-%@5B;!A>9*&4;Q-ABJAE1GY@:G)B: JM6('V'M<&5K4T.
MM6H&UF9$6D@L$XUA2%(O20!B%6^J8R)MO5]@:[NYY@!7H,CZ:/BP)?E[2'M\
MNKCH /?.CNZ(14.6E-MSH5(SA+;*#;6*"BD8ZZHY24 Z:LAS1^F"E5YG1HR
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M)^D"7K\?IEF.#=YXZH<L.F41/PPCGN5)S!^T4_L/E%1.K],*)A.OYWOM#MS
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M#;;C@[M?,LRMP#Q0Y,%51[>0Y%BC.)W+3#G*Q"!(:;K828+'*=B%+^9H?+"
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M=Y"3<,)XI,"/?1"3('21%N!\X43/42XT+!ZG210A730JHMJ4I3DP=J&C(&\
M@:)E<):#H)>"<$DPBU].DXRK'\*&1" ,8 XH*1/-94+?FK,TQW2:FL*V<*J;
M*0Q5'S;G!9#-DN9F,)ADTI"TP$$7""-,KD)U%]1+-DN$#G4WZD#UB 67I#GA
M:"93P[>LL+W,*C*EAWX%G06UPG..) RS"V/2=C_MOVM8.?>G,>SF^<*:@V:+
M^M2*'BNG#G/@H).A1LI10>,1_"-=>45<^!%G&6JL])(CB5N'U\$%@</PTW!.
M[%:JCFHR]G@?_@UO$:N!/2MOED?I9_GWW9*MO1:M_J.Y%CC5S=="'E.FC"[F
M_[<(A<_0I/QQ>7LR:S\ELCYMCIJG3:(%]9C\YCD2)4^!Y*1QDEGCZQT>1?2;
M%T^4)H09_BAH J>Z6:,VV4>&7NXPFQ)#F*$QB=DO)0,$AM( :\KG,7&OTLK,
M0!!'# 9+4S3.9\OV]M64TW- /6B0(>T9H\J>P\; JG<%?9YANJHU+\ F![YE
M?$E]+5Z'R3F/K<-1PSJ(_2;]0GYV@ Z@F%X /.K-S/N]0:_5/%(\!\8B]]&?
MHMEG+>VW<*JW6Q<I.GH*>"&Y)/AUF.G^)C%,H4)QF1;]4HE$^N3)I#[Z+9SJ
M9NZEG'5TFLNVI.!-_!HKR_!:A=_&J=Y)+B4>R2$6\/\6:">:AE[%P,NP52":
M?=HB7-&[B37X19JN.AR01\@19/T$6%V!6G"1UB;@=DYULZ[[_1:=(CM3%TKY
M>1'A[Q86FP-Y7:)# 13@FTT\LJU6+;F:HK9PJG?B2* NSD%_1 6T]"&$LSGS
MA<%OD$D*3"M,E4J<@'Y];B@@(+_R-!3YX]B6#=_C(>'PK&8XVSC5.Y$'N7&0
M%.!C8!R<3 Z,M<$7<Y["0\2**#[(*V=.)(6MXL-XDL)[D(,4\T3$9-</1> Q
M(?)0WUF-<ZX(4OD+^ !'!0N("\_/!+0ES:90C$K:Q<B94JY6 J%\@Z2MJ7<+
MI[J9>H$/A3,26\"[6!I(DP@4(BQM'/+87VAW.<NFR+C@W[Z*-1>EG@TV-IN'
M.4662]8GK3"@)926. UIELMX>'S>T".M4_U6GZ\); NG>B?V.*.R9(+YI,E5
M/E6454N^+9[JYJ,%YO\%I%*)HY%.EQ+J8D!!ZK/=PJEN/EN-C)*V=@32(1*@
MHU<"KP>?UD>Z?5.]X;I&+"93Y(OP=F.P'62WGQMV24B(4_TGPBZDI[_$3Q&D
M3&&LIF$&Y@YY8=!CDC7O#K4T"&"KD9>"  Y@9A@L\$4,=9$4J/1:(:XGG"QN
M O$AO(VGLPR4*O189B\5,K-T8F<-A<647WD\0M#<RN<(^ S1V;WZ11$%RQ]J
M[6[E"SKXE8_I^(.5CV=LL?R1(*:E#S/.+U8_G*Z;V5481>HC"O;(2)+$!Q(%
MBMD(,^0.^[P6%CJ)E$&FG'^7(;^2O='A3;@-./X29!3)VV,$4\3(9E;,YL:M
M2%$_IFN$/R6F*+&9!ABS:;V!2T86'$QJPT."D,06T7V"??4YPL8+1%1&H4!E
MJE%N6OQ';@5AYA<9(B+CA8SUZE>#-GV><@1R@DD'KX\$-IVTL2EGR#,R=3@G
M\ MK7\  S$.27Y?E9?$#I_\JH^[Q!1T;/3@"L;'(0K).R^3G'05\E:7T!* '
M'CG6,%SU-H5FUKE@340 \WF.869MGL+%BMA5P[KB8C$YNT"N9'A;\'R*.2'.
M$HP:7(8828QOO*YXI))NT#4<EET,<8P*H> '1O0!3N$$MI+<R"FRB@)_Q<7)
MHG]@\^'>,"%8WS0$Q@&TRB[@\6B!FR!#^8$$4-%NC>(8700G @(. Y?;]\VY
M2NTZ5^G>LJ)=YRK5N4IUKM)3R54R*B-],QOMK6.CA@;LN%ND F_8AX/QWJ&L
MGT.J@ ."^O7[TX.CO=-3:Z/>_\@6>?QA[^3#P=['IVK'@)J(NHD!X@1-XQRT
MW3 Q0I48Z!)J$JAU0@NF4$$DO#QR022]2%DA3S%%*A(,+"2ST+=F/ #K)N92
MV49MI0RZ8Q""8@^HH8 %%*I\-% G+42PFG%4%3BM1BE0HZ48!L$6%PUK.XQS
M>O%+=(2'_ET.A%^#27*9;,?D;YXJ[;<-QXH^/Q^AGH]\[X&$'M/>$U@132CI
M:-V.>?\$FR[C^I2S^?0$@\ T'QMI=E:8B8#-=3C#4"_R[DL6%5R!'G2615&F
MTZQ!NHC$34LZ/.0/R>UQQ:5[AV 5;$Y&=?F:$L@U3T.>LW11X?4TC:4+H9+"
MT"L0QKYLQBKCF3#+)=DA4X5+J!>%(C>G_AJYPF)1PB^Z:4D24"1$'\C6^92E
M,[#^"RHA(^4KSL0(L>L58#KU7*P=CJ-I[7(_%"XQ8^0UR"-TJF&^KO9<H<,#
MR$/N9BAPT5$9Q&V4GR&(WYXF5XWE=?OPWC HUWX0KQR-5B7,[:.4+C83&X,J
MAZE+@'VQE*T#JD3V$J8#GY%XF<'07@(L!;U:9>+*P>$N1IKA!2E!]]++I,BL
M;)'E?$8/[!R=-O1/A$][-BL$72I/"NY^&F9$!Y.(S682V86^O2)/Z =<#_($
M7=KBQFM5,"*GE25+ &S$U@(9K4E:THE"Z#:U8@97B3+%$Q\]KGC__(AEPF&U
M)L](#P/T45 $PIH6L#8SF1V]M.11A1E/V26W!!V9)*W(5S HO.I$D.CG3G-T
M^IE0E@KQ9HL87H(TB' ]K6K2Q36R4A6) [52/!OFN1T2[.[B5YRZU#>W9/8W
MS_7IZ)MB/8]"]1%3?0KZ9F73MV3VMQ+\LKZ)G)5"C2#8.2(#.9?0O!F&.V[+
M\=3LE<*V<ASBGS ",=8)\C5@V+,DP #;[M'(ROA_"T[U.SQ*[_/)R@\I *+_
M1+ABQBE.@O=4O+1*-1M23.VU*:8WSY27Z5NP8M06N(B^R'^3>EA&#TE/(9=#
MFOA<B!_)_X5*"!INF5E[)>5*B3?#((OOIP7'T.1Y3)L$(I <'3G^U;A)=02%
M5N">2#$4@%_1.$K+*1U%]]*$!1'ARH&@L=R<0FA.0AX%./$5U;<4@K00'#3B
MP3DW$Y)9]6=JL4]9FQ%GB+'9+&=";J_'SF)\; +*I8;L*D^38<-0DLB*CDTZ
MB K"XW:+[$4N@4]P>!@SQ) ^6A#B2'.ENH-Y!3<83B262G:<P20"!0;6F6OR
MYWJ6]%*)"!"$LQEAK )L:,+Y6%G)%]ZV)2S>2K4CDY[Y&K3O%KG:W.]4?1Z#
M(-A65]LW[WVM^M2;?I=-+U4?PQ^" "'9%FJS_'HT@2:QX-<J]>,]X5.RIRJ7
M00_;YUY:H*WMMMP6:5L4]Z6JA:BQ6.=1XH&8*BL!+%4)6)OZ/Y&E >]3N$\I
M4P:5:0^>'C!'G)3R>,2\2,EK2/XM[8HJ<VU.QW:WY9!3H4Q/%4KMFKI7] Y6
M)"#BI\(1J<8915]AXV"^&E0EWR9K)^)KW,9]WL.B^939V8+, DIB%#JH]HZ5
M+W_'4M#ILR1>\_)9@LJ1\'8"Y7&$.8T0L;*NGH,^*5%;(2N+*S34N9&7<LX6
MH,#"RJQB/DD3U';80NWY+X[;;;8LH,:(5/F=));H/9E\1V_FU]POU*G>,!7A
M@(RR9)GJ[E=@ I[+"K0!X+?"C;A2@@('(&N%"JR &O6+:RX$YYE-0>?/R@I4
M,]A=,1%2\L@?1U.-PO-0V@)PWAPV<#VA5Y(.EURW\%X.8P.]R\U5MA7!#?,$
MDW6*.4T8W<W7A!6%+?[%;;;[EB=G'4[42H41!J<616K/)47@1\D5#PQ08;68
M!Q,:C+(XT<&K)I?!N#D2+&RZ=$$:O\4-$04D ^6^E<4>,SGW7X:530Y1<'!;
MI>FNVP2"88K?.HU.9^G7DS#-<G,;,Q9QTQL)?V:V\+&O#DXH5%+ML7B]29ZY
MT3-8[A.'I:FOY1YOND\JVW0CT8:9"4JE1V&,;"+>B&_Q"_CQ3#CL$\EF)2*S
MPM'$Y9J'J08](GPYC"NK,<S5*R8C," A$I,$?F=I;I_Z29[;)PD,G5@C,)SR
M%.9A'<SP?"3D4E=\[??,8K(BT#)+4EY!858SU>2^Z8V I61<%[\E?N:^VJG4
M )$?BE\V)>;T"<M?JHV["UQDYL')N"UG2#R1LIDY54B=FJF@B?5N F](=8W>
MUW;7[5I3/DOF4[ @F36J^A;"^!*1YN<J801-X" MSD7$YFBW85K"))K$149%
M@*4(D&7 <\QKN'*O#*H26/J5&GYK% 6Y#"77I99Q=RVAJAJ8ZR?WDMY(XMC5
MW:PXATRWPNHV-]4\X0;'&,$@!PZI%F+CI;AZ1Q>^C>0?4J!6;':E]J$.<869
M3.X0 @GO6AB(""MPKE"L"/'ZHD[Q2G4#NH5FA*YIH7Q"]QI*T4"BJC&M$SF_
M#>Q44HN8IO.K"QI-SJQ3G!5"Z-$O9ZX)UEE$N<;^B!/+X&Q27B4U9.BR/,,T
MG%=.EHF:4CTGRT=PANBCLTX3/^2B ,3O'"-[(O('RQV=_HZZ%&&D9YSGTJ=9
MN1B"?</2&*+RK^@TX2URUE>P*T@9(L)U169Y$E$Z=R##92#/110=3!;@<ZHX
MM_!2!A)5;WTX.#BP(B3$3.X@D8E6/&F1\J7Y%+C)^12/L=.!EV*.A>31N528
MRD-0M!Z!T@8W2 R)%5C%-BL!V^9.V[H\__7BW JP(J:?3$'^/F7?8*E9(<*
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M$@V"EQ"25(Q6Z6U8=>:(H(J?!#RKZ'3T&OW8<S#Z>"HK@5&RGI2#H"0FJ1*
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MY2E6^H0@_A$(DJ4X%P2L40%QVB:SH3&U:%CZM/R%8ALP7SE%:ZA"FH'BPXS
MN2*>J->M4P>I!8AUBJE@<@EK6I,TC.%OHC5QP$WK-0?9'I.]D=.HEM-N5)X1
M$V!EG>1)A.4_F$;RBF%!LH'Q(]XDX/1@64:1Q'AZB<0QTI@4L%2=;RBUS4),
M=LYBCBF'0(8<!09<5C6GP>J<RG5Z_)S)/$K!W"400F?](0PBRQ75">-3CNQV
M&MI,I@FE(1:$/TKNUI*%RM2F%%T(]+Q5MIY@&*HIS!+!X0SCI;< '9MC8TYB
M2.2AJF>5&.;RZ)5 IRH5(H0Y743(2WSYPSM&AA^CMG>GQC]"4F-F9E52C\TR
MT;9JO\@"+-;'U2'*;G8OX?<L1C6 2JBH-E$JO7GT=MRP.!"G+(W5[C4[_VQ8
M\?]V@/W,%RF_QN0QM]]LTZ?M%PT#+<LRC.*B!KH\MO7<&31=^HD+/T'([L+'
MYFI,?B._F,!KSPMX?-ATZ&GD>M,%Q;.(#QE?B)2*!8O.<93R\Z9U3/V\-E']
M&H)G:[8/3Q(O<64;D3 KTSE/60"COVB8,'!0**D<H?P6N#]\C^5YI@D"Z4N2
M#T1[O&H7)KC1DR(2";PB 52*4;<C!J!;K5BY/%W2Z>!>P<K*YCM+#%C7A9?-
M&04?/EHC;<T)5?8I1@(QZ&,Y=8&2C*DM1=E^RI0MMV@7I&?KV9AO)EJB T7N
M+/:U,I7,>OZO\_R5T^Q:UUK5?:$2 E+JE,;.U3P1 HZ#4V_"(LUDN3HJ LXQ
MAU/>*F$_! G/*-FJH+DB4"%1SU7XE*IZ3=::=)W-1(J62DY65+2RE333$!LH
MX1E0F<K8@N64JWG"[.\O:!Z(O;#J]H"/OCW@T[T#KTF&BD[1NGB#=FR4[@R1
M'HE-U*9&OS78/($KPRP5!0F1AZ@A@:(_X<GA:-R0J1_E79"G7+DSA!X!=K3>
M9X/C5(8)R^F(Y)XU,RJ)&5/;8JD]TUL:LL8;&C$D<VFV/N;],"V.=2O9AG&#
MS<X[FA YDII RPBK."MA7'HZ4YE25D',:+1BO :?* 3#ZMI5LV#5@=B#Q4\P
M*U0RJ D5/TV!Z$0N+/KD=<M%N=_F@"J :>+M@$V)'$>JLD)23V-^@"":F@OB
MM1$9F5BV;DV;/9S"/LYH3#,R7RQ-6=']KU1JY*\/Q<[!9JB@]IK?[A4@%'GY
M-&S+"(C!%_2W=SBZ$^AM*^[LO2.RHLN6;*7NM)RGR+ TGO51=+ND?I/4QA+;
MQ3Q\D\K'V*#MCI5?'Q>9;N@>5,82L&&/1#R3G)17%FGO1@I>(=WYE,>+Z(*#
MK@BJ%A/9)'^^7T/$ ;:W"509^B0-S['A.9>2G@$WG0CDLSC:T>\E(-\HZ(38
M?RPU!:1>S!0*')TF- ]EX6/:*566D'(F*83T\Y) %A "D>>'<]R=21C))%J\
M1J00T%Y4!(SL7.3<#9TUW ;:V,B_-X"(]K80)KIAJIM[AVT$/SU^*2O+QU#U
M(KH5JF[14\T: ?;U!UAQJ-H"!^N(%EI4=E)6U\#PW#5HB!GJV24X9\DDA9V"
MO>4QYEFO) 9>"C5=9L(]1_-/=AA\(RHE-DJ8E(=X<=2.,8N,0LKTI&A#1_]$
M!]]R)I#('=$&+(X58M)'/@TQU8+0[\+Z62E5)2M4E:@HO@2*6DIJ64,;CP\W
M+<[^46#6;V9&\GC7';MAV!B]-:T;>FM*4JA&N9KK3IR(0KERUT#O1-*# $I@
M(5"C8 F5W=/U5HPJ>DRY)O\'C+JK.Q5RD^_!JH.784I>'YEQ)<J&&B\N=4.!
M\5/S6^D=NUZ]4Z5-TMDR#N.NR!"QB1JU@?[JK/ P 4LJH<O'T;1.N)\6H=9U
M<?3QE+16#1E)XO.$ ($TQ 1Y%/6QO#;\O'&*I2 #4N='Q3F6'$5EC3P_81IH
M7SZJ[H83FZ_L2+#J6Z=IA9E:"O$+H\=J;ZVWK]*T%2T'4=-'-IW\Q6TZ^D?:
M05/#&+^-<0QJ&&,-8ZQAC(^\,(7LL@*,!V1]#*+Z( :#.2]R49ONQ/0%*Z?@
M.M1?KF% FF$O,WVL5BJ%XI*H6Q8!$M-V!S&POM6V(0::2AR$6'B/I-ZJ@"X[
M;#^0C-;:#?;XJ<CF-8VAJU.NU@I<@O1O!O)O#DVAGUM:%%K#NFON_B-U(ZU&
M)V59=-J!,@2Q$KR1P#;JKK,>VE;599:\@C C'3JOJCQ4(]BLIEUBL/2;9%@%
M&PCH8M%5W=:,"R:5BMM[IWM*L1.5F'7-/:"*=)'0^@D/-D_#)!78):G'XP&6
M*?H:=*5OYVP!- =\G\GZ@S*NHP$18&@6T83=E KXZ(EJI,-#A$/&?@ !R\L[
M*NG+*(NZ@8@$JQ(JO(F;@(LY@[.LFBI8E56R9QJW"HZ,P5:GLCL1=E](0=^:
M22"-T[%=%R:X$.44J,IJQ//EQUS7;G?I,4*7@*&.1X(N9W*>EG/! /"4!2)*
M50*2J[!*,)UDN3ZJ#*^1B#!EM+,$<LS8&K4C:HO02I&PF"5$E#2V5OJ"B5KT
M>7*-S:="T1AAEB!>]*L\"#;'=E54ADB D$Q*5G1;(>DF,(^<A9%YWN*8.=:M
MI \K!RON279+5>@J[=^M0(3Y0]L9P._F6!L6*XGS2?ZROTV9GANN#94=[KW:
M;K\(3K6RLTZG*6P\A?C$0,,YM]J]AHC86O_ZQ[!C+ L,\;]X53V:X:W+NL1"
MLJ"]2$,3;C.LJ@7S+N;;?!K/?ONUWN&_(#LAP1JY0EP1V%VB1ZBT"'"Z\>X8
MJ[@J/4 [GH3>T+! ]15B0OH+2ZRT IJBUQL10M<A-B2)%A98_-;YK\%;A$/O
MLH75[<F(&=9>A1\(F!TG57;.9#5SG1 #/VHUAWH PE.WA\8"!%I_&7=-,@<V
M;UF$-ZT1^BA$8G(H"Z5J_Z8]03X?%*G6I'LJO<#4DU"'G D7/U:QSDE$S>&P
M">L3B#P<TO=%L/'D]4[#?$W6T!7@R;T/VGJ[_4]1F%I7EX_C G5Z& Y_3Q[]
M3 ^"&-@0@Z*&>&]JM+I343/06KHCA);PO/AGC,XM2A,)A*FQ1 A"-@?<2*\H
MX[!"UZ1VDQ><L++BE4K;5!Y?TE$34'!S+ G(K_UP+G3BW</38R&]!81(@VWE
MJW@<J'-5$[HA4]ED\^U:%&_C5&\6Q:X4Q2UJM#I-9LG7Q3G2KK:6!0\3\N/_
M60<?3NT#NVL]?X.HXYT7NFK\=W(VEI4L2EA!DDF)5)2R<O._HOR5(UB61I$E
MEEOA)9@@EI'>+.^\2%HQ<WAN,"G0%(1_"#B,AM-G!G9%>,2%!FYP*>(E)BNZ
MP8*K;\YCOSEM<7/<=E6);?VJKHI2""3"7>$DC4M%E^G [G4[UO,=O$_C[[Q/
M=$W67ZJ*W$?NSX45B(E3Y L1F5,W)UW!-VYS4-$XABUSIC>)?I2:2:":R\7K
MA#]NI XW8?+@RI42/CF!SX89]*19/@=MQ=;RZMO:>3\"M\E1H@E)<S'355*V
MY2Z=<J2=!6'F%Z+,/V7RH0M $7)'$+(S4"DBC]I6^#A^#,;"<]SC[BOQWQ>2
M9?SK'\Z@]ZKZ7>4YP\80/0/$ 7:E#.]6#U ,I]G1<Y/IV([3LDB$C\Q1E4]&
MY8>D7(8@*/AX@^+_D<M\!_+H4UR;TFZO9:70"2&GEW+39*Q<I<?.R#D*FS>]
M27!NVX6]+[3E3^P<N;."41K_G]MJ/5U_[T%L[7,O56BNP1HTU_IR5#?@MV@G
M17'U1EG+'#]=P;%BR"<,0B;P)V_"B+/ .A5%13/CQ^*;;ZY[933MK2*!1)\J
M:HFXL<B52LEB,Y$=(I&ON8J5G"*V>ZE.2$K -]%(3'5#+?<FB44[8%J"PD8*
MB!K"N&43UI@J%L/&7W+,7<S,4 A^*;L7@>J@FJ01$G=LR]:NF 8M^W]=A%'$
MS5:.1W_:\@\#\K3<DLEH_RFJ:5C^%/ND8"D!4$_@:]()YC@Y&G5G= +_$!-8
M^FJ\<R)]T_+52]\?_8G?BRK+L*VBLW1>4-8Q'48@>^0 "Z(]7!-#1)>"#F/>
MB2ZPW+^(C<G2(10SI.=)==2X;)6GLS"XJ:J!0_V>EPO-N"VW90;-_CP8[]FM
M=E]TAP*M##=7;J2]L^L,<?/L<04U^X1CE_N5D/@QT+>\/P.+^?\M0@$SDF#.
M<S9+*L7_K?U4@..;H^9I4P$]Z3'YS7-T[7',31I?[Y!+"I]]H2_G39V)Z"!2
M?IYAJT&= #BVR]M#W\)@L@DQ$:D.:4I1#Z-04#R)0NRC1'444%U&A+\R),Q\
M%0-D9_920E$LBZ#K]G' D@1'$2W(1#%OLC#*=>@!8,-461%6Y$DXFQ72T "M
M/&*SF5A>661<]373C=VK+2X.3QNKO_; KH^,,>"Y@]>[E2Y_LFP49MCA8JBF
M@FS.=D/HURSLK_"[,1*_0F\D8EGP//GU"!JG+Y<ZR75,ORC352KI,7?9)%J8
MD<*Q-H]'I)S1NTB'$#>_G.NZR2W,.*OLD4!VV5HJ M8EJ]$OZ7F:,U%\'E^^
M@4,]@:RWE50$K==L'5!YPU17^EK<EBOQZ+F_:AXG_7Q&:XCM.*^?J)JX;K>T
MW+4(ZP!MJ.::O<2TWJ'3MIX?WM214L@+T92R@3]I@W@772IE1R7X;/_@_ZSG
M1AKWZQ<"=0TD$:W+D"--K(8V?QL<<EA#FVMH<PUM?N309L')K[!QEVBYCMI@
M61K#Z*]NEKI#;5NP;<V+#1:\Q.%5<@RB1 U5FQP3YR$&"43))MU\2-26(*L9
M9R1[N1JU_J2NS6!:"RP2:A0.EV&])ZWOH)V'QR0* LI^;!657)8\0;&JCU((
MSPH8.T.H9& O'TK9+JVT 85)JCICE_W>5LJ+\'C*1*MUHV:N"?,FGYATCU#X
ME8PG"G=\VUMH</3RT?#;H3@]9:W/S/+#_4>:63(:T2"NEBY&(EU!?POZ6V$*
MZ*]C%]PHQP0</,Q4+1]9$ N)6[D[F7 $!, W1.T",NPQ:W&.;DERSC7,'R]Q
M+*6YUC;L%MFP1@O ^YFQCY*I5SJ@R[S26SNARY9\]GB_L6;7S/1;U6*1^1K=
MAPT#!68&$V+)\T\IQZJ_.UI<LN?\NH[INJ>@=.TG*N>(ZGQD5!+52(]'-LV1
MX[]9F:<HL"LS2G2?SDJ?*J.7)R@@A-0QN[M3GTYR= &?X TK3;PBRX5=&,%F
MVNCM5(NA^:=F%WM*?Q8[P 4[,C(YF,IL&GWXH)M'&H$K73\1\QM@7%'F2S@#
M!;0?-GI=?TI])(@KB1,Z"&._U)I7FL\_Y9018%.'%,C"G5VRVROI2&5LAI /
M///3T%,N>$%JF4A#%YLLCD(]($O<Z& 4?E^H<N\-)>&4 WXT^J +/,\2E&VB
M+' \I5;",$L$ZHK0T^_O&J*39]/:D3UJS+.3Z1>,7EA6B# J]E.D,&29]IV/
MHJ^P1S.>+K>M;@B'_U*14F,AI@;E@:B%"Q4LLDD1^U*E)\H3,2LIS$.@WS #
MX@]4>EQ9A$?DHIAM2LEY#7?!GH;S>>*SV1P&%3M>:@E4@(@J/H6^*OTG='AJ
M8$J50 >M?]+$-8!7Q05@<# 0T,4MAUVZ@/0#BN<5"A[E+:QNR^[#B$;Q?]S3
M5)V>/!\XUG7D 2,1)J+L$ULB;\5"X) MO>)"E4$ )3NR"3AQ>')@GQ=A0.7:
MX>=)SJ[A0I?(I;&$+Z8J>1/>*>G+')<2).,\2:<$K,#:K/P:G\<)7!'N*U70
M8''VZ,X7$9"25:L:XN-*=.)*%K^SRPK,2CTRT=L:P4$,K-HP5L:B"=R5\=5+
M2>R<#IU"M;^_RT138+SO2QJ]:"^M,DBK1TS,69X^' /M&^V8J)ZI5T337W^I
M-EZA)\Y*5U,ZL:EJ3*=].K:[+4=LHGET<J=7JHHL[^]=ME>B]+'F5E9XP%@R
M(3157:Z@++GU488NER;HWG."+)I/F9TMXL*/L'.'NAYE.+&<]CN&H(HLB;]U
MVBYYEPW(B]M:!WFY3ZTBQ$' CR9%2FJ0"E.JPXK5M@!_G"7(/.@QC6;8)_V#
M2K)AT%KQR',L1BY%GWQ)95(-K%)K$62W]8IVPWU502]E\D/QXR8]Z;QZJMKX
MTLWIKSM4C;BY\^DN%4J^$Z:DY)#KNNU)^8XB3<LQY>T9O96Q=>#",..<S^94
M 1SA5TA7I<TM>NJ,W^XVC(;A"J L]9[M,!OOZU3AUL[P^&2_[V[']._4^&9C
M<T03!F;2TT;\%]8'SJG@,$;3P/:!B7T5LMA@IP860M,0$E4&QY]-D-2X+3%3
M/M9X3+$R4EE+>QDV59==N->AORO2K$#TQ3I!464?8P97DQ$ID$+/UCD'Z Q^
M+Q#O?YZO"C:\S"4$L0I=8J7B7MK5LO6-1LV@[2(-=^$2(#Y1RE?;9T(9GLHY
MR/;JQ&-^'X_E'Z(AIRROH(VVBG<A+]L687J=\2G=DZ?2/_DMR&9_8>VH<SQ1
M%_E;&BAO*7?>L/33UW;?W9*>9/?%=]/%<EYM>[!AP\[_3FZ+ P2F)>@RE\&3
M#V%:"+S=[P<?A/(P\F5OHY6'3Q=Q /:=[*MSL'OZ])1!N5D''U";%M@XLTJQ
M4.+ &$+&)%%^$M:)C8)"'[@D@D9W=CO_KT1\DH+(64"J&NY;@QB_K*51,FA5
MR5BS</F&;$&E&,G_J5IA)-)7A&H=%0E1C0",O,9">$C1MB#[.YE,2 33.^7J
MP(!X'^4RZUR;]2KL"^_PBYF'0R1SK#E2H)$N_!KR]Y8&P-]5:"_1PU845;ZE
M"IA*$*4-2H4<I1:4[1;9B"G/L1$(U<-,B_-,MONH5FS7>OJ<)XB+%7NH_#A
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MAJ8&JC+:,Y@Q<X*I@1"(9WYSWB,UK[3.Z3 R4=U4;NF%874<(%66[JQC]8H
MZ&DH"Q<7:^IF$1Z4?0 I\8[Y:C*B5]18P-#JR3Z.R57E_"QAH-Q7;/U$/./J
M(&W<F5Q"*N%M:A7VW00YR-R5FBO9&3F+HEPUPTVO.KT^EG>'/J95%/G8+%B#
M\8^9FY(S0ZP+. I^Y?#PX/:0=F@%QX\&!9U.H?2ST09W%))?4()YHGZS(4WJ
M[>/:E25T&ST-.2+H44JQ1.*BA([SC(#!:]Y52I%P?^,\AV"'6.C4ZI-LQ:40
M;:=^(>_P$8$V12WK*S.JI=!FF@*.X(O'K1AS&,BMH;-ETE!JJY;2"$!\D2:(
M1GN;DTC-\-Z*EH%[;-<X;JI;CL;3&T)*+,2N!$&;<)0T9P[C##MJU!6>3@D-
M#@O(I4:$=!-6HHCE4I+07)B1A8P9^L8-8FQ$+K R4M^V&:<NE[$4NCF+BUP(
M2%ZWJ]KT/7>)GL,0<;.9>Z:D0T5(/A-GQF6% RN!!Q& GO*]2QVN)>%R$K/7
MZ ;E>X0'-K2N)N4P$0*L3C-QRBB%CXJBFV4W$J&T0AI"\#'!DZTS6E,-8$0_
M&@TK:8OTB5,A*L1IQ!>")#98$X@9,,J=2<T?=U+D<ZW'U-DZ W,$V"*1_)47
MVJ@5]DU>!6S FF@W)O]JK($YQ$HYH4!MV/BAE;,!P3MV5&87+$!;9L%DQ=RT
M!(U9>BZ<3-!-_.MLN635*Q4WS& 9IR74>DJ5>*5=1NN"%'9Y\P4_/G8LF3=9
M04; E EF)=6#>-6LKJM;P3V;2<8< N&!*%<8T@\=#FD$X Y47USG&D/$5]/@
M+"7@GEV!S#9+ZF!D##]4/UE>:.=VO%+;?!G( 7-0F]2975-&TVS.P<3:!WKG
ML&48(+W-ZJF;IDF.7;E6J56 H7@%IHN> ,QAUA:'R8B< >127J71AG3V?^,!
MSTBU&3M*,S7@MH 5H(2"R@-MM8NIJB%.7.)P]C1&PV_5M3'D[X)27V]3B\&?
M%5@SBYE#O63XFQ7R^\SS!K:>3DAT:#;-O:,-K-J2.]0;9]WLDV@.6<)&.E5F
MZTRJ7;V+I.4Q,T2FG6.$:R;GJ$?X9_G^[E+?QK*U9ICO=+>!'A3O*# R)VQ7
M:\D#Y2E]8T#)4]- -4DNBD=!DFTIQRD3#O<<"<I ,%%WHIS"6<1+6;0%/TJK
M&B-K2*\%38GZGP>4.SG;9D%).4P=\UM1D26YJ'B/:7D'ZK0XSXS9_LZB7#B7
M$.CHZ/DGU(ZO,J2Q;+8CE/^M94 $JCNAB33))W.3WUE*OLWGBK;G^/G.U/6?
M?GQ_?G;Y]O+MQP]_-/G-CT9?\9L)1)C26J;69EQ-X;(I\VQ+1*S3,26T*QUL
M/F[*64EK;(? ?UO-@B]HW8[!WU$SL*:@%5=_.\;_K8N?2'7EELC.YL$.E+3F
MVS'N;UWV'Z&D-8A\IZ25PW!85O3RP^A B\B4*^0PV5DC6)K<H M'&1)%CH08
MS:R:M-K'4_(YC%*E/LXBM]REG2$)O*CR2UL40*YV@M"=)7.P2SK,NF+XD0E:
MU_DDP75:-,QII-FN#D07=ZR_FX9*>(@;D4WK0%L94RBL+_"_%V$QKN,UK'"Q
M\@D>'[^_I>5 %\S_B8.J"Z1T:I8:]<58_&RE5ZBT&";?-#/+YD',20/W\22F
M.KP3*>LW^'E8\*@G1RXLR^A6/.?)>O!'P'RP2XSP)F+Z-P%B1LJ'RLV^_T-?
MZP5?8[84S^D>>HGT:7R(OLI3^3SK</GL;&JJ%T*9=#( L&(85B,B$8\/' BI
M<R->_..KEZ.$0A$WF)ON-+?C@*>7Z> 8"@X8(TQO9]Q9 KY%:=EPM#4W1EVN
M?&J&0T020=1055 ^)!576-/D3-PQU8=,X=#4^;CUIQX6M27$-N/]LP4[O0PQ
MQ&KAD$#6%(/J(\(1TOFLJ2-,)]5%?G<WO><C0K323<.1%#T!O=R"^PKCC9,?
M##7&86#JXAK^SFD05,79C*-OIK73IA;!/[HT&\1X5OOTXP0^2BK,:G[0;IS0
M1Z_8<*Y*#DL9I"+BW+[\!;8@&V#QPI=&>:"?JDXF#7?7$O<&2::M\OK,Z#+A
M@QK($C-CO)GB'T97\0/L_%85D7U[R=BYE@-%5^[ GF)(__[WLK_OSF<PPCI-
M7F0K>-[H=8KH^@K^!W1_\R49_71!/)+5+$]]:[L7>?4^ QV8G,?OX\Y5\%>X
MOU.,P;O"U95^3/Z\1VM^)UKSESU:<X_6W*,UUZ U?_1K:@0:\C6J3=:2(_"8
MVB9B(- _X8T BNLK*MKEP-]#4\"#=YEO"7A(BAW3)0UI>; 6]&=V'SUMJO0'
MO5<QY/WLQ;\;G<W><C"6PVL3># 7O\&74#""V^U8>(4WBI?4[^LP^0@>>U9/
M8SZ,13'QM T7\,DY/#;'3K _/SUYGCS()M+8F"(+KXOL:W4!KM#UK]17#[Y,
M(OCZXM>'F#)DK]!6!H+5L< &>/T3X-_Z[O-_7G[^]&&D[^P\IX]MH[)$>3H)
M=-&Z,:810;+]4__[OSY<GKU^]W'-4WW=(IT2ZQ/G0E<W@7==85DZ9S&)#8N!
M99*^5Y]P6:6@'O/_P/C+A\._'-YE6'TZ>WWVX3]?O/TH/W\NEEAE6ZZ^#G_^
M+]4J0]:J(26BIIR:?Z]JQQT/XP]O4$-$4R :9*\&MF&HPVK@U$09A]4 M;B-
MU<"AWUIM[?SK:@[:X%I/!>[^ZQS3<?[@_)=K)O"53#Z24CLP4C%S)5(Q;S)9
M. H1FR,&QOOUQM/[AYV^T31;+(GXI4/V<X[M>JUZ4*D_Y:PYO.CB<'1(KA&<
MHG<K^+5^Y%=X_$^\-O"&F[IZ$;[^WDU=-7PB.<08#P,O:L[4Y]GPEV MQ[V_
M78+ED_W/:N[T8__]]N/YF]&G]\G'<E*%'L+P29@ZHC:&GUUDTSJ'XP\3:*21
ML?_BI]'IY?#7<(7*+U7CY4"TE[NB@/=I!3^P03(J"G0589BO,-P5/^W#KRA,
M\7J@"+RH,8Q5).]7F B^@%MF/-[KGVT8ZAK.&V73BN);_?"%- >^JWTKZQ+?
MT$\S$OW QMDT7V;25RHOW5W'[!3NW7'5]F6=A&[#(;2:='.JH*L][#<I[1"8
M1IE0ZBKSOQG21O;[;ZHY_N<,"Y.BI[R'I\##^8?SVDVHQ@NG>1%/TSPL>O/^
M;&W#4(?/UJ@$6>(F>UTU"78QHX(IBS=QG6[>>F[@8SE+6SZI*_A) =UX*?>3
M:KVD0^NQ.)W<:0FW>3$4(F^(,Y+[I5%$GH$\ENZMD]K5LHIH.-0IE*#0\F(N
M&.QGF,-<1T6Y*K)YQUCV%]?;JH2#N>:/[RO05WC5\X\<$>6%QJ%W;&3ZU/[<
M;,%0A\_-Q1RKK>85*&,L"TU"V05?1>BRDA6:EP?7%98Z3>OVBMJF8I9ZY4G*
M!VBCUH?8P=F-@C"BG^O)E^3?LOGB.9M&XEV%U#:/9DT87XG@$%8KO8-M7I**
M%:+)FDEPK4N8MHY7;5<-^P]97.S_O2ZJ,4SY15%5TT%CD'4)]YWJC$/S5-VU
M!S/@XO2>G0!_N-.SA8S)]^='UM/SOBJK24$M;+ &9EQ-K40:6GR;@^0:-*EQ
M&H@D!ND#Y5\NJ<FV-[]&<[@2[J]4?\#\]&\>O+/$OMX3)T@=%X%Y3 &1A5#A
M3T61C2GHCL7:-3)!"DD2:8AO2 P2\*I!['[>7..UR>DXL,*O\X4VFKD3TY/2
M<WP352X ]S#^3C]@:D?+O'6^UU,G",G4AQ'[;(TF@-"Y^M)+$Q)($Y=SK554
M'<.EI?&"!9!Q!]AB;7MK?51U!V6!8YDC3"6JR:3R9RP0HXHZXMBI=Y@E#+9-
MRT"P=;78B1%ZA5!93 ^6*@E"JAP"X<O[?AI;.-3AVT#Q2 @H2E'\X=1.B-<I
MAN%C$=B2*=9OXJ(>/4G;396^WW2SZ5KT2"<;#SNC7)&;=N9B5%(9RP#"Y,!T
MH I&!_?^?M.W<*@;-UV(V#P8&X/MBNK<;^<V#O6.[<SG8S!+G'>_.F69-C<S
MU8CL?I^W<*C#^RRWKMCJM.?_K\T*SLA1K)N(U2/'+8+#@F%<E:4K]GN^A4,=
MWG,F^"**GXYK2#1'-29),20K?D_P[,BY['&<1UZ5J<+H()"'7?^]V&SA4#>;
M=5@6("P9GEC&^_*>HJ-CPW<;$T<\1]9[W@O$%@YU6""P-HHZ7Z6F^(5^\+2!
M#86I3?U*A\=DO]M;.-3-KKPE>>_$N<!]FUQ;YLA97DMI89PQG)"WU[18\(29
M_0KUAI2!%M4M13";I43%5)UXDS.\8-_S:$N'.BQ"M9O4;;ZTX5RAGND&=(DS
M">GB04QF&9@@5;F^-"1ZU].UFWH'(<8?]9A]H<K&0I6G^T*5?:'*OE#E;EKQ
M;;J.UM 3O1]]^/QJ='KY^=/;#Z]W-7'UF].:7@I0%Q*UYH:PG:KOJK[*2J$4
M8C+>T_<?V2MF T:()>$BU N/\B#ZPQH2YPYY.57*(][Y_0C?SSR/ 22%H.FB
MJ; #Y6V)27,M2;Y"($8\8"$=%N;@R>OWYQ%U>\8V&XW-U#LWRVPV4TN,:]N5
M6KYINFQ+6;%:=JNH4PXR+5>\D%41?N&[;%$--'4K@R%GG+!.!RKM.26.N4&B
MC/1DAHYZSS3$FB>DAKP98'8R-S#_T@2J9T2XS3ZI^TJ4V]('N%OT(MPEXS8O
MN*\7K5UG9#*LE6:M2Y#(:Y=-8:KU$M$R_NOP <31C#.$HIZ.,%^=-^;[C4>S
M(4L=X=.MRX6XM,8EQS^==$9*<RTT<8]CL(0C+'NV F"1+[C0@X(UIL+<Q(F8
M:YP!3D0:TICS@9"/2;[(&$,/HR8*02\Z&9%^GAR='/DE)%&UZVC'LV8]A1V0
M&L?#\_Z2%6.,06*A2D;T";\)0F+*J69L!-U*\R ^OR@)"BJ.5C)PQO8P*NBB
M8(=,6NM'79F0-@8S'Q!/!7OA62AH+U8TN%#^CUN;%3CJ*7^3/*@JGGE*#-V-
M]@8@Y":N)8*YL,W\3Q&JZ_8Z+QS&\5QY!=,K39QNGG-[;"0Z_=IY2,KI=\?I
M-Z;EG3O'2VWWU0M)Z=P4SL)(B"I04%+>W^-GQ$S!LHJM![Z"@J<6:ZZ^076#
M_3,=)Q5(I;T <8)U0N1Q\GX$:TF L7F5O,H;=/\N?"1:@#](LIM/<VI= <LL
MWU=,F;3LHRY1@DG17.3449H"_C8:_66 M .7(FD7W!SUZ.C@'6)AT+'%+MX-
M[+=C#%U!L@(.ZI1XUJGIX@']/36;?G!%C,MU*\T;O1NK@*:+RX-G)T=I_VSV
M"3_P^Z^R,>@IP;4PF5!823I*&9))-+)_A9->B[(^OASG)D<<[(VC6<6+@-?&
MP75U:[66*J=8I=6(TN>KC1LDPO9F<X*U4++7P)(<,<7:Q &.#F9U0'W">OY?
MC [@=8W'N;- F<C>\!NX!*N3 $V@!'IFAQ(5-7\BH99M#3UBK?8?H)':('2@
MUMY<G)_&A17ZM/CJZ&M,CA1SRUG?*#O4=I$F1/AL%FE)VFK8E+8 J:K;9LU<
MNU=@F#B?M#NFF@HX%M6M73,0ANR*;Z) <J5M=4&E+=R$\F'2'F&)QWYI<I^H
MC/[[U0<^FEU;B^TC73Y:V+O6$$R0 J2GT?XQJ ;]*4;[#I_B 6[T \?:&&TQ
M69(2I+H-!/T;0Q1&*6$[F82?VTOX(-ZM3:<GC:_4"^]4IEW=%#]<IM/Z8!-
MN&0T*OS@Z>C3P2687G*OMDO\C.*",BG]@K'T1,9W[\$28E$QH(@OLO(JP_M"
M;,=;L2RR*5X#T?W8$1QC_TDK=[%L?6T"V&OETG]W3$++'101<XA<Q 5H5\$Z
MX/!A-E(W" >6U.0&7-\/1DG[^N-?SCY]>'_VX1)+CC^_&WT;.>T/IXO9=F7/
M2SP>L.%O<G(&27+0)(H1M#.X;=UM57]A=P6O>K$K@Q-ELZAE50[[@VI:1JY3
MQS3L<=FF@:U,TOH6P]%I ST$TSE$0FAN)F7_W"ZOJUH+!TSI+#X1RV=M[2PN
M$[BI_(\SM.A.T?ID,D;IAN5;!'\N:=2@!\X^8Q4LL0Q>L#OGN[2&U:+BWU]]
M[1ZKC#<N*Y;7$QS+N=I8G\+@1_@<-A7?O_DTVEGCX>T LX'?#2^PC6]O;_,J
MNKX]%_&ZA8&%#O:=VTK+->DETB_I556!__.R;J_8+3JMFKE#53J:+%-MH_SJ
MY:D(R'D[+N"/O(?)!?L(T6?/WUR,THCD4WG7KMJ<0R,Y=DE#$1<9:;@% 5]3
M_"Y\BK(V$LP;S*QF43'CJGTPTTW""^=(C<<9*#S^5[*82W;&>F<18:[H20G0
M%?X%7K.3+EYJ6J38[02-.F(_A.LA^>+<@OY@207QK]*X*67.^F7>Z)GV2;%Y
M)7ZUC^1(0WG\9&^7P5FSA;-BQ% \J78!NR>DBN XDP&)[( L EXOB3.*'4=Z
MDB3M_.B(?_9:!=1@0R7VOL>3[W@!^N$PHG_DJ[OW!1E6U -F8(JXWVIKH=KU
M])-#NLZ3>*)#R=V[^DUD34Q).H*EW X,]K=2I:W-8? /K9J_5JBT1RTUZ/E*
M'>$UY&!;QE"39'I@CEVB\5<@I4RSJE2N ^T^!)W!]9(;,)@_D"&RE@9ZC6DB
MG'+LW#<-[#^J@UU5]2/#Q[ONFM1(L;^%N5VC62=_Y#2F9Q\QH^9!)?P])EV5
M$^XCOT@Z#+< J/AD3N&5@F)#@3?W_-/;]V=!*9A6:!Q'U*.1^2(P='P+?+;#
MT (>Q:D#94SH-"J:)TVK'*6D;+EBA#RDQD8=!B,,A\E9N:Q7DH$NM45G$Z].
M,[EV<R'<-"T^&V1,CIN)&J@D5@0I*>PL:Q!KYU>94MIHM!PF%]7<O-4O!;ZJ
M0L<S^6N5<V,FT8E]4VZ*]^1A\E8[T1%S"G@DV/@GID@@W%:\\?Z R"R5$Y?_
M@&XC7>LXT2GR._FAIZ;)SX!]B&$>:IVV!"% )4PU7>2)8<DV%T*!HFVX']H^
MD?Z=B?1G^T3Z/I&^3Z3?G4C_,8V9SX<7AY@.8>O6^[0O30C]G(W<735P/@[G
MX=0M\(4GXY6W=<1#@!]7>IU1FS)L $A>PQKRO]AI"'Y0[\E9S^$P"1IYX\8W
MA=:3XJ=):->3@.^+6[=PJ,-P1FG,+B$M"^J07'E%U>S: 70[IGG_WCJ\1_F/
MT%R'APKC:J?Y,&9&SK%/G2@FYC5B8MZ%[3J7, H3D+X[3WL!)[&KT>T611%8
M!R@ZC*$23FPAFCD\.BOS.9$5:(E$]"3_DCTD?@N'.JP FG:L,6T32D-_/'*_
M!#J2O/WP$F%%\P6']X1*B_/UW0 ;I\$IW03["683I=7I\8*=EH3$HZ-_^Y?C
M)T?/IV#6[T5G"X>ZINY2W?HQ*@9,(!/M!765#TPI%/N[R6$<XPI\<%)*;S^]
M2.6W& BA#+:7&X)$B:T2_X7Q8+Y),7=8GNXE9@N'.BPQ"U=CYIRN-%0QVF6:
M0\)%<2!0RL)-UVB33)LV&6WE+T2Z"$_U&_$U>!I?@YR(02Q<YJ%?PW>A*?S#
M,"&-RC,"^2J0D)&YY@Q07M),64TB5DT9ASC4-A#ZDY0BQNDKC%UML-(IJ,FU
M)ZYDC)C;'X,M'.J:8U"[15:'9GOK[V O!(V6I]I+F6&#[T8,TS09<Q^JO29L
M!R6ZFRA#XT/2TBD+,WZ+MM:NUX2;!9FD$#1'C1LFO2Q[";2!;/]>%K=PJ.OJ
MV>AN#LJ'5 W?Z)1ZF=X@_F<ET-NE<ZD@A,7NW^_U%@YUC:T/6J.9$0R8"?&"
MYR^[#7;;(EQV,; \@J^#OI%_,UQ;DRD;+JV\4=P> <\X1]-+5%,-0G019Z5^
MOJVE92!%F_SK4]]3E2&W9$(PA-!;& 0:= C=OFN<WII !;DD4+DJ2,6C^TJ/
MU"M*4IJD/_?G80N'NN8>UNH0UG0M&((J]IOA; PM95GD8"CG+5T"$I01)VTH
MT,%?PR6]K_/>TJ&ND8ULI4S?8%R#MG,"76$0&EV:$DH+[5[91B,"B;#Q.PO4
M>R&9"F\'KC:J_Y*=IPB=D=V!W4\CJ\2D*3"!0GFXJRJ*6LM@#JD3@/VE5A36
M;N;J6J^@Z)Q+Z%7'YVS@T\$6MZ%7@Q_1M9LCWFV%/M[7?*+VL]**<._;0'6]
M':?AGR%^'BP,DB"OZ8WG34R=9,S,UHB9F![!=\\2+0)TO7X>K58S">8P/+8C
MB2R]9/BLV.@11%XO3A_90>'4O'YWOKLDNZ=P(B6QP09A%T@>F)S;IN6\J%]/
MHN-%4!+V@SY _LTA[1! 79S/D&V!_0+'7"J.$&.&@%7PN!&*)';H)*LG>8F%
M'3G7&S(XOI'"-<\O$V)*)@Z4@#IIV7CU>H,-Q^M5P]3ZUQD&K1SRT://+Q)$
MW/P*I\3:%)!#6XG3*2;6;^26F=16@ SDEGIF]Z;J'TU?FR)"D'D$E''%%Z\A
M?D,KHL?9$J8<3R@Z9NMQRJ;.I>8W^P;A8O73091+"+]A#/>NP6[L=!T+K2F/
M2/:^6PYJL;.AN$H7H7$%ER@Q"UBC_T2=P;Z2JB2_;*P?^ X*D$#CVW369UHY
MPL;Y&Z\M$0:W6-+J3]V2*(BD=NO&<6RPN7;%#"R2V>[V/']#P=B8F1?#M=5$
M_3]3)=(-%H?*^@!&[UCYO7BQ^0YO%$.G&>@)ZJ1Q1#!*X=_D@Y:+OY5D",L_
M5PAP?]*W;]+D=0ORJGA**5]CN0LU"?!!\[F46:=N\B8*2G<8BI6$2()_P8#A
MNR] )S5[8S,V8,?)16G"/IBX>7&*A<T\[?@K_H/*HX4F<A.6#>UG'S?G&CL&
MM,,7QP@37^(+FE4)$\;KE/HS(6OG))^:3B;94J.:_N6LJF!HBOML;(Q=CKE_
M-0%_IPQT)9/>]*%/:FP)CK$"KN:06+YD EQYD]=5&4@<Z!817R"&U](=!-M%
MJ2JRDB5=I>&6CJ@=8FU1% ?I;SL&4)@J@W@>"-=,%?57&56,QHN"BSUQ.=50
MX'-F($W25B"T,] B"[L)+S^,L+_N+5;M4G%(M_<%'Y6X%P(J)_K]+39IZ9RZ
MKO3"6]MRF=58?\:8(?S8?&?5%-F$G?C! I:MDON,PO]+E5(-M0^:CNAF7#G:
M )*2^'Z.<DZ6M21;9BDGNVZRO*!;PS^7(A;DNRXQCH$Q-E(0(1%EJ5U(MZ91
MU4U#+*LZY+<?7@HN?,#PDO9:PF7!$&^$].HW4<1Y->!VE&,-O\5B5)P64^XQ
M(4=C&E%8_( \D(1_L33PMU0!"#KP19%-1%5T=@=U9/C==57 6-Z68C3"O=R(
M7XICTYW4$@5\,NTJ%KP41$@+.JA=$@:="!K OG5UV1B@7_?]</,S9D(+OT92
M380=/^>X*?'H&A[Q!N<;&WC .*@N1]X+8YX*940GQSIEGA%_ <AXX0O@+1^$
M@"TLRLS/F<?5=!<NU8=JN0^IFKE3/8<&,0??"'G_/^&&0MH/F!=LN-R#2*;O
M/Q<A&\%@T[0PWINW:)F64EL4@L8FR\8!;]P^X@L)>ML+M2 9DVYPP,-9I*PO
MH^8>$US5JQ9^"2]HJ6L5/!9' %JN\>]O$!Y!WX.Y@+;EWB'7^NQ]'<%W*MB3
MHWT=P;Z.8%]'L*MU!&>?J0[[GZEPX"*'IV:U&EH#Q?"P*);VS=,U@ _:<&_'
ML\\'M\1I!)=.*<YHS$UPX/E2!J%/ENO(YCI0_N9,71 (_[ PNP8;#6S+IP\>
M/<3/O(0GLH5V<G1T_-/31S^=G?+X?!Q,I)A](H-@L>8 4QZ,T@B/*APK'/ Q
M,3;NXJJQ&;4E_92,&\RO[$X#/#$IW[3VZP.RO_#:AF=19NOH.1E#\@'ZU?'S
MAY+_,_47EF1*>,F&B**0TJ#VO"S8F*T"4P7S3FA;KEL9NR*'V&W<FRD-6%8%
M&%'9%\>&[E#0[_6[<[^.!LC=Y;K(?%]Z."_2/A9< Y=GQ%P@WFD5KU@GF4*D
M#$IS4)4A@6Y7,<ZT9@1%:(:%C21':N(Q\*'.@>?W(1:<G78I2<0(+)O-863+
M;@$'B2*+7"/'&=GLAL(/*0.]A((Q>4"<YP?8&W8(A/DP\9V-*_Y.DYS0WCVR
MS96',([4D;4B"@B55 JDB+8#0QQ>,5F3 $$117)-7Y2$Y66@ S,&A';GGAJ&
M!#K^?-J824IHMK1HJINAD>,3$C^(UYL[8KS4W($F_%*ESJFFJQ)V6_I3ZR^_
MY"2=Y$XC_X7J;XU(:SMH'[D;TJPOV25C BW4LL1B4F9*OA!E4?L/2+&2F;32
MI+HJR7N26#,&C9;>.6.+&-70 M7/.&2YXG,J6QOY1)QN($V,T_)!K 7XF)-\
M47#TTZL<68_DKZ"J RV;K'NDNAE<!%_(;ZHEEN6O&<F*VO"RV^=*$V5G_Q'?
M7&,(<6>5PFG75\53.*E;2O]X>@W-DO@;BO2$AB^B \<4,OH%D];LW6#PHEE;
M<T40QIW(/P?;X79G%QLOVX%KB61[>L-DJ)L.)!RKT>7[<P2OB;%B$EW3=>5?
M\7U+>/?W40@P!KV_/T\]T07^I"#BJ0?RJ<+FD).-W.+' QQPESE7.(WD3\\E
MR_1GTAH<)MI5(3[MG&,IYV5RPND<_LAD)0$.NB'&"#+#^9*51/@=WI9$2"F$
M)B&AU4E@A79M<4J#93.4&Z.>X61Y#M,F7<\LWQ0.))FG=Z3>N:BK0H<>1=X/
MD^[<L]KU[HS;&J^@4JZ7D%J<8I<YIL1:E[;F$K?\)B2]NR:7V$&45)_"H:>\
M'A\_SBFK[>V^@@5-2S6I,4B?!W5MS)*8UA%&E2]#UVD/80W6> ,R2GV?Z5)D
M4T PMEWSD,.9J![P.XXHHI7DI@.2D N\FDQ:6..SC(F,:=E"Q0W<+E.^8=2F
MT8_T';<[,@W=7>SGV FAP:NQ7J_:Q+ %X6"PNV;*,OS8Z],8)-'E*C)_DP7E
MZ'*G6$C)AMEO=819;N [.WM9OF+;(!VNYY,MXT2J[)AE1D =_.D%,:;7PK[M
MJP9-&A(_P IC(*6B$NSE MQE?BQROU\C>^Q4.LE+O9=LZ:TK9IGDQ&J<DW1J
MQX>R*9[#PB\]]KS)D2H5C&KD#U)7 4Q841".4LPD^$BX"V+0HMCZ)RE/;7\*
MK*%0)\_)@->.5*;?,#4[+20.4D6$YV/0H;-<83VTG$0MR\NL_ WUW$/H!?L:
MPBM!3#LQ%F9(AWT:VER1>25!S&LFLR"@E<.'43HCC> "T:!BU6L 5ZKA!C8;
M[IZ\\("PZ<X>JS?#!=>KA01#XBN-I H9N(4CD"28O7?>4&3M F5>9 O<+3HL
M" IPTSV?Q[99LM\ 9*< #>?'CP^W8UIW0'@O[Z@C(B0-L<]0!:S6%!$-7I8T
M<[QT Z\@A[#B0EU&Z6%H0^TB,,:(HKY";CEBW\:$:2TT!V!B9>.JR)MYE]\4
M;+/:J:5&E7$:.2&0Q!5W&Q46/S(J/1  QH8X/0]C *<.U+/=KM[1CB,]ZN*'
M Q\==F]V@P7/EP\,I&^AWT\[[@_WMA_ND]TXW!ZI*,:ZI^06<8;SM6B#C2-(
MOE4(6'J'A,Z5Q)<Y2DBFEW2R<OC<DD%H^D;.$/7K\0>J[T,3!6H\@&$T;FCB
MZQ4)ECO''C-]W5*!7D'<N?S%1L4GU^ ,%O?$[.Y/Y;:?RD<_QJFT(Q[T.Q"T
M16"L3OV4Y$(E-B]IT)#\$W_,7U @M17Q2HM=KZV.R!5H0@6E1\(3$8*23=5#
ME/[$BL_^'?)512=/_2Z"KE%44WR+ ;0<0?RB=?"SN+NP68-E3E?&](OJ*Z[4
MAK30DRJ6F""!WR*![N):%RL'+5-'"$Q;?4K!%T.@PL/F_^V2J0R0,FG=*IA&
MJ/%HB+SV%?%_4PF*6A6SO)Z'0BI)Y,4 :UT72EA+XDU)DH<DRG.7],A1T FA
MP FHZY_$<>6ZJ\V56KZ'DUF8<=;D4=LJSV:_LU[A>=4L#SQ4HU<^A=#T);VP
M<Y2-[/_<_YJP+IFX&N%LQ1B_UXYK;)*-XE BA43R=4Z04,^G3VUIM #76[(2
M& FB8\KO0O^B--D#*;\32'F\!U+N@91[(.7=0,H?X!X(0)&"RX5"3:S<W%Q\
M<] NN&*#;P5_<S#R3*_-G"!77F>WBTJ"U#&!+-X] :S618/M[)W[DK/O:+5(
M2-6B)*+65UW;%:,X#SRFZ#KN.65K$[$(J[9,J_81#WW_"6R*6C8(NI0(N7)T
M$;^)!)YPH %HQW7P9.K&Z+$!YI,H08M)E++5SAO,.XVT)R9#.E36U#4.-F7]
M=E9D?I/<,A4127Q"%D_7 WLC+;"@>FAA4E];I\G@.'<.Q_=/F"W+M2-A6Z*A
MQ;9;E+1]3EG964YA26D[(@EM,?ZVPX?=9=J*'MLV*-_M&/AWK3KXG=LQ^CN6
M/= &4('6U95#*@?*:1(H$6,-6!*,=V&<2'B>2"]M568%U^;5R+"(L #,RSKU
M6,C1)N"MGDBJ!HL.(S5H]B7\-*(B;PP)OT=)=$I_DW%=3:[;6NA'AFI+LP$]
MH^S+QX\3[%>+'7(24T&Y-(_R$94F1&8LZ%[Q.UI@+#W?XO&$AFAE12%;']^9
MT4(:_33+$.A)1:DS=X!92U@_ B)N6#:93D-EI7?,*)"\B?^J]:)1RIMQ];MZ
M 5V&\)K=:Z&6I?M?Y,48$L3A3,$ +6?L@85LK2ELRTW& L]3[[ _R:43I*H/
MEK$ ,HPBC!V!/[YR;3+'VB(^#"G:QW,+=BTCRXG&@_$>$SK$ Z68MKIE:%),
MN!O@)OF0,2-=K&2443YN"'<$ S*X(P.]Q5VX$W&'>&?".F=-4TV(#)L?;8Z2
MZAM$HU/F0]9RY\5:R8&TX'@JNDOD')9XS'207M(H2NBI("RD_H#"19CD04J'
MG@%%WVP7)(R@3@]6(,()QK2P@Z@5=T+OM'.4L!E:Z/A!KGUB,]I]S4@8"7O&
MWAE#:XZEPKW[A?_78N0,#I7+A94!W]MP#V_XGO8H*[,<KX>W9?+G#+X(5L;)
MT<E1Z*I*9<LPO1HT9:C3P<BL&"9TE(D,0FES,NY3SFOJ8?N*@/(E5W >@M_)
M2[[;:O6M=@A,^T'08EXUOLK"-PST#C<:WIDOU2./SQ$0*_2E\VPFD@F).PT3
MP++[P#(Y@VV8-%S2A0PMOG"_!TP7-U^WD#&EV7"%555?925!(@AJ_C'EDGWX
M5Z=A*EW\I@DJF06U8U5)B@GN%REH&[OE+6HT.Z_&%/D0,AF?CE@S4OZFJQ\5
MF)C7:_Y)W4^T#HQE-[F&";GR2G.V>&'9"J2=%='+S=4<<IH#-4M 8W8NNPC:
M.QZL,1PH 3H]/TQ>;RY8D@R1SQ)T*648L\P/(T5#M13) V&.H\Y4HLW0D'NH
MDE"U2UR/D+XW:0@T=JY -T[[I6?839RZ'-=T'G% <64:C99-_JD9CWCF>,AK
M<VB#0I0UAKLC-*DV=7/+.ILXI1&+!K2[U1A=(B1BIOMDYKZKI_*](;IK;%_H
M <)(4ZT;=8$:+@;B<J,)E0-%G&;!-M%J1*V90.GSG'E8%4 ;0N#;C-)OVL.#
MVW\W@F&9M'/&]&(]<CPA'\GT92;>L3653_P< ['CUM)<1B"JP?N1,!?*N0NR
MV&>1^5!:<#]',J5DH>'+4B*GA\D++):?(J<0YA%M'^R87JGS_'@(40)ZF/[1
ME#)H^#P/&50# 4?GHKLRAG\1HZ[8#)!*08@TDNXP>7QGS'!N)/#L^XG7Q-]F
MJWJ\?H^_3,7% 9Z/7GT(07IMQ@B,G[R-<IB<=1:*4\=&A;-MG$^0DPF9>MJ2
M 9R^V@QM5ZX^G%O[AV+E06@'X^!49T]E+/>CEN=(9Y'=8IEMWDSPK2OA^(7S
M->]U3K8#8Z))JK#G 9GZ9>)D$JE-8QI+C"95Q50:7Y=A_:F9!Y^R%4?R:;UY
MT/@&G C<:[=9T<-=:.J<TR]"193<9ES!B9@UJ;(NW'(II5F-<U_(4<UO<C"7
M)C6!XBCT8NN_T$N"=92Z;,S?-\K?@,QPJ\!3%8B//- &YJ346_ER,)0T*.5B
ME9DN V(3W&];+?._E#4%CE)=-',$=!DEBN2K8]52V&VGY3M(=SW?KM%V P00
MW\N0>Q<G[B:RL\"W?6_"W$&^\M_%GHO5D,4"?HOH=%_Y$P*,RT@$,:! +Z!L
MS97&@- ZSYBQ0/HMQH$'?\=)J\;NJ@AX[?S-Q0@K):\SE I.,VJPFJ_Q>$74
M"C"X*2QB0N*Y;,E7,SPED*SAON>-(X#?S+MX?ROVX$'T5UR)&1?IV?#F[V40
M'FKY$5,)]X&%_V@ZX0UGY6]&+;Q'6FU&6IWLD59[I-4>:;6KE'7$3?0IM(D9
M:43T7*W;734E+_MXGSZ_TD#/P"ZU,2.(R"T,]B%?)J'[IUQH/H=V&OJQQ*$0
M?.$I6S4<#3E]?YJJT\ZI1 6&#W,Z")O\1E8"]G70]M"6.+X18R5N60\J7Y5$
MQ3MGCG"%,.]N[/FSYP Y!RD!AY-*+)G?\3,V6GKE7#*2BO'SEY]?C:B!#G%&
MN*DP". RJ_F#MCC[)DP6$(7XM763(5*>(N,4F\#T>-/>B:HX-;5&E0/\/?X<
M^2^>YMA_CJ!OV1R?8&H?3/]6> C.Z3;+;\3K)I] G&D,>7E2;O0Y)$@UR>M)
M.V_(0.\DS?E))G83FG2[0-A%'&[Q7^DX\1I1D>P8/0L,*.VJL.FF>W8!DAQQ
M\9]8UG"*,MHNK*&(*)\)>YKIGVK]7\/C+<5(;$%3N -W8T9 R"""'$^:2;42
M[@H!)G!H2L@V=1AX@DW7ET@%$Y.F458;9T1"(T8^XRVB:6@@2332&J>;TL+T
M8G(JV5VR)PRUN2=C4X=SW;-4_>L7(LY..D&-C01J:_"PAG1(AQ?P8RF>M)EC
MWLBG)?$R$UX>?121=3?<X0),F06Z<GXC;Y1UY)^A75OW,.@V6V$?OOLL?8F_
M+@?KX#!WE?@&PJS$?8%[.MBW.B482U8FQN\4MQI>(:=CVAU#_]6,N+F+1(TB
M-2$DR : Z0OZA[<#[1U[5]LSP;&'LL(&,KW@#8$X>K^DHRHED\DTQ^(]#$TK
MU*,)+9UE];F<F9%20^U\#6$(F#*EZ_:-9D.-&+="P)R*MC"XPH@_%*FTUV0F
M@&_DEY2EL%MIU4- D?@[E''+1,6%0_(5"$U85@5<X4'3G@#Q:QN-L@_,?=R2
MO@W$/=+3)?[^)$-]C2MTBQ"'>49!\RD&O7@P+_N11&_[2=PKJ"12@Q0H[U>J
M9APE["PDC!:AGK1(%-NY8K*S3V?O+U): 8>O0%R/[93+'*P:&QP4[T-Z!GV$
M7BS\0M&[,-@T=JM*.<?@5#I2OC Y-9I-VB6$G81SJ/ORJEV2I@H%I;[W#@=.
MAY:%ADDS=60'ZF+2.NKV\9PQWJNO#&0!1?X% Y0P3KIXPWA2Q<B5E!V3#F5<
MS9\F'DBGA:CQ9,P'IJVARM/RQ=[#OY35+:&SPL3CF&ZZ5MWA50?SO]5N2%DM
M^:?#9,3K,Z$#I.TK"5;!0R+>R"8-Y'ET!MI2_[XH]'2[PGEJ-A$D%:+0-D_S
M7*Z3JY5X:NIKGCD]6L>M@_J"MJS +8O:B6#7$=8^PUOOT:K^WH[QSN&>PF\_
MC\7%YJ?TV]J,)--#-?,YH)VU"*2!*R\%^Q:4@(P62[*R"OKSR3A+MC9X(=NK
M>$."</C[/T[",(QY8^JPZ:8!QG<L?KB5HVVP\8*0:^-VU/TFZ5UHUZWK4H)U
M%P?+!+3[76>%NNR'.WLN/C+X@KD#C(8A,9%PPZK7<*M+!1F%P *V07\3R[#M
M9J\20.V>*(EO09V<O:<,??!!X6VH$)W\E<@-N]_PK9,:F]@,Q9KK$JLD%AXP
MM^"HS;@S_9@4QP:RDM':81H:# 'F*5$]$U),)-W:<?FL6YMS6$[]<NN6:D*/
MJF7"0'U#!@V4T&&KR.8S5D346>'M3"]E' RF0:,A7F<W3H#XTRF604810N]!
M-$BJ,9-J%4*2B*/LFU*)H'4U\!H9V-GSA\L]H%^YH:'S#*V$^_%0WX!C(JE>
M*3>EA )!QI1)"@E.5%(CUB:F8VJT(L9(,2/\&\<DB4MM= BOD(<>)I[CU!Y?
M%5%2R#ZTAW'HS#P]590.5[O /#/IX4B86C*$;!58S&,2.9C2'J[72"%X3MRH
M@Y\1<]G9HXU%7T@_4S:&D)0(0BG.S3:2$O/06M!"\%&=5 NG55V!&.1M@/,.
M+]*ZXO'?R5S";2_XPYZDGEN#]UF S&&UW2L"0U_J$_.:5H ;]\;!.:4[5*+!
MC>5@5D>,@0+>MXT=^J!#@G)&GM>=/>0JM13]N:I==#!Q>5Q-2AM7]:IB=G*Y
M635B!ZK2DHI3F!ZCA-)6#[^%AF@(,Q+W(A:PT3>Q]E%BP+!5RVM;)VBCD'K]
MV_ B!XYR+LK0IS7YUX2?E'+7"H)Y9OIVC1?(F(CR?VI2$QZ+(04B<^>XZHSS
M#S2=*=5#T&6K<^D/A2C_D?B1W\NKUVF'S*A100UBZ!@O+/BO1G#IFPK9T0KS
MSD!4S3)045LR(L6LK&<>'#J)07OEB@OJG3BO1 1!VZS#AR&,&?S>T# D5(9$
M,+("_&^F#<;'30>,"#'6\;=%1FA&,VX3CNY,>0]X^5[ RZ,]X&4/>-D#7G85
M\'+V>1/<95>-&(V@#5122D<=:KXW32JMYR 02!YJ1'-ATB?[3SP<JN)\/\*K
MF.HQJ149%_B.*=_K2T3A/H2%+Q#.*H80#*5=MLQH@+V^V-P&D7;H=)!)2;>H
M^=%W( ';J:W[CI<&TLKJAFL!?'3;,WQ*>X5,Z?C!O@YW-)P$+(=#P?B)" 86
MUQE7X;08'N"<BW'@!!L;=SKT@R3K"5\R- ,=CU08-;R0DAL$P[Q<AL;1OJ6A
M:77(]7@<C>-K&:9;+<"CP-I4^1[NS"AZ_WM*0S4Y,GEFI:O:!MQ-$/^<<Y"P
M-K!+<4FKFE1^%&?@HE5S\$1&L+KD6YV=C=+DP=L)V!.(;WZ7N\DU<CLM7<Y!
MD ]5#;?CPX'14(K)E+TB*J:\*A!>+'T"):5@C*8'&K2WORQ<-BNPFH3<S2+X
M//-YYLMD6%QBG/Y#!L,,3'VG/1JM1?;1)1(ZH92(]PAV1. ,"MWH)D1!IDZ.
MCYC"1)_'GJLR8W:_88JCA)EW4E23+]2XIU%V7O\H_F*Y%$;L!?<Y:6ZEG1!^
M)F25?7T1R/]#]A)\03D]\KU7@>?JV>*ON4G%Y\9I#Y#D] T6(E*%$RLU7S=G
MSER=E.XJL^?O,'FUX72F:\^T4 .WTC( 8VGH'%$?$OC-6"A(\-20^_?D%UIQ
M/%7=(:C# ROGLB*HDK"2M]=5)Q&EX!O.DQ\8BH< 1)(77FI9/*<ND="<(?]T
ME, ;+8BQMU/Q/D7H7 ]2 '^_8CYT'5MC>[V9LA0OLK#EQX]Y+*FZ;F%F^"T^
MZQ%E<-2_<6>/MF0F44;,:9,>M"A+C?2*<M="OD?=%CA<H>D@[[ W7<Q6YQBG
M&FG6RO%%.X:_*;.-,.EP1G6&''+:,"CC3+_<L$-M!^4 2]Q-4 YZV(=.CR+2
MZ.!@Q P1)XXJQ98K#?-Q=V:E+&G^E#S('G)@)4,CV+OR\.('?"TJ])6H4KC<
MOF0\V\,P^P&KJKFN",?GC[^DY0\HJ3S."E^GS,3\#=,#S>':XW1X06ED"9%0
MNP'-W_NDF3G-TC6*0$FD)%E1Q5O-/9_+9-KB7]JZ<40.]F"L:T V")MG%%]\
M\MQ]Q="2T'Q8I*?$'V4->(34YNYWCS+JP2OA2!KY Y8AW!$J?:VS&(K\<(?)
M!F*N['\&EH%/^555*R5DX KE$)U2 PR6$I*ZRTO2 G11AMQ+1#5+^4+,]&FD
ML5\<V6$&J(V6Q"\,$QU$^6C5>/SLOQNEP4>V5R*IZ?6HEO%BB+>WAHK-\1QY
M5/Z(LYB"]RSWMV_'E5'F@9-1'GXH&,-449)T#0AEODDSA.1.R#6D,K>#+\YQ
M[\>H3C(:5*>/BOUKNYB2&3+4X3L*PU+B"3=32]<3JFZLJQ+6A(?"ZBB_DE[6
ML9R,6,XH6)PW/G62QD [XH/H<0Q49*)@LK1:$ED!7(X>8F0@54-?D8^K>>?9
M5J,B?K;P,%,T5VH;*D[ ]QF_*&)LC2I<,O^>A6]OA_<;&[C&Q<+O7\-N5ORC
MI<N0O^([0PMGCSQ D>""&\FFA$@$?,,41>@2RL=LJA);/T3$I"5^EU&FU=P%
MT9:@.<])81#TT1EG$WVJ<4TN4' IC25#]7R RL#FV2=\"ECMJD:GIOA</A\Q
M*#?*Y0VJ.7 SLKP@%$VLBKKI_*X6,%U#R<!6PHB8LJ$'#\51<5MFC,#LZK4S
M&J !W;2X6D@CL2 ?\/(L(_Z3I*>6W*-5ZKGF58^B*6 7Y?A?@V_%5UVI7V$H
M6?!<VX:Q *&7FL&3:L=<D!.TSZ:<.N^EZ<,P->WK$;,/& H:FNB ^CF@O^*;
MQ5E_V",E@6N"XTMMR0_P/"5:^+->?*/;U!^@Z *+R4ZZA"8AAJFW1$#UUO<G
M)[$4#;YQ%W&04&Q264@\YTA'86QDO#$T-]KDW.",/-8 $Z:L^_0@BO[B6&&.
M.AU71'P%*8@ CX>IW>,1='/Z0=JX/Q2A=BV<A &'WB_R,C$ILGPNU89T4,SM
MI-B%4,-ANJ5FQ0Y;Z1_9G\79?GH_NA1$!RWEKNK+WQQ;I7@)#P3D V1$214]
MR]799_7_S3(=)A>.HSVB:T@OG3R_- UT)&J7O S="GP_+^U&/@8IUQ8_':X^
M@0!0<!'S V1>:@?:W*I,-FIG[E:;4IX<':6PGF!]5(O"<V9C";7$#,.WYIR7
MC[Z$?*<-57*H-@[>,N/Z;@35,:D:MER$ $3OC*#2,M-Y" -K4AS'N9HES;L[
M*?Q1:$_PQ,.N2(2RQBH.)TY%69FQ$_DK3-.16C\>FOW99ZEW&\HMD4+O[[((
M \9'S(R\EY9K4HH+&81N-'Q2^LS?4.D5,73)%<# XYD [P4Y)Z\/6HVV/F#"
M*2P9&(I50TI7$7X\VI!$U\V\MF;CE89-:'67W<_@\E!V; [&IF2%O QR\1+Z
M2S?Y_Z@E:IIPD!'-BZJ4Y;2)@@5DNUC7VM<9BT_GCR55MO3V($6G@?!I3BAT
M2?# 9$&V-GRSCXW% L+R*5)%T_<!)%O1/%R&PMPL3!AK[9C ]&H]%R9>119*
M]*YD7IA8J)<AON3G[YQ@H 8$+LRKUDA5-PIE8L6!1(GSGF!J%)44XVC,DNT#
M(XI[Q,WW(FY^WB-N]HB;/>)F#>+FQS<0R?Z33+_@1KKF,>=9VCJY>''P^.3Q
M *@>+RBT>.@BKK%[PKQ:7(/;E"6CP_[S[#6+)9]@:$WSI07E8IX;PT[,[9S*
M/]C$7'+ZU96PT,[5YJ9*A?R8OLMLW/11_V?MME+-QYH^U<DP/QYY7$O?&-TP
MUZ71D&FV*=.8KS"J26%.9LBEDG#?,F&H_XC8"/3IZ+(.QD_H+1V:PX"EAP'<
MB4^L.$WR:A$HWL!</#*0KA+$+_F4@T,X7-_R\@>7\YX$>HAP6#M?:&SKUMG<
MGE'ZO60SABHL(EI@Y#[(FTG;-#T;$4MB/52B=VY2*9;%)'O(T6.W70ZK>_?<
M([-CH@D-9R+A1,!+*$*I-VE*!@B-OL_L=U$!H8%)IWX-@\EU75UE3"2"IP%#
MP119@W.QJ'(JU<W CX+;8F5*I4&600HM8[F7:%GTE EMI(20 .^45?1^J;H9
M+L,#-&M!HEM" Z'QCW6+<>4<B-[5-3=/5BH6R]&.7SA,WE2W>&S3_D)Y#+W@
MV[MQQ1 LMCV!0Y%*7*/9>[R ^F OJR\8ZYO%UGT 7K!,3.B@"M:?PUYQ@STW
M=_75)DC4#Q^[.=7Y7E)1Z4N<-48TP? ';;NK6NL]WE5_;>N\F6KTE&[K.4H?
M!5U[;15-D<.X$+8'BKEJPQH3BDBHKTINBU\N074TB.#"3,>GD,G]4!TFQT<_
M/_L) R;'*8$_SBO8O%5R=/3SH\XO?CE*;6P6'XRARW@3F^[S'S]Z\M/)T?'/
M*26<X%P+")-KT<P4V-/STV-W^HOB6Y" Q%-A:0;*+DRS=/,Y5<NB3NDU%^V$
M:K![0EB269W-W6U5?PD7"(<B;M%)K7'SZ!</SCX?C*F-@]::5W@=/&2MR7RL
ME.[FZ&_HKX::N*'?:<ZX\=@OQ=>\YR*BN!PU+N\S@9L(_VIQ1U,,F4L%:Z!N
M[Z%],("$.%2,,6GM8_1J!+^X.5,GX8I._;E,'N2'[M"4HFD;^*E<N5'ELVPW
MMXY9UBV]A[IA(.ATE8 I5%>WQ4KS,TL.SG'D3E3A0]@^RL?Z?,"L\A$-[C14
MZ1H3*PS%#?+&HV^6Q*:/"1&?,Z0$OKW2M3@/3N<M8^UXT4$NBBG<9 S(] _U
MT2;!7TTK#/[LL+(.MY\YXKNJHT<%,GZ L7'KFV@@@75%Y@/[5N4J1+FC[%>*
M7^IC#HREPEB]"6-;O+8DHQ&/SH222PHPF+DIYJ>BE@?,9F0['V@16P"0:Y^*
M^*;!G#.C\DV;'_ !/=U?<H&>!+8\4/63>OX34A3LBM]KXP\>'1]B2&C!F:Z#
MPLV6?WIV%$O#H^V7!DIU/'F^_5U+HX4^>4HK:V7("-X(=/7!K_GD"\Z T/?M
MTI=(: Z\&>9\T[0*70R8:&953C0(>5$P&U:#=@,UE4X1/$,>?2K1"*DBY]N6
MG:)YBVE8J4C)X6-XX.@^U)]2"F3+KR?R[Y1X2K+F6I+Q7W(LAX#CEI>$1B8'
MY!:,^E0^4+ME6Y/SYAOCL<^%5>/2X)$S%S"TEEN=>W3ZHH6K(^.(P)2)-CHL
M9M4L)=5PA1UWJ(E&?9-/A-Y.%C=;T2D6%8%UOKX^9V"CE$-4L\8$I<^$GXY_
MR*?/?^=YW!_ O]T!U#UE# /AWA3$, .#V4EBGW1NERE&O_N*/GC*'R0&7'H.
M/1$.J%MB0&GAX)G@6?*#XI,\?)"#F%-$RVD;B\[!%D)!/LJU[SK!OJO\T?&Q
M&[ZQNM,:E&%O@J6Z(N2&RVFI J8TH&MX_1#-46?MM"WD@\+!E\G?Z5*DA^ U
M?%/E4RIZJTVD#)QQW)J._P'OIM5=K9_9_N!MQU#ONOG><'G$VU*QO>?8X$1"
M,525.IG 7/RO1IS5/G[V[ G)_)NWYZ-1&CFO33C'X3 6>69B?N!"35K!#C23
M:\=4"E-'XDKWA%'TFKU5A4\ 'HSK32C$//5S\:\E*TTH/S<=\W57-!Z/?+:B
M<RV'0&YFNEX9SDLP &DGAEEB>\!,JS%YG#EM#5.(E:4+/;@EDEKDBEDS)YSZ
MJ/>6@]+!@F"3R[39'[KM&.K0H9.#$FC9U8_Q)S $&2[=Y+I$B"V?%E_E2H3\
M&L&1[RGM^YNWEV>G;U)%-&.3/(7CF;9OPIP4A9I"Y,Q>1R;J1M1+$RJ0QG!V
MD_;*%7P;T$#HFM]DB+=OX*![Q#T%EPQU5[AFL<J0PB2SW/8CMY&7:U?0FFF0
M*S8%;XB)-M4O!FY.\[%)X3(\O."S-4Z./V%)Z52[J;_G>16M$< ^J%@!K%D$
M]:UG3],><TVH4#'U-TW1C$C=SM"E?'^XMV2H=]VHYYXN]IP5>)-<M&5SC=6B
M>'OJK64XF 0H?<Y1/HUYC&8SI.%&63DESY2OWI.CXZ,->N14S<<S\//XY& ?
MWA)1O?QC]!RZTXJ"\?T%IYZ3T:F_TA7\V_AS-^^V7$70&E&&W7#;U-""E6""
MDI)M6@S&.F&6PJH8:091>"ORE"!"32B,[EG"%W+8I!L)4LYV&YUPPGJA2V]P
MR*A\9C)FI(IFQ)7N5D-KJIA$6--&XCU*7I9-T&I(KJMF@<%!41)P7N&1U_E"
M5,:-:Q@(J:'OQBNN\*I(26M2D645U@L3??O3OB5#'3KM&=B8U16B'1K?0EZC
MBF1Z<FVNN7 U1J&?7^8'7S3$Q/R[/7^7LM>+!9^.)BL8GF$R'76-R=H@Y?)M
MOGA(4L/-U[,487CY?(QEMR2:954>!-^-/,F\GAY@SF:%9ZFJ(]N ;G=J]]B0
M%GC.54T\.UH!+1G8XQ"_$X?X>(]#W.,0]SC$-3C$'^Z^6UQG8*5,"-&'D0K?
M&7B@X*SS60S88W<V#\<!_8X!F7IE><BI60'3FX2:5FDVWOF8<J[.V^(J,]Q.
M0^%)U>-4F!!;?L&.^[TV&/]MR)_K>G#!0;,5& N'B#X854,<$C16N**P'>YS
M)=#R?3:<]E?P1?M\N7+NIG0%?65O?6W%4(>LKS4V%TNM#3YPE;S&'V"C!X(*
M2$#KV7,[[>/F&,;SP!RF<.$, )6LL]02@VVH-"$.VL QH[55B]H)9@3.FD2"
MEM=M(T=SPI5?YIPZ]/T0C;)[0(+CQT(.A.EU[,RFY9V8MZ"&1)P_@96] 4_2
M'U/9C<:GX07=S/L06:^VKIQS(FI(M\T:%(+=1,X7Y1'*<BC9GPZEKLR7I]D<
MJ=%3['&M/0I &K%%IZ9NJ%:XU3+<JKLHJ1;U("H=)8])0_*%EUY5VAFWNUZZ
M@11IE-#"L%^=@ZJ33CLM$Y8S3W!<C(QC,0X'$U-XFFT_!%/LAM^(\$\]XNZT
M6\8;&#)ZO3-P2QL"F>4SW+4QII1C[ B\K5Y4-3LC2W?%H49DQM85;F!?L.M/
M^"5=7 U%YV",SJ,&9^0&=7M[</TB^V210F"*26'\*#SO""Z!ICKP;J.]=!&6
MA"?7UM3[O!3R#.*?P/:WB/N;2AJ1XPD>V"A(6F3 .F ?LX''3-P!8LC:N=\E
M+#C#3 +FTLN,G<105+\D"+A*%(&>/<AE5$K@(WHS>X[+)8>30\<DR132I@M-
M=:"E%C10AQ,%(4$QKH:J;*7"]A,24KT"$P,<SNVXG=:BP=;H-:D11DY0P4?Q
M5=4*4XNHI>M\(:CZX3#V!$P^D/5:K;FN-^X/0<L8O\!10,&%1*,+::(I-?C_
M,>+_@C%FWCP4M: RR%NF1NB:J:)UTGL'0$+L(+PUC2YJ0@_ZVWKX*83-0MD#
M*S1N8>*UKC];*F"IY7:QFC4<OK@H!7:!])F2R&(9:^>0FPX#VWS'2B7ZO:&7
M\K.$4[;"B/A6,.:;(-.?'.5G[F] _<,G>S=3JJ_RIGC;,)(QTR9<4\Y4P\F8
M:$\?TLGT"\1JFZ(2RZN![A''Y.P)Q$P@]X?#?%AHAD \2V'5FQ4"S@E.B:8P
M]W#AFW+P?FP0-5\-,RACT\0<FYNNB%I3;0FXI2B7OV  /H+A14^*;M22^)+0
MVX8[V!6-(PPS5]AQ]U5C^&G,/LDMOXWREL0Y1YZH*8TB53B5QA%(=U)1R7LG
M$DL794I&&'<P\^QJ1"VWR/CN9]"V1^='4TDW10D,>X!AF -1F;3:5ZOQ[D5@
M?I;JK^RO6+]G!"!',FSZ9X<-B%)$9$EY3E2<&DT\(T>;BY+,X@U*BKT:R++V
MH&'QX%/.SH(5DXHX2N!:20DZ"T$8X+SJ_#:8GV2LLG'*&;C@.1S,6DJHB9_8
M,:$YO\,VSS3V-Y0M3XEE9>C,B0 KY9N+K$_)#\%30F,L:6%)G2(9%S!>R=[5
M;DSR7=VR=QD':4*2T>?0J&O\)_H69AP94H.2F14H*]H36M-]E-W35>6\7IP*
M$*BWVMEH\PX>YS3 T_+R&IF *7L'-@G] XS-@G\WQ^3]DBG7\_*O=-^F9ND)
M48Z=,-MYF-4?L0QI:,IRYXJA+PDC5C>(6::0SFKAO0F+'W EECERQ8I_+AOG
M4Q:TJK[*2GD<G;4QS[P?=2NI2K(D#*[3>%_V52 (NF_C.J.9V&%IJE93T"Q6
MFG[F]"O\^F.[1$<+2Y:D*.0M;D\'",WU0,H9PJ',T,E)BDK90QB.+GJ/A**A
M-2N<F&M.JU+PV.)%D#?7?M@^0WP.:BYYZ=5$<I4MJ"H'86LZHC0 _./U)*:2
MLKIE_U (#4%6?CGZUW^HB7=R/Z,@V6X[5(+?6"M[4,T.,-+JMP;/R S9PBN\
M84A2*3/)[;[4G2$Q%B6$M?-:Q\LH.%#DU"=WZEM)YW4L"$R:PW@)8^AKC;(5
MAL"CURZ5N\Z_>.P\2HB524?\!'CL#Y9G)S1%=-0+B]B>#[ S0H]$<?=B?=YR
M)=\7"\&80IZMM0J;=U(ZY!H#,4H.IQHL$S=,JK_)XC!UEF+#:/;">]M3O!M\
M?)^S%([;?L"_L+/(AC<@YQ?1PL+V%(C[8G4DJ#9_?7NEKT]B_1NN&;ST0W<Z
MZ:4'IZ!"SY;M@LOL:W+:2JCKS]6X,<"<7PC@@I\@>)^O=\Q8\0:2<9X;WH]>
M<29_!IG&[-!QBH]Z)G6=V5<IT6S ,G)3;2NJ5=<*-F50H,\)X3RPA-L7EH8K
M#5G[-3;@^9W(FB7DK+>B]#1J:PM"MM;2WF'%[4^R)5="SL$**E;=5H6&@LW$
M,1F@J)R/ _2H)T<G1_[::2A)A 8+' X<#B@&> +7KPGWQ'+#.IX<>6C4@;QY
MJH,ZS:;8RG"BS&^PUKAHUW &#L@H=B WU<K5!U+3:VQ,71T+E6(D%3V&FIBL
M&])QRCAH/_S&V-@*SL#'#"S.BYR\ SC7R8MV>N661OJ>^KJ>%R]&:TS3>;"3
MZ&!N$C\XTIZR*E+.B";#]?&ZE*WG@M!8]Y"&:56VR^2Z*MSA7;&.'UR%?BR3
MEV["'6&P9IQW*4LNW5=8$@H+O,R9=C0Y!?M[F?P9=S6IV\+RW^-QI@IX*CI&
MBRZ7=H'DGJ E5R,[]1B[J3;N7B</'/W&ZR'4&Z<@+C5C5_U)7XK" R'K\D54
M=FI/K<ZB:?%LL!T2]0\)35T>(]@1,W;Y,FD7!++#7W>6 1: M;>L0'\:-/[>
MBK"K.<^\E%.?" )L"5JQ\R*J7Y"NZ]B(P%30S24,X'6WO7'$(>(.#W*][6+:
M3^28EL5&&#1 $&Y+CC()AVPVK1;+4.D?QW1"-R!<2-Q'B6V1PANU5VC<@SP=
MB\YC17<JWGI0>,?#2DZM.:%+;+1?=RFEF=+<OK%"CQUP_DS<,'OHVW="WY[L
MH6][Z-L>^G9WT\L?0-]?4.\*T_2,;GMTW)?))U6@H)VS!JFAI*Q("L>%6IA:
M$KDI0?/Q:U[OD@>QQ&Y[H.7_]_'A"=("%85U[YG^%C3\(Q^09KN9[WRE7:T)
MT./;J5 (7U($Z ?5^=65TP!#N+RJ,N346]#"V9(:=.CH*+EQTZ6HT B9,/&*
M9X?=O*^P+3.Q OI[!2;H36./I@LTL0RC._E7]&626=Z@[X S]@TFI0ZATMP[
M7**C!:P1K4C*SL64,7B83!76MR@!A!OAWZMI#@H$QI7+=_@3U&Y)(@#(X:P]
M6OR>/(/MH(Y@)A.E=ZI89!,EX%EF7QSWPU!?@^=#AL <=@H!$&!MPI+!PGP"
M]\C-S'!.O'LSNOPT8EGH>.BR@L-F@7+*<^IC.KQ%NO4FIV]RX%I#HG"-B:L-
MAS;?T[V4@UE]G$G (35*#>W[)P9Y,V3>^#_#4B1 $ F $M$VG9R=C4B-P&W6
M'*!/F/%'7-G-[C23&FN5J?<;QPMH.7L9)LKYP']14"><\BH(O:3TA=QO0]-D
M_<!\G&41QAG_]FMRLQ#*P.:P2AB/JG-8\A)UF>(A(HM:T[]]Y)C1;$+@1T[W
M\"D8DT)D>G;+&<:"1;D?G\$3&D?/X2@(&%CVY2U;_+QV3"MO2+=]"Y$H"U=S
M9K^O53O)P9 OR\5X7Y,5!*-]&24IJ#FP!^P-Q!6]YA^SLM/,.,=X@RKF()2D
M@G'117?X-*'SR4/O99B<^3ADZT.(V[Q3FW: ./#N",[([&2$8>3:>^J]E)H7
M5A0-RY>]G J7T5+.2<+T/C7K;/B3Q7<H,/Z"XC\9!KU-D5#GF6$UXH<@(47&
M@% ?X^+S@T%,(K6#"5&C$F0:HT'@;S#"#K.F3DLL0=BAB)=^TZYJ;RD,M$K8
MXT71.AA9:.N %T1U&VVA(I7P.F#R>?Y?3"1@VF-139"?/312X*0";[-TPS37
M7H2R\#FT'@+?\[SI)H=<FZXLZ2,:K-FK]50Z?$=)"P#73SSRO,D&@B4+4L!I
MEQCA:7 !&U8AI(\7F! =4[%YTR+PC8/D+['![E)3_5+BBL_G#KE1/>B;-Q<I
M:4EA6"(=YZ84LT$BQ,KW#6U<$'XR@B0XU("YPX^PK6SH9*E@4ICL*[9K#FR#
MR]5A\MMUCIVBHW<$J)U_&W<*XIH*L^4Q;2&EFTAZ?50U-5$U*>]8(\(,\<D(
MU<&LR1+_RZ7II78D9"O%?:%D:@?T@Q43]KDW+M(6JK)H"VE#O0;5FX3TISZ5
MOD<#BR@.%QF!&^RU0Q:/67N+Y#97DA_!,/B#+E#3^L-?1%$)([-@Z1437QU,
MRHA9#<1Q:\8R[?5VTD/E27$#V6) 3I/&,CR1G@I![TQ=6S')<Q%6##E28768
M-WR\:BE^CHF:6A)19+^QI-% _<4_;HLO2LZ%@)1=M>?6PZ3./IMCZ-FOD8;-
MX+YXJQI/_#X$7K$T@X9?< T\EX.Z1M81=3U?+ 773;8[9R1)OCO7JB:"0K<@
MJF1171=U#IU1U^];\17*ZH:/:_35I3*\JV?8M259LV>2FFFD:3U?;O[F1%LO
ME2"Z^B0PIVMFS"X]G,76':]#XE$C:)34E6(,]>X+EF#O1.*)-\UL6)TML(61
MO3Q=0X?,<-T;.]0^D1E1"5BFR)#5,)Y?K"K?3YD*Q@2 WX<6AUY//!3&[8.]
MTC@^J9B44<-<G05N41G@0'BZ%K!??VVGW%YSZB:2.\ O1@[*$%C:%N*I198&
MZ%&GKHXMZK2K3N/U(KQE<"EXHV WI%'<SBJ7-?4)@O3?#@#._<L4I$. NK(>
M#!R*%(:=ATAYMN4LNZEJBI^I)%CATT*0OHRQ91S!2O'81>8KEMJA?A-4+%V?
MW%N2\%E$DF]AR8'#?]:K4G+KP,647 JM@L60E]HP?L>=264CQ\^V08Z_N9.W
M*L93"T/X9$_]KA[J\[47#>%2EJ8!2V@@5Z"NK:_P=@BY7I2>3*AZ&$L3MQEC
M?\AFA$TC90D"C>4$"DF.E$^SYZKJ-C!N4'%:*"%'@<60*$<O,^;KL_;*AJC(
M8?*RU89KW)ZP'RB2VK> O.*CS?%8A*H:2ZHMQ2*&92 WB5  VM#-2ED\*(IK
M-EKF.7!< TWLK=N@ H:,(WBK#?6 K3B&&2 Q.5:X3:+J);$$T^B.[TI'.5#7
MR-(Q=9@=)@L>QY$JEIUPQ12,U5Y_?7H51=>;C5,RL\#_Z36;D02)FG5MKPA0
M[#O+Q6!ZCZH%NP>\4DX_V.F2(]>DH95.6,?+>UB]"NPSM'"H9>'7]97@S#?:
MNNH/5A(Y%1.0$&<X874^!\9"C?+(S/9BAPZO=F*T%.69:;6(D0V!57DR-NI1
M,D>16GE3D0*[6-JMM1/2Q6')O5,.^@(B31Q#34;H MF%Q,@MA%V,Q-FEXT!,
M!PU9]VRG54Z9 :6= P4"B8&9X"AS]F*7H3[CH-?+VUR/VOFPMY;"[ZY51=%W
M/#C6/EP@W3Q\C1M['T1T3=@G?OA-]\D9=[+7E:2=4#)0#[7$R!-%*9&.FGO+
M("%]*KDZ//LPRXX*E'>.HTZ+/D[9-D.522PJH2A)>@4=KJM?_:'MPS-L,,I5
MUT3")HG2^UA6J;WCPOY*N[7X$EBC=20?U9/#M>ZDCW^'\(<E]*<PUZ;A>\>8
MP^YXNJ(BTNW8Q,U;=J>UNL<=;<8=_;+''>UQ1WO<T6ZV_C1MKM;'&+-: [&.
M.O_A?448' (G\WU#T3V*94@P-*8MH2GW?89^HRD*"MX@> 6;:16KP^0,DS;V
M7?01+ACBQMFW8JAF"$TQ-"@,E9>X(AJA)KF0QGE"<G9J,"PQ8T"?G(H' ?>R
M$)?*2ATFU)$MFKT-"+TB]R--7E,EQ<HGIN1Z_A4^ V])=0:9NC/+P&Z-":"F
M828:S.!=CE).:T^I<DK=@WCAK(W+#]A@WF;!?3<7/'Q>>A(*UDR<D7C?0CD/
M=S+T25/OGX@P<-<KX_>XKU(=3V6@@6Z*R.1K H/#7,6B#'QNW'R2T19GG[MR
M%R<Y_/+B[S[H^'RA)DW'Y$N)%OCL*[:*Y9:JO&CC:KKR*U/R^M+(R*K";K)-
MX(QC2Y^W,Y0(^=B]K T\,J>8-]6[^H9SN-#,_(VSY_!V/V3,2N3?_\^X_NG?
MU_QQ"XWH7GB-^3?.A=YD]]N"_<9N@D=0=NAB[N!YN=NL'V*ZB"Q\H5F*.0K@
M"+WFW 2WT#3\VF%+2/&\?GG^R5/GPUDI<GACF6=X01(<(=&][%9)G9Z>>ZYL
MSS+&ZHA9M?$-+79&"@G@U/,@IB%2+F@>H0&+VOPQ%.)>#[S7\_#("E>_+>A3
MQ=_6L)H@:[ ?G0R /D1..CXK)0Z-<!7Q2O)Z8!61!3&@NGL/[N#)8RY@XGG9
M;^0-W88'2&TLV:5F J-)?6N1@'HSMRX[-)Q:Y;47/@;"Z453'Z^B.5-$3EBP
MNFM4!&_6ZG")I$WU9>9Q_&%M9<D?QU@.EJ%HB21_)FJ+8)M$VOBQ'4\JPV>H
M,CC4%''UF G\/!9L51*_2<1O9B$0WWFHY\B=8H?;P_$POP5<]B36!@M-D+^N
MK"%EGDRH*UF>1 !^91O\>5@-QP@$&R/5C1P-5/PWA>,-^Q,'?,M XM;%*8<&
MV(S4*]EB:A>XG>!!/WKR\_.3HV0N0'+XS,__JN,7TH6KHAJ3!(*5T3I?RV5>
MNY3HO(8+4691MJ^HH*@V"QL;CZ0_,%A"=8\D7R$&0DOL@^YC3'OCKE!W=L.J
M:D55\95MH,5"G'<^E;)Y5987<-S ZO 675@RJ5R-3H 9/D&E/!@ G]\I*^8Z
M;UWRT 0H+ST25."'1F0(KG3K93,*)E)K\(XD,6(["OQWL;?9!-8YB$UWPI2A
M\;20]AI#> %&\ZENW. ,Y@XMO+R9,RT!E_H/< =&ZHV-S_M0\UGDMR?8(]1<
MA=L2V/-\5V\X1XM<B ;!?J2/:8D\&FY,,$DAKP!0UGMZ>,PN#I02M E[D4M[
M0*D< !\F1R[\&8<]Z2EY*8,6/:R7DGX&E )&DNV'M)4M";7O9TNB4%2^]_?"
MM,@P*!P<)^'+F*75]U\ 1TXA\B((/+7"94JQ&*0SIQK0O(&?&>: =CBLNDZP
M(W0=ZQR9$[$<GK G-3-+HE<AOWH0SA3%L1DY0COJ.  ]T?@][I% +8PWQ/3_
M"L*S-Y[OM1.95I8BF9L"S]M2KHSF(=Z#;8]]FC-]$2]1& D3-U1UU ^HTSQ(
M.*A"P_@ <<(LG?<D!H9/S,W=":QTG1!F8B$O'6),3E>:&T35)#),7(F=-_/L
MV.&^()PC\U-ROV("<^ZJF3X,DS/FKE;;DA5L+-N>)9?;VIN3([X2\!N&J*<A
MYYLW-R9!428556-Q7 &M 21"HTP7-63Q>MO?$_:6\UZ%OHP:D[,M8.8&DD1&
M5F,&&\JOS C99;%00=2P6GN#<BS$OE%F7EZ*(0<2OG\L0^1]Z8-^"/X@OUVA
M%Y$(4,2CKREN1$,&WXC^9,3  \R3!YF \&'7,=@!=V2530G;P4V Q"'"5S_T
MUBH;3>$I^#:F.D2RW^6!V+L*#);.+1M$EW..G!W&AS'S@I<C^HNQ_5VSEZP_
M3B$NI2B1&""P/5QR7=WZ76=0Q]@%8P(98LCT;DS[\]L::UO155:04/X%,4+@
MJF2=-N*TJ3<!.NR^HH6-]//LW=RT!08L I H^O*R"M[!9#6FX"2Z%(UQ!Q!M
MHAV S-7KRIN\KA0/%'HT1 [?7K#^L )#@A(RGV>/T]V+5X1\%.YT-<:Y3F:-
M_W287%"ER1@#T:B%R/@%V;!D+_0*=CG0%.1XKP-SI11O/\.:4RJOPD;@7,N'
MSGUYQ35U?)O:\HRA2-U>:OY@=A2ID.->K[I=! AL LTFFNH[B[@^'>3@I\O2
M-WPP'('?1B-.3B:::U5=26"$"/51QPNZBN,.OS,L0#&!3EL/[V&3C=)Q:"F@
MMHEU/2M7<?N++CDZ#I2IT0TD<\CML;3,0P4/@3Q]'4OZFLJ'?JT(;X'T0?$.
MMC9J#TLCJ@6#:H+!Q4AP Y=N-HUBGT04URPQ8[HKK0-"5YY_?.N ?>> ?^K.
M :9!U#=T#MB6^V1-G<.91+&;7;TP1R2CK]RXYI",IZR\17Z+:?+H\<\)MK8_
MP)O.!_4Q:HEPDJ\Y-JL'&3UY=F0XXO53I+TQ!BO%@L&93BDT4M[C.^_@H& ,
M+@8O^-15X,A[_,OZA^R1C=^);'RZ1S;ND8U[9.-.,*IQRO(P^5"53@-$06,.
MJFET%5@!"TH'J\Z87V&\(EIT;0"?C&$M1!/;^J'$!NW7?\7W6$O!VI=N,QP&
M@<DB[&R:4(0=#-0%JANX@#ZN&_XK*6[J#YAB&U4Y^[=_.7GTZ/F4_R/L%_@M
M_,7Q\PS+K:=P?TAV]:R<9%/.M"<':[__FG\J]9?(5P_C.L6OPFA_0Y>\R.'2
M8Q>*,][J6)*!&^\'E7)7U72]J_X#-&':;%R=^@Y\;T-D>U<-K=]0H+G*3:=-
MTOKG%D[C\;-GC]6/9?<&SN=+$(_;3%@_HK09LKS?*@$NNQXE9MFH^D6\6@4J
MO,BK"TH28ZKL;3DY-'1$G8]>AM+5SF<_4O8?AIXOP'=Q7\%E$HCSC(OMC+D%
MP@W[?92\1YZE+'E1W$S3Y$6=-^.L=%'.\!DLU6,^R&!$NL4U*B;I+ 6^^H/'
MQT</DV>_'!T\@><=)A>C#Z]'[S_^V[\<__+S<WBD6V*1EQUT\F(%JX8A#/W0
M?[\ZMY_@7]."GB%.S#$Y(V+]L)[S%+,^^IG:R2'%GK^DOPCRC '1#<##H;6$
M5?SYZ0F_]AQ$?/BM\AEY;7@7F-I83K:4+L@Z@DI^HIUO(JIS&APLX(A11Y^X
MUS+J."0_.SXZ^-7@U=$]]<BQO-:>G+2[MZ4;HO+;:JCM9I4SNLGR@D(6^1^@
M<K97XZX+$X-DW;IQ@W"?O+%'=CMB"]\:^+J]O3UL^,0=3JKY=DSBCF([IF]=
M?S93.O__ :H>M$ZQDH\T]C/_X2-.IQ+NZW[H*3Z' G =&E;LIE#+AV=YP;VR
M9BWH8VJ0M&CKILVXI/5"HLO'CQYD#_%CQX\?3!]Z2*86*E"?$;JF_-EZ@'4B
ME,NF<NV'VKI518^8UBJJD,8,5H5TNBN%EW% D0IXT0)$8[&NJ!( R_)S@G;E
M"-R"3V D#6VGU,P"<ZE+J>*]X-B>QNC\F$]]20%]\^+L]-#:(-)-6O[*S%P"
M*B/:V32:#0P&(]29MBP0]M5&B[SM=<\#V[C_ RTW8'P>!8PI"+^.RX1.@)L<
M7E4W'5Y V66"'WQ=B1$1IDAF!@E&:N*S]A,&ZXWE'+4$_VD+.MOBLQ.XDGUU
MFD__[_^ZVP$[?O:_?AP?:\W]\O;R['UR/"++ZA@,IT]O+WY-7HU.+S]^NOAQ
M+=MO5<NC4F!V6A:FW;U)[JK)%_PSMM&.FVB"C?A%U&.P5+P\@V!BLOF@J*HO
MC/ W<&5&$<N+1">B\SA9:F+AA30FH2ZB#$'4(#TFOQC^Z;4*JIJ:PHRKWHO#
MR8&/@P$V)@2B=J=VUUDQDT/>.*TW\6 QA!>U32.H-*'BPUR;X%O7M#WE ?N$
M#HT[XF=%& ?J&R*N$/)=-E\9:YX*!P3^"\Q.N/J%;-#_@%3@U.'I,/FOJH5_
MTB P:8+QWU7@<.B6-4P]$8U8Q5SG13 23*W)U)#.]8JI;+RZZ"N=#'NU</=9
M;;GJ[5G6:#!7JJ'$]JT"^C/"IF1G1GMUA>]>'O56G+O-N@;SEMAI,0!B/_FF
MAR^1OJ):<$3EU) 7!/38IP#Q&1D:+%RM<\NH<NF++G=0@:U9VH]4[\",G,S,
MT]C4'Q)YEY)^\'D^7Z^X1 7B&5(Z?%#<Y))3H[Z5\69BLG5D&3'&(/0DL.PM
M339SVB(8?76"2Z][Y,ZB0J3(,/-[! *!1"+CO#(EQ5)YPPR'&16=<3%$=V<=
M;$PK',E]OBG2X'#3W,L9^9<9_9\NQ<GQR>.39W_+I>"M!RDC(G0_>ZD@0$)&
MD=A5^@?XA'_$?+[5^'!?DYO\IMK2Y<<5/G!3NJ.QI/I'7VT0FNU>;2+#1F=*
M>!M^Z&6^W^C_[NLLRQQP,S\$5 5S,L)/1NK>\ >*%N=;8"P=&(:N9[K(:]<Q
M#MAD(#C:[S$33(W>4LDBRBJY:K,:VYP[7^ZH8'.U ++)-66:&*, _Y@1#\:0
M,: CRV/?J?+4Q=WQKF>Z[H*W!NP0_"[;.GYH\?.#;X.K&FR:N7-+X4-<<'-S
MQ*/@I@8(26]E:^W*0,5RB/62-C>-;5R 33 \75EXX_?99.2L@1A@HH19Z,G]
M$I[U]7RR\B<!@5'#$6&+8R/Q=CTLS/=L$@(RDF1?FR;]DM0[U7J  $IC(%T?
ME]98;FMVG;/(6P=/B]9?)(?]>J)I_('MR&]U%,2R!*DD\E,LL\#B'H0'U^2>
M94U33;A+.7F]PI7"-1:""AXZ8D0'$)RXN_R ^^D'4XF+/:Q+[PL,'!V1_U *
MZL6?"H[*?U(_@A@9 JVF K^["SA HOE-KIC&.&Z9RNGNS>#:,J.+?W.L"S0@
M%* 40NB@8H@5/50Z<-6?!A/$<B4W5E8K8U+I4(XP&0WZ&F:@A*OTDB7B)Q2\
MZY92]\9//$Q._2L<MT+)FT!/FI):EQHYM=@\,S!-"N:(H^D(.2Y!=_ J]3)7
MY@%%QL^2LQXZ/@H<-I-K-VVQN5%.O0$S[*4["G79L%$EE6=3K4OW5;1'DPDJ
M?QX++>=A@F28:DS@.BYJ1JF;@XAG':^RE8Y'0H/^%58+2" QZJO5_.E>Q^W@
M^"D(^0(3"^750>%FH--.XA/X:/M/( $2GFP)->JFH48+??SS(0-(IZ[ @D^R
M*]!(HSZ5*.U8\M%H%\M@<1BB K0D:V[G@+?PGJSS>R&MS_:0UCVD=0]IO0=9
MY_[*V-(K0\&RQ ()EL2"6<6QKT2CO'F5AW%Y2Z*6]%!,\,]D=)\^BB?1\<<1
M9]"LOVSVXK*UX@(N?MG/7O"&!@<O<D1SX0#EBE3IO3JNLGI*0O+VTPL.EY0A
MP.66UPB\G/@VW2$TMN1F@@/OW\O3%@[U;O4SJ=L01W=E77&SMZ:5K@92'LJ4
M*L2I1E$P'UN,G::]$&SA4(>%(&9.#&G4Y+HJJ+!BC<_2X2O#6ELF1//1R1L)
M-DO##H1R\+W%K^J+C8U<$@1Z?TEM\U"'Y4FC*D0EEU+ ! T0PGN65QB(TA"C
M-(!17E+A:\JF%.[$&%,W>Q!(,??RL(5#W2P/3"M$R(2<+%MLC1:Q7[QZ.4J3
MUZ?G#,P-! 0=JD#*#-F&GP'AZON\[.5C"X=ZEQ%"C,$<.$X3L#(QVDTPZ=!R
M7 T4% *X938%V97T694(W2.6.$)>3*6#5@>1/!+]\ZV$V97:TI-CD10KEQOE
M*!%Z/VO+2?"Z.O=C/(>JUN9AW " D.M,%C<XF[T\;^%0[Y)GD!TVH<5R]CF3
M8#\+>U:F]@]FM4%$F-YO@:TKELCDQNVO"'E[T"[VPK"%0QT6AG7^N9>):5TM
M%@QDUAZC^,G]%F_A4(>WN'%%\&G\?KMRNJARGQ\4VQ4U>U%172\F;*MIC!IB
MXCY?6I^56;&B+NHS S2BJRM;9GL1V<*A#HL(98]K2L_#5@[ZR:8YMF )I"E0
M'V5B^B@&"T$RY2!B&->3#IOMDL9*7:("7:3TRO1$5G0!:6!/;B\_&&-[PZ>I
MQ8.W<'P_Q-HM6J[%V0OE%@[U;R&4>6DPCHR 06Q'D4E_K2OZ>D!GC-7?ISX0
M5=T\OQ^=^EY4MD!4C L? Y^RI>FD%G015L>!O"@<2E)5:-*2)M)NXJ'3\5YM
M;.%0UUBTXJK&\-FX80UL>^@.9\T?*E@7_Q=,8,PJX4_$;ZY&$%*?5C#%O<^[
MC4,=%HJV]-#M0%"M-:GT0P&SH'LF--:>M2P+?=PVL:GL=W_[ACJ\^U1AC%VW
M\@EO.,;N,4LTH;X&2T>D8"V?;<*0[C:,6%G7DY5;,K #X:D>UW$7$/#:A4B1
MQ8<NLN7U;;;B5BD2>UP'&><67N;!-"9J>14J4X4O0ZNJR=KS>EM&20D[(01&
M#P'C\=ZW[737DOZ*4=4EN!S4#8U,!YJ+1'J;_\_>NS8Y;ES9HG^%<3_-1*#*
MDCR>L8\B;D2[97D4U[(ZU.VC$_,-))-5<), #9!5HG_]S;WV(W<""=;#GC-5
M)7Z2NKL*2.1CYWZLO1; ]?5PO?B&!:-8+"W^"!,6N2^47@YTB%A8W88@:GO#
M<0^>C4(WQY )+RR]$)2(R5/>-L[1#?70T">D]@[6;HI_GR8L(7L3HA>RP'9Y
M92";1T+\'5K9HZDM(]Z _ M$4&YXE1 )N!@N\8VS$8XC/F)127&BX<X>]S4W
M$,$DC1J5K,.<Z! A42(<*=QQY">86;I'G>?Q/,48L5-B\;X[,8<RGC+$O1A#
M4.[$DN3'FK/AIM=I@EWAY]7V.) DQNG-6@K"CP.07O"@[Z4$FNTX:11([0&]
M2%1^^\T[XTVO>YQ19<\NVQDNR]J#=C0L)>/(^H#08" 5>:</<@314$H'P":1
MJ2#)$K)U0:1\J\5]#6%C4-402X=5][FHDF( WB72\.ZD0Y?'/J[P0#V(2(C;
MJ(?#<8VN,Q!1)-V\S!DE@K6AX^\]T^XU;8TKGE0$R](R6.E8R5*N^_J^U1ZY
M8J\9=ULPS4]Q)/.]=\#8N 8%+W<K)]2OII&JS"PDZ 6YH4Q$_'2H9A$*76Y8
MLR4)8P=K7Z..BO^>_K17?.B?VF7V4:@HL"T$P\FT\>E:H:TNNG0!5VVYL=(+
M,^K!8JUZZU'5?E=2PD1OD+;N_"G>D??- !+]0+NEK?L3E4N;@U2FH';4[*39
MDFS/N%-&:&6X+0=\,L&3S(#3 GUR; ;B!N4(47M8\60Y58ZL9W)IAT>-<>J=
MX/10U0UD,A"/X UM[&:O>-^=OVQ^E T@5_RCMU82Z="VL 9L;@'VAS=7L9G8
M-?N"G(S7Q?5*U^-?*+THW\6\2^09UT)<.K&6+'?";<J#ZG918PWMQE*C'K7,
ME7PVU4Y-.2^P@FASL^NNGIE0*P"[2SS:QAJ4QT(W9[NWT*;I=CDWG96:S*\7
MW^)4D)M(;G3\;V7(!>WQ4_(FN=N.D&+D<C-\Y\><I^O%AT=;AE+?*;>R=H/Q
M4]/Q)!+2>;.53(/;."PLW>0-^NHMH$Y&_@ 3,;M;4WXS%=N.!SK[_'9G;20J
MHG9"L12,AL662 %-?/>O]-'G3<KB.Z.XN@':&DZ^V3IL49W,0'(MDI*WD4K!
MQB3FY'6#C09NDE)S!19GF1O8D$;FF =J-VGD3'C& K[%)92298J.NQ"MIM'(
MC.#'8DPI\F6D<<U[,O[;I:_M>=;[UU]<^MHN?6V7OK8W(=6P@F&D8GPT=J='
MWJI0\60]''_=U='78#VP.QJ-A-)>'MS:TU.B:.1P+P,Y*?/^-JZKQSD([Q+F
M\9%QQ%-#AF.<MNWX"S*"XC?KPG^:IP'QC!U289LC3$C.Z/7B^^@C=* @4G]Q
M[K>9TE4)-_\>XS::_YMXM[?'%6AX.!'Q7]_^N7()8$H/!&&C'[LS\86#N!.A
M]77E-?.7$/8I> @!I9"EXPCTHF4"/TKX1"^3/&M)Q8 58E)F3%P>PO@7%L?]
M&J^/'S$X4'E"SNRZM9TQ_M7VMM80]F54;_X[*=[^IRF]/.B;9IS627U8(NE8
M4OQ(<*ECGTK/!08M@R2 S0O/Y#5GM?"XW3R=I.U7-+Z)KPM4K@*R9AFS/-4W
M_=!=TS/$BC]C. V'((2A\?TY8:/W[:'<'(31MV&MQ7K@@\-V4M#R?'9NCW&R
M9XF'O&N/"HR=$Z*'C^<$:<PSP^5CGH]6J-:,R4OA0GV#6P7Y7N9VT0FVH)Q+
M2F/*LGME ZL<#6K\A)76? 8R5>@2"SU=,D+$H\196C="Y2&$S_$"C3_8<F29
M#1V5J;0)WNSU,2:>U\#OEA""BO!!]A?2\OV1<O;+!M.T2MQYJ#,D;DN:07@;
M ?>&)C4F1OE[D/B A+5)S3M[@A#6*VQ&B>=SVM8XW<<!'3U\/Q%\ "Z"SVT/
MX4"3/6A2\ZK,=P1-0NE%1$5+.%YWS<"-TL5TCC(9(6-41V\V].7G7R^^(5_$
M,JR33%M6&_2"[WD&XR[Z2TR!+N+REK4WQC: -"O.Z4N>Z(X+'Y.R E<QX<+9
M-#U7X7=&^307.7W%Y^<Y1-(ERK]\/>O%-K0WA]M3SG=5K &)Q#3M0;37^TJ/
MN%+VLP2RH[-V>,4S_H#20*EZ*9M9L 94^91[;?&'[]]53.'&<\2DGWP9CA@X
ML63"PM8<U'E@!C:^0_$2/_VD76 :X#"1\6B'YHY-QW0IH< S)CD3V1;G4NI@
M- 5*#@61C8H *LF1<])3S!!":ND&F-T_ 9((^#H4Z>,Y+OKT/#EEP2N^=VDV
M&:A'=;WO0,7?W-0",Z"%_B9>%-JL>5#-E>_^_$VEV=BX1->+][+IK4&3TJ\4
M[JDOEXMM<>[:5.UUUCV6D-<?8S/%A6E)(8TK?@M)I#>?V4^((R0^2]H[G4)N
M:**"HC6*3I3D<JGKM,(>"#_7A-RH"J_F_?KW-"GO/^G^7 9%/X8U/R;CTE $
M)%P__ MF[222A3%JT@5@[6MW-K"]VK,D'M>+'UH8?6G*IYG0U' "ZTHR%RY5
MZL2-GY \3R:G"5Q@&&^N9;@A3C\OQ?Y[N5M$T/R/%'FV.Q8X4FYAU:2#"Q*O
MOF:K:7/V+A[8]GZLL[V4<50_W;+4D#A! !?0<+;UOAJ_)8.V@OF0^2%+Y0UX
MF@4B1[K3"0*?&Y3%F8C>.=%:4$H1*9(>6JQ?N]#>L)7<IDK']GAVT!1IQU_.
M$ 5RT0B98L7Z)]%CMQ=6/$1FI<QW/496'L\\S65Q$$V;8$'D"K7L]],$\P5@
M#HY#74"J*<==C!DM"Q@Q-S^%NI4"M SK%/R^,H[A;%#L!,!-8SI*B5=H[N*:
M_"-H"=(%9,>U65DE[7$**"_>'7@&0:\K'>K"1\]UG7AK+&0G: _]2YQ_2G 2
M+N# .1RJ[J6?4QS.9!OP=F3G&4OK7>]C0L]I+,1YRW%5]Q?'J_L=#;S9G#2(
M^MN11$+QQY1.F7 */7K>R'P:V%ALON0XV64[-"";G2%#5@$8.74.'BF42+.#
M1.(D;IS:&KO%"S'&+6O85KSC-4E?)9_A-NRZ?;R)FCI])2$D#_7G .<Q]&Z#
MKA-,5G+=/-3XQO!SP]ZA-8L/=KL@-T[%@UK55VDF.+%91)IY! 1U;;%YV<?/
M8Z&G^]M._B)83@G-7TI&K$7G?;>76YT9BYMV<P2/-I+W_6!3J_[GAULJC'SY
MJZ_&MXK39/GXZ2KNLY3,LN[X^%7+Z##0U41-:&$79]5J'?2RO['H(OW@5U]\
M^;ND!,/S2^L%U 'W8>.KFI_C6O0W0>B%Y:_7(N'K9*NN9^X@6;K\#DK+8%N+
M*0"8*7A'UVYO::^1<3.D<&$S8Y89_;(*YCROXH10!,J0%$<A=]3>OL[GN,O*
M /C 5.D'P)&N>=&F*A"">;49<V&6JM.VB?-QP\DX@%%6M)-9E"UO0'2@4YK%
M/#O4C5ZS:<)V/52V7TODW4"J:EPQW:G"S&'=KR1@*=AS$R60X$\)TW1:*D^\
MG3EMCHSO"8(#FO44-P+6; BZ@F/T=],RXD(Z<"JWT@PYTN)-"=CJ.%@DS@38
M7J,!]D-FQ^F2L&("LWJ/^L=;E8A[LU==V1]IY *L[$I)%'L4Y"8O>6H9*LYN
M$&A*&C+D;L%19D@;Z; 2.4U/E\ *4GQGS43!VEPO/DRQ3NQM<@;0[C=*&6N*
M?7DR94-CU;GPE;_ H<X05R"4X<,ZM82:U;5T5^/\.*4ON;1HOL"ASM$24<DD
MQT]JHNG"-_]<7-Z7%US>!9=WP>5=^.9?VE#+ET",7VX:R1MPBS[:+(F!4) :
MEQO]!0ZUO)C[T%,!DEKT6(V,T!/"[61^W:2SE N(Z)V\K/4+'.KSUMJG0:Z6
M2 ,@P4#< TR%ZA-EZV8 9/.R 5[@4,L;8)SRE1079VH$AS55^+BL\$L<ZAR/
M)$'X#X9NE4,J!KOQT(O+JK[ H3[NW)*A)A"2YEDW6?)=TWZ7!7Z!0YVYF?ON
M9RI\"?9F;*9+_+^B &P:3I=LV@L>ZLRQ3G7B$K^'PC]9_?%P6=@7.-3RPJ8V
M:"L+&U<W=S;WW1Y%XJ4!+%WMWW*KER5_@4.=L>!2^^C#)O0]TN*$SE\QV\+^
M]C0TJR:^],)*^$*'^J")WG4M@5?22:[7X6_4\D<-8$E4A"&Q%BF_V3(U8U6
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M&S%LN74%@BNR/X1.Q*]S8"J;3)?)LFMF#'7!M*_G,1QWDT[:B47N:\J%K6J
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MX+)=%X@G 2NZZ81\\^JXC\M"P;2C=W)<'V/"3MKT7_[FZA2BQ2$JWFX]%M=
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ME(YT?[V17@O%20,65^8,PX5\1TQR-=D-,$H[+5?Y5B$?>\)3_;#S;9DVXKW
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MRIN8]%;RLIH[%=W@ECO*+S=*VC1YBFE0$L@U$UHP_L="EV/1NA=O@I')/R,
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M0!CI^^K37C=3*G#-U;&WFO!:'R&,W)D!YVKK6[YB,<=*7;Z>FUA<HC?$K)J
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MT7YHJ1-1870@:.ENXXZ/WVTJ(KS4-1WWNVY[%W39%]L8W_ 3-P("_-N1:GB
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MZ<-N')\Y]89SA2GE44"OU$"4(Z?)-<:*#U['S\-^$C6$>+OR#[ZY"EP4\X.
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M-_5=#(UQ$XAA6 F.B"AJA&_+=W":OV:>:K)BZ#60S4BR=GCN#"&=.H7\AA5
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MY"%QPC8X" !%AM4(*R! !B<4I&SJ/(@56A[JTK@73@Q9B6?MQ^(8"!5)L!;
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M>OR1YF[Q(S82)1GXC/Q>I_8'RVF_BK#O]=YP3W5K/KIZ?71<2-I<FUV%!<'
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MY>>(1,E(B44#R=X0YVBU1ZT3%L_$$&R<R)J,*[-[U)U38-UVR,VIO(O(_-X
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MEZEA?28KS8N0J<,<CX9(+*GW3%*.UZ99EX*^*N3 2&CM(8<6_B<4T4-G_GL
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M7Q;X,ZP43CKDIZ+G75;A8A<U@QS.N6KV!WP;JLA/:7;#+%:E_-]Y7'P"WJE
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MON0]78L )[<]Q_\+)L5R%8#9A<&)F2AO,#11N[%GK95>CA-<[_BT4_6T*9F
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MBRDQ7+&+%]>!_VG&<-1>8T%=VJ!=%BQIIF#\8.T6MI9J+^.6.M,SI09H]#0
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M7R2T:?-QMJS5Z,IFQ&607@7+S'N;(\.BW:E.PS6<I.I$IW?!T0,<FJ#+-R_
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M^Z0='MPIT,7@WS4>3Z? 9&.;QKWA/KNDG\_/+KRMPJ2\G!=DJL&C7M[$4;D
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MN$O]R(2+$E?:;M$%#B/N3J+3802KRVI;>>^1 *4;'3@QQ:_Q>B^YJTILN;H
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M;E/T\[62\3B9G>?(KLALIWM_<67L!LE+N)AP\<G<-KBVL1534@)NE,&RWZL
M7'9XZMRU7EQSL"_!V[+"6Y0Z)A*\/3]2K#J\L4OP=CC9W0UVX,%X[SH!70*Z
M>0 =BX6I$M ]/V:L.M#)6X%NJWMVWG.GKM./*:MON_T$> GPY@)X00XY3(#W
M_-BQXH G\*V =WA-6N!.F1:8@"\!WQR +\HC1PGXGA]#5AWXZ.V67LRB>]/N
M?DL67@*ZN0!=D#^.$] ]/V:L.M")M8W];GVT?@;QWHP/:TRP+Z%=0KMYH%T0
M0I[?AG97JC55G-KXE^[]NO'@=&N>TJWOGVY-4[IU2K=.Z=8WG!!>]F3<]SOO
M#MX?90=OLIB6^VXG_-@_RM[O_+%[>+3S?F<[>_?A][>[6]GFUM;!A_VCW?T_
MLC>[[_=^EIG;N/3KFZJO5$?MKM;]*$\#3<>[ROB7ZIRHLVX\(MQ3YVX8C))^
M*]OMF)N3M9M*CQO$X>"\Z)3'>:MS7-?;A$LVU9^<$E=#6QY6*PN\&-,]"V,N
M2Q.9:>NX/D*7]<L,GMN%(7L5G[55/>F7>+Q\ZLC>I;./DW-[U7'?Z@3HS*O[
M,Z&(R<GP6"5G>@,J'D5KW7)TNU77K^J?9CZ&,LJ#<^61]JH>4#Q\[JIC=.,#
M\^%E1=?>=*JN>N+TP#NE:_$JIM*/C@V&[[PKSZ"6A>[*R^/ ,/QM9IK7'18O
MKT.__5(>:JT.WI7R65'KI[=7A;XZ@\RKHA</,,9#B^WVI-Y,?;RQ7SUO\HB1
M93>B3,W+6%WGMJ.7$VJ,3VW'TD%3A_G+HEFQ#-*3<B%<%F@1'G063PF7];6J
M$DFN$]X<3R\&P7;GD4QJDH9[WBO";,_;[I9CV<NWIE6[WYU9V!773:QY4*[@
MDCR1JD%..C;@?G]$^3I3><3LJ8SE@^"!]N.+:DWQ:N: ZR_9JW=;FP>__]*:
M%I9Z\?6KRD>=4>^Z;CN+A:NFA*U79E"7%>6N/]S;FI24,[VB%-U)D<CJ*.[N
MZ!U;U3M _."D5SGVL=[<MV[O2U6,JBQV58\SR,N@*K-Y6)70*B?;.U&=XL>D
M_$2\^"C8]C:8]-5=_7Y<'*_"X/+,CQ[_2RG=<956,\KJN(+3O:'J753 AT6<
M$X:Q*D98)OVRB%FPULH"<64!LWJ)5Q6SNIWED\T;5.NFK6N)!HK&9TZ)U^%(
M$I=NKC>?4K=%WPQ+_@;QC!&G#(T*&_P4MV?647U4O,+-,S<X[=JJ*,*8?!%!
MZ]K'L?I=#;\CR553=+^.YMF'\SB2[%6ME#8//XS43ACW>ER!#$#<&BFMM]6;
M7AT%0369(/B75GU]YKROM%[V']6),I^-=$2LRW)2#N>L:RLY[[FP4$>GZZO#
MZ5$+E/"D,C,\&U;A"% ]-<SC\["J>[:>)3EYJ)STW%?7&;J?"LKAAQ'S"8!R
MQ/OW]=V^USVKH%8%ZZ'BV5;@3O<L>@JU:##()J(1WW=6*O#6C6(B?BXFU;Q6
M!A-_5_VBLH!JQV/I)G9S5<^^N]XFC26A:B,QZMRBK.5\<<G2_)]^++>LJG+*
M5?G*2]<7902_UJ)5I>H9U^VR%7+M6&9*U9;V4G]<MDIEYY4]-+V"BMY9&,CX
M;-?8EBKMGW$QREYT.&J+7\?Z'9.#8>4=M=D]6N>C!7R#G5::LM[9:,I.5P)M
MJV_]L<FM8A5J4YX [@W;=46<,-)A>]:..9RM)#JNAS9EUHP>6<YI^9;:S:9Q
M726LKF%2L?ONQG%)C>#M=OO3W]:LKNI]?@NN2G"32PH&GR4Z)!5SXJO*6LZZ
M+"T<2[AT.R6S5#!)RQX"F=+=87C$J8N&WR5_[-+R\;W*:!W[<9%UHTM:XV?4
MI<J"\QD )K8_Z(6!5(MI//FRVOQXM)5;U#7.#GMN5)D]KJ]RP1;]+_T;7SNB
MT_5ZZM8AM:8)=GD(D:[5TJ\+0T7ZET-9SPZ'5;7DT<7CZ;CO*A;E[9RTXN)6
MV2 67M41;(/V^5J$E6CB*CT)+!PIG*JV;;4JHDYNEW6YQR[H==.:(67I=TT&
M$$NV5A5R1G&5*UYG5?*LK"5<G'2"MC.Q>G\8:5VF]DQ9%WV5"1"VIDOV77I%
M=*JB;U^[_&K:?;]^\&%%S%2KG5H4L2IP478AF!)5/5964Y&(Y<.'&U3Q5D3%
M6)UILURL>RIXAKVEF]PM1;;-:((5&IV5$RQ+3P\[=2^)( [=;U&SJM'7*JRT
M4O%%@Z^T2:OZU:.03/6L6\2L!D;5GWU3:8G.*,F9KVO%6#W=C/WT2C.IP>OL
M%?IEND9^O;[Z\;G3B[>JPMR;%+(:/?EZ: V/?X5C7<*OW?;76DV4JKHJ@154
M9;OM.B<EKM3UOX-1VHIOC:'(MON>?1[:DZEB_)-932W'ZSEANV' L?*6:L<_
MZ[+:,>0PM=Q&ULT-WD LK5B9]M].NVU7 >LW-ZJ<WHIP,C6D&CJN'T\I#*T:
M"JJ6(;%T?ZQD5XVE/QK,]?='G.A,H]]5[G3K\IVQ#GC%S'O#R4T[XFES^TZ;
MVRQM;J?-[;2Y?:666!-J*86ULP[K]7/O8DH(K7.9/[!>$ER_M0P3Q>3!]][R
M5H'7B;CKD)>J3%.S1M/ ?-D[]D\<%XPJ+YVI S_'$E*;LQ'42S'0V,>N!J9L
M<]RY[CXEIVJHDV&RS1*4-+";![9\.>EW7&/D2=987OYW]S566O';KA]<B?-I
M5^F2&YX@]CF/)#Q+9>_9/:Y8']W,8&Y9/[YN/#KI'%H%<O^O"-[JNU/5.U-5
M9E(K>^?#F'I5FE*9XJ8Z75]D?[C.CXNJC5R,GZF>.6V-.FA6:4/C%EVQ^]Q7
MU2NZP_[XVN@EG_346:SU??V6WLCUO]^67FQ5<=();^R/-N[ZE=X9OWC<QW,J
MUZ4_U=VS[/97!O-L=+;C]L#,@SK=8,<Z'Z2@M'B'Y^'3F##DZIO'([!5VL8@
M\#QS11G,C;%)I_I5-\"2 F6HN/NMC(SW W_ZOBY/7T\_>.'NJZK"1S'86P:^
M)^U/I_;_BL[Y<##:QGQ5K+OUJ2WAV!%@6":4]*L@=E7C?^3CET&>;@"N<3#5
M5I?^4@<EHI_34U'X0!3$.K+Y[=257?^N'UJXP'T_K]KR51&K:H)%&>UUG4#X
MDD!J%!J+4X[$>E4^MVQ.6#5G.RT#-.46 HA9)1=3K_GE3F5OXT9XX2_N& .Y
M^<;&0D&,(XTDX?)&WH2GE?"53MU8^NI(8QF+JSLT5K&\Z1C[*$A7IM6=JXBH
M0;*J+G733YU=*J.U<6G)E$LEQDS+7>TJO6@2LK\R[/&&4B6AE0A/QT*KT=?]
M3ZX7QM%.QXA$U:/&>5;AIGYL3SUZ>J1#;(Q9)V'UJYZ[>JH[QF1;H4JF"THF
M[E.9F.E1465"]>L%MY;Z]6RKW$\<[9OTW=3$ ^VO=+RKDSNZG7%FP@1QUE?B
M+&#S[:Y_=[_%S:!-:^N,M(GE%=D8-[G*%9G,L)4VPQ"M]\FK7>I19F),I(Y+
MOMSUJ#<=:QFQ+J)JM2T3EGG]Z:0YR#C1I^S)538Z+;,S^[4M<0VZSQIWES"A
M IJXW]NO+*V(W:/>4'$$Y1B_5696,'EZ52KYI5=.-T:OL7@6G*> N=R=O0WP
M(@V"TZ(CM73W:[5'U2W-H]*$J7=YZUUD&_L>EQUDIHRBVE09&1?5;3-;O5?G
M,%(2G2KYI<QK'O:4&>?1! M3E:^^:E#<:C0T53@G+;.K3:9K=OU;<0\_MHR/
MU \$C/VERJSB2U(\EM>?61A3TC#F3B46KTJ5.E:)H\W0_E0:SB_1#J@[.;>N
MO/*G_*M"W.4YC#$KIQ*71_E"Q:!_[2(YZUK7+K?X:PNB%*QH9!03"V3L1)0Y
M#U.K8F) C).NHJ%3]QDJ-T2#)35[2S73?F7!]'I=7;4OOL82BBDO9^>5'3.]
M.!; A@E\31(F)Z<,>MVRB>#TM*(%7[H(X4V_=GOC5DS57J8;_5$_X=I!3MY?
MN1[_'0;0BKP=):14YEE,6"E=B3H[I3\\'Z7%?W$7(S 9<^X&ED\9AE7F3OQM
ME'QSO=?TS?7J]-OS8)$-:M&KYA/ :EI:1EF89I3Y64I8>62H5X/_SYDV18]R
MY_ZZ,5U'J#)OJ.;?M6)5)P;6;2:#[3JH'EME],7TG"DE5;>R+MNT]P?=7KE_
M?6D4%2'*LRFC$8]RX\+59CAI_3A*'IKREB=4O)E9KR;<B@.>>>2LAWJ##JK?
M>]EKO.4<^>.VTY<L[>77_J_5J8N=]_N'1]6O_Z\Z._\M.S[XL/]']O;MNR?.
M-U@R HW. ,9X4>4&7@?$I<8->!? )  3DI(O7];7#01X[^RW;M 96^7YP*UX
M!J?;ZQ1JR>RBZ\\8/;1.1"RDG5)I[IM*PU,J34JE2:DT*UHGX@7VJ9MI3_?[
MYMO-_:V=[/#?.SM'AS<?P&OJI.7=YORJ].2ZP_ ,&\\*?(_'QK/^:7D@J#JD
M,/JK-KV7KT??H_+*&%E'",^C29]8Q_E#[[TUZ0RND_R6[G^/2%A[Q(AO_Q*N
M<Y$:%K[(AH73"1"EKQF3(-+.RXO@LV@PG^>P\?H/8YP+UNY/63R_1-)YIHT>
M'NY,M?"]!T>OH<M\FS7.;W#/_?X%$V>)UZ(O_WN^M(<YKL2M^LQBW!$9]%\_
M:$G>C3SSD_H7_OXE7EAWPZOE7%BQBMNXJ%[,8?NJVE>./TR\ET73KUG4^N=\
MJ5*5]+Z%+)4459YC@\CRK^+[ZTZW\Z97IPH/.\7@?0Q$#OMVK=QJ#G,L/RAR
M3G(/L<Z=R8G03@IE-'8"Y4X:[LFGW>@L(9RCM;@Y7YRI=O]_UT!8P&42Y2 \
MXOO@=6=X9KN#^ONUK*/.7'P9.%'J_'44Z<V.C?_L3.1Y<["E>KV8C?&7:@]=
M (1 8E="0[FE8O._+O1V]^M;_/[K<;XWM)]WOG[\0WX^^-P^W3O[S]G!T>;W
M/?SF='_[3WJP_7NQ__?.]X^?/Y#][>.+@Z/?B[V_=\C;?+]]_*-+CX_^4WS\
M_.7;WM'^Z?'1G_#@Z.3;\>>_3O?^/D8'VW_BO?#=\><WIP=O1+ZW)<_,V9O.
MP6>#CS]_N=C?_MC>/]O]OO?YSV_'>+_XN/V^V/NQ2?=^?$$?S]Y_/CC:^?XV
M?W]Z?/:]?7#V_LO>'[OH&/\)]S[_YRS<$YYOZ/'97Y^/\0X]_O$![Y\=7WS<
M;K=']X1W#3_B#^SC'W_&,7W^N/WGQ5ZX9G\[S.5'N_CX]_[GXZ/VY_VC8_SQ
M\W^^'/S]E]^[@-_?'NT,]@[AMT]44Y(CCX"4# 'B#0-*0058;J% RBJJZ-J&
M@"V"@S,T*QD;U>Y6(U91\]#E>N(\MT6?@#\!_Q, O_+.,:DU-3DD6$J!N"&<
MB]Q @G*!2N 7"?B;!OP_QL#O79YSJB3 -M> :&* H$H *[B43F,*D5W;0"0@
M/TK(OR#D;X97-=JJJKJHW#J#9EZ:PC'WDM<]U?OBZHW0<37"&\47/S4=?[K.
M;R#D,NO/!3A.FU]5T8Y,?=/M'08=.2DTN>WT8/)7'8Q+FO0>FG1_:\J%,AA9
M87,.&,DE("2HT\!#"(PP)+A/!#H27"@L< L2M@!-^H 5UE1D>H0/M8CX:(+"
MY7 E$A3.%0HG3@4C1#LG'$"".4"8)D!Z$_Z$.6/*<8VT#%!(98LCFJ#P)3D5
M::MFEI]E@Y18!;GGC"N^1G2:E\G] -=Z!?7,PTWN664R8MS[,=^2VGB VCB<
MLJ!Q#IWUT /*+03$0!LL:"D!SC6W-K?0$[NVP01.<:CEWX%(J-8,ZSFAVEQ0
M;6(,$\>,A,:#@%\*$,$X4)!:@(E12@C!!$-K&SE?A"&<4&VY#>$5CCYOCHK1
MS]\03@&71<6>:YY.M,F^&R2%\@"%4DR;R1Q2!#T"U'@#B!<8**$1D,(IS7/(
MO&1!H;"6A#(%5U*<.<'>HN/,"?:>#/8F=C1&BC.1,Q# 3P!BI0 Z<!)X1AC2
MUC$J\[4-TF(\3ZB7+.F7&U)^UW/GJK!E?:].OVXH694^-#,G;E*@><GMZYK3
M.Q6C-SOV(')YLV1NTC</T#?3*?%2&H:8"/K&A1]$. L$#;8V\C3G""FO#%[;
MH"T"4UYDBD<G\%NTE9W [\G!;RIHS3@B5@G@.#. :"V "/8WH#;'0N7$**HB
M^.4$)O!+QO:<PM9H'=,E,+B/JL+D"[&M[^%W/J;&PC+KGD4$MI.6>:"6.9A)
MF<X1MIAY@+4.6@9I#(2V.<@%UY@$E@5[86V#P&!D-RVH<Z?%U53 >M(X]T/-
MV^:1I5%C&3$GJ9'5=6&2&GF$&IDX*XAY8@(O@/6YB,Z* A)3'O,&J49!]UN#
M@AI!L$4Q2FJD 6IDB7V9%=XXN/8 :*OLJU<[-VG'8-D=ESL>@=KO=DQ22_<O
MK7"T&552Y>%L?G*Y=9YH HSE#A#O.-#2<P"5SS%2Q-'8T@&CELA33GO:0TAP
M. <#_(?K=:WJGR8D7#P27HR1$'&O,648Y!)J0*3/@;0$ N\1AKED(H<HKFJ!
M$?XM06&RPE]N(OR[7FS4.KBH^@_^=UB4'0^#&>[F9GZGS-"%)>Q4O'W75IW!
M9L?NC-B[[Y)ZN9]ZV9DVM)E#QGN&@#$R!T0+":2D#E!A<BRL@M#J8&C+EL2I
M]$I*B4_ M_ADG01\3P=\$[N:BMQ!!SU@P@6[VFH&%-8$*!D^SGU.#%9K&URT
M.&[8!NKJ M\2F]4K'-S>[0Q4YZ1LF)ZRWU?"F)YPM-I'#:IDYWO=M_N/;M=^
M*]KMI%ONI5MVIXUJK8013'J04Q</7"$#A*$<..6X,CFBRL*U#9JW$%V$49U"
M-BEZ_=R,:Y91G0!P'@ X,:X]<4928D#N!0$$*@\4)P)(*HF"N8I'[0, DA8F
MBS"N$P NMW&]PC'K$=JD /62V]1);3Q(;>S-V,VYAL0S&*0&2D 4IT JX@%C
MAAN1$YM3O;:1RQ9N6E)[TV$F!:-7'^068#<GD'LHR$UL8Z;"4B0BX)NF,>=:
MY$!HSH'/A<RQRJT0.A[=:4%"$L@EV_CE!IX/SEU/#<((L[93?9>5XP1=#X;]
M%(I>$;-YS..WD<7O(Q4._(=^%9=):N9>:N;/L2U]<'2<?R+<^6 0$*"QH+%\
MK@*:ZQP$AFE/J&..!$7#>0N+150[?#E!&'RO*/3J ,OUPK+2DI#TSP,63YFJ
MG  F6;(O)LI;%EB:/@[8G%HGRP8?#3-?)Y6STG&71YNM\>"?$1!IHX"$#@'B
M$0>"X!PX+"QWC'K!_=J&;$'&4W D18 3X"TX IP [TD ;RI5 BKA-8, <D5
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M(7*QQR031-X7(J=JE^1>8,$)H)+%P+8W0"*M@2568B>E@3)"),Y;@6\)(AL
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M')QV>P'';9+*YY/*[WO;?\+]HSV\%VGQXPO>__:)46\HYQ@HQQT@4A.@O9
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MB&-[5AZ%RP!#N><HSUUN@NH,IOEC=M6;F&!T13K3-D'#Q//'YK=/W&*+E%0
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MD8#ONKTXP,W!H%?HX4#IMCOJ!E]IRE5*2NI!2NIXVN:FR'*CC !.D&!S:\:
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MTY&RQIK""2\;%2I(>/E(O)P$!PQ1-J=" 494P$NN,0@BB8!A*F?$(&*X7]M
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MQ#(-)-.Q?+Z5!A$/J46-2O594872H&R?90CW_:[ZA2F[H]BB/1PX&_NB5 '
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M:'K=;T^1P/JR!&@SC"ZZ0:K]+]W[=>.=*FRPF\K?M]1Y,0B?/V"') G \@B
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ME'/JO,@=D%)B$%RV\)O+.;">,>MM3 6T:QNR!1?2!"G!:(+19K NV0E)P).
M)P%/ IX$/ EX$O#&"7A#-V62I]<L3V^F.CX6TN8P!];$EH\\IT '(0#,8P^-
M<-HSF'R])F_EI,((8XY>4QAAWPT"#/9<H,(/9[-VM]_/ C*>J=X7-U"Z[;*^
M,\-> !.7^JDWW,Q:]8W>U%8H"7@2\"3@#6!=$O DX$G DX G 5]. 7]UCU 0
MD9I8Q2A7(B>"<FV0A=@8YCQBCNL[A(+Z@5+AM\N!GX/!J>O%>$[/G;I.O_CJ
M=CNF>^8^C!VR?W?;D8I_J*+S-KAF!YW#L3>VV2OZX:OI--[@S!WX(_4]!7SN
M$_"Y@'2\M8]QSI2F$&AB<D DC0?R-03<:TJ]T((KNK:1PZN="GY),)E@<M5@
M,MD!2<!76L#O8P<\P990L@,:;0=,;_P@A );)0$V1Q00RC$0DCF@),P9UC W
M5"=+H)$[/BM]>"=NV,1=FG18ITGVS*IOS*8,ER3@2<"3@#> =4G DX"OL(#?
MQR.%!#+/$<5&8()1<$PUQ(81CDGX3^#[>*1WSE9\U^OZ8A"]T.1>WL.]/-B"
M^3C,;"@+?J3Q0!*C 2&Q&[@1$F N'-)">Y?+M0U*6I1=[;?TI/YE@KT$>\U@
M7=+K2<"3@"<!3P*^G +^7%LIR7"=N^$ZO2\"&<GSX' $@U7[8+HB#D2>0T"U
M])"I7$+'DNG:U*V1.>PW-X>&OZMV;-;9S]0@VW;&G6G7RW+4RB*&-*.*I>[V
MK.N5;PCDR_K==F&S.-%E0_O[-?2DWB"C.%8*,4(5T1!ZX6TLE&B%I.S3[N/[
M>&Z5;5W+VG95[\ZJS&5JW'D/K ^?E<UI:JS'AG!FL0-,2P2(\A0((@W0G&GH
M<H2T"%@O:(M*T:)Y\WJG_7RY-13*4DK12\+,JP;RPP#SALZ2I]UV(&!_Y[_#
M8G"QVS'M8232NVXOCF)S,.@5>EB>]3SJ[G<[<1R];KL=+MD-(PI .DCV\GTQ
M=&(O,Z,,T<X$>UD10 030.?1KW&(8<P$QYY'#+V:1Y3 ,X%G L\'@*?"2%C/
MO)+($X.\YB:'0@M!?'@B5C>#Y_WJJ"=<732N[D]L4VZELCGU@"-N 6$$ HU)
M#LS_S]Z[-[61).O#7Z6#<^*-W0B5M^Z7F?,2P=B>63;&X!GP;GC^<=05VA82
MVRW9QI_^5]42DC#8!IM+2^2)/1Y K>[JJJPG,Y_,R@P*)^)$8%AL;4M-!QKW
MKW<B8"M@:W\6]2;4K2:!N+S=J#0QVS7"<$*"8(11HK@07P'7FS.V@+(/@[)+
MZY428U7@#HD08DE4X,@HKQ%1GHHL ,H8L[7-C1CD'_N4"0\ "P#;GT6]"< Z
MP0SSB2M, U>::Y6$)C11JKES*EP#8 %%>X"B^RL\*E.:6NV0E%@@KIU#FF.%
MI/.,8J^43AE%J>[562) 4$#0_BSJ#0"4L&R2.F-ILIXG21VWQ1\D+!(K\W^N
MY_Y_BLTXV/88T+07:/IBECJ;$77GC<OK:*FG*$B5X30)B4P*&&6U2;SS09%2
MI&&>< 6N/^ JX.JME$1V*AI!DPM,<\:%%LD8D:)B7DK+.="JZPNN+Q;@:G04
M7H12YCCC*G?*E^:5#"7-+<=<>)G8UC;1:F P!G!=L_RO.TB2W:!BR$^G)].A
MG=3O(\JS%/VDLHO2[*7N\<[!T^IP?%K[2F)9RB3_RXZFMCFK9CEF^FZ+(F]T
M]C"DQ]^""?:UQNP;+3W7;LR^4=( )4  : !H &@ :/HH*@ T #0 -  T?:+P
MDHS)B*!#9(%;%;2)3"JLH[:!DS1+WM'EW.5W4WA+'_IYYT+OI_RR.][G%YD4
M&J^I1[X^'<;=T:Q6Y7[:">/3,G"@[;XW3^<PWWOGC26,!5W"(JQD1.K@D28R
M(>H"-T(&X[78VB8#4@[#0:LRT%*@I4!+@3G<LUD"H &@ : !H &@Z<66 Z !
MH+F%X]S64RRTTC@$SK5RDF=W+%I-J& 1@]^]5G[W,EWF>;[NCS>4.!8]M4A*
M*1"GA"#CDD%8).6)CB30 (YWG]-B[B _<8/28DHAG5)8J:3 ^*[*3A[HV+^K
MIJ?YQ_@Q-KYNNT]G?Y[!2EO94:CJ44'"49Q!Y(=Z<ER5%+VF]I,8SF^3@1.:
MBS]$72;G#<V:QT?N/ ],6.L)-I&8B*.P)'5U^/1Y'3[]8P6:NN3.65&FU69%
MLV)-W;^_V#:&T@<ICEI[035!\:;KJ*;GJ\6;=/ D82.1%](@;C!&6@B#&&=1
M6N.8TFIKFPX(9@-%[T,S;7HOHT>;#;\I&'G%8<P? \@O%&2Z#(+_ML-I_ 8&
M@GE^30Q<'E\W(8,@I00Q74X*">^1,=8BC[45BNF\;C%C8/_RV '\ /P>'/R$
M#9I&:[G@FJ?\"^-$I8 ],<PFSJX!?C]J' (NWAXNKA1/,DPPP;U%RIE2/"DX
MI#'C**28E1UF1#N\M4WX@',P# $;'PLV0KMK$' 0<!!P$' 0<!!P$/ >"OA-
MDKVC5<IQDSTNS(EG5D<7 HN*,F\I5^"^K97[=J%( TG&!&*0Q"DB+IA"3J2$
MDG>)<\FY%GSFOTGPW_H9<H9*#-\7<L[OU%3QY'0X/HMQ_L?3:>./,\!4IT,[
M@B(,CRYX_'PN#MU%+^?"\#++0@L!Y!MIF=W5 +*EB@B>,++!2L2I"<C:K&FT
MPUI(&Q26?FN;43U0Y#XB*)N>V 2-+M<<)1\X?/Q%% 13^Z8@N(P@:T5H_O^(
M!/$><<(5,EIB) 2SV>95E,12 !W@#^ /X*^O 61 QMM"QI48LK18<^\-BBD(
MQ*-TR"1/D+*4J9B7V7E?LMZY!N,0T/&QH".</@0!!P$' 0<!!P$' 0<![Z&
MKV$(&1RX6Z.V5J+(SDJ<G)'(1.H0-T(C[9-#1% <G;0B637SX(#?ZF<0&<XM
M_T 0^73JAK7/'Z98X&9Q +D^_YH?MY,6SB(_NG!RGH3N(X@>WTR[O%B-'O,8
M/+&8(TVSAN%:A*Q<%$?>$"D=<X9RTJ4H$2$'HH>M9-9/PT .YYKCX@,'D"_C
M'EC5U\2]E2/'3B1*&$78E+(+BEAD->/9J(Y42X6#H\6HYA0 #P / *^O(6/
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M3$@UOF/K=:.EY]K6ZT9) U1H * !H &@ :#IHZ@ T #0 -  T #0]&26 &@
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MWQ*@[J V4'_F<"].JM(JKP#6,"-";"'GM4^$_:9G+$)R/237 ]  T #0 -
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M0 \"#@(. @X"#@(. MY# ;])\89D./:EE##CW+)D6#1:B62YIXIRT;G*IIR
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MB)WJ^M9@9),AB$>=?]*)(:ZQ\<+GC[3.6,CD@&@"> AX^$CP$ ZI@8"#@(.
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MF,K3<5L7"?^IB4,[J=_'GS_487(\:Q(R'S2G3Y0X_;S_R>*;UN413R?QY[D
MXM5;7-$SY<+"]7RA%/FLW<G*O\?-$@".(G)-M.^03?FM?K+##_:LW?K'A9?_
M;#8O3=*/SD1*=S<3W<)EY39N;+?F69]FR"F7E<';]1MT==P4Y?\_W]XW:FO[
M,./0__W#;OZ+QM+CYVDQCC+2=&]\A?1?%XAECW!8?0&'=_9^VWFQ7QW^\_F?
M.R^?OSK<?7HPJ';WGEZ!LAORRD_W]P[V?]]]MG/X_%EU<)C_\^+YWN%!M?]K
M]73GX)_5K[_O_^=@[=[>7._E_U:/JLGQ>)KO$=J_?_$MY^\TUV?SUYKWQ+IP
M1>=2VNED?#X-,PNK^\O<*LNO-K2G;?SI_(=+/N]J([&RB*%N3X?V[*=ZU+U!
M]]REMGB"YQIC?E!P/J#YYT]FGWUFH,X^E.0)%U_Y_*M?_NJ'YHDTXCN_BY^0
MKWTHV/=^=^-&K/!UU^<;!TFON2GO]&0]$3]T"O.;(YZCTV=CSH_XL4.N3_@5
M0'/7_M'K:)OJ>0:(<.&4ZS7HP',HR:YLO'(9'N32-1#/'SMU_0/2^55'?_U$
M]ZL'L>]HR6]A"D$>[DX>-,@#R,.*/*B>%(=?3]M@_S06IW]T5.WX2?V^:Q+Q
MT]W74[K;/?4PQ9Y@<M9I<AZN6,[M \5#-I%XH/GJV>P\1!1^=5ZN$41_D'F!
M(F\WCX[O'<RCXV^/W^T]>_YA[^2/CW_]Y]_'K]_^6;]^NW?\XM/PW8M/.^SU
MX1'=?[;S<>_D%5U&Q_?JOWY[?;;W]C5YG<=3[KU'7_']W_Y=OWCV7/SU-IR\
M>+9#7Y_LO?T\.OZ"_NO=7V]WZ5X>U^O#Y^4]V%^'1_RO_^SF<0]/]NCK#R^>
M_56_IGMI40;A ']XHPD)B="$,HX3Q,O146=)0B'21#'5DCI\/Q7>OGOG]!!2
M'FO.%L#]XX#[%*U2CIL,S)@3SZR.+@06%67>4JXZN-?G<*\![A\6[C\MX-YH
MB;&($F&E N)&"N2"Q$ADO8V3P4[&L+4M]4!K@'N >X![@/L,KU%9QLK_K+1<
M)U^.X%N3DL7::,5Y!_?J'.X5P/W#PCU9P+W*RY07PR$>N"J'.0*R@AB4#+6!
MDNR=.;:U+?A R,NE80#NUZ&OZ7HR4COA[;2==$FM)?.UB1EO?#V,U6A.596_
MEI^];8^KOTW;&*IZ]/?JM!F_KTLPW)U5XP7];>^3_GYH$A6>OS;/[Q-/39Y0
ML0[(\"R>9C2HNV36RHY"94_**9E/W1\>N*[[-;"V?X;>_;*XUS;O5M<Y_SR,
MW4FH4=A966XP_&Y@^"V* G:TKG.":DF0\#HB3I1#SK"(2/;O#54AI1"WMMG
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M;RU2'AN4_2*,LD?DD29)6&)=PIAEVYGS <=W7&KJMK=B;^$/3I9N)*+VE(4
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M#!^JBQ2 X:V X=DJ&/HW+H@,A5@C*W@&0Y<MX^S<>*2$US;Y*#"W6]MDP#6
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M_9TWF G'HK#(,Z9FK7MTPA(9G4+PD1G)Y-<\L@VTBSZ7G"O2.S;#-GH:FV)
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M\+-!>!T[_L@W;1KM'W46+2S@LZX(OSN7X'>'OK67[C9FU=^R<6UWLOO'O#;
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M:%/!YWK2[2T <@&[VP,[%W%@E'L!.GZRKAF08:.L.'QDM3=5T?/O%>Q6]?S
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M.U*W'9<S4,'+%BV>E\@/='*H_Q4=]CVLV),?YKSOOW7?7N\>>*84J&<$<<=
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M*DCOL>.WWECY58X\>6N^%CM3U\[T>O<@@HJE2& (5YXA#NN!3.4XDK(BE=%
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ME08\K*Q!6E+""?7<R5@DP@TWBS[^6B*W6@7Z:J;X,PLB7*(FPD/&^CLH!%T
M_U8 _T77$%HI%[33$LG*5R#L<H*L P&8<,\9<'"G,-MZ2H7>ED1LG!_L4H=O
M4T&L1 H4%+V9>M!%8KYK %U(S)PK)23EB$6)$6 F!XD9?AA;>5]9[+'=X+XI
M!4 +@#YH +V9BM!%#+T/%.U87V7@-H:4@6^U2.%8%3(^@E0:(A$N5+"<O(BA
M!44W82$?(8K>;G7H J"W!: +,133*@18-L2U9X@'(Y'%S"!>A5@1[8@V&]S
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MV'"S8L/)DMB@C:!.8($PJ5+7#J)!;* &.1]B19D354H,>G#&RVN<P,V#MB)
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M7'Z.AW?!P>_9,'2'Z04]>,[G,-E>?)*^'L7>H/^I2]'M]/L4QI VR#%< Y^
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M#R$,ZA\P*A[T@H5.5L^'(3PYRN_(T)XO RDI!P6>=0+M*:1L+8]GL3!@)/*
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MP_(T%*!0'8_/A^8OCLV/'LK"?>$\,C>"?.JLP&#18@P.KQ7$21:=U!KK9&S
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MB)!)>:850)U9-PW4W0GJFGCW0V2:/Z8AVX0R9@@O*0_!.L=B()QKHP6UT$K
M>*TIB[(Q9)\0X6>&K&7!,BX(8L(1Q+$/R''C$$]*)$*Q-D(^FB'[LH(4]Q78
M7CE#MH&YN8QC'HRDPOM@(L?!.VJ,#R(EGFA2+C:&[)/!W/*I2A]YQ#X)E"FW
M$&<A(6M<0M@X3"G,F,U4#WI=-DBW<G;LRX_$GI]RW(1AGR@^P9STSDJ+E>,,
M)^-5D QK:ZB0W%]0\[R!]4>!];DPK-,N6&Z195$A[I5&6F+X1!Q1G#)#7'SS
M5CX*I+_DT$03A7V1*,>L9<2IQ)4VW'H!RX4EP24//B\@UABO3X9RRZ?F<&*1
M$>M02,0C;K! FBN)G**4<)@]10SXZ>M-YO'J&:\O/PC[L3OZUBKJZ!9&:\XR
M?C<8C4NJ15>P'KW_<11]3DM^7],S;EYFR][[D+^L],!+B%)2\$80+SUAGGOM
M'%=**B%53!HKJ2\A2BGH>,[!\ITX/&Q ^SJ@/3--J=>)BBB1<3E#H(@V>&F1
M=)Y9F6<H;YO]NZ""/<-LLB*!PU62^%5JRX.6-W[-V*4!I!@.(@K)>,#,6<RY
M9V"":NP%Y@5VZ1J[=(-=]X9=VPMGW3[\V%5*14&$05CQ3.D=,C&N#XC$3(YH
MN#>Y3,,U\*NPJ'XI6$;.(PX[YYN:GN5BGK#,W5),Z95L, 3C-^<POC1\49?S
M19&&+ZKABVKXHB[GBRIJ7-*S"O;)5K,Z?S5WMG?>MUBK.&Q ?FL],,OB5O][
M'(USW&>TU<_>WT8_M.WP6RQ4P/O_3D I?\J<B@7M(OSX#NP:V^WO#&VV6TIN
MQLWNR/<&.8"T(L2*/]J;&]^_]O^Y_Q7NV][<[VUO_O/@R^G6CWQ?>_./@^T_
M._OMT]^[VYOPOK\_D,[!QX,OGPS^^I]][ __W;=_F\GVP3>^_>=GWC[L'+0/
MBC8>M_]N\R_T_6G[SRW>WOFC]W7S,^W L_YSZNGV3FY'5OS^M+W3WHW4<NH=
M1T&GB+BC#EGL+5*8,R<%(9'R999%:VWT*OD\;3RHZ'@0'MQ!"[-(!';++(OM
MC8__^WYGX_=_O6]]>O_N\\>MG:WWGRY4\#5KYUG&LRO?^]!LGQO?;;>71>Z/
MP?"3[<69S#4B58O4AUU+90K<4(2YY8@'IL',@T])$1[@3V&D/T/$>0'9*U5'
M%Y&]/CDT7F#H[.S'5DF\YV)O<-P:30ZA _"$T3RW?(&<ZK=1R]O1?BL"A'T'
M@0* *R)=MA8TE 9#-+*9Q6\J:ZV?"LKYP02:&48__WK6CEW4*8L<A"O"":@%
MNQTG(.=P[VV9^ZXBV%-,/0PGH&"7-/E.G(!-DQ^ER?RZ-S\#YL7GRN3W%'18
M&X<#Z,9I#$7((.] /#:G7#/)#S[)?PX'HU$QP9_[PPA=J>?[3W B+JY@TTSX
MBYOP?\'WE]0L:F;\N<[XM(95,<U_V.ZP]6_;F\2'3S--"2?_%'MHCTU,W+HM
MX^K-QN@>V#8?KG%/_?YF<)K!>=K!>0KN\)>6^_1N*29T';;PU3)(FM8TK6E:
M<]O6K)8=2GFYS;[JJ-D>].-)Z[#8%VPEN/Z,'_=T=OQJC=3]\J">&9@72A"T
M?$Q7466(=LFKO)L8M.&2$Y>(L\PD>L%Y+L06ZRKV)X=A,*Y^7]YOS'9 WLV&
M_[R?60,;XW=V.#R!42P\V.DI"/9,]QZ__/W/T=<=N.?OCX=?-[^QKP>>M0\V
M</O@]_TO!QND_??7P_;?G6[G\-_=]N'GTZ_=ZI[__'/?'8;>]L$W\?7/K]^V
M=\)A)^>\;7XX:><<N,W//[X>?OGQA6[1KW]OG7S=Z1S^Y[1=Y*,5>6D;NS!?
M2E*,41)&9,()GK<J*5*>)6Q%8D[S-V\97N/F4<Y[W6$IK1[*W(5RXN$\IT8'
M-#I@Q73 <FW=(N_X NSW?G(XZ>5 9A'#GH6O\U;%[Q$>&W?LCT8GW%0GG$QU
M@N/1B< M,L$GQ(/QR)F@$0$9X<0**<6CEMEME$*C%!JE\-0C\SR50M[.;)3"
M;95"9^8H&"Z83B8@RIU%7"2)X$\#2L%81X7#*II&*31*H5$*C5)8K6A13G4H
MXD2S\P^-(KBI(IAY!U0D&KT02*DD$$^)(Y<P1=0*Y9443"C11(SN3P^L\G;R
M<]D8>3<X/,P%,FRO=62/XG#N+$%3MOB!<9\2QH-PEBH7.8W,<,UEM"+*9)RS
MMMDE6$G,_S#=)8"^_-C^L$L5-C':@%A2"7%L";(X*.1E],EI2Q37;][2-6-T
M4^OST<S_)\@.:(#QJ8&Q"9(_%22>3"'QI/UAU^L(+HQ.*&86.NZ(1]I1AD)T
M7!ML!$W^S5O2P&$#APT</HZ=V 2-GQPD.S.[\:2SL2N4#E)JBBAS G%E.#+.
M)A1HYG73S#(>&]+.!BH;J%Q]E[H)I=X#/,[9D)WC7<:)\IY&9"4FV8;$R*2
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MV_YRTGI#C$0^!8&X8AAI1@FB##,;8V)85HXSI;RQ"5_V)M?SB9P.CP9#L(T
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M!/ **)HC2!DA%Y 1Y"=T0X:>&A-?*E!LEJ=MSQ\O0(UBK$<S-*E5)X #J!E
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MJS'G6L92]BRZ.9:UN$62XV Y3@?6U/?*H)P][JA<X3F+J?)0+E:6571U=C,
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MX-;[A;KO+7!$+J1P>Q*)>_)+GX'(WXW\]@X2?RD!T7-;#MG\O(;LW^N$W\,
M-M+P4-*@7Y8TK YF-A3=9\2MCN3..>Z+^PV_WD88[Y$X\\[B]R@S^@2#\^0M
M>^W D(K_N<U@R6<!#$58HMZSFM^5FM\52C'>)P_E[<=T]4;P7BESSP[,]3F:
MGS/IK3 T!"H8\91QSHG5CCN!F1>1,1?25:?W;L)^6^G"/X:#P_.V$M[_J')
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MUA-:<!U-M0#,1W>8'U7.<(WU4\W0[4]?-O(PS_-5W\]M?M&<DKA@F.<RTQ?
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M_-D\_1?-_D:R,XG8*+_Q"NE?4">EQ8C, )[D-##E.1-6!8:Q%MA%L(S>\-*
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MPKZ=TK%J)\=T<)6>9#O@H\%D@^LU=0?+."V@KL^AW-^31YT;&&IYV._"8&1
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M!@0/Z@Q9[ '/2*LYUM%$['=>%+<"^*G23D&@S)M4J6D_6V3U[AB!UYGE=&6
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MXI:!*%88'+P$+<(#+I1S0E@32"2% $NQ(0UT8QE^L&4XG/H,SL"*81&0=RJ
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M*@$D.F.QY:OA1I.!^'TV[/4'=L(CUDX(@RP =<1)T$@9Z9 P7'@I3,#:[[S
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MV:P+"%-1F."X3,5JUE$MF.!&I6)L(Q0CI0M>51F6?WSE4=(*J3W,>^0HEFU
M*@'U6]0%Y'L+Z $[^.N$^>A /UC$/ :G.QB-M+$!.4&Q$"X!EB(1+;8%^$R8
M+=<HM?H#\%=32O)R/Y!*YFI.K*/ZE^42U 1.*92<^Z_G5D,VX8RRWU4E4[G#
M7D(B)3-\=19>:EI2^7$_)5&O'C.SYJV79C1#%+4W*7!,3,%S.1(SV3C5J!=Z
M)!Z''*,\BA'^>UIBL+P]ZMM4>7'IXE+6-MTLIK <%](I'C@+Q'JG%,.%X@PT
MAY&+FP507;-9'FRS_'6=Q@/C)@>?0+-_>G7BM!,$,P&  DO$I>-(<^=1]*#=
M:"BXCS2=V;0%5>V"+6?^M!;VPZ1J= A+T[H8I&.)BY3OD[5]E;*V0IW_W3$I
M 3VE#XU*(>UG(5W8-X?]OV=2<B@K=\YNZW6_V^U?UEGF2]NOO7SG,L)6DJ?T
M+T*O!5#M<QA-VD-E'5#*]/PN*QM<;H9B5,$*PL%<V) 8P8/QGD;!(^$:U)-=
M0]C.UODW:V#,__133OX4QBP*_#/$+XL2?WJ"F6'8@(C; &+/C8G(>%<@%H.R
MW$MO&-]YH=4N78UFDB@LRKS)PK(R70RT>G^PH=(45#!)N0.$*[F06+E"@O?E
M)+6@0"F[)<C?*,U[%2'W!<8,]WM/#U[NP1CW3C1/J-? [ /*0!Q;BS1Q$C'E
M#.:JX,:%E-70QERV"[G<4VA1@/ZQLO/G"BU95TC-J<@U%)%E*Z(Y^S\]^9YQ
MUF9@L[FX&/2_=!([(+ALFPGMUSEJB-V#J+Z&]R\G\E^AZW^[^E?Y1HW,UC+[
M:?\D!DY!IS#D"#6)BYR VDLY\872 >-T7B1V7G IVWB%'U>CT@@S71G%"I"N
M0,K+:'*TD+0QE[8^Z<=8I@17**).*JBE\Z<$#KK=JACL'U43&[B@_D%N_C&?
M#Y]RU>=9IE<\(R67I!_E_ZT2?\\['C0K)>FI%^/1Y*$_.8 9]?E*:P:M)PFL
MC<%1_O%P"MCW4U2E%ZH3FX7)LL$EH&0>*;WJL.\Z_^^_*&._CLK_24Y0JY2:
MU";Z_*+;B=4OMH5"]N8WJOV\=[M[N^]VI^X=R-MEKOE,.JG*>JE^>OSE=Q"U
M>D. ,-6WJ);Z>%JM.:S6O;YQ3?M;RL:<^JZC$]^BE+754A)F'362$RY2Q"*2
MPMLB$$-N)]&Y#^W< (DU0.+SB<?.!J\#\M)R! J:(.6I12IJP!%&*EQD[XNL
M5LI_ \K/HCA1RHGJT0V"F;3*3\[*8'C6N5@'73<NT@F<A]2DAWH9P5,,2AE,
M:4HT((Q:73*E+4G2DBMST.GU!S-!UZ-ZH%.'YK>K-S#$F:SIY^V_7.]1^/\3
M9@B6 ="FB@+,MP,$J@47B#E&"EJ0J%SIORRWUOCOFQP5?;<$O4=XJK%7<B\N
M1M1*=1M-9U Q*58[9(4MSYH?A#0K85_Q**;$T:KMVZ;UYM$::EDLK(B4*Z*M
MPBR"]TDU#M&'N#H<</?T\Q7:^%4]^M?PPKDW<-VTKA.&LQ!ZBQ)U?NAF2XKZ
M1,4HP%1J5$2C$3<>(["?$>G$10?K0R7/;6R68P6+O>I I@[[(P"!+;0E,&A3
MJ)<$IY4EIW4 %F8\R([D=KS+S2.?'.INQV WGO@9A90RZD8_3_I-;L<+W3+[
M*2+<Z96:JRP(/34#7\=JD^ZM2J7#Z"P1S1S?72VGO/B_$YHIF^+"3>(XE2:W
MP*/LG4[)D193TW-S]RHZ/<,!6G4:J1EO-AC(*OO0R_3#&S.04!AC"J#$=,C(
MM-(F"&M%P3$3RGJ[&F#=LW'(<M;8A=(N? ";X*X/C@_$X?7^%_C=25$()HK$
M,H 3".,N(HN-1YP4PD>%E1/V#G;A>>*Q7&<\ \:6(TAI.U5$V,F_28V04J&.
MK20W5:74^5TW\W>KU%=L.Y3DIEJ_WJ:MF62VX7:\RLT#+_5F_R)4+:)*SNY5
M1^IE"_)5V+R,YMD0TOI6).IK5/GO,"W];L=GS?MN!/]3QK?A<4<750^"81X3
MF(5<A=.;B3F6)L#X3^/AJ+PN,=>%_QN'*2WZC*P^V2*FF>G9I$;I:U(VUQ]4
MY1I,,%R7L)N'H;<8,OBCW_?)XN^# '0&:;7^[ ^?<Y1_UE_9A]_NG5#8$RJR
M FE#%>*R, A0!$'I9$99J0PS9.?%)IYJ,#(1LL.B84X<,RI8[UF0E"5N;KGA
M462SPM^ZPMZ%1-U(4=08\$94#JG"1A0SM0SV4GA 'KW^$O!8#A^>5K/=ZDRF
M>SB+AF_O^YTJ2NL*E':RT;U^;ML1NOW+=M:D(]-+S3A3 FBW6R-H& 5*4C;H
M PI*@<HJ!MBJ" >6K$'" U.]W)T)CMNKQ0RH=@4'X,8I/VKM(*9OGUA;NGU7
M0_>Y^]V S^JR&[5@%!XVQ?V=.PM^W$U-C2:-W/<G-= E;*]C[7L]/Q/D@>]@
M3#[5(SSS7/B#$^8XIZ#.D(ZR0%RD=!""';)"*Q>5-5J3FW+;'[^U!ZT\R9A*
M$@$;Y1Q> NY2'L].O=GY;DZSG*]U-L*RCYS(1K+S.YPYQYH0>"[M[Y\RMNN/
MX:7\\!^_K 59U2Q7M6+51%?#G_M%-\31+V8\ZM<+DP^%RT\L*(<P2 O1-1?#
M\$O]QZ\S!6;I^E]G%SE-K.\,+[KFZI=.+T]I?FY5B:7UKA(L%V.-!O#_OAY/
M5:BU6Q9J_3SRRU\JL4L+NO[[&R^^^4N\*YFZX\4_YX&7@X<I22N0CVTV$^'%
M.4PM#1(O;/59N7*_7J14E]YIN4P$IK;^H%PF4BYL/>85HZE_G_8;O?@RN;Z2
MC/31Y@/.#_^F$<_N^>FN5"L*4.Z\N>=UPAU?:N=%S41<):%-=M0=5OIKYO:_
M7(PXNGM=_M63N5+%/?1L_KY.!<[-ZW1[/?P45DHL%U==C%K9 V[5[[4TO]LU
MF__?P\[:3=OX3M-62F&I&K=HVC;I$O%M)2IW2ONXH>9R;KL<3W<+F7AR[)'B
MS@__^??PXW%J''# /O[Q%S[\S^L.C U_//[WYP^?_MT]?'GPY<.G#Y<?S]]^
M^G!\V/E87_.__SZSY[Z;&@<<7/O/'U_^13[\9Q\?OGS;/3A_VSDX?X\/KN%>
MGWX[A_&<'=!_=__W^M7HX!W^\N<Q_._>B8N&%.FTGT3 K=Q;CHRD&!5!."FP
M,I;CG1=<M#591V+Y*/;=]NFK%9/W ";TX?'4%DWIZSF/85T\8%%>)S--MQ8(
M/F:K8:6F%$<1-8V<@H:)Q'K"21&)3^>155;*/1N+&6?P*/X)WQV?F1X\I,H#
M.^SW9D2CSA:;G%,V%F4CB[(_:U&PMIB$J!&F42&N90HE.H&TL+RPE!J:"&F9
M:"NZCA3['BW*O>S*;=5WW\>$/'$O;-YHS)\E-HY8XX@U)K4RJ<LG RE4.7\V
M4!^UK3PC. RCQK!N9%@/9@VKI%;C8 G"WA'$)65(4RM1P9G1)'H<BF+GA2)M
MR=<U>WL4.W/[--KF=K8^&$EI5-L5XWZPD<VL,(,5]OUQ.D!9:[/6C[N!,!L'
MDLWP[(=!E0:-W,U]: #'0P".E4 C[0?X(O7? F"?$E :W+$1[G@_BSNT+JR4
M1B 0@=0&"6MD18&1X990$0K+6-QYP=M2?@=__INVX/9IIR8(?/_&<#P8E"0,
M24\TP=[&4-Q@*$I9*7_9V(B-;,2'N6-$'AQ7"B-*3.X"2Y'FTB.<"KE#X:.C
M8N<%;7.Z7#_<Q'RWSV(\<8?IS2 5DHS*WH8!%,3%;-'I/=N*KX0LC77XT=:A
MEI(WB:.V\B<NY@CW&DMQ%TOAYKP)KE@,E*&"1)F.!RW21A;(1Y;Z>3DN7>KZ
MVU;B.UB*QIMHO(F;IW3_S=O_9\XO?GW9.!)/Q53,E:O?AYW8[X&E<'"SMQ7G
M,_SJY93"O;$6&UF+TUEKP8FD$OMD'JQ%/ B'-"$,"05KS[1GPN*=%R!BF#3)
M)(_!>#QQQ^(H-WY^T-!3XTY\NXUX.)\A"T#*+FPB2U]M 3[/60"NA13:("QL
M@;@/&EEJ I*QH($*QE7@X"^(Y1[RC;>P#0K_67D+]=E#=ZH7&K_AVZ?UI^UP
M'![P!&+FB\98;%;-=)D-1388>R=1LAB)H<C)R!"WWB#E&9@,'0IG)"$^];'0
M;5DL5S/]H_$4MLEP/'%/H=K_H(/L][ 73]QK>,(6HC$-7VT:OLR:!H&QT4Y(
M<!]X1!Q'BY3R ?Y21%(G!/@6*8U),_:@IJ'Q(AHOXN8I?1FJ3C@C\V7:#;R=
MVM\TWD1C*VZP%;7D')LO,U].PU&- =G,@%S-&A#-E,3><P1.1(&XY 89(PQB
M5AH:I20\%#LOBK;4JO$MMMN</''?8J$/0AC!9I_JD<46:MOA<6Q6\;KE)N;I
M6IBFAG-C(W(]:T0H*83&SB!5&# BU'&D:!0HR$@U*8H0M ,OA+8EW[X3C::(
M\ZD7<39EF@\H@75Q_'88W,:F?HM-K=>R,8:;&4,R:PR#M+S0EB!:6(VX\!9I
M)P("&^E,9)KP0NV\8*JM]?89PVW7-H\M,$=VJ7@$2ORX/S+=A=[4*_I2?T]_
M_VO["%5?5L^^2].&[5J*^RSM_Z:@ROW,<F-WF[Y$C\6,TUDS[KRS+!"'HO88
M<4,C4CIX5$C.6>*'MB1^O\9$6[.3MT]AKH,$/V?2@9H9X><YJI%53 EY>N@V
M$%*LI3^3JRDJ#A=ZPNXO]H1]>@1<JW@TUC'EF-6<QIDI9\*%F7YQ(_/DFS#(
MY([W8ATRU]-J&S SS/R\-XEU[1G3.KUGA\<?3ABU05$'.E@F$DEA'5)4<L24
M4\%@;%C2QG17+Q?,S/$GEAQV%V%0DL!GOL2T]&M7?E@1>M[7HG\U[^AA)I@_
MBB7#:** ][]=O0O=;A@,W\-6'F2.HMQ!OGR'9RTS1\?O3TQA.2,.HP#^..+P
M+Z0XEX@(C"5W-EJ6DNQ)6X,55\5R96[K*%%C)<K<BL)V= :ZI.)%'$V($9>8
MM2KV19L6I&3 J*1J#6?7;NO=$I'BDK8J"81 "Y^>K2;94NUY.JZ:2V@ST69I
MUG AG>*! _ZQWBG%<*$X*VPT<I$.@5#V4#)>P]QG+,@?\.'Q7R=..T$P$V!.
ML41<.HXT=QY%'XRBH> ^TBS(@JIVP9:C2HN"W&Y=GG7<&?QWZ+7,Z6EBF4[T
M59D1=G-U6"C#L8,'2R,X =$)'$='&:$T2$[9+10:C<S<K\R0@^/]$^\9Q59'
MY+@DB#-+D/%*(!M"05D1"V(%R QK"Z+;F!6W*[\I.=EJ/-6NV&N7Z&=;_<M>
M F1KA:J7EW!!J%3!"L(5MQ9D2(H 7@B-@D?"M7#:NLK&+I!HKBV#FQEMU2W?
MG(:C^#_]Q+M; ^9E\4'T&<K/$0 NS S#)G']!5 \W)@(\N,*Q&)0EGOI33*>
M6JV@[?[OA,@3>^22!*UGB%2[K9<EFV8B<UQCR<S%Q:#_)5/M=:\VU%'::BD)
MLXX:F;SW1/832>%M$8@AG-Y"O[MY#7ZCHF[ 9W!?1PZ/3[\<?MJ_3"23'CL;
MO [(2X!IG(+.4IY:I*+&7!FI<)%-'&F#;[FLJ_Z&S9O8SP<AM.:]WAO\_HM^
MN3R_#$+7C#I_UP2%8)_^^]?*X^1T5XK2(UYUI;'#?G<\"K]6X1,\>XL5-)AE
M6"9IGS#8=B];XX69G/GOL\$TF'4:D!T$\QEEBO)?3/?27 UW?IY[^8797)JD
M;YV)&!]N)O+"P4[OEQQ=OX"B 6\K_2P-WCR^0;?.!DDE_E='&VIA?Q%F#.=:
M82L,B4+Q@FILB5$G<N=%HL#]Y\_FZ;]HCB/]GDQ&+W4Y@#=>(?V@3))5Z?3&
M);UAUMM*,$.])@"O!&>16Z:QC ")$W^QHG9G7;3Q$83:2EN:PR3SUO?&6-D]
MVUZQP5'*&W.5R;F/^Y6=W?,^ZVK3K5'>?B^YVQW?,8/9\J/BN9OA:W?"N ''
M7SI$E3'@-7"/=-0,%13V"TAW$ &\!KR[7$Q4HCD0P6X.=,26,\.S=HJ1#,=F
M&M8(7P!\=X:3H.WK9+$K>'ATD>X$SFFGY\"@#',0=S1,[D,8#,\Z%_5%2V&9
M_H:^1> \P-;DU,L(CG1JYXDI5;#Y"*-6A^Q;+,GADF]QT.GU!YW152U81_5
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M 39QV0>O1^1<,4,ET3K1>A4F^L(%2Y3"BD1_Q[CL=1CTO1F>-?K[ ?7W^UD
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M2NMF0W:X7T!ZFK/35HM+XV!TTAC9G[$<3Z<'CU+8"\5?H$BZ,-I21\#C7]Q
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M .B<>8FT8A9)PIU/+D1M=$9U+I^BI7'=)ZEFZI=1G=5,_76A^KO^>%"#^JU
M_>,TJ"<C-:6&(JI]S&&^!CE%,3)",1QXL#&1#.I/4ZF\INHU5;\,ZKRFZJ\,
MU#L_:J9^.U#_,@WJ@E%OHO/(D,01Y\X@XX-&UGM&E?*6!)-!79JZH^F"@OK+
M9NH[^W$0BZR1FJ^_'FC?R M>X_N=\'UW&M]Q4L100'7ML$0\*H=T1OH@<"2<
M&"]SQ6,J5^&/FK4O)L#?@[63-2J6 >2+UGYE@.\DZG<QF/PM@H]J1? (BJ#&
M_EMAOY_&?B:"E]A0I(B-B!OFD19,($*D-8D(4 9I95WH54*>HI]K'4I3T_X;
M3V+&AS>+TCQ\@>9EH<8R)TI]L?B/7((5_7!X-!X552[ Y(G#T6+PGF5C-W]?
M(GKSI1<ZPZ(S80Q;/SU<NE'4W:FYSJVXSO?S7KJ;6[3YL6UD5)*J  3'.<2]
M4,C"JB(EO>=$)$^\6EDG;%61RYG*_ZC]F,M+:.@2X/SE/*0']Z7,FZ_#3@C=
M6"?1W,;]=.,Y6U!EN%BZ\ HM6&N[V^7('!=6?:'Q/OYL'6RUF8J&\110B):!
M>>\"TD90E+Q7@I,8C'(KZYRO<KQ  1FWW%N+!TBWUX9GZ?LPVB?M%?^X8YE:
MPIFNR+59O0QF]:WXP]*MZ*>8J\V6U6'G%6ZOG4OU+GCYSJ7M7U3J18VB#'YO
ME(OBG-=>W?"^+ )\9$^*HBNY6)/U?C#.Y?BG[N_/*8C^A^T619H_[\<X>F23
M^C8[;[%6Y1D+ ]26R_TME[?EMJD-F-L9,">S!DQ0.A#G-'*>!L2]Y<@0S9 *
MS',<*"&,K:RS54KJV,.E]MG-XY#+KSV[_3Q;<7#XS(&)-V/H-=3?!>I;_9ZO
MT?XN:'\ZB_8B$N(B=D@S1A&/3"%CO$,F2NJI3#0FN;+.R2HQ5S7Q>CYWU:(C
MU>)'(K[*(YJ;S=>U+M'JG>JKKG6V+=:D/H>Q\T S6FO.^GCGJ?0EOJ0O8>D8
MIQYQ+@SB"2OD. 5]:60RT4=)F'C"XYWGV'F+!V97Z=G?BCK!Z_.*)=^F85BA
M)1>\N<?%1JCS^FR6]\> + B'W9ON5EXU6@6C*?=P^U6Y]]L@UQ16P6/Y-V$\
MR.W'?HU47ZM1;I2#_#098_'F#HR0+"EP/5"3K]/FYI=V)$$HYC4B*K?:%,PA
M)R1&5+)H:1+*B;"RKL\[.4\*J1?]W\K6?7-%HM/S93\YVVT ) S*ZNQ%)[ZB
MY]>H?]X<MOB$JWK.G11-9*Y4B:"Z0$H?1"NR6\G39A7B]PD>Z<\X\-,F)**O
M7;1VFNUL?N%H)(I.@SVHG4#66H.B#EYIYH/5.?-X3D?G_SUK,GAU.\NJQ>I-
M:]4_.^867_RF ]NAXV_2!" WH<KS,8;]DYN)=T87DZ9>6)O*7W7?/NOKO ]
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MOG@+^]3NE>=!Y1OZ66J$OAE"G[M9A#+1*9H0)0J,!N4X<EPPI+&VF$?!%7Y
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MG%T*M6!W[%*HUQB]:V.^:[L4,O58+?]^,>1[M/Q;SB'SFR[1$G2M(N(Y>O#
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M*/T^E!*:I&4X1JP,M\IJKT04F$N#D_#4_S@!N$#I4D+I.2%;L-9$FMO\&J,
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MN2EK6NW\RP(/\_+FAVF#GVX1Q1\'EO[J#0:O^[W.RW'X#R9TYSCVJXJ+P:4
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MN2&/$:N<7.5FJ.N1PRTW<_U0LAR)%PU8\TVSU!IP68)Z10,^E 8\C_I%,'!
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M*#X(*#;/0-%8JIUQ"<0K>,294<@Y&Y#0$AP:SAE8QP44"R@64*Q/-*" XH.
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M)H7V@_>'MA__R$(Q^X:7O<%3J<%?E&[8F[6K!=%")DI! I//]6P>@9(P*-C
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MF$Q-+%8YJ3N_YD_MO+I"7 D#%WBM&[=$@=>[P6OS#%XCP2%:J5!F,4:<$H4
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ME&%RD04+!2;O"Y,SY0C.!B&HCBB9P!!/Q"-K@T+:25!PUEDC8P63%"_@W+3
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M.$D"G/\@$2@QYKD/4K()X28N!$P%_9X%^M64<+-@WKTP[]SBXU)*2K!'/IJ
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MP;X%AN9V N:*U.6@((F1$B/OC9'WS/&4&/EHKLA:9J?MF*!.ZK2I,9"T"?:
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MT:SJ=C#/$[@B9WDYG'/3F"N-*7.#P'7H@LD+/2*[CMF3X@0OBN'Q+!_(G=<
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M><H3?6L[O;2<DK?%QM=&KG&COI*97.25Z1EK]NK%:BNUK%8^\W4UJ[5Q"W3
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M:]Z;?!&B[WYBK1<UU%A3RTJIX_Z@=S0Z&PP;2N]_>T??1OW?>LK9IT_]H]Z
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M M?,,>'L6(TC_,*]DX7WI?ZR12RCSB_H'41\*]+6;KBY6#Z^2,VU45LW"ZC
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M58I7N):-50^FTK8Z.Q^6TDY)RD,TJ8J7?'=)OQULM9B^T ?U]N=1KE:BMC+
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MWALL-UZH7)632]6C]>F,Q8* 6A=("2?R1<"!RT#;FV-ZF1=60,.S@UL,*V:
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MSAVEMPJC)?JYJ_GV"?_&&D>),ZNX0^NT"-0"U_7#L$6AQ>A&1N(K\A9\I[R
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MG*16W5<.E7U:GU*1:;]1Y!.S\FJ[!W)A=);3 R_.Y/K\[+R*NV>M8>MDW-5
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MHMYXB4Z4:^*0WGMAH3<Y_8=SXH%$_YWD7C'#_^*BFUTL,E]&J225XXR&42R
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ME>,A/OY\W1NX:?+*@Z\\3K;*]J,^O*]@"1/=;5&S7S? ^YY5HTW/5CB;B>.
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M:,6T]: >L[:V?UV?<K9:$Z.1$EKM6^NA2IYU=-*1I ''"\D03RDN>H;&*$4
M$]H4K=H(IT\Y2R?:D?913#62O/L,Y8[UZ/PM^.E5E[$U)IYE J$\,4Q9(GG@
MQ%IIB +#DZ8J>=8D5^YA6#LF\?P0I*FHJ);!YQ?CBXMN=K'J=U7J]B%D&)7N
MWOOX^0\]KH+?OC7:@^,E#[QI_R#HXP]M*Z,FH= 'WE?YQO.>;VHKT^/=>7X
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M=ON3,1GG2\V]S?4$63H&1A3F)');RP[FT,3J/>9=6FN%;;YKVT;:#3R?;^+
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M#^+X7(N>DM'R<E[2>3*<KMZ8+3!CTI$,7\[ YQKC&!T+0D=6$$V1OI"_U,0
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M'J)4W9R !Q+IOI7\[XITWT9X#8[K5[W,R[*<B!QLBIXEK.>\D KA\IIY)R$
MUUP[WV*B;P+TW?!8K7'9A^8:')*NP[68.%V0M30Y-D,[CJW1CPH[\&(/^;>H
MB;L9(4AE7:%55:94$:)F85Y>)=)*6&BY16A2#/70S+C#KC@T,;81^P$(<77=
MN*P &S*7LE@6<VTDX+)A09%1E27XHH))H4VPV%W #F^=]*7$.[BQEP8.8*9<
MA+#]S[A>#%YK!H@I6N[)>O(^$DJ5/0-C"G-!")ET(>FT*:O="=ZC94L/VCC
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M;TN&4@1ODGW;ZRB>$%6/SX+>:[KNNI(/@K%.NGK/F.NU1"&[,2IR*&Q*&2&
M<ZO<[7L??D+$.Z"N>J_>>NEO5/=C.)HS?^Z26B5,1,YK4 GM_+P>8=ABF-,A
M")YH,MAN]OZF-SPU@O0BZ1:%69>C_L=P]FEY^GYYZC[PBKN"2'MXJ:E612$+
MQ4?FI)%%*A.U;-,WZS943X@[_6MI#8?V[\-VT2^$EKZ7I6":G13R))ZE5,,S
MAJ./9!V.TO#S*;X>D72&XWQ2GN7Q_%QLH#G(X)6N&7R1-EAG:/FK;2 PNV!"
M+=S?)G-]9\A/D7V'T>\::N[=TNUG+#B9U/WW"X[.<<"5ES$YR:13EI9;FUAT
MNIZUNL!E31A)3:JGK.!X@B3:1Q-KF+'?L??EM=X"S<6-WCR% [A'/:_THHRX
MJ.O@.;FRW@,/P7'E5#?C>?,[GI#V^Y3V&A;LW>EL@>@526S='OORSW1ZGFF-
M>S:=(OV7:\,%!Y([*\@I1 1B+LWV:'ABAA=;6Z%KK1NE"6^-]0DQ[5 :7</"
M_4[@GWTDW^ C.8E788I7\V3\\4)AEU/H%YQ]&B\7T9M1,%*Y(J3G9/LIFD^U
M #%84(PG;T41B5OL%M;6)ZHGQ,+C:G0--W<^A>_D>EQ9AB]@EC[]]OE9_N?Y
MHA33>#&D%Y^JT%^/?D&H37Y/RMO)F.0SG0Z2B1ZES"S)6L25>U.OO!+C"$HJ
MKJ1-71+!^O4N]QK2$V+Z/>/'&NKOV<KMZDB/]#?*;X8)1]>2#Z;+" ^"F\_3
M;/KL\^?)^ OFWT;T^JN;_"!**EPGAK4"B@8@Y]R 9\(&")CILRG;'L;N ^@)
M4?1H>EQ#QOWN I887]!/APE.3R;O\&.=6>/)56CL]/6HVC:87X]NW,UE6XI+
M0C(!F= C6=Q1:L$(=A2TCQ3INGDU^R)Y:O0[J.;6Q)CN&3V_X5YC*=/%5<8K
MQ.D@R*ADCIG)7 LB%LG)B-; :A*J4U& 2W';A>ZNESXU-K72QQKB[!<1_W>"
M-B^@6SVMLWI0.# 6I"H0&6A!1,XJ,1]!L"2LY27+Q'.W4,*;SWYJ--A3NFNT
MO?<=P'QL2[MOB--:!^I\,JD[IXU>YD0>#(^2S+B@) O99:8)<Y')"8]-0BDV
M0WI"?.E9/VNHL_<9_:T>Q+>.\[\Q#Z33B1P RV(MKZ-E"0SJO9?#F'3DEEO5
MJ''0-C"?(,4:ZG$-[?:[ %B:99?QCM7GA+-!T#9(T)R1?^G)RM>.!3#(E)28
M0B&#JV/HS(87/"%:]";G-<K?^]R_QYI?6@A5R!4DBYQ,+&V]9U[7Y5-H&F3,
M):]F$G^O^'>D%>I(6K^W%?\D@+79)!92'004QZ">,DNC@BL"5>Y4%^ I5_S;
MB@=W5?S;1A]'*]_6!>13K_BWE2)WJN.VBQ:.1AGA@C4%)8M:1*93,LP7L,P'
M3(BN)*7+(Z'*MA7_VC-E&^$?HN)?L1!""8&9Z'PMV>M9+*;V43$Y@4K"NVY7
MU ^HXM]6.KBKXM\V FQ?\4^A"B7IPD3AN08P"Q:D)G J\AR<HDUPFR)Q#Z#B
MW\[*W$]X!ZGX1]8*9*<81KTH:!$EN64E2YU,,DZK;F?X#ZCBWY[JW%V 32O^
M%<-5;3K$BHB2K%':4L"A8Y%'<I%B 9&Z'60\A(I_.ZMP9Y'U7;SC_:?AA(:Y
M9)%-R:="GFV0M,(K#BQZH$'Y9,DD "S8;4W]YK&/3WL["ZW',AI+G[*VGCLI
MUSS'N7GGN0Z\DBAP'VM\JV5!TWKOO9.U71R8U1IB_1P.K47S1-WM_C34H'GT
MS?8IL+YCRF7C\[OAMNPDO27>X[25[D'3X\.KJ4&[T&UA8TY9^T X;>W.'H2M
ME4@,@\2]CL%$6HX?+:ON:$!]?%)MHYW^2QS>'D:W@)@-9N<A,Z%JOI?/R+SB
M!-&B#]Z5G-W6U3AN>=_AK].:ZFR;N,4=!-[W8<"SLWD-JXY(:>,N*25;"QP9
MIDL-9!-D\#GMO8J:-O3<,:=\F]<^8H:T$W^#G6@/R^_YU[KTSE=;9[115AH6
MHD6F8X[D)<3(D+M:$DU)'IMD#/2"_HF;WX=G0(].>@^#J$-8>+Q=!M'2B.]E
M%,<Q[8_ HOYXO"<%[M>R?'TP"5-PM'&Y7+LP:EM+O:O,9(U<-T4!M F!N<<\
MOL.9>#0TWD+S?;LDS]*G(2&O6$_*^\^8AF5X55%UF7!Q;7!7F1<TZ%?#R93&
M>'9&&^D03FO)[ZM\C(7-9)Q$;Y5FS@G:Y'02+-;J*H ^)N]$\99W,UE;0WU0
M<86[\F=\;Y7?NV>U=G1KRM)/7Y=GH]$YG/YC/#G-?PPS_HJS^>^=E(4CD)>)
M;>\0TJ?+A[VIHEF.-:1"8R7AJUJ"0QNM641IF;$)8B#G0(MN#0@.#/P[[>\1
M,0ZSOJ^9VJ]',SP]Q32CX=*8R#6:U4F^+M%N,2SI,D@TG 93YE77YLU".+/"
M626S<EYTRT5JA_$[M8^C[KYOY;\95I=])R=5XSXTLUG53*[D6"C(F?)""\<]
MQM62:%VX^=V&N(-Q?:NF[PB!]=/C[033S1FR9M)T-'HL%]Q!THQ&!$PK6O2A
MA,RLBTX5KDJ6W:H5' 3NTV;LO2!!WPU)OAGA%<X;&''>Y5,8IEW$VB5#,J^J
M=0+9)Z-2#>79GJB;7_BTJ=:3(OKN5-+99+C=/ ##"R;R[XS@O/(],.] ,>MM
M++(8(SIVQ^T'S].FVF'4V'<;E5O\LIM61-8YRY18\+4P0VT8ZP--(&_HLXZ\
MD$6ZK[/]G5.-%-)[GQ,X'=+@1T-X/9K.AK/S&9(<B.4XPHLR'[]@'J;AZ,:%
M+CDP/)@"#)P*A#IR!J&V(?0Y&J6T,KH;C7:&\.1(=1AE]=@;91Z(6V4SORZ(
M7J.$H!C'1%MUL)K<8 [,TGX-0E@976_IGI=O?:*WWKM+OD^+>@EBP<(N,'I/
MW;QZ_^&3,W?4P*H.]Q!?WSF7U^ (H$4C&%I)H"A:4Z#4XC^TEH58#/EJ!7O,
MJFRMQ5OR)OM5XC92ZUEYO\"?P[/SLZ67G;/P21DFO/:TEGC+HG:!95>X(8O5
M:.A2QZ:3^KYY\X'S0':5_;@/P?5Y,5>!D*BN@.C$DP[9,J,-V1%6619JMU\!
M4G#@)J#ITDR@FP:OO_D!:G!GP?4\!Q=W7B>31:F\^;JBO<\)!#*,TM"Z(A.+
M1@I&AG(EE/:F4Q>23HI<!^ )VTA[ZZ//,Z4K/#5R=X%HNO :NH#JVWC:B.;P
MIM3^BKJI]9ZDW&:)6 ,NY>P%8J*=AQ>F$W+F4PW55E8I@XD[8QZHZF^QOPZD
M^6V$VW>HP?OGK\AY__#'^-7<A[\XV$XJE9J,6I(D/"%[!CQ&YJR'5 "MSMU2
M6=8\_+ ;>$\R'_<HL+X#IN9;T7*<RV,]Y:QR.;.HG& Z6U$'IY@-6:(7RFG5
M[8IHS<,?O +W%5B#6.1EXLKE()>P(CEV@FS$)'VM^(:113(76?12&H<R<=ZD
M9]<&/ ]9]7V*NN] F1>_#D=X\N[5^UHIE%:69>Q.M-R:4ACJ $P[5YM#D<=A
M0!KN(_D1'2]ZUS__(6NS+[$UR).95ZA>UM7 (GG)B95:@UR[Z&IW)4(63= 8
M<TC09/Y>P_"0M;RO2!O4NKCJXC(E-W"E&>1X1%^F1?YC-16SE"77R.EDO6,:
M;&!>866F*%9R!THU2=K;"N43=<';:[3'F_:53/Q%C]'EUM4!4\N<NG6@CI,B
MUU"7ZRNJ[*^(!M;D6FR)FYRM=;4\5V+:"UIZ,9.%*\GL"5A#VYHDJAV.''?D
MG1V9&]O(OT4YE,O!OI_!*,,D3W_[G&&&I#;-PW)S==GHS#73!FGU5+2.AF3K
M#EO(C\THK)=-]JLNZ X?<[&_(E?WFMZUT.-IPN6^/"- =2:\_-=Y;60W/OL\
M'EU.#$%&EJPMP(2G/W3VD0$9U,R70&*0",Z&%A2Y%=43-V'ZTUB/,5Y+<"N8
MEI7O.H!J:;.L174<HZ5'[8U;B;[!CK0>'*!30IM:JZ5VQ^")G'>I@!9 %PE2
ML3QVN8^\SWRXPTXY-!VVD7B3,@PS0H'Y)4Q&M"]>IB 'M,:B9NB!ED,L-$[N
M!*V),2J14!75J*[".CB'-SUZT-6-J@=["[KOJXMO>_I=QHTN@Y07AKC/W"O.
M"D?)=!*T0T:D(8-7-3]'TH=NAZ!WO^R)FA%-=-%G*&\'?(L)T@7A>K-B-]8<
M)22AB;JVX,(>LFY8F_$6I,7HH&AU9$*!(9>MZ(MZ%E(D%8L'5WC'BY3CL6%3
ME,(](<,V(NZ;!)=83D;+V[P 2@:5ZF@=^=&I<.:]11:"-UG0E\%VJ^9_\]D'
MO%!I)/YQ?[+KVR*XA'-UG5>2U1@<C2I7 R5YQX)$1[9;T0J %XMI.U4>XP;T
MD*K<37;-9N4'TLJ26QJB,,X%YKD'LC8]LDB6)I->$)8<);?;*O/JZ8]5G3O*
M;V.4PG_^M"*@-_1Q_H/Y]ZL WF'YH?[]V[O7E\+ZXX\__C(E.Q3.QG])X[.?
MYH+Z!?XYGBQ;GD[?PF0VHK\_#3_3;^;W9*K.\.,P/3L]'<(HX731"W5ZU0SU
M?$30+J7W<W523K\=P71X]OGTSHX=;8#\="66;\6U0/,-FXXE(/QS-B^'^^,/
MP_RW'X<A2&EXX2G*I*7@42E4LA0-FB/]8( J9:SEDB$+,@6XELQ'1Y1,*928
MI- J_'BTXHIOKOI=6BR&F,UX+J6V<;<,; !6@@:TO)HO3;IG]P%^_V.1"QX\
MB]/YJP:T;*O,2V)<I<"T$XJ%:#)+VL<<1)#TJ8TPO@7RH#)?=^/2S9.3/731
MX()F@><526I=X^F7?Z;3\SP<?7PVG2+]ES_ GP-,/N0<(DLQ.1I_L"RHG!B(
M IYSR8MO29]ML!Z#8?LH>#U;FFFGP1ELC^=/6&I'(^68"K6 3A&1S!U>6.+"
M.J>X%;I)UY^GVA)ZCV7M2%I?Q]][T1*ZU.P^-(D5S6N"7S6+LB-99B$X" QV
MM>3M]Y;0^_#@_V?OW9K;RI%TT;\R,>_8@_OEQ-D/+E>YQQ'596_;W1/[B9$
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MG4G:01EC%9F>Y$+7CL:*^>HG60]<9>N,5%W.#E]R78M]C?F#]=&&']LJ+G0
M]>+J6O115+>Z%GM(^6AU+90,Q48C6<I!,*UB(/-!!2:4"+Y(C\(,5ACPW.M:
M#*[Y/L(]8E9]DB;:4 J#E&FS\YXSD(ZS[ P:9X03IDD*PYEGU??25L>L^CZB
M;G!3L@N6U<7S2 ,4MI;O5L3W4,@$E4$DX!FSL4UN%CLQH*<A>[W/7VOS.E+
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MBM?LI9GM8>-[B+5)69V]=[E?OM=6$4OJ.QJ$U<(PY$4RK;1B47C:<&,HJO#
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M^VEM]@G]F0AS(C?K1%H_VT08+T.TD>:?Y\Z2O6\< VT-V?L^)"6"C?EG(LR
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ML/+6D5YK(*B3K%V_*X,#T\ C TM;0LS6626\@V"'4M^=-Q_YCF]?V4^'$-S
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MZ'<ZA)P'C@B[ 7(=<-P!RM !FAL8CA^D>8 VMNGT %$VUFZ(.GI7[[Q41EH
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MOKC:J4!F&HA.,3=)U>F-]#FRJJVZ&F0BW%LQ!3&ZZ%J5L6A!>$@.ON3,DO2
MR0>I4A,/_.'MZ?"!K8[BG)=9.JV8L)+V R7K18,0+$K%N0%>A&G2+V,KFF.=
MAC>RO@X6\+F<=W]<P&+YQ!I=OOC^>GKY=3I9ELJLART2:4YJ41@HI DAP+-H
M7&)">.,"!A\V2X(.=+?R$*I3G7T/H/3-&Y7!A-_ ?MO M#Z@Z0*JY='V5E2G
M.<X>4'O35J(_'B^<%Z' \C"6IH$)@46?4IT0-!,R\IB:W&(?D0^/'%@?G0X]
M)-Z !MM-NNN35^ I2XV,K*9E@E)BWM1;/]I4C8,@32,[_ %0QS>Y!]#;IHD]
ME-"/<MR]S(+X!2Z69[U?$-<GNO-]SK%W/NOP ^IN,#=.GK.,"GA0SNJL(0D
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M=OP\ K&V 'U1Q#I444,V!UKYX>-4E\UW\6+\&5:EZI#[D++A3.J8:^L77E/
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M>/O-3U"#>PNNP87@1BS=JHN?2-Y#K>^H>:H]8Q7Q2XG"#$@?'#<RE38I4EO
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MQ!:C.5;9E',B[^EI<2[U5-Y.:!?'F[S^W]?C7!XX6PYD!$7).(C =(S(0/O
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MU_OC*&4?K5"2><G)WK-DZGF#P)*.422+,8LNYUY[)P7WP/K4Z=1:/0U3TCM
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M%ZU5I4AA:5=Z^HQX)%3\F(3H(_ &1*@A6O/%[/N[\ND+_D:;T/3R^YOQI)Y
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MA_%]F9ECCO*-^4Z2BU\7\\!U=64U98" @ "PN/P!+A:NHY60,#L T-0$[@(
M0 Q<)9 &KOQ% XC5PV' U4N=X%+7^9CVQU_@^N5O[P8S +Z\1W9Y+7<I //&
M7]_Q)_[$G_@3?^)/_(G_,V%@8^L.%Q$% ,(XT%^8!,TE8\B,N_IWO3HA_B\Z
MZ)X8 "0D_+O^[ZR"^.T?,_W)*O[$G_@3?^)/_(G_LR$B)'Q?2DA"2EB875A"
M2O2>E(C(?WCODG\ -H MX [  1'@DH4 %PNDC X>'L^E! 6=W04L;5RL; 6L
M71""2,OG@L("0H* #!3YW-(:;NO!;F5K#W.6Y=EM:N-AA]G(\AB(:PII/E>T
M=8"I^KK9ZOH^?FKM"[>^;\,#E2,GD4%*(1'/$;8>ENQ(A).SNQ12]N9?9I>Z
MU/^X+7A33L;-QDY*YZ'RWT9<7LG>_-M:O+V]!;Q%!5S<[ 6%[]^_+R@D(B@B
MPG\Y@M_=Q]G#$LGO[,[YMPD>VKI;N\&>>\!<G-G_N+:T<O'TD+WIZ0FSD;*S
MM!.WLK$1Y[>R%+7A%Q:VL>2WM!$5YK<1%;61%!>^)V(G;'7S;^9MK/]N_;FG
MF]-?;-M8"]HZV2)LG3W<+Z,A+'A3\'^OS<L0_=WH?QC^2Q\OQT@INME:>M@^
MO!2Y/]+*+R1Q.?'3?TNKP#TQ$1G!?QHG(_A/"_W_(%IR,C;64M9_K,G%[:_F
M=6U=_WO9=H+)_8U"_]7!R^N_*I<S7Y;=M6O79 3_T>C_/0J"?ZNZ2^WO-7KY
M3O;_%_"GD3^-_&GD3R-_&OG3R)]&_O]EY-]YKJWS);GUOF2Q%U. (@ F)"0B
MO HF(B0B!H.)22A)+SD&"2WD.AGE#5I&AANT-^B96'DXF%BX6>AOW!2XR7W[
M#B\?+R.[H*C@71&>N[QW_YB$ $Q,3'*-A(:4E.8N\PWFN_]E7'P!*(D)=*X\
M!Q'<!*Y0$H H"2XZ #8 (" D^ O^[2! < 5TE9 (3'R-A/1R0,UUX H!"'3E
M*HB0\.K5RU<#+E\'KE(24G$(*Q!1/[$$WW2E$7D1_XF8\T'%5UJ=(0R7J)5;
MR#42.OH;#(S<MWANW[DK)BXA>>^^E.)#)645535UW:=Z^@:&SXRL;6SM[!U@
MCNX>GE[>2!_?EZ]"P\)?1T0F)+Y-2G[W_D-*5G9.;EY^06%1955U36U=?4/C
MM_:.SJ[N[SV]PR.C8^.H7Q.3"^C%I>65U;7U#>S>_L'AT3'N]\D??A$ (()_
MPW_H%^6E7U>N7@5=!?_A%\$5[S\&4%XEY! FHE)X K9TI;XI\H*8YD'\IXJO
MUSA%=3"T5FY#)'1<8@O<V#]<^XMG_YIC(?^///N[8__NUR1 !B*X3!Z($H "
M)TS:HWP'30R"GKSO2_DMF7)2[$F*9'O6GXK%TN&".B2I%#[!]:5>50BL:L!#
MXPI^BLC+\G[ K5X 7+H=08??H&>,2=\G9^'I;#C-$L=!G(H6IN/H1,8%5C"A
M1I9@PDQA2+B(^GB8"4'T,Y3S)'9.HO#<YF3\U$]<>(T^)R 4KI3OOI<ON;88
MH[8>N;#C;[LXBE'.7Z3!:NU4!\"VJ=JW"B-&^D&K+KCK()87N_)LJC9/ _T?
MZ#+$>X?^_+$?F^NC.5N(=KGAKSTF \U!1N-E8=D3"D)[B&'E=#7@/F+NFV@4
MR6KNH+]BP*GBAM=1JV!ZU^XIU?WH48EXR9YFT'7=+M&?OH/@ZK56]F&\(IS[
MYQL?VB5*]<&F+C=:5$$I'VI "AK=K 9I/Y/[UGM.[,EOWC&\'C3Y8)R+4I A
M(/)*LMQA'<_K9JT%A$MG.F,S:GE<KC-3K7#"7(V$[_.]JXA[-V3V!VH /S.'
M?N3C%V@MA@G'<]#HH0L5N3*J8[$OO6.RB$O1H?W*??[I#'/'0G0&*]S(JU2@
M.!.7^G34HFZ,;F+QO._AR" ]T+G"^BR\8'==GG7"'LTO< &8M0R5.K]*"0TI
MGE:LJ7S1NOY3>*!&J1C9U#Y)^$VA[#)K_F5-\0+.="+M><I:ZFA_C@N AW Q
M\0)X7)MQ0EP4R/&Y8O0"@,FRSCVI#MFASE)]Y-[%HO7CUSQ6GC7?NN#9AE>$
M9[ZIHC?H;,(B3BJC0^\C:N )_.7";F0@)QMQ3M#$N-=@;QR/D(+'LD'F^G$$
MNZ]UC;.Q8ZL ICP"S^X)I6YM0J"UDOU\$(M/2&G)&$6:Y^T/CC,AL,M22'7&
M6R^.86+RT?7^VE2RHL9^MTNBBVCC_;_(>>T&?P%D-RN&9!30FB#TK>Q/N-2.
MX@"GD_NC@2/\E9DU3OO!T&#WT:-,B"5_L-H:KZ REB()3;S#-51NW63\+(KJ
M_?Z>JE1A.3UF-?IP";L;_DG3SV!<K 66J\;V9(1N\H[0/23Q*C"FCVV+X)=C
M@],W(O 2QX7H=]4Q2K51@N^:R:Z#Y9;V+ZM-T2ZYN?BK;UV$Q]R;E'>A,HIE
M+([4^:4;CP;Y["3X0S(A"YLG!D6#!$HTVO]3,91Z%^TOFCW'Q&]L-E)25I%Q
M"[U,&3ZOZ<*:M!\>G;["]F:6/V6@G2[PYM-A:Q'N/L$=^HR/5Z[Q_'*79WMH
M/*WH3J*)N*M!\])-2LC6<H-X4]>NU:L258X7GS<GPOFU^Z8M56R<KB1O:M90
M_7@SVDTE^8CU?JE&+#-R3@G#,NW[NJFN*5$WLD]KU)-7+U*1^@)@RESDS 7\
MRASZ?>@C=OV?S;N0&1M!:&KSO8OF5!#DA_W5C@C%@,70A9:JIQD=Z7<Q6I'B
M 23'9HQ[97''X\?T\5P(TG+KNHHM<L!/WX$G$A,+VDP7'J\Y-7Y_N.VX^L@8
MW-AZZIP>UU6UN!Q]HX#;#Z-I.XEK[WZ"-%?#(@8B.@;5BDGI1LY[(RN5S9V?
MA=_/A'C68&_%^Q7/KGNAL++;KXE6R.8[(.[IPAJ%R%C5H>A/H^4+=:=.6;QN
M_1GBL?+"9HIHIC,M_=% SG7L;&F.5ZUP#Q-WLVU%U&<>AOO',OJW,MA>'T!(
MD"0X7%*YD\N.5;3'[RUV7@ ZXT:J#1Z:"F4HAS2AFLW1:C*FQ>OI/%+\;>%V
M#J5;V2&2S]3)$CDLTP,*7W:>\V)=7LO<R5_W'1Q$/1OJ[^_C;U35>_'U+D3Q
MLJ>Y\T1^;<9VAU;/*)6(0RAAR:C(YX.:'J^_G%TK<UF O!9'^+5+PLMGSFIW
MNHZ,=9\_O1-W9S[N7IE+NR]K=)F_(>X%74O^Q.R#<K9^=ZK:+PH_;\3<!OVR
M3)=^G6S(]<S*,LF#(RF\@E9 R7]J(8-F8Y+^!9,JYG AA&GNND2&)7*SV?B;
M%K?"YH#ZAG&'W&U,_NMFA86^"^!Z3PEQM7U;;7/*537VYU(LS=;U_8#?8X?O
MY6G;_HK8:^^^HH(P[SZYT'"$9L%I)IR G\N@8NNV1^,[L8LL=NWMYX(C>"5T
M<HPIZX'QUV(F;A]5)]?E&%)6^4R(37-+W<A67E-SDF4(C2!7]-!3LD1M&&-+
M3$.>0L&Z)*\G[-X,<^''>WAX9[/L(MMU<HV.$Z65[$*SJ?;LFN4F.-T=LMXI
M+8PUH5:+DC4ZB';N%QXZXA$-$UL=+^4Z?50(8R)X,2H 7/7J9ATEV*TV2,5S
MH0[3'LL&:6 )+X"CZ*[80MFBF<J[U:\!]KA[NV;Q\H0T3_XE83#C'.23T5TX
M;:$W4/&3KB&]FXVX=Y45,DKBV15N[;G0/;ACN>]Q5'LJJMQ=XN>U"'U\F*\$
M/&>$?-TEP;GK58R66#7[]5U1:AZ9$4W2R?6RP%;;S/N-H7#F"PTR/ $+76&+
MIU(GF-D?Z:[3MGQ,+W_9JM!./)%G-GC=2H?T[F@L\4U::ZYK-GP(X4\;>6 7
M%42Z6%#H?,ZT)IG./5(S_\[KN-%?C0;AXO:=Y?JR7C<6LCK;1'(;%!D4:D:?
MV*Z[Y@(7KDK&EK\09<$^"HI@*AJI+@\]9QGV.'L\SM54'Z!/33@S,].G(5.@
M++$K"QYNDKH-2F:#''"PA:/W\J86T.2QNUI]77(NNQXE?ADO66D;T[WC/0G#
MX+$U3$HMGJ'</S6*/*ZB,H?D;R2STH]X[%)O2!U6?A>LX8H6N.9?2"Q4SU+,
MTPDEPT/19W8LNGK&-4UAU"0:"(^AZPT_Y<P+R[HB@>7JMO!9AB&\I'OFK_5X
M4M(O2KWW!4:6+)*MW()RGV!VO\62(^%/P[6KZ>L,Z-:L:R3K-(5J=4>5(:2F
M+30$7=!ON^1J"TTMQ%]=CYCZ1@)$(GXNWK&8\2-[T6G>B)&(\"O7+)XQ;GXG
M:IAZ#:3J)<-3P&O*34/P=9V-&"^>[9A,CY'(%IMTIW80<#%3"G;?*TJ_LJ]O
MO. 2EJJ6H2ED$I"RJ'T^%.?3?<OIY<<3U[]$B$+PVOIS7)<Y=9;:6;[XYQJO
M6:_?%JL[)ZLMSD^4 )K_A= .=,]OWQ2D,8=O,H>=G$P;_]1(*+VQ75?C0:,-
M!O-\$R25"Z=+KC#M)F]I-YE28^GCJ]V9\1):@CC6RS$Z:"VDIE'@9C?H4 )<
MR1I]=<DZB]E@GA#9XL]9P?<<Y*B15E"(R=HQY:R9@L?&GIJGQYYZ29M'\05P
MC:7BV7'&M:WJ79)-KUE&&/?8(6\0EYEC(L.O\F-OUI"66Y$ %DKH?P]+EXKF
ME_!Q>AQJ#0<I^;XT2-C<SHEZ'OZ*9;/I @BU7YC#*9=64Y-W_T*4=2[!5].^
MR4]593PZ^B.7*XE?3NYN&+7L)NP*5%P/VQ(+AQ?<^,+26I.4C[^%F<W(GWS6
M>33!7M5$[[4N/B(4W2W?^F;;=.PR'9M0XF;!,K@D8U+O;#OW%%%3V.0Z.G*5
M;4YAO%;W*R.7&<?G<8LZA[+J4VNX,]4#2D[9"E,6&H*(A5V2]72ZNOIP535*
M@3)&M.:.L<!,8$A#O_7\<:CGC..N7ELD;L#W:[YA.:M8XD:QZ2$-09\C&P5>
MO "G(TBAEI?C:\,E)ORMD_$6"X,A\\O=E-)LO"!F)QI6T'[%U*2O4&G)9,9T
M6JQ*RIK).UW^Q,!6"7!SQ4L/W@Q7B+;*< Y6JSC#]F)C4T_':%'M4/)9XTU*
MK:L_&CO0Z*6(US<5AN(N0_]':- > Z'IK","@@+7-^CIZ<?#AM%^Q5U)2U%1
MGK+G28Y]"[,O+.7"N:M%B0:S';:J[DCKA5$$P$NR@H4.!$E@@<S-HV5B'?$V
MHSN:8UW'_!\@^;G_2K']9P+.M5YCQ/MB1F4*6 4_S_;83;W^_0'@BG6&6]6W
MA4/=.^:.V!K.U>19<O_%1OE7,6!!0Y@U%Z82!/"R!3U.(WQWW*D?/HSJ!CGN
M3@?=!;8<2N"F=I*2YDX*-G&:R\7]=^/P]C*L<F&EG46_^JQ0\68/CHI$1L()
ME:7VAX,%G^A9C/*7E?2/Y6"G%4,4.Q;>+DX;"&<CQQ%NXQI-FE?.I842Q+Q%
MFBUM)E7/CY15=VZ#*K(JK5$E"5W7RG<X*F&4AMU\?4D#3B]?'M+*CE?D&]X5
MWSYL:>PY+^F[;=H^Q9,"M"G9]Y2L?_Y]"[[IL7\!C"8GJ7PX6$WQGTQ+:OEF
MW.=-YM9 8 T#['@RNUL TZR&-DID^2GD2<7GEQI-HV7EBM6NQHCYVST]5H3V
MIO[JPTYX09\2+81OJ:U0R$9/UA7DQR/>C,U^P*O:0-H%O2VWJSW,7ZK8*Z[*
MBN0&+9/4?Y?#'^09(D>T1OUM_19^Z=C65\G[=YDGF.\2RG[?E6?AIXU&(WP%
MR1T2''6_BFW$%-Q\=>7'C^? 0$-)L193[I)4",O-G2GMS\3#$R8T^I=4B6C:
M@"T:\!S5AV_271?A[EQN%FFE[_-Y*H&6\MS4:U9$\PI"UNOH1?LH4VX;/:V#
M/:A^SU(ES^2A3Y=6_J9!5+QM(O-4S/WWL'J._P70CN)D15?S'QJ3YKR?,E,0
M>H5^D$ T<7B025JM'Y!7E>](UI<_^]6M5Z2/)K(#DBG>#V>CY#^(MCH?U^34
M3B<7XC0SDR\8^G;CRC6F.M;F>6TP7,FNNQ0VK$$&]X.DWB,2$P!)*"N#S3Z.
M9(][]*0[H-OJO.NN_J#2?H0\7(T$!K,^'Y33.33^C/'48,(9C04>A 9/3&6H
M)P0XRQCVY!>9M7M+OEOI%+%4ALBD^WHP#Q)UTJ:G=*7Q#T]V^CF/U*J^5I5D
M]B4;@U+![15K:QRR]E>;FV(F;U1%)6\$ =?PMT%ND8LU6LP#.8[/C<V0WCI[
M.\ZA):+9ROK*/&&@P"UK+JS.^JQ(@*YIX\A6M?1OBYHFOV?E+Z*4RUJTYF9B
MOP5+]?*&?\;%P_P"G!/6?4-ST\:F)J;FU(NL$O2XK,.X[&%=*H[3F)6FLP9"
M5"HDWMW6F[L$N_-S7/<K:X?%&3EP^0#3 /^J&#!@-G>0J>?MQ] >WJHRT074
M-%;R+'PG*$$;;/^_.DG\HYC!_0JU)#OL,PR':F!\U<VWTN,F9.)[."$I3L$J
M+.!\\?6GVN $<YSSOG9]8\RJ1@H<AE>B;>?L;E>J]N^>_%"$=-R;.<RM'<H-
MX/=\XY=<&2*8C S!GVI[,G2#RGA1!9D4?@\D$AT2)=YE]^4I<O@K<-<EF"SN
M.BTR''>ZL=[ 1,^$MT_E)VMJS_8CGF=8I.A8ZW1^IA4^@X_>SH3P5&+>F)EG
M;S0*?KR)V?C*ED$Q7[F8!& ;&^"G\+D#4[E]+5B4+Z,2DKOZ5''J%EJ--.[I
M?*#X <2Q8\R?)PMN '<O7*\8$#)-MT/GOAN<CXJUEF?5"\HBG5$KHW2Q&W(Y
M6+.J2)Y3I^>Z&T7;)<IDGQ[2> ;ZALWO8$K=W"1J4!7;="@M*UOL<P9]M ^>
MK5]IJF>/F:0)NVJX*$]+J7SEQ2"!KC:8''W4^!F;]Z*H.V]V=LJX6ZKOR)!1
M_\$7:W8#Z8(UH]9"^V*X8*Z)_$ERKN/@).V/8AJ;*SO@![Z+-;XS- 1+A9\V
M61EP88PCCU,V56IJ&^JK$L1_=CV'7!ZR SQ.QOR@Y,@JI5C%\5Q# :Z0[=R&
M$&+C;4)[J!SZ,<6][<F6R+B/),#^'/.:T8]9DE%.OZD6TYP4GAABQ+=F1V;J
M.A<N=$/88,W]@S:J()OUR4^?FT.N9.OH.'-_,'6O\_[Q]/:)KT$U9[A)X57?
M2$_ 1R!_@4%0)4K@UI#_::%%'9U;L_'[I&CD Y^K;.K9:!;&Y1S4PBA>W+-X
M>D/B>EZ&E+%/B&Q%L($WYOJ$;)79D!+@PUJX</88W6T2>RJWT'Q&-4Q(0&$Z
M%K;,BL[$VH6)W:Z!B9W==RI9'EQX_=[Z5X+FRB*L6[_;^8SWUT;N>0:\<*('
M%G#%Q+A7"'OONR.PWQ:&OHJER$35!EF.[?"C[>J,!3D>JDL47J7^.+_Z^VGY
M?%^T=W<@%^(!^ARET;!'$,G,YVW!_IU/X=XB^*H!+ ?IHC:([QHNT9E9^N+=
M8V<A[6SU6+;8*%AF&JFVC)5\(X X6(K<T%"='W'.4=BC))J+CWWL%]DWZ.'N
M5X1T9H*23\,JURM4&W-&IGS@['?J^OB'3>KZTY5\EVD(%GH63H?F2T5ZYY0;
MJP,$G_ 7=*4$+M[%3YD^#>8&L1^7!DBW)RC1Q0NDN02):9:E%CX\,K??>]OU
MI;(;?R?#.:_%,1+8(W4A'D!DP5!/'$I9"UJY1'ON=IX.47HS\)3-Y 32CN$V
MCQE1KW9M+H G1,65BF?#V,I"/ X/KRZJJZ6;C&Z+]R/1I%M&E(F(Y+.?*= 0
MK YN)$[[/VP8]2RE-YBRNP!L1BCYTK*5>,B%+8@)8QFVP"W/,-ZA9598BKHB
M,ZU"HRK'_1[:^G=.(I]DY'ZX9Q@=$&IG D) UYU1@I5 ,(:W)JETMD46*U&W
M/VT,V[?DC(Z*KL$0:8$Y>:+&NU]4";2@^[ZW+<XB#$OLJVBB]5Y? "^N0$FV
M?MD5&_XR6L?PT6GG"-_AHP4S<"4$-O#L9Y(^_2\0$]HN?ZG3]%L7P.>S@3WU
MK<THG.>QC.8%8'F:L?268&+HO] Q_S-Y*NG_3"L&ZC77FU?@? $L]@:=K,SU
M!M\/"B,;P.P^$NB,&>^QSD"+HPPX,$WG:C_?G6\&K2DWG@"WLR+_MPGO/SJ6
M-('ZA^Y^&U25%7D;^.]*N2QN7-RP]<;<[)I!XJ3ILZ3WU6#"M\\5\)N#Q=(F
M(XGZ@X+5OXGT5\!1YS>#972/;%*-1CW2U(]UV^K3?_(8\G^*WWLS\QJ_.<<;
MAE-9,,"$MV]J2B'Q32&[7$6^.WQ!N=YB_^U4_*<;7&E#0]CP3'YC$D<$^,?.
M<\+G<^0U&@PV6#)A,P6NRLUW O$EP<DF/&($<_^7BM!;:JV-6>?/J8_@<4V*
MJB>;"WU,+'N;P.&?$U"T&>"(TG2JHV08M<V:EB0X*/X/UJ2';JVI3U'-K(]4
MX[SG87"U?%3OG_,8]UF/*PY@3I0G53*H;:UIUAE/[!;2#1/^[,18\4_46$>Z
MB%,TKBB;*W%0^\J0WG8YHIP3 I-QO^7:*$$FJO_/^8N!9=>%YJ8KQ8@SV%D'
M$P)J2HJ$/R2%^9+W<@IF6)B>0Z,U_R5.?B-09$BWPXQTS.,=PZEI<5?;+N5>
MQ@#M_L!6R\)J8N=D5[DG UCKE;& G^IJ1C=)D-3)ZZ@HQJ5FR/QW_YN-WU\)
MXA]YWG&1,^O]]05_'[\&*OUC>67>>EBIR1GQL%1G%*I79"W?\8&L:2-DQ;$[
M0OR^V)FXSB"OV0PTT:D$.>U;<03B.N/M+RTI\]<KTUJ8H=LP%$L587HZ2G.^
MA]8=4SC';F[=!@7N=AW3#6\WHSS\)%FL]&#".*R^D[^UG]2[NH81<8=1V^1K
M,@W $3AVO$9L-_R<?H3C&M$;QR5!09%KIBT]3B@0%M)^SJAIU:X^O)7P\]QK
MO^Q6C37;.V"#& QV_:TR.DB4ZJ _1RW^$,L_EE,[GNQ:+>478OUA#BKV ;P3
M(M3Z6WP0:6W6_%);C@5+O=,6[6UL2OG"Y\;NUF(]'F[>[OU<(I6VFJ2BFX10
M==3B;@Q0-'L7L[%)1Y!I33C3= V1KQ 6J3!X&M/A34,P3/'60'I!\+I<77[E
M;-=G1WV7I5EYZ(MNU_,^,DI36H!&Q^XM\U__^:OG4LXQLI7;V!AO%<8ML#4-
M$!J5BV*3FUC+T0[^LDPO[>WTX7A6+ED=P8V @BLWFCDNSY("G]P7&?0U);4;
MM/G,J/30T5J].]+).Q#'#3P_^KZGH/2CL45#3S^^:]DLW&;#/$49PS75J1TM
ME2;6[!;!]ZY\]G^6.<"36+S6H5+X*PTKJ7#S.+KE:8Q<-0$JYJV^5OAAO8Q"
MMF* $XES;P^39W0W6?XTXWC_96M.^6MEEFS;Z]4.B166[TPYN9+->UI/J#2(
M9\'[/!&!_'Y=FU?N!4BK)N8A4Q91TX+[F41&.*K#P"&TG_O9!S33A-S@59O?
M#M+*FX-+GG(UDSCC#D[32L_ZJ"E'NO[*G8E8X;9#<(%XH;7;NV3'+ZLQ[B;Y
M$0=]I7=/H%0.!9ICC>@5P@O@W7N_PF,6A4R*V<A/N1L2)V6I+@$."PMIH$*V
M\?*58)([HAI_+7XKY#LC37H-P>6SK(V%YE2XZS@,HG!P>%0:P66X:.]%4G2-
MSY? S#0?%R&CL'A'O'*BIO;6G);R&E&@CUQ^_G P7=\75"MYE:EN>W^T=D7Z
MSK0PI:G-<IR@0DR'@4\FW.N<?3BKM8;;FZ52&>GPT5.?Y74I<9K MEX]1ZBK
M5(<(3M)<ZBR%.G\Z+N7MG4$O:H(-Z5-ML)^2(ED/WQTN)Q9F9WWF)=9# =?+
MWG$+YO"7X,KRIF'-:L7ZQ?FW%XR;3A>7)J=8'T:I<(<?RR^-;W=@IXQ[Q':H
M;H]6-3$3@@K+A0<]A\J092[7M<Y+JP@C)?%5K]A:M@SW#SH!_O"7 N=LOY2\
M%TKW^MD& AQN;#6!DR<A,Y93J!OE"D.>;S3]-,+.N^0QO:([^8T9KOI=?<46
MOF$,M.VS81B5RSV]AD/W++;@GO$::N<KQ[UG\EL093PYX#VJ2_DRJS+N:50(
MY(E6_Q_%G!Q,<COS(!/ R,(3L+G[TY,\X7P<D>@+0$\YBNNEFQ(]MG=QT.OP
M7EFX[FAI=;3(ROGO#J\C[ <N*S^"E/U=(L<![R*3S<88PI6L+Z'0O6^4QYQL
M\C['8L!4 $E0V'-%UX7E]$6UT"MSAE5TW"K/LB\ !V\S= M$J_7EDXK(G>&G
M*0QOI:28P\ MFEPP5XBSLD+9S?[8%WCU9">)-:.<^O#3VL1TKU/>_5C%>'F6
M;1J[J,N'[]\B_C^7[*(-[74IT_[#H2D:8I/3TT /@J^X55,Z_F)'^Z3A[<YJ
MT#B,R!A+6AWTI3@3Y[.PN#! -#'U4]1;)#6U5M;(8.G\&0A3!GE2DVJ$I0_W
M%[\W(SLV-"8NOE5$[):_]Q3/.Q&N#JA8Q%>Q1EXKCYM"7TUIZS"U.EEXO5^F
MK@S!=.6$FO=E%):7WR#2@3P0@B]JO9DE:,'01]N-(K+MAG=7819O*2@C>A37
M0X(8@6,(,2Z6G"E\8'&\16<6+5VLE_18+UQ\+RBD6?V1JRVN_'%J]Q-%N$M6
MD$.WM4"65TM'=&Q5)QYQN"7;#WC-TD6+0^CA1LN94S9Z3I\LA[VB$@9V0[Q>
M;CF6Q_A[7P#$OR62C:-^ZW%3^]$[QV<=6T$)C,=1D_I)"Q*IR@EW2IP0$0K4
M83>>I,]< %W-/ HM0?0;NIN^:1? 1!F7NRO=>/?;Y\#4;C"1 Z@B#(56SF:;
M7!R>!.:$-%I4;%X% %^*)^UC#EN8=#0E.VK=OXH&_"IS_0 .$E#8:QN<'U]M
MAU)-;Z8$;.<>M/J/4]V]%FN@^]%^+G)=1F'AE(UJ711V\E9AT?.W,2[;^4=^
M!>LH@=R'PJF-6KB[W;F-DVOB5W ]9P6XQL$@WE]V5/# A<K4@;$Y=S4DJ$I]
M^P+@1_[061R-*CR\5V["YA4L>MC_$,9(?I39?G,<G CZ9=>JB7D7O=PRZBP@
M:"XZ_7/XN]KYK?OG)I#< /<@6[KL?"W[YY)*,@BF6"MA<TIDWS>CV'9S!MFT
MWK:)9WW&6C%<C["XF+!@N11,[.MOC<XN;P_+'Z:L$%@=4TN]UB,5I1XD^1W^
M]9SSA^OR&>]@;)3'F?[17+ODR5N)9$2$BTW\T<[C(=#&S%D!J ;#7553FUOL
M)-1>9/IA&\UY0UZ(:>/7P+)AH##VK#/W^,@LG&9D6G7EWO",MX9H;$O=9U 3
MXQK^&1HI<W^>=,;ZL?"CY$$TA"^D84W*JYP.LR$^5MTXVEBL6'"SBC=LR6;I
MQ7:B/,LK+S:JI2C3(+O7W;-[J;IGNWM= <4J#W 108B@LPPT*0R=!AU7E/&S
M>W*V$,/%]AB>CPM",_BK+3CLE+V&OUYRL+60P[)< (R)78%4=5C]F*$+H+#U
ME4MUHQDK _@!)+\@DWS3N*"<?S%]5BGA#F!K*ZMD6"Z,>U:N):*6-U?6DY1F
M)CQT2S$<-,C6$GFP :S(<>!>- O/LQCKO9%SNB[QP\OZ2WFJ#"EZ0$3L&=>/
MJ,Z/B3U<2QD_6[.PRB_!$<VB0=DSKBS3_ S0&9Y/^$TT0DMY3(X-V6@J^%0Y
M>C$H"=M>;D=#<!C^2N9!OF.3?VFG%V/-65E&CE8 \HL""3T/ZE< ?-4%C$OD
MO2XXV=0D2+\>R(4E;(TOW*@].I+RXTOH%GM_^FCNVT=LZ(8#J!;#_W;2._1)
M66(/_(/9TL.YO4Z3)<%ED]@(.79' Z.L=3.FFOJ&E$>_M2<+]ED4NHZLOPD$
M2<WB,M!5"P- OY_%]ST3J:F.^9!L;P9\<>^!PJV,'(DZ6+&,Y#SP>,>$HGLR
M6*KC,RX)P3;Y,X68^?<31^,<MA<WH.J_,',=X0GS$YNN/<SQ:941G!-\T-UR
MU_-!=./<-3A/!RM]Y>A[R[Q8/O!Q.%%%( =.Y=1=#:'RZ E=C56>!BQX^<M2
MUVR1RHU,BGXN->T_/B2.4YB/#'AN3B9^ 6QK4B+F.&VL5$?3GV@1!A%]+SNN
M 7SJNJ'4?0NQ809NQLG49E)3O(*8L-/NO7)V##12;SLKVM _DV! _3@HHA5B
MSHQDW575H7.3Z?-R'J;(2//WL3ZZ $B0(:;2NM';*V$/8J*D&(%3TF^^)^IO
M2.MZVV.MC>0$VT*ZV]]!Q +=?^3=L.AZ5#9-V+WXVR 2I]61P6<?*-OOU7H#
M:Q>/'J!^DWIF-,$Y8MAI#><+%HO%Z\3YGI  .]4:+CB59C9[0GR#1/)BOYNO
MA0TJW7'V/NIPVTI3M%V"7I**9S;R"J?AB_4555]6'.TG;&JGR-H)87*JG3Q"
MYT&TX+&VQ4>_%+3'Z83,G;S.$EA**D-.P/X78SF'W:;98"E=!)9)3='3-5\L
MOJ"'SON;@3D.!$EIA)+X/WBI-^%2(!2C>4KVGK?F JC?\%$^@SAN59]6%,"2
MC]6%>*+DY++%5S-H9$0X:EQHUS#;S57 K/++*QL0]%5O=C>(DS8XWU[V=IGU
ME\FVH]J0U)Q]5F:!"V"WD$$?7V$J"_B8;Q.@8?[2F-V>X*1$G??R/Z1Y]/$G
M@>(K9B18G7XRC7H ^#*@Y7AD_B8=[,**8X23NK_YQ310*U<&GL$K^<=FFYHA
M_8P2OIVQ7OOD%A/]51],0W $#14?K0^U\/JIPCS:*MT4R4:FZ6S];,?E:TUM
M.,,^2Q>4HP>JOB=(@HQUS!9[\2 JF2?7*QV"?1R/;J-,TSE]6D-EM%,WLLTJ
MSZ"B_/;E3$5W#> MT20CN^! =V359^M<S)F8\!RJ:P8/6H12(=\8OM/"S(1V
MMC_TZHVKC[PM"_KN6U? <G>@*X.F/Z\];\W+99GEX0?NU+.WG(#?ZF\#8<N"
MGOD^#5,-C5&-D@27ACH>CJ\RJW.M#B#__ Y-<CF49[X:'[R/E+=-]JU?-B05
M4Y;_+>@Z_V&Y &GMP_A4*_4&@O>>RKJ]T H\;T7($U<X<]&]>!"DP^"#OS9F
MR]?H OAFG-NY_/M1<9'2C2\I5*XKUJ=K/D3!LCJ17S!A!9-Y8;'2X'0Z8=4O
M9V@I2;10$..<[&U0!Q0&H>O)AAG)Q=/-OQMAL._V?'2][</ @LGJRV;M.LHN
MC7/3XA8<%K,7Q(13EXX6EG24LH3=5!A_R+EB7@ZBW1<,]8PXF-J'NS?>Y[3*
M-0ZA<(W2!D^D,XPG[TU8N>\3[*5\PI(BSM^Y?#(N\#O3MXUD]HQX&@8+FF?W
M/+S9/-4N=S=F$K5-W;_<3>+B-2!_7WP"1VH^C%<KU"R?<?3J+S05?.<"6P&.
M/H.^+9[V'\?.2VN#70HWKJ]-*IH,-.!K]/3,F[<"M<$-/+3+@NAR.ESMN4/S
M?6OQ46&YGEMJK^B^J^A!QK[+JN;AK;"R7[$2:0OON24PKSNG*PO;J31N Z=
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M,S]JF(\MWR]W-0]=$23@'\]G^U!D>CMY]?E ,F1&X8 E8+,>%SW/&W1C_?,
MLX.XIFS'44+\V(N?[5NN!M5!M.N3,U%Q<]^3O2.;!/@%##F[9DX.65]Y9D*2
M6E'E2%"'976$C<0(])UX-I5UDA:A^BE*?PY2\QZ1UX+I_P&W24#45]=_3^EL
M*O8MV/*+W+;'1-=%M-Z:F)"W3A\?.D=Y<SDQZ-'@B^-G4@^(FC*HU@V,['(O
MC\\4$=?]"D;Y9SZ?UCV/*5(Y#N=B!+[A^.72;'.GUT5%;S6M^-3%]RK;L- F
MC@FOFQ5_->/M\K?/,U99Z,26OYH)F>QRMA1FEFWR9MNQ#],=;H)0X!5"5K6J
MM*B^3"I_$E/O4(>Z<W"R%Q^LE@*N%\ -9V<\6SGL_$YE+=57U\K)[7#69P9D
MT?CN1;.:G(WDQI])+D'6[ FDKRA>L1GEH_FI^CH#F1J'=Q_T(;P9M'O=7TZ\
M.!P07P@D0QWNALMQMF!F-FJ^5"&&C:C/6P5_;]+7LZCX B=2S9+HG009'[3$
M($WPD6O65(;:D@SU%E!N/5RCH0E_%'8!/'ZKZ2*RH\SV_?34(%D.T2II=JU1
M=KGZ3<;.V[M0(P##<FO$8-#?@"?,F3_C5,WN>B?#^2T>(-;Y<'N6!Z='E+;
MA'Q-/2VRT_ ^*CDN1FOD<UE?MQF91K3+8VQ8H@/WN-@["FT*9TX6@\UUX^NX
ME\I8UM<+@I8ZFV&1]L38ND^Z@Y' ;VN5%I08"Q+G<:W\($W[+-WXRL0TQ&-
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M""G-K 655+B$:*7"R/ZZV3/,7/=D1ECS-H^I&NOD-ZU;.W3+6P/VYD_ET@I
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M:\U'2DW4W3??VK2:T_<Q#%K,T0:7_./W#@W 6(E'Y>&("R!,\YEI>-GW)?]
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M+ 9SH=;VZ4$2_WK77_G]6)&#CK@%.TK5PF4\,[*F6]]\CA0+Z=]!]W7J&B!
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M80LK?RCC;;#8='<K"H_C.-@^TE5(I^ND:#C5/N>O!W"P5M52T,HHJ#$2W#9
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M@_0GLWDUQ?>/:Q:;*0#[H;03L9WAR@&N(9FQU-(Q_=><J8IY5 0 &VBPGO
MT;WYF36P7HR &#^/L,:DWX?8"6AWNA5YC%WG@((N20E1*5WA5T&2'.P5<4SB
MEZ[8I:^!"-V4VV5B&A2W, (Y_PO_=]&5S!9 _"9 X5T_#K3 %K]_N##72 *?
MWB 6G,90?]:58!1A$;[\F+-0 %]$!+M<4^>-2CSA3[O3'A#9A-DS\L9/=:OX
MW(D%4@1?WKB$8J/SPG[UH&53\4Z":XLR R0NG4#)[/S;9Q9]\OFUG5K8Q1;7
MP$[:!=7ZB1O^.QGY./9-<K.)!UZ>[7> *:J.&5/+UA\.",D<F(4N;,AZM&8?
M4-=$H/CDDQ&WP^2"'7AK=A[=.K3(RF98."W:0)]<L6$FZWMH;;JW!;OS$WU\
M9%M7F"[4OFTE;(H+!6L;.)::JRFIET4Q/%+W:G_[,(>+:$."%GY5Y'(-B#6]
M@<!+(!O56Q\V4_&M"W52.8[RV;8'O&ZS393@WC8AP.UFO'5?6[4Q8L%Y3&8,
M+I$C[\P<:VC2*O>T6='#!F^Y^GA&COTAI&(K*!B[MK5SQDNL2_D:F$R]-8Z6
MR9O1N1VV K+RW,Q76&[0D#2MQ\W(,U:\_;((UG4#8AN8\/+)Z\4&I%]L6%;E
M]%7L6ABKH 93-Z5X)L$PWT_:)Q,!X%T7<,2+,+-KX$N!^C604H*V5Q,SO@V'
MYW[M,O.6G2FK!MPF4HJ 3[!6E8(-.HN-JY'7HAKY52_F<8PO6U[\4&-==@O<
M=>?QX"PSCC3L5,N]M9C2&\K^=O13.Q^T[U[4:VD:HYY(#X6222_A!=0;>/CY
MQ370)45W$&M!=W1R#80%=67\N;M:@2TF?BJGE^WODL3LN%:C/^SG=7)I\-<J
MW5]+XXF%[/"Z.I'-?[V;W^W$#C2'+1[S8TUO74R@3]D.%>*L#50A\'T^WZ?@
MTI6$GM&FU8>T8CM>R+#B@>7XNBJM*BK<T(Q#1A-IN\_T'P67/,Q $TUP:\A&
MR9;,'VX^O6(7QUNIJPIRED=E2S(\%9,D8\;F@IG/7P-#>J,)=1WCP74B?@Z#
MO%_N:X>'L?*8G9;U,$I9VKJ1JLGG4 8D2XIY+YK ^0?XWHPQ?[</2 NHH?WX
MXGREC)$?J_:_@$$(_]!KP-?++0&H1 R,UF5HTSNN/FYF/<BY!BQT-KXWO3FT
M<*JD?:CC>BD?_*'^N9%NCT!G3]%,?VM^F*NKK6Y<DX/M<,C1+T4<RZ' $_6]
MS ]UK04VSX("4!6J2B#=)W&;E&P#IKJPKN-I#++X1>=DE\J$PW>'K-#UZMI?
MP>PKO2%8E>%O3P9 8F ,<9$AQK,).2*#9M;L0E_!5M++XA]20+L!P^3QIK]\
M7PC(UC531U<J<0<+J"GV.!<2O4A[7<S8_D4NS^S4R<IP;(\%)AB'H/8^S!/_
MGN/LL!QV^;XB7/YKZVL:]PX?G>YI:@]"P''AWVZ'+#V9N 8V=JX!&K)PB0?T
MKL,X73?L2Z^!^$8%RW3OY2*]/V72?6];A+4\M!M[*1--.%S6_7(-UY5\;FQ_
MRE,XQ'Z(]AAK-KO(];U"XCBV<];-&9W%^F9T3+GS866=>?\PZ$C,26=Z14.@
M!C,^ GW^'H$=28(O[1P;;+_T#;; CWM2LJLU=+Y[H?2/*)"W]OJVBQ(O4;6A
M%*!E^7&+I\Y!^WA68@"_4.=I[V"A6*E%.,K;P,)A,4G)+4!EM0KNY#=T\#RW
MR)*\=4I^-"VH][;/<RF[?.&D!C.0]:7J$<85$^.O5J\H)T]Z-W,E*._]K%:;
MD]7D&4]A1 UB<XX0T*,:Z'M&OD9Y<FX#99[85Z4P3HS(#!,K^'K $FMH>54@
M2MX=+9,WVQH%BKH'N2-64)B($<N\.=?7P!.@[^:@Y*@!1'!'S&:F'OEVH9;Q
M=IFR#Z <7F1'^Z0F>:KU3$E+I'.!H7MK0K'F;MMFK8!TKPCA\P[RN+@$>]QX
M\KUAG0[Q]4@UJ(A_H^L&'"2R_]^?SU0W3 Q6,89CPE!G5#>?RS9.A7JLZ2_O
M[5=Y;A;CO.:$*U#I:5G<B7II;4JBV<:X]/K3OL$0J^"#79W;A38=4&K'=DH5
MS[?4/FP@IQNP_>58N6L 3[K8F4+'U3V]K "_8[3>E9]]O5)1P87@N5+>FH')
M>>UOP4Z/35"E KEYE%&7:Y&OKU<.3O$6+>/X'CQ1W:1F[F$-P5.A$J'1N-&^
M#A+UEFQ),\VI@2!GEEGFD*<@FY.S?9TX[VN \7:8\'G3J)>8L&QZL'4B \N*
M=ZU73\:0_RZMS+=DJSF,[M)/*]L?KJ8--C!2?GC#L)51=7E%W<^P046FFII#
MQ#0/I@SL"$Y;B9RLJF?/0;PCI:4/DMV(NP84JJ5<4,:A:O2&94Q1'@/TPI]&
M(K4WPO8<=KAO;:N)$U>3;(]T?;OG96?'*['GN(%=X4F^@,I1.A#E0RW/MN55
M%@+V=P8H+PN;[86&Z-X .XB]6S5RC@D"WUL>/S"H]=J6V#;71B8<[),X^RF$
M[+NK4%.,7@/Z"QV6UDR*?"\LAV/KSNN(&J<AQ_UJ4-J<O)U&_HDT^)3:N_)1
MVEFI.^GW;<KI[0;5/<:2,L!%@.,91=6IXY"M$[_-2\J^'L;;*A?1H]DWZ8<^
M7!/9<!$6OZ07\'S4O'S^H<<+^["',=)2(@ST*[3^E%N[6E1-02>A$*UQM A-
M,Y7?[D#>*!.;N#KS\LNPRV="D/<2M(D)/LNGB$&0P"RRC5(_:]4FE=@&1\%]
MZEO/\M4K5)\\9G"<VZKR<D#G>)J@[%4I ;NQ,IV0\1,A48?"RP<"--S-5&NS
M"9GQ_75',P%[AM(JUX"<"BOEV87K1R^QN)"@PP'#=M>12J1\-;0P^/[29?0M
M81>IQVP?I$4.>>7VZ VS<9Z(F>HA&>G(S)\EY%7X2GY]^,V2@&VF[V5#;,^#
MKO>=;*")(RE)"PB"\U$BY1&C6E>VM+GKGP5_U[@[3\;VF>SGW*WA607*ULK@
M9.&5+<W\GQ(@+V$"6X4,QDDO'GCWO"S#KY!?@S9\&IQ0OL>JWC=)VW)'1SNZ
M@URTZ\/0VX3PW;B%(P3D<MM+2,M#$*'5=;LH0XK4 GY?V>N)0H4V;.@!9#]A
MJW':\B8)9* W+XVKT:?A1]G@IY.?A6,M7"B?ME#NJ"2^"CQ&_0Y+P832SD5^
M.E>&=C=?'.GXSW V;53"DN@^55T#R2,WM?$'K/ZKA)4?;2RN*7'A_]/-4^^*
MO!].FTA5=Z"![/+DS=Z*W #/C&95C#:VF,=-JIK@DNQU!GKOZYC^M?_9!)WE
MOQELU'6$KLQCQU4\10CAOC/4<[:$L\6)7#W>(Y/_("H3GI/E^G,[[OXSII]^
M"AF"V3<I:ZOIZ!)\=<H&ZN<\E@N6L_>9D8]CBS!X_U&0C/74\@Q]/G0-N%,=
M#^UZB&!@^M= 8P?K:6/B-0 IA2U\]*8U0:CL/%8M_Q[[%9<GB@C^H?P@'SHJ
MRQP6-BQR\*;]LV[)5<D-EZ'?=&>_,B[UWMW4![\@^V42M-"K1-@U(/[Y1FB<
M\-\SU\#Y40H&); %0UQ8HS$MUX!'$ 1^O'!^Y8NY),5:*TA]$W>HE?V=_JO2
MV\ UZF>NZUGO6 [9X@1_FWR0PI((6<0:;7C^[_UE3AN3_B&BE]"[9Z-;]JBV
MEB>1R7<2W%U?=-&TV_[:E?O*R?O[&E!_W<*ZH_/1G#RL5BZ@^X10_B\G8"Y2
M3=EQDB>'96XW%,B0&IHS9&.'OXG^/7:CR]^==F./W']1W%7=>/O<<<C:P<SD
MJZ1_Z-@3F0:U,7>(=>:KD:T$I^G80;V/'BO[.O'_$UQ@G'MN3#UR:A%^OL)Z
M=:3S_#_78>RQVA26:)YM7^Y64_';:5L1KE/61<Y>3J9,F](=MBI<KM=95VG!
MAFY*POU\\7^+!QK@.MZ9K(\IREPE%[LW:3SU9:6Q3BNQ@;*/%_;PA9TG?(=5
M=2PVP*);DL9N.?IO/@KGHS(^Z+J@GO_U4NXJT6-^$':Y.)7U-\A@IL9@&Z=$
ME[\5P?%S9LJZ,Y44KH9#)!ZKSF&$,H9+%=D9S%_CF6L,XV;NGS=F-RC?[-WI
M.8,#62"%_1MV Y *ZYN,],?F(W_#1 /W?WCSGX#S$JW&W-^Z'5A.I77U[22\
M5U!T(Z4SA\IX>X6<S[NY*\Z&_2;25O'_B1O,G1L$[?]U!6P85M4<3IWQFH)0
MYECIKZJ(-3B_<AK/&@7W+573?MY)V&F<^>2J0'=U(G?:9WV^>W,A,:C#D1TF
M\'IW[KTTV8L#R!VG:2O(1DC*V8#]PC\]XE$^@W&3.1\&<W[.$9BKK#I[5L3!
MFZ?!:+P4<YK#F;F91@Y6H08H $.X_37PGT0W"%<$\_W3V3+3IOL$_\W6?ZYZ
M;)WM$?.:L[#_A2R5!C;K[5^'T#'$[$,7P.>%XP_WQHGQJW^(86TIP31$"<J;
MDZ#51!CO9##^ZN]N]BEZ0(^)E1YJY=DZP['@?) 6_]"I4(;>"71<HODO#[Z_
M*OO',3U09/S?=<D-9>N*\N/3*YIB L,[FHQ=5:[+A5V9\R^INLA""JBX)E1"
MO(!-H.3=W]B5_(L=WQ_L+C7^##-&=6+]!Y5\T,,>DN))U8"(MF$?]K&F?\4!
MV"?HG[!!D^(>NG'?*4YDE#7(%+V[0M!WOX=N;BC+<K/.8]5U-[''@I<MQOC[
M73#9_+_A^GAD.X[D=5F7$[X(]1/_!RS>,2<*A%"J6>10_A92N^\>HHA^%?MS
M> [<7.9.>YJA8GXJ -R$E<P,?B\^:2D#5$5[G.Z]@X'UG_DN7Q$C(-[.G]\#
M!17!;U>#\A:MJ;8P8@>]%L)*<J32TH$9WPQBXW.[+X* <?^78ZFC1F,,E:$<
M)G>9?*U[6WHX(_?4)QZ[4RR=[W-:98TN0BT9U9?L&LC$-\] \_6'"C0[^,O!
MEUKO]&4]R!M.'UJ2(HJG]<^?/T-CX]Z>$6GRSW)0@Q';7^I\M#"ICIC6FN>,
M.4O_@,7,+(UM:HOUXS&]C>QQ*N$TFCE=P0%F^RR)I"<W->SW[C6@C2,<WDS4
M6CB0#IT2;JC*$\CDU44P,I'$/LQ0O6RF<U?C<4$R/&1//+R0VE&'QON,GEZ]
M^?TEJ49?N/1AI^W8?&%3N$&PZL3NZMB>ZI 4@?5^'W<\.>,1#EBU6[!YJP,P
MZUH<(I(IA$&SXZVJLZU%WU*L$W^.H_5/Z>*_!E"O*AD%5INFA_>:(HUKSYTC
MQWTHP[6]++#'EAV^(.?@5S&G)O,=\%L*/,R\K0V>6R):L8L7)WE9R&M@VEW,
M,D]GB[?S+![O=B'$+#3.Q"!67%]$8A$#T00FZPX<?6$%A&]VWE7'_;[W-J3)
MS?J%S N9C^:KB+N)-O%;8IE6=5%^/V_!BK$<O6!W6A+;D0B+TL;LJ6?WBR,Y
M?T_VWX]Z&I(:U1;5)JJ_Z .-\Q2CH+!IRS4[<[6IKW)+?!8;<Y5VW^E^R[D6
M% R>]Q)A&S&4>D6I K#1>.5,42SMTW44FU/9$T.?Q_&8E_)/\@VJD5AB!32O
M.0MM%#GZ9OUY__AS,B-2_V#=J&:,VXJ3,;R_IM;[0R;[#Z-5']B=ZAP+7Z5)
M[D^+51$OS<JB;61Z?Z^(R-100@**#9>?I7PNU+H*(F15KDWL&R@\G<(R(-Z@
M?YWU5:)Y&W?]IYCXX^4R/ZO3Q'!.]Q7*UHI%*T9D*L$5[,H(\E)]5+CC8<\C
M1$!6H)A749+;U2?(2VU8L*7U?KV(V-<H'K$M+<=H #<RO']C"B2JC*U'Y.PS
MU%YGJ ?=8:"/:.][LFLCPQAN(TG;">?1;O(_ME1^A11;K'$N_F3-&?DEHI5!
M?2U\#;^:-=_IM#C;&R]H([%#OFYS5-HW[\%IO"JM[JC7+G?2=.?KY;HG'1;L
M&2O=)55TY<4_#K[SH:7&O<-;O9[92C\V2R5H4-/TE8O"O46B,S='LCHC@>4$
MRMOP N?E'>],-5:;)G0N=TQ4?2L&;KGY$#&4G>RP_W*7,BW2U)3U(-:2A=K>
MXB*74FTY(A$U,J3)UP//;)-/.C59:=4L1^UX9#I%NT1ENDFT" EN5/,#%OH>
M-; :2-+GJ8MV1Z?W""EK@;79X :#+P1^U%:?#L!'Q<%:UT#X$F:Q6.0#O!8^
ME3G^$9YPB%@?U^J/&[T=)TKMPQ=&)$\(?-*8]<B?,W:#6B:R\KS%6>L:@ZLO
ME[OSW=YM#%%^?^3[/2E#(W-^YP&$S7 ($FJAB$V<7SC8HB+)E-RLJI)=SVT4
M6E0Y,U496Y4UV?'+ _EC9;YD?B;Q)WZPQPS!2+G5<7>QYD-+-<=8RU.1/I??
MWQD3/OQP(7[5((^UP5C%]N"7K=3C;=O1*.\'PH-5=4]5H^7K:@(#E)D>O2:0
M!UH$TBQY:JHTC*N='U1\RVQA/%S.=0X;=9M[S%#U8H^+T1T4!E+-6TTI NQ=
MU>FF1S "B06H;YL77YX592QHN^PQ?GWMWE",&A32EX)NZ1T2!B/S-4]"!R;3
MTF4M'QA5-1"_^1Q:4!DRC)/)9?)5B(HE,,GN/;)6+$P0G?]6:7$]",C(WXZK
M$XNLJ^=0LWD52O&Y=R,]=\]<C$\YX4(M;.5-P]BT&OMI:):V&YF81WY)D/UE
M7Y\6>^@SYH05A9]:D58#E6^!%NWCH2RE8<9Q(Z38[LK,36O@7DHTNZ#0Q+L1
ME<$*(L4:_QBB-#+JQ</E_CK2G$13?6LJP5<S@HMV6NT^R4P4K^TOU=$E+]'C
M?6UXR6F*_TFH/%ME<.B+^8N-W7L*H%S\&KN2FE7#<36E6GKR6[2\?!>*8$ZW
M\*H!#+)0KLCV8U/<X&CK-D:=9\,%2R)8=(4U[Y2LVNT:H*N U5L$-Y0U5GBH
MSHO(_0RPSGI.?C3=?S_#C@=>"WYP,0Q6(SDO8_QM=A;RV_:KWD<Q*%I%ATLD
MH#+Q];XZO+4]7:F+J4JHI^ #EN[A(:%XK]S/BG*V*5MZH^1FK-EQ<JJ0^.(^
MEB0'$X @7%!;$/*RY52 (J#0=-Q>XU'E'5,UV??JBT*J@PN?EC/'3AXF;EA7
M0N/))25Z8N/7K1;UC]&Y#](ZP)1;"6RITDSBC%#XUS%8.7>4,=:/I&\?1'%V
MQH)F0)$GA;E%K'J4.O.\]ZV9?]@6;.P__6A[,5FZ+5Z)-=$)L<\IZ87$ZB-0
M><4.7:-??7.[;(D+>K7Z9JB>V4P3C@5M,EX#'YKV@CHJ2^L4J,W51J6"H9\6
MPX1XQ4UT9FIV)[V>(:7!KIIL(,9V\4?E!Q,QSX6#NGOX"X@+)<AIBXYIWIF'
M%F*!Z;U>NH9-].Y<W,U;)KH?23V"4&\Q.N"(:EO'T]1KE.AN ;!27"<.*IT.
M4.:C,ZKAQG-UYW=AC11>;;2I=X#)#A"8;C"NXN3(E1]__W>F:8-SB T@@1@X
MW!LJ%4*S83?Z+8O0W8,OEFN03@^L-GU+M5IY%#\A+RB0\_0:D(F_:D,71 [7
M"Q4XN[4[RIL$[0UJ$97+&WR16OLV^#X<PB-DD+"S<1,&7""SD%XO(3RC,$JC
M.!,\:C.-7\FD=[,K*G<M+M^\/H5.1<ST9BW71$JHT;U=<T7NJ JX\>5M5L>Q
M8;2TM>HEK_!NP33S,A;T9*G)G5S?5A412#)_SU2FE0"M=7&FI'8 %IZD]:XW
MN<%X;D?6.E<@-"NVXZK_-:V*]P<7B4,020OK:,E,-VMUF![GROS/^EJ<!QX!
M)\5VAZ-[?4H3X=-<>T4.CXF-HP8MH]JW4\E$0Q[3TQ(5?3*SU6E)G7Z91VZ1
MZ:?ZL<N6<UNA"#"S59R;DS0V%9@8.[=I]5NUEA >7]#L1Y(G/2M8FIEAMRL0
MS;UC=9D5ZPMXA/%(W!V#RS3%?THPGDN/F8]Z6P"?$K47]2"T%R:'+-&770/%
M3:.UNR+*/QLCBB9C;3^2V0WP!TGO\>9CK3H(%?M*;NB5T1U/72CRE4S4J_,O
MW.M*1VRIU?F-:>''D2\]#:S)EE^GZ= 9<TC9I;%0*@N;?!6N8!8Q^WPN<MJ)
MC&[/I_9BBGWEZO$)_G>J-LFFF@G$4$_Y>)'I_8!$VR>4>[=N?WK^,F'7'F7J
MTSG'-:V[]O$]7VJS4U<_C&2 GD1IC-/!4MR"4!HADB@[9131G1;KGT:;M,WY
M\-58O5A6=DKZ=(>I!?F;#N)%HQ.T^?$8T_W*J+K.('P^GF; @6G,<B_U9[7&
M+DN8L[:Q4: O.]%'-E!0+<IC UI7:+O X12O.70*SYJ*C;9D[?';Z3['W4WJ
M3 ]?.HY+9JQKJ/(0V.7F]IQFF/T5R"+#1'[G?%.!D7Z%E2SC\XK/1>A<MG_:
MP@Z=/NS)MH5=0&0CKR*Y0:V_C3#M21UBSJ\AJ_+"K]^1#@KJTZI6_Q8].$LR
MA? 2O2#"L7"=& HLM"KQ[$I?V&&1U7?[U,-A\%$H]*BU:BZ'_GB%;.RY3WI-
M%?)=T>\!)MI'T9^?<!&\,5!'IJ#N6J3^G.2?@V @^[N6SN"SL2<VK@[BX]4)
M52DYK5$+"UJ:7:RS+NL?"(^9CB2HX_P7=^7>5-6&#XVJJL(O1?E:LK\PG4+%
MK1-SZ/55M/0 /819]6G9[%8QPJ\[0<NTG&6"E&LN/[&<[ZPB&3XSNWWA\>.%
M5M^.&:/Q/*U&K*2N4(^8$/7E"'F!@=C&]*.&JJ@-_>@>V9C&L6[+VD&Q35 (
M'&6>9V%IX9([8'O'[ @:Q:,M@J>C92/FLP(X-N<@G%E5X@Y']>Y9/':Y2H0R
MP^-CK=<.MTI[6&1G9SR>"HFJ&9 7Y<SJ]1C?/JFL?A]2C\<;KY#O&ZF.84"J
MG9)GY$"'H4Z:L?/I3$\[K+IK<'FG.60,)<@X1"DGE9U5_-;W?^/2$HLVG<RD
M3R?7NTYI9]YO*8PLUFK):G$HB!E=_:8OZ2#,CM,U-VBC,%I>J?>@*V]+TS%-
M(+6J^F=5W+(L4XVVQ+V5"'EY#QEL+^'^$>W=E.#C*\T^^8:1(#TMW;>,7!7T
M3WWP>FYM"-+9?];,*X26SW$6.IV6V#1'WNG/ZJ:1G]TH2\6/@4O"!SBM&SL1
ML>ES5OBK#Z8\%22KA0;T4N]0A25;)^%&F\R>YL-^T1TO7 /4175L())+$.:F
M]5J)@>G3G>]!]H-FTKUX(*5$Z#.ZLPZZ_U@(W+18MC=MU?LK+]A&S370R&X5
M!+1CFC?$81@AF5-PX4U9OF8Y(D&==>:K>PCCV_5V[A1MPC2H7@-?[E_J70.K
M$$R#8\Q[&\$AE"0=YJ81/*2[!G3#41(S_YK\%&;["0JY(2!LN@F:U\"C:^!D
M"[)TR]WPIN,X)[H&2G2R2'6\.V&M. M'?RR(N 8NCO]C=C(](O6+VA1-'W[3
M4?Z#2 9-;_J?/)(K#WJJX.JAS98-IQ\6_I?TA!S-PA9(FWZ!,3?9>R46+@5\
M_*?1_FFP&^TI_URP@L&2.<6Z:;U7,*BB?#906&+S+L<0ZXR-^@;MC25TOU\#
MN ]O^& @NRE_B/2&K>8/D2W_0^2_S722_JO6_LUA+I<PS,MK8&<**D6A;YMR
MX%V-_N/G/PQ-]_>)H_U[1S#%#<^;A'O3&?]),_*'""%TU?_RBR,.U>8M-AP;
M&YZSQ[!2R%831DC+7A&']9]Z9/S+,JISI%B!5][7P$W_CNR%_+=K_X)5;/6?
M5H*-P=!VB:S^P>V;K""[R*0D=L<@8/D:6 +!SF_L?@V,_2FQ#^3?$O^%D[]!
MX[_B))CV3_)KH!MVY:KW_P:CS?^<[E2D!Y<*5BP^_P3+^8NE^AB:ZE0SA@+V
M:6'MZ<<LGI3)NEZV&KR0DZST(&"CWGHI'/56]$&NF9P#<\K,/>X?OLRO]>=$
M?*OI0DW1SPY>.H-;RC:+W,_VRBL'V+F&\1W?_R)2*'+D5P1':+?DH6!O)BOQ
M?CLL,27X=9PFP3+R& P><Y%-RW\HX &+WKNM.LEO:0G7>7;6SJ/WCAIQB[R<
M7]A5EU?;SD15.>EGH'*-;:?(G=.@-\ 1/@1'ACO X-U+^03,Z$PK4K--[%CR
M6^-IMYCT54WW6>'<L]9]66NB>>>4%XWCNQ1M(].%LE:F%A9>"X)&HJ%]E5;7
M@"FXR(V,%&LU >Q;C%E8PH4/,/6092=YZC#K['S2?666P5J+^R8\+=O9NE5-
MV"1I,4]_E*FJ/NAP8S?J4ULZ:0S7T=5"[8UY*W0;$BR>@34!Y- M9[M#&L/7
M_NKA'_S?CQ4SQTE3N7+(=WG*R0LY?#H>=%7=;[<46T>:?MTW*9^PXK",6Y6_
M4(?QX#/LKN$*,JFE<IX4<+RMOA?[;3?PBR\QK3-M Y'"F^]:_%AK"5GYSP-^
M"[ O$)F[9D=S14Q6E?99KO<1S.L/?2NTRXKQ6-E2=-9K<XUY[_P&?X!7?71!
MNM''/I*WK*)N5_IBY;A$>T"*?Z0%OX_O2YA 'Q\U(&8&ZN4G9%EUMF@YC=B,
M5W6B,LE-1PDT#KX0Y$X.J0]/2(0N">W:)SW9%GNT,D[1/F#+T2KZNO1[(D=7
M\5S.88EZ54W0WKQ(L OYZRP)9-V/K^ TV@G&SYVP.\#!-7"G4LDY_%W#)"<Z
M46J2R[/-A2;5NO+MWG;^F%4/C7^O$.C'G;,G&T7U#U*GS>5R-;<B9.R+==3O
MDH4K@244BJP+0/->-/\[7[7Z_W& L9#6'Y!AT4O.Q:(@LRF*(IL"GK!'[)G.
MK(\4=&W8TP[&+^!3OAPF2&I\RWQ9<ZIUYD7&^]W-6UJ9!$?GRAIDWN ,&S-0
MAR?%\T2!B"GYF9]:X.B7-[#)YR&WYNDJK+V<#PYQ$"A9*KF'BE1KK4LN* C>
MA/_*U. DG[[/R/Y0.);>:JC/=TAH\<Y^=)LPO^KITZZ<%Y'0?MWQVUU1\G8?
M3K?-7]=#LK2Z#*G)%=.ATY?T^)@<>M_PY@3@:("O'7$-_!(56'YPXE 7KEM_
M3RZ;4MGHS67I/>^?=H8_HH?7<\KJ)TZ&<+:I=D]KJ![F6@U#/U*VOKI7E^][
M5DV8^B/9@[VT_,#:WW[7 *[%^60>?_*C^X0V&6L>*)6U47B$PL==!"?'%D8>
MC3VGP\XQB/6PS6-/F."F:^,\*- 8%R@2L9Q=,'XG/HEO-/8L=+M1G<'$ZO(<
M@=4,FOQ>N.,Z-W$6Q%(Q.?4VN"TW6:<IYLM;1Y?$S+GHRJMYGN$I:XO4K2JU
M,AW-Z2ZR]F>M$TSOCW!E7@W9/!6/55,^@/F?)$EQG[Q[@I^8VXPM3>?\N/N6
MO;X8(6!7YMSW/IG3T<543J]B,V[JH+T7',T4T'ZRS0O6>U.2%JJ@B(K,TNTK
MG,U-;#N8[;,JR^YBCK?9:F;:$//H<'0M\3TF=#QD+U*3JZY+9OI5Q&"Z=LPH
M&FXXFA7?1L4_Y4C!^^N%Z5@,9T&(+W%8&TT-M2).\QH4B@,F-7(- C3_\4S3
M_\DAQ$V'EAAMI-FTW19N_]Q;\?91$"4IN4F+&(J:8#(Y:5F+4ZOUO;-/?VU%
MPLPN?HU!U8K8$QVGM@2%P,IKH'2GSOUY54L;[OI;+QG;K?G"KAS-MFQ"\8?.
M*Y7JZ"P_M3L4E)ULH/"#&J1TM4$.*NQ(1\Z9^\5L$H=&6BB]U8O]P=T9VR/3
M$O.$H66RAOY3>83*;V'=-'M+CA/6QVM]+*_U8IZM$4@"*\EB4'YN/%2P9-",
MK*^NCP[.1%4':9Q&S7W'@)XF*T!PKEJ03$L>!<N=*?Z>/6^.'$J#/G^Q/GH;
MSLY']K$[[++TQ0_[]S]!_%A/4;'@4_&"@F>!N5Q)V:(1/38O/"]>1?<92\U%
M[T1W6<$Y%\(10[^K#LW4+'*UI8^"'[/Z/6!0PCG].",I=%D[I/>&Z8 C?%%K
M_V[1'M7>MD8[1NT.K=*E;8H\&Q+B8S0)W]$Q[[H4*DZOMC#U5RZ[?*7TZ)'_
M@]NO&7-%5X<!\4<(W;:;Y-D*R=;=/J.H6M^\,2[!>W9+YN"GP-ZYC7"*.7\3
MN7G\-7"/NU*#7]:@S ?Q0'4I"<1RT+7QL*$4V)0\R1Y8G%-%8+J4AQT>LK.C
M/H7&;$]"-@\?Z4^K3WB_H+0=<N4^)G1Z-U$"GV-99I^VXE_SL9#QM1AX@O.K
M>\9+4<X.EQ]+LEY6E'.YA,1E5"PKF8/_TJ/+L+O)>7?O;0@%Y/?X!47(7F4*
MGGF4<Z]*HO((ZV$Q8OYIMD<SO_$'U[V9$\T8M+C6$-ZF)AEZ&EX1:\6=WC(P
M_J,"NSE,M"VE-7\>_;@">D(VRD4G#Q_G5!)BN/TC<,5FI!>?9"Q")@N0 H<5
M6Z(U"A1*IA>@SYY1O9@52^J</ ^^6D.\9JUZ,AFX;*F@AHJ*4U.E0*C4C+Z]
M!HSKGKPLBW0L?:) 3XPKQO=^X.!,>9)I?!W)4D%]9$Z.W>\1-];WVF;&%Y =
M$OTQ&>>W9&DUU8%?O'-1U/![Y^.G278WO<? [$,G)3O;(6N)/[[\^?_!-[/^
M+QN@Z^G_ 5!+ P04    " "=AEQ01Z Q7:)#  "V;@  %    '-G;6\M,C Q
M.3$R,S%?9S(N:G!G[+L'6%1+MC^ZR4A4R1D%D2 YQP:5)"(Y)\DT44*3L0$5
M) L("$C.DD229,DBDJ-DFIQS;KK_[9DS,\<SX[DS<^]][WWO?Y;61U5U5:U0
M:U7]:N_:R''D''#U@9RB'("&A@8\1OT#D/-78;*>8"L 4%8&V $ P 4PT<0!
M]%]R .Z#8#" B<JCH?+J;U.^_P6NHOY_6:<%<%!U!*BR%"H!M.M_Z?$G_4E_
MTI_T)_U)?]+_G:1C8>EJQ\</ %BO,'Y!$J0HQ)#^"O-O^8J8Z%_R&#R\ ! 3
M\_?\WU$%[NOO(_V)*OZD/^E/^I/^I#_I_V[BX^$5%>,1$N/E9>05%N,5$1/@
M^Z=U*/P!6 "6@"M@!_ !*!0"(.?QJ6W<W)Z(<7,[NG*96CB967*9.SEP>YH^
MX>;EXN$&)$">3TS-[2S=&,TLK<&.DK=WZIIN,X(M)&_K""KS*#^Y9VD#5O!V
ML=3P?J1I[FUG+FIQ&R1%B"?A*>;I\,3!TLV4T=/!WM%5S%/RYB^CBZ'RWZNY
M;TI)N%A8B:G?E_NU!:HD>?-763P\/+@\^+F<7*RY>45%1;EY^+CY^#A1+3A=
MO1S=3#TY'5V9?AW@OJ6KN0OXB1O8R9'Q>]G4S GB)GD3 @%;B%F96@F:65@(
M<IJ9\EMP\O):F'*:6O#S<EKP\UL("_**\%GQFMW\E;V%^=^X/X&XV/_"V\*<
MV]+>TL'2T<T590U>[IO<_[,\42;Z&]-_:GZ4CJ@V8O=<+$W=+.^CDM3W:>7D
M$4(-K/G7:>7BX>61X/Y=.PGNWPGZ_X*UI"0LS,7,O\ODY/(7]AJ6SO^]V;8'
M2_T*H?^B(*K\EPQJ9)3;7;ER18+[MTS_T0K<OWH=*O<W'T7U9/Q_@/YD\B>3
M/YG\R>1/)G\R^9/)_[>8_!WG6CJBP*T'"L4B)X%[  X6%C86)@XV%C8N#@XN
MWC5\%,; (R.^2G"-DHR:BI*,DH*&_O8-&KI;=!24-[ENWF)EX[C#0<W(S<_-
MSG>;G8/]^R!H.+BX>%?P2/'Q2=EI*6G9_VU"?@*NX:(]1;?"0+L)H%]#P[B&
MAFP#&   #0OM%_KK00 -'0,3"QL']PH>/JI!Y54 '0T# QT3 PL+$Q/UJQ_J
M=P#S&M;U&[PRV"1JIC@WG4GY J(S<)GNEC63J0_L,O.;N01>P2.GH*2BOL5R
MFY6-74!02%A$5.S>?5DY>07%!QJ:6MHZNGKZYA:65M8V8%M7-XB[AZ>7][/G
M+X*"7X:$QL2^CHM/>).8E)F5G9.;EU_P[D-Y1655]<>:VI;6MO:.SL]=7P:'
MAD=&Q\:_3<S#%A:7EE=6U];W]@\.CXY/3L_.O^N%!F"@_97^J5[74'JA8V)B
M8.)\UPL-W>-[@VN86#=XL:_+J.&8.I/<Y O );T;G5'6?(6)7WV7S,QE (^<
M66#^UMYWU7[1[%]3+/ _TNQOBOU=KPF   ,--7D8UP 0<"X7RIJ._J^F+*^%
M4)88'=T%525^6@#',"GFXRS9]LC1-*AU,:XBFGI]DZWS3:@TKE\(DU2+_QT&
MAO$^)D*&AR."GL-S?=;H+T..O:CN^<D(0%L<0)=X^DC@\L !"72^VY>+EBOK
M>/?RF>V[<$"2]Q$2 *V$ GU(X/D$])RT$@E<+$\B@2@U)'"E @D<LMDA@9.>
M:B1 7TQ\@/#,@B.!5+:7_U9S5@P0@@2,!%;5QY# 3K(30E(>SC*$!/IS2I'
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M4E_HKJ[ORF3=E+<BMK0&%L\?JY_6;<8WLNX^J1F@-0CS\@#GUX7NI7P\9FG
M'FO1KIJY63&J#P.7;-F_> ,FGE55^>IW5E *%[3+]XQ]-&KEA7GNZ4Q=.BU>
M]K8?&Z=5\N:%4L5(3FUE3,?H]FX7V/K&,NE*]9*>E,CN:'@CU^X05QJN\$3
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M5@?7A3 _%Z]7K6!;TVI_;M:V_6_GM#HROTCU$V'E1T/E'H?J?=9B:'L$I!.
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MM^"&<-^!RPHR\C( 'AX>\ K\ ^"F+F.E/:TM $!)"6 # . << 9/%#@%SDC
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MS^;@^JO[@;._.2OXDS?^&\8O)K^8_&+RB\DO)K^8_&+R?Q:3OP-><WL0Y7J
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M:.^^D?><EA^N."L5@M[Q:22^1Z%)8$YIVW5T'1TZPI*"%&KX421\N< BH8P
MBP3\?6YV_T8=.DP$CG'#!A7EH86]>5//8S=A_?Z6^=W2Y%O!2U-_?1F8(%AP
M JJKH'G<@I(W>NC_X#=PHM>S?J7]0)&'MUDCLB&1^G;]9RL*IF/>)(F9KD(A
MCIO7=>E$KBK71<"\FS(:Q<IZ.<JV^%2Y9-0"V5GOKBTN9NC%.'<XM!QMH5\2
M[J4*AWUXA3_[2GYFI)2HM.JS /)64R@Q4Q^ZY[LS=!QBU)XM^/Q6F8705(CS
M[=[F-Z8[*\3BTA:\O(66C&\2HY3ELV9?([_UCC0@&D9W1['$NQ6,??/+6];M
MJSP5OMYF?>HJ>HSFII%EXR= H.E$=F_B1L0A_@1\T FL>2&]FW7H%V"^O@>&
MUD"Q!#48:;>VL541F#.:"!!'SRK5'3%C@TJWA,OZ:R"S_DF-DXV-1P48ELUE
MEI0Z?JCN;[E0(/>#X-7K)G?V+[^'<3I2#JZ?*J=L3XSR8U?6?L2_.%/>9[#*
MI?!X7V#SL+#=4=B<.L<9;S]?A2;5KKN8W;4]D>J;2$?M7CSY]M 5IM#7HN&W
ME85F('GNO06TACK@MH(-3% ^K?[8M]Y>^!9R=PEIG6&MJQ\X3XE031(.2WO>
M>,8RE/?J[,R-[QJ$!0R*FM75IU>O!+%</]/:E=@6*+%VEN ]N32_&DTERU.Q
M=N)U,Y,AX>MR-'AX3CO9+F.*+JQ1EAPM@TCA3SMD"X9L H'(##2-/8OQ_)QW
M.-8!>S:6'LPJ3]=_J"ISG+&D*#?IBF$Y/0%&WN'94?@@&?9N.2($LKS3E5MW
MS.D^\D^/W7NY<8!37,>V;(,Y8GWS$'M_&[1@+<?QCXR8?B;GE,B32'EIX)&D
M%X>:K)=M\?7MFXYR=QLOY 6TVBN?]<QB*.S)U_NJ657(V?;"F)09C1\ R3.5
M9F\XGC;)"^01/U>/89._%1HBT!Q9YJPKEN_9S(WU'E3(3K1C=(GIMM%Z69B[
M3EZ*'"K)9&!R5V&_[\0Q(SQ"YM>_-,E4[,"$K\GX$+T>&7RWR0^/8DDI:G-8
MA^[>L^O"ZC0R+H%^A1K9-NJUS[-=*]R,I<DT">Z<I 3-NF?PV4>]<%0Y5J:(
MW:BA;DO NFYW#$ZO!Q:Z,&*-PS<F\ "H["%MMZ'T3-TA=0%T/ +,4.2HTEE#
M43!EM6]CP,JY@V>DD@2O*M XY)W=XMK/ !-^:A)H[5E8\0]SEYHST4QSJ,M)
MJ/(X-L9\IZV827Z;7:+VLK@\K2(FK"_V?)7U(WY@@\/YFOS>VF4Y_ZU7PFQ.
MB<?JD"&.2PM])7/!6._SKSQQ@*OO9!!;FD<="^E-DVP-,ZG2QR-WC#*@86(3
M7,DX0'1E1 $96_7RX>Y>&W]_E[*\"P@I#925%2(=(D>/%HWBS:21O3M-,:FJ
M9O*4[F_GQ!Q:'A+ TLT-6B-8M!-<G3*EA>@E#ABFD\3G=UV?$7$@_!+7+*DO
M$^[190^XL;E8U16@CK8'8B0,C'8Q<$-I,A7MZS_0OC=S(_'!3A\<E0*G-_0P
M?+'1B!7GAQPM(EH',V+@-2T+A[QMG="Q]"UT]_@ - 0,1XTZ$-?"^S0_FQX4
M8*7UP*YT 2/MUP^9;NF')$WC@/%EL*G: DMM;2ZZZ:0Y.[GZ/E:41<,$!._?
M-&:-8GWK<8,!D")NS./<\0X$[,U>E1O%2ONUL5U:EJ6&<Z6;:U1Q*D^WL%\G
M>!:N2WE6I>Y2RYCFK8NB3<MA9H,<.]M&V=A:\P3\/@:[O0+N-X'J:Y\DQU^(
MX2E7E9>5]<Z7A$B7E[]]W<%A>DY@(0 STZ6;YY4]9M!\\] 827/SN3$<8M2<
M]>#=:'6@QFLM#OYM>%@<ZA $/GK4[W]+N;D'LEAI4<@^,?:I[:N#)+#2BQ(?
M@:I]T3*:@AR2K<#'H$<D^5+3'NBG*U#42QS ;827##^;4;#LW]8(;TK%0C E
MTZ#:!Z8[=TYB*VO5[-[K%_#^RAB3LW+[E.L/5)1$15_DY%S_J)RW,&34T"-Y
M\])7TK/FKYSFF?>#1,+1?="A/1_D19O!]EUN^3KLX2C&YJE6Z'/ZF'O=X2&S
M&\+?:1N9A;(DQH^_NPC&(6.V)>R&4(C,KZ['<O*WS.&HUKD]EY>^^9,>*#\E
MR@6YU*!&V(M8H/GN]FW-J/L/12.F5)()9N+;JR)I'Q0Z1^9_DP,*UY1%MB=B
M%5O,6*\\5ZG=4'4> R3%Y6:$LON3%!)'Z!74#W\$'M./LO2[ \6*Y47?\V!E
M2XKK@6&N]O<^Q0&>&<MUO'&4V%4U-->6N'<UNQK8@G]>Q_B"/_">:E]W(P^&
ME;I6M[O)#!IXHDOBG&]74JN$2/+S'!"&?H%HG]0(<@^8.X?Q_<-G3YJ$YX+M
MRREIEF/(5>+8*W@B> K+\VRSAAA+OP3UYPWEE7X)<;_LQ5W+&TI:GQEW]UQ]
M_BX[Q11VQX50IVY<8Q:1SY;K\;ULJ9%0"+-B=LJ+1O8N0,-J6GTO\B5? GE0
M%Z>&SF/ZK!5' OH:U^W>F,08T+TSN!CEQJ6'X7KP^N.7@X*$+K>10:R<JWG3
M1 %!"DU>EF);VI$M&3V%"Z^['+=(PEINF"5>:HSW'622:Y)+$6HF5$$K8:;]
M;(C:TY7=[100=& B*13X2VOS>VQD:IBTT8N5'D4<'3M@\-@'VJ$3<:EBCU"8
M[J/4PGS8- 3]F!,'H&;ABYP&YC]#I^-JKLUI?[NW.*"B;T=L/H2E( ,J_(,+
M7N/I11>PO?E6TO*@TO8KK0I-7S#/*/?(:LM-O8-@Y-FBC&LJ]\EUC<N_LU\A
M0DBMJZ.4.;WG3,^+2+NV8?/EXURX*%"3FU^-6Z<VEMU]K/H/QA&QDQXPE(GG
MPTI;HTG]YX^0%O*6PCK7,3'+0WL8MN0L#_POKUJL<F\B(SI4,7I1\BWV-6PU
M7\?VH[V0JB41WZYX$]\1)0K*OEU<19<.!K'[]B268#=319H\Z\N/W?['(RYS
MS8)GH*+6O:#F!3O\,0Y3'=U)%$;[(?XYVS^.N5Y#8;\5?3'AVLVC'E7D"48Z
M/KWU^*_'7Z=\%-D3EJA$A70M-,;NAC\92/>C?Q .9UR9TQ&@%(A93LTZTLQX
M6N85G_&&$/:Q]GO&F="0G@ULCH.'S\5<]RZ:]*2T(2V_SOH*,2QYFVK)])QY
MBK@(A8(&_25KG0[TZB@2T3KWOK?@%EVXMMVL60RZ?.@230U!'@^[Z(O9F)O/
MQE-4>P")11KY_!08/QJ69LB0?:2GD-+W;B0R8HUD.!CU8$E%T3H3U:,OTUHX
MJI KMZAX@;@YPGX5CO(AZ)OY$C.QZG^M+G5IUGGG@8B*@>6;WU#??P8Y41=6
ML?/DD!MJ!WPZZHNP=8P\C#B3C9A@N8-&V4J!A5*O";+[&;K#AF*(@33E6-UB
MYOV:@1\^'/301'T+=&6%':OO_7)9P@X.GTN/:.T>V:8+DE\?P0&!L%VQ.<Y;
M#!%?Y!C-4.4WZ;<S;5/K:JH*-]8"]D3?/K0KCIX3IJ13&ZT1_+R9/:[]9;'0
M$&8594 7:MSE+$JJK1P8>AUFZ\\VW[=YY76?;G>%WNR*2Y^*M'-2P$D6.H%
MK-;7UQ#I@$\S"*MOC#H<32-:M4@WI3"&;W?C<(!Y_B@,S#QV2(P3;);]Q<%[
M;,']HPX<4#0X8@%=XSGTMSJX7XS!0J%MR7Y@YOF,</_-SMK(CY650=9V[[Q,
M SP4VGDN>\=SKMCGS\0K6M&J!WBTM@M)+MMF;6C,NE-IYCB)!#V[KW@#.FXQ
M I?2W="6?+<DDAQ#2L@8W^,39-Q)>N8&.J<W/3!,3L9C7!0K<+SBQ5^XE:'Z
M8&XXQ_\B9A"M3,/'J:H(+65\_>%*5:-I5.T[-_J)8E2A'/%S71:NAQ6]I><X
M:N6;[SE0A?.(GE[5=W,>3*>R%EK! 7F5-&^\>S)'8E%'$T<X0!<L8_HM#_Y[
ML)&OBKQ8H)"I-4TEVX7H S7VM-X)1>CI"8.EV;P. PZU]D0^IQEZ@H_,AP-]
M6=EADRD.:]QY*KTAMNX]QU\(5^?+_.(NMY&:BAHH( 92\I'WQG,.[/=H=":T
M;\9S%;<O<.1_#7R'4 D77T+Z0WH9[>Y.PD@;Q<.:'L3%WFF?&K5W&B6O:E!0
M47O2O3]9<,C[UI2>4DA=-Z/7'C$?KAI7H+"XQI?$6=JUHFA>$3YGJ>W_;8T(
MN1\^,=%'0Z]4^5(5VZ7WW+SWDJ+"U--W L0T$>00C:212AP0-+G&A7(L<O<>
M7?.!ONWZ>J%LFT^+I%J5ZT)X&LGNV=3\CB81OW@;JOR<3$(FZ4KM*Q0(!T:\
M-O%*]2L'-@T]PNMS7FG%BMIK5X!/<AZ) .S=;A[SD_AHQ8RY_+J RRUJCB]C
MUR;]X[FJYUCR:R&7EK0^#E\W=KI0^:PZ[U0;TYU([TN)3[Z:H.(?B2CJZK&Z
MN#Z\HA^TF#OV6"*P..M9EK+8N@,*O68-NZ:<=DB^CC7:T C-_G&F47#O -Q7
MVO@(C"MLUK83U2U! 6_YD I"2-)#JIVM@OWR'P>RPBW'KVN-XD4K__&,;.BG
M1_:5J6CMH]3M:J/C&ACH((I@9/0CWL2NNN:@ABX,E/4H4MBEOW9*+L?8$'Z/
M';$(<66EVU4;0>89=HM=OKC#<Q\Q0G!*<$1RJ\57_4C@K:D3F8NB!<*RHF+K
M_;9!\EWNUNN.!'V#[/DS'HPIV*KDD/JLK69BS>A![/5=X<'B9%&6M0DQ279R
MV=;9\&JW3/;"NG!.:./')@Z)L4@C):I@YH@W1Q[\-/-Q&=::E:]Q@.FULY1T
M)"WLB/%U_5=.2_$J31F5J(Q)DXRXTI(R^:I)I>NKLYT*N;K:!D:\>8G$W)*Q
M(R)$B_DE>0+B;'860BW#'\HDSXC6KC1]QVIWS:B[DB0QZZ^?/#HHUCBVK6\7
MY^,]2GVF013A.I$4Y7Z\8J%O/1A;S* ET-.\Y?>I8[\VN?1"M_R9+K+6[M;@
M"[FW)?-#.H53-D*7,H/D9BM>KE@S25EZ?-$:A0P4T###?#JJ/%?%.CY41-(?
M2SKF XOY0JWK\1&YSLBO![YA5PF2F EL1^&B2\C8Y"IJ<_(AIHCT42ES_"^&
MUN5/JZ/HJB2\.K^^"V?I=15E?1AT/I.>4^R*0A2KZ4V51 G_Y;WIA,^2[,,O
MS/OU5"KKT(*'B7[DO1_BS)W>%PSG!2I_)+3P"5M<YNTHV"B:*57*MM;5*)K4
MS66D';G1W?Z"7EC\);7=B)\UQD2P]"WT05;'UR]Y#MN]&\)L+"F5,+%=Q+\\
M3D2A031"EQ1Q''QR%-;JJPRFW*1@C!-\GOT[;]?WOET,;%C(X> UO!$'E"6"
MK8?1!?_G/Q+MK(P'48A.!( 795U:,&5T>)UO\F@-&IF30>N5N>_.FR.AX(PP
M&W[+6?W-M//%3)?2LHR-R-HM%3?Q:QJER,ID#\4^'K^<M#NU$LI**GTEG+2M
M!DT6[)PI"YS.51GTV:M8B,U*\B5%[1HH*'3K3$;XRWVS4C#&P58^)J6*1E&Q
M-]]7;D/2E(Y!LX,CW4+[V\67@?+4E[QV<XTN+\4>V7W.*C8QJ4#J/.:LLI>G
MN#CF-%"4\RR);WPMNC"=0Y]-J'G 3K\5S(:O5WX4TM_!X"XMJ>]&A]0KM5'P
MQ;+\1.;CSU"-P\3RKGT;Q!0\$M7_NR?KE8//;.!;%#4XH. %=(?><,]K0VK>
M=TURLV]'^J21>GCT*>MA6?)<^Z@4PY>S<F&*)(?J&CV&2OP13_CJ5N:M3,LM
M;=_2/;KJZ*DJB[09B>&7L-A3 *%VF&XX=;8HTJ$!G'?)D[UJ-7U+)6B8W7C&
MGZQ]=>=8:!=S38&J5ZZGYDND["W'=8J[WOM 2*KU% :J3>4;2^M6XG&-1XJN
M=:J-J*I(O'75@)A T)+ 9W4RXS UQO1=_H<\NV,W,*TX]QW,>*5K3\E$R0AI
MJ$3!WI%7F1JGV1P]#QH0K3)[P1!KT$E=R=))D$I5E;HTH*:8L5SIK 2$8VYZ
MIOL=%[?> !'$<V-S@=S^NJF"??V>#[=N*R]-8FDG_<)5NE,CHZ39EAW;&\]
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M7>YQ^GC8FESQCM&#P6 =+GATJV]NL7Y^RDCI0\Q2K/:+E]#[=2+41P1F';,
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M_4I#G5?DR&GW^M"NF+$ZEFR!.$X0 5[85WD'6GS25 ^],/FA?^M-AXAK36P
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MN7=Q7FA.AS3GJ!1M11)44]D6S+#^F"-\@OH47BM+UNO0LF(Y-DF4:SM=E>=
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M.!K*>7A3^D[' WKVFTYBUI6J.$9\J'RK4]4%6!0,XJ9'RWY>E@R7IP_<B=6
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M^79/%"DB8?6B.V9FW>)\E([0"NF;!Q)X3Q'&9W786<2Y5%T5BXN<?#?FS$Q
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M--*WT0#W9>K_M(V_[;?3P\?UOV>2=7TM9:/XY8$TY#*4%J !?S'A,3&3N6+
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M$8G51YADPH\&:74VRK!,9.X90[8&W<T"$I\13(!G@M  :N(FO5U>UP)CB8T
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M$1&8(Y7C VP,N9/<3V7JC6RNZ1X=7AP])"ZU(O5PA.U1%6=_Z":0J.89J6H
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MXC$5X/P>L#<Q.NOQBJ[,(EMAK8.I\LI9B#S3Z.5YXFU;!<B#1O&CAP/YU3W
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MN(42O5&$V-L @(8&P $  !: CB(!H-Z5".X.U*+M ?2[,LI=6>]-WN]/@ X
MB""[= #HK@[O[E@:^%VY^\=W_Z0_Z4_ZD_ZD/^E/^K^4GIN[VULP/;>SMO,W
MM[K##O^*%; <?K?_B17^I#_I3_J3_J0_Z?]V>@Z8 ^Z /6 !,-V5[0#K._:_
MJ[M##L M%,?&SLO+39R7U\63Q]S*U<*:Q]+5F1=B[L;+Q_.(%Y"4@;B96SI:
M>S%96-O:NTBQ'[5WLS/96TFQ@X4T'FFX*5C;V:OX>U@_]W^J8^GO:"EFQ2XC
MC8\C"1&'.+LY6WN9,T&<G5P\Q2%2S'_T+GY7_EW-RRPMZ6%E(Z[]6.DO9]P=
M23'_Y5I\?7UY? 5X7#UL>?G$Q,1X'_'S\O-SWYW![>GGXF4.X7;Q9/E+!X^M
M/2T][-V\[%U=F'X?FUNX>GM),7M[VUN)VYC;"%E860EQ6Y@+6''S\5F9<YM;
M"?!Q6PD(6(D(\8GRV_!9,/]%O)7EOTAW\_9P^D.VE26OM9.UL[6+E^?=:/#Q
M,O/^%\B4EK2R%+?TL#;W<O7X[^*?6[O_^\;,R5[ZKR"D).]?:O][X:[_.Q-B
M8V-+\O[/HGG_'ZK_I>;.@G>E?['WW3>9_A/H3R%_"OE3R)]"_A3RIY _A?QS
M"?E7S&CM<@<4?>\0X>TBH " ,# P,=!!F!B86" 0%@XQ[AW&P"$G),(CIB*G
MH:8BIZ*D96"_1TO/1D])Q<S#S/;@(2<7)PT3KP O!S\[!R?'[TY00%A8.-@X
M9+BX9!QT5'0<_S#=?@*(L5 KT'C14)@!5&(4-&*4VSZ $0!0,%#^H/\!FU%0
MT= Q,$%8V#BX=R<T$@&H*&AHJ.AH&!CHZ'>M07?M #HQ!LD]/CE,TF?F(&9W
M,OZPU+=8+/)UG\FU)^"L A8>X=@X%)14U#1L]]D?/.00%!(6$1435WBLJ*2L
MHJKV7.>%+EA/W\#2RMK&UL[>P=/+V\<7XN<?\3(R*CHF-BXM_55&9M;K[)RB
MXI+2=V7ORRL^UC<T-C6WM+;U]/;U#PP.#7^9G)J>F9W[/K\ A:UO;&YM_]C9
M11R?G)Z=7R!__OJM%PJ AO(_Z'^I%_&=7JCHZ&CHH-]ZH:#Z_CZ!&!WC'A\F
MB=PSD+D[*3-_&!:9?.K;NL_8+ +:<'(+CPD<"E9!*!OBMVI_:/;W*1;^OZ79
MORCVKWHM 'AH*'?&0R,&9(!?7 H9(%]3!U/VZYK)$M.6;C4#('[X%G \+?[C
MO=RN$*NCX+Q;3?+W6V;<GXU_-OX?U9B8Y4@\^V'&+V26!L@+AET_M*<\Y)W,
M#,5Y4/0WN)IT72;.]>H>O$9G^C3ZN.;IT+VL&S]*L]+H%O3U53*4Y0D3'!G;
MAU7<SMZKA)#>YQ']-Q9C/&\E6Q.7;X'9?,I@%9O=D?:48 3S=G+#M29,I+^2
M-QK<]NU<7*CI55M4\;E<[8HTG"\B!=,GA6"-0).=#.5@&ARJ#*66!@6JPRN0
MI@9=;1.2BK[GN"/29[V!VW8D^(4\2LJBZ,XLK'QH67#\'?C<8*>"88YV)DUF
M]_L=2M8W'"2!0[> ,&,I$*2I&%@#[W%,!)\GU2'8OHH9![D>F>'QQ7ARV<D0
M<B47DF\N/("CP#O631G87(F(V>?[DU//M=TO.Q>[@CO=%^]Z.%$,/( =6.K<
M I$":\F8R%XM9PD=!-Y03F+_59%(^*28"$7JFP3A*<:5#6C8MM#T%3Z"\CRY
MUQC<.[6BX.<-;;7^>/+6;8=+1N35KC+&4RI4\4@RE'TR< \#301T>32>CN;4
MA#O7-".;)5G=T"?R^QLEP/5-^H#RIDGW!SD8KFND#*X%PJW%6#50%7.C;2RG
M[BB$2]H/Y+)"R&3&X"G+J/+,E#?0<LI<,\X@\:*?-H3T*[2>3+UXV6Y @.SQ
M^V7J$\SQOLHT?MK-42RFQ&W$<Z3FN5M;""9R0),(#=)$ ?XH._[5G-;,[S$?
M.T?A@:2EVZ=/9"BG].0G*ZV74I^A(3@KR&(UA$EM%_M4U497P!3SRTQ%[;%0
M3$1[:MIVC=@'QEB:YIA 1W-XC>[$Z!B1T<+2TF.+GLQ\/EJ2XG>J"F%3*>):
MH&D=\)ANET CXFA ,XIF^6-,:8!CRV$AZ/KQ5]HCS5VIF)K'R&58HG)/ >X1
MSZGJ$\HY_D%[LK43BI/PWE5@[9Q=ZCW:N%U-_MG8_"$A+E+WHI\&''<6B9#.
M<V4[6<DF8_W(D1D(B"0N)61)^8UX%)!?R5G"\MBA^8WK]R#<+ONVCD?[:^$6
M<K)JF#^5]&Q!=86$E3]J\*[SN22Q+A96BM>4$)399.YR;FW#$>A\-AB2-1<$
MGN ;"7N#P9BS9&R[7ZZ11Y**%LW\RR:+C[>P"AQ"X^88?20CV+4)GWC8H<T_
MJ!% LO-&#<16SD,">NLA#K^^_'P[(SCODK\V^( *CS[V2PK?8@ID 'O[AKG?
M'5X (PLA.0U0;IEL)+^\WVY+/*"7O/Q% E4MH>#9S7PAH5-1EW\+/.^@X%,!
M-62P'[> &)FY9#368K;88_S$'?!W#U=V?<78;O(,>JGYTN"EOW5^4:!36^FG
MN(??,,=E[SMA+A;DVL#<\]UE&5V>F0@@+G4:IPU[5S!:9LPFH;,N'9=[Y9LZ
M*L[KVUM<LM0N^3MQ(3UCI$V=<%*=VO9\L2,O"<,\:7!B+V>14F 3NAO8!9 Z
MSP'.Q3FA])AST+.+://&SHC^"X:'V<8LT4_5?9O3++XQOWA^V8,UGSHG-NAP
M20I-,-B0P3L51.B_WNU9O+@%[%B',-=KI?V6ZUT\1SWS[= JBCI0)!F"Q0+E
M$9;(&OUI[M-DPEW\,KWO^BH5Y"D9]@2;YNG-8@-/]ZTP4&L<3;!F.[#AI -M
M3XNKFVK*,$9?)WTP62$";]JP[QR'A87+_:P%I ;B$"$T(<-YBR'?<35NW,!Y
M@>"Z]M8926KNB :PO^_+XN[$T,TGP% (T[M0Z:JB+E4D D:(U.3E=CV]8'\Z
M*1C@F,6XE+-?B2X=;3-U"Z#4Z,"1+.<U,\=\!;@#RMUC&$  .3GL4<0M@(^+
M8%H/@VY0WP)-?&#U2^F086SXQ77'+;#SI %E1Q"<<!4\P^U- ;\(<Q'2$VSQ
MSJV1_K7K]X*$%O+S9SP1IF%9FT4V?%1",ZX;U18>$L/+REWVI2WHVZQVN46J
M>,>3!(6'VN1@4;&%X :4 T'P5VE:)"DTSQ(V%B_)ZQE4R9T9EWG@RNKYF-63
M&5-B."%B>!W0J8&:'JRB7NG'39-ZEB#3'!=M!O2HLB\LZ;^X,#Z79=2:,,%>
M[R81Z1O#O)*";[XJU( -%^=?VLCXTK%<],*#^MS'LDS\$$J\F'*(D[XZR(10
MR<<DVA=-QF3RU'J&CQ^MV-*Z[\@RFCXS4;Z46D#*2?)6+$.H]D*L,^'*CV;Q
M)'HKT(Y_!EH2B)_DA RL1K:QQYTZ:_;[)\Y<^2Y()_.%B[+*D?HY'/.L::4/
M;Z.[RS+4*P:6VT/57:-#,)QNF) NMX!6?!]-9X7^H=_S+Q&CKMFOT/&P<$-]
MZ4CS9Z;V"NJ7&"CA54=Q@C7D>[BP(/$5]>U._@>J5B^XD( K;2LUC_])#O"+
M) Z1I_#9WW6@.XJ! 2$3Q^-:=535,,](H4G#TLK(=R^UA4T@+,&F9>QE,"[\
M*$J:SC#0J+VM6SPI#V.C:'5$#BUU2[XR,?>C!VAE-TBTD/"=7<WK8)R] GA2
MH,K4Y)Y1X[1R(E<.#&&>1U]U)-)>T:*MEE9&);DY=& 2^RYD>-'A%CCGXKU)
MB@N5<HCCW B)[X;'AO3*0B)N2 L.:CX&Y:\.WPP>=XP)#"<?^;UQ'O#W?*,%
MFB,#C\C@<_%P2](B2)PQZ5T8,8SL/DKG77^LJ&'M4@!YXQ[G*Z""PU'1AM:_
MG/(B7S!^SUR%I]T"/=;7Y0W7Q9<R^UU*'N[U(2,)EC6!XZ!EG;OYIX-4A!YX
M?B:$85>?"1;(PD_8<KCJ(KVCA+U.,'M4V:NQSOO]/B/!13N,]:6KB54\WJ#I
MHX:AE[4=,>9:<\3; ),K]'#@MYMTF,)JKG)>F9Y!RT)^/+MS*@<: ''Q4CD!
M\YW@9^A0X,0[O^#@@TGGP>SCLP'/A3\\RQE):GX7X?(OH*?2+,D])#O[69-[
M'&'6+7ANE%]_4H6"&?OXKY/%9#"NG@>M77M A)Q[>[M8._-GL>LSHA!\";]<
M\"J/C@N@@BAGBN0GMKU'N'L,/-?Y7M><\JUMS0&YEZ]MO3.%FO5>AX_P/^):
M<^YY^?FK+1.X'<(SIU4/3WSE/^4 TC*;-,)7@HEMJE+'\Q\E8'!@2[AA4MI]
M&@ P#\B>R6+\+09G79M7DIN8GD6%LO^Q(E"\C#\M+42->_#_S762YE!'1AK(
MTTO9&5PNRAC0ZP)_873^V@MTM%^ZRV0H:Y-7+,C*BL5%I*<QXOI#/D7X"Y1"
M>9X<T5'+L<//W#UP*S-"&>&)_'H8J&=94V_Z=(P826ODS-+79H3K3'?!9<QC
M 2I)C&(-U=NH=/FA[+[3H 5*08*AMO$UDN[6L(*X+K;F61>O4A;-QOHGCQ-"
M$JYB4!C"/%2T#7'COLT$@QP-LEY*OC _7Y;B/6,DRK/4>*7.I!=F\6C;1L')
MYK(P83W_[%!0"Y3Q(P2G$9]T<(5P!MI2+TQ#$7F=Y_9V\5N:DVKKM// Y%B^
MBA2DJB#B!FNZBQ&"[:5A$Z!_J/@MW;7!QZK7DNYC^1A#QO(<:142=O($T=_X
MDF)<M:A7D*(M;\HVD-3(A2A2; "%^'!HA]_CD1T:I1%2D3&QZ\'*7I>8NN,!
MB01KXY33V]8,>BR)[%67);K,3^AP)7\=?_8>=KAMG[TW+T90YEAOUH*CP<KW
M$4_.(;:-RNJU^6U772J,NAUCACH$N^:$-_?3E2!.W1Q\9A52K8YP,KNJOK=J
MPKC1[M$;S/5X=$E@WCM$%VU+W=+<,2FDKJ%&;18G):P36]9BW^QGB*/R'/0U
MG2W;9]_B.YH@RE=(P-J7.W]+O05>,O97V4L-I>F;MS9RP;"I8Y6UOY2Q2,+Y
ML>GQY;SAVP._5B,"[[U#1FA-EDT'RGQ0\.3^,L:)&P\9I'O]F=\S"2(Z[)1N
M[-1-PG5/Q2*(Y07-JYSH<T_[?".30$\_#8[#ZZV1#_$IT+B382HGM0(B9_:H
M>6ZO1.WUYRTM^:N7#RF()9U1KG=L[-'EE)YOK<BMM R+%A)H]C-@(4L)XVH:
M>:-7Q)-PZ>5>IND[]'UIZB-LI_BQ@:+*Y89Z3K=&8Q,)%Q=">E;_"'XXG7GT
M?.Y0>M[;UYE*)]S-HY02C4E84W&(U0Q<B SI.U]A@Z\[TGA7+3QFS>'#Z M@
MXR;]^&@Q/2%#%%2@)0Y^""V@<Y1FRAP(D#@BW.66J#2UTRT9#'CW>!!O=.SA
MB@6; AJ)[1LSJ J(DK<G.3ZG.K^+9DXRQ.KF+F5J'Y"0>L!KED$79FEN*)CR
M4HMTYP99O0_!_?DHK>,,"_3L/>5<'HH2S3F[0Q7M;B6DQVFJ+%5>H$%BQ<IY
M_14[@_Z\SNM%_473)06:?M9",32;6T!([OMW;BI0Q'B$SFER;)M))7WBMS:7
MLC(]!Z*O0E5G^^Y<VC_O7+AG:+2$H_7K _1[3*D)H1ZJ<-T@D?6SFB1!U0/F
MR?AAJ9G*>FP*V\29)J"$2!US(ZGJP"1B/01+#[G70]F&63)"Y\N!\R2"F[3\
M2^W99WJ)A*2S EL$R>CNKX6%(%*#>I',YZ8&#;,5*X%\D:P5 _N7,=X]Y(1#
M7Q(2^CT1_&-/DD[W<BCJ2E7MRZ3+-HU*\*9D$RKZ UOU,#'F./HU!5&VM:\>
M(%LK=O:@59Z#YYK0@C.>B7LBO#C7XR$^V.P D17+<MV8^?NK1]F2EFN<(Q@'
M;R<#N<E25<DF17)V=3@R>E(TJ5E39QMYI._+.7)?"2 =3?1/+\T#/ DS,#>:
M[L7D7KM@_:1R&LM."7Z*K]>)C"]=4/5DUE]=ML]48NN<,4N4'G.PPODDO$W@
M5IW03QP>M9$@#(@O;%Q9FZ]GNW+Q!F)\L*_U8\O<>SIC=A\WD@EZ491-_FH]
M5%:Z@VB1!CFK&)LEWUG7 ,G(UVS2E_KDABF+8IWL.E=0ZNX&&>N;_9US8QJ5
MIH[F# .XFW1IO%*'PKV6GNF7F8VD >QVAY ?**7P]<^4763)X.G&RR%>H66?
M_653J8I4' :?(MNT8O;TB+%&&=A@Q-&5+_SP0G;R?E/4+DPEVV0G6PO#;9!-
M)S]B\H/R^J4JMQ%/1ODM8%]Z\5WFHW"?RY,>OH?4)'Z&@1\9W8-:UB5J&^D*
MB)TB%A;EBG>;Q3/ZOS5%/TV\1ZH@J%+]8[.$.#DU I- )_S14UDF0D1!9$V@
M(OSC9:^N]N*@G[M-"FNZ %8O?BMKZ%/1TQJAJ4!"Q(G*9)7@LLS "F/4Y"A9
M.-95J7-,'+F21AT[0* ZXN_5)9:TJ-/0U#'NG6MH^'6U5N&]!IXCJ9HO(.R7
M;Z>M$]HOG$_@)E?Q"]R7**&3-K'X9'K?R=4Z#==9_E!T%IM-8_XIW<?KP5[^
M2(FGV.M,=/USGUNN3!&$NG,W+*7593:S\,6=S-D+@7NQ.H'[ESYFZ6D :^#!
MCX=MRCVX!=B09A-74&=I351C%5N5R1?'6/WUE@7YEB&G&O:T>=I%M#!C*QEB
M+@;1[=;),PD)]?=L^3U;,-&>558[*PG X\L3!R-L<FS@%Q$GI![&ZL\>M;#W
MI+:EK:ME@D?(4=!:(ZZ.@W3+>BYLJ_R>*BNG)3L0ZCDK@WDS!6<8^\QP+T!I
MABO3MJFSF>LK^@AG&W\:FB4>&A[>R;YC*]RX)N9#()NU_3IGO'JGP?(3CZ4%
ME=%Z(%A7(N/IOJ6DAU+ FG7_^@^H8\T!I\3[[3A< 8;\E'O96RTK%$+6&1FQ
M#V^&G@U;\.OZ(F EL^<A\"1'TX5F0H[JU\.HZA\?E9803,9D2WM1@R6;^%*^
M ^N2ZO#V 8.0A#-&XJL'"*&FY/NU"@X4OG51,2TW0E]$A\4DJ^6XHSY_&H>7
M]3@NRJ!!XM40/MW29>^1K]I71FCKXBBM!W[,M'!/;7T:>D&%HNC/D^??EIGK
M"DE9DJT?8"4VZIM0R6;T3FW5EHC;\@ZAPT<SF2N>AG*_VQ%W+MUR7N<6$)S\
MDL#WADBR\1.:E#_\ =I7S<\U<;Z_6*6)9J[<RYI?PCB)5-;ON[(1:)D-8 ]0
M;O(3/1(/Y>R<":89"T$(*,R2J%L6V?\2;+,:EVA^ \V8-L-84*+RI4=6)2/U
M=!_UO\=75Y\^O5R\AT)!.DBKX;Y=I_+80L2:;5EMK?8SM7-QSL)$8_1,VIIF
MZ>J.Y^(0\5K78_1-!4Q=)2MOIC-=4::(<*Q"0H*&Z_RS/<U(_^WH+*TIUAEO
M;B5L;9],3=Y]>'(*WWS*J@ <!2W)L0HQUZM)OHP<&.M?)>B0<RUQY+3A<LG<
M\:1+37AS/3@FNE8M"F**.^/,-L'5MX[#YC$1Y*KMTY%\B1=IW,>C*9<&*B??
M6F% YGW8=4="EI >,)@Q6#'@HJE.[ZIG%Y'XP\2YDI@ 8K.<5UQ#AD(9UD6%
MC%"19IT--*^6JT FFS0)'[&J/7[V7ILRK_@Z'S64+Q3?PX0!Z8SXVM.&WY58
MB!SL/<\):CKBH,\]/[38WG*TT/S6=QPP5\&;O']XX+0YWM"IJ9^VV\][%2^8
M:$*EE_+AQK$0/<.,C*2OTGW 09,84FMP)=")T(QFP"ULDG%LL$]MDE8">\![
M:UC"Q=UEZ4RO'F8B;).$\'UA,0TS;X4SSV<?&2Q]R\6I.:)O>CE@R(J2>I+_
MFOSMVE'D1R0:S/K\+=32V1GJ+#_,DO-Y.V,SR4N2_Q#$4J,[-KKDQFE 2#\2
M4/(CO=<A\R*+YJ.]?U[)O$U#EB4U$9$R4R3',DZMZ%::#.V*2-^+*9H%E,*O
M$CNU*^81N1O)(]:C[O4N9SMYB-3TR5!::#>&@[A,?P$%I&C+4??C;-JR\WKB
M]Z$H01S?\$("9:K[V6N\J"M(6VU$0EM'9A;%KYL:H?V'N (6[%P^+1R/W/S0
M6%8JC9#KNBUS9^KX$L_@UWEGB5.&BW8&,=;MT_(5M5:>'.@DJ/*IM&$):7[/
M2BDJ8566?;]*H[*]2^W==A"+I/1;!6S3D27)[AAI4,J(0>#:#BT1:0BWU($K
M)_$(.=MJ-734-H0;.C-0Y<T7*K^JXZ*6!:$G85]NYV,HPERC;@&2.5A3*ZP;
M0$8H3\)F6*+X>3R.R55259AZ=J6MV",FVZDEG<M5UQ!LG1D-)BSIS\3E#=JS
MH@_DAFR&%IZ8DY?N^R0;>#&(MTU+LA>.O9M7N&ZN4G.F6+!EYC2,F?FV.;3Q
MP89]S:P.L+)E0@FFMR\@\OI^AH)@,:J=65%@_#Z2AG'\:;G;A_EIJZE)=*DK
MI%ZMP 1NTERBWV#O_M[^9*%O,HU8?]T:(P9]G?T-FG[M'LU*(DQ*0ATAV$19
MN]N_WMA1UQ00PF.E<"]QW8]UZ,$'!4RZ:N%C?(U*1_&2F_NFA!#(@IQ79OCY
MUO'Y_1S18ELK1>+*MS86R:-K9+R!L-!'YDB+G.3/M)JHD#B[J^]5N@+N#NI8
MF\];C7T!%1 =$3^_Q!SAWX.I?H5<L2[DQSIN0'*?7NH6<V_/.U&JX=X"I%SE
M04-)MT#;PML+4"#^RR@Q<MQ Y=I;0#&<F_U%KG9+>^;03CF=B9> 4NZ\438J
M\!R/BD\;2VPK5/C#E8QS"41:"DW%E&=E96R_%B2V[C*N=R$U7,-E&G'#FKXV
M&[8F5G,Z'4>O/#I3FF3/Q];]9JQ))CWS9]BV*X?8D7%G=%^G^"VP[WJ=7FEH
ML#S&5F&L269. 1/R@*>P<K?XN8@ 6JFA ^E/D'DEJ_,&IB9ZNP8:D6=OLIJ:
MLQ#,@X+N9:_7-WRL[WE\-Q/!L&@/'0'<;SBN\T_))Z&M2'=[@E@8K?K[:N[J
MLHZ\%#*GM8TN*3DT,;0F^RYNI!_B_AY,)Y\'KM1<;"]"2>/DX^FW^081Y88F
MWTO[R@P..3 N#E2=<C;+,;9\,B.8H)^[9]V9]&@N%17EN$?"/ QRG%P7=3:T
M%ULM:2WH@Q :2"RW?YZGA"N <=#@0?TX#T=<8W/MF)\N@R5C)P4KF,&^2W+*
MJ08,DVZTK#22C',V&4&-F0.YB29*K,^6VW>A=$:L\\9*/@^>?;XC/E! 7[1(
M,G*O9^ #O=K!@@_#=HU:2'07L[&#.'[)W +&R6YSELBSS^;V&X>9HM8<DZA3
MSB^,*NILJ2V/PW&VWTTU7@99]DXZ^' RDY&PICQM-Z&V9#,1 <YTM0FP0=3H
MX=C R3(M-+@;6H*(BBPVU6N.]&[7OP7J#VPS^C(%AB+=$U_Z^8GN/B5_*O#F
M1)RRMSNIBV:"NR&1<B"8L:FN4;NV?S-Z 9OU>+8O7W77<;SA%HCEOI]8E-V@
MH?!LAK=!5,@/-F69H$PC?M5';662^,DH4XQJE(!UMHMM8?$'&+S".'7D[<JN
M;JQ8%L5V[)RZSDNJWCH3P^3"$?8:)0U325;PC)M2;^:&POB'0>1,Q\+R5MRY
MY]+U]WSHVH.QGH2''IJX4\T.PU,W# W=Z% X3[,[5?H^HW5F@-/'RHB4KRVH
MLJ*289-EFC$IBN^XO_VROE[R:4H9JUC65XJBI4=\B':S)?BN1/#88>,A_1!F
M[Y7\9+I.EOJEU*)#O!]]@S '"[]19?59ODR!?;R9#Y?*)R5T5#Y9!IU; //F
MH:.X<4UDA\9Z +;D0]R*5V&X3RTU6\1B2,?=1F773AIP3CE744R_(LKD$=8?
M9BM+=W*>ZW5P'6Q32-M@T?JL;],/!G-V%85*KBLB?2L@RK#&E7JHZGXA?*"*
MX4!!W=>*[QO*]08'65+'6NK%:Z_%A$3.M8;)0(:9#D;8PP.&W=T;QT7U>!];
M/58F/R??!V)KX7SCJ3EGNP_0HI&*:U7*GV0(H>-GL54V;4E^K+P.^\-18K^7
MWE#C?C(M%,6_@U]LW@)Z#OV_-SL*L>=^WQ-*_7U[R XHBGOP=W.-I&NDVVX7
M[<QSDXYVFM$JUCE*$GV'K(<NZ7S7$\28.J[<NDRX]S4S!4RB%0&_;UT@!,5;
MJ"N)H8,O3<AY?@,W;:!':X*D5E^2Z@,LC&(+44EBL- 8AD-6OD!!GT'@;+ 3
MKZ70&X%V%)8>GK3''F3[>%FLF"BU2FIOS"YTM$ 8H/"SW +2>4B\3N: Q-B!
MN9^G,WH2HA?'0!W=+DF+FI;?A362+@7T12"^7%\D+/ %0Z=O^8_S"\J<R$L%
MAE)/ML:.VB>U=;HMQ_.6KP0YY%-\\;_OI.Z>:H'(X9.S5U>BMX!:UOX%N!D\
MARWYS#+6A<TKX\7)9SQJN3%T6R'=DYY\IKE#P;<P6FYL%Z_%U];&_@M@$:>Z
M(;J7,7WH)C9+CT@>H>1&P=I_W0$^[F#:/063R9JCMY.V[5-G<M["-4+34RLF
MBB?OGW7*N+W58WRHG\Z2V*F1FQR=E;RVBKOC']DGK9OH[$U^:1B=FFU5G\.X
M_,"H[EOH.O#&/;W?_P49"JQ)Q+\[R=M8>$IQ]C3*48;01+8M,]'MQ(]$K?:#
MAWK&<]RF25VN3%JZC?5X7T:<QH#R1MIX1WR06L RS;:F._[2',D(5UH_4XYA
M=(+DRU=FOJC@B-9F\Z#@.&!#R!7;U'1OA:TSRM [67<\72-40'@S]<E/[D'<
MRYD-*SCD;"#]4S!3LMQ,H)"]=-YU1E5%T+N#37>IZA]I8C,LWW5EY4D^Z MG
M;=!WG-)$)S%/"9%'G<C/LM0Y_MC'?#<^4$MM'%Y--L3&V1&YNGG GJ*R55B+
M3#0/\76)4)_A/N!QW9HJ[LYF)LJ-^19:0T+Y^3@7O]E55D4,0"MOB?A6F[G"
MA3]!9I0/HB+_(@>E1790KAW<>]<D0D,Z+_05TSEY8["QB;Y53(H?!'TA [4<
M#H(1XBW:&[R8M&];GBZGOUY28VF-O)?:V]]XP:-6SF!1O<D:ZA_;\6S=^/EC
MA-1 KGU)=M7Z>'4CL<>B<"SSP-(-7'C43=9H,XO.A0F-4Q]IZ_W>\5=4[?F"
M]+NQ2NZ#KH+RAW;L,0N#:"4OBYW<GGO4@B\+B4_H['^LX+;6SC0$;$YYT3-+
MJ!Z69HZIQ!0]2!-Z_+.IYO4JCSKY4RPJT>&L)\A4:Z'7Z0:U79.YER*7JE;Y
M;)R>6!S4ZSH^P=6OE7%N 7'$FW53982\@W^Z?7..\4UJ,-.EFJ$I5KPJA4_6
M<](VN HZ"965E<<#M!@9_,;RQJ^T>T->\;GM4N:\IGJM;3F.Y6ND EBI^GRH
M+UU;$K0R?K2R*D!="1VEN>$FB>:505'T."M^MJ2?!7*S/_%S#%@^;'RDE[:8
M*Z'\183.2[=+HD4SCB8YZLQ0#SK55[>X<S%$."869F-GQ;KNKLOF;VM)H"&_
M(CS+(TGJZOEN<7ZX9E>\:C3/'*W2C[7?DX/2O%U4S]Q6E(759X@,14$>:<^=
MT:%+*0YZZ8Q.D;:09_-E3"1++&&@IMDB1B^BM<M/X$M2^TM?$U2$4KTU1E/%
M+\7WS?"[W%#E+/GQR*\X5E>;1FA!6B%C(TG:9HPFZQ8@,KTA"@(9-%[RO!&R
M3Z/-'9'3KSH=6%B\&L?9)LC7^OI@J9>++P)C+D%2T16:7<-M.W[V8+/S8_/4
M6:40K[W;_18]*TSRU[5VPS+'4Z D.70 (^NS^.;H6Y[J@[+>$*JIK>;0I\=*
MUDVD(*6@T$CK+)3P-$*)IX^<(!&]-TP(H3CE&CMIBNFBE5O@!ZG1TRH7G% &
MB3IJLY]XP7HIT%#\C*^F\>"Y!E.2G3;76)NIFJI&&XASM9.SR?=>?A;5NHG-
M=#<KI7MA5)P)]//D@H2T*PY=PBU3AU5ODU7:24,LEPK-3G)]L46=WM#5?5DC
MS%#=K@(<D!;X8)6&N@EOI8"+J&_#PD63[5OR5\I9U$YHO11<\L>82AZ!ZFN=
MROK3'7+NCD(5]\O*Y@UZ6'TP#*@W4^/-GZ(0\"6<Y+^ZEM%'V,8*UE?;R<Q3
M_ I,&AC]<HC-FGG(9H'6\)5)3WV=R<_#&9TT32V>)CKA:^#]#D1P.J#/,L76
M$8=;RFY91%KWB:48E8#0I0%%N4\::[I1D\)DSP=,\7X/(T*_I+1VRE"3*]+J
M$Y1*U+B7U2JOC$J*(9<WECIB]SQ'1^W$K-?1F^6U)5:P\P'5"563M/%[@#V3
M)5]!%7$V,ACCQ&6)X(T*5"2?)NT8+E'>_&K[40JFQ&B7(IXF[/SSJ1[=&LUX
M$S+5Z1=WQK2!2VE%O;V; WA2;Y&9^X/'_;5OB3P>LI:;;U-#3:Y(4&;L?7TI
MFU =ORK8\N8R^RG&!U:R<#2I@+:T:,MH*U/@X BA(-1M!6?5_3A[<:X<?>$3
MB6S-;%+.M:)U9H'446PT]BKQ.9AHD*D1)4W@0>E\:7EM:ZC2%J(,[:LBJKRJ
M1Z_KET*\0T[PZN"YEK([^7EVN8&#VS">>JE*JE#?@%%,$YE/0M2#JR,4'^&#
M0BT08]G5@[;)@].=:B]7?$@23(J/RX7[3,OG,:+]XS!9%*4HLQ)>NY);F:39
MN?A89+7K#94QQ.&;_>R<@#ZM%\4X;8"5Y?4T;5Q-LY#\!0QCGV8VU98PZHR/
M>WVIGZ> BR\^;Z*"_U6(H/QS/-6@30@' ;3I WM? &?R_OO3 T;=KK89YI8T
M3CUM-L@W$BZ/XJS49VIU+$=F!Z+LG"DX^9QPX;=!L&N1/FG:EJ8HO7?ZK@<N
M^ID2[Q*I%.[KD-#[DK/3E=\"UHK/"J#28QC]^$EOO21540R_'Y9,5P=_<>WU
M2V1/[RC4]9COL<4+F(5=*7QL:_B8KC3I;6P04"G33*NN4DSRF<BYI/OU[MMF
M3*VWL6R&0*C&<\U878WW*R/4E 9J.TTB/C(VL8G]WYKYU>*)M)6_J3$!D0OJ
M=]$W%'//A '!T_ANQ9YFH !ZX/,%!D[#3937!=>O8 &/:\E3!EO#6^R^XJ$U
M;,8W+(/ZI6EF>:TG"Z>$(#S.5<PG-6</N;>X\0QQ'^FQHM=MBU56(7 &V')P
M\WBU(W3CMFB?E8@_=F'UTVD(4!NRY'AA=+@:MMFEPJ%X/P-!JCDC]'**\>GT
M!Q>#<PVIR"65M^PJNA8O*]]L8G^F!EF:K=LS4>N:XA_:S'#?1^#_S'F T;_>
M5> I59(<)'&UC^=$;:GR29%V^%XN2ZMS=V_E-;M.6ZY"EPJTN9OF728O>R8T
MTS:VJ#5.^Z=%&EJ[#TR!SXG.[)QHSSX NI>G_85=)T%C\^?7Q!M#_L-/,MY-
M&UZLQ).MN::Q,@CNJ<=M]XO?[PK\<'.DY-N9&&!)$@&Y8^I3%J,=;]2A6XHZ
M 0H$J>NYMP"CO7]R+-/$HF)=CO[;YOI.O_OAX-AB/'7YL'%,,Q"Z*SMW \[B
MK&"0 2&9(HP1/_[A(</</M@G:[+CH:!#_[IUZHLO_/4RM%2/@K]C?KQ20/"L
M?)6==@V4*5MQ>#?UY#+ 2)'D)P44QDN<Y5E)I$3U$D_^V#U55[./TX[+8,M9
M^-?6RBA6Z0QO%8L"1JS=K-(2=6_3M-D&<RN.DE\A%H^D%*Q]>/_L:_N(M(;!
MP'6U<\.G?6Z6R"([ UX)V]=ZE5DG.)9N !,U6XYK^)G>E;XSC%LM0+-1_;VF
MGQ\>3S^S;I,A9#TA P/^OM6"DIT=K=2.,49<;\9J,K(1.D/QTYFDC\M&/^-5
MVVB!-!X;FC!,"35%UC6SK0(X&4/*"W%JXND9JDJ5!^!['.F\JFS"TZ9-JY V
M[;S<'!*E8_"WI92#1]6M%T0S4#;-E=353[T=1Z WI4FF/YF:?_TBF_K%<PNU
MOM"QUKH+V<]G"P_0PEOA8W%"V<RML\7CC]N"\X2J&NM.>)R/K%X]\,G6URDB
M?X).B^A(,[3#3,J&'^DT9GD]^VXOK*#3T!&OTM"5 UM (4MFK:'VTDK81&Q6
M<"1&Y$-.VWYO'O9*'#>1K-CG,\X::K1TJQP(4?#BCW3VK7BTWJ<XMM;]] F,
M[D+;Y2)AC/LX2*#GJ.PZ6G6J)$4E>*14;M.PSU 4+:PE"26HLKUZ9L>P00M$
M#.W&V!47MX=M.8(O1:*X3Z./EY-LDB5>6RL/CX%J&BUV5E 1X.@K;IZ,XJ\E
M8_??%AM^7^[\=LR\J$$FK9HFJ138SYG\:O^ST<8VVK1=(2%7,M3I'$S:,A[X
ML*IQ7_>RVCM&9-B60SY5>F*3+U.@3N_^CY_+8R.I%2NX<S+01\G]ZNYE5=>Y
M57FE.13J(?M71+M/>W25N+?P4,F*WJDL#7;]K4?5_A=<P_NK5Y>CHWL/'WC:
M[1[\JB'^@G)'_6_?_/T[F.%%1:#0G!"WSM*28HF)4?\'Q1""J@!OP694]%:2
M>,CZ ]TE##:/! 5G:M-<CWW>,"$T:!7+DTQ'[5G_JX57_<:UXQTG0^1/5SN;
M7JRM63$$!=Q-E='351 R?V&[AX*2Q-Y6!=XQ\M$[1\'=FZHYC2I6DXOC$9B:
M]C7#4Z5'WI)@:-!S\.S"D89P%&<BR8GZ:Z,G0Q/9/OSBH8DMUH_D.$,]!";;
M<1Z@C4DJPU?V^BQZJ*N=B\)7Y;,T4[.?%'3QHA4[,6$^Z?' 1H](NK)'RO1,
MVOUZE94.L>QI(Z4-8<VC()E4ZPOO&]X<;)1^=NSL](9^R>R<3 MTSWLMK$(3
M5C)=^B):+Q^[BBTL.=<!\9F&*W1]T]MKJ86]\((\ EH3Y5_TKH QP1LCV^O'
M83[E9(T+M_XACXM5IBIVPELT<T7<-/ZQ?<UW$[)T%+E01A*D+NQ&!M?48/@=
M+<+/V3+$G27[96SL>IH-V(OYR9=JD8UZ3/H]Z3WH894[0UF(M7F1/;C95Y<4
M7WP4VM^0Z.JYW?!1[1[ZT$_.5$9:)77;9(VB4%%G0T5$5#>_B9%R\4Z6N)-V
M5S:92-H2I[$J[6.VU&^JC<^,:]\:LM6GAN5<,.)6G8[(**?W9(G8E_]H)OKJ
MX-JHGLUDS<A57I<](S)@%%@Y$,0Y?C>I9;+D$'/1IX(3':32<>?GD_4&1@[\
M0Y'WV.K04S]H=/ <TAL3?FD%X7=-(M5N7,/G&,@6\;N*>;*%4NWO\U)G9+P:
M,GH@H9>WZD5$6R@)=E8$W$7$*6.NY()*Z3V^JDRM32YO)ZFK[_!89RK@/B;=
MBGH4&XO-SO5TG&]4R2=];8P,XJ@2-Z64KIJC7D4SV8,XM$E5;!A7V/2K"XT>
MT2;P$<FZ4)8184B^6V9'SO5\K:DUVO$ITVRI50^27*#='V(P%,)BSN%^S=<6
MCHLY-(;CK@N%TV^XEQX6%"(-93OKNZ(.%^:>).P76+1]'!%-)*"V<N.C_A[L
M6B"A7/1,EJY$7";&]>I9B:/XZKD5:I]1>5-#IJHP5UR8\NLO[:,O8B6> V$1
M"6^.<)&,VA-"U]*_#@/ <?/>6C 1B\$#L+T@Y$M27(G(VYW\QI4[_W%_"Q'H
M6R%5X3D-V<]=G*T+X(QQJ6:+XXN/M8E3]$Z,'7SS^=7[,2KS)/-HJ$]Q6?BL
M>&+#U,*"_=:L_LPK#4]GR2F9UX7TJ:U9:!AQ&V_HNT7N9A,#&*;!<?)DAAG1
M'5/C526BK;ZGTQBVE?%A/9$E3UC=?3,\]V;BX0DU:OGQ' CY4<%D-Y@20?"N
M^9QBH;H4IF<[OMV4,DS>5TY&'$9*_^Y%SU#D)VJ411SQ@+MU=BY%,GU69)92
M;<\@?L&\^?(XD*ODF#,A2?E^IPM<(%3I!.^O3O&18%Q5WG)Q 1\&KH-J3#!\
M3K5 609(4+\X[TN7AB :X_NVTZ>& ;3E/+:I& T(0UP?R*>$GW%?*D-]B)3\
M1@%IRA'[ *^]0HBFP:5;Y,*>7D1@DP>7.FTD@_Y)\4\T#%[J8?-\#RFE.&"M
M&XHW!THD[2^"?7(0/FS2TB^W#K5?.M18Y&?E"ORV%JISWSU3ZN#OW ?Z3]DG
M^F?EBN-;X(.01>77F]IQ]+W?&4+ECV0!/%,D^S^>7_Q^Z+ON#_O9H7K_?H;I
M+S]P>% 4]W\\_Y':]?ZPGR"*^'7_+^U)WB734FZ [)GB7S$Y3/Q@I;CP9D(\
M:"R.5\BN87'KV,MOGQV3CB\,3^ Q1&?U31._^EMT9XR@ME:_&WJ(R_I '>2=
M^OV;B82L!39SW.%C"]UD"?7$"-"/IVKE !UF:\ 'QEC*',W> V6]66]:1\[Y
MQI &4\;Z3\>*-XFH#SE)1-/M:67-4(9=<\GOSPEI@'KG3*C:G)6F3 SS.!9^
MG5RZP"Y&HJ ]#:F2KQ^U]L7)AR6$EZP1_Q@/Y(.7-F0=X"<.::BI6G>&[H+O
MTT:G$.TCJ(7YQ Y%UQ+,7KR61(.V!]V_U* @Y*()4_"8HWRNP94+W V#_Z&1
MTP(.-&IJZ/-6J$ PK>GR:!?;E(MM_A8]BU'^Z*QZMH$^NN&SGOHZKN\\LJSI
M"00ST\:[]T>]]+D.\7AV&!?(WGTR#D](7&Q+7<@MMLNDP0BKGWQK5\0O66T"
MSMCPE<A>7LKT83VST! QN@52 DW/?CK> L7KA?@T_R@V^Z_B?Q03VCH6'!/&
MWW1SAYP&>A?K+VQ?1<!N@9JOIM>,](#=Q#^!B___$@8X)?[*P%4THW,R&XR4
MU\$&M\ /Y \TI;_U(.0_"_\.ZS-QOZTN2UKS.S@P_XX3X__O-$>^WA8=+[3'
MN("SJ#8G5-Z@P6.Y:5_;69;M6,[I)]..)T9RR'M">IP2BDH5!9QS< Y(^JX?
MA'QFN)^_,FA$<_"IKK.S?>IFD$;N71]14%[LLRU;/RU?L27:HDT']55Z2+3B
MS??QDAFKSG;5T_<'C6*%+U6Q.B2L?A*3$RQ_ '->*?BLB0'GXG\US'NXGV@V
MS\L9.LTKC!HW%GAJA,*7Q9D[$)%@7;-0GC5&^T_  8ANMJG=CTC%66UD2VBY
M'%UV4V;N[25R048<^/Y?G5G_E;$_#=^98\V[FVQEU^!5E@E!1]*))OS7==DS
MBF\?<9O8\5VP;M@25)",?187U5L+6[1?55RJK/3-\BA4-I[WEE.C!\D58MO]
MN]- _VX!/E=C,H,^,ND6>#'-'C73,3UEG2+)K&7)\45E*0[// XM_!,#YMIR
M*1E*CT'@_<DJ5Z%A1MT9GD($VM!"1N/@_+P+6CFM[T_Y%R^6CR/=FQF-%C2C
M_)]--M(:+A[(G^]I!?BF/\M;IR3.#?2CQ2DJ_*ZD_,5#W64YW3B1#"4=NDJP
M@'09@.':E[5F[FZIMU=6IG59]XWZ^2Q4%(<68F@!6GS:>__T >=)IMU;')M4
M%H+/E $HK<FR4F.E[N<F#Q"8G>OJB?R]O5D4XN2YZO@KY<%/>#E#92_%0XA&
M"4X^,T;)BIPY!R\^:>XX)F[$O33T=/-:5 *WIOKCE[\YAHQXS.9HQDC?@^@>
MS\'PR\[)JY:&SL_]G1>K/L5X)_G^\%S"<__A:-C#2'BJB7%=Y"SDPM.(6Y];
MI?;+5'QK_<W5V. &0 ?6E*43B0ZF7T8J/PD2Z35A$J;0$/AVSQ K%R/)SW+X
MTZ?A?0PO$ZKQY*A3+*]ZR(4CKIBR%W:C?CPZX/7L#<IW@-/D/P!O_,N$RZL.
M&9+F_775> M,(&83_^=DXH52_!\!S?^WF3RO9N^7:^2I1**I8:NA(Z<;7AJ1
MYO-0@"Y-%< !)JJ5!_+%0_"6%G;\G\8&5#MF?3&8'5W&>3?N9J*JLA G45 V
M6Y^C80M+?DG\P68FD-J1>UX?+_5!:UOCXLQ33PJ8_S%$2JZZ6W["Z4KB[8(]
MC<504U/L1S[6R$7J,2X_*3NT-^U(/UL8(:4A,KUOCA(<M<P2H'%?U=/9^@$:
M%S!P/C2JB;2L_X\$@?_L1O&@Z>YSEM!$!$I337UP;4PTZ@BQ#_]"%Z^R"/J6
M.DJ&1^2>X\1 /'?8X;&PU0IKS^;B?F<S=9K+>GSO!0O:*-/6\XC5A!L=%(8\
M!,5@?UM3<3&$2\./K;&A "'RB-0:[YH<EP3WV#-RC/XRGH$0;KT23;\Y%G.V
M-T;D8!"FU!J0'D-4SHI5]".4])=/]3M<B+,YL4$O'5^XBLKT VHQ24+_M/]X
MD.5G&:@PQX;<7R'3]VJGQ?6^5^7:K,P&>Q03RYQ>+//M4@O/G)&=E?Q,_&2,
M.%"H&\';E\AN--WX?FO2JS5XRM5AME 3/:S(+)9Y?8.;096IEMK$UUJ6TSA0
M:_H@$ QSE%BFO)1Y.G&JVLAIVP8:;>,;FCA:(""G3@U/*@'F44*)#*Z>3&=]
M]C#5]"U;VO/0M+3C"OEXR'73*S0,4.OJXPZ]ME#@&5_$ KVI 8>L7<87T)I
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MSH9Q37XX(<+E>YYW*K5=Q-:VL%"\JW,(AQZSN@CR&GP0/$^=8]V(N: 49Q?
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M"M.$ U\R+Q[#V@]C'$98:K/P^.[ZD9T85^6$[M;[RUZ/">\!DCS)0N)=U[=
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MCVEX+*_[.A/%UOSY7I2S7./%W)%3SRN.KAMA%]XTO%U!<-88MM/<Z?H+NQP
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MV2E&,'9#G1\MWIGRD8_3X:?Q91Y]4^5F; ,/2K^[%ZS[*+]4>BTSO.Z=]=4
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M_8H6&XCO.QDDS'M;226G)J,:;\.$8?)1%3UBIYIM<A''XAXP'$=,7ML^4,R
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M"OY4IY?Q=^FBMS!UL=%W-1)1N$SH:(]"GK=L;B1M?"/'-!XD2N>[PH7.O9,
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MVK8CDBZN)I6JDD[?-89,S#QME-_^3$=[SNI.A")*+"L_RY/N.7?$(ZH\JA9
M8SIH:9_ 7(LRKQ"/THX!.EO2ZZ+@"Z!RA#1"8[[&QU="-P=>4\5DD=#SH&1+
MR]HYX"S5:)%4Y8V]#5A/XL,NRS/CI _$W.9]_K\=2H/%QE*QN58Q4DEAPIWA
M2UM\MU!5C?]J%NUJK239?K?!OZ5HEJ8F+RQ!V_(RNMK:8,5!GI&G].^FDD10
MCJQ0=9DC(2D*>CKZ?(46%=:XX98OZY7J6#N9*]-@_53^W"G.C3W?['Y(YH\6
MS4L7+1:[LRZ[$"ID$2AD"](^$@GX=:7Z:( YIK0,+(13I0])2<](!;9V)9W
MGFE^)*PAH27T5Q;]#KT'1'H+YDM!^(K7<-@'6/IN!BWK6V)XTSEQ-UAE8'T;
M#Z8ZFU.L"Q$RN(MW4:16F-A6>3)D"TLW9&5WHUY=!V*(((+4P%>),>4FU!>)
M'G8^8';OIDBPIMP*6E"(FF0[FH\T0">GJN1& W8KJ^[#K3+K//@#.8A1$WC"
MGZB0QJ=*%05J=GAO/7^4D+60=[55;%[02?]1GH.=@-BBQQX+_W&;B.JC*Q;&
MT>X,ZJF/MN7.MWZ*C375!K/<[1Z4O8!V05>,)YQX1@J3(59E-NL9RV^2R-5%
M'&7:$Z>B C'W,(\E\')R^3G9)G1KQB-#9>(^L/-7%0,JJ.4>?2$\$K56 +PH
M*CLZ/&#=;&RMCYB?)^9@G11X$RVKI@W':"B4XM'B0XS:T2EB?P<)TAL/[,E(
MHKF@N65AC/^%HP$4I;G^CJ_]&_?I_Y$0)>7&,/9KE"V/!IQ.;Q&! Q/I 08O
MNI.+F)T5%V7A\?WMJG;-[99 _*;!YB<RI1]A&2/&R!1X7IL,RTM18\\4A"";
M98&B12<+7$6J9(G7;;CN:RV^$8#+067$7?TR\SAIIR]E_!ZB+.\>\-HH[$<1
M5OZUR)R,3%RB!.QWW RG4$7YFS_M<9:&I_ "&#0AHH= /]6&UDW[DOM9S,G3
MZI2+UQUNG6@U?7R7U)M5YK2NE)'IM,:!H\1>G:5KS9<#RZI$B#RON2[Z]<)G
MM.9[%<R>.R$N2JM\FEI/:L)EWZQNEJ=)5 '-9Y=XL_'M]U_T]MB8&&A1UV,8
M(Q=W+./'OI1(+P7HE L-AH$LSF)E>^%^SD3W@)Q4@OV:/!FW[8O(IK2H=1Q=
M78O\-3RRA1N6BGJ$3&5ANFZG*NDL"2FCH,53=J*$/K;@ZR["?E%ER*(Y?":8
MQ_4Q7V2A7 H8O=MP'!-*3W;2(Z;2*'8DA*?@4A?JK,A8#1$%=2R5>+=;?8!*
M\]U9<E0#-Y<2TDQ%=X#;AP]P)BFGE6SL1F.]5/'-)%VF&H'UH&>%HAL#P:-H
MD"6:,?K.' :]H+"#VF#WRGP&9E7E=+-3N=Y>M(./PZ/5&5*5$*L)"8Q4%OI6
MA_2XG+@,3J%8?<3/CJ)FQ=LO=S13)O#3W3H"?5:6@FXG&Y;Z=M> BA )#UQ'
M&17OIX4PNU *\= ;_H+=QBA.B)LFH>B D>$"O4#ZBE>??U#U5@^G4]M&7 K@
MQ(?DM$M,X!X0[%1HX%ZN.YG\;OP8=.(CMM/+VL/40>!I>ZG%*LE@NQUO71@$
M'27.#^T\)NA?L]%[WS"CM)DV[]*U4+IDHD,B_AF[.MX_F:&2J=0'!0Q;(FD_
MS.B5K:B%2+O46MF\PWZRS4X(W,269Z)6T57TP[5*^CPG#<D%PWL+JT539*TC
MV+Y5U_< +A_W]Y.-* '<^3\UJWC:-9.6Z+A?J\ZZ+'FIXD,HB.J8X>U8=EQ<
M"P%?O5MR,[BX9$CI6B!K9='Y>WXXWI(.Q>#:Y(0Y,'_\_* #:M^8>'RO(P%7
M(3.NS,-Y[;!Y"^=H[TU:U^J*!K?FVF.FG+"HR^?UHQW9<SE*,#%!#1IJ T]F
M]/3Z3#.6S5X-$A61,ZAQ:@2L!N)B\J"<-H/P*^IGQ/ 7=KJ0ONOJ8P5>@[>,
M+V -GV_CN?1\5YH=5U[U4X93G6I3)$=[:S%&9^V<[NLFZ$GQ7HG.0RK!3DMD
M!;\"CO+1J+_+#D[7F6T#:508(_-EV:(J=Y/ C.GD$?TS2Y+0U]D*/0XG.%G8
M#Q\-O=C'[H['*B2DAC036]6$E %VS[_8D'W9YJB)LA44.=\8PXC,[XWPUA'O
M9*/71K!G%Z@4ZUFCWFV_F4JXI94*C&((_T;V.9<IC6")A0=91_/467$4V[U7
MKS'D6!M"&8FCJ*U#:;48)9U30""6:I#J('(X.FST.IKF+2F)4[30Y$B%%'5>
MQNNC6C6^Q*CU%Y@ 8], ]0UX;*@A>-L ZZW>MVV];TPD[X[!R<_-F<C9L5[A
M3)F=#@.\[P&K- 2&)89H4Z6MM-:>,]!B:[\/4S6*J2N"IG6,2B.FXIS,J.G;
M@J-4V.JZ>%'-X"+OMWJ)4Q:G^3-YT(;*S"[-_B<+QZ^^KE=\8,#-0B4CD#?\
M5,E[V(J"=,IWIY&8/$3C<VM,_Z+R=-JW*TZ)KKK:5) 58SC*5I3%Y^& &>OG
M)ZPNL+Y7=!IAJ1-F)MMQF;HI"YVM^8M@=+9RI7:)$2(A.;&D*WP__#Q<< LO
M;*1;IXJ\VPJDXB7)U9I:4,B[WR/]7-CCX+-M0 4$,2+CM+M2TL\L>4[1Y901
MI-Q]_7T5@WD.6]EK=NRSNVRG:]W6U4+GE3Z_#7^&+7U5M!F7T^D14+C58KM\
MR =L B\,M?G%0X&>_)24[H"H.NJ#0YIBV_4ZT];^J"X X4/810-!4*7,5"*$
M?BO,XH595-J@G(K6!^O$?;AF7BT'^"+AF/V#9A,W+(A'TZ%=[C71?MT4(4T>
M/MA-[&PB4NCYA4,:WKUV+VB][-%1M\EI [J]C.%'8;R3I=&@-NO>(+\+]=/1
MP;I;"WZ?E>1R969A&JP=(8V-WYZ:X87:2_HO=<K82NECY%$$GWW%3ON,]Q"S
M,I'117/6/Q]YRWOE+TMZ@=F3[4TSYC7B^3L^VP_(B02*/SD5/#SWL>O23%$J
MC'#Y&T6^3?/W/BC5^0,.<QJJC[!9% $Z=\1%*4LGA68"3-M;F+C&:7>\ZX.5
M+;VFCA2!GN,J!T-"#2!7 (#]I"H%E$#=FPE*-DOP^:IS&6D;T!PPP;HN+#ZW
M>RA!(ZJ'+#CN&M_M7SL.\PS]M Z%=_'75NLMAOG."7.CQ_6B>W\$#E*E4=<_
MKSXVI)G]Z((CKE)'T=UR?E/[U("_?T.1QPQEVP-C2]IT3V"$6]$%AH=C.*^K
MN_R0).KK*A_9F"0-\"O:.WR.T,)*P_VZPXR<_"A3Y/+,TI9CGH9V"3-Y^-6V
M,/^ZL-,(=]38HY3_F9$%EH!=K;Q3WA*U*=O^XI5GZS_YMW5"O(VI?S:]RU#&
M,.26"5@SHM@3H]53<FJC^77EL))Z6M(IQHF[LE0TR@0L)R\;B  @K)KM_O;'
M(23E84<WW'RIL):7&[5-)^?:!:\C#JH;I-L=\YZAV;>^CTKOI:X+;5995WIO
MJ&ACV28E/TGUZF[\;CYPW9_K9Y-D0E/,C47-!APCR")N([E#E[*ITL)BTN1Y
M^)[\0G_IKYP83#4R>NVUZ-<Y=#!U7 # F0BESPKT'%&6N_:H9E8$Y3:VD/KR
MI] 0]SK@\'8^ZL1>")&RX2MDA;,6;=DN)*+EJ*/DXF/_K"$*EO-9JH$2;HQ'
MM9Y-#?G%#!U)-_=PLG%PL[03N8@R7-;YH&FE'47P*:JXEYP(Y70EM)5N!;Q,
MCQ@-:Y:'7"A9RHW!:AK"_;&>SPO3)=X#S'\5W[CWM;^$1]RI//&6G&!E=[;Q
MDJ>X2+$Y?\P;21)@ZX)FF>SYBLD-=X\[:'*6^%C+D&S,KJR@L66<9S\R,C $
M;%X3O?PZT\F!GLD6G7L2JM<\R>J"4>?S>F!YM]2<<*$&P?+5C)K:44P3E)L"
MN"SO<=IIQ(N^D2S):Z5&L-5==*D9[/YN-:^MA C5/[))W;2,HL[#UY&CYB3+
MB%2AP5,)$V/  _D9W^;M)7@8S:,_<]B\E!+3/,X4'.$[S4B;K5&!I:/O:\=J
M-8[S[$)?#'QIB9_@^Z9P.T$5W4G=L/9]$4G3X59W[.,!BZ98.Y)=_DVPB^")
M6EEFU6)X*%:&HOW<ULIQ=T#4,SP&?CJ1TO";X&3%*DA2R-XJ9RT878;8!+-M
M6RRHQ?6J,-S&6R?;FW7JQD)R3&R.1^A7/=H;#M-8,T-[D4?L97*V? D9W(8(
M2,&O.7W]19TYO85AUS7%<+IPC0)C3O(^<M.8K1^Q>%:=*HT5%-+^U<UQ^0UU
MUUP>3DVF3D+KV,KH\OL/QGB,#A$CF1(3:<O$.:2KAE*8#^EV:3J@^7_Y@OD5
MLS^Z84-H^UFO8!\IAQ^,^*%*.%VS0^JLS/EJ7?AD7C!=S(S2][6?UGID,A[S
M(ZY_K?/N"KD%>G/G6L?M";$'FQ08]%+V;FFWU5Z/5R8:?\7ERH)5!W*]TG*Q
MP]N9OW'H+=OE$TIYHRA3E]3/^=KS,QF5*D9(:WE6)\P(W:H5'T%2"BM_M.?V
M>]_EN\@PVOC7D0WI;\AHZDCCF"RG$9A.+45!RQH>L948&111!F6,<BE5Z%G1
MAC:P\"XU2D1Q,RU]*69%^RKJ**PU-JO+F.B3QY[H5:"S"![X'FG)UBCR3(M2
MXO6K@( 8@6X^&KR=F7N R0E/*MG/ZCHLMJ0^L<%ZD^9FO 3ZLE<I #@-WAZ(
ML<8($Z(%XI@I-[A1=V:$9JQS]MLT])CI^YXH_Q0FD!V,LD$OMC)D:(T0I=<.
M6B,I]E@#KAE5\(=NM9S2>UE\^Q+T^#)V8(Z *J C"A_SZKFW8 Z#:E>*6$;E
MPN)M&1%)$9K31B:OC("ORI#@=JFQ.PNL-0%&J3UO]?&<6IE\.YY-OB2.,=K,
MU29BCA6 VQDTHD(UAA&'S.PFO0=8(T*@XK&\.$Q=NHPE,XVRH6MIK/SX/XJB
M4C]:V,!BAQ>*5S\4-B% V;G>!A&G1@B-\PU2W0@ZG9U6VB";C .ZA>'"QJ0/
ME"'FHKC'+8;[#@\%W+%VJ&;3^ '35!9 VH/M.\_XNL#\ABU9_X[7)$VG$';*
M]L7D3HJ3=0/&X=8$M]CK0XRAGN/&5[.%#Q$@?37!8.R&N @9VZU;&N4'_[RB
M.^ASF[])Z;RXJ2]W.=_&/N8)<'@_O,Y!ONAMT)J$(Z.=7XT ZG2;\X>5EI:F
MS.DS)5^\Q 23?XEGP(B7!-*U!F5V^%(W3I(J-8SQ-)1HF@K-]UM2OF$0'/Q$
M3QFSM4V^<355Y>XFG:RG9&$ :C^7ZR&X+%4=:38-?U5O[S";_[]^ZQ=EP+VZ
M"\0^P8MI O\9* ZCJW.ODW>X+<4I3+JDMYA%RP ([@X;WP,Z;!#"=^$T=_JU
M*S=*GDI$*!M!&A3+#;Z^++(<GW2Q'L7W=%Y#, F=+A-*XHAQ:)]AJ*F;!C0Q
MVM#W9!),2E=KMU(._NC=*!B\/&]ZR*):5'+C7)MD401XWG AK2(5B)U3]2&G
M+%_/8L8']'D?&4^*)'^1A3M"N_"5,[E[P,EF[3U@#:*W]J9Z%*[5Q;6L=YNT
MI@323,*!W12^VBB#M;>OBR(,TJ7=P'9^EFREY\U:?),OY4V^ ?,B/ ,+ T6C
M =Z='WE5L%>\A> AV5M+X,E](=_RO&4Q,>TE/Q^4WSH,?1>V#I^9Q8F1.3ZR
M/4*S,:S.;)Y'!DSO_<&ZT= XR'-H+6LUBU(&\,A5A,HAS2FVP'+L++7H8&);
ML>H;*[GNN%F=#,FF#$HL_28M2M2'I 69B8,SI[QY<.UG<#XY3IHJ<R>T2L<5
MI0Z#B9[JH5"-]]:_ZY_AS7QB73N_'9K;J <NA%;]"]CK8] 8M*.WKN]8-2.,
MFZ1"7.'FP@P4CF%?,F@G>5JX92)&WX?H02Z[9@*E/YH;6GPL]DY$2[,$I*'Z
M?FJ"]P3XY2_LUEV!4IU,(;%T,Q"YY1?VG'S99/JX L34QY]$>(OUYA?VQ$ 3
M9;#JV,':&"^R)6-E,?5']KD!;6</AEH>!FVBQ"JGW,E "3_BL<,WF-/1D\KI
M>OYZ^1VD&I5CH-?XR6O$:;GU#/RNTL-FU2\<1 R_2_ZQ<TC<M*>K%)-M:]P8
ML_PN7.,]4S#M(6UFR[[A*>0A.;27I/2^>:C"0NX!E5]MZ%6J[:[O##'ZFY@$
M>KRF<PNT:XL:4W7T4L\C^_2J"2YS1+:-O2UM/7H<_I:LNG5'.[V,4'9J#5%K
M:HR(F7\M@MU<7W%D6)ZB-BKLN(4L-+$PHBS6]]-P^%U+^O4)=_B=8-T#/A_X
MG9#= V+%S^WNFFYCC:R/RL6HD4*W6_%^V.#7'E^;]#NMXE2:TXX)LG!+,]Q0
M<;UFRDJSP4+GC9)E8%?=+Z]JSV).EA@U/IK2<M)2$3[4\4NF1?)Y^R#NI!$C
M7&GO.X)X;7;OIX)ZBC[Q5,D ,P5Y-;*G_A@8;I17&5#&RA]ZNW<O$7?Y,&%%
M<6Q=0QU1Z/%<RA68<#MN\?3E(X<*JC0JXZ/1FKF'DMG3)7VI+!-VR#PS?_[:
M0.K1%ZN$HA%@D3[G92R&J$JIN"J\+O3<"P+QT7L]:9=58U"+T)_KI>O@1,?G
M?"8#H/)\ K@\[N2_2M_N^D%#N)_2?2"TM!+4DVUG/8M%8#A0TA>'">>G#[M9
M8?.L9!58JVP67;\'4,_OUC5"8\IYUT?S]56<V6^DP)ZF/DTSVJ7H()Q"P;><
M@!. [E72NO3$,:^PC\*Q4G7&U=13.Q?6)Q,=XG..7"TJ4N^TD4YO)HYM.7B6
M*%6J&QI'YYGJH'++']/2AP!L":,\*&MX3H62J^(DVKM^3X^;M=E%N'ZKS1L*
M&Z2ZM3_J;KLT'7'8R$QM4<U8-X2'I-@<-K\O,9 M=J=0O$W0-[&Q>&-0 ,CR
M,,85V&Y@;-D;?0AVDR6V)36W0$5H3;-!':>D)86L0#N9"Q";4\5(-]X/=R?Y
MF?1(;.$0P:]YCF_6T;7 F6=Q'0Z_/;U4,0)'2Y#5[0*-E0B^\I+18G=>*)_2
M:TDNO9$F;@8K&2+F>'NGL20V=1<;U3FPVY5=Z(U+D7O'H#J\96FD*#GYP_Z!
M;5QT3&&)CB5+Q>FDH+##F;.G3"KQ=,N4KDN.OI[4A?MS;2*1=WZCO (#Y<"
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MY?>;K%P6U;*PK.1Z>,+9[8MJHOQ5-K$L;[+Z^O,\"<,$$5=- EX$41([D.!
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M\O/]S^!QK08L6SV _)<B)Z8N?Y=K+<QFJ5YFTIMQA@9_X-GCRSWX]1#J'0W
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M(8U]9)@HP+9]QKGE?]VU2EJ)WQBGJ4 '\&/!JP7,$';0W-JPC>W0NQ05FK7
MH):XB>N8U3L/,R#%KA^P4&BI%TQ6=PVT.AYW \ $B[VUO-'+_6:1W_+79L?Y
MMS3+B^I.NJ1D7BX_YXO%Q[Q0>P-S'#G,87X"(P]'$%'?D[.(Y\$(N:$3.TD2
M>D8YU+5ZG=HL4IE#U8>1??USFXSB:B=2X7?Y7:B,1E(--=Q:M<Q(2\\H>J1E
M'>HQ2*LGRN /I1-HE+*XH#<"T2:EZ74\*J498;%+:68O]W2,5Z3D_[F2O7QX
ME?]Y4!_-/& H"*D;0A:0 *)8.L.QXS'HA[XO0ASXB1!&?O"!3B9'6&L9024D
M^*,2T_#"QT$X-1VF"T$:FFI,\3%WA4X 8-7S.=3/N([."4WW_)I3S_:\7EKO
M$99W^+MJK4T^D'#B48(3Z&$60L0IAMA)D%P'.RA&41B&U&CU>[B;J8W[5DI5
M0E*):7C#]#"4>B/^<H &'O-K;!H)ATCM<!(#JW=,#_<T[B73D]KNW3(]_;3%
MT.NY'\LA+H0#D2_DC(\(A80D%+H>08)$..#8Z"SQ8"]3&_KKR-YU*/0,$"6H
MA8#H2\*@)\0 1X.?!PYX'H( #G?T]L'-QX;_Z8>M3/U7&9._*5:<=0I0K3,Y
M$1[&R*-0$,(A(@F#.* ))%$0DL@/O0 9K0(,^IX:4^Q.A%7H?R,]Z(A_?H*\
MV"HABSS?Q3ZD28PE4[L8)D'HP$ $"0L8#I@3&N77&L@JHV7?PCL.7&4;W-AF
ML5%B.)/T\O9L 3VR"]C_R[_4-=0!;$!_\63W;^E$ZN!RQK/4:J)'T,B[5;I@
M#_G]*EU6-4INR2)]K,[;R[GC1FX2" $#WXD@<D/)8UZ<P)#*_PKJ""?4\CC/
M=32UJ>13GCW"*FKY)2_:ZL=5D21SLCH+\FEFL@G=P#1420D><J#DK&L;@8ZD
MEN R"#ZQ!-M(02B5M'"9PU+!5W]M^49B6U$I&J"<C$XY]?YX42H:6FQ%J^@\
MW^?:89JESZOG^RK>0IWJ7V79"B\^<E[>OW"JRD-_YO3//%N?=<X9(AYC/H.^
M4]74\!",L4#0IPG#G'@!#;1R0/7L?VI4VVBPB8JH% !":@#*1@50M#HTR4!,
MKLN96TB#D(?%?6">;B'?2 ]J\8&2'[0*@+4&Y\H.V!D7!G<5!T5_K"N+C17*
MC16TOGU;\T!_$$_?9#1O=L0+C;UUWK[7V+^9?CM"=T4NC;_\KHJK+N5"0 41
M5&6GOI1<K!:?4L'GE%$ND@!#YF("$?4$C ,FIYDD(L2-B<>I4=4^C3ZG-I=L
MBD"O*AGEI/(JAY+TW8LF-5V?[-\ZX.OM+EB&=.!IHI5V5E7>7E:;"FN)9Z"6
M&2BA[6TG&"!D<QM!I]M1MP\,<-C=-C!Y=>3+UK?M)3Q>T+14FQHWV;)(LS*E
M50B@.P_"R)%P!3!,A"0QG[@P\0,7$D>$@:!$N([;H\[8(,*:#-5Q8HX;D0'?
MR#P#^/&QX(_J<EC:RE_76A_I&O9YHV/7#[G'A1R8<C&$7(0@3H0+@SCA0>A1
MY&"C]/;3,/DX%;SW# [P$O"L2I=HLE8:P<QZ<^0TC#?PU&KAMOWMYGI]9["O
M5:[#X2=PVU[;+).X;7]>VK_&;7MMU*W=MM?OT7";K5BJDKMR-5YU?\7^8U4N
MU4_-7<3(CWW*70_B@'D0<>DLQ!@QR(B+" I\1ZZ*M+;33O<S->;?R%>"]ZLJ
MA'SYQ,$5JY/B*OJ_NK\&#_F+Y((8>9I[-V? /K,S9@_"@?FW(R78B&FQOIHF
M%"<X3[;0X3OYKUVN.]?%.+LJ>GJN=T\T'^]9$S(KU@E1'_"W=SSC(EV6[SDM
MU)9_*7M>+=2M^X]2_COI&Q7UYHQ\]BXOT_IX203$"5@@8!@' 41JCYY@Y$),
M?3<*8^ZYB3?/*H>:Z;FC-L32&CM)/7:ZP@TYA-3%W\K[5"F5E_@;>&FEK9Q/
MI4B=\,FP9*0-*^KYFJ-99J22DAUU@)01M K-0*L26*L$U" &E5)M:FSUREHO
MBS4F+:)LM>:D#;G&K4%I$<F]FI0VV[:\R_T[7\XIPDSZ>@&,0^)"Y"<()DA@
MZ H1Q4GH"=FDE>UMV=G4G+U6UFH+EF^V8#-N&,-X$N$+][ -<7O;S>O?3R!G
M;].Z \DHN]6JOVEL4W<TU]Z?[K[3,R-;_OR<UHLBV?!U7J58XAE->;FI1_/
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MNR.IXZ\RIG)#%RE=<E:)^B5+E]U3A-]75?!\D-"$<DZAZR<A1*%+8!*K%7U
M?!]'D8,2+>H>5>K)L7O%'WE30$3EI?M\_^7"P\AQ/X/3T\%DC3O&C '>G2XM
M\JXI+=(\MU5:I)U3P)7Z)M;:-Q-.I7_WM!74"$SQ S%)*3+!#V6L="75AU"[
M&+3[P>#M6C1EY[F7YH/!U0?3)9%B\\%440Y@57TP75K)*B1LQ4*/;;G3R5?&
M$F;$Q"XCX[N=-&;LSOLM1U4*X^7W]=W@.&2"H""$22B]542H#Q/&$(P#59Z&
M1I%'C:Y=;S<_-4>BED[GJK .=GIKO/Z(##S[ZH-AO/@ZK+/-A=1.#Z,NB@YK
MM[O .?)4OU'[,<UP1E.\N*EN25;<\2TMYS'V8R*"!$:>\"!RL( $40(]3L-0
M#F2/N=AD^![I9VKC>"TFV,AI-I2/ :HWIBW -/#@/H20'.I22(O#_ P,-L?[
ML:Y&'?AG]-UE@'./]Z."3[PL.=\.;&K#H;]_D8Y"2?-5)GV(#]^H?/3J6?UK
MSC&.>.2Z,$J$(XF"^!!35T >>#X3 8F3!)F5BNHEA]8(&;4VU,WSRVI9I3JJ
MTXJ:T4@_8^B1S'  CT-!M?Q;X0%UR.-:B1GHJ@%J/4"MB#V6N@A'FQS63Y!1
M&>XBK';Y[[+&^K'C9_[*LU4G@1NF**881=)#BI$D/M^#&+D)#'CLN%Y$W"@Q
M*IRRV\'47*-6/L,$4GNXA=B)W!@'T(]##A&E%&(/!7+^H"%A*'%8G)A5-[\$
MN7%JDC<2@H(OU,RC"I4V&8/Q8\&K1?REL.I1_R50#<SJK6B#K!N/Z6V3A??Z
M&)5@CVFXRYU'G^MQV-7>IKO)/N*TJ"H<WPJ52KV^^E(%=5UE;$W-\\!%4<S]
M&"8N(1 13B&)$@8Y\VA"<4(YTL]S8]K[U AU?<TTS8"0&H!7I8**-!"JO$!S
M,:X*2*UVE=N;O9HQ!_TLI'&>-"3N W/,&O*;#"CAZP+QX%;4%1UJ!>KPT^KD
MY],8D!N<T P)_4@G+?9-8'94TA?"DT<>QHV.=W315]^M(XC>C?3SM>MHX'57
MF^IA\]@E$GO*H)\$ B(L/6^2A %T?4Y]ZK@("3)?YDN\T',=C_9D-%FL^QMN
MV#RH/@!5V915[5,Y5:Q+Z3WCXD^^K *>RG6 H9DW>1QP/;?2"HP#<W][J:!#
M.ALY[7F:9Z&PZ7(>[VQ4W_.LSKM.Z/D7Q@R]NI.?V)/\Y5V14LEKG2O<=UQ^
M?-E2A>^^<)J*M#E ?<H73.6'E>M_+R8(AFK;$V'A0^*Y'$:8Q21!B6"!UB')
MVX@_-7^XU4/ECJ.5'TP[F2)4+CFE#%AE4O;F=VFF?I6^RG=D4_6EK+)5M7ZF
MUG6,R)S>GY&&SSWICV-@XKX\F&O]954H*%^SFS\#-$BH"V5@C06X_XM\/6,$
M>(WQ%?UE(KU>]'CJ*!>]>=#7I=8<)OJKMU1_@3"P2Q&W$P]VL11]*Y7=/_'%
M0@F+L^]S'XDD$G+-%O#$@RCV0NDT\0!ZTEEB@4NQ"+4"UP\W/S6GIBFW58D(
M&AE-RY%MP7?:6;@<E($G<R,\>M0<.Z3VQ;7&MAH=N<;8(87V:XL=?*I'9?7\
ME1>:1TI[ST_H*ZODDM/V([<PV1Y5])*BWEOMC5?)^Y :6^6[#S[0\W[JA7'+
M^W<97.0Q['HN1($?0J32OR:>BZ#K!P[Q2"BG#C&O<X[?+W&QU-L#M"ZGR4#8
ME7:X,='>:.G>0L#2U>6/:9:I?Z@""G6^]MX)&.V;W.,.=L,(PS"JO 6.(&$.
MAG%$HEC@2"3,;4S^(=,,,)N P5M91S<WS]@T#:VWT?RFIAMCG^/ ->>M?0[2
M[',TSVWM<\PV-Z$[>L[.74XSOP$]E!&L7HBV+N2X]Z.'PGCONO1@'?78PO^<
MTB>Y)F77>)&*O,A2W)0*"V(G( )QR%" 5=8RJM*]AY"Z#G<=/R1.J!5L=[*7
MJ:T=6SEG8".IP5;D43 U]IMM0#0P71Y"YWRQ-0.8##96;< UTOZGT4=EMB%Y
M#H63^X9'7QYO>^^<_%N[<&<?-E]]OV^^@ ?YZCSR@L C00(YB2E$',40(R0@
MY31.O#"($\'UPF1WFS;Y*,<)CVVE TH\_=VQ+;S.;U;TQ6!@'M-3WFBWXI"F
M%VQ6;#4WVE[%(26Z6Q4'_][#Y[C.%_+G7%TE>.4=O^<W_"U]7CW_EBYXN<PS
MWO@^GSGEZ6N5DB[$(1*N+Z ;1QPB%WD0TYC "*$@HHRXE ?:3DEO,:;FM30"
M@^=6XO7Q6;&6V6!Z[F\>#3=G%- 'W^OLZ-!=*\Y :XJU'NOUXN=Q36'@2HUB
MDI%\K:%,8^:678SH2;^M?^OC.787([#E^5W>FJTB:==Y5FW4_R-=/EVO9*?/
MO-C$E2-"/1XF"*+8]2 *'0;C.)%NI!_PR&$L27RMZ:EG_U.;E]89IHOF!LRE
MY=%.HZ^WGSD@I@-/.T>*I+7B@Z]2?M J,+,9QG\A=L,62SLMPAO72]/"YWS)
M-+UF^I'<NU699NK.KBJ64!>&;8)3\"._%7_/U87?F^9*?=F65)@3QPMBYB<0
M"0=#Y ?5:CF U'$(<5@<"!J:<%T_,:9&>1N1U9E/'=%&\4NJKA*HFP.OE1J@
M2!^?U%V"7O55>AI,CQZ'-\/ +-DJ #H:S,"V76HMP%J-=?D6>U1Y&8XV&;.G
M)*,2YV5H[?+GA:U=1J/7^3-)LVJ9\WE=I_N&J:!YD2J?M+Z)T?;:N<.55M>Z
MY"J)[53(K-^8NS@(7>J[T&6B*DG%I6.)"8PHBI 7(AZB7HP[F,13(^>ZG&Q=
M;Z8?Y0YG7#-VGH3)QB+RCK(SL%$7=/5M"MALZG#ASD76M+[>JI2>[=<4OCK]
M/?1F_L%M-,0D,9S0;S*?#&Z#8U//\!WWO.=[M#[&>TZ6FW_-?>I$L0H2IX)+
M']]G")(P2*#+4> &+DK"Q*C.J6['4YLSZEO -B[\ZB(?T21B,?:A[S&YL&(N
M@EB@!#K")0@EQ$%N:):M9PCLQSFF/%"<9X/_#$CW+7VNTOMLLGD,9!67!)$G
MA L90SY$GN-!$L0Q#'TY'.(@X#R)C*[!#S$>1KL5GV:O$GNUURH7L7LV&L@$
M>B[2$, .[.DHP<!]Y[O>_^PMWI8WQ,?JY7G=OL>]2V^(R-[5>M/W;10C__!-
M10[RN8,(X23Q84B\$"(W8A!+8H*"$^$E,1=RK=B_'GG3R]0FY;V2Y+R6\Y*J
MY"V@>BQS,4P#4\I>HLX/9Q"ZL#SY#@+#52AO.WK#(N4[NIZN4[[[<+^QKR)N
M;L45JTM>--&2A(6!X )#/T(J0C>(8.(&!%+D$-D*]P@W2AA^J).IC7PE8U6U
ML9'2;,0?A%%OP%\*SL#C?1<7\,?[_!FGF<6$CJ<0L#G>#_8SZG _I>GN:#_Y
M;(_8N).)=A]XAK/ES?-+D;]6 1!7BT7^%4NEYE$4NX1RZ0>XL0N12!@D-/+D
M^H12N3Y!#O?UP_5["C$ULJC5Z!85KX[/UUD=P;)2!:0;70!NE3&(TNIKL]/,
M,Y8E!F:FQ@@[#LDF.@'46H".&N!J1",8!,J-8(R1PN2&,8I9D-R%:)X,D>O;
M]G@!<A=JOQ4>=VE;%D.X'^1/):;5D:O*>3+G''G4D_YIQ!("$<8.Q$C.2VX@
MY/\&0411<G'$]FZO4YN(MJ-2NVF/EAO)Z^1&%H*#]VR@,<\,@>S $\O14%_0
M$;K./S8$J!8"K"\!]TWBJ4]^N;:2;)FBU2M6>J^QMP^-/J:?5B3TT9<'*$S4
M1%F7[U=\[I H\&).(8M<E5[>4=4'.8.NQ[TXCGC$8F1R+*+;\32/1>KU17/Y
MQO!\4!MRO?V*(8 <9:5PNLA0*_D,O#]QU&>WKM !M$8K)=3M>SK5@PX@8E0P
MZ-#[_8BJ3H!P*]8=W?/'JNFY\#@.B"0EG+ 0(B>B\B<>0.XZP@D%=;R8F>R.
M'NUI:LYF+:C:#-QL?)2-K&:4=!Q</0ZR MG I+-!:T,[]^?0,N:7LTC8))3C
MG8W*(&=UWJ6,\R_TXXAK7#Y=J;0!Y=.'32+_NWR14KDZ_K9\)Z7^<^X+[$64
M<^A'/H7(=Q.88.;(GPA&) C=)"0F?*'5Z]2X0TFKTE243^##3LV#34'KZN]F
M3*)G CU6L0[LT.M4A:9"<!=6Z<U40H,_FO]5TH-*?(O'-D9PV:0AO8Y'I20C
M+';IR>SEGE3UI!9T-]D5K<HI2@[\T(2XJ7.F^DAO'GK$QU&8P)B'$42,$$A8
MZ,((!]2)>829:\94&IU.CJ@JF=7UQXW4H!5[9I#5Q AY38*RC.?0_'0>R@%.
MDTU LLI*.OV.2TH&2.QQDLF[/;;YKQX?BZIT\Q5CU3TJO&BJ&391[=6A=WO]
M_C>^?,I9\\"'1?J8D@5_R.OK^'SN^Q'B?NQ!1@6!*,9R;<:Q#YW C6F F1>'
MCO91@$W)ID9N=_E271105T:K.KJJ>"GA0*@Z+*RJ<H#I4\J;<SEUSW1=]$#5
M1>"%*E1>79%1;H<*'RTWN6$TUX#VS:]Q"O%61AV88==J@8U>H"U0V]&LDYJD
MUFW]4*L=>,B;;"4F9QI6S6AP[O%6YASI;&1C5KPQ:[&N.[PQZR8OTW-MUO8A
MWII5#O Z59.U4Y0AL#]YTF*UP_%.8X; :>O$9I .^J:S85RDLD?YW;UR=B-'
M2%9UL'T9;8Y\5S O"F%,N,K\+C@DW&/0P0&CS F%E_AF:6RT^IW:-+P1&U9R
M-S>' 00W=Y__/_S\\M_?FR:TT<-?;YDQ *H#SX-[@&YDWKV_:S-GC1%,=G/5
MZ'4]<HX:(SSV<].8O=Z/J=ZK/E1^[&Q9I&15'6O+3^DZ+Y>;Z[3S$#O8\T@$
MJ2L<B-1N+8XPA<01,96K"20"K=@BHUZGQE(;+X0_ORSR[[SXYU(N S8JE,J[
M8+5J6W^H*CB:,9B>7?3XRSK: [-7(R_H"@R4Q#.@9+;'6$; V.0KO8Y'92LC
M+':YRNSEGCNVZP7W'7[A17.GA O?91$*(8IB(?]#(X@%YS")$">88,]WC*[F
M'.QE:DRT$1*\*"E[7Y4_C*GFYNNE2 V]V[H!J1+P?/Y\\ZW54Q!8W4L]V-&X
MFZ>G=-W;+3WY\-N4W/J[7/=5^3_414%UNOJ0JU]U:GS\@ZMD<?*95U[@1_[A
MFU*A*2DY]\,8^XD7PX0Y'D2N() @PJ ;TH0G"#EQ9'3]]VW5F1JCM16=7BNM
MJMU4WNBEG"KUZ\,5GI@*TRQ*4+&@PFOD8D\7?E5Z5/O7^58&YG2;9:3^OOG4
M/G0^-?7KG1I3+3B@00>T\)R)>1^]^)0=.T^I4M6%&OVEREK9L9[M&EB6I.KM
M\[\4_$E*G;[RFXSFS_QWOKP5#_C;G$2"4B_VH6#8@2@4'.($^3"2DS$702A\
MZID$Q)_HRVBV'"$&?DM4L,C+4DZ.]<H+-X<<]_)Y_)R#AR=IE!<NEV14<IY4
MZ_BQA[$%M-<)-G =?K70@;06$_SX24+[TPQ(>97;(26>@:L=H.^P2AEG=4UQ
M#B[+*XNCW8V]OCBG]X%5QME7^H1BL/]8-2FW'O+-6=(=3ME-=EVGF.XDO+T5
M*G.@VOF0KF@GW>W<Y\P5JIBO\'P7(LX9)"XAT$D<^0^7ATFB%3UF4ZBI^?T=
MD=4(ZQSOUJ5;U2];*OM8&%Y4MV5(G7B*\<TS="C%1B,5"]&)IU!*288$C5K=
M]-_@5H!MS=:IO]_ ;B8!%./;;ZS8B8X=Y735&6$ORHYR";W.FK\]%K,\@UU#
MIHV.UN(F[$)^.F3"4E\C1DO816<[4,)RVSWFV#OY>3_)%8<Z)5C_7.WJS!,G
MH8D7,8@27UT*02'$(4GDM(DCZ?!3&J%(>]H\WL_49L)6NNJL$+RL_U4):T">
M)Y#5F,?LX#7PU+2&2DD)-O^R")7!U&$'LI%F@Y-?F2UF/X_(2;(^\?IX_'M>
MARU*U7B\WP[(9UYR^9*Z#_.>O_)%_J*^DB;785M '/NN0U ,F4NIJHA&((D2
M"@4-? >+B"?$*#I#H\^IL6<K<K6=RS9"FVUVZ("MM^EA&<*!"74+O8Z\;2[3
M 8Y.#0"RN=VAT^VHVQX&..QN?YB\VB?QU,%;>%=4SE.KA4H%_VN1E^67K.#U
M%0BU5_:.B[S@:F^0.B) @4LA=Y'D)#=,(!9.%3OF)H@(PJ-8/QO5):),C:K6
MMU2I^H%W+_]N% */2B.P6JM4[_*22BFPQ-],$BU=9$@-IW$T\PR]!ZP,<G7@
M_C#HZ (J9<!&&Z#4 ;4^:HMX-,N8Y,4:RT)C)<NR,H:LY=&R@>[IY%H7]3!B
MQBT;2&RGX;+28H_I[]TJ7;"'_'Z5+JN4.N6<)-P3F$:0QJ&<TB+BP=B).8P"
MXD8.#7CH<+UR,8<[,!EGXQ2%J42$RQR64L@ZYY;)I<9]"#4FDXM@&7B"J&13
MN^%*NCIGUF5X&%#X1;B,1,LU/LL<Z'PO9AQ[5/V3O+G_UGA<>%3B+7X[_E2?
MDTMI8U8%:Z@<,HH='[[F#T_YJI1SY<-36BPYS^Z7.?WS)E-%.M/7:L.B6=G&
M(18!=R*8Q$$,D< N)"JM5Q3&5/@1#4),]<\K+Q%E:BY[H\PZ.T_E7<BOS0>5
M!F"M0K4C:7+2=9'!=,XEQS+#T*>1C06NNA:0JH!6%] J<] DYS<P;-O&Y.QQ
M+!N-=>+8&2W%UF@I*].D:].H36AKQXDV4#Q]B'A1#R,>'=I 8OO T$J+?2:T
M3?:-6W'?YMZX*SB5;Z04+SH;7]?[OY("?TR+<KFYCJ"JAJVO@)?M6$UBQTM"
M!CE-0H@"',"84 *)YR0N\JDJ!ZD_\8TA\N0FR&-94EXV>G>WY<'!7RK"$$KY
M3G*5*JE*SYPJHWP\.I/PU#Z)H2?KSM=P*\!:8]!1>>N8X?K0+]547^D-.C>Y
ME.:;Y"UEKWE]'$XQF/^G]GF,Y2>,1AK6?(PQ+77:%QE%DA%]EC&1W?9M1NVY
MAP^T;NM!?A'M*73LD,1Q< @3P@A$2:PR4SH>=(F(?19R' 9"VV4YU,/4/(Q-
MPJY*2 .^/XB?QJQ]*2H#3[([@/29"0\B8S!Q78K02/.,[J=C-A><4OXD=1]\
M<3RF/27W%C&>?'#D*]P?<5K\7=6<ORK+U7-],:V]C_8^?4V97)]^ENO2N1<&
M3N03#N.(2UZD*A3*#SSH!)X3>HA@%AN%0@TN\=1X=GT5EC5"@N\I7U2WKJO=
MFY%N5VL;_#213]*, T\,%NY(*ZU!I3;HZ#W;W)-N50=*]PG<?S8UTR2N.&L+
M_=>XQ6QJ VL7E8T[?IO\([_*!Y?E35:'!5=A"W-U@]E#B,"(1#Y$A")(>$!@
M@(40#N<>=3V]D((!I9Q>7$+G,IJ*_5E^!UBI4"4$J>\-CIP%Y)!M$8HY9WX"
M6:PR4_FJ:#RA 8R]F/JAYP4"C9HPYD++CID%YE&)RB=FSX$]#3M6FKYOL<Z_
M4FNJ+B#6NL[JR,H)>!/G33$)_^&$F'\-C^$\SK:3F9SJJL?6W/U36O"KQV;G
M1$(7A]BAD/G$5]6L&"2$"4A0Z"+A<M\7^O$S6TU/C:<KX<#5KP9[3=M0:6R_
M]09@< JL='_LL^&V#8+!3EMO,$;:8JM!P8^V#EH.ZGMR5VW[C?&VTPY*NK6/
M=OB)'FS35NUK3R%NB\_\405!Y\7WS8'#3487*Z;R1>\5TG89\Y+003"B1'JD
MQ,40.PF%).)!PC'RD!]J$]2ETDR-TS;E*3?GABI4J1)?>2F7%)"_V'0:A#FF
M00;FV,86MV(3&7!;@(TZW0B 5B&5D>22<O07F\B SL<TU4@SP&;XK$_I\P(4
M&Y/ICBI;4X@MC$_..A=W,MY$90N/K;G-6J.]+\<WE5(/7Q-2>4M6A<K/-G="
M'F#J)9 (/X H\A!,XE# **%AX#)$:.P:WI'7['IR$YW*ZU.+5H7G-J5FJ7&I
M60/T]?9.AL%TX+EJIUKOD?JS&]&M7J$WA,OR37K=WL>^4&^(RH%[]:8M]*.O
M.VD.+AMB5>ATM7%17JV63WE1%?<0R$4^IPB&F'&($A) ^8. +&:4>HA$S-=*
MA*37W=1H:BUMFPD0KT7MOR]\!G$]FK*'X\#4M(&PDG16;\N68".L/3+2 \4F
M 9WI<532T=-^EV@TW[K@N)*<WRHENUNEZ_1%RD&3KEW^_)S7ESON>*%N=\Q#
MPJB($88Q"QR(G)!!XH14$A-!B0AI$$1&OM1PHDZ.U&JQU#))J!B+URK&8EV[
MH%H^54HT5Z54)L9JY[H^$@/L5+C%V)^!P8'8FQMW^N=BFS1V2E_U)=0:M]S=
M*&WY>&Q0PU@_)1M&VO$/RP9%_>"9V; ]]INA?N49+_!".MA7[#G-4NEU8W5U
M<#O?6APPS%76#<0B 5$<(;F$5WFEJ)R!",%.A)G)9*/5Z]3FC4;H:G&)M\0V
MFPWT(-<C=NM #LS170RW)1XPS9T12#;Y4J_C4:G/"(M=%C-[>627N?J/JHJ2
M9H^?53&4LF%(_,CG3AP[./81%''@0H0XA3%E/A2$$>9ZKL^1>4BZ;2FG1GAU
M$H=\)Q[LM19>.<R-W",YPR<-/+ ?;,MLTW>!J_\!C:J@UG7M^)XR]GB^KXXQ
M)N'VGA3TK^'QZF!MS=G5ZJS?M/*)ER7GMY*TL&J]2O/T*<4D7:3+[XT,Y?L5
M_W>.BX]R2ILG+.8^\3RHXC)45+@<+PPC&*$H$IB[8>AH!9+U%6!JDX'G>,B,
MZ(TAU^/P(8$<F)YKT57X;2-\G;YN!M;RSUHZEIPK=0!*"?#QU!+#F';[XF>3
M48UE&)4L^R*TRX.]V^E'<5>RMV4Y#[''1+4=' JY8'>=&,8A8M!1E7.](.!N
MC$U*\M7-&M'1"-7W'O*J6DXEFQDM-3#ID8VY\@-3R-5IC8W98%M!FV.\:7G4
MD;NMS>YXW/EKOU%6E[A3&6X_RNZO\TP.[94<W<TPERNE.O-M_=P#_L;+]_('
MZ=/0>2P21W 2P9@3Z5.(V(,81RYD/L?$H<+% 3?Q*2Z096KN12N7V5B^Q!AZ
M!# 2Q .SQE8I3:#&#=BH C:ZM'FYF^<K=:0C<LXVQJQC 56;5'6).*/RFP7<
M=DG11I-]F51M)2DGZ$$V</4M+><T3KPX<7Q(*9<$Z3L<QAX)H>N3$#L)<3VA
ME5'G>!=3X[V-A$"):$I_>PCJLMHEN Q.5EN0@#^4?!:/ XXK;Y=3]GH9F2J.
M:;G/ $>?[!L1_,JS%6_YI,!T^8]T^72]*I>2.8H/WU0DLJ08Y8_)_\>J4C4T
M='TL!ST)?0X1]2F,H\"%/!$\3'@D$F08&FPLP]2HH5'!<'G3!_R0"$'<)(1)
MZ*@," &#"8M#Z+EN1)TX=**$F&5 &!C^<3(<5&O,X='7H^R!$1V8TQOI-ZZG
MDA]\E0J 5@.5V:;1 ;1*G"SETR-6NS>$=H.VS<48.7J[-T[[8=S]F^HW^1SJ
M9KWIUHCSF=/\,:NBC6F0X) % ?0"X4$4>!Z,0^% X7$6R&_9)[%1?+=9]].;
M<BK)VNK3Z^MB9B1H: (]_AL.V(&I[QC;=?;\6W;<R&^/]/KA9I/O#"48E>KZ
MH;/+<CU;Z5D/LEN"*V-7KSB5?U[PCWFALM[><[HJY CFY>FZ=8P[!$<1#)"0
M*VU76HY(/QNBA$EO+_02QPOG&7]4=09.,Y]5N;3&;5*/VZYT0Q\T[)>X4T&
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M[Q_3!:_34<[]F+&$>P%TD>]#%(6!2AD10R]&<8QX[ 5Z 5V'&I_:X*WE TI
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M[@^B3<KJ(<6H3-8?I5V"NZ"E@0[]RS,'.!_S0O!TN2HV1SC_X*HF*&=7K[S
MC[P]XKDK4LKG'DD(99$D3*YB96-*E>L50L]#%'%!@X2&5@, +"LP-<YMM !4
M?1(+E;TVS0#+%PM<E&J;HMZGU<QE^V9?A:78@#>T]00V)TK=0($.#-U0@18*
MT&"Q#B@ %1HCA@X,9,=1PPALZS"MD(*!+&0<7C"4'&\30G>[.4$[)>5G2>\B
M+]2+<QZ3  LOE%.ID/,I5@5E$Q9"U_,"[K/$]X-1 ^K,59C:C-J*#?=Y4,VG
ME?9G&'$J'\<X(7?#FGP"$ZONO-H!XNQL"OZX(F55C<+B<NWM+#FE"+T>6DQK
M<AW,2K:C]RZ0Q%I^G$W!EALFQ4M%JG+NUG%$;1I*N79N;PFI]+MEN7J6*M<1
M1IT_S%TG=@./$X@Q(A"%80 3.<%"['+AX\BG(M2LMC*.P%H\.FI&W4;&]4VY
MU+0NXL 6UIL1)V"UMTRBL]$5=)5M+Z*VZE:;D!V]0*/Q#+1?P2>-K\!&/IT!
MC#-P<AV;$K]UIIT!T-=(NS-$K^;Y%-\WM^<^IB7%BWJ!^5'^KIR'-/03'ZE2
M77X,$5.Q67'DPIAA&KJAX(PZNHD5C_8RM;53*RBH)6W3DE2RZN=:/ [J:?JV
M!M7 K-L+):,\C&=1N" AX_&V1\O,>%:];HK&\P_W\T5WZSN\YV39J?% 9:^K
MA7*Y=FH9_8K3;%,S#(4!#5"((6>)"U',74B2R($NYY2[81!1L[3F5J2:&JU<
M&5;P>Y3*&/J==JRIYUZ.;J.A^4S*WRE8,P/[]E*9&==J[1?O4YK9+?<V"-8V
MG4([@HWJ^UG%<M?%L]MX/TK?3RUU^\)5M%'V>(U?TB5>M)MV<T=EQHX]! /7
M2:2/ASE,N,^A'R&*J2"<^4;[[OI=3XV<51;#.O%6=9J8MV*WB734*K&S'? W
M,UXV,(D>^0X#], ,>R"OG\)Z+3EH1!]D5]D<,9L\:=#[J&1HCLHNX_5HH5<>
MNR)]Q>JJW3I1T@,OGN<D"5'(60P%5O6D6<PA3D('!CZ. A%%/(AB@Z1U!SN9
M&E558;P?"]XDP%3,I$JPJ2B[RH<AW\&';^IBHG1)UL<U[^6C1NG5#N-]FIUL
MH3BXI]=*N$D]!Y2,%@ R2C9W,5"C999; [9.'@?DIVXMZ]$9*,ZDBSO\[IBY
MX4Y*OY,([O2S_5R^W_E7Z5NJ(BN2=N^*/),_TCJTY+:XKMR:FZS[1)K1]&4A
MG4WIJLYI3!V7)Q2&3N)!A)E<O3NN@#&B81S+/T6!5ODC*]),C6VE,F C*]A6
M1QH)U HI1V;KL48G\$>EU7%'9@![ZKF0HUEI8#8?VD#&GJ858&TZGY<)-*H_
M:@6[71?53J-]F7FI\C_+7E]3QMF[[U]*SFZRF^RU*6>G\D?4I[H.(B1Q$PP%
MY3Y$!/L0(T>NS4/NHH3'#/F.25D"_:Z-.'>DD@)5U8!56=]43UN9 5X+;<JH
MVG;0I<\AT!V<*Y=UVOU6;+58^/%+C?)/8"T\N#H/<P]>-$7,+@EJ]SXRXYFB
MLD]OQBWT6('WCK(Z>XFZOBU]E;%VU?J0JU]UPK*:8G4,A:Y/? ^J6KD02;"E
MGXHB*(B(2(Q=7PBMW<J)Z#,U3[>;'41M*O!V$V&95[]6Z9"XRI DFLPAU2V=
M.H.2YM6<B2"OLXWQ]E).:-ZHP\7?G8XO?M?$%S?/;<47'T\J\M!)*M(D#@$2
MF\T6UD->_;H;EVQ4]W(BUC39&7I[:2>X"55_6W7L.NU^@W@[QKWL//?2?(.X
M^@9Y_0VFG6\PWR2V:;,/GV+ ;G*XK +*U@[8=$Q^<K-M F*.MZ\W 64/;2%.
M2*Q^:^)UV< FSG$KOO$WCLM5P=FMBHU<%85R8#/V>YX5[3^E7FE9K<T?^+?E
M.VFN/^>.'R:1RP6,21RJ<Z 0XD =:1,O](B#,7:-$N+8%W%JWM[]ZOD9U[D9
M-O5"0:-:0X[B0(VV[:@8%>/0"9JI6+,ZFJK9VK"RSX ?B-ZB_FW-/K 3=\3,
M5:1\+7]EOJY"S>8H4.J 2A^+^Z3#@6USWV  *4?=7Q@.Y=U]B %[LI1!K2EF
MBQ^Y.P]#.4DP)X;4<UV(!(IA3'$$0S]R/(PY<Q*CU.FG.IL:]V]$JTO9O/)L
M9;JA>A)</;:U!=G O+F?1&T&-I(.F$+M !R#YE#K]O>V2=0.:'XVB]JA=WK&
MQ+/_6)7+:G)\R*\8JZIBX\4=3ME-U@0U'<XI^9G75;3Y/2]>4\KK./WFDH]Z
MH,[V'0OJAX12Z#AA#)$?8XB)%T"/18CZ/D4TTKI5,Y; 4^.O*N\UW-\*, R6
M']K,>BPX)>,-S*0=5=66RD99H+15!WV-OK.M3 5=G96WVF@-&K7;FT<=Q2U&
MWH]D':M!^4/+/&Z\_D@6V OE'ZO??I/4KWG.OJ:+A71DI0.+G0AZF$00!0C!
MQ,$<HCBDR*4\XH%6".QNPU,C_58N,Y)?PT3B(,0153$5'H+(=1A,(AY"/Q%Q
M@JGG(3>>U^=:]TM<+(<#:[>3X2%3EY(>TRQ3*WJ"%RK)7D\4Y=<5^BB6 'HN
MABB,.,0^\R#G(N2A2M0D4(/BATPSNT1_#-LNQD"0U[O^E\&GYQ'T 63@F?OL
MX#.>6'>5M#D!KML>=:+:U6AW0MG[>S_BK\I%=W;[5?;HJV]I.1>)&P44^9#*
MP2@':"P@B<( !G' )+NI/,]:59[/=32UB:$N(M\1=-8C(_Q15/6&K VL!A["
M1V "?R@Y+6[KGH/"YD _VM>H _^<QKM$</;YD?,VGCT7_%4VL3R6>K+ZH[I>
MM-[_G;M$>0(808]R#Z*$4TC\D,$H"*CC.X*XCM'^QF0TFQKU51("ME/I225X
MK",>ZD+ERR*MHABJ^GE@)=<@Y3@)ED?[X/1(>C+R3FA6&*]>5(W1R53-]>>L
MH.J<24\@L>10]I]$ODGKROTUTE .95-KV2D'$_"" M2J[&1:[XE5SG%(8S]"
M20RQA]5!!@X@CID/>1!PZD:4";/J,8<ZF=J<6W-;1\AS'K0^G'K3V*4@#3RC
M&./3K_CT$0"LUY[>[6?\TM-'-#U8>?K8LY<EJJTR$9;5UG7UG<K1S;E*\H4B
M!T'D1!'$U'$@Q4F  [4;[1D-^R/]3&WDK_.,=N3LEQ=V%U"]@6\!IH''_B&$
MK __,S ,D?-TMZLW259Z1-]C64://?YV,;OJ_<K[>>#T*4O_<\5WHS0]X3D\
M0B&,41A"1$.JJM%%D&$4<<<1#G:,"MN/(O74:*H3V?NA7*;/5;*Z3O"GBO@]
M$*);)SZN7<OQPW7/?QMZ'#DYBP_,N(>#>N5B_&759"U;:P,VZDP^KE?;!%,+
M]3TO^%\N^E?;%D,$!.MWWG-9VR8KJS;E/ZLU]*WX4M8BSUGB\] /7.CZZL:Q
MY[MR/A(!=!S"Y9*7"DR,CM1.]C:U>623EV]1'1T52ER8"[B2_ZC3(AJN>4]B
M'02.&Q*40!\)5;:"$QA[40R)XX>"L3 DH3=_Y07)1T>[V^O_-7AK;C;8PG#H
M78<U>)6@,_"Y1>^+.O54TEK<@- !Q>I.Q,D.Q]V2T-%];V]"ZZ4>62D.+';6
M/N]Z^NG,.K="N;Z5YUO.L>M*QO%]Z$8^@HA1)AF'.S ,$/&8QQ+Y?]KY)"Z1
M9&K,OU[&X\XRGJ_7$IVCQDY*7+6N$&I=46>$,+B<?Y$13]/8J*9YB\V5@RN\
M;CF;V^YJ;S2K&"0[&,LZ(Z4I&-1*9CD%;"![,AO 11V,=X_?!@Y;-_"M-&AC
MO;)SZ/>9/^,T:_^H\HJZ\] -0\_S,"2ARR!*F .3,!)0A*$@3"389;3_$N:\
M %.;VW:\[!GXVD8AX"8*H6B5:/SPI79FX-Y&ZN.+VX5^;/=\+_9C+7_]Q.E\
MS!=Z[/K0#>?$:\CPAGZ]/D*G77V#=JSFUUQ+L4E^MZZP$,64!T&UJ1-)1O1=
M'R9.D, D2D+,P@@EH=&FCKD(T^7$C:R&%2YZV$&/](9%=V#:.Y-O\Q#N@Q2_
MZ _B""DX3TDQA52<&BAIIN34::G')LB=2/^+%_?O B_XC5>YYL)8NNHB"B#Q
M'2R=OIC#F"'I^3&?AZ[P:1QIU6,[W/S4Z*L6$-R_@U)$@Q7N/FX:FPD7H3$P
MW6P! ?ZHY=,,3#N"B,%"_B)D1EJ=ZWTJ9LOLHWJ?7#OOOS7>@OBHQ%NKW.-/
MC7P_I8EW;6K9J-._)J5FZ'LQB7 (XX"X$'EA" E/8LA\X:I#(QQ2H[6M=0FG
MQI1MGE6^$=1"5M_A#*SG(KZIV0:F= OW,]8W,#IZSLZET!WO<L4Y(TSBDL11
M(?\:EQW.86SMTL+9CGI.'=(OJ/J]%1_3#&<TQ8N[O EN;->3L5R[XP13Z'D<
M0102!#&F"+(HB7A$O#!BQ&@VT.AT:@2_EKF*\FNE!JW8.HO+_@;09&O+L Y-
MP)<C:LZE!A!9I4>=?L=E/ ,D]DC,Y%T[L0<UV76/>_XG7\CE___,%[+1<NX0
M'@1)E$ _Q@(BZ:%"',8$4A3%3DRDS^IK453/_J?&5K6X.X$#X$F*K%R:Y1,'
M3[7@/2M-]+!0OW "B[B_11!!8X?M0VB@5%!%'1HEAL7]LH !B_B/'2;0";&9
M-34%- :$K;(#_;$T#0PXU^R;A@-HZGPN"$"WF;Y.<$[_;.S?7@ZFBY5*2W67
M%]6LMEP6*5DMJP#I_'>)19XM)2ZRT<>;3#(Z+Y?S,.#$B<,8$H0B=?R%88+C
M!#(O=!S'BP*?!"9EYNR(930UC5""[D'U46?,:'3[YZ9^B*GC;,5H/A<,B9A!
M1X5$(R<0TG$($0P2CU 11A$+7?/L=>.;;KS<=^_6&>_>U2G;#(.G+1DNP,(C
M!'-876M#?I+ F+ 8<M\C;N)$0H3&"?/>RFS#I]O[4"?9>U.+Z:YBQ[;!X.O<
M+M75*LW 6BG0: 6Z:JDDOMN*@58SFXMAFTC;72Y;D6SD!;5--/>7W%9;[^DG
MT2?.5@M^*S[SA0K)O).SS?>' F>EJAZ;9^6[[UM_J8IF!QYEGHK^YQ0SB)#*
M%(L]1U(V)3SV(C\*C8J@]Y)B:@OT5@FU(FF$!96TH*O(3"U.MO_<J^IY/\-I
M\O70YAB:GH>RA#D?7X*D5?KM)<BX;'L)5GOD>E%C/9/-;H+8UX'M[].2+G)U
M>7?N)2$BV(N@6R75CD,*XR )H?1M@X"@T&>142*8T]U-C1WK-6+G"I1ARMG3
MV.KQFCW$!B:PS=%)4V1,K'_1T6'6O2"ST<-B=EHMO*SFJ#W=X[B9:K6TW\M7
MJ_=6[R)=U4G,/]+ET_6J7.;/O%CG))D'" L6.C&,8A9!A'T"DT3(?_J!")($
M$>'%9I?"3_9G,E[&N13^G@M>%'(V;ZIT&1?I.@&N'L-8 VQ@@FGE!%^EH*"5
M=*91@[)/I:[SD%@NU76BP[%K=9W7_4"Q+HV7+DM2=YT_$SFEU 58JE(K_\79
M#>/9,A6I<H6:+"1JN[ZHJMQV>*W*?<39]4J.M6Q9/SGW_3C@-/0AB5  4<0H
M)$XHC<-#S)+0YZX0?=+<69=T:HY1(UROI!7#F5./[B9AI+$.@3M*SL!&3=#5
MLTZ>T1P8%TUE].[=Y4;9&6C-?G7:[+T3_@UFDB%2!MH7]DV2#@Z&^;&TA<-U
MV"/$Y^%K_O"4KTKYR3\\I<62\ZS:XKRI:D^FK_Q.CJOFI@0.<!)'S(6NITJ0
M4X8@<6D$N1L'PI-_<R-7.[;'H..ID;\<%SZHA 5K:8$2UR" Q 1WC8B=@= <
MF*6EU* 5&[1R'T2VSU4?$X@-@G,&@GJDJ!P%^;*%?-E"7M?-2->0O\AW; 7@
M],#K9.2-27OCA=STT'(KUJ;/^V9TSW@ZOY)?&%-?V<<%?IQ'$EKFL1 R06+)
MYY+4)8G'D H/<8][0N!0A\_W6IX:8:^% THZ/0K9A^LT#5\$PL \JZF_]K@^
MJNO&S2Q;/[/D].?'_/47^8YR,1/U0S6J.Y[E?GNC#-RC:K0C\_@#?0O;27^-
M[Z2*XQG_BA<J4\0<8X>H)3=TL2.7XSQP8>QP#EGB\,1CTNURC4YHS_0WM6%:
MIT7!CP5OJK?Q;TL)?K5$ZYNHYASDFF<0]H <>*C7DL[ ?K;(6ES+66<T@;%;
M$>]TER,7QM/2?[\^GMYK_6AF/Z/P^UQEI9G'(::Q$!1&&,L%'$DX3$(N('>P
MZSM.*.E'*QWDN8ZF1BR;!.%7+R]%CNE3M<6SEMJ,4H["J\<E-D ;F$3.X07^
MJ$6V&'-Q#A6;#'*TKU&IXYS&NYQQ]GF[%[SJZ/[;KYE*[G+/%PLY3K]DLMTJ
M)WDG)F,>48=A+XE@''*YC&#$@TG$(LA]WW=<#T6QL'+E2UNBJ='/YA)8<]TE
MRY?@1;;^5%UF;^Z]X'J_[_B%]8',I[&[-+91QCH<.'Q#K+D<5NFD;H<U6H%*
MK;J61#<D;6Q[V;E'-HC=WO!F6>=B63/(\LI^<G"5C?U6E?U(9;_E1L$1+IH9
M@]WWZIE^1Y.XC&:,B^[U-/.&^R0EXX7:F\./*EXQ_XX7ZGSF(7\G/7G*TU?.
M/DH@[E=DD<K'I*B/<^9QQ+U(P#AV5&DYQF#BQVJE[_D\B!%'>ME\^G4_M6EQ
MHT!5Q;E505VY("I';:T%4)\3*#MZF&3[,C:1QFPX*/ #3WT=S.5,MY8>/.3@
MG<I0VV"N- #W8V%NDH%M2.S'RM#6\[NW-5'UQO!TMC?C5D?,!M=7X^UL<;U;
MZ3&YW+]PFHJ4L\Z%(S6?%>53^K*19![Y**:)0.H6CZKP0=2UV81#X<?8IXDK
M7*X5P672Z=0FDK78W=O,E?]7":ZROC62&]"8K@$T)HP!8!UXFM@@VA$9K&4&
M=T,B:C =#(#L2). _C=KB_8-L3I)]KIMC4?QAMIM$;OIN_UVY:]><;I09UD?
M\^(>+_B]J@)8Q71M*H!B'Y$D<@(8Q@&%R D))%0D,.&NSUA,O!@9I?O4Z'-R
M9+ZI[5KE%5>7;%^EZ%E3['.M$A1Y 9528*.5V4:^CD7T]O0MXSQT., 6A.4V
MA(,63C7 R>:&OTZWH^[]&^"P>PQ@\FH_HFJR74K7M@E!O2MR.1TMOZL0I.55
MQM20?%&/S*.0L%@P!WH)<R'""*O+2Q&,4!*XF%/D$S[/^*.ZL:G'6/J=:PVH
MI!Y071$&7-@U6_I5H;B71NZ*M'@KM!E!&5A"CZ<LHSO2GD4CM%H@-V*#5NY9
M%1VZG%4H?SB+LC%AF0-FD[<,>A^5OLQ1V66Q'BW8.=[L+N+;_!UU3H[R2@4>
ML;5$\YB2A+B. T,BF%I:<Q@'3@BY$T1N2*/0<^)+SC7U19F:C[:]@U4G#0-I
M*WP=P<74<&W.-"\[(C,P6;^SS&$,\1:'F-O;N[4NZX1%\M':, ]K'AW-,)<=
M6@YCH#?-@_EB.(0&/*4T1]?T>-*@AS<]ES1'XMR!9(\6^SGM.Q6G;\D22UG8
M3?;AF_1)LT>U7-B.-^RD(* T]A'!$'MA!%&"Y$1'P@!2+&(W\#S.]:I$6Y!E
M:C/=Y_T*]2!O])'#%?!&(R!7TDV,<DX6Z6/%*8;;$9>84,_]'\DP \]\^W7O
MP6W')!^Z)MD)@QXB58(%4&VN&2X19]1%A 7<=E<5-IKLN;G+_F-5+MLE#6,5
M^>/%'4YE[]?X)5WB17V?JRQ74B+Y7Y7_\SJ7$\$\<6(1H9A(4U)/+C0\!R8T
M"J ($'($C;CLTFC7]P)AID; K7" *NE T61^DX[1O7P,/^?@8U']O3/I&NX"
M7V(ZS>WAD0PR]+[Q1HUJ+V:M"%":*.YM=)FU=W@K=69@;<1*(XO;R19PM;K/
M?(D\XVY 6T!N;V?:1IN]4VPI-[NHDRJDY9^?)._?+/ES.8\8#7W'=V#D(E60
MA# 84U5"2<2(L-CWJ&N4P.]X5U.CSBU)@1(5_*&$!96TAIE+3R"LQX%V<!N8
MX?I"UB>_UADT+"?7.M;;V)FUSFA](*W6N3=Z[ NW*><>\+<Z@\K.:BKR."-!
M0J$( PZ1)^F"A,*#/G.<A'@>B@/]G=\SG4V--=;I^*2\39ZCF?;BR1QJC1U;
MBP .3!\C8V>PJ6H1PY&V32_"TFQ/5!.<D[N>Y]H8;U]34YNMG4O==WIP[4U&
M\V<N&^9EG<T\(G'B.Q2I4NVQ)-?$A=A/Y)+7HQ$*"4Y\EFB3ZV[K4V/36CY0
M"6B6,OXP>!IT>0DD _.C;30,"/ 25$9BO :=I9+1UG'/,;5/<MG>2^.1US%Y
MM]CJZ$,]Z.DZ7\B?<^5@OO).^=\/Y3)]5EM-GWGZ3%9%5>GWGA>O:;OUXS!"
ML!.[D#DNA2@2,<0T9E#@$(7"#;&+(VT>ZRW&U AO2Q& .R6\>:L**#JZ@+)6
MIM[?,R"#_H;3X-!1S#'X6K9KB6XQ];46H*L&:/0XLTEGTQ(&_#V*148B^LO&
MB*VIX6)$3\XA_5L?;[*Y&(&M6>GRUJQE!R_7!<L#XB8AB5S($U7S*40!3&+*
MH8N9RX/ ]3QB5#'^5&=3FXH.Y8 N>]>'/PFSWA:H+? &GCAZXV8C[?4>( -G
MKB[?INJ[CN8:^:/WW^E94$[E2[@K)"/-O9!QC[@(8C>4;FT@(IA@P6"$7>+Z
MD8<X-BH)L&EZ:OS0'B#79Y65B.#'+_?O?ZIJL:]*IH+TZFPBFB79#\"IQPS]
M0!J8!RJA:EPLUE;;T]1JP;1-Z^-60=O3:J^TV?X3E]9^O*(T7V7+\@Y_K[+&
M9TS^IECQ;KKX:GV\N<VF2IG1 !%(O8A Q'T7QJZ$D;HQ]ZC'G3AP^I6 -!=F
M<G2PN7C8*@,:;>J+A[4^W<(0?8L_]K"<)H^,9(^AF:=3"E+7%H/>6[2!ZS"%
M(7O(\T;U(?LC=[Q,Y 5M]@TT.;S(VQ2+VPQ9@5SDTT2NN%S7@\CC B:^$T$N
M$C>AC#DX-%I[&?0]-6[]#?]'7JPKEI6SJG)K<\&^OM9]K\[X^6-*P=5BD?:H
MC6YB&3TR'0CO-]OVV\@MN7((ENP!F-TH%_WN1PY[,<9E/P[&O(E^#+>N?]E4
M(=JJ/O0;QZHO=JLJ%ZV*(LT>Y0._YUG1_O,=+M/RTSHVC/M4A 0[T"%Q#)&3
M,)C$,88>C3"AR$V8;^1P6I5N:BRY*0P[:TN2[58B:U4$*CRMU:JM-[M6$U1Z
M7A#M9_<CT*/;-S/MP(3\)E8UYNY!T+?)[G8%')7_!\%V=X88II-^<\A-QKA(
MLW3)/ZF\>#?94@Z(=%W9[F->\/0QJVO8T;J^^Z+:S_P5I]FGO)3S1H@2S) '
M>1Q)WSF67G3,Y4<A2"@</XB83[')O'&Q1).;*VJ) 6U$KC,:US(#O([$-Z/]
MR^VF1_6C6F-@>M_H A=5WLZ--NNPQ=98K4:@HQ)0.H$?E5;'=YF-Z=P:PC8I
M_'*A1J5M:QCN4K6]AOO1\^]\J5*KW17Y:\I4ANPOI9+B8YK)=;>:&JA<9=35
M1ML#3I<0'H=>!$F@$CUQ3B#Q(A^Z-%9'1,@5KM$5<7,1)D? K:A@(^O?S.BV
MAQWT^'58= <F5"E\G?FO%5_E\/]1:0#2["=P"/=!#J?[@VB3,WM(,2I)]D=I
MEQ4O:,E>X,Q=ODCI][GC"Q93$<+8<SE$ 4O^#W?OVN0VCJ4)_Q5$O&_L5D<D
M9D@"),#=3UF^]#BBNM*OG=T;$_5!@1O3W%9*.;JX[?WU+\"+1*4D"B !)FLG
M>ESI-$F<\QSRP0%P+I";I$&IDH3E+"U8;)4 ='NHN=':Q>"/\9$R#:YV].4'
MK< T=3E*IA83_-'\-\@VZVUX0L?,-*.]><3,J=8V\3*O[G#OH/N;-L_R\[?U
M2M6]1A8%Y9C%IG^N,L4;$,/:,\H22").\IA10B*K=)9+#Y\;.53R@4K IE^2
M?2_=,^#ZN6 L'(&_?@<DG+KJ7E-Y1&/=LT=.UEOWFC+=]KI7KQE8NW:S%DK)
MK6G%<#PS66^VBQC+*$D$@RPUO7<DBR"/]0R?Z-D\5S%..7.J W!UI+E]M*V@
M=4,1T175L1KM56SMIG4OB 7^KD_!>F<%EGM1V5M >*TA>W6P:4O&WM+YK$+L
MS1O&QL]IO^!%\\YJMWTH#BEE'WZ\J-56_:I6JBAWKX*PHDBD@A$,(V1.,XFI
M"Y#2"&9*$PC2'$**>%CXG+,L<V.93O1<(V]5?ZV;\3DT6L[=3G9\-!'Z@1FK
M&RMWU,/\[8@]:'0!OS3:_&6B:+G!P(8)EG,7YXUBY0;C=CU4;O@CA_%L<^1H
M#J$^K5[VNV, ]-]4Y?\G>9)R&@M("ZX,F7+(\TS!B.0RB16-*<8N9'IKP+DQ
M9D=>4 E\!VPB[H>!;<>(/B$,3'O]Z($_:H$]DIHM-CZ9Z^:8D]*3+0*O.<CZ
MOH%$4Z[6FTYAY47*6":2M("2(P:QR 5D,D$0QXE(,M,M3SB5TWP]P-R(Y/?U
M"FH3[O2 2W,NTE81=Z20US"J.%91@7)(:)Y#G$4(,H$YI$FA4LP5$80L7M2F
M7,NO.[;9A0?S]6 !G:IC([#M?V^KL[/=;E/R_:YRG'9KL-*?S078[P!73^5J
M97['V=*$,H^T1!8+A:2)?LF1@!AG"%(6QS!2-&5Q'F<DBAM+?%A9]MD9;X=V
MJ+E:0:VD/Q-8SI\C0 V]3#C!LND,<?\*R]]/L?QTBTC<)]$K 'F=-%^/,>TD
M>47#LTGQVG4#R_^KK=(W?;M?R??JNUJNJ]XYC7N_T'.@RA,20\T:$F)*),QQ
MC"$B,J$)BQ.5NA7X[QMM;M-C*VP53RN/XCH6Y^\%V(X>O,$6F"M.$.M(VFXC
M>*R=;X.(U^KXO0-.6__>1O>S"O=6-PW,;6/;;YUNF_>[=VRS^:DG@BJL>($R
M'J=1*F&&#8EP[85PF2*(6)86,M:N2.J6SM8[W-Q8I(I(,M^#,#^HH]R.66K]
M&-OQB#_D A/)ZP:N=]I[ ZVP=4Z$Q^PS*U2\)ISUCSAMCIF5]F=I979W#>.3
MA]TWM>DD(1COLHIIU6M+D:>$ZR4Z%I29/L>:2^*804FS3*\YDR0I4A<NN3[4
MW'BDDM0L6F C(%@.K2?0@R]*59XI2J D"8&8J 0R5N20:=;.8ID7(H\6W]6&
MKZ=%N#MD:(R7Z]43U"9]#H*P'5/[02TP2]=P=:2\ T<Y_?'S;2Q\<G//:)/R
M\FVM7W.RQ1T#_;OZ*5<.?][IA7^YVFON;SHD=>N;L5RD::H8%#'B$!<L@WF2
M4)BD12QCGJ@HMPIR&R_*W/B\T<0Q\G^$*2Q=Q$D #NT^-C-DWT'V'3@J X[:
M!,D(& ^J5^]SN#33>J:C43OS6L<_<4"EZ'N]TI9*=BHQK%=5EJTP@U?=/,U:
MO#EP18KFG#.D/=Q"Z3\DAC3C#$848QFE$4?$ZA#*?>BY,60C?"?RL$I1U4OI
M92U_W>S6?DMN@#7Z23,LQH%)LH7W1'!P7U48J.$]R'[[5'PLS@X%G8/A/5$1
M9P?</15L'H18;Y%FMR=.5YAYD*8GQ9B'/6' K/!1J?=[M6!%JHHTDY#'*H78
M9,KF.<EAI)(8*TP3FEL%,W6>.3<>UU(!V;-A=Q4;"_)UUS@PJQIEWP]1UH$!
MW96>B-H:2_LJ-'^J9R\A-9=.QS2GLIU0R*M_&L -OZM=-XJ];7CY><^UY_-0
M%,H47EGH%37F,E-0\32!."88,D(()%*D/$8%$HE5P67[(>?&+*=)%R^5K&#=
M"&LBF;6?_ZPGUZV)8;@#*[4SORQ/.@,[?*EV9N$10JE(<TA01K0#SPCD>21@
ME".I$*8J487=%FH8PTRSE6J2\5].S'. _<PNK- O"]"S[E[L:L,U%E3U^LR_
MC2QF%N^X!YYX#."'[\%(?&R>7,L,6J&]H^DP=7E'=:*9K>=U?D4[OB8_)Z1Z
MYT:[)TTW=3II=C*SNMTYLHQE%7*\_<T$2Z!VE<H4(X6D,"\PAECF$61IS&&J
M:,PERO*"..UF]XPUMZFVD@V@@=4@+V!IMQWM":'03G^G4F,MJ.DX6@$6(*'
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MM=<DTIAD$>:0TCB%&!%D"EA&D$DDF4(XC5,G;]5M^+G-!HWTIGCA^FE5FOG
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M$9WWIK-J*+OO31W\"UC[WICUPK+SWK#FO2E7ICQ ]=X<>E6::^41"E_U/-[
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MQC0':4%A/IVJ>(C9B"RTQ$VMJ 'AIO;6L%B>!<4X,!\=0CT[PH,CYAVZ>BB
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MUJ"9?XZ.7$&4R&DDH$),0)QP 3G*"R@P5YEF=BP+J]24ZT/,C:(/$HYPH"\
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M2@N8)PF#>BXCF4)IPI13VEC/6'/CM5K4EM8:,F,'<8<S6!_>=H3E"<7 _-0
MV-!30TI'2?TQD04</HFG;[A)><9"[]>T8G/+4!:I:Z[^KW+WK:W#>JB_^JZN
M*%Y^5^_83GS[^\N]_-_[^L#=E&"M*H>VZ;1- [\JP.A)2[A=8*[=JD@4D!7:
MY<)QE$..H@R2"!E7BU%%B%NJ0SAAK;Z_27,C#F6H_Z65!:+1]NY8]O@.B(/&
M0!B5X?X%L(/2=>WC2FU]Z2%'_KE6O3H0:Y1WY<%@;XPMC;[I6S 5"W?-_^Y@
M_M^.YC^J"MZUYK\_,?^7UOS'$@E_.YK_\RWS#V#TT);Q.R$$DW;B^20TZN?3
M4? 1A[9V_;SGRU)\7*[9;D%3F1-F&@C%<0HQEACFBBDH4XD3'I&(8RLO^.+3
MY^;WU@*"6D)0B>C:T;6+73\5CT8D,'NZ@#&@D>L%I4=W<>T^<^(6KA?4.>_?
M>NFBH4'B^GM0VUU=P]]$G;_;;TSRU2+'&>)9S*&(B6G7:&*GTBR"2O(,XXPG
M*G:JP']UI+E]O*V@3;,*(ZEKC/<U3.U\*B](!?ZH#R =A31.T*8W;V] K/8-
M)/R&9E\;;.)([!LZGP=>W[IA2'NI]5+_O-Y4OD/GM/]07^^+'G%35GMGGY5^
MJ58[]J3:#;;_4$NYR*,H820F,)6).2XG$E(484@0)@F),LP*9M]F:K0\<Z.9
M8Z'/S5'T.Q,8V0C?V?__IN5W:6DTWG@6Y^'3FB3X$J^C3#<H\:Y3D?5+UU!'
ME:K#\]I0_S&YH5QZ4$UJL*EZ44U@.,>F5-Y@[F].-7Z8"9M4></DM%F5O\<.
M//'>O[PLJY'8\E>V-$U[OWY3:O>^W(KEVBRGMX_JQ^Y7#<0_%T61,(;T7!CI
M_X/8-%]D),HAY23-<DFC/+.:$(<,/K?9KRL[:(0'E?2@([[CL;:+,2R/M0-!
M'/I8VPI=\(>1'53"^TP8'X"9UT-ME_&G/=0>@,S9H?:09PPDM\NAOR:XUYR<
MBV_J8=7T*%_D4@I.: K3)-/<AA"&-&$2(I;%4J),)&ZU41W&GAVU&='AI507
M(_WV#C0*@-B1WAS,8<EN84 .36X5OOP*OD=X34%2_\W$!F#FE=P<AI^6V]QQ
M.:.V 8\8UXSLD?VXWV[5;ON@E]W,E)\V_;G?L<WF9['>5)_K22.A18RB+"V4
MA'%4<$US L$<,P[3+$I43'(>)TZ;HD,%F1OG'1IL[=@/P"I-[L!*NQOK5A^@
M)Z<M$%V-@/X!;(U:PSJ;.5O/CA6GL$E@BCR8PQ0:O&_,<5 #&#W B2)G#='\
M=SX;"F>()FC.LKQ)/[2AB%UKC3;X>9Y(5O_0_JYIQW;"\RO9=&?;7IX(WJVW
MNP5#.(X99Y!)@B#&N( T0@(*D2@I(A6G+!I%P!Z$G!LY5Z%J\#S)=23K^C#G
M0$:>V$AOP=;FY\,_-$K>G?J[AJQ;19O@T$MNL=$V()U[M$50JO<AY]M. QZ1
MOCE%^!QK:/B0EN&35/K'HA354^LH_@61*699K&#&< 1QBA+]VIMNFFF$$DX$
MR7.KS*&;(\V-R)M(&D,-I^(VB2NN,4;7 .YG9:^P!:;6P8@-"$2Z@<;HH*1K
MSY\X0.F&FN?!2K=N&%@%KBXUL/VBEJRJ':"',2&0W]9+J3U;TV/D(C,MF")Y
M1GD&5:I1QDC&D+'4)/5'2K%,)JAPC(0?*HK5=S)IG+L67&U!4X"[4L9$+IMU
M?%T 1<\,N^4AU;@I?5+507$\JAELO2P549P("0F/),1$<DB+"$,6RTA%F8QR
MXG2&%M1V$TX-CZ9!?%N:IMY9V7U30#V_+-<_E=K^]VIG9LV7Y1.K2])HP^I?
M55VZZOP54Z)Q(BO:N?U3V";P_-.J +X</R<S&774J&QUS7GW6-=P))A>*R .
ME67:6HDC$3NKJCCV>0/"^'XMUT]J];?[3RO1G QE+,52QC%4)-$$*J,,YHPF
M$,=YP65*:6K7D/;RX^=&B[6 X&_WIB6+0V#6.6[]E#4>C<!$= +$D(HMYX@X
M1)Z-0F:B0#*[5\4M%.RJWKV17>=W31>H=57BD[BKZU>%BC1XU(BUA]MQ$B<<
MQQ+FI- >?$:5=O^H@'&2)J1 .-$NOM]8@\[H<V,XZV@#Y#O:H&L27_$& X&>
M2<1!)?V;Q!Q<P&W:J(.N #.+.[B C7ODP:6'#.Q'+9I4<26KBHAFQ(WZI@<M
MOZNZNUCS42&<BHQKBLOS7+MJ*D$P+S3/H82F+$M2442)4[]IVY'GQG$=P9N:
MOR>B-^WV_AW\8LXS'2N)V)O#CN."@!R8W^X?WGT"][O=IN3[G4D@,LO4S\SD
M$ 5@,V>$O#9GMAY\VN;+KIB<-5=V?L#0YLEK\4^S8M6??5OA52SW9@'[>;VI
M6+/S'CVN?]?ZFP3U]5(_]*E-53OTN"GB/(T*'D,F8J77H%@[=0P5$*<J880P
MI)A;$3BOXLV-![O:_?=F^_5_N/9L]FH_2[_OS:P2VC$\,4BMVATX* <:[<ZX
M]51!<$BF#='O* SX?GM5>Y5PXC[7(= ][Y$=9)0A#5W4"]OH6>;O+QJ+U>ZC
M4@O%XERR*(>"B4AS.-)N*N(YS%#"(G-,0U.KF-@KSY\="3<2@D*O]<S>/9.R
M-"9@2Z#'?W9I)G$.IL4VXSB(0C-BBTXC'=#BC4/$I='%*&2F:CG1(K1O$-+O
MD;=.#U<!Z.^Y<'[;A-T/KLI\VH?@^F7#/-E?]]MRI;;;>Z$)=5M]P=4VP.=-
M*=2"YHI)RB/(288@+AB%')$,HE0F*,H)4H@OOJL-7]NZIKWCN;RGW5$#OJ;Z
M+^QY#3YNZN1!,P.!2E;PRX>_?_E+5;OSPWZS-A4+ZO  QY5WOP&R*$Z(TG-)
ME@MS.I6:MGY<0"P+A2,1Q8HZ!?IZ@W^2+G_Z0=_85H&7"O #PA7HTB0];[:!
M<+?SZ+VA&?K8JY$3= 1M0F7KE]F?GVT%B4^WN7_ 2;U@*]U?.[5V-PW-R^=;
MO3[6L_F'[^;,_;!@9;F@+.<49E&BG=7$= M-:0*+C"2IB(J4<.J6@W]YH+DQ
MRE%.4 LZN(/Q56@M]P(\ !;:AQV"U8 T^7X@_*;$7QEKXO3W?HW/4]UO7#^0
M&P[MUS\TT7%?U>9[:?+H+YX"+2M;ZI\>BB]*K)]6IM+SYZI_I0ES[]242"FB
M",<YI)CE$"N!(,TS"3.5T8P4D4JQ<B*74)+.CIVJ#*4+A]A-[H$C0P4SL"7%
MS<%LH3FRT='$ ;=:@D;-J]&,=^"HJ[GQJ"VHU:URE4Q=DFJC-$QUDM#&\<K;
MP82=EOA#8WXV<P0?<.B>0UG%>C8GRC2*"LKU?(&(B<#,HP12Q2AD:2Q(D>$H
M5[';&K?[^+F1?"N=8Y#Y*\QLUZ=#D0B^(*T%"W"N?EEGORO.DQ$F7F)>TNY\
M37GQJH&1.H>-_<^LE)]6[]A+N6/+-CHGX2E-10$1)BG$G F8\QS!&*,XH;(H
M$'+Z>'M'F]NW?!06&&EAN0*-O([1-[T0VWWKWH +_.E?QRQ$D(T-*%X#:WH'
MG#:8QD;WLP :JYN&$<EO:F<^RH?BW4;I41[VN^V.K0Q/W3^O]ZO= N<\91'6
M/G/."<1IA"!/D,:8I"S'+(J5=(IHOC7@W.BDEM<L"40EL!N)W(37CD=\@A:8
M2AI1#6"UL* CK5YE5?+Z(Q-;9'SRR<TQ)Z446P1>LXKU?5[S)FXW9__(RDW5
M5OU^N]T_U_W8VS;L_UB;CC&F>\P7ME,+)+@J)"&PB)%9I!3:SR&Y@)+B!"4R
MYXG(/&1;^)1Y;O362@F^'\3TDHSAU<Z6>UOSLE[H7:ZKB1]'A0'_>;+AU2C=
MYH88O4&E..AH?@<.[\11>?"EKQ2>KZR1$*::(-?$J]ASR% )80?+O)8@0[M7
M^7G<,#,3?OWYS-?+188)$PG.828B[0,3H>>9-#<!'['B$4&*R]2VJL_)D^<V
M&S3"@5HZ^YH]IW#UT_4H$ *3JJ7^3A5X+NHZHN+.Z?,FJ[!S48UN19W+%PSL
M-EMW"?JXWJCR:?7(?C2';4UEKP7-:(QH7L!$L0QB'!/(]"(5II(DF9 "(6SU
M05J.-[?/M)'3L1_K#4SMG"R/2 7^EAM)02-J5=ND$1;\THA[/3S-O:>I'3!>
M&Y/>&'+:[J)V^I^U"+6\;5S7ZCU;/ASJ"RUXREB:"JJ7C51/XD610!ZK J8I
M*S#B"F54N'6]OS#*W#BC(V2GUM*PELZG<%H2QUB00M-%!Y^'V_@,[GE\4?\0
M[8I/!WJ33L,7=;W6)/CRQ4/R@ XG[)=SC:H(CF/@#)$4%RGB$',3S9U%!:0B
M$7K)7%!!6)909K6)-&#LN7'$U_WS,]O\-'NW6GQX*0_0)6'&S0[]-!(8W=";
M-6U(TD-Q-<&R#BRRZGLT&FN7Q*5@F$^5U-0)!UN=8E\V.GC+<1J$57_^D]LC
M)\R-&J3K:=[4L$<,<P7_NF&K71L?86J7)#F#*"=4.X!<4WZL(L@%PBA&6<1B
MITC[SK/G1NE?U%9IK+Z!)R.C8WQ3%S,[+V\@$H'IMY(J0"3#!6U]>G+=QT_J
MOUW0Z[77=NF2<;TXZDH@>@7X6\FXV<,MU7:ALH)AE&<P13327VJ20IHI A,L
M%"IXCG :MQ61JSJS=A]LWYA6[^UIZ>/CR.'>X=_5#LAN*Z-E([+C>5TOW'8?
M^6CTWJ!W14?$._#7S7I[G0H']YWHPR-$_XB+X[U)'X@^S:_U<^B]9T@]V?.<
MO;J:^T/Q<:/J\.IM)\KAZY[_;R5VC^LVHW7!DCPAB:8819E>"9(L@7DJE28;
M%J$T09EV&^SKSXX59VZ>Q"%?E77S55>53L:W+DR!P:8I_/JH%]C6BIG:,B]M
M[K#)%:XOM4P0]F1ABS7FI'8+S("74XQK=<Q2U"C4=AGOJ 0:G<#C&K1:36HF
ME_*]4YIKJG*_$YC-L5BP+Y3[BPN/'F7"8L2^$#DM7NSMJ4//2RXWK6_6@(KG
M&4I$!N.49Q"G:0Y9'F-(.&=YBA(>4;=CU][AYC8!GD@+V%%<UT.47HQM3U-\
M(1?\6*4+6C<VS?]RW X4OV<MO2-.?.ABH_WYZ8O576/3V=MMJ/N5?*^^J^7Z
MI8KG.H[7G@)I*E.;8KUY_KC>5-5"M]4NX")528ZD8! 5J808$0RIS! 42%%"
MHRR+:#XL?WVL:'.CJ>Y^]V'WS_1C[&C7_1!-Y\9:P:JT;JUB53VN5K))>78M
MQ>'/]':,^#8&G>K<:"I;CLA9]P5[F"3UT=*]45:Z+U2OIZ%[&V&HR_G\O%Y5
M539J]_;3=KM7<D%SB5A<E2E)$XAI0B%CE$""$X63*,WCO'#S-2^.,S?VKL4$
M6R/G7;N=4E:BNN^:W,*8<89(GC.(54H@CF0.>8HBR#*JD,F>25B\>*EJ#7S=
ML<UN,J1?CQEPK:V>RM7*K)Y_94M33G#K'V84,\5XE$%B@DMP'5P29Y!I?/.,
M1A2KK('YP\JRL:,WD-L1PT'\H=Z="(>O[9)I-&+!UTK5M_^U_O9K(>] +:;/
M55(O#GZ71Y>'FGA=U*OO^8*H__)AL]S?5YM#\99']J/M4+V@1*F,"P$IBA'$
M+"XT^481%)'^!R%E0CEV9^ KH\V=@7G-$&ZD< W9)(V+(DLY1"I7$"<TA9PP
MO6",T@31(D)2Q:ZDZPW7R4C7*Z1V/.L!I, \VY6P.AQN9?1'LC= \$FRUX::
ME&1OZ/N:9&]=/N#X]UZ(C>;IRZN9)JE@NV"%DKDF!HA8D4(<:ZKE2 J8%B++
M(I+%D;1:5=@/.;<%1B,TV'2W$V1G.T$U@CN<^-EA;W'XZAW1P$S2@GG8F[E_
MM3?S(128#D>DWD&=Z!C4^DWU%;[K!%3O2:;=DZ8[K732[.1$TNW.\<<$[:SP
M2>KGET6IY/UVJW;UB>A&_TU[3L=XH2H%W$PA)]'M412+G&N'#U.208PR#&F:
MQK!("Y;03!1(.>5W>99O;C-")^OCPW97/E>]##NU(4PVB-J!6D_0*CK\.,"'
MB=W/!"8VW*0' P=G]JC<:W-5Y-E1$#0:3E30UBO^H4X(?(CX9L<$'O'M.ROP
M.<P +_]AI1[+9_5;*<S$\U&I#VRS4G*11B*),)4PX<QD=(@,LCR1,.<XR7C"
M]$1@[]=?&61NO*W%A)JN%5C6@E9=OU0E*EBOM'>D-J+<5A2Q?K%/]NW%V<*'
M]X!>8/+4$@(C(FAD-(W 0"VE!X@</',/4$WDBQO(KKQKOKSO&V#T^MO7[IW.
MP[XA_8E/?>O:85YT4R-I^[ANN/A8-K1-J/NT,GTK2EFRC<GV0#P6E#(%<Y$0
MB#,L(*,Y@41BFA"*A:*J3:ZQ\Y2=9;!ZU4^3;0*SZJ&_E:;-3OO$5SW'ZO,K
M-Q_8W4 9(@AGF81%; P4Y1(RD5'S1YHF2D@]N;DL9,*89\KF8XT")KJ%U2IT
MC=3F\P)SPMA1([2=[%8C0=$//&5V@6^D!YVBT9\ZP'^U =YY*3$8/)^+!7<A
M)ET.#,;HM<,__$'#IJZZ;["I [A>Z7'?KY]9N5J@C*7Z?S&,!9&:_2B'-,7Z
M)T*9X*D4-'7*TKXXRMP8KA82'*1THZ[+0-K1TVAX E/0:V3 '[6('O<K>B'P
M2227!YJ4+'IU?4T(_1</^^C_H9G#[ O\IK2W95K9+%B2ID5."IAFL3#[MMK=
M4=QLWG),BE1@*9W<G;,1YO:QMP*"I9'P#HBU;8&=ZR#:?>RCH G\H1]0^:U&
MY5T?*L[?^%7-?7[?YX-,^FU?U?'U=WW]PH$3N9>65DU_"_/;IDM"1J*$4IQ#
M5F2I=@ 0@USJA1#B"5,RH4C%3L' @>2<&[]T!*PCBILZX*KMBB>ZA</5D(:&
MH2QNZ;.\O1U#>SV>&QC>@>Y+X;L;1V![>'7! HDZK1,7%N\S-S#P<,,FG4,A
MD=/2L29MI5SMR]73PXO:5 (=&T(C16*5DT2_&%D&,>419'F!8)RKB.:,42R=
MVN$.D&%NDT4C<I4M5E;JF#)#:OL_W":$(=:P(_O & <F\EKZRU6HZ[2]6@EP
MU")(;^\1*/JDWR%B3$JM(W!Z39MC'C6#YDM?RNT_3?6)=NNO:LF3*UF@&'$H
M)><09UQ!2M,,(A07<:)]\Y0Z;<X%EWAN=&MDA%7-I,.IQ::OQ\X;V=F.FF=E
MO<!$'K#QDM&\KNYS.%"9<=^E/CO-MNO21:'_O#V7^FP0M.-2[\##)JU'?=M#
MT9'G_D>Y7:1)H7))8DA3)B$6*H=YEB20HR@J2![GE#MM"E\<96Z3@Q'2+.*[
ME&(".$U5]D[A(?"H?]QJ=\%8Q&WFN RV'=N/AC P0P]!3_O:6@F/?G8O2#[I
M\?) DU):KZZO::C_X@$QH0?WVNPVK$2Y+"MBT]:62NZU>?E2-9YW?>EE(ERP
M&%.2%AQ2E<40QYS"7*,!HXSBE.>XH(F52^M3J+D1D_F$C@J<;"IW]Y(=PBA]
M6:^?NM[*)M-M*ISJ!$Z4.NPX--=7>H%?SUS8-S";0[3L&YAOHNC:3X?M-K Y
M->/JQ(S-"4V[/5<%(8+SK\]71*YGP'LC>'V--5W$KV=T3B*$?3][F$-^N2M'
M4Z<R)S%+\S2#7.41Q&F,(,T2# 4I9$%2&BGN5)"O;[ YSH)UI;5!W9&L\+5S
MQ7VA%GB>NM;SR'\-4!M ?'K?O>--ZH3;:/[:%[>Z9V0HB'$1'ZI-@^;-3BB+
M>$8)C"+!#',HR$1>0!+%"N,X3E0D!P5SO!YI;K1Q/,LWDH):5,=U^W58'2,F
MQH U6<Q#!Z< 7'$3BR#Q!F>#O4W$P#6=KY[Y7[UAX!&5>C*>]1?ULM[L-/E\
M7B]+\;/^\YCG73"J:"YS2&*NU^3(5,UCL= @TRQ-,LI2A9V.F6Q&G1MO-$([
M,H4=P);G.[YA"WU&4\L+#@+?@5I8\$?SWS#Y[BXP>3TBL1IXVF,.%RS.CBJ<
M;AX3-O15K^VK7<C?FJ"E:A]<%K1(HQS!1&H_!2O"81ZI&*I");$0,LMS)]KI
M&6MN9--N$;6R@E;8(6% E]&UXQQ/F$VS W<.E_<#!0L\_ ?H7![N#0)Q>O6^
M''#3?\N @X:V%4OCN#^N/_S8J97\M"IW)5NV)9(>U>9YP910&<L3&'-I6LP+
M 5FA08Z4H E.BB(I8NNS!/MQYT8FOQ^Z@]45**K\455)#\I:_&-Y+RW0L\,.
MM(,U+,X&PF <>EOET!*J$=NT?JH%!XWDQ])TC\'@==C##P/S1-OT_N!VVX=W
M!ZUWJ]WA<=/MIKOK>+)A/N#V035&OY7J>S6G/!1?7Y2H"B!]94NU_5NI_]BM
M5_JG>CLF)@H)HE+M,R(.<62*O@L60RYY+/6:-J)V1>A<!Y[;%- 1W<P#VU9X
ML#72@^>#^$XE,NWM8,']@= -3/Y=8#4E'>0&E>#@*/GMG;-Q"#N5(@V"]&0%
M24]>Y>N(^RM(Z@S7C;*D]L^;LCBILY:O2I2ZWS^HOW"YE(_KK_MR5Z7+-F\_
MSO(B%@F# F41Q%1PR,Q>98PR0:7^/R*MM@IZQI@;I5=2PMT:&CGK+&T7]KX"
MI 51CX<G,"=7 AJO\(C,$/:]@I!36]RQ2$W6Z[9YE[8&L:H.@B_V[,?@1B?:
MB[=.V5ZV3_97/6-[+QVV.=H4]6P3]$R?HA2Q!#*"B2:Y+-?.;)' /,L2G",D
M:>J4+GGZ^+GQV_W7KQ\>O[KM=[X"S&Z+<S@,H7W+NGAPB/S#RSK[W+E\-<*D
MFY67M7N]/WGEJF&?ZGM5J,U&R8]*WV,*=%U,-EQP:9JF:C\ESX2 .,D1I%&>
M0*Q8$<N<<)PY'6G8#3NW3[N1UNW;MD38[IOWCUM@+F@%!HW$H!-T?);)[(\G
MW'#RR1^6(T_**VYHO.8;Q[L'!GRQC>GBM?VL-E4TZNM( \893F@A-.U@O5"2
M&GN&<@9IQFG$,<X8=2*@&^/-C7E,"X7?UMNMJ<92!^ [!G[=@->.?3R"%IAV
M6DF/>$T3PV&)D-?0L!M#3AL@9J?_69B8Y6T#:UMO&@:KHM ^L\W#ICK=E55:
M:COF J6Y9$EJ2A'$#.(X+6".:5[5M\8JP83$5J>N;L/.C6D.4M?I6>"%;<#W
M*MG<=%Z5Z^62;;;@17]650*)8Q-62U/8T9%_@ .STA';IDNKEEF_R77\AVQR
M^F\SO'OY8R>@O-8\MAMYVD+'3FB<53=VNWL@8^G7YG?](E4!3SE-HY1BT\O<
M5#*.502Y+%*8LC@7JD"**>3$2YV'SXY]]-^ $<Z15KIX69+'0!1"4T0+@/<(
ML$L*>_W4N\^?]H.^H-G99WOIF@'G.']EY>IA96I7U/V=%PD5+!(1@3+C"<1$
M)#"/> '3&&4%BFD:9[E=&XR+S[=Z-2=M<6$D-!V"JNI#+ITL+N-G<7 S")-I
M/M<*C(=577;GZV@P',YHQH RT>F,"SANAS/7E.\]ECF[:;H#F6ORGAS%7+W(
MC::D*A?ORMW/^XUB[]92+3@A:9YE'"*6QQ!'/(8L+2*8,:HM6-"(4RO_X?6#
MY^8[&-F $0X8Z>P^PS.P^NEH# 2!F<A2>^OO[)JJ1Y=AV_H,6R7^[6G]_=_U
M+<9=R,T/U??7\1+.'C?)QW=-B?:[N_KO0\+[5JL]6WY4:OM%+<T\_+B^?](?
MLR':19;'M,BE@ DS<1Y$2<@2RB!"B118?XZQW?G)S9'F]E'6LIJ&;TXA>GU8
M6G@,OA *_,TVX!@Y02.H"?\XB.H+,9<8.T_(3154=WR]P*9!T'3W:D7V%DMG
M 4M_\%S? R:,EK/0XS0\SN:&B<O,-F':#_O==L=6LEP]?5DOEQ_7&_./BU@@
M7*B$0D533;5*DRY510$CA#!-LA01Y=3M(8R8<^/I8ZZ-RRHFL"GM=G+>WD"!
MIPD/-6,?VB*Q'67!'T9=T.CK,Y$YJ$%F41RV7](_1T58*[2]E8&U&VV WUT?
M&#9]5P]S4QM?G2913E@$>5XPDXJ=P#Q!>NVK:*RRI-!_V/O=?2/-C<^_?KYW
M\!Y[,;3PMWTA,P61@D./WH.@0Z*L>R%S<+A]03>1PUU#^-)"Z-W1MH&CU]'N
M?<!TCK:-'B>.MM4-XV(\AS17*;B,&<48XA@AB'E$8!ZG%"(E%5>,BX2Q(8&?
M_Q>TO&E5<6QQ,\8:=@[Q1!@')NM#Y.A<>M]X@#5$H.GL>^%XP.U:2.J?J#=.
MX_]JA[=0Y6ZOOY1/J[JMV8(DJ8PYRF&1I1QBK#"D.$N@(*K(4Y)&!<5V1\@!
MI9S?071;1D$P_1HN-5&8 +7Z0-HQ*BV$4:?9NQAJJ#_?QD5'4Z#M7.LZGSV+
M'D/,:</BDIA_JMV*'IQ];U7T#35L\M!R/*]75>!@LU!$!4-*40R3/#?5;(F
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MLC#);5S"7*09S*E2.4%*9")9O%2+[P\KE]W/-U+(A4I.U0K')5^^_GT+UIW
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M>(R#7)CMPO</,[7%HI42%%LQ+6,8)^ T8^K+0?),L*V BD^W(@(MHSN2[,?
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M^(ZBW08V](' KAZCY+]=#*O3J.!@8<:-%5Z*V:L(XL4/'$:HU\^DF.M>"4J
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MO$H_MKW?4<;#E]7R2:S6+[J-SEHG=?US4U0M%F:<\E1DG,&8Y!%$C#!(:1[
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MZ;,@$88Q21A$44"ALK6D CH-2(S2($*YS0I\":XCKJ W6R !K25T Z?98N<
M),^+5:>V6B,C^*61\G1OCN%5U8[CX*6@VL%0;U-+[;B^)\NHG;A\8)2F6"Q7
MU2:[\D%$N;[7+#]+(IIG29HH2B6*!Q).H=[.AAF):9RFB/#,:+.J=Y2I.4B?
MU;3I[I'+^5SOOK2R@F^5M*<C$1:X&L9K+D7+,QT,!<H^9-,'A-.(S=&!Q@W8
M].GZ*E[3>_&%UI:V_!9,&7.5'5CME6L#3\W6?'N-WJ_"(DCS-(#*9@@@2G$
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MO>5ET ,L%XW56KND?,.JYS=;<>6'Y2,I%K,H2F089 E,,MUG!"<YS"F7$),
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M'%G%]RP%F!I3MO+KXPS'DKS+*WV&OIOU/:C0O?4\&88$/:+O.S+H''C[".%
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MR""+91AR'H04([,CV68#VGS,XYS*WLH+YE7HK)-T"2!@M=AV9OH9S..0L##
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M'. /?9'J":OW^/;N4Q8U>6U$D%BJ900&F1#*V5$_81H@Y?'P,%360L2X>6+
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MHM@K3#$A@5$]%8.QIL9+'5&;F$-'6&M:.HFP,0VYP,WWKLH!9.^-(!O".N?
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M:1 /< &19THYALX05_XD3!:>N@NX1G+$K5XJ.Q_[' J]+O3)F\?SD,_)O^<
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M>-U<MU?Q^NITR>MUI^3U%=AB<-4<_'48YAA[XIQ&3D83?MQ@S-AS\BJ^,[H
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MI2%*]1GX&")$(XC#A,,D%!E)"0IX8-7?QGSHJ7V\K>15M;F=[* 6WLXTL)@
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MIZ0WB,,X'MW%>"/GHC=.IQV(_H^ZNFI3QWINAS*C'@IR^/,LS6/&[:Y<JH1
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M'@PF3\H\2915#LA_UJS:?$GZUUWK.?=N=#O\C Y,NJ\.9&H5JFBN>IX[:MR
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MRZV*UGMAE:SVLYW):UR/.T7!+_:*1E?0*%N7JRA_!3M]P1^#5.X=>E;"$O9
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M8N_BF=E-1%F><!BG20H1MUU0.-<P9K&(%$.*ZF3VK%9\Z>H="B"5SQO:E6U
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M\%5(%LYRHE :0961*A/!K#698I#',N4R4PHK[!K#=O#LJ:T<'?&\X]@.8;M
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M)+V)[WFG*^@JVU:^:-6MHW%V"H-&XYM=L2"70DPA_-8#S,[ GNZ0$K^U;WP
M]!V\Z4.,VK<$Y=-*B:*2RGR>JZH<[D+>/MH4H7_5;L&(I@F/HPCJ1&NST8X0
MI$H8VULR(C.B6,(]JT]>'G1JRT%7YHH?6$=8WY*3#IB[L7UH) ?F[*ZX-V K
M<(7GK0N>/4I,N@,4MKJDP[@C%Y9T1^)U34F/>WL<!'[\N58+J;:EMW^HU>.=
MWE;EGB'&%&)<0I3B&").$DBBG$'!69+2.*8H=:J9X3+8U(BG%;=3,,T(; L)
ML%9DC].B2T@[G-0%Q&]@NME"MZUK9F6U70IN!X#.XR@M((0C'99= Z7?09@C
M-F>/NBX]8[S#+$=M]HZK7._I9_'98Z[6^OS!?C:1ZN7GA5C9BMJV5-EF;GV\
M59>M.MC]:U4JQ5S]=5F7/R]G228DBY($<BT,+Q.B(<MU#!G+J(X2*JGRL@G#
MB#4U\KZ5LA8,<*.$!#;LC/T$3ZV\AM3K8^;U$JP?%!!-[HA_C9A T^IF=HX_
M60.O%%V%JO2<5J6J:D*E%-@JU70/;*:JUJNZ::M9./LU+-(A+=Q DHUJ X=%
M\]!*#OST'G;T5_,^/)BAOIHO]YW65:.;>H19KG',<YI#$2G#UY@12'(208$9
MQRC)(R7<VPJ>'F=J!-Q*"I[,KXW17,L*ZMI?'L;?&60=3.8P> W,@5NHK)2@
M%;/AMS!0>9C(82 ;R3H^^RT+%2%V&9&S-O&9V\<SAR_KL&<).US>,_! B-5&
M25N61Y6E^6ZP^2>ERH:49S36*:9)9MA14H@$YI JS*R9BUC,$RQX[A5G<':X
MJ7%F(RUXZH@+M/*--+J L6/$0##DA@X0:$#K2@JLJ#>MI1@P&, )E*!G_^='
M'/>HWTG[5R?[;G?U3-3>CRQMHY5H3!EC"10BBR%*A88DI0FD0B">2YY'D5?+
MFZ.C3(T\#G,/_LLS._LHDFY<<34^ U/$Z_8SP3O-GX4@:&;VT8'&3<P^I^NK
MO.RS%_=[Z[^H=9W36=6*C'-!<<YCR")I+(6$V+>=Q)!'>:I(IA7-B$]8]][3
MO=[R$8N0 G900?*[N8H]+L&/![5B3VJS+D3M0_E/4*Z7XA\/R[D!V-.2V =:
M9223,L)0:TNKE%'#J,A\RI14.I)9%'FEO?<'>J02IK]8I']MLMP]$+\&9#?&
M[0W=P$S[JOCIJTJG7UE8D^PH$B$)=W^ 48GVJ&Z'!'O\HI!]46UQVF;O$&7$
MO.1Q!FE$JLJ&#'*4<!AE>9;*/$UX1*YOA[H;<&JLL.T@U'#"VC5CT!EAM_<_
M)&X#4\+I'J?FFWL#=C(/W=[T-3K#=S7MC#F!9J:O$7#K87KDOIY%E!\,^[^S
M!W+OEX\VD:5N M^)_7[WLKOF*WNI^L/81DYW3Y6/_N-/M1)%J<K/B]H=]7=E
M^Q K>?ML%N%[U?[]ZZH0:H9)CA/.S%Q1GD'$$UNEF3.8(Q1K&:E<*[_:S*.*
M/S7N:W0 JA%2@E^*!9#+^9RM2NMR!:75_70]O2E\)=SH=;H3/3!95TK!^LB\
MJ_I>'VK 7T#WPD9_4 %P QH(;L 6!+-:-J<9-Z % C1(;*\"%18!*V*_R1P&
M+;0]K@;CUN]^D]EY51;\;:3HMWAV%N193F.58+.4\=R8X"B.)>2$4XBIPA3+
M+*8Z\_%Y=)X]-8]'G<0^WPGHM[YT47,C_YY8#,S,OSL X,V11U0-26#=QX_*
M+D?T.GSUCUW2MTCDLRK759ZB><![ME;WRU43F]V69#< Q<;DA&:+K""2BIJE
M,\NA)%)KK%(6::]CS<M#3LUXW$GLW7+P(KINKW58S 9^VSMP#9#3[ Y%V$*2
M%T<=N:BD*PJO"TPZWWE5G^%ZXF=9(J-$J-C6D,00)3B#E$8))(*)B,0ZS:1;
M!-FQIT^-*/9Z[%[ZYCN =YX<KH9D8![P0J-OS^%]K0-V'6X>_!9]A_=U.M%Y
M^."B/DV V&*CF5AO;(#4>V9FL5B_-,L2QUAGQAB'<9JD-H&*0,*3!)K5GZJ,
M1GGNUN[OTD!3>X/W1 6MK#Z];<Z >N%U#@C5P&_V<91ZM0(Z Y=/+Z PL(W5
M#,CO2^;9#>@R%.?; 9VY?\1^0)>UV&\(Y'!]SZ#/9U;,[0'PI^7J.YNK[TJ8
M0>S6ZX/BZ[^P=?/3WXOU0[&X6ZC_J]CJ$RM6?V/SC9K)C*6Q9!%,F2VW'XG(
M$*DRE"HRFFJ[@_(+Y[I.G.G1;?,2% M@FV/9#"8S.V"N?/NO7CE-;MNP\< ?
M_%R3K\%.^ANPU0SJY0J61K<;T.CS8OXZKTBGJ8#RW4S87&W_##Z8O]R /RN=
M@5$:6*UO@-4;5(H'C&$-,@%!8URODVC<&-@@Z+V*D0WSU%/LW/WR_&X^_?=_
MM+\Q_]@SG/_^C_\'4$L#!!0    ( )V&7%!L+P=F(M,  $/+"0 5    <V=M
M;RTR,#$Y,3(S,5]P<F4N>&ULY+U9<UM)DB;ZWK\B;\[KC<K8E[+N'M-:+6ME
M4B8IJV;N"RP6#PF3(* &0*78OWX\#D 2)$$2RPF<8-U:*!($<7SYPL/=P\/]
M7__GC_/)3]]AOAC/IO_V,_L+_?DGF,99&D^__-O/OW]^2^S/__/?_^5?_O7_
M(>1_O?SX_J?7LWAQ#M/E3Z_FX)>0?OISO/SZTS\2+/[X*<]GYS_]8S;_8_S=
M$_+OW1^]FGV[G(^_?%W^Q"FG=W\[_ZL.C*J4/9')4R*S=<0;80G+7EOA#!A/
M_]\O?TW>2!9M(BX%2:24G@3)(Z$ZRNBSUES'[D,GX^D??RU?@E_ 3\C<=-']
M^&\_?UTNO_WUEU_^_///O_P(\\E?9O,OOW!*Q2]7[_YY_?8?]][_I^C>S9QS
MOW2_O7[K8KSMC?BQ[)?_]>O[3_$KG'LRGBZ6?AK+ Q;CORZZ%]_/HE]V,G^2
MKI\>?$?YB5R]C927".-$L+_\6*2?__U??OII)8[Y; (?(?]4_OW]X[M;CUSX
MZ1=_/OM+G)W_4G[_RZL9H@$I[?YR>?D-_NWGQ?C\VP2N7OLZAXRO?3F?X1.9
M8WSUO/^Q^L-?;A[[;0X+1$K'YGM\8?WWY2E[DP _EC!-L.+JZ@&36;SUIDF1
MZ>SZ+R<^P*1[=91@/.H^]458+.<^+D<J) 80!9'<92(9#R2X% GWUEDN:*+)
MW.:X4+Q DCL5+"#^Y<OL^R_XP;\4*91O.G$0RM8*^!_W'KH2SF'47ZV[S_C>
M$9/@4UDO.@9+I&:)6,\5R=1Z(9A3FN8>B-]\YFW:-U7[8AY_FLT3S-%\7#W4
MS^,]-=^&[OH=OWSS<_P@$K^.)^GJKXL=Z4-ORUD/\ELI!\G]^2?D.L-\#NG]
M2C</,M=QAE2'V0*Z]_:A^1?3Z86??(1OL_ER9+(1DEE)%'.12(,&U'HEB!%"
M2,^S!)%Z1,#FLW=" F\?"0?+\V!$+'&;[0\/'V ^GJ4WT_0:]^&1<\KEJ(%(
MD,B DYEXD)IX#98"V* ][Q$0MQZ^$R)$^X@X7**-0.+SW$\7XR+X*U@G9C,R
M0:(,C$B? K':>9*TTS8YS9V6?6X4=YZ_$S!D^\ X2JX#8^/-=#E>7KX=3^"W
MB_, \Q'W6I@DT-09E8A4EB*DLR#4@1  6FG7A^=S][D[84&UBX6CY-@$!C["
MEW$1PG3YFS^'D>=<8/3EB>,<Z?>XY3EF*.HR)JZ#M=F*WG!P^]D[84&WCH4C
MY-D$'MYAG#]'<]8)_A/*'U[-+J;+^>6K68*1Q:@ZF8!.<1*.R!AX\8@223;P
MJ)@(0=+>X/$H*3NAQ;2.EOZDW01X/OL?[Q**;YS'JT3&VBI*+;6*-)&<J<;0
M*AKB,WY!BQAM8B9X9GN#S0-$[ 08VSI@^I!P$U!YD1*J8+'^Y_UX"FR$$95C
M#K=,GA4Z4(DJ8H$#H=%$ !4]S?TY(5L(V DBKG6('"O9EN#Q"K\]FW^>_3D=
M42T9&CZ-HK"&2.& ^,0RH3XI'M&[EM+U#8Z;Q^^6Z:+/!!L'BK4E9'2;Y=G\
MPWSV?3R-@&]0V1DO2>(Q8&#N*+I<X F+5*K(K8NIORUF.PV[8:3A=&AO FX)
M*!]FBZ6?_'_C;YU+E0# E=0NQF(<_7$NB?=:$I&9,-QYH5U_\<TV"G8#2<.9
MTIZ$.S!$B@5\,0??T:V\-\%02Q#BZ#Q%QXD3B'1/#=-1&AML+\<^&\_<#08-
MIT</%N# BB]'K),/7V?3JXP-FC,.3@KBI4+0"ID)AE>,Z$@C1"UD@#XLPMWG
M[@: AM.@1PER8!!\@G@Q1P CLY_'RPF,*&C-),V$R:10$A2](!<9"=QC+"5\
M3+R/O,;=Y^X&@H;SGT<)<F 0?)[[4M#RZ?(\S"8CGW0V.@$)LHA!>DN"B9XH
M)E4.Z/I0Z7M P*V'[J;^AE.>AXNP$0/PYD?\ZJ=?H,O5JN2-]AKUY4O54>2)
MV!PLX2(9ET*@#OHX%]OV[-V0T' Z\VB!-A$R_ ,FD_^<8EC\"?P"=[;T;K&X
MP*W-41MU1$:41UE(RS@&R0I_M-)K(1(-&GI QJ-$[ :1YA.8?8BX":S\?3:Y
M0 7,N]._^6)43)]C:/U,"%"LGR*6HFQ,5M0YE5A2?=1:;'WX;MAH/G-YC$B;
MP,2KBWF1UZH>H&R,J(2+!89'SH%/@D0;/)'!..3#2,*MX<HBN*UFO4%C.PV[
MU6<UG[_L0<!- .7=%#\-Q3'^#J_]TJ_9&F5)C;4HC2!H0.%83YQ&MK@!)DH%
M-#5].*&/T; ;4)I/8O8@X": TEG"5WX)7V;SRY$5H#U0CC$U1YE0H8@S(N*>
M:8 "5X%!?X;DUJ-W@T7S:<O#Q=D$&CZ=^\GDY<5B/(7%8A2L<M&:2*Q!;TEF
M:8BSJ$EON)79<1M4'_'*ED?OAH:&LY?'BK,)-+PYA_D7W 3_-I_]N?SZ:G;^
MS4\O1S%$)Y,SQ(*3"&J->R$7C%!TF6AP+*34QS6 1TC8#1T-IS;[$F\3*/GT
M%2.N*^H]#51Z@2$X=QB1>Z5)\(D13:52VB@54W\;R.:3=\-$PYG.(X79!!0^
M7(3).+Z=S/QRI&V,N,-9 IDB\90GXB$J(E*.0<N@=>[/U=QX\&Y :#CG>9PH
MF\ ! OB\E!O.XA^?OJ+8%F<7RW(9L>1R1R#!*IX91E >#9Q)C@1:,O@L6*XS
M9UKU5TCQ&"6[(:7AG&C/PF[D.LGBIF85TLO+CX42F$;X##^6+_'-?XPPMN(R
MQ$Q4*DSA$B N"2"*<2&$#SQ%U0."=B9H-R UG#FM(_J!\?0".4J%J[<3_V7D
MHBPAN4&_6Z,--12(RU83W%FU5X*"X'UDV&\]=#=<-)PU/5R$C=B2M^-%])/_
M#7[^%E]9C))0CD9+"<NVW/L7 0VC2R0)GCQEAG/=1RW& X_?[<9BPSG2/L3:
M%#)6=R]73+BL,O-@B-;E,""#)5;S3&)&@4CKH^-]7FZ^1\!NZ&@X,=J/:-MP
M8)&-N9^\FR;X\9]P.6+>V7(AAHCH%9'):&*54<0;=+ @&"9"[,]GO?WPW7#1
M?&;T&)$.7<NY2N[?6+VKR]H@6(PV(_DAZ8)K3YS*DG#F%,LYQ^3Z<$0?>OYN
MR&@X2]J+8'L#Q[_^<D^.[_&%@SO:3!>SR3AUKK2?E$X\G[X"+!>WZ=ZUR\U#
M']9/YYN=2#VR&\[%@GSQ_MNHJ_LO^\19?CN>XL/&N%G,5A?=KQ$EA5*Q0"AQ
MCX@*(A*?G"4ZLY""DH*J+4GFJX65_2)TREX_LZPN^PM,EHNK5XIX[<8RVX>X
M0TW)U3->+!8HVVM6&944>2LAN@M$JEPNR$A*;!*2*\<Y6L,:K-XF8YA..]4P
M<65E>I#Y@)O/;>K7UO*:"6>SY38(XIV))3TL28"4"3I38&A4@ODM3DE?P+E#
MS;#X.4:]6Y%RC*P; ,PKO_CZ8IK*/V_^ZV+\W4]*=N?%\I6?SR_'TR]_]Y,+
M&!D5;01TRX,I8DHFHYA")(#K"V-]:3C;<EAS/(!VHJX%0!V%@EEME32 LQ??
M_1A?GL#;V?P3<K2NTAW#XC6$Y<U/5^4QC#$5C-4DIVB)E*6.2F9#2CM%C<*S
MTFQQF'LP6?O1.4RSL7K8JZFF!E#8U6+!8OD1(N#"0CZO&/$.(PF+ZX=:YXET
MRA O@R/:YL@H\NC3EIS.\7A[D*)AFI;50U8_HF\ 0R]B+(U1%C>,_ ;+&UZT
M-PI7 =)LB-2J5/5E3GRVT3L;6!);[F_V8+8>(6J8+F<5;51?"F@ 3!_F\,V/
MTYL?WV"Z -SUSY9?87Y+9B,-WF+<8DFF(944!^[Y'#"DX>BAFL2EARK>^PZT
M#=,TK1ZT^E9' PB[33S+U 1F%4DI<"*9P(6".S7A6F?#2]-(T%7LT]ZHZ;WN
MIJ)!.EC$A^-CMO23DSKFO\VF\<K&2A%9LHZ([!V1-BKB(MK8("5-SF5<'U5\
MI?U);<$][R?74%=+#=BI#_/9-Y@O+S],?.E]G$KH^ZTD^G!S'S$-0FIMB0OX
M17**P2X5C#CK!7.!2K[M^*2/+?!AHEIPT'O!5F^2;P!%&&7XZ9<Q+I25@)"%
M-S_BY**4N/UM-DM_CB>3409-022-(C*E6M8&9$=G0IWQ&1@U>5MSMUYBO2>)
M:\%9[P55O6NB 71=TRTQ,C692=2P0,%H&4E0@-(1*O,,D4:_I3KH> 3MA9+*
M?G<O*#E(H@T@X0PMIB_7/M^#7\#',D#F+/^^6&%]I!(Z>T)KPDP"A#5ZE"ZJ
M0)+*1@NFD^55(K9'J6K!Z^X%,_W)O@4@W028&[Y;$#[JF K\RP4PK4IX:0WQ
M7F (D2FZ<%LJWWL T#9JANEO7 ,X1\NZ <!\!)3$."ZA.R#:X$,QK[RCB3B
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M5D7)2,AEQGST!K_+N%("^*@,![9M;%D%4*WH&?K(Y-2 .D ++8)I\PP[\Z3
M"8S1,RLG.:7M<NF,ZXRWRG.15=@R*K,"HO:M/ZAXXG%J6!VJCP:P=;M"XL%]
M/7E# ;=P EZH,E+4DL#0!M.8 ZBDDY%54+8;>4.?5U3&6P4=-8>\>QL^34E2
M:PRQO,3#HC3U\:)8:YVB &;%*2JK#O+ *AY*G!1I1^FD482M/0",422-KLRS
MM+A6M,8XA>:$0F*4)V.-IU7\L(=)&OHH8@!D':"+1E&UZ0!PF2G5@F)H(I&=
M&-$!8%$288(SB:F0ZB1HGJ!KZ,.! ?!UJ%:>P8S2:WDN9GE]P[?<3CTRM?K
MI_:=5MV%^)Y2JJL:C>L'WIPNA=):D"' 2G9*VG*T$URY9\]YCE!J-JM4SCY
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M64:"D,=1U@ Z4$NLILA1M)[@:BXE?#PS'21^OUO/UIT>UV2RIS>%SZI*OZ&
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MP0#['>IE^F5<>C-W[</OKI)$':2D% &!4I.Q^)@&(VL K[A2QJM4Q9[M3N+
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M:RR^GD4S3>_'R/&B"]KO\'YU*2+S)%341"=9VM.@7?;=75?OP%(1J;-WP/?
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M\?$?RS]IM5AWEOFZ7%PLF89?6E;TU]7\8GO>^TUBJZ@JU$Q@!+;)V]H#9EM
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M!"[@9[GYZ=LG_HAU+E70;$8DK2%$VY+=A864#-N^UDEGD*Q5QW5*[FB;ROB
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MU]$4,DG0M7]^7U[^)UTV ;,\J7R'W:J2JH(YE<U)->0J1)($@DU5K3&*L#T
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MMEKI8J<KJMMZW4!S8B_90\G[]'J3WDY+?-"^]>8FOUJ4=B8_(:<#!DD.2,W
M/4Y[%=8H?5"CS.TZ=4 ^\GF8;60[S'O +(*2UA7G!@EQ'+7]]'?3.6ZT]?,5
M_<XJ^/07G?U)OS%!7RYFU:C@4&IP6K6MKBN$&MF7S3I+)%+LU!XKKZL+P:?4
M:747Y'5)_NI=H1.P(;OR^9^$JT]_+6<E9"&]T%!RK&"HA5U-]E""16^%S](/
MTDQ^1SK'K=>8'DSW4=^IH9/A1C-/HD@K#&1%S>MG/PZS<6Q).6/0\.ZC0;(Q
M=J9TW/*0B2)T9Q6>&$;?+*]6LU"DDMY7:*V P'AC(!4LS!^&G$(5.NFQ(=H(
M'7<^YS01NK,"3PV@\S]I1M8YR_<!A.+:S+2L 47*$ AE#DKXJ@9*!=B-T'''
M?$X4H+LJ\(0 ^JKRFK=,VNB+-*6"#RW\$VP"#"U4K9T61GJEQ"!#C?>B=MSA
MH-.#ZOZJ/"&\SF0M+LJ:@4IH,X;:"%17*V1A7%:>C'"#Y.5U)7#<2:'30^5.
M"NMM6NA 0/QC43:Y$U1^^3OSG[XZ;]_-*"8E0F"G+[=VMQ45A& #"S:A0*_X
MZNC2/[I?5#Y'[3C9I!.#:"^JW!VO\1JO"_K<IO@.D*%UR^#,D?*U&@M6M2J0
M8#Q$Y1+$E$IC \4PSTK/T#-._NGQ4=>'.B9P#C[#QLT,:,I6A)(01*ZF93$F
M2 DU*"VCCB*B3D=(C]\F:Z1,T\F ;!_M3,#X>X:;WY>+O&$H>B.#,QIXIS19
M>0/!A03*J10+FQ<DXQ'A=D?92%FDDT'<GCK:&W1_TBHM!XRQ?[Q<YO_^LCQC
MO5VTP2E\;^T1&W_B4_J(:?^(N)YBT=<??8N:*J(5OB3PTK4>-=0&;RL-K%#R
M#K5'*X;8>P_).'B8\2/9_;Z\I*>F?^<JC);4NIP0XS@4"<D9!YEQS'9AM=H.
M\I;<F<)QX\4'H./1U.%!=#+1[)W'S.X_B/W9SQKFE!EP[/H6FEQRHA230-L0
MP! [7REB!-MF.:3"JO:#/)/W?-;<3M/^^(7WU$]\8?+=?-ZJTM;J6$OXW==U
M3M&K?#G_\T;&=X"OL9B<+6^F6@NC/E2(52<H43M;?<&Z/2BFIT/H8-(G=3KM
M@J?G9Z(?18L3L,-_Q/$'8K'.\R65->]_+.9L=OZ%J_(,^\6*5"DJL-K(EAE1
M(>EDV.7%'$PFEV@4$._(Q[B)+T=$])#Z/9E;^54I\_:A>/9V49>K\_4*^Z?)
M[K; ,/=W9Y8&NM25BC8Q+I*K",:U4S 9"Y&"55(*ZU,^_4O]U6K5)ARL??&?
MOMW]S286LMY'UTT_?8B!LBM@DR(P2K3BWVC \<^H)&F%'>1AMC<.IG7%[X"N
M70_$870ZA9O^9G#CM3 ;S\L%W33-+SIE*HA0#0/)1.7X7&>V4,6BM#(NFD&B
M6=^E:ES0C8241PYS7VJ;  :W>-ATTRX.I8PLCYQ-;D_7!8+3;$&'0!1U1!_D
M<)?%%C4C8ZX_;2_[%OT$\-/>OC=>V,TX*$K.NF2!4+<7:&6!-QN;RE)6=,:&
MX@=)5'Y$R10NR(.T^Z@J\Q!13P KU^<O__%ZZRB4BH_<"E:V80S&:(B!16&#
M#<(X(>0PKTP/J!C7JYS&?;:_6B: J?T%=\?VHKP_P\7O>$Z;7:I2M%ID!)19
M@&$_&H)P_%4M-EJK,.,@E>9#,#/N*7@ MK:MKK$5/0&P_W+^]6SYC>C>H^?-
M38 NZA(L^*!;TU#/KE?D?ZI!4LR(\#A(+>JS%(ULM(T.EFU;KQ?-30""3[U.
M?OCXQX8923Z2,0&8]-9GQ&G@^TB!+CEXDEFK.HC?\%VJ1K[CIP;%_C0XA0'.
MZWLER5Q=T2W-WA3VPMKKDR<'.BFD6+.(H@OL3F&0]S1,Q_W%/P7,;*">7$!7
MV1I1;1"<B3ZT/EJN%1,%D6(E1UW2V4YQZ/=.&GMFZ/<NXIO4V&>IBI':$=BB
M6A\CTT;%U0AD52&19+2A-[WO/O9Y\*'?.^GMV;'/NPAQ F;+S?UY/?(^NN2#
MEU""4&#(MGEOQ8,KU3N?I,]QD!>J^T2,6X,\C8>'O94R(4#=ONNQ%(K/X(WW
MK="OS?EH2;T!40IOZD#^UY1\_?W5^0PN]I#MV'WG/OVU_/1E>=6Z77WZ,E]=
M$ET_V+Y=M :_\S^I\;8Y0D71GI(P4 2[?X:-:\!F>==HM)3129NW7IF>:3ZW
MPZ+30,@^BET>0<ICH^?5^3KQ8]U#_Z+%G<HNG 9G&V<>I"E\)5/-$$.R()11
M+D@;W+9=\PR>#B)C7&^[+X0=3Q-C8^X>7[^L&Y1_AR]7E<HY"1#KR[[Y#B%5
M!5X:E833!6NWH74[+#JNFSW B=6KE,=&SX-WS?=7J_RES2"ZX\7'-O@L(V3?
M2@9L"W5*G<!Y80MO$5&W@WS/(.8'"XUK3O>%DCZE.0$;^=_YZ)PO/J_M0>^I
M:.L$NYFM+DW'"%&$Z](WG9%25(.$U.[1,&Y7G6FX7/NJ9#IHVNRQH%6ES/Z%
MR)C >%LA&O3@E91(5IGBU8!XFH*_M;<NG\;$'H*= "J>V4SKW<(;BC?=N\7-
MRY>(BK!U+!>26H](;&:9%8""#;;0&O7D05*@=Z!Q$HC:!PG=HO4'J^4D$,?&
MWH8UHZW@$YGWH6^C.FI$2-;*UJ14\A>Z6C],[4UW&L?UUXZ)N/W4<AJ(:_U%
M-\QE+6I)E"")]C+O:GO?MPFR;3UUV#!- U5.[T+EN%[=45&WIVJFB[L[0_4Y
M._77VX$2%2/Z+/A8=Z*E$Y0(V-J')S9@A4KDT QBIAU.^KB-#:?A+1P9 !.
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M%I 4CSQ8+K..331B[Z6>:8?CAH!O*^W]\>RO\#Q;'Z3G+C8!XG/!:0W ;]-
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M-R(SQCAIN(7 *8Y7#CD$=*$.,2W)&J=$/,U XZ?7-^XMX@"Q72^RZV5C&>:
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M9)#91 +)$0&+)G4JMH SF>!=E& B667:3 MY*1EDI7B14U U7S\1UPQ"R+%
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M4S!-ZOQ>2E*=MEP7&SF@< X4PP1!10=<FR(I2/39M/'B_DJJVQ.][9+J]L%
M!Q[9=7N;]350U,Y)YCUPK$?JLA:4N4R[H4BB1,^MR[ODUNV-W[N+>"FI=GOA
M8#Z04#H"U.:^!GE2005:?;U/5$%:\#HD<"R4Z%2P+C2Y9^BI#]KAXMR"BP-X
MVVTETN8&SKG"B'P#I9"_K60PY'F[#%GK4)PL07C]G(>YRXOZ0,(A MRI)N@
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MDS-2*U%S[]'[4DK2(3<Y[-QGD2,71_2P.0\HQ<'.=XXJV%F_]A">%F.S-XC
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M6_FX]_='8V>[$3N!(+NH4GN:Y'J6,YU]?K58U,JFJRH2P4/QWB10M:.RBKF
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MF#I<&&/O?4_9WA**\A$E%&8X*"$\1,8T2.<R=]HSX7:[:^UF9VLDN_F C.S
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ML+QI)^PD]\P($$'4+(+:,=ODVOJ?I:Q"P9 :C<![:CECCR0;1-9;$'0$XWN
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M')[GK<5I1-2^[>[FB_I'#$O\G__E_P-02P,$%     @ G89<4-;XO--""
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MOIH;7>:B%6NES=C,H[W^:-2L/ZS;[NY/0MVKKO^;D(!6PC.I5N.?9S(#RS[
MDEWJC.<_-RW:JF7!R"0TM/)_@,KC//SC,LSM#<I1,H=6-==>W\]N>IW*2#HV
MZ+5[=Z>V>5(QF@#,).-F+O.6TP4**I[Y++WZ F)M.$%ZS% O,-0,]3Z;7LXN
MWEV<G<XN/GYX= 6>ZWR'FZUZT62G"JXYS9.=M]EO/#8<FBP&XV2R8B[E[O6K
MT>'DRR:7V#]WX]9HB,,67 CTW):"Q(U]R=JB'#S_->FUZ\D^7RWOK/'PH#WR
MRWK!4KX 9F A88D1U*72,I[G)5=86&CCF,[9.VTRUNNV?F4Z8?_D^9QGFLU2
M,+R TLG8-ME%'K?1[$<OR>S]G37[+]RBL=&RV8I=Y7JI0,S1A[WU*[,+C3KD
M&I,K#L%ECJA8871SI@2<*:9;GWD1#YQE^&0D(B;A,189IC,,^TZ'=@\:Y!"#
MM=RLJ$G&KP#'79-IL4R@,CBD\FD;QZ &L328IK%9CMU#G&7+5,8ILR5]W?9?
M@H%*"$T@DU9A/B=JL)0NQ0G: F*O(,DM4#4M<)H+["98M%I?AI<&Z<'W!VE@
MB<P1-(2_6Y T$<_8'*O-6KW,$PQU/I7C[UB5 F4B$-<0T4002Z-6K$ <D0N0
M:RAUB_$*7O;>T.A&PM/>)K4H%39 8&M$GQ_.>GUB;E.6*+VT->H-S*5UR)D=
MXU08]$8MFVO@M;4R#[1]:?@=[BQ^9W>,_?K58;_W9F(KA%;DBD*83A*)CWMV
MWR/A@G$#'G.((1DI(&PP0*!'2MJ4>E"S#",X17%Z%M+&2ML2^U%L-UH%\!5&
MQR"PV+(]Q)H !&\ U/0Z3C'K SO%L'E9*FS1&_!6;[0'08O>2(2G\"B)R.<!
M]"2?46Q=\X6 3=)EZX&2.P,E.!#-\[Z'8 OB,T_BG[WNX<[!?H_O[QKN^^VC
MGE_8<["X^T/[^S3^=7 VB6'$O+3;=Z%4'P$"K1HID ==&A2 $70AK8_+V IR
M+X<V,;<1?3TK&%#<([=B#[?H:U89@RHE1G?4Q6HEA3^9L&5DI9#<2)J #!S'
MYZF<))66>(?W=>M)BH_BV@(JY#!K4*>"H\O$I>*4?'!:7HE;_H(] AM:)W'X
M*P)JB/D!^X-X4C[82<^(=M S!L,-GK%]4+WG']MWW-I-T+464A#ZN=4YI[3#
M+7H.<7-R"6Y$#4]T&,DCJ:1;$:?9-"PYJT>R!VGPLSM-U[B]SV[7U82*TA3H
M)-9SL#C61G@%/,N?0X[42J&O8 T4Y(34!'<PP1_0666!">;E>42\@QY1Y8KI
M@JO2!U3""R0)$FVY0$O;#83YAD-MD2#"XV8.[3T .V)PMX&I1[ITCVNP30KC
M-ZV!MB')UW>B+*HW.-ZI(:P$ZN,!3 .\*!"+'01Q'=8#/A[BC$Y8*O[K:S:"
M^1NB.9$8'<>E(32M,88-4C-M'9;3$3S*LC$*^KU$PH&B]Q[IDJ!;8)R]U[I2
M'#>RX ^'\KNGB?M!JY3;&WI%$=J[$0A/[?QZ5&EEQ92\ E6=%-UKWWSR$CW9
M=79PASQZ>3MD?\0M:J]KWD92"NSKR+\-JH3=K6'4?+@9N-&.XX; :6-O2(XO
M0)%9)IT#^$+:BC32**H7$O7S0O;0/S!+6,I"^)^V);53P^^E1/6] Y=Y[,^4
M]G]LA)^CFH^0FU.%3!>9MT3XTFD&G8O$$A!L%4&YV9 N@5\1XPC,UW,.S]G]
MV7M]HOA-$*[VCN$L:4/PY0([6KB)O8_"O6+ZV,706U'T-D][+'(>6V8()EPF
M/YDJYVT\>WV9E&:'=ZJGR%P2@Z&MB4 "'Y 1BO[E2X799DC\,E]HM0#*_CF?
M5^^03!7#(2N47@'6+E,=HC:_XQ&(X#^%&K6_]C(^TL[IK$:-\QO<NRW\ O#2
MZ1IE_DI&*(D0]V#(7(H7%L;UC\G:90?J/UE',2T_YJA"\=58YG[A_;C5C9&C
MH_:;[AM_:<09_(A:G^I"23M<*.DX\;!R>-CN=K]0_\7.?Y[DCE<\*(]+8@N>
MOVT,&G6/&EKDKOWB^@9JE2VH:$M?N+_,"^(&2%*KLB#P7L!8BR#!DKV'$>,K
MSK*UT]WUU2TGA?L&="6?T-D[B$Q)+U#[ATU_J^D&SY41-BSO7[!VVUB]#BY$
M\?XJ%9^O9C]<YFDN\_K5$!.#_V:G[Z?_/OUP/KWTMY9.SRY/I[OK-O]ORU<I
MS5]2*]"Z]&*#U>;8.5ALN,#V PK?;1#X9'!S1!S+[SO.4@D)FUY#7-+!+?L8
M3@M^V/^[M?_>I_"R!W< #\R^_]SMWO&;@+6=RJ/WQ==V,84.-^S'X6WU M:O
MG=^[D-[8W)-'&.-+!Y,*1MUOOKE>?8=+]/XZ_\D?4$L#!!0    ( )V&7%#F
MA<2,50@  (TP   7    <V=M;RTR,#$Y,3(S,7AE>#,Q,BYH=&WM6VUOVS@2
M_GZ_@NOBN@G@-_DE+W9:H)ND=\'UVJ+U7G&?#I0TLHE(HI:D[/A^_3TD)<=.
MG-:++&[CI@'B6.20''*>F7E(,6<_77PXG_S[XR6;F2QE'W_]Y=W5.6NT.ITO
M_?-.YV)RP?X^^><[-FAW S91/-?"")GSM-.Y?-]@C9DQQ:C362P6[46_+=6T
M,_G4L5T-.JF4FMJQB1NOSVP)/HG'K_]R]E.KQ2YD5&:4&Q8IXH9B5FJ13]F7
MF/0U:[4JJ7-9+)68S@SK=7M=]D6J:S'GOMX(D]+KNI^SCG\^Z[A!SD(9+U^?
MQ6+.1/RJ(8[X\.B4HG!XFG0'O6' B0_ZQ_V XRGI]N+_!%"R W'?1IME2J\:
M,[)CCP:]]O&P,..%B,UL%'2[?QTW-N0RKJ8B;QE9C(X@A\I$Y@9**'3JO_J^
M[XU@Z,:T>"JF^<C-<[R]JUH\Y-'U5,DRCUN13*4:J6EXT!L.F_4OZ[:[AV-?
M]Z+K?L:V@U;",Y$N1S]/1$::O:<%^R0SGO_<U#!I2Y,2B1?4XK^$.6)L][CP
M2W",?E*14ZM:DJ#G%N'R9B9"85@_:/<V9[I]CA$L16I]DD'OJ<_2J1]3)!6W
MR!\QZ$7*BD'O\\M/DZNW5^=O)E<?WC^X D]UOH/M5KUJLL\EG/$=49-%I(Q(
MELS,N'GY8G@R_KJ=!18G-Z/6<("Q"A['\.I62HD9N9(G"N\'%B)HUY-]NEIN
MK/'@J#UTRWK%9GQ.3-%<T +1U<R$9CS/2YZBL)#*,)FSMU)E+.BV_L%DPC[S
M?,HSR28S4KR@THA(-]E5'K5A]M/G9/;>WIK]%ZYA;%@V6[+K7"Y2BJ?P86?]
MRNRQA ZY1.+%$%SD0,42(<VHDC!3I&*7E8$'SC(\*0'$)#Q"D6(R0ZPWTLO=
M$\@I(JVY6EJ1C%\3QEWK4Z,LAC(8,G4I'6-8@4@HI'"(Y6CN@RM;S$0T8[JT
M'[?M%Z2HZL1.(!,Z1:ZWM&$AS P3U 5%3D';;P'59(QISM$L9N%R?1F>&Z3[
MWQ^DB24B!V@L_FY!T@2>(8YJM58O\@2ASN5O?(_2,D:? .(:(IH L5#IDA7
MD74!ZQII>HOQ"E[ZSM!PH]A1XJ:5*%,( -@2Z'/#::=/Q/6,):E<Z!KUBJ9"
M&_!IP[@M]'I#R^8:>'6MS#UMGQM^!WN+W\F&L5^^..D%QV-=(;0B5S:$R201
M>#S0APX)5XPK<I@#AD28DL4&(P ]3(6>V196+$,$MU'</L="1ZG4)=K9V*YD
MZL%7*!E1C&+-#H"UF !>#ZC+FVB&K$_L#<+FIS*%1-#GK6!X0%Z+8!C[)_\H
M+'O//>AM_\S&UC5?\-BTNNP\4+(Q4(*![#SO>@@D+)]Y%/\,NB=[!_L#?KAO
MN.^U3P.WL!>DL>6#_5T:_S8XFY9A1+S4NS>QJ3XD *T:R9,'62IT@ @Z%]K%
M94A1[OJQFYC;B+Z>%12EW"&W8@^WZ&M6&<-6"D1WZ*)E*F)W:J'+4(M8<"7L
M!(3G."Y/Y;:G4EO>X7Q=.Y+BHKC4!(4,LH9M5'"X3%2FW"8?3,LI<<M?T,*S
MH742AV\A64'D![2G^%'Y8"\](]Q#S^@/MGC&[D'UCG_LWG!G-X%KS45LT<^U
MS+E-.US#<RPWMR[!55S#$PXC>"A289:6TVP;UCJK0[(#J?>S#=$U;N^RVTTU
MH:)4!9Q$.PX615+%3@''\J>4@UJE\!744&&=T(I@!^/] <XJ"B28Y^<1T1YZ
M1)4K+N<\+5U M7BA) '1%G-86F\AS"L.M4."\(_;.;3S #1$<->>J8>R- ]K
ML$L*XRMILMN0Y-L[41;6&QSGU.17 OHX -L!GA6(XST$<1W6/3[NX\R>L%3\
MU]5L!?/OB.:6Q,@H*I5%TQICV-)K)K5!N3UW1U\Z0D>_E2 <Z/K@@28)W )Q
M]HYTI3@VLN0.A_+-T\1#K]6,ZQ6]LA':N1'%CMJY]:C2RI*EXIK2ZJ3HCGSS
MT4OT:-?9PQWR\/GMD-T1=UQ[7?,VDMK OH[\VZ!JL;LSC)KW-P,K[3@V!$8J
MO2(YK@!=9IDPAN@K:2N4H%&V/A;0SW5R /] EM V"^&OW9;43DV_E0+J.P<N
M\\B=*1W^V @_134?(#=O4C!=,&\!^-K3#'LN$@D"V"J"LMJ0+HA?6\;AF:_C
M'(ZSN[/W^D3Q=T&XVCOZLZ0MP9?':*AI%7L?A'O%]-%$V5>A\#9'>S0XCRXS
M@ G+Y"93Y;RM9Z^KN,R>%7;W>*OZ!M0E48AM32")7$0&%MW;EPJT39_Y13Z7
MZ9QL^L_YM'J)I*H@3EF1RB6A=C&3/FSS#9< A/\0;M3>Y17\T2V"0FF,S&H0
M&;?AW6S@UH.71M9-W#4-7Q+"#TA9ZZ6\T#2JOXS7;CS8]N-U4%MK(&<5*5^.
M1.[LX,:M;I><GK:/N\?N@HE1^(UK?:K+)VU_^:1CXON5Q_UV+SA]N/ZKC;]:
MV>NUCT^"'1MWG.)>>2R)+GC^JM%OU"UJI%E3](J;%?(J6]BB'5WC[C+/+5<
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M@JGQU7V0TPK^@4?@I U4F92[07 *0ABDK;LQ+QIFQAA,=Q3M288"VLE]>%"
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M='GBZ8$RDJM*"7:E9%X=RY"/[W>\H9S%*;/)>:_89G%U^I&P#8!XR0#B9QL
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MDD@F?_88)%;)M&YL $V#VR1/K1K0<GL8O-O08=O:&@)#[4&\@?W"$!BI1_/
MYUH$/"SN"BLDVMH5EM0.$=O8J23[M>9T+BNF\9(&#IZ4@P:=ON2;S+B<C-[%
M;?&H(!#1!V_*)*/,Z'PFUT.)N2DQ.,0H,\:>N!M<O&^02VJ<^0).G%_A2(FT
MR4KF)Y@:'QP"AZZ;0)V?&V*1RLI8W.RF-\-OOFR/>+^LV2 (?Q^"L!,#MT$0
M+A-!^!A/P$VIR>6>@%VY1B+IRYET# EGHGD%%@,7SH45:2#U18S6XOSHA7-P
ME,$+/FH$L(1)D)S8PO+9A9^K.YW>8ISY8#L80Y]&I3&OM-R"^ L*-@O]$#7%
M2]5K1 T>>7@1Q,-*K;P%U/V#W0,3$K@^.SE=%[#BL2V>Y<$&\\)+^^K,:C+(
M/2S"E37\;A6I4".MXM]J5528!I?F)GG?8_R2BEWP5'I&:++0.,L0<^7BF)!1
MJJ2:BPW+/9BH:9&G4OBZ:J3<NML\4N(STIQ<.A^FEHF_71HB?DUZ".BWY_RM
MZ:?;HN31(L_1I))(0UTJ<C**&W+*!2/E$^O8D2XJ3CVD6VZP0_@3>J1"TP3S
M,E2 DUA+H1E2]P8:6LJ#/<16;+W8=A'.&-0)0:S T7J'J89$KDE $4,W9B./
MH+556+"^JY4@$A-VSAE<&KO,F"GA@0TU.2PR*BS<8+A2CZY!W_=.,]2/V[NQ
MO[]:XN*A\NZGLQ.+*SL__=E@RR[7!4V!KN14&W.18Q(-8-.9)<>S\8_*.O\E
ME)%!:UQTTZ\C20[#>R)WH1]?99<J RV,UW?6?+;PS,>B#?3MCH/UW1WO3L]/
M+X_?8[3OGV=7A##ZUEQ^,'T;G]^?0!2(XL'GG5R)%O<JFM<]"B1U18H'84H,
M%:^NB6X DT2$2\.6QS#<K)582A[-NRJE0C=>A_$[XJ]EW<3"+<H&2,,HG0-M
M/'HZ%O2<$'.!1>>]8J#!CM.-KT!CH>!9^>VE]\/&WK@REDOOCT05:I @6^V:
M[.NS+(B4%/@5)NHQ!O%EHSI?.K&]2?V%,F3<-,(CT?*<AP=%21'.P.UAQXYT
M:C9ODE%MW3" :XEH!+$DF?B )%X@MU.X5<H,RVT$?9<[$Z[;Z]U,D^$@$(K]
M.]96G"&.;BIU'(GO%'V>J",6%+])<WIBWP<&%R)B$?A"5M><061;#^<EOV4L
M[3V3=>^,M":D-1^8)% *5^2@R%4LI<+CNA#XPXW.B7@'5.B4F0Y#DYU$$R A
M\I LVID!@\."4!:&T(IHT@GDAU.;R]L&EF#,Y!9ZQ9@0/0!MP1\<49"K7@>'
M"$V+O)W %,S>]4W*^4W9Y>7*>5NORE( WJQ-)9^6)I=P+A2Q3V5ZF#A$N_GL
M&]+H''35ND(A3RHI.XFWI>6W*4UFDV0[RP<\14!F*Z1,0^8P!-T($S25O2^B
M$9Q'1>D!<!%\C_>#@#" -"H(%@KS%+<D'B<94CRHRLR+<+R0'+:H7PJ0WI=Q
M_"B%P*:\UY*%0'&;P&F_GMN^'#$,$?N@%V I9/J-%/V[HFU8\K]9ALE9=Y?G
M'!/$A)4BE")C")TM&$-8V>Z#Q3W*C;HIA;1<1E^'43^N=GZ&$V5-MJP)8[?2
M_[AZ9H[.C9L^]1X.400(8QP.WD.\KFX4X#%5;7C-A@( 9Y!5FRU5Z$P[*@ U
M(+89P5GA+4G%>WF(94_%:$,J89, PV]QZ''D(37H+I?I.T- 8K"SX0QXEG!P
M%$:,;PG.M1":]E&*C4TYEZ6*C9^1N[18$U%QGC/7:N&?M$)RU@<H=/P]YEZY
M88)!VUCR5>B<YD_\H-WY;^/M/!=UT/"<M%_N(2G;Q;.DO*C%.8#,P%"U!P$P
M %$A%U,QIN9D M-$/P#!5!\ K7R\TF)3.&:Y2L87L'O7K4H,;B@BFYX06S=\
M)7^9U*FAXR=I4QFQ%Q)KBL"NBD89>0)C52F7G4L(.0_%(Z%QK/M1!G4%AO^_
M+8D]WDDYLRW,>9L9GELHP23"XM3" O(M;N)-[8\EU_YH$F^LR7:>]>@1"R%6
M-@IMFITD#DH1*#\K7X('7D%)WP(@$C])>!NKJN*3NB,#HZPQW4W'DH<WU@7F
MJ5 ]4LK/=Z0[I0W$>B_FW$1)1HS#8)3?,>V[S>YG[S\Z_#HS4BBEU.?V/PON
MT HQ'1._@^MXDU&TU4>3T\L),C,JC.VLJUOD1@,ZP5F!7&PK2U<L&-BS^M<#
M[ 6ZYSB/&^ M/%I@X&/#*=%>%W+T-/5,P79U8[DZ<*-9RFPTKA@LKGFN'. Q
M;F8=E23,%G.9T,?D !N4F$B+7G.VUM$@I[]*J0<1UQ5YR4N58D(M&>Q2&X0K
M9,P&-4U$E%1W4X&L*YJ8Y<;39M<M@SG*%CD =:OAVTL<E:APM4GV-H+E<82D
M4 -"69&!*,GK,IT*HR'GEXT#PY5:4YT'\UL'Y?(FW6E)Z4XOFEW9I#LMH-1_
M6X3I3$S83<L7,F;"@\'ZM0<-,*1#-Z"ZC;$I9MC+5O#1UFHN37%#E#QRVW%#
M #FR#',IAS.HL-9B=@"MR-69H 55_J,-8FO)RO/L8DGBOS])#E\>O3K<TX?1
MJQ?Q<WVDU?#Y8#AX.3PZ>G[T:N_5BW_M/WO2L<)D057YA*>TOY[D_+.E<V%R
M;G+S"I*EH''DYE6DUO W TI!PW%.U:34K\T?OO&+][_Q]P7.,!S^DU1-7R<9
MC1B]5^3\JY>[+U^^)%%?0?NKV+1'CH%=/@:>5O'LC\^/=O?VYOP^]^;E/?DI
M-9P;#T-2@K+Q]R?/GK3.MH,#G*P%EVM[0&\Q72A2J7P'RZ%Y^.U[IR%/V/Z,
MNM)< B]^W\IYL4)GSLP9RS-V]>G\7?#^]!3LOZ,W"W;KJQ9F7;!?9\$_CO^)
M3"'';\/@T_G;T\NKZ^-S^!N91(Y/3DX_7@?7_SB[<J2#_0?70\7('_OMJX]H
MI_Y*>RS&R@.D+[QFRPTOLP>._^\'J.W-T3U:A:5%+WZ=5-#.:!'5?NO*U%;<
M7JM)??+#CU/:^/]:^']!,'MFK^N:?O+#-2K'#QJ!A_9_#21HS]B\514/3;#H
MV"S:^;VY M2H$!OEX*L?HE?'Y^^./US 07EZ>?SQ]-/UV<E5&)R=G^P^2%W8
M6_V>LD9P^I;5 U0)WO[>+OX9.L'ZR=:_2E]8C<7US2D,"Y\)CU=C6'@(-BK#
MP\;F]VL-Y%MX2@Z3!X[UC&_R7G_R MZD!5U9+[M<69LHR^];@B];R^(/1UD.
M#^Z-LO#XD+(X;X4^^&C[FCN^[1'O"=$<7U\?G_R#:C;L__XS? TZ^O'R[.(2
M5-]_0E>1AV(A2;)#.[1A7M WZ]?]ZPN2ZZRL7:GL1HWSX'JD"S71-=A3)9@%
M6;1@<N?C&9:?+B\^^ -3(ZF$UM_:,+P]OC[UAN&K1IX6:O("ULF"4_B2J6J:
MLWA$(,?UF\>K3S_^S^G)M3>5'PG]Y16O715U?<$>?65FL 7CRCS6IUP;T#'V
M)9DM!7(0#'2:WX52X#B%ORG]J)1*!P0QQ-M,A0,/)(2XX3$B^X3"!31*?:NR
M.?#"F4(^<R3^ED $5FJ<>U:#8)M6JJF]2X*0%=N,@'3D@%0\FE/'J/P&X;F&
M25%63./ >1D3!(U@4H9 XU*AJ_@U3ZB8!:=Q44W*9ODFPH&U\LOF.\(:Z.Y7
M+ U76/+-W8&+__L\G[/#%H3"?S.#=:4UBZ_%5]+A?/C&:H[, WV>\_^]&:;-
M,/W%P[1S<-A69;\=(74LI;&04&FDL?X0J$,J&NEX5IRO2,][M)R#W14TPWIF
MZ6W-R:&BA40>/!51]%Z=Q[,@4AE741-UUY22%J \IQ*(PLPC(.7S9I)JYBC'
M-SH#%3=-IT8)]_1N3*U/D7\9B[/8TE@>2VU<5Y2(V^Y&^_T&H9_?65XMI]-3
M0<^M1)?;CTKQZEFLUK0DGG$W$V)^>F.!GX-+K^CX.@1.'J&9NOHM?8!W9W4[
ML3XMW0SWJ@[W(Y",7YF\_-M=.ZO;B?5IZ6:X5W6X'X%D?+:1C)NMNAGNS7#_
MR9)QXR'\W1["AT.Z'P+_.SQ8 OQO]29GKRLS^"_!\7V3; E?&=;Y<)SAP7Q)
MU=6K=<&X+C@8[\\^G&&NRNG_GKS_A%6Q@G.OBMSODC<SZW]5AJ!'=A/G5D*L
M4E1+;AI,\YH8;ZGN$5'1DM?= FB.#@\L$9"K/_1>#8@--_:JU<)/^B9'5[Q'
MH"V,6?@6OU)ZG.N2.("$%9,NX)+QL)Z(3WN(%+_N*[_:)_S?^;_I_7A[K&]U
MFD]<):6<W@N/NLNX^J=AW\42EC<.IG%TL'_XIJ1"ZA,.FI0U%7$JPV"H(BS%
M@DQ<S"X(/2YU5&AD#+8T("'5'IEP 5YX1ZE][!>U4"<(&^D.3?SY2/M578];
M:ONK:H'KPPRRX(!2H$<W:MYR8 V7IX2+"/#$>\>#/+D-9G>$J?7*7&0<OT-*
M/#TF*EPU2'$SPMW)1&',#TM5J"(:\46T&SDFA1QY>?&MK>W!9FTO>6V7=5HQ
M/RLQX^7%9Z^"WH /LZ&C:7\ I]**KZ7K1A4IY97C,H1T'8?OI,:J-A6=]MWG
MK,J\@]06=F6^S=A0X7*-+L.M/5&%HAI:8;-X%V%J;U0"@H%_J =I$@63'/[M
M*LF65$&1*NN4S0IC#[,%UW8><1"HB)BVM*8P=E8=(BHPP_F)0C6CL@-NDJ+<
MULU6EN;,58CT>$1G28B%4!*I$-$(O]%9E-@"[#BWPQK)QC%3D\C1D."XJPVF
M^MWL*Y9GT*^(L;_ZMD[/0CO>F;7W5C![^(][-9X.\G@*_QE5X_2'_P]02P,$
M%     @ G89<4)^H9^G[0P  O? ! !D   !S9VUO+3(P,3DQ,C,Q>&5X>#$P
M,C4N:'1M[7UI<]M6UN;W^15XG9E^I2I(MF3+:SI5LJRXU2-+'DE.WGSJN@0N
M1<0@P,8BF?WKYVQW 0A05$+'I,RN="*26.YZ[EF>\YP?_^O=^='5;Q^/@U$U
M3H./G]Z>GAP%CW8>/_[UZ='CQ^^NW@7_N/IP&CS;?;(77!4J*Y,JR3.5/GY\
M?/8H>#2JJLGKQX]O;V]W;Y_NYL7UXZN+Q_BH9X_3/"_U;ES%CW[Z$;^!?VL5
M__2_?OROG9W@71[58YU5051H5>DXJ,LDNPY^C77Y.=C9D:N.\LFT2*Y'5;#_
M9/])\&M>?$YN%/]>)56J?S+/^?$Q?_[Q,;WDQT$>3W_Z,4YN@B3^^Z/DX.7^
M_F#PZM6K SUX-M3JY<'!X)F.G[\:[.FA?O+T7WO0R,=P.=]35M-4__W12..[
M7[_8GU1O;I.X&KW>>_+D_[QYU+BHTE^JG22+H1&OGSZ'*R<JCJ$O.ZD>PC>O
M\"NX8YA#9^66@8H^7Q=YG<4[49[FQ>OB>K"U?W 0FO\'3W:?;+_AWWYX0O][
M@P_8&:IQDDY?__=5,M9E<*9O@XM\K++_#DN8F9U2%\F0+RR3_VAH+;R;/MY*
M3^ Y:9+I'>G9WCYUY_C+*!DD5;#W9'?_X,?'>(<9C9DQH>ZJ-+G.7D?095V\
M&:OB.LEV!GE5Y>/7^\^^87_W%^SO_QP??;HZ^>4X./[P\?3\MP_'9U?!X?N+
MXV/\JSD \V:ZV7-Z^ZKT_%E/S\>3-)_2QCN\+K2FO[;^]@-LCR=O[#?T>>_-
M=C!6L0Y4&>3#H!KIX+D9FK*>_-4]?+'[<I$NWNBB2B*5RA*M\@GTNAK]^!B:
MO-I3$\1JB@/]SSK3(.[V7@6#::"R.!CHZE;K++A4V;4:Y\'52!=JHFOH9QD&
M)UFT&P8J>*=3=:L*'41Y,<D+A5(ZV,)9D]D]RL<3E4W-W(;T[/>JF :GN1[8
M17#\14?PZ!MM%\$6#$&J(_PNG8:!]\B/"@9;E^;*W?D[9X[06*FMTR,T+H+C
MX"@X"4!2!*?!Y>)2PNO\[W59)</I&O;^UW\<7QP?VEZO1%-[-A(O45GN 2@4
M20%/K_) D_ +[ KG+6 _^I<.M%P-F@EL0^^!80#["C_#*AZ7](0HSV+2BLJ@
MU%4PS(MJ%"1X55(Z,?M-AZZM"/0,W1T[>$W.OIXE?';^:QA<X3K^^?SB>#U6
M,JPB6%UE$FN1Z'(2C^NJ5FDP*?)Q4FI_W<'AH).,]X#(YT#A&H3?TS2_!6E]
M\/)-[SRO\+3V#-+>[DI-9>?B:Y@$^R]H4)TJME+M?]"2H:=S5]YY@?L'%2_<
M,IVG1NO0F+E>19&>0%?K:"3WXAS_X6,C#&X3^%[!V,%N!B6QTB@$0$U,I\'^
MJXU&_A4U<E;#?27Z>#AD33AX!Q-QM^*[?GMA_]N*TP45E;_]L/?\R9N5$IP]
M6L=AM?-KDJ;!1MRO3.><\"Y'"J;&5_9!2BOX!QZ!DS9095+N!L$QB&!=>%(_
M+QI&QAA,=Q3L28;BV4E]>%" OU?0?A'D<"?^-Z^K(%)U*49(^R<5WZ@LTD&6
M@^S4T((')&&>;B3,4B7,QYQ]\F'PKF9U'Q;4^0!.6S(9RI7JPY^2-^2(7[\%
MOZ6V-RO^*PMP-9GD28:!)%62:';7_ (2-/A8:+2B423#[C@:)7H8G.IKL*&/
MH%^E3NE[?APT"VX#39QT^(G=7GB%^3:G \'\5IJWOLU5$=.%[>-A"*8ZG0-H
M(]!_"ZW*/%.#%)U4?'K :5#6@]]!Q:23 ]I2T<#A+?"\."E0^\2V@/(,K4S*
MA XL>&4-!T>15%/C(> NNE$X'PYA'(IY1\E#V&J#S59;ZH"^JPN,RS:B GLO
MWI0-T[:]'V%I@C4[[K@KYA-JJ$#/&=9IRA$.6=X#75:X?&=O4X,DA;4=>ILT
MUC<YZ%JP7< PSJI$T</@A\X'##"\K,M2-#%55=!PVDB?L_PVU?$U;KW/H/.5
MLLUA0T)S[-:S#S#;2[;V%ET-URG87VD"ZE^)>APV*XD354!OMQ_ZGHLV>^[;
M[SFP%,#"&&DZE_B@@ T!2Q$6EWP*X<B!E5:028*''!P(M*!5$.7CL2XBV$5X
MRZ3(A[#6"><1@$E3%W1JX6UR[NFB1&=T ?]<JRSYC^+-9-X/NQ\?.=%9*6[K
M@N^\34HQA-#*P8TT*1*T>^#H@BU)SFX\I.\ZQ![T?HHW^VGI[EU8D?HZQVUE
M/*R7K$H%3]T&@L6HH[2.?>V1]#;:+' O*5M3&V*'I1PEL(MP>4<C$/85:'-P
M5J 22,< ;BM<V+C-,M@="6B.[M%):1_L,!9-#R,=1G%21FE>.CVP9UO(7I*+
M6@_"'3C;!-KW6:1+(P\D2H1M(CV7_,WDG9CS8BN@>K>E491?%SI5>*N/I_)A
M5H^Z;U.#,D_K2K^1??QD%H_%:_"G'P?%3UT0)O[WJ+"/5M=Z9P Z^.<=-83#
M_K5*;]6T?+0!@-T! %L_@=H\8L!2+/(;E8*^EP=ISIN/UKK"[9*0@AKG) ](
M#1R")NBV@.BVY)WK5#5!;9Q@R)945GP61HAJ/'<?NAZH-^?6UW%SV+4%*SF+
MD@E&_E/%"] :)NRPUK"D(P+4PCGWMDC*@4*O0G"DT@36;9:HA^UJ&V[6X%=R
MM14:M"-4SM'3I2I/"T#W%J'Z4%[F,_%K<D_UZ#=AL+=M(N9>V,0I'&)FD_ST
MXN?TL-G7[&];WP/YRYP_?$8J@Z51X1MIKQ#$RW^<-5%NDAP5%CPEK/6C[%6Y
M]Z&4( X;2(*\@>T*^B3>/H"'X9&2)J 1ZICMJ9B>RN>3A*"*\B%%DY]M8CU+
MC?4<^48UKI^W.M/#I-H$>;YUYS9!GB4O];>J9/EOUOM*-;IOB0>!#R83=SBB
M _(&@@S^R1# .<!.EBI%&#Z<:?\;'AM"$X-W8(6KH@S1%5?0$84N-3HL\&2!
M.[W3$HZ\).>H$[R*7!"@_.E_XPO&T.91.H4OR@K:P@<5_ IG;E[$9,6T#UNG
M;:IID6,\+!KIN$ZUUSDK@XZ,A\.<[QP!XXYS)^'MA;Y)8(3I_![I;">JBP);
MGNH;W>>Q]T9F:TA^3$P5@R_S+)UNXX#:J!D]6(UA&8 >D P#AFD/T2>379/K
MDNP[?MK#ED*;^->2X5N\3S]Z5O_;/*O7X[P-FLY&G2;7"4H'1+6J(O/DD._5
M&&#_C&<055<K( @.&:E49[$J@BD\HW$CRR&1$A7L'5W)KNR)ZO&[(U6.Y*4V
MG/_LR?_!QT7ZCGL]*2'O]>7/2&%X)$\UN5 +31*K(3A,P (EZVQSC$D]44E,
MKXJ#>H**5S1*0'*-I74@'T;.)QSD%,"'QI9-J+"3JQ0]P5"+O3*TF &+"NAO
M-)E?*J(, #>^=-Z@F*.V-^9^7)<5@20R8V70"7&=PZF!T=-8?-MD,V$7Z U.
MFH_59RT^,M,*EOX)1G;(,K,KRF]$*/[FYDUVDBF[4+)K^$59'J!!AI8>M/6#
M*N#FIWOF:&FNO&%2E)7GKFX[Y^14;-PD:T3&CB<9K5=L3%Z0DSRE*#&^OII9
MQ=X2Z#HO&\OB1NQ5>>TA# R_#X:J[84?:-AM,,(8DZY2<]CS41_5L+A;7;<C
M2 NSYS3W#&6"QZ1))-$); 48OEE(1BG<#L,.[<;SV T^WE5JQ*A;/4!&M!4A
MX)EK3/&?5A1F]PRJ#:W9& H(<W;?+DE?:+SN8:L-FQ#^DC/,[=Z^A)U5T,[\
M"%MNI=J^B-I@14V,7BXT,H)CHT8<F[.$'5D= 4G\P0HUV%:%CC2%'751*832
MV<$9B!_#\_3UYSL'?<-+IU<<_*P'18V&P_-P-H6C>8?-<C:X.XF>=J;IB.1J
M/@&%.UPTF7;_#$H(&#.8OXUAIR3F@? CL)E80R#^1'C[GDAX_%E>X0_VI*[\
M>';( 6TM$MR>W,8$Q3OC0MV6_-Q\.,1Y&9*WMJ(0='*=L0NT"6\W</:R[1J=
M%V4V5BIK,>(,I?-D5J0/59(*L@3$;03G+B/")JHL117Z=YT4XESE(]'M%1#6
M.OH<1"D<B#C888 '33F$LSTOL $8ML-)H.L$.>9? =,!$]:I7*8$#&7B$3RN
M\^*S&>5/&7EO+RL:&6EA+*O60 I>;JEM/Q$SZ]I0_KYP^\ M_V\92^_/VU_Q
M@VP_V,3^-[%_KW<M84PP[;R^'@4HT_R($_YB1%X[Y]^78RB'CC!QQTC 4HUA
M,W^I"%N.T7Z0%W4:.[Q;8[./5"S*I6<1Y1$= ;'(Y5FY^K<?#EZ]L0=(&(SR
M6^Q7V([$.2136\"0_\N.!>B\\ X\F?!:3#(:)M@X&!/CFC/A*)20^#U"(;**
M#W$\,MH#*,<.(]R]H4LRM,A@7)*Q.2#-D<1@P\9 M,-Z#UOKW@#]EAPR6*=@
MF*]E&T>3OV5)IS,:ME6/K^&/@DQE7YUD^:2=_L;Z]PQ:?5(79:VREI;;X2/@
MUY&7H)QMJ0@83V56 ?E=4O9(D!" -F ;KPLU;CLBATA'@4U0GW7K#H);DL*%
M@O9&18(L!ML#D\A-G@_IA*S4<=_+45Y4.]B? /0;AC3&-;T%6HP &0;F^_AE
MU/%(3\4NGOBX1H\)AMKHFD=::%P+&P?"QZS#Y#8/MO:W@UNM/Z-7*5/XDT&;
M8;>-M@AO^Y09'$"S^W"5N@&]F&:!4X90V2=7E_!#.9F[P9-MQ..]G!*P_*KI
M2K5TCG"T"A!CAP[K:_1B.Q5UPWCQ%1@OR%LB?M6J4.1N0+F3C%$ @R9*!X^.
M=&RA],;SL)F@OV*"$E;956-V?/?6^P+/=Y^=Q/&AW>&,7RG)T"/#@I5J9,\L
ML1EV33/AH3Y@YK*=LE)530ZHLLJCST$^,0$^4,ZB$08L8-_ Q_T#AH+ PPK=
MUN2LJPIG$FZ_I&<Q4U"&BF 1H>4Y*1*.A/%3!!,BRM]0)07H*<5G78&BE=9Z
MH7=([,LML\;J.Z?>6*>J\V:UGPF"YF7 !Q*Z=%'QO1$;W7^>[Z*5J!*_PJG,
MJ 3# ZS-3FY2"BWYX^LPFZY-[!$@]@U^UL(^8(R_V@>:R.U'"JDQ"!26! QU
M4;']7+EFRVS>Z)) I=6M3J'?6WN@.!)4IW1:GS?$+C@\5@FUWSQ@/M"'0V1)
M44UA 7\)MIX^MZ]!/5B3OR%TIH2/]L4WE:C8UVFZ0PJJM4:J44$^%*W0JX"N
M!=,<]+_#//TB'YM]-WA73(Z%1I.7@5< ;16)MT>:]P NM*9K8-91:Y*68.IU
M8H&WTY8;^J'KR1O,^Y)!MJFZQ3:M5%O[->5V> @6/NQY%"XLQA#I7F TK(-;
M#L^I1J(NFZ-^@*KE"MTRD!D#-6SZ%!J1(C_K=[M+RH(Q7 NA!2B5B)D@0H"_
M_?#LQ1NX&;^K)V/M'!;B9[5Q%Z)()I6TE!<.:TI7ABD,@VM\8C;F.Z[KU.8B
M\]&@OTC /TU87'D!IV#+X"WS-(G@+3$<)+..849RP.C5!>44@(1,FC",1A#+
MA^G\V1;>1;>\YD+M>B/4EDM?35Y[7E^D8AC:J'7QEG:(.>/-0_6E[(P?M&5@
M* "^;-I6+KQ0AA5Q-WE:9Q5ALQ%/9#]N>_0+\D2378H;%&E,K!9'EE4HD1G?
MC)8P"EW(@L9P"7GDHJJ<S84RDLERC&![+)"Q% / M$Y<P:'5WD(B6:A39$T)
MA2DBQU!2 >8[_CQ,0"@GTFLKOQ]25M+!)BMIR5E)V9#(M1*5KI&'T5GFCKQW
MD#A,ZCP,D,4^^7T'2Y;"(-;:.<ENF&<H."QQM[<*;YC*#DUN86^OAT3-PM B
M5C4P0%!5"C,R<*^O_E"3+A*#(L<AD]=L?^-E'O;@</7[T5HRP[IPN:"2$=N@
M;"-0>'PWDT];HR0CF6  <^_265R&[;C<9ZTG0AD_9*\(+RB4[*'S=* #$0$,
M>6&I14)4-3$)%]84'PD=A0^8^L1;[DP5-"D27;%]X59_TY4TSP+?P)GZE]S3
M#9QI V?R>_=\H[DL57.Y4E^"7T'!'N4IKO-UL84.S4&12MY#U,X+9\O(PD:V
M'!&!838@ (*@*[PTJM"F5E$J!<%F06#NP'/IF^T.%Y%QJ3<L+PMT]6$B:>K#
M3"H8_5LW^@U?2=C6A>2!F(OD4[#&QH5$'*R2S&/]0YXS26'6BKB,7!-2==NX
MJ#1,JO]A"A6TZXB^P8-'/R13Z,5&H"PW7[2 PZ=8HWQU%"6@!4[JBCT#58$N
MR1(3HHH@2E4R=LX%]J)P\AS\BN%,[ZOP;GO&"85"@]9VP]MQD(A'QXT=7((9
M#G3O/T%N$3.E-[;TX _D2\%/EQ('\D.'_SS\<.E"X#U)<GA1X!=%]%YQ4:>2
MPOFQR",0,P7E:5IX%JC[6/;T=S4N55SL@@AN&I6MKE.PC"LQD;4@/9S@LQE.
M@0+2O9_"]E/6V,5K9":J; P/=@&%FER5&]"9T^#Q$H:XC>V08?9%*7!>G FZ
M<(S$N$78CM+Y$V-G$&WBVM@)&$B5BWK>3^/!9:N0J)<H?Y0D(_<.&AYUR/4K
MW?87:&*29FF-EGWM"K"L+$Z6;1TNYYPOIU)8<#9N\^% UI $(=PA $]QY%G0
ML)CBY$?)39*ZA6%3/_;V7^Z#,04;7O][E_:0\U.ZQS?B%XW#B)'>V*^M!-J5
ME&6-R %+7G>+D6U:/Z7F *^L9$0XLE4VY.U$K@I,=C$>#%  2N/"P&//TD$2
M^),>G##O@LGA]J;42ZBFRRW=."[:6R8]QWZE2!#9'#U\%QNEF0R2W7X*&EW@
M5,DDLD5*<PU-P)U_S3%[DW+K6N2R;F\Y17DJ %I=\,G-UBJ8Z=AJW%Z_@S%>
M@BAAO 6&O_-A&_C9WK0(FJ@SLTYY]TI3[&XS::C>"N-L5;/R#:M\2EJ0=RMI
M'>X^&77:D+5O1<N8F.TT,RT#A(AF)(%Y[D.2S;"RM")9Q3N%TZLT6NF19ISO
ME!Q,.$B8_HI*),77&D/E !,_:ZQ#UQ3$AU'56BTDGF]=<N] ^XJ48_!FE51S
M::O*9M.[)/C2I?CBXSI>8U\PTBE-^B4(HI\QQP&W6NBSWO41L^!_<99")QN%
MLFQVJ0VU-O[ $C74I$!:,8$IDHL.Q*E*,$F<@@ZXJ.V2 IT;L[PI!NBZ\)!T
MR9<;77*INN0'6,0Z356F\S4A''G0$>D-P=?2HT8FJ )GZVK4R;T/S5?#VY$P
MHR2<<%9?6;5LY9Z0EX#_2%^*\ZC&[E@8BN_2;R:6>WS''/&&1T%CD5Z3&61T
M*<8-IMX\= C>AG9KN;+A/>&B4%\\5;<KU>"%)8*G_()-,BE LXX9>U$5-?[)
MV"]V4AJM/!8OA0??2Y&[P5!+5%+^]7NA<][PTBR[&BF<)IF>EB*^P:33ZZ%:
M@J'N9QL)DK+AL&1[R_D0K#\2;Q-&9CA:P;0E;'I-3R&8J5 \=R)8\68,KD9<
M6ST?AN9;N['Y?#2_TJ6,0S<R0!54(RJ_S>2TMI:D_H)Q&SH@[T/S0D5[Q-%C
M0+#]S@XB(Z.8"3OX!*X@;*(8N <]S+!<4QD$S^QOC =Z#3GEF%Q!RJ>K@\.>
MC&%L'(P*^DF%5P[[+J[D3O\%/:O)=F<<7=I_%+=6M==PTRQ'OP*S*<"X),(E
M+G:ZI4*P2X4[*]Z!O_WP]-F;]OOHRV"L55;:A>15[(L[O#)F>,;0GB"#V>>L
MN1L:O)"F$"D8N+P@/RZ)30$:O(K\5Q3LPNDJ0Z9IT*A+P?)-^85YQHZ545YB
M,L\-I2;_;EQFE&^,4ZCC_B-B@[WHESC/-MB+KXF]> C:R8:_8\G:"4BNF*+_
M*]7:>9CT0)DVXVDRSN-DF$0-")QP;!0S(-)N:^$&9"3RB1$/:=MO;JG:*-]0
M:DR@WE'E#]L.V%!!+'>G,2T65U5=J?;.4?^'DNK5G^R!Z!V,IIKR*D:_996,
M=.2DB.HQJM@1LF4141<2(\>H-YF0\5T!,4S F*?_$=DL;N4<=C)<6V=^S*V9
MFQJ*)4';WI9O5I773Q,M0YK>6XQ8$3-&L"7^@;'ZDHSKL4F-FV"SRC*1\%ZJ
M;K=]=A\CF5CWM.]@9=\?'<0!#\DK:9-94,^DD4HBGR1-AFO^F(1=C5@HA<>:
M6W80:=5*2DYCV&86 RK'5+?@DJ?ZK@7$1,SX:,=X*B\)D4>(;+>9&95@<V.-
M#!P')A\#991/"&9=R5EA283@ C*0T$I36(>8HL>M"9KA8<5CQR.*XL<:$X'"
M\@C5IDI(>1OP5N9$A)>[\\9S0=%5.&')S"J)5&:HGW+; H,G'"-WM"G#C'^*
M"<O$<=Z!:"WQKG[:)-&J2*+/.O.)T4WN>]_IR0[XFB8$8]T!]8?[1GOF89^1
MFS3P)9^13$J;%^Q<X R>==%,"4B"WW'C\P%8WJJ1P=0NK=:QH6 S%9;GTG#"
MD=SVL!T&O6<Q.F5SW!2/VVQ&R *TE7POGQ.=M3:YAPC"\3K8U:.'O?4WR=)+
M9DJ#-0@K?[UCTLCND)OR+1W5"Y$^I1($H2&KGI\F0%:GE_#5F^[8: 6%O)*J
M9BIQWN"%]@AT.MST,U[;RK)A&IS8 G#\A["U1VNXM=U$)/'?'R4'+_?W!X-7
MKUX=Z,&SH58O#PX&SW3\_-5@3P_UDZ?_>O:HRS?MNS_W]SSW9T>-[XU/>['$
M]V_AT^8!HJ-ZS@PN,O_-[2LK@E'D3= DW:/J*C>WT-OYFP%5+,+Y2-6DU*_-
M'V^\QN+];WSI@=L HXJIFKY.,AI9>J]T_=FKW;U7+ZGW%72LBDU[9&1V>60>
M5W''C_N[3YX\G_/[W)OG_7BP^W+OQ==X\(MGNP?/_NB3G^SNS;OSV=-%[WU,
M0\W##9-8@EKY]T>O'K773Y5/7N]/OMAPBJP>_&K![=E>&!WTD8W%NN<%;WCA
M[<V(&^^9O]=P/ ZGJWPXS:A)O-4O#\_>'WXX#Z[^<7QQ^/'XT]7)T648G)P=
MM8YD,Y=VEI[:63*;*LN)$&!)ERYG8GDF%IS;_B7Y_%%+9NX]@UN^51/_]-BN
M;B=6H66=*^#I1BC]%3H."Z6W4TKKND,"K?0YX0_O'0.P\$ VQW_!'CTB1>U,
MC36GR@7XD?YUA3X:[TL[W%]/U*_U>;_"^ZCG<']_>/%;<'I^_/8/9"AUZ?=K
MK0.(T8!K"^86:\HF<6 FX<\>#]]H#4N?S/3]P6ZMF*SZ"^307[?<_N34N!7W
MF(S5NXSL!NJ,GP2&[<&D>C/KZ.@TQ><X9Q9S!+WH= 1]?8?.'5Z)/^,@.7CV
MESA(EC)WJW<4W<T@]S__.'E[<N48Y+J=P"OII.L+/GSX>'K^V_%Q<'1^]O/)
MN^.SJY/#4["J?SZ_^'!X=7)^%AR>O;LCG6K.?*^V[L%#<'+V"W8;NWIY>?+^
M[ -\"@[?7QP?XU\+^?N?]CH,OTG']Q9ST)X03T*98)Z]P4R,IXW(1V%Q#G&+
M1G!.P=PM4_R6+_%X42I#^$<1'(SET@=++DM(C8DJA)-I.$Q2I"+!+PL=:XGT
MAGU1WZTJOV;R&(KHR/LYE"1M^J;QC?:\].:J4M1ZI9K:&XHQ<VN0,S/D8)86
MS*\A-]9!EA,9EJ&M;"Z\-@\QK"P*&V+MA8S*"6<F?V8IY*A;:[9$5B-8?.]%
MPA0P!G8EZ#+=*KY5M8O0S5\:'0Z87K-Q6:KCWI,NW?%.C]8JG0D]"VOOV])J
M+-3*9K#NQ>Z+ QK77@WFX\7YU?$1_GFY6/A^?[^MS*ZCA]),Z-[ZQ?17=^UA
M;8,HO\X2HS"U&0HN""5&S%HKU9N^&F\KU<B>(3_#9!;BCJX+O5H"JF]805\A
MRY$2;%E)C3Z#RI/J^%HX^9K'&C*_"4@R F,?\4M*DH5!1Q\E$\X1F.7:GD$O
MS594Z]&+MI!_&W0SPM#K-+_=%BT.&F?:,B)D.ZAN%3Q= .C(>E96S&J68#KK
MH<]%+OJ<HQ9O]!,5.3K_D8:U@S[<<H8[LO :_X5T9H@/1> G@?0G]2!-RI&!
M:R[::9][G-#@;F&%AJ><'BV) VV.UPYN.>B?K2%LU57"[5-:E<I,60ROG9B*
M#8-8IA[[WTR#, ^%!R0?5"K)9CIIB?I,W5]#\\AC0PG1F(L]P/J+^&G8ZAVV
MQ$#I@RUY'#8>Z=V:!95H59A)*7T:VR2+\F*"#A/Z?MH[]M0?T>(%; O+U1B2
ME*;"$-L3&G;*:J:L:1I[''H:H+EZ?L'2^3^RQW!9]EYO4<4$),Y30>]_(>["
M&\HQG^B"\SU<*V,R8\7D=%-$I9OQ>8TD=1VIVK(.8;XUE8FA1 45HSN6DD>B
MB-JG4F_R>;'T#N0=^?M^G:R]E\&GW<O=HUW'&_GRZ=.MP3;NQ08:FHCMHB+!
M4C686H'F/U)/PI]@AV./&.V,4S44>CXJ'T4D/(6*81@UYM53XH?ATVOV234O
MQ%F2R-[6'E)0PM3'NB48N.8WOS#DU]'R3'.LTNV5M:*-EN!%4J&/'0RI)/"8
M3Z%-TK+Y_<*"!(L@G=J6PRA., \)FEUH6.&5[*@DHQ*$U\)B ,N2A"^(AYLD
M3ZTOQ3)LPBU8K-OKG.+R7;"I7>$R2X@$UD\JM))$R%(GWD6.PM4ES0R90< \
MGR>IU"I=KKJ[2L[;7FUW?Z/M+M<7U2."5JKQO5K8E>1$KX6:*_ZGOB$7-\I*
M]:1OX(4^7RO6,6SY +]K5AT.L9*K:C/ .64)CKNW4\I&Q>S%%$YG2]Q=5W1V
M^7D#*S4^#W^FA5BW!&MBF\6:?[XC;ZW-TPCA>"H_D[*,W\>@*(6.M2_$8W=<
MI_AEF0^K6R4Z7UYC8B6E75%IAPA9L8F5FYZ):X<><UVH,7SF8Y)>0OH&J==H
M0(6TXG9&^2V\?$RDX5+\P7!E4_@A!B4MS2?F)\VA!3*,=#3*$B0@M-6%[9EL
MTU3H(AC]:[?J3\!B2LF 4<3BS4HE.PJ,%15L(32<_:"HH*S4W,]?Q2X19XW6
M[39K9J %\Z+U)0]HT:J0&B&@1171J+$JPB"#1L"<(_,[+6JL:FYI,V"J23D;
M@!&1H0$(:AZNTP$F_4N&9)V)B09J'I)I9U1RP#)3P]5@HA%55\AEU1M,T*R5
MF75;T_6PV6)0$XG_@^\Q#1HD*?-+86U96N'_KG-J[L2K-##6L$UBVC%L;!+7
MEW2!MB:8,O1VJ7E+O:(73/)*1!C)97U-+W'=@M?\KDW5%&R0&1C_<MP4-/IX
M P^8/$&Z$:D)B/AT!RFOJ?%\$5)JW224Q47;S>:;A>RHP.=)X6Y)3O5>!,L(
MMF2S]\+HCZ\PMKH;AK(FQ@<).YI/_K'%=@08#M%(83MEF47;0?<*B^ PR\?F
MB6XHW??N'/0SYLSO5*P7.;O4&(<1S!2N3DS8%4Y[3PI8L#IFPGL09T5/QELU
MG>B2^=1X:9-M9\8N)WZ&V/-3D= %^XA&<)#$IF*"BF25\[OQ.TH I YZZ?CT
M0OKVWVBJ"K&"?3EO)GF[C1UBD[ <?"6, GY0\3YCZ=4M0O9Z=HJTYL@1]=WY
M9)GFN&^:>[Q43D; N&3F^3QNIN_^K/?-\E\W$2 &='+36@?W&LN9/LO8Z;ZQ
M@PU;HLLM=65ES:KW@\W<#'M%^1GD7NE5N!AN>R=V3SLY/JF$BR6A@@MNR41$
MZX%.0EOHER]+F%%0Q3<P?.I:-W77NZ@6B3Y/G,5YSO[7T-1W)/N>'*OHK5'C
M8$@U77)JQFS3X4G7.D,_23HE=2<S5(ZLE;$;!!5HY$PI<"<ATXM03LYR75BW
M Y;VP ]$]\*4(V-T4/[,I2F)-+"_EU*:9,%*\<U")MVIN_XV'FMZ/3U\]F%L
MBI"%@*Y:2UV-AV<-RW &\<*N'BR1S,0VUJ?CBID4?@%UF_)L7&*>0PH60Q:1
M]ZF$!J2J^'.E*0G?]Q60ARN)8+O3E\(=V_L&(,KOC#EQ59V""^KZ[)^V_F*W
M)STIX,CS9DLP=^!/2#25+4(D%],A7JQ*:*N,U_V% ;><&?WS5 V@%1<FR,?E
M;;X_E^W3C<MVF6;YU2@I8B)LG+:"1BO5^CY0JA<WYTIZ,6_%<#8P;9314."D
MK'2P?4I!.;D@-*1R.#"&],,JQ<X%YP4U?9?.'8[*K94:UOF^FIZUL4Z.FT:)
MUR"NT5J9#8WC+!/0%$-L2I:&/]EBY9!^G;2"R$:]!G4PDW!@I MZ#.F1.C:A
M00P O^L"L(K9!1K'D(H<^JB'GDE8! TAU)+(QKW%ZC%L"MM[9RI1=3"T^O$&
M7+^S'>VNDI<4,V"&;0(S>&7;%\5 ]/53@!$=$ A3WK$#,.'8:;_#H.:SS0FY
M7#Q9<#)F=$?PB>/[)\W(T\<B@94LT')QRYR3SK<F@<].H>3[;$Z<<$ED+& G
M"@+*BIO&\=B(SA5!.\Y#%*NAH5K%2V%XQ1]3-&UZEE-40&H$!_.)%'C(/&8]
M'^XF\IJ/>:_A@X)K/H@:#N)DG)2ZY>:;-KSM!F-1F@99D \BX+)K4QKWZ_3
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MSHLTODUB;7(/0D&)2YX*'A<#^<EB1\=U6B43K/2& KCDB+JYBN#%#>]!GW/
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MKB[.DSU*CI@IW>564"OE@>P8J425$]@3:RVY.DM4A"D4 B5/CVV68&JL.AD
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MIP?*2*XJ)=B5DGEU+$,^OM_QAG(6I\PFY[UBF\75Z4?"-@#B)0.(GVX Q!L
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M'[<D[\'CX\LP.#H_N_QT>G5X=@4?SB_P\]7%X='5^<7EFE"HWW=_&L O7M.
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M?G;X]O3X[/B2JH]<'%]>79P<<?V1-91W K(!211S] 'U=#C9/6JB+/9!.HE
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M+R>7A##ZWEQ^,'T;G]]7( I$\>#S3JY$BWL5S:L>!9*Z(L6#,"6&BE?71#>
M22+"I6'+8QANUDHL)8_F7952H1NOP_@=\=>R;F+A%F4#I&&4SH$V'CT="WI.
MB+G HO->,=!@Q^G&5Z"Q4/"L_/[2^V%C;UP9RZ7W1Z(*-4B0K79-]O5)%D1*
M"OP*$_48@_BR49TOG=C>I/Y"&3)N&N&1:'G.PX.BI AGX/:P8T<Z-9LWR:BV
M;AC M40T@EB23'Q $B^0VRG<*F6&Y3:"OLN="=?M]6ZFR7 0",7^'6LKSA!'
M-Y4ZCL1WBCY/U!$+BM^D.3VQ[P.#"Q&Q"'PAJVO.(+*MA_.2WS"6]H[)NG-&
M6A/2F@],$BB%*W)0Y"J64N%Q70C\X5KG1+P#*G3*3(>AR4ZB"9 0>4@6[<R
MP6%!* M#:$4TZ03RPZG-Y6T#2S!F<@N]8DR('H"VX ^.*,A5KX-#A*9%WDY@
M"F;O^B[E_*;L\G+EO*U792D K]>FDD]+DTLX%XK8IS(]3!RBW7SV#6ET#KIJ
M7:&0)Y64G<3;TO+;E":S2;*=Y0.>(B"S%5*F(7,8@FZ$"9K*WA?1",ZCHO0
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M2JJ[J4#6%4W,<N-IL^N6P1QEBQR NM7P[26.2E2XVB1[&\'R.$)2J &AK,A
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MX?$A97'>"KWWT?8M=WS;)=X3HSF\NCH\^@<5;=C[XV?X&G3TX\7)^06HOK]
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MS;YB>0;]BAC[JV_K]"RTPYU9>V\%LX?_O%?C\2"/I_"?435.?_K_4$L#!!0
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MO^[7?.N-.K,-.RW=E0D$*7H*N<I[$V\L_&+MFG^ %D6:5YF(*(ZP'O$*W$L
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MIX@L;4I>K%VX)6SWN-[NAF7:FM9 ;D#,=HT[T67>>*=>>EA-FHB&9>[-^-A
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M=7ZHY)Y%=@Y6?Y5?T+9W@0?YF_OD-Z+I[Q%-^XG*)O!7OQSD+_X/4$L#!!0
M   ( )V&7%!]>PBXZPD  #0U   9    <V=M;RTR,#$Y,3(S,7AE>'@Q,#0U
M+FAT;>U;6U/;NA9^/[]".YW3W9[)G5 @H<P$DDXS!P@#YG3ZU)%M)=;!MCR2
M3$A__5Y+LAV')$!Y:<+>F6D:6]+2NGSK)IOC/P;C,^?[U9 $.@K)U>WI^>B,
M5&J-QK>]LT9CX S(5^?BG'3JS19Q)(T5UUS$-&PTAI<54@FT3KJ-QFPVJ\_V
MZD).&\YU TEU&J$0BM5][5=.CO$.?#/JG_SK^(]:C0R$ET8LUL23C&KFDU3Q
M>$J^^4S=D5HMFW4FDKGDTT"3=K/=)-^$O./WU(YKKD-VDM,Y;MCKXX;9Y-@5
M_OSDV.?WA/N?*WSB';2:GR9[';J_UW'9IZ/V?O.PTVD?> >T>;1_]*,%3#9@
MNEVC]#QDGRL!P[V[!^U$]V;<UT&WU6S^NU=9FJ39@Z[1D$_CKF$5AR<"),O&
M7>K=3:5(8[_FB5#(KIRZ']K[^]7\'VG6FQ][=NQ=TWQZ2* VH1$/Y]T_'1XQ
M12[9C%R+B,9_5A68H::8Y!,[4?&?#%@#+LWE+&,;Z(0\9K5,C%;;\#Y\"+C+
M-6DUZYW]XP:NR$4O%+#=$IP-KYW^Z)*<C2^_C ;#2V?4/R>CRR_CZXN^,QJ;
M 9PP',!=XGP=W1  ^>T%S*R2B_[U?V'@]#MY_^ZHU?L/?._UJN1K_X:<#H>7
M9'PQ<AR<,#SKW]X,R<@AL/YT['PE'T8?R>78 1+.\!KW[%\.X";<_3:^/<<E
ML//%U= 9.:/_#<^_ ]'KBR^WP-N7S+'@WF!T<W8^OAD.ZLNZ+[0.V)4G:\9X
M-"4TU)\K"?=T*EFK5?]_,JT0);W5>TOX;8%B'W( 'QW"[\KOMW7[D:T[ZVT]
M8!Z+7"9)ZZ *0:!U](M:VV;9;FCLS\D%]21E57(5U#=B8ELE. LXFY#A _-2
MS>\9&4\FW&-RQZ0 .TQI)(@3,$D3!J)XJDI&L5<G.R8)!,PF $KRF)+3\-[?
M,?9/)5<NC<$9SOKDJ'/8[+S"V[<Z$FS(:-?L_;O]PQZY.:WMM_<A:PV(QEIK
M H$/@D0Y51'8GRDM8D: ?1C7 8,Z*0RI*R3%VLRL. <_C!4C_:EDS!1:+M,S
MQF+R!-H_O']WV&XW>]D4<]7J?30$KR8@D%R>9^_ETZK$-Y7<!9U#<6&B]4$Q
M=9G#@JM\;9UL<K6=-?7&A$8E&<AZ$??MYPU)Z 1<D9!I#7#)S7]N+_M@<[]L
M=Z*85F0BI Y("76M@YXJH:ZX91"O-(Q@LX 3:(%OR4(#/RT*WY$X"_T#'0HV
MR?VKA.=$:%C,:1C.24+G^8+U#E<F@6T&$9.EF8MQP+-1PV.Y"4>Y""VND=L5
M!UXX+7+JT81K:#!^HG!,1J &!3_!?1F/B9MJ$@M-!)"1,PXN[[,)&,4G*@"I
M2$ A+^,6$:.QT9KR)'<S104L(D#D"19>YYG;BLT;YAGQ]NMM--Y3JB\A4P=4
M%W%S)M+0![1I"HH3LQ@ &? DI[8&:=8.+H,U*A'00+NAA1+>EFR: FZ%G!,*
MK-U#=\U4F4)FG=OZ3;V*%XQZ 4!"H5%!L=.@V';1G9,!> (8KA_JX*DI  YE
MP#-GF!\@.4@DSWRSDY FO0A"_7L:>Q9%&5<^NV>A2%!1U=R5K&)"?L=PD<NF
M&>N)%!Y3"C64ZW#)09_281L0$H.W@'?BW=8!].WD@_50$UC@[E*:6J)<*)R'
M7,]?K'/0W"F#2Y9+YJ'+)B!'YDK("F[VB'Z^=Z&1*%6:0!J&SLRL ^U"X,IT
M423XA=15,@LXF)?'7ICZP!,Z-[<F"GG$L_!6#CD?P'5"!#788UXE)<TX.?TK
MR1*:P[N0=Y&U49+<,+#9C(>A"8.">$(D4"1HP[D2,77!#C,.'H%K4!_<+XTQ
MB"V*8WCV# 0R+92AY(DH@=1@U $0?H9'(G I0,D8HR0V6&B<(_(Y&A26YMLN
ML I"H@!1HD$DQ=@=L G!-:9A9FGX ?SF,LXDAT .*$C!HR3_:7>!"06B07>Q
MTC+U=.&OY,N@7TY'ST:+0F?6*"H%+!3<V#""4'"Q]'MDD8"%/FAE%$7,YV Q
MN$TGF'I6 G0>FA-A(T'7)$[ 3_F(JWSR55F_C+I*A*EF/5=H+:)N<_6(;&.>
M*'\'LB!-IZSF@F!W-<-[EX8S.E>5EY_)/;/AUJ>G#)V2>0P,HBP"5H )T5E;
M!/,8T!,5("Q[LH7+ZS )S<A1+\>^_RC]X;Y 6LQR7P)JDMUS4($IR$IQ,M\=
MX**09Y0D]E79L;+ZIV MD5P8DCX+004FC&=:*-%ZM J ?PN!>*6"5*D;<0A)
M(EYV?,U-1C'#>H4%#GF?>AY+;" #M:SU6VK88),)1-\48^3JNGQJH6QWOGSJ
M"*(:X4SQ9MHG)!NE0! +4E/<^AA ,?Z@*H  $KVB$F.;J3*970?BV^21"6J%
M4QNX6BO18T487;EL8_6PJ?\LUXXC6P- N1#K%X=K#')YR/97E%9&>]FJI8CH
M<^6ED&;9 P*NP) /^1>]KFJ3& 2N (I^HTKT.3&-^4^3^@ ?F HSW4#"9J@[
M4U^@+QABSPFB E,/N:PD"AA7">S059G;1&(9XF$&M1J+1:8PBU9@84VQ@%6)
MQ^RP<$,^I=8W8(:I$4OE5DE3F[+ZBQ*ZV<I %;66E0)035&9._5"$[#]]:+.
MNH#M)'19MLRB\1RT)GQPYZK1"92?MM+^._8B1_7.+_0B'I.F\RA5X(L.5=G*
M&\S#C=\LC)Y#82(P=.=M+N"$ QU#!%C(.\=%QVM@F,>9<MTYR\%MMEHNS9;:
MCO*BE78CVQ_Z#?"J1T1L]H-<M\!QF=8J;(I3!U,&QR3%E/#H &&1$5#>E\?&
MZHHL"QTE=&X4B,@NSRCZ/C^%B+,LW1K/S ,06YQKV&BSO/)10%T>1T6 0%!N
M&X&,?YKP88X-S&&"@'AH \5"?5E6V82^(B?K=4<:O_H<:YM=\KM((7/R:4SQ
M:1K8#LL<V^G!C=@"8G&Z9<(S['5OTO;*^56AP"QT@NYUYFEE*C:M/&LD>][S
MQD(@=+H@%G2N?Y/3WY*O_L/YUG"^FTAJ?6KV7OZ]"Z(7[W^8C;OFU-M[F3(.
MVWLHZ6_YK[XUC^U?K<!KZ(RJY-8^7A'"MP=0?=M_CF/(A%#,3,H]Q>KCPUT/
MX:]6WH\?[]]U,./W0_9 35-L'^[]*'UV7LJ;O"QZX[;$SU.&? .FO))X$N>3
M2QIA4[-WV",.OCWY]BT[8%[Q)MF/S9^=%Q;/YW[GR?^:EV,]AN?86_-V[";7
MH%-6=%A;P>B&5X;:6\7D!FUBP;!5?#ZGS.<CW^][=+5]/O7"M]OR-\[[.Y5?
M7MQ4/O&(E?KX\*$6LHGN[GU*BK\-6"_QVF6M0U@643GE<2V+MX;'EU'Z)]+O
M?J3?VRHF=SS2[[TNTC?LWQ.9OVPZ^0M02P,$%     @ G89<4"][B2DI @
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M9CGRY@GG;*F"I[X'C=G0(DD"7=4.@4"2"?^P%9EEDLUX"C[TG(A-J3SV#<1
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M !$              ( !     '-G;6\M,C Q.3$R,S$N:'1M4$L! A0#%
M  @ G89<4(O;+-+?&P  *SH! !$              ( !O9\$ '-G;6\M,C Q
M.3$R,S$N>'-D4$L! A0#%     @ G89<4!U+Z3%Y+@  C?\! !4
M     ( !R[L$ '-G;6\M,C Q.3$R,S%?8V%L+GAM;%!+ 0(4 Q0    ( )V&
M7%"$/&'6P9P  )B,!@ 5              "  7?J! !S9VUO+3(P,3DQ,C,Q
M7V1E9BYX;6Q02P$"% ,4    " "=AEQ00!H,NC%^   8H   %
M    @ %KAP4 <V=M;RTR,#$Y,3(S,5]G,2YJ<&=02P$"% ,4    " "=AEQ0
M1Z Q7:)#  "V;@  %               @ '.!08 <V=M;RTR,#$Y,3(S,5]G
M,BYJ<&=02P$"% ,4    " "=AEQ0#K^+)5$L 0#[I@$ %
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M+FAT;5!+ 0(4 Q0    ( )V&7%"^-_-XAP8   <H   7              "
M 4=0"@!S9VUO+3(P,3DQ,C,Q>&5X,S(Q+FAT;5!+ 0(4 Q0    ( )V&7%!@
M:N\B&$@  /X$ @ 9              "  0-7"@!S9VUO+3(P,3DQ,C,Q>&5X
M>#$P,C0N:'1M4$L! A0#%     @ G89<4)^H9^G[0P  O? ! !D
M     ( !4I\* '-G;6\M,C Q.3$R,S%X97AX,3 R-2YH=&U02P$"% ,4
M" "=AEQ0O6DSXLT9  #[N@  &0              @ &$XPH <V=M;RTR,#$Y
M,3(S,7AE>'@Q,#(V+FAT;5!+ 0(4 Q0    ( )V&7%!]>PBXZPD  #0U   9
M              "  8C]"@!S9VUO+3(P,3DQ,C,Q>&5X>#$P-#4N:'1M4$L!
M A0#%     @ G89<4"][B2DI @  =P8  !@              ( !J@<+ '-G
M;6\M,C Q.3$R,S%X97AX,C$Q+FAT;5!+ 0(4 Q0    ( )V&7%"&')7L[ 0
M -X5   8              "  0D*"P!S9VUO+3(P,3DQ,C,Q>&5X>#(S,2YH
M=&U02P$"% ,4    " "=AEQ0KD*!<W82   B>0  %P              @ $K
M#PL <V=M;RTR,#$Y,3(S,7AE>'@T,2YH=&U02P4&     !0 % !.!0  UB$+
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6861294416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Summary of Domestic and Foreign Components of Loss Before Income Taxes</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The domestic and foreign components of loss before income taxes were as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:61.343%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.731%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Domestic</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(77,354)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(65,695)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(54,568)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18,065)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,194)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss before income taxes</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(95,419)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(68,889)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(54,568)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Summary of Benefit for Income Taxes</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The benefit for income taxes consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:61.343%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.731%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Benefit for income taxes:</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Federal</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Subtotal</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred:</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Federal</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Subtotal</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax benefit</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Difference Between Benefit for Income Taxes and Federal Statutory Income Tax Rate</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The difference between the benefit for income taxes and the amount computed by applying the federal statutory income tax rate to loss before taxes is explained as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:60.848%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.894%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.894%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.896%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Tax at federal statutory rate</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(20,038)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(14,467)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18,553)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State taxes, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,597)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,849)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">795&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Federal rate change</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,045&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign rate differential</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(665)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(177)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-deductible stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,817&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,729)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,120&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research credits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,429)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,005)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(869)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in valuation allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,655&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,271&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(36,575)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,257&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">956&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax benefit</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">___________________</span></div><div style="text-indent:-36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(1)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt;">For the year ended December&#160;31, 2017 the statutory tax rate was 35%. For the years ended December&#160;31, 2018 and 2019, as a result of Tax Reform, the statutory tax rate was decreased to 21%.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Company's Deferred Tax Assets</a></td>
<td class="text">Significant components of the Company&#8217;s deferred tax assets are as follows (in thousands):<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:73.806%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.731%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax assets:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net operating loss carryforwards</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">133,765&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">138,896&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development tax credit carryforwards</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,459&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,829&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,194&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,801&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,171&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,191&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fixed assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,282&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lease liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,722&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Build to suit lease liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,400&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accruals and reserves</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">675&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">151&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">604&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total deferred tax asset</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">215,419&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">169,721&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Valuation allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">187,724&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">158,150&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net deferred tax assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,695&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,571&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13,609)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(14,100)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(20,656)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fixed assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,176)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net deferred tax liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(34,265)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18,276)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total deferred tax liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,570)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,705)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock', window );">Summary of Activity Related to Company's Unrecognized Tax Benefits</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the activity related to the Company&#8217;s unrecognized tax benefits (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:61.343%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.731%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Beginning balance</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,288&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,659&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,045&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions based on tax positions related to the current year</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,393&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">636&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">622&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions for tax positions of prior years</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(51)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Reductions for tax positions of prior years</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ending balance</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,630&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,288&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,659&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrecognized tax benefits for which a material change is reasonably possible in the next twelve months, typically including the nature of the uncertainty, the event(s) that could cause a material change, and an estimate of the range of the reasonably possible change or a statement that an estimate of the range cannot be made. An unrecognized tax benefit is the difference between a tax position taken in a tax return and the amounts recognized in the financial statements for which it is more likely than not, based on the technical merits of the position, that the tax position will not be sustained upon examination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6850051792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Balance Sheet Details - Schedule of Intangible Assets and Goodwill (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_IntangibleAssetsExcludingGoodwillRollForward', window );"><strong>Intangible Assets (Excluding Goodwill)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Balance, beginning of year</a></td>
<td class="nump">$ 54,243<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefinitelivedIntangibleAssetsAcquired', window );">Indefinite-lived assets - IPR&amp;D</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">55,019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustment</a></td>
<td class="num">(1,087)<span></span>
</td>
<td class="num">(776)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Balance, end of year</a></td>
<td class="nump">53,156<span></span>
</td>
<td class="nump">54,243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">40,044<span></span>
</td>
<td class="nump">1,585<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">38,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustment</a></td>
<td class="num">(771)<span></span>
</td>
<td class="num">(536)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">$ 39,273<span></span>
</td>
<td class="nump">$ 40,044<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_IntangibleAssetsExcludingGoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets (Excluding Goodwill)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_IntangibleAssetsExcludingGoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefinitelivedIntangibleAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefinitelivedIntangibleAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6867265504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>installment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NetProceedsFromIssuancePublicOffering', window );">Net proceeds from issuance of common stock, after deducting offering expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136,308<span></span>
</td>
<td class="nump">$ 215,758<span></span>
</td>
<td class="nump">$ 81,573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Stock option maximum term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 6 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_SpecifiedStockholderOwnershipPercentage', window );">Specified stockholder ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder', window );">Purchase price of common stock percent under stock incentive plans for specified stockholder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder', window );">Stock option maximum term for specified stockholder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommonStockExchangeRatio', window );">Share of common stock subject to a stock option or stock appreciation right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Additional equity award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,530,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700<span></span>
</td>
<td class="nump">27,000<span></span>
</td>
<td class="nump">12,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Options vested and expected to vest, aggregate intrinsic value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="nump">24,500<span></span>
</td>
<td class="nump">71,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, aggregate intrinsic value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units awarded (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">834,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Total payments for the employees' tax obligations to taxing authorities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 422<span></span>
</td>
<td class="nump">$ 254<span></span>
</td>
<td class="nump">$ 654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance of future awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,757,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Share-Based Compensation Awards, Tranche 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock options granted vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember', window );">Share-Based Compensation Awards, Tranche 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock options granted vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sgmo_TwoThousandThirteenStockIncentivePlanMember', window );">2013 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance of future awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,691,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sgmo_AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember', window );">Amended and Restated 2013 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Additional equity award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sgmo_TwoThousandEighteenStockIncentivePlanMember', window );">2018 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percent of fair value per share of common stock on option grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm', window );">Stock options expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Fixed ratio shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sgmo_EmployeeStockPurchasePlanMember', window );">2010 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percent of fair value per share of common stock on option grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Stock reserved for issuance under plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_PurchasePlanOfferingPeriod', window );">Purchase plan offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_PurchasePlanPurchasePeriod', window );">Purchase plan purchase period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | 2018 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Stock option maximum term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Options | 2018 Stock Incentive Plan | Share-Based Compensation Awards, Tranche 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock options granted vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Options | 2018 Stock Incentive Plan | Share-Based Compensation Awards, Tranche 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock options granted vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.08%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units awarded (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">834,745<span></span>
</td>
<td class="nump">346,055<span></span>
</td>
<td class="nump">12,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value per award of restricted stock units (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.49<span></span>
</td>
<td class="nump">$ 17.87<span></span>
</td>
<td class="nump">$ 15.85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment', window );">Share-based compensation arrangement by share-based payment award, number of vesting installment | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Aggregate fair value of RSUs vested in period | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares withheld from issuance in order to pay employee taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,160<span></span>
</td>
<td class="nump">20,193<span></span>
</td>
<td class="nump">42,243<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | Share-Based Compensation Awards, Tranche 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock options granted vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under public offering, net of issuance costs (in shares)</a></td>
<td class="nump">12,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,200,000<span></span>
</td>
<td class="nump">11,500,000<span></span>
</td>
<td class="nump">12,650,000<span></span>
</td>
<td class="nump">14,156,500<span></span>
</td>
<td class="nump">12,371,149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Public offering price of common stock issued (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.25<span></span>
</td>
<td class="nump">$ 7.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NetProceedsFromIssuancePublicOffering', window );">Net proceeds from issuance of common stock, after deducting offering expenses | $</a></td>
<td class="nump">$ 136,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 215,800<span></span>
</td>
<td class="nump">$ 78,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CommonStockExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock exchange ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CommonStockExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NetProceedsFromIssuancePublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from issuance public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NetProceedsFromIssuancePublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_PurchasePlanOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase plan offering period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_PurchasePlanOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_PurchasePlanPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase plan purchase period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_PurchasePlanPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of vesting installment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options expiration term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options maximum term for specified stock holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award purchase price of common stock percent for specified stockholder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_SpecifiedStockholderOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specified stockholder ownership percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_SpecifiedStockholderOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 25<br> -Paragraph 19A<br> -URI http://asc.fasb.org/extlink&amp;oid=107668666&amp;loc=SL79513924-113897<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of equity-based compensation awards vested. Excludes stock and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For net-share settlement of share-based awards when the employer settles employees' income tax withholding obligations, this element represents the number of shares the employees use to repay the employer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sgmo_TwoThousandThirteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sgmo_TwoThousandThirteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sgmo_AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sgmo_AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sgmo_TwoThousandEighteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sgmo_TwoThousandEighteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sgmo_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sgmo_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6860740128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Disclosures (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2018</div></th>
<th class="th"><div>Nov. 23, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Payments to acquire additional interest in subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 262<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">TxCell S.A.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfSharesAcquired', window );">Number of ordinary shares acquired (in shares)</a></td>
<td class="nump">13,519,036<span></span>
</td>
<td class="nump">11,528,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">TxCell S.A. | Share Purchase Agreement and Tender Offer Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfSharesAcquired', window );">Number of ordinary shares acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,000<span></span>
</td>
<td class="nump">25,047,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Payments to acquire additional interest in subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_FormerExecutiveOfSangamoFranceMember', window );">Former Executive of TxCell | TxCell S.A. | Share Purchase Agreement and Tender Offer Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfSharesAcquired', window );">Number of ordinary shares acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Payments to acquire additional interest in subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionNumberOfSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition, number of shares acquired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionNumberOfSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of noncontrolling interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_FormerExecutiveOfSangamoFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_FormerExecutiveOfSangamoFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>87
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M^L/O*NP[Z_;N'QM?!)L:?MU%\P502P,$%     @ G89<4)E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M*CUWPZWO[YOS(>GYH:N/EP/@XGH*O?P/4$L#!!0    ( )V&7% 0X:%V00(
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MNS'&:J<ROG/K8>=N3N=!H3>V?97NO>ZO#_W FOUP-8K.][/9/U!+ P04
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MP_OIPT53[?IW[]/C?P"X^1]02P,$%     @ G89<4,5(^6\&!@  [1\  !@
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MMNY<%N\Z?\]U]7#\L:X?V_YKV7W?'2Z@#S_:YF6\7)\=;_CO_@502P,$%
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MKS#7<TW)7/QWN(#TX4&)SU&BM'$EY6 =JIG%2U'B9=H['?=QNMFG,VP;P&<
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MO;?-M&:3X["?7Q!;GG'Q"U!+ P04    " "=AEQ0-^,J [0!  #2 P  &0
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MV/_*& \H97.%(]3@!YL-"94/QUL\VW',1L.;;OI!;/[&^1M02P,$%     @
MG89<4"N%(Y2U 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T,C N>&UL
M?5/;;MP@$/T5Q <$+^NTZ<JVE$T4M5(KK5*U>6;ML8T"Q@6\3O^^ W9<*['R
M LQPSID+0S8:^^Q: $]>M.I<3EOO^P-CKFQ!"W=E>NCPIC96"X^F;9CK+8@J
MDK1B/$D^,2UD1XLL^DZVR,S@E>S@9(D;M!;V[Q&4&7.ZHZ^.1]FT/CA8D?6B
M@9_@?_4GBQ9;5"JIH7/2=,1"G=/;W>&8!GP$_)8PNM69A$K.QCP'XUN5TR0D
M! I*'Q0$;A>X Z6"$*;Q9]:D2\A 7)]?U1]B[5C+63BX,^I)5K[-Z0TE%=1B
M4/[1C%]AKN>:DKGX[W !A?"0"<8HC7)Q)>7@O-&S"J:BQ<NTRR[NXW1SG<ZT
M;0*?"7PAW,0X; H4,[\77A29-2.Q4^][$9YX=^#8FS(X8ROB'2;OT'LI^/Y+
MQBY!:,8<)PQ?878+@J'Z$H)OA3CR=W2^3=]O9KB/]/V:GB;; NFF0!H%T@]+
MW,"D;XMDJYYJL$V<)D=*,W1QDE?>96!O>7R3__!IVG\(V\C.D;/Q^+*Q_[4Q
M'C"5Y I'J,4/MA@*:A^.G_%LIS&;#&_Z^0>QY1L7_P!02P,$%     @ G89<
M4*+ GZZV 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL;5-A
M;]P@#/TKB!]0[KATZTY)I%ZG:9,VZ=1IVV<N<1)4P!F02_?O!R3-TBY? !N_
MYV=C\A'MD^L /'G6RKB"=M[W1\9<U8$6[@9[,.&F0:N%#Z9MF>LMB#J!M&)\
MMWO'M)"&EGGRG6V9X^"5-'"VQ U:"_OG! K'@N[IB^-1MIV/#E;FO6CA._@?
M_=D&BRTLM=1@G$1#+#0%O=\?3UF,3P$_)8QN=2:QD@OB4S2^U 7=14&@H/*1
M083M"@^@5"0*,G[/G'1)&8'K\PO[IU1[J.4B'#R@^B5KWQ7TCI(:&C$H_XCC
M9YCKN:5D+OXK7$&%\*@DY*A0N;22:G >]<P2I&CQ/.W2I'V<;OB'&;8-X#.
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M_?:]V^OE+2^&5>,ZIF3[5U1_ %!+ P04    " "=AEQ0-R6HY=(!  "<!
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MNLWU1"6$!I-*\& ^76.&WG)@4&F[/9B]G%I_.FC1SU.-+*.U^ U02P,$%
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MOVSL?X/HP*>2W/@1ZOP'6PP)C0O'.W\VTYA-AL-^_D%L^<;E7U!+ P04
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M^@6%H]336,UYV_';A61U]YJA_DE-_P-02P,$%     @ G89<4""[SD@< @
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MQ427F#CL8FXQ#'0QJR$FZB+NA@A&NY#[(00@[F(>L&3^API,0\Y=B="N1(T
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M>9"+K;:OB7E7[6VN'6A9N9MJ<+XN+_\!4$L#!!0    ( )V&7%!Z:"ER-@,
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M=ECW/;2%^NS0/)+3M5&#>G;T;])/+D=/JS"*%MY)$1G,NL/@ 0;U"$^R]Z_
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M::R]\=L 6<(4>AES:"<'=MBSDX-T\:$@-8%T43%&4PR,:)]-\82,0:)@RJ@
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M8H(5QE\02*DO6P1;6Q3!#3VXW&!_BTCB2\CA%N+[T;:+<+/0T B$:Q?>X[9
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M>POJ/YZ5?HS? :!$ )R66CPML-C?)[EJ!-TU@=@@MX/X$<XEP45T=%%7S%1
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M5X%H^@X 55!IUZ[S VCRM,1DO^E'XH/7\4&GWQXD$LGZ!/I5.I+8.HK>P1E
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M(%LXB1T)Q Y/GL]$F)Y&],,2865"7>XL/WF>P OGP><S$5:FDBYW LDU[)\
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M;2#OB_JD7#\(OFV^ CBG3Q&C_U!+ P04    " "=AEQ0Y('"=V,#  #+#P
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M)G1; ^HW*!*&XZ[@)H& +D%#.RON=O9+KF#Q(U?9$76.U-A=K4NNX!: @!Z
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MA!9L!! A:@N!(P0I71+".QPB1(C90I$C1&D(2WN'6P&X7L#BQ%:*W9+H0OL
MWL'@MC"+4UN'.#H?LH0M=!#@K0X447+,GKI*))L<SKD2[@F F(+]R<@'T$R)
M)5FZH(3; B"^0&Q? -<8] $G2^\)=P9PK<'^-N3@6D.<9MF2$.X-@)@#L3UH
M -'_F% PN0>8J]\WWAR*NO6>I=)7BN[#OY=2"4T9WFBRH[YMCI-2[)49)GK<
M]%>N?J+D:;A.!N.==O,74$L#!!0    ( )V&7%"CGN80^0(  (T,   9
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M2_U5.U,JL'0,7Z19+2_&>4+P6:AA+L=LO![&B:#]=/,%\_5;_@-02P,$%
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MZ#HX:O^\BO\?=Y80P80H2,A*Z27486@02"BC(K\'0I@49,F#K4-87,,43MK
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ME):FF'AARCB:?P#CH)1[W9TR<][T;7 _T.HTM/C1^#]C_1M02P,$%     @
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M:2KGS#1.LQ"TZ^\$-%Q,^3]02P,$%     @ G89<4'S2 <TS @  2@8  !D
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M)FR, M5$_%K%A5#4R"Q,I0$?P[-JQ;.7^6]AZ@!?!OAC@!=K P(9$'P&A-J
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MJ<%NB0C\*62_A " S%EXQD(]+>!-"H5F 6040%H 302\V4EU&%]C:HWY!./
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MORL:>XF0ET(+!38(B0^(Q@8AL-KP\3P,0#P4ECS8181<-)Z, 2@*;., ^X>
M?\1X/@:@,+#IP28CL'X)-LZ#%CF+F0D[D8 3A6W3@]W%_>M'"<?NXF#U$7PT
M[W>@X7Q 0I#/ LNHYMB''/A0C'W8@1@?SK@WQ/@L?KLL:2V;0^!'$8PU3M<V
MLLSSWF /GLMR;XXKE;-1I\*<E0:]_9'HCLP>_@W>GJ>^)^4^+2KG4=7Z)&#V
MZSNE:JDK\F]T+0=]A.L;F=S5S6.HG\OV'-,V:G7LSFA>?U!<_@-02P,$%
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M_]$+Y00J.N@.@K(#MPFSX(NGRGDZ_J.)(2CSYH50=1]=YR+$<K^YMKT%85Y
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MV&685M!D'Z%KMAG-8DVO\#GO*S;0^H1Q[ G"NI NHQ$F;"A!L;%<%IG5H@1
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M"4PNC6Z*?'>/#@[*A"ZRSRY?D9+XO$B'5@R7\UO]7CN)P+MP>,63:UPC8TD
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MJTGNJTQQ_7X$%_MH?JR6.&^!&X\FT7 ,/_;A5S7![3&7[#]]-L'U1CW\:SS
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M[:-[?!N3'8B>R58NH -/PXH;2#*?$U9)>+*R,,D6?""YG@V5(+!D()R8Z6)
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M33774J)-M6*QG" .T<5B<@=E*WD/*^;;!E!NSK)%/LO*,4CIR]L$XR#3@KI
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MDK*.2RED74=A07 Z,!J'S;FB5]C9E*8%$V&ICTI;</%)ATNGK @SVC7<&I)
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M+B]YSG8QE]2+P-9\%S+-B(X)@V2CVKB=;1;Z%B4#1(0?AFSE UX?1W;MD_G
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MP_T1+J1YOQBC2;@/OW7QM_XD'Q=#PN<WFDYU7+IH2,YZZM_+YH,ZC0],L[&
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M.N6[HPG9V/+^<)B]V6]6!&S&L)J+7QGDK)\/8;) AX<52$D+A(2[>,343_$
M@> >PW'9HXO9*YM88>T'H/\/2=KL-GL;TVYICD'2=+K9<) 7('#ZW7S8&67C
M<=[I]>!]6[B2-@:&Q9LEG"6P6&"[][J=\P->Z0(NBL70N:?K@@-"VB"LTNSI
MQN>#@D.(D..<=N>KW6F#?E[T>TJ5>5LE"Y&7MY1DM:X5EK -H8M@^//.> 2C
M/QH-DYMOT,N[@Z%K6654;$CS7V,P^AVX_?9)IQF,E42VHL8N61;1C3L^PCB
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M!-=I@S0>M<F/,,K[H\+60XP(<XL4:)AOOM(EX 7U2C]YE<?JZ8&(1[5QP/6
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M<@X;2_"Y?H<%<_;>0?FZM_P.EQ(8YDB=*HMM-W]$6P!<=_OGE.R CKH!_3H
M97"(MF-IWQD<U)TA?'?6 ]';=V'][U)-A4HFH!9Q2,G9$,[Y\<2KNF8:7AF8
M^4KZ:.,QOE45>*V2>UXY/WS3:SB6KQ*O^LD8]G_*WI1S.LCB\3 V%@\/W.2>
M,!.1^OYF?\M*0*J ,1^XYB2K^NLV1!%*F&FJ'Y@Z.^=K1P[Q2I)Y4XN'][3T
M'?NX)QNS*T+AA#&9GF"@2"XRXQ(3+ >-<XTP#391^DX:L[6-4?F_&R&PU+*
MJV?"SR7S([Q<&&#/I[M(8Z@%F&J#<4,=4,G&]"OH37V^W:%0& QZY[)BJ'7B
M>IKD@PF:5D&7[L.V'Z%U4EY U4J\9W5M#'IYI^\,F1R>):-/N(5G0Q)"W='(
MB2!T"$$GT59/&G%*!T2_[@B;-,(XL"+O%AVGE3+^P!;E6Q^_1N-P!U\U'L)?
MES:1.\;C 7?+X6  HYE3EE5OF ]&\"B;Y;IY,1AED\$PZXV.7_NI[*<WAY$\
M1XRJ8J?3+BKTA_4&OVM[E6P3M3 8$L,#3!VB%B4-XY;!A?F8U[W*@)G2O:OH
M_BY$"-=)M7P;^:>M,W?B:Z*<WG'QKS.O_5,U%C4;XT29GF3)-QD-$;J;G\A'
MK]*]<$L3X@L,'A-&83A!+Q]1N%ZW!X?E9)B^,6'-@I?AUT+&VPFF*J)_^R:U
M$?IXA*.?"V[IRJK,D1@]V!BPBO&8[V9O%K\ZETL7EO+8!>:\\TQWS_CUJ'!?
MDV,-IUPEP+G"-B$B[W<Z;  W+'LRD]ML.'))"[*7!MULV.G+92^<.Q@ 4CE@
M!";0F&[VI\AN[8Y'\%T?*AOG7;CH?TBP[V#2XP1C>F$W=_WDAK>!+PQ-LL,.
MR0UT!W3"_,18HBB*U>%@Z$29-]XV(A1J1 ]5T% WG&>]/L9ZGI-(+K!P9(AT
M&L89RJ@.JV;Y" 5=K8='#$O7+DK';=0O*V56P,TJ!W!S;>U %(JU:U4@$*M[
M>:\;XE'[--S"HL\91YQ!6T;/$%M%03\>B'T"3JD+B0'0I%^*S"A@K3/F=9+9
M@[PWZ67#WC ;PJ9Q51$TF5<+\1LL! ($^C) WQV>K7 <7_.QU^C!Y&V+[6JN
MM^B5)@N)W^WJ OG%@MH[M(S7T]TT._NRFN[G:,<[;W+G2M5S^O(I&>I:@?/L
M38L4%+\#?4$^-XL)1_=W4RQU*DX8L\15NUCA.<BB!@41OYX3-Q1=&B+VEY;_
M:3M]+ 50QB"-1:K#@!'6]=!WM*C2+Z$_6&7%KZ"EVRT.K2(Y0,N", U%&\J]
M<0?41N&%(R:+90H0XNP%+)D96^)@ JNE[]@A9XA3+K"%@CO!2<QN+PJZC^92
MX9)MM2U_Z6:_%-DOO>R7OO>[#55$PV&'7+?HQNR/V8TY&8S9;3\>=#E*;]@;
MB8>3XO:*'EQ$T<9;P'D)7SF);5V[ ZAF.,8?G4&!/XK.D$ =X!R$\WK8ZZ.#
M''U\O0D<I[VL/\)C@$3U&1[SYT:E/^L7\' /+] =N' C[!<<,#T,\H+[<*=+
M9T&7PA'@^!XB<-$91B+V\1%0O@J\2'](T<*D XM0/3\;%>CN[\L_*4%P-A@,
MSB--/X*#!GL)9RKWLACWI9=HX8=>@HY<V\MQ/ASVSX5QB)0>Q;GCM^DD\IVS
M3KN/PK/3)M@U^-%'*Q8H%/A[CS[JCOB'_!6Q4[P$]J=E)3VAQ+FM>,;!6W@@
M_]Y$E,%&02\1M/Y'_/VSV335!O4P"P<9Z.FN%\EW;%NQ]>7F=7;VXSF_(&3D
M>6IC-I8N62WS+_O5P3+OIYO@C76M&C=NU;A!JU)E=*M29:)CQ1Q$;E[BS=2/
MCFH[]"]3:&RG?GATF51C7[(.Z]) WI6[';L+^8X1=659#P0A355]=*AO<>?/
ML]^R^#!\4 0,1N[*6&_Q(?XUB$.QK!J6_^6.L @57)K%A:.X/<NU:[!L @N/
M!8OYS0,F><W )+79'/"(,PTD@+&R[0QZB"53H+C55UQ--RL*2;12CM@MH96_
M*?D0+' .@ DJ2[+&^XSQH50AM3'<1K_&WC*(EWZ9K/1QQ[XC IJ5MO8=_ J;
M/$5X=2;%2Y5ZPZ7B[\Q-]1<K#'S#1"/QJB+HF12GY.7_>$_:9+#U>&V%L5=A
M!37[UT=VVR0PW?IP[H5.LOXH]FFO'_TT6D-1Q#[M#F.?OG1U5/'3DC!:9L*W
M..,B3@\<JEJ>#X,9^=M@BGW?\7IKD;VJ<%F(0+8&W6'%T0E)$"^U;9H-HG?4
M!0[VFYNKSS?!ZE4X6<')I&PPP=@TB6P+)UF%5!Y7HPU22QXGM>?,D3AFU;HL
MNM0-&M<$G/^WT\M_AR8E8&!:V=\6'^KX1>H:E>M8>;783&/IXGZ-;> 49"CU
M88U&)_G@%5WEZV0S6^6B,"O!01MDUL<KJTJA6.1N(D,^+)I(B:\6/#8+/CKD
M$NF Y&=F ,D6TJR;:;R:HUX&"__P0!^JX8@A/E25X"6=^-AWZ8VKZ[OW*RXT
M#C_V'?M5_#7ZU3OQL>_8K][W[5=C47!R1:<O]L-5'KW.#E=Y]!3_567D"?6?
M/MXGO^GH:3CY34?/3@!\]^(*3A_?=%5'#V"ZJA>-T#*!OGE:)=]GI,+J7C1:
M877Q$8MIN(=LNDTUT8^SG;/Z!?:R]=<VNBRB7_[+?HD>D_B7!(KF5.>J9DW
M-[4&!9.5A*#\G'JH\Y^MKP&-?OO;[6*^B.*KO3+<ZU.7^9\K'M8[-1O:F AU
M_F?)@#8V%%89& -U\=?+<KG,;MH70:"),CENH&J\E 3)VXTJAC7"UPX;$&RM
M0,P=5E+NV4<,7')?I9NCN_Z (;*W[*R3I*:Z5L5&-4YHY^5J>>^,1,TR_3 2
M5WA!R7>!?,'N)L7#58)8K^;=S?LC41+UU;UXTN IR1!#:$-<C^^)Y>B4Z^^I
M$)96DM3Z*]*68<_9TJS8Q*!2I@I[LBI=9V)8WJZ>]G*'<R$ZG\O9PVKQE_T!
M_T0<-3*X/E??EIO91X3*P*>1Q,'$K;??SITI/I[:(\]$H"NKQ1L4.0B'67W
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M61:79W7K6$'"?MF*/4JBB%'^^&'$"7.*6O7Q$H%9QDBH.1RA<Y1-SPN\P>/
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M[OIZ\S_O=>J?"#>M*$^_ 5!+ P04    " "=AEQ0SA;>=@X"  #7*@  $P
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ML_G_K%?/4$L! A0#%     @ G89<4!\CSP/     $P(   L
M ( !     %]R96QS+RYR96QS4$L! A0#%     @ G89<4"?HAPZ"    L0
M !               ( !Z0   &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M" "=AEQ05I/Y3N\    K @  $0              @ &9 0  9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    " "=AEQ0F5R<(Q &  "<)P  $P
M    @ &W @  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( )V&7% G
M0:W>?@,  "\1   8              "  ?@(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    " "=AEQ0UP%4.IT$  "1%@  &
M    @ &L#   >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @
MG89<4!#AH79! @  O <  !@              ( !?Q$  'AL+W=O<FMS:&5E
M=',O<VAE970S+GAM;%!+ 0(4 Q0    ( )V&7% 1LMND6@,  *L-   8
M          "  ?83  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M    " "=AEQ0V98\V* "   *"0  &               @ &&%P  >&PO=V]R
M:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ G89<4'NG\J8$!@  #"
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M965T,3 N>&UL4$L! A0#%     @ G89<4'R^MIBO 0  T@,  !D
M     ( !DBP  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
M" "=AEQ0-^,J [0!  #2 P  &0              @ %X+@  >&PO=V]R:W-H
M965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( )V&7%!R=N(HMP$  -(#   9
M              "  6,P  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L!
M A0#%     @ G89<4"4#+&"S 0  T@,  !D              ( !43(  'AL
M+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " "=AEQ0'HLR=K0!
M  #2 P  &0              @ $[-   >&PO=V]R:W-H965T<R]S:&5E=#$U
M+GAM;%!+ 0(4 Q0    ( )V&7%"+BM@PM0$  -(#   9              "
M 28V  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ G89<
M4':$=["T 0  T@,  !D              ( !$C@  'AL+W=O<FMS:&5E=',O
M<VAE970Q-RYX;6Q02P$"% ,4    " "=AEQ0/]$%";0!  #2 P  &0
M        @ '].0  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0
M   ( )V&7%!>HMW?MP$  -(#   9              "  >@[  !X;"]W;W)K
M<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ G89<4"N%(Y2U 0  T@,
M !D              ( !UCT  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q0
M2P$"% ,4    " "=AEQ0HL"?KK8!  #2 P  &0              @ '"/P
M>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( )V&7% .7:L,
MK0(  !0+   9              "  :]!  !X;"]W;W)K<VAE971S+W-H965T
M,C(N>&UL4$L! A0#%     @ G89<4(E9T]S; 0   04  !D
M ( !DT0  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " "=
MAEQ0U$3BU<$!   W!   &0              @ &E1@  >&PO=V]R:W-H965T
M<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( )V&7% <3KHPMP$  -(#   9
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M970R.2YX;6Q02P$"% ,4    " "=AEQ0#>96@\8!   W!   &0
M    @ ')4@  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    (
M )V&7% CK_,YS@$  )P$   9              "  <94  !X;"]W;W)K<VAE
M971S+W-H965T,S$N>&UL4$L! A0#%     @ G89<4%N7ON3I 0  9@4  !D
M             ( !RU8  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"
M% ,4    " "=AEQ02?^29[<!  #2 P  &0              @ 'K6   >&PO
M=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( )V&7%!%7 ?LK 0
M !<7   9              "  =E:  !X;"]W;W)K<VAE971S+W-H965T,S0N
M>&UL4$L! A0#%     @ G89<4)0)>4,Z @  7@<  !D              ( !
MO%\  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " "=AEQ0
M(+O.2!P"   M!@  &0              @ $M8@  >&PO=V]R:W-H965T<R]S
M:&5E=#,V+GAM;%!+ 0(4 Q0    ( )V&7% 15OBSA0,  #81   9
M      "  8!D  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%
M  @ G89<4.2GGO-E!@  LBL  !D              ( !/&@  'AL+W=O<FMS
M:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " "=AEQ0L3PNT\0"   Z"P
M&0              @ '8;@  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+
M 0(4 Q0    ( )V&7%!Z:"ER-@,  %,.   9              "  =-Q  !X
M;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ G89<4.A,8)AH
M!   E!<  !D              ( !0'4  'AL+W=O<FMS:&5E=',O<VAE970T
M,2YX;6Q02P$"% ,4    " "=AEQ0YR"SR^,!  #N!   &0
M@ '?>0  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( )V&
M7%"[__H>^@$  %H%   9              "  ?E[  !X;"]W;W)K<VAE971S
M+W-H965T-#,N>&UL4$L! A0#%     @ G89<4"B#A9ML"@  FT8  !D
M         ( !*GX  'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4
M    " "=AEQ0$TM$]$4$   3%0  &0              @ '-B   >&PO=V]R
M:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( )V&7%"YF-B_I@,  !<0
M   9              "  4F-  !X;"]W;W)K<VAE971S+W-H965T-#8N>&UL
M4$L! A0#%     @ G89<4%YK]@*9 P  EA   !D              ( !)I$
M 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    " "=AEQ0Y('"
M=V,#  #+#P  &0              @ 'VE   >&PO=V]R:W-H965T<R]S:&5E
M=#0X+GAM;%!+ 0(4 Q0    ( )V&7%#Z$87BV0(  -\*   9
M  "  9"8  !X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @
MG89<4*.>YA#Y @  C0P  !D              ( !H)L  'AL+W=O<FMS:&5E
M=',O<VAE970U,"YX;6Q02P$"% ,4    " "=AEQ0^]?*"Z@"  !/"@  &0
M            @ '0G@  >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4
M Q0    ( )V&7%"9=U82B@(  'X(   9              "  :^A  !X;"]W
M;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ G89<4 A%A\M0 @
MB@<  !D              ( !<*0  'AL+W=O<FMS:&5E=',O<VAE970U,RYX
M;6Q02P$"% ,4    " "=AEQ0C.JAR?8#  #K$P  &0              @ 'W
MI@  >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( )V&7%#3
MXQ6Q>@(  'T(   9              "  22K  !X;"]W;W)K<VAE971S+W-H
M965T-34N>&UL4$L! A0#%     @ G89<4&?VS\V>!0  D1\  !D
M     ( !U:T  'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )V&7%"B_Z!:D0(   $*   9              "
M 1:_  !X;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ G89<
M4+DI(2^2 @   0H  !D              ( !WL$  'AL+W=O<FMS:&5E=',O
M<VAE970V,BYX;6Q02P$"% ,4    " "=AEQ07-GV:"\"  "D!@  &0
M        @ &GQ   >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0
M   ( )V&7%!\T@'-,P(  $H&   9              "  0W'  !X;"]W;W)K
M<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @ G89<4&<ALFN' @  8PH
M !D              ( !=\D  'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q0
M2P$"% ,4    " "=AEQ0U\)X"V<"  #N!P  &0              @ $US
M>&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( )V&7%"%W\/.
MU@(  &@*   9              "  =/.  !X;"]W;W)K<VAE971S+W-H965T
M-C<N>&UL4$L! A0#%     @ G89<4!>@[,WH 0  VP0  !D
M ( !X-$  'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"% ,4    " "=
MAEQ0N)+" R4#  #3#   &0              @ '_TP  >&PO=V]R:W-H965T
M<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( )V&7%!A&U-H70(  (\'   9
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MI:4! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "=AEQ0B4<Z&FD%  "7,
M#P              @ %2J $ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
MG89<4$W.S.U< @  T"L  !H              ( !Z*T! 'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ G89<4,X6WG8. @  URH  !,
M             ( !?+ ! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     %(
,4@!P%@  N[(!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6850027936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 11 &#8211; INCOME TAXES </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The domestic and foreign components of loss before income taxes were as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:61.343%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.731%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Domestic</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(77,354)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(65,695)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(54,568)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18,065)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,194)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss before income taxes</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(95,419)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(68,889)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(54,568)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The benefit for income taxes consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:61.343%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.731%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Benefit for income taxes:</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Federal</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Subtotal</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred:</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Federal</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Subtotal</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax benefit</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The difference between the benefit for income taxes and the amount computed by applying the federal statutory income tax rate to loss before taxes is explained as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:60.848%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.894%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.894%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.896%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Tax at federal statutory rate</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(20,038)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(14,467)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18,553)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State taxes, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,597)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,849)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">795&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Federal rate change</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,045&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign rate differential</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(665)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(177)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-deductible stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,817&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,729)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,120&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research credits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,429)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,005)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(869)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in valuation allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,655&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,271&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(36,575)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,257&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">956&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax benefit</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">___________________</span></div><div style="text-indent:-36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(1)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt;">For the year ended December&#160;31, 2017 the statutory tax rate was 35%. For the years ended December&#160;31, 2018 and 2019, as a result of Tax Reform, the statutory tax rate was decreased to 21%.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company&#8217;s deferred tax assets are as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:73.806%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.731%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax assets:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net operating loss carryforwards</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">133,765&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">138,896&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development tax credit carryforwards</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,459&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,829&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,194&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,801&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,171&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,191&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fixed assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,282&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lease liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,722&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Build to suit lease liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,400&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accruals and reserves</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">675&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">151&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">604&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total deferred tax asset</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">215,419&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">169,721&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Valuation allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">187,724&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">158,150&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net deferred tax assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,695&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,571&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13,609)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(14,100)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(20,656)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fixed assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,176)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net deferred tax liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(34,265)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18,276)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total deferred tax liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,570)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,705)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2018, the Company acquired Sangamo France. The Company recorded goodwill and intangible assets as part of accounting for the acquisition of Sangamo France. There is no corresponding tax basis for the goodwill or intangible assets. A portion of the intangible assets acquired were for the use in a particular research and development project IPR&amp;D and are considered indefinite-lived assets with no tax basis.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The changes in the fair value of the unrealized gain/loss on securities investment are recorded as a component of accumulated other comprehensive income, net of a provision for income taxes.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A valuation allowance is recorded when it is more likely than not that all or some portion of the deferred income tax assets will not be realized. The Company regularly assesses the need for a valuation allowance against its deferred income tax assets by considering both positive and negative evidence related to whether it is more likely than not that the Company&#8217;s deferred income tax assets will be realized. In evaluating the Company&#8217;s ability to recover its deferred income tax assets within the jurisdiction from which they arise, the Company considers all available positive and negative evidence, including scheduled reversals of deferred income tax liabilities, projected future taxable income, tax-planning strategies, and results of recent operations. Accordingly, based upon the Company&#8217;s analysis of these factors the net deferred tax assets have been substantially offset by a valuation allowance. The valuation allowance (decreased) increased by $(29.6)&#160;million, $45.3&#160;million and $(28.9)&#160;million for the years ended December&#160;31, 2019, 2018 and 2017, respectively. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, Sangamo had net operating loss carryforwards for federal and state income tax purposes of approximately $489.4&#160;million and $164.7&#160;million, respectively. The federal net operating loss generated before 2018 will begin to expire in 2024 and will keep expiring through 2037, if not utilized. Federal net operating loss generated in 2018 will carry forward indefinitely. If not utilized, the state net operating loss carryforwards will begin to expire in 2029, respectively. The Company&#8217;s French net operating loss carryforward balance is $147.9&#160;million, which carries over indefinitely. The Company also has federal and state research tax credit carryforwards of $16.4&#160;million and $15.2&#160;million, respectively. The federal research credits began to expire in 2018 while the state research credits have no expiration date. Utilization of the Company&#8217;s net operating loss carryforwards and research tax credit carryforwards may be subject to substantial annual limitations due to the ownership change limitations provided by the Internal Revenue Code and similar state provisions. The annual limitation could result in the expiration of the net operating loss carryforwards and research tax credit carryforwards before utilization.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On December&#160;22, 2017, the current administration signed the Tax Cuts and Jobs Act (&#8220;Tax Reform&#8221;) into legislation. The Tax Reform makes significant changes to the U.S. corporate income tax law including, but not limited to, (1) reducing the </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">U.S. federal corporate tax rate to 35% from 21% and (2) requiring a one-time mandatory transition tax on previously deferred foreign earnings of U.S. subsidiaries. Under ASC Topic 740, the effects of changes in tax rates and laws are recognized in the period in which the new legislation is enacted. In the case of U.S. federal income taxes, the enactment date is the date the bill becomes law.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On December 22, 2017, the SEC staff issued Staff Accounting Bulletin No. 118 (&#8220;SAB 118&#8221;), which provides guidance on accounting for the tax effects of the Tax Reform. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Reform enactment date for companies to complete the accounting under ASC Topic 740 for the year ended December&#160;31, 2018. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Tax Reform for which the accounting under ASC Topic 740 is complete. The Company has finished their analysis as of the measurement period closing of December 22, 2018 after application of law changes were reviewed by the Company. There were no subsequent adjustments as the conclusions have remained the same.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s policy is to reinvest the earnings of its non-U.S. subsidiaries in those operations. The Company does not provide for U.S. taxes on the earnings of foreign subsidiaries because the Company intends to reinvest such earnings offshore indefinitely. However, if these funds were repatriated, the Company would be required to accrue and pay applicable U.S. taxes and withholding taxes. Due to the losses generated in foreign countries there are no earnings to repatriate.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company files federal and state income tax returns with varying statutes of limitations. The tax years from 2002 forward remain open to examination due to the carryover of net operating losses or tax credits. The Company also files United Kingdom and French income tax returns, and the tax years from 2008 and thereafter remain open in the United Kingdom and 2016 and thereafter in France are still subject to examination.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. As of December&#160;31, 2019, the Company had no accrued interest and/or penalties. The unrecognized tax benefits may change during the next year for items that arise in the ordinary course of business. In the event that any unrecognized tax benefits are recognized, the effective tax rate will not be affected.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the activity related to the Company&#8217;s unrecognized tax benefits (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:61.343%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.731%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Beginning balance</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,288&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,659&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,045&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions based on tax positions related to the current year</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,393&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">636&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">622&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions for tax positions of prior years</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(51)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Reductions for tax positions of prior years</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ending balance</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,630&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,288&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,659&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6842358640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text">MARKETABLE SECURITIES<div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The table below summarizes the Company&#8217;s cash equivalents and available-for-sale securities (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:44.852%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.741%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,496&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,496&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,998&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,999&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,494&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,495&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">155,230&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">145&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">155,368&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">94,905&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">115&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">95,017&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,411&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">91&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,493&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">303,546&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">351&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(19)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">303,878&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and available-for-sale securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">337,040&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">352&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(19)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">337,373&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103,291&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103,291&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103,291&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103,291&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Available-for-sale securities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">177,353&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(129)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">177,224&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63,981&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(111)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63,870&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,640&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(19)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,621&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">259,974&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(259)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">259,715&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and available-for-sale securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">363,265&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(259)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">363,006&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of investments available-for-sale by contractual maturity were as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:57.064%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.883%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.969%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.884%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Maturing in one year or less</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">282,046&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">259,715&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Maturing after one year through five years</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,832&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total investments available-for-sale</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">303,878&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">259,715&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company had no material realized losses from the sale of available-for-sale securities for the years ended December&#160;31, 2019, 2018 or 2017. Sangamo has the intent and ability to hold its investments for a period of time sufficient to allow for any anticipated recovery in market value. No investments were other-than-temporarily impaired at either December&#160;31, 2019 or 2018.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6849965584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 7 &#8211; COMMITMENTS AND CONTINGENCIES</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Leases</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sangamo occupies approximately 87,700 square feet of office and research and development laboratory facilities in Brisbane, California pursuant to a lease that expires in May 2029. Sangamo also occupies approximately 45,600 square feet of research and office space in Richmond, California pursuant to leases that expire in August 2026. In addition, the Company leases approximately 20,800 square feet of office and research space in Valbonne, France subject to leases that expire beginning in June 2025 through March 2028.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain of these leases also include renewal options at the election of the Company to renew or extend the lease for an additional <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzc2OTY1ODE0MDcwOTQ_38c04c15-1abf-4f53-8e13-ebfe9bb10579">five</span> to ten years. These optional periods have not been considered in the determination of the ROU assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain it would exercise the options.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">With respect to the Brisbane lease, the commencement date for approximately 35,080 square feet of the office space occurred in January 2019 while the commencement date for the remaining approximately 52,620 square feet occurred in June 2019. The Company has the right and exercised that right to make tenant improvements, including the addition of laboratory space, with a lease incentive allowance of $6.8&#160;million on the first portion of the space occupied and $10.2&#160;million on the portion of the lease that commenced in June 2019. As of December 31, 2019, these incentives have been received and used.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company performed evaluations of its contracts and determined each of its identified leases are operating leases. For the year ended December&#160;31, 2019, the Company incurred $7.9&#160;million of lease costs included in operating expenses in the Consolidated Statement of Operations in relation to these operating leases. Variable lease expense was $1.9&#160;million for the year ended December&#160;31, 2019 and was not included in the measurement of the Company&#8217;s operating ROU assets and lease liabilities. The variable expense consists primarily of the Company&#8217;s proportionate share of operating expenses, property taxes and insurance and is classified as lease expense due to the Company&#8217;s election to not separate lease and non-lease components.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash paid for amounts included in the measurement of operating lease liabilities for the year ended December&#160;31, 2019 was $3.5&#160;million and was included in net cash used in operating activities in the Company&#8217;s Consolidated Statement of Cash Flow.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Rent expense related to lease agreements was $7.9&#160;million, $2.3&#160;million, and $1.1&#160;million for 2019, 2018 and 2017, respectively. Future minimum payments under lease obligations at December&#160;31, 2019 consist of the following (in thousands):</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">&#160;</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:85.262%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.738%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,870&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,390&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,468&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,556&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,694&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,141&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58,119&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Imputed interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13,713)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,406&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Reported as of December 31, 2019:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities - current (included in Accounts payable and accrued liabilities on the Consolidated Balance Sheet)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,214&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities - long-term</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41,192&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,406&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, the weighted-average remaining lease term is 8.8 years and the weighted-average incremental borrowing rate used to determine the operating lease liability was 6.2% for the Company&#8217;s operating leases.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Contractual Commitments</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December 31, 2019, the Company has manufacturing obligations that include a fee of $6.3&#160;million for dedicated capacity pursuant to the Development and Manufacturing Services Agreement with Brammer Bio MA, now a </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Thermo Fisher</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Scientific Inc. subsidiary ("Brammer"). The Company also has an Option Agreement ("Option") with Brammer, entered in April 2019, whereby Brammer granted the Company an option to secure dedicated capacity for manufacturing in Brammer&#8217;s facilities. The Company paid $3.0&#160;million for the Option, which expires on December&#160;31, 2021. In addition, the Company agreed to pay Brammer $2.0 million, $0.5 million of which was paid upon execution of the agreement, to assist it in establishing its manufacturing capabilities in Brisbane, California, which may increase Sangamo's contractual commitments in the future. Furthermore, the Company has non-cancelable contractual commitments under manufacturing-related supplier arrangements with Brammer, which requires minimum purchase commitments totaling approximately $2.5&#160;million through December 2021, $0.5&#160;million of which was paid upon execution of the agreement.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company also has $1.2&#160;million of license obligations related to its intellectual property.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Contingencies</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sangamo is not party to any material pending legal proceeding. From time to time, Sangamo may be involved in legal proceedings arising in the ordinary course of business.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>sgmo-20191231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sgmo="http://www.sangamo.com/20191231"
  xmlns:srt="http://fasb.org/srt/2018-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sgmo-20191231.xsd" xlink:type="simple"/>
    <context id="i55958765beef474786d9beecda94838d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i91529fcfc109499ebb3512672c167060_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ia8c647fb84f84583814d2cba60abe33f_I20200221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2020-02-21</instant>
        </period>
    </context>
    <context id="i3743f02b3ec348be98acb2e813e9c7f4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iafee69bb5c304299817c47783c041381_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i0627710456a349f7b90cec0a3f5536e8_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="i6a9e59eb89204d6cb59dbc5b2e145c09_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="i5063163868264343bb3c8784a605dabf_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="id50e642517aa459b9ada4af0f93e6b20_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="ifeb2f797e05149138caa5e72c8aa0d2b_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="ie9057cb83ba040218834cc92910f7361_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="i0ce63a9e5f5542dc8d3b24259ad1ee2e_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ibc70b211d0654544a6f9c1e9fc810641_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i49b4da657a834857bc1d02cc6ef16e7b_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i0406f7152c82421aa6b02c6472444482_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i5fc1ca72aa1645a4b00f8fd2b31d8956_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ia218df6fa91f4c1fb7c308b884f2552a_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i81d1b464269e4be59411d5313217455a_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ib5393cf4702d478487f5812f2284bb7d_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i13411b9a2fac4f62b4a1b5d13e1a6d13_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ieb7e952fbd38434585f995fe73c66a44_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="if6ef95d8de3d4a7d89e36708e8ad41fa_I20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="i5ac2058780dd4487b64d9cea81253e0a_I20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="ibc92201ce4bc4d35aac109e19e0e5a1f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5ad82eaa45484fad83417fd0c193af43_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ifaf1fb068f504cafbf0b5ee6c15f15a7_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iaa3c4c19d5b248f48eeab6d3449c0692_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5616295424184a8eb8bbc9e26f43ed70_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6b94d20f29c94303b0b5f428bcfaa12b_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib9161aaed0bc4db88c75c765dcacf1d8_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ifce327bcf3b8435a8b434c043c9be74b_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i782ffb68f66c4a7b9ab9b5592f7c00fc_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic99ff13e6b8d4ef18b9878c555ae3844_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5f940ceeab344a3f93e9875fa4c27245_I20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="icbd33d4a7d834496bd26b17d12cc0d71_I20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="i10b0f55eb1164865bbf902ed106c9883_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if320296fd6c04201a11aab2ec6e01e0d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i700728c6360146ffb84d3df9926f1c1b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib6afa72951bb45c09b9a911552d7f480_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id40d07a651074bf1bafbd2a12252b23a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ife70daa8790b4a53b4ff57301234df5f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i35c1aa897a6e445787fa8eaaa2d7f0f3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i30d904a948194419aebb5c1fd3919342_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i96b90ecaf62c4fada95bd7bb490b3aca_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icc3f21983c41481ba4b01cd8667c5b3d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id41b3e1cb35b4ad89ad6d22858d66005_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:PropertyAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibfc6db4e7428415f9b757be31f7ba5f9_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:PropertyAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i551b7506aa0a43339495e3e41d87f7ab_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:PropertyAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ib59d1ac11e5d43868c898a5a5456c02a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:BuildToSuitLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i49968469b9074ef393d1c026828923c4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:BuildToSuitLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i00b9b5a15df54eed86abd682441fe4d1_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:BuildToSuitLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i45cd48c8f1eb454abb081e66040be393_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">sgmo:ChangeInCollaborationAgreementScopeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if75e5c9704ce446986262d7c7d8c3fab_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0e56cd6c5fb74bd3a43294ab0e9b6330_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id1d7fbe1eb014de78444bda067a30d18_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ifeac1a9c1b7f4146b761b39496879f94_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icf0e324d5bd3407ea444f76424db9da6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0028bf4ff4f2447683894820f58ee41f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i09768b80227d4cb4a5a55bae2bc04a19_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia9d921a5d8f94da6821ac519170255b3_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i0c83aa6622144db1929cedd8491d3519_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i213fcfde123a4b9abd25cc2767af7914_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie5649d96e1864877aaa84d3a06395606_I20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="ifb9ede9189214fb0ba40172a1dbc591a_I20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="i3f20aa798c164804836d3c58f6e64322_I20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="icbc9e04f074c44ffa8daa55bc133f128_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sgmo:LeaseArrangementsAxis">sgmo:BuildToSuitLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ibf1327e2b600430586f7a8218d35f3f2_I20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:LeaseArrangementsAxis">sgmo:BuildToSuitLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="id5dfe7b638ae41cda6e177ad875be7b5_I20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:LeaseArrangementsAxis">sgmo:BuildToSuitLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="i425b175434d04e418b20de221af1fd33_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if327c6ba5afb4ee28f9cca2b391023fe_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i13e727b552f840888ab401cd0d611095_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1916c386d59845db85c0f6b195b6c309_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6fedc4e1ca23438283a2d2c6f237fe8b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifedb75e8c33345abb30ce39ac8828048_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9a555374195740708b7b535422475c40_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9fe30ec7f787449981feb883fd8e7408_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id6a8c12c301e487cab97f3ac6cb97945_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0d0f5ceb90cd496f91d1edf2102c57d2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4dd1f80319a84afbb69e15090417a474_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibe28cfabe6384c78b965211fe2b259d6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i70b955824d6240a6badd8bb4bbb12d0b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i98bf1a1fb6c946f99d2a94a5222f559e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i84e857a6b4d64be5bce0f89cc006035f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic69943e18c9d4e908720f488efa6db9c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i23ea33c72d45452c8dca1b18861249d0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i878065655eff40a59fa226fbcc58557f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i357038a3295843f7b8bb19efe35d46b1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia948e7072e51466fa0d1a823a8cda9e4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i55aa029ca6dd458a8a361b0d9ce3fc27_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie4ed7f86404f4a6ba7c31faa2f653426_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id7fd88b4bbe14d53a36b2a34dcf1fcbf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i42972542d5a643f4ad2306c25b585428_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9501ce5f7d6e456bb6d923b2208d2e71_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1d2d295786cf43beaed8e20c63959a56_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i94d4458c66c647e9ae4004aea884aea7_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia12bf2d0855544e080b1e3c549ce02c2_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iad708dc4322e4296b7279fb10923aa64_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0fac6e5a93cf4932b299c93b29103ee4_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id07ed358181b47e991569dc03d1eca59_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8487d3169fa14869a2959a37cb1a1924_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i874bf2bbf8044c5ea86c5b6dec868699_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7ac8366f1cf74cbda4eae920c042daef_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i329183fcaae04a14b76d777f4591b0cb_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ibf402857bd034d28ad83a9627a535af3_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i604e1c483a2144499182a3abf3334884_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i27b1fd12142f4694b5053b6268cd9c5a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i44eb81c1bb054e35a82f0ad07d8dd13a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i52f56fd373e54acdbc14ae1ad4e8621d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i149c7986f92344c09f4c6801f030875f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if20ea12b7bd2424fa4f0d5ddc716792c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5913e464612f4a46aa67a602001a2466_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i07c312494713484fb523d49996228eaa_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i64c1c287bd47404da4ea630212dedc2e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i51862de68d334a6d90ced8ff154add77_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i9017742317a7426b8f1655ea852cf27f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if73c9eef08404834bb4f125b2f8334e8_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia4b36a1c4d88462a8ee8d85f748c7b16_I20180720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-20</instant>
        </period>
    </context>
    <context id="i9b97713bc2a74145a84bf16db6e1a142_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifba2b3f6b5f24819b803f8b4290efdef_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2821462afaec43989ae5bb5640358bdb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8637425832d24b439a5841eb6340fe09_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5cd83c646e0741f2a6f9af0abef8b909_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id158af407d9041baa888cbe9abf2ea9d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8e015bf5f3134e418d8cb590b4182340_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2ba502e8004f4a51b63eb68808f9ad0c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sgmo:MeasurementInputStockPriceCorrelationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iaa539cfd54e24b8e8f9bad28ca1ca2e2_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sgmo:MeasurementInputStockPriceCorrelationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i33f3835a3a9548d0bb177195bca1c91d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if0c0f4a598494b73a9f02d3c32a0337a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i624ddabb3ed14489852a400d3c8823e6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i84d9625ccd9e40dcb299cd5ff4f2f7be_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if3b6cba6a07b430f9c7d6308a92564cb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3aa31b7f47894ac591b3f5464dc1b173_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ifdc951c6c13c4c8bb47767567ef80768_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i87ef30d5e5634d03ba044c381280c504_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8727918bfc77478d894641bf1ba39f2b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2134d5ba27be42e394846ea5e6f9bbaa_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i75f08675fb7643a590d56bf4bcb13e36_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ieeb73dab1cf94f2584bc9b78fb4369c1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i30cc7310d6c14807bc817509966f5218_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic0b60e45bbb54cb5814c2623600b05a7_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iea5cd444cca1404bad4fad46fe35b1b5_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4c5421c8d9b34ac193b12f580b0e45fe_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib6b4614c3ed0431ab9570835b20a0800_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1f19f6eef7f447ee90aa653000871c5d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie60f0866d78349d39fcb444b085ce632_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="i61fd7d98b04648caaf9d32dec4a807ec_D20180404-20180405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-04</startDate>
            <endDate>2018-04-05</endDate>
        </period>
    </context>
    <context id="i5a2cd91a4f284017a4ef2d70e422e99c_D20180404-20180405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-04</startDate>
            <endDate>2018-04-05</endDate>
        </period>
    </context>
    <context id="i48416dd30d974b1aad80f204b2aabe20_D20180404-20180405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-04</startDate>
            <endDate>2018-04-05</endDate>
        </period>
    </context>
    <context id="id7d82acff2b8474488fc135b1be65d92_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6fff5fa4d22f420dbc13bcf64a19b587_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0c5a81250c2e4e6992c7624e2f50a5b0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i654a0f9976964892b5f266a6a5e30461_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if5e9da2152d548ad9e46e4ebe09d9cc7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i592dd2531c234441a8b4b503c5e33bdf_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i88cf0e3541a3458eae231fe54f01b5e1_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i55753e9172b14060be72e0417c8e4ee5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i60584ff2a34d45fb9afa66b5a623a4b2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ied53c137399045e198eb8eede660e8f2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib08e3f2b116d4fe8846432aa9f1fb42f_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="i8a64f9da293b4fb5998f17bc3ebc159f_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="i0eb4d4a7fdf7414bbcd0bcbb337d0b56_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="i9107973e10124be1aa15439229671e5f_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfFirstCommercialSaleMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="i45470bac3a3d46c59bc142131a59b782_I20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="ibfcf378e55cd4dc89b34b84d7fc85aa2_I20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="if20dd4173a934bb9bfd3c1d39c91de1b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:AmendedCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idc78178116cc4805a2503e4d1f1172dd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9b68588d42cd47f383c50071fab098fa_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8bbeb9bd0c5c4a2da841e90386104e1a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1e978c226de34436b68f163f5e4d3354_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i842d5727afc443408e09ed5a522e2a9e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:AmendedCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1ea749f7283a4e3fbab4d679c510b03b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if9de85d493b645f38a1e2fc527b2126e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iee1c5c93e9564920af22cdeb55d9889b_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i8eb9a2216c044b17b0ac853396d42bed_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6f1ee4fd337946f69c2e711004e9eb21_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1c6f765722544bbfaa11a0f9c28106ee_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i76d9c47628c147369b1a84918e870f8d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib5b7be714d56483bab2fd4aec159f370_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i0a295f36997b4eaf8c2fed03755d5526_I20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="i252ea1e80afe41d99972b07af7af8a3c_I20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="id9888cd53fcb4fb4984e5cdbd778c03e_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icbb6596bfa944145ba083c1d73a1a730_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i5b20df771908439ba01919ecb4994be8_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ie5bbca9d2dbf4f0e989cbeebb1a8e942_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i784a445513064edf8cf105a58b0207fe_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfCommercialMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i669f42753a6d4d3b8f142135705a640e_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i954ad6bfa1174ad180a78ff9de20535e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i79f178df8ea344e18c904ab658ab8f74_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6c762905a0724124a285c0f906b72d49_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1e9a9a3d68204a2f8ed5bcfe24fa0f3e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6c7f53a3724d4a1ea2ce16319a2ee764_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i46960a0dc45d40db8392d2fe6db2d9e9_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i1c5f6e7f39144671adf58c072211193c_D20140101-20140131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-01-31</endDate>
        </period>
    </context>
    <context id="ide4c76d2770741e89547b697a3e8b894_D20140101-20140131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-01-31</endDate>
        </period>
    </context>
    <context id="ifcd9eaedbbb14396a42bb76c734bf9f5_D20140101-20140131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedSalesMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-01-31</endDate>
        </period>
    </context>
    <context id="icb1c764229f147c2a7d82f2bb4a2592a_D20140101-20140131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-01-31</endDate>
        </period>
    </context>
    <context id="i6b38594263d44b798c13984fcfd972f8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia2073bd7907645caa45aa97ed6850de4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i468bde9877fb45c2847c91221ba681bc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8c872fa7b5024839a68c8f629085727c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id798c385c8724e4b930793259339b22a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1ca1d25b473647beac3e5c4cee84dd0f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i93e6aa3bc6514e649306cb264521204b_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i92f62c13c94a433aa1ad8a4a8220be8f_I20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="id06c1dce0e884cdcba296deaf34a622e_D20190801-20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="i39eb352d7a3a4602a414826990f703bc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5c9ff652355349cab75acdd86216b11a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1836a0ed76fa4e068cc55bae1f1659ca_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i0bdd6ca51cf249bc84de380a836fb539_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibab98dee0c264ff0a13f3976dfdd1ed3_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i4c1fc611498b4ec7ab651f582d24bb0b_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="iab2ce2c2494147e0a8a6070d64cfe4c8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4c8c31caf97141fd95d9194c142029af_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="icca18901cecd47eb8ace5d534e3446cc_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i9bf7f5b8498c4b08a82bb59829d36e28_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7420753e3bf04bfea9bc58e19fe42eea_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i975e5690b7e44643ac9b6ff7c837d1d5_I20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="idfdae914eb9f4568924b2c36819385c0_I20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="i80b254e375704b6cbd33bf07e5d5a03d_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="i0b157638f47c4c3b8ec4455978598450_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i37cb993a72c14f14a87486e3f9d110bb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ide489651fbb64d8cb62d9ee459e221fc_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia988894eec924d3699114435116dcbb8_D20120101-20120131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-01-01</startDate>
            <endDate>2012-01-31</endDate>
        </period>
    </context>
    <context id="i603d866010f94461ba687f9d9fc9fe07_D20140101-20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="i0396d61761914d09b41700c5324f9ab2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8ea0635e2f754a1a98f8b6ff31ee597e_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i225c2ca24fb245b1aef427d88cab0b42_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if423ade1135f4a90ba7c01bd4622b719_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i60cee58107b34ab3abb80c1536bbbb25_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ie07937e9122d4e52ae687f94e550ec89_D20070101-20071231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2007-01-01</startDate>
            <endDate>2007-12-31</endDate>
        </period>
    </context>
    <context id="ic7e8b05b2b84429ea591ae9027f2f01c_I20091031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2009-10-31</instant>
        </period>
    </context>
    <context id="i19ed0c7322dc4072986f0f09203dc043_D20091001-20091031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-10-01</startDate>
            <endDate>2009-10-31</endDate>
        </period>
    </context>
    <context id="i2d0454da729b48fc9e22bda7f76d2ad5_I20091031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2009-10-31</instant>
        </period>
    </context>
    <context id="i278e40ede357423c89bdc1aee03bef48_D20091001-20091031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-10-01</startDate>
            <endDate>2009-10-31</endDate>
        </period>
    </context>
    <context id="i12a07f5e2768459da813de50c58f1b60_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7e4cd48445e44370bba7e39d5af5ce52_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3087b4ee5afa4f2dabb514f4cf15f16c_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="if0b4d17d3d8d4ebc977872aa77c541e2_D20050101-20051231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2005-01-01</startDate>
            <endDate>2005-12-31</endDate>
        </period>
    </context>
    <context id="id1d7e675aff548549bda7f384c0b71fe_I20051231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2005-12-31</instant>
        </period>
    </context>
    <context id="i6d6e0b311090479699df435b03b0f9b4_D20050101-20051231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2005-01-01</startDate>
            <endDate>2005-12-31</endDate>
        </period>
    </context>
    <context id="i9b2070f38ef740d580ee67b0026687db_D20050101-20051231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2005-01-01</startDate>
            <endDate>2005-12-31</endDate>
        </period>
    </context>
    <context id="i700b128806b74604a574c5a9d52798f4_D20050101-20051231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2005-01-01</startDate>
            <endDate>2005-12-31</endDate>
        </period>
    </context>
    <context id="i5b28cb60703942d78f84fa70547f2d7a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i35e0ebbeae2040128ef7a7deb5f4d32f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6c13afb7fbda4eb8bf0c38bac4d2c1ff_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i38f5aec47ea84bc295354a823c8a5831_D20181001-20181001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-01</endDate>
        </period>
    </context>
    <context id="i3a6b4067c84e43e1bdc883068436bfa7_D20181001-20181123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-11-23</endDate>
        </period>
    </context>
    <context id="i86361484bbe7475eadd2f54f1495c9bc_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5253724c8c7745708c6743fc72b1bd23_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie44e76842d7f4cde88a0228bac132b9e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib79220f5f92f424dbf1bd1416f1d62af_I20181001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-01</instant>
        </period>
    </context>
    <context id="i68a40c6357a5417c8e40fc23122e7423_D20181001-20181001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-01</endDate>
        </period>
    </context>
    <context id="if8a9cbb45d2746dcb48a28a379d261b4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0638fbc591ba4ce589a9cfe88a114e95_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ibe70b54fab8e46b4bea40c2b35ede19a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iac226c28c7fb4c64920cad2ca7e259a1_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie3c60a720f6b4df19f3f92b51be623e5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iac6944dea140420e82c37c6b728de97a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic4483a2719984476afd6ceb188081fda_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2471a22261164bf78fea22576f465fb3_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="icf9dff888e724c4fbe02ba474671d5fe_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5620868d7a3f4744aeeaa72cb2948e05_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iaf513274ee0c43639e9c1500db2d7963_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:BrisbaneCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:OfficeAndLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i61974f1d85ab49f78df77bf7c87828b4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:RichmondCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:OfficeAndLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i545fe0f072c9408797e00f296a4a44dd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:ValbonneFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:ResearchAndOfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if46ca43d45c948e98319922d7565a9f7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i83dc1a1104c8410f962b75bd5a2646f0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iebf52cf79a6041878e2eb875ad9b53ba_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:BrisbaneCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i38763d7e12814008b53fbac4a892782d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:BrisbaneCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i37d7eb43c08a471b816747e6c8de433d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">sgmo:ManufacturingCapacityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7e239f59de424eaeb896378613c4c2fc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">sgmo:ManufacturingCapacityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i30aa48009d514a9694cf66cf00207e2e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">sgmo:ManufacturingObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i22655d04f591458ebb9c3737889fcaa1_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">sgmo:ManufacturingObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="i2fba1b8b532b45cc848f39f189b1366e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">sgmo:NonCancelableContractualCommitmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4c3d46edbdfc47afb7a1080ab7235f2a_I20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">sgmo:NonCancelableContractualCommitmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="icb4b35fddcc442cb8c1b62aa13aad983_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="ie4f08396a6674db59b83934997d376ca_I20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="i17fa15d6fbd948fcbb752fa955283c6b_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="ib60221bf695b4b5c95ff088c3caaf236_I20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="if150961a5ee14928826e68c655e5d53f_D20170601-20170630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-01</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="i70ff8798b92448c0b579928fa54468cd_I20170630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="i37807fd639dc45328330120e8b98348c_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="ic0f7d9825feb4e208361c4ad02284de8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i86e7f798089c4c66a4e5b968d764d534_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2c7aa74b5db84179b2918daa34c73c69_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i38ea9f2d9931428fba1f41e0b36e7bea_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="i57406eb823ae4dcba23a5c69e7941851_D20180601-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i413bd4488b904c0eb127a3a7f3af5412_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i91e4fec1d21b4176925e0d7555154914_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7afd1bb162e74f8188a0eebdfa207e9c_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i6a1a6094e01242c48030234e32514b5b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:TwoThousandThirteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2079b275b8624be6a51a9674c1a69829_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4c22448f844d48b8a90cd6b5030ab3b6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia89fc661975a4524b5aefcb074dba5af_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic900024014ad40cb84ea43fd53db5e7d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id5101aded6334b1c9c3a881011b6abae_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i277c3b7360f04d3780bef6a633da1c71_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia4360f72084d45c580dd59abd6150a88_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ib25eb7ae48804546b9f361611f4966bb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6f39fb4590c1429f8543e94bc2f27f17_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if9d63f212ff549b3a6d95bbdc6243555_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i11cbad67c18a49ca910e920c1e2d9646_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i280d0aff0b424211b1e87b1cc76e27a7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia0b92851791b4e9e8a15edb926cc2b4e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6568a8c2edac4a3c89060b40650283bd_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ibf6eda356cbb4886a9bc71ebb4c979a6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i12f6a30ee0794a7a8c75e504690f5c2c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib7ba96e253094ecbb1f17619de72a1e5_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ic84a9796c7a541749fdbca1dc1d961a0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4875c47b73b649d89f3d228c46b40d73_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i545150c912bd475bb5cc4cfafe39b8c4_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i2a0099de9f314f5a919f8b231d4109ab_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5c838e5e7b0b46cab8713879fa0ce0e9_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="icd62021ceb204760b751e409e802a4b3_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i822b57314be44262a52169433cb095e6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i52b452cf7faf4507b5d8744d6e2ccbe1_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2f722ff8a1bb4847896b093c5949157c_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i5ccdd9ccdd8248799ab22a4b8eb8f471_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i99276d8c006448148b510e8ed81523da_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i803d3fabb4d84a7fa36d5b64f9f5b98d_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ic95b30c3bdb047e09c97a070b92d9bd5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:MinistryOfTheEconomyFinanceAndIndustryFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i52834b9e08624c8bacef183387dd51ed_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:FormerExecutiveOfSangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7904976381aa418691f37a32d64b07c0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:FormerExecutiveOfSangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i650fabb9fd3342b194a201cbf6d40308_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i7d3836ab6ab8497ea22f279a0bfeb107_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="id2195a0eb53f457697e901d30824c2b3_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iecf9c60eda6d47d4a66bc7797840c1d5_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iad063cfae7ac486cb8c7a7931ccbc02e_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="if2cf250af72b4f33993772a39178733a_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="ibac9f542f2ce4f519e06c7aabb195095_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ibbad735aad064fe6bda84e11e1e8baab_D20181001-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i815aed8f3ed04efa8895ee3a5a249f46_D20200201-20200228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-28</endDate>
        </period>
    </context>
    <context id="id2fcb8b96ce04f23aa5b97d6cacdf777_I20200228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-28</instant>
        </period>
    </context>
    <context id="i68abcab0cf41405fae245c20e792bbf2_D20200201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7c5278bbcb4141f78ac8881b4edfac94_I20200228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-28</instant>
        </period>
    </context>
    <context id="i1640dffb6cb34c52994dcc5099a67ffd_I20200228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:PreApprovalMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-28</instant>
        </period>
    </context>
    <context id="i21a4261ff2844d9d957100ee0d0f8fa3_I20200228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:SalesBasedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-28</instant>
        </period>
    </context>
    <context id="i908ad6d97bab414e84166e66b25274be_D20200201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2be6d9a350e04b98992adc724912b287_I20200228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-28</instant>
        </period>
    </context>
    <context id="i3107101abd5c446e81202399471630f8_D20200201-20200228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-28</endDate>
        </period>
    </context>
    <context id="i5dbb06595ef34d1581373015fa20fc10_I20200228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-28</instant>
        </period>
    </context>
    <context id="if7c1080eb5384ad88c89d65e002242e1_I20200228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-28</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>sgmo:segment</measure>
    </unit>
    <unit id="eurPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:EUR</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="option">
        <measure>sgmo:option</measure>
    </unit>
    <unit id="product">
        <measure>sgmo:product</measure>
    </unit>
    <unit id="milestone">
        <measure>sgmo:milestone</measure>
    </unit>
    <unit id="program">
        <measure>sgmo:program</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="installment">
        <measure>sgmo:installment</measure>
    </unit>
    <unit id="product_target">
        <measure>sgmo:product_target</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF80L2ZyYWc6OWZiNGYxOWM0MGM3NDgzZGJkYzEyMTVmNjA4MzBlMmUvdGFibGU6ZTM1OTBkY2RjM2IyNDU0MDk1ZTZmMTU2NWM1NDM0ZWUvdGFibGVyYW5nZTplMzU5MGRjZGMzYjI0NTQwOTVlNmYxNTY1YzU0MzRlZV8zLTEtMS0xLTA_33a0ba27-13ba-4f77-81fc-2397367aff4b">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF80L2ZyYWc6OWZiNGYxOWM0MGM3NDgzZGJkYzEyMTVmNjA4MzBlMmUvdGFibGU6ZTM1OTBkY2RjM2IyNDU0MDk1ZTZmMTU2NWM1NDM0ZWUvdGFibGVyYW5nZTplMzU5MGRjZGMzYjI0NTQwOTVlNmYxNTY1YzU0MzRlZV81LTEtMS0xLTA_6647db9d-9d14-46db-a28e-41e90a74da75">2019</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF80L2ZyYWc6OWZiNGYxOWM0MGM3NDgzZGJkYzEyMTVmNjA4MzBlMmUvdGFibGU6ZTM1OTBkY2RjM2IyNDU0MDk1ZTZmMTU2NWM1NDM0ZWUvdGFibGVyYW5nZTplMzU5MGRjZGMzYjI0NTQwOTVlNmYxNTY1YzU0MzRlZV82LTEtMS0xLTA_fb0fdb89-421f-4003-8ee6-bf3f5b044ef3">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF80L2ZyYWc6OWZiNGYxOWM0MGM3NDgzZGJkYzEyMTVmNjA4MzBlMmUvdGFibGU6ZTM1OTBkY2RjM2IyNDU0MDk1ZTZmMTU2NWM1NDM0ZWUvdGFibGVyYW5nZTplMzU5MGRjZGMzYjI0NTQwOTVlNmYxNTY1YzU0MzRlZV85LTEtMS0xLTA_545adc6b-4db6-4905-b111-fc01be803b8f">0001001233</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF80L2ZyYWc6OWZiNGYxOWM0MGM3NDgzZGJkYzEyMTVmNjA4MzBlMmUvdGFibGU6ZTM1OTBkY2RjM2IyNDU0MDk1ZTZmMTU2NWM1NDM0ZWUvdGFibGVyYW5nZTplMzU5MGRjZGMzYjI0NTQwOTVlNmYxNTY1YzU0MzRlZV8xMC0xLTEtMS0w_81cbc724-71cd-42ce-a843-ceb9578b6d9e">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i0c83aa6622144db1929cedd8491d3519_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfNTczOA_d3889db1-4c3b-4768-aeb6-f18ca1502096">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <sgmo:ExtendedResearchTermOfAgreement
      contextRef="id7d82acff2b8474488fc135b1be65d92_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzc2OTY1ODE1MDUyMDY_67f3e1f2-17aa-46c8-a608-4185bf8992f1">P1Y</sgmo:ExtendedResearchTermOfAgreement>
    <sgmo:ResearchServicesPeriod
      contextRef="ie07937e9122d4e52ae687f94e550ec89_D20070101-20071231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI3OTg0_c09101db-17d8-4575-842f-cc8f133a684e">P3Y</sgmo:ResearchServicesPeriod>
    <sgmo:InitialResearchTermOfAgreement
      contextRef="if0b4d17d3d8d4ebc977872aa77c541e2_D20050101-20051231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI5MzIy_7d482839-f2da-4dcc-a0a2-fb576c2847cb">P3Y</sgmo:InitialResearchTermOfAgreement>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="if46ca43d45c948e98319922d7565a9f7_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzc2OTY1ODE0MDcwOTQ_38c04c15-1abf-4f53-8e13-ebfe9bb10579">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <sgmo:PurchasePlanOfferingPeriod
      contextRef="i57406eb823ae4dcba23a5c69e7941851_D20180601-20180630"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzk0NTg_a01f06c3-4780-4e1a-a835-8d6a1d1c86ad">P2Y</sgmo:PurchasePlanOfferingPeriod>
    <sgmo:PurchasePlanPurchasePeriod
      contextRef="i57406eb823ae4dcba23a5c69e7941851_D20180601-20180630"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzk1MTY_14ef30bf-8a48-4b2c-8cc7-f55e130f23b6">P6M</sgmo:PurchasePlanPurchasePeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i2079b275b8624be6a51a9674c1a69829_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzYvZnJhZzpjODA1NjZmZjllMjA0ZDhmOWZkMjNmNzZiMjVjNDJhZi90YWJsZTozZjk4OTY5MjBlODQ0YzdiYjJkMWMwZTYzNTgxYjYxZC90YWJsZXJhbmdlOjNmOTg5NjkyMGU4NDRjN2JiMmQxYzBlNjM1ODFiNjFkXzUtMS0xLTEtMA_68db17eb-36a5-482f-b6b9-9a9a43b39fb7"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i4c22448f844d48b8a90cd6b5030ab3b6_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzYvZnJhZzpjODA1NjZmZjllMjA0ZDhmOWZkMjNmNzZiMjVjNDJhZi90YWJsZTozZjk4OTY5MjBlODQ0YzdiYjJkMWMwZTYzNTgxYjYxZC90YWJsZXJhbmdlOjNmOTg5NjkyMGU4NDRjN2JiMmQxYzBlNjM1ODFiNjFkXzctMS0xLTEtMA_543353b8-7ae1-480d-b7e6-57002b790c74"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ia89fc661975a4524b5aefcb074dba5af_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzYvZnJhZzpjODA1NjZmZjllMjA0ZDhmOWZkMjNmNzZiMjVjNDJhZi90YWJsZTozZjk4OTY5MjBlODQ0YzdiYjJkMWMwZTYzNTgxYjYxZC90YWJsZXJhbmdlOjNmOTg5NjkyMGU4NDRjN2JiMmQxYzBlNjM1ODFiNjFkXzktMS0xLTEtMA_1dee2af6-6c4c-4e03-95cb-bf5970e7eca0"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ic900024014ad40cb84ea43fd53db5e7d_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzYvZnJhZzpjODA1NjZmZjllMjA0ZDhmOWZkMjNmNzZiMjVjNDJhZi90YWJsZTozZjk4OTY5MjBlODQ0YzdiYjJkMWMwZTYzNTgxYjYxZC90YWJsZXJhbmdlOjNmOTg5NjkyMGU4NDRjN2JiMmQxYzBlNjM1ODFiNjFkXzEyLTEtMS0xLTk0Nzk_ca892515-186c-463a-8ec7-b09ae53be422"
      unitRef="number">0.0208</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ic84a9796c7a541749fdbca1dc1d961a0_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1ZThmNTE5ZGI2YzA0M2RiYTg0NDBjMTE0Y2E0N2NmMC90YWJsZXJhbmdlOjVlOGY1MTlkYjZjMDQzZGJhODQ0MGMxMTRjYTQ3Y2YwXzItMS0xLTEtMA_b2acf6c7-9730-4a23-b4d4-96749ef2606e"
      unitRef="number">0.0253</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i4875c47b73b649d89f3d228c46b40d73_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1ZThmNTE5ZGI2YzA0M2RiYTg0NDBjMTE0Y2E0N2NmMC90YWJsZXJhbmdlOjVlOGY1MTlkYjZjMDQzZGJhODQ0MGMxMTRjYTQ3Y2YwXzItMi0xLTEtMA_dd431afd-72e6-45c4-acb5-8f24b8b1afcb"
      unitRef="number">0.0181</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i545150c912bd475bb5cc4cfafe39b8c4_D20170101-20171231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1ZThmNTE5ZGI2YzA0M2RiYTg0NDBjMTE0Y2E0N2NmMC90YWJsZXJhbmdlOjVlOGY1MTlkYjZjMDQzZGJhODQ0MGMxMTRjYTQ3Y2YwXzItMy0xLTEtMA_460d101a-1e2e-4e3b-8052-e9bfb3758301"
      unitRef="number">0.0113</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i2a0099de9f314f5a919f8b231d4109ab_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1ZThmNTE5ZGI2YzA0M2RiYTg0NDBjMTE0Y2E0N2NmMC90YWJsZXJhbmdlOjVlOGY1MTlkYjZjMDQzZGJhODQ0MGMxMTRjYTQ3Y2YwXzMtMS0xLTEtMA_980876e9-40ba-4e1e-ab0b-e9768d537e70"
      unitRef="number">0.0296</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i5c838e5e7b0b46cab8713879fa0ce0e9_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1ZThmNTE5ZGI2YzA0M2RiYTg0NDBjMTE0Y2E0N2NmMC90YWJsZXJhbmdlOjVlOGY1MTlkYjZjMDQzZGJhODQ0MGMxMTRjYTQ3Y2YwXzMtMi0xLTEtMA_c7af1fb2-aff0-4f04-96af-a85a43ce2dee"
      unitRef="number">0.0228</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="icd62021ceb204760b751e409e802a4b3_D20170101-20171231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1ZThmNTE5ZGI2YzA0M2RiYTg0NDBjMTE0Y2E0N2NmMC90YWJsZXJhbmdlOjVlOGY1MTlkYjZjMDQzZGJhODQ0MGMxMTRjYTQ3Y2YwXzMtMy0xLTEtMA_b24bd317-ff64-4bb2-b062-dbeea118527a"
      unitRef="number">0.0161</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ic84a9796c7a541749fdbca1dc1d961a0_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1ZThmNTE5ZGI2YzA0M2RiYTg0NDBjMTE0Y2E0N2NmMC90YWJsZXJhbmdlOjVlOGY1MTlkYjZjMDQzZGJhODQ0MGMxMTRjYTQ3Y2YwXzQtMS0xLTEtMA_1d0ab852-51d6-4982-a591-9b59481d53fb">P5Y7M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i4875c47b73b649d89f3d228c46b40d73_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1ZThmNTE5ZGI2YzA0M2RiYTg0NDBjMTE0Y2E0N2NmMC90YWJsZXJhbmdlOjVlOGY1MTlkYjZjMDQzZGJhODQ0MGMxMTRjYTQ3Y2YwXzQtMi0xLTEtMA_95b1f39c-d076-48ab-8586-3db30e67fe69">P5Y8M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i545150c912bd475bb5cc4cfafe39b8c4_D20170101-20171231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1ZThmNTE5ZGI2YzA0M2RiYTg0NDBjMTE0Y2E0N2NmMC90YWJsZXJhbmdlOjVlOGY1MTlkYjZjMDQzZGJhODQ0MGMxMTRjYTQ3Y2YwXzQtMy0xLTEtMA_73fc753c-886b-41f9-9095-bcb754b759da">P5Y3M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i2a0099de9f314f5a919f8b231d4109ab_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1ZThmNTE5ZGI2YzA0M2RiYTg0NDBjMTE0Y2E0N2NmMC90YWJsZXJhbmdlOjVlOGY1MTlkYjZjMDQzZGJhODQ0MGMxMTRjYTQ3Y2YwXzUtMS0xLTEtMA_e26449ef-3546-49ce-93f5-6acf46f01b5c">P5Y7M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i5c838e5e7b0b46cab8713879fa0ce0e9_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1ZThmNTE5ZGI2YzA0M2RiYTg0NDBjMTE0Y2E0N2NmMC90YWJsZXJhbmdlOjVlOGY1MTlkYjZjMDQzZGJhODQ0MGMxMTRjYTQ3Y2YwXzUtMi0xLTEtMA_f14d72cd-975b-4c6d-a125-d9ea1367f994">P5Y9M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="icd62021ceb204760b751e409e802a4b3_D20170101-20171231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1ZThmNTE5ZGI2YzA0M2RiYTg0NDBjMTE0Y2E0N2NmMC90YWJsZXJhbmdlOjVlOGY1MTlkYjZjMDQzZGJhODQ0MGMxMTRjYTQ3Y2YwXzUtMy0xLTEtMA_19ca7edf-e25a-41eb-812f-43e0c98df7fe">P5Y3M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ic84a9796c7a541749fdbca1dc1d961a0_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1ZThmNTE5ZGI2YzA0M2RiYTg0NDBjMTE0Y2E0N2NmMC90YWJsZXJhbmdlOjVlOGY1MTlkYjZjMDQzZGJhODQ0MGMxMTRjYTQ3Y2YwXzYtMS0xLTEtMA_a35c9e91-216a-420c-bf31-39071a9757cf"
      unitRef="number">0.0072</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i4875c47b73b649d89f3d228c46b40d73_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1ZThmNTE5ZGI2YzA0M2RiYTg0NDBjMTE0Y2E0N2NmMC90YWJsZXJhbmdlOjVlOGY1MTlkYjZjMDQzZGJhODQ0MGMxMTRjYTQ3Y2YwXzYtMi0xLTEtMA_b33e8446-242c-46f6-8c62-9f3df70a1759"
      unitRef="number">0.0071</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i545150c912bd475bb5cc4cfafe39b8c4_D20170101-20171231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1ZThmNTE5ZGI2YzA0M2RiYTg0NDBjMTE0Y2E0N2NmMC90YWJsZXJhbmdlOjVlOGY1MTlkYjZjMDQzZGJhODQ0MGMxMTRjYTQ3Y2YwXzYtMy0xLTEtMA_52bf5c0c-9e9f-42e9-bdf6-d2c18654a0fb"
      unitRef="number">0.0068</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i2a0099de9f314f5a919f8b231d4109ab_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1ZThmNTE5ZGI2YzA0M2RiYTg0NDBjMTE0Y2E0N2NmMC90YWJsZXJhbmdlOjVlOGY1MTlkYjZjMDQzZGJhODQ0MGMxMTRjYTQ3Y2YwXzctMS0xLTEtMA_333205cc-64f8-4f57-8885-c398db84bf2d"
      unitRef="number">0.0075</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i5c838e5e7b0b46cab8713879fa0ce0e9_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1ZThmNTE5ZGI2YzA0M2RiYTg0NDBjMTE0Y2E0N2NmMC90YWJsZXJhbmdlOjVlOGY1MTlkYjZjMDQzZGJhODQ0MGMxMTRjYTQ3Y2YwXzctMi0xLTEtMA_b2c41338-0e5a-4761-b3c5-b945f1860d69"
      unitRef="number">0.0072</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="icd62021ceb204760b751e409e802a4b3_D20170101-20171231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1ZThmNTE5ZGI2YzA0M2RiYTg0NDBjMTE0Y2E0N2NmMC90YWJsZXJhbmdlOjVlOGY1MTlkYjZjMDQzZGJhODQ0MGMxMTRjYTQ3Y2YwXzctMy0xLTEtMA_f5f15f65-8fee-4d0c-b517-bea3f77beb45"
      unitRef="number">0.0070</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i822b57314be44262a52169433cb095e6_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1OGNhNzJlNWQzMTQ0MjQyODU0NWMxNWJjNDg2ZmRlMi90YWJsZXJhbmdlOjU4Y2E3MmU1ZDMxNDQyNDI4NTQ1YzE1YmM0ODZmZGUyXzItMS0xLTEtMA_7c2c8ef5-6b7e-4acf-b52d-0a0679e65bc2"
      unitRef="number">0.0216</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i52b452cf7faf4507b5d8744d6e2ccbe1_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1OGNhNzJlNWQzMTQ0MjQyODU0NWMxNWJjNDg2ZmRlMi90YWJsZXJhbmdlOjU4Y2E3MmU1ZDMxNDQyNDI4NTQ1YzE1YmM0ODZmZGUyXzItMi0xLTEtMA_7d214929-0a35-425d-9c90-a4459e7fa49f"
      unitRef="number">0.0044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i2f722ff8a1bb4847896b093c5949157c_D20170101-20171231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1OGNhNzJlNWQzMTQ0MjQyODU0NWMxNWJjNDg2ZmRlMi90YWJsZXJhbmdlOjU4Y2E3MmU1ZDMxNDQyNDI4NTQ1YzE1YmM0ODZmZGUyXzItMy0xLTEtMA_fc77004d-c058-4a13-89cd-10719c75e3b0"
      unitRef="number">0.0041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i5ccdd9ccdd8248799ab22a4b8eb8f471_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1OGNhNzJlNWQzMTQ0MjQyODU0NWMxNWJjNDg2ZmRlMi90YWJsZXJhbmdlOjU4Y2E3MmU1ZDMxNDQyNDI4NTQ1YzE1YmM0ODZmZGUyXzMtMS0xLTEtMA_013a7d80-0309-4f2f-9f64-d17a9d25f0cb"
      unitRef="number">0.0280</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i99276d8c006448148b510e8ed81523da_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1OGNhNzJlNWQzMTQ0MjQyODU0NWMxNWJjNDg2ZmRlMi90YWJsZXJhbmdlOjU4Y2E3MmU1ZDMxNDQyNDI4NTQ1YzE1YmM0ODZmZGUyXzMtMi0xLTEtMA_ff0015ae-d10f-4cd2-841e-9c2a49a26322"
      unitRef="number">0.0076</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i803d3fabb4d84a7fa36d5b64f9f5b98d_D20170101-20171231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1OGNhNzJlNWQzMTQ0MjQyODU0NWMxNWJjNDg2ZmRlMi90YWJsZXJhbmdlOjU4Y2E3MmU1ZDMxNDQyNDI4NTQ1YzE1YmM0ODZmZGUyXzMtMy0xLTEtMA_7bd3debc-63ef-4e5d-bde6-06afbc6fee73"
      unitRef="number">0.0080</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i822b57314be44262a52169433cb095e6_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1OGNhNzJlNWQzMTQ0MjQyODU0NWMxNWJjNDg2ZmRlMi90YWJsZXJhbmdlOjU4Y2E3MmU1ZDMxNDQyNDI4NTQ1YzE1YmM0ODZmZGUyXzQtMS0xLTEtMA_54445af0-a1bc-4994-b34e-2bac0683e7a0">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i52b452cf7faf4507b5d8744d6e2ccbe1_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1OGNhNzJlNWQzMTQ0MjQyODU0NWMxNWJjNDg2ZmRlMi90YWJsZXJhbmdlOjU4Y2E3MmU1ZDMxNDQyNDI4NTQ1YzE1YmM0ODZmZGUyXzQtMi0xLTEtMA_4e1f82fd-5201-492c-836b-ab40012d43d8">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i2f722ff8a1bb4847896b093c5949157c_D20170101-20171231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1OGNhNzJlNWQzMTQ0MjQyODU0NWMxNWJjNDg2ZmRlMi90YWJsZXJhbmdlOjU4Y2E3MmU1ZDMxNDQyNDI4NTQ1YzE1YmM0ODZmZGUyXzQtMy0xLTEtMA_ff240962-e298-4945-a3ec-666b9847359f">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i5ccdd9ccdd8248799ab22a4b8eb8f471_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1OGNhNzJlNWQzMTQ0MjQyODU0NWMxNWJjNDg2ZmRlMi90YWJsZXJhbmdlOjU4Y2E3MmU1ZDMxNDQyNDI4NTQ1YzE1YmM0ODZmZGUyXzUtMS0xLTEtMA_7f3cd019-aafe-4f42-a6dd-82f61d9da711">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i99276d8c006448148b510e8ed81523da_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1OGNhNzJlNWQzMTQ0MjQyODU0NWMxNWJjNDg2ZmRlMi90YWJsZXJhbmdlOjU4Y2E3MmU1ZDMxNDQyNDI4NTQ1YzE1YmM0ODZmZGUyXzUtMi0xLTEtMA_0066f92d-3606-4e35-b7cc-ee5fcc18c8f6">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i803d3fabb4d84a7fa36d5b64f9f5b98d_D20170101-20171231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1OGNhNzJlNWQzMTQ0MjQyODU0NWMxNWJjNDg2ZmRlMi90YWJsZXJhbmdlOjU4Y2E3MmU1ZDMxNDQyNDI4NTQ1YzE1YmM0ODZmZGUyXzUtMy0xLTEtMA_879dac81-c3ad-4925-93b3-b238eb39ba56">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i822b57314be44262a52169433cb095e6_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1OGNhNzJlNWQzMTQ0MjQyODU0NWMxNWJjNDg2ZmRlMi90YWJsZXJhbmdlOjU4Y2E3MmU1ZDMxNDQyNDI4NTQ1YzE1YmM0ODZmZGUyXzYtMS0xLTEtMA_c3753c4f-f548-4fb3-91f6-75995f14d78f"
      unitRef="number">0.0073</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i52b452cf7faf4507b5d8744d6e2ccbe1_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1OGNhNzJlNWQzMTQ0MjQyODU0NWMxNWJjNDg2ZmRlMi90YWJsZXJhbmdlOjU4Y2E3MmU1ZDMxNDQyNDI4NTQ1YzE1YmM0ODZmZGUyXzYtMi0xLTEtMA_2c984510-c0b2-4701-b7d1-6a802f891538"
      unitRef="number">0.0066</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i2f722ff8a1bb4847896b093c5949157c_D20170101-20171231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1OGNhNzJlNWQzMTQ0MjQyODU0NWMxNWJjNDg2ZmRlMi90YWJsZXJhbmdlOjU4Y2E3MmU1ZDMxNDQyNDI4NTQ1YzE1YmM0ODZmZGUyXzYtMy0xLTEtMA_c1f3a594-97e6-4be5-987e-2b68b53e0371"
      unitRef="number">0.0071</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i5ccdd9ccdd8248799ab22a4b8eb8f471_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1OGNhNzJlNWQzMTQ0MjQyODU0NWMxNWJjNDg2ZmRlMi90YWJsZXJhbmdlOjU4Y2E3MmU1ZDMxNDQyNDI4NTQ1YzE1YmM0ODZmZGUyXzctMS0xLTEtMA_4711fffc-385c-4c26-bd83-e2fc0012254f"
      unitRef="number">0.0083</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i99276d8c006448148b510e8ed81523da_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1OGNhNzJlNWQzMTQ0MjQyODU0NWMxNWJjNDg2ZmRlMi90YWJsZXJhbmdlOjU4Y2E3MmU1ZDMxNDQyNDI4NTQ1YzE1YmM0ODZmZGUyXzctMi0xLTEtMA_ae7f0eb4-66bd-498e-b29c-0a722e3812ba"
      unitRef="number">0.0082</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i803d3fabb4d84a7fa36d5b64f9f5b98d_D20170101-20171231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDkvZnJhZzo0MjNlZDlmZWU1ODI0MzkxYWJkZmI5YTY5YWE5NmI2MC90YWJsZTo1OGNhNzJlNWQzMTQ0MjQyODU0NWMxNWJjNDg2ZmRlMi90YWJsZXJhbmdlOjU4Y2E3MmU1ZDMxNDQyNDI4NTQ1YzE1YmM0ODZmZGUyXzctMy0xLTEtMA_4a3f5ad3-e22a-4316-9596-84650a8c5943"
      unitRef="number">0.0076</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <sgmo:CollaborativeArrangementStandstillRestrictionPeriod
      contextRef="i3107101abd5c446e81202399471630f8_D20200201-20200228"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV83Njk2NTgxNDE2MDUx_0d84836a-c95f-4eb8-a58e-c4a119cbf42f">P3Y</sgmo:CollaborativeArrangementStandstillRestrictionPeriod>
    <sgmo:CollaborativeArrangementVotingProvisionsExpirationPeriod
      contextRef="i3107101abd5c446e81202399471630f8_D20200201-20200228"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV83Njk2NTgxNDE2MTM1_d2c3c96b-72c7-45db-9430-d8a812b9fc92">P2Y</sgmo:CollaborativeArrangementVotingProvisionsExpirationPeriod>
    <dei:DocumentType
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGV4dHJlZ2lvbjoyYzI4NzJiODEwMDQ0ZTA5Yjc5NTllZDcyODVkYzVlZF83Njk2NTgxMzk5MTEw_97be82aa-e712-48ea-902c-dfb75bc68458">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGFibGU6OWJkZWUzMmEzYTdlNGVjYzk3ZjY1OWYwOTM0NTE3YTMvdGFibGVyYW5nZTo5YmRlZTMyYTNhN2U0ZWNjOTdmNjU5ZjA5MzQ1MTdhM18wLTAtMS0xLTgxMzg_8fe33855-6ded-44c4-9f71-2c7715f28d74">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGV4dHJlZ2lvbjoyYzI4NzJiODEwMDQ0ZTA5Yjc5NTllZDcyODVkYzVlZF83Njk2NTgxMzk5MTc5_894f12a1-544f-426c-9a7b-b619cbaee07e">2019-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGFibGU6OGY3YmNlYmM1NTg2NGYzYTk4ZGFjZjc3MTRhZjY3OGIvdGFibGVyYW5nZTo4ZjdiY2ViYzU1ODY0ZjNhOThkYWNmNzcxNGFmNjc4Yl8wLTAtMS0xLTgxNDA_e2a26bda-66ea-4422-b696-b074d0d05d50">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGV4dHJlZ2lvbjoyYzI4NzJiODEwMDQ0ZTA5Yjc5NTllZDcyODVkYzVlZF83Njk2NTgxMzk5MTE3_bcbb6d59-ccfd-4e85-b763-d058a3f8d978">000-30171</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGV4dHJlZ2lvbjoyYzI4NzJiODEwMDQ0ZTA5Yjc5NTllZDcyODVkYzVlZF83Njk2NTgxMzk5MTI4_2037a7b5-ca12-4f06-ae6e-609db679797c">SANGAMO THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGFibGU6NTIyOWIxOWY1ODNlNGU5MzhjOWYwOTgxYTEyZTQxMTEvdGFibGVyYW5nZTo1MjI5YjE5ZjU4M2U0ZTkzOGM5ZjA5ODFhMTJlNDExMV8wLTAtMS0xLTgxNTI_ff7fe91d-6030-4822-a053-5f35dfab9efc">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGFibGU6NTIyOWIxOWY1ODNlNGU5MzhjOWYwOTgxYTEyZTQxMTEvdGFibGVyYW5nZTo1MjI5YjE5ZjU4M2U0ZTkzOGM5ZjA5ODFhMTJlNDExMV8wLTQtMS0xLTgxNTQ_eb7eea35-369f-4c59-a428-cb686d067ea1">68-0359556</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGFibGU6NTIyOWIxOWY1ODNlNGU5MzhjOWYwOTgxYTEyZTQxMTEvdGFibGVyYW5nZTo1MjI5YjE5ZjU4M2U0ZTkzOGM5ZjA5ODFhMTJlNDExMV8zLTAtMS0xLTgxNTY_266e1553-319a-4e5d-82a0-10c81270c855">7000 Marina Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGFibGU6NTIyOWIxOWY1ODNlNGU5MzhjOWYwOTgxYTEyZTQxMTEvdGFibGVyYW5nZTo1MjI5YjE5ZjU4M2U0ZTkzOGM5ZjA5ODFhMTJlNDExMV80LTAtMS0xLTE0OTA4L3RleHRyZWdpb246YmRhNzFkNGNmYmRiNDE5ZTg1Yzc4YTNmNGY4ZmU3MDlfNzY5NjU4MTM5NDQ2NA_fcb68523-663f-4725-8db2-d0f36ead84d3">Brisbane</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGFibGU6NTIyOWIxOWY1ODNlNGU5MzhjOWYwOTgxYTEyZTQxMTEvdGFibGVyYW5nZTo1MjI5YjE5ZjU4M2U0ZTkzOGM5ZjA5ODFhMTJlNDExMV80LTAtMS0xLTE0OTA4L3RleHRyZWdpb246YmRhNzFkNGNmYmRiNDE5ZTg1Yzc4YTNmNGY4ZmU3MDlfNzY5NjU4MTM5NDQ3Ng_2c19dd99-9798-4134-9331-f707b0dfcc01">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGFibGU6NTIyOWIxOWY1ODNlNGU5MzhjOWYwOTgxYTEyZTQxMTEvdGFibGVyYW5nZTo1MjI5YjE5ZjU4M2U0ZTkzOGM5ZjA5ODFhMTJlNDExMV80LTQtMS0xLTE0OTM2_7f60a280-c15b-4b08-89cc-a41bc129a3b7">94005</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGV4dHJlZ2lvbjoyYzI4NzJiODEwMDQ0ZTA5Yjc5NTllZDcyODVkYzVlZF83Njk2NTgxMzk5MTU2_ba06d585-c157-4b9f-9874-a89cafed304d">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGV4dHJlZ2lvbjoyYzI4NzJiODEwMDQ0ZTA5Yjc5NTllZDcyODVkYzVlZF83Njk2NTgxMzk5MTYx_3e09fcfb-bff2-42ae-bb2a-3e1ebe5e1a19">970-6000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGFibGU6YTE4YjcyMGE3YThiNGVmOThiYzNmMzAwNWExNDM2MjIvdGFibGVyYW5nZTphMThiNzIwYTdhOGI0ZWY5OGJjM2YzMDA1YTE0MzYyMl8xLTAtMS0xLTgxNzc_bf8abc58-bb3b-49d6-b5c5-cffd75bfa15d">Common Stock, par value  $0.01&#160;per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGFibGU6YTE4YjcyMGE3YThiNGVmOThiYzNmMzAwNWExNDM2MjIvdGFibGVyYW5nZTphMThiNzIwYTdhOGI0ZWY5OGJjM2YzMDA1YTE0MzYyMl8xLTEtMS0xLTgxNzc_eb156579-49ab-44aa-bf12-caa74070755a">SGMO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGFibGU6YTE4YjcyMGE3YThiNGVmOThiYzNmMzAwNWExNDM2MjIvdGFibGVyYW5nZTphMThiNzIwYTdhOGI0ZWY5OGJjM2YzMDA1YTE0MzYyMl8xLTItMS0xLTgxNzc_93212ca9-0d59-4120-a566-e93a76407d13">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGV4dHJlZ2lvbjoyYzI4NzJiODEwMDQ0ZTA5Yjc5NTllZDcyODVkYzVlZF83Njk2NTgxMzk5MTcw_6a0c0535-cf89-4cb5-b381-03aec2e38a8f">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGV4dHJlZ2lvbjoyYzI4NzJiODEwMDQ0ZTA5Yjc5NTllZDcyODVkYzVlZF83Njk2NTgxMzk5MTcx_cdaee1f2-21d5-40cc-b28f-4f5f11d4cf52">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGV4dHJlZ2lvbjoyYzI4NzJiODEwMDQ0ZTA5Yjc5NTllZDcyODVkYzVlZF83Njk2NTgxMzk5MTcy_09063e7a-eadf-454c-a23a-736acdf2c5c6">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGV4dHJlZ2lvbjoyYzI4NzJiODEwMDQ0ZTA5Yjc5NTllZDcyODVkYzVlZF83Njk2NTgxMzk5MTcz_0d458b7a-cbcd-4ce6-bfb8-7fed85730e1f">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGFibGU6MThmYWU4NjYyY2FlNGQzMTlhNTMxNDRiYTAyYzIyNDQvdGFibGVyYW5nZToxOGZhZTg2NjJjYWU0ZDMxOWE1MzE0NGJhMDJjMjI0NF8wLTAtMS0xLTgxOTE_18859e08-bf4f-408f-80cb-9999419c9861">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGFibGU6MThmYWU4NjYyY2FlNGQzMTlhNTMxNDRiYTAyYzIyNDQvdGFibGVyYW5nZToxOGZhZTg2NjJjYWU0ZDMxOWE1MzE0NGJhMDJjMjI0NF8xLTQtMS0xLTgxOTM_90a03f86-b7ee-42b3-b641-8d65ef1c7ab4">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGFibGU6MThmYWU4NjYyY2FlNGQzMTlhNTMxNDRiYTAyYzIyNDQvdGFibGVyYW5nZToxOGZhZTg2NjJjYWU0ZDMxOWE1MzE0NGJhMDJjMjI0NF8yLTQtMS0xLTgxOTU_35663eca-4473-413e-be66-6ada400acb3f">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGV4dHJlZ2lvbjoyYzI4NzJiODEwMDQ0ZTA5Yjc5NTllZDcyODVkYzVlZF83Njk2NTgxMzk5MTc0_5c633d71-acd6-44b8-a495-f1e40e89fd22">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i91529fcfc109499ebb3512672c167060_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGV4dHJlZ2lvbjoyYzI4NzJiODEwMDQ0ZTA5Yjc5NTllZDcyODVkYzVlZF83Njk2NTgxMzk5MTc1_897a2ca4-5bb5-46b3-a6dc-61c737bfbe76"
      unitRef="usd">1244723752</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ia8c647fb84f84583814d2cba60abe33f_I20200221"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGV4dHJlZ2lvbjoyYzI4NzJiODEwMDQ0ZTA5Yjc5NTllZDcyODVkYzVlZF84Nzk2MDkzMDI3Mzgw_06d2b42c-fc19-4ff4-8d77-5192e79c07e2"
      unitRef="shares">116022630</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xL2ZyYWc6MmMyODcyYjgxMDA0NGUwOWI3OTU5ZWQ3Mjg1ZGM1ZWQvdGV4dHJlZ2lvbjoyYzI4NzJiODEwMDQ0ZTA5Yjc5NTllZDcyODVkYzVlZF83Njk2NTgxMzk5NTg4_0cada863-60a8-4ace-8b60-63e0ee956207">&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;"&gt;Certain information required by Part III, Items 10-14 of this Form 10-K is incorporated by reference to the registrant&#x2019;s definitive Proxy Statement for the 2020 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Form 10-K, provided that if such Proxy Statement is not filed within such period, such information will be included in an amendment to this Form 10-K to be filed within such 120-day period&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%;"&gt;.&lt;/span&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMy0xLTEtMS0w_5b5431f1-9961-4fc6-aa0a-63d081ada5a5"
      unitRef="usd">80428000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMy0zLTEtMS0w_fe3375a9-2d3b-4b4c-85a8-d8799eb2501d"
      unitRef="usd">140418000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfNC0xLTEtMS0w_c21d8d37-6439-443b-9c70-c8c4a5a40e45"
      unitRef="usd">282046000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfNC0zLTEtMS0w_644bee8e-186e-46b4-9fce-10366ae7b1b9"
      unitRef="usd">259715000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfNS0xLTEtMS0w_230edf0f-57d0-4c0d-9c99-23b7dd3d0f4d"
      unitRef="usd">682000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfNS0zLTEtMS0w_4e6c90cf-d0fa-4867-a05d-24caa8886861"
      unitRef="usd">375000</us-gaap:InterestReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfNi0xLTEtMS0w_270510f1-5cfc-4f82-a8b1-98eab7306f96"
      unitRef="usd">36909000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfNi0zLTEtMS0w_21a76836-5108-4d98-be69-f6461bde6593"
      unitRef="usd">4673000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfNy0xLTEtMS0w_99c61686-5e86-48ed-8582-1f53711afac2"
      unitRef="usd">5408000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfNy0zLTEtMS0w_46714da8-e76c-4bb8-81a7-5d328a34ca5a"
      unitRef="usd">5340000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfOC0xLTEtMS0w_c312d26f-2bbc-41b2-8bd3-387b242e883c"
      unitRef="usd">405473000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfOC0zLTEtMS0w_16f4c018-df38-4bba-9257-23b5b1cb2dc1"
      unitRef="usd">410521000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMTAtMS0xLTEtMA_e3def4b4-cd7e-4fe7-b9f7-0af321a4e570"
      unitRef="usd">21832000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMTAtMy0xLTEtMA_17fb2562-390b-49f3-9d40-ff1203968301"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMTEtMS0xLTEtMA_6e1cff61-cc93-4b89-995e-58c328da00db"
      unitRef="usd">29926000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMTEtMy0xLTEtMA_583e0e0f-68eb-4db6-a2b4-a9e0e3f34c2a"
      unitRef="usd">78723000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMTItMS0xLTEtMA_ba8c869f-35e8-4d1c-8c57-eae7ac315ad0"
      unitRef="usd">53156000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMTItMy0xLTEtMA_f4ec954c-3f84-40af-a748-9594a03a306f"
      unitRef="usd">54243000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMTMtMS0xLTEtMA_b3b04f60-fa09-4a75-9a4f-66c7c834d35b"
      unitRef="usd">39273000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMTMtMy0xLTEtMA_6a160489-4b58-4b83-8b77-f38932a3d88b"
      unitRef="usd">40044000</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMTQtMS0xLTEtOTY3_47efe694-b285-486a-b7b3-912bf45e6e4b"
      unitRef="usd">77289000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMTQtMS0xLTEtMA_ec801bca-90e1-4f17-8423-e28d7e65f87f"
      unitRef="usd">9067000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMTQtMy0xLTEtMA_f0a8fb60-07a4-4130-bb5a-7315f6c49bfc"
      unitRef="usd">3364000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMTUtMS0xLTEtMA_72ab48b3-a477-4036-ae89-90dc6a7b6457"
      unitRef="usd">1500000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMTUtMy0xLTEtMA_6c4111c8-7fad-4fa3-a794-5f0d60cc573f"
      unitRef="usd">3500000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:Assets
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMTYtMS0xLTEtMA_af095824-e3f7-4bab-b916-1c73725757e0"
      unitRef="usd">637516000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMTYtMy0xLTEtMA_d337cc18-8a8f-4456-9ff5-ccc4b40e87be"
      unitRef="usd">590395000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMTktMS0xLTEtMA_4993e932-eb89-4960-87da-143c4ed2edbd"
      unitRef="usd">17556000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMTktMy0xLTEtMA_9f490b1f-75c4-4231-9140-82bc56444e32"
      unitRef="usd">21457000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMjAtMS0xLTEtMA_49a2fe65-b819-4d6c-8395-1f771c34070e"
      unitRef="usd">13605000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMjAtMy0xLTEtMA_efb72e4b-ddcc-43e7-8fb8-3b20147bb575"
      unitRef="usd">9490000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMjEtMS0xLTEtMA_ff8be191-b35b-4144-af05-f28feedb0e6d"
      unitRef="usd">38711000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMjEtMy0xLTEtMA_08b9bded-1fcb-429b-8e2d-f75bbffa6309"
      unitRef="usd">47564000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMjItMS0xLTEtMA_1d7a8a68-e674-41bc-a239-66df0a2b3978"
      unitRef="usd">69872000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMjItMy0xLTEtMA_463d6f05-6ed8-452f-8bee-becdc0ffb8fa"
      unitRef="usd">78511000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMjMtMS0xLTEtMA_eefb5fb4-78f5-4a26-bb76-7f65c150cbde"
      unitRef="usd">81432000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMjMtMy0xLTEtMA_bf71befc-b61b-4299-8c75-b280e70408bd"
      unitRef="usd">108273000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMjQtMS0xLTEtMA_c5fd7c00-de43-4532-a7d4-da7878bc1f6c"
      unitRef="usd">41192000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <sgmo:BuildToSuitLeaseObligations
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMjQtMy0xLTEtMA_8c31fa3c-c7c8-469d-b5ae-1cb97f4e70e6"
      unitRef="usd">27689000</sgmo:BuildToSuitLeaseObligations>
    <us-gaap:DeferredTaxLiabilitiesNoncurrent
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMjUtMS0xLTEtMA_f8225c7e-6af9-47a5-afdc-0e88d903f03d"
      unitRef="usd">6570000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
    <us-gaap:DeferredTaxLiabilitiesNoncurrent
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMjUtMy0xLTEtMA_edf4c2dc-d7fe-41aa-9ebc-b3316ad499dd"
      unitRef="usd">6705000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMjYtMS0xLTEtMA_fff2e510-6b58-4af4-990a-1bbaac4c128f"
      unitRef="usd">5711000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMjYtMy0xLTEtMA_95910610-a195-4404-8a1f-e9fe230848a9"
      unitRef="usd">1960000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMjctMS0xLTEtMA_1b8816c6-ad94-4397-a152-2713adf76858"
      unitRef="usd">204777000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMjctMy0xLTEtMA_03f82874-596e-41fc-91bb-d4d92e99c098"
      unitRef="usd">223138000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMjgtMS0xLTEtMA_57278f5a-fbf0-4539-8c4e-225072196542"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMjgtMy0xLTEtMA_20521eac-4581-4d19-8d68-bda342360481"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzEtMC0xLTEtMTMzMDUvdGV4dHJlZ2lvbjo5YTM0NjhhYjI5Mjk0OTg1YTdiNTY5MjI3MjQ1MWJjMF84MjQ2MzM3MjA4NDcy_8b948fb8-678b-44f4-9963-1991ccc8f131"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzEtMC0xLTEtMTMzMDUvdGV4dHJlZ2lvbjo5YTM0NjhhYjI5Mjk0OTg1YTdiNTY5MjI3MjQ1MWJjMF84MjQ2MzM3MjA4NDcy_cc0df052-63ea-453c-86ed-bcbdb1a9e79d"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzEtMC0xLTEtMTMzMDUvdGV4dHJlZ2lvbjo5YTM0NjhhYjI5Mjk0OTg1YTdiNTY5MjI3MjQ1MWJjMF8xMDQ0NTM2MDQ2Mzk2Nw_65fc5772-ae7e-49b4-bf89-1e025f5dfe5a"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzEtMC0xLTEtMTMzMDUvdGV4dHJlZ2lvbjo5YTM0NjhhYjI5Mjk0OTg1YTdiNTY5MjI3MjQ1MWJjMF8xMDQ0NTM2MDQ2Mzk2Nw_7e25e9a3-d3bb-4b30-85da-dc80d6dca9fa"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzEtMC0xLTEtMTMzMDUvdGV4dHJlZ2lvbjo5YTM0NjhhYjI5Mjk0OTg1YTdiNTY5MjI3MjQ1MWJjMF84MjQ2MzM3MjA4NDQz_1275b8dd-f96e-4fee-9726-0b7f33711978"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzEtMC0xLTEtMTMzMDUvdGV4dHJlZ2lvbjo5YTM0NjhhYjI5Mjk0OTg1YTdiNTY5MjI3MjQ1MWJjMF84MjQ2MzM3MjA4NDQz_2ec37ff1-04a8-4d14-bdbf-8fbfa450415c"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzEtMC0xLTEtMTMzMDUvdGV4dHJlZ2lvbjo5YTM0NjhhYjI5Mjk0OTg1YTdiNTY5MjI3MjQ1MWJjMF84MjQ2MzM3MjA4NDQz_85684e26-bd8d-4e25-9fba-58ed785aa015"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzEtMC0xLTEtMTMzMDUvdGV4dHJlZ2lvbjo5YTM0NjhhYjI5Mjk0OTg1YTdiNTY5MjI3MjQ1MWJjMF84MjQ2MzM3MjA4NDQz_f041562f-766e-47c4-8e31-f19be9800763"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzEtMS0xLTEtMTU0MzQ_f661d10d-c82d-4890-b4e9-faeca18e9d39"
      unitRef="usd">0</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzEtMy0xLTEtMTU0Mzg_63248324-3646-43bc-900a-6acda09c6105"
      unitRef="usd">0</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzAtMC0xLTEtNjgvdGV4dHJlZ2lvbjoyN2NmOGY0OGFlMDg0OGU1ODQzNWY4ZGZiM2UxMmI0Zl83Njk2NTgxMzk0Njc0_17b3f855-2473-44ed-b0cd-5ccd4b08a9ea"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzAtMC0xLTEtNjgvdGV4dHJlZ2lvbjoyN2NmOGY0OGFlMDg0OGU1ODQzNWY4ZGZiM2UxMmI0Zl83Njk2NTgxMzk0Njc0_1cb4fbd1-5069-4a37-8b7e-0fef1be6145e"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzAtMC0xLTEtNjgvdGV4dHJlZ2lvbjoyN2NmOGY0OGFlMDg0OGU1ODQzNWY4ZGZiM2UxMmI0Zl83Njk2NTgxMzk0Njg3_7e70d220-b138-4238-9f10-fa2cbf4451cc"
      unitRef="shares">160000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzAtMC0xLTEtNjgvdGV4dHJlZ2lvbjoyN2NmOGY0OGFlMDg0OGU1ODQzNWY4ZGZiM2UxMmI0Zl83Njk2NTgxMzk0Njg3_fac48357-a102-41b7-9f1c-c57f7133e3ca"
      unitRef="shares">160000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzAtMC0xLTEtNjgvdGV4dHJlZ2lvbjoyN2NmOGY0OGFlMDg0OGU1ODQzNWY4ZGZiM2UxMmI0Zl83Njk2NTgxMzk0NzAw_7d2d1a9a-0931-4309-bb68-8e441b402ad8"
      unitRef="shares">115972708</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzAtMC0xLTEtNjgvdGV4dHJlZ2lvbjoyN2NmOGY0OGFlMDg0OGU1ODQzNWY4ZGZiM2UxMmI0Zl83Njk2NTgxMzk0NzAw_b40cb739-c905-4b12-8cf3-1f8cc37a1753"
      unitRef="shares">115972708</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzAtMC0xLTEtNjgvdGV4dHJlZ2lvbjoyN2NmOGY0OGFlMDg0OGU1ODQzNWY4ZGZiM2UxMmI0Zl83Njk2NTgxMzk0NzEz_213eaec7-0323-4e48-b56c-a52884ceac86"
      unitRef="shares">102187471</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzAtMC0xLTEtNjgvdGV4dHJlZ2lvbjoyN2NmOGY0OGFlMDg0OGU1ODQzNWY4ZGZiM2UxMmI0Zl83Njk2NTgxMzk0NzEz_619cf7d6-f587-4fe3-b802-bb7e1a9d84a3"
      unitRef="shares">102187471</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzAtMS0xLTEtMA_0eab8a65-e12d-4957-8141-a1125ad527bc"
      unitRef="usd">1160000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzAtMy0xLTEtMA_7fc57de7-4fb4-486d-97f8-b943dcbfc4d1"
      unitRef="usd">1022000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzEtMS0xLTEtMA_81591f08-93af-4a7f-b2b8-5c91d67c1d18"
      unitRef="usd">1090828000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzEtMy0xLTEtMA_50d26e70-4cf5-4d91-b798-3b180bb5356d"
      unitRef="usd">929632000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzItMS0xLTEtMA_8d3440d9-c374-4888-8971-9c07bed1bd2e"
      unitRef="usd">-656985000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzItMy0xLTEtMA_62fa0367-54a0-4529-8e77-ed7d4d5f1335"
      unitRef="usd">-562696000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzMtMS0xLTEtMA_99171b10-ede4-4d4a-8a74-6079d86eacbb"
      unitRef="usd">-2449000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzMtMy0xLTEtMA_989bb7e7-6f6a-4c3a-889f-6ac114263166"
      unitRef="usd">-1440000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzQtMS0xLTEtMA_2b3d65bb-915e-4307-8660-2786f09bd138"
      unitRef="usd">432554000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzQtMy0xLTEtMA_2f5210ed-aa9b-4cdd-9f6f-0909d9a0f2a2"
      unitRef="usd">366518000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzUtMS0xLTEtMA_33bf6199-ebc3-4f36-a2f5-06123be94c09"
      unitRef="usd">185000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzUtMy0xLTEtMA_ae6a5ca9-4737-474d-bde0-eec00e4db485"
      unitRef="usd">739000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzYtMS0xLTEtMA_51d7cac8-e843-4b66-9eec-8dccc24657f3"
      unitRef="usd">432739000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzYtMy0xLTEtMA_d2c88160-96c7-4db8-8618-f521db828753"
      unitRef="usd">367257000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzctMS0xLTEtMA_dd6ee818-70ad-497c-9403-8f23e0322822"
      unitRef="usd">637516000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83MC9mcmFnOjc2YjkyNDZlNmIxMjQwY2NiZDRiMzA5Mzk1ZmRjOTExL3RhYmxlOmRkMGI1Y2Q0MjJmMjQ1ODc5YmVjY2E5YzU2NmYyZDllL3RhYmxlcmFuZ2U6ZGQwYjVjZDQyMmYyNDU4NzliZWNjYTljNTY2ZjJkOWVfMzctMy0xLTEtMA_76dee698-36fd-488e-8510-140341644571"
      unitRef="usd">590395000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfNS0xLTEtMS0w_5b646f89-c05c-452c-a381-80a3b9f1bed0"
      unitRef="usd">102428000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfNS0zLTEtMS0w_9cc35105-4649-49b7-bc41-de6365aeeae9"
      unitRef="usd">84452000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfNS01LTEtMS0w_7fe58254-891b-45cd-b778-912b2121d0a7"
      unitRef="usd">36567000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfNy0xLTEtMS0w_3ec5b0cb-8042-4dc8-a82a-878f93e6e116"
      unitRef="usd">145922000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfNy0zLTEtMS0w_61d666bf-ab96-4ad2-8407-d68d7c7ef5d0"
      unitRef="usd">114866000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfNy01LTEtMS0w_4d90f836-1f72-4c02-9f4f-bd9eb9b9711c"
      unitRef="usd">65728000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfOC0xLTEtMS0w_10e1dcfa-cbb7-489c-bbc2-8808cf2db8a2"
      unitRef="usd">61686000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfOC0zLTEtMS0w_8d67ec14-e267-4196-b91a-f3df386b4248"
      unitRef="usd">46736000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfOC01LTEtMS0w_e2194c48-1605-4549-a1a4-96744828760d"
      unitRef="usd">27200000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfOS0xLTEtMS0w_5c83815a-dbd2-45c1-a376-af84938f7a4d"
      unitRef="usd">207608000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfOS0zLTEtMS0w_c4ad358a-64a2-47b2-add1-c6a364c14c7f"
      unitRef="usd">161602000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfOS01LTEtMS0w_d75bae5c-07da-4f2f-b333-ce55a7072137"
      unitRef="usd">92928000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTAtMS0xLTEtMA_94d57d53-ecd1-46c0-b1d3-4dd26e724173"
      unitRef="usd">-105180000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTAtMy0xLTEtMA_a401aef0-3bbc-4734-8bb6-3b256d0f9597"
      unitRef="usd">-77150000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTAtNS0xLTEtMA_ae513691-a09a-4a15-ac7c-48c6935b4065"
      unitRef="usd">-56361000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndOtherIncome
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTEtMS0xLTEtMA_9e6dd69e-5ebe-42de-8496-054bcf47dbf5"
      unitRef="usd">9761000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTEtMy0xLTEtMA_0a784928-486c-43e3-9e8a-dde44cd83cfe"
      unitRef="usd">8261000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTEtNS0xLTEtMA_e5e1839d-352d-4460-ba66-f3f174f73083"
      unitRef="usd">1793000</us-gaap:InterestAndOtherIncome>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTItMS0xLTEtMA_f06e4a9e-2be9-415c-b2eb-23a33c296b2b"
      unitRef="usd">-95419000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTItMy0xLTEtMA_4374c5b8-6307-482c-8d01-2a486d4eb181"
      unitRef="usd">-68889000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTItNS0xLTEtMA_0eee9a42-6a11-4798-b16b-d23b3a01d8b9"
      unitRef="usd">-54568000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTMtMS0xLTEtMA_d357dd1c-5fc4-4137-9e78-79159d2d254c"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTMtMy0xLTEtMA_c6457de7-06eb-4c90-bf50-127cf2af87fe"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTMtNS0xLTEtMA_2573828f-2db6-474d-9254-33b62f68d7b8"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTQtMS0xLTEtMA_cb15ac6b-0fce-4b8c-b5c8-61b973a71e0d"
      unitRef="usd">-95419000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTQtMy0xLTEtMA_fe0963a4-9dfa-4f2b-a48b-ef5bca10b86e"
      unitRef="usd">-68889000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTQtNS0xLTEtMA_0549d2ca-50e3-4e6a-8700-811f9cfdaff0"
      unitRef="usd">-54568000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTUtMS0xLTEtMA_5487631a-c4a2-4253-8fcb-bb51b8df9542"
      unitRef="usd">-233000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTUtMy0xLTEtMA_2625ee9a-f5cd-44cf-96cc-70b1d6da19a4"
      unitRef="usd">-555000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTUtNS0xLTEtMA_cf2b94da-f497-4b7e-aa5e-283fd898e32c"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTYtMS0xLTEtMA_d5efbbff-57ce-4417-af9e-d8e99cfd44d2"
      unitRef="usd">-95186000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTYtMy0xLTEtMA_5c38618b-bf06-4e85-9187-1b4ba131a45d"
      unitRef="usd">-68334000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTYtNS0xLTEtMA_d7404029-f5b5-4d6b-96be-5ed9c14f05d1"
      unitRef="usd">-54568000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTctMS0xLTEtMA_41b3358c-cfe0-46c7-8fe9-8b0d45ea7d86"
      unitRef="usdPerShare">-0.85</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTctMy0xLTEtMA_13c7869d-c520-429c-8b80-401e291edbef"
      unitRef="usdPerShare">-0.70</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTctNS0xLTEtMA_314b956e-c4d6-4a37-a606-2ec030bac8ec"
      unitRef="usdPerShare">-0.70</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTgtMS0xLTEtMA_82069ab4-38ee-4963-9505-acfda748482f"
      unitRef="shares">112114000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTgtMy0xLTEtMA_a17c674d-66fe-4d17-b079-39592c001cb4"
      unitRef="shares">96941000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83Ni9mcmFnOmE0MGYxOTdiODdlNDQ2ODY4ZDY0YTJhNTU0YjNiMWFjL3RhYmxlOmQwOTgyM2Q5OGU5YjQzODQ5ZDE0ZmY2Yzg2N2M1ZTM0L3RhYmxlcmFuZ2U6ZDA5ODIzZDk4ZTliNDM4NDlkMTRmZjZjODY3YzVlMzRfMTgtNS0xLTEtMA_8e25fdcc-0e97-4f7c-bfdd-737c2ad7d6c9"
      unitRef="shares">78084000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:ProfitLoss
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83OS9mcmFnOjZjYjUxMjQ5YzBlMjQxZWU4YmJkYWE2OGZiODU2M2ZlL3RhYmxlOmU1Y2Y5M2NiMDYxNDQxMmVhZDRlNjdkNDIxODA1MWEzL3RhYmxlcmFuZ2U6ZTVjZjkzY2IwNjE0NDEyZWFkNGU2N2Q0MjE4MDUxYTNfMi0xLTEtMS0w_77f52c93-30d2-4e27-a364-c0581103ff97"
      unitRef="usd">-95419000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83OS9mcmFnOjZjYjUxMjQ5YzBlMjQxZWU4YmJkYWE2OGZiODU2M2ZlL3RhYmxlOmU1Y2Y5M2NiMDYxNDQxMmVhZDRlNjdkNDIxODA1MWEzL3RhYmxlcmFuZ2U6ZTVjZjkzY2IwNjE0NDEyZWFkNGU2N2Q0MjE4MDUxYTNfMi0zLTEtMS0w_015b3895-6dd2-4141-acb9-0c932ac176ca"
      unitRef="usd">-68889000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83OS9mcmFnOjZjYjUxMjQ5YzBlMjQxZWU4YmJkYWE2OGZiODU2M2ZlL3RhYmxlOmU1Y2Y5M2NiMDYxNDQxMmVhZDRlNjdkNDIxODA1MWEzL3RhYmxlcmFuZ2U6ZTVjZjkzY2IwNjE0NDEyZWFkNGU2N2Q0MjE4MDUxYTNfMi01LTEtMS0w_761c2e19-95aa-4942-9dc0-d4ff486a20da"
      unitRef="usd">-54568000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83OS9mcmFnOjZjYjUxMjQ5YzBlMjQxZWU4YmJkYWE2OGZiODU2M2ZlL3RhYmxlOmU1Y2Y5M2NiMDYxNDQxMmVhZDRlNjdkNDIxODA1MWEzL3RhYmxlcmFuZ2U6ZTVjZjkzY2IwNjE0NDEyZWFkNGU2N2Q0MjE4MDUxYTNfMy0xLTEtMS0w_5980e0d0-6b3e-45ca-9eea-e0148e9e099f"
      unitRef="usd">-1573000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83OS9mcmFnOjZjYjUxMjQ5YzBlMjQxZWU4YmJkYWE2OGZiODU2M2ZlL3RhYmxlOmU1Y2Y5M2NiMDYxNDQxMmVhZDRlNjdkNDIxODA1MWEzL3RhYmxlcmFuZ2U6ZTVjZjkzY2IwNjE0NDEyZWFkNGU2N2Q0MjE4MDUxYTNfMy0zLTEtMS0w_7f1c46a7-6043-4cbf-93a0-cedf2f869c69"
      unitRef="usd">-1148000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83OS9mcmFnOjZjYjUxMjQ5YzBlMjQxZWU4YmJkYWE2OGZiODU2M2ZlL3RhYmxlOmU1Y2Y5M2NiMDYxNDQxMmVhZDRlNjdkNDIxODA1MWEzL3RhYmxlcmFuZ2U6ZTVjZjkzY2IwNjE0NDEyZWFkNGU2N2Q0MjE4MDUxYTNfMy01LTEtMS0w_b70568c1-e34d-4289-b81d-8fa8443868d1"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83OS9mcmFnOjZjYjUxMjQ5YzBlMjQxZWU4YmJkYWE2OGZiODU2M2ZlL3RhYmxlOmU1Y2Y5M2NiMDYxNDQxMmVhZDRlNjdkNDIxODA1MWEzL3RhYmxlcmFuZ2U6ZTVjZjkzY2IwNjE0NDEyZWFkNGU2N2Q0MjE4MDUxYTNfNC0xLTEtMS0w_c62bf110-e86c-4459-92be-bb3e0d82806e"
      unitRef="usd">28000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83OS9mcmFnOjZjYjUxMjQ5YzBlMjQxZWU4YmJkYWE2OGZiODU2M2ZlL3RhYmxlOmU1Y2Y5M2NiMDYxNDQxMmVhZDRlNjdkNDIxODA1MWEzL3RhYmxlcmFuZ2U6ZTVjZjkzY2IwNjE0NDEyZWFkNGU2N2Q0MjE4MDUxYTNfNC0zLTEtMS0w_3c1ea55e-2728-45aa-8bd1-964509e8a1ed"
      unitRef="usd">21000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83OS9mcmFnOjZjYjUxMjQ5YzBlMjQxZWU4YmJkYWE2OGZiODU2M2ZlL3RhYmxlOmU1Y2Y5M2NiMDYxNDQxMmVhZDRlNjdkNDIxODA1MWEzL3RhYmxlcmFuZ2U6ZTVjZjkzY2IwNjE0NDEyZWFkNGU2N2Q0MjE4MDUxYTNfNC01LTEtMS0w_a3a8cc8f-a1c4-4747-b5db-e73228e79a8e"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83OS9mcmFnOjZjYjUxMjQ5YzBlMjQxZWU4YmJkYWE2OGZiODU2M2ZlL3RhYmxlOmU1Y2Y5M2NiMDYxNDQxMmVhZDRlNjdkNDIxODA1MWEzL3RhYmxlcmFuZ2U6ZTVjZjkzY2IwNjE0NDEyZWFkNGU2N2Q0MjE4MDUxYTNfNS0xLTEtMS0w_94725f39-1236-40a8-89e0-5f613d2d5cac"
      unitRef="usd">592000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83OS9mcmFnOjZjYjUxMjQ5YzBlMjQxZWU4YmJkYWE2OGZiODU2M2ZlL3RhYmxlOmU1Y2Y5M2NiMDYxNDQxMmVhZDRlNjdkNDIxODA1MWEzL3RhYmxlcmFuZ2U6ZTVjZjkzY2IwNjE0NDEyZWFkNGU2N2Q0MjE4MDUxYTNfNS0zLTEtMS0w_f08aeb2d-9a93-456f-ab10-fcf9daaadfdb"
      unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83OS9mcmFnOjZjYjUxMjQ5YzBlMjQxZWU4YmJkYWE2OGZiODU2M2ZlL3RhYmxlOmU1Y2Y5M2NiMDYxNDQxMmVhZDRlNjdkNDIxODA1MWEzL3RhYmxlcmFuZ2U6ZTVjZjkzY2IwNjE0NDEyZWFkNGU2N2Q0MjE4MDUxYTNfNS01LTEtMS0w_567c17ac-a455-45c7-8cbc-008526fd5851"
      unitRef="usd">-306000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83OS9mcmFnOjZjYjUxMjQ5YzBlMjQxZWU4YmJkYWE2OGZiODU2M2ZlL3RhYmxlOmU1Y2Y5M2NiMDYxNDQxMmVhZDRlNjdkNDIxODA1MWEzL3RhYmxlcmFuZ2U6ZTVjZjkzY2IwNjE0NDEyZWFkNGU2N2Q0MjE4MDUxYTNfNi0xLTEtMS0w_54d7f259-499e-4b7b-b4fc-7ed971e5dce9"
      unitRef="usd">-96428000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83OS9mcmFnOjZjYjUxMjQ5YzBlMjQxZWU4YmJkYWE2OGZiODU2M2ZlL3RhYmxlOmU1Y2Y5M2NiMDYxNDQxMmVhZDRlNjdkNDIxODA1MWEzL3RhYmxlcmFuZ2U6ZTVjZjkzY2IwNjE0NDEyZWFkNGU2N2Q0MjE4MDUxYTNfNi0zLTEtMS0w_de63d1fd-2d5d-4129-99bf-ec3839189ebd"
      unitRef="usd">-70062000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83OS9mcmFnOjZjYjUxMjQ5YzBlMjQxZWU4YmJkYWE2OGZiODU2M2ZlL3RhYmxlOmU1Y2Y5M2NiMDYxNDQxMmVhZDRlNjdkNDIxODA1MWEzL3RhYmxlcmFuZ2U6ZTVjZjkzY2IwNjE0NDEyZWFkNGU2N2Q0MjE4MDUxYTNfNi01LTEtMS0w_b1967fba-1684-4a38-871a-c6f6dffeb827"
      unitRef="usd">-54874000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83OS9mcmFnOjZjYjUxMjQ5YzBlMjQxZWU4YmJkYWE2OGZiODU2M2ZlL3RhYmxlOmU1Y2Y5M2NiMDYxNDQxMmVhZDRlNjdkNDIxODA1MWEzL3RhYmxlcmFuZ2U6ZTVjZjkzY2IwNjE0NDEyZWFkNGU2N2Q0MjE4MDUxYTNfNy0xLTEtMS0w_09457987-13ab-45d3-9e91-9724f0100764"
      unitRef="usd">-233000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83OS9mcmFnOjZjYjUxMjQ5YzBlMjQxZWU4YmJkYWE2OGZiODU2M2ZlL3RhYmxlOmU1Y2Y5M2NiMDYxNDQxMmVhZDRlNjdkNDIxODA1MWEzL3RhYmxlcmFuZ2U6ZTVjZjkzY2IwNjE0NDEyZWFkNGU2N2Q0MjE4MDUxYTNfNy0zLTEtMS0w_55f49090-3f45-406a-a956-4f5ca49b75f4"
      unitRef="usd">-574000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83OS9mcmFnOjZjYjUxMjQ5YzBlMjQxZWU4YmJkYWE2OGZiODU2M2ZlL3RhYmxlOmU1Y2Y5M2NiMDYxNDQxMmVhZDRlNjdkNDIxODA1MWEzL3RhYmxlcmFuZ2U6ZTVjZjkzY2IwNjE0NDEyZWFkNGU2N2Q0MjE4MDUxYTNfNy01LTEtMS0w_d727afd4-5a39-499b-b9dd-a811396eff6c"
      unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83OS9mcmFnOjZjYjUxMjQ5YzBlMjQxZWU4YmJkYWE2OGZiODU2M2ZlL3RhYmxlOmU1Y2Y5M2NiMDYxNDQxMmVhZDRlNjdkNDIxODA1MWEzL3RhYmxlcmFuZ2U6ZTVjZjkzY2IwNjE0NDEyZWFkNGU2N2Q0MjE4MDUxYTNfOC0xLTEtMS0w_91c7eb4a-1eac-43f9-a193-fa1122a31799"
      unitRef="usd">-96195000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83OS9mcmFnOjZjYjUxMjQ5YzBlMjQxZWU4YmJkYWE2OGZiODU2M2ZlL3RhYmxlOmU1Y2Y5M2NiMDYxNDQxMmVhZDRlNjdkNDIxODA1MWEzL3RhYmxlcmFuZ2U6ZTVjZjkzY2IwNjE0NDEyZWFkNGU2N2Q0MjE4MDUxYTNfOC0zLTEtMS0w_4850d5c7-f76b-49e6-936e-aac6bc26a30d"
      unitRef="usd">-69488000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF83OS9mcmFnOjZjYjUxMjQ5YzBlMjQxZWU4YmJkYWE2OGZiODU2M2ZlL3RhYmxlOmU1Y2Y5M2NiMDYxNDQxMmVhZDRlNjdkNDIxODA1MWEzL3RhYmxlcmFuZ2U6ZTVjZjkzY2IwNjE0NDEyZWFkNGU2N2Q0MjE4MDUxYTNfOC01LTEtMS0w_c887be97-eb49-4e48-9761-e13b6f95009a"
      unitRef="usd">-54874000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="i0627710456a349f7b90cec0a3f5536e8_I20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMi0xLTEtMS0w_29c0aa8e-eb18-4307-8424-d5cf063c1757"
      unitRef="shares">70871902</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0627710456a349f7b90cec0a3f5536e8_I20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMi0zLTEtMS0w_fbe9ff62-031a-46db-bf13-973cc476649b"
      unitRef="usd">709000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6a9e59eb89204d6cb59dbc5b2e145c09_I20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMi01LTEtMS0w_af8b67b9-9c89-4f6c-a674-71510f464c62"
      unitRef="usd">576377000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5063163868264343bb3c8784a605dabf_I20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMi03LTEtMS0w_509dc75e-d804-48f2-b29b-d169d68c1b30"
      unitRef="usd">-440911000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id50e642517aa459b9ada4af0f93e6b20_I20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMi05LTEtMS0w_953ea09f-908a-40da-9ec3-b8437c920ee6"
      unitRef="usd">20000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifeb2f797e05149138caa5e72c8aa0d2b_I20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMi0xMS0xLTEtMA_a87d6f5a-602a-4a9e-91e4-535d84e1acd7"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie9057cb83ba040218834cc92910f7361_I20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMi0xMy0xLTEtMA_fd4a3f7a-a7e5-4c11-96f9-bd6aba60ce67"
      unitRef="usd">136195000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i0ce63a9e5f5542dc8d3b24259ad1ee2e_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMy0xLTEtMS0w_ab894c3d-c1b3-4821-a389-4334376c245a"
      unitRef="shares">2101489</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0ce63a9e5f5542dc8d3b24259ad1ee2e_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMy0zLTEtMS0w_67600ee2-84e0-4845-9e9e-6dbf56b094fa"
      unitRef="usd">21000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ibc70b211d0654544a6f9c1e9fc810641_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMy01LTEtMS0w_0cd84bed-897e-4d66-beac-715a8816e451"
      unitRef="usd">15078000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMy0xMy0xLTEtMA_ee5d70b9-a4bf-4ab1-88b4-6781f7d4b18f"
      unitRef="usd">15099000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i0ce63a9e5f5542dc8d3b24259ad1ee2e_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfNC0xLTEtMS0w_9c10756b-90d6-403b-af02-8b2269f4d5f0"
      unitRef="shares">253994</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i0ce63a9e5f5542dc8d3b24259ad1ee2e_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfNC0zLTEtMS0w_76dd4244-f313-4f50-a132-681654c10514"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ibc70b211d0654544a6f9c1e9fc810641_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfNC01LTEtMS0w_9505956b-872f-447a-9d76-9c7c85fa597c"
      unitRef="usd">816000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfNC0xMy0xLTEtMA_fe47b73b-704d-430e-9122-5d1c11a35f3f"
      unitRef="usd">818000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i0ce63a9e5f5542dc8d3b24259ad1ee2e_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfNS0xLTEtMS0xMDYw_02155fac-0534-4c19-bf5b-562f411bab89"
      unitRef="shares">12371149</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0ce63a9e5f5542dc8d3b24259ad1ee2e_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfNS0zLTEtMS0xMDYw_698f0df2-ed22-4c70-9eef-f1d44ec68507"
      unitRef="usd">124000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ibc70b211d0654544a6f9c1e9fc810641_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfNS01LTEtMS0xMDYw_768bfdf5-bd65-4ed7-b041-5f0e1fa75ca1"
      unitRef="usd">81449000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfNS0xMy0xLTEtMTA2MA_2b31786d-fc2a-4073-ae71-1102f8828722"
      unitRef="usd">81573000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ibc70b211d0654544a6f9c1e9fc810641_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfNS01LTEtMS0w_375ef83e-9992-48fe-9e37-df66dfd2425d"
      unitRef="usd">9089000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfNS0xMy0xLTEtMA_e289d303-dce0-4735-bfa0-6f2f0c8ebf60"
      unitRef="usd">9089000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i49b4da657a834857bc1d02cc6ef16e7b_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfNy05LTEtMS0w_2236ab50-b4c3-4957-b0b0-7fb55f8b87a5"
      unitRef="usd">-306000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfNy0xMy0xLTEtMA_11189894-d315-4572-896e-a90362b03c5b"
      unitRef="usd">-306000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i0406f7152c82421aa6b02c6472444482_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfOC03LTEtMS0w_c56a90cf-94cb-4450-ac89-278e1b8bfe39"
      unitRef="usd">-54568000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfOC0xMy0xLTEtMA_064332c8-acbf-4417-8330-5b9f06a390e6"
      unitRef="usd">-54568000</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5fc1ca72aa1645a4b00f8fd2b31d8956_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTAtMS0xLTEtMA_2c476d2e-6b91-4af5-849c-b76b0e311b86"
      unitRef="shares">85598534</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5fc1ca72aa1645a4b00f8fd2b31d8956_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTAtMy0xLTEtMA_6cac4bec-aca4-4868-b301-2e16226872f7"
      unitRef="usd">856000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia218df6fa91f4c1fb7c308b884f2552a_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTAtNS0xLTEtMA_7d9ad35f-717d-4640-b243-cd70f1b5d305"
      unitRef="usd">682809000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i81d1b464269e4be59411d5313217455a_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTAtNy0xLTEtMA_219a7d4b-5dde-4454-97c8-17c259e47999"
      unitRef="usd">-495479000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib5393cf4702d478487f5812f2284bb7d_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTAtOS0xLTEtMA_23782a8b-6605-48bb-8407-6bc320c778f9"
      unitRef="usd">-286000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i13411b9a2fac4f62b4a1b5d13e1a6d13_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTAtMTEtMS0xLTA_b1a6a2c2-d675-4f56-9fd0-93c1cbcd71a5"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieb7e952fbd38434585f995fe73c66a44_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTAtMTMtMS0xLTA_98e5c5d5-bf56-4b7c-ae73-f84a4045c6f3"
      unitRef="usd">187900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="if6ef95d8de3d4a7d89e36708e8ad41fa_I20180101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTAtNy0xLTEtMTEwNA_a133d8c2-d37d-48dc-816f-2bd4956d9c85"
      unitRef="usd">1117000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="i5ac2058780dd4487b64d9cea81253e0a_I20180101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTAtMTMtMS0xLTExMDQ_21b3ec2a-6665-4211-9bf9-05f7c18e1d2d"
      unitRef="usd">1117000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ibc92201ce4bc4d35aac109e19e0e5a1f_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTEtMS0xLTEtMA_8dc1f096-c569-4900-8559-343e6a9b3787"
      unitRef="shares">2103727</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ibc92201ce4bc4d35aac109e19e0e5a1f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTEtMy0xLTEtMA_9ddc1221-3875-45cc-99aa-c08a5738101e"
      unitRef="usd">20000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i5ad82eaa45484fad83417fd0c193af43_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTEtNS0xLTEtMA_935354ca-7b9d-46db-8034-dfe01c0318b0"
      unitRef="usd">14447000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTEtMTMtMS0xLTA_91f99d19-60fe-4537-b5ff-fcbf44644854"
      unitRef="usd">14467000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ibc92201ce4bc4d35aac109e19e0e5a1f_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTItMS0xLTEtMA_a27154f0-ada6-429d-aa37-8b0856ad706c"
      unitRef="shares">328710</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ibc92201ce4bc4d35aac109e19e0e5a1f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTItMy0xLTEtMA_8712871e-51cc-4147-9860-553afff721e9"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i5ad82eaa45484fad83417fd0c193af43_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTItNS0xLTEtMA_6a084cc9-efd5-4e6b-9fc1-7a237e7fdbcc"
      unitRef="usd">1480000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTItMTMtMS0xLTA_ba60fb96-9e2b-4958-8cfb-1520eb6a5fa7"
      unitRef="usd">1484000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ibc92201ce4bc4d35aac109e19e0e5a1f_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTMtMS0xLTEtMA_4edc1a04-8296-485d-8c74-c9166b3b9241"
      unitRef="shares">14156500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ibc92201ce4bc4d35aac109e19e0e5a1f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTMtMy0xLTEtMA_9b5f2132-0969-471a-a834-15e28670db27"
      unitRef="usd">142000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i5ad82eaa45484fad83417fd0c193af43_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTMtNS0xLTEtMA_1264990f-4380-470c-a8ee-7c7570e841ac"
      unitRef="usd">215616000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTMtMTMtMS0xLTA_8bcf1199-1820-4243-945e-2986f6c72807"
      unitRef="usd">215758000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5ad82eaa45484fad83417fd0c193af43_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTQtNS0xLTEtMA_22bc9bfe-514c-4b4f-9500-807fb531e2f1"
      unitRef="usd">14677000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTQtMTMtMS0xLTA_38839e63-10af-4bc3-92d4-252f42608d9c"
      unitRef="usd">14677000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest
      contextRef="i5ad82eaa45484fad83417fd0c193af43_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTUtNS0xLTEtMTE2OQ_dde9df4a-1dce-4db1-b609-dffcbe46d401"
      unitRef="usd">603000</sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest>
    <sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTUtMTMtMS0xLTExNjk_0618a39e-4fad-428d-934d-e37b46e9b885"
      unitRef="usd">603000</sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest>
    <us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination
      contextRef="ifaf1fb068f504cafbf0b5ee6c15f15a7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTYtMTEtMS0xLTExNjk_381c883f-694a-4d35-b6b1-a5e055335e9c"
      unitRef="usd">1313000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
    <us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTYtMTMtMS0xLTExNjk_3fcf4a2e-d350-4a3c-97a7-08bb48b002c2"
      unitRef="usd">1313000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="iaa3c4c19d5b248f48eeab6d3449c0692_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTctOS0xLTEtMTE2OQ_c400ebc2-8504-4490-9212-f6d3ba01ba5a"
      unitRef="usd">1129000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="ifaf1fb068f504cafbf0b5ee6c15f15a7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTctMTEtMS0xLTExNjk_28764f6c-6382-4c80-b2c3-8a2b2f3a0d42"
      unitRef="usd">19000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTctMTMtMS0xLTExNjk_eea70803-006c-4b04-af97-967c96fd9957"
      unitRef="usd">1148000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="iaa3c4c19d5b248f48eeab6d3449c0692_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTgtOS0xLTEtMTE2OQ_b84f1c6c-c2e3-40f1-a8d5-9a3ea74501e0"
      unitRef="usd">21000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTgtMTMtMS0xLTExNjk_e3c365af-6121-4bc6-bf2e-3506f18ad182"
      unitRef="usd">21000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="iaa3c4c19d5b248f48eeab6d3449c0692_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTYtOS0xLTEtMA_782f8a29-7ffb-45c2-ba91-979894ff673c"
      unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTYtMTMtMS0xLTA_c0ca9c89-1698-4304-9a9a-df55a6f2e867"
      unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i5616295424184a8eb8bbc9e26f43ed70_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTctNy0xLTEtMA_c74294a5-bb32-431f-92db-a64b9313a176"
      unitRef="usd">-68334000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ifaf1fb068f504cafbf0b5ee6c15f15a7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjAtMTEtMS0xLTEwMTQz_d1aa1766-c8f7-485d-b7b0-8a6f599118b1"
      unitRef="usd">-555000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTctMTMtMS0xLTA_1114a103-af26-43bc-9c66-c88866bc2dea"
      unitRef="usd">-68889000</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="i6b94d20f29c94303b0b5f428bcfaa12b_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTktMS0xLTEtMA_fb5757e0-b011-49ec-ae99-0d6195e4027f"
      unitRef="shares">102187471</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6b94d20f29c94303b0b5f428bcfaa12b_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTktMy0xLTEtMA_6bd71c10-d459-4e59-8f6e-879cdd4f8fbf"
      unitRef="usd">1022000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib9161aaed0bc4db88c75c765dcacf1d8_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTktNS0xLTEtMA_5c70f2c5-ff18-4401-a262-63fab2defa35"
      unitRef="usd">929632000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifce327bcf3b8435a8b434c043c9be74b_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTktNy0xLTEtMA_090bfe52-3d8f-4967-8dc2-1320fd7b269d"
      unitRef="usd">-562696000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i782ffb68f66c4a7b9ab9b5592f7c00fc_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTktOS0xLTEtMA_137fec20-d325-4a48-ba42-d56246b8ef3c"
      unitRef="usd">-1440000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic99ff13e6b8d4ef18b9878c555ae3844_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTktMTEtMS0xLTA_9f0c3e5a-449b-4aea-b240-277444f8291b"
      unitRef="usd">739000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMTktMTMtMS0xLTA_e957110a-c368-4a61-aa69-5846c7014e72"
      unitRef="usd">367257000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="i5f940ceeab344a3f93e9875fa4c27245_I20190101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjAtNy0xLTEtMA_20756cb1-9b8a-4910-876b-352094e26231"
      unitRef="usd">897000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="icbd33d4a7d834496bd26b17d12cc0d71_I20190101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjAtMTMtMS0xLTA_b81ad02d-72a8-4222-a120-ea43a2470618"
      unitRef="usd">897000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i10b0f55eb1164865bbf902ed106c9883_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjEtMS0xLTEtMA_8b7169bd-69d1-4970-91c9-449e2c36c66f"
      unitRef="shares">885873</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i10b0f55eb1164865bbf902ed106c9883_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjEtMy0xLTEtMA_61bd80f4-7836-4b1c-9f5d-6b54a82eb69b"
      unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if320296fd6c04201a11aab2ec6e01e0d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjEtNS0xLTEtMA_df5968c0-2ad2-4412-a5d0-467f7370268b"
      unitRef="usd">3668000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjEtMTMtMS0xLTA_81d24595-db70-4564-ab66-ac947c75ea84"
      unitRef="usd">3677000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i10b0f55eb1164865bbf902ed106c9883_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjItMS0xLTEtMA_5d8670f9-ea05-4f51-8063-5e0aec565269"
      unitRef="shares">249364</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i10b0f55eb1164865bbf902ed106c9883_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjItMy0xLTEtMA_e0f47b7e-1a1d-47af-a5e3-921e73ab7bab"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="if320296fd6c04201a11aab2ec6e01e0d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjItNS0xLTEtMA_2163beb8-824d-430d-8896-1a45fca3137f"
      unitRef="usd">2042000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjItMTMtMS0xLTA_08474911-5243-44a0-b048-2fb9a6067bfe"
      unitRef="usd">2044000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i10b0f55eb1164865bbf902ed106c9883_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjMtMS0xLTEtMA_952ab4f2-aa4d-4bd4-9c20-47c243cb0ba7"
      unitRef="shares">12650000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i10b0f55eb1164865bbf902ed106c9883_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjMtMy0xLTEtMA_2efaf576-6a1b-45e3-b6f6-75d65b69b019"
      unitRef="usd">127000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if320296fd6c04201a11aab2ec6e01e0d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjMtNS0xLTEtMA_b714e720-af91-4e80-a8f3-4809c5ce7288"
      unitRef="usd">136181000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjMtMTMtMS0xLTA_dcf4d1ea-ee79-48f3-9ad6-5b67cf41dc20"
      unitRef="usd">136308000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if320296fd6c04201a11aab2ec6e01e0d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjQtNS0xLTEtMA_0cc101b3-862c-4052-a434-c719ecccb1d6"
      unitRef="usd">19330000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjQtMTMtMS0xLTA_e2b75e1c-089a-4403-9cbf-a02ffe7076f5"
      unitRef="usd">19330000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest
      contextRef="i700728c6360146ffb84d3df9926f1c1b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjUtMTEtMS0xLTA_d3481a2d-13fa-415f-8987-f38b0a128446"
      unitRef="usd">-321000</sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest>
    <sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjUtMTMtMS0xLTA_7192b271-741b-4bac-9840-a8ee5258b3e5"
      unitRef="usd">-321000</sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="if320296fd6c04201a11aab2ec6e01e0d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjYtNS0xLTEtMA_3ee11253-b549-44d3-8a23-aa9194799def"
      unitRef="usd">25000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjYtMTMtMS0xLTA_1033d482-ba7e-41c7-b1a3-aecbea5a9359"
      unitRef="usd">25000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="ib6afa72951bb45c09b9a911552d7f480_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjgtOS0xLTEtMA_b0b048bf-ef7e-4142-9f0e-243b596eabff"
      unitRef="usd">1573000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i700728c6360146ffb84d3df9926f1c1b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjgtMTEtMS0xLTA_7024f64e-633b-4224-ac3d-0222e99d5357"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjgtMTMtMS0xLTA_5f725343-ace5-4260-9000-c756b74136b6"
      unitRef="usd">1573000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="ib6afa72951bb45c09b9a911552d7f480_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjktOS0xLTEtMA_76f4457f-a9d3-4fad-acc0-e4ac9b7a3ce1"
      unitRef="usd">28000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMjktMTMtMS0xLTA_1f0b14ec-2ad0-4d79-b3bd-cabf865d14bb"
      unitRef="usd">28000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ib6afa72951bb45c09b9a911552d7f480_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMzAtOS0xLTEtMA_af373f93-4bb5-48af-9dea-b203d670066c"
      unitRef="usd">592000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMzAtMTMtMS0xLTA_9b2b2ef2-0974-4fc8-aa94-58f1f3f438c0"
      unitRef="usd">592000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="id40d07a651074bf1bafbd2a12252b23a_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMzEtNy0xLTEtMA_7ddf06f1-cc89-4909-a627-9d6e0a77a85d"
      unitRef="usd">-95186000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i700728c6360146ffb84d3df9926f1c1b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMzEtMTEtMS0xLTA_6f38b607-db34-4344-a119-6f81bcd393b2"
      unitRef="usd">-233000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMzEtMTMtMS0xLTA_91d9fae2-fe38-4dfc-b4c7-6e1b63a9e741"
      unitRef="usd">-95419000</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="ife70daa8790b4a53b4ff57301234df5f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMzMtMS0xLTEtMA_8b680394-da43-435c-ade7-a60fdde36d1b"
      unitRef="shares">115972708</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ife70daa8790b4a53b4ff57301234df5f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMzMtMy0xLTEtMA_5fd9fd3e-51b9-476d-b312-c12601b5564a"
      unitRef="usd">1160000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i35c1aa897a6e445787fa8eaaa2d7f0f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMzMtNS0xLTEtMA_2669ba05-c633-494b-9726-3c516f12227f"
      unitRef="usd">1090828000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i30d904a948194419aebb5c1fd3919342_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMzMtNy0xLTEtMA_95cada81-0bff-4618-a562-ecfc34904c6f"
      unitRef="usd">-656985000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i96b90ecaf62c4fada95bd7bb490b3aca_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMzMtOS0xLTEtMA_ae3eab69-8c36-4bfb-a2d8-c09ec9496725"
      unitRef="usd">-2449000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icc3f21983c41481ba4b01cd8667c5b3d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMzMtMTEtMS0xLTA_f2bd4643-955a-4d97-b64b-3c7f09562019"
      unitRef="usd">185000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84Mi9mcmFnOmRjZWI5NDE0NmE4ODQyNTdiM2U0MzViYjdkYWEyZDUxL3RhYmxlOjg0NWFiYmI0MWU5OTQ3MTA4YjEwNGM3NGVlOWUzYzJlL3RhYmxlcmFuZ2U6ODQ1YWJiYjQxZTk5NDcxMDhiMTA0Yzc0ZWU5ZTNjMmVfMzMtMTMtMS0xLTA_c40ca502-52b8-456d-be00-d9f6c2e02425"
      unitRef="usd">432739000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMy0xLTEtMS0w_811df12f-cee1-4726-ba1f-de2f202862b0"
      unitRef="usd">-95419000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMy0zLTEtMS0w_986005e6-077d-4965-bd60-5eef0f90b6ed"
      unitRef="usd">-68889000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMy01LTEtMS0w_74a9231b-4d47-4d9d-a519-f92ad21da9b3"
      unitRef="usd">-54568000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNS0xLTEtMS0w_8bb52861-5c8e-417b-b93e-16ed927dffde"
      unitRef="usd">3930000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNS0zLTEtMS0w_531592d4-0ecb-4356-b6d6-21bcd1b64b28"
      unitRef="usd">2359000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNS01LTEtMS0w_4ddd897e-dbfd-4e05-9d75-8513a9ffb977"
      unitRef="usd">1498000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNi0xLTEtMS0w_8fdff2b5-54ba-4512-bdf9-98711025a9f7"
      unitRef="usd">4708000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNi0zLTEtMS0w_019651cb-7c88-4bfc-a738-2bc23780e01e"
      unitRef="usd">5829000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNi01LTEtMS0w_1035ac04-f722-4c18-9aa3-0f6218c6862d"
      unitRef="usd">673000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <sgmo:AmortizationAndOtherChangesInRightOfUseAssets
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNy0xLTEtMS0xMTM4NA_60d29ed3-b2a5-4225-acad-0c50b25bd3c7"
      unitRef="usd">-5677000</sgmo:AmortizationAndOtherChangesInRightOfUseAssets>
    <sgmo:GainOnFreeShares
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNy0xLTEtMS0xMjE1_7775bff5-b171-4d5d-b6b0-8de376845de6"
      unitRef="usd">488000</sgmo:GainOnFreeShares>
    <sgmo:GainOnFreeShares
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNy0zLTEtMS0xMjE1_14333ac9-5ceb-4c72-90eb-bad596e7154c"
      unitRef="usd">0</sgmo:GainOnFreeShares>
    <sgmo:GainOnFreeShares
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNy01LTEtMS0xMjE1_36c337cc-9686-456f-8a99-f2c761cb8e03"
      unitRef="usd">0</sgmo:GainOnFreeShares>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfOC0xLTEtMS0w_a3254e38-3121-4848-b52a-df58b2ec5abe"
      unitRef="usd">-68000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfOC0zLTEtMS0w_214df1f8-834c-4a0f-885c-89fad0e053bf"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfOC01LTEtMS0w_82a13681-a394-4c1c-94df-805b02ad3b62"
      unitRef="usd">-12000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ShareBasedCompensation
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfOS0xLTEtMS0w_dba63f68-49da-4c02-947f-905c666ffdb9"
      unitRef="usd">19330000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfOS0zLTEtMS0w_2dae782e-d611-4a5e-8be0-39e59e022da2"
      unitRef="usd">14677000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfOS01LTEtMS0w_d1854149-d59b-4ed7-95b7-80405731afb8"
      unitRef="usd">9089000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTItMS0xLTEtMTIxOA_6d0304d4-956e-484c-b500-2ac33b74c35a"
      unitRef="usd">-218000</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTItMy0xLTEtMTIxOA_eea52941-d39a-4a19-aa81-0a2f7e9788ce"
      unitRef="usd">0</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTItNS0xLTEtMTIxOA_01905524-07cf-4b43-9006-5534e099163c"
      unitRef="usd">0</us-gaap:GainLossOnTerminationOfLease>
    <sgmo:BuildToSuitLeases
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTEtMy0xLTEtMA_8a9addbf-9400-44d8-ae66-22a0fc268880"
      unitRef="usd">966000</sgmo:BuildToSuitLeases>
    <sgmo:BuildToSuitLeases
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTEtNS0xLTEtMA_c2936154-517f-4e98-87fa-7de4b588d0c2"
      unitRef="usd">80000</sgmo:BuildToSuitLeases>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTMtMS0xLTEtMA_96b644c5-4e3f-4491-82a9-552495e5c5f6"
      unitRef="usd">307000</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTMtMy0xLTEtMA_4efe77ae-962a-4017-9d49-5da59dd0efc2"
      unitRef="usd">135000</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTMtNS0xLTEtMA_f3e38e0d-59a1-4442-9441-283c31fa1286"
      unitRef="usd">16000</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTQtMS0xLTEtMA_8c28564a-9a13-4075-9e8b-8c67a64355e5"
      unitRef="usd">32236000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTQtMy0xLTEtMA_b9f3417a-b834-4333-b1fb-61fd1df9f376"
      unitRef="usd">1330000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTQtNS0xLTEtMA_746e77d5-2548-4d17-bab5-6e49e453d746"
      unitRef="usd">-1629000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTUtMS0xLTEtMA_d805e982-ec8e-47e7-8999-81962f703839"
      unitRef="usd">6660000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTUtMy0xLTEtMA_ecea793f-5dbc-449b-9e0d-f2d5edf65863"
      unitRef="usd">2828000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTUtNS0xLTEtMA_f486eb07-2105-4d69-bf92-0763a8e58018"
      unitRef="usd">669000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTYtMS0xLTEtMA_68d22552-4728-4e87-9752-c0e622cdc60d"
      unitRef="usd">-4192000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTYtMy0xLTEtMA_b949da49-cd5a-46a4-8945-185175dda685"
      unitRef="usd">-6372000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTYtNS0xLTEtMA_483232fa-dd3d-434c-ad00-305dc9fa2dc1"
      unitRef="usd">3219000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTctMS0xLTEtMA_72aa5d0e-65d5-4231-83cb-01e1c95ccb84"
      unitRef="usd">4129000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTctMy0xLTEtMA_81312912-bdf2-493a-98b5-7a9a79892cb5"
      unitRef="usd">2604000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTctNS0xLTEtMA_ba52d5c7-2f66-4a03-81e1-a0e9567bb8d0"
      unitRef="usd">2594000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTgtMS0xLTEtMA_9efc20f1-ffb8-4181-8669-7435752a4337"
      unitRef="usd">-35693000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTgtMy0xLTEtMA_6982c226-9266-4520-9d65-d59ecb3a2037"
      unitRef="usd">99364000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTgtNS0xLTEtMA_474aa066-784d-4db1-9f02-e3ed50b19fe6"
      unitRef="usd">48984000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <sgmo:IncreaseDecreaseInLongTermPortionOfLeaseLiabilities
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjItMS0xLTEtMTIyNA_8caaace3-e37a-4573-b336-9890a4bee232"
      unitRef="usd">-1800000</sgmo:IncreaseDecreaseInLongTermPortionOfLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTktMS0xLTEtMA_cbf3ec48-f156-4c6e-bedd-fd6ca96707ba"
      unitRef="usd">3749000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTktMy0xLTEtMA_20ec9adf-94ab-4743-8a8e-a3efed2c4634"
      unitRef="usd">1963000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMTktNS0xLTEtMA_fd5ff72c-cd77-4a1d-9267-0ac0e2b87734"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjAtMS0xLTEtMA_48b44caa-7c09-49d0-8ebc-81f5a1abf003"
      unitRef="usd">-144402000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjAtMy0xLTEtMA_12535e62-191e-48c2-83e7-2110ddd5a7da"
      unitRef="usd">36550000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjAtNS0xLTEtMA_6c71fd15-e6a3-4665-b9c9-113ca8817f33"
      unitRef="usd">11179000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjItMS0xLTEtMA_dd7d5e38-f4bb-4757-aa66-617fcb6f39c0"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjItMy0xLTEtMA_ebb6301b-334a-48a4-8e0c-61dd9b00161a"
      unitRef="usd">75647000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjItNS0xLTEtMA_6c7cbe8e-463d-44f3-a5e3-cfa1faf09285"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjMtMS0xLTEtMA_ddfcdd08-1e36-41aa-8309-d116703930fd"
      unitRef="usd">443711000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjMtMy0xLTEtMA_3534f578-c5b5-4da2-b078-72569b627c84"
      unitRef="usd">451239000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjMtNS0xLTEtMA_f38df938-5bda-4640-ad48-e3e3827c2fb4"
      unitRef="usd">252328000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjQtMS0xLTEtMA_854f0fb7-3523-4b37-aa2b-659beac050fe"
      unitRef="usd">404847000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjQtMy0xLTEtMA_87dbfa37-49ca-402f-989b-8be0cd047319"
      unitRef="usd">391845000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjQtNS0xLTEtMA_811272d3-4ce1-402b-a7c6-f1d9423f723c"
      unitRef="usd">178675000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjUtMS0xLTEtMA_6a2102ac-c321-49c8-beaa-02ad5e301f64"
      unitRef="usd">20675000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjUtMy0xLTEtMA_2af3f2e8-0b25-4147-8c8c-cc9009553dcd"
      unitRef="usd">43065000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjUtNS0xLTEtMA_4d37ba41-e9c1-4a78-b57e-6780ba51bd70"
      unitRef="usd">3751000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzAtMS0xLTEtMTIyNw_88845d3a-1a03-40a1-a2c6-21a1d09df916"
      unitRef="usd">262000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzAtMy0xLTEtMTIyNw_19821904-8640-4f58-b33e-44269fa97de1"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzAtNS0xLTEtMTIyNw_99b29f18-ac06-4824-8c5a-2ffcd1caf1b2"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjYtMS0xLTEtMA_de484838-c3c8-45ce-b476-02c19cb1dd18"
      unitRef="usd">-59801000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjYtMy0xLTEtMA_d668c579-668e-43da-ae73-32e060bc2b85"
      unitRef="usd">-178106000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjYtNS0xLTEtMA_a4137d5f-d735-43cb-ac5c-b821af94cfe8"
      unitRef="usd">-77404000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <sgmo:NetProceedsFromIssuancePublicOffering
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjgtMS0xLTEtMA_6fade93b-a52e-43fb-99d8-eb3e2d78f2b2"
      unitRef="usd">136308000</sgmo:NetProceedsFromIssuancePublicOffering>
    <sgmo:NetProceedsFromIssuancePublicOffering
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjgtMy0xLTEtMA_be57582a-5e10-421b-8863-8ccb62481ecf"
      unitRef="usd">215758000</sgmo:NetProceedsFromIssuancePublicOffering>
    <sgmo:NetProceedsFromIssuancePublicOffering
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjgtNS0xLTEtMA_f29dd3db-6b6f-4937-b9ef-00c5b6bad797"
      unitRef="usd">81573000</sgmo:NetProceedsFromIssuancePublicOffering>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjktMS0xLTEtMA_45bee5fd-e350-4c30-b4a4-213ba77e9df6"
      unitRef="usd">422000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjktMy0xLTEtMA_694f813c-2a37-4526-afd4-7a4cadd2380e"
      unitRef="usd">254000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMjktNS0xLTEtMA_6bd95da9-533a-43eb-af6f-b1eef0aed9ab"
      unitRef="usd">654000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzktMS0xLTEtMTEzNzQ_7bd766bd-0d58-42aa-bf7c-37a6c9400da8"
      unitRef="usd">2044000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzktMy0xLTEtMTEzNzc_bd56bd08-a548-4beb-9ffc-75c8afce504a"
      unitRef="usd">1484000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzktNS0xLTEtMTEzODA_dad51edb-3fe9-4f42-a76d-0eb31b66fa98"
      unitRef="usd">818000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzAtMS0xLTEtMA_003ba7d4-b8c8-44db-9d55-b66413299227"
      unitRef="usd">4099000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzAtMy0xLTEtMA_d92e6e34-e977-41c3-8df1-bf7b321d2d21"
      unitRef="usd">14721000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzAtNS0xLTEtMA_a75afde5-c19f-4279-89de-73106fe4049a"
      unitRef="usd">15753000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzEtMS0xLTEtMA_0020d590-daee-4231-9233-47db39b16633"
      unitRef="usd">142029000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzEtMy0xLTEtMA_b85d1139-63c7-43c9-9896-1c2cf138ef66"
      unitRef="usd">231709000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzEtNS0xLTEtMA_dd5ba316-8c70-4f9e-8c51-1434c3e9a139"
      unitRef="usd">97490000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzItMS0xLTEtMA_1842073b-5474-4c04-a7ac-e334715ab6f8"
      unitRef="usd">184000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzItMy0xLTEtMA_216790a1-c210-4c25-abf8-b2a149e79b06"
      unitRef="usd">439000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzItNS0xLTEtMA_48debb3d-af14-4b80-83da-1e9d26dc89d3"
      unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzMtMS0xLTEtMA_69665da1-27e8-4509-b9b7-e5862890f683"
      unitRef="usd">-61990000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzMtMy0xLTEtMA_5c69a110-19f8-42d3-bd8d-899e47c8c864"
      unitRef="usd">90592000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzMtNS0xLTEtMA_890a6a3f-9c69-46a0-97b4-8fe2a837ffbe"
      unitRef="usd">31265000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzQtMS0xLTEtMA_a44e144a-3f52-4e66-9bac-835067d3e75c"
      unitRef="usd">143918000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ieb7e952fbd38434585f995fe73c66a44_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzQtMy0xLTEtMA_08611366-a95c-4bec-9c3a-c44811c7d65e"
      unitRef="usd">53326000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie9057cb83ba040218834cc92910f7361_I20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzQtNS0xLTEtMA_107b779c-e5d6-48e8-a4d8-be1279f68d95"
      unitRef="usd">22061000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzUtMS0xLTEtMA_604d4fae-493f-41d4-b31a-dd639dc0dc1b"
      unitRef="usd">81928000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzUtMy0xLTEtMA_5119056c-b1d7-4d4b-868a-1fff07c93160"
      unitRef="usd">143918000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ieb7e952fbd38434585f995fe73c66a44_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfMzUtNS0xLTEtMA_fb18fbc4-4b5b-45f7-b074-51250e068e49"
      unitRef="usd">53326000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <sgmo:NoncashOrPartNoncashNonControllingInterestAcquisition
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNDctMS0xLTEtMTE2NDc_39d5b103-e71a-4907-9521-28c63f7abbf6"
      unitRef="usd">0</sgmo:NoncashOrPartNoncashNonControllingInterestAcquisition>
    <sgmo:NoncashOrPartNoncashNonControllingInterestAcquisition
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNDctMy0xLTEtMTE2NTk_e2bd67ba-6957-44d8-805d-caf3b480faac"
      unitRef="usd">1313000</sgmo:NoncashOrPartNoncashNonControllingInterestAcquisition>
    <sgmo:NoncashOrPartNoncashNonControllingInterestAcquisition
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNDctNS0xLTEtMTE2Njc_fa5795cd-8cd5-4e08-aeb5-1bb2f53a4a50"
      unitRef="usd">0</sgmo:NoncashOrPartNoncashNonControllingInterestAcquisition>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="id41b3e1cb35b4ad89ad6d22858d66005_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNDgtMS0xLTEtMTE2NDk_12e45b29-4401-4ea1-bbcc-2edae4dfd345"
      unitRef="usd">2114000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ibfc6db4e7428415f9b757be31f7ba5f9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNDgtMy0xLTEtMTE2NjE_ef5c8094-bf42-467f-b780-e98999d6aca2"
      unitRef="usd">4953000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i551b7506aa0a43339495e3e41d87f7ab_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNDgtNS0xLTEtMTE2Njc_691be13b-ce03-4ae4-96eb-0ed4ed10d4c8"
      unitRef="usd">1214000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ib59d1ac11e5d43868c898a5a5456c02a_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNDktMS0xLTEtMTE2NTU_966be2b8-806b-4bd0-9f17-97bde81b2ae1"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i49968469b9074ef393d1c026828923c4_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNDktMy0xLTEtMTE2NjM_29d82a11-089d-4221-a796-e4c0214c84ea"
      unitRef="usd">2950000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i00b9b5a15df54eed86abd682441fe4d1_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNDktNS0xLTEtMTE2Njc_3388ddbc-94a5-4212-b0ca-1151a521fd96"
      unitRef="usd">20793000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNTAtMS0xLTEtMTE2NTc_0b9296dc-7812-4663-a99e-9c2156673a06"
      unitRef="usd">31291000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNTAtMy0xLTEtMTE2NjU_b6c58bca-1ee9-4029-801b-eaef3f72ccca"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF84NS9mcmFnOjhkNDEwNmQxZWVhYjRiYjNhMzlkMzA3YTg2ODAxNmU2L3RhYmxlOjNiZGYyNjY1YWExODQ2N2U4OGViMDE5ZjdmMDA2YmNjL3RhYmxlcmFuZ2U6M2JkZjI2NjVhYTE4NDY3ZTg4ZWIwMTlmN2YwMDZiY2NfNTAtNS0xLTEtMTE2Njc_24760538-eb9b-4b7e-8caa-77690a06a98f"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfMjgzOTg_80451064-f17c-4b4f-a733-8aeda73c5483">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;NOTE 1 &#x2013; ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Business Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Sangamo Therapeutics, Inc. (&#x201c;Sangamo&#x201d; or &#x201c;the Company&#x201d;) was incorporated in the State of Delaware in June 1995 and changed its name from Sangamo Biosciences, Inc. in January 2017. Sangamo is a clinical-stage biotechnology company focused on translating ground-breaking science into genomic medicines with the potential to transform patients&#x2019; lives using our platform technologies in gene therapy, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;ex vivo&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; gene-edited cell therapy, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;in vivo&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; genome editing and &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;in vivo&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; genome regulation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying Consolidated Financial Statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#x201c;U.S.&#160;GAAP&#x201d;) and include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Consolidated Financial Statements. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net loss attributable to &#x2002;non-controlling interests on our Consolidated Statements of Operations equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Going Concern&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Sangamo is currently working on a number of long-term development projects that will involve experimental technology. The projects may require several years and substantial expenditures to complete and ultimately may be unsuccessful. The Company plans to finance operations with available cash resources, collaborations and strategic partnerships funds, research grants and from the issuance of equity or debt securities. Sangamo believes that its available cash, cash equivalents and investments as of December&#160;31, 2019, and expected revenues from collaborations, strategic partnerships and research grants, will be adequate to fund its operations at least through the next 12&#160;months from the date the financial statements are issued. Sangamo will require substantial additional financial resources to complete the development and commercialization of its products including ZFP therapeutic products. Additional capital may not be available on terms acceptable to the Company, or at all. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, the Company&#x2019;s business and ability to develop its technology and therapeutic products would be harmed. Furthermore, any sales of additional equity securities may result in dilution to the Company&#x2019;s stockholders, and any debt financing may include covenants that restrict the Company&#x2019;s business.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Certain prior period amounts in the accompanying Consolidated Financial Statements have been reclassified to conform to the current period presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of the accompanying Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities, including from acquisitions, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. In March 2019, the Company recorded an adjustment to revenue related to a change in estimate in connection with the hemophilia A collaboration agreement with Pfizer Inc. (&#x201c;Pfizer&#x201d;). This adjustment was a direct result of the decision to increase the project scope during the first quarter of 2019 and the corresponding costs, both of which resulted in a decrease in the measure of proportional performance. In December 2019, the Company updated its estimated project cost and related revenues upon the transfer of the investigational new drug (&#x201c;IND&#x201d;) for Pfizer SB-525. This adjustment directly resulted in a decrease in project scope during the fourth quarter of 2019 and a decrease in the corresponding costs, which resulted in an increase in the measure of proportional performance. These adjustments increased revenue by $5.7&#160;million, decreased net loss by $5.7&#160;million and decreased the Company&#x2019;s basic net loss per share by $0.05 for the year ended December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Effective January&#160;1, 2018, the Company adopted the provisions of Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;ASC Topic 606&#x201d;) using the modified retrospective method, resulting in a change to its accounting policy for revenue recognition. ASC Topic 606 establishes a unified model to determine how revenue is recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s contract revenues are derived from collaboration agreements and research activity grants and licensing. Research and licensing agreements typically include upfront signing or license fees, cost reimbursements, research services, minimum sublicense fees, milestone payments and royalties on future licensee&#x2019;s product sales. The Company has both fixed and variable consideration. Non-refundable upfront fees and funding of research and development activities are considered fixed, while milestone payments are generally identified as variable consideration. Sangamo&#x2019;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenues under research grant agreements are generally recognized when the related qualified research expenses are incurred. Deferred revenue represents the portion of research or license payments received but not earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic 606. The Company&#x2019;s performance obligations include license rights, development services and services associated with regulatory submission and approval processes. Revenues from research services earned under collaboration agreements are generally recognized as revenue as the related services are provided. Revenues from non-refundable upfront fees are recognized over time either by measuring progress towards satisfaction of the relevant performance obligation, using the input method (i.e. cumulative actual costs incurred relative to total estimated costs) or on a straight-line basis when a performance obligation is expected to be satisfied evenly over a period of time (or when the entity has a stand-ready obligation). Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement which may include total internal personnel costs and external costs to be incurred as well as, in certain cases, the estimated stand-ready obligation period. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. The estimated period of performance and project costs, such as personnel and manufacturing cost, are reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its deliverables.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Related costs and expenses under these arrangements have historically approximated the revenues recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues from collaboration agreements and research activity grants as a percentage of total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:58.322%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.740%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Pfizer Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Kite Pharma, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Sanofi Genzyme&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Receivables from collaborations are typically unsecured and are concentrated in the biopharmaceutical industry. Accordingly, the Company may be exposed to credit risk generally associated with biopharmaceutical companies or specific to its collaboration agreements. To date, the Company has not experienced any losses related to these receivables.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Funds received from third parties under contract or funds received from grant arrangements are generally recorded as revenue if the Company is deemed to be the principal participant in the arrangements because the activities under the contracts or grants are part of the Company&#x2019;s development programs. Contract funds received are not refundable and are recognized when the related qualified research and development costs are incurred and there is reasonable assurance that the funds will be received. Funds received in advance are recorded as deferred revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accounts for acquisitions using the acquisition method of accounting, which requires that assets acquired, including in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) projects, liabilities assumed and any non-controlling interests in the acquired target in an acquisition be recorded at their fair values as of the acquisition date on the Company&#x2019;s Consolidated Balance Sheets. Any excess of purchase price over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires the Company to make significant estimates and assumptions. As a result, the Company may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Goodwill and Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Goodwill represents the excess of the consideration transferred over the estimated fair values of assets acquired and liabilities assumed in a business combination. Intangible assets with indefinite useful lives are related to purchased IPR&amp;amp;D projects and are measured at their respective fair values as of the acquisition date. Goodwill and intangible assets with indefinite useful lives are not amortized. Intangible assets related to IPR&amp;amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed&#160;finite-lived&#160;and would then be amortized based on their respective estimated useful lives at that point in time. The Company tests goodwill and indefinite-lived intangible assets for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate the fair values of the assets are below their respective carrying amounts. As of December 31, 2019, no impairment of goodwill or indefinite-lived intangible assets has been identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Valuation of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Long-lived assets, including property and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may suggest that the carrying value of an asset may not be recoverable. Recoverability of these assets is measured by comparison of the carrying amount of each asset to the future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. As of December 31, 2019, no impairment of any long-lived assets has been identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short maturities. Marketable securities are stated at their estimated fair values. The free share asset/liability is measured using a binomial-lattice pricing model and is reviewed each reporting period and adjusted, as needed, and is expected to approximate fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;margin-top:15pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Sangamo considers all highly-liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; cash, deposits in demand money market accounts, and commercial paper.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; Restricted cash consists of a letter of credit for $1.5&#160;million as a deposit for the Brisbane lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A reconciliation of cash, cash equivalents and restricted cash reported within the Consolidated Balance Sheets to the amounts reported within the accompanying Consolidated Statements of Cash Flows is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:61.450%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.700%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;140,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Non-current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash, cash equivalents and restricted cash as reported within the Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;81,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;143,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%;"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Sangamo classifies its marketable securities as available-for-sale and records its investments at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in accumulated other comprehensive loss (&#x201c;AOCI&#x201d;). The Company classifies those investments that are not required for use in current operations and that mature in more than 12 months as non-current marketable securities in the accompanying Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s investments are subject to a periodic impairment review. The Company recognizes an impairment charge, if material, when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the fair value has been less than the Company&#x2019;s cost basis, the financial condition and near-term prospects of the investee and the Company&#x2019;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. Realized gains and losses on available-for-sale securities are included in other income, net, which are determined using the specific identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method based on the estimated useful lives of the related assets which is generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfNTczOA_d3889db1-4c3b-4768-aeb6-f18ca1502096"&gt;three&lt;/span&gt; to five years. For leasehold improvements, amortization is calculated using the straight-line method based on the shorter of the useful life or the lease term. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Research and development expenses consist primarily of personnel costs, including salaries, benefits and stock-based compensation, clinical studies performed by contract research organizations ("CROs"), materials and supplies and overhead allocations consisting of various support and facility-related costs.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Research and development costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;General and administrative expenses consist of finance, human resources, legal and other administrative activities. These expenses consist primarily of personnel costs, including salaries, benefits and stock-based compensation, facilities and overhead costs, legal expenses, and other general and administrative costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Stock-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company measures and recognizes compensation expense for all stock-based payment awards made to Sangamo employees and directors, including employee share options, restricted stock units (&#x201c;RSUs&#x201d;) and employee stock purchases related to the 2010 Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;), as amended, based on estimated fair values at the award grant date. The fair value of stock-based awards is amortized over the vesting period of the award using a straight-line method.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;To estimate the fair value of an award, the Company uses the Black-Scholes option pricing model. This model requires inputs such as expected life, expected volatility and risk-free interest rate. These inputs are subjective and generally require significant analysis and judgment to develop. While estimates of expected life and volatility are derived primarily from the Company&#x2019;s historical data, the risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected life assumption. The Company accounts for forfeitures in the period they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Income tax expense has been provided using the liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities as measured by the enacted tax rates that will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets if, based upon the available evidence, it is not more likely than not that the deferred tax assets will be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company recognizes a tax benefit from an&#160;uncertain&#160;tax&#160;position&#160;only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the Company&#x2019;s consolidated financial statements from such positions are measured based on the largest benefit that has a greater than 50% likelihood of being realized. The Company recognizes interest and penalties associated with tax matters as part of the income tax provision and includes accrued interest and penalties with the related income tax liability within account payable and accrued liabilities on its Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%;"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The functional currency of the Company&#x2019;s foreign subsidiaries is primarily the Euro. Assets and liabilities denominated in foreign currencies are translated to U.S. dollars using the exchange rates at the balance sheet date. Foreign currency translation adjustments are recorded as a component of AOCI within stockholders&#x2019; equity. Revenues and expenses from the Company&#x2019;s foreign subsidiaries are translated using the monthly average exchange rates in effect during the period in which the transactions occur. Foreign currency transaction gains and losses are recorded in interest and other income, net, on the Company&#x2019;s Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Basic net loss per share attributable to Sangamo Therapeutics, Inc. stockholders has been computed by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders is calculated by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock plus potential dilutive securities outstanding during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The total number of shares subject to stock options and RSUs outstanding and the ESPP shares reserved for issuance, which are all anti-dilutive, were excluded from consideration in the calculation of diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders. Stock options and RSUs outstanding and ESPP shares reserved for issuance as of December 31, 2019, 2018 and 2017 were 10,750,550, 9,048,793, and 8,367,628, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company operates in one segment. Management uses one measure of profitability and does not segregate its business for internal reporting. As of December&#160;31, 2019 and 2018, substantially all of the Company&#x2019;s assets were maintained in the United States. For the years ended December&#160;31, 2019, 2018 and 2017, substantially all of the Company&#x2019;s revenues and operating expenses were generated and incurred in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Simplified Disclosure&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2018, the Securities and Exchange Commission ("SEC") adopted amendments to certain disclosure requirements in Securities Act Release No.&#160;33-10532, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Disclosure Update and Simplification&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, as updated. These amendments eliminate, modify, or integrate into other SEC requirements certain disclosure rules. Among the amendments is the requirement to present an analysis of changes in stockholders&#x2019; equity in the interim financial statements included in quarterly reports on Form 10-Q. The analysis, which can be presented as a footnote or separate statement, is required for the current and comparative quarter and year-to-date interim periods. The amendments are effective for all filings made on or after November&#160;5, 2018. The Company&#x2019;s adoption of these SEC amendments had no material effect on the Company&#x2019;s reporting of financial position, results of operations, cash flows or stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Accounting for Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU 2016-2, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Leases&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;ASC Topic 842&#x201d;). ASC Topic 842 amends a number of aspects of lease accounting, including requiring lessees to recognize almost all leases with a term greater than one year as a right-of-use (&#x201c;ROU&#x201d;) asset and corresponding liability, measured at the present value of the lease payments. On January&#160;1, 2019, the Company adopted ASC Topic 842 using the modified retrospective &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;approach with a cumulative-effect adjustment of $0.9 million reflected as a decrease to the opening balance of accumulated deficit as of the adoption date. Results for the year ended December&#160;31, 2019 are presented under ASC Topic 842. No prior period amounts were adjusted and continue to be reported in accordance with previous lease guidance, ASC Topic 840 &#x2013; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Leases&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;ASC Topic 840&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;ASC Topic 842 provides a number of optional practical expedients in transition. The Company elected the practical expedients to not reassess its prior conclusions about lease identification under the new standard, to not reassess lease classification, and to not reassess initial direct costs. The Company did not elect the practical expedient allowing the use-of-hindsight, which would require the Company to reassess the lease term of its leases based on all facts and circumstances through the effective date. The Company also did not elect the practical expedient pertaining to land easements, as this is not applicable to the current contract portfolio.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The impact of the adoption of ASC Topic 842 on the accompanying Consolidated Balance Sheet as of January&#160;1, 2019 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:60.352%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.617%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.794%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.682%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.620%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Adjustments Due to the Adoption of ASC Topic 842&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;78,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(62,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid rent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Operating lease liabilities - current&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Deferred rent&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(271)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Build-to-suit lease obligation&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(27,689)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Operating lease liabilities - long-term&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accumulated deficit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(562,696)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(561,799)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;___________________&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-36pt;padding-left:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;(1)&#160;Operating lease liabilities &#x2013; current and deferred rent are included in accounts payable and accrued liabilities on the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-36pt;padding-left:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;(2)&#160;Build-to-suit lease obligation and operating lease liabilities &#x2013; long-term are included in long-term portion of lease liabilities on the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The adjustments due to the adoption of ASC Topic 842 primarily related to the recognition of operating lease ROU assets and operating lease liabilities for the Company&#x2019;s leases. In addition, the adoption of ASC Topic 842 resulted in a change in accounting of the build-to-suit component of two leases under ASC Topic 840 to operating leases under ASC Topic 842. As a result, the Company derecognized the estimated fair value of the building shells that were included in Property and equipment, net as of December&#160;31, 2018, as the Company had been deemed to own these buildings under ASC Topic 840. For a description of the leases, see &#x201c;Note 7 &#x2013; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Commitments and Contingencies &#x2013; Leases&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x201d; in these Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In November 2018, the FASB issued ASU 2018-18, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Collaborative Arrangements (ASC Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;ASC Topic 808&#x201d;), which clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC Topic 606 when the counterparty is a customer. In addition, ASC Topic 808 precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. This guidance will be effective for the Company beginning January&#160;1, 2020. The Company has determined the adoption of ASU 2018-18 will not have a material impact on its Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Goodwill Impairment Testing&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In January 2017, the FASB issued ASU No. 2017-4,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt; Intangibles &#x2013; Goodwill and Other (Topic 350): Simplifying the Test of Goodwill Impairment&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;ASU 2017-4&#x201d;). The new guidance simplifies the subsequent measurement of goodwill by eliminating Step 2 from the goodwill impairment test. ASU 2017-4 requires goodwill impairment to be measured as the amount by which a reporting unit&#x2019;s carrying amount exceeds its fair value, not to exceed the carrying amount of its goodwill. ASU &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;2017-4 requires prospective application and is effective for annual periods beginning after December&#160;15, 2019. ASU 2017-4 will require the Company to amend its methodology for determining any goodwill impairment beginning in 2020. The Company does not expect the adoption of ASU 2017-4 to have a material impact on its Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Financial Instruments &#x2013; Credit Losses (Topic 326)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; ("ASU 2016-13"). ASU 2016-13 implements an impairment model, known as the current expected credit loss model that is based on expected losses rather than incurred losses. Under the new guidance, an entity will recognize as an allowance its estimate of expected credit losses. ASU 2016-13 is effective for all interim and annual reporting periods beginning after December 15, 2019 and must be adopted using a modified retrospective approach, with certain exceptions. Early adoption is permitted. The Company does not expect the adoption of ASU 2016-13 to have a material impact on its Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Income Taxes &#x2013; Simplifying the Accounting for Income Taxes &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;(&#x201c;ASU 2019-12&#x201d;). The guidance removes exceptions to the general principles in &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Income Taxes&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;(Topic 740)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; for allocating tax expense between financial statement components, accounting basis differences stemming from an ownership change in foreign investments and interim period income tax accounting for year-to-date losses that exceed projected losses. The guidance becomes effective for annual reporting periods beginning after December 15, 2020 and interim periods within those fiscal years with early adoption permitted. The Company plans to adopt ASU 2019-12 effective January 1, 2020 and does not expect this adoption to have a material impact on its Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfMjgzOTM_f432e0c8-a930-4900-b20f-643c6cbfd8a8">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying Consolidated Financial Statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#x201c;U.S.&#160;GAAP&#x201d;) and include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Consolidated Financial Statements. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net loss attributable to &#x2002;non-controlling interests on our Consolidated Statements of Operations equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfNzY5NjU4MTQ4NTk4OA_035b3e5a-c337-4e08-8f06-98fddce39636">&lt;div style="padding-left:18pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Certain prior period amounts in the accompanying Consolidated Financial Statements have been reclassified to conform to the current period presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:UseOfEstimates
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfODI0NjMzNzQwODU3MA_ab6a5604-dc6c-4bb6-adbc-daa94c7b78f9">Use of EstimatesThe preparation of the accompanying Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities, including from acquisitions, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. In March 2019, the Company recorded an adjustment to revenue related to a change in estimate in connection with the hemophilia A collaboration agreement with Pfizer Inc. (&#x201c;Pfizer&#x201d;). This adjustment was a direct result of the decision to increase the project scope during the first quarter of 2019 and the corresponding costs, both of which resulted in a decrease in the measure of proportional performance. In December 2019, the Company updated its estimated project cost and related revenues upon the transfer of the investigational new drug (&#x201c;IND&#x201d;) for Pfizer SB-525. This adjustment directly resulted in a decrease in project scope during the fourth quarter of 2019 and a decrease in the corresponding costs, which resulted in an increase in the measure of proportional performance.</us-gaap:UseOfEstimates>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i45cd48c8f1eb454abb081e66040be393_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfODc5NjA5MzE5OTM3NQ_262f942f-4a0c-42db-aa9f-0cc8526e6713"
      unitRef="usd">5700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ProfitLoss
      contextRef="i45cd48c8f1eb454abb081e66040be393_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfODc5NjA5MzE5OTM4MQ_9e47b02f-3845-4510-b73f-1056f875555d"
      unitRef="usd">5700000</us-gaap:ProfitLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i45cd48c8f1eb454abb081e66040be393_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfODc5NjA5MzE5OTM4OA_51eb7fa0-dc31-4b78-b5d8-884e11836545"
      unitRef="usdPerShare">0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfODI0NjMzNzQwODU3MQ_b6d0adfe-e1cc-4e1c-949b-e23cc3c51a98">&lt;div style="text-indent:18pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Effective January&#160;1, 2018, the Company adopted the provisions of Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;ASC Topic 606&#x201d;) using the modified retrospective method, resulting in a change to its accounting policy for revenue recognition. ASC Topic 606 establishes a unified model to determine how revenue is recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s contract revenues are derived from collaboration agreements and research activity grants and licensing. Research and licensing agreements typically include upfront signing or license fees, cost reimbursements, research services, minimum sublicense fees, milestone payments and royalties on future licensee&#x2019;s product sales. The Company has both fixed and variable consideration. Non-refundable upfront fees and funding of research and development activities are considered fixed, while milestone payments are generally identified as variable consideration. Sangamo&#x2019;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenues under research grant agreements are generally recognized when the related qualified research expenses are incurred. Deferred revenue represents the portion of research or license payments received but not earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic 606. The Company&#x2019;s performance obligations include license rights, development services and services associated with regulatory submission and approval processes. Revenues from research services earned under collaboration agreements are generally recognized as revenue as the related services are provided. Revenues from non-refundable upfront fees are recognized over time either by measuring progress towards satisfaction of the relevant performance obligation, using the input method (i.e. cumulative actual costs incurred relative to total estimated costs) or on a straight-line basis when a performance obligation is expected to be satisfied evenly over a period of time (or when the entity has a stand-ready obligation). Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement which may include total internal personnel costs and external costs to be incurred as well as, in certain cases, the estimated stand-ready obligation period. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. The estimated period of performance and project costs, such as personnel and manufacturing cost, are reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its deliverables.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Related costs and expenses under these arrangements have historically approximated the revenues recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Receivables from collaborations are typically unsecured and are concentrated in the biopharmaceutical industry. Accordingly, the Company may be exposed to credit risk generally associated with biopharmaceutical companies or specific to its collaboration agreements. To date, the Company has not experienced any losses related to these receivables.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Funds received from third parties under contract or funds received from grant arrangements are generally recorded as revenue if the Company is deemed to be the principal participant in the arrangements because the activities under the contracts or grants are part of the Company&#x2019;s development programs. Contract funds received are not refundable and are recognized when the related qualified research and development costs are incurred and there is reasonable assurance that the funds will be received. Funds received in advance are recorded as deferred revenue.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfODI0NjMzNzQwODU4MQ_dc7f700d-296e-4613-baaa-9e887ae6e69f">&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues from collaboration agreements and research activity grants as a percentage of total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:58.322%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.740%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Pfizer Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Kite Pharma, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Sanofi Genzyme&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if75e5c9704ce446986262d7c7d8c3fab_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjI3MTVhOTFiZTY2YTQxNWE4OTQ4N2IwM2FkMDJkMjJjL3RhYmxlcmFuZ2U6MjcxNWE5MWJlNjZhNDE1YTg5NDg3YjAzYWQwMmQyMmNfMi0xLTEtMS0xMDc3Nw_a601b464-be77-407e-8add-b2a27dc707b9"
      unitRef="number">0.40</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0e56cd6c5fb74bd3a43294ab0e9b6330_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjI3MTVhOTFiZTY2YTQxNWE4OTQ4N2IwM2FkMDJkMjJjL3RhYmxlcmFuZ2U6MjcxNWE5MWJlNjZhNDE1YTg5NDg3YjAzYWQwMmQyMmNfMi0zLTEtMS0xMDc3Nw_b132aabf-d1ab-4233-b384-9b9b9f6c2dcb"
      unitRef="number">0.47</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id1d7fbe1eb014de78444bda067a30d18_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjI3MTVhOTFiZTY2YTQxNWE4OTQ4N2IwM2FkMDJkMjJjL3RhYmxlcmFuZ2U6MjcxNWE5MWJlNjZhNDE1YTg5NDg3YjAzYWQwMmQyMmNfMi01LTEtMS0xMDc3Nw_8eb10019-3843-4ce0-80ae-856c9347956b"
      unitRef="number">0.47</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ifeac1a9c1b7f4146b761b39496879f94_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjI3MTVhOTFiZTY2YTQxNWE4OTQ4N2IwM2FkMDJkMjJjL3RhYmxlcmFuZ2U6MjcxNWE5MWJlNjZhNDE1YTg5NDg3YjAzYWQwMmQyMmNfMy0xLTEtMS0xMDc3Nw_b126cc00-69df-4900-a365-6e6777e302cb"
      unitRef="number">0.34</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icf0e324d5bd3407ea444f76424db9da6_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjI3MTVhOTFiZTY2YTQxNWE4OTQ4N2IwM2FkMDJkMjJjL3RhYmxlcmFuZ2U6MjcxNWE5MWJlNjZhNDE1YTg5NDg3YjAzYWQwMmQyMmNfMy0zLTEtMS0xMDc3Nw_e4637922-a3ee-46b5-a514-d73959a7b668"
      unitRef="number">0.30</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0028bf4ff4f2447683894820f58ee41f_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjI3MTVhOTFiZTY2YTQxNWE4OTQ4N2IwM2FkMDJkMjJjL3RhYmxlcmFuZ2U6MjcxNWE5MWJlNjZhNDE1YTg5NDg3YjAzYWQwMmQyMmNfNC0xLTEtMS0xMDc3Nw_4b5eb01e-32b2-4057-b704-7d3bfed3012c"
      unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i09768b80227d4cb4a5a55bae2bc04a19_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjI3MTVhOTFiZTY2YTQxNWE4OTQ4N2IwM2FkMDJkMjJjL3RhYmxlcmFuZ2U6MjcxNWE5MWJlNjZhNDE1YTg5NDg3YjAzYWQwMmQyMmNfNC0zLTEtMS0xMDc3Nw_1f3f71fb-9af8-4842-9a8e-75aec63392eb"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia9d921a5d8f94da6821ac519170255b3_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjI3MTVhOTFiZTY2YTQxNWE4OTQ4N2IwM2FkMDJkMjJjL3RhYmxlcmFuZ2U6MjcxNWE5MWJlNjZhNDE1YTg5NDg3YjAzYWQwMmQyMmNfNC01LTEtMS0xMDc3Nw_ceb2a797-bfb6-408f-a365-015b6e7c5e15"
      unitRef="number">0.34</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfMjgzOTQ_fc9c7ea5-ca07-4674-b41c-2d1b55a13d63">&lt;div style="padding-left:18pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accounts for acquisitions using the acquisition method of accounting, which requires that assets acquired, including in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) projects, liabilities assumed and any non-controlling interests in the acquired target in an acquisition be recorded at their fair values as of the acquisition date on the Company&#x2019;s Consolidated Balance Sheets. Any excess of purchase price over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires the Company to make significant estimates and assumptions. As a result, the Company may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfODI0NjMzNzQwODU3Mw_bed72a73-3b5a-42e4-a5f8-216a3808ff9a">&lt;div style="padding-left:18pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Goodwill and Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Goodwill represents the excess of the consideration transferred over the estimated fair values of assets acquired and liabilities assumed in a business combination. Intangible assets with indefinite useful lives are related to purchased IPR&amp;amp;D projects and are measured at their respective fair values as of the acquisition date. Goodwill and intangible assets with indefinite useful lives are not amortized. Intangible assets related to IPR&amp;amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed&#160;finite-lived&#160;and would then be amortized based on their respective estimated useful lives at that point in time. The Company tests goodwill and indefinite-lived intangible assets for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate the fair values of the assets are below their respective carrying amounts. As of December 31, 2019, no impairment of goodwill or indefinite-lived intangible assets has been identified.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfODI0NjMzNzQwODU3NA_88e7d175-2e7f-4ec5-a744-6e2b39a1a0fb">&lt;div style="padding-left:18pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Valuation of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Long-lived assets, including property and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may suggest that the carrying value of an asset may not be recoverable. Recoverability of these assets is measured by comparison of the carrying amount of each asset to the future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. As of December 31, 2019, no impairment of any long-lived assets has been identified.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfODI0NjMzNzQwODU3NQ_bb8a1a5d-446d-49bc-a999-d807b63e7b86">&lt;div style="text-indent:22.5pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short maturities. Marketable securities are stated at their estimated fair values. The free share asset/liability is measured using a binomial-lattice pricing model and is reviewed each reporting period and adjusted, as needed, and is expected to approximate fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfODI0NjMzNzQwODU3Ng_55ce7654-c834-40ce-bd0c-8a2c4a6a83a6">Cash, Cash Equivalents and Restricted Cash&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Sangamo considers all highly-liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; cash, deposits in demand money market accounts, and commercial paper.&lt;/span&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfMTA0NDUzNjA2MjExODU_16b018e8-6cac-44d5-a0b0-62edac88b19b"
      unitRef="usd">1500000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfODI0NjMzNzQwODU4Mg_95aab638-e17b-464f-ba81-4e2566cfe61e">&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A reconciliation of cash, cash equivalents and restricted cash reported within the Consolidated Balance Sheets to the amounts reported within the accompanying Consolidated Statements of Cash Flows is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:61.450%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.700%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;140,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Non-current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash, cash equivalents and restricted cash as reported within the Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;81,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;143,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfODI0NjMzNzQwODU4Mw_5fef88be-4f1c-4b54-9838-95c81710747b">&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A reconciliation of cash, cash equivalents and restricted cash reported within the Consolidated Balance Sheets to the amounts reported within the accompanying Consolidated Statements of Cash Flows is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:61.450%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.700%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;140,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Non-current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash, cash equivalents and restricted cash as reported within the Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;81,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;143,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjc2ODk3Nzg3ZjE4YjRjYTBiYmY4MTVlODYyZGQ2ZjQ4L3RhYmxlcmFuZ2U6NzY4OTc3ODdmMThiNGNhMGJiZjgxNWU4NjJkZDZmNDhfMi0xLTEtMS0xMTI3OQ_3bcaa95b-2ae1-457b-b73b-d429fc896589"
      unitRef="usd">80428000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjc2ODk3Nzg3ZjE4YjRjYTBiYmY4MTVlODYyZGQ2ZjQ4L3RhYmxlcmFuZ2U6NzY4OTc3ODdmMThiNGNhMGJiZjgxNWU4NjJkZDZmNDhfMi0zLTEtMS0xMTI3OQ_1f2f052e-66fb-4915-9fd3-03c9f056a997"
      unitRef="usd">140418000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="ieb7e952fbd38434585f995fe73c66a44_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjc2ODk3Nzg3ZjE4YjRjYTBiYmY4MTVlODYyZGQ2ZjQ4L3RhYmxlcmFuZ2U6NzY4OTc3ODdmMThiNGNhMGJiZjgxNWU4NjJkZDZmNDhfMi01LTEtMS0xMTI3OQ_db234c3a-da5c-4a27-b477-33c8dc35bafb"
      unitRef="usd">49826000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjc2ODk3Nzg3ZjE4YjRjYTBiYmY4MTVlODYyZGQ2ZjQ4L3RhYmxlcmFuZ2U6NzY4OTc3ODdmMThiNGNhMGJiZjgxNWU4NjJkZDZmNDhfNC0xLTEtMS0xMTI3OQ_6f3b5fb6-51fa-47aa-b9cf-c943a34a5dc8"
      unitRef="usd">1500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjc2ODk3Nzg3ZjE4YjRjYTBiYmY4MTVlODYyZGQ2ZjQ4L3RhYmxlcmFuZ2U6NzY4OTc3ODdmMThiNGNhMGJiZjgxNWU4NjJkZDZmNDhfNC0zLTEtMS0xMTI3OQ_55dfa4d9-35b9-4520-a0b4-7cae2e8f81c5"
      unitRef="usd">3500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="ieb7e952fbd38434585f995fe73c66a44_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjc2ODk3Nzg3ZjE4YjRjYTBiYmY4MTVlODYyZGQ2ZjQ4L3RhYmxlcmFuZ2U6NzY4OTc3ODdmMThiNGNhMGJiZjgxNWU4NjJkZDZmNDhfNC01LTEtMS0xMTI3OQ_c45df9c2-722d-4400-8a2d-1ac0858a6244"
      unitRef="usd">3500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjc2ODk3Nzg3ZjE4YjRjYTBiYmY4MTVlODYyZGQ2ZjQ4L3RhYmxlcmFuZ2U6NzY4OTc3ODdmMThiNGNhMGJiZjgxNWU4NjJkZDZmNDhfNS0xLTEtMS0xMTI3OQ_7d5306f7-15b2-4d10-ac1c-ada6715b6f64"
      unitRef="usd">81928000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjc2ODk3Nzg3ZjE4YjRjYTBiYmY4MTVlODYyZGQ2ZjQ4L3RhYmxlcmFuZ2U6NzY4OTc3ODdmMThiNGNhMGJiZjgxNWU4NjJkZDZmNDhfNS0zLTEtMS0xMTI3OQ_9e003e3c-3957-4d43-8172-a179a7facb9d"
      unitRef="usd">143918000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ieb7e952fbd38434585f995fe73c66a44_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjc2ODk3Nzg3ZjE4YjRjYTBiYmY4MTVlODYyZGQ2ZjQ4L3RhYmxlcmFuZ2U6NzY4OTc3ODdmMThiNGNhMGJiZjgxNWU4NjJkZDZmNDhfNS01LTEtMS0xMTI3OQ_a8d2686e-e3ae-4ad5-884b-7b0fccc462ea"
      unitRef="usd">53326000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfMjgzOTk_512dc31d-655b-4f4f-9dba-1de3ae9deed2">&lt;div style="text-indent:18pt;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%;"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Sangamo classifies its marketable securities as available-for-sale and records its investments at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in accumulated other comprehensive loss (&#x201c;AOCI&#x201d;). The Company classifies those investments that are not required for use in current operations and that mature in more than 12 months as non-current marketable securities in the accompanying Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s investments are subject to a periodic impairment review. The Company recognizes an impairment charge, if material, when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the fair value has been less than the Company&#x2019;s cost basis, the financial condition and near-term prospects of the investee and the Company&#x2019;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. Realized gains and losses on available-for-sale securities are included in other income, net, which are determined using the specific identification method.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfMjgzODE_ac3caacc-fa0d-481a-8abe-8b6303df1800">&lt;div style="padding-left:18pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method based on the estimated useful lives of the related assets which is generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfNTczOA_d3889db1-4c3b-4768-aeb6-f18ca1502096"&gt;three&lt;/span&gt; to five years. For leasehold improvements, amortization is calculated using the straight-line method based on the shorter of the useful life or the lease term. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i213fcfde123a4b9abd25cc2767af7914_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfNTc0NA_7a076fad-ab1f-46bf-862a-74b9fa52bc21">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfMjgzODI_e02f7fb5-15ad-4edb-9786-8a431a73e274">&lt;div style="padding-left:18pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Research and development expenses consist primarily of personnel costs, including salaries, benefits and stock-based compensation, clinical studies performed by contract research organizations ("CROs"), materials and supplies and overhead allocations consisting of various support and facility-related costs.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Research and development costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfODI0NjMzNzQwODU3Nw_f66b35f0-51c7-40d0-81cc-a264f6c28767">&lt;div style="padding-left:18pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;General and administrative expenses consist of finance, human resources, legal and other administrative activities. These expenses consist primarily of personnel costs, including salaries, benefits and stock-based compensation, facilities and overhead costs, legal expenses, and other general and administrative costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfMjgzODc_b8ad13ed-8bfb-4016-adf5-17263304d178">&lt;div style="padding-left:18pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Stock-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company measures and recognizes compensation expense for all stock-based payment awards made to Sangamo employees and directors, including employee share options, restricted stock units (&#x201c;RSUs&#x201d;) and employee stock purchases related to the 2010 Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;), as amended, based on estimated fair values at the award grant date. The fair value of stock-based awards is amortized over the vesting period of the award using a straight-line method.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;To estimate the fair value of an award, the Company uses the Black-Scholes option pricing model. This model requires inputs such as expected life, expected volatility and risk-free interest rate. These inputs are subjective and generally require significant analysis and judgment to develop. While estimates of expected life and volatility are derived primarily from the Company&#x2019;s historical data, the risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected life assumption. The Company accounts for forfeitures in the period they occur.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfODI0NjMzNzQwODU3OA_fdf581e3-06d3-47dd-a6c4-77616a9f47c2">&lt;div style="padding-left:18pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Income tax expense has been provided using the liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities as measured by the enacted tax rates that will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets if, based upon the available evidence, it is not more likely than not that the deferred tax assets will be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company recognizes a tax benefit from an&#160;uncertain&#160;tax&#160;position&#160;only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the Company&#x2019;s consolidated financial statements from such positions are measured based on the largest benefit that has a greater than 50% likelihood of being realized. The Company recognizes interest and penalties associated with tax matters as part of the income tax provision and includes accrued interest and penalties with the related income tax liability within account payable and accrued liabilities on its Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfMjgzODg_06df22c8-05c2-49e9-89a7-1e9c726bf865">&lt;div style="padding-left:18pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%;"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The functional currency of the Company&#x2019;s foreign subsidiaries is primarily the Euro. Assets and liabilities denominated in foreign currencies are translated to U.S. dollars using the exchange rates at the balance sheet date. Foreign currency translation adjustments are recorded as a component of AOCI within stockholders&#x2019; equity. Revenues and expenses from the Company&#x2019;s foreign subsidiaries are translated using the monthly average exchange rates in effect during the period in which the transactions occur. Foreign currency transaction gains and losses are recorded in interest and other income, net, on the Company&#x2019;s Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfODI0NjMzNzQwODU3OQ_a07d0ac6-86b6-47dc-9201-17fdfad38a15">&lt;div style="padding-left:18pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Basic net loss per share attributable to Sangamo Therapeutics, Inc. stockholders has been computed by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders is calculated by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock plus potential dilutive securities outstanding during the period.&lt;/span&gt;&lt;/div&gt;The total number of shares subject to stock options and RSUs outstanding and the ESPP shares reserved for issuance, which are all anti-dilutive, were excluded from consideration in the calculation of diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders.</us-gaap:EarningsPerSharePolicyTextBlock>
    <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfMjEyNTM_a561c564-4569-4731-b392-2827c61434e7"
      unitRef="shares">10750550</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber>
    <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfMjEyNTc_b73d24a7-4066-4c1e-925a-6f4a80a133eb"
      unitRef="shares">9048793</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber>
    <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber
      contextRef="ieb7e952fbd38434585f995fe73c66a44_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfMjEyNjU_84dc8bf2-fcdc-4781-8f80-9f6c04c0bc50"
      unitRef="shares">8367628</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfODI0NjMzNzQwODU4MA_8a7d002f-25b0-4e4e-aea3-afcc75168ab5">SegmentsThe Company operates in one segment. Management uses one measure of profitability and does not segregate its business for internal reporting.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfMjEzMTY_80bc33c5-630a-4039-a374-02aef45fedce"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfMjgzOTE_82940aea-96ff-4b0d-9e27-d030707b4984">&lt;div style="text-indent:18pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Simplified Disclosure&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2018, the Securities and Exchange Commission ("SEC") adopted amendments to certain disclosure requirements in Securities Act Release No.&#160;33-10532, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Disclosure Update and Simplification&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, as updated. These amendments eliminate, modify, or integrate into other SEC requirements certain disclosure rules. Among the amendments is the requirement to present an analysis of changes in stockholders&#x2019; equity in the interim financial statements included in quarterly reports on Form 10-Q. The analysis, which can be presented as a footnote or separate statement, is required for the current and comparative quarter and year-to-date interim periods. The amendments are effective for all filings made on or after November&#160;5, 2018. The Company&#x2019;s adoption of these SEC amendments had no material effect on the Company&#x2019;s reporting of financial position, results of operations, cash flows or stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Accounting for Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU 2016-2, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Leases&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;ASC Topic 842&#x201d;). ASC Topic 842 amends a number of aspects of lease accounting, including requiring lessees to recognize almost all leases with a term greater than one year as a right-of-use (&#x201c;ROU&#x201d;) asset and corresponding liability, measured at the present value of the lease payments. On January&#160;1, 2019, the Company adopted ASC Topic 842 using the modified retrospective &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;approach with a cumulative-effect adjustment of $0.9 million reflected as a decrease to the opening balance of accumulated deficit as of the adoption date. Results for the year ended December&#160;31, 2019 are presented under ASC Topic 842. No prior period amounts were adjusted and continue to be reported in accordance with previous lease guidance, ASC Topic 840 &#x2013; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Leases&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;ASC Topic 840&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;ASC Topic 842 provides a number of optional practical expedients in transition. The Company elected the practical expedients to not reassess its prior conclusions about lease identification under the new standard, to not reassess lease classification, and to not reassess initial direct costs. The Company did not elect the practical expedient allowing the use-of-hindsight, which would require the Company to reassess the lease term of its leases based on all facts and circumstances through the effective date. The Company also did not elect the practical expedient pertaining to land easements, as this is not applicable to the current contract portfolio.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The impact of the adoption of ASC Topic 842 on the accompanying Consolidated Balance Sheet as of January&#160;1, 2019 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:60.352%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.617%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.794%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.682%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.620%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Adjustments Due to the Adoption of ASC Topic 842&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;78,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(62,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid rent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Operating lease liabilities - current&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Deferred rent&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(271)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Build-to-suit lease obligation&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(27,689)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Operating lease liabilities - long-term&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accumulated deficit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(562,696)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(561,799)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;___________________&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-36pt;padding-left:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;(1)&#160;Operating lease liabilities &#x2013; current and deferred rent are included in accounts payable and accrued liabilities on the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-36pt;padding-left:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;(2)&#160;Build-to-suit lease obligation and operating lease liabilities &#x2013; long-term are included in long-term portion of lease liabilities on the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The adjustments due to the adoption of ASC Topic 842 primarily related to the recognition of operating lease ROU assets and operating lease liabilities for the Company&#x2019;s leases. In addition, the adoption of ASC Topic 842 resulted in a change in accounting of the build-to-suit component of two leases under ASC Topic 840 to operating leases under ASC Topic 842. As a result, the Company derecognized the estimated fair value of the building shells that were included in Property and equipment, net as of December&#160;31, 2018, as the Company had been deemed to own these buildings under ASC Topic 840. For a description of the leases, see &#x201c;Note 7 &#x2013; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Commitments and Contingencies &#x2013; Leases&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x201d; in these Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In November 2018, the FASB issued ASU 2018-18, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Collaborative Arrangements (ASC Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;ASC Topic 808&#x201d;), which clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC Topic 606 when the counterparty is a customer. In addition, ASC Topic 808 precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. This guidance will be effective for the Company beginning January&#160;1, 2020. The Company has determined the adoption of ASU 2018-18 will not have a material impact on its Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Goodwill Impairment Testing&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In January 2017, the FASB issued ASU No. 2017-4,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt; Intangibles &#x2013; Goodwill and Other (Topic 350): Simplifying the Test of Goodwill Impairment&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;ASU 2017-4&#x201d;). The new guidance simplifies the subsequent measurement of goodwill by eliminating Step 2 from the goodwill impairment test. ASU 2017-4 requires goodwill impairment to be measured as the amount by which a reporting unit&#x2019;s carrying amount exceeds its fair value, not to exceed the carrying amount of its goodwill. ASU &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;2017-4 requires prospective application and is effective for annual periods beginning after December&#160;15, 2019. ASU 2017-4 will require the Company to amend its methodology for determining any goodwill impairment beginning in 2020. The Company does not expect the adoption of ASU 2017-4 to have a material impact on its Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Financial Instruments &#x2013; Credit Losses (Topic 326)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; ("ASU 2016-13"). ASU 2016-13 implements an impairment model, known as the current expected credit loss model that is based on expected losses rather than incurred losses. Under the new guidance, an entity will recognize as an allowance its estimate of expected credit losses. ASU 2016-13 is effective for all interim and annual reporting periods beginning after December 15, 2019 and must be adopted using a modified retrospective approach, with certain exceptions. Early adoption is permitted. The Company does not expect the adoption of ASU 2016-13 to have a material impact on its Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Income Taxes &#x2013; Simplifying the Accounting for Income Taxes &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;(&#x201c;ASU 2019-12&#x201d;). The guidance removes exceptions to the general principles in &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Income Taxes&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;(Topic 740)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; for allocating tax expense between financial statement components, accounting basis differences stemming from an ownership change in foreign investments and interim period income tax accounting for year-to-date losses that exceed projected losses. The guidance becomes effective for annual reporting periods beginning after December 15, 2020 and interim periods within those fiscal years with early adoption permitted. The Company plans to adopt ASU 2019-12 effective January 1, 2020 and does not expect this adoption to have a material impact on its Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="ie5649d96e1864877aaa84d3a06395606_I20190101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfNzY5NjU4MTQ4NTk5Mw_b90c09f3-9a69-44d3-910f-0c9105b94fb4"
      unitRef="usd">-900000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfNzY5NjU4MTQ4NTk5MA_92b61914-9fbb-4a2d-a1d3-f39e5827e87e">&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The impact of the adoption of ASC Topic 842 on the accompanying Consolidated Balance Sheet as of January&#160;1, 2019 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:60.352%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.617%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.794%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.682%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.620%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Adjustments Due to the Adoption of ASC Topic 842&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;78,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(62,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid rent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Operating lease liabilities - current&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Deferred rent&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(271)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Build-to-suit lease obligation&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(27,689)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Operating lease liabilities - long-term&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accumulated deficit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(562,696)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(561,799)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;___________________&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-36pt;padding-left:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;(1)&#160;Operating lease liabilities &#x2013; current and deferred rent are included in accounts payable and accrued liabilities on the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-36pt;padding-left:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;(2)&#160;Build-to-suit lease obligation and operating lease liabilities &#x2013; long-term are included in long-term portion of lease liabilities on the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfMS0xLTEtMS00MDM1_752df9ec-8818-4034-ba25-65181c0ead27"
      unitRef="usd">78723000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ifb9ede9189214fb0ba40172a1dbc591a_I20190101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfMS0zLTEtMS00MDMy_e61ae70a-e449-4e17-87e4-a364407140e8"
      unitRef="usd">-62500000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i3f20aa798c164804836d3c58f6e64322_I20190101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfMS01LTEtMS00MDI5_39a83626-d1f4-4b90-9fb5-9821d42b7ac2"
      unitRef="usd">16223000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfMi0xLTEtMS00MDM1_01e432da-f057-4013-929f-26b180d4d3b6"
      unitRef="usd">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ifb9ede9189214fb0ba40172a1dbc591a_I20190101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfMi0zLTEtMS00MDMy_89b19609-257c-494b-9798-fefc2a00730d"
      unitRef="usd">8753000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i3f20aa798c164804836d3c58f6e64322_I20190101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfMi01LTEtMS00MDI5_96405b59-c499-4800-99a3-f7b91aa7b94d"
      unitRef="usd">8753000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PrepaidRent
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfMy0xLTEtMS00MDM1_78000533-41c7-47fe-a16f-f8834f9931d5"
      unitRef="usd">0</us-gaap:PrepaidRent>
    <us-gaap:PrepaidRent
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfMy0xLTEtMS00MDM1_de08b112-ac15-4176-86a5-8eac67b66ca4"
      unitRef="usd">0</us-gaap:PrepaidRent>
    <us-gaap:PrepaidRent
      contextRef="ifb9ede9189214fb0ba40172a1dbc591a_I20190101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfMy0zLTEtMS00MDMy_7c4bc311-cf72-46c7-a0df-7717ac2315de"
      unitRef="usd">36025000</us-gaap:PrepaidRent>
    <us-gaap:PrepaidRent
      contextRef="i3f20aa798c164804836d3c58f6e64322_I20190101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfMy01LTEtMS00MDI5_b561a4e4-e984-4d01-87c5-6bcecd620491"
      unitRef="usd">36025000</us-gaap:PrepaidRent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfNi0xLTEtMS00MDM1_be005753-0703-4e5a-ab0d-9c584fb353dd"
      unitRef="usd">0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="icbd33d4a7d834496bd26b17d12cc0d71_I20190101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfNi0zLTEtMS00MDMy_f312d05e-1ee7-44e0-bec6-5c80a97b0d36"
      unitRef="usd">1408000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i3f20aa798c164804836d3c58f6e64322_I20190101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfNi01LTEtMS00MDI5_480e5ad7-cf50-4f74-8cea-2e55f5cd0a12"
      unitRef="usd">1408000</us-gaap:OperatingLeaseLiabilityCurrent>
    <sgmo:DeferredRentNoncurrent
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfNy0xLTEtMS00MDM1_0de402e2-87d4-4179-a639-1581a79c20b6"
      unitRef="usd">271000</sgmo:DeferredRentNoncurrent>
    <sgmo:DeferredRentNoncurrent
      contextRef="ifb9ede9189214fb0ba40172a1dbc591a_I20190101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfNy0zLTEtMS00MDMy_42f34b06-87e1-497d-b360-1114ff39164c"
      unitRef="usd">-271000</sgmo:DeferredRentNoncurrent>
    <sgmo:DeferredRentNoncurrent
      contextRef="i3f20aa798c164804836d3c58f6e64322_I20190101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfNy01LTEtMS00MDI5_fe79e6a6-78f1-431f-be40-fceac54dd07a"
      unitRef="usd">0</sgmo:DeferredRentNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="icbc9e04f074c44ffa8daa55bc133f128_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfOC0xLTEtMS00MDM1_05810877-0683-4aef-bc5e-85a1e14fca2f"
      unitRef="usd">27689000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ibf1327e2b600430586f7a8218d35f3f2_I20190101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfOC0zLTEtMS00MDMy_4f20ac98-d973-473a-bd4d-e8ccd2bdf760"
      unitRef="usd">-27689000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="id5dfe7b638ae41cda6e177ad875be7b5_I20190101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfOC01LTEtMS00MDI5_69c2007e-d2e0-4228-b5ef-a71429f418d6"
      unitRef="usd">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfOS0xLTEtMS00MDM1_fd790fa5-a1af-4f63-a288-e555880f201d"
      unitRef="usd">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ifb9ede9189214fb0ba40172a1dbc591a_I20190101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfOS0zLTEtMS00MDMy_d3088d9f-73b8-4aba-b475-9d27f0ec7241"
      unitRef="usd">7933000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i3f20aa798c164804836d3c58f6e64322_I20190101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfOS01LTEtMS00MDI5_84dbc1d0-169b-44d0-bd47-8c04f1aa0fa8"
      unitRef="usd">7933000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfMTEtMS0xLTEtNDAzNQ_a360f277-470f-4973-af5c-af32c4317e34"
      unitRef="usd">-562696000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ifb9ede9189214fb0ba40172a1dbc591a_I20190101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfMTEtMy0xLTEtNDAzMg_e962ac5a-42d9-4ad2-92a1-de9c20235d43"
      unitRef="usd">897000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i3f20aa798c164804836d3c58f6e64322_I20190101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RhYmxlOjZlMzlhNjJjYTNjMjQzOGZhODAwYjgyZjIyZmVkNDM0L3RhYmxlcmFuZ2U6NmUzOWE2MmNhM2MyNDM4ZmE4MDBiODJmMjJmZWQ0MzRfMTEtNS0xLTEtNDAyOQ_8377becb-f27e-4347-8070-6310457f12cb"
      unitRef="usd">-561799000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RleHRyZWdpb246MmM1Y2FkN2U3MWY3NDFkYWIyZmIzNzIzZTIxMTQ4MDlfNDQ4MQ_4d56d9f9-7d68-45a0-ac08-3b1fb671af6e">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;NOTE 2 &#x2013; FAIR VALUE MEASUREMENT&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company measures certain assets and liabilities at fair value on a recurring basis, including cash equivalents, available-for-sale securities and the free share asset/liability.&#160;The accounting guidance establishes a three-tier hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;i.e.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; supported by little or no market activity).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value measurements of the Company&#x2019;s cash equivalents, available-for-sale securities and the free share asset/liability are identified at the following levels within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.852%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.741%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value Measurement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;155,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;155,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;95,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;95,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;303,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;303,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;337,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;306,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Free shares asset&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.852%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.741%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt; Fair Value Measurement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;103,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;103,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;103,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;103,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;177,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;177,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;63,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;63,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;259,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;259,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;363,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;103,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;259,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Free shares liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company generally classifies its marketable securities and some cash equivalents as Level 2. Instruments are classified as Level 2 when observable market prices for identical securities that are traded in less active markets are used. When observable market prices for identical securities are not available, such instruments are priced using benchmark curves, benchmarking of like securities, sector groupings, matrix pricing and valuation models. These valuation models are proprietary to the pricing providers or brokers and incorporate a number of inputs, including in approximate order of priority: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. For certain security types, additional inputs may be used, or some of the standard inputs may not be applicable. Evaluators may prioritize inputs differently on any given day for any security based on market conditions, and not all inputs listed are available for use in the evaluation process for each security evaluation on any given day.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Free Shares Asset/Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As a result of the July&#160;20, 2018 Share Purchase Agreement (&#x201c;Sangamo France SPA&#x201d;) to acquire Sangamo France (see Note 5 &#x2013; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Acquisition of Sangamo France&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;), the Company entered into arrangements with the holders of approximately 477,000 &#x201c;free shares&#x201d; of Sangamo France pursuant to which the Company has the right to purchase such shares from the holders (a call option) and such holders have the right to sell to the Company such shares from time to time through mid-2021 (a put option). The Company initially recorded a liability of $0.2&#160;million on the acquisition date. The put options were classified within Level&#160;3 of the fair value hierarchy as the Company utilized a binomial-lattice pricing model (the &#x201c;Monte Carlo simulation model&#x201d;) that involved certain market conditions to estimate the fair value of the options. The assumptions used in this simulation model are reviewed on a quarterly basis and adjusted, as needed. Subsequent changes in the fair value of the free shares are recorded in general and administrative expenses in the Consolidated Statements of Operations. During the year, the Company purchased approximately 111,000 shares of the 477,000 total free shares for a cash payment of approximately $0.3&#160;million upon exercise of the put options. As of December&#160;31, 2019, approximately 366,000 free shares remain outstanding and subject to purchase by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The free shares liability was approximately $0.2&#160;million at December 31, 2018 and the Company recognized a gain due to an increase in the fair value of the free shares of approximately $0.5&#160;million for the year ended December&#160;31, 2019, offset by approximately $0.1&#160;million for the shares purchased during the year, bringing the balance to an asset of approximately $0.2&#160;million at December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.784%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.812%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.389%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.815%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Free Shares valuation assumptions:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Sangamo Stock Price (USD)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Sangamo France Stock Price (EUR)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x20ac;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x20ac;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;USD/ EUR Exchange Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated Correlation Sangamo and Sangamo France Stock Prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Sangamo Stock Price (USD) Volatility Estimate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;72.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;79.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Sangamo France Stock Price (EUR) Volatility Estimate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;72.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;USD/ EUR Exchange Rate Volatility Estimate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk Free Rate and Cost of Debt by Expected Exercise Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Varies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Varies&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RleHRyZWdpb246MmM1Y2FkN2U3MWY3NDFkYWIyZmIzNzIzZTIxMTQ4MDlfNDQ4Mg_a07d8065-6ef0-4ed9-9730-5e96cb87637f">&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value measurements of the Company&#x2019;s cash equivalents, available-for-sale securities and the free share asset/liability are identified at the following levels within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.852%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.741%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value Measurement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;155,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;155,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;95,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;95,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;303,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;303,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;337,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;306,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Free shares asset&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.852%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.741%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt; Fair Value Measurement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;103,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;103,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;103,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;103,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;177,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;177,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;63,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;63,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;259,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;259,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;363,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;103,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;259,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Free shares liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i425b175434d04e418b20de221af1fd33_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfNC0xLTEtMS0w_5145ea1f-ead6-4058-a520-e4d1a5ba851c"
      unitRef="usd">30496000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if327c6ba5afb4ee28f9cca2b391023fe_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfNC0zLTEtMS0w_9d655f44-a61d-4149-b136-133fe3a5a774"
      unitRef="usd">30496000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i13e727b552f840888ab401cd0d611095_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfNC01LTEtMS0w_c7139feb-eeb2-46b1-9888-9ced1d10e5dd"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1916c386d59845db85c0f6b195b6c309_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfNC03LTEtMS0w_68a0565c-25a8-419b-ab91-84bae89e56f3"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6fedc4e1ca23438283a2d2c6f237fe8b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfNS0xLTEtMS05MTI3_f106016d-f8fc-4447-a6be-885bc4d80a11"
      unitRef="usd">2999000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ifedb75e8c33345abb30ce39ac8828048_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfNS0zLTEtMS05MTMw_399eb320-0690-4312-a35c-fea359a50400"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9a555374195740708b7b535422475c40_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfNS01LTEtMS05MTMz_5cbf6928-0c86-41b2-9588-8544245e1851"
      unitRef="usd">2999000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9fe30ec7f787449981feb883fd8e7408_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfNS03LTEtMS05MTM2_dbc16da6-3ed5-47bb-a3f0-3d9cee40da74"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id6a8c12c301e487cab97f3ac6cb97945_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfNS0xLTEtMS0w_0e0149b9-2e63-4278-bfb3-4e7b6d758765"
      unitRef="usd">33495000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0d0f5ceb90cd496f91d1edf2102c57d2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfNS0zLTEtMS0w_fc8ea343-9618-45be-9dc7-bd8720c73887"
      unitRef="usd">30496000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4dd1f80319a84afbb69e15090417a474_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfNS01LTEtMS0w_d40ea339-79a9-4910-8ebf-8048b9a7eb3e"
      unitRef="usd">2999000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibe28cfabe6384c78b965211fe2b259d6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfNS03LTEtMS0w_e38a7a01-4166-4875-8071-1a012e98e8ef"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6fedc4e1ca23438283a2d2c6f237fe8b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfNy0xLTEtMS0w_a05a39e3-c943-4117-85fe-a11698670967"
      unitRef="usd">155368000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifedb75e8c33345abb30ce39ac8828048_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfNy0zLTEtMS0w_83510d71-b6c0-4364-a41b-8f96abec3040"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9a555374195740708b7b535422475c40_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfNy01LTEtMS0w_305c9683-502d-4ad6-ad2d-86d86cbf1f9f"
      unitRef="usd">155368000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9fe30ec7f787449981feb883fd8e7408_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfNy03LTEtMS0w_73753ebe-67ee-4ea1-bd8e-3acae57f5153"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i70b955824d6240a6badd8bb4bbb12d0b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfOC0xLTEtMS0w_4323d803-bedd-484a-b090-38f00295ff22"
      unitRef="usd">95017000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i98bf1a1fb6c946f99d2a94a5222f559e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfOC0zLTEtMS0w_18c14ab0-82c1-4a59-8179-64173ec72b29"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i84e857a6b4d64be5bce0f89cc006035f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfOC01LTEtMS0w_cad4b385-60ed-4c2d-8637-abf643dc072e"
      unitRef="usd">95017000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic69943e18c9d4e908720f488efa6db9c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfOC03LTEtMS0w_f48b3b32-82bd-411c-ab35-257fb4e2705d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i23ea33c72d45452c8dca1b18861249d0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfOS0xLTEtMS0w_84d71f55-d708-41d2-87d2-5b5cc138b07b"
      unitRef="usd">53493000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i878065655eff40a59fa226fbcc58557f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfOS0zLTEtMS0w_8055e87e-fd6b-4734-a402-69ad278f5073"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i357038a3295843f7b8bb19efe35d46b1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfOS01LTEtMS0w_ea89848b-7bde-4a97-a7d7-a8d3bb2049e1"
      unitRef="usd">53493000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia948e7072e51466fa0d1a823a8cda9e4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfOS03LTEtMS0w_acd49d01-2467-44a6-8d4c-21e2cb095da2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id6a8c12c301e487cab97f3ac6cb97945_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfMTAtMS0xLTEtMA_6e1eff69-c7ab-4487-8457-d8fa12152d2b"
      unitRef="usd">303878000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0d0f5ceb90cd496f91d1edf2102c57d2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfMTAtMy0xLTEtMA_e9e06234-fed6-451c-8287-88aa227b5f89"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4dd1f80319a84afbb69e15090417a474_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfMTAtNS0xLTEtMA_aa104d02-3a44-42de-aae7-d26fc3a0e948"
      unitRef="usd">303878000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibe28cfabe6384c78b965211fe2b259d6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfMTAtNy0xLTEtMA_94c36982-9050-42e6-9724-080017ef1948"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id6a8c12c301e487cab97f3ac6cb97945_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfMTEtMS0xLTEtMA_d0df4f96-e910-4d5b-a05a-cb56436d6e19"
      unitRef="usd">337373000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0d0f5ceb90cd496f91d1edf2102c57d2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfMTEtMy0xLTEtMA_d6fedeb8-5f8a-4bec-9884-e910437b941f"
      unitRef="usd">30496000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4dd1f80319a84afbb69e15090417a474_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfMTEtNS0xLTEtMA_1ce0d8fb-d862-404c-96c3-169b2eb541cc"
      unitRef="usd">306877000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibe28cfabe6384c78b965211fe2b259d6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfMTEtNy0xLTEtMA_6afe8e68-9cae-4ddc-a725-490125f159ef"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i55aa029ca6dd458a8a361b0d9ce3fc27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfMTMtMS0xLTEtMA_ba610570-6534-4d6e-b9b6-1d69cad32ad9"
      unitRef="usd">236000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie4ed7f86404f4a6ba7c31faa2f653426_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfMTMtMy0xLTEtMA_dd520389-76ec-4314-ade3-7328462ab8f5"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id7fd88b4bbe14d53a36b2a34dcf1fcbf_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfMTMtNS0xLTEtMA_1cd9a637-ab16-42b4-8d56-a3b49701848a"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i42972542d5a643f4ad2306c25b585428_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmQ4OTQyNmQzNmIyMTQ0ZWZhNzExMDhiNWI5MjBkNGVjL3RhYmxlcmFuZ2U6ZDg5NDI2ZDM2YjIxNDRlZmE3MTEwOGI1YjkyMGQ0ZWNfMTMtNy0xLTEtMA_987c1e7a-08cb-4903-9c17-59c68678fe98"
      unitRef="usd">236000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9501ce5f7d6e456bb6d923b2208d2e71_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfNC0xLTEtMS0w_afa85389-7c80-446e-bdf6-19dab65ef969"
      unitRef="usd">103291000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1d2d295786cf43beaed8e20c63959a56_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfNC0zLTEtMS0w_2b7fd4c8-5844-4861-a4c8-4a5f05134856"
      unitRef="usd">103291000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i94d4458c66c647e9ae4004aea884aea7_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfNC01LTEtMS0w_02794a93-893c-4c4a-ae8a-a73955bbb3c8"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia12bf2d0855544e080b1e3c549ce02c2_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfNC03LTEtMS0w_fd9d8ed0-c01e-4470-847f-f35cad38ffdc"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iad708dc4322e4296b7279fb10923aa64_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfNi0xLTEtMS0w_51363672-06a4-4142-9b21-b62595993167"
      unitRef="usd">103291000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0fac6e5a93cf4932b299c93b29103ee4_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfNi0zLTEtMS0w_a1febfad-3f84-4e60-9c44-32d3cf793c8b"
      unitRef="usd">103291000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id07ed358181b47e991569dc03d1eca59_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfNi01LTEtMS0w_e118f81b-4bd9-461c-88e9-8da7233493f4"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8487d3169fa14869a2959a37cb1a1924_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfNi03LTEtMS0w_23f38198-cea0-4e45-8678-2aacbb2bd773"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i874bf2bbf8044c5ea86c5b6dec868699_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfOC0xLTEtMS0w_d404250a-a583-492c-88bd-04dc9e76b18f"
      unitRef="usd">177224000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7ac8366f1cf74cbda4eae920c042daef_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfOC0zLTEtMS0w_39b385aa-32d1-40ea-bf64-50e3824f96f8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i329183fcaae04a14b76d777f4591b0cb_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfOC01LTEtMS0w_13af415d-085e-4dff-8117-41a608c9ba00"
      unitRef="usd">177224000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibf402857bd034d28ad83a9627a535af3_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfOC03LTEtMS0w_dedd15b8-5094-4e5a-b1bb-e5badbe31168"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i604e1c483a2144499182a3abf3334884_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfOS0xLTEtMS0w_3818bff9-6e02-4e37-a1b9-8747e6678644"
      unitRef="usd">63870000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i27b1fd12142f4694b5053b6268cd9c5a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfOS0zLTEtMS0w_b3117293-83a5-4520-8a83-cbfe84a50509"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i44eb81c1bb054e35a82f0ad07d8dd13a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfOS01LTEtMS0w_6fa6726c-342d-42e0-a82e-90f1eca30ba3"
      unitRef="usd">63870000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i52f56fd373e54acdbc14ae1ad4e8621d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfOS03LTEtMS0w_d77d0f40-debf-4437-9316-350c32d3ce82"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i149c7986f92344c09f4c6801f030875f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfMTAtMS0xLTEtMA_1cf7e96a-d70a-4b76-9be6-0fabc81b9bdf"
      unitRef="usd">18621000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if20ea12b7bd2424fa4f0d5ddc716792c_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfMTAtMy0xLTEtMA_b4795cca-fa14-4afa-886e-4170c0524f8a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5913e464612f4a46aa67a602001a2466_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfMTAtNS0xLTEtMA_a5474e3c-b152-4172-878f-487a60dfcac2"
      unitRef="usd">18621000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i07c312494713484fb523d49996228eaa_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfMTAtNy0xLTEtMA_b64b1550-fb2b-469c-b6ba-9721412d4c7f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iad708dc4322e4296b7279fb10923aa64_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfMTEtMS0xLTEtMA_68ce9c97-76d6-4841-bc52-14d434fbc803"
      unitRef="usd">259715000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0fac6e5a93cf4932b299c93b29103ee4_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfMTEtMy0xLTEtMA_44885724-3f70-4344-b644-ab6dd6b0d0bc"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id07ed358181b47e991569dc03d1eca59_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfMTEtNS0xLTEtMA_7e4bfeff-8b95-4436-adf7-7ef15ce63d14"
      unitRef="usd">259715000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8487d3169fa14869a2959a37cb1a1924_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfMTEtNy0xLTEtMA_026eea29-49d3-4ea7-b03a-46ef619c19a8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iad708dc4322e4296b7279fb10923aa64_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfMTItMS0xLTEtMA_628e5d77-4827-4dea-ba3a-2d827c54d8d3"
      unitRef="usd">363006000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0fac6e5a93cf4932b299c93b29103ee4_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfMTItMy0xLTEtMA_aaa93e0d-fe13-45f2-af7a-a39c7ab1a478"
      unitRef="usd">103291000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id07ed358181b47e991569dc03d1eca59_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfMTItNS0xLTEtMA_b145ac0c-a79f-49b3-a647-57e8da4a8bf9"
      unitRef="usd">259715000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8487d3169fa14869a2959a37cb1a1924_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfMTItNy0xLTEtMA_5257a73e-0cc0-4f97-a5ac-d5c0176ae135"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i64c1c287bd47404da4ea630212dedc2e_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfMTQtMS0xLTEtMTYxNA_1a2e177a-a5cc-46af-8033-1f3c490cec72"
      unitRef="usd">154000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i51862de68d334a6d90ced8ff154add77_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfMTQtMy0xLTEtMTYxNA_9a52c505-0165-4519-802a-cdef623c5614"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i9017742317a7426b8f1655ea852cf27f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfMTQtNS0xLTEtMTYxNA_11466d40-b124-48ef-9be4-93a6879d168c"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="if73c9eef08404834bb4f125b2f8334e8_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOjcxYjYzNGMyMDQ2YjQ2ZmM5OGY1Njc5MWFiYWM4M2UxL3RhYmxlcmFuZ2U6NzFiNjM0YzIwNDZiNDZmYzk4ZjU2NzkxYWJhYzgzZTFfMTQtNy0xLTEtMTYxNA_a088f105-4c74-4f84-a0d4-5dc835e3763f"
      unitRef="usd">154000</us-gaap:LiabilitiesFairValueDisclosure>
    <sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders
      contextRef="ia4b36a1c4d88462a8ee8d85f748c7b16_I20180720"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RleHRyZWdpb246MmM1Y2FkN2U3MWY3NDFkYWIyZmIzNzIzZTIxMTQ4MDlfNDM5ODA0NjUyNzAxMA_fe427243-c12a-4c11-ad93-4689e00b8bf5"
      unitRef="shares">477000</sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders>
    <sgmo:BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares
      contextRef="ia4b36a1c4d88462a8ee8d85f748c7b16_I20180720"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RleHRyZWdpb246MmM1Y2FkN2U3MWY3NDFkYWIyZmIzNzIzZTIxMTQ4MDlfNDM5ODA0NjUyNjk4OA_cb8ccf64-b4b5-4dbe-8080-d3b0ce8894e8"
      unitRef="usd">200000</sgmo:BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares>
    <sgmo:BusinessAcquisitionNumberOfSharesAcquired
      contextRef="i9b97713bc2a74145a84bf16db6e1a142_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RleHRyZWdpb246MmM1Y2FkN2U3MWY3NDFkYWIyZmIzNzIzZTIxMTQ4MDlfNDM5ODA0NjUyNzAyOA_d0cbed9e-d7b4-4271-8d2b-8f9048a78062"
      unitRef="shares">111000</sgmo:BusinessAcquisitionNumberOfSharesAcquired>
    <sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders
      contextRef="ia4b36a1c4d88462a8ee8d85f748c7b16_I20180720"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RleHRyZWdpb246MmM1Y2FkN2U3MWY3NDFkYWIyZmIzNzIzZTIxMTQ4MDlfNDM5ODA0NjUyNzAxOQ_fe427243-c12a-4c11-ad93-4689e00b8bf5"
      unitRef="shares">477000</sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="i9b97713bc2a74145a84bf16db6e1a142_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RleHRyZWdpb246MmM1Y2FkN2U3MWY3NDFkYWIyZmIzNzIzZTIxMTQ4MDlfNDM5ODA0NjUyNzA0Mg_34ac847c-28aa-434d-9f93-621f5554e5e5"
      unitRef="usd">300000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <sgmo:BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RleHRyZWdpb246MmM1Y2FkN2U3MWY3NDFkYWIyZmIzNzIzZTIxMTQ4MDlfNDM5ODA0NjUyNzA3MA_fc611ce1-9f20-4df6-8e83-cf7601bd45a5"
      unitRef="shares">366000</sgmo:BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase>
    <sgmo:BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares
      contextRef="ifba2b3f6b5f24819b803f8b4290efdef_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RleHRyZWdpb246MmM1Y2FkN2U3MWY3NDFkYWIyZmIzNzIzZTIxMTQ4MDlfNjA0NzMxMzk2ODU5NQ_8ff56e19-6fa9-4ad0-bf1f-9f427123274a"
      unitRef="usd">200000</sgmo:BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares>
    <sgmo:IncreaseInFairValueOfFreeSharesAssetAndLiability
      contextRef="i9b97713bc2a74145a84bf16db6e1a142_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RleHRyZWdpb246MmM1Y2FkN2U3MWY3NDFkYWIyZmIzNzIzZTIxMTQ4MDlfODc5NjA5MzAzODI3Ng_2d1a203c-2e73-4afc-9df6-f86692a109c0"
      unitRef="usd">500000</sgmo:IncreaseInFairValueOfFreeSharesAssetAndLiability>
    <sgmo:BusinessAcquisitionEstimatedFairValueOfFreeShares
      contextRef="i9b97713bc2a74145a84bf16db6e1a142_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RleHRyZWdpb246MmM1Y2FkN2U3MWY3NDFkYWIyZmIzNzIzZTIxMTQ4MDlfNDM5ODA0NjUyNzA4NQ_29a8c537-d89d-4512-b4a6-3911ca4b179d"
      unitRef="usd">100000</sgmo:BusinessAcquisitionEstimatedFairValueOfFreeShares>
    <sgmo:BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares
      contextRef="i2821462afaec43989ae5bb5640358bdb_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RleHRyZWdpb246MmM1Y2FkN2U3MWY3NDFkYWIyZmIzNzIzZTIxMTQ4MDlfNjA0NzMxMzk2ODYxNQ_665356ca-6053-44cf-b0ad-4165df808c5b"
      unitRef="usd">200000</sgmo:BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RleHRyZWdpb246MmM1Y2FkN2U3MWY3NDFkYWIyZmIzNzIzZTIxMTQ4MDlfNDQ4MA_7d8e1fdb-f354-4189-aaf3-790f046b85ff">&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.784%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.812%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.389%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.815%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Free Shares valuation assumptions:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Sangamo Stock Price (USD)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Sangamo France Stock Price (EUR)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x20ac;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x20ac;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;USD/ EUR Exchange Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated Correlation Sangamo and Sangamo France Stock Prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Sangamo Stock Price (USD) Volatility Estimate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;72.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;79.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Sangamo France Stock Price (EUR) Volatility Estimate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;72.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;USD/ EUR Exchange Rate Volatility Estimate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk Free Rate and Cost of Debt by Expected Exercise Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Varies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Varies&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:SharePrice
      contextRef="i8637425832d24b439a5841eb6340fe09_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmIxZjJkZmEzOTk1MDQ3NWU4NDllNzBmZjIyMWQxNjdjL3RhYmxlcmFuZ2U6YjFmMmRmYTM5OTUwNDc1ZTg0OWU3MGZmMjIxZDE2N2NfMS0yLTEtMS0w_cfbd6ef8-b938-4eb9-bd1d-60fd6d86c124"
      unitRef="usdPerShare">8.68</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="i5cd83c646e0741f2a6f9af0abef8b909_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmIxZjJkZmEzOTk1MDQ3NWU4NDllNzBmZjIyMWQxNjdjL3RhYmxlcmFuZ2U6YjFmMmRmYTM5OTUwNDc1ZTg0OWU3MGZmMjIxZDE2N2NfMi0zLTEtMS0xODUx_db581f7b-10d9-4029-a94a-b666a84d4996"
      unitRef="usdPerShare">11.48</us-gaap:SharePrice>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="id158af407d9041baa888cbe9abf2ea9d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmIxZjJkZmEzOTk1MDQ3NWU4NDllNzBmZjIyMWQxNjdjL3RhYmxlcmFuZ2U6YjFmMmRmYTM5OTUwNDc1ZTg0OWU3MGZmMjIxZDE2N2NfMi0yLTEtMS0w_c3ff1561-597f-4671-95f1-8d9531fa2308"
      unitRef="eurPerShare">2.14</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="i8e015bf5f3134e418d8cb590b4182340_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmIxZjJkZmEzOTk1MDQ3NWU4NDllNzBmZjIyMWQxNjdjL3RhYmxlcmFuZ2U6YjFmMmRmYTM5OTUwNDc1ZTg0OWU3MGZmMjIxZDE2N2NfMy0zLTEtMS0xODUx_e4203da1-dcc1-449f-9679-14f4282fbd63"
      unitRef="usdPerShare">2.58</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmIxZjJkZmEzOTk1MDQ3NWU4NDllNzBmZjIyMWQxNjdjL3RhYmxlcmFuZ2U6YjFmMmRmYTM5OTUwNDc1ZTg0OWU3MGZmMjIxZDE2N2NfMy0yLTEtMS0w_7c62b185-d612-4112-925c-42351085ec9d"
      unitRef="number">0.91</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmIxZjJkZmEzOTk1MDQ3NWU4NDllNzBmZjIyMWQxNjdjL3RhYmxlcmFuZ2U6YjFmMmRmYTM5OTUwNDc1ZTg0OWU3MGZmMjIxZDE2N2NfNC0zLTEtMS0xODUx_57b516fd-2111-48a5-b9c0-c8c90f4a6f41"
      unitRef="number">0.87</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i2ba502e8004f4a51b63eb68808f9ad0c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmIxZjJkZmEzOTk1MDQ3NWU4NDllNzBmZjIyMWQxNjdjL3RhYmxlcmFuZ2U6YjFmMmRmYTM5OTUwNDc1ZTg0OWU3MGZmMjIxZDE2N2NfNS0xLTEtMS0xODY5_25d27eab-ede8-4c20-a234-ec105d4dc0c3"
      unitRef="number">1.000</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="iaa539cfd54e24b8e8f9bad28ca1ca2e2_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmIxZjJkZmEzOTk1MDQ3NWU4NDllNzBmZjIyMWQxNjdjL3RhYmxlcmFuZ2U6YjFmMmRmYTM5OTUwNDc1ZTg0OWU3MGZmMjIxZDE2N2NfNS0zLTEtMS0xODY5_a11c06e3-9786-48ab-9d83-8d6cfeb6ea14"
      unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i33f3835a3a9548d0bb177195bca1c91d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmIxZjJkZmEzOTk1MDQ3NWU4NDllNzBmZjIyMWQxNjdjL3RhYmxlcmFuZ2U6YjFmMmRmYTM5OTUwNDc1ZTg0OWU3MGZmMjIxZDE2N2NfNC0yLTEtMS0w_9a5c351e-e600-42c0-94f6-b866085cafef"
      unitRef="number">0.725</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="if0c0f4a598494b73a9f02d3c32a0337a_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmIxZjJkZmEzOTk1MDQ3NWU4NDllNzBmZjIyMWQxNjdjL3RhYmxlcmFuZ2U6YjFmMmRmYTM5OTUwNDc1ZTg0OWU3MGZmMjIxZDE2N2NfNS0zLTEtMS0xODUx_7f6ba4fb-817e-4def-8f22-5b9156f7c387"
      unitRef="number">0.799</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i624ddabb3ed14489852a400d3c8823e6_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmIxZjJkZmEzOTk1MDQ3NWU4NDllNzBmZjIyMWQxNjdjL3RhYmxlcmFuZ2U6YjFmMmRmYTM5OTUwNDc1ZTg0OWU3MGZmMjIxZDE2N2NfNS0yLTEtMS0w_a3da3451-35b1-40cd-b49b-4f75f1208956"
      unitRef="number">0.725</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i84d9625ccd9e40dcb299cd5ff4f2f7be_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmIxZjJkZmEzOTk1MDQ3NWU4NDllNzBmZjIyMWQxNjdjL3RhYmxlcmFuZ2U6YjFmMmRmYTM5OTUwNDc1ZTg0OWU3MGZmMjIxZDE2N2NfNi0zLTEtMS0xODUx_ce4e0cf5-eede-43df-a9bf-09b022ff4aa5"
      unitRef="number">0.086</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="if3b6cba6a07b430f9c7d6308a92564cb_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmIxZjJkZmEzOTk1MDQ3NWU4NDllNzBmZjIyMWQxNjdjL3RhYmxlcmFuZ2U6YjFmMmRmYTM5OTUwNDc1ZTg0OWU3MGZmMjIxZDE2N2NfNi0yLTEtMS0w_9b8bda4a-a3e7-4c78-8607-41b1742391be"
      unitRef="number">0.066</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i3aa31b7f47894ac591b3f5464dc1b173_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmIxZjJkZmEzOTk1MDQ3NWU4NDllNzBmZjIyMWQxNjdjL3RhYmxlcmFuZ2U6YjFmMmRmYTM5OTUwNDc1ZTg0OWU3MGZmMjIxZDE2N2NfNy0zLTEtMS0xODUx_0f3e31ab-df1c-4905-8476-b7221494a719"
      unitRef="number">0.077</us-gaap:DerivativeLiabilityMeasurementInput>
    <sgmo:DerivativeLiabilityTerm
      contextRef="ifdc951c6c13c4c8bb47767567ef80768_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmIxZjJkZmEzOTk1MDQ3NWU4NDllNzBmZjIyMWQxNjdjL3RhYmxlcmFuZ2U6YjFmMmRmYTM5OTUwNDc1ZTg0OWU3MGZmMjIxZDE2N2NfNy0yLTEtMS0w_2c8f25e6-9b00-43df-ac6a-6bc3a6951c87">Varies</sgmo:DerivativeLiabilityTerm>
    <sgmo:DerivativeLiabilityTerm
      contextRef="i87ef30d5e5634d03ba044c381280c504_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85Ny9mcmFnOjJjNWNhZDdlNzFmNzQxZGFiMmZiMzcyM2UyMTE0ODA5L3RhYmxlOmIxZjJkZmEzOTk1MDQ3NWU4NDllNzBmZjIyMWQxNjdjL3RhYmxlcmFuZ2U6YjFmMmRmYTM5OTUwNDc1ZTg0OWU3MGZmMjIxZDE2N2NfOC0zLTEtMS0xODQx_777e5159-0743-46d6-8ecd-1e09c094c963">Varies</sgmo:DerivativeLiabilityTerm>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90ZXh0cmVnaW9uOjk4OGU4MmNjMjFhNDQwMWM4Y2EzMGI4MTFlZDU2NGNhXzc2OTY1ODEzOTczMTM_e2a42cb4-d8fe-4b2b-a0ca-7043b6511e24">MARKETABLE SECURITIES&lt;div style="text-indent:27pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The table below summarizes the Company&#x2019;s cash equivalents and available-for-sale securities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.852%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.741%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;155,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;155,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;94,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;95,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;303,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;303,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash equivalents and available-for-sale securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;337,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;337,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;103,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;103,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;103,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;103,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;177,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;177,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;63,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(111)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;63,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;259,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(259)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;259,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash equivalents and available-for-sale securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;363,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(259)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;363,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of investments available-for-sale by contractual maturity were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:57.064%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.883%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.969%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.884%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;282,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;259,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total investments available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;303,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;259,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company had no material realized losses from the sale of available-for-sale securities for the years ended December&#160;31, 2019, 2018 or 2017. Sangamo has the intent and ability to hold its investments for a period of time sufficient to allow for any anticipated recovery in market value. No investments were other-than-temporarily impaired at either December&#160;31, 2019 or 2018.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:AvailableForSaleSecuritiesTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90ZXh0cmVnaW9uOjk4OGU4MmNjMjFhNDQwMWM4Y2EzMGI4MTFlZDU2NGNhXzc2OTY1ODEzOTczMTQ_a26fd492-04a4-4d38-8ea4-f714d4d3596c">&lt;div style="text-indent:27pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The table below summarizes the Company&#x2019;s cash equivalents and available-for-sale securities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.852%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.741%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;155,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;155,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;94,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;95,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;303,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;303,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash equivalents and available-for-sale securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;337,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;337,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;103,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;103,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;103,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;103,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;177,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;177,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;63,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(111)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;63,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;259,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(259)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;259,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash equivalents and available-for-sale securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;363,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(259)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;363,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of investments available-for-sale by contractual maturity were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:57.064%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.883%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.969%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.884%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;282,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;259,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total investments available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;303,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;259,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8727918bfc77478d894641bf1ba39f2b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzMtMS0xLTEtMA_41b76200-f595-4114-8ea2-7c3f0a5f3b84"
      unitRef="usd">30496000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8727918bfc77478d894641bf1ba39f2b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzMtMy0xLTEtMA_b4eb5d4a-9dcf-4d9c-b9d8-125541a56654"
      unitRef="usd">0</sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax>
    <sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8727918bfc77478d894641bf1ba39f2b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzMtNS0xLTEtMA_94538f9d-24ba-45f6-8f99-129ab25b07e9"
      unitRef="usd">0</sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8727918bfc77478d894641bf1ba39f2b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzMtNy0xLTEtMA_25f2ec55-77f5-4ff4-bf02-2a57c7653575"
      unitRef="usd">30496000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2134d5ba27be42e394846ea5e6f9bbaa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzQtMS0xLTEtOTgxOQ_2709eead-3f7f-40a1-a0d7-c6ecfb8a1748"
      unitRef="usd">2998000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2134d5ba27be42e394846ea5e6f9bbaa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzQtMy0xLTEtOTgyMQ_c8e6418f-ed83-4b1c-8b23-deb4890952fc"
      unitRef="usd">1000</sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax>
    <sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2134d5ba27be42e394846ea5e6f9bbaa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzQtNS0xLTEtOTgyNA_578d6682-23b5-4794-9baf-d2b86683a34e"
      unitRef="usd">0</sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2134d5ba27be42e394846ea5e6f9bbaa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzQtNy0xLTEtOTgyNw_3417cc2e-a601-4b10-9fd0-1836a2cc2dbb"
      unitRef="usd">2999000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i75f08675fb7643a590d56bf4bcb13e36_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzQtMS0xLTEtMA_51d4092a-6214-4e0f-9221-413eeeb9b5d9"
      unitRef="usd">33494000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i75f08675fb7643a590d56bf4bcb13e36_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzQtMy0xLTEtMA_a97aebb8-5377-4093-af5a-f0e4e2e7973f"
      unitRef="usd">1000</sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax>
    <sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i75f08675fb7643a590d56bf4bcb13e36_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzQtNS0xLTEtMA_c3d87803-5ba6-4752-b68a-f831b9e44c4b"
      unitRef="usd">0</sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i75f08675fb7643a590d56bf4bcb13e36_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzQtNy0xLTEtMA_85c14972-3b2c-4a71-ac81-9039bfba3a72"
      unitRef="usd">33495000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2134d5ba27be42e394846ea5e6f9bbaa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzYtMS0xLTEtMA_a261ba77-f96c-4061-9bd9-7d43e011b1ae"
      unitRef="usd">155230000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2134d5ba27be42e394846ea5e6f9bbaa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzYtMy0xLTEtMA_8b49b208-a9dc-4602-9dff-291e0468828e"
      unitRef="usd">145000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2134d5ba27be42e394846ea5e6f9bbaa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzYtNS0xLTEtMA_835651a5-3e2e-4bc9-b2f8-81cf0ed894a5"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2134d5ba27be42e394846ea5e6f9bbaa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzYtNy0xLTEtMA_ab852e45-3c51-46de-8a1b-d88024d5adef"
      unitRef="usd">155368000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ieeb73dab1cf94f2584bc9b78fb4369c1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzctMS0xLTEtMA_665dba77-ce45-4b7a-a4c8-6399c65fc1a5"
      unitRef="usd">94905000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ieeb73dab1cf94f2584bc9b78fb4369c1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzctMy0xLTEtMA_12a2a344-dddf-4a0f-ba39-655257975b64"
      unitRef="usd">115000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ieeb73dab1cf94f2584bc9b78fb4369c1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzctNS0xLTEtMA_cecca78a-d42d-457a-81de-1d9bdcfe9b53"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ieeb73dab1cf94f2584bc9b78fb4369c1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzctNy0xLTEtMA_3868a510-740f-43e6-a641-de4330faf23b"
      unitRef="usd">95017000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i30cc7310d6c14807bc817509966f5218_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzgtMS0xLTEtMA_08bb1006-11f3-464b-b4d0-de7dd25061b6"
      unitRef="usd">53411000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i30cc7310d6c14807bc817509966f5218_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzgtMy0xLTEtMA_b6a7c7fa-a732-44c5-a214-40de303a7de6"
      unitRef="usd">91000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i30cc7310d6c14807bc817509966f5218_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzgtNS0xLTEtMA_b8dd0713-e664-4776-9682-acf666cba936"
      unitRef="usd">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i30cc7310d6c14807bc817509966f5218_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzgtNy0xLTEtMA_8b7c67af-2409-4e5c-8de6-6289fb679b25"
      unitRef="usd">53493000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzktMS0xLTEtMA_380bbaaf-23aa-4a01-881a-53ba81ea0331"
      unitRef="usd">303546000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzktMy0xLTEtMA_4160c61b-7ed9-4658-9b51-b3eb0d5074a4"
      unitRef="usd">351000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzktNS0xLTEtMA_9a60c53c-8c45-406d-979a-490e3ac92673"
      unitRef="usd">19000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzktNy0xLTEtMA_8c76f846-7f16-4a9e-9026-d6e8441270de"
      unitRef="usd">303878000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzEwLTEtMS0xLTA_dafb283a-7119-432d-8f17-b8dc0055043a"
      unitRef="usd">337040000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzEwLTMtMS0xLTA_779093e7-287a-4100-9f9c-056e5228599a"
      unitRef="usd">352000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzEwLTUtMS0xLTA_ae6eba2c-1d23-4ef0-8b0e-bb9ae435436b"
      unitRef="usd">19000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax>
    <sgmo:CashEquivalentsAndAvailableForSaleSecurities
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzEwLTctMS0xLTA_794e6e08-3701-4626-83e5-1738ed81239e"
      unitRef="usd">337373000</sgmo:CashEquivalentsAndAvailableForSaleSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic0b60e45bbb54cb5814c2623600b05a7_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzEzLTEtMS0xLTA_fff5e664-1244-458c-8290-2145b2be52a2"
      unitRef="usd">103291000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic0b60e45bbb54cb5814c2623600b05a7_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzEzLTMtMS0xLTA_72ee3432-e75d-44be-ba0e-953ee66d43cd"
      unitRef="usd">0</sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax>
    <sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic0b60e45bbb54cb5814c2623600b05a7_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzEzLTUtMS0xLTA_0fdbd4f4-e1f1-4ee1-a931-f1845e90c694"
      unitRef="usd">0</sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic0b60e45bbb54cb5814c2623600b05a7_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzEzLTctMS0xLTA_d7f5050f-bc05-4f5a-9b10-dab07400bdfa"
      unitRef="usd">103291000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iea5cd444cca1404bad4fad46fe35b1b5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzE1LTEtMS0xLTA_99bf04a3-dfb8-467d-acc2-8677552a8063"
      unitRef="usd">103291000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iea5cd444cca1404bad4fad46fe35b1b5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzE1LTMtMS0xLTA_312a73ab-663e-47cc-9316-150544a2add3"
      unitRef="usd">0</sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax>
    <sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iea5cd444cca1404bad4fad46fe35b1b5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzE1LTUtMS0xLTA_da41f887-1f4f-43df-a67e-6fd3d6414a16"
      unitRef="usd">0</sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iea5cd444cca1404bad4fad46fe35b1b5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzE1LTctMS0xLTA_01b5ef84-3b06-4ce4-944a-2d37e5deb663"
      unitRef="usd">103291000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4c5421c8d9b34ac193b12f580b0e45fe_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzE3LTEtMS0xLTA_81175dc8-763a-4b7a-8b44-b5664e233631"
      unitRef="usd">177353000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4c5421c8d9b34ac193b12f580b0e45fe_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzE3LTMtMS0xLTA_29d84263-d541-4d78-8465-8da3fc371e41"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4c5421c8d9b34ac193b12f580b0e45fe_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzE3LTUtMS0xLTA_acf5d5ce-aadf-420a-8f16-5ae5dd517723"
      unitRef="usd">129000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4c5421c8d9b34ac193b12f580b0e45fe_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzE3LTctMS0xLTA_b6ac9196-cfd5-4730-8321-2303aeef3061"
      unitRef="usd">177224000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib6b4614c3ed0431ab9570835b20a0800_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzE4LTEtMS0xLTA_e5a1991c-c6dd-4d65-85e9-cf49bd4918ff"
      unitRef="usd">63981000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib6b4614c3ed0431ab9570835b20a0800_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzE4LTMtMS0xLTA_9f7ed94b-ebe9-4f52-bba1-be44b90862aa"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib6b4614c3ed0431ab9570835b20a0800_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzE4LTUtMS0xLTA_82c3e20f-a150-46d8-96bd-8a4b751032bd"
      unitRef="usd">111000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib6b4614c3ed0431ab9570835b20a0800_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzE4LTctMS0xLTA_4e14171b-65ad-41b5-966d-f4048ab45e78"
      unitRef="usd">63870000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1f19f6eef7f447ee90aa653000871c5d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzE5LTEtMS0xLTA_289ab4b9-a36b-4c72-94eb-bd292e85d506"
      unitRef="usd">18640000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1f19f6eef7f447ee90aa653000871c5d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzE5LTMtMS0xLTA_5722358e-0c0f-4f6d-a934-69c2d8c3deae"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1f19f6eef7f447ee90aa653000871c5d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzE5LTUtMS0xLTA_ee664206-8e6e-438f-8662-69ff2f10ab6c"
      unitRef="usd">19000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1f19f6eef7f447ee90aa653000871c5d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzE5LTctMS0xLTA_de3c3010-442b-47ac-810a-8855a3a35b3b"
      unitRef="usd">18621000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzIwLTEtMS0xLTA_fb9b08ff-b577-4485-b584-956f5bee36a3"
      unitRef="usd">259974000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzIwLTMtMS0xLTA_a99ee895-52ac-48cc-aeab-3af95c342c5c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzIwLTUtMS0xLTA_dff372fc-0816-4020-ae82-9f582ae3c463"
      unitRef="usd">259000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzIwLTctMS0xLTA_16e8d93d-3a33-4df2-aae3-7ca70638c7a7"
      unitRef="usd">259715000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzIxLTEtMS0xLTA_6d1cd510-7593-42cb-b70e-8c0601e4454f"
      unitRef="usd">363265000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzIxLTMtMS0xLTA_fcfcfcbc-99ad-4ca7-b838-fc9e07b06b29"
      unitRef="usd">0</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzIxLTUtMS0xLTA_398da313-cf9e-4efc-b43c-cdf15b0542dd"
      unitRef="usd">259000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax>
    <sgmo:CashEquivalentsAndAvailableForSaleSecurities
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo5OWRmZDk3Zjc3MjA0MjBhYjA1MWZmMWNiNmViMmUzZi90YWJsZXJhbmdlOjk5ZGZkOTdmNzcyMDQyMGFiMDUxZmYxY2I2ZWIyZTNmXzIxLTctMS0xLTA_f00c0b1c-fa31-4a7c-8660-7b3fb7727f30"
      unitRef="usd">363006000</sgmo:CashEquivalentsAndAvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo2ZjRkY2E2Yzg4YjU0MDU2YWNmYjQ4NmNjNWQ4ODU5OS90YWJsZXJhbmdlOjZmNGRjYTZjODhiNTQwNTZhY2ZiNDg2Y2M1ZDg4NTk5XzItMS0xLTEtMTEwNDA_55e4d7f0-d37b-40e5-b15f-7992f7fb6d03"
      unitRef="usd">282046000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo2ZjRkY2E2Yzg4YjU0MDU2YWNmYjQ4NmNjNWQ4ODU5OS90YWJsZXJhbmdlOjZmNGRjYTZjODhiNTQwNTZhY2ZiNDg2Y2M1ZDg4NTk5XzItMy0xLTEtMTEwNDY_9d4a1ea2-b18d-4e5c-a1f0-dfa21d211ce1"
      unitRef="usd">259715000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo2ZjRkY2E2Yzg4YjU0MDU2YWNmYjQ4NmNjNWQ4ODU5OS90YWJsZXJhbmdlOjZmNGRjYTZjODhiNTQwNTZhY2ZiNDg2Y2M1ZDg4NTk5XzMtMS0xLTEtMTEwNDM_0d2beba0-9bda-4b1f-9a78-80113993e287"
      unitRef="usd">21832000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo2ZjRkY2E2Yzg4YjU0MDU2YWNmYjQ4NmNjNWQ4ODU5OS90YWJsZXJhbmdlOjZmNGRjYTZjODhiNTQwNTZhY2ZiNDg2Y2M1ZDg4NTk5XzMtMy0xLTEtMTEwNDk_195316b3-cf66-47b1-b21c-6e3ff45ff18e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo2ZjRkY2E2Yzg4YjU0MDU2YWNmYjQ4NmNjNWQ4ODU5OS90YWJsZXJhbmdlOjZmNGRjYTZjODhiNTQwNTZhY2ZiNDg2Y2M1ZDg4NTk5XzQtMS0xLTEtMTEwNTU_a4301887-2aef-4750-9842-9b3e8028781f"
      unitRef="usd">303878000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90YWJsZTo2ZjRkY2E2Yzg4YjU0MDU2YWNmYjQ4NmNjNWQ4ODU5OS90YWJsZXJhbmdlOjZmNGRjYTZjODhiNTQwNTZhY2ZiNDg2Y2M1ZDg4NTk5XzQtMy0xLTEtMTEwNTI_0e621754-1053-436f-8e90-754f44b6c4fc"
      unitRef="usd">259715000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90ZXh0cmVnaW9uOjk4OGU4MmNjMjFhNDQwMWM4Y2EzMGI4MTFlZDU2NGNhXzI2NA_21c326a9-9753-4ada-a30b-3b5cfad5c5c7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
    <us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90ZXh0cmVnaW9uOjk4OGU4MmNjMjFhNDQwMWM4Y2EzMGI4MTFlZDU2NGNhXzI2NA_231b6234-0bdf-499f-ade4-590facf5bfd7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
    <us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90ZXh0cmVnaW9uOjk4OGU4MmNjMjFhNDQwMWM4Y2EzMGI4MTFlZDU2NGNhXzI2NA_f167d444-d5ee-4321-8616-4de7880a9307"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
    <sgmo:OtherThanTemporarilyImpairedInvestment
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90ZXh0cmVnaW9uOjk4OGU4MmNjMjFhNDQwMWM4Y2EzMGI4MTFlZDU2NGNhXzUxOQ_484f5d90-b581-4d5b-a238-27763592375f"
      unitRef="usd">0</sgmo:OtherThanTemporarilyImpairedInvestment>
    <sgmo:OtherThanTemporarilyImpairedInvestment
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDAvZnJhZzo5ODhlODJjYzIxYTQ0MDFjOGNhMzBiODExZWQ1NjRjYS90ZXh0cmVnaW9uOjk4OGU4MmNjMjFhNDQwMWM4Y2EzMGI4MTFlZDU2NGNhXzUxOQ_b4350391-c1e5-4701-bfb7-542ca1148267"
      unitRef="usd">0</sgmo:OtherThanTemporarilyImpairedInvestment>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzMxMzM4_f9c979d1-0afb-4ce8-a11d-bea86faa1a20">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;NOTE 4 &#x2013; MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Collaboration Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Kite &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2018, the Company entered into a global collaboration and license agreement with Kite Pharma, Inc. (&#x201c;Kite&#x201d;), which became effective on April 5, 2018, and was amended and restated in September 2019, for the research, development and commercialization of potential engineered cell therapies for cancer. In this collaboration, Sangamo is working together with Kite on a research program under which the companies are designing zinc finger nucleases (&#x201c;ZFNs&#x201d;) and viral vectors to disrupt and insert certain genes in T-cells and natural killer cells (&#x201c;NK-cells&#x201d;) including the insertion of genes that encode chimeric antigen receptors (&#x201c;CARs&#x201d;), T-cell receptors (&#x201c;TCRs&#x201d;), and NK-cell receptors (&#x201c;NKRs&#x201d;) directed to mutually agreed targets. Kite is responsible for all clinical development and commercialization of any resulting products and has announced that they expect to initiate a clinical trial evaluating KITE-037, an allogeneic anti-CD19 CAR-T cell therapy, in 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Subject to the terms of this agreement, the Company granted Kite an exclusive, royalty-bearing, worldwide sublicensable license under the Company&#x2019;s relevant patents and know-how to develop, manufacture and commercialize, for the purpose of treating cancer, specific cell therapy products that may result from the research program and that are engineered &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;ex vivo&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; using selected ZFNs and viral vectors developed under the research program to express CARs, TCRs or NKRs directed to candidate targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the research program term and subject to certain exceptions, except pursuant to this agreement, the Company is prohibited from researching, developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;ex vivo&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; genome editing, expresses a CAR, TCR or NKR that is directed to a target expressed on or in a human cancer cell. After the research program term concludes and subject to certain exceptions, except pursuant to this agreement, the Company will be prohibited from developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;ex vivo&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; genome editing, expresses a CAR, TCR or NKR that is directed to a candidate target.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Following the effective date, in April 2018, the Company received a $150.0&#160;million upfront payment from Kite. In addition, Kite will reimburse the Company&#x2019;s direct costs to conduct service under the joint research program provisions of the agreement, and Kite will be responsible for all subsequent development, manufacturing and commercialization of any licensed products. Sangamo is also eligible to receive contingent development- and sales-based milestone payments that could total up to $3.01&#160;billion if all of the specified milestones in this agreement are achieved.&#160;Of this amount, approximately $1.26&#160;billion relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones, and approximately $1.75&#160;billion relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels.&#160;Each development- and sales-based milestone payment is payable (i)&#160;only once for each licensed product, regardless of the number of times that the associated milestone event is achieved by such licensed product, and (ii)&#160;only for the first ten times that the associated milestone event is achieved, regardless of the number of licensed products that may achieve such milestone event. In addition, the Company will be entitled to receive escalating, tiered royalty payments with a percentage in the single digits based on potential future annual worldwide net sales of licensed products. These royalty payments will be subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The initial research term of the agreement is six years. Kite has an option to extend the research term for up to two additional &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzc2OTY1ODE1MDUyMDY_67f3e1f2-17aa-46c8-a608-4185bf8992f1"&gt;one&lt;/span&gt;-year periods for a separate fee of $10.0&#160;million per year. All contingent payments under the agreement, when earned, will be non-refundable and non-creditable. In connection with the amendment and restatement of the agreement in September 2019, the Company entered into a new research plan with Kite, with estimated reimbursable service costs of approximately $3.4&#160;million. The Company concluded the transaction price under this agreement is $189.3&#160;million and includes the upfront license fee of $150.0&#160;million and $39.3&#160;million estimated reimbursable service costs for identified research projects over the estimated performance period. The Company concluded that the estimated fees for the presumed exercise of the research term extension options and all milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur. None of the development and sales-based milestone payments have been included in the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company assessed the agreement with Kite in accordance with ASC Topic 606 and concluded that Kite is a customer. Kite has the right to terminate this agreement, in its entirety or on a per licensed product or per candidate target basis, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;for any reason after a specified notice period. Each party has the right to terminate this agreement on account of the other party&#x2019;s bankruptcy or material, uncured breach.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has identified the primary performance obligations within the Kite agreement as: (1) a license to the technology along with the stand by ready obligation to perform research services, and (2) the on-going research services. Revenue from the upfront license fee relates to access to the license and Company&#x2019;s obligation to stand-ready to perform such research services as additional targets are selected by Kite. As a result of this obligation to perform research services when and if requested throughout the duration of the contract, the fee for the license and the stand-ready obligation will be recognized over time on a straight-line basis through June 2024, the estimated period of the stand-ready obligation. Revenue from the reimbursable costs related to the integrated service deliverable is recognized as the research services are performed. Related costs and expenses under these arrangements have historically approximated the revenues recognized. The estimated period of performance and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its deliverables. As of December&#160;31, 2019, and 2018 the Company had deferred revenue of $106.5&#160;million and $131.5&#160;million, respectively, related to this agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues recognized under the agreement were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.538%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:70.848%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.908%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.541%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.908%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.395%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="12" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenue related to Kite agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Recognition of license and stand-ready fee&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-top:15pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Pfizer &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;SB-525 Global Collaboration and License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In May 2017, the Company entered into an exclusive, global collaboration and license agreement with Pfizer, pursuant to which it established a collaboration for the research, development and commercialization of SB-525, its gene therapy product candidate for hemophilia A, and closely related products.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under this agreement, the Company is responsible for conducting the Phase 1/2 clinical trial and certain manufacturing activities for SB-525, while Pfizer is responsible for subsequent worldwide development, manufacturing, marketing and commercialization of SB-525. Sangamo may also collaborate in the research and development of additional adeno-associated virus ("AAV") based gene therapy products for hemophilia A.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company originally received an upfront fee of $70.0&#160;million and is eligible to receive development milestone payments contingent on the achievement of specified clinical development, intellectual property, regulatory and first commercial sale milestones for SB-525 and potentially other products. In addition, Sangamo is eligible to receive up to $208.5&#160;million in payments upon the achievement of specified clinical development, intellectual property and regulatory milestones and up to $266.5&#160;million in payments upon first commercial sale milestones for SB-525 and potentially other products. The total amount of potential clinical development, intellectual property, regulatory, and first commercial sale milestone payments, assuming the achievement of all specified milestones in the hemophilia A Pfizer agreement, is up to $475.0&#160;million, which includes up to $300.0&#160;million for SB-525 and up to $175.0&#160;million for other products that may be developed under the agreement, subject to reduction on account of payments made under certain licenses for third party intellectual property. In addition, Pfizer agreed to pay the Company royalties for each potential licensed product developed under the agreement based on an escalating tiered, double-digit percentage of the annual net sales of such product. These royalties are subject to reduction due to patent expiration, entry of biosimilar products to the market and payment made under certain licenses for third-party intellectual property. To date, a $25.0&#160;million milestone has been achieved, however no products have been approved and therefore no royalty fees have been earned under the hemophilia A Pfizer agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company assessed the agreement with Pfizer in accordance with ASC Topic 606 and concluded that Pfizer is a customer. As of December 31, 2019, the total transaction price under this agreement is $105.0&#160;million, which represents the upfront and research services fees of $80.0&#160;million and one unconstrained milestone in the amount of $25.0&#160;million. Sangamo is responsible for internal and external research costs as part of the upfront fee and has the ability to request additional reimbursement from Pfizer if certain conditions are met. None of the clinical or regulatory milestones have been included in the transaction price, as all such milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts in each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Subject to the terms of the agreement, the Company granted Pfizer an exclusive worldwide royalty-bearing license, with the right to grant sublicenses, to use certain technology controlled by the Company for the purpose of developing, manufacturing and commercializing SB-525 and related products. Pfizer granted the Company a non-exclusive, worldwide, royalty free, fully paid license, with the right to grant sublicenses, to use certain manufacturing technology developed under the agreement and controlled by Pfizer to manufacture the Company&#x2019;s products that utilize the AAV delivery system. During a specified period, neither the Company nor Pfizer will be permitted to clinically develop or commercialize, outside of the collaboration, certain AAV-based gene therapy products for hemophilia A.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Unless earlier terminated, the agreement has a term that continues on a per product and per country basis until the later of (i)&#160;the expiration of patent claims that cover the product in a country, (ii)&#160;the expiration of regulatory exclusivity for a product in a country, and (iii)&#160;15 years after the first commercial sale of a product in a country. Pfizer has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize SB-525 and related products will automatically terminate. Upon termination by the Company for cause or by Pfizer in any country or countries, Pfizer will automatically grant the Company an exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize SB-525 in the terminated country or countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has identified one performance obligation within the hemophilia A Pfizer agreement as a license to the technology and on-going research services. The Company concluded that the license is not discrete, as it does not have stand-alone value to Pfizer apart from the research services to be performed by the Company pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the on-going services through 2020, the estimated period the Company will perform research services. The estimate of progress towards the satisfaction of its performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its deliverables. As of December&#160;31, 2019 and 2018, the Company had deferred revenue of $4.0&#160;million and $10.0&#160;million, respectively, related to this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2019, the Company entered into an amendment to the collaboration agreement, pursuant to which the Company transferred the IND for SB-525 to Pfizer. Upon this transfer the Company achieved a $25.0&#160;million milestone as the conditions for achieving the milestone were met. The Company recognized approximately $23.7&#160;million attributed to this milestone as revenue during the year ended December 31, 2019. The balance of this payment of $1.3&#160;million will be recognized as revenue commensurate with the provision of research services over the remaining term of the agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues recognized under the agreement were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:57.009%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.063%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.550%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.063%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.851%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.064%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenue related to Pfizer SB-525 agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Recognition of upfront fee and research services&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Milestone achievement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company adopted ASC Topic 606 effective January 1, 2018, using the modified retrospective method. The impact on the hemophilia A Pfizer agreement was to increase the amount of the recognition of the up-front payment by approximately $5.2 million. This amount resulted in a decrease to the opening balance of accumulated deficit and a decrease to deferred revenues, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In the first quarter of 2019, the Company updated its estimated project cost and related revenues under this program. This adjustment was a direct result of the increase in project scope during the first quarter of 2019 and the corresponding costs, which resulted in a decrease in the measure of proportional performance. In December 2019, the Company updated its estimated project cost and related revenues upon transfer of the IND for SB-525 to Pfizer. This adjustment was a direct result of the decrease in project scope during the fourth quarter of 2019 and the corresponding costs, which resulted in an increase in the measure of proportional performance. During the year ended December&#160;31, 2019, the Company recognized $15.7&#160;million in revenues related to the Pfizer SB-525 agreement, which included approximately $8.7 million acceleration in revenues recorded in the three months ended December 31, 2019 related to the updated estimated project cost, offset by approximately $3.0&#160;million reduction in revenues recorded in the three months ended March&#160;31, 2019 related to the updated estimated project cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;C9ORF72 Research Collaboration and License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2017, the Company entered into a separate exclusive, global collaboration and license agreement with Pfizer for the development and commercialization of potential gene therapy products that use ZFP transcription factors (&#x201c;TFs&#x201d;) to treat amyotrophic lateral sclerosis (&#x201c;ALS&#x201d;) and frontotemporal lobar degeneration (&#x201c;FTLD&#x201d;) linked to mutations of the &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;C9ORF72&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; gene. Pursuant to this agreement, the Company agreed to work with Pfizer on a research program to identify, characterize and preclinically develop ZFP-TFs that bind to and specifically reduce expression of the mutant form of the &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;C9ORF72&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; gene.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company received a $12.0&#160;million upfront payment from Pfizer and is eligible to receive up to $60.0&#160;million in development milestone payments from Pfizer contingent on the achievement of specified preclinical development, clinical development and first commercial sale milestones, and up to $90.0&#160;million commercial milestone payments if annual worldwide net sales of the licensed products reach specified levels. In addition, Pfizer will pay the Company royalties based on an escalating tiered, mid- to high-single digit percentage of the annual worldwide net sales of the licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third party intellectual property. Each party will be responsible for the cost of its performance of the research program. Pfizer will be operationally and financially responsible for subsequent development, manufacturing and commercialization of the licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company assessed the agreement with Pfizer in accordance with ASC Topic 606 and concluded that Pfizer is a customer. The Company concluded the total transaction price under this agreement is $12.0&#160;million, which represents the upfront fee. None of the clinical or regulatory milestones have been included in the transaction price, as all milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Subject to the terms of this agreement, the Company granted Pfizer an exclusive, royalty-bearing, worldwide license under the Company&#x2019;s relevant patents and know-how to develop, manufacture and commercialize gene therapy products that use resulting ZFP-TFs that satisfy pre-agreed criteria. During a specified period, neither the Company nor Pfizer will be permitted to research, develop, manufacture or commercialize outside of the collaboration any ZFPs that specifically bind to the &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;C9ORF7&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;2 gene.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Unless earlier terminated, the agreement has a term that continues on a per licensed product and per country basis until the later of (i)&#160;the expiration of patent claims that cover the licensed product in a country, (ii)&#160;the expiration of regulatory exclusivity for a licensed product in a country, and (iii)&#160;15 years after the first commercial sale of a licensed product in a major market country. Pfizer also has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. The agreement will also terminate if the Company is unable to identify any lead candidates for development within a specified period of time or if Pfizer elects not to advance a lead candidate beyond a certain development milestone within a specified period of time. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize licensed products under the agreement will automatically terminate. Upon termination by the Company for cause or by Pfizer without cause for any licensed product or licensed products in any country or countries, the Company will have the right to negotiate with Pfizer to obtain a non-exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize the licensed product or licensed products in the terminated country or countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Following termination by the Company for Pfizer&#x2019;s material breach, Pfizer will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;C9ORF72 &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;gene for a period of time. Following termination by Pfizer for the Company&#x2019;s material breach, the Company will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;C9ORF72&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; gene for a period of time.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has identified the performance obligation within this agreement as a license to the technology and on-going research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Pfizer apart from the services to be performed by the Company pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the on-going services over the estimated period the Company will perform research services. The estimation of progress towards the satisfaction of its performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its deliverables. As of December&#160;31, 2019 and 2018, the Company had deferred revenue of $8.0&#160;million and $9.8&#160;million, respectively, related to this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues recognized under the agreement were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:58.557%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.756%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.386%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.756%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.386%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.759%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Recognition of upfront fee related to Pfizer &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;"&gt;C9ORF72&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt; agreement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-top:15pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Sanofi&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In January 2014, the Company entered into an exclusive worldwide collaboration and license agreement with Bioverativ Inc., (now Sanofi Genzyme, a global business unit of Sanofi S.A. (&#x201c;Sanofi&#x201d;)), to develop therapeutics for hemoglobinopathies, focused on beta thalassemia and sickle cell disease (&#x201c;SCD&#x201d;). The agreement was originally signed with Biogen MA Inc., who subsequently assigned it to Bioverativ Inc., which was later acquired by Sanofi. Under the agreement, the Company is jointly conducting two research programs: the beta thalassemia program and the SCD program. In the beta thalassemia program, the Company is responsible for all discovery, research and development activities through the first human clinical trial. In the SCD program, both parties are responsible for research and development activities through the submission of an IND application for ZFP therapeutics intended to treat SCD.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under both programs, Sanofi is responsible for subsequent worldwide clinical development, manufacturing and commercialization of licensed products developed under the agreement. At the end of the specified research terms for each program or under certain specified circumstances, Sanofi has the right to step in and take over any of the Company&#x2019;s remaining activities. Furthermore, the Company has an option to co-promote in the U.S. any licensed products to treat beta thalassemia and SCD developed under the agreement, and Sanofi will compensate the Company for such co-promotion activities. Subject to the terms of the agreement, the Company has granted Sanofi an exclusive, royalty-bearing license, with the right to grant sublicenses, to use certain ZFP and other technology controlled by the Company for the purpose of researching, developing, manufacturing and commercializing licensed products developed under the agreement. The Company also granted Sanofi a non-exclusive worldwide, royalty-free fully paid license with the right to grant sublicenses, under the Company&#x2019;s interest in certain other intellectual property developed pursuant to the agreement. During the term of the agreement, the Company is not permitted to research, develop, manufacture or commercialize, outside of the agreement, certain gene therapy products that target genes relevant to the licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the agreement, the Company received an upfront license fee of $20.0&#160;million and is eligible to receive development and sales milestone payments upon the achievement of specified regulatory, clinical development and sales milestones. In addition, the Company will also be eligible to receive up to $115.8&#160;million in payments upon the achievement of specified clinical development and regulatory milestones, as well as up to $160.5&#160;million in payments upon the achievement of specified sales milestones. The total amount of potential regulatory, clinical development, and sales milestone payments, assuming the achievement of all specified milestones in the agreement, is up to $276.3&#160;million. In addition, the Company will receive royalty payments for each licensed product that are a tiered double-digit percentage of annual net sales of each product. Sanofi reimburses Sangamo for agreed upon costs incurred in connection with research and development activities conducted by Sangamo. To date, a $6.0&#160;million milestone has been achieved related to ST-400 for beta thalassemia and another $7.5&#160;million milestone has been achieved related to SCD, however no products have been approved and therefore no royalty fees have been earned under the Sanofi agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The agreement may be terminated by (i)&#160;the Company or Sanofi for the uncured material breach of the other party, (ii)&#160;the Company or Sanofi for the bankruptcy or other insolvency proceeding of the other party; (iii)&#160;Sanofi, upon 180 days&#x2019; advance written notice to the Company and (iv)&#160;Sanofi, for certain safety reasons upon written notice to, and after consultation with, the Company. As a result, actual future milestone payments could be lower than the amounts stated above.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;All contingent payments under the agreement, when earned, will be non-refundable and non-creditable. The transaction price as of December 31, 2019 of $89.2&#160;million includes the upfront license fee of $20.0&#160;million, milestones of $13.5&#160;million achieved to date and $55.7&#160;million of estimated research service fees for identified research projects over the estimated performance period, as all unachieved milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur. None of the clinical or regulatory milestones have been included in the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company assessed the agreement with Sanofi in accordance with ASC Topic 606 and concluded that Sanofi is a customer. The Company has identified the performance obligations within this arrangement as a license to the technology and on-going research services activities. The Company concluded that the license is not discrete as it does not have stand-alone value to Sanofi apart from the research services to be performed pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the ongoing services through 2022, the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;estimated period the Company will perform research services. The estimate of progress towards the satisfaction of performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its deliverables. Revenue from the reimbursable costs related to the integrated service deliverable is recognized as the research services are performed. Related costs and expenses under these arrangements have historically approximated the revenues recognized. As of December&#160;31, 2019 and 2018, the Company had deferred revenue of $1.7&#160;million and $4.6&#160;million, respectively, related to this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2019, the Company achieved a $6.0 million milestone with Sanofi upon dosing of the third subject in the ST-400 beta thalassemia Phase 1 clinical trial. The Company recognized approximately $5.7&#160;million attributed to this milestone as revenue during the year ended December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2019, the Company achieved a $7.5 million milestone with Sanofi upon dosing of the first subject in the SCD Phase 1 clinical trial. The Company recognized approximately $7.1&#160;million attributed to this milestone as revenue during the year ended December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues recognized under the agreement were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:58.322%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.740%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenue related to Sanofi agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Recognition of upfront fee&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Milestone achievement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company adopted ASC Topic 606 effective January 1, 2018, using the modified retrospective method. The impact on the Sanofi agreement was to reduce the amount of the recognition of the up-front payment by approximately $4.1 million. This amount resulted in an increase to the opening balance of accumulated deficit and an increase to deferred revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;California Institute for Regenerative Medicine&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In May 2018, the California Institute for Regenerative Medicine (&#x201c;CIRM&#x201d;) granted a Strategic Partnership Award for $8.0&#160;million to fund the clinical studies of a potentially curative ZFP therapeutic for the treatment of beta thalassemia based on the application of Sangamo&#x2019;s ZFN genome editing technology. The grant exists through December&#160;31, 2022 and provides matching funds to support the evaluate ST-400, a gene-edited cell therapy candidate for people with transfusion-dependent beta&#160;thalassemia. As of December&#160;31, 2019, the Company had received $5.2&#160;million under the award.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the terms of the CIRM grants, the Company is obligated to pay royalties and licensing fees based on a low single digit royalty percentage on net sales of CIRM-funded product candidates or CIRM-funded technology. The Company has the option to decline any and all amounts awarded by CIRM and as an alternative to revenue sharing, the Company has the option to convert the award to a loan. No such election has been made as of the date of the issuance of these financial statements. In the event that the Company terminates a CIRM-funded clinical trial, it will be obligated to repay the remaining CIRM funds on hand. As of December&#160;31, 2019 and 2018, $5.7&#160;million and $1.8&#160;million, respectively, including accrued interest, related to this award is recorded as a loan in other long-term liabilities on the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Amended Collaboration and License Agreement with Takeda&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In January 2012, the Company entered into a collaboration and license agreement with Shire International GmbH, a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (&#x201c;Takeda&#x201d;), to research, develop and commercialize a ZFP therapeutic for treating Huntington&#x2019;s disease. The Company received an upfront license fee of $13.0&#160;million. In 2014, Sangamo recognized a $1.0&#160;million milestone payment related to the hemophilia program. Takeda does not have any milestone payment obligations, but is required to pay single digit percentage royalties to the Company, up to a specified maximum cap, on the commercial sales of therapeutic products for Huntington&#x2019;s disease. The Company is required to pay single digit percentage royalties to Takeda, up to a specified maximum cap, on commercial sales of therapeutic products from programs returned under the original agreement (which include blood clotting Factors VIII and IX) that use two zinc fingers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Pursuant to the agreement, the Company granted Takeda an exclusive, world-wide, royalty-bearing license, with the right to grant sublicenses, to use the Company&#x2019;s ZFP technology for the purpose of developing and commercializing human therapeutic and diagnostic products for the Huntingtin gene (&#x201c;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;HTT&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; gene&#x201d;). During the term of the agreement, the Company is not permitted to research, develop or commercialize, outside of the agreement, certain products that target the &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;HTT&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; gene. The agreement may be terminated by (i)&#160;the Company or Takeda, in whole or in part, for the uncured material breach of the other &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;party, (ii)&#160;the Company or Takeda for the bankruptcy or other insolvency proceeding of the other party and (iii)&#160;Takeda, in its entirety, effective upon at least 90 days&#x2019; advance written notice.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company assessed the agreement with Takeda in accordance with ASC Topic 606 and concluded that Takeda is a customer. The Company has concluded that the license is not a separate unit of accounting as it does not have stand-alone value to Takeda apart from the research services to be performed pursuant to the Takeda agreement. The Company satisfied the deliverables and research services responsibilities within the amended arrangement which were completed in 2017. As a result, the Company recognized the remaining $2.3&#160;million of deferred revenue from the upfront payment during the year ended December 31, 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues recognized under the Takeda agreement for the years ended December&#160;31, 2019, 2018 and 2017, were $0.0&#160;million, $0.0&#160;million and $2.4&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Agreement with Sigma-Aldrich Corporation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In 2007, Sangamo entered into a license agreement with Sigma-Aldrich Corporation ("Sigma") to provide Sigma with access to Sangamo&#x2019;s proprietary ZFP technology and the exclusive right to use the technology to develop and commercialize research reagent products and services in the research field, excluding certain agricultural research uses that Sangamo previously licensed to Dow AgroSciences LLC ("DAS"), a wholly-owned subsidiary of Dow Chemical Company. Sangamo developed laboratory research reagents using its ZFP technology over a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI3OTg0_c09101db-17d8-4575-842f-cc8f133a684e"&gt;three&lt;/span&gt;-year research services period. Sangamo has since transferred the ZFP manufacturing technology to Sigma.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In October 2009, Sangamo expanded its license agreement with Sigma. In addition to the original terms of the license agreement, Sigma received exclusive rights to develop and distribute ZFP-modified cell lines for commercial production of protein pharmaceuticals and certain ZFP-engineered transgenic animals for commercial applications. Under the terms of the agreement, Sigma made an upfront cash payment of $20.0&#160;million consisting of a $4.9&#160;million purchase of 636,133 shares of Sangamo common stock, valued at $4.9&#160;million, and a $15.1&#160;million upfront license fee. Sangamo is also eligible to receive commercial license fees of $5.0&#160;million based upon a percentage of net sales and sublicensing revenue and thereafter a reduced royalty rate of 10.5% of net sales and sublicensing revenue. In addition, upon the achievement of certain cumulative commercial milestones, Sigma will make milestone payments to Sangamo up to an aggregate of $25.0&#160;million. Sangamo does not have additional ongoing performance obligations under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues recognized under the agreement with Sigma for the years ended December&#160;31, 2019, 2018 and 2017, were $0.6&#160;million, $0.5&#160;million and $0.7&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Agreement with DAS&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In 2005, Sangamo entered into an exclusive commercial license with DAS, with an initial &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI5MzIy_7d482839-f2da-4dcc-a0a2-fb576c2847cb"&gt;three&lt;/span&gt;-year research term. Under this agreement, Sangamo is providing DAS with access to its proprietary ZFP technology and the exclusive right to use the technology to modify the genomes or alter the nucleic acid or protein expression of plant cells, plants, or plant cell cultures. Sangamo has retained rights to use plants or plant-derived products to deliver ZFP-TFs or ZFNs into humans or animals for diagnostic, therapeutic or prophylactic purposes. In 2008, DAS exercised its option and obtained a commercial license to sell products incorporating or derived from plant cells generated using the Company&#x2019;s ZFP technology. The exercise of the option triggered a one-time commercial license fee of $6.0&#160;million, payment of the remaining $2.3&#160;million of the previously agreed upon $4.0&#160;million in research milestones, development and commercialization milestone payments for each product, and royalties on sales of products. Furthermore, DAS has the right to sublicense Sangamo&#x2019;s ZFP technology to third parties for use in plant cells, plants, or plant cell cultures, and Sangamo will be entitled to 25% of any cash consideration received by DAS under such sublicenses. In December 2010, the Company amended its agreement with DAS to extend the period of reagent manufacturing services and research services through December&#160;31, 2012.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The agreement with DAS also provides for minimum sublicense fees each year due to Sangamo every October, provided the agreement is not terminated by DAS. Annual fees range from $0.3&#160;million to $3.0&#160;million and total $25.3&#160;million over 11 years unless terminated at any time by DAS. The Company has identified the performance obligation within this arrangement as a license to the technology. In the event of any termination of the agreement, all rights to use the Company&#x2019;s ZFP technology will revert to Sangamo, and DAS will no longer be permitted to practice Sangamo&#x2019;s ZFP technology or to develop or, except in limited circumstances, commercialize any products derived from the Company&#x2019;s ZFP technology.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues under the agreement with DAS were $3.0&#160;million, $3.0&#160;million, and $3.0&#160;million during 2019, 2018 and 2017, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <sgmo:MilestonePaymentsReceived
      contextRef="ie60f0866d78349d39fcb444b085ce632_D20180401-20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzIwNzI_60538a14-24fb-4a48-aee8-6cfc4b5520b0"
      unitRef="usd">150000000.0</sgmo:MilestonePaymentsReceived>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="i61fd7d98b04648caaf9d32dec4a807ec_D20180404-20180405"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI0ODQ_e724bd82-72cb-4153-88c2-61bbde39d989"
      unitRef="usd">3010000000.00</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived
      contextRef="i5a2cd91a4f284017a4ef2d70e422e99c_D20180404-20180405"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI1OTQ_71ebece2-d367-4309-8c93-eaa4cce64611"
      unitRef="usd">1260000000</sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived>
    <sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived
      contextRef="i48416dd30d974b1aad80f204b2aabe20_D20180404-20180405"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI3MzY_f9bcbaff-e6b4-4ec6-963a-5a9e85cdd82a"
      unitRef="usd">1750000000</sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived>
    <sgmo:InitialResearchTermOfAgreement
      contextRef="id7d82acff2b8474488fc135b1be65d92_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzM3MTI_dd0efe33-72c4-42af-86d2-1b9ca6f1ad7a">P6Y</sgmo:InitialResearchTermOfAgreement>
    <sgmo:NumberOfOptionsToExtendInitialResearchTerm
      contextRef="id7d82acff2b8474488fc135b1be65d92_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzc2OTY1ODE1MDUyMjE_a71e27a5-5a6e-444e-83df-53024f477c51"
      unitRef="option">2</sgmo:NumberOfOptionsToExtendInitialResearchTerm>
    <sgmo:SeparateUpfrontFee
      contextRef="id7d82acff2b8474488fc135b1be65d92_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzM4MjE_6dd3e40f-9591-48c2-8b21-a9e18c8f3d86"
      unitRef="usd">10000000.0</sgmo:SeparateUpfrontFee>
    <sgmo:CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan
      contextRef="i6fff5fa4d22f420dbc13bcf64a19b587_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzE0MjkzNjUxMjU2NzM1_2b7a1fe4-86c7-4520-a98f-2c870dd722c2"
      unitRef="usd">3400000</sgmo:CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan>
    <sgmo:CollaborativeArrangementTransactionPrice
      contextRef="i6fff5fa4d22f420dbc13bcf64a19b587_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzQwMDM_2aee23c6-bcf4-4f44-b331-4f6b311b5d14"
      unitRef="usd">189300000</sgmo:CollaborativeArrangementTransactionPrice>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="i6fff5fa4d22f420dbc13bcf64a19b587_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzQwNDY_66a7ac79-69ef-4e27-bddc-c3ab9b86e0f6"
      unitRef="usd">150000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts
      contextRef="i6fff5fa4d22f420dbc13bcf64a19b587_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzQwNTM_36dfe647-6662-40f7-b7be-1bff11b74540"
      unitRef="usd">39300000</sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i0c5a81250c2e4e6992c7624e2f50a5b0_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzQ5NDc4MDIzNzY0MDE_44544706-fa52-4b0c-8007-b296e0c860a9"
      unitRef="usd">106500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i654a0f9976964892b5f266a6a5e30461_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzQ5NDc4MDIzNzYzNzQ_1cb8a823-c7f3-4f12-ba44-db83c7d3ba4c"
      unitRef="usd">131500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="if5e9da2152d548ad9e46e4ebe09d9cc7_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzc2OTY1ODE0ODMyMTE_c5118510-1497-4015-be21-3a7dc6473234">&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues recognized under the agreement were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.538%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:70.848%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.908%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.541%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.908%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.395%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="12" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenue related to Kite agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Recognition of license and stand-ready fee&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i592dd2531c234441a8b4b503c5e33bdf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTo4ZGIyMzU4NzY1YmM0ZTNhYWY5MGY2NTU3MzZkZjRmMS90YWJsZXJhbmdlOjhkYjIzNTg3NjViYzRlM2FhZjkwZjY1NTczNmRmNGYxXzMtMS0xLTEtNTA0OA_682b513b-5a2b-4d57-a9ac-dfb0123ab60c"
      unitRef="usd">24977000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i88cf0e3541a3458eae231fe54f01b5e1_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTo4ZGIyMzU4NzY1YmM0ZTNhYWY5MGY2NTU3MzZkZjRmMS90YWJsZXJhbmdlOjhkYjIzNTg3NjViYzRlM2FhZjkwZjY1NTczNmRmNGYxXzMtMy0xLTEtNTA0NQ_2cca5209-07c5-4360-b55f-0c8781d1a991"
      unitRef="usd">18545000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i55753e9172b14060be72e0417c8e4ee5_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTo4ZGIyMzU4NzY1YmM0ZTNhYWY5MGY2NTU3MzZkZjRmMS90YWJsZXJhbmdlOjhkYjIzNTg3NjViYzRlM2FhZjkwZjY1NTczNmRmNGYxXzQtMS0xLTEtNTA0OA_a5a6e28a-5e4e-4cc9-8e9b-dcbe09e75ae6"
      unitRef="usd">9373000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60584ff2a34d45fb9afa66b5a623a4b2_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTo4ZGIyMzU4NzY1YmM0ZTNhYWY5MGY2NTU3MzZkZjRmMS90YWJsZXJhbmdlOjhkYjIzNTg3NjViYzRlM2FhZjkwZjY1NTczNmRmNGYxXzQtMy0xLTEtNTA0NQ_d1eb89cb-b222-485b-8c2f-85931ee6e898"
      unitRef="usd">6972000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if5e9da2152d548ad9e46e4ebe09d9cc7_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTo4ZGIyMzU4NzY1YmM0ZTNhYWY5MGY2NTU3MzZkZjRmMS90YWJsZXJhbmdlOjhkYjIzNTg3NjViYzRlM2FhZjkwZjY1NTczNmRmNGYxXzUtMS0xLTEtNTA0OA_b0bef5f8-09c1-4fa4-a67f-49fe00813944"
      unitRef="usd">34350000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ied53c137399045e198eb8eede660e8f2_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTo4ZGIyMzU4NzY1YmM0ZTNhYWY5MGY2NTU3MzZkZjRmMS90YWJsZXJhbmdlOjhkYjIzNTg3NjViYzRlM2FhZjkwZjY1NTczNmRmNGYxXzUtMy0xLTEtNTA0NQ_3becda25-74f1-43f0-be64-ca5e95bf428f"
      unitRef="usd">25517000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="ib08e3f2b116d4fe8846432aa9f1fb42f_D20170501-20170531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzcwMjU_63ea5a25-2faf-4228-8d1a-935d17d2fbca"
      unitRef="usd">70000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="i8a64f9da293b4fb5998f17bc3ebc159f_D20170501-20170531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzczMTU_259e4915-2fdb-4a8c-bf8f-955c8e62f325"
      unitRef="usd">208500000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive
      contextRef="i0eb4d4a7fdf7414bbcd0bcbb337d0b56_D20170501-20170531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzc0NDQ_131f73d4-df78-4cc0-ad26-60a3bdf3456f"
      unitRef="usd">266500000</sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="i9107973e10124be1aa15439229671e5f_D20170501-20170531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzc3NzM_13d6630a-ffcc-46b1-914e-33b741edfcb5"
      unitRef="usd">475000000.0</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:MilestoneRevenueReceivable
      contextRef="i45470bac3a3d46c59bc142131a59b782_I20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzc3OTg_1e4ecab5-a2c2-4ab6-975e-b2bff467828d"
      unitRef="usd">300000000.0</sgmo:MilestoneRevenueReceivable>
    <sgmo:MilestoneRevenueReceivable
      contextRef="ibfcf378e55cd4dc89b34b84d7fc85aa2_I20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzc4MjI_c39b0fa2-d743-46ad-9db9-62d0cd253781"
      unitRef="usd">175000000.0</sgmo:MilestoneRevenueReceivable>
    <sgmo:MilestoneRevenueReceivable
      contextRef="if20dd4173a934bb9bfd3c1d39c91de1b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzEwNDQ1MzYwNTUyNzYy_c5d77b87-3d51-4e57-ab48-346073d56802"
      unitRef="usd">25000000.0</sgmo:MilestoneRevenueReceivable>
    <sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement
      contextRef="idc78178116cc4805a2503e4d1f1172dd_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzg0NDY_2d8319df-5439-4270-80f4-2c636938293e"
      unitRef="product">0</sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement>
    <sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice
      contextRef="i9b68588d42cd47f383c50071fab098fa_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzg0OTE_dc4ddd87-87e8-404f-9613-05663c06774f"
      unitRef="milestone">0</sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice>
    <sgmo:CollaborativeArrangementTransactionPrice
      contextRef="idc78178116cc4805a2503e4d1f1172dd_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzg3OTYwOTMxMzQyNDc_519dd27b-e3b7-48e3-9515-d46829025d1a"
      unitRef="usd">105000000.0</sgmo:CollaborativeArrangementTransactionPrice>
    <sgmo:CollaborativeArrangementResearchServiceFees
      contextRef="idc78178116cc4805a2503e4d1f1172dd_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzg3OTYwOTMxMzQzMTc_cbe27861-8039-41b9-acc2-27da27bd3b28"
      unitRef="usd">80000000.0</sgmo:CollaborativeArrangementResearchServiceFees>
    <sgmo:MilestoneRevenueReceivable
      contextRef="if20dd4173a934bb9bfd3c1d39c91de1b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzg3OTYwOTMxMzQzNTI_c5d77b87-3d51-4e57-ab48-346073d56802"
      unitRef="usd">25000000.0</sgmo:MilestoneRevenueReceivable>
    <sgmo:AgreementTerminationTerm
      contextRef="idc78178116cc4805a2503e4d1f1172dd_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzc2OTY1ODE1MDQ4MDE_d3b54ce5-2367-429f-a8da-409807b32697">P15Y</sgmo:AgreementTerminationTerm>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i8bbeb9bd0c5c4a2da841e90386104e1a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzQ5NDc4MDIzNzY0MjQ_0a286c2a-8c11-41a4-aa2d-248fb240e5c5"
      unitRef="usd">4000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i1e978c226de34436b68f163f5e4d3354_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzQ5NDc4MDIzNzY0MzA_51b7a418-74bc-4092-aea0-7146ea754b70"
      unitRef="usd">10000000.0</us-gaap:ContractWithCustomerLiability>
    <sgmo:MilestoneRevenueReceivable
      contextRef="if20dd4173a934bb9bfd3c1d39c91de1b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzg3OTYwOTMxMTcwMDA_c5d77b87-3d51-4e57-ab48-346073d56802"
      unitRef="usd">25000000.0</sgmo:MilestoneRevenueReceivable>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i842d5727afc443408e09ed5a522e2a9e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzg3OTYwOTMxMzQxNzk_5666f5f7-a024-4ee2-8bcc-f91bdad28510"
      unitRef="usd">23700000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="if20dd4173a934bb9bfd3c1d39c91de1b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzg3OTYwOTMxMzUwMTY_275e3874-abad-49a9-adf9-00c9b5591e55"
      unitRef="usd">1300000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="idc78178116cc4805a2503e4d1f1172dd_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzc2OTY1ODE1MDYxMTU_d762121d-ec88-463e-a8e9-130adf9a4b70">&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues recognized under the agreement were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:57.009%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.063%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.550%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.063%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.851%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.064%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenue related to Pfizer SB-525 agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Recognition of upfront fee and research services&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Milestone achievement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ea749f7283a4e3fbab4d679c510b03b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTphMjQxNWNkZDU5MmM0ZTdhOTNmZjNjYjhhOGIwZThjYi90YWJsZXJhbmdlOmEyNDE1Y2RkNTkyYzRlN2E5M2ZmM2NiOGE4YjBlOGNiXzMtMS0xLTEtNTIxMw_31964fdf-4c7e-4848-998d-916fd3dff137"
      unitRef="usd">15697000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if9de85d493b645f38a1e2fc527b2126e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTphMjQxNWNkZDU5MmM0ZTdhOTNmZjNjYjhhOGIwZThjYi90YWJsZXJhbmdlOmEyNDE1Y2RkNTkyYzRlN2E5M2ZmM2NiOGE4YjBlOGNiXzMtMy0xLTEtNTIxMA_4e42e66c-dd9a-4ffe-baf6-4b84a39f4923"
      unitRef="usd">37810000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee1c5c93e9564920af22cdeb55d9889b_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTphMjQxNWNkZDU5MmM0ZTdhOTNmZjNjYjhhOGIwZThjYi90YWJsZXJhbmdlOmEyNDE1Y2RkNTkyYzRlN2E5M2ZmM2NiOGE4YjBlOGNiXzMtNS0xLTEtOTM3Mw_a417a27a-bb63-4904-a6df-5501faba41d0"
      unitRef="usd">17008000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8eb9a2216c044b17b0ac853396d42bed_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTphMjQxNWNkZDU5MmM0ZTdhOTNmZjNjYjhhOGIwZThjYi90YWJsZXJhbmdlOmEyNDE1Y2RkNTkyYzRlN2E5M2ZmM2NiOGE4YjBlOGNiXzQtMS0xLTEtOTc1OQ_d0fd1934-dfd6-4fba-b982-cbefa94f9b38"
      unitRef="usd">23662000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f1ee4fd337946f69c2e711004e9eb21_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTphMjQxNWNkZDU5MmM0ZTdhOTNmZjNjYjhhOGIwZThjYi90YWJsZXJhbmdlOmEyNDE1Y2RkNTkyYzRlN2E5M2ZmM2NiOGE4YjBlOGNiXzQtMy0xLTEtOTg0Mg_bcab4248-11bd-407f-8727-d660d9074681"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1c6f765722544bbfaa11a0f9c28106ee_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTphMjQxNWNkZDU5MmM0ZTdhOTNmZjNjYjhhOGIwZThjYi90YWJsZXJhbmdlOmEyNDE1Y2RkNTkyYzRlN2E5M2ZmM2NiOGE4YjBlOGNiXzQtNS0xLTEtOTg0NA_40bab3bb-ab52-48f0-8114-14af8b0fc7ca"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc78178116cc4805a2503e4d1f1172dd_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTphMjQxNWNkZDU5MmM0ZTdhOTNmZjNjYjhhOGIwZThjYi90YWJsZXJhbmdlOmEyNDE1Y2RkNTkyYzRlN2E5M2ZmM2NiOGE4YjBlOGNiXzUtMS0xLTEtOTc2Ng_bd3e1e7d-cffb-45e6-9a47-af196b48c8a2"
      unitRef="usd">39359000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i76d9c47628c147369b1a84918e870f8d_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTphMjQxNWNkZDU5MmM0ZTdhOTNmZjNjYjhhOGIwZThjYi90YWJsZXJhbmdlOmEyNDE1Y2RkNTkyYzRlN2E5M2ZmM2NiOGE4YjBlOGNiXzUtMy0xLTEtOTc2OQ_72f93d34-65eb-4d8f-8406-b89572f9c5dd"
      unitRef="usd">37810000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib5b7be714d56483bab2fd4aec159f370_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTphMjQxNWNkZDU5MmM0ZTdhOTNmZjNjYjhhOGIwZThjYi90YWJsZXJhbmdlOmEyNDE1Y2RkNTkyYzRlN2E5M2ZmM2NiOGE4YjBlOGNiXzUtNS0xLTEtOTc3MQ_21d50077-3973-43d1-9bb3-16375d363282"
      unitRef="usd">17008000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DeferredRevenue
      contextRef="i0a295f36997b4eaf8c2fed03755d5526_I20180101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzg3OTYwOTMxMzM4ODE_58071a9f-3cfa-43bc-8087-444c61174905"
      unitRef="usd">-5200000</us-gaap:DeferredRevenue>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="i252ea1e80afe41d99972b07af7af8a3c_I20180101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzg3OTYwOTMxMzM4ODE_c1861cb3-12a0-4fc0-aa08-d8395a176fb5"
      unitRef="usd">5200000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ea749f7283a4e3fbab4d679c510b03b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzQ5NDc4MDIzNzgzMDU_a4a63c57-a40e-4f80-8031-dba559fd269d"
      unitRef="usd">15700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id9888cd53fcb4fb4984e5cdbd778c03e_D20191001-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzE0ODQzNDA3MDcxMzI2_9744cc83-d3cc-4189-b5c4-04724118c686"
      unitRef="usd">8700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
      contextRef="icbb6596bfa944145ba083c1d73a1a730_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzQ5NDc4MDIzNzgyOTA_33b769ef-5e51-4195-8a6f-43d361284770"
      unitRef="usd">-3000000.0</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress>
    <sgmo:MilestonePaymentsReceived
      contextRef="i5b20df771908439ba01919ecb4994be8_D20171201-20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzEyODc4_49e0f507-2cc6-4161-8951-33af6ae45f68"
      unitRef="usd">12000000.0</sgmo:MilestonePaymentsReceived>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="ie5bbca9d2dbf4f0e989cbeebb1a8e942_D20171201-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzEyOTQy_0cd6c361-26a3-462c-b6d1-e6b1b347061a"
      unitRef="usd">60000000.0</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="i784a445513064edf8cf105a58b0207fe_D20171201-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzEzMTI4_2952de68-9c12-4b6b-95f1-49e3b2c73230"
      unitRef="usd">90000000.0</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="i669f42753a6d4d3b8f142135705a640e_D20171201-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzEzOTIz_897706d7-be73-446c-9e98-fa230de0d500"
      unitRef="usd">12000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <sgmo:AgreementTerminationTerm
      contextRef="i954ad6bfa1174ad180a78ff9de20535e_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzc2OTY1ODE1MDQ3ODI_9fe24986-5388-46b5-9448-e19683f11b84">P15Y</sgmo:AgreementTerminationTerm>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i79f178df8ea344e18c904ab658ab8f74_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzQ5NDc4MDI0MDIwODY_1571f3b1-be01-40f3-89d7-19402489c511"
      unitRef="usd">8000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i6c762905a0724124a285c0f906b72d49_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzQ5NDc4MDI0MDIwNjQ_d247f5c3-b393-47b9-925f-7d16d88093b1"
      unitRef="usd">9800000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i954ad6bfa1174ad180a78ff9de20535e_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzc2OTY1ODE0ODMyMTM_2e0953d8-539b-43ee-956a-4f4624cbbe87">&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues recognized under the agreement were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:58.557%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.756%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.386%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.756%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.386%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.759%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Recognition of upfront fee related to Pfizer &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;"&gt;C9ORF72&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt; agreement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e9a9a3d68204a2f8ed5bcfe24fa0f3e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTo0NzUwNTkyNzBmYzk0N2M3OGNmMTcxZTcwNDYwYmZmZS90YWJsZXJhbmdlOjQ3NTA1OTI3MGZjOTQ3Yzc4Y2YxNzFlNzA0NjBiZmZlXzMtMS0xLTEtNTQ1Nw_99fb3ca1-c751-44bf-8cb6-f58c090dc6b9"
      unitRef="usd">1827000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c7f53a3724d4a1ea2ce16319a2ee764_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTo0NzUwNTkyNzBmYzk0N2M3OGNmMTcxZTcwNDYwYmZmZS90YWJsZXJhbmdlOjQ3NTA1OTI3MGZjOTQ3Yzc4Y2YxNzFlNzA0NjBiZmZlXzMtMy0xLTEtNTQ1Mw_7eec5af8-e52e-429e-8b4f-d8965fc72a45"
      unitRef="usd">2188000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i46960a0dc45d40db8392d2fe6db2d9e9_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTo0NzUwNTkyNzBmYzk0N2M3OGNmMTcxZTcwNDYwYmZmZS90YWJsZXJhbmdlOjQ3NTA1OTI3MGZjOTQ3Yzc4Y2YxNzFlNzA0NjBiZmZlXzMtNS0xLTEtMTM5OTU_8b551e63-0a55-4f08-b0c2-46cbed43a895"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:NumberOfResearchProgram
      contextRef="i1c5f6e7f39144671adf58c072211193c_D20140101-20140131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzE4MjU1_c2277b96-d795-4a93-8911-5b49060c9258"
      unitRef="program">2</sgmo:NumberOfResearchProgram>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="i1c5f6e7f39144671adf58c072211193c_D20140101-20140131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzIwMTc5_9d3f5bf6-cc79-47b1-a5a3-42fe887a8151"
      unitRef="usd">20000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="ide4c76d2770741e89547b697a3e8b894_D20140101-20140131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzIwNDAz_001d9b50-dc7d-48fa-8616-8b82dd30c94c"
      unitRef="usd">115800000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="ifcd9eaedbbb14396a42bb76c734bf9f5_D20140101-20140131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzIwNTE3_7150f758-a473-47a1-ac89-c14175b30c87"
      unitRef="usd">160500000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="icb1c764229f147c2a7d82f2bb4a2592a_D20140101-20140131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzIwNzU4_056ddd75-f0ab-4c6c-8847-47861146ddda"
      unitRef="usd">276300000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:MilestonePaymentsReceived
      contextRef="i6b38594263d44b798c13984fcfd972f8_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzg3OTYwOTMxMTcxMTE_98f21333-5f09-492a-b0da-87b9409faf0d"
      unitRef="usd">6000000.0</sgmo:MilestonePaymentsReceived>
    <sgmo:MilestoneRevenueReceivable
      contextRef="ia2073bd7907645caa45aa97ed6850de4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzU0OTc1NTgyMjI1MTY_2fb2af08-0c4b-470b-97e1-34a71d6b5551"
      unitRef="usd">7500000</sgmo:MilestoneRevenueReceivable>
    <sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement
      contextRef="i468bde9877fb45c2847c91221ba681bc_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzIxMTE0_0993b003-3df9-42a8-a8fd-9943f3dfd2e9"
      unitRef="product">0</sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement>
    <sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice
      contextRef="i8c872fa7b5024839a68c8f629085727c_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzIxMTU5_6c2f2b2f-121c-480b-899f-024c1823cb07"
      unitRef="milestone">0</sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice>
    <sgmo:AgreementTerminationTerm
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzExNTQ0ODcyMjAzMzYy_91ad9bf8-a028-45f6-a008-b9f0eb015c57">P180D</sgmo:AgreementTerminationTerm>
    <sgmo:CollaborativeArrangementTransactionPrice
      contextRef="i8c872fa7b5024839a68c8f629085727c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzg3OTYwOTMxMzQ1MTA_dbad5923-72f9-43ad-9546-6c45f87f162e"
      unitRef="usd">89200000</sgmo:CollaborativeArrangementTransactionPrice>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="i8c872fa7b5024839a68c8f629085727c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzIxODgz_0ef3d919-0a19-4cde-aef8-fc8f7338e783"
      unitRef="usd">20000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <sgmo:MilestoneRevenueReceivable
      contextRef="id798c385c8724e4b930793259339b22a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzg3OTYwOTMxMzQ0MzU_6be9dfcc-0fa7-48ab-80cf-b2e55f97eb6e"
      unitRef="usd">13500000</sgmo:MilestoneRevenueReceivable>
    <sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts
      contextRef="i8c872fa7b5024839a68c8f629085727c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzIxODkw_de6fe6d0-c605-4a97-8278-85fcc9037a7e"
      unitRef="usd">55700000</sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i1ca1d25b473647beac3e5c4cee84dd0f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzU0OTc1NTgyMjU3NTM_479b9c01-1c9b-4cd6-a523-32f22f0ce0ea"
      unitRef="usd">1700000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i93e6aa3bc6514e649306cb264521204b_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzU0OTc1NTgyMjU3MzI_60ae53a9-e61a-45b2-ba3e-7de261dc9bb1"
      unitRef="usd">4600000</us-gaap:ContractWithCustomerLiability>
    <sgmo:MilestoneRevenueReceivable
      contextRef="i92f62c13c94a433aa1ad8a4a8220be8f_I20190831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzc2OTY1ODE0ODk0MTE_d81f87a0-d4e0-4c03-a7af-4888c2c29f14"
      unitRef="usd">6000000.0</sgmo:MilestoneRevenueReceivable>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="id06c1dce0e884cdcba296deaf34a622e_D20190801-20190831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzg3OTYwOTMxMzQwMTg_0932f9d3-da36-4059-a76a-5c8de8a36e2b"
      unitRef="usd">5700000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <sgmo:MilestoneRevenueReceivable
      contextRef="ia2073bd7907645caa45aa97ed6850de4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzc2OTY1ODE0ODkzOTI_b9377ae2-8073-475c-91a1-b1467fc20a6d"
      unitRef="usd">7500000</sgmo:MilestoneRevenueReceivable>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i8c872fa7b5024839a68c8f629085727c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzg3OTYwOTMxMzQwODQ_27540115-482a-4dfe-8937-10ad271e873d"
      unitRef="usd">7100000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i468bde9877fb45c2847c91221ba681bc_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzMxMzM3_35ef29ef-6c56-4894-b71f-f7fcdcb1855a">&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues recognized under the agreement were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:58.322%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.740%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenue related to Sanofi agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Recognition of upfront fee&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Milestone achievement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i39eb352d7a3a4602a414826990f703bc_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTo2N2I0NmI0ZjU0MTk0M2RiYmNiMTMyNmUwOWEzZmE3Yy90YWJsZXJhbmdlOjY3YjQ2YjRmNTQxOTQzZGJiY2IxMzI2ZTA5YTNmYTdjXzMtMS0xLTEtMA_106f255d-2edf-48f1-95a5-91141d70f1ba"
      unitRef="usd">3494000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5c9ff652355349cab75acdd86216b11a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTo2N2I0NmI0ZjU0MTk0M2RiYmNiMTMyNmUwOWEzZmE3Yy90YWJsZXJhbmdlOjY3YjQ2YjRmNTQxOTQzZGJiY2IxMzI2ZTA5YTNmYTdjXzMtMy0xLTEtMA_ed6faedc-2548-4134-8738-3012b1e8ffd9"
      unitRef="usd">4013000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1836a0ed76fa4e068cc55bae1f1659ca_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTo2N2I0NmI0ZjU0MTk0M2RiYmNiMTMyNmUwOWEzZmE3Yy90YWJsZXJhbmdlOjY3YjQ2YjRmNTQxOTQzZGJiY2IxMzI2ZTA5YTNmYTdjXzMtNS0xLTEtMA_ca20105e-dc8e-48c9-8525-d4ae1dcd1f06"
      unitRef="usd">1769000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0bdd6ca51cf249bc84de380a836fb539_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTo2N2I0NmI0ZjU0MTk0M2RiYmNiMTMyNmUwOWEzZmE3Yy90YWJsZXJhbmdlOjY3YjQ2YjRmNTQxOTQzZGJiY2IxMzI2ZTA5YTNmYTdjXzQtMS0xLTEtMA_ac51cd8b-1381-4643-8de1-78e5bdf609b6"
      unitRef="usd">6367000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibab98dee0c264ff0a13f3976dfdd1ed3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTo2N2I0NmI0ZjU0MTk0M2RiYmNiMTMyNmUwOWEzZmE3Yy90YWJsZXJhbmdlOjY3YjQ2YjRmNTQxOTQzZGJiY2IxMzI2ZTA5YTNmYTdjXzQtMy0xLTEtMA_e8c7c1b9-bf34-40fb-a9f2-3e6a249cbe13"
      unitRef="usd">9503000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4c1fc611498b4ec7ab651f582d24bb0b_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTo2N2I0NmI0ZjU0MTk0M2RiYmNiMTMyNmUwOWEzZmE3Yy90YWJsZXJhbmdlOjY3YjQ2YjRmNTQxOTQzZGJiY2IxMzI2ZTA5YTNmYTdjXzQtNS0xLTEtMA_ff4d43e8-657f-4bc3-9c3d-b7ed079954b9"
      unitRef="usd">10489000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab2ce2c2494147e0a8a6070d64cfe4c8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTo2N2I0NmI0ZjU0MTk0M2RiYmNiMTMyNmUwOWEzZmE3Yy90YWJsZXJhbmdlOjY3YjQ2YjRmNTQxOTQzZGJiY2IxMzI2ZTA5YTNmYTdjXzUtMS0xLTEtOTgwMw_1be66698-25ac-4868-9922-fd924dfb605f"
      unitRef="usd">12819000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4c8c31caf97141fd95d9194c142029af_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTo2N2I0NmI0ZjU0MTk0M2RiYmNiMTMyNmUwOWEzZmE3Yy90YWJsZXJhbmdlOjY3YjQ2YjRmNTQxOTQzZGJiY2IxMzI2ZTA5YTNmYTdjXzUtMy0xLTEtOTgwNg_a4dbbca3-f4eb-4155-8c3b-2251b64100e6"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icca18901cecd47eb8ace5d534e3446cc_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTo2N2I0NmI0ZjU0MTk0M2RiYmNiMTMyNmUwOWEzZmE3Yy90YWJsZXJhbmdlOjY3YjQ2YjRmNTQxOTQzZGJiY2IxMzI2ZTA5YTNmYTdjXzUtNS0xLTEtOTgxMA_74520482-8657-4777-ac52-f927e9673da9"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i468bde9877fb45c2847c91221ba681bc_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTo2N2I0NmI0ZjU0MTk0M2RiYmNiMTMyNmUwOWEzZmE3Yy90YWJsZXJhbmdlOjY3YjQ2YjRmNTQxOTQzZGJiY2IxMzI2ZTA5YTNmYTdjXzUtMS0xLTEtMA_04045d36-dadc-452a-8689-f14cc599c510"
      unitRef="usd">22680000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9bf7f5b8498c4b08a82bb59829d36e28_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTo2N2I0NmI0ZjU0MTk0M2RiYmNiMTMyNmUwOWEzZmE3Yy90YWJsZXJhbmdlOjY3YjQ2YjRmNTQxOTQzZGJiY2IxMzI2ZTA5YTNmYTdjXzUtMy0xLTEtMA_f194691c-f8c1-4c20-ab2c-9ac425deea89"
      unitRef="usd">13516000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7420753e3bf04bfea9bc58e19fe42eea_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90YWJsZTo2N2I0NmI0ZjU0MTk0M2RiYmNiMTMyNmUwOWEzZmE3Yy90YWJsZXJhbmdlOjY3YjQ2YjRmNTQxOTQzZGJiY2IxMzI2ZTA5YTNmYTdjXzUtNS0xLTEtMA_0a5a9420-7a9b-4082-9662-152e50acbd41"
      unitRef="usd">12258000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DeferredRevenue
      contextRef="i975e5690b7e44643ac9b6ff7c837d1d5_I20180101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzg3OTYwOTMxMzM4ODc_10845203-0394-4de1-ab09-5df06b7fb1b5"
      unitRef="usd">-4100000</us-gaap:DeferredRevenue>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="idfdae914eb9f4568924b2c36819385c0_I20180101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4Xzg3OTYwOTMxMzM4ODc_4c1a6d62-fb6a-409c-b4b0-e2201a6ead1d"
      unitRef="usd">4100000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <sgmo:GrantFundingAmount
      contextRef="i80b254e375704b6cbd33bf07e5d5a03d_D20180501-20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzIzNzM2_aa9c02da-5f0a-441f-ad33-cc8aed2000d5"
      unitRef="usd">8000000.0</sgmo:GrantFundingAmount>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b157638f47c4c3b8ec4455978598450_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzU0OTc1NTgyMjU5MDk_22857852-b53e-4b7f-ad6d-c60b62c4911b"
      unitRef="usd">5200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i37cb993a72c14f14a87486e3f9d110bb_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzU0OTc1NTgyMjcxOTU_6e21272a-8d28-4247-b2d6-e8e26d5b8a8c"
      unitRef="usd">5700000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ide489651fbb64d8cb62d9ee459e221fc_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzU0OTc1NTgyMjcxNjg_06ea4fde-f2f1-4a64-8633-a27c90897475"
      unitRef="usd">1800000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="ia988894eec924d3699114435116dcbb8_D20120101-20120131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI1Mjkz_901f08d4-7105-4c1f-afed-b218542494a8"
      unitRef="usd">13000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i603d866010f94461ba687f9d9fc9fe07_D20140101-20141231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI1MzI3_01d06464-56a7-495a-9c87-600825cb39c3"
      unitRef="usd">1000000.0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <sgmo:AgreementTerminationTerm
      contextRef="i0396d61761914d09b41700c5324f9ab2_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzExNTQ0ODcyMjAzMzQz_0d6b0641-2576-48b8-88e4-5d837f4b3010">P90D</sgmo:AgreementTerminationTerm>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i8ea0635e2f754a1a98f8b6ff31ee597e_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI3MjA3_61687f6f-7b49-4247-bb84-87890e605619"
      unitRef="usd">2300000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i225c2ca24fb245b1aef427d88cab0b42_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI3MzY3_4f09c55a-b2c9-41e9-8a7c-5a45d75ae09d"
      unitRef="usd">0.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if423ade1135f4a90ba7c01bd4622b719_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI3Mzcx_7f275523-0d59-4310-b8ee-14aa4aa355dd"
      unitRef="usd">0.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60cee58107b34ab3abb80c1536bbbb25_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI3Mzc4_3c6254c9-20fe-4ce3-a81b-55018e5f5312"
      unitRef="usd">2400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ic7e8b05b2b84429ea591ae9027f2f01c_I20091031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI4NTAx_4bb7baa3-166b-4958-a3d4-9bfcb2efb32a"
      unitRef="usd">20000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i19ed0c7322dc4072986f0f09203dc043_D20091001-20091031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI4NTIw_ccf2fb18-3e2f-4c0a-9a6a-c63362506811"
      unitRef="usd">4900000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i19ed0c7322dc4072986f0f09203dc043_D20091001-20091031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI4NTM1_68b661ce-4f1d-4d98-97ca-68e23c33567e"
      unitRef="shares">636133</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i19ed0c7322dc4072986f0f09203dc043_D20091001-20091031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI4NTgw_94e4f027-804d-4c65-afcd-686a48c65b4e"
      unitRef="usd">4900000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i2d0454da729b48fc9e22bda7f76d2ad5_I20091031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI4NTkw_4f837c9f-745b-4031-a7d5-ed44a367957a"
      unitRef="usd">15100000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="i278e40ede357423c89bdc1aee03bef48_D20091001-20091031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI4Njc3_d3f2705a-6ac0-4d3b-a06e-e8e30a6935cd"
      unitRef="usd">5000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <sgmo:ReducedRoyaltyRate
      contextRef="i19ed0c7322dc4072986f0f09203dc043_D20091001-20091031"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI4Nzgz_9514ee6b-1a3d-4e98-b274-f6b920d6e1e3"
      unitRef="number">0.105</sgmo:ReducedRoyaltyRate>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="i19ed0c7322dc4072986f0f09203dc043_D20091001-20091031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI4OTcy_35083ec9-d248-4a25-a742-14b2bea847a8"
      unitRef="usd">25000000.0</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i12a07f5e2768459da813de50c58f1b60_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI5MTUz_0d170848-f2c6-440e-ba3f-ca629ab43703"
      unitRef="usd">600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e4cd48445e44370bba7e39d5af5ce52_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI5MTU2_3f882910-b2f9-4502-ab5c-9c5f33e645b8"
      unitRef="usd">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3087b4ee5afa4f2dabb514f4cf15f16c_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzI5MTYz_7333e704-163b-483e-8637-d73fcfe3b9ea"
      unitRef="usd">700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:OneTimeLicenseFeeEarned
      contextRef="id1d7e675aff548549bda7f384c0b71fe_I20051231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzMwMDIw_4385ca99-273f-4cb5-a6ab-0f1c64b86aed"
      unitRef="usd">6000000.0</sgmo:OneTimeLicenseFeeEarned>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d6e0b311090479699df435b03b0f9b4_D20050101-20051231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzMwMDQ5_0a01e32a-8072-45ff-acf4-7d2e6eaaa1d4"
      unitRef="usd">2300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement
      contextRef="if0b4d17d3d8d4ebc977872aa77c541e2_D20050101-20051231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzMwMDgy_228c37e2-f193-4b59-80a5-cbd97dfe450b"
      unitRef="usd">4000000.0</sgmo:MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement>
    <sgmo:PercentageOfRoyaltiesToBeReceivedFromSublicensing
      contextRef="if0b4d17d3d8d4ebc977872aa77c541e2_D20050101-20051231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzMwMzkx_5e809f63-c8e6-4e77-9529-442ed0fbbdad"
      unitRef="number">0.25</sgmo:PercentageOfRoyaltiesToBeReceivedFromSublicensing>
    <sgmo:AnnualFeesRelatedToAgreement
      contextRef="i9b2070f38ef740d580ee67b0026687db_D20050101-20051231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzMwODAx_d73c76d0-ed55-44e3-a34a-8ce0e3271a19"
      unitRef="usd">300000</sgmo:AnnualFeesRelatedToAgreement>
    <sgmo:AnnualFeesRelatedToAgreement
      contextRef="i700b128806b74604a574c5a9d52798f4_D20050101-20051231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzMwODA3_734b491d-cafc-43b2-ab72-b1f353a40311"
      unitRef="usd">3000000.0</sgmo:AnnualFeesRelatedToAgreement>
    <sgmo:FeeDue
      contextRef="if0b4d17d3d8d4ebc977872aa77c541e2_D20050101-20051231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzMwODIw_b8137729-c63b-4148-9687-615c5d29fb01"
      unitRef="usd">25300000</sgmo:FeeDue>
    <sgmo:MinimumSublicenseAnnualFeesSpecificReckoningPeriod
      contextRef="if0b4d17d3d8d4ebc977872aa77c541e2_D20050101-20051231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzMwODI4_f5e87216-e760-4329-9805-d6df453434a0">P11Y</sgmo:MinimumSublicenseAnnualFeesSpecificReckoningPeriod>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b28cb60703942d78f84fa70547f2d7a_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzMxMjg4_a78d1b19-03e0-4f9c-960e-ce3366edb41c"
      unitRef="usd">3000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i35e0ebbeae2040128ef7a7deb5f4d32f_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzMxMjky_6a11ea07-fe43-411b-b7e1-cebc89a69e6b"
      unitRef="usd">3000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c13afb7fbda4eb8bf0c38bac4d2c1ff_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTIvZnJhZzo2NjQ1M2RmZTc2ZTg0MjQ4YTFjOWY2YzQyZDMzOTBiOC90ZXh0cmVnaW9uOjY2NDUzZGZlNzZlODQyNDhhMWM5ZjZjNDJkMzM5MGI4XzMxMzAw_36fe978a-10c7-4a1e-96c7-959d4152c371"
      unitRef="usd">3000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzkxMjY_62bbfce0-b861-4f00-bcac-def5dbe44d99">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;NOTE 5 &#x2013; ACQUISITION OF SANGAMO FRANCE&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On July&#160;20, 2018, Sangamo entered into various agreements with the goal of eventually acquiring 100% of Sangamo France&#x2019;s share capital. The Company entered into the Sangamo France SPA with certain shareholders of Sangamo France, pursuant to which it acquired 13,519,036 ordinary shares of Sangamo France (&#x201c;Ordinary Shares&#x201d;) as part of a block transaction that closed on October&#160;1, 2018 (the &#x201c;Acquisition Date&#x201d;). Additionally, the Company and Sangamo France entered into a Tender Offer Agreement pursuant to which Sangamo agreed to acquire 11,528,635 Ordinary Shares for the same price per share as the Sangamo France SPA via a cash tender offer that closed on November&#160;23, 2018. Following the block transaction, cash tender offer, and other open market purchases of shares, the Company owned 98.2% of the Ordinary Shares as of December&#160;31, 2018 (or 25,047,671 Ordinary Shares). In addition to the Sangamo France SPA and the tender offer agreement, the Company also entered into arrangements with the holders of approximately 477,000 &#x201c;free shares&#x201d; of Sangamo France pursuant to which the Company has the right to purchase such shares from the holders (a call option) and such holders have the right to sell to the Company such shares from time to time through mid-2021 (a put option) (collectively the &#x201c;Free Shares Options&#x201d;). In June 2019, Sangamo France became a &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;soci&#xe9;t&#xe9; par actions simplifi&#xe9;e &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;(&#x201c;S.A.S.&#x201d;) and was renamed from &#x201c;TxCell&#x201d; to &#x201c;Sangamo Therapeutics France.&#x201d; During 2019, the Company acquired approximately 111,000 vested free shares, increasing its ownership of the Ordinary Shares to 98.7% as of December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At the Acquisition Date, the fair value of the Free Shares Options was estimated to be a liability of $0.2&#160;million. See Note 2 - &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &#x2013; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Free Shares Asset/Liability&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; for information regarding the valuation method. The fair value of the Free Shares Options will vary based on future changes in the Company&#x2019;s stock price during the option period. The fair value of the Free Shares Options was estimated to be an asset of $0.2&#160;million as of December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The acquisition of Sangamo France was accounted for as a business combination in accordance with ASC Topic 805, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Business Combinations&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;. The operating results of Sangamo France after the Acquisition Date have been included in the Company&#x2019;s Consolidated Statements of Operations. There were no purchase price adjustments subsequent to the acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;There were no goodwill impairments during the years ended December&#160;31, 2019 or 2018 and, as noted below, substantially all of the non-controlling interest on the Acquisition Date was subsequently acquired by the Company and, accordingly, substantially all of the goodwill is allocated to the Company as of December&#160;31, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the estimated consideration transferred and the fair value of the net assets acquired as of the Acquisition Date (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:85.262%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.738%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;October 1, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value of non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value of Sangamo France&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;81,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;55,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9,761)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assumed debt liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,933)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred tax liability, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(6,798)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value of net identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total fair value of net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;81,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Non-controlling Interest&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of the non-controlling interest at the Acquisition Date was based on the $2.99 acquisition price per share for the 11,981,867 Ordinary Shares that were not purchased by the Company in the block transaction on the Acquisition Date. Subsequent to the Acquisition Date and through December&#160;31, 2018, the Company acquired 11,528,635 Ordinary Shares, which when aggregated with the 13,519,036 Ordinary Shares acquired at the Acquisition Date, resulted in the Company owning 98.2% of all Ordinary Shares as of December&#160;31, 2018. During 2019, the Company acquired approximately 111,000 vested free &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;shares for approximately $0.3&#160;million of cash, pursuant to the exercise of the Free Shares Options, increasing its ownership of the Ordinary Shares to 98.7% as of December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Non-controlling interest as of December&#160;31, 2019 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:85.262%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.738%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value of additional shares acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(321)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Loss attributable to non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(233)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <sgmo:BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire
      contextRef="ia4b36a1c4d88462a8ee8d85f748c7b16_I20180720"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzI2MA_3b4ed0cf-fc86-4c0d-90a2-98ad6bf95907"
      unitRef="number">1</sgmo:BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire>
    <sgmo:BusinessAcquisitionNumberOfSharesAcquired
      contextRef="i38f5aec47ea84bc295354a823c8a5831_D20181001-20181001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzM3MQ_3dfcd88b-3d03-4ea9-9abe-c52055c980b6"
      unitRef="shares">13519036</sgmo:BusinessAcquisitionNumberOfSharesAcquired>
    <sgmo:BusinessAcquisitionNumberOfSharesAcquired
      contextRef="i3a6b4067c84e43e1bdc883068436bfa7_D20181001-20181123"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzQzOTgwNDY1MjI2MjE_c9c51035-fa07-47c4-94cd-fdea82e64df2"
      unitRef="shares">11528635</sgmo:BusinessAcquisitionNumberOfSharesAcquired>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i86361484bbe7475eadd2f54f1495c9bc_I20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzQzOTgwNDY1MjI2Mjg_03a30acd-be35-4aaf-adc6-3fe8b4d7da34"
      unitRef="number">0.982</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <sgmo:BusinessAcquisitionNumberOfSharesAcquired
      contextRef="i5253724c8c7745708c6743fc72b1bd23_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzcxNDY4MjU2MDAwMTA_946bf9a1-29ab-40bb-91c7-38ca04864ace"
      unitRef="shares">25047671</sgmo:BusinessAcquisitionNumberOfSharesAcquired>
    <sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders
      contextRef="ia4b36a1c4d88462a8ee8d85f748c7b16_I20180720"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzcxNDY4MjU2MDAwMjI_fe427243-c12a-4c11-ad93-4689e00b8bf5"
      unitRef="shares">477000</sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders>
    <sgmo:BusinessAcquisitionNumberOfSharesAcquired
      contextRef="i9b97713bc2a74145a84bf16db6e1a142_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzcxNDY4MjU2MDAwMTk_d0cbed9e-d7b4-4271-8d2b-8f9048a78062"
      unitRef="shares">111000</sgmo:BusinessAcquisitionNumberOfSharesAcquired>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="ie44e76842d7f4cde88a0228bac132b9e_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzQzOTgwNDY1MzA2MzA_3a107ec7-8f53-4cab-9545-3c316261f8c4"
      unitRef="number">0.987</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <sgmo:BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares
      contextRef="ifba2b3f6b5f24819b803f8b4290efdef_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzQzOTgwNDY1MzA4MjU_8ff56e19-6fa9-4ad0-bf1f-9f427123274a"
      unitRef="usd">200000</sgmo:BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares>
    <sgmo:BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares
      contextRef="i2821462afaec43989ae5bb5640358bdb_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzYwNDczMTM5NzIxODY_665356ca-6053-44cf-b0ad-4165df808c5b"
      unitRef="usd">200000</sgmo:BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzQzOTgwNDY1MzIwNjA_22178f36-9a28-476a-aec1-36a18b78a3a1"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzQzOTgwNDY1MzIwNjA_dce684e2-f90d-4f8c-86bf-f9b48f0d75db"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzkxMjM_3c4421c3-9f76-45cd-b10c-b598cf8ba991">&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the estimated consideration transferred and the fair value of the net assets acquired as of the Acquisition Date (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:85.262%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.738%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;October 1, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value of non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value of Sangamo France&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;81,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;55,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9,761)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assumed debt liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,933)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred tax liability, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(6,798)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value of net identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total fair value of net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;81,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i38f5aec47ea84bc295354a823c8a5831_D20181001-20181001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90YWJsZTo2NjM3ZGQ0NWFiNDQ0ZTJkYjJlNDMxYjYwZmRjYTNiZS90YWJsZXJhbmdlOjY2MzdkZDQ1YWI0NDRlMmRiMmU0MzFiNjBmZGNhM2JlXzEtMS0xLTEtMA_cfa16cab-1fc3-4db4-a720-6e5c7508ab40"
      unitRef="usd">45911000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue
      contextRef="ib79220f5f92f424dbf1bd1416f1d62af_I20181001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90YWJsZTo2NjM3ZGQ0NWFiNDQ0ZTJkYjJlNDMxYjYwZmRjYTNiZS90YWJsZXJhbmdlOjY2MzdkZDQ1YWI0NDRlMmRiMmU0MzFiNjBmZGNhM2JlXzItMS0xLTEtMA_09b01ef9-02f8-497c-86c5-95b46b22a2cd"
      unitRef="usd">35829000</us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="ib79220f5f92f424dbf1bd1416f1d62af_I20181001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90YWJsZTo2NjM3ZGQ0NWFiNDQ0ZTJkYjJlNDMxYjYwZmRjYTNiZS90YWJsZXJhbmdlOjY2MzdkZDQ1YWI0NDRlMmRiMmU0MzFiNjBmZGNhM2JlXzMtMS0xLTEtMA_72b90eb1-0dc1-4723-92b7-643a91fd0e66"
      unitRef="usd">81740000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="ib79220f5f92f424dbf1bd1416f1d62af_I20181001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90YWJsZTo2NjM3ZGQ0NWFiNDQ0ZTJkYjJlNDMxYjYwZmRjYTNiZS90YWJsZXJhbmdlOjY2MzdkZDQ1YWI0NDRlMmRiMmU0MzFiNjBmZGNhM2JlXzUtMS0xLTEtMA_996b77a5-2203-4e09-b560-a4b125e6b33f"
      unitRef="usd">4779000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets
      contextRef="ib79220f5f92f424dbf1bd1416f1d62af_I20181001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90YWJsZTo2NjM3ZGQ0NWFiNDQ0ZTJkYjJlNDMxYjYwZmRjYTNiZS90YWJsZXJhbmdlOjY2MzdkZDQ1YWI0NDRlMmRiMmU0MzFiNjBmZGNhM2JlXzYtMS0xLTEtMA_c4ec4880-21a1-4f02-947d-0e88ae6dfc25"
      unitRef="usd">2427000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="ib79220f5f92f424dbf1bd1416f1d62af_I20181001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90YWJsZTo2NjM3ZGQ0NWFiNDQ0ZTJkYjJlNDMxYjYwZmRjYTNiZS90YWJsZXJhbmdlOjY2MzdkZDQ1YWI0NDRlMmRiMmU0MzFiNjBmZGNhM2JlXzctMS0xLTEtMA_9483fe23-61f7-497b-9a76-df37b16c47c7"
      unitRef="usd">1857000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <sgmo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment
      contextRef="ib79220f5f92f424dbf1bd1416f1d62af_I20181001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90YWJsZTo2NjM3ZGQ0NWFiNDQ0ZTJkYjJlNDMxYjYwZmRjYTNiZS90YWJsZXJhbmdlOjY2MzdkZDQ1YWI0NDRlMmRiMmU0MzFiNjBmZGNhM2JlXzgtMS0xLTEtMA_417270d6-dfbb-4e5c-9113-5881039d35b0"
      unitRef="usd">55019000</sgmo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="ib79220f5f92f424dbf1bd1416f1d62af_I20181001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90YWJsZTo2NjM3ZGQ0NWFiNDQ0ZTJkYjJlNDMxYjYwZmRjYTNiZS90YWJsZXJhbmdlOjY2MzdkZDQ1YWI0NDRlMmRiMmU0MzFiNjBmZGNhM2JlXzktMS0xLTEtMA_4495759a-05b6-4de9-b2ae-7f62e25348e4"
      unitRef="usd">155000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
      contextRef="ib79220f5f92f424dbf1bd1416f1d62af_I20181001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90YWJsZTo2NjM3ZGQ0NWFiNDQ0ZTJkYjJlNDMxYjYwZmRjYTNiZS90YWJsZXJhbmdlOjY2MzdkZDQ1YWI0NDRlMmRiMmU0MzFiNjBmZGNhM2JlXzEwLTEtMS0xLTA_f73ff1a2-c7f3-4bda-8d39-b9e6ca711ddb"
      unitRef="usd">9761000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="ib79220f5f92f424dbf1bd1416f1d62af_I20181001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90YWJsZTo2NjM3ZGQ0NWFiNDQ0ZTJkYjJlNDMxYjYwZmRjYTNiZS90YWJsZXJhbmdlOjY2MzdkZDQ1YWI0NDRlMmRiMmU0MzFiNjBmZGNhM2JlXzExLTEtMS0xLTA_500a9c57-b24f-40fb-88de-408172c554de"
      unitRef="usd">4933000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent
      contextRef="ib79220f5f92f424dbf1bd1416f1d62af_I20181001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90YWJsZTo2NjM3ZGQ0NWFiNDQ0ZTJkYjJlNDMxYjYwZmRjYTNiZS90YWJsZXJhbmdlOjY2MzdkZDQ1YWI0NDRlMmRiMmU0MzFiNjBmZGNhM2JlXzEyLTEtMS0xLTA_93870dd4-1dd6-474a-aa5a-3b7a2f7714e6"
      unitRef="usd">6798000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="ib79220f5f92f424dbf1bd1416f1d62af_I20181001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90YWJsZTo2NjM3ZGQ0NWFiNDQ0ZTJkYjJlNDMxYjYwZmRjYTNiZS90YWJsZXJhbmdlOjY2MzdkZDQ1YWI0NDRlMmRiMmU0MzFiNjBmZGNhM2JlXzEzLTEtMS0xLTA_216590ca-86a6-42c4-82f5-e7f29166ee9c"
      unitRef="usd">42745000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill
      contextRef="ib79220f5f92f424dbf1bd1416f1d62af_I20181001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90YWJsZTo2NjM3ZGQ0NWFiNDQ0ZTJkYjJlNDMxYjYwZmRjYTNiZS90YWJsZXJhbmdlOjY2MzdkZDQ1YWI0NDRlMmRiMmU0MzFiNjBmZGNhM2JlXzE1LTEtMS0xLTA_e7b469b1-26b9-45db-9c5e-165caf391468"
      unitRef="usd">38995000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="ib79220f5f92f424dbf1bd1416f1d62af_I20181001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90YWJsZTo2NjM3ZGQ0NWFiNDQ0ZTJkYjJlNDMxYjYwZmRjYTNiZS90YWJsZXJhbmdlOjY2MzdkZDQ1YWI0NDRlMmRiMmU0MzFiNjBmZGNhM2JlXzE2LTEtMS0xLTA_cdcb3e1c-f9d0-4a2f-89ed-674434145b1f"
      unitRef="usd">81740000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="ib79220f5f92f424dbf1bd1416f1d62af_I20181001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzU3NTY_32be82cf-8753-45bc-8274-38c8ea00a31f"
      unitRef="usdPerShare">2.99</us-gaap:BusinessAcquisitionSharePrice>
    <sgmo:BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction
      contextRef="ib79220f5f92f424dbf1bd1416f1d62af_I20181001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzU3OTU_a6b431c0-e469-46b4-8447-150074cbfb34"
      unitRef="shares">11981867</sgmo:BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction>
    <sgmo:BusinessAcquisitionNumberOfSharesAcquired
      contextRef="i3a6b4067c84e43e1bdc883068436bfa7_D20181001-20181123"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzY0NTQ_c9c51035-fa07-47c4-94cd-fdea82e64df2"
      unitRef="shares">11528635</sgmo:BusinessAcquisitionNumberOfSharesAcquired>
    <sgmo:BusinessAcquisitionNumberOfSharesAcquired
      contextRef="i68a40c6357a5417c8e40fc23122e7423_D20181001-20181001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzY1MTI_dd320b9f-c471-43b1-ad85-bee6236f61b5"
      unitRef="shares">13519036</sgmo:BusinessAcquisitionNumberOfSharesAcquired>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i86361484bbe7475eadd2f54f1495c9bc_I20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzY1OTY_03a30acd-be35-4aaf-adc6-3fe8b4d7da34"
      unitRef="number">0.982</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <sgmo:BusinessAcquisitionNumberOfSharesAcquired
      contextRef="i9b97713bc2a74145a84bf16db6e1a142_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzU0OTc1NTgxNjIwMjM_d0cbed9e-d7b4-4271-8d2b-8f9048a78062"
      unitRef="shares">111000</sgmo:BusinessAcquisitionNumberOfSharesAcquired>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="i9b97713bc2a74145a84bf16db6e1a142_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzU0OTc1NTgxNjIwMzc_34ac847c-28aa-434d-9f93-621f5554e5e5"
      unitRef="usd">300000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="ie44e76842d7f4cde88a0228bac132b9e_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzU0OTc1NTgxNjIwNjU_3a107ec7-8f53-4cab-9545-3c316261f8c4"
      unitRef="number">0.987</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <sgmo:ScheduleOfNoncontrollingInterestTableTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90ZXh0cmVnaW9uOjRkY2ZkNTIyOGEwNjQ5ODY4YzljOTgyNjcyM2Q2N2IxXzkxMjQ_9c6f543e-3753-439f-b8ae-ddbabf75649b">&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Non-controlling interest as of December&#160;31, 2019 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:85.262%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.738%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value of additional shares acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(321)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Loss attributable to non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(233)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sgmo:ScheduleOfNoncontrollingInterestTableTextBlock>
    <us-gaap:MinorityInterest
      contextRef="ic99ff13e6b8d4ef18b9878c555ae3844_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90YWJsZToyNTAwZmNhNGJmZDA0YTkzOWViZGJkN2E1N2IyOTg0Yy90YWJsZXJhbmdlOjI1MDBmY2E0YmZkMDRhOTM5ZWJkYmQ3YTU3YjI5ODRjXzctMS0xLTEtMA_b467b38c-2c83-4971-bcf1-966c27e8a995"
      unitRef="usd">739000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90YWJsZToyNTAwZmNhNGJmZDA0YTkzOWViZGJkN2E1N2IyOTg0Yy90YWJsZXJhbmdlOjI1MDBmY2E0YmZkMDRhOTM5ZWJkYmQ3YTU3YjI5ODRjXzgtMS0xLTEtNzg3MQ_6003d0c2-81cc-457c-be56-1c270f49e457"
      unitRef="usd">321000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90YWJsZToyNTAwZmNhNGJmZDA0YTkzOWViZGJkN2E1N2IyOTg0Yy90YWJsZXJhbmdlOjI1MDBmY2E0YmZkMDRhOTM5ZWJkYmQ3YTU3YjI5ODRjXzktMS0xLTEtNzg3MQ_e31a13d0-bf5d-4fbc-ac3f-2af15d0deaa3"
      unitRef="usd">-233000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterest
      contextRef="icc3f21983c41481ba4b01cd8667c5b3d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMTgvZnJhZzo0ZGNmZDUyMjhhMDY0OTg2OGM5Yzk4MjY3MjNkNjdiMS90YWJsZToyNTAwZmNhNGJmZDA0YTkzOWViZGJkN2E1N2IyOTg0Yy90YWJsZXJhbmdlOjI1MDBmY2E0YmZkMDRhOTM5ZWJkYmQ3YTU3YjI5ODRjXzEwLTEtMS0xLTc4NzE_170dfe02-06e5-4ebe-94c1-19e787e5f333"
      unitRef="usd">185000</us-gaap:MinorityInterest>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90ZXh0cmVnaW9uOjNjMjgxYjg5MWNkODRlZGM5MzNhODYwMmFjNzgyNDllXzgzMQ_d4758078-7647-41ac-8984-465822ce8f7b">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;NOTE 6 &#x2013; OTHER BALANCE SHEET DETAILS&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Property and equipment, net consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.792%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;65,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;41,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;88,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(11,681)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9,310)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;78,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Depreciation and amortization expense was $3.9&#160;million in 2019, $2.4&#160;million in 2018 and $1.5&#160;million in 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The changes in intangible assets were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.245%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.452%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;54,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Indefinite-lived assets - IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;55,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign currency translation adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,087)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(776)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;54,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The changes in goodwill were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:70.660%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.823%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.598%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;40,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign currency translation adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(771)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(536)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;40,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Accounts Payable and Accrued Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Accounts payable and accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:70.474%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.117%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.472%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liabilities - current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred rent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90ZXh0cmVnaW9uOjNjMjgxYjg5MWNkODRlZGM5MzNhODYwMmFjNzgyNDllXzgzMg_c5bba676-2089-4bdb-ae98-367947995798">&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Property and equipment, net consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.792%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;65,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;41,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;88,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(11,681)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9,310)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;78,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if8a9cbb45d2746dcb48a28a379d261b4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTpiYTQ0MWM1ODI5NmM0NTQ3YTUwMDViMGU5NmI0ZGZhNy90YWJsZXJhbmdlOmJhNDQxYzU4Mjk2YzQ1NDdhNTAwNWIwZTk2YjRkZmE3XzItMS0xLTEtMA_c889bed0-034a-463c-8149-ccac2bc0afed"
      unitRef="usd">17179000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0638fbc591ba4ce589a9cfe88a114e95_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTpiYTQ0MWM1ODI5NmM0NTQ3YTUwMDViMGU5NmI0ZGZhNy90YWJsZXJhbmdlOmJhNDQxYzU4Mjk2YzQ1NDdhNTAwNWIwZTk2YjRkZmE3XzItMy0xLTEtMA_6779b5c1-47ce-4430-a80a-9853ba51cfcc"
      unitRef="usd">11466000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibe70b54fab8e46b4bea40c2b35ede19a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTpiYTQ0MWM1ODI5NmM0NTQ3YTUwMDViMGU5NmI0ZGZhNy90YWJsZXJhbmdlOmJhNDQxYzU4Mjk2YzQ1NDdhNTAwNWIwZTk2YjRkZmE3XzMtMS0xLTEtMA_3f60c06e-71bb-4711-b6c8-42bca4c85d64"
      unitRef="usd">4639000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iac226c28c7fb4c64920cad2ca7e259a1_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTpiYTQ0MWM1ODI5NmM0NTQ3YTUwMDViMGU5NmI0ZGZhNy90YWJsZXJhbmdlOmJhNDQxYzU4Mjk2YzQ1NDdhNTAwNWIwZTk2YjRkZmE3XzMtMy0xLTEtMA_19d69232-4a76-4e52-b4a0-d38af1378654"
      unitRef="usd">3840000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie3c60a720f6b4df19f3f92b51be623e5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTpiYTQ0MWM1ODI5NmM0NTQ3YTUwMDViMGU5NmI0ZGZhNy90YWJsZXJhbmdlOmJhNDQxYzU4Mjk2YzQ1NDdhNTAwNWIwZTk2YjRkZmE3XzQtMS0xLTEtMA_3c7bcaa2-f26e-4a95-8944-10b915c2dc30"
      unitRef="usd">13888000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iac6944dea140420e82c37c6b728de97a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTpiYTQ0MWM1ODI5NmM0NTQ3YTUwMDViMGU5NmI0ZGZhNy90YWJsZXJhbmdlOmJhNDQxYzU4Mjk2YzQ1NDdhNTAwNWIwZTk2YjRkZmE3XzQtMy0xLTEtMA_bb5cf320-49dc-4148-901b-9d15b4d4deb5"
      unitRef="usd">3640000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic4483a2719984476afd6ceb188081fda_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTpiYTQ0MWM1ODI5NmM0NTQ3YTUwMDViMGU5NmI0ZGZhNy90YWJsZXJhbmdlOmJhNDQxYzU4Mjk2YzQ1NDdhNTAwNWIwZTk2YjRkZmE3XzUtMS0xLTEtMA_88714802-5e76-4939-b4e4-9fd56c738c48"
      unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2471a22261164bf78fea22576f465fb3_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTpiYTQ0MWM1ODI5NmM0NTQ3YTUwMDViMGU5NmI0ZGZhNy90YWJsZXJhbmdlOmJhNDQxYzU4Mjk2YzQ1NDdhNTAwNWIwZTk2YjRkZmE3XzUtMy0xLTEtMA_4adeb0bb-8135-4f35-847e-8f161fb13524"
      unitRef="usd">3876000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="icf9dff888e724c4fbe02ba474671d5fe_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTpiYTQ0MWM1ODI5NmM0NTQ3YTUwMDViMGU5NmI0ZGZhNy90YWJsZXJhbmdlOmJhNDQxYzU4Mjk2YzQ1NDdhNTAwNWIwZTk2YjRkZmE3XzYtMS0xLTEtMTEwODc_925eb936-9d87-4b65-a204-63a82cd9b763"
      unitRef="usd">5901000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5620868d7a3f4744aeeaa72cb2948e05_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTpiYTQ0MWM1ODI5NmM0NTQ3YTUwMDViMGU5NmI0ZGZhNy90YWJsZXJhbmdlOmJhNDQxYzU4Mjk2YzQ1NDdhNTAwNWIwZTk2YjRkZmE3XzYtMy0xLTEtMTExMDA_1a791dbf-71a8-456b-82dc-b864f1d11f8c"
      unitRef="usd">65211000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTpiYTQ0MWM1ODI5NmM0NTQ3YTUwMDViMGU5NmI0ZGZhNy90YWJsZXJhbmdlOmJhNDQxYzU4Mjk2YzQ1NDdhNTAwNWIwZTk2YjRkZmE3XzYtMS0xLTEtMA_6dcf3177-3036-4044-8a8e-1c69e72fec2b"
      unitRef="usd">41607000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTpiYTQ0MWM1ODI5NmM0NTQ3YTUwMDViMGU5NmI0ZGZhNy90YWJsZXJhbmdlOmJhNDQxYzU4Mjk2YzQ1NDdhNTAwNWIwZTk2YjRkZmE3XzYtMy0xLTEtMA_5cf1c73b-d682-476a-9d29-43b3be30a663"
      unitRef="usd">88033000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTpiYTQ0MWM1ODI5NmM0NTQ3YTUwMDViMGU5NmI0ZGZhNy90YWJsZXJhbmdlOmJhNDQxYzU4Mjk2YzQ1NDdhNTAwNWIwZTk2YjRkZmE3XzctMS0xLTEtMA_0b2a9afa-0cbe-4573-9f12-febdd682902e"
      unitRef="usd">11681000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTpiYTQ0MWM1ODI5NmM0NTQ3YTUwMDViMGU5NmI0ZGZhNy90YWJsZXJhbmdlOmJhNDQxYzU4Mjk2YzQ1NDdhNTAwNWIwZTk2YjRkZmE3XzctMy0xLTEtMA_dc39ebdd-b2d0-4906-86cc-f0d26c65ac77"
      unitRef="usd">9310000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTpiYTQ0MWM1ODI5NmM0NTQ3YTUwMDViMGU5NmI0ZGZhNy90YWJsZXJhbmdlOmJhNDQxYzU4Mjk2YzQ1NDdhNTAwNWIwZTk2YjRkZmE3XzktMS0xLTEtMA_4606b17a-233b-48d3-9a44-8001d8fe06cb"
      unitRef="usd">29926000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTpiYTQ0MWM1ODI5NmM0NTQ3YTUwMDViMGU5NmI0ZGZhNy90YWJsZXJhbmdlOmJhNDQxYzU4Mjk2YzQ1NDdhNTAwNWIwZTk2YjRkZmE3XzktMy0xLTEtMA_7861bbef-7001-4911-8e66-c6a3cdca2f3b"
      unitRef="usd">78723000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90ZXh0cmVnaW9uOjNjMjgxYjg5MWNkODRlZGM5MzNhODYwMmFjNzgyNDllXzE1NQ_8effbb8b-cca7-40be-a1fc-e515d8fbb6ab"
      unitRef="usd">3900000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90ZXh0cmVnaW9uOjNjMjgxYjg5MWNkODRlZGM5MzNhODYwMmFjNzgyNDllXzE2NQ_6ef6f2d5-6438-454e-9743-8c630f352d62"
      unitRef="usd">2400000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90ZXh0cmVnaW9uOjNjMjgxYjg5MWNkODRlZGM5MzNhODYwMmFjNzgyNDllXzE3OA_4d9ec318-97b6-4b6f-9333-7686cddf706b"
      unitRef="usd">1500000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90ZXh0cmVnaW9uOjNjMjgxYjg5MWNkODRlZGM5MzNhODYwMmFjNzgyNDllXzc2OTY1ODEzOTY5MjI_b1d37c1d-65e7-4d3b-b0ae-ea8b3ca1974a">&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The changes in intangible assets were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.245%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.452%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;54,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Indefinite-lived assets - IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;55,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign currency translation adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,087)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(776)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;54,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The changes in goodwill were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:70.660%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.823%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.598%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;40,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign currency translation adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(771)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(536)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;40,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplMTE0MjQ5OGEwNzM0ZmMyYTgzODhiMTRmOTJiZDNkOC90YWJsZXJhbmdlOmUxMTQyNDk4YTA3MzRmYzJhODM4OGIxNGY5MmJkM2Q4XzItMS0xLTEtNzExNQ_c9b9a398-4830-4bdd-9cf6-9cb2f7968aef"
      unitRef="usd">54243000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ieb7e952fbd38434585f995fe73c66a44_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplMTE0MjQ5OGEwNzM0ZmMyYTgzODhiMTRmOTJiZDNkOC90YWJsZXJhbmdlOmUxMTQyNDk4YTA3MzRmYzJhODM4OGIxNGY5MmJkM2Q4XzItMy0xLTEtNzEwNg_fd914552-78f1-476e-ae70-ead1c847a293"
      unitRef="usd">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IndefinitelivedIntangibleAssetsAcquired
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplMTE0MjQ5OGEwNzM0ZmMyYTgzODhiMTRmOTJiZDNkOC90YWJsZXJhbmdlOmUxMTQyNDk4YTA3MzRmYzJhODM4OGIxNGY5MmJkM2Q4XzMtMS0xLTEtNzExNQ_e83183d2-b5be-4373-abde-3ff9c2f7ac6e"
      unitRef="usd">0</us-gaap:IndefinitelivedIntangibleAssetsAcquired>
    <us-gaap:IndefinitelivedIntangibleAssetsAcquired
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplMTE0MjQ5OGEwNzM0ZmMyYTgzODhiMTRmOTJiZDNkOC90YWJsZXJhbmdlOmUxMTQyNDk4YTA3MzRmYzJhODM4OGIxNGY5MmJkM2Q4XzMtMy0xLTEtNzEwNg_9580fe1d-9b18-45b8-a1b2-24306e280b07"
      unitRef="usd">55019000</us-gaap:IndefinitelivedIntangibleAssetsAcquired>
    <us-gaap:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplMTE0MjQ5OGEwNzM0ZmMyYTgzODhiMTRmOTJiZDNkOC90YWJsZXJhbmdlOmUxMTQyNDk4YTA3MzRmYzJhODM4OGIxNGY5MmJkM2Q4XzQtMS0xLTEtNzExNQ_1c329a43-54c2-42d6-87b8-b2eed29e494a"
      unitRef="usd">-1087000</us-gaap:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplMTE0MjQ5OGEwNzM0ZmMyYTgzODhiMTRmOTJiZDNkOC90YWJsZXJhbmdlOmUxMTQyNDk4YTA3MzRmYzJhODM4OGIxNGY5MmJkM2Q4XzQtMy0xLTEtNzEwNg_44647a19-1633-4509-94a3-4f307346657b"
      unitRef="usd">-776000</us-gaap:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplMTE0MjQ5OGEwNzM0ZmMyYTgzODhiMTRmOTJiZDNkOC90YWJsZXJhbmdlOmUxMTQyNDk4YTA3MzRmYzJhODM4OGIxNGY5MmJkM2Q4XzUtMS0xLTEtNzExNQ_23706826-25cc-4b19-a161-91b57234b5e4"
      unitRef="usd">53156000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplMTE0MjQ5OGEwNzM0ZmMyYTgzODhiMTRmOTJiZDNkOC90YWJsZXJhbmdlOmUxMTQyNDk4YTA3MzRmYzJhODM4OGIxNGY5MmJkM2Q4XzUtMy0xLTEtNzEwNg_17ba5094-8c24-4c58-94d0-2ec59f66b0f4"
      unitRef="usd">54243000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTo1NTc5ZGNmMTllMzY0MDg2YWI0MzI1MzgyNjFjYWI5OS90YWJsZXJhbmdlOjU1NzlkY2YxOWUzNjQwODZhYjQzMjUzODI2MWNhYjk5XzItMS0xLTEtNzEyMQ_36ffd26e-8462-499e-b916-f56c5e069bfc"
      unitRef="usd">40044000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ieb7e952fbd38434585f995fe73c66a44_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTo1NTc5ZGNmMTllMzY0MDg2YWI0MzI1MzgyNjFjYWI5OS90YWJsZXJhbmdlOjU1NzlkY2YxOWUzNjQwODZhYjQzMjUzODI2MWNhYjk5XzItMy0xLTEtNzExOA_82c58abc-5724-4b63-b611-d90cf5eb06fa"
      unitRef="usd">1585000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTo1NTc5ZGNmMTllMzY0MDg2YWI0MzI1MzgyNjFjYWI5OS90YWJsZXJhbmdlOjU1NzlkY2YxOWUzNjQwODZhYjQzMjUzODI2MWNhYjk5XzMtMS0xLTEtNzEyMQ_048dfea7-2521-4346-86b0-bfd3f5ec40cf"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTo1NTc5ZGNmMTllMzY0MDg2YWI0MzI1MzgyNjFjYWI5OS90YWJsZXJhbmdlOjU1NzlkY2YxOWUzNjQwODZhYjQzMjUzODI2MWNhYjk5XzMtMy0xLTEtNzExOA_ee30facf-dca0-4efd-a790-242e2f6f9d4c"
      unitRef="usd">38995000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTo1NTc5ZGNmMTllMzY0MDg2YWI0MzI1MzgyNjFjYWI5OS90YWJsZXJhbmdlOjU1NzlkY2YxOWUzNjQwODZhYjQzMjUzODI2MWNhYjk5XzQtMS0xLTEtNzEyMQ_890d7c22-578c-4165-91f6-afbfb617d1a5"
      unitRef="usd">-771000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTo1NTc5ZGNmMTllMzY0MDg2YWI0MzI1MzgyNjFjYWI5OS90YWJsZXJhbmdlOjU1NzlkY2YxOWUzNjQwODZhYjQzMjUzODI2MWNhYjk5XzQtMy0xLTEtNzExOA_04e696d2-6901-4393-855c-072a9f8e7fae"
      unitRef="usd">-536000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTo1NTc5ZGNmMTllMzY0MDg2YWI0MzI1MzgyNjFjYWI5OS90YWJsZXJhbmdlOjU1NzlkY2YxOWUzNjQwODZhYjQzMjUzODI2MWNhYjk5XzUtMS0xLTEtNzEyMQ_b8ff7ae1-6367-44d4-a53d-ebde795f7b8d"
      unitRef="usd">39273000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTo1NTc5ZGNmMTllMzY0MDg2YWI0MzI1MzgyNjFjYWI5OS90YWJsZXJhbmdlOjU1NzlkY2YxOWUzNjQwODZhYjQzMjUzODI2MWNhYjk5XzUtMy0xLTEtNzExOA_35c48126-d5bd-4afb-b68d-2ec91f780126"
      unitRef="usd">40044000</us-gaap:Goodwill>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90ZXh0cmVnaW9uOjNjMjgxYjg5MWNkODRlZGM5MzNhODYwMmFjNzgyNDllXzc2OTY1ODEzOTY5MjQ_7beaa069-8487-474c-aca2-c854d2c33540">&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Accounts payable and accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:70.474%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.117%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.472%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liabilities - current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred rent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplZDFkNjNkYWQ2NDg0NzJjOWRlZjY5ZmFjOTc5MjNkNy90YWJsZXJhbmdlOmVkMWQ2M2RhZDY0ODQ3MmM5ZGVmNjlmYWM5NzkyM2Q3XzItMS0xLTEtNzIyMA_ce867f3c-c44b-449f-a8fd-a0b828acb235"
      unitRef="usd">6671000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplZDFkNjNkYWQ2NDg0NzJjOWRlZjY5ZmFjOTc5MjNkNy90YWJsZXJhbmdlOmVkMWQ2M2RhZDY0ODQ3MmM5ZGVmNjlmYWM5NzkyM2Q3XzItMy0xLTEtNzIyMA_45476fe7-f93c-4814-a3b6-c7ac7b3408f1"
      unitRef="usd">3355000</us-gaap:AccountsPayableCurrent>
    <sgmo:AccruedResearchAndDevelopmentExpenses
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplZDFkNjNkYWQ2NDg0NzJjOWRlZjY5ZmFjOTc5MjNkNy90YWJsZXJhbmdlOmVkMWQ2M2RhZDY0ODQ3MmM5ZGVmNjlmYWM5NzkyM2Q3XzMtMS0xLTEtNzIyMA_7d6b0358-a3db-44ae-a608-883503214a9c"
      unitRef="usd">4102000</sgmo:AccruedResearchAndDevelopmentExpenses>
    <sgmo:AccruedResearchAndDevelopmentExpenses
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplZDFkNjNkYWQ2NDg0NzJjOWRlZjY5ZmFjOTc5MjNkNy90YWJsZXJhbmdlOmVkMWQ2M2RhZDY0ODQ3MmM5ZGVmNjlmYWM5NzkyM2Q3XzMtMy0xLTEtNzIyMA_d1475878-b5c3-4bf1-ac59-8ecb12f59998"
      unitRef="usd">10999000</sgmo:AccruedResearchAndDevelopmentExpenses>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplZDFkNjNkYWQ2NDg0NzJjOWRlZjY5ZmFjOTc5MjNkNy90YWJsZXJhbmdlOmVkMWQ2M2RhZDY0ODQ3MmM5ZGVmNjlmYWM5NzkyM2Q3XzQtMS0xLTEtMTQyMDU_a1df79da-9010-47e2-84c9-ec04233b8676"
      unitRef="usd">3214000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplZDFkNjNkYWQ2NDg0NzJjOWRlZjY5ZmFjOTc5MjNkNy90YWJsZXJhbmdlOmVkMWQ2M2RhZDY0ODQ3MmM5ZGVmNjlmYWM5NzkyM2Q3XzQtMy0xLTEtMTQyMDc_b468c714-7dde-469b-bf06-32993bcbd087"
      unitRef="usd">0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplZDFkNjNkYWQ2NDg0NzJjOWRlZjY5ZmFjOTc5MjNkNy90YWJsZXJhbmdlOmVkMWQ2M2RhZDY0ODQ3MmM5ZGVmNjlmYWM5NzkyM2Q3XzQtMS0xLTEtNzIyMA_f2580c4d-93a4-41d6-84f4-21060e2c1fd7"
      unitRef="usd">1118000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplZDFkNjNkYWQ2NDg0NzJjOWRlZjY5ZmFjOTc5MjNkNy90YWJsZXJhbmdlOmVkMWQ2M2RhZDY0ODQ3MmM5ZGVmNjlmYWM5NzkyM2Q3XzQtMy0xLTEtNzIyMA_6afdd311-9e3a-4ff4-85bf-c1311a35bd3d"
      unitRef="usd">1930000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:DeferredRentCreditCurrent
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplZDFkNjNkYWQ2NDg0NzJjOWRlZjY5ZmFjOTc5MjNkNy90YWJsZXJhbmdlOmVkMWQ2M2RhZDY0ODQ3MmM5ZGVmNjlmYWM5NzkyM2Q3XzUtMS0xLTEtNzIyMA_52afa974-1bb7-40dd-b8a7-33428d25c597"
      unitRef="usd">0</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:DeferredRentCreditCurrent
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplZDFkNjNkYWQ2NDg0NzJjOWRlZjY5ZmFjOTc5MjNkNy90YWJsZXJhbmdlOmVkMWQ2M2RhZDY0ODQ3MmM5ZGVmNjlmYWM5NzkyM2Q3XzUtMy0xLTEtNzIyMA_0ecbee2f-1271-468a-9920-2e1926ca7f4f"
      unitRef="usd">204000</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplZDFkNjNkYWQ2NDg0NzJjOWRlZjY5ZmFjOTc5MjNkNy90YWJsZXJhbmdlOmVkMWQ2M2RhZDY0ODQ3MmM5ZGVmNjlmYWM5NzkyM2Q3XzYtMS0xLTEtNzIyMA_38e4d619-c7e3-448a-80d2-af3b531545d7"
      unitRef="usd">2451000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplZDFkNjNkYWQ2NDg0NzJjOWRlZjY5ZmFjOTc5MjNkNy90YWJsZXJhbmdlOmVkMWQ2M2RhZDY0ODQ3MmM5ZGVmNjlmYWM5NzkyM2Q3XzYtMy0xLTEtNzIyMA_87517caf-2474-4615-8927-4e420f9dc112"
      unitRef="usd">4969000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplZDFkNjNkYWQ2NDg0NzJjOWRlZjY5ZmFjOTc5MjNkNy90YWJsZXJhbmdlOmVkMWQ2M2RhZDY0ODQ3MmM5ZGVmNjlmYWM5NzkyM2Q3XzctMS0xLTEtNzIyMA_af93019f-fbec-4f0e-a25c-bfa64d949524"
      unitRef="usd">17556000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjQvZnJhZzozYzI4MWI4OTFjZDg0ZWRjOTMzYTg2MDJhYzc4MjQ5ZS90YWJsZTplZDFkNjNkYWQ2NDg0NzJjOWRlZjY5ZmFjOTc5MjNkNy90YWJsZXJhbmdlOmVkMWQ2M2RhZDY0ODQ3MmM5ZGVmNjlmYWM5NzkyM2Q3XzctMy0xLTEtNzIyMA_db8bc027-0a95-4f51-988d-ac486f363180"
      unitRef="usd">21457000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzEzODU_485412a4-c287-446c-90e9-326b4a5a57b0">&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;NOTE 7 &#x2013; COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Sangamo occupies approximately 87,700 square feet of office and research and development laboratory facilities in Brisbane, California pursuant to a lease that expires in May 2029. Sangamo also occupies approximately 45,600 square feet of research and office space in Richmond, California pursuant to leases that expire in August 2026. In addition, the Company leases approximately 20,800 square feet of office and research space in Valbonne, France subject to leases that expire beginning in June 2025 through March 2028.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Certain of these leases also include renewal options at the election of the Company to renew or extend the lease for an additional &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzc2OTY1ODE0MDcwOTQ_38c04c15-1abf-4f53-8e13-ebfe9bb10579"&gt;five&lt;/span&gt; to ten years. These optional periods have not been considered in the determination of the ROU assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain it would exercise the options.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;With respect to the Brisbane lease, the commencement date for approximately 35,080 square feet of the office space occurred in January 2019 while the commencement date for the remaining approximately 52,620 square feet occurred in June 2019. The Company has the right and exercised that right to make tenant improvements, including the addition of laboratory space, with a lease incentive allowance of $6.8&#160;million on the first portion of the space occupied and $10.2&#160;million on the portion of the lease that commenced in June 2019. As of December 31, 2019, these incentives have been received and used.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company performed evaluations of its contracts and determined each of its identified leases are operating leases. For the year ended December&#160;31, 2019, the Company incurred $7.9&#160;million of lease costs included in operating expenses in the Consolidated Statement of Operations in relation to these operating leases. Variable lease expense was $1.9&#160;million for the year ended December&#160;31, 2019 and was not included in the measurement of the Company&#x2019;s operating ROU assets and lease liabilities. The variable expense consists primarily of the Company&#x2019;s proportionate share of operating expenses, property taxes and insurance and is classified as lease expense due to the Company&#x2019;s election to not separate lease and non-lease components.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cash paid for amounts included in the measurement of operating lease liabilities for the year ended December&#160;31, 2019 was $3.5&#160;million and was included in net cash used in operating activities in the Company&#x2019;s Consolidated Statement of Cash Flow.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Rent expense related to lease agreements was $7.9&#160;million, $2.3&#160;million, and $1.1&#160;million for 2019, 2018 and 2017, respectively. Future minimum payments under lease obligations at December&#160;31, 2019 consist of the following (in thousands):&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:85.262%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.738%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(13,713)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Reported as of December 31, 2019:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liabilities - current (included in Accounts payable and accrued liabilities on the Consolidated Balance Sheet)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liabilities - long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;41,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of December&#160;31, 2019, the weighted-average remaining lease term is 8.8 years and the weighted-average incremental borrowing rate used to determine the operating lease liability was 6.2% for the Company&#x2019;s operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Contractual Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of December 31, 2019, the Company has manufacturing obligations that include a fee of $6.3&#160;million for dedicated capacity pursuant to the Development and Manufacturing Services Agreement with Brammer Bio MA, now a &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Thermo Fisher&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; Scientific Inc. subsidiary ("Brammer"). The Company also has an Option Agreement ("Option") with Brammer, entered in April 2019, whereby Brammer granted the Company an option to secure dedicated capacity for manufacturing in Brammer&#x2019;s facilities. The Company paid $3.0&#160;million for the Option, which expires on December&#160;31, 2021. In addition, the Company agreed to pay Brammer $2.0 million, $0.5 million of which was paid upon execution of the agreement, to assist it in establishing its manufacturing capabilities in Brisbane, California, which may increase Sangamo's contractual commitments in the future. Furthermore, the Company has non-cancelable contractual commitments under manufacturing-related supplier arrangements with Brammer, which requires minimum purchase commitments totaling approximately $2.5&#160;million through December 2021, $0.5&#160;million of which was paid upon execution of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company also has $1.2&#160;million of license obligations related to its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Sangamo is not party to any material pending legal proceeding. From time to time, Sangamo may be involved in legal proceedings arising in the ordinary course of business.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="iaf513274ee0c43639e9c1500db2d7963_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzYwNDczMTM5NjQ5MjY_687f31c2-9af0-4366-826f-452ce062bc29"
      unitRef="sqft">87700</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="i61974f1d85ab49f78df77bf7c87828b4_I20191231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzYwNDczMTM5NjQ5NjU_3954b1ac-4917-4639-8cac-8209ebff4dda"
      unitRef="sqft">45600</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="i545fe0f072c9408797e00f296a4a44dd_I20191231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzc2OTY1ODE0MTAxMzY_9d2b2bc3-3340-4fa8-935b-17e3c259d274"
      unitRef="sqft">20800</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i83dc1a1104c8410f962b75bd5a2646f0_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzc2OTY1ODE0MDcwNzk_e7af62b1-b666-4910-94db-d3da2add664f">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="iebf52cf79a6041878e2eb875ad9b53ba_I20191231"
      decimals="-1"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzYwNDczMTM5NjQ5MzQ_0a501eb5-1d1e-46a6-9a08-2817240f542a"
      unitRef="sqft">35080</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="i38763d7e12814008b53fbac4a892782d_I20191231"
      decimals="-1"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzYwNDczMTM5NjQ5NTc_a939df97-7307-45ef-9167-0fa349999fca"
      unitRef="sqft">52620</us-gaap:LandSubjectToGroundLeases>
    <sgmo:LesseeOperatingLeaseLiabilityTenantImprovementAllowance
      contextRef="i38763d7e12814008b53fbac4a892782d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzYwNDczMTM5NjUyMTk_3c5a1d3f-c4b8-48a7-bd4d-eca2ccce4ec4"
      unitRef="usd">6800000</sgmo:LesseeOperatingLeaseLiabilityTenantImprovementAllowance>
    <sgmo:LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance
      contextRef="i38763d7e12814008b53fbac4a892782d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzYwNDczMTM5NjUyMzg_daf4646b-898f-44ae-bd3b-4de6b651ab3c"
      unitRef="usd">10200000</sgmo:LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance>
    <us-gaap:OperatingLeaseCost
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzYwNDczMTM5NjUyNTM_e1406aa6-ab6b-48fd-96e6-ce1c78505aff"
      unitRef="usd">7900000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzYwNDczMTM5NjUyNzY_fbdc1bdb-1f80-4aae-b97c-6b70b010c74f"
      unitRef="usd">1900000</us-gaap:VariableLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzYwNDczMTM5NjUyOTM_44169a9a-1b94-4966-a4fb-40d861495ec2"
      unitRef="usd">3500000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseExpense
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzk3MQ_3f971ad3-dff9-41e7-85af-0d34de94a371"
      unitRef="usd">7900000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzk3NQ_7518c3e0-6ee6-4684-abd7-bd7382ab962c"
      unitRef="usd">2300000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzk4Mw_6934224d-a21a-4654-b9ee-8e8ee8d6cc5e"
      unitRef="usd">1100000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzEzODY_10a3b359-0864-4d76-af10-05926678a7c1">Future minimum payments under lease obligations at December&#160;31, 2019 consist of the following (in thousands):&#160;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:85.262%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.738%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(13,713)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Reported as of December 31, 2019:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liabilities - current (included in Accounts payable and accrued liabilities on the Consolidated Balance Sheet)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liabilities - long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;41,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90YWJsZTo0MmY2ZWEyZjVkM2M0YjZlYjM1OTA2YzM2ZWVhZTBmMy90YWJsZXJhbmdlOjQyZjZlYTJmNWQzYzRiNmViMzU5MDZjMzZlZWFlMGYzXzEtMS0xLTEtMA_7701510d-ec01-4888-a5e7-652c4431d028"
      unitRef="usd">5870000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90YWJsZTo0MmY2ZWEyZjVkM2M0YjZlYjM1OTA2YzM2ZWVhZTBmMy90YWJsZXJhbmdlOjQyZjZlYTJmNWQzYzRiNmViMzU5MDZjMzZlZWFlMGYzXzItMS0xLTEtMA_6846eddc-f3d8-41c2-854b-6f564922d65f"
      unitRef="usd">6390000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90YWJsZTo0MmY2ZWEyZjVkM2M0YjZlYjM1OTA2YzM2ZWVhZTBmMy90YWJsZXJhbmdlOjQyZjZlYTJmNWQzYzRiNmViMzU5MDZjMzZlZWFlMGYzXzMtMS0xLTEtMA_87a08819-45c2-43c6-873a-614bcfbde898"
      unitRef="usd">6468000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90YWJsZTo0MmY2ZWEyZjVkM2M0YjZlYjM1OTA2YzM2ZWVhZTBmMy90YWJsZXJhbmdlOjQyZjZlYTJmNWQzYzRiNmViMzU5MDZjMzZlZWFlMGYzXzQtMS0xLTEtMA_f9682292-28ce-40d9-b720-95730d4daef1"
      unitRef="usd">6556000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90YWJsZTo0MmY2ZWEyZjVkM2M0YjZlYjM1OTA2YzM2ZWVhZTBmMy90YWJsZXJhbmdlOjQyZjZlYTJmNWQzYzRiNmViMzU5MDZjMzZlZWFlMGYzXzUtMS0xLTEtMA_532c9ebc-91f4-44b9-9cd8-acc3277ca1d9"
      unitRef="usd">6694000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90YWJsZTo0MmY2ZWEyZjVkM2M0YjZlYjM1OTA2YzM2ZWVhZTBmMy90YWJsZXJhbmdlOjQyZjZlYTJmNWQzYzRiNmViMzU5MDZjMzZlZWFlMGYzXzYtMS0xLTEtMA_0f7192b9-8b06-4e7b-81f4-d50e1419c629"
      unitRef="usd">26141000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90YWJsZTo0MmY2ZWEyZjVkM2M0YjZlYjM1OTA2YzM2ZWVhZTBmMy90YWJsZXJhbmdlOjQyZjZlYTJmNWQzYzRiNmViMzU5MDZjMzZlZWFlMGYzXzctMS0xLTEtMA_35dc6092-71ae-493c-8535-116a9f15e7bf"
      unitRef="usd">58119000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90YWJsZTo0MmY2ZWEyZjVkM2M0YjZlYjM1OTA2YzM2ZWVhZTBmMy90YWJsZXJhbmdlOjQyZjZlYTJmNWQzYzRiNmViMzU5MDZjMzZlZWFlMGYzXzktMS0xLTEtNDE2MQ_96e7627d-11bb-4c57-ae81-76cc415fc1c7"
      unitRef="usd">13713000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90YWJsZTo0MmY2ZWEyZjVkM2M0YjZlYjM1OTA2YzM2ZWVhZTBmMy90YWJsZXJhbmdlOjQyZjZlYTJmNWQzYzRiNmViMzU5MDZjMzZlZWFlMGYzXzEwLTEtMS0xLTQxNjE_37e934fd-dea3-49bd-8952-fcc7541ed97b"
      unitRef="usd">44406000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90YWJsZTo0MmY2ZWEyZjVkM2M0YjZlYjM1OTA2YzM2ZWVhZTBmMy90YWJsZXJhbmdlOjQyZjZlYTJmNWQzYzRiNmViMzU5MDZjMzZlZWFlMGYzXzEyLTEtMS0xLTQxNjE_d78d1bb8-bc2d-4ca4-9183-7d3c40d21133"
      unitRef="usd">3214000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90YWJsZTo0MmY2ZWEyZjVkM2M0YjZlYjM1OTA2YzM2ZWVhZTBmMy90YWJsZXJhbmdlOjQyZjZlYTJmNWQzYzRiNmViMzU5MDZjMzZlZWFlMGYzXzEzLTEtMS0xLTQxNjE_5e11be0b-8332-4e37-99cb-9e62c26f2ef6"
      unitRef="usd">41192000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90YWJsZTo0MmY2ZWEyZjVkM2M0YjZlYjM1OTA2YzM2ZWVhZTBmMy90YWJsZXJhbmdlOjQyZjZlYTJmNWQzYzRiNmViMzU5MDZjMzZlZWFlMGYzXzE0LTEtMS0xLTQxNjE_5743342c-4459-4f07-b42b-996f9ece6135"
      unitRef="usd">44406000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzYwNDczMTM5NjUzMDU_e1d573c8-176b-453b-b560-263ea2f57b5d">P8Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzYwNDczMTM5NjUzMTM_ffff0e96-eb82-48b5-aaa9-e8dc783cda89"
      unitRef="number">0.062</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OtherCommitment
      contextRef="i37d7eb43c08a471b816747e6c8de433d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzg3OTYwOTMwMzg3MTI_fcb020d6-c3cd-4328-81a8-61f16048dc40"
      unitRef="usd">6300000</us-gaap:OtherCommitment>
    <sgmo:PaymentsForOtherCommitment
      contextRef="i7e239f59de424eaeb896378613c4c2fc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzE0MjkzNjUxMTc1MDI0_e42fdc36-1d61-4896-8b57-d620c4120930"
      unitRef="usd">3000000.0</sgmo:PaymentsForOtherCommitment>
    <us-gaap:OtherCommitment
      contextRef="i30aa48009d514a9694cf66cf00207e2e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzg3OTYwOTMwMzcyNjA_8a49b977-4002-426f-8a64-d5082fb2ba4e"
      unitRef="usd">2000000.0</us-gaap:OtherCommitment>
    <sgmo:PaymentsForOtherCommitment
      contextRef="i22655d04f591458ebb9c3737889fcaa1_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzg3OTYwOTMwMzcyNjQ_ab9fa899-8581-4b9b-b8df-04bdbc1c2420"
      unitRef="usd">500000</sgmo:PaymentsForOtherCommitment>
    <us-gaap:ContractualObligation
      contextRef="i2fba1b8b532b45cc848f39f189b1366e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzE0MjkzNjUxMTc1NDYz_68271a17-ef1f-4e23-81dc-dec03c69c9a7"
      unitRef="usd">2500000</us-gaap:ContractualObligation>
    <sgmo:ContractualObligationPaidUponExecution
      contextRef="i4c3d46edbdfc47afb7a1080ab7235f2a_I20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzE0MjkzNjUxMTc1NDk4_949b43c5-a853-43ec-8a57-175a94cf339b"
      unitRef="usd">500000</sgmo:ContractualObligationPaidUponExecution>
    <sgmo:LicenseObligations
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMjcvZnJhZzowOGE5M2RhZWEzMjQ0NDU1ODMxMzczMjVjZTI0OWY0My90ZXh0cmVnaW9uOjA4YTkzZGFlYTMyNDQ0NTU4MzEzNzMyNWNlMjQ5ZjQzXzIxOTkwMjMyNzExMDY_df4966f3-1f00-4f4d-881e-f8b447366fd1"
      unitRef="usd">1200000</sgmo:LicenseObligations>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzExODA4_6a25e3b7-daea-4975-98dd-16fd0870d89f">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;NOTE 8 &#x2013; STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has 5,000,000 preferred shares authorized, which may be issued at the discretion of the Company&#x2019;s Board of Director&#x2019;s discretion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In April 2019, Sangamo completed an underwritten public offering of its common stock, in which the Company sold an aggregate of 12.7&#160;million shares of its common stock at a public offering price of $11.50 per share. The net proceeds to Sangamo from the sale of shares in this offering, after deducting underwriting discounts and commissions and other offering expenses, were approximately $136.3&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In April 2018, Sangamo completed an underwritten public offering of its common stock, in which the Company sold an aggregate of 14.2&#160;million shares of its common stock at a public offering price of $16.25 per share. The net proceeds to Sangamo from the sale of shares in this offering, after deducting underwriting discounts and commissions and other offering expenses, were approximately $215.8&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2017, Sangamo completed an underwritten public offering of its common stock, in which the Company sold an aggregate of 11.5&#160;million shares of its common stock at a public offering price of $7.25 per share. The net proceeds to Sangamo from the sale of shares in this offering, after deducting underwriting discounts and commissions and other offering expenses, were approximately $78.1&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Stock Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In April 2018, the Compensation Committee of the Company&#x2019;s Board of Directors approved the Sangamo Therapeutics, Inc. 2018 Equity Incentive Plan (the &#x201c;2018 Plan&#x201d;), subject to approval by the Company&#x2019;s stockholders. The 2018 Plan became effective on June&#160;11, 2018 upon approval at the Company&#x2019;s Annual Meeting of Stockholders. In connection with the approval of the 2018 Plan, no additional equity awards will be granted under the 2013 Plan, however all outstanding equity awards under the 2013 Plan will continue to be subject to the terms and conditions as set forth in the agreements evidencing such awards and the terms of the 2013 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The exercise price of a stock option granted under the 2018 Plan may not be less than 100% of the fair market value of the Company's common stock subject to the stock option on the date of grant, and the option term will not exceed 10 years. If the person to whom the stock option is granted is a 10% stockholder of the Company, and the stock option granted qualifies as an incentive stock option, then the exercise price per share will not be less than 110% of the fair market value of the Company&#x2019;s common stock on the date of grant, and the option term will not exceed five years. Generally, stock options granted under the 2018 Plan vest over four years at a rate of 25% on the one year anniversary of the date of grant and 1/48 per month thereafter and expire 10 years after the date of grant, or earlier upon termination of employment or services to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The number of shares of common stock reserved for issuance under the 2018 Plan will be reduced: (i)&#160;on a 1-for-1 basis for each share of common stock subject to a stock option or stock appreciation right granted under the plan, (ii)&#160;by a fixed ratio of 1.33 shares of common stock for each share of common stock issued pursuant to a full-value award granted under the plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Shares subject to any outstanding stock options or other awards under the 2018 Plan that expire or otherwise terminate prior to the issuance of the shares subject to those stock options or awards will be available for subsequent issuance under the 2018 Plan. Any unvested shares issued under the 2018 Plan that the Company subsequently purchases, pursuant to repurchase rights under the 2018 Plan, will be added back to the number of shares reserved for issuance under the 2018 Plan on a 1-for-1 basis or a 1.33-for-1 basis (depending on the ratio at which the share reserve was debited for the original award) and will accordingly be available for subsequent issuance in accordance with the terms of the 2018 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2018, the Company&#x2019;s stockholders approved the amendment and restatement of the ESPP. As amended, the ESPP provides a total reserve of 4.6&#160;million&#160;shares of common stock for issuance under the ESPP. Eligible employees may purchase common stock at 85% of the lesser of the fair market value of the Company&#x2019;s common stock on the first day of the applicable &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzk0NTg_a01f06c3-4780-4e1a-a835-8d6a1d1c86ad"&gt;two&lt;/span&gt;-year offering period or the last day of the applicable &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzk1MTY_14ef30bf-8a48-4b2c-8cc7-f55e130f23b6"&gt;six&lt;/span&gt;-month purchase period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Stock Option Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A summary of Sangamo&#x2019;s stock option activity is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:46.680%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.929%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.732%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise per&lt;br/&gt;Share Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&#160;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options outstanding at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,726,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,530,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(806,226)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,620,867)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,829,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options vested and expected to vest at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,829,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options exercisable at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,993,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.54&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Newly created shares are issued upon exercises of options. There were no shares subject to Sangamo&#x2019;s right of repurchase as of December&#160;31, 2019. The intrinsic value of options exercised was $4.7&#160;million, $27.0&#160;million and $12.3&#160;million during 2019, 2018 and 2017, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At December&#160;31, 2019, the aggregate intrinsic values of outstanding and exercisable options were $7.5 million and $5.4 million, respectively. The aggregate intrinsic value of options vested and expected to vest as of December&#160;31, 2019, 2018 and 2017 was $7.5&#160;million, $24.5&#160;million and $71.7&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During 2019, 2018 and 2017, the Company awarded 834,745, 346,055, and 12,600 RSUs, respectively. The RSUs awarded in 2019, 2018 and 2017 had an average grant date fair value per award of $9.49, $17.87 and $15.85, respectively. These awards generally vest in a series of three successive equal annual installments. The aggregate fair value of RSUs vested during 2019, 2018 and 2017 was $2.0&#160;million, $0.6&#160;million and $1.2&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A summary of Sangamo&#x2019;s RSU activity is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:54.451%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.756%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.662%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.665%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&#160;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Aggregate&#160;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;RSUs outstanding at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;322,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;RSUs awarded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;834,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;RSUs released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(118,807)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;RSUs forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(175,789)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;RSUs outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;862,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;RSUs vested and expected to vest at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;862,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;RSUs that vested in 2019, 2018 and 2017 were net-share settled such that the Company withheld shares with value equivalent to the employees&#x2019; minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. The total shares withheld were approximately 39,160, 20,193, and 42,243 for 2019, 2018 and 2017, respectively, and were based on the value of the RSUs on their respective issuance dates as determined by the Company&#x2019;s closing stock price. Total payments for the employees&#x2019; tax obligations to taxing authorities &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;were $0.4&#160;million&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, $0.3&#160;million and $0.7&#160;million in 2019, 2018 and 2017, respectively and are reflected as a financing activity within the accompanying Consolidated Statements of Cash Flows.&#160;These net-share settlements had the effect of share repurchases by the Company as they reduced and retired the number of shares that would have otherwise been issued as a result of the vesting and did not represent an expense to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of December&#160;31, 2019, there were 6,691,209 shares reserved for future awards under the Company&#x2019;s 2018 Plan and 2,757,600 shares of common stock reserved for future issuance under the ESPP.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzY3_4cad8adf-a444-47ef-b54b-548fd5e19790"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="icb4b35fddcc442cb8c1b62aa13aad983_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzYwNDczMTM5NjQ5NzE_7aaedcc6-f89e-4d13-95ca-15110437192e"
      unitRef="shares">12700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="ie4f08396a6674db59b83934997d376ca_I20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzYwNDczMTM5NjQ5ODA_dd582a1a-4bd2-4d9e-b568-0d1ba54972c1"
      unitRef="usdPerShare">11.50</us-gaap:SharesIssuedPricePerShare>
    <sgmo:NetProceedsFromIssuancePublicOffering
      contextRef="icb4b35fddcc442cb8c1b62aa13aad983_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzYwNDczMTM5NjQ5ODM_649f442c-2846-49cf-92e3-60ef04efcf20"
      unitRef="usd">136300000</sgmo:NetProceedsFromIssuancePublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i17fa15d6fbd948fcbb752fa955283c6b_D20180401-20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzMyNw_279d8267-7f3b-4a33-b6dd-7ec573e2f459"
      unitRef="shares">14200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="ib60221bf695b4b5c95ff088c3caaf236_I20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzM4Nw_c7cbe13b-c16e-49fa-91e3-9ad8bef546d9"
      unitRef="usdPerShare">16.25</us-gaap:SharesIssuedPricePerShare>
    <sgmo:NetProceedsFromIssuancePublicOffering
      contextRef="i17fa15d6fbd948fcbb752fa955283c6b_D20180401-20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzU3NA_fd3030b1-fc3b-4977-8c8c-42453a233e8f"
      unitRef="usd">215800000</sgmo:NetProceedsFromIssuancePublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="if150961a5ee14928826e68c655e5d53f_D20170601-20170630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzcwNQ_fe337829-3c3c-43ee-bd18-2b1bb027d273"
      unitRef="shares">11500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i70ff8798b92448c0b579928fa54468cd_I20170630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzc2NQ_0249e658-44f3-4413-9f2e-98fad154e237"
      unitRef="usdPerShare">7.25</us-gaap:SharesIssuedPricePerShare>
    <sgmo:NetProceedsFromIssuancePublicOffering
      contextRef="if150961a5ee14928826e68c655e5d53f_D20170601-20170630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzk1Mg_bf150e0e-d8e0-48de-8a5b-3e5d2ade8f12"
      unitRef="usd">78100000</sgmo:NetProceedsFromIssuancePublicOffering>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i37807fd639dc45328330120e8b98348c_D20180401-20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzY4NjE_cd6870d5-184f-47ae-8088-e6d7fe6ece1c"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="ic0f7d9825feb4e208361c4ad02284de8_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzcyMTA_05b97402-a08d-4b31-941b-1bc36e38cd12"
      unitRef="number">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i86e7f798089c4c66a4e5b968d764d534_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzczNDQ_0e408012-4fac-469b-b838-2a199eac52ef">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <sgmo:SpecifiedStockholderOwnershipPercentage
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzc0MDU_bdb47443-08c3-4993-8135-9fd720908179"
      unitRef="number">0.10</sgmo:SpecifiedStockholderOwnershipPercentage>
    <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzc1NzU_5de2d371-5115-411a-b716-2d97a2bbd9c8"
      unitRef="number">1.10</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder>
    <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzc2OTE_a1b062a9-ae58-41e6-ac49-f9985161d7aa">P5Y</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ic0f7d9825feb4e208361c4ad02284de8_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzc3NTg_8e12248e-85e0-440c-a70e-d51de388e15f">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i2c7aa74b5db84179b2918daa34c73c69_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzc3OTQ_7506fa0f-4c6f-472e-8ba3-9196a4bf5234"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm
      contextRef="ic0f7d9825feb4e208361c4ad02284de8_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzc5MDA_ec353e14-bc7a-423c-ac71-b724c2f2949e">P10Y</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm>
    <sgmo:CommonStockExchangeRatio
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzc2OTY1ODE0MTk2Mjk_489a15c3-2f1e-4173-9ebb-b19a4ea190da"
      unitRef="number">1</sgmo:CommonStockExchangeRatio>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="ic0f7d9825feb4e208361c4ad02284de8_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzgyNTE_dc4485fb-83d7-4e04-8886-7600c70bf398"
      unitRef="number">1.33</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <sgmo:CommonStockExchangeRatio
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzc2OTY1ODE0MTk2MzU_443a7dc0-9cf7-47df-b984-f6d4e4ff8be7"
      unitRef="number">1</sgmo:CommonStockExchangeRatio>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="ic0f7d9825feb4e208361c4ad02284de8_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzg4NzA_dc4485fb-83d7-4e04-8886-7600c70bf398"
      unitRef="number">1.33</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i38ea9f2d9931428fba1f41e0b36e7bea_I20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzg3OTYwOTMwNDA5NDE_44756444-7c83-4134-b1ff-6b668779d6fb"
      unitRef="shares">4600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i57406eb823ae4dcba23a5c69e7941851_D20180601-20180630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzkzNTE_a7ea9237-4205-4d0d-a626-46aeff2f8bec"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzExODA5_5e24d1e9-94a3-4345-b6fd-66749005c292">&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A summary of Sangamo&#x2019;s stock option activity is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:46.680%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.929%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.732%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise per&lt;br/&gt;Share Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&#160;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options outstanding at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,726,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,530,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(806,226)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,620,867)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,829,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options vested and expected to vest at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,829,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options exercisable at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,993,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.54&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTpmMmZlNDNkY2U2MGE0YmQ3YWRmNmUwM2JkZmZlZDQ2NS90YWJsZXJhbmdlOmYyZmU0M2RjZTYwYTRiZDdhZGY2ZTAzYmRmZmVkNDY1XzItMS0xLTEtMA_f2976f4b-16f0-4e9b-a2ad-0f31542e624b"
      unitRef="shares">8726092</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTpmMmZlNDNkY2U2MGE0YmQ3YWRmNmUwM2JkZmZlZDQ2NS90YWJsZXJhbmdlOmYyZmU0M2RjZTYwYTRiZDdhZGY2ZTAzYmRmZmVkNDY1XzItMy0xLTEtMA_45e8a6d8-bbfd-4103-becf-1f2ab4ba87df"
      unitRef="usdPerShare">11.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTpmMmZlNDNkY2U2MGE0YmQ3YWRmNmUwM2JkZmZlZDQ2NS90YWJsZXJhbmdlOmYyZmU0M2RjZTYwYTRiZDdhZGY2ZTAzYmRmZmVkNDY1XzMtMS0xLTEtMA_5c2d2697-1cc7-4ee0-9b0c-5f1478dff833"
      unitRef="shares">4530288</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTpmMmZlNDNkY2U2MGE0YmQ3YWRmNmUwM2JkZmZlZDQ2NS90YWJsZXJhbmdlOmYyZmU0M2RjZTYwYTRiZDdhZGY2ZTAzYmRmZmVkNDY1XzMtMy0xLTEtMA_ecbde3f2-0a5b-4d74-96fb-856388a223a0"
      unitRef="usdPerShare">9.68</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTpmMmZlNDNkY2U2MGE0YmQ3YWRmNmUwM2JkZmZlZDQ2NS90YWJsZXJhbmdlOmYyZmU0M2RjZTYwYTRiZDdhZGY2ZTAzYmRmZmVkNDY1XzQtMS0xLTEtMA_00ab107d-23e7-400c-92a4-0db99405ba5f"
      unitRef="shares">806226</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTpmMmZlNDNkY2U2MGE0YmQ3YWRmNmUwM2JkZmZlZDQ2NS90YWJsZXJhbmdlOmYyZmU0M2RjZTYwYTRiZDdhZGY2ZTAzYmRmZmVkNDY1XzQtMy0xLTEtMA_f24a209d-fa46-4d8e-b473-b5e7e85f8284"
      unitRef="usdPerShare">5.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTpmMmZlNDNkY2U2MGE0YmQ3YWRmNmUwM2JkZmZlZDQ2NS90YWJsZXJhbmdlOmYyZmU0M2RjZTYwYTRiZDdhZGY2ZTAzYmRmZmVkNDY1XzUtMS0xLTEtMA_fdd0b2a5-62f6-4964-b7c2-eaa2f485bbbd"
      unitRef="shares">2620867</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTpmMmZlNDNkY2U2MGE0YmQ3YWRmNmUwM2JkZmZlZDQ2NS90YWJsZXJhbmdlOmYyZmU0M2RjZTYwYTRiZDdhZGY2ZTAzYmRmZmVkNDY1XzUtMy0xLTEtMA_6e6652fb-de28-4b9b-85bc-759113ff5bfc"
      unitRef="usdPerShare">12.39</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTpmMmZlNDNkY2U2MGE0YmQ3YWRmNmUwM2JkZmZlZDQ2NS90YWJsZXJhbmdlOmYyZmU0M2RjZTYwYTRiZDdhZGY2ZTAzYmRmZmVkNDY1XzYtMS0xLTEtMA_799c6360-34c0-4726-8ad2-e3006b0bc884"
      unitRef="shares">9829287</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTpmMmZlNDNkY2U2MGE0YmQ3YWRmNmUwM2JkZmZlZDQ2NS90YWJsZXJhbmdlOmYyZmU0M2RjZTYwYTRiZDdhZGY2ZTAzYmRmZmVkNDY1XzYtMy0xLTEtMA_f9cf6248-30bd-4e2b-b2dc-f81a233f9d8b"
      unitRef="usdPerShare">10.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTpmMmZlNDNkY2U2MGE0YmQ3YWRmNmUwM2JkZmZlZDQ2NS90YWJsZXJhbmdlOmYyZmU0M2RjZTYwYTRiZDdhZGY2ZTAzYmRmZmVkNDY1XzYtNS0xLTEtMA_01cf798f-b8e8-48db-8290-adadec8f7d64">P7Y10M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTpmMmZlNDNkY2U2MGE0YmQ3YWRmNmUwM2JkZmZlZDQ2NS90YWJsZXJhbmdlOmYyZmU0M2RjZTYwYTRiZDdhZGY2ZTAzYmRmZmVkNDY1XzYtNy0xLTEtMA_09fa8e74-62ac-47e0-a28a-3e2483f0a83e"
      unitRef="usd">7472000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTpmMmZlNDNkY2U2MGE0YmQ3YWRmNmUwM2JkZmZlZDQ2NS90YWJsZXJhbmdlOmYyZmU0M2RjZTYwYTRiZDdhZGY2ZTAzYmRmZmVkNDY1XzctMS0xLTEtMA_393634d1-e1a5-45f9-85e3-db9a2a38de04"
      unitRef="shares">9829287</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTpmMmZlNDNkY2U2MGE0YmQ3YWRmNmUwM2JkZmZlZDQ2NS90YWJsZXJhbmdlOmYyZmU0M2RjZTYwYTRiZDdhZGY2ZTAzYmRmZmVkNDY1XzctMy0xLTEtMA_3b18b7e7-a513-4ccc-9ac1-55db4eee553f"
      unitRef="usdPerShare">10.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTpmMmZlNDNkY2U2MGE0YmQ3YWRmNmUwM2JkZmZlZDQ2NS90YWJsZXJhbmdlOmYyZmU0M2RjZTYwYTRiZDdhZGY2ZTAzYmRmZmVkNDY1XzctNS0xLTEtMA_75633d12-45ed-4899-b37a-bd4182c1304c">P7Y10M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTpmMmZlNDNkY2U2MGE0YmQ3YWRmNmUwM2JkZmZlZDQ2NS90YWJsZXJhbmdlOmYyZmU0M2RjZTYwYTRiZDdhZGY2ZTAzYmRmZmVkNDY1XzctNy0xLTEtMA_d1c8f9a0-c2f9-4d5a-8c22-2344ce5f4352"
      unitRef="usd">7472000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTpmMmZlNDNkY2U2MGE0YmQ3YWRmNmUwM2JkZmZlZDQ2NS90YWJsZXJhbmdlOmYyZmU0M2RjZTYwYTRiZDdhZGY2ZTAzYmRmZmVkNDY1XzgtMS0xLTEtMA_31193cff-fdcb-4f81-a1e4-a89cb29cff1a"
      unitRef="shares">3993645</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTpmMmZlNDNkY2U2MGE0YmQ3YWRmNmUwM2JkZmZlZDQ2NS90YWJsZXJhbmdlOmYyZmU0M2RjZTYwYTRiZDdhZGY2ZTAzYmRmZmVkNDY1XzgtMy0xLTEtMA_bc7d66a2-6801-4a0d-9efa-123365c02cb7"
      unitRef="usdPerShare">10.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTpmMmZlNDNkY2U2MGE0YmQ3YWRmNmUwM2JkZmZlZDQ2NS90YWJsZXJhbmdlOmYyZmU0M2RjZTYwYTRiZDdhZGY2ZTAzYmRmZmVkNDY1XzgtNS0xLTEtMA_73b9a0a7-0840-4f69-a657-ab23b069b6cb">P6Y6M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTpmMmZlNDNkY2U2MGE0YmQ3YWRmNmUwM2JkZmZlZDQ2NS90YWJsZXJhbmdlOmYyZmU0M2RjZTYwYTRiZDdhZGY2ZTAzYmRmZmVkNDY1XzgtNy0xLTEtMA_3eaf44e4-9a4b-4b65-9e82-dd96b7a3468a"
      unitRef="usd">5442000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzk4MDI_6c6bfe43-0d6c-4fc6-b52f-8a0b16634688"
      unitRef="usd">4700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzk4MDY_bf4af03d-e24c-4ef8-a574-8b3022763b24"
      unitRef="usd">27000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzk4MTM_c2aab8f5-c73a-4cf9-af6b-6d7726a90bec"
      unitRef="usd">12300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzk5MzQ_d4fce347-b105-4ca0-96a9-d907157ec250"
      unitRef="usd">7500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0Xzk5NDE_6a6b7247-7da5-405a-9f56-46cb3b09f4ac"
      unitRef="usd">5400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzEwMDUy_d8ed90f2-acd4-4430-a5fa-4603d7529015"
      unitRef="usd">7500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzEwMDU2_38138f58-9eb5-4b65-9f8a-c2d320669972"
      unitRef="usd">24500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="ieb7e952fbd38434585f995fe73c66a44_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzEwMDYz_69025db3-6257-455b-952f-c038415dbaaa"
      unitRef="usd">71700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i413bd4488b904c0eb127a3a7f3af5412_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzEwMjQw_17aaf444-4dbc-486f-a665-fb95ec8d4b8f"
      unitRef="shares">834745</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i91e4fec1d21b4176925e0d7555154914_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzEwMjQ0_d1c74da2-a84c-474b-8abf-0d6d498133f0"
      unitRef="shares">346055</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i7afd1bb162e74f8188a0eebdfa207e9c_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzEwMjUy_fd84cbe8-a2e8-4f57-a893-1ad033f162ef"
      unitRef="shares">12600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i413bd4488b904c0eb127a3a7f3af5412_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzEwMzU5_c1434acd-65a3-4cf0-9ac5-ed5c5687004d"
      unitRef="usdPerShare">9.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i91e4fec1d21b4176925e0d7555154914_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzEwMzYz_4fccf640-c948-48a5-852a-e06b564cac0d"
      unitRef="usdPerShare">17.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7afd1bb162e74f8188a0eebdfa207e9c_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzEwMzcw_590fd47c-3fae-42a8-8498-265a2f9c11e4"
      unitRef="usdPerShare">15.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment
      contextRef="i413bd4488b904c0eb127a3a7f3af5412_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzEwNDc2_1930a00e-4286-400b-a523-21f3a729c4bc"
      unitRef="installment">3</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="i413bd4488b904c0eb127a3a7f3af5412_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzEwNTgy_7ab80eed-14f0-4b03-a82c-5bec9108d632"
      unitRef="usd">2000000.0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="i91e4fec1d21b4176925e0d7555154914_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzEwNTk0_ebe43988-0d29-4e0c-83fb-883a6ab11a2a"
      unitRef="usd">600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="i7afd1bb162e74f8188a0eebdfa207e9c_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzEwNjAx_f419a938-1acb-4879-8268-735ca790a689"
      unitRef="usd">1200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzExODEx_d2ecb868-5a81-4fb8-8a47-9c133674c2f1">&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A summary of Sangamo&#x2019;s RSU activity is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:54.451%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.756%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.662%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.665%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&#160;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Aggregate&#160;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;RSUs outstanding at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;322,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;RSUs awarded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;834,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;RSUs released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(118,807)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;RSUs forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(175,789)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;RSUs outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;862,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;RSUs vested and expected to vest at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;862,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTplOWY5YTI3ZWIxYjY0ZWVjYjk2NWQxMDNhMzRlMjhkNi90YWJsZXJhbmdlOmU5ZjlhMjdlYjFiNjRlZWNiOTY1ZDEwM2EzNGUyOGQ2XzItMS0xLTEtMA_ae4440fa-f117-4f9f-ad47-b9ccc35ff7d2"
      unitRef="shares">322701</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTplOWY5YTI3ZWIxYjY0ZWVjYjk2NWQxMDNhMzRlMjhkNi90YWJsZXJhbmdlOmU5ZjlhMjdlYjFiNjRlZWNiOTY1ZDEwM2EzNGUyOGQ2XzMtMS0xLTEtMA_836d1b9c-f420-46a7-9fd7-eb5abd4cc0f4"
      unitRef="shares">834745</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTplOWY5YTI3ZWIxYjY0ZWVjYjk2NWQxMDNhMzRlMjhkNi90YWJsZXJhbmdlOmU5ZjlhMjdlYjFiNjRlZWNiOTY1ZDEwM2EzNGUyOGQ2XzQtMS0xLTEtMA_2fd09729-e06d-4f65-aa71-1d9a9555778d"
      unitRef="shares">118807</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTplOWY5YTI3ZWIxYjY0ZWVjYjk2NWQxMDNhMzRlMjhkNi90YWJsZXJhbmdlOmU5ZjlhMjdlYjFiNjRlZWNiOTY1ZDEwM2EzNGUyOGQ2XzUtMS0xLTEtMA_a097a622-d44a-42b6-8339-f0ea613e4903"
      unitRef="shares">175789</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTplOWY5YTI3ZWIxYjY0ZWVjYjk2NWQxMDNhMzRlMjhkNi90YWJsZXJhbmdlOmU5ZjlhMjdlYjFiNjRlZWNiOTY1ZDEwM2EzNGUyOGQ2XzYtMS0xLTEtMA_997d88d5-86ad-4568-8072-e601d99f6f3d"
      unitRef="shares">862850</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTplOWY5YTI3ZWIxYjY0ZWVjYjk2NWQxMDNhMzRlMjhkNi90YWJsZXJhbmdlOmU5ZjlhMjdlYjFiNjRlZWNiOTY1ZDEwM2EzNGUyOGQ2XzYtMy0xLTEtMA_ebdf48cc-646a-4f54-a034-8009c9ae6fe9">P1Y2M19D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTplOWY5YTI3ZWIxYjY0ZWVjYjk2NWQxMDNhMzRlMjhkNi90YWJsZXJhbmdlOmU5ZjlhMjdlYjFiNjRlZWNiOTY1ZDEwM2EzNGUyOGQ2XzYtNS0xLTEtMA_95b972a7-33c2-44d5-96bb-bcc4487ee011"
      unitRef="usd">7222000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTplOWY5YTI3ZWIxYjY0ZWVjYjk2NWQxMDNhMzRlMjhkNi90YWJsZXJhbmdlOmU5ZjlhMjdlYjFiNjRlZWNiOTY1ZDEwM2EzNGUyOGQ2XzctMS0xLTEtMA_b2f0d9e9-14e9-4cd1-a90c-bd67256e38bb"
      unitRef="shares">862850</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber>
    <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTplOWY5YTI3ZWIxYjY0ZWVjYjk2NWQxMDNhMzRlMjhkNi90YWJsZXJhbmdlOmU5ZjlhMjdlYjFiNjRlZWNiOTY1ZDEwM2EzNGUyOGQ2XzctMy0xLTEtMA_579eb72f-2172-47b4-b453-808a04e54709">P1Y2M19D</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm>
    <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90YWJsZTplOWY5YTI3ZWIxYjY0ZWVjYjk2NWQxMDNhMzRlMjhkNi90YWJsZXJhbmdlOmU5ZjlhMjdlYjFiNjRlZWNiOTY1ZDEwM2EzNGUyOGQ2XzctNS0xLTEtMA_be9eab51-fb67-4b26-82a1-f224e61cb981"
      unitRef="usd">7222000</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i413bd4488b904c0eb127a3a7f3af5412_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzEwOTk2_ceff72c3-f037-4036-9231-a0ca959efca4"
      unitRef="shares">39160</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i91e4fec1d21b4176925e0d7555154914_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzExMDAw_5e826b37-2be5-4b67-8102-231c76b22910"
      unitRef="shares">20193</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i7afd1bb162e74f8188a0eebdfa207e9c_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzExMDA4_abd7d098-f2b9-4401-bc0c-394e3cffa7c1"
      unitRef="shares">42243</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzExMjQ4_48990781-e720-4923-9456-198acebb8110"
      unitRef="usd">400000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzExMjUy_3191f580-9d21-45ae-980a-89a266124dfa"
      unitRef="usd">300000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzExMjU4_15ce1633-a89a-4809-abf3-d1cc58e89265"
      unitRef="usd">700000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i6a1a6094e01242c48030234e32514b5b_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzExNjYw_88a728bd-2f97-413a-926f-580a224616dd"
      unitRef="shares">6691209</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzMvZnJhZzozMzQ1ZjA3MmM2Yjc0ZmIwODBkMzc0MzZjNzdkMTA2NC90ZXh0cmVnaW9uOjMzNDVmMDcyYzZiNzRmYjA4MGQzNzQzNmM3N2QxMDY0XzYwNDczMTM5NjYwOTk_2acafd96-aafc-41a1-b8cb-ef103e6beee8"
      unitRef="shares">2757600</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzIwMTQ_a6739eba-2807-4156-a9a7-f52eb3d7cdf2">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;NOTE 9 &#x2013; STOCK-BASED COMPENSATION&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table shows total stock-based compensation expense recognized in the accompanying Consolidated Statements of Operations (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:58.322%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.740%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of December&#160;31, 2019, total stock-based compensation expense to be recognized in future periods related to unvested stock options was $37.4&#160;million, which is expected to be expensed over a weighted-average period of 2.76 years. As of December&#160;31, 2019, total stock-based compensation expense to be recognized in future periods related to unvested RSUs was $7.0&#160;million, which is expected to be expensed over a weighted-average period of 2.11 years. There was no capitalized stock-based employee compensation expense as of December&#160;31, 2019, 2018 or 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Valuation Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Employee stock-based compensation expense was determined using the Black-Scholes option valuation model for stock options and employee share purchases under the ESPP. Option valuation models require the input of subjective assumptions and these assumptions can vary over time. The fair value of RSUs was based on the closing price of the underlying common stock on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company bases its determination of expected volatility through its assessment of the historical volatility of its common stock. The Company relied on its historical exercise and post-vested termination activity for estimating its expected term for use in determining the fair value of these options.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The weighted-average estimated fair value per share of options granted during 2019, 2018 and 2017 was $6.37, $11.39, and $4.10, respectively, based upon the assumptions used in the Black-Scholes valuation model. The assumptions used for estimating the fair value of the employee stock options were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:54.158%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.929%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.929%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.518%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.68-2.25%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.53-2.96%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.81-2.28%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.50-5.62&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.59-5.61&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.73-5.83&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected dividend yield of stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;76.46-78.39%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;72.33-75.49%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;71.11-72.30%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Employees purchased 249,364, 328,710 and 253,994 shares of common stock through the ESPP at an average exercise price of $8.53, $4.51, and $3.22 per share during 2019, 2018 and 2017, respectively. The weighted-average estimated fair values of shares purchased under the Company&#x2019;s ESPP during 2019, 2018 and 2017 were $4.70, $7.07 and $2.37, respectively, based upon the assumptions used in the Black-Scholes valuation model.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The weighted&#x2013;average assumptions used for estimating the fair value of the ESPP purchase rights are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:53.701%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.035%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.181%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.623%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.53-2.42%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.16-2.80%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.44-0.76%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.5 &#x2013; 2.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.5-2.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.5-2.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected dividend yield of stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51.02-91.96%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73.21-83.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;66.39-82.19%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzIwMTU_d35e26bf-9a67-4be2-9b62-4a97423ac32e">&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table shows total stock-based compensation expense recognized in the accompanying Consolidated Statements of Operations (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:58.322%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.740%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id5101aded6334b1c9c3a881011b6abae_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90YWJsZTphMGU0YTA0MzAxZTU0YzJmOWFlYzdlOTRkOTZhNjU0OC90YWJsZXJhbmdlOmEwZTRhMDQzMDFlNTRjMmY5YWVjN2U5NGQ5NmE2NTQ4XzItMS0xLTEtMA_bf3ba541-f254-4308-bdbd-630cb584a31e"
      unitRef="usd">10135000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i277c3b7360f04d3780bef6a633da1c71_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90YWJsZTphMGU0YTA0MzAxZTU0YzJmOWFlYzdlOTRkOTZhNjU0OC90YWJsZXJhbmdlOmEwZTRhMDQzMDFlNTRjMmY5YWVjN2U5NGQ5NmE2NTQ4XzItMy0xLTEtMA_9681eeef-8bee-4273-9ba7-c2a4f6e6274f"
      unitRef="usd">8249000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia4360f72084d45c580dd59abd6150a88_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90YWJsZTphMGU0YTA0MzAxZTU0YzJmOWFlYzdlOTRkOTZhNjU0OC90YWJsZXJhbmdlOmEwZTRhMDQzMDFlNTRjMmY5YWVjN2U5NGQ5NmE2NTQ4XzItNS0xLTEtMA_8f888b14-37dc-4038-8a43-45008d8a0dd3"
      unitRef="usd">5031000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib25eb7ae48804546b9f361611f4966bb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90YWJsZTphMGU0YTA0MzAxZTU0YzJmOWFlYzdlOTRkOTZhNjU0OC90YWJsZXJhbmdlOmEwZTRhMDQzMDFlNTRjMmY5YWVjN2U5NGQ5NmE2NTQ4XzMtMS0xLTEtMA_bfa52156-a069-4866-a231-0b8fa35b285c"
      unitRef="usd">9195000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6f39fb4590c1429f8543e94bc2f27f17_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90YWJsZTphMGU0YTA0MzAxZTU0YzJmOWFlYzdlOTRkOTZhNjU0OC90YWJsZXJhbmdlOmEwZTRhMDQzMDFlNTRjMmY5YWVjN2U5NGQ5NmE2NTQ4XzMtMy0xLTEtMA_747b1b09-ac88-42ee-b3e5-198fca53e62d"
      unitRef="usd">6428000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if9d63f212ff549b3a6d95bbdc6243555_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90YWJsZTphMGU0YTA0MzAxZTU0YzJmOWFlYzdlOTRkOTZhNjU0OC90YWJsZXJhbmdlOmEwZTRhMDQzMDFlNTRjMmY5YWVjN2U5NGQ5NmE2NTQ4XzMtNS0xLTEtMA_9659ce93-be62-47e7-a2ed-70f67b6512c3"
      unitRef="usd">4058000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90YWJsZTphMGU0YTA0MzAxZTU0YzJmOWFlYzdlOTRkOTZhNjU0OC90YWJsZXJhbmdlOmEwZTRhMDQzMDFlNTRjMmY5YWVjN2U5NGQ5NmE2NTQ4XzQtMS0xLTEtMA_1059be01-9cb9-4a53-bff3-d08702a90d18"
      unitRef="usd">19330000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90YWJsZTphMGU0YTA0MzAxZTU0YzJmOWFlYzdlOTRkOTZhNjU0OC90YWJsZXJhbmdlOmEwZTRhMDQzMDFlNTRjMmY5YWVjN2U5NGQ5NmE2NTQ4XzQtMy0xLTEtMA_b1c3d286-ea6f-47da-b3c6-a5a0613094cf"
      unitRef="usd">14677000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90YWJsZTphMGU0YTA0MzAxZTU0YzJmOWFlYzdlOTRkOTZhNjU0OC90YWJsZXJhbmdlOmEwZTRhMDQzMDFlNTRjMmY5YWVjN2U5NGQ5NmE2NTQ4XzQtNS0xLTEtMA_5a59f224-242f-4f94-9596-48f25b56f485"
      unitRef="usd">9089000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzMxMw_02ddce33-a27a-45ff-a7d1-ec909a3a5f9b"
      unitRef="usd">37400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzM4NA_5ca358f8-31e6-497a-a0ba-9b72f7454353">P2Y9M3D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i11cbad67c18a49ca910e920c1e2d9646_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzUwMg_bd3ec0a8-ef78-4769-a27a-b20ae1d6c5a7"
      unitRef="usd">7000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i413bd4488b904c0eb127a3a7f3af5412_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzU3Mw_e3d8aff4-d00f-414e-8cfd-a0097a192c0e">P2Y1M9D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzU4Nw_14451ecf-0525-4f28-a6bc-af32b2389540"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzU4Nw_87d8beff-197a-4af5-a47d-b685fa210e8a"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzU4Nw_f9d3c00a-23f9-4cd2-87ec-02d375a542c0"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzEzMDg_e4ae4763-d18c-4988-b8f5-29bf0907458c"
      unitRef="usdPerShare">6.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzEzMTI_aa7df587-213d-48dc-aa12-9e816f0fe218"
      unitRef="usdPerShare">11.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzEzMjA_3217d15c-7ee4-4fda-9a27-cdca33eb7226"
      unitRef="usdPerShare">4.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzIwMTY_6d5f9d4a-0cb2-4d6e-8bda-d058a1e1afed">The assumptions used for estimating the fair value of the employee stock options were as follows:&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:54.158%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.929%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.929%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.518%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.68-2.25%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.53-2.96%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.81-2.28%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.50-5.62&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.59-5.61&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.73-5.83&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected dividend yield of stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;76.46-78.39%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;72.33-75.49%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;71.11-72.30%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i280d0aff0b424211b1e87b1cc76e27a7_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90YWJsZTo2YWEwNDRiZmRiOGU0MDQxYmM5ZmU1Y2VkZmI0YTRkZi90YWJsZXJhbmdlOjZhYTA0NGJmZGI4ZTQwNDFiYzlmZTVjZWRmYjRhNGRmXzQtMS0xLTEtMA_f7a4dd8b-55a8-4e16-a391-cc12829a28a8"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ia0b92851791b4e9e8a15edb926cc2b4e_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90YWJsZTo2YWEwNDRiZmRiOGU0MDQxYmM5ZmU1Y2VkZmI0YTRkZi90YWJsZXJhbmdlOjZhYTA0NGJmZGI4ZTQwNDFiYzlmZTVjZWRmYjRhNGRmXzQtMy0xLTEtMA_17c202d8-e3cc-4039-bc73-5c40ece065ad"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i6568a8c2edac4a3c89060b40650283bd_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90YWJsZTo2YWEwNDRiZmRiOGU0MDQxYmM5ZmU1Y2VkZmI0YTRkZi90YWJsZXJhbmdlOjZhYTA0NGJmZGI4ZTQwNDFiYzlmZTVjZWRmYjRhNGRmXzQtNS0xLTEtMA_5fea366b-daa3-4d44-8568-f482ffe9be08"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzE1NDE_d4d2cb3a-b5ac-4c59-896f-ff8cc17c7c49"
      unitRef="shares">249364</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzE1NDU_f1792845-12ee-4a2e-94ae-b689b73efd97"
      unitRef="shares">328710</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzE1NTI_dd75c6e1-1443-48ff-936c-2fc736aa721b"
      unitRef="shares">253994</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <sgmo:StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzE2Mjc_0b8f26ba-6d00-46bd-839a-fc38e4394573"
      unitRef="usdPerShare">8.53</sgmo:StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice>
    <sgmo:StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzE2MzE_b018a22b-de6c-40ae-bf8b-dce1ad2dee7b"
      unitRef="usdPerShare">4.51</sgmo:StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice>
    <sgmo:StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzE2Mzk_b43cd491-fb81-48f9-952b-dbf3b360f126"
      unitRef="usdPerShare">3.22</sgmo:StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice>
    <sgmo:EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzE4MDE_d49ac7e8-a86e-410f-9c14-6d5ca7212e83"
      unitRef="usdPerShare">4.70</sgmo:EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue>
    <sgmo:EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzE4MDU_834bb94a-d62a-417a-afdd-7b48a686b30c"
      unitRef="usdPerShare">7.07</sgmo:EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue>
    <sgmo:EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzE4MTI_731016d3-aba5-4d3a-80c4-b060928ee04d"
      unitRef="usdPerShare">2.37</sgmo:EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90ZXh0cmVnaW9uOjAwNWRmZWEwNTRhMDQxMWJiZTJhYTM0NzcwOTJjMTdiXzIwMTM_40c270eb-8da1-4310-bbef-11a2fcbcab34">&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The weighted&#x2013;average assumptions used for estimating the fair value of the ESPP purchase rights are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:53.701%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.035%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.181%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.623%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.53-2.42%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.16-2.80%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.44-0.76%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.5 &#x2013; 2.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.5-2.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.5-2.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected dividend yield of stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51.02-91.96%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73.21-83.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;66.39-82.19%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ibf6eda356cbb4886a9bc71ebb4c979a6_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90YWJsZTpjZmY1NWYyNjlmMWU0YzAyYjNkY2Y3MzFjMzFjYzgxMC90YWJsZXJhbmdlOmNmZjU1ZjI2OWYxZTRjMDJiM2RjZjczMWMzMWNjODEwXzQtMS0xLTEtMA_fd20f79a-652b-432c-a522-9bb3c8553d70"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i12f6a30ee0794a7a8c75e504690f5c2c_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90YWJsZTpjZmY1NWYyNjlmMWU0YzAyYjNkY2Y3MzFjMzFjYzgxMC90YWJsZXJhbmdlOmNmZjU1ZjI2OWYxZTRjMDJiM2RjZjczMWMzMWNjODEwXzQtMy0xLTEtMA_daa9e24a-0997-4342-a099-3781a59b398a"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ib7ba96e253094ecbb1f17619de72a1e5_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMDYvZnJhZzowMDVkZmVhMDU0YTA0MTFiYmUyYWEzNDc3MDkyYzE3Yi90YWJsZTpjZmY1NWYyNjlmMWU0YzAyYjNkY2Y3MzFjMzFjYzgxMC90YWJsZXJhbmdlOmNmZjU1ZjI2OWYxZTRjMDJiM2RjZjczMWMzMWNjODEwXzQtNS0xLTEtMA_4d0414db-1d49-4ede-b35f-47769843bb96"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNDgvZnJhZzo0YzJlZmNmNjJhNzI0M2U3YTRmM2FlMjE0ODNmOGJlZS90ZXh0cmVnaW9uOjRjMmVmY2Y2MmE3MjQzZTdhNGYzYWUyMTQ4M2Y4YmVlXzU5OA_8d6bc1c1-8e1c-48bb-8151-e359cbe17243">&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;NOTE 10 &#x2013; EMPLOYEE BENEFIT PLAN&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company sponsors a defined-contribution savings plan under Section&#160;401(k) of the Internal Revenue Code covering all full-time employees (&#x201c;Sangamo 401(k) Plan&#x201d;). The Sangamo 401(k) Plan is intended to qualify under Section&#160;401 of the Internal Revenue Code.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company matched employee contributions equal to 50% for the first 8% in 2019, 2018 and 2017, up to a limit of $4,000 in 2019, 2018 and 2017. Matching funds are fully vested when contributed. Contributions to the Sangamo 401(k) Plan by the Company were $0.9&#160;million, $0.8&#160;million, and $0.5&#160;million for the years ended December&#160;31, 2019, 2018 and 2017, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNDgvZnJhZzo0YzJlZmNmNjJhNzI0M2U3YTRmM2FlMjE0ODNmOGJlZS90ZXh0cmVnaW9uOjRjMmVmY2Y2MmE3MjQzZTdhNGYzYWUyMTQ4M2Y4YmVlXzQ5NDc4MDIzMjU2MTA_0b52a11d-6d01-427e-aa36-cc89831c6ee9"
      unitRef="number">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNDgvZnJhZzo0YzJlZmNmNjJhNzI0M2U3YTRmM2FlMjE0ODNmOGJlZS90ZXh0cmVnaW9uOjRjMmVmY2Y2MmE3MjQzZTdhNGYzYWUyMTQ4M2Y4YmVlXzQ5NDc4MDIzMjU2MTA_ec7ac6f5-5d78-49f0-af47-3d401ae3bbc2"
      unitRef="number">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNDgvZnJhZzo0YzJlZmNmNjJhNzI0M2U3YTRmM2FlMjE0ODNmOGJlZS90ZXh0cmVnaW9uOjRjMmVmY2Y2MmE3MjQzZTdhNGYzYWUyMTQ4M2Y4YmVlXzQ5NDc4MDIzMjU2MTA_f0c07e03-2316-4041-80be-f775c07b7094"
      unitRef="number">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNDgvZnJhZzo0YzJlZmNmNjJhNzI0M2U3YTRmM2FlMjE0ODNmOGJlZS90ZXh0cmVnaW9uOjRjMmVmY2Y2MmE3MjQzZTdhNGYzYWUyMTQ4M2Y4YmVlXzQ5NDc4MDIzMjU2MTM_20c15a2c-c6e1-4bae-a798-e70ffccfd34c"
      unitRef="number">0.08</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNDgvZnJhZzo0YzJlZmNmNjJhNzI0M2U3YTRmM2FlMjE0ODNmOGJlZS90ZXh0cmVnaW9uOjRjMmVmY2Y2MmE3MjQzZTdhNGYzYWUyMTQ4M2Y4YmVlXzQ5NDc4MDIzMjU2MTM_754739f1-e1ec-4323-a502-c5eaefa57e19"
      unitRef="number">0.08</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNDgvZnJhZzo0YzJlZmNmNjJhNzI0M2U3YTRmM2FlMjE0ODNmOGJlZS90ZXh0cmVnaW9uOjRjMmVmY2Y2MmE3MjQzZTdhNGYzYWUyMTQ4M2Y4YmVlXzQ5NDc4MDIzMjU2MTM_fc0aa7cc-6822-42e7-877a-0c5e65f4edc9"
      unitRef="number">0.08</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNDgvZnJhZzo0YzJlZmNmNjJhNzI0M2U3YTRmM2FlMjE0ODNmOGJlZS90ZXh0cmVnaW9uOjRjMmVmY2Y2MmE3MjQzZTdhNGYzYWUyMTQ4M2Y4YmVlXzM5NA_c1d67471-7000-4053-b43c-1bfb5ecc0c95"
      unitRef="usd">4000</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNDgvZnJhZzo0YzJlZmNmNjJhNzI0M2U3YTRmM2FlMjE0ODNmOGJlZS90ZXh0cmVnaW9uOjRjMmVmY2Y2MmE3MjQzZTdhNGYzYWUyMTQ4M2Y4YmVlXzUzNg_bfd11135-343c-458f-a01c-2863120f3700"
      unitRef="usd">900000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNDgvZnJhZzo0YzJlZmNmNjJhNzI0M2U3YTRmM2FlMjE0ODNmOGJlZS90ZXh0cmVnaW9uOjRjMmVmY2Y2MmE3MjQzZTdhNGYzYWUyMTQ4M2Y4YmVlXzU0MA_9faae97b-e3e0-46b7-93d6-3bc623646877"
      unitRef="usd">800000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNDgvZnJhZzo0YzJlZmNmNjJhNzI0M2U3YTRmM2FlMjE0ODNmOGJlZS90ZXh0cmVnaW9uOjRjMmVmY2Y2MmE3MjQzZTdhNGYzYWUyMTQ4M2Y4YmVlXzU0OA_44952aaf-7fc3-4a3b-bb74-59c96c3fbb87"
      unitRef="usd">500000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90ZXh0cmVnaW9uOmU1ZTQ2NmFmOGMxZjRhMjE5OTAyMTIwZmRkMDc4ZDc5XzY4NTc_cd150003-8bbc-4ccf-b74c-3452728e537c">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;NOTE 11 &#x2013; INCOME TAXES &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The domestic and foreign components of loss before income taxes were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:61.343%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.731%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(77,354)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(65,695)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(54,568)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(18,065)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,194)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(95,419)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(68,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(54,568)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The benefit for income taxes consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:61.343%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.731%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Benefit for income taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The difference between the benefit for income taxes and the amount computed by applying the federal statutory income tax rate to loss before taxes is explained as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:60.848%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.894%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.894%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.896%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Tax at federal statutory rate&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(20,038)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(14,467)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(18,553)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;State taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9,597)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,849)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Federal rate change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(665)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(177)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Non-deductible stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,729)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,429)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,005)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(869)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(36,575)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;___________________&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-36pt;padding-left:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;(1)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt;"&gt;For the year ended December&#160;31, 2017 the statutory tax rate was 35%. For the years ended December&#160;31, 2018 and 2019, as a result of Tax Reform, the statutory tax rate was decreased to 21%.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company&#x2019;s deferred tax assets are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:73.806%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.731%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;133,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;138,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Build to suit lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accruals and reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;215,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;169,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;187,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;158,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(13,609)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(14,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(20,656)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,176)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(34,265)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(18,276)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(6,570)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(6,705)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In October 2018, the Company acquired Sangamo France. The Company recorded goodwill and intangible assets as part of accounting for the acquisition of Sangamo France. There is no corresponding tax basis for the goodwill or intangible assets. A portion of the intangible assets acquired were for the use in a particular research and development project IPR&amp;amp;D and are considered indefinite-lived assets with no tax basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The changes in the fair value of the unrealized gain/loss on securities investment are recorded as a component of accumulated other comprehensive income, net of a provision for income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A valuation allowance is recorded when it is more likely than not that all or some portion of the deferred income tax assets will not be realized. The Company regularly assesses the need for a valuation allowance against its deferred income tax assets by considering both positive and negative evidence related to whether it is more likely than not that the Company&#x2019;s deferred income tax assets will be realized. In evaluating the Company&#x2019;s ability to recover its deferred income tax assets within the jurisdiction from which they arise, the Company considers all available positive and negative evidence, including scheduled reversals of deferred income tax liabilities, projected future taxable income, tax-planning strategies, and results of recent operations. Accordingly, based upon the Company&#x2019;s analysis of these factors the net deferred tax assets have been substantially offset by a valuation allowance. The valuation allowance (decreased) increased by $(29.6)&#160;million, $45.3&#160;million and $(28.9)&#160;million for the years ended December&#160;31, 2019, 2018 and 2017, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of December&#160;31, 2019, Sangamo had net operating loss carryforwards for federal and state income tax purposes of approximately $489.4&#160;million and $164.7&#160;million, respectively. The federal net operating loss generated before 2018 will begin to expire in 2024 and will keep expiring through 2037, if not utilized. Federal net operating loss generated in 2018 will carry forward indefinitely. If not utilized, the state net operating loss carryforwards will begin to expire in 2029, respectively. The Company&#x2019;s French net operating loss carryforward balance is $147.9&#160;million, which carries over indefinitely. The Company also has federal and state research tax credit carryforwards of $16.4&#160;million and $15.2&#160;million, respectively. The federal research credits began to expire in 2018 while the state research credits have no expiration date. Utilization of the Company&#x2019;s net operating loss carryforwards and research tax credit carryforwards may be subject to substantial annual limitations due to the ownership change limitations provided by the Internal Revenue Code and similar state provisions. The annual limitation could result in the expiration of the net operating loss carryforwards and research tax credit carryforwards before utilization.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On December&#160;22, 2017, the current administration signed the Tax Cuts and Jobs Act (&#x201c;Tax Reform&#x201d;) into legislation. The Tax Reform makes significant changes to the U.S. corporate income tax law including, but not limited to, (1) reducing the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;U.S. federal corporate tax rate to 35% from 21% and (2) requiring a one-time mandatory transition tax on previously deferred foreign earnings of U.S. subsidiaries. Under ASC Topic 740, the effects of changes in tax rates and laws are recognized in the period in which the new legislation is enacted. In the case of U.S. federal income taxes, the enactment date is the date the bill becomes law.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On December 22, 2017, the SEC staff issued Staff Accounting Bulletin No. 118 (&#x201c;SAB 118&#x201d;), which provides guidance on accounting for the tax effects of the Tax Reform. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Reform enactment date for companies to complete the accounting under ASC Topic 740 for the year ended December&#160;31, 2018. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Tax Reform for which the accounting under ASC Topic 740 is complete. The Company has finished their analysis as of the measurement period closing of December 22, 2018 after application of law changes were reviewed by the Company. There were no subsequent adjustments as the conclusions have remained the same.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s policy is to reinvest the earnings of its non-U.S. subsidiaries in those operations. The Company does not provide for U.S. taxes on the earnings of foreign subsidiaries because the Company intends to reinvest such earnings offshore indefinitely. However, if these funds were repatriated, the Company would be required to accrue and pay applicable U.S. taxes and withholding taxes. Due to the losses generated in foreign countries there are no earnings to repatriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company files federal and state income tax returns with varying statutes of limitations. The tax years from 2002 forward remain open to examination due to the carryover of net operating losses or tax credits. The Company also files United Kingdom and French income tax returns, and the tax years from 2008 and thereafter remain open in the United Kingdom and 2016 and thereafter in France are still subject to examination.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. As of December&#160;31, 2019, the Company had no accrued interest and/or penalties. The unrecognized tax benefits may change during the next year for items that arise in the ordinary course of business. In the event that any unrecognized tax benefits are recognized, the effective tax rate will not be affected.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the activity related to the Company&#x2019;s unrecognized tax benefits (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:61.343%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.731%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Additions based on tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Additions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Reductions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90ZXh0cmVnaW9uOmU1ZTQ2NmFmOGMxZjRhMjE5OTAyMTIwZmRkMDc4ZDc5XzY4NTI_59120dca-788b-4126-b030-08c07e21163c">&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The domestic and foreign components of loss before income taxes were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:61.343%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.731%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(77,354)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(65,695)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(54,568)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(18,065)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,194)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(95,419)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(68,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(54,568)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZToyYzMxYzE0MGIxMjU0ODRiODAzOWViYTAwY2MwNzFmMy90YWJsZXJhbmdlOjJjMzFjMTQwYjEyNTQ4NGI4MDM5ZWJhMDBjYzA3MWYzXzItMS0xLTEtMA_af04ce59-2972-44b5-9917-f2f430264f84"
      unitRef="usd">-77354000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZToyYzMxYzE0MGIxMjU0ODRiODAzOWViYTAwY2MwNzFmMy90YWJsZXJhbmdlOjJjMzFjMTQwYjEyNTQ4NGI4MDM5ZWJhMDBjYzA3MWYzXzItMy0xLTEtMA_7fbd9a40-8408-4709-9592-320cffe1654a"
      unitRef="usd">-65695000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZToyYzMxYzE0MGIxMjU0ODRiODAzOWViYTAwY2MwNzFmMy90YWJsZXJhbmdlOjJjMzFjMTQwYjEyNTQ4NGI4MDM5ZWJhMDBjYzA3MWYzXzItNS0xLTEtMA_fbe79e08-e406-4f7b-91a5-8fee51b53448"
      unitRef="usd">-54568000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZToyYzMxYzE0MGIxMjU0ODRiODAzOWViYTAwY2MwNzFmMy90YWJsZXJhbmdlOjJjMzFjMTQwYjEyNTQ4NGI4MDM5ZWJhMDBjYzA3MWYzXzMtMS0xLTEtMA_61d4fcb3-22f2-43fd-9d0b-d54307272728"
      unitRef="usd">-18065000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZToyYzMxYzE0MGIxMjU0ODRiODAzOWViYTAwY2MwNzFmMy90YWJsZXJhbmdlOjJjMzFjMTQwYjEyNTQ4NGI4MDM5ZWJhMDBjYzA3MWYzXzMtMy0xLTEtMA_a53e988a-a6b4-4fac-b395-8099dfc4191d"
      unitRef="usd">-3194000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZToyYzMxYzE0MGIxMjU0ODRiODAzOWViYTAwY2MwNzFmMy90YWJsZXJhbmdlOjJjMzFjMTQwYjEyNTQ4NGI4MDM5ZWJhMDBjYzA3MWYzXzMtNS0xLTEtMA_177238ab-7a11-4f2d-ab02-cf21a2d0ae20"
      unitRef="usd">0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZToyYzMxYzE0MGIxMjU0ODRiODAzOWViYTAwY2MwNzFmMy90YWJsZXJhbmdlOjJjMzFjMTQwYjEyNTQ4NGI4MDM5ZWJhMDBjYzA3MWYzXzQtMS0xLTEtMA_c51aa813-b33b-4e37-9864-e11c5ac1528a"
      unitRef="usd">-95419000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZToyYzMxYzE0MGIxMjU0ODRiODAzOWViYTAwY2MwNzFmMy90YWJsZXJhbmdlOjJjMzFjMTQwYjEyNTQ4NGI4MDM5ZWJhMDBjYzA3MWYzXzQtMy0xLTEtMA_e912b330-9c1f-4016-9e23-412f7e71e8ce"
      unitRef="usd">-68889000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZToyYzMxYzE0MGIxMjU0ODRiODAzOWViYTAwY2MwNzFmMy90YWJsZXJhbmdlOjJjMzFjMTQwYjEyNTQ4NGI4MDM5ZWJhMDBjYzA3MWYzXzQtNS0xLTEtMA_752c1a1d-7728-49b6-8b10-09c91c436b39"
      unitRef="usd">-54568000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90ZXh0cmVnaW9uOmU1ZTQ2NmFmOGMxZjRhMjE5OTAyMTIwZmRkMDc4ZDc5XzY4NTM_224bece4-5798-4206-b7cb-637c2d7d3b45">&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The benefit for income taxes consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:61.343%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.731%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Benefit for income taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzQtMS0xLTEtMA_524e74a7-4fdb-4ed4-bebd-9969996c1c73"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzQtMy0xLTEtMA_3c7ae08d-79ee-4333-bb3f-67e73f8f5764"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzQtNS0xLTEtMA_75520391-2932-46e4-8024-69ce02fdec4e"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzUtMS0xLTEtMA_84b90953-08b9-4e8f-a676-ab290ffb77aa"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzUtMy0xLTEtMA_38a1ad35-391a-411f-83d4-68ed0ea371f6"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzUtNS0xLTEtMA_29f1711f-d378-4958-9005-6aa5e70b9c05"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzYtMS0xLTEtMA_cd5b9f9a-b37a-472a-8d32-304d5ad07f24"
      unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzYtMy0xLTEtMA_70942325-fea5-42ee-afd5-c25763e92f6b"
      unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzYtNS0xLTEtMA_2d299333-24cc-4a26-851d-a58c86aceaa7"
      unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzctMS0xLTEtMA_0a3d967d-4ea4-4cf0-b934-a819826640a0"
      unitRef="usd">0</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzctMy0xLTEtMA_4551dd94-b957-4484-817b-82fcb3fd057f"
      unitRef="usd">0</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzctNS0xLTEtMA_e57cda2d-ab52-46ba-baa9-bde1141b625c"
      unitRef="usd">0</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzktMS0xLTEtMA_6d2bab09-037f-4c14-9c7f-15876f888e6e"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzktMy0xLTEtMA_ce2a663e-9978-4655-994e-708efeb2bbbb"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzktNS0xLTEtMA_83e12766-f053-4654-a465-362356e9f044"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzEwLTEtMS0xLTA_e2db9a0b-3632-4800-96c3-dd610a7f6528"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzEwLTMtMS0xLTA_9a28b9bf-fadc-4397-bbad-5864a9443127"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzEwLTUtMS0xLTA_62823e6d-18d6-49db-9e58-2f708a49b2f4"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzExLTEtMS0xLTA_805aa502-3606-47c4-94c4-afc28766f06f"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzExLTMtMS0xLTA_5e63028b-c2ef-4f44-82b9-80b24aad1913"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzExLTUtMS0xLTA_d549e7a5-1112-437f-b357-5cb41ac29e9d"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzEyLTEtMS0xLTA_94cc6af1-b74d-4e26-8152-27993b9ca6ee"
      unitRef="usd">0</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzEyLTMtMS0xLTA_dad6bb14-1cea-4934-80c5-979aefd3d986"
      unitRef="usd">0</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzEyLTUtMS0xLTA_5e5fc1be-ee79-4909-ba11-ba88fa7f0a24"
      unitRef="usd">0</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzEzLTEtMS0xLTA_b4f2255f-2a1f-4494-8f87-904d157317f8"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzEzLTMtMS0xLTA_f5bfdf78-1bb4-4512-a213-b48cade41bf4"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpjOGQ1Y2FhYWYwNDQ0YzA0OTdiN2IxYTZhNWJhN2VmOC90YWJsZXJhbmdlOmM4ZDVjYWFhZjA0NDRjMDQ5N2I3YjFhNmE1YmE3ZWY4XzEzLTUtMS0xLTA_f7b3f53c-6411-4d6e-952e-1c292b530746"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90ZXh0cmVnaW9uOmU1ZTQ2NmFmOGMxZjRhMjE5OTAyMTIwZmRkMDc4ZDc5Xzc2OTY1ODE0MDIyMzY_b0e7ecda-66d0-47b2-a708-8d5c409bf427">&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The difference between the benefit for income taxes and the amount computed by applying the federal statutory income tax rate to loss before taxes is explained as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:60.848%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.894%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.894%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.896%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Tax at federal statutory rate&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(20,038)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(14,467)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(18,553)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;State taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9,597)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,849)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Federal rate change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(665)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(177)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Non-deductible stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,729)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,429)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,005)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(869)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(36,575)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;___________________&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-36pt;padding-left:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;(1)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt;"&gt;For the year ended December&#160;31, 2017 the statutory tax rate was 35%. For the years ended December&#160;31, 2018 and 2019, as a result of Tax Reform, the statutory tax rate was decreased to 21%.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzItMS0xLTEtMA_502148dd-38e2-49f5-a401-67f736015f2d"
      unitRef="usd">-20038000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzItMy0xLTEtMA_c9778374-f7be-4810-92bb-e56e8c5cbee7"
      unitRef="usd">-14467000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzItNS0xLTEtMA_dce8ad90-3918-46cc-8b25-35a9e1bc5f73"
      unitRef="usd">-18553000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzMtMS0xLTEtMA_fa7037bf-6753-41cb-a332-5714d8d6eb4f"
      unitRef="usd">-9597000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzMtMy0xLTEtMA_5b3731ca-d81d-47eb-bd72-b214f85f20ea"
      unitRef="usd">-2849000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzMtNS0xLTEtMA_587cd78d-cf3e-458e-a15f-40914f32e47e"
      unitRef="usd">795000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzQtMS0xLTEtMA_175202e5-c042-4475-8690-a824c18ca791"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzQtMy0xLTEtMA_1504d724-bd57-4e22-a992-9dc42d90e15f"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzQtNS0xLTEtMA_1e42d817-bd36-4b9d-b301-182b96a7edc7"
      unitRef="usd">53045000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzUtMS0xLTEtMA_5575b7a6-a4c1-4e7d-8c8d-fe138db6b41e"
      unitRef="usd">-665000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzUtMy0xLTEtMA_0f625b00-0aba-42e9-a6dd-e03d9e1278b0"
      unitRef="usd">-177000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzUtNS0xLTEtMA_b92f3f9e-f35d-44bf-bb6c-b534db5843f5"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <sgmo:IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzYtMS0xLTEtMA_791fa3ac-f1c5-415c-bafa-327792e92c2d"
      unitRef="usd">2817000</sgmo:IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation>
    <sgmo:IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzYtMy0xLTEtMA_995719e7-a338-4d45-9c90-620104650e15"
      unitRef="usd">-2729000</sgmo:IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation>
    <sgmo:IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzYtNS0xLTEtMA_b43a6b23-2f1c-410e-9c35-deba0f3a174f"
      unitRef="usd">2120000</sgmo:IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzctMS0xLTEtMA_302490ed-4f04-4993-8b36-d534020085e5"
      unitRef="usd">3429000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzctMy0xLTEtMA_57867961-00be-40f4-93c7-0ce2aeacdba8"
      unitRef="usd">1005000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzctNS0xLTEtMA_fec83c4e-99d9-4b33-8a4f-1c77b9517555"
      unitRef="usd">869000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzgtMS0xLTEtMA_96c09646-07ed-4291-adc6-44670632aca8"
      unitRef="usd">29655000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzgtMy0xLTEtMA_a752299c-d4d1-429a-b196-9380d6d4f1a9"
      unitRef="usd">20271000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzgtNS0xLTEtMA_67d39f4d-44ec-4fb9-9e2c-ec0fb0e40a58"
      unitRef="usd">-36575000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzktMS0xLTEtMA_0215e937-6980-4b3f-ab92-a519daf8db2e"
      unitRef="usd">1257000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzktMy0xLTEtMA_cce2fb62-17d4-43a5-886b-6966c0ddfc4c"
      unitRef="usd">956000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzktNS0xLTEtMA_07880771-6a1c-4592-a905-a11ef7fef985"
      unitRef="usd">37000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzEwLTEtMS0xLTA_25d84bae-f288-46a2-80ad-c430974415a3"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzEwLTMtMS0xLTA_b60f2d01-219b-4c72-9027-e41c17fbf45a"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozNjkzNjgwNWY0N2I0NGY3OGY5NTNjODAyODJlZTg5Yy90YWJsZXJhbmdlOjM2OTM2ODA1ZjQ3YjQ0Zjc4Zjk1M2M4MDI4MmVlODljXzEwLTUtMS0xLTA_3d23ff14-d8b8-4e1b-83f5-75f7f41e51ea"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90ZXh0cmVnaW9uOmU1ZTQ2NmFmOGMxZjRhMjE5OTAyMTIwZmRkMDc4ZDc5XzQ5NDc4MDIzMzE5MDQ_764c711a-4552-46fc-80b5-371a444166a2"
      unitRef="number">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90ZXh0cmVnaW9uOmU1ZTQ2NmFmOGMxZjRhMjE5OTAyMTIwZmRkMDc4ZDc5XzU2NQ_53615296-0189-4005-9922-17cdf83bbda4"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90ZXh0cmVnaW9uOmU1ZTQ2NmFmOGMxZjRhMjE5OTAyMTIwZmRkMDc4ZDc5XzU2NQ_6d4c8a72-c25d-49e0-b02c-eddbf96d897a"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90ZXh0cmVnaW9uOmU1ZTQ2NmFmOGMxZjRhMjE5OTAyMTIwZmRkMDc4ZDc5XzY4NTU_d73aee2c-8f27-46a7-ba35-7d623b5c7b3c">Significant components of the Company&#x2019;s deferred tax assets are as follows (in thousands):&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:73.806%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.731%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;133,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;138,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Build to suit lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accruals and reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;215,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;169,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;187,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;158,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(13,609)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(14,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(20,656)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,176)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(34,265)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(18,276)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(6,570)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(6,705)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzQtMS0xLTEtMA_e4f920a7-e170-43ec-afae-b0f4e5f6a7d2"
      unitRef="usd">133765000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzQtMy0xLTEtMA_6a3a027c-04bc-43dc-84f9-055057267a98"
      unitRef="usd">138896000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzUtMS0xLTEtMA_0a6e06c8-c78a-442a-b450-6733d16c6f68"
      unitRef="usd">21459000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzUtMy0xLTEtMA_b468fb62-187f-4878-b17f-8f0a53279837"
      unitRef="usd">16829000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzYtMS0xLTEtMA_51856f22-fafc-400c-87f9-dad458a481b9"
      unitRef="usd">4194000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzYtMy0xLTEtMA_85856380-eaf6-4382-8278-7568f174ee09"
      unitRef="usd">3801000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzctMS0xLTEtMA_8819dca6-3aab-4fab-9e26-4781cfd73b34"
      unitRef="usd">32171000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzctMy0xLTEtMA_759bc0bd-22a8-43dc-b528-fd9c5016ac12"
      unitRef="usd">3191000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzgtMS0xLTEtMTUwMTg_96e00a51-273f-4b67-b103-fd542aa6ab6f"
      unitRef="usd">11282000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzgtMy0xLTEtMTUwMjE_d2968cf3-b27b-4272-bc75-0ad7c58ad49c"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <sgmo:DeferredTaxAssetsLeaseLiability
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzktMS0xLTEtMTUwMTI_3e35606d-3546-4246-b9c2-5d3384e53009"
      unitRef="usd">11722000</sgmo:DeferredTaxAssetsLeaseLiability>
    <sgmo:DeferredTaxAssetsLeaseLiability
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzktMy0xLTEtMTUwMTU_495bf6aa-83f2-4239-a8bb-f29753aeb67c"
      unitRef="usd">0</sgmo:DeferredTaxAssetsLeaseLiability>
    <sgmo:DeferredTaxAssetsBuildToSuitLeaseLiability
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzgtMS0xLTEtMA_b3878636-0700-43e5-8606-e042ca77dfa6"
      unitRef="usd">0</sgmo:DeferredTaxAssetsBuildToSuitLeaseLiability>
    <sgmo:DeferredTaxAssetsBuildToSuitLeaseLiability
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzgtMy0xLTEtMA_5d4c6c50-faeb-4a3a-ba53-7bf3a8bbd355"
      unitRef="usd">6400000</sgmo:DeferredTaxAssetsBuildToSuitLeaseLiability>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzExLTEtMS0xLTE1MTAx_1f114e25-33a5-4d4b-b4e8-e570db9c63e1"
      unitRef="usd">675000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzExLTMtMS0xLTE1MTA0_b96a9919-7ef9-496a-bfde-22f71cbf920d"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzktMS0xLTEtMA_40981d9c-827f-4c2b-aef0-814f65a94542"
      unitRef="usd">151000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzktMy0xLTEtMA_fac6a64e-faa1-49d8-a47e-e53037d181fd"
      unitRef="usd">604000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzEwLTEtMS0xLTA_4f47bdec-502d-4388-a437-d89655f3d999"
      unitRef="usd">215419000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzEwLTMtMS0xLTA_e10dea67-468f-4217-999a-303d49fd957b"
      unitRef="usd">169721000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzExLTEtMS0xLTA_c8a7dbd7-5d6e-4e55-8c67-55476b807caa"
      unitRef="usd">187724000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzExLTMtMS0xLTA_003befcf-7791-4ff9-b0d1-de9bbb973f96"
      unitRef="usd">158150000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzEyLTEtMS0xLTA_ac72e818-4e02-4617-a5b0-a47685c7fb94"
      unitRef="usd">27695000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzEyLTMtMS0xLTA_f795e806-cede-4c15-90f6-9fb8984f89af"
      unitRef="usd">11571000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzE0LTEtMS0xLTA_8aac447a-bbcf-4f55-8877-e3c949065f81"
      unitRef="usd">13609000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzE0LTMtMS0xLTA_ff67a815-288e-447d-a37b-151537ee57bb"
      unitRef="usd">14100000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzE3LTEtMS0xLTE1MDMw_b4e1dcb8-d007-44d3-bee8-c407a8d4f1eb"
      unitRef="usd">20656000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzE1LTEtMS0xLTA_1fea8c5b-ccc4-439d-b692-3755001211b1"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzE1LTMtMS0xLTA_d5d38ad0-887e-4d8f-b4bc-84bfd48e44bf"
      unitRef="usd">4176000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzE2LTEtMS0xLTA_54c0bd7b-ef51-421e-914a-d1b764c84035"
      unitRef="usd">34265000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzE2LTMtMS0xLTA_d7826a1c-9093-4a4e-b744-9385f4374f60"
      unitRef="usd">18276000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzE3LTEtMS0xLTA_36c936ac-b3a9-4130-8751-242c86d41575"
      unitRef="usd">6570000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTpmMzYxYTBiMDIyMjA0MjM2YThmMTY3NDM5MmM4MTk2Mi90YWJsZXJhbmdlOmYzNjFhMGIwMjIyMDQyMzZhOGYxNjc0MzkyYzgxOTYyXzE3LTMtMS0xLTA_19cfb23b-a7bb-4124-86a1-8433b3da351e"
      unitRef="usd">6705000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90ZXh0cmVnaW9uOmU1ZTQ2NmFmOGMxZjRhMjE5OTAyMTIwZmRkMDc4ZDc5XzI0NTM_86f86cfe-8524-43ac-ae4d-198b88517d24"
      unitRef="usd">-29600000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90ZXh0cmVnaW9uOmU1ZTQ2NmFmOGMxZjRhMjE5OTAyMTIwZmRkMDc4ZDc5XzI0NTc_0e85893d-ca39-43be-83b1-633870032308"
      unitRef="usd">45300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90ZXh0cmVnaW9uOmU1ZTQ2NmFmOGMxZjRhMjE5OTAyMTIwZmRkMDc4ZDc5XzI0NjQ_b063db8e-0f53-42a8-ae3e-68ae1116591d"
      unitRef="usd">-28900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90ZXh0cmVnaW9uOmU1ZTQ2NmFmOGMxZjRhMjE5OTAyMTIwZmRkMDc4ZDc5XzI2MzA_3a26383d-d6b3-41a2-bcbb-3a1996226c84"
      unitRef="usd">489400000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90ZXh0cmVnaW9uOmU1ZTQ2NmFmOGMxZjRhMjE5OTAyMTIwZmRkMDc4ZDc5XzI2Mzc_769a6166-d1d4-494d-b2a4-2a6dbd94b684"
      unitRef="usd">164700000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="ic95b30c3bdb047e09c97a070b92d9bd5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90ZXh0cmVnaW9uOmU1ZTQ2NmFmOGMxZjRhMjE5OTAyMTIwZmRkMDc4ZDc5XzI3OTU_cad090ec-a2a5-4acb-94e7-6825cfd7aee8"
      unitRef="usd">147900000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <sgmo:DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90ZXh0cmVnaW9uOmU1ZTQ2NmFmOGMxZjRhMjE5OTAyMTIwZmRkMDc4ZDc5XzI5MDc_b93ec417-21b0-4e6d-870a-1013f0d93bca"
      unitRef="usd">16400000</sgmo:DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal>
    <sgmo:DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90ZXh0cmVnaW9uOmU1ZTQ2NmFmOGMxZjRhMjE5OTAyMTIwZmRkMDc4ZDc5XzI5MTQ_cbb36661-5dd1-4b00-b48a-48a5fab691d8"
      unitRef="usd">15200000</sgmo:DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90ZXh0cmVnaW9uOmU1ZTQ2NmFmOGMxZjRhMjE5OTAyMTIwZmRkMDc4ZDc5XzY0NzQ_2206131c-cc14-4e67-93b2-c99867f2e50c"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90ZXh0cmVnaW9uOmU1ZTQ2NmFmOGMxZjRhMjE5OTAyMTIwZmRkMDc4ZDc5XzY4NTY_0ba3d87e-5d87-4e6a-b7b9-6965baaa5210">&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the activity related to the Company&#x2019;s unrecognized tax benefits (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:61.343%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.731%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Additions based on tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Additions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Reductions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozZmUzM2U1N2I0NzQ0ZTRkYjg0ZTMyMWJmZDc0MmE0ZS90YWJsZXJhbmdlOjNmZTMzZTU3YjQ3NDRlNGRiODRlMzIxYmZkNzQyYTRlXzItMS0xLTEtMA_28efb193-1b85-4f8e-a802-319edc822407"
      unitRef="usd">6288000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ieb7e952fbd38434585f995fe73c66a44_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozZmUzM2U1N2I0NzQ0ZTRkYjg0ZTMyMWJmZDc0MmE0ZS90YWJsZXJhbmdlOjNmZTMzZTU3YjQ3NDRlNGRiODRlMzIxYmZkNzQyYTRlXzItMy0xLTEtMA_a393d7bf-32e3-4880-933d-f1c9637865ed"
      unitRef="usd">5659000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ie9057cb83ba040218834cc92910f7361_I20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozZmUzM2U1N2I0NzQ0ZTRkYjg0ZTMyMWJmZDc0MmE0ZS90YWJsZXJhbmdlOjNmZTMzZTU3YjQ3NDRlNGRiODRlMzIxYmZkNzQyYTRlXzItNS0xLTEtMA_0d8a87f1-b8d8-4923-bfa8-83bcc52a41dd"
      unitRef="usd">5045000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozZmUzM2U1N2I0NzQ0ZTRkYjg0ZTMyMWJmZDc0MmE0ZS90YWJsZXJhbmdlOjNmZTMzZTU3YjQ3NDRlNGRiODRlMzIxYmZkNzQyYTRlXzMtMS0xLTEtMA_44ce048b-789a-4325-8a1c-ed23179dc1e9"
      unitRef="usd">5393000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozZmUzM2U1N2I0NzQ0ZTRkYjg0ZTMyMWJmZDc0MmE0ZS90YWJsZXJhbmdlOjNmZTMzZTU3YjQ3NDRlNGRiODRlMzIxYmZkNzQyYTRlXzMtMy0xLTEtMA_f722c4b6-6bd9-4811-916f-6894c5eb55c0"
      unitRef="usd">636000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozZmUzM2U1N2I0NzQ0ZTRkYjg0ZTMyMWJmZDc0MmE0ZS90YWJsZXJhbmdlOjNmZTMzZTU3YjQ3NDRlNGRiODRlMzIxYmZkNzQyYTRlXzMtNS0xLTEtMA_9aacfb49-5075-49ef-bc86-8f264c313de0"
      unitRef="usd">622000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <sgmo:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozZmUzM2U1N2I0NzQ0ZTRkYjg0ZTMyMWJmZDc0MmE0ZS90YWJsZXJhbmdlOjNmZTMzZTU3YjQ3NDRlNGRiODRlMzIxYmZkNzQyYTRlXzQtMS0xLTEtMA_12e3614b-592d-41eb-ba87-8ed11891f1c4"
      unitRef="usd">-51000</sgmo:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions>
    <sgmo:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozZmUzM2U1N2I0NzQ0ZTRkYjg0ZTMyMWJmZDc0MmE0ZS90YWJsZXJhbmdlOjNmZTMzZTU3YjQ3NDRlNGRiODRlMzIxYmZkNzQyYTRlXzQtMy0xLTEtMA_afd8dc87-4655-4787-87d4-6bdba599e182"
      unitRef="usd">-7000</sgmo:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions>
    <sgmo:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozZmUzM2U1N2I0NzQ0ZTRkYjg0ZTMyMWJmZDc0MmE0ZS90YWJsZXJhbmdlOjNmZTMzZTU3YjQ3NDRlNGRiODRlMzIxYmZkNzQyYTRlXzQtNS0xLTEtMA_90265e9a-9341-48f8-bd3a-297e738fd0e3"
      unitRef="usd">-8000</sgmo:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozZmUzM2U1N2I0NzQ0ZTRkYjg0ZTMyMWJmZDc0MmE0ZS90YWJsZXJhbmdlOjNmZTMzZTU3YjQ3NDRlNGRiODRlMzIxYmZkNzQyYTRlXzUtMS0xLTEtMA_24ee2c3c-6ba6-42bc-b8aa-c6f698c2830c"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="ifea77b49dec041c3a8ebdd3e723ca247_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozZmUzM2U1N2I0NzQ0ZTRkYjg0ZTMyMWJmZDc0MmE0ZS90YWJsZXJhbmdlOjNmZTMzZTU3YjQ3NDRlNGRiODRlMzIxYmZkNzQyYTRlXzUtMy0xLTEtMA_8236e677-6f9f-41d8-b6d1-812e3a93d2fd"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="ie7a33a33aa6a48fc8194a9ffa0898744_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozZmUzM2U1N2I0NzQ0ZTRkYjg0ZTMyMWJmZDc0MmE0ZS90YWJsZXJhbmdlOjNmZTMzZTU3YjQ3NDRlNGRiODRlMzIxYmZkNzQyYTRlXzUtNS0xLTEtMA_7b2dfbed-01a0-4e85-bebe-bacd347a9b3f"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i3743f02b3ec348be98acb2e813e9c7f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozZmUzM2U1N2I0NzQ0ZTRkYjg0ZTMyMWJmZDc0MmE0ZS90YWJsZXJhbmdlOjNmZTMzZTU3YjQ3NDRlNGRiODRlMzIxYmZkNzQyYTRlXzYtMS0xLTEtMA_6ad9fef9-359b-4643-9556-db3d0b7fb469"
      unitRef="usd">11630000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="iafee69bb5c304299817c47783c041381_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozZmUzM2U1N2I0NzQ0ZTRkYjg0ZTMyMWJmZDc0MmE0ZS90YWJsZXJhbmdlOjNmZTMzZTU3YjQ3NDRlNGRiODRlMzIxYmZkNzQyYTRlXzYtMy0xLTEtMA_1e4e713b-60d5-468f-a1fa-da0de68d5f25"
      unitRef="usd">6288000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ieb7e952fbd38434585f995fe73c66a44_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xMzkvZnJhZzplNWU0NjZhZjhjMWY0YTIxOTkwMjEyMGZkZDA3OGQ3OS90YWJsZTozZmUzM2U1N2I0NzQ0ZTRkYjg0ZTMyMWJmZDc0MmE0ZS90YWJsZXJhbmdlOjNmZTMzZTU3YjQ3NDRlNGRiODRlMzIxYmZkNzQyYTRlXzYtNS0xLTEtMA_042b82ef-4d31-4d32-8ccf-0f83f142aeef"
      unitRef="usd">5659000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTY1L2ZyYWc6MmJjNjFmOTUxOGFlNDgwYzg5NWIyNmI1YzRiODc1YmYvdGV4dHJlZ2lvbjoyYmM2MWY5NTE4YWU0ODBjODk1YjI2YjVjNGI4NzViZl84MjQ2MzM3MjA4NzY3_51df043e-0455-4e78-8ae3-bc3a7301a98c">RELATED PARTY TRANSACTIONDuring the year, the Company acquired 52,700 vested free shares from a former executive of Sangamo France who is now an executive of Sangamo, pursuant to the exercise of the Free Shares Options for approximately $0.1&#160;million of cash.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <sgmo:BusinessAcquisitionNumberOfSharesAcquired
      contextRef="i52834b9e08624c8bacef183387dd51ed_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTY1L2ZyYWc6MmJjNjFmOTUxOGFlNDgwYzg5NWIyNmI1YzRiODc1YmYvdGV4dHJlZ2lvbjoyYmM2MWY5NTE4YWU0ODBjODk1YjI2YjVjNGI4NzViZl84Nzk2MDkzMDIyMzU4_c07d524d-bcb6-47f6-8c98-b3144f01c664"
      unitRef="shares">52700</sgmo:BusinessAcquisitionNumberOfSharesAcquired>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="i7904976381aa418691f37a32d64b07c0_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTY1L2ZyYWc6MmJjNjFmOTUxOGFlNDgwYzg5NWIyNmI1YzRiODc1YmYvdGV4dHJlZ2lvbjoyYmM2MWY5NTE4YWU0ODBjODk1YjI2YjVjNGI4NzViZl84MjQ2MzM3MjA4Nzc1_8d2faf70-3ae0-489f-934b-08c07d61ba71"
      unitRef="usd">100000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:QuarterlyFinancialInformationTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90ZXh0cmVnaW9uOmFmNGFkZGZkZTg5OTRiNGQ5NTMzNzg5YTI1OTA1N2IwXzUwNg_ea36a779-83a0-4bcb-ba65-cfaca76ef3c9">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;NOTE 13 &#x2013; QUARTERLY FINANCIAL DATA (UNAUDITED)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table sets forth certain unaudited quarterly financial data for the eight quarters ended December&#160;31, 2019. The unaudited information set forth below has been prepared on the same basis as the audited information contained herein and includes all adjustments necessary to present fairly the information set forth. The operating results for any quarter are not indicative of results for any future period. All amounts are in thousands except per share amounts.&lt;/span&gt;&lt;/div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:22.264%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.823%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.823%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.823%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.823%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.823%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.823%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.823%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.830%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Q1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Q2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Q3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Q4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Q1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Q2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Q3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Q4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;54,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;40,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;47,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(42,203)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(30,356)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(27,361)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(20,187)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(16,640)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(12,843)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(19,219)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss attributable to non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(555)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net (loss) income attributable to Sangamo Therapeutics, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(42,150)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(30,284)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(27,307)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(20,187)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(16,640)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(12,843)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(18,664)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Basic and diluted net (loss) income per share attributable to Sangamo Therapeutics, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.41)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.26)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.24)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.23)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.18)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90ZXh0cmVnaW9uOmFmNGFkZGZkZTg5OTRiNGQ5NTMzNzg5YTI1OTA1N2IwXzc2OTY1ODEzOTQ5OTA_fadb5da0-77c9-4844-83b2-067a091f365a">The following table sets forth certain unaudited quarterly financial data for the eight quarters ended December&#160;31, 2019. The unaudited information set forth below has been prepared on the same basis as the audited information contained herein and includes all adjustments necessary to present fairly the information set forth. The operating results for any quarter are not indicative of results for any future period. All amounts are in thousands except per share amounts.&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:22.264%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.823%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.823%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.823%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.823%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.823%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.823%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.823%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.830%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Q1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Q2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Q3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Q4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Q1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Q2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Q3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Q4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;54,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;40,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;47,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(42,203)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(30,356)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(27,361)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(20,187)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(16,640)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(12,843)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(19,219)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss attributable to non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(555)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net (loss) income attributable to Sangamo Therapeutics, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(42,150)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(30,284)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(27,307)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(20,187)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(16,640)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(12,843)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(18,664)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Basic and diluted net (loss) income per share attributable to Sangamo Therapeutics, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.41)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.26)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.24)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.23)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.18)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i650fabb9fd3342b194a201cbf6d40308_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzItMS0xLTEtMA_a614f01a-3e4d-41c3-86c5-4e91de1383dc"
      unitRef="usd">8071000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7d3836ab6ab8497ea22f279a0bfeb107_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzItMy0xLTEtMA_e8df0ecf-4e3e-4b00-a9e1-62606f8c0b7f"
      unitRef="usd">17548000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id2195a0eb53f457697e901d30824c2b3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzItNS0xLTEtMA_ab6da33e-1ffd-4157-833f-3fc88eade9ef"
      unitRef="usd">21958000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iecf9c60eda6d47d4a66bc7797840c1d5_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzItNy0xLTEtMA_af356e16-0c0d-4187-b58c-f04de82d791a"
      unitRef="usd">54851000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iad063cfae7ac486cb8c7a7931ccbc02e_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzItOS0xLTEtMA_c9f95a2f-7f7a-4008-8cb4-ef8220270664"
      unitRef="usd">12637000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if2cf250af72b4f33993772a39178733a_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzItMTEtMS0xLTA_c07c5e56-7801-4adf-8a76-bf76b017dd13"
      unitRef="usd">21416000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibac9f542f2ce4f519e06c7aabb195095_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzItMTMtMS0xLTA_af1c139f-bdae-48d0-b56f-13a2129bc5ed"
      unitRef="usd">23562000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibbad735aad064fe6bda84e11e1e8baab_D20181001-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzItMTUtMS0xLTA_02d597d9-abe0-45c1-960f-0c642b7cfc1a"
      unitRef="usd">26837000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingExpenses
      contextRef="i650fabb9fd3342b194a201cbf6d40308_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzMtMS0xLTEtMA_0bd87fae-6dc8-40d5-b38f-e1d774ee20af"
      unitRef="usd">51968000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i7d3836ab6ab8497ea22f279a0bfeb107_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzMtMy0xLTEtMA_98560fd1-84ee-4854-bc6b-f4e709495394"
      unitRef="usd">51052000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="id2195a0eb53f457697e901d30824c2b3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzMtNS0xLTEtMA_bad5528e-f9d3-4f1c-aad7-8b6febaba96e"
      unitRef="usd">51206000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="iecf9c60eda6d47d4a66bc7797840c1d5_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzMtNy0xLTEtMA_ace46951-31dd-4771-9b35-543a10dc7e73"
      unitRef="usd">53382000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="iad063cfae7ac486cb8c7a7931ccbc02e_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzMtOS0xLTEtMA_f9a27e2a-e451-4562-a8ac-8ddbeeb3730c"
      unitRef="usd">33634000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="if2cf250af72b4f33993772a39178733a_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzMtMTEtMS0xLTA_e4d2e284-52a4-4351-926d-3aa299e1e08f"
      unitRef="usd">40556000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ibac9f542f2ce4f519e06c7aabb195095_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzMtMTMtMS0xLTA_9d2acad8-6fa9-4579-b732-cc58aa4dd6c5"
      unitRef="usd">39803000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ibbad735aad064fe6bda84e11e1e8baab_D20181001-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzMtMTUtMS0xLTA_155dc1ad-ed93-478c-abc0-0527385029a2"
      unitRef="usd">47609000</us-gaap:OperatingExpenses>
    <us-gaap:ProfitLoss
      contextRef="i650fabb9fd3342b194a201cbf6d40308_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzQtMS0xLTEtMA_89419bbb-6825-4e31-a17b-5f168c5aef3b"
      unitRef="usd">-42203000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i7d3836ab6ab8497ea22f279a0bfeb107_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzQtMy0xLTEtMA_166d2398-c7c9-497f-b534-24ebe40f7a42"
      unitRef="usd">-30356000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id2195a0eb53f457697e901d30824c2b3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzQtNS0xLTEtMA_99a6f024-8fd9-43a3-b82b-a9d8df175dfa"
      unitRef="usd">-27361000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iecf9c60eda6d47d4a66bc7797840c1d5_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzQtNy0xLTEtMA_ee225bc6-4d0a-4020-9cc0-9b6e7ddae9f8"
      unitRef="usd">4501000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iad063cfae7ac486cb8c7a7931ccbc02e_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzQtOS0xLTEtMA_a4950fad-e593-4ba0-8ef4-52efafd1f960"
      unitRef="usd">-20187000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if2cf250af72b4f33993772a39178733a_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzQtMTEtMS0xLTA_db828562-2817-4e05-8f6f-7e7e33528f00"
      unitRef="usd">-16640000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ibac9f542f2ce4f519e06c7aabb195095_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzQtMTMtMS0xLTA_c22acb9e-bb54-4caa-811a-053116af3525"
      unitRef="usd">-12843000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ibbad735aad064fe6bda84e11e1e8baab_D20181001-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzQtMTUtMS0xLTA_1d1a6d96-56e1-4b02-9971-adddf79a3318"
      unitRef="usd">-19219000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i650fabb9fd3342b194a201cbf6d40308_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzUtMS0xLTEtMA_7d37849e-3ad4-47dd-b904-3b98d1b532ce"
      unitRef="usd">-53000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i7d3836ab6ab8497ea22f279a0bfeb107_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzUtMy0xLTEtMA_7cee9991-cbe2-42e9-97c2-cf859b41d4b3"
      unitRef="usd">-72000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="id2195a0eb53f457697e901d30824c2b3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzUtNS0xLTEtMA_8363b8fb-3d9b-4ee6-a086-3f993053bb09"
      unitRef="usd">-54000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="iecf9c60eda6d47d4a66bc7797840c1d5_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzUtNy0xLTEtMA_9a4c881f-3066-4423-930f-730083e409bb"
      unitRef="usd">-54000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="iad063cfae7ac486cb8c7a7931ccbc02e_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzUtOS0xLTEtMA_6559ec6d-9cd3-48da-8ad8-ca42dcd2d2f7"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="if2cf250af72b4f33993772a39178733a_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzUtMTEtMS0xLTA_914de789-80ec-4197-9dad-52d53fd2669a"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ibac9f542f2ce4f519e06c7aabb195095_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzUtMTMtMS0xLTA_efc941b4-061b-4560-94d8-15805c1eadc0"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ibbad735aad064fe6bda84e11e1e8baab_D20181001-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzUtMTUtMS0xLTA_e6df3d09-65d5-4ebb-9086-ce717c7bbd2e"
      unitRef="usd">-555000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i650fabb9fd3342b194a201cbf6d40308_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzYtMS0xLTEtMA_36d4a91e-c537-4353-b57f-2eaa96335088"
      unitRef="usd">-42150000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7d3836ab6ab8497ea22f279a0bfeb107_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzYtMy0xLTEtMA_26bd5d57-3a6c-40e1-85d8-e44a66881857"
      unitRef="usd">-30284000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id2195a0eb53f457697e901d30824c2b3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzYtNS0xLTEtMA_676b5c31-1d0e-41f5-90d6-ea23c4cd663a"
      unitRef="usd">-27307000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iecf9c60eda6d47d4a66bc7797840c1d5_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzYtNy0xLTEtMA_4666210c-ce9d-4a02-9f48-51cbfe44ba4c"
      unitRef="usd">4555000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iad063cfae7ac486cb8c7a7931ccbc02e_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzYtOS0xLTEtMA_007a316a-2fc8-429d-b039-5c8bdff78813"
      unitRef="usd">-20187000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if2cf250af72b4f33993772a39178733a_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzYtMTEtMS0xLTA_5276900b-2942-4e91-8f44-eb9d9e0555a2"
      unitRef="usd">-16640000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibac9f542f2ce4f519e06c7aabb195095_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzYtMTMtMS0xLTA_a4754850-6d9b-4fca-9d7d-9a5f43c7b559"
      unitRef="usd">-12843000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibbad735aad064fe6bda84e11e1e8baab_D20181001-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzYtMTUtMS0xLTA_3e26795a-f48f-46b1-a060-f4fefc7666e0"
      unitRef="usd">-18664000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i650fabb9fd3342b194a201cbf6d40308_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzctMS0xLTEtMA_e3c0b2bf-89bb-4a20-bd97-9237667255b8"
      unitRef="usdPerShare">-0.41</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i7d3836ab6ab8497ea22f279a0bfeb107_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzctMy0xLTEtMA_27c706b3-6b98-46a3-9719-d4bf0539309d"
      unitRef="usdPerShare">-0.26</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="id2195a0eb53f457697e901d30824c2b3_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzctNS0xLTEtMA_299e6318-67e1-4166-8bcf-ce3a8d0b463c"
      unitRef="usdPerShare">-0.24</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="iecf9c60eda6d47d4a66bc7797840c1d5_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzctNy0xLTEtMA_1c8e98a4-9b74-4d12-abd6-470841e6b165"
      unitRef="usdPerShare">0.04</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="iad063cfae7ac486cb8c7a7931ccbc02e_D20180101-20180331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzctOS0xLTEtMA_74acff7e-a5dc-4cf2-88de-35931f31b7f8"
      unitRef="usdPerShare">-0.23</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="if2cf250af72b4f33993772a39178733a_D20180401-20180630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzctMTEtMS0xLTA_8948e92e-15dc-48a0-9427-178ec2a1dc6b"
      unitRef="usdPerShare">-0.17</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ibac9f542f2ce4f519e06c7aabb195095_D20180701-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzctMTMtMS0xLTA_969f9a7f-3943-48c5-b4be-3bd33e50f24d"
      unitRef="usdPerShare">-0.13</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ibbad735aad064fe6bda84e11e1e8baab_D20181001-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xNTQvZnJhZzphZjRhZGRmZGU4OTk0YjRkOTUzMzc4OWEyNTkwNTdiMC90YWJsZTplODRiZjBmNzU0NGI0Mzk4OGY1OWQ1NzViMGExMjNhZS90YWJsZXJhbmdlOmU4NGJmMGY3NTQ0YjQzOTg4ZjU5ZDU3NWIwYTEyM2FlXzctMTUtMS0xLTA_f24e6065-3ed5-4877-858d-78f5de5d69c0"
      unitRef="usdPerShare">-0.18</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i55958765beef474786d9beecda94838d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV83Njk2NTgxNDE2MDY1_f9189503-c0eb-4c10-8576-fac0095f6565">SUBSEQUENT EVENTS&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2020, the Company entered into a global licensing collaboration agreement with Biogen MA, Inc. and its affiliate, Biogen International GmbH, for the research, development and commercialization of gene regulation therapies for the treatment of neurological diseases. The companies plan to leverage the Company&#x2019;s proprietary ZFP technology delivered via AAV to modulate expression of key genes involved in neurological diseases.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the Biogen collaboration agreement, the Company will grant to Biogen an exclusive, royalty bearing and worldwide license, under its relevant patents and know-how, to develop, manufacture and commercialize certain ZFP and/or  AAV-based products directed to up to 12 neurological disease gene targets selected by Biogen. Biogen has already selected three of these: ST-501 for tauopathies including Alzheimer&#x2019;s disease, ST-502 for synucleinopathies including Parkinson&#x2019;s disease, and a third undisclosed neuromuscular disease target. Biogen has exclusive rights to nominate up to nine additional targets over a target selection period of five years. For each gene target selected by Biogen, the Company will perform early research activities, costs for which will be shared by the companies, aimed at the development of the combination of proprietary CNS delivery vectors and ZFP-TFs (or potential other ZFP products) targeting therapeutically relevant genes. Biogen will then assume responsibility and costs for the IND-enabling studies, clinical development, related regulatory interactions, and global commercialization. The Company will be responsible for GMP manufacturing activities for the initial clinical trials for the first three products of the collaboration and plans to leverage its in-house manufacturing capacity. Biogen will assume responsibility for GMP manufacturing activities beyond the first clinical trial for each of the first three products. Subject to certain exceptions set forth in the Biogen collaboration agreement, the Company will be prohibited from developing, manufacturing or commercializing any therapeutic product directed to the targets selected by Biogen.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;After the Biogen collaboration agreement becomes effective, Biogen will pay the Company an upfront payment of $125.0&#160;million. The Company is also eligible to receive research, development, regulatory and commercial milestone payments that could total up to approximately $2.37&#160;billion if Biogen selects all of the targets allowed under the agreement and all the specified milestones set forth in the agreement are achieved, which includes up to $925.0&#160;million in pre-approval milestone payments and up to $1,445.0 million in first commercial sale and other sales-based milestone payments.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"&gt; I&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;n addition, the Company will also be eligible to receive tiered high single-digit to sub-teen royalties on potential net commercial sales of licensed products arising from the collaboration. These royalty payments will be subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Biogen collaboration agreement will continue, on a product-by-product and country-by-country basis, until the expiration of the applicable royalty term. Biogen has the right to terminate the collaboration agreement, in its entirety or on target-by-target basis, for any reason after a specified notice period. Each party has the right to terminate this agreement on account of the other party&#x2019;s bankruptcy or material, uncured breach. In addition, the Company may terminate the collaboration agreement if Biogen challenges any patents licensed by the Company to Biogen.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Concurrently with the execution of the collaboration agreement, the Company also entered into a stock purchase agreement with Biogen MA, Inc., pursuant to which Biogen will purchase 24,420,157 shares of the Company&#x2019;s common stock (the &#x201c;Biogen Shares&#x201d;), at a price per share of $9.2137, for an aggregate purchase price of $225.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Pursuant to the terms of the stock purchase agreement, Biogen has agreed not to, without the Company&#x2019;s prior written and subject to specified conditions and exceptions, directly or indirectly acquire shares of the Company&#x2019;s outstanding common stock, seek or propose a tender or exchange offer or merger between the parties, solicit proxies or consents with respect to any &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;matter, or undertake other specified actions related to the potential acquisition of additional equity interests in the Company. Such standstill restrictions expire on the earlier of the &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV83Njk2NTgxNDE2MDUx_0d84836a-c95f-4eb8-a58e-c4a119cbf42f"&gt;three&lt;/span&gt;-year anniversary of the effectiveness of the Biogen collaboration agreement and the date that Biogen beneficially owns less than 5% of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The stock purchase agreement also provides that until the first anniversary of the effectiveness of the Biogen collaboration agreement, Biogen will hold and not sell any of the Biogen Shares and from the first anniversary through the second anniversary, Biogen will hold and not sell at least 50% of the Biogen Shares, in addition to being subject to certain volume limitations. The stock purchase agreement further provides that, subject to certain limitations, upon Biogen&#x2019;s request, the Company will register for resale any of the Biogen Shares on a registration statement to be filed with the SEC, until such time as all remaining Biogen Shares may be sold pursuant to Rule 144 promulgated under the Securities Act during any 90-day period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In addition, Biogen has agreed that, excluding specified extraordinary matters, it will vote the Biogen Shares in accordance with the Company&#x2019;s recommendation and has granted the Company an irrevocable proxy with respect to the foregoing. Such voting provisions expire on the earlier of (i) the &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV83Njk2NTgxNDE2MTM1_d2c3c96b-72c7-45db-9430-d8a812b9fc92"&gt;two&lt;/span&gt;-year anniversary of the effectiveness of the Biogen collaboration agreement, (ii) the date that Biogen beneficially owns less than 5% of the Company&#x2019;s common stock and (iii) the date the Biogen collaboration agreement is terminated; provided, however, that in no event shall such expiration date be prior to the one-year anniversary of the effectiveness of the Biogen collaboration agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The consummation of the transactions under each of the Biogen collaboration agreement and the stock purchase agreement is subject to the satisfaction of customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <sgmo:CollaborativeArrangementNumberOfProductTargets
      contextRef="i815aed8f3ed04efa8895ee3a5a249f46_D20200201-20200228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV83Njk2NTgxNDE1MzAz_ada8f3f1-b39e-4861-91b2-04594043630a"
      unitRef="product_target">12</sgmo:CollaborativeArrangementNumberOfProductTargets>
    <sgmo:CollaborativeArrangementNumberOfProductTargetsSelected
      contextRef="id2fcb8b96ce04f23aa5b97d6cacdf777_I20200228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV84MjQ2MzM3MjMwMDMy_f1d2a6df-a6e3-4d7c-90c3-66f5c75a6be3"
      unitRef="product_target">3</sgmo:CollaborativeArrangementNumberOfProductTargetsSelected>
    <sgmo:CollaborationAgreementNumberOfAdditionalProductTargets
      contextRef="i815aed8f3ed04efa8895ee3a5a249f46_D20200201-20200228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV83Njk2NTgxNDE1MzE0_8ac4c0a1-340f-4063-a7b4-1b4c4284c163"
      unitRef="product_target">9</sgmo:CollaborationAgreementNumberOfAdditionalProductTargets>
    <sgmo:CollaborationAgreementTargetSelectionPeriod
      contextRef="i815aed8f3ed04efa8895ee3a5a249f46_D20200201-20200228"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV83Njk2NTgxNDE1MzMx_49b83e20-f738-4b9c-a8f7-e2192742c64a">P5Y</sgmo:CollaborationAgreementTargetSelectionPeriod>
    <sgmo:CollaborativeArrangementNumberOfProductTargetsSelected
      contextRef="id2fcb8b96ce04f23aa5b97d6cacdf777_I20200228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV83Njk2NTgxNDE1MzQz_be3c3b47-41a0-41a9-aa40-4c4763a36a55"
      unitRef="product_target">3</sgmo:CollaborativeArrangementNumberOfProductTargetsSelected>
    <sgmo:CollaborativeArrangementNumberOfProductTargetsSelected
      contextRef="id2fcb8b96ce04f23aa5b97d6cacdf777_I20200228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV83Njk2NTgxNDE1MzUz_f183def7-4fcc-4f73-bb51-9e50e39f490e"
      unitRef="product_target">3</sgmo:CollaborativeArrangementNumberOfProductTargetsSelected>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i68abcab0cf41405fae245c20e792bbf2_D20200201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV83Njk2NTgxNDE1OTU2_a81acf4d-4979-45d8-8bec-8c22d2fd91f9"
      unitRef="usd">125000000.0</us-gaap:ProceedsFromCollaborators>
    <sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable
      contextRef="i7c5278bbcb4141f78ac8881b4edfac94_I20200228"
      decimals="7"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV83Njk2NTgxNDE1OTcy_e12887d1-b2cf-49b5-9a2b-8c76ea3c7179"
      unitRef="usd">2370000000</sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable>
    <sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable
      contextRef="i1640dffb6cb34c52994dcc5099a67ffd_I20200228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV83Njk2NTgxNDE1OTg3_4fba908d-466f-42e6-8bdb-4f580a42c7a5"
      unitRef="usd">925000000.0</sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable>
    <sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable
      contextRef="i21a4261ff2844d9d957100ee0d0f8fa3_I20200228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV83Njk2NTgxNDE2MTA2_de32d922-d5f7-4945-816e-bb9053dee949"
      unitRef="usd">1445000000.0</sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i908ad6d97bab414e84166e66b25274be_D20200201-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV83Njk2NTgxNDE2MDEx_e29580be-2be6-4b77-9fc5-d27063157b47"
      unitRef="shares">24420157</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i2be6d9a350e04b98992adc724912b287_I20200228"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV83Njk2NTgxNDE2ODcz_37e11695-ef79-45cd-90b7-3809cfb0cb43"
      unitRef="usdPerShare">9.2137</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i908ad6d97bab414e84166e66b25274be_D20200201-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV83Njk2NTgxNDE2MDIz_d6cf5073-9a1f-4bad-9ca5-985edf40b54a"
      unitRef="usd">225000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <sgmo:CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage
      contextRef="i5dbb06595ef34d1581373015fa20fc10_I20200228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV83Njk2NTgxNDE2MDM5_0bd8dc82-da26-4b1f-b9a4-17e868818298"
      unitRef="number">0.05</sgmo:CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage>
    <sgmo:CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld
      contextRef="if7c1080eb5384ad88c89d65e002242e1_I20200228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV83Njk2NTgxNDE2MDU3_25eda8de-ca01-4ba8-ab51-7db993946cdf"
      unitRef="number">0.50</sgmo:CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld>
    <sgmo:CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage
      contextRef="if7c1080eb5384ad88c89d65e002242e1_I20200228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF8xOTcyL2ZyYWc6ZTY2ZmU4YjM5NTI2NDZkODk3MjhlMGYyNDY3MDk0ZDEvdGV4dHJlZ2lvbjplNjZmZThiMzk1MjY0NmQ4OTcyOGUwZjI0NjcwOTRkMV83Njk2NTgxNDE2MDYy_443f7495-8a4a-4aef-b807-289e341cc7e6"
      unitRef="number">0.05</sgmo:CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6855816240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Impact of Adoption of ASC on Condensed Consolidated Balance Sheet (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 29,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">77,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidRent', window );">Prepaid rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities - current</a></td>
<td class="nump">3,214<span></span>
</td>
<td class="nump">$ 1,408<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_DeferredRentNoncurrent', window );">Deferred rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - long-term</a></td>
<td class="nump">41,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (656,985)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(562,696)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Topic 842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidRent', window );">Prepaid rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities - current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_DeferredRentNoncurrent', window );">Deferred rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - long-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(561,799)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Topic 842 | Adjustments Due to the Adoption of ASC Topic 842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(62,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidRent', window );">Prepaid rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_DeferredRentNoncurrent', window );">Deferred rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(271)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - long-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_LeaseArrangementsAxis=sgmo_BuildToSuitLeaseMember', window );">Build-to-Suit Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - long-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_LeaseArrangementsAxis=sgmo_BuildToSuitLeaseMember', window );">Build-to-Suit Leases | Topic 842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - long-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_LeaseArrangementsAxis=sgmo_BuildToSuitLeaseMember', window );">Build-to-Suit Leases | Topic 842 | Adjustments Due to the Adoption of ASC Topic 842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - long-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (27,689)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_DeferredRentNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Rent Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_DeferredRentNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5865-108316<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_LeaseArrangementsAxis=sgmo_BuildToSuitLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_LeaseArrangementsAxis=sgmo_BuildToSuitLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6847638976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Summary of Quarterly Financial Data</a></td>
<td class="text">The following table sets forth certain unaudited quarterly financial data for the eight quarters ended December&#160;31, 2019. The unaudited information set forth below has been prepared on the same basis as the audited information contained herein and includes all adjustments necessary to present fairly the information set forth. The operating results for any quarter are not indicative of results for any future period. All amounts are in thousands except per share amounts.<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:22.264%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:6.823%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.823%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.823%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.823%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.823%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.823%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.823%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.830%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Q1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Q2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Q3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Q4</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Q1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Q2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Q3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Q4</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,071&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,548&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,958&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">54,851&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,637&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,416&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,562&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,837&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51,968&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51,052&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51,206&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,382&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,634&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40,556&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,803&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">47,609&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net (loss) income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(42,203)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(30,356)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(27,361)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,501&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(20,187)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16,640)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(12,843)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(19,219)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(53)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(72)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(54)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(54)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(555)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net (loss) income attributable to Sangamo Therapeutics, Inc.</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(42,150)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(30,284)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(27,307)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,555&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(20,187)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16,640)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(12,843)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18,664)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted net (loss) income per share attributable to Sangamo Therapeutics, Inc.</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.41)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.26)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.24)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.04&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.23)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.17)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.13)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.18)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109225645&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>94
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "sgmo-20191231.htm": {
   "axisCustom": 2,
   "axisStandard": 31,
   "contextCount": 344,
   "dts": {
    "calculationLink": {
     "local": [
      "sgmo-20191231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sgmo-20191231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml",
      "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "sgmo-20191231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "sgmo-20191231_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-doc-2018-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sgmo-20191231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-ref-2018-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "sgmo-20191231.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd",
      "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd",
      "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-parts-codification-2018-01-31.xsd"
     ]
    }
   },
   "elementCount": 697,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2018-01-31": 42,
    "http://www.sangamo.com/20191231": 7,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 54
   },
   "keyCustom": 92,
   "keyStandard": 417,
   "memberCustom": 55,
   "memberStandard": 46,
   "nsprefix": "sgmo",
   "nsuri": "http://www.sangamo.com/20191231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.sangamo.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113103 - Disclosure - Marketable Securities",
     "role": "http://www.sangamo.com/role/MarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118104 - Disclosure - Major Customers, Partnerships and Strategic Alliances",
     "role": "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliances",
     "shortName": "Major Customers, Partnerships and Strategic Alliances",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124105 - Disclosure - Acquisition of Sangamo France",
     "role": "http://www.sangamo.com/role/AcquisitionofSangamoFrance",
     "shortName": "Acquisition of Sangamo France",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129106 - Disclosure - Other Balance Sheet Details",
     "role": "http://www.sangamo.com/role/OtherBalanceSheetDetails",
     "shortName": "Other Balance Sheet Details",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134107 - Disclosure - Commitments and Contingencies",
     "role": "http://www.sangamo.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2138108 - Disclosure - Stockholders' Equity",
     "role": "http://www.sangamo.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143109 - Disclosure - Stock-Based Compensation",
     "role": "http://www.sangamo.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2149110 - Disclosure - Employee Benefit Plan",
     "role": "http://www.sangamo.com/role/EmployeeBenefitPlan",
     "shortName": "Employee Benefit Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2151111 - Disclosure - Income Taxes",
     "role": "http://www.sangamo.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2160112 - Disclosure - Related Party Disclosures",
     "role": "http://www.sangamo.com/role/RelatedPartyDisclosures",
     "shortName": "Related Party Disclosures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i3743f02b3ec348be98acb2e813e9c7f4_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Balance Sheets",
     "role": "http://www.sangamo.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i3743f02b3ec348be98acb2e813e9c7f4_I20191231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2162113 - Disclosure - Quarterly Financial Data (Unaudited)",
     "role": "http://www.sangamo.com/role/QuarterlyFinancialDataUnaudited",
     "shortName": "Quarterly Financial Data (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2165114 - Disclosure - Subsequent Events",
     "role": "http://www.sangamo.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables",
     "shortName": "Organization and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309302 - Disclosure - Fair Value Measurement (Tables)",
     "role": "http://www.sangamo.com/role/FairValueMeasurementTables",
     "shortName": "Fair Value Measurement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314303 - Disclosure - Marketable Securities (Tables)",
     "role": "http://www.sangamo.com/role/MarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "if5e9da2152d548ad9e46e4ebe09d9cc7_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319304 - Disclosure - Major Customers, Partnerships and Strategic Alliances (Tables)",
     "role": "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesTables",
     "shortName": "Major Customers, Partnerships and Strategic Alliances (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "if5e9da2152d548ad9e46e4ebe09d9cc7_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325305 - Disclosure - Acquisition of Acquisition of Sangamo France (Tables)",
     "role": "http://www.sangamo.com/role/AcquisitionofAcquisitionofSangamoFranceTables",
     "shortName": "Acquisition of Acquisition of Sangamo France (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330306 - Disclosure - Other Balance Sheet Details (Tables)",
     "role": "http://www.sangamo.com/role/OtherBalanceSheetDetailsTables",
     "shortName": "Other Balance Sheet Details (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2335307 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.sangamo.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i3743f02b3ec348be98acb2e813e9c7f4_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.sangamo.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i3743f02b3ec348be98acb2e813e9c7f4_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2339308 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.sangamo.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2344309 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.sangamo.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2352310 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.sangamo.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2363311 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)",
     "role": "http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedTables",
     "shortName": "Quarterly Financial Data (Unaudited) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "iecf9c60eda6d47d4a66bc7797840c1d5_D20191001-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Organization and Summary of Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "ieb7e952fbd38434585f995fe73c66a44_I20171231",
      "decimals": "INF",
      "lang": null,
      "name": "sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "if75e5c9704ce446986262d7c7d8c3fab_D20190101-20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Organization and Summary of Significant Accounting Policies - Revenues from Strategic Partnering Collaboration Agreements and Research Activity Grants (Detail)",
     "role": "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail",
     "shortName": "Organization and Summary of Significant Accounting Policies - Revenues from Strategic Partnering Collaboration Agreements and Research Activity Grants (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "if75e5c9704ce446986262d7c7d8c3fab_D20190101-20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i3743f02b3ec348be98acb2e813e9c7f4_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406403 - Disclosure - Organization and Summary of Significant Accounting Policies - Reconciliation of Cash and Cash Equivalents (Details)",
     "role": "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofCashandCashEquivalentsDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies - Reconciliation of Cash and Cash Equivalents (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i3743f02b3ec348be98acb2e813e9c7f4_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i3743f02b3ec348be98acb2e813e9c7f4_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407404 - Disclosure - Organization and Summary of Significant Accounting Policies - Impact of Adoption of ASC on Condensed Consolidated Balance Sheet (Detail)",
     "role": "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesImpactofAdoptionofASConCondensedConsolidatedBalanceSheetDetail",
     "shortName": "Organization and Summary of Significant Accounting Policies - Impact of Adoption of ASC on Condensed Consolidated Balance Sheet (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PrepaidRent",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "iafee69bb5c304299817c47783c041381_I20181231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PrepaidRent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AvailableForSaleSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i3743f02b3ec348be98acb2e813e9c7f4_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - Fair Value Measurement - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Securities and Free Share Liability (Detail)",
     "role": "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail",
     "shortName": "Fair Value Measurement - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Securities and Free Share Liability (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "id6a8c12c301e487cab97f3ac6cb97945_I20191231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411406 - Disclosure - Fair Value Measurement - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail",
     "shortName": "Fair Value Measurement - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": "-3",
      "lang": null,
      "name": "sgmo:BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Statements of Operations",
     "role": "http://www.sangamo.com/role/ConsolidatedStatementsofOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i3743f02b3ec348be98acb2e813e9c7f4_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ForeignCurrencyExchangeRateTranslation1",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412407 - Disclosure - Fair Value Measurement - Summary of Estimated Fair Value of Free Share Liability Assumptions (Detail)",
     "role": "http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail",
     "shortName": "Fair Value Measurement - Summary of Estimated Fair Value of Free Share Liability Assumptions (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "iafee69bb5c304299817c47783c041381_I20181231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ForeignCurrencyExchangeRateTranslation1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i3743f02b3ec348be98acb2e813e9c7f4_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415408 - Disclosure - Marketable Securities - Summary of Cash Equivalents and Available-for-Sale Securities (Detail)",
     "role": "http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
     "shortName": "Marketable Securities - Summary of Cash Equivalents and Available-for-Sale Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AvailableForSaleSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i3743f02b3ec348be98acb2e813e9c7f4_I20191231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AvailableForSaleSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i3743f02b3ec348be98acb2e813e9c7f4_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416409 - Disclosure - Marketable Securities - Summary of Available-for-Sale Securities by Contractual Maturity (Detail)",
     "role": "http://www.sangamo.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetail",
     "shortName": "Marketable Securities - Summary of Available-for-Sale Securities by Contractual Maturity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AvailableForSaleSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i3743f02b3ec348be98acb2e813e9c7f4_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417410 - Disclosure - Marketable Securities - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/MarketableSecuritiesAdditionalInformationDetail",
     "shortName": "Marketable Securities - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sgmo:AgreementTerminationTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420411 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
     "shortName": "Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sgmo:AgreementTerminationTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "iecf9c60eda6d47d4a66bc7797840c1d5_D20191001-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421412 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Revenues Recognized under Agreement (Detail)",
     "role": "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail",
     "shortName": "Major Customers, Partnerships and Strategic Alliances - Revenues Recognized under Agreement (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55753e9172b14060be72e0417c8e4ee5_D20190101-20191231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422413 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Agreement with Sigma-Aldrich Corporation - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationAdditionalInformationDetail",
     "shortName": "Major Customers, Partnerships and Strategic Alliances - Agreement with Sigma-Aldrich Corporation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "ic7e8b05b2b84429ea591ae9027f2f01c_I20091031",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "iecf9c60eda6d47d4a66bc7797840c1d5_D20191001-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423414 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Agreement with Dow AgroSciences in Plant Agriculture - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDowAgroSciencesinPlantAgricultureAdditionalInformationDetail",
     "shortName": "Major Customers, Partnerships and Strategic Alliances - Agreement with Dow AgroSciences in Plant Agriculture - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "id1d7e675aff548549bda7f384c0b71fe_I20051231",
      "decimals": "-5",
      "lang": null,
      "name": "sgmo:OneTimeLicenseFeeEarned",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426415 - Disclosure - Acquisition of Sangamo France - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail",
     "shortName": "Acquisition of Sangamo France - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i3743f02b3ec348be98acb2e813e9c7f4_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427416 - Disclosure - Acquisition of Sangamo France - Summary of Estimated Fair Value of Net Assets Acquired (Detail)",
     "role": "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofEstimatedFairValueofNetAssetsAcquiredDetail",
     "shortName": "Acquisition of Sangamo France - Summary of Estimated Fair Value of Net Assets Acquired (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i38f5aec47ea84bc295354a823c8a5831_D20181001-20181001",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Consolidated Statements of Comprehensive Loss",
     "role": "http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "iafee69bb5c304299817c47783c041381_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:MinorityInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428417 - Disclosure - Acquisition of Sangamo France - Summary of Non-controlling Interest (Detail)",
     "role": "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail",
     "shortName": "Acquisition of Sangamo France - Summary of Non-controlling Interest (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sgmo:ScheduleOfNoncontrollingInterestTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:MinorityInterestDecreaseFromRedemptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i3743f02b3ec348be98acb2e813e9c7f4_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431418 - Disclosure - Other Balance Sheet Details (Detail)",
     "role": "http://www.sangamo.com/role/OtherBalanceSheetDetailsDetail",
     "shortName": "Other Balance Sheet Details (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i3743f02b3ec348be98acb2e813e9c7f4_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "iafee69bb5c304299817c47783c041381_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432419 - Disclosure - Other Balance Sheet Details - Schedule of Intangible Assets and Goodwill (Detail)",
     "role": "http://www.sangamo.com/role/OtherBalanceSheetDetailsScheduleofIntangibleAssetsandGoodwillDetail",
     "shortName": "Other Balance Sheet Details - Schedule of Intangible Assets and Goodwill (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "ieb7e952fbd38434585f995fe73c66a44_I20171231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i3743f02b3ec348be98acb2e813e9c7f4_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433420 - Disclosure - Other Balance Sheet Details - Summary of Accounts Payable and Accrued Liabilities (Detail)",
     "role": "http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail",
     "shortName": "Other Balance Sheet Details - Summary of Accounts Payable and Accrued Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i3743f02b3ec348be98acb2e813e9c7f4_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436421 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i3743f02b3ec348be98acb2e813e9c7f4_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437422 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Payments under Contractual Obligations (Detail)",
     "role": "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail",
     "shortName": "Commitments and Contingencies - Summary of Future Minimum Payments under Contractual Obligations (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i3743f02b3ec348be98acb2e813e9c7f4_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i3743f02b3ec348be98acb2e813e9c7f4_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440423 - Disclosure - Stockholders' Equity - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail",
     "shortName": "Stockholders' Equity - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": "INF",
      "lang": null,
      "name": "sgmo:SpecifiedStockholderOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "iafee69bb5c304299817c47783c041381_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441424 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Detail)",
     "role": "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail",
     "shortName": "Stockholders' Equity - Summary of Stock Option Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "iafee69bb5c304299817c47783c041381_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "iafee69bb5c304299817c47783c041381_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442425 - Disclosure - Stockholders' Equity - Summary of Restricted Stock Unit Activity (Detail)",
     "role": "http://www.sangamo.com/role/StockholdersEquitySummaryofRestrictedStockUnitActivityDetail",
     "shortName": "Stockholders' Equity - Summary of Restricted Stock Unit Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "iafee69bb5c304299817c47783c041381_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445426 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)",
     "role": "http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail",
     "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i0627710456a349f7b90cec0a3f5536e8_I20161231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i0627710456a349f7b90cec0a3f5536e8_I20161231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i3743f02b3ec348be98acb2e813e9c7f4_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446427 - Disclosure - Stock-Based Compensation - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/StockBasedCompensationAdditionalInformationDetail",
     "shortName": "Stock-Based Compensation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i3743f02b3ec348be98acb2e813e9c7f4_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i280d0aff0b424211b1e87b1cc76e27a7_D20190101-20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447428 - Disclosure - Stock-Based Compensation - Assumptions Used for Estimating Fair Value of Employee Stock Options (Detail)",
     "role": "http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail",
     "shortName": "Stock-Based Compensation - Assumptions Used for Estimating Fair Value of Employee Stock Options (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i280d0aff0b424211b1e87b1cc76e27a7_D20190101-20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "ibf6eda356cbb4886a9bc71ebb4c979a6_D20190101-20191231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448429 - Disclosure - Stock-Based Compensation - Weighted-Average Assumptions Used for Estimating Fair Value of ESPP Purchased Rights (Detail)",
     "role": "http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail",
     "shortName": "Stock-Based Compensation - Weighted-Average Assumptions Used for Estimating Fair Value of ESPP Purchased Rights (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "ibf6eda356cbb4886a9bc71ebb4c979a6_D20190101-20191231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
       "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
       "span",
       "div",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450430 - Disclosure - Employee Benefit Plan - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/EmployeeBenefitPlanAdditionalInformationDetail",
     "shortName": "Employee Benefit Plan - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
       "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
       "span",
       "div",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453431 - Disclosure - Income Taxes - Summary of Domestic and Foreign Components of Loss Before Income Taxes (Detail)",
     "role": "http://www.sangamo.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetail",
     "shortName": "Income Taxes - Summary of Domestic and Foreign Components of Loss Before Income Taxes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454432 - Disclosure - Income Taxes - Summary of Benefit for Income Taxes (Detail)",
     "role": "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail",
     "shortName": "Income Taxes - Summary of Benefit for Income Taxes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455433 - Disclosure - Income Taxes - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/IncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456434 - Disclosure - Income Taxes - Schedule of Difference Between Benefit for Income Taxes and Federal Statutory Income Tax Rate (Detail)",
     "role": "http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail",
     "shortName": "Income Taxes - Schedule of Difference Between Benefit for Income Taxes and Federal Statutory Income Tax Rate (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457435 - Disclosure - Income Taxes - Schedule of Difference Between Benefit for Income Taxes and Federal Statutory Income Tax Rate, Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateAdditionalInformationDetail",
     "shortName": "Income Taxes - Schedule of Difference Between Benefit for Income Taxes and Federal Statutory Income Tax Rate, Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i3743f02b3ec348be98acb2e813e9c7f4_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458436 - Disclosure - Income Taxes - Schedule of Company's Deferred Tax Assets (Detail)",
     "role": "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail",
     "shortName": "Income Taxes - Schedule of Company's Deferred Tax Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i3743f02b3ec348be98acb2e813e9c7f4_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "iafee69bb5c304299817c47783c041381_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459437 - Disclosure - Income Taxes - Summary of Activity Related to Company's Unrecognized Tax Benefits (Detail)",
     "role": "http://www.sangamo.com/role/IncomeTaxesSummaryofActivityRelatedtoCompanysUnrecognizedTaxBenefitsDetail",
     "shortName": "Income Taxes - Summary of Activity Related to Company's Unrecognized Tax Benefits (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "ie9057cb83ba040218834cc92910f7361_I20161231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461438 - Disclosure - Related Party Disclosures (Details)",
     "role": "http://www.sangamo.com/role/RelatedPartyDisclosuresDetails",
     "shortName": "Related Party Disclosures (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "iecf9c60eda6d47d4a66bc7797840c1d5_D20191001-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2464439 - Disclosure - Quarterly Financial Data (Unaudited) - Summary of Quarterly Financial Data (Detail)",
     "role": "http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedSummaryofQuarterlyFinancialDataDetail",
     "shortName": "Quarterly Financial Data (Unaudited) - Summary of Quarterly Financial Data (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "iecf9c60eda6d47d4a66bc7797840c1d5_D20191001-20191231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OperatingExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i5dbb06595ef34d1581373015fa20fc10_I20200228",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "sgmo:CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2466440 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.sangamo.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i5dbb06595ef34d1581373015fa20fc10_I20200228",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "sgmo:CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "role": "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108102 - Disclosure - Fair Value Measurement",
     "role": "http://www.sangamo.com/role/FairValueMeasurement",
     "shortName": "Fair Value Measurement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sgmo-20191231.htm",
      "contextRef": "i55958765beef474786d9beecda94838d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 104,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "sgmo_AccruedResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued research and development expenses.",
        "label": "Accrued Research And Development Expenses",
        "terseLabel": "Accrued research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpenses",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_AchievementOfCommercialMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Achievement of Commercial Milestones.",
        "label": "Achievement Of Commercial Milestones [Member]",
        "terseLabel": "Achievement of commercial milestones"
       }
      }
     },
     "localname": "AchievementOfCommercialMilestonesMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfFirstCommercialSaleMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Achievement of first commercial sale milestones.",
        "label": "Achievement Of First Commercial Sale Milestones [Member]",
        "terseLabel": "Achievement of first commercial sale milestones"
       }
      }
     },
     "localname": "AchievementOfFirstCommercialSaleMilestonesMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Achievement of Specified Clinical Development and Regulatory Milestones.",
        "label": "Achievement Of Specified Clinical Development And Regulatory Milestones [Member]",
        "terseLabel": "Achievement of specified clinical development and regulatory milestones"
       }
      }
     },
     "localname": "AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Achievement of specified clinical development intellectual property and regulatory milestones.",
        "label": "Achievement Of Specified Clinical Development Intellectual Property And Regulatory Milestones [Member]",
        "terseLabel": "Achievement of specified clinical development intellectual property and regulatory milestones"
       }
      }
     },
     "localname": "AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Achievement of specified preclinical development clinical development and first commercial sale milestones.",
        "label": "Achievement Of Specified Preclinical Development Clinical Development And First Commercial Sale Milestones [Member]",
        "terseLabel": "Achievement of specified preclinical development clinical development and first commercial sale milestones"
       }
      }
     },
     "localname": "AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Achievement of specified research, clinical development, regulatory and first commercial sale milestones.",
        "label": "Achievement Of Specified Research Clinical Development Regulatory And First Commercial Sale Milestones [Member]",
        "terseLabel": "Achievement of specified research, clinical development, regulatory and first commercial sale milestones"
       }
      }
     },
     "localname": "AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Achievement of specified sales based milestones if annual worldwide net sales of licensed products reach specified levels.",
        "label": "Achievement Of Specified Sales Based Milestones If Annual Worldwide Net Sales Of Licensed Products Reach Specified Levels [Member]",
        "terseLabel": "Achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels"
       }
      }
     },
     "localname": "AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedSalesMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Achievement of Specified Sales Milestones.",
        "label": "Achievement Of Specified Sales Milestones [Member]",
        "terseLabel": "Achievement of specified sales milestones"
       }
      }
     },
     "localname": "AchievementOfSpecifiedSalesMilestonesMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adjustments to additional paid in capital acquisition of non-controlling interest.",
        "label": "Adjustments To Additional Paid In Capital Acquisition Of Noncontrolling Interest",
        "terseLabel": "Acquisition of additional shares of Sangamo France"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate additional revenue recognition milestone method revenue eligible to receive.",
        "label": "Aggregate Additional Revenue Recognition Milestone Method Revenue Eligible To Receive",
        "terseLabel": "Potential amount to be funded for achievement of specified commercialized and sales milestones"
       }
      }
     },
     "localname": "AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_AgreementTerminationTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agreement Termination, Term",
        "label": "Agreement Termination, Term",
        "terseLabel": "Agreement termination, term"
       }
      }
     },
     "localname": "AgreementTerminationTerm",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amended and restated 2013 stock incentive plan.",
        "label": "Amended And Restated Two Thousand Thirteen Stock Incentive Plan [Member]",
        "terseLabel": "Amended and Restated 2013 Stock Incentive Plan"
       }
      }
     },
     "localname": "AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AmendedCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amended Collaboration And License Agreement",
        "label": "Amended Collaboration And License Agreement [Member]",
        "terseLabel": "Amended collaboration and license agreement"
       }
      }
     },
     "localname": "AmendedCollaborationAndLicenseAgreementMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AmortizationAndOtherChangesInRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortization And Other Changes In Right-of-Use Assets",
        "label": "Amortization And Other Changes In Right-of-Use Assets",
        "terseLabel": "Amortization and other changes in right-of-use assets"
       }
      }
     },
     "localname": "AmortizationAndOtherChangesInRightOfUseAssets",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_AnnualFeesRelatedToAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Annual fees related to agreement.",
        "label": "Annual Fees Related To Agreement",
        "terseLabel": "Annual fees"
       }
      }
     },
     "localname": "AnnualFeesRelatedToAgreement",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDowAgroSciencesinPlantAgricultureAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_BiogenMAIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Biogen MA Inc",
        "label": "Biogen MA Inc [Member]",
        "terseLabel": "Biogen MA Inc"
       }
      }
     },
     "localname": "BiogenMAIncMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_BrisbaneCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Brisbane, California",
        "label": "Brisbane, California [Member]",
        "terseLabel": "Brisbane, California"
       }
      }
     },
     "localname": "BrisbaneCaliforniaMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_BuildToSuitLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Build-to-suit lease.",
        "label": "Build To Suit Lease [Member]",
        "terseLabel": "Build-to-Suit Leases"
       }
      }
     },
     "localname": "BuildToSuitLeaseMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesImpactofAdoptionofASConCondensedConsolidatedBalanceSheetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_BuildToSuitLeaseObligations": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Build-to-suit lease obligations.",
        "label": "Build To Suit Lease Obligations",
        "terseLabel": "Long-term portion of lease liabilities"
       }
      }
     },
     "localname": "BuildToSuitLeaseObligations",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_BuildToSuitLeases": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Build to suit leases",
        "label": "Build To Suit Leases",
        "verboseLabel": "Build-to-suit leases"
       }
      }
     },
     "localname": "BuildToSuitLeases",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Acquisition Estimated Fair Value Assets Of Free Shares",
        "label": "Business Acquisition Estimated Fair Value Assets Of Free Shares",
        "terseLabel": "Business acquisition estimated fair value assets of free shares"
       }
      }
     },
     "localname": "BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Acquisition Estimated Fair Value Liabilities Of Free Shares",
        "label": "Business Acquisition Estimated Fair Value Liabilities Of Free Shares",
        "terseLabel": "Business acquisition estimated fair value liabilities of free shares"
       }
      }
     },
     "localname": "BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_BusinessAcquisitionEstimatedFairValueOfFreeShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business acquisition, estimated fair value of free shares.",
        "label": "Business Acquisition Estimated Fair Value Of Free Shares",
        "terseLabel": "Estimated fair value of free shares"
       }
      }
     },
     "localname": "BusinessAcquisitionEstimatedFairValueOfFreeShares",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business acquisition, number of free shares held by the holders.",
        "label": "Business Acquisition Number Of Free Shares Held By Holders",
        "terseLabel": "Number of free shares held by the holders (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionNumberOfFreeSharesHeldByHolders",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Acquisition, Number Of Free Shares Outstanding Subject To Purchase",
        "label": "Business Acquisition, Number Of Free Shares Outstanding Subject To Purchase",
        "terseLabel": "Business acquisition, number of free shares outstanding subject to purchase (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "sgmo_BusinessAcquisitionNumberOfSharesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business acquisition, number of shares acquired.",
        "label": "Business Acquisition Number Of Shares Acquired",
        "terseLabel": "Number of ordinary shares acquired (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionNumberOfSharesAcquired",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.sangamo.com/role/RelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sgmo_BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business acquisition number of shares owned by sellers under block transaction.",
        "label": "Business Acquisition Number Of Shares Owned By Sellers Under Block Transaction",
        "terseLabel": "Number of shares not purchased by the acquirer"
       }
      }
     },
     "localname": "BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business acquisition, percentage of equity interests agreed to acquire.",
        "label": "Business Acquisition Percentage Of Equity Interests Agreed To Acquire",
        "terseLabel": "Percentage of equity interests agreed to acquire"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofEstimatedFairValueofNetAssetsAcquiredDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed in process research and development.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed In Process Research And Development",
        "terseLabel": "IPR&amp;D"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofEstimatedFairValueofNetAssetsAcquiredDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CNineORFSevenTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "C nine ORF seven two.",
        "label": "C Nine O R F Seven Two [Member]",
        "terseLabel": "C9ORF72"
       }
      }
     },
     "localname": "CNineORFSevenTwoMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "California institute for regenerative medicine agreement.",
        "label": "California Institute For Regenerative Medicine Agreement [Member]",
        "terseLabel": "California Institute for Regenerative Medicine (\"CIRM\")"
       }
      }
     },
     "localname": "CaliforniaInstituteForRegenerativeMedicineAgreementMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash and cash equivalents accumulated gross unrealized gain before tax.",
        "label": "Cash And Cash Equivalents Accumulated Gross Unrealized Gain Before Tax",
        "terseLabel": "Cash equivalents, gross unrealized gains"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash and cash equivalents accumulated gross unrealized loss before tax.",
        "label": "Cash And Cash Equivalents Accumulated Gross Unrealized Loss Before Tax",
        "terseLabel": "Cash and cash equivalents accumulated gross unrealized loss before tax"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CashEquivalentsAndAvailableForSaleSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash equivalents and available for sale securities.",
        "label": "Cash Equivalents And Available For Sale Securities",
        "terseLabel": "Total cash equivalents and available-for-sale securities, estimated fair value"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleSecurities",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash equivalents and available for Sale Securities Amortized Cost",
        "label": "Cash Equivalents And Available For Sale Securities Amortized Cost",
        "totalLabel": "Total cash equivalents and available-for-sale securities, amortized cost"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash equivalents and available for sale securities, gross unrealized gain, before tax.",
        "label": "Cash Equivalents And Available For Sale Securities Gross Unrealized Gain Before Tax",
        "terseLabel": "Total cash equivalents and available-for-sale securities, gross unrealized gains"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash equivalents and available for sale securities, gross unrealized loss, before Tax",
        "label": "Cash Equivalents And Available For Sale Securities Gross Unrealized Loss Before Tax",
        "negatedLabel": "Total cash equivalents and available-for-sale securities, gross unrealized (losses)"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_ChangeInCollaborationAgreementScopeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Change In Collaboration Agreement Scope",
        "label": "Change In Collaboration Agreement Scope [Member]",
        "terseLabel": "Change in collaboration agreement scope"
       }
      }
     },
     "localname": "ChangeInCollaborationAgreementScopeMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_CollaborationAgreementNumberOfAdditionalProductTargets": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Number Of Additional Product Targets",
        "label": "Collaboration Agreement, Number Of Additional Product Targets",
        "terseLabel": "Number of additional neurological disease gene targets"
       }
      }
     },
     "localname": "CollaborationAgreementNumberOfAdditionalProductTargets",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_CollaborationAgreementTargetSelectionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Target Selection Period",
        "label": "Collaboration Agreement, Target Selection Period",
        "terseLabel": "Target selection period"
       }
      }
     },
     "localname": "CollaborationAgreementTargetSelectionPeriod",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_CollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration and license agreement.",
        "label": "Collaboration And License Agreement [Member]",
        "terseLabel": "Collaboration and license agreement"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration and license agreements number of products approved under agreement.",
        "label": "Collaboration And License Agreements Number Of Products Approved Under Agreement",
        "terseLabel": "Number of products approved"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_CollaborativeAgreementMilestoneAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Agreement Milestone",
        "label": "Collaborative Agreement Milestone [Axis]",
        "terseLabel": "Collaborative Agreement Milestone [Axis]"
       }
      }
     },
     "localname": "CollaborativeAgreementMilestoneAxis",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sgmo_CollaborativeAgreementMilestoneDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Agreement Milestone",
        "label": "Collaborative Agreement Milestone [Domain]",
        "terseLabel": "Collaborative Agreement Milestone"
       }
      }
     },
     "localname": "CollaborativeAgreementMilestoneDomain",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Agreement Restriction, Percentage Of Shares Held",
        "label": "Collaborative Arrangement, Agreement Restriction, Percentage Of Shares Held",
        "terseLabel": "Agreement restriction, percentage of shares held"
       }
      }
     },
     "localname": "CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement estimated reimbursable service costs.",
        "label": "Collaborative Arrangement Estimated Reimbursable Service Costs",
        "terseLabel": "Collaborative arrangement estimated reimbursable service costs"
       }
      }
     },
     "localname": "CollaborativeArrangementEstimatedReimbursableServiceCosts",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement Estimated Reimbursable Service Costs For New Research Plan",
        "label": "Collaborative Arrangement Estimated Reimbursable Service Costs For New Research Plan",
        "terseLabel": "Collaborative arrangement estimated reimbursable service costs for new research plan"
       }
      }
     },
     "localname": "CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Maximum Milestone Payment Receivable",
        "label": "Collaborative Arrangement, Maximum Milestone Payment Receivable",
        "terseLabel": "Maximum milestone payment receivable"
       }
      }
     },
     "localname": "CollaborativeArrangementMaximumMilestonePaymentReceivable",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementNumberOfProductTargets": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Number Of Product Targets",
        "label": "Collaborative Arrangement, Number Of Product Targets",
        "terseLabel": "Number of neurological disease gene targets"
       }
      }
     },
     "localname": "CollaborativeArrangementNumberOfProductTargets",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_CollaborativeArrangementNumberOfProductTargetsSelected": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Number Of Product Targets Selected",
        "label": "Collaborative Arrangement, Number Of Product Targets Selected",
        "terseLabel": "Number of product targets selected"
       }
      }
     },
     "localname": "CollaborativeArrangementNumberOfProductTargetsSelected",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_CollaborativeArrangementResearchServiceFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Research Service Fees",
        "label": "Collaborative Arrangement, Research Service Fees",
        "terseLabel": "Research service fees"
       }
      }
     },
     "localname": "CollaborativeArrangementResearchServiceFees",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Standstill Restriction, Ownership Threshold Percentage Ownership Percentage",
        "label": "Collaborative Arrangement, Standstill Restriction, Ownership Threshold Percentage Ownership Percentage",
        "terseLabel": "Agreement restriction, ownership percentage (less than)"
       }
      }
     },
     "localname": "CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sgmo_CollaborativeArrangementStandstillRestrictionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Standstill Restriction Period",
        "label": "Collaborative Arrangement, Standstill Restriction Period",
        "terseLabel": "Agreement restriction expiration period"
       }
      }
     },
     "localname": "CollaborativeArrangementStandstillRestrictionPeriod",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_CollaborativeArrangementTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement transaction price.",
        "label": "Collaborative Arrangement Transaction Price",
        "terseLabel": "Collaborative arrangement transaction price"
       }
      }
     },
     "localname": "CollaborativeArrangementTransactionPrice",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Voting Provisions Expiration Period",
        "label": "Collaborative Arrangement, Voting Provisions Expiration Period",
        "terseLabel": "Agreement provision, expiration period"
       }
      }
     },
     "localname": "CollaborativeArrangementVotingProvisionsExpirationPeriod",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Voting Provisions, Ownership Threshold Percentage",
        "label": "Collaborative Arrangement, Voting Provisions, Ownership Threshold Percentage",
        "terseLabel": "Agreement provision, ownership percentage (less than)"
       }
      }
     },
     "localname": "CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sgmo_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sgmo_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Table]",
        "terseLabel": "Commitments And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sgmo_CommonStockExchangeRatio": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common stock exchange ratio.",
        "label": "Common Stock Exchange Ratio",
        "terseLabel": "Share of common stock subject to a stock option or stock appreciation right (in shares)"
       }
      }
     },
     "localname": "CommonStockExchangeRatio",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contingent development and sales based milestone payments to be received.",
        "label": "Contingent Development And Sales Based Milestone Payments To Be Received",
        "terseLabel": "Contingent development - and sales-based milestone payments to be received"
       }
      }
     },
     "localname": "ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_ContractualObligationPaidUponExecution": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual Obligation, Paid Upon Execution",
        "label": "Contractual Obligation, Paid Upon Execution",
        "terseLabel": "Contractual obligation, paid upon execution"
       }
      }
     },
     "localname": "ContractualObligationPaidUponExecution",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Customer contract liability milestone payment eligible to receive.",
        "label": "Customer Contract Liability Milestone Payment Eligible To Receive",
        "terseLabel": "Development and sales-based milestone payments to be received"
       }
      }
     },
     "localname": "CustomerContractLiabilityMilestonePaymentEligibleToReceive",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_DeferredRentNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Rent Noncurrent",
        "label": "Deferred Rent Noncurrent",
        "terseLabel": "Deferred rent"
       }
      }
     },
     "localname": "DeferredRentNoncurrent",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesImpactofAdoptionofASConCondensedConsolidatedBalanceSheetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_DeferredTaxAssetsBuildToSuitLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred tax assets build to suit lease liability.",
        "label": "Deferred Tax Assets Build To Suit Lease Liability",
        "terseLabel": "Build to suit lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsBuildToSuitLeaseLiability",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_DeferredTaxAssetsLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Assets, Lease Liability",
        "label": "Deferred Tax Assets, Lease Liability",
        "terseLabel": "Deferred Tax Assets, Lease Liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiability",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred tax assets tax credit carryforwards research federal.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards Research Federal",
        "terseLabel": "Federal research tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred tax assets tax credit carryforwards research state and local.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards Research State And Local",
        "terseLabel": "State research tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_DerivativeLiabilityTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative liability term.",
        "label": "Derivative Liability Term",
        "terseLabel": "Risk Free Rate and Cost of Debt by Expected Exercise Date"
       }
      }
     },
     "localname": "DerivativeLiabilityTerm",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sgmo_DowAgroSciencesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Dow agro sciences.",
        "label": "Dow Agro Sciences [Member]",
        "terseLabel": "Dow Agro Sciences"
       }
      }
     },
     "localname": "DowAgroSciencesMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDowAgroSciencesinPlantAgricultureAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "2010 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee stock purchase plan rights weighted average estimated fair value.",
        "label": "Employee Stock Purchase Plan Rights Weighted Average Estimated Fair Value",
        "terseLabel": "Weighted-average estimated fair value of shares purchased under ESPP plan (in dollars per share)"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "sgmo_ExtendedResearchTermOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Extended Research Term Of Agreement",
        "label": "Extended Research Term Of Agreement",
        "terseLabel": "Extended research term of agreement"
       }
      }
     },
     "localname": "ExtendedResearchTermOfAgreement",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_FeeDue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fee due.",
        "label": "Fee Due",
        "terseLabel": "Fee due"
       }
      }
     },
     "localname": "FeeDue",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDowAgroSciencesinPlantAgricultureAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_FormerExecutiveOfSangamoFranceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Former Executive Of Sangamo France",
        "label": "Former Executive Of Sangamo France [Member]",
        "terseLabel": "Former Executive of TxCell"
       }
      }
     },
     "localname": "FormerExecutiveOfSangamoFranceMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail",
      "http://www.sangamo.com/role/RelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_FreeSharesAssetMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Free Shares Asset",
        "label": "Free Shares Asset [Member]",
        "terseLabel": "Free shares asset"
       }
      }
     },
     "localname": "FreeSharesAssetMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_FreeSharesLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Free Shares Liability",
        "label": "Free Shares Liability [Member]",
        "terseLabel": "Free shares liability"
       }
      }
     },
     "localname": "FreeSharesLiabilityMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_GainOnFreeShares": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gain On Free Shares",
        "label": "Gain On Free Shares",
        "negatedLabel": "Gain on free shares"
       }
      }
     },
     "localname": "GainOnFreeShares",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_GrantFundingAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Grant funding amount.",
        "label": "Grant Funding Amount",
        "terseLabel": "Funds due under the agreement"
       }
      }
     },
     "localname": "GrantFundingAmount",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Income tax reconciliation nondeductible expense income share based compensation.",
        "label": "Income Tax Reconciliation Nondeductible Expense Income Share Based Compensation",
        "terseLabel": "Non-deductible stock-based compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sgmo_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase Decrease In Long Term Portion Of Lease Liabilities",
        "label": "Increase Decrease In Long Term Portion Of Lease Liabilities",
        "terseLabel": "Long-term portion of lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInLongTermPortionOfLeaseLiabilities",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase In Fair Value Of Free Shares Asset And Liability",
        "label": "Increase In Fair Value Of Free Shares Asset And Liability",
        "terseLabel": "Increase in fair value of free shares asset and liability"
       }
      }
     },
     "localname": "IncreaseInFairValueOfFreeSharesAssetAndLiability",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_InitialResearchTermOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Initial research term of agreement.",
        "label": "Initial Research Term Of Agreement",
        "terseLabel": "Initial research term of agreement",
        "verboseLabel": "Research program to develop laboratory research reagents"
       }
      }
     },
     "localname": "InitialResearchTermOfAgreement",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDowAgroSciencesinPlantAgricultureAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_IntangibleAssetsExcludingGoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intangible Assets (Excluding Goodwill)",
        "label": "Intangible Assets (Excluding Goodwill) [Roll Forward]",
        "terseLabel": "Intangible Assets (Excluding Goodwill)"
       }
      }
     },
     "localname": "IntangibleAssetsExcludingGoodwillRollForward",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsScheduleofIntangibleAssetsandGoodwillDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sgmo_KitePharmaIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Kite Pharma Inc.",
        "label": "Kite Pharma Inc [Member]",
        "terseLabel": "Kite Pharma, Inc. (\"Kite\")"
       }
      }
     },
     "localname": "KitePharmaIncMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesTables",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_LeaseArrangementsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lease Arrangements",
        "label": "Lease Arrangements [Axis]",
        "terseLabel": "Lease Arrangements [Axis]"
       }
      }
     },
     "localname": "LeaseArrangementsAxis",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesImpactofAdoptionofASConCondensedConsolidatedBalanceSheetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sgmo_LeaseArrangementsDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lease Arrangements",
        "label": "Lease Arrangements [Domain]",
        "terseLabel": "Lease Arrangements [Domain]"
       }
      }
     },
     "localname": "LeaseArrangementsDomain",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesImpactofAdoptionofASConCondensedConsolidatedBalanceSheetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee Operating Lease, Lease Not Yet Commenced Tenant Improvement Allowance",
        "label": "Lessee Operating Lease, Lease Not Yet Commenced Tenant Improvement Allowance",
        "terseLabel": "Lessee operating lease, lease not yet commenced tenant improvement allowance"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_LesseeOperatingLeaseLiabilityTenantImprovementAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee Operating Lease Liability Tenant Improvement Allowance",
        "label": "Lessee Operating Lease Liability Tenant Improvement Allowance",
        "terseLabel": "Lessee operating lease liability tenant improvement allowance"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityTenantImprovementAllowance",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_LicenseObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License obligations.",
        "label": "License Obligations",
        "terseLabel": "License obligations"
       }
      }
     },
     "localname": "LicenseObligations",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_ManufacturingCapacityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Manufacturing Capacity",
        "label": "Manufacturing Capacity [Member]",
        "terseLabel": "Manufacturing Capacity"
       }
      }
     },
     "localname": "ManufacturingCapacityMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_ManufacturingObligationsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Manufacturing Obligations",
        "label": "Manufacturing Obligations [Member]",
        "terseLabel": "Manufacturing Obligations"
       }
      }
     },
     "localname": "ManufacturingObligationsMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_MeasurementInputStockPriceCorrelationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement Input Stock Price Correlation",
        "label": "Measurement Input Stock Price Correlation [Member]",
        "terseLabel": "Measurement Input Stock Price Correlation"
       }
      }
     },
     "localname": "MeasurementInputStockPriceCorrelationMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_MilestoneAchievementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone Achievement",
        "label": "Milestone Achievement [Member]",
        "terseLabel": "Milestone achievement"
       }
      }
     },
     "localname": "MilestoneAchievementMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_MilestoneOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone One",
        "label": "Milestone One [Member]",
        "terseLabel": "Milestone One"
       }
      }
     },
     "localname": "MilestoneOneMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone payment and royalty revenue of previous agreement.",
        "label": "Milestone Payment And Royalty Revenue Of Previous Agreement",
        "verboseLabel": "Previously agreed research, development and commercialization milestone payments, and royalties on sales of products"
       }
      }
     },
     "localname": "MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDowAgroSciencesinPlantAgricultureAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_MilestonePaymentsReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone payments received.",
        "label": "Milestone Payments Received",
        "terseLabel": "Milestone payments received"
       }
      }
     },
     "localname": "MilestonePaymentsReceived",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_MilestoneRevenueReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone\u200b revenue receivable.",
        "label": "Milestone Revenue Receivable",
        "terseLabel": "Milestone revenue receivable"
       }
      }
     },
     "localname": "MilestoneRevenueReceivable",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_MilestoneThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone Three",
        "label": "Milestone Three [Member]",
        "terseLabel": "Milestone Three"
       }
      }
     },
     "localname": "MilestoneThreeMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_MilestoneTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone Two",
        "label": "Milestone Two [Member]",
        "terseLabel": "Milestone Two"
       }
      }
     },
     "localname": "MilestoneTwoMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum sublicense annual fees specific reckoning period.",
        "label": "Minimum Sublicense Annual Fees Specific Reckoning Period",
        "terseLabel": "Minimum license annual fees specific reckoning period"
       }
      }
     },
     "localname": "MinimumSublicenseAnnualFeesSpecificReckoningPeriod",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDowAgroSciencesinPlantAgricultureAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_NetProceedsFromIssuancePublicOffering": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net proceeds from issuance public offering.",
        "label": "Net Proceeds From Issuance Public Offering",
        "terseLabel": "Proceeds from public offering of common stock, net of issuance costs",
        "verboseLabel": "Net proceeds from issuance of common stock, after deducting offering expenses"
       }
      }
     },
     "localname": "NetProceedsFromIssuancePublicOffering",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_NonCancelableContractualCommitmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non-cancelable Contractual Commitment",
        "label": "Non-cancelable Contractual Commitment [Member]",
        "terseLabel": "Non-cancelable Contractual Commitment"
       }
      }
     },
     "localname": "NonCancelableContractualCommitmentMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_NoncashOrPartNoncashNonControllingInterestAcquisition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Noncash or part noncash non-controlling interest acquisition.",
        "label": "Noncash Or Part Noncash Non Controlling Interest Acquisition",
        "terseLabel": "Non-controlling interest for acquisition"
       }
      }
     },
     "localname": "NoncashOrPartNoncashNonControllingInterestAcquisition",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of clinical or regulatory milestones included in transaction price.",
        "label": "Number Of Clinical Or Regulatory Milestones Included In Transaction Price",
        "terseLabel": "Number of milestones included in transaction price"
       }
      }
     },
     "localname": "NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_NumberOfOptionsToExtendInitialResearchTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number Of Options To Extend Initial Research Term",
        "label": "Number Of Options To Extend Initial Research Term",
        "terseLabel": "Number of options to extend initial research term"
       }
      }
     },
     "localname": "NumberOfOptionsToExtendInitialResearchTerm",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_NumberOfResearchProgram": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of research program.",
        "label": "Number Of Research Program",
        "terseLabel": "Number of research programs"
       }
      }
     },
     "localname": "NumberOfResearchProgram",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_OfficeAndLaboratoryMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Office And Laboratory",
        "label": "Office And Laboratory [Member]",
        "terseLabel": "Office And Laboratory"
       }
      }
     },
     "localname": "OfficeAndLaboratoryMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_OfficeSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Office Space",
        "label": "Office Space [Member]",
        "terseLabel": "Office Space"
       }
      }
     },
     "localname": "OfficeSpaceMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_OneTimeLicenseFeeEarned": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "One time license fee earned.",
        "label": "One Time License Fee Earned",
        "terseLabel": "One-time license fee earned on exercise of option"
       }
      }
     },
     "localname": "OneTimeLicenseFeeEarned",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDowAgroSciencesinPlantAgricultureAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Organization and summary of significant accounting policies.",
        "label": "Organization And Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Organization and Summary of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Organization and summary of significant accounting policies.",
        "label": "Organization And Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Organization And Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sgmo_OtherProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other products.",
        "label": "Other Products [Member]",
        "terseLabel": "Other products"
       }
      }
     },
     "localname": "OtherProductsMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_OtherThanTemporarilyImpairedInvestment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other than temporarily impaired investment.",
        "label": "Other Than Temporarily Impaired Investment",
        "terseLabel": "Investments other-than-temporarily impaired"
       }
      }
     },
     "localname": "OtherThanTemporarilyImpairedInvestment",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_PaymentsForOtherCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments For Other Commitment",
        "label": "Payments For Other Commitment",
        "terseLabel": "Payment to secure manufacturing capacity"
       }
      }
     },
     "localname": "PaymentsForOtherCommitment",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of royalties to be received from sublicensing.",
        "label": "Percentage Of Royalties To Be Received From Sublicensing",
        "terseLabel": "Percentage of royalties to be received from sublicensing"
       }
      }
     },
     "localname": "PercentageOfRoyaltiesToBeReceivedFromSublicensing",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDowAgroSciencesinPlantAgricultureAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sgmo_PfizerC9ORF72Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pfizer C9ORF72",
        "label": "Pfizer C9ORF72 [Member]",
        "terseLabel": "Pfizer C9ORF72"
       }
      }
     },
     "localname": "PfizerC9ORF72Member",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_PfizerMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pfizer.",
        "label": "Pfizer [Member]",
        "terseLabel": "Pfizer"
       }
      }
     },
     "localname": "PfizerMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_PfizerSB525Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pfizer SB-525",
        "label": "Pfizer SB-525 [Member]",
        "terseLabel": "Pfizer SB-525"
       }
      }
     },
     "localname": "PfizerSB525Member",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesTables",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_PreApprovalMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pre-approval Milestone",
        "label": "Pre-approval Milestone [Member]",
        "terseLabel": "Pre-approval Milestone"
       }
      }
     },
     "localname": "PreApprovalMilestoneMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_PropertyAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Property and equipment.",
        "label": "Property And Equipment [Member]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyAndEquipmentMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_PurchasePlanOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase plan offering period.",
        "label": "Purchase Plan Offering Period",
        "terseLabel": "Purchase plan offering period"
       }
      }
     },
     "localname": "PurchasePlanOfferingPeriod",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_PurchasePlanPurchasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase plan purchase period.",
        "label": "Purchase Plan Purchase Period",
        "terseLabel": "Purchase plan purchase period"
       }
      }
     },
     "localname": "PurchasePlanPurchasePeriod",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_ReducedRoyaltyRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reduced royalty rate.",
        "label": "Reduced Royalty Rate",
        "terseLabel": "Reduced royalty rate"
       }
      }
     },
     "localname": "ReducedRoyaltyRate",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sgmo_ResearchAndOfficeSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research and office space",
        "label": "Research And Office Space [Member]",
        "terseLabel": "Research and Office Space"
       }
      }
     },
     "localname": "ResearchAndOfficeSpaceMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_ResearchServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research services.",
        "label": "Research Services [Member]",
        "terseLabel": "Research services"
       }
      }
     },
     "localname": "ResearchServicesMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_ResearchServicesPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research services period.",
        "label": "Research Services Period",
        "terseLabel": "Developed laboratory research reagents, research services period"
       }
      }
     },
     "localname": "ResearchServicesPeriod",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue From Collaboration Agreements, Grants And Licensing Concentration Risk",
        "label": "Revenue From Collaboration Agreements, Grants And Licensing Concentration Risk [Member]",
        "terseLabel": "Revenue From Collaboration Agreements, Grants And Licensing Concentration Risk [Member]"
       }
      }
     },
     "localname": "RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_RichmondCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Richmond, California",
        "label": "Richmond, California [Member]",
        "terseLabel": "Richmond, California"
       }
      }
     },
     "localname": "RichmondCaliforniaMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_SBFiveTwoFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "SB five two five.",
        "label": "S B Five Two Five [Member]",
        "terseLabel": "SB-525"
       }
      }
     },
     "localname": "SBFiveTwoFiveMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_SalesBasedMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sales-based Milestone",
        "label": "Sales-based Milestone [Member]",
        "terseLabel": "Sales-based Milestone"
       }
      }
     },
     "localname": "SalesBasedMilestoneMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_SangamoFranceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sangamo France",
        "label": "Sangamo France [Member]",
        "terseLabel": "TxCell S.A."
       }
      }
     },
     "localname": "SangamoFranceMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail",
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofEstimatedFairValueofNetAssetsAcquiredDetail",
      "http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail",
      "http://www.sangamo.com/role/RelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_SanofiMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sanofi",
        "label": "Sanofi [Member]",
        "terseLabel": "Sanofi"
       }
      }
     },
     "localname": "SanofiMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesTables",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_ScheduleOfNoncontrollingInterestTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of noncontrolling interest.",
        "label": "Schedule Of Noncontrolling Interest Table [Text Block]",
        "terseLabel": "Summary of Non-controlling Interest"
       }
      }
     },
     "localname": "ScheduleOfNoncontrollingInterestTableTextBlock",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofAcquisitionofSangamoFranceTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues",
        "label": "Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues [Table Text Block]",
        "terseLabel": "Schedule of Revenue from Strategic Partnering Collaboration Agreements and Research Activity Grants as a Percentage of Total Revenues"
       }
      }
     },
     "localname": "ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sgmo_SeparateUpfrontFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Separate upfront fee.",
        "label": "Separate Upfront Fee",
        "terseLabel": "Separate fee for additional term"
       }
      }
     },
     "localname": "SeparateUpfrontFee",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options released in period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Released In Period",
        "negatedLabel": "RSUs released (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options vested and expected to vest aggregate intrinsic value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Aggregate Intrinsic Value",
        "terseLabel": "RSUs vested and expected to vest at end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options vested and expected to vest outstanding number.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Number",
        "terseLabel": "RSUs vested and expected to vest at end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options vested and expected to vest weighted average remaining contractual term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Weighted Average Remaining Contractual Term",
        "terseLabel": "RSUs vested and expected to vest at end of period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of vesting installment.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Vesting Installment",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, number of vesting installment"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options and restricted stock units outstanding number.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options And Restricted Stock Units Outstanding Number",
        "terseLabel": "Stock options and RSUs outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options expiration term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Expiration Term",
        "terseLabel": "Stock options expiration term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options maximum term for specified stock holder.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Maximum Term For Specified Stock Holder",
        "terseLabel": "Stock option maximum term for specified stockholder"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award purchase price of common stock percent for specified stockholder.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Purchase Price Of Common Stock Percent For Specified Stockholder",
        "terseLabel": "Purchase price of common stock percent under stock incentive plans for specified stockholder"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share purchase agreement and tender offer agreement.",
        "label": "Share Purchase Agreement And Tender Offer Agreement [Member]",
        "terseLabel": "Share Purchase Agreement and Tender Offer Agreement",
        "verboseLabel": "SPA and TOA"
       }
      }
     },
     "localname": "SharePurchaseAgreementAndTenderOfferAgreementMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.sangamo.com/role/RelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_SharePurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share purchase agreement.",
        "label": "Share Purchase Agreement [Member]",
        "terseLabel": "SPA"
       }
      }
     },
     "localname": "SharePurchaseAgreementMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_ShireAgMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shire ag.",
        "label": "Shire Ag [Member]",
        "terseLabel": "Shire AG"
       }
      }
     },
     "localname": "ShireAgMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_SigmaAldrichCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sigma-Aldrich corporation.",
        "label": "Sigma Aldrich Corporation [Member]",
        "terseLabel": "Sigma-Aldrich Corporation"
       }
      }
     },
     "localname": "SigmaAldrichCorporationMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_SpecifiedStockholderOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Specified stockholder ownership percentage.",
        "label": "Specified Stockholder Ownership Percentage",
        "terseLabel": "Specified stockholder ownership percentage"
       }
      }
     },
     "localname": "SpecifiedStockholderOwnershipPercentage",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock issued under employee stock purchase plans average exercise price.",
        "label": "Stock Issued Under Employee Stock Purchase Plans Average Exercise Price",
        "terseLabel": "Stock issued under employee stock purchase plans, average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "sgmo_StockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Purchase Agreement",
        "label": "Stock Purchase Agreement [Member]",
        "terseLabel": "Stock Purchase Agreement"
       }
      }
     },
     "localname": "StockPurchaseAgreementMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_TwoThousandEighteenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two thousand eighteen stock incentive plan.",
        "label": "Two Thousand Eighteen Stock Incentive Plan [Member]",
        "terseLabel": "2018 Stock Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandEighteenStockIncentivePlanMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_TwoThousandThirteenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two thousand thirteen stock incentive plan.",
        "label": "Two Thousand Thirteen Stock Incentive Plan [Member]",
        "terseLabel": "2013 Stock Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandThirteenStockIncentivePlanMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unrecognized tax benefits increase decrease resulting from prior period tax positions.",
        "label": "Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions",
        "terseLabel": "Additions for tax positions of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesSummaryofActivityRelatedtoCompanysUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_ValbonneFranceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valbonne, France",
        "label": "Valbonne, France [Member]",
        "terseLabel": "Valbonne, France"
       }
      }
     },
     "localname": "ValbonneFranceMember",
     "nsuri": "http://www.sangamo.com/20191231",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r43",
      "r88"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDowAgroSciencesinPlantAgricultureAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesTables",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail",
      "http://www.sangamo.com/role/RelatedPartyDisclosuresDetails",
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDowAgroSciencesinPlantAgricultureAdditionalInformationDetail",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail",
      "http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDowAgroSciencesinPlantAgricultureAdditionalInformationDetail",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail",
      "http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r133",
      "r188",
      "r191",
      "r390"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDowAgroSciencesinPlantAgricultureAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDowAgroSciencesinPlantAgricultureAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDowAgroSciencesinPlantAgricultureAdditionalInformationDetail",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail",
      "http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Domain]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDowAgroSciencesinPlantAgricultureAdditionalInformationDetail",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail",
      "http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDowAgroSciencesinPlantAgricultureAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesTables",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail",
      "http://www.sangamo.com/role/RelatedPartyDisclosuresDetails",
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAdjustmentMember": {
     "auth_ref": [
      "r94",
      "r98",
      "r99",
      "r100"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Restatement Adjustment [Member]",
        "terseLabel": "Adjustments Due to the Adoption of ASC Topic 842"
       }
      }
     },
     "localname": "RestatementAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesImpactofAdoptionofASConCondensedConsolidatedBalanceSheetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Restatement [Axis]",
        "terseLabel": "Restatement [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesImpactofAdoptionofASConCondensedConsolidatedBalanceSheetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Restatement [Domain]",
        "terseLabel": "Restatement [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesImpactofAdoptionofASConCondensedConsolidatedBalanceSheetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r134",
      "r188",
      "r192",
      "r397",
      "r400"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201409Member": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).",
        "label": "Accounting Standards Update 2014-09 [Member]",
        "terseLabel": "Topic 606"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201409Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "Topic 842"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesImpactofAdoptionofASConCondensedConsolidatedBalanceSheetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts Payable and Accrued Liabilities, Current",
        "totalLabel": "Total accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets",
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.",
        "label": "Accounts Payable and Other Accrued Liabilities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r18",
      "r189"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.",
        "label": "Accounts Receivable, Net, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of discount on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r34"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Accrued compensation and employee benefits"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r34"
     ],
     "calculation": {
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r29",
      "r169"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r49",
      "r51",
      "r52"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r48",
      "r52",
      "r53",
      "r307"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income/ (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by new accounting pronouncement.",
        "label": "Adjustments for New Accounting Pronouncements [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesImpactofAdoptionofASConCondensedConsolidatedBalanceSheetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r201",
      "r203",
      "r237",
      "r238"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r177",
      "r178"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Issuance costs related to Sangamo France Acquisition"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash (used in) provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r203",
      "r230",
      "r236"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item is to be populated with the collective of (i) types (categories) of arrangements of the entity applicable to its revenue-generating activities or operations and non-arrangement transactions, including but not limited to, for instance, sales of product manufactured by the entity, if such comparison of arrangements as a component of all transactions is provided by the entity.",
        "label": "Arrangements and Non-arrangement Transactions [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/RelatedPartyDisclosuresDetails",
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r131",
      "r364",
      "r380"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets",
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesImpactofAdoptionofASConCondensedConsolidatedBalanceSheetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r6",
      "r42"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r314"
     ],
     "calculation": {
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total cash equivalents and marketable securities"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r142"
     ],
     "calculation": {
      "http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Available-for-sale securities, gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r143"
     ],
     "calculation": {
      "http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Available-for-sale securities, gross unrealized (Losses)"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Available-for-sale securities, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r144",
      "r147",
      "r375"
     ],
     "calculation": {
      "http://www.sangamo.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value",
        "terseLabel": "Maturing after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r144",
      "r146",
      "r374"
     ],
     "calculation": {
      "http://www.sangamo.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value",
        "terseLabel": "Maturing in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r137",
      "r141"
     ],
     "calculation": {
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Total marketable securities",
        "totalLabel": "Total investments available-for-sale",
        "verboseLabel": "Available-for-sale securities, estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail",
      "http://www.sangamo.com/role/MarketableSecuritiesSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetail",
      "http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Marketable securities, non-current"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the gross loss realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.",
        "label": "Available-for-sale Securities, Gross Realized Losses",
        "terseLabel": "Realized losses from the sale of available-for-sale securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesGrossRealizedLosses",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Available-for-sale Securities [Table Text Block]",
        "terseLabel": "Summary of Cash Equivalents and Available-for-Sale Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r205",
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by award type pertaining to equity-based compensation.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Buildings"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail",
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofEstimatedFairValueofNetAssetsAcquiredDetail",
      "http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail",
      "http://www.sangamo.com/role/RelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r284",
      "r285"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail",
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofEstimatedFairValueofNetAssetsAcquiredDetail",
      "http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail",
      "http://www.sangamo.com/role/RelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail",
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofEstimatedFairValueofNetAssetsAcquiredDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Percentage of share capital and voting rights acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Purchase price per share (in dollars per share)",
        "verboseLabel": "Sangamo France Stock Price (EUR) (in Euro per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue": {
     "auth_ref": [
      "r288"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.",
        "label": "Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value",
        "terseLabel": "Fair value of non-controlling interest"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofEstimatedFairValueofNetAssetsAcquiredDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r290",
      "r291",
      "r292"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "verboseLabel": "Consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofEstimatedFairValueofNetAssetsAcquiredDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisition of Sangamo France"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFrance"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r287"
     ],
     "calculation": {
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofEstimatedFairValueofNetAssetsAcquiredDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofEstimatedFairValueofNetAssetsAcquiredDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets": {
     "auth_ref": [
      "r287"
     ],
     "calculation": {
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofEstimatedFairValueofNetAssetsAcquiredDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofEstimatedFairValueofNetAssetsAcquiredDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": {
     "auth_ref": [
      "r287"
     ],
     "calculation": {
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofEstimatedFairValueofNetAssetsAcquiredDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities",
        "negatedLabel": "Current liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofEstimatedFairValueofNetAssetsAcquiredDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent": {
     "auth_ref": [
      "r287"
     ],
     "calculation": {
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofEstimatedFairValueofNetAssetsAcquiredDetail": {
       "order": 8.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary difference assumed at the acquisition date that are classified as noncurrent.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent",
        "negatedLabel": "Deferred tax liability, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofEstimatedFairValueofNetAssetsAcquiredDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r287"
     ],
     "calculation": {
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofEstimatedFairValueofNetAssetsAcquiredDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "negatedLabel": "Assumed debt liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofEstimatedFairValueofNetAssetsAcquiredDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r286",
      "r287"
     ],
     "calculation": {
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofEstimatedFairValueofNetAssetsAcquiredDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "totalLabel": "Fair value of net identifiable assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofEstimatedFairValueofNetAssetsAcquiredDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "auth_ref": [
      "r287"
     ],
     "calculation": {
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofEstimatedFairValueofNetAssetsAcquiredDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofEstimatedFairValueofNetAssetsAcquiredDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r286",
      "r287"
     ],
     "calculation": {
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofEstimatedFairValueofNetAssetsAcquiredDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofEstimatedFairValueofNetAssetsAcquiredDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r287"
     ],
     "calculation": {
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofEstimatedFairValueofNetAssetsAcquiredDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "terseLabel": "Fair value of Sangamo France",
        "totalLabel": "Total fair value of net assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofEstimatedFairValueofNetAssetsAcquiredDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r82",
      "r282"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r78",
      "r79",
      "r80"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Capital expenditures included in unpaid liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r26",
      "r76"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and cash equivalents, at carrying value, total"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets",
      "http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Total cash equivalents",
        "verboseLabel": "Cash equivalents, estimated fair value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail",
      "http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r10",
      "r77",
      "r82",
      "r135"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r70",
      "r76",
      "r81"
     ],
     "calculation": {
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofCashandCashEquivalentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash, beginning of period",
        "totalLabel": "Cash, cash equivalents and restricted cash as reported within the Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r70",
      "r327"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofCashandCashEquivalentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Cash equivalents:"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInAccountingEstimateByTypeAxis": {
     "auth_ref": [
      "r92",
      "r97",
      "r111",
      "r113"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of change in accounting estimate.",
        "label": "Change in Accounting Estimate by Type [Axis]",
        "terseLabel": "Change in Accounting Estimate by Type"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingEstimateTypeDomain": {
     "auth_ref": [
      "r92",
      "r97",
      "r111",
      "r114"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities.",
        "label": "Change in Accounting Estimate, Type [Domain]",
        "terseLabel": "Change in Accounting Estimate, Type"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Major Customers, Partnerships and Strategic Alliances"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliances"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper securities"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail",
      "http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r37",
      "r174",
      "r369",
      "r386"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r173",
      "r175"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares reserved for issuance of future awards (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Ending Balances (in shares)",
        "periodStartLabel": "Beginning Balances (in shares)",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r17",
      "r177"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.01 par value; 160,000,000 shares authorized, 115,972,708 and 102,187,471 shares issued and outstanding at December 31, 2019 and 2018, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r55",
      "r57",
      "r58"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss attributable to Sangamo Therapeutics, Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r55",
      "r57",
      "r299",
      "r300",
      "r311"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive loss attributable to non-controlling interest"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r55",
      "r57",
      "r298",
      "r311"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r122",
      "r123",
      "r323",
      "r324"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r122",
      "r123",
      "r323",
      "r324",
      "r391"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r122",
      "r123",
      "r323",
      "r324",
      "r391"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r122",
      "r123",
      "r323",
      "r324"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percentage of revenues"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r124",
      "r323",
      "r325"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r122",
      "r123",
      "r323",
      "r324"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r183",
      "r184",
      "r189"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress": {
     "auth_ref": [
      "r186"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress",
        "negatedLabel": "Contract with customer, liability, cumulative catch-up adjustment to revenue, change in measure of progress"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r183",
      "r184",
      "r189"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenues"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r183",
      "r184",
      "r189"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenues, non-current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r190"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Recognition of milestone"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "terseLabel": "Contractual obligation"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r195",
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail",
      "http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.",
        "label": "Cumulative Effect of New Accounting Principle in Period of Adoption",
        "negatedLabel": "Cumulative effect of new accounting principle in period of adoption",
        "terseLabel": "Cumulative-effect adjustment"
       }
      }
     },
     "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal, State and Local, Tax Expense (Benefit)",
        "totalLabel": "Subtotal"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r86",
      "r274",
      "r278"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r90",
      "r276"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r86",
      "r274",
      "r278"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of deferred compensation related to equity-based payment arrangements. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes broad group equity-based compensation plans, defined benefit pension plans, defined benefit other postretirement benefit plans and other deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan.",
        "label": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]",
        "terseLabel": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r86",
      "r275",
      "r278"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit)",
        "totalLabel": "Subtotal"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r86",
      "r275",
      "r278"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r14",
      "r15",
      "r265",
      "r365",
      "r379"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Net deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditCurrent": {
     "auth_ref": [
      "r34",
      "r331"
     ],
     "calculation": {
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.",
        "label": "Deferred Rent Credit, Current",
        "terseLabel": "Deferred rent"
       }
      }
     },
     "localname": "DeferredRentCreditCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.",
        "label": "Deferred Revenue",
        "terseLabel": "Deferred Revenue"
       }
      }
     },
     "localname": "DeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r86",
      "r275",
      "r278"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r246",
      "r272",
      "r273"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r266"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r267"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r245",
      "r272",
      "r273"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "auth_ref": [
      "r245",
      "r272",
      "r273"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "terseLabel": "Deferred tax assets, net operating loss carryforwards for federal"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": {
     "auth_ref": [
      "r245",
      "r272",
      "r273"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign",
        "terseLabel": "Deferred tax assets, net operating loss carryforwards for foreign"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [
      "r245",
      "r272",
      "r273"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "terseLabel": "Deferred tax assets, net operating loss carryforwards for state"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r246",
      "r272",
      "r273"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r271",
      "r272",
      "r273"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "verboseLabel": "Research and development tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r245",
      "r272",
      "r273"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r245",
      "r272",
      "r273"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accruals and reserves"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r268"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r253",
      "r269"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Total deferred tax liability"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r246",
      "r272",
      "r273"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r246",
      "r272",
      "r273"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNoncurrent": {
     "auth_ref": [
      "r252",
      "r253",
      "r254"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.",
        "label": "Deferred Tax Liabilities, Net, Noncurrent",
        "terseLabel": "Deferred income tax"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r246",
      "r272",
      "r273"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r198"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Aggregate employer's contributions to defined contribution plan"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/EmployeeBenefitPlanAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Defined contribution plan, employer's matching contribution percent"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/EmployeeBenefitPlanAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum amount the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount",
        "terseLabel": "Defined contribution plan, maximum employer's contribution per employee"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/EmployeeBenefitPlanAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Maximum percentage limit of employee contributions"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/EmployeeBenefitPlanAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r74",
      "r129"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of input used to measure derivative liability.",
        "label": "Derivative Liability, Measurement Input",
        "terseLabel": "Volatility Estimate"
       }
      }
     },
     "localname": "DerivativeLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r181",
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.",
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r61",
      "r94",
      "r101",
      "r102",
      "r103",
      "r104",
      "r108",
      "r372",
      "r388"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Earnings per share, basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Basic and diluted net (loss) income per share attributable to Sangamo Therapeutics, Inc. (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations",
      "http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedSummaryofQuarterlyFinancialDataDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r82",
      "r105",
      "r106",
      "r107"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effects of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r255",
      "r256",
      "r277"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "verboseLabel": "Statutory tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "auth_ref": [
      "r231"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the compensation cost capitalized during the period arising from equity-based compensation arrangements (for example, shares of stock, units, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.",
        "label": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount",
        "terseLabel": "Capitalized stock-based employee compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unrecognized cost of unvested share-based compensation awards.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized",
        "terseLabel": "Total compensation cost related to unvested stock options and RSU"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average period of unvested stock options and RSU"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred compensation related to equity-based payment arrangements. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes broad group equity-based compensation plans, defined benefit pension plans, defined benefit other postretirement benefit plans and other deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan.",
        "label": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain]",
        "terseLabel": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation"
       }
      }
     },
     "localname": "EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail",
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r313",
      "r314",
      "r315",
      "r316",
      "r320",
      "r321"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r313",
      "r314",
      "r315",
      "r316",
      "r320",
      "r321"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Securities and Free Share Liability"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Summary of Estimated Fair Value of Free Share Liability Assumptions"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r315",
      "r356"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r315",
      "r357"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r315",
      "r358"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r315",
      "r359"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [
      "r313",
      "r319"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Provides the general categories used to describe the frequency with which financial assets and liabilities (as defined) are measured at fair value (on a recurring or nonrecurring basis).",
        "label": "Fair Value, Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r313",
      "r319"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents a description of the frequency with which certain items are measured at fair value. Items measured at fair value on a recurring basis generally include those items for which measurement inputs are readily available and which are measured at fair value at successive reporting periods.",
        "label": "Fair Value, Measurements, Recurring [Member]",
        "terseLabel": "Fair value on recurring basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail",
      "http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyExchangeRateTranslation1": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.",
        "label": "Foreign Currency Exchange Rate, Translation",
        "verboseLabel": "USD/ EUR Exchange Rate"
       }
      }
     },
     "localname": "ForeignCurrencyExchangeRateTranslation1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r82",
      "r326",
      "r329"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Net loss on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnTerminationOfLease": {
     "auth_ref": [
      "r334"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term.",
        "label": "Gain (Loss) on Termination of Lease",
        "negatedLabel": "Net loss on lease termination"
       }
      }
     },
     "localname": "GainLossOnTerminationOfLease",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r156",
      "r158"
     ],
     "calculation": {
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofEstimatedFairValueofNetAssetsAcquiredDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill, ending balance",
        "periodStartLabel": "Goodwill, beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofEstimatedFairValueofNetAssetsAcquiredDetail",
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets",
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsScheduleofIntangibleAssetsandGoodwillDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r159"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill acquired"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsScheduleofIntangibleAssetsandGoodwillDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r82",
      "r162",
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r161"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsScheduleofIntangibleAssetsandGoodwillDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r74",
      "r157",
      "r160",
      "r163"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill impairments"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsScheduleofIntangibleAssetsandGoodwillDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]",
        "terseLabel": "Research grants"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r82",
      "r167",
      "r172"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Valuation of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r59",
      "r94",
      "r361",
      "r370",
      "r389"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations",
      "http://www.sangamo.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r86",
      "r130",
      "r279"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      },
      "http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Benefit from income taxes",
        "totalLabel": "Income tax benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations",
      "http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail",
      "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Benefit for income taxes:"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r82",
      "r250",
      "r251",
      "r263",
      "r264",
      "r270",
      "r280",
      "r399"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r249",
      "r255",
      "r256"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r248",
      "r255",
      "r256"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "terseLabel": "Federal rate change"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r84",
      "r255",
      "r256"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "terseLabel": "Foreign rate differential"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r85",
      "r255",
      "r256"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Tax at federal statutory rate(1)"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r255"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r85",
      "r255",
      "r256"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State taxes, net"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r255",
      "r256"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedLabel": "Research credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.",
        "label": "Increase (Decrease) in Accrued Interest Receivable, Net",
        "negatedLabel": "Interest receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedInterestReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenues"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation and employee benefits"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Net changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Indefinite-lived Intangible Assets, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsScheduleofIntangibleAssetsandGoodwillDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefinitelivedIntangibleAssetsAcquired": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition.",
        "label": "Indefinite-lived Intangible Assets Acquired",
        "terseLabel": "Indefinite-lived assets - IPR&amp;D"
       }
      }
     },
     "localname": "IndefinitelivedIntangibleAssetsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsScheduleofIntangibleAssetsandGoodwillDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r164",
      "r166"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "periodEndLabel": "Balance, end of year",
        "periodStartLabel": "Balance, beginning of year",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets",
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsScheduleofIntangibleAssetsandGoodwillDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestAndOtherIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).",
        "label": "Interest and Other Income",
        "terseLabel": "Interest and other income, net"
       }
      }
     },
     "localname": "InterestAndOtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivableCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Interest Receivable, Current",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r392",
      "r393",
      "r394",
      "r395"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail",
      "http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r392",
      "r393",
      "r394",
      "r395"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail",
      "http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r153",
      "r362",
      "r378",
      "r396"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LandSubjectToGroundLeases": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area of land subject to a ground lease.",
        "label": "Land Subject to Ground Leases",
        "terseLabel": "Area of space leased (in sqft)"
       }
      }
     },
     "localname": "LandSubjectToGroundLeases",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense",
        "terseLabel": "Rent expenses"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseArrangementTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.",
        "label": "Lease Arrangement, Type [Axis]",
        "terseLabel": "Lease Arrangement, Type"
       }
      }
     },
     "localname": "LeaseArrangementTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseArrangementTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.",
        "label": "Lease Arrangement, Type [Domain]",
        "terseLabel": "Lease Arrangement, Type"
       }
      }
     },
     "localname": "LeaseArrangementTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r346"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r346"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r346"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r346"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r346"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r346"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r346"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r346"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease agreement, extendable lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letter of credit"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesImpactofAdoptionofASConCondensedConsolidatedBalanceSheetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r23",
      "r367",
      "r384"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r314"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "terseLabel": "Total liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicenseAgreementTermsMember": {
     "auth_ref": [
      "r243",
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "License Agreement Terms [Member]",
        "terseLabel": "License agreement terms"
       }
      }
     },
     "localname": "LicenseAgreementTermsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDowAgroSciencesinPlantAgricultureAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LicenseAndServiceMember": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License and Service [Member]",
        "terseLabel": "Collaboration agreements",
        "verboseLabel": "Recognition of upfront fee"
       }
      }
     },
     "localname": "LicenseAndServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License fee revenues"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDowAgroSciencesinPlantAgricultureAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MeasurementInputOptionVolatilityMember": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns.",
        "label": "Measurement Input, Option Volatility [Member]",
        "terseLabel": "Stock Price Volatility Estimate"
       }
      }
     },
     "localname": "MeasurementInputOptionVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Exchange Rate Volatility Estimate"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Risk Free Rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using share price of saleable stock.",
        "label": "Measurement Input, Share Price [Member]",
        "terseLabel": "Measurement Input, Share Price"
       }
      }
     },
     "localname": "MeasurementInputSharePriceMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinistryOfTheEconomyFinanceAndIndustryFranceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax department of the government of France.",
        "label": "Ministry of the Economy, Finance and Industry, France [Member]",
        "terseLabel": "French"
       }
      }
     },
     "localname": "MinistryOfTheEconomyFinanceAndIndustryFranceMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r40",
      "r366",
      "r383"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "periodEndLabel": "Stockholders' equity attributable to noncontrolling interest, ending balance",
        "periodStartLabel": "Stockholders' equity attributable to noncontrolling interest, beginning balance",
        "terseLabel": "Non-controlling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail",
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromRedemptions": {
     "auth_ref": [
      "r178",
      "r301",
      "r302"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).",
        "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests",
        "negatedLabel": "Fair value of additional shares acquired"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromRedemptions",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Noncontrolling Interest [Line Items]",
        "terseLabel": "Noncontrolling Interest [Line Items]"
       }
      }
     },
     "localname": "MinorityInterestLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Noncontrolling interest, ownership percentage by parent"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestTable": {
     "auth_ref": [
      "r40",
      "r63",
      "r297",
      "r308"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest [Table]",
        "terseLabel": "Noncontrolling Interest [Table]"
       }
      }
     },
     "localname": "MinorityInterestTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail",
      "http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInMinorityInterestRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]",
        "terseLabel": "Stockholders' Equity Attributable to Noncontrolling Interest"
       }
      }
     },
     "localname": "MovementInMinorityInterestRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r70",
      "r72",
      "r75"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash (used in) provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r54",
      "r56",
      "r60",
      "r75",
      "r106",
      "r371",
      "r387"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net (loss) income attributable to Sangamo Therapeutics, Inc.",
        "totalLabel": "Net loss attributable to Sangamo Therapeutics, Inc. stockholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations",
      "http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedSummaryofQuarterlyFinancialDataDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r54",
      "r56",
      "r304",
      "r310"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss attributable to non-controlling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail",
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations",
      "http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedSummaryofQuarterlyFinancialDataDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesImpactofAdoptionofASConCondensedConsolidatedBalanceSheetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r93",
      "r95",
      "r96"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesImpactofAdoptionofASConCondensedConsolidatedBalanceSheetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination": {
     "auth_ref": [
      "r179",
      "r288",
      "r306"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from a business combination.",
        "label": "Noncontrolling Interest, Increase from Business Combination",
        "terseLabel": "Non-controlling interest upon Acquisition of Sangamo France"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromBusinessCombination",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non- Controlling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail",
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "verboseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations",
      "http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedSummaryofQuarterlyFinancialDataDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r340",
      "r347"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease, cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r337"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease, expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r336"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r336"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities - current (included in Accounts payable and accrued liabilities on the Consolidated Balance Sheet)",
        "verboseLabel": "Operating lease liabilities - current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesImpactofAdoptionofASConCondensedConsolidatedBalanceSheetDetail",
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r336"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term portion of lease liabilities",
        "verboseLabel": "Operating lease liabilities - long-term"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail",
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesImpactofAdoptionofASConCondensedConsolidatedBalanceSheetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r338",
      "r342"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating lease, payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r335"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "verboseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesImpactofAdoptionofASConCondensedConsolidatedBalanceSheetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r345",
      "r347"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating lease, weighted average discount rate, percent"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r344",
      "r347"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating lease, weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r1",
      "r91",
      "r128",
      "r312"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Organization and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.",
        "label": "Other Commitment",
        "terseLabel": "Other commitment"
       }
      }
     },
     "localname": "OtherCommitment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of other commitment.",
        "label": "Other Commitments [Axis]",
        "terseLabel": "Other Commitments [Axis]"
       }
      }
     },
     "localname": "OtherCommitmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other future obligation.",
        "label": "Other Commitments [Domain]",
        "terseLabel": "Other Commitments [Domain]"
       }
      }
     },
     "localname": "OtherCommitmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r45",
      "r328"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "auth_ref": [
      "r45",
      "r50"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "negatedLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r47",
      "r49"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedLabel": "Net pension losses"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r46",
      "r49"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax",
        "terseLabel": "Change in unrealized gain (loss) on available-for-sale securities",
        "verboseLabel": "Net unrealized loss on marketable securities, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities",
        "verboseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r68",
      "r200"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.",
        "label": "Payments Related to Tax Withholding for Share-based Compensation",
        "negatedLabel": "Taxes paid related to net share settlement of equity awards",
        "terseLabel": "Total payments for the employees' tax obligations to taxing authorities"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of noncontrolling interest during the period.",
        "label": "Payments to Acquire Additional Interest in Subsidiaries",
        "negatedLabel": "Purchase of additional Sangamo France shares",
        "terseLabel": "Payments to acquire additional interest in subsidiaries"
       }
      }
     },
     "localname": "PaymentsToAcquireAdditionalInterestInSubsidiaries",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail",
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.sangamo.com/role/RelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisition, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for pension and other postretirement benefits.",
        "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]",
        "terseLabel": "Employee Benefit Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/EmployeeBenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r205",
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name pertaining to equity-based compensation arrangements.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the equity-based compensation arrangement plan.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValueOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.",
        "label": "Preferred Stock, Value, Outstanding",
        "terseLabel": "Preferred stock, $0.01 par value, 5,000,000 shares authorized and no shares issued or outstanding"
       }
      }
     },
     "localname": "PreferredStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r24",
      "r25"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidRent": {
     "auth_ref": [
      "r3",
      "r5",
      "r154",
      "r155"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Rent",
        "terseLabel": "Prepaid rent"
       }
      }
     },
     "localname": "PrepaidRent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesImpactofAdoptionofASConCondensedConsolidatedBalanceSheetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.",
        "label": "Reclassification, Policy [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromCollaborators": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash received from collaborators during the current period.",
        "label": "Proceeds from Collaborators",
        "terseLabel": "Proceeds from collaborators"
       }
      }
     },
     "localname": "ProceedsFromCollaborators",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock under employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r67",
      "r234"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based compensation arrangement. Issuance includes, but is not limited to, exercise of stock options and similar instruments.",
        "label": "Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options",
        "terseLabel": "Proceeds from exercise of stock options and restricted stock units"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r54",
      "r56",
      "r69",
      "r131",
      "r132",
      "r298",
      "r303",
      "r305",
      "r310",
      "r311"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations",
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedSummaryofQuarterlyFinancialDataDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r29",
      "r170"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r28",
      "r168"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r170",
      "r385"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesImpactofAdoptionofASConCondensedConsolidatedBalanceSheetDetail",
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r27",
      "r82",
      "r170"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r11",
      "r170"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Summary of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r11",
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives of related assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Quarterly Financial Information Disclosure [Abstract]",
        "terseLabel": "Quarterly Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]",
        "terseLabel": "Quarterly Financial Data (Unaudited)"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/QuarterlyFinancialDataUnaudited"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesSummaryofActivityRelatedtoCompanysUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/RelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/RelatedPartyDisclosures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r243",
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDowAgroSciencesinPlantAgricultureAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationAdditionalInformationDetail",
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "auth_ref": [
      "r242",
      "r244"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned",
        "terseLabel": "Revenues under agreement"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDowAgroSciencesinPlantAgricultureAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r243",
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDowAgroSciencesinPlantAgricultureAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationAdditionalInformationDetail",
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r241",
      "r401"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r82",
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r7",
      "r13",
      "r76",
      "r81",
      "r398"
     ],
     "calculation": {
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofCashandCashEquivalentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Non-current restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r7",
      "r13",
      "r81",
      "r398"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Non-current restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r20",
      "r178",
      "r382"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesImpactofAdoptionofASConCondensedConsolidatedBalanceSheetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r185",
      "r187",
      "r188"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDowAgroSciencesinPlantAgricultureAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedSummaryofQuarterlyFinancialDataDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised good or service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer [Member]",
        "terseLabel": "Revenue from Contract with Customer"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r83",
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:",
        "verboseLabel": "Revenue related to Sanofi agreement:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r343",
      "r347"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty revenues"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDowAgroSciencesinPlantAgricultureAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Consideration received from sale of stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock, number of shares issued in transaction (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScenarioForecastMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The reporting scenario used to indicate financial results forecast for a future period.",
        "label": "Scenario, Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScenarioUnspecifiedDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Any scenario, that is, the particular reporting scenario is left unspecified. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.",
        "label": "Scenario, Unspecified [Domain]",
        "terseLabel": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Summary of Accounts Payable and Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r145",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r373",
      "r376"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r284",
      "r285"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail",
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofEstimatedFairValueofNetAssetsAcquiredDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired.",
        "label": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]",
        "terseLabel": "Revenues recognized under agreement"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Summary of Benefit for Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Company's Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Difference Between Benefit for Income Taxes and Federal Statutory Income Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r203",
      "r229",
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule that sets forth the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r203",
      "r229",
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "terseLabel": "Summary of Future Minimum Payments under Contractual Obligations"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Summary of Domestic and Foreign Components of Loss Before Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r93",
      "r95",
      "r96",
      "r109",
      "r110",
      "r115"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.",
        "label": "Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]",
        "terseLabel": "Schedule of New Accounting Pronouncements and Changes in Accounting Principles"
       }
      }
     },
     "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r29",
      "r170"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Quarterly Financial Information [Table Text Block]",
        "terseLabel": "Summary of Quarterly Financial Data"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Summary of Estimated Fair Value of Net Assets Acquired"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofAcquisitionofSangamoFranceTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r87",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/RelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r243",
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDowAgroSciencesinPlantAgricultureAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r10",
      "r81",
      "r363",
      "r381"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Restrictions on Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r205",
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail",
      "http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Unit Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r210",
      "r218",
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Weighted-Average Assumptions Used for Estimating Fair Value of ESPP Purchase Rights"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Assumptions Used for Estimating Fair Value of Employee Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r82",
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "terseLabel": "General and Administrative Expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.",
        "label": "Share-based Compensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Stock options vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted-Average Remaining Contractual\u00a0Term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "RSUs forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock units awarded (in shares)",
        "verboseLabel": "RSUs awarded (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.sangamo.com/role/StockholdersEquitySummaryofRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Grant date fair value per award of restricted stock units (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "RSUs outstanding at end of period (in shares)",
        "periodStartLabel": "RSUs outstanding at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "RSUs outstanding at end of period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield of stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail",
      "http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail",
      "http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail",
      "http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail",
      "http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Stock reserved for issuance under plan (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted-Average Remaining Contractual\u00a0Term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable at end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable at end of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r220"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted (in shares)",
        "verboseLabel": "Additional equity award (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average estimated fair value per share of options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options outstanding at end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r212",
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding at end of period (in shares)",
        "periodStartLabel": "Options outstanding at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding at end of period (in dollars per share)",
        "periodStartLabel": "Options outstanding at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise per Share Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Options vested and expected to vest, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r221"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Options vested and expected to vest at end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Options vested and expected to vest at end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Options vested and expected to vest at end of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r202",
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity-based compensation award.",
        "label": "Equity Award [Domain]",
        "terseLabel": "Equity Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options canceled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "First portion of share-based compensation award differentiated by a particular vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Compensation Award, Tranche One [Member]",
        "terseLabel": "Share-Based Compensation Awards, Tranche 1"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Third portion of share-based compensation award differentiated by a particular vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Compensation Award, Tranche Three [Member]",
        "terseLabel": "Share-Based Compensation Awards, Tranche 3"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Second portion of share-based compensation award differentiated by a particular vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Compensation Award, Tranche Two [Member]",
        "terseLabel": "Share-Based Compensation Awards, Tranche 2"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r82",
      "r205",
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.",
        "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Sangamo Stock Price (USD) (in usd per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of vesting of share-based compensation awards.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Stock options granted vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate\u00a0Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intrinsic value of equity-based compensation awards outstanding. Excludes stock and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "periodEndLabel": "RSUs outstanding at end of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intrinsic value of equity-based compensation awards vested. Excludes stock and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "terseLabel": "Aggregate fair value of RSUs vested in period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r225",
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail",
      "http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options exercisable at end of period",
        "verboseLabel": "Options exercisable, aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable at end of period (in years)",
        "verboseLabel": "Stock option maximum term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options outstanding at end of period (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options vested and expected to vest at end of period (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Percent of fair value per share of common stock on option grant date"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Public offering price of common stock issued (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For net-share settlement of share-based awards when the employer settles employees' income tax withholding obligations, this element represents the number of shares the employees use to repay the employer.",
        "label": "Shares Paid for Tax Withholding for Share Based Compensation",
        "terseLabel": "Shares withheld from issuance in order to pay employee taxes (in shares)"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r39",
      "r177"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail",
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementScenarioAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by scenario to be reported. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.",
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r16",
      "r17",
      "r177",
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.sangamo.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r16",
      "r17",
      "r177",
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock under public offering, net of issuance costs (in shares)",
        "verboseLabel": "Public offering, common stock shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationAdditionalInformationDetail",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r16",
      "r17",
      "r177",
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.",
        "label": "Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures",
        "terseLabel": "Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r16",
      "r17",
      "r177",
      "r178",
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r16",
      "r17",
      "r177",
      "r178"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r16",
      "r17",
      "r177",
      "r178"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock under public offering, net of issuance costs",
        "verboseLabel": "Common stock issued under license agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r16",
      "r17",
      "r178",
      "r204",
      "r219"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.",
        "label": "Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures",
        "terseLabel": "Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r17",
      "r21",
      "r22",
      "r136"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Sangamo Therapeutics, Inc. stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r296",
      "r297",
      "r309"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending Balances",
        "periodStartLabel": "Beginning Balances",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets",
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Fixed ratio shares of common stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of unrecognized tax benefits for which a material change is reasonably possible in the next twelve months, typically including the nature of the uncertainty, the event(s) that could cause a material change, and an estimate of the range of the reasonably possible change or a statement that an estimate of the range cannot be made. An unrecognized tax benefit is the difference between a tax position taken in a tax return and the amounts recognized in the financial statements for which it is more likely than not, based on the technical merits of the position, that the tax position will not be sustained upon examination.",
        "label": "Summary of Positions for which Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table Text Block]",
        "terseLabel": "Summary of Activity Related to Company's Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Supplemental Balance Sheet Disclosures"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetails"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail",
      "http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.",
        "label": "Type of Adoption [Domain]",
        "terseLabel": "Type of Adoption"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesImpactofAdoptionofASConCondensedConsolidatedBalanceSheetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by category of arrangement, including but not limited to collaborative arrangements and non-collaborative arrangements.",
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/RelatedPartyDisclosuresDetails",
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "auth_ref": [
      "r195",
      "r368"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "terseLabel": "U.S. government-sponsored entity debt securities"
       }
      }
     },
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail",
      "http://www.sangamo.com/role/MarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r247",
      "r260"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesSummaryofActivityRelatedtoCompanysUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r261"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedLabel": "Reductions for tax positions of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesSummaryofActivityRelatedtoCompanysUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r257"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accrued interest and/or penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r262"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions based on tax positions related to the current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesSummaryofActivityRelatedtoCompanysUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r120",
      "r125",
      "r126",
      "r127"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r249"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase (decrease) in deferred tax assets valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Approach and Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Approach and Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationTechniqueOptionPricingModelMember": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation technique calculating price of option.",
        "label": "Valuation Technique, Option Pricing Model [Member]",
        "terseLabel": "Option Pricing Method"
       }
      }
     },
     "localname": "ValuationTechniqueOptionPricingModelMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r341",
      "r347"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease, cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by vesting schedule for share-based compensation.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vesting schedule for share-based compensation.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Estimated Correlation Sangamo and Sangamo France Stock Prices"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Shares used in computing basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 13
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=109236672&loc=d3e725-108305"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=109236672&loc=d3e765-108305"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=109236672&loc=d3e777-108305"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=109225645&loc=d3e1280-108306"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.10-01(a)(5))",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.10-01.(a)(5))",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.10-01.(b)(6))",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "http://asc.fasb.org/topic&trid=2126967"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "305",
   "URI": "http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26610-111562"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26853-111562"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26626-111562"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27290-111563"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27337-111563"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27340-111563"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27357-111563"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5865-108316"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/subtopic&trid=2208855"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130551-203045"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=112275985&loc=d3e4179-114921"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=107668666&loc=SL79513924-113897"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=79507207&loc=d3e4534-113899"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=SL79508275-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11149-113907"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11178-113907"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=115928272&loc=d3e28680-109314"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=115928272&loc=d3e28680-109314"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=SL37586934-109318"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32059-109318"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32123-109318"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32247-109318"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32280-109318"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31917-109318"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31931-109318"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31958-109318"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "30",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=108330185&loc=d3e2207-128464"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=109124213&loc=d3e6578-128477"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=109124213&loc=d3e6613-128477"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(3)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569655-111683"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4616395-111683"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4590271-111686"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4591551-111686"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4591552-111686"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=SL7498348-110258"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19279-110258"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "820",
   "URI": "http://asc.fasb.org/topic&trid=2155941"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13531-108611"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13537-108611"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13537-108611"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b,c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240241&loc=d3e32211-110900"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6897108&loc=SL6897125-166521"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902458&loc=d3e39927-112707"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=113997351&loc=SL77916155-209984"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888415&loc=SL77918607-209975"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=68078379&loc=d3e122625-111746"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6)(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62557-112803"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62652-112803"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99384497&loc=SL65671331-158438"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(2)(i))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C(1)(a))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "305",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=84242212&loc=d3e2352-115587"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r402": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r403": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r404": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r405": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r406": {
   "Name": "Forms 10-K, 20-F, 40-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d-1"
  },
  "r407": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r408": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6787-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e640-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e681-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL34724394-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e557-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.19)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3000-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6812-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21843-107793"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22580-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6855252128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying Consolidated Financial Statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;U.S.&#160;GAAP&#8221;) and include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Consolidated Financial Statements. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net loss attributable to &#8194;non-controlling interests on our Consolidated Statements of Operations equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div style="padding-left:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Reclassifications</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain prior period amounts in the accompanying Consolidated Financial Statements have been reclassified to conform to the current period presentation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">Use of EstimatesThe preparation of the accompanying Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities, including from acquisitions, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. In March 2019, the Company recorded an adjustment to revenue related to a change in estimate in connection with the hemophilia A collaboration agreement with Pfizer Inc. (&#8220;Pfizer&#8221;). This adjustment was a direct result of the decision to increase the project scope during the first quarter of 2019 and the corresponding costs, both of which resulted in a decrease in the measure of proportional performance. In December 2019, the Company updated its estimated project cost and related revenues upon the transfer of the investigational new drug (&#8220;IND&#8221;) for Pfizer SB-525. This adjustment directly resulted in a decrease in project scope during the fourth quarter of 2019 and a decrease in the corresponding costs, which resulted in an increase in the measure of proportional performance.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="text-indent:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Effective January&#160;1, 2018, the Company adopted the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from Contracts with Customers</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASC Topic 606&#8221;) using the modified retrospective method, resulting in a change to its accounting policy for revenue recognition. ASC Topic 606 establishes a unified model to determine how revenue is recognized.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s contract revenues are derived from collaboration agreements and research activity grants and licensing. Research and licensing agreements typically include upfront signing or license fees, cost reimbursements, research services, minimum sublicense fees, milestone payments and royalties on future licensee&#8217;s product sales. The Company has both fixed and variable consideration. Non-refundable upfront fees and funding of research and development activities are considered fixed, while milestone payments are generally identified as variable consideration. Sangamo&#8217;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenues under research grant agreements are generally recognized when the related qualified research expenses are incurred. Deferred revenue represents the portion of research or license payments received but not earned.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic 606. The Company&#8217;s performance obligations include license rights, development services and services associated with regulatory submission and approval processes. Revenues from research services earned under collaboration agreements are generally recognized as revenue as the related services are provided. Revenues from non-refundable upfront fees are recognized over time either by measuring progress towards satisfaction of the relevant performance obligation, using the input method (i.e. cumulative actual costs incurred relative to total estimated costs) or on a straight-line basis when a performance obligation is expected to be satisfied evenly over a period of time (or when the entity has a stand-ready obligation). Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement which may include total internal personnel costs and external costs to be incurred as well as, in certain cases, the estimated stand-ready obligation period. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. The estimated period of performance and project costs, such as personnel and manufacturing cost, are reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Related costs and expenses under these arrangements have historically approximated the revenues recognized.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Receivables from collaborations are typically unsecured and are concentrated in the biopharmaceutical industry. Accordingly, the Company may be exposed to credit risk generally associated with biopharmaceutical companies or specific to its collaboration agreements. To date, the Company has not experienced any losses related to these receivables.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Funds received from third parties under contract or funds received from grant arrangements are generally recorded as revenue if the Company is deemed to be the principal participant in the arrangements because the activities under the contracts or grants are part of the Company&#8217;s development programs. Contract funds received are not refundable and are recognized when the related qualified research and development costs are incurred and there is reasonable assurance that the funds will be received. Funds received in advance are recorded as deferred revenue.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div style="padding-left:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Business Combinations</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for acquisitions using the acquisition method of accounting, which requires that assets acquired, including in-process research and development (&#8220;IPR&amp;D&#8221;) projects, liabilities assumed and any non-controlling interests in the acquired target in an acquisition be recorded at their fair values as of the acquisition date on the Company&#8217;s Consolidated Balance Sheets. Any excess of purchase price over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires the Company to make significant estimates and assumptions. As a result, the Company may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text"><div style="padding-left:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Goodwill and Intangible Assets</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Goodwill represents the excess of the consideration transferred over the estimated fair values of assets acquired and liabilities assumed in a business combination. Intangible assets with indefinite useful lives are related to purchased IPR&amp;D projects and are measured at their respective fair values as of the acquisition date. Goodwill and intangible assets with indefinite useful lives are not amortized. Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed&#160;finite-lived&#160;and would then be amortized based on their respective estimated useful lives at that point in time. The Company tests goodwill and indefinite-lived intangible assets for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate the fair values of the assets are below their respective carrying amounts. As of December 31, 2019, no impairment of goodwill or indefinite-lived intangible assets has been identified.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Valuation of Long-Lived Assets</a></td>
<td class="text"><div style="padding-left:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Valuation of Long-Lived Assets</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Long-lived assets, including property and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may suggest that the carrying value of an asset may not be recoverable. Recoverability of these assets is measured by comparison of the carrying amount of each asset to the future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. As of December 31, 2019, no impairment of any long-lived assets has been identified.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="text-indent:22.5pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Fair Value Measurements</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short maturities. Marketable securities are stated at their estimated fair values. The free share asset/liability is measured using a binomial-lattice pricing model and is reviewed each reporting period and adjusted, as needed, and is expected to approximate fair value.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text">Cash, Cash Equivalents and Restricted Cash<span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sangamo considers all highly-liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> cash, deposits in demand money market accounts, and commercial paper.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><div style="text-indent:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%;">Marketable Securities</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sangamo classifies its marketable securities as available-for-sale and records its investments at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in accumulated other comprehensive loss (&#8220;AOCI&#8221;). The Company classifies those investments that are not required for use in current operations and that mature in more than 12 months as non-current marketable securities in the accompanying Consolidated Balance Sheets.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s investments are subject to a periodic impairment review. The Company recognizes an impairment charge, if material, when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the fair value has been less than the Company&#8217;s cost basis, the financial condition and near-term prospects of the investee and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. Realized gains and losses on available-for-sale securities are included in other income, net, which are determined using the specific identification method.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="padding-left:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Property and Equipment</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method based on the estimated useful lives of the related assets which is generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhMmJmOTAxM2FhNDQ5ODBiNWExZjU4NDYyOTBiMWE4L3NlYzo5YTJiZjkwMTNhYTQ0OTgwYjVhMWY1ODQ2MjkwYjFhOF85MS9mcmFnOmJjNGMwYzI4NGI3MTQyMmQ4NzQzMmRkNjhiYWIwZGFhL3RleHRyZWdpb246YmM0YzBjMjg0YjcxNDIyZDg3NDMyZGQ2OGJhYjBkYWFfNTczOA_d3889db1-4c3b-4768-aeb6-f18ca1502096">three</span> to five years. For leasehold improvements, amortization is calculated using the straight-line method based on the shorter of the useful life or the lease term. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="padding-left:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development Expenses</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development expenses consist primarily of personnel costs, including salaries, benefits and stock-based compensation, clinical studies performed by contract research organizations ("CROs"), materials and supplies and overhead allocations consisting of various support and facility-related costs.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development costs are expensed as incurred.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative Expenses</a></td>
<td class="text"><div style="padding-left:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">General and Administrative Expenses</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">General and administrative expenses consist of finance, human resources, legal and other administrative activities. These expenses consist primarily of personnel costs, including salaries, benefits and stock-based compensation, facilities and overhead costs, legal expenses, and other general and administrative costs.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation</a></td>
<td class="text"><div style="padding-left:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-based Compensation</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company measures and recognizes compensation expense for all stock-based payment awards made to Sangamo employees and directors, including employee share options, restricted stock units (&#8220;RSUs&#8221;) and employee stock purchases related to the 2010 Employee Stock Purchase Plan (&#8220;ESPP&#8221;), as amended, based on estimated fair values at the award grant date. The fair value of stock-based awards is amortized over the vesting period of the award using a straight-line method.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To estimate the fair value of an award, the Company uses the Black-Scholes option pricing model. This model requires inputs such as expected life, expected volatility and risk-free interest rate. These inputs are subjective and generally require significant analysis and judgment to develop. While estimates of expected life and volatility are derived primarily from the Company&#8217;s historical data, the risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected life assumption. The Company accounts for forfeitures in the period they occur.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="padding-left:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income Taxes</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Income tax expense has been provided using the liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities as measured by the enacted tax rates that will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets if, based upon the available evidence, it is not more likely than not that the deferred tax assets will be realized.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company recognizes a tax benefit from an&#160;uncertain&#160;tax&#160;position&#160;only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the Company&#8217;s consolidated financial statements from such positions are measured based on the largest benefit that has a greater than 50% likelihood of being realized. The Company recognizes interest and penalties associated with tax matters as part of the income tax provision and includes accrued interest and penalties with the related income tax liability within account payable and accrued liabilities on its Consolidated Balance Sheets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><div style="padding-left:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%;">Foreign Currency Translation</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The functional currency of the Company&#8217;s foreign subsidiaries is primarily the Euro. Assets and liabilities denominated in foreign currencies are translated to U.S. dollars using the exchange rates at the balance sheet date. Foreign currency translation adjustments are recorded as a component of AOCI within stockholders&#8217; equity. Revenues and expenses from the Company&#8217;s foreign subsidiaries are translated using the monthly average exchange rates in effect during the period in which the transactions occur. Foreign currency transaction gains and losses are recorded in interest and other income, net, on the Company&#8217;s Consolidated Statements of Operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="padding-left:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net Loss Per Share</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic net loss per share attributable to Sangamo Therapeutics, Inc. stockholders has been computed by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders is calculated by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock plus potential dilutive securities outstanding during the period.</span></div>The total number of shares subject to stock options and RSUs outstanding and the ESPP shares reserved for issuance, which are all anti-dilutive, were excluded from consideration in the calculation of diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text">SegmentsThe Company operates in one segment. Management uses one measure of profitability and does not segregate its business for internal reporting.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="text-indent:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Pronouncements</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Recently Adopted</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Simplified Disclosure</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the Securities and Exchange Commission ("SEC") adopted amendments to certain disclosure requirements in Securities Act Release No.&#160;33-10532, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Disclosure Update and Simplification</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, as updated. These amendments eliminate, modify, or integrate into other SEC requirements certain disclosure rules. Among the amendments is the requirement to present an analysis of changes in stockholders&#8217; equity in the interim financial statements included in quarterly reports on Form 10-Q. The analysis, which can be presented as a footnote or separate statement, is required for the current and comparative quarter and year-to-date interim periods. The amendments are effective for all filings made on or after November&#160;5, 2018. The Company&#8217;s adoption of these SEC amendments had no material effect on the Company&#8217;s reporting of financial position, results of operations, cash flows or stockholders&#8217; equity.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Accounting for Leases</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2016-2, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASC Topic 842&#8221;). ASC Topic 842 amends a number of aspects of lease accounting, including requiring lessees to recognize almost all leases with a term greater than one year as a right-of-use (&#8220;ROU&#8221;) asset and corresponding liability, measured at the present value of the lease payments. On January&#160;1, 2019, the Company adopted ASC Topic 842 using the modified retrospective </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">approach with a cumulative-effect adjustment of $0.9 million reflected as a decrease to the opening balance of accumulated deficit as of the adoption date. Results for the year ended December&#160;31, 2019 are presented under ASC Topic 842. No prior period amounts were adjusted and continue to be reported in accordance with previous lease guidance, ASC Topic 840 &#8211; </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASC Topic 840&#8221;).</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ASC Topic 842 provides a number of optional practical expedients in transition. The Company elected the practical expedients to not reassess its prior conclusions about lease identification under the new standard, to not reassess lease classification, and to not reassess initial direct costs. The Company did not elect the practical expedient allowing the use-of-hindsight, which would require the Company to reassess the lease term of its leases based on all facts and circumstances through the effective date. The Company also did not elect the practical expedient pertaining to land easements, as this is not applicable to the current contract portfolio.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The impact of the adoption of ASC Topic 842 on the accompanying Consolidated Balance Sheet as of January&#160;1, 2019 was as follows (in thousands):</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:60.352%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.617%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.794%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.682%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.620%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments Due to the Adoption of ASC Topic 842</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">78,723&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(62,500)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,223&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,753&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,753&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid rent</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,025&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,025&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Operating lease liabilities - current</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,408&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,408&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Deferred rent</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">271&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(271)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Build-to-suit lease obligation</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,689&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(27,689)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Operating lease liabilities - long-term</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,933&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,933&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(562,696)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">897&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(561,799)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">___________________</span></div><div style="text-indent:-36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(1)&#160;Operating lease liabilities &#8211; current and deferred rent are included in accounts payable and accrued liabilities on the Consolidated Balance Sheets.</span></div><div style="text-indent:-36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(2)&#160;Build-to-suit lease obligation and operating lease liabilities &#8211; long-term are included in long-term portion of lease liabilities on the Consolidated Balance Sheets.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The adjustments due to the adoption of ASC Topic 842 primarily related to the recognition of operating lease ROU assets and operating lease liabilities for the Company&#8217;s leases. In addition, the adoption of ASC Topic 842 resulted in a change in accounting of the build-to-suit component of two leases under ASC Topic 840 to operating leases under ASC Topic 842. As a result, the Company derecognized the estimated fair value of the building shells that were included in Property and equipment, net as of December&#160;31, 2018, as the Company had been deemed to own these buildings under ASC Topic 840. For a description of the leases, see &#8220;Note 7 &#8211; </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Commitments and Contingencies &#8211; Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; in these Consolidated Financial Statements.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Not Yet Adopted</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Collaborative Arrangements</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2018, the FASB issued ASU 2018-18, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative Arrangements (ASC Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASC Topic 808&#8221;), which clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC Topic 606 when the counterparty is a customer. In addition, ASC Topic 808 precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. This guidance will be effective for the Company beginning January&#160;1, 2020. The Company has determined the adoption of ASU 2018-18 will not have a material impact on its Consolidated Financial Statements.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Goodwill Impairment Testing</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2017, the FASB issued ASU No. 2017-4,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> Intangibles &#8211; Goodwill and Other (Topic 350): Simplifying the Test of Goodwill Impairment</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASU 2017-4&#8221;). The new guidance simplifies the subsequent measurement of goodwill by eliminating Step 2 from the goodwill impairment test. ASU 2017-4 requires goodwill impairment to be measured as the amount by which a reporting unit&#8217;s carrying amount exceeds its fair value, not to exceed the carrying amount of its goodwill. ASU </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2017-4 requires prospective application and is effective for annual periods beginning after December&#160;15, 2019. ASU 2017-4 will require the Company to amend its methodology for determining any goodwill impairment beginning in 2020. The Company does not expect the adoption of ASU 2017-4 to have a material impact on its Consolidated Financial Statements.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Credit Losses</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments &#8211; Credit Losses (Topic 326)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> ("ASU 2016-13"). ASU 2016-13 implements an impairment model, known as the current expected credit loss model that is based on expected losses rather than incurred losses. Under the new guidance, an entity will recognize as an allowance its estimate of expected credit losses. ASU 2016-13 is effective for all interim and annual reporting periods beginning after December 15, 2019 and must be adopted using a modified retrospective approach, with certain exceptions. Early adoption is permitted. The Company does not expect the adoption of ASU 2016-13 to have a material impact on its Consolidated Financial Statements.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Income Taxes</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income Taxes &#8211; Simplifying the Accounting for Income Taxes </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(&#8220;ASU 2019-12&#8221;). The guidance removes exceptions to the general principles in </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income Taxes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">(Topic 740)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> for allocating tax expense between financial statement components, accounting basis differences stemming from an ownership change in foreign investments and interim period income tax accounting for year-to-date losses that exceed projected losses. The guidance becomes effective for annual reporting periods beginning after December 15, 2020 and interim periods within those fiscal years with early adoption permitted. The Company plans to adopt ASU 2019-12 effective January 1, 2020 and does not expect this adoption to have a material impact on its Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6860947696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Major Customers, Partnerships and Strategic Alliances (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. ("Kite")</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Revenues recognized under agreement</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues recognized under the agreement were as follows (in thousands):</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.538%;"><tr><td style="width:1.0%;"/><td style="width:70.848%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.908%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.541%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.908%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.395%;"/><td style="width:0.1%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="12" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue related to Kite agreement:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Recognition of license and stand-ready fee</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,977&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,545&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,373&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,972&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,350&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,517&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Revenues recognized under agreement</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues recognized under the agreement were as follows (in thousands):</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368%;"><tr><td style="width:1.0%;"/><td style="width:57.009%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.063%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.550%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.063%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.851%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.064%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue related to Pfizer SB-525 agreement:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Recognition of upfront fee and research services</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,697&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,810&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,008&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Milestone achievement</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,662&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,359&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,810&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,008&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member', window );">Pfizer C9ORF72</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Revenues recognized under agreement</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues recognized under the agreement were as follows (in thousands):</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:58.557%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.756%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.386%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.756%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.386%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.759%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Recognition of upfront fee related to Pfizer </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">C9ORF72</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> agreement</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,827&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,188&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Revenues recognized under agreement</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues recognized under the agreement were as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:58.322%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.740%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue related to Sanofi agreement:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Recognition of upfront fee</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,494&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,013&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,769&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,367&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,503&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,489&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Milestone achievement</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,819&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,680&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,516&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,258&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerSB525Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6856238320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Major Customers, Partnerships and Strategic Alliances - Agreement with Dow AgroSciences in Plant Agriculture - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2005</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 54,851,000<span></span>
</td>
<td class="nump">$ 21,958,000<span></span>
</td>
<td class="nump">$ 17,548,000<span></span>
</td>
<td class="nump">$ 8,071,000<span></span>
</td>
<td class="nump">$ 26,837,000<span></span>
</td>
<td class="nump">$ 23,562,000<span></span>
</td>
<td class="nump">$ 21,416,000<span></span>
</td>
<td class="nump">$ 12,637,000<span></span>
</td>
<td class="nump">$ 102,428,000<span></span>
</td>
<td class="nump">$ 84,452,000<span></span>
</td>
<td class="nump">$ 36,567,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_DowAgroSciencesMember', window );">Dow Agro Sciences | License agreement terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_InitialResearchTermOfAgreement', window );">Research program to develop laboratory research reagents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OneTimeLicenseFeeEarned', window );">One-time license fee earned on exercise of option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement', window );">Previously agreed research, development and commercialization milestone payments, and royalties on sales of products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing', window );">Percentage of royalties to be received from sublicensing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_FeeDue', window );">Fee due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod', window );">Minimum license annual fees specific reckoning period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_DowAgroSciencesMember', window );">Dow Agro Sciences | License agreement terms | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AnnualFeesRelatedToAgreement', window );">Annual fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_DowAgroSciencesMember', window );">Dow Agro Sciences | License agreement terms | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AnnualFeesRelatedToAgreement', window );">Annual fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_DowAgroSciencesMember', window );">Dow Agro Sciences | License agreement terms | Royalty revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_DowAgroSciencesMember', window );">Dow Agro Sciences | License agreement terms | License fee revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AnnualFeesRelatedToAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual fees related to agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AnnualFeesRelatedToAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_FeeDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fee due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_FeeDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_InitialResearchTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial research term of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_InitialResearchTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment and royalty revenue of previous agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum sublicense annual fees specific reckoning period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_OneTimeLicenseFeeEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>One time license fee earned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_OneTimeLicenseFeeEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalties to be received from sublicensing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_DowAgroSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_DowAgroSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6850103264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses', window );">Realized losses from the sale of available-for-sale securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OtherThanTemporarilyImpairedInvestment', window );">Investments other-than-temporarily impaired</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_OtherThanTemporarilyImpairedInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other than temporarily impaired investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_OtherThanTemporarilyImpairedInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the gross loss realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6862497344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (95,419)<span></span>
</td>
<td class="num">$ (68,889)<span></span>
</td>
<td class="num">$ (54,568)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">3,930<span></span>
</td>
<td class="nump">2,359<span></span>
</td>
<td class="nump">1,498<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of discount on marketable securities</a></td>
<td class="num">(4,708)<span></span>
</td>
<td class="num">(5,829)<span></span>
</td>
<td class="num">(673)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AmortizationAndOtherChangesInRightOfUseAssets', window );">Amortization and other changes in right-of-use assets</a></td>
<td class="num">(5,677)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_GainOnFreeShares', window );">Gain on free shares</a></td>
<td class="num">(488)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Net loss on disposal of property and equipment</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">19,330<span></span>
</td>
<td class="nump">14,677<span></span>
</td>
<td class="nump">9,089<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Net loss on lease termination</a></td>
<td class="nump">218<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BuildToSuitLeases', window );">Build-to-suit leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">966<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet', window );">Interest receivable</a></td>
<td class="num">(307)<span></span>
</td>
<td class="num">(135)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(32,236)<span></span>
</td>
<td class="num">(1,330)<span></span>
</td>
<td class="nump">1,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(6,660)<span></span>
</td>
<td class="num">(2,828)<span></span>
</td>
<td class="num">(669)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(4,192)<span></span>
</td>
<td class="num">(6,372)<span></span>
</td>
<td class="nump">3,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and employee benefits</a></td>
<td class="nump">4,129<span></span>
</td>
<td class="nump">2,604<span></span>
</td>
<td class="nump">2,594<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenues</a></td>
<td class="num">(35,693)<span></span>
</td>
<td class="nump">99,364<span></span>
</td>
<td class="nump">48,984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities', window );">Long-term portion of lease liabilities</a></td>
<td class="num">(1,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="nump">3,749<span></span>
</td>
<td class="nump">1,963<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
<td class="num">(144,402)<span></span>
</td>
<td class="nump">36,550<span></span>
</td>
<td class="nump">11,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition, net of cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(75,647)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(443,711)<span></span>
</td>
<td class="num">(451,239)<span></span>
</td>
<td class="num">(252,328)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">404,847<span></span>
</td>
<td class="nump">391,845<span></span>
</td>
<td class="nump">178,675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(20,675)<span></span>
</td>
<td class="num">(43,065)<span></span>
</td>
<td class="num">(3,751)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Purchase of additional Sangamo France shares</a></td>
<td class="num">(262)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(59,801)<span></span>
</td>
<td class="num">(178,106)<span></span>
</td>
<td class="num">(77,404)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NetProceedsFromIssuancePublicOffering', window );">Proceeds from public offering of common stock, net of issuance costs</a></td>
<td class="nump">136,308<span></span>
</td>
<td class="nump">215,758<span></span>
</td>
<td class="nump">81,573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(422)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
<td class="num">(654)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">2,044<span></span>
</td>
<td class="nump">1,484<span></span>
</td>
<td class="nump">818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from exercise of stock options and restricted stock units</a></td>
<td class="nump">4,099<span></span>
</td>
<td class="nump">14,721<span></span>
</td>
<td class="nump">15,753<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">142,029<span></span>
</td>
<td class="nump">231,709<span></span>
</td>
<td class="nump">97,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effects of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">184<span></span>
</td>
<td class="nump">439<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(61,990)<span></span>
</td>
<td class="nump">90,592<span></span>
</td>
<td class="nump">31,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, beginning of period</a></td>
<td class="nump">143,918<span></span>
</td>
<td class="nump">53,326<span></span>
</td>
<td class="nump">22,061<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, end of period</a></td>
<td class="nump">81,928<span></span>
</td>
<td class="nump">143,918<span></span>
</td>
<td class="nump">53,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NoncashOrPartNoncashNonControllingInterestAcquisition', window );">Non-controlling interest for acquisition</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,313<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="nump">31,291<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_PropertyAndEquipmentMember', window );">Property and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital expenditures included in unpaid liabilities</a></td>
<td class="nump">2,114<span></span>
</td>
<td class="nump">4,953<span></span>
</td>
<td class="nump">1,214<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=sgmo_BuildToSuitLeaseMember', window );">Build-to-Suit Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital expenditures included in unpaid liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,950<span></span>
</td>
<td class="nump">$ 20,793<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AmortizationAndOtherChangesInRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization And Other Changes In Right-of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AmortizationAndOtherChangesInRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BuildToSuitLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Build to suit leases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BuildToSuitLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_GainOnFreeShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain On Free Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_GainOnFreeShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease In Long Term Portion Of Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NetProceedsFromIssuancePublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from issuance public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NetProceedsFromIssuancePublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NoncashOrPartNoncashNonControllingInterestAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash or part noncash non-controlling interest acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NoncashOrPartNoncashNonControllingInterestAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 40<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77888415&amp;loc=SL77918607-209975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 25<br> -Paragraph 19A<br> -URI http://asc.fasb.org/extlink&amp;oid=107668666&amp;loc=SL79513924-113897<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of noncontrolling interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based compensation arrangement. Issuance includes, but is not limited to, exercise of stock options and similar instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_PropertyAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_PropertyAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=sgmo_BuildToSuitLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=sgmo_BuildToSuitLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6843097680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Difference Between Benefit for Income Taxes and Federal Statutory Income Tax Rate, Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6850153056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">160,000,000<span></span>
</td>
<td class="nump">160,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">115,972,708<span></span>
</td>
<td class="nump">102,187,471<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">115,972,708<span></span>
</td>
<td class="nump">102,187,471<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6608880704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total compensation cost related to unvested stock options and RSU</a></td>
<td class="nump">$ 37,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period of unvested stock options and RSU</a></td>
<td class="text">2 years 9 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized stock-based employee compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average estimated fair value per share of options granted (in dollars per share)</a></td>
<td class="nump">$ 6.37<span></span>
</td>
<td class="nump">$ 11.39<span></span>
</td>
<td class="nump">$ 4.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="nump">249,364<span></span>
</td>
<td class="nump">328,710<span></span>
</td>
<td class="nump">253,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice', window );">Stock issued under employee stock purchase plans, average exercise price (in dollars per share)</a></td>
<td class="nump">$ 8.53<span></span>
</td>
<td class="nump">$ 4.51<span></span>
</td>
<td class="nump">$ 3.22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue', window );">Weighted-average estimated fair value of shares purchased under ESPP plan (in dollars per share)</a></td>
<td class="nump">$ 4.70<span></span>
</td>
<td class="nump">$ 7.07<span></span>
</td>
<td class="nump">$ 2.37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total compensation cost related to unvested stock options and RSU</a></td>
<td class="nump">$ 7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period of unvested stock options and RSU</a></td>
<td class="text">2 years 1 month 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee stock purchase plan rights weighted average estimated fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued under employee stock purchase plans average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the compensation cost capitalized during the period arising from equity-based compensation arrangements (for example, shares of stock, units, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6608466912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Domestic and Foreign Components of Loss Before Income Taxes (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (77,354)<span></span>
</td>
<td class="num">$ (65,695)<span></span>
</td>
<td class="num">$ (54,568)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(18,065)<span></span>
</td>
<td class="num">(3,194)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">$ (95,419)<span></span>
</td>
<td class="num">$ (68,889)<span></span>
</td>
<td class="num">$ (54,568)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
